<SEC-DOCUMENT>0001628280-25-023426.txt : 20250508
<SEC-HEADER>0001628280-25-023426.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508063840
ACCESSION NUMBER:		0001628280-25-023426
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPASS Pathways plc
		CENTRAL INDEX KEY:			0001816590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39522
		FILM NUMBER:		25923714

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		1-716-676-6461

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Compass Rx Ltd.
		DATE OF NAME CHANGE:	20200701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cmps-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ecce3bbb-f5c6-429b-99e4-462edd6def85,g:b4bd98cb-b7e6-4e40-b9b6-c78a12b28ef2,d:387913fc30d8481bbd7cf8b08db88d3a-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:cmps="http://compasspathways.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cmps-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0001816590</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-25">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-26">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-410">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-458">0.25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-459">0.75</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cmps-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="day"><xbrli:measure>cmps:day</xbrli:measure></xbrli:unit><xbrli:unit id="vestingcondition"><xbrli:measure>cmps:vestingCondition</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>cmps:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-08</xbrli:startDate><xbrli:endDate>2021-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-09</xbrli:startDate><xbrli:endDate>2025-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-16</xbrli:startDate><xbrli:endDate>2023-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:FacilityFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:CompanyFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:EndOfTermChargeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:HerculesCapitalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-18</xbrli:startDate><xbrli:endDate>2023-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-18</xbrli:startDate><xbrli:endDate>2023-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-19</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:OptionsGrantedBeforeJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:DevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:DevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:PersonnelExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:PersonnelExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:NonCashShareBasedCompensationExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:NonCashShareBasedCompensationExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:FacilitiesAndOtherExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:FacilitiesAndOtherExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:LegalAndProfessionalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:LegalAndProfessionalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_1"></div><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.377%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#8864;</ix:nonNumeric>   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2025</ix:nonNumeric><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric>   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39522</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">COMPASS Pathways plc</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.035%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-7">England and Wales</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">33 Broadwick Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">London</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">W1F 0DQ</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-11">United Kingdom</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> +1 (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">716</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">676-6461</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.265%"><tr><td style="width:1.0%"/><td style="width:32.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-14">American Depositary Shares, each representing one ordinary share, par value of &#163;0.008 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-15">CMPS</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-16">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-17">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-18">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.956%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.390%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-19">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-20">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-22">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-23">93,561,753</ix:nonFraction> shares of common stock outstanding as of May 6. 2025. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_7"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.206%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i387913fc30d8481bbd7cf8b08db88d3a_16">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_19">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets As of March&#160;31, 2025 and December&#160;31, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2025 and 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity for the Three Months ended March 31, 2025 and 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2025 and 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_37">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_103">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_103">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_124">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_127">34</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i387913fc30d8481bbd7cf8b08db88d3a_130">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_133">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_133">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_559">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_139">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_139">Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_139">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_142">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_142">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_142">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_145">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_145">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_145">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_148">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_148">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_148">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_151">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_151">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_151">141</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i387913fc30d8481bbd7cf8b08db88d3a_154">142</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_583"></div><hr style="page-break-after:always"/><div style="min-height:58.32pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:244%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:165%">This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the &#8220;Securities Act,&#8221; and Section 21E of the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act&#8221;. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these words or other similar terms or expressions. The forward-looking statements and opinions contained in this Form 10-Q are based upon information available to our management as of the date of this Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the timing, progress and results of our Phase 3 program for treatment-resistant depression, or TRD, and our other clinical trials of investigational COMP360 psilocybin treatment, including statements regarding the timing of initiation and completion of trials or studies and related preparatory work, our expectations regarding discussions with the Food and Drug Administration, or FDA, regarding our trial design and protocols, and our expectations regarding the periods during which the results of our clinical trials will become available;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our plans for a late-stage program in post-traumatic stress disorder, or PTSD, including statements regarding our proposed trial designs;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our estimates regarding our expenses, capital requirements, the sufficiency of our cash resources and our expected cash runway;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to raise additional capital or secure other financing to fund our operations; </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the potential for outstanding warrants to be exercised in full for cash and any expected proceeds from the exercise of these warrants;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our reliance on the success of our investigational COMP360 psilocybin treatment;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the timing, scope or likelihood of regulatory filings and approvals;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our expectations regarding the size of the eligible patient populations for COMP360 psilocybin treatment, if approved for commercial use;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to identify third-party clinical sites to conduct our trials and our ability to identify and train appropriately qualified healthcare professionals to monitor and safeguard participants receiving COMP360 psilocybin treatment in our clinical trials;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to implement our business model and our strategic plans for our business and our investigational COMP360 psilocybin treatment;</span></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">3</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.32pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to identify new indications for COMP360 beyond our current primary focus on TRD and post-traumatic stress disorder, or PTSD;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the pricing, coverage and reimbursement of our investigational COMP360 psilocybin treatment, if approved;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the scalability and commercial viability of our manufacturing methods and processes;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our investigational COMP360 psilocybin treatment, in particular, and psilocybin-based treatments, in general;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to establish or maintain collaborations or strategic relationships;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our expectations regarding potential benefits of our investigational COMP360 psilocybin treatment and our treatment approach generally;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations around feedback from, and discussions with regulators, regulatory development paths and with respect to Controlled Substances Act designation, including potential impacts of regulatory agency staffing cuts and policy changes on regulatory feedback and timing thereof;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the scope of protection we and any current or future licensors or collaboration partners are able to establish and maintain for intellectual property rights covering COMP360;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to identify, maintain, utilize, acquire or purchase digital technologies to enhance the administration of our investigational COMP360 psilocybin treatment in the conduct of our clinical trials;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">regulatory developments in the United States, or U.S., under the laws and regulations of England and Wales, and other jurisdictions;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the effectiveness of our internal control over financial reporting;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to achieve the specified data milestone and to achieve sufficient appreciation in the trading price of our American Depositary Shares, or ADSs, such that the closing price of our ADSs is above the exercise price for our outstanding warrants to purchase ADSs, or the 2025 ADS Warrants, issued in our registered financing in January 2025, or the 2025 Financing, for three consecutive trading days to allow us to force the cash exercise of the 2025 ADS Warrants;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">our ability to meet milestones to draw down additional amounts in accordance with the terms of our Loan and Security Agreement, as amended, or the Loan Agreement, with Hercules Capital, Inc., or Hercules, and our ability to comply with the operating and financial covenants, including the minimum cash covenant, in our Loan Agreement;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the effect of global financial and economic conditions and geopolitical events, including fluctuating interest rates and inflation, foreign exchange fluctuations, particularly the Pound Sterling to U.S. Dollar, the risk of economic slowdown or recession in the U.S., instability in the banking system, overall market volatility in the U.S. or the UK, </span></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">4</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.32pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:7pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">including as a result of, among other factors, the ongoing war between Russia and Ukraine, conflict in the Middle East, the effects of announced or future tariff increases, international tensions or instability, significant changes in U.S. policies or regulatory environment or the disruption of U.S. government agencies or similar events, on our business;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the effect of public health crises, pandemics or epidemics and any future mitigation efforts, and current or future economic effects, on any of the foregoing or other aspects of our business or operations;</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">whether we are classified as a controlled foreign corporation, or CFC, or a passive foreign investment company, or PFIC, under the Internal Revenue Code of 1986, as amended, for current and future periods; and</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">the future trading price of the ADSs and impact of securities analysts&#8217; reports on these prices.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:165%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:165%">You should not rely upon forward-looking statements as predictions of future events, which speak only as of the date made. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A, of this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Except as otherwise required by law, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.&#160;</span></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">5</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_586"></div><hr style="page-break-after:always"/><div style="min-height:58.32pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks and uncertainties include, but are not limited to, the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We are a clinical-stage biotechnology company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable  future and may never achieve or maintain profitability;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin treatment. Failure to obtain additional funding when needed or on favorable terms may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts or grant rights to develop and market products or therapeutic candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Raising additional capital through the sale of equity or convertible securities may cause significant dilution to holders of our ordinary shares and ADSs, and raising additional capital through debt financings, strategic partnerships, collaborations, or other means may restrict our operations or require us to relinquish rights to therapeutic candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">COMP360 is, and any future therapeutic candidates we may develop may be, subject to controlled substance laws and regulations in the jurisdictions where our products, if approved, may be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, or changes in these laws and regulations may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Adverse publicity or public perception regarding COMP360, in particular, and psilocybin-based treatments, in general, or our future investigational treatments using psilocybin may negatively influence the success of these treatments;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We are dependent on the successful development of our investigational COMP360 psilocybin treatment. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. We have experienced delays in recruitment for our clinical trials of COMP360 psilocybin treatment, which has increased the costs of our Phase 3 clinical trials and caused delays in expected timing to complete such clinical trials. If we experience additional delays in the future for our clinical trials of COMP360 psilocybin treatment, we or our future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our investigational COMP360 psilocybin treatment on a timely basis or at all, which will adversely affect our business;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">COMP360 psilocybin treatment may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval or adversely affect the commercial profile for the treatment;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our treatments on our own or with suitable collaborators;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">The future commercial success of our investigational COMP360 psilocybin treatment will depend on the degree of market access and acceptance of our potential treatments;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Our business and commercialization strategy for our investigational COMP360 psilocybin treatment depends on our ability to identify, qualify, prepare, and support third-party treatment sites. If we are unable to do so, our commercialization prospects would be limited and our business would be harmed;</span></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">6</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.32pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">In our clinical trials, we currently rely on specially trained, licensed healthcare professionals working at third-party clinical trial sites and upon regulatory approval we expected to continue to rely on healthcare professionals working at third-party sites, to monitor and safeguard participants during administration of our COMP360 psilocybin treatment. If third-party sites fail to recruit, retain or effectively manage a sufficient number of qualified healthcare professionals, our clinical trials may be delayed and our business, financial condition and results of operations would be materially harmed;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Intellectual property rights of third parties could adversely affect our ability to develop or commercialize our investigational treatments, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational treatments. Such litigation or licenses could be costly or not available on commercially reasonable terms;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Our failure to comply with the financial and other covenants, including the minimum cash covenant, or payment obligations under our existing Loan Agreement with Hercules could result in a default or an event of default, which may result in increased interest charges, acceleration of our repayment obligations or other actions by Hercules, any of which could negatively impact our business, financial condition and results of operations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">Enacted and future legislation or changes in regulatory conditions may increase the difficulty and cost for us to obtain marketing approval of and commercialize our investigational COMP360 psilocybin treatment and could have a material adverse effect on our business;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We rely on third parties to supply drug substances and manufacture, package and distribute COMP360 for our clinical trials, and, if approved, we will continue to rely on third parties for commercial supply. If any third-party provider fails to meet its obligations to supply drug substance or manufacture COMP360, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substance and the commercialization of any treatments, if approved, could be stopped, delayed or made commercially unviable, or less profitable or may result in enforcement actions against us;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">There are a number of third parties who conduct investigator-initiated studies, or IISs, using COMP360 provided by us. IISs of COMP360 may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.68pt">Unfavorable global economic conditions and geopolitical events as well as volatility in the financial markets could adversely affect our business, financial condition or results of operations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We face substantial competition and our competitors may discover, develop or commercialize treatments before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">We may face business interruptions, data loss, unauthorized access to or disclosure of personal health information or other personally identifiable information, failures or significant downtime of our information technology systems, negative publicity or reputational damage resulting from cyber-attacks on our systems or other cybersecurity incidents.</span></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">7</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_16"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_19"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_22"></div><div><span><br/></span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_25"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-29">260,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">165,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-31">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-32">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">44,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">35,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">305,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">201,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-37">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-38">2,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-39">4,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-40">3,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">8,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">6,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-43">319,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">213,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">8,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">12,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">11,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">14,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">8,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">5,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">29,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">34,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, non-current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">21,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">24,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-57">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-58">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">71,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-61">123,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">58,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-63"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-64"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares, &#163;<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-65"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-66">0.008</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-67"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-69">92,848,326</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-72">68,552,215</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-73">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-74">702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-75">763,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-76">704,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-77">16,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-78">16,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-79">552,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-80">534,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">195,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-82">154,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-83">319,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-84">213,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">8</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_28"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months ended March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-85">30,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">24,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">18,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">13,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-89">49,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-90">38,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-91">49,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">38,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE), NET:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-93">19,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-95">8,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-96">3,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-97">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-98">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-99">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-100">783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-101">1,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-102">1,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-103">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-104">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">32,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">3,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-107">17,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-108">34,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-109">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-110">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-111">17,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-112">35,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders: basic</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-113">0.20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-114">0.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ordinary shares outstanding: basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-115">89,192,252</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-116">64,222,178</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders: diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-117">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-118">0.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ordinary shares outstanding: diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119">98,641,623</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-120">64,222,178</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">17,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">35,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-123">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-124">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-125">17,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-126">35,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%">9</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.028%"><tr><td style="width:1.0%"/><td style="width:27.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.859%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ORDINARY SHARES &#163;<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-127"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-128">0.008</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADDITIONAL PAID-IN CAPITAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ACCUMULATED OTHER COMPREHENSIVE LOSS</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ACCUMULATED DEFICIT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAR VALUE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-129">61,943,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-130">635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">621,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">16,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">379,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-134">225,744</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-135">86,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-136">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-137">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-138">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-139">2,509,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-140">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-141">26,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-142">26,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares to settle vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-143">50,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares to settle warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="cmps:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-145">3,752,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="cmps:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="f-146">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="cmps:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-147">37,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="cmps:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-148">37,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares tendered for withholding taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-149">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-150">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-151">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-152">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-153">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-154">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">35,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">35,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">68,342,534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-158">699</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">690,222</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">16,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">414,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-162">259,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.232%"><tr><td style="width:1.0%"/><td style="width:28.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-163">68,552,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-164">702</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">704,919</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">16,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">534,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">154,695</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-169">24,014,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-170">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-171">54,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-172">54,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of share options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-173">164,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-174">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-175">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of ordinary shares to settle vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-176">116,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-177">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-178">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-180">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-181">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-182">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-183">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">17,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">17,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-186">92,848,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-187">938</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">763,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">16,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">552,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">195,467</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_34"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-192">17,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">35,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-194">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-195">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-196">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-197">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash (gain)/loss on foreign currency remeasurement</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-198">1,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-199">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-200">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-201">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-202">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-203">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs allocated to warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cmps:TransactionCostsIncurredInConnectionWithWarrants" format="ixt:num-dot-decimal" scale="3" id="f-204">5,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="cmps:TransactionCostsIncurredInConnectionWithWarrants" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-206">19,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-208">7,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-209">8,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and prepaid tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="f-210">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="f-211">322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-212">1,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-213">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-214">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-215">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-216">3,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-217">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-218">3,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-219">3,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-220">45,657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-221">20,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares and Pre-funded Warrants, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-222">140,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-223">26,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-225">37,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of withholding tax on stock award</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-227">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-228">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-229">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">140,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-231">63,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-232">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-233">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-234">95,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-235">42,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-236">165,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-237">220,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-238">260,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-239">263,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the cash, cash equivalents and restricted cash balances as of each of the periods, shown above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.377%"><tr><td style="width:1.0%"/><td style="width:72.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.945%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-240">260,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-241">262,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-242">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-243">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-244">260,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-245">263,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_37"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-246" continuedAt="f-246-1" escape="true">Nature of Business </ix:nonNumeric></span></div><ix:continuation id="f-246-1" continuedAt="f-246-2"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Compass Pathways plc, or the Company, is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin treatment through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. The therapeutic candidate currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company has funded its operations with proceeds from the sale of its ordinary shares, American Depository Shares, or ADSs, including in its offerings pursuant to its at-the-market, or ATM, offering program, proceeds from a loan agreement with Hercules Capital, Inc., and proceeds from a private placement transaction, or the PIPE. The Company was party to a Sales Agreement for its ATM offering program, dated October 8, 2021, with TD Securities (USA) LLC, or TD Cowen, under which the Company was able to issue and sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="cmps:SaleOfStockMaximumAmountAllowableForSale" format="ixt:num-dot-decimal" scale="6" id="f-247">150.0</ix:nonFraction>&#160;million of its ADSs, each representing <ix:nonFraction unitRef="number" contextRef="c-41" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-248">one</ix:nonFraction> ordinary share, through TD Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">hrough February 27, 2025, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-249">5,491,836</ix:nonFraction> ADSs under the Company&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> ATM offering program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-250">54.8</ix:nonFraction>&#160;million in net proceeds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 27, 2025, the Company entered into a new Sales Agreement to govern the Company&#8217;s ATM offering program with TD Cowen, or the Sales Agreement, under which the Company may issue and sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="cmps:SaleOfStockAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-251">150.0</ix:nonFraction>&#160;million of our ADSs, subject to the terms of the Sales Agreement. Sales of its ADSs, if any, will generally be made at market prices. To date, the Company has not sold any ADSs under this Sales Agreement.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 30, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">the Company entered into a Loan Agreement with Hercules, which provided for aggregate maximum borrowings of up to $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-252">50.0</ix:nonFraction>&#160;million, including a term loan of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-253">30.0</ix:nonFraction>&#160;million, which was funded on June 30, 2023. On August 16, 2023, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell and issue in a private placement transaction (i) <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-254">16,076,750</ix:nonFraction> ADSs and (ii) PIPE Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-255">16,076,750</ix:nonFraction> ADSs, at a purchase price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-47" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-256">7.78</ix:nonFraction> per ADS and accompanying PIPE Warrant to purchase <ix:nonFraction unitRef="number" contextRef="c-46" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-257">one</ix:nonFraction> ADS. Each PIPE Warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-258">9.93</ix:nonFraction> per ADS and is exercisable for a <ix:nonNumeric contextRef="c-49" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-259">three year</ix:nonNumeric> period beginning in February 2024. The PIPE Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the PIPE Warrants. Through March&#160;31, 2025, PIPE Warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-260">3,752,050</ix:nonFraction> ADS, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="f-261">37.3</ix:nonFraction>&#160;million in exercise proceeds. The Company will receive up to an additional approximately $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="cmps:ProceedsFromWarrantExercisesFullyExercised" format="ixt:num-dot-decimal" scale="6" id="f-262">122.4</ix:nonFraction>&#160;million in gross proceeds if the PIPE Warrants are fully exercised. During the three months ended March 31, 2025, no PIPE warrants were exercised.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company issued and sold (i) <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-263">24,014,728</ix:nonFraction> American Depositary Shares, each representing <ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-264">one</ix:nonFraction> ordinary share, nominal value &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-53" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-265">0.008</ix:nonFraction> each, of the Company and accompanying warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-266">24,014,728</ix:nonFraction> ADSs, and (ii) in lieu of ADSs, to certain investors, Pre-funded Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-267">11,044,720</ix:nonFraction> ADSs and accompanying 2025 ADS Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-268">11,044,720</ix:nonFraction> ADSs. The offering price was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-269">4.2750</ix:nonFraction> per ADS and accompanying 2025 ADS Warrant, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-270">4.2649</ix:nonFraction> per Pre-funded Warrant and accompanying 2025 ADS Warrant. The Pre-funded Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-271">0.0001</ix:nonFraction> per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-272">5.7960</ix:nonFraction> per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after <ix:nonNumeric contextRef="c-53" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-273">three years</ix:nonNumeric>. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#8217;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the Company&#8217;s ADSs on Nasdaq </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="f-246-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exceeded the warrant exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-274">5.7960</ix:nonFraction> for the <ix:nonFraction unitRef="day" contextRef="c-52" decimals="INF" name="cmps:ClassOfWarrantOrRightThresholdConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-275">three</ix:nonFraction> consecutive trading days prior to the date on which the notice of forced exercise is delivered.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company has incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-276">17.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-277">35.2</ix:nonFraction> million for the three months ended March 31, 2025 and 2024, respectively. In addition, as of March&#160;31, 2025, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-278">552.6</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March&#160;31, 2025 of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-279">260.1</ix:nonFraction> million will be sufficient to fund its operating expenses and capital expenditure requirements at least </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">through the planned 26-week data read-out from our COMP006 study, which is expected in the second half of 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial conditions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Market volatility, geopolitical tensions or instability, including from the effects of announced or future tariff increases, resulting from the ongoing war between Ukraine and Russia and conflict in the Middle East, fluctuating inflation and interest rates and the related impact on U.S., UK and global economies, instability in the banking system, the risk of economic slowdown or recession in the U.S., significant changes in U.S. policies or regulatory environment or other factors could adversely impact the Company&#8217;s operations, financial results and ability to raise additional funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:130%">.</span></div></ix:continuation><div id="i387913fc30d8481bbd7cf8b08db88d3a_46"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-280" continuedAt="f-280-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-280-1" continuedAt="f-280-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-281" continuedAt="f-281-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December&#160;31, 2024, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position for the reported periods. </span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-281-1">The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2024, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 27, 2025. The condensed consolidated balance sheet at December&#160;31, 2024, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-282" continuedAt="f-282-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-282-1">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company&#8217;s significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-283" continuedAt="f-283-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to warrant liabilities. Estimates are periodically reviewed in light of changes in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="f-280-2"><ix:continuation id="f-283-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-284" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our year-end consolidated financial statement disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03 - Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statement disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i387913fc30d8481bbd7cf8b08db88d3a_58"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-285" continuedAt="f-285-1" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="f-285-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-286" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="f-287">30,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cmps:ResearchAndDevelopmentTaxCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="f-288">20,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:PrepaidExpenseResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-289">10,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cmps:PrepaidExpenseResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-290">11,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-291">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-292">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="f-293">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-294">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-295">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-296">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-297">44,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-298">35,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was uncertain whether it would meet the R&amp;D intensity condition and be eligible for the enhanced effective rate for their tax submission relating to the year ended December 31, 2023. The Company sought clarity from HMRC in the form of a non-statutory clearance and received a positive response in April 2025. Therefore,&#160; the Company intends to file a resubmission to claim relating to the year ended December 31, 2023 at the enhanced rate, which results in an increase in its R&amp;D tax relief claim of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="cmps:ResearchAndDevelopmentTaxCreditPayable" format="ixt:num-dot-decimal" scale="6" id="f-299">3.9</ix:nonFraction>&#160;million. For the period March 31, 2025, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="cmps:PrepaidResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="6" id="f-300">3.9</ix:nonFraction>&#160;million prepaid for the 2023 R&amp;D tax credit.</span></div></ix:continuation><div id="i387913fc30d8481bbd7cf8b08db88d3a_73"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-301" continuedAt="f-301-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-301-1" continuedAt="f-301-2"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 30, 2023, or the Effective Date, the Company entered into the Loan Agreement with Hercules, which provided for aggregate maximum borrowings of up to $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-302">50.0</ix:nonFraction>&#160;million, consisting of (i) a term loan of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-303">30.0</ix:nonFraction>&#160;million, which was funded on the Effective Date, (ii) subject to the Company achieving certain performance milestones and available until June 30, 2025, an additional term loan of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-304">10.0</ix:nonFraction>&#160;million, and (iii) subject to the approval of Hercules&#8217; investment committee in its sole discretion, and available during the interest-only period, an additional term loan of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-305">10.0</ix:nonFraction>&#160;million. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan will mature on July 1, 2027. The outstanding principal balance of the term loan bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in The Wall Street Journal plus <ix:nonFraction unitRef="number" contextRef="c-57" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-306">1.50</ix:nonFraction>% or (ii) <ix:nonFraction unitRef="number" contextRef="c-44" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-307">9.75</ix:nonFraction>%. Accrued interest is payable monthly following the funding of each term loan. In addition to accrued interest, payment-in-kind (PIK) interest of <ix:nonFraction unitRef="number" contextRef="c-57" decimals="4" name="cmps:PaidInKindInterestRate" scale="-2" id="f-308">1.40</ix:nonFraction>% will be added to the balance of the loan. Payments under the Loan Agreement are interest only until the first principal payment is due on July 1, 2025 (or if the Borrowers achieve certain performance milestones, the interest only period may be extended to January 2, 2026 and, upon the achievement of certain additional performance milestones, the interest only period may be extended to July 1, 2026), followed by equal monthly payments of principal and interest through the scheduled </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="f-301-2" continuedAt="f-301-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maturity date, July 1, 2027. The carrying value of the Company&#8217;s outstanding debt approximates fair value, reflecting interest rates currently available to the Company.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred fees and transaction costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-309">3.3</ix:nonFraction>&#160;million associated with the initial term loan, which are recorded as a reduction to the carrying value of the long-term debt in the condensed consolidated balance sheets. These fees included $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-310">0.4</ix:nonFraction>&#160;million of facility fees, $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-311">0.8</ix:nonFraction>&#160;million of company fees, $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-312">0.7</ix:nonFraction>&#160;million in warrants, and $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-313">1.4</ix:nonFraction>&#160;million of end of term charges. The fees, transaction costs, and the end of term charge are amortized to interest expense through the maturity date using the effective interest method. The effective interest rate of the Loan Agreement was <ix:nonFraction unitRef="number" contextRef="c-62" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-314">15.6</ix:nonFraction>% as of March&#160;31, 2025.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company issued warrants to Hercules to purchase the Company&#8217;s Ordinary Shares equal to the quotient derived by dividing (i) the amount equal to (a) <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="cmps:OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" scale="-2" id="f-315">2.5</ix:nonFraction>% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price of the warrants. Upon receipt of the first term loan, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="cmps:OptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-316">94,222</ix:nonFraction> shares became exercisable to Hercules with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="cmps:OptionsExercisableFairValue" format="ixt:num-dot-decimal" scale="6" id="f-317">0.7</ix:nonFraction>&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Loan Agreement includes a financial covenant requiring us to maintain a minimum level of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="cmps:DebtInstrumentCovenantMinimumCashOnHandAmount" format="ixt:num-dot-decimal" scale="6" id="f-318">22.5</ix:nonFraction>&#160;million of cash during the period commencing on July 1, 2024 (subject to adjustment if certain performance milestones are met). If the Company meets the performance milestones, the minimum cash covenant will not apply if its market capitalization is at least $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="cmps:DebtInstrumentMarketCapitalization" format="ixt:num-dot-decimal" scale="6" id="f-319">750.0</ix:nonFraction>&#160;million. The Company was in compliance with all covenants of the Loan Agreement as of March&#160;31, 2025</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:107%">.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-320" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-321">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-322">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:LongTermDebtEndOfTermCharge" format="ixt:num-dot-decimal" scale="3" id="f-323">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cmps:LongTermDebtEndOfTermCharge" format="ixt:num-dot-decimal" scale="3" id="f-324">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future principal payments and end of term charge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:LongTermDebtIncludingEndOfTermCharge" format="ixt:num-dot-decimal" scale="3" id="f-325">31,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cmps:LongTermDebtIncludingEndOfTermCharge" format="ixt:num-dot-decimal" scale="3" id="f-326">31,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PIK interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:DebtInstrumentPaidInKindInterestPayable" scale="3" id="f-327">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cmps:DebtInstrumentPaidInKindInterestPayable" scale="3" id="f-328">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-329">1,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-330">1,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-331">30,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-332">30,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-333">8,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-334">5,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-335">21,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-336">24,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-337" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, including End of Term Charge, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.150%"><tr><td style="width:1.0%"/><td style="width:84.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-338">6,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-339">14,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-340">10,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:LongTermDebtIncludingEndOfTermCharge" format="ixt:num-dot-decimal" scale="3" id="f-341">31,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-301-3"> Interest expense associated with the Loan Agreement for the three months ended March 31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-342">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-343">1.1</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_674"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-344" continuedAt="f-344-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-344-1" continuedAt="f-344-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="f-345" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, as of March 31, 2025, information about the Company&#8217;s warrant liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:58.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 13, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-346">31,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-347">37,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 ADS Warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-348">40,270</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-349">55,726</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Warrant Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-350">71,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="cmps:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-351">92,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-funded Warrants and 2025 ADS Warrants are accounted for as liabilities in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging, Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815-40&#8221;), as both warrants contain contingent exercise provisions that do not meet the requirements of the indexation guidance under ASC 815-40 and could require the Company to pay cash to settle the warrants. The warrants are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-funded Warrants are considered to be Level 2 in the fair value hierarchy as the inputs used to determine fair market value are observable against the Company&#8217;s stock price. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-352" continuedAt="f-352-1" escape="true">The 2025 ADS Warrant are considered to be Level 3 in the fair value hierarchy as they have been recorded at fair value using the Black-Scholes model, using unobservable assumptions that have been probability-weighted for specified data milestones. As of March 31, 2025, the assumptions are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-352-1"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:58.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 13, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-353">5.7960</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-70" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-354">5.7960</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="number" contextRef="c-71" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-355">2.86</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="number" contextRef="c-72" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-356">3.37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonFraction unitRef="number" contextRef="c-73" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-357">141.9</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-74" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-358">148.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonFraction unitRef="number" contextRef="c-75" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-359">146.1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-360">158.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-361">4.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-362">4.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-363">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-364">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-81" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-365">3.8</ix:nonNumeric> to <ix:nonNumeric contextRef="c-82" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-366">4.2</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-367">4.0</ix:nonNumeric> to <ix:nonNumeric contextRef="c-84" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-368">4.4</ix:nonNumeric> years</span></div></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock" id="f-369" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the fair value of the Company&#8217;s warrant liabilities for the three months ended March 31, 2025:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:58.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-Funded Warrants</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS Warrants</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial fair value as of January 13, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-372">37,220</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-373">55,726</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-374">5,633</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-375">15,455</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March 31, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-376">31,587</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-377">40,271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-344-2">The fair value change of warrant liabilities at March 31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-378">19.5</ix:nonFraction>&#160;million, which included a $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" sign="-" name="cmps:GainLossOnIssuanceOfWarrant" format="ixt:num-dot-decimal" scale="6" id="f-379">1.6</ix:nonFraction>&#160;million loss upon issuance of the Pre-funded warrants and a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="cmps:GainLossOnFairValueOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-380">21.1</ix:nonFraction>&#160;million gain in fair value between the initial fair value and the fair value as of the balance sheet date. During the three months ended March 31, 2025, there were no transfers between Level 1, Level 2 and Level 3.</ix:continuation> </span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_76"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-381" continuedAt="f-381-1" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-381-1" continuedAt="f-381-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ordinary Shares</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each ordinary share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through March&#160;31, 2025, no cash dividends had been declared or paid by the Company.<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>At-the-Market Facility</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may have issued and sold from time to time up to $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="cmps:SaleOfStockAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-382">150.0</ix:nonFraction>&#160;million of its ADSs, each representing <ix:nonFraction unitRef="number" contextRef="c-41" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-383">one</ix:nonFraction> ordinary share, through Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">hrough February 27, 2025, we sold <ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-384">5,491,836</ix:nonFraction> ADSs under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">our ATM offering program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-385">54.8</ix:nonFraction>&#160;million in net proceeds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 27, 2025, the Company entered into a new Sales Agreement under which the Company may issue and sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="cmps:SaleOfStockAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-386">150.0</ix:nonFraction>&#160;million of our ADSs, subject to the terms of the Sales Agreement. Sales of our ADSs, if any, will generally be made at market prices. To date, we have not sold any ADSs under this Sales Agreement. <br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-classified</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 30, 2023, the Company entered into a Warrant Agreement with Hercules, which provides Hercules with the right to purchase a number of the Company&#8217;s Ordinary Shares, equal to the quotient derived by dividing (i) the amount equal to (a) <ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="cmps:OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" scale="-2" id="f-387">2.5</ix:nonFraction>% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price. Upon receipt of each term loan, the Warrant will automatically become exercisable and will expire in <ix:nonNumeric contextRef="c-93" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-388">10</ix:nonNumeric> years (on June 30, 2033). On June 30, 2023, with the receipt of the first term loan, <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="cmps:OptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-389">94,222</ix:nonFraction> shares became exercisable to Hercules with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="cmps:OptionsExercisableFairValue" format="ixt:num-dot-decimal" scale="6" id="f-390">0.7</ix:nonFraction>&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 18, 2023, in connection with the PIPE, the Company issued and sold warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-391">16,076,750</ix:nonFraction> ADSs, each representing <ix:nonFraction unitRef="number" contextRef="c-95" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-392">one</ix:nonFraction> ordinary share, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-96" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-393">9.93</ix:nonFraction> per ADS. The PIPE Warrants became exercisable for a <ix:nonNumeric contextRef="c-49" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-394">three year</ix:nonNumeric> period beginning in February 2024. Through March&#160;31, 2025, PIPE Warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-395">3,752,050</ix:nonFraction> ADSs, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="f-396">37.3</ix:nonFraction>&#160;million in exercise proceeds. During the three months ended March 31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-397">no</ix:nonFraction> PIPE warrants were exercised.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company evaluated the terms of the outstanding Hercules and PIPE warrants in accordance with ASC 815-40, D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">erivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, and concluded that the warrants meet the criteria for equity classification. As such, the warrants are classified as equity instruments in the condensed consolidated balance sheets and are not subject to recurring fair value measurement or remeasurement.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Liability-classified</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, in connection with the 2025 Financing, the Company issued and sold (i) <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-398">24,014,728</ix:nonFraction> ADSs, each representing <ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="cmps:NumberOfOrdinarySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-399">one</ix:nonFraction> ordinary share, (ii) in lieu of ADSs, Pre-funded Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-400">11,044,720</ix:nonFraction> ADSs, and (iii) accompanying 2025 ADS Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-401">11,044,720</ix:nonFraction> ADSs, each representing one ordinary share. The Pre-funded Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-402">0.0001</ix:nonFraction> per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-403">5.7960</ix:nonFraction> per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after <ix:nonNumeric contextRef="c-53" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-404">three years</ix:nonNumeric>. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#8217;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="f-381-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s ADSs on Nasdaq exceeded the warrant exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-405">5.796</ix:nonFraction> for the <ix:nonFraction unitRef="day" contextRef="c-52" decimals="INF" name="cmps:ClassOfWarrantOrRightThresholdConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-406">three</ix:nonFraction> consecutive trading days prior to the date on which the notice of forced exercise is delivered.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Financing comprising of ADSs, Pre-funded Warrants and 2025 ADS Warrants, resulted in aggregate proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-407">149.8</ix:nonFraction>&#160;million, with issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="f-408">9.4</ix:nonFraction>&#160;million. Since the Pre-funded Warrants and 2025 ADS Warrants have been classified as a liability and recorded at fair value with changes in fair value recorded in the condensed consolidated income statement, the aggregate proceeds have been allocated first to these warrants at their respective fair values at the issuance date. The residual has been allocated to the ADSs issued as part of the 2025 Financing and recognized within equity.</span></div></ix:continuation><div id="i387913fc30d8481bbd7cf8b08db88d3a_79"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-409" continuedAt="f-409-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-409-1" continuedAt="f-409-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#8217;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2017 Plan typically vest over a <span style="-sec-ix-hidden:f-410">three</span> or <ix:nonNumeric contextRef="c-100" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-411">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-412">33.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-413">25</ix:nonFraction>% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire <ix:nonNumeric contextRef="c-103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-414">10</ix:nonNumeric> years from the date of grant. Restricted share units granted under the 2017 Plan typically vest over a <ix:nonNumeric contextRef="c-104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-415">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-416">25</ix:nonFraction>% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted on June 30, 2020 were subject to <ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-417">25</ix:nonFraction>% vesting upon the earlier occurrence of (i) the <ix:nonNumeric contextRef="c-105" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-418">one year</ix:nonNumeric> anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for <ix:nonNumeric contextRef="c-106" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-419">three years</ix:nonNumeric> for the remaining <ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-420">75</ix:nonFraction>% of the allocation until vested in full.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted share units granted on June 30, 2020 are subject to <ix:nonFraction unitRef="number" contextRef="c-107" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-421">25</ix:nonFraction>% vesting upon the earlier of (i) the <ix:nonNumeric contextRef="c-107" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-422">one year</ix:nonNumeric> anniversary of the date of grant, or (ii) the first day following the <ix:nonNumeric contextRef="c-108" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-423">six-month</ix:nonNumeric> anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is <ix:nonFraction unitRef="number" contextRef="c-108" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" scale="-2" id="f-424">20</ix:nonFraction>% higher than the listing price for at least <ix:nonFraction unitRef="day" contextRef="c-108" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-425">five</ix:nonFraction> consecutive trading days.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company was authorized to issue a total of <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-426">1,148,947</ix:nonFraction> ordinary shares underlying outstanding options granted under the 2017 Plan prior to our initial public offering, or IPO.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Share Purchase Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-427">340,053</ix:nonFraction> ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" scale="-2" id="f-428">1</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="f-429">510,080</ix:nonFraction> ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in our capitalization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2021, the Company launched the SIP, and the ESPP, through which employees can purchase shares at a discounted price. At the end of <ix:nonNumeric contextRef="c-112" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" format="ixt-sec:durwordsen" id="f-430">six months</ix:nonNumeric>, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a <ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-431">15</ix:nonFraction>% discount.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Share Option Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="f-409-2"><div style="margin-bottom:10pt;margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and other key persons (including consultants).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2020 Plan generally expire <ix:nonNumeric contextRef="c-113" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-432">10</ix:nonNumeric> years from the date of grant and typically vest over a <ix:nonNumeric contextRef="c-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-433">4</ix:nonNumeric> year service period with <ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-434">25</ix:nonFraction>% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-435">2,074,325</ix:nonFraction> of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to <ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" scale="-2" id="f-436">4</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by our compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-437">7,938,129</ix:nonFraction> shares as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-438">2,026,449</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares remained available for future grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted under the 2020 Plan to employees generally expire <ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-439">10</ix:nonNumeric> years from the date of grant. There are <ix:nonFraction unitRef="vestingcondition" contextRef="c-115" decimals="INF" name="cmps:NumberOfVestingConditions" format="ixt-sec:numwordsen" scale="0" id="f-440">three</ix:nonFraction> potential vesting terms for the grants including: (i) <ix:nonFraction unitRef="number" contextRef="c-117" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-441">25</ix:nonFraction>% per year over <ix:nonNumeric contextRef="c-117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-442">four year</ix:nonNumeric> service period, (ii) <ix:nonNumeric contextRef="c-118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-443">four year</ix:nonNumeric> service period with <ix:nonFraction unitRef="number" contextRef="c-118" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-444">25</ix:nonFraction>% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years, (iii) monthly vesting over <ix:nonNumeric contextRef="c-119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-445">four year</ix:nonNumeric> service period, (iv) monthly vesting over <ix:nonNumeric contextRef="c-120" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-446">three year</ix:nonNumeric> service period, and (v) <ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-447">100</ix:nonFraction>% vesting on the earlier of the next Annual General Meeting or the first anniversary of the grant date.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>2022 Inducement Option Award</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company granted a non-qualified share option to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-448">600,000</ix:nonFraction> ordinary shares as an inducement grant to our chief executive officer. The non-qualified share option has a <ix:nonNumeric contextRef="c-123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-449">10</ix:nonNumeric> year term and one-fourth vested on August 1, 2023 and the remaining three-fourths will vest in equal monthly installments over the following <ix:nonNumeric contextRef="c-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-450">36</ix:nonNumeric> months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#8217;s 2020 Plan and the Company&#8217;s standard form of non-qualified share option agreement.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-451" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.206%"><tr><td style="width:1.0%"/><td style="width:60.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-452">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-453">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-454">2,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-455">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-456">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-457">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_85"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-460" continuedAt="f-460-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-460-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-461" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:70.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-462">17,864</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-463">35,187</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of pre-funded warrant liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cmps:FairValueChangeOfPreFundedWarrantLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-464">5,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="cmps:FairValueChangeOfPreFundedWarrantLiabilities" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - diluted</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-466">23,497</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-467">35,187</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-468">89,192,252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-469">64,222,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Weighted-average pre-funded warrants</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-470">9,449,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" format="ixt:fixed-zero" scale="0" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - diluted</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-472">98,641,623</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-473">64,222,178</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-474">0.20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-475">0.55</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-476">0.24</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-477">0.55</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share by dividing net loss by the weighted-average number of shares outstanding. The Company computes diluted net loss per share by dividing net loss by the weighted-average number of shares and dilutive potential share equivalents then outstanding during the period. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within the weighted-average number of ordinary shares used in net loss per share for the three-months ended March 31, 2025, are ADSs issuable upon the exercise of the Pre-funded Warrants, as the Pre-funded Warrants are exercisable at any time for nominal consideration, and as such are considered outstanding for the purpose of calculating diluted net loss per share. There were no Pre-funded Warrants outstanding during the three-months ended March 31, 2024. The Company&#8217;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, options granted and warrants (other than the Pre-funded Warrants), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-478" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.690%"><tr><td style="width:1.0%"/><td style="width:61.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-479">1,003,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-480">647,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-481">9,093,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-482">8,187,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-483">49,073,719</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-484">12,418,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-485">59,170,255</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-486">21,254,085</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_91"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-487" continuedAt="f-487-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-487-1"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of March&#160;31, 2025 or December&#160;31, 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.</span></div></ix:continuation><div id="i387913fc30d8481bbd7cf8b08db88d3a_657"></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-488" continuedAt="f-488-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-488-1" continuedAt="f-488-2"><div style="margin-bottom:4pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-489">one</ix:nonFraction> operating segment. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-490" continuedAt="f-490-1" escape="true">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-490-1" continuedAt="f-490-2"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"/><td style="width:71.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Research and Development:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development expenses </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-491">21,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-492">13,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-493">6,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-494">6,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-495">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-496">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-497">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-498">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General and Administrative:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-499">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-500">5,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-501">9,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-502">2,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-503">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-504">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-505">2,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-506">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-507">49,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-508">38,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-509">49,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-510">38,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-511">19,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-513">8,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" sign="-" name="cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-514">3,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-515">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-516">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-517">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-518">783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" sign="-" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-519">1,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" sign="-" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-520">1,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-521">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-522">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-523">354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-524">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-525">17,864</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-526">35,187</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><ix:continuation id="f-490-2" continuedAt="f-490-3"><ix:continuation id="f-488-2" continuedAt="f-488-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-490-3"><ix:continuation id="f-488-3">Other expenses include subscriptions and memberships, consulting fees and company insurance.</ix:continuation></ix:continuation> <br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_665"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-527" continuedAt="f-527-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-527-1"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of a consulting agreement between the Company and Alithos, Inc., a company founded by our co-founder, former chief executive officer, former chairman of the board of directors and former greater than 5% shareholder, George Goldsmith, the Company provided consulting services to Alithos. Through March 31, 2025, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-528">0.6</ix:nonFraction>&#160;million in other income as a result of this transaction.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_103"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND&#160;RESULTS&#160;OF&#160;OPERATIONS</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_106"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"> You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the related notes to those statements included earlier in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. &#8220;Risk Factors&#8221; and the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">References to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;the Company&#8221; refer to Compass Pathways plc. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Operating Results</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Overview</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 psilocybin treatment, potentially a first in class treatment. COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our COMP360 psilocybin treatment could offer a new approach to treatment of serious mental health conditions, including treatment-resistant depression, or TRD, which is a subset of major depressive disorder, or MDD, post-traumatic stress disorder, or PTSD, and potentially many other serious mental health conditions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our initial focus is on TRD, comprising patients who are inadequately served by current treatment options. In 2018, we received Breakthrough Therapy designation from the FDA for COMP360 for the treatment of TRD. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">November 2021, we announced positive top-line results from our Phase 2b clinical trial evaluating COMP360 for the treatment of TRD. On November 3, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">The New England Journal of Medicine </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">published the positive results from our Phase 2b trial. This is the largest, randomized, controlled, double-blind psilocybin treatment clinical trial completed to date. The objective of the Phase 2b study was to evaluate the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. The trial achieved its primary endpoint for the 25mg dose, with a 25mg dose of COMP360 demonstrating a statistically significant and clinically relevant treatment difference against the 1mg dose of COMP360 in reducing depressive symptom severity after three weeks.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">At the beginning of 2023, we commenced our Phase 3 program evaluating our COMP360 psilocybin treatment in TRD. The Phase 3 program is composed of two pivotal trials, each with a long-term follow-up component. The pivotal program design is as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226; Pivotal trial 1 (COMP005) (n=258): a single dose (25mg) monotherapy compared with placebo. In April 2025, we announced that all participants had completed dosing in Part A of this trial. We expect to report top-line 6 week primary endpoint results in late June 2025 and then the 26-week data once all participants in the COMP006 trial have completed Part A of the COMP006 trial.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226; Pivotal trial 2 (COMP006) (n= 568): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg. This trial is designed to investigate whether a second dose can increase therapeutic response. We expect to report top-line data by the second half of 2026.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226; The primary endpoint in both pivotal trials is the change from baseline in the MADRS (Montgomery-&#197;sberg Depression Rating Scale) total score at week 6.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Beyond TRD, we have been exploring other indications, including PTSD. In May 2024, we completed and announced top-line results from our open label Phase 2 study</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> to assess the safety and tolerability of COMP360 psilocybin treatment in participants with PTSD, as a result of trauma experienced as adults. In line with the study design, the study enrolled 22 participants who were monitored for a 12-week period post dosing. The study met its primary safety endpoint and available secondary efficacy endpoints. Study observations included meaningful and sustained symptom improvement from baseline in mean CAPS-5 total score, a measure of disease severity, and in Sheehan Disability Scale (SDS) score, a measure of functional impairment in daily life. Administration of COMP360 was well-tolerated, with a safety profile consistent with previous studies of COMP360. Based on the data from this trial, we are in the process of designing a late-stage PTSD program.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Since our formation, we have devoted substantially all of our resources to conducting preclinical studies and clinical trials, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. We do not have any therapeutic candidates approved for sale and have not generated any revenue. We have funded our operations primarily with proceeds from the sale of our ordinary shares, ADSs, including in our offerings pursuant to our at-the-market, or ATM, offering program, proceeds from a loan agreement with Hercules, or the Hercules Loan Agreement, and proceeds from a private placement transaction, or the PIPE. We were party to a Sales Agreement for our ATM offering program, dated October 8, 2021, with TD Securities (USA) LLC, or TD Cowen, under which we were able to issue and sell from time to time up to $150.0&#160;million of our ADSs, each representing one ordinary share, through TD Cowen, as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">hrough February 27, 2025, we sold 5,491,836 ADSs under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">our ATM offering program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, resulting in $54.8&#160;million in net proceeds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 27, 2025, we entered into a new Sales Agreement under which we may issue and sell from time to time up to $150.0 million of our ADSs, subject to the terms of the Sales Agreement. Sales of our ADSs, if any, will generally be made at market prices. To date, we have not sold any ADSs under this Sales Agreement.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into the Hercules Loan Agreement, which provided for aggregate maximum borrowings of up to $50.0&#160;million, including a term loan of $30.0&#160;million, which was funded on June 30, 2023. On August 16, 2023, we entered into a Securities Purchase Agreement, pursuant to which we agreed to sell and issue in a private placement transaction (i) 16,076,750 ADSs and (ii) PIPE Warrants to purchase up to 16,076,750 ADSs, at a purchase price of approximately $7.78 per ADS and accompanying PIPE Warrant to purchase one ADS. Each PIPE Warrant has an exercise price of $9.93 per ADS and is exercisable for a three year period beginning in February 2024. The PIPE Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the PIPE Warrants. Through March&#160;31, 2025, PIPE Warrants were exercised for 3,752,050 ADS, resulting in $37.3 million in exercise proceeds. We will receive up to an additional approximately $122.4 million in gross proceeds if the PIPE Warrants are fully exercised. During the three months ended March 31, 2025, no PIPE warrants were exercised.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we issued and sold (i) 24,014,728 ADSs and accompanying warrants to purchase up to 24,014,728 ADSs, and (ii) in lieu of ADSs, to certain investors, Pre-funded Warrants to purchase up to 11,044,720 ADSs and accompanying 2025 ADS Warrants to purchase up to 11,044,720 ADSs. The offering price was $4.2750 per ADS and accompanying 2025 ADS Warrant, and $4.2649 per Pre-funded Warrant and accompanying 2025 ADS Warrant. The Pre-funded Warrants have an exercise price of $0.0001 per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $5.7960 per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after three years. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#8217;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the Company&#8217;s ADSs on Nasdaq exceeded the warrant exercise price of $5.7960 for the three consecutive trading days prior to the date on which the notice of forced exercise is delivered.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred recurring losses since our inception, including net losses of $17.9 million and $35.2 million for the three months ended March 31, 2025 and 2024, respectively. In addition, as of March&#160;31, 2025, we had an accumulated deficit of $552.6 million. Our historical losses resulted principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. In the future, we intend to continue to conduct research and development, preclinical testing, clinical trials, regulatory compliance, market access and commercialization activities that, together with anticipated general and administrative expenses, will result in incurring further significant losses for at least the next several years. Our operating losses stem primarily from development of our investigational COMP360 psilocybin treatment for TRD, and we expect they will continue to increase as we conduct our Phase 3 program in TRD for our investigational COMP360 psilocybin treatment candidate. In addition, although our non-COMP360 preclinical efforts have been stopped, in connection with the strategic reorganization that took place in the fourth quarter of 2024, our spending in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future may increase if we choose to expand into additional indications or initiate the development for different therapeutic candidates. Furthermore, since the completion of our IPO, we have incurred, and expect to continue to incur, significant costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result, we will need substantial additional funding in the longer term to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of therapeutic candidates, if ever, we expect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finance our operations through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, we had cash and cash equivalents of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$260.1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> million. We believe that our existing cash and cash equivalents will be sufficient for us to fund our operating expenses and capital expenditure requirements at least through the planned 26-week data read-out from our COMP006 study, which is expected in the second half of 2026. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources&#8212;Funding Requirements&#8221; below.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Macroeconomic Conditions and Changes in Regulatory Landscape</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We continue to monitor current macroeconomic and geopolitical events, including, among others, fluctuating inflation and interest rates, instability in the banking system and the related impact on U.S. and global economies, fluctuations in foreign exchange rates, significant changes in U.S. policies or regulatory environment or disruption for U.S government agencies, the risk of economic slowdown or recession in the U.S., significant changes in geopolitics and international tensions, including from the effects from announced or future tariff increases, the ongoing war between Ukraine and Russia and conflict in the Middle East, for any potential impact that these or other events or conditions may have on our business.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Changes in policy or resources of governmental agencies, including, but not limited to, changes at the FDA, DEA, SEC and U.S. Patent and Trademark Office,  could impact our business and results of operations. The Trump administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of our current product or future products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. In addition, the ability of the DEA to inspect clinical trial sites and issue controlled substance licenses to our clinical trial sites in a timely manner and the ability of FDA to review and clear or approve new products has in the past and may in the future be affected by changes in government budget and funding levels, the ability of the government to hire and retain key personnel, and shifting policy priorities. If we become negatively impacted by future governmental orders, regulations, policies or guidance as a result of the Trump administration, there could be a material adverse effect on us and our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to raise additional funds may be adversely impacted by macroeconomic conditions and geopolitical events, changing regulatory conditions, including potential impacts of regulatory agency staffing cuts and policy changes on regulatory feedback and timing thereof, and disruptions to and volatility in the credit and financial markets in the U.S. and worldwide. Failure to raise capital or secure other funding as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that our current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_109"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Components of Our Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Revenue</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">To date, we have not generated any revenue and do not expect to generate any revenue from the sale of therapeutic candidates in the near future. If our development efforts for our investigational COMP360 psilocybin treatment are successful and result in regulatory approval of COMP360, we may generate revenue in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Operating Expenses</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Research and Development </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Research and development activities are central to our business model. Product or therapeutic candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product manufacturing expenses. As a result, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">expect that our research and development expenses will continue to increase as we seek to complete the clinical development for our investigational COMP360 psilocybin treatment for TRD and prepare for regulatory filings related to our potential or future therapeutic candidates.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The successful development and commercialization of our investigational COMP360 psilocybin treatment is highly uncertain. This is due to the numerous risks and uncertainties associated with development and commercialization, including the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical trials and preclinical studies, including our Phase 3 clinical trials in TRD;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials, including our Phase 3 clinical trials in TRD, and our ability to raise capital on favorable terms or at all;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving regulatory approvals or clearance for conducting our planned clinical trials or future clinical trials;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving positive data from our clinical trials that support an acceptable risk-benefit profile of COMP360 psilocybin treatment and any future therapeutic candidates in the intended patient populations;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and scaling up, through third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any therapeutic candidates are approved;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into collaborations to further the development of our investigational COMP360 psilocybin treatment and our future therapeutic candidates;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for COMP360 and any future therapeutic candidates;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching commercial sales of our investigational COMP360 psilocybin treatment and any future therapeutic candidates, if approved;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our current and future therapeutic candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our investigational COMP360 psilocybin treatment and our future therapeutic candidates following approval.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A change in the outcome of any of these variables, amongst others, with respect to the development of our investigational COMP360 psilocybin treatment in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of our investigational COMP360 psilocybin treatment. For example, if the FDA, the European Medicines Agency, or EMA, the Medicines and Healthcare products Regulatory Agency, or MHRA, or another regulatory authority were to require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience additional significant delays in enrollment in any of our planned clinical trials, we could be required to commit significant additional financial resources and time on the completion of clinical development of that therapeutic candidate.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">General and Administrative </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We anticipate we will continue to incur significant accounting, audit, legal, regulatory and compliance costs, as well as investor and public relations expenses associated with being a public company. In the short-term, we expect reduced personnel expenses as a result of the reorganization that we undertook in the fourth quarter of 2024. However, in the long-term, we anticipate future increases in both personnel and other expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our therapeutic candidate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Other Income, Net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Benefit from Research and Development Tax Credit</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Benefit from R&amp;D tax credit consists of the R&amp;D tax credit received in the UK, which is recorded within other income, net. As a company that carries out extensive research and development activities, we seek to benefit from the Small and Medium sized Enterprise, or SME, Program and from January 1, 2025, the new merged regime. Qualifying expenditures largely comprise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Based on criteria established by His Majesty&#8217;s Revenue and Customs, or HMRC, a portion of expenditures being recognized in relation to our pipeline research and development, clinical trial management and third-party manufacturing development activities were eligible for the SME regime for the three months ended March 31, 2025 and 2024. We expect such elements to be eligible for R&amp;D incentives under the new merged regime in the year ended December 31, 2025 although there may be some limitations on expenditure on activities undertaken outside the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The UK R&amp;D tax credit is fully refundable to us and is not dependent on current or future taxable income. As a result, we have recorded the entire benefit from the UK research and development tax credit as a benefit which is included in our net loss before income tax and, accordingly, not reflected as part of the income tax provision. If, in the future, any UK R&amp;D tax credits generated are needed to offset a corporation tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income, net.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income relates to interest earned on cash deposits.</span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense relates to interest paid on debt.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value changes of warrant liabilities</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value changes in warrant liabilities is attributable to the warrant liabilities which are subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value will be recognized in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains (losses)</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Foreign exchange gains (losses) consist of foreign exchange impacts arising from foreign currency transactions, primarily related to the translation of intercompany balances as a result of a change in our functional currency, as well as bank balances held in a foreign currency.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Corporate Income Tax Expense</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are subject to corporate taxation in the U.S. and the UK (known as corporation tax in the UK). Due to the nature of our business, we have generated losses since inception and have therefore not been required to pay UK corporation tax. Our corporate income tax expense represents only income taxes in the U.S.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Unsurrendered UK losses may be carried forward indefinitely and may be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits. After accounting for tax credits receivable, we had accumulated trading losses for carry forward in the UK of $339.7 million and $252.3 million as of December&#160;31, 2024 and 2023, respectively, which is offset by a full valuation allowance.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the three months ended March 31, 2025 and 2024, we recorded a tax provision of $0.4 million and $0.2 million, respectively, related to the corporate income tax obligations of our operating company in the U.S., which generates a profit for tax purposes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_112"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,573)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER INCOME, NET:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,510)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,965)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,864)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,187)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison For The Three Months Ended March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d 2024<br/></span></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Research and development expenses consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"/><td style="width:52.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities and other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">three months ended March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, the increase in research and development expenses, as compared to the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, was primarily attributable to the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">an increase in development expenses associated with advancing our late-stage COMP360 clinical trials;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partially offset by:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in personnel expenses and non-cash share based compensation expense as a result of decreased staffing levels associated with the reorganization that took place in the fourth quarter of 2024.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development costs to continue to increase substantially at least through completion of our Phase 3 program for COMP360 psilocybin therapy in TRD.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:2pt;margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">General and administrative expenses consist of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the three months ended March 31, 2025, the increase in general and administrative expenses, as compared to the same period in 2024, was primarily attributable to the following: </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">an increase in legal and professional fees, primarily related to issuance costs related to the 2025 Financing as well as expenses associated with consulting, accounting and legal advice.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partially offset by:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in facilities and other expenses, primarily due to lower subscription and memberships needs following the reorganization that took place in the fourth quarter of 2024; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in personnel expenses and non-cash share based compensation expense as a result of decreased staffing levels associated with the reorganization that took place in the fourth quarter of 2024,</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We expect to continue to incur significant general and administrative expenses as a result of ongoing requirements as a public company, in addition to ongoing general and administrative support for research and development activities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Other income, net consists of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.985%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,106&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,498&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, the increase in other income, net, as compared to the same periods in 2024, was primarily attributable to the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">an increase due to the change in fair value of the warrant liabilities during the period, related to the warrants issued in the 2025 Financing; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the benefit from R&amp;D tax credit due to higher R&amp;D expenditures claimed at the enhanced research intensive rate in the current year as well as a resubmission of the Company&#8217;s 2023 claim at the enhanced rate given clarity provided by HMRC in the current year; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">an increase due to foreign exchange gains following remeasurement of foreign currency denominated assets and liabilities.<br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_115"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are a clinical-stage biotechnology company and we have not yet generated any revenue to date. We have incurred significant operating losses since our formation. We have not yet commercialized any therapeutic candidates and we do not expect to generate revenue from sales of any therapeutic candidates in the near future, if at all. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We have primarily funded our operations with proceeds from the sale of our ordinary shares, ADSs, including our ATM offering program, proceeds from the Hercules Loan Agreement, and proceeds from the PIPE. The ATM offering program allows us to issue and sell from time to time up to $150.0&#160;million of our ADSs. Pursuant to the Sales Agreement dated October 8, 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">hrough February 27, 2025, we sold 5,491,836 ADSs under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">our ATM offering program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, resulting in $54.8&#160;million in net proceeds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 27, 2025, we entered into a new Sales Agreement under which we may issue and sell from time to time up to $150.0 million of our ADSs, subject to the terms of the Sales Agreement. Sales of our ADSs, if any, will generally be made at market prices. To date, we have not sold any ADSs under this Sales Agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Hercules Loan Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">provided for aggregate maximum borrowings of up to $50.0&#160;million, of which we have funded $30.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Within the PIPE agreement, we agreed to sell and issue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> PIPE Warrants to purchase up to 16,076,750 ADSs. Each PIPE Warrant has an exercise price of $9.93 per ADS and is exercisable for a three year period beginning in February 2024. Through March&#160;31, 2025, PIPE Warrants were exercised for 3,752,050 ADS, resulting in $37.3 million in exercise proceeds. We will receive up to an additional approximately $122.4 million in gross proceeds if the PIPE Warrants are fully exercised. In January 2025, we completed the 2025 Financing in which it issued and sold ADSs and, in lieu of ADSs, Pre-funded Warrants to certain investors along with accompanying 2025 ADS Warrants to purchase ADSs. The 2025 ADS Warrants have an exercise price of $5.7960 per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after three years. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#8217;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the Company&#8217;s ADSs on Nasdaq exceeded the warrant exercise price of $5.7960 for the three consecutive trading days prior to the date on which the notice of forced exercise is delivered.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than our operating leases, and debt obligations under our Loan Agreement with Hercules described in the footnotes to our condensed consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Cash Flows</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following table summarizes our cash flows for each of the periods (in thousands):</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.017%"><tr><td style="width:1.0%"/><td style="width:58.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,657)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,829)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"><br/>&#160;&#160;&#160;&#160;Net Cash Used in Operating Activities</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash used in operating activities increased during the three months ended March 31, 2025, compared to the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2024, primarily due to unfavorable working capital related activities of $25.7 million, as well as an increase of $16.5 million of non-cash adjustments, including the change in fair value of warrant liabilities of $19.5 million, which was offset by a $17.3 million decrease in our net loss.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.823%"><tr><td style="width:1.0%"/><td style="width:6.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:-20.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Net cash provided by financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">activities increased during the three months ended March 31, 2025, compared to the same period in 2024, primarily as a result of proceeds from the 2025 Financing for the issuance of ADSs and proceeds from the Pre-funded Warrants of $140.4 million, partially offset by the proceeds from the issuance of ordinary shares to settle warrants exercised of $26.2 million and the proceeds from the exercise of warrants of $37.3 million in 2024. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Funding Requirements</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We expect our expenses to continue to increase substantially in connection with our ongoing activities, particularly as we continue to advance our Phase 3 program of COMP360 in TRD and clinical and preclinical activities supporting studies and related preparatory work for an NDA filing, as well as manufacturing activities and commercial preparedness activities. In addition, we expect to continue to incur significant costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. Our expenses will also increase as we:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">continue to advance our Phase 3 program for investigational COMP360 psilocybin treatment in TRD and clinical and preclinical supporting studies and related preparatory work for the NDA filing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate and advance a late-stage development program in PTSD;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">continue the training of qualified healthcare professionals to monitor and safeguard participants in our Phase 3 program and other clinical trials; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">service our outstanding indebtedness;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">may in the future resume and pursue research and development programs for our other preclinical stage therapeutic candidates and discovery-stage programs;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">may in the future invest in further discovery efforts and/or develop additional therapeutic candidates;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any therapeutic candidates for which we may obtain regulatory approval, including COMP360; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">advance our commercialization strategy; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">establish and expand the network of public healthcare institutions and private clinics that administer our investigational COMP360 psilocybin treatment in conjunction with psychological support if approved;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">seek regulatory approvals for any future therapeutic candidates that successfully complete clinical trials; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">experience heightened regulatory scrutiny;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">pursue necessary scheduling-related decisions by the U.S. Drug Enforcement Administration, or the DEA, and various state governments to enable us to commercialize any therapeutic candidates containing controlled substances for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">obtain, maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent or other intellectual property infringement claims; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our therapeutic development and potential future commercialization efforts; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">experience any delays or encounter any issues with respect to any of the above, including failed studies, ambiguous trial results, safety issues or other regulatory challenges, including, for example, delays and other impacts as a result of pandemics or other public health crises;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">expand our operations in the U.S. and Europe in the future; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.823%"><tr><td style="width:1.0%"/><td style="width:6.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:-20.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as an English-domiciled public company listed in the U.S.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, we had cash and cash equivalents of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">$260.1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> million. We believe that our existing cash and cash equivalents will be sufficient for us to fund our operating expenses and capital expenditure requirements at least through the planned 26-week data read-out from our COMP006 study, which is expected in the second half of 2026. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. As we progress with our development programs and the regulatory review process, we expect to incur significant commercialization expenses related to product manufacturing, pre-commercial activities and commercialization.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Because of the numerous risks and uncertainties associated with research, development and commercialization of therapeutic candidates and programs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the progress, timing and completion of our Phase 3 program for our current investigational COMP360 psilocybin treatment program for TRD, and clinical and preclinical supporting studies and related preparatory work for the NDA filing;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA, the EMA, the MHRA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the outcome and timing of any scheduling-related decisions by the DEA, individual states, and comparable foreign authorities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the number of potential new therapeutic candidates we may choose to pursue and identify in the future and decide to develop, either internally through our research and development efforts or externally through acquisitions, licensing or other collaboration agreements;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs involved in growing our organization in the long-term to the size needed to prepare for the potential commercialization of our investigational COMP360 psilocybin treatment and future therapeutic candidates, including increases to personnel costs;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs of developing sales and marketing capabilities to target public and private healthcare providers and clinic networks in major markets;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs of training and qualifying healthcare professionals to monitor and safeguard participants receiving our investigational COMP360 psilocybin treatment in our Phase 3 program and other clinical trials;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs of establishing and maintaining research collaborations, such as our Centers of Excellence and the Center for Mental Health Research, which includes conducting clinical trials, including proof of concept studies, to refine our treatment delivery model; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the time and costs involved in generating and collecting data and advancing and defending our intellectual property portfolio, including the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringements or invalidity raised by third parties;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs of developing, testing and deploying digital technology solutions or paying a third-party to provide such digital technology solutions to improve the patient experience and therapeutic process via third-party vendors or internally;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for COMP360 or any future therapeutic candidates, and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to COMP360 or any future therapeutic candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.823%"><tr><td style="width:1.0%"/><td style="width:6.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:-20.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the amount of revenue, if any, we may derive either directly or in the form of royalty, milestone or other payments from future sales of our investigational COMP360 psilocybin treatment and any future therapeutic candidates, if approved; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the impact of macroeconomic and geopolitical events, including, among others, fluctuating inflation and interest rates, fluctuations in foreign exchange rates, and the risk of economic slowdown or recession in the U.S., international tensions and changes in governmental policies, including the effects of announced or future tariff increases; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the costs of operating as a public company.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available at all or on acceptable terms. To the extent that we raise additional capital through the sale of equity, current ownership interests will be diluted. If we raise additional funds through government or third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish future revenue streams, research programs or therapeutic candidates or grant licenses on terms that may not be favorable to us. Debt financing, if available, may involve high interest rates or agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_118"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2025, our significant accounting policies or critical accounting estimates have been updated to include warrant liabilities, as described below. For a complete discussion of our other significant accounting policies and critical accounting estimates, see the &#8220;Critical Accounting Policies and Significant Judgments and Estimates&#8221; section of the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation in our Form 10-K for the year ended December&#160;31, 2024, which we filed with the SEC on February 27, 2025.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We account for the warrants in accordance with the guidance contained in ASC Topic 815-40-15-7D, (&#8220;Derivatives and Hedging&#8221;), under which the warrants that do not meet the criteria for equity treatment must be recorded as liabilities. Accordingly, we classify the warrants as liabilities at their fair value and adjust the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value will be recognized in our condensed consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes pricing model. These values are subject to a significant degree of management&#8217;s judgment.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The warrant liabilities are classified as non-current on the condensed consolidated balance sheets due to the underlying warrants having expiration dates beyond 12 months from the reporting date and it is not reasonably expected that the Company would be required to use existing resources classified as current assets, or create other current liabilities, to settle the warrant liabilities at this time. Management reviews the classification of warrant liabilities at each reporting period to determine whether any change in classification is warranted based on changes in facts or circumstances, including the proximity to expiration or likelihood of exercise.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.823%"><tr><td style="width:1.0%"/><td style="width:6.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:-20.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_121"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Smaller Reporting Company Status</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. As a result, we may take advantage of certain of the scaled disclosures available to smaller reporting companies. These include, but are not limited to, reduced disclosure obligations regarding executive compensation and an exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures. As a smaller reporting company with annual revenues of less than $100.0 million and a non-accelerated filer, we are also not required to provide an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will be able to take advantage of these scaled disclosures and exemptions for so long as (i) our voting and non-voting shares held by non-affiliates is less than $250.0 million measured on the last business day of our most recent second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting shares held by non-affiliates is less than $700.0 million measured on the last business day of our most recent second fiscal quarter. </span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_124"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">There have been no material changes in market risk exposures that affect the disclosures presented in Part II, Item 7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024.</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_127"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March&#160;31, 2025. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the&#160;Exchange Act&#160;is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">There were no changes in our internal control over financial reporting during the three months ended March 31, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.823%"><tr><td style="width:1.0%"/><td style="width:6.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:-20.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_130"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:292%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_133"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We are not currently a party to any litigation or claims that we believe, if determined adversely to us, would have a material adverse effect on our business, operating results, financial condition or cash flows. From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.<br/></span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_559"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">You should carefully consider the following risk factors as well as the other information included in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our condensed consolidated financial statements and related notes thereto. Any of the following risks could materially and adversely affect our business, financial condition, or results of operations. The selected risks described below, however, are not the only risks facing us. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial may also materially and adversely affect our business, financial condition, or results of operations. The summary of the material risks associated with our business is included in the &#8220;Special Note Regarding Forward-Looking Statements&#8221; on page 4 above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We are a clinical-stage biotechnology company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are a clinical-stage biotechnology company and we have not generated any revenue to date. We have incurred significant operating losses since our formation. We incurred total net losses of $17.9 million for the three months ended March 31, 2025 and $35.2 million for the three months ended March 31, 2024. As of March&#160;31, 2025, we had an accumulated deficit of $552.6 million. Our historical losses resulted principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. During the term of our Pre-funded Warrants and ADS Warrants, which were issued in January 2025 and are classified as liabilities, our net loss can change significantly quarter to quarter due to non-cash increases or decreases in the fair value of these warrants. We intend to continue to conduct research and development, clinical trials, regulatory compliance, market access and commercialization activities that, together with anticipated general and administrative expenses, will result in incurring further significant operating losses for at least the next several years. Our expected operating losses, among other things, may continue to cause our working capital and shareholders&#8217; equity to decrease. We anticipate that our expenses will increase substantially if and as we, among other things: </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">continue to advance our Phase 3 program for investigational COMP360 psilocybin treatment in TRD and clinical and preclinical supporting studies and related preparatory work for the NDA filing; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">initiate and advance a late-stage development program in PTSD;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-left:36pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.790%"><tr><td style="width:1.0%"/><td style="width:5.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">continue the training of qualified healthcare professionals to provide psychological support in our Phase 3 program and other clinical trials;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">service our outstanding indebtedness; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">may in the future resume and pursue research and development programs for our other preclinical stage therapeutic candidates and discovery-stage programs and/or develop and seek regulatory approval for any future therapeutic candidates that successfully complete clinical trials;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any therapeutic candidates for which we may obtain regulatory approval, including COMP360;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">advance our commercialization strategy;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">establish and expand the network of public healthcare institutions and private clinics that administer our investigational COMP360 psilocybin treatment in conjunction with psychological support if approved; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">experience heightened regulatory scrutiny; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">pursue necessary scheduling-related decisions by the U.S. Drug Enforcement Administration, or the DEA, and various state governments to enable us to commercialize any therapeutic candidates containing controlled substances for which we may obtain regulatory approval, including COMP360; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">obtain, maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent or other intellectual property infringement claims;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our therapeutic development and potential future commercialization efforts;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">experience any delays or encounter any issues with respect to any of the above, including failed studies, ambiguous trial results, safety issues or other regulatory challenges, including, for example, delays and other impacts as a result of pandemics or other public health crises; </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">expand our operations in the U.S. and Europe in the future; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as an English-domiciled public company listed in the U.S. <br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have funded our operations since our initial public offering, or IPO, in 2020, through public equity offerings, private placements of ADSs and warrants and debt financing. To become and remain profitable, we will need to continue developing and eventually commercialize treatments that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing our Phase 3 program of COMP360 in TRD and other clinical trials of COMP360 or any future therapeutic candidates, training a sufficient number of qualified healthcare professionals to monitor and safeguard participants in our clinical trials, discovering and developing any future therapeutic candidates, obtaining regulatory approval for COMP360 psilocybin treatment and any future therapeutic candidates that successfully complete clinical trials, and establishing marketing capabilities. Even if COMP360 psilocybin treatment or any of the future therapeutic candidates that we may develop are approved for commercial sale, we anticipate incurring significant costs associated with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">36</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">commercializing COMP360 or any other approved future therapeutic candidate. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Because of the numerous risks and uncertainties associated with therapeutic development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the EMA, the MHRA, or other comparable foreign authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, our expenses could increase beyond our current expectations and revenue could be further delayed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Even if we or any future collaborators do generate sales, we may never achieve, sustain or increase profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our ADSs and could impair our ability to raise capital, repay our outstanding indebtedness, expand our business, diversify our therapeutic offerings or continue our operations. If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. Failure to obtain additional funding when needed or on favorable terms may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">or grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We expect to require substantial additional funding in the future to sufficiently finance our operations and to complete the development and commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. Under the terms of the 2025 ADS Warrants, following the time when the 2025 ADS Warrants become exercisable and provided the closing price of our ADSs is above the warrant exercise price of $5.7960 per ADS for at least three consecutive trading days, we may elect to force the exercise of some or all of the 2025 ADS Warrants. If we force the exercise of all of the 2025 ADS Warrants, we would receive an additional $203.2 million in gross proceeds. However, we cannot predict if we will have the ability to force the exercise of the 2025 ADS Warrants. We are only permitted to force the exercise of the 2025 ADS Warrants following the public release of the 26-week results from our COMP005 clinical study and only if the closing price of our ADSs is greater than the 2025 ADS Warrant exercise price of $5.7960 per ADS for each of the three consecutive trading days prior to the delivery of the forced exercise notice. Therefore, we have not included any anticipated proceeds from such exercises of the 2025 ADS Warrants in our estimate of our cash runway. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">f the outstanding PIPE Warrants are exercised in full for cash, we would receive an additional $122.4 million in gross proceeds. However, because the holders of the PIPE Warrants are not obligated to exercise such warrants, we have not included any anticipated proceeds from such exercises of PIPE Warrants in our estimate of our cash runway.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We expect that our cash and cash equivalents of $260.1 million as of March&#160;31, 2025, will enable us to fund our operating expenses and capital expenditure requirements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">at least through the planned 26-week data read-out from our COMP006 study, which is expected in the second half of 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">. We have experienced delays in our Phase 3 program in the past and if we experience additional delays in the future, we may not have sufficient cash and cash equivalents to fund our operating expenses and capital requirements through completion of the 26-week data read-out from our COMP006 study. We have based our estimated cash runway on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">37</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, such as fluctuating inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the progress, timing and completion of our Phase 3 program for our current investigational COMP360 psilocybin treatment program for TRD and clinical and preclinical supporting studies and related preparatory work for the NDA filing; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the design, size and timing of the late-stage development program in PTSD that we plan to initiate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA, the EMA, the MHRA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed to;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the outcome and timing of any scheduling-related decisions by the DEA, individual states, and comparable foreign authorities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the number of potential future therapeutic candidates we may choose to pursue and identify in the future and decide to develop, either internally through our research and development efforts or externally through acquisitions, licensing or other collaboration agreements; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the costs involved in growing our organization in the long-term to the size needed to prepare for the potential commercialization of our investigational COMP360 psilocybin treatment and any future therapeutic candidates, including increases to personnel costs; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the costs of developing sales and marketing capabilities in the long-term to target public and private healthcare providers and clinic networks in the U.S. and other major markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the costs of training qualified healthcare professionals to monitor and safeguard participants in our Phase 3 program and other clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the costs of establishing and maintaining research collaborations, such as our Centers of Excellence and the Center for Mental Health Research, which includes conducting clinical trials, including proof of concept studies, to refine our treatment delivery model; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the time and costs involved in generating and collecting data and advancing and defending our intellectual property portfolio, including the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringements or invalidity raised by third parties;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:14.5pt">the costs of developing, testing and deploying digital technology solutions or paying a third-party to provide such technology solutions to improve the patient experience and therapeutic process via third-party service providers or internally;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">38</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for COMP360 or any future therapeutic candidates, and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to COMP360 or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the potential commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the amount of revenue, if any, we may derive either directly or in the form of royalty, milestone or other payments from future sales of our investigational COMP360 psilocybin treatment and any future therapeutic candidates, if approved; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the impact of macroeconomic and geopolitical events, including, among others, fluctuating inflation and interest rates, fluctuations in foreign exchange rates, and the risk of economic slowdown or recession in the U.S., international tensions and changes in governmental policies, including the effects of announced or future tariff increases; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the costs of operating as a public company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, strategic collaborations and alliances, licensing arrangements or monetization transactions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our ability to raise additional funds when needed and on acceptable terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. For example, the volatile capital markets environment, lower prices for many securities, fluctuating inflation and interest rates, concerns about potential recessionary factors may affect our ability to raise additional funding, including through the exercise for cash of the 2025 ADS Warrants and/or PIPE Warrants, sales of our securities or issuance of indebtedness, which may harm our liquidity, force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization planning efforts or cause us to grant rights to develop and market products or therapeutic candidates that we would otherwise prefer to develop and market ourselves. If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or our investigational COMP360 psilocybin treatment or any future therapeutic candidate, or we may be unable to take advantage of future business opportunities. Market volatility, geopolitical tensions, such as those resulting from the ongoing war between Ukraine and Russia, conflict in the Middle East, changes in governmental policies, including the effects of announced or future tariff increases, fluctuating inflation and interest rates, instability in the banking system, and the related impact on U.S. and global economies, the risk of economic slowdown or recession in the U.S., the potential for significant changes in U.S. policies or regulatory environment or disruption for U.S. government agencies or other factors could also adversely impact our ability to access capital as and when needed or increase our costs in order to raise capital.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We cannot guarantee that future financing will be available in sufficient amounts, or on commercially reasonable terms, or at all. Recent capital market conditions, including the impact of inflation, have increased borrowing rates compared to rates in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">39</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">the recent past and can be expected to significantly increase our cost of capital as compared to prior periods. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our ADSs, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline. Our Loan Agreement with Hercules includes, and any future debt financing, if available, may involve agreements that include affirmative and negative restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. For example, our Loan Agreement with Hercules contains financial covenants requiring us to maintain a minimum cash balance of $22.5&#160;million and we will need to raise additional financing or significantly reduce our operating expenses to maintain compliance with this financial covenant. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to COMP360 or any future therapeutics candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, heightened regulatory scrutiny, regulatory delays or uncertainty in the regulatory environment could have a negative impact on our ability to raise capital. Our business activities rely on developing laws and regulations in multiple jurisdictions. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding our investigational COMP360 psilocybin treatment or any future therapeutic candidates may adversely affect our business and operations, including without limitation, our ability to raise additional capital.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Outstanding warrants for our securities may not be exercised and we may not receive any additional funds upon the exercise of outstanding warrants.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As of March 31, 2025, we had 12,324,700 outstanding PIPE Warrants. The holders of the outstanding PIPE Warrants are not obligated to exercise the PIPE Warrants, so we may not receive any additional proceeds from the PIPE. The PIPE Warrants are exercisable for a three year period ending in February 2027 and have an exercise price of $9.93, which is significantly higher than the current trading price of our ADSs. We believe the likelihood that these holders will exercise the PIPE Warrants, and therefore any cash proceeds that we may receive in relation to the exercise of such PIPE Warrants, will be dependent on the trading price of our ADSs relative to the exercise price. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In our 2025 Financing, we issued and sold an aggregate of 35,059,448 2025 ADS Warrants which have an exercise price of $5.7960 per ADS. The 2025 ADS Warrants are not yet exercisable and will become exercisable following the public release of the 26-week results from our COMP005 clinical study. The 2025 ADS Warrants will expire after three years. Once the 2025 ADS Warrants become exercisable, we may force the exercise of the 2025 ADS Warrants, in whole or in part, by delivering a notice of forced exercise to the holders if our ADS price is above the warrant exercise price, which is $5.7960, for the three prior consecutive trading days prior to the delivery of the forced exercise notice. Even though we have the right to force the exercise of the 2025 ADS Warrants, the 2025 ADS Warrants may never become exercisable and even if exercisable, the closing price of our ADSs may never exceed the exercise price of the 2025 ADS Warrant for three consecutive trading days, in which case we would not be able to force the exercise of the 2025 ADS Warrants. In addition, there is no guarantee holders </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">40</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">will elect to exercise the 2025 ADS Warrants, in the event we are not able to or choose not to force the exercise of such warrants. We believe that whether the holders elect to exercise the 2025 ADS Warrants is dependent on the trading price of our ADSs relative to the exercise price and the trading price of our ADSs may not exceed the exercise price of the 2025 ADS Warrants prior to their expiration. Thus, the 2025 ADS Warrants may expire unexercised and we may never receive any additional proceeds.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, the PIPE Warrants and the 2025 ADS Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the PIPE Warrants and 2025 ADS Warrants, respectively, in which case we would not receive any additional proceeds. If the PIPE Warrants and the 2025 ADS Warrants are not exercised for cash, or only a portion of the PIPE Warrants or the 2025 ADS Warrants are exercised for cash, we would need to obtain additional funding from other sources and may need to raise funds earlier than expected. Further, changing circumstances, some of which may be beyond our control, such as fluctuating inflation and interest rates, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Adequate additional financing may not be available to us on acceptable terms or at all.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We will not receive any meaningful amount of additional funds upon the exercise of the Pre-funded Warrants; however, any exercise would increase the number of ADSs outstanding and result in dilution to our existing shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In our 2025 Financing, we issued and sold 11,044,720 Pre-funded Warrants. Each Pre-funded Warrant will be exercisable until it is fully exercised and by means of a cash payment of the exercise price of $0.0001 per ADS or by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of ADSs representing ordinary shares determined according to the formula set forth in the Pre-funded Warrant. Accordingly, we will not receive any meaningful, or potentially any, additional funds upon the exercise of the Pre-funded Warrants. To the extent such Pre-funded Warrants are exercised, additional ADSs will be issued for nominal or no additional consideration, which will result in dilution to the then existing holders of our ADSs and will increase the number of ADSs and ordinary shares outstanding. </span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our history as a clinical stage company may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We were formed in 2016 and to date, we have invested most of our resources in developing our investigational COMP360 psilocybin treatment, building our intellectual property portfolio, conducting business planning, raising capital and providing administrative support for these operations. Although we are conducting our first Phase 3 program for our COMP360 psilocybin treatment for TRD, we have not yet demonstrated an ability to successfully complete such later-stage clinical trials, obtain regulatory approvals, manufacture a commercial-scale product, conduct sales and marketing activities necessary for successful product commercialization or obtain reimbursement in the countries of sale.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">have in the past and may in the future encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. If we receive regulatory approval for our COMP360 psilocybin treatment or any future product candidate, we will need to transition from a company with a clinical development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">41</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. In addition, during the term of our ADS Warrants, which are classified as liabilities, our net loss is expected to fluctuate significantly quarter to quarter due to non-cash increases or decreases in the fair value of these ADS Warrants. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Raising additional capital through equity financings may cause dilution to holders of our ordinary shares and ADSs and raising additional capital through debt financings, strategic partnerships, collaborations or any other means may restrict our operations or require us to relinquish rights to COMP360 or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may seek additional capital through a combination of equity offerings, debt financings, strategic collaborations and alliances, licensing arrangements or monetization transactions. To the extent that we raise additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities or the exercise of the PIPE Warrants and/or the 2025 ADS Warrants, your ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. For example, if all of the outstanding PIPE Warrants, 2025 ADS Warrants and the Pre-funded Warrants were exercised, we would issue 58,428,868 ADSs which would result in significant dilution to our shareholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, we have raised additional funds in the past and may raise additional funds in the future by issuing equity securities under our ATM Facility and, as a result, our stockholders have in the past experienced and may in the future experience dilution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our Loan Agreement with Hercules includes, and any future debt financing, if available, may involve agreements that include affirmative and negative restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. For example, our Loan Agreement with Hercules contains financial covenants requiring us to maintain a minimum cash balance of $22.5 million and we will need to raise additional financing or significantly reduce our operating expenses to maintain compliance with this financial covenant. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through strategic collaborations and alliances, licensing arrangements or monetization transactions with third parties, we may have to relinquish valuable rights to our investigational COMP360 psilocybin treatment or any future therapeutic candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our investigational COMP360 psilocybin treatment or any future therapeutic candidates that we would otherwise prefer to develop and market ourselves. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Furthermore, certain shareholders and holders of ADSs, including those in the U.S., may, even in the case where preferential subscription rights have not been cancelled or limited, not be entitled to exercise such rights, unless the offering is registered or the ordinary shares are qualified for sale under the relevant regulatory framework. In addition, we have in the past </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">42</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">and intend in the future to submit to shareholders a special resolution at our annual meeting to disapply preemptive rights. As a result, there is the risk that investors may suffer dilution of their holdings should they not be permitted to participate in preference right equity or other offerings that we may conduct in the future.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may not satisfy the milestones or conditions set forth in our Loan Agreement with Hercules in order to draw down additional funding on our term loan facility.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The second tranche of term loans under our Loan Agreement with Hercules, in an amount up to $10.0 million, may only be drawn subject to the achievement of specified performance milestones related to satisfaction of the protocol specified primary endpoint from our Phase 3 COMP005 clinical trial and the satisfaction of customary conditions. The second tranche is only available through the earlier of: (a) 30 days following achievement of certain performance milestones and (b) June 30, 2025. The third tranche of term loans under our Loan Agreement, in an amount up to $10.0 million, is available solely at the lender&#8217;s discretion and is only available during the interest-only period, which ends on July 1, 2025 and is subject to extension if certain performance milestones are met. If these milestones and conditions are met, each of the remaining tranches may be borrowed in up to two drawings of a minimum of $5.0 million each. Without the achievement of the required clinical milestones and satisfaction of certain customary conditions, we will not be eligible to draw additional funds under the second tranche. If we do not receive approval from Hercules&#8217; investment committee, which is beyond our control, we will not be eligible to draw funds under the final remaining tranche under our Loan Agreement and will not realize the full benefits of our Loan Agreement. If we are unable to draw down additional funding under the terms of the Loan Agreement, our business, financial condition and results of operation may be harmed and we may be required to seek out alternative financing sources which may have less favorable terms. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our operating activities may be restricted as a result of covenants related to our Loan Agreement, which could have a material adverse effect on our business, financial condition and results of operation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">On June 30, 2023, we entered into a Loan Agreement with Hercules for an aggregate principal amount of up to $50.0 million, of which the first tranche of $30.0 million was funded at closing. Until we have repaid such indebtedness, the Loan Agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance, and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to engage in transactions with affiliates, or to encumber our intellectual property. These covenants may adversely affect our ability to raise funds or enter into license agreements or strategic transactions in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">For example, if we were to seek additional sources of debt financing in the future and indebtedness under the Loan Agreement is outstanding, we would be required to seek the consent of Hercules in order to raise such additional funds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, there is a financial covenant requiring us to maintain at least $22.5 million of cash in accounts subject to a control agreement in favor of Hercules during the period that commenced on July 1, 2024 and at all times thereafter, provided that if we have achieved certain performance milestones, the minimum cash covenant shall not apply on any day that our market capitalization is at least $750.0 million measured on a consecutive 15-calendar day period immediately prior to such date of measurement and tested on a daily basis. We need to raise additional financing or significantly reduce our operating expenses to maintain compliance with this financial covenant. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">43</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our business may be adversely affected by these restrictions on our ability to operate our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may not have cash available in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due and our payment obligations may be accelerated upon an event of default. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our ability to make scheduled payments on or to refinance our indebtedness depends on our future performance and ability to raise additional sources of cash, which is subject to economic, financial, competitive and other factors beyond our control. If we are unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets, restructuring our debt or obtaining additional equity capital or other funding on terms that may be onerous or highly dilutive. If we desire to refinance our indebtedness, our ability to do so will depend on the state of the capital and lending markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Failure to satisfy our current and future debt obligations under our Loan Agreement could result in an event of default. Additionally, we may be required to repay the outstanding indebtedness under our Loan Agreement if an event of default occurs under the Loan Agreement. Under the Loan Agreement, an event of default will occur if, among other things: we fail to make payments under the Loan Agreement; we breach any of our covenants under the Loan Agreement, subject to specified cure periods with respect to certain breaches; the lender determines that a material adverse effect has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; or we are unable to pay our debts as they become due. As a result of the occurrence of an event of default, Hercules could accelerate all of the amounts due. In the event of an acceleration of amounts due under our Loan Agreement, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our investigational COMP360 psilocybin treatment or any future therapeutic candidates that we would otherwise prefer to develop and market ourselves. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events. In addition, the Loan Agreement includes customary affirmative and negative covenants and other defaults or events of default, the occurrence and continuance of which provide Hercules with the right to demand immediate repayment of all principal and unpaid interest under the Loan Agreement, and to exercise remedies against us and the collateral securing the Loan Agreement. These defaults or events of default include, among other things, insolvency, liquidation, bankruptcy or similar events; failure to observe any covenant or secured obligation under the Loan Agreement, which failure, in most cases, is not cured within 10 days; occurrence of an event that could reasonably be expected to have a material adverse effect on our business, operations, properties, assets or financial condition; material misrepresentations; and certain money judgments being entered against us or any portion of our assets are attached or seized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If an event of default occurs, Hercules could accelerate all of the amounts due under the Loan Agreement. Under such circumstances, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time of such acceleration. In that case, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our investigational COMP360 psilocybin treatment or any future therapeutic candidates that we would otherwise prefer to develop and market </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">44</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">ourselves. Hercules could also exercise their rights to take possession and dispose of the collateral securing the Loan Agreement, which includes substantially all of our property. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Development, Clinical Testing and Commercialization of Our Investigational COMP360 Psilocybin Treatment and Any Future Therapeutic Candidates</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We are dependent on the successful development of our investigational COMP360 psilocybin treatment. We cannot give any assurance that COMP360 will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We currently have no treatments that are approved for commercial sale and may never be able to develop marketable treatments. We expect that a substantial portion of our efforts and expenditures over the next several years will be devoted to our investigational COMP360 psilocybin treatment, which is currently our only therapeutic candidate in clinical development, and the potential commercialization of our COMP360 psilocybin treatment, if approved. Accordingly, our business currently depends on the successful regulatory approval of COMP360 and the commercialization of our investigational COMP360 psilocybin treatment. We cannot be certain that COMP360 will receive regulatory approval or that our COMP360 psilocybin treatment will be successfully commercialized even if we receive regulatory approval. If we were required to discontinue development of our investigational COMP360 psilocybin treatment, or if COMP360 does not receive regulatory approval or fails to achieve significant market acceptance, we would be delayed by many years in our ability to achieve profitability, if ever.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of psilocybin is, and will remain, subject to comprehensive regulation by the FDA, the DEA, the EMA, the MHRA and comparable foreign regulatory authorities. Failure to obtain regulatory approval in the U.S., Europe or other jurisdictions will prevent us from commercializing and marketing our investigational COMP360 psilocybin treatment in such jurisdictions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Even if we were to obtain approval from the FDA, the EMA, the MHRA and foreign regulatory authorities for COMP360, any approval might contain significant limitations related to use, as well as restrictions for specified age groups, warnings, precautions or contraindications, such as a black box warning for increased risk of suicidal thoughts and behaviors. Furthermore, even if we obtain regulatory approval for COMP360, we will still need to develop a commercial infrastructure or develop relationships with collaborators to commercialize including securing availability of third-party treatment sites for the appropriate administration of our investigational COMP360 psilocybin treatment, secure adequate manufacturing, train and secure access to qualified healthcare professionals to monitor and safeguard patients during administration of COMP360 psilocybin treatment, establish a commercially viable pricing structure, obtain coverage and adequate reimbursement from third-party payors, including government healthcare programs, and achieve the rescheduling of psilocybin and psilocin. If we, or any future collaborators, are unable to successfully commercialize our investigational COMP360 psilocybin treatment, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The success of our investigational COMP360 psilocybin treatment and any future therapeutic candidates will depend on several factors, including the following:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">45</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">successful completion of clinical trials, including our Phase 3 program in TRD and related clinical and preclinical studies which will support an application for approval of our investigational COMP360 psilocybin treatment;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">receiving regulatory approvals or clearance for conducting our planned clinical trials or future clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">successful patient enrollment in and completion of clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">positive data from our clinical trials that support an acceptable risk-benefit profile of COMP360 and any future therapeutic candidates in the intended populations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if COMP360 or any future therapeutic candidates are approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">recruiting and training qualified healthcare professionals to monitor and safeguard participants receiving our investigational COMP360 psilocybin treatment in our Phase 3 program and other clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">entry into collaborations to further the development of our investigational COMP360 psilocybin treatment and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">obtaining and maintaining and defending patent and trade secret protection and/or regulatory exclusivity for COMP360 and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">successfully launching commercial sales of our investigational COMP360 psilocybin treatment and any future therapeutic candidates, if approved;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">acceptance of COMP360 and any future therapeutic candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">maintaining a continued acceptable safety profile of COMP360 and any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">effectively competing, including with respect to cost, with companies developing and commercializing other treatments in the indications which our investigational COMP360 psilocybin treatment targets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">achieving the federal and state-level rescheduling of psilocybin and psilocin;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">maintaining the strength of our reputation; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">complying with laws and regulations, including laws applicable to controlled substances, data privacy, and pre-commercial activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">46</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates we develop, which would materially harm our business. If we do not receive marketing approvals for COMP360 and any future therapeutic candidates, we may not be able to continue our operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:154%">COMP360 psilocybin treatment is, and any future therapeutic candidates we may develop in the future may be, subject to controlled substance laws and regulations in jurisdictions where our products, if approved, may be marketed, such as the U.S., the UK and the rest of Europe, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, or changes in these laws and regulations may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition. In addition, during the review process of COMP360 psilocybin treatment, and prior to any potential approval, the FDA and/or other regulatory bodies may require additional data, including with respect to whether COMP360 has abuse or misuse potential. This may delay approval and any potential rescheduling process.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In the U.S., psilocybin and its active metabolite, psilocin, are listed by the DEA as &#8220;Controlled Substances&#8221; or scheduled substances, under the Comprehensive Drug Abuse Prevention and Control Act of 1970, also known as the Controlled Substances Act, or CSA, specifically as a Schedule I substance. The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, have no currently &#8220;accepted medical use&#8221; in the U.S., lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements to guard against the theft or diversion of such controlled substances, including with respect to the transportation and distribution of such substances, and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. For example, they may not be refilled without a new prescription and may have a black box warning. Further, most state laws in the U.S. classify psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocybin to be available for commercial marketing in the U.S., psilocybin and psilocin must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Commercial marketing in the U.S. will also require scheduling-related legislative or administrative action.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance. Therefore, while psilocybin and psilocin are Schedule I controlled substances, products approved by the FDA for medical use in the U.S. that contain psilocybin or psilocin should be placed in Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement. If or when COMP360 receives FDA approval, we anticipate that the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed to patients in the U.S. This scheduling determination will be dependent on FDA approval and the FDA&#8217;s recommendation as to the appropriate schedule. During the review process, and prior to approval, the FDA may determine that it requires additional data, either from non-clinical or clinical studies, including with respect to whether, or to what extent, the substance has abuse or misuse potential. This may introduce a delay into the approval and any potential rescheduling process. That delay would be dependent on the quantity of additional data required by the FDA. This scheduling determination will require DEA to conduct notice and comment rule making including issuing an interim final rule. Such action will be subject to public comment and requests for hearing which could affect the scheduling of these substances. There can be no assurance that the DEA will make </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">47</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">a favorable scheduling decision. Even assuming categorization as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the federal level, such substances would also require scheduling determinations under state laws and regulations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If approved by the FDA, and if the finished dosage form of COMP360 is listed by the DEA as a Schedule II, III, or IV controlled substance, its manufacture, importation, exportation, domestic distribution, storage, sale and legitimate use will continue to be subject to a significant degree of regulation by the DEA. In addition, the scheduling process may take significantly longer than the 90-day deadline set forth in the CSA, thereby delaying the launch of our investigational COMP360 psilocybin treatment in the U.S. Furthermore, the FDA, DEA, or any foreign regulatory authority could require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance has an abuse potential, which could increase the cost and/or delay the launch of our investigational COMP360 psilocybin treatment and any future therapeutic candidates containing controlled substances. In addition, therapeutic candidates containing controlled substances are subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">DEA registration and inspection of facilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations may result in delay of the importation, manufacturing or distribution of COMP360. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">State-controlled substances laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> Individual U.S. states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule COMP360. While some states automatically schedule a drug based on federal action, other states schedule drugs through rule making or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product. We or our partners must also obtain separate state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">Clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">. Because our investigational COMP360 psilocybin treatment contains psilocybin, to conduct clinical trials with COMP360 in the U.S. prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense COMP360 and to obtain the product from our importer. If the DEA delays or denies the grant of a researcher </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">48</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites. The importer for the clinical trials must also obtain a Schedule I importer registration and an import permit for each import. The transportation of COMP360 to clinical trial sites is subject to security requirements and other controls under applicable controlled substance laws and regulations. We do not currently conduct any manufacturing or repackaging/relabeling of either COMP360 or its active ingredients (i.e., psilocybin) in the U.S. COMP360 is imported in its fully-finished, packaged and labeled dosage form. Our clinical trials outside the U.S. are subject to similar controlled substance legislation in other countries.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">Importation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> If COMP360 is approved and classified as a Schedule II, III or IV substance, an importer can import it for commercial purposes if it obtains an importer registration and files an application for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled substances that the DEA authorizes to be imported. The failure to identify an importer or obtain the necessary import authority, including specific quantities, could affect the availability of COMP360 and have a material adverse effect on our business, results of operations and financial condition. In addition, an application for a Schedule II importer registration must be published in the Federal Register, and there is a waiting period for third-party comments to be submitted. It is always possible that adverse comments may delay the grant of an importer registration. If COMP360 is approved and classified as a Schedule II controlled substance, federal law may prohibit the import of the substance for commercial purposes. If COMP360 is listed as a Schedule II substance, we will not be allowed to import the drug for commercial purposes unless the DEA determines that domestic supplies are inadequate or there is inadequate domestic competition among domestic manufacturers for the substance as defined by the DEA. Moreover, Schedule I controlled substances, including psilocybin and psilocin, have never been registered with the DEA for importation for commercial purposes, only for scientific and research needs. Therefore, if neither COMP360 nor its drug substance could be imported, COMP360 would have to be wholly manufactured in the U.S., and we would need to secure a manufacturer that would be required to obtain and maintain a separate DEA registration for that activity.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">Manufacture in the U.S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">. If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing or repackaging/relabeling in the U.S., our contract manufacturers would be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements. Additionally, regardless of the scheduling of COMP360, the active ingredient in the final dosage form is currently a Schedule I controlled substance and would be subject to such quotas as this substance could remain listed on Schedule I. The annual quota allocated to us or our contract manufacturers for the active ingredient in COMP360 may not be sufficient to complete clinical trials or meet commercial demand. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&#8217;, procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">Distribution in the U.S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">. If COMP360 is scheduled as Schedule II, III or IV, we would also need to identify wholesale distributors with the appropriate DEA registrations and authority to distribute COMP360 and any future therapeutic candidates. These distributors would need to obtain Schedule II, III or IV distribution registrations. This limitation in the ability to distribute COMP360 more broadly may limit commercial uptake and could negatively </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">49</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">impact our prospects. The failure to obtain, or delay in obtaining, or the loss of any of those registrations could result in increased costs to us. If COMP360 is a Schedule II drug, participants in our supply chain may have to maintain enhanced security with alarms and monitoring systems and they may be required to adhere to recordkeeping and inventory requirements. This may discourage some pharmacies from carrying the product. In addition, COMP360 could be determined to have a high potential for abuse and therefore required to be administered at our trial sites, which could limit commercial uptake. Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended to reduce prescription drug abuse, such as the requirement that physicians consult a state prescription drug monitoring program, may make physicians less willing to prescribe, and pharmacies to dispense, Schedule II products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%;padding-left:14.5pt">Controlled Drug Status in the UK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">. Psilocybin and psilocin are &#8220;controlled drugs&#8221; in the UK, as they are listed under Schedule 1 of the UK&#8217;s Misuse of Drugs Regulations 2001 and are classified as Class A controlled substances under the Misuse of Drugs Act 1971. Substances listed under Schedule 1 of the Misuse of Drugs Regulations 2001 are considered to have little or no therapeutic benefit and are the most strictly controlled. These substances can therefore only be imported, exported, produced and supplied under a license issued by the UK Government&#8217;s Home Office. Psilocybin and psilocin may never be rescheduled under the Misuse of Drugs Regulations 2001, or reclassified under the UK&#8217;s Misuse of Drugs Act 1971.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The potential reclassification of psilocybin and psilocin in the U.S. could create additional regulatory burdens on our operations and negatively affect our results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If psilocybin and/or psilocin, other than the FDA-approved formulation, is rescheduled under the CSA as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), the ability to conduct research on psilocybin and psilocin would most likely be improved. However, rescheduling psilocybin and psilocin may materially alter enforcement policies across many federal agencies, primarily the FDA and DEA. The FDA is responsible for ensuring public health and safety through regulation of food, drugs, supplements, and cosmetics, among other products, through its enforcement authority pursuant to the Federal Food, Drug, and Cosmetic Act, or the FDCA. The FDA&#8217;s responsibilities include regulating the ingredients as well as the marketing and labeling of drugs sold in interstate commerce. Because it is currently illegal under federal law to produce and sell psilocybin and psilocin, and because there are no federally recognized medical uses, the FDA has historically deferred enforcement related to psilocybin and psilocin to the DEA. If psilocybin and psilocin were to be rescheduled to a federally controlled, yet legal, substance, the FDA would likely play a more active regulatory role. The DEA would continue to be active in regulating manufacturing, distribution and dispensing of such substances. The potential for multi-agency enforcement post-rescheduling could threaten or have a materially adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">COMP360 contains controlled substances, the use of which may generate public controversy. Adverse publicity or public perception regarding psilocybin or our current or future investigational treatments using psilocybin, or regarding other controlled substances, may negatively influence the success of these treatments.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Treatments containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses for, COMP360 and any future therapeutic candidates we may develop. Opponents of these treatments may seek restrictions on marketing and withdrawal of any regulatory approvals. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">50</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, these opponents may seek to generate negative publicity in an effort to persuade the medical community to reject these treatments. For example, we may face media-communicated criticism directed at our clinical development program. Adverse publicity from psilocybin misuse or risky behavior associated with recreational use of psilocybin may adversely affect our ability to obtain regulatory approval of our investigational COMP360 psilocybin treatment and, if approved, may adversely affect the commercial success or market penetration achievable by our investigational COMP360 psilocybin treatment. Anti-psychedelic protests have historically occurred and may occur in the future and generate media coverage. Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit or restrict the introduction and marketing of, our investigational COMP360 psilocybin treatment or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If COMP360 or any future therapeutic candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of the safety and quality of our treatments. We may face limited adoption if third-party treatment sites, prescribing healthcare professionals, qualified healthcare professionals, and patients are unwilling to try such a novel treatment. There has been a history of negative media coverage regarding psychedelic substances, including psilocybin, which may affect the public&#8217;s perception of our treatments. In addition, psilocybin elicits intense psychological experiences, and this could deter patients from choosing this course of treatment. We could be adversely affected if we were subject to negative publicity or if any of our treatments or any similar treatments distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perception, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our treatments or any similar treatments distributed by other companies could have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Future adverse events in research into depression and mental health diseases on which we focus our research efforts, or the pharmaceutical industry more generally, could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our treatments. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for COMP360 or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. We have experienced delays in our clinical trials of COMP360 and if we experience delays in the future, we or our future collaborators may be unable to obtain required regulatory approvals, and therefore we will be unable to commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates on a timely basis or at all, which will adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have experienced delays in recruiting and enrolling patients in our Phase 3 programs and in the future may experience additional delays in completing our Phase 3 program of COMP360 psilocybin treatment in TRD and initiating or completing additional clinical trials. We may also experience numerous unforeseen events, and in some cases have experienced such events, during our clinical trials that could further delay or prevent our ability to receive marketing approval or commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">delays in or failure to obtain regulatory approval to commence or modify a trial, including the imposition of a temporary or permanent clinical hold by regulatory authorities for a number of reasons, including after review of an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">51</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Investigational New Drug Application, or IND, or amendment, clinical trial application, or CTA, or amendment, or equivalent application or amendment, as a result of a finding that the trial presents unreasonable risk to clinical trial participants or a negative finding from an inspection of our clinical trial operations or study sites, or the occurrence of a suspected, unexpected serious adverse reaction, or SUSAR, which we have experienced in the past, or serious adverse reaction, or SAE, during our clinical trials or IISs using COMP360; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">delays in or failure to obtain institutional review board, or IRB, or ethics committee approval at each site; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">additional delays in or failure to recruit and enroll a sufficient number of suitable patients to participate in a trial; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in studies given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">adding new clinical trial sites; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">availability of adequately trained healthcare professionals and appropriate third-party clinical trial sites for the administration of COMP360 psilocybin treatment in our Phase 3 program and other clinical trials, including preparation, the COMP360 administration session, and post-administration follow-up (integration);</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">sufficiency of any supporting digital services that may form part of the preparation, post-administration follow-up or long-term follow-up relating to any drug we develop;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">failure to contract for the manufacture of sufficient quantities of the underlying therapeutic substance for use in clinical trials in a timely manner; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">third-party actions claiming infringement by our investigational COMP360 psilocybin treatment or any future therapeutic candidates in clinical trials and obtaining injunctions interfering with our progress; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">safety or tolerability concerns which could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines, including proposed amendments to the European Union regulations related to pharmaceutical product development and marketing currently under consideration, which, once approved, will replace the current European Union regulatory framework for medicines; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">lower than anticipated retention rates of patients in clinical trials; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">52</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">delays in establishing the appropriate dosage levels in clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">delays in our clinical trials due to public health crises, due to factors such as a decrease in the willingness or availability of patients to enroll in our clinical trials and challenges in procuring sufficient supplies of the underlying therapeutic substance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the quality or stability of the underlying therapeutic substance falling below acceptable standards; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, pandemics, or failures or significant downtime of our information technology systems resulting from cyber-attacks on such systems or those of our third-party providers or otherwise.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We could encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards, or IRBs of the institutions in which such trials are being conducted or ethics committees, by the Data Review Committee, or DRC, or Data Safety Monitoring Board for such trial or by the FDA, the EMA, the MHRA or other regulatory authorities or if the DEA registration of an investigator or site conducting the clinical trial is revoked. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, the EMA, the MHRA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including any SUSARs or SAEs which have in the past or may in the future occur in our trials or any IISs or other studies using COMP360 and those relating to the class to which COMP360 or any future therapeutic candidates belong, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience future additional delays in the completion of, or termination of, any clinical trial of COMP360 or any future therapeutic candidates, the commercial prospects of our investigational COMP360 psilocybin treatment or any future therapeutic candidates will be harmed, and our ability to generate revenue from any such therapeutic candidates will be delayed. In addition, any delays in completing our clinical trials will likely increase our costs, slow down COMP360 or any future therapeutic candidate development and approval process and jeopardize our ability to commence sales and generate revenue. Moreover, if we make changes to COMP360 or any future therapeutic candidates, we may need to conduct additional studies to bridge such modified therapeutic candidates to earlier versions, which could delay our clinical development plan or marketing approval for our investigational COMP360 psilocybin treatment or any future therapeutic candidates. Significant clinical trial delays could also allow our competitors, such as Usona Institute or Cybin Inc., to bring treatments to market before we do or shorten any periods during which we have the exclusive right to commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates and impair our ability to commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates and may harm our business and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">53</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">denial of regulatory approval of COMP360 or any future therapeutic candidates or result in the development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates being stopped early. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our clinical trials may fail to demonstrate substantial evidence of the safety and effectiveness of COMP360 or any future product candidates that we may identify and pursue, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Before obtaining regulatory approvals for the commercial sale of our investigational COMP360 psilocybin treatment or future therapeutic candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that the applicable therapeutic candidate is both safe and effective for use in each target indication. A therapeutic candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process, including during Phase 3 pivotal trials, and, because our investigational COMP360 psilocybin treatment is our only product in clinical development, there is a high risk of failure and we may never succeed in developing marketable products. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in managing late-stage clinical trials; our Phase 3 pivotal trials for COMP360 in TRD represent our first pivotal trials and we may not be able to successfully execute our Phase 3 pivotal trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We cannot be certain that our Phase 3 pivotal trials for COMP360 in TRD or any other future clinical trials will be successful. Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our investigational COMP360 psilocybin treatment. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same therapeutic candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of COMP360, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with COMP360, we may be delayed in obtaining marketing approval, or we may never obtain marketing approval. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of COMP360 in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Even if our clinical trials are successfully completed, preclinical and clinical data are often susceptible to varying interpretations and analyses and we cannot guarantee that the FDA, the EMA or comparable foreign regulatory authorities will interpret the results as we do, or agree that our clinical trials have been appropriately designed or powered to demonstrate the safety and efficacy of COMP360. Accordingly, more trials could be required before we submit COMP360 for approval. To the extent that the results of the trials are not satisfactory to the FDA, the EMA or comparable foreign regulatory authorities for support of a marketing application, approval of COMP360 may be significantly delayed, or we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of COMP360. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. Due to the inherent risk in the development of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">54</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">therapeutic substances, there is a significant likelihood that COMP360 and any future therapeutic candidates will not successfully complete development and receive approval. Many other companies that believed their therapeutic candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval for the marketing of their product. If we do not receive regulatory approvals for COMP360 or future therapeutic candidates, we may not be able to continue our operations. Even if regulatory approval is secured for COMP360 or any future therapeutic candidate, the terms of such approval may limit the scope and use of a specific therapeutic candidate, which may also limit its commercial potential.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. This data may not be sufficient to support regulatory submissions or approvals.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have in the past published and, from time to time in the future we may publish interim, top-line or preliminary data from our clinical trials. We may decide to conduct an interim analysis of the data after a certain number or percentage of subjects have been enrolled, but before completion of the trial. Similarly, we may report top-line or preliminary results of primary and key secondary endpoints before the final trial results are completed. Interim, top-line and preliminary data from our clinical trials may change as more patient data or analyses become available and are not necessarily predictive of final results. Further interim, top-line and preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Interim, top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, top-line and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects or cause the price of our stock to decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular therapeutic candidate and our company in general, and regulatory agencies may request further data from us. In addition, you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular therapeutic candidate. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize COMP360 or any future product candidate, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The regulatory approval process of the FDA, the EMA, the MHRA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for COMP360 and any future therapeutic candidates, our business will be substantially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have not previously submitted a new drug application, or NDA, to the FDA, or a marketing authorization application, or MAA, to the EMA or the MHRA, and have not obtained regulatory approval for COMP360. Before obtaining regulatory approvals for the commercial sale of COMP360 or any future therapeutic candidates, we must demonstrate through lengthy, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">55</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">complex and expensive preclinical testing and clinical trials that COMP360 and any future therapeutic candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and while COMP360 is in a late stage of development, there continues to be a high risk of failure and we may never succeed in developing marketable products. </span></div><div style="margin-bottom:10pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The time required to obtain approval by the FDA, the EMA, the MHRA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a therapeutic candidate&#8217;s clinical development and may vary among jurisdictions and legal or regulatory changes could prevent, limit or delay regulatory approval of a therapeutic candidate. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad. For example, we cannot be certain of the impact on our therapeutic candidates of the proposed amendments to the European Union regulations related to pharmaceutical product development and marketing currently under consideration, which, once approved, will replace the current European Union regulatory framework for medicines. In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn prior established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes.</span></div><div style="margin-bottom:10pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have in the past and may in the future also experience delays in the development and approval of COMP360.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are conducting a Phase 3 program for COMP360 in TRD. We have Breakthrough Therapy Designation and have had dialogue with FDA regarding our Phase 3 trial design, including certain protocol amendments that we implemented in the first half of 2023. We anticipate having on-going dialogue with FDA throughout the conduct of the Phase 3 trials. In June 2023, the FDA published draft guidance regarding the nonclinical, clinical and safety considerations, as well as abuse potential assessment and risk mitigation and public health considerations for conducting trials for psychedelics, such as psilocybin. We believe our Phase 3 program reflects the key principles set forth in the draft guidance. We continue to conduct our Phase 3 program in accordance with our previously announced study design. However, FDA may disagree with our study design or conduct, and may make recommendations or request changes in the design or conduct of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">pivotal programs that may require us to conduct additional clinical trials or otherwise delay our Phase 3 program or may impact the review process for our new drug application for COMP360. Given these uncertainties in the regulatory review and approval process, it is possible that neither COMP360 nor any future therapeutic candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="margin-bottom:10pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">COMP360 or any future therapeutic candidates could fail to receive regulatory approval from the FDA, the EMA, the MHRA or comparable foreign regulatory authorities or be precluded from commercial marketing for many reasons, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may disagree with, question or request changes in the size, design or implementation of our clinical trials; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">56</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may determine that COMP360 or any future therapeutic candidates are not safe and effective, only moderately effective, or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA, the MHRA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may be unable to demonstrate that our investigational COMP360 psilocybin treatment or any future therapeutic candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the data collected from clinical trials of our investigational COMP360 psilocybin treatment or any future therapeutic candidates may not be sufficient to support the submission of an NDA or other submission, or to obtain regulatory approval in the U.S. or elsewhere;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the potential risk of our novel treatment and delivery method, including the use of third-party clinical trial sites and qualified healthcare professionals to monitor and safeguard patients receiving COMP360 psilocybin treatment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any COMP360 or any future therapeutic candidates, which would significantly harm our business, results of operations and prospects. The FDA, the EMA, the MHRA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any of COMP360 or any future therapeutic candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">and may decide that our data are insufficient for approval or require additional preclinical, clinical, or other data. Even if we believe the data collected from clinical trials of COMP360 or any future therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA, the MHRA or any other regulatory authority. For example, concerns about functional unblinding, expectancy bias or the impact of psychological support provided with COMP360 could hinder interpretability or regulatory acceptability of data from clinical trials of our investigational COMP360 psilocybin treatment. If COMP360 or any future therapeutic candidates fails to obtain approval on the basis of any applicable condensed regulatory approval process, this will prevent such therapeutic candidates from obtaining approval on a shortened time frame, or at all, resulting in increased expenses which would materially harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">57</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, even if we were to obtain approval, regulatory or pricing authorities may approve COMP360 or any future therapeutic candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our treatments, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a therapeutic candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that therapeutic candidate. For example, esketamine, a drug targeting major depressive disorder, or MDD, is only available through a Risk Evaluation and Mitigation Strategy, or REMS, program, under the applicable FDA regulations and, as is required for antidepressants, has a black box warning for increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Any of the foregoing scenarios may have a negative impact on the commercial prospects for our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Even if COMP360 or any future therapeutic candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any such therapeutic candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If the FDA, the EMA, the MHRA or a comparable foreign regulatory authority approves COMP360 or any future therapeutic candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the treatment and underlying drug substance will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices, or cGMPs, and with good clinical practices, or GCPs, for any clinical trials that we conduct post-approval, as well as applicable product tracking and tracing requirements, all of which may result in significant expense and limit our ability to commercialize such treatments. Additionally, a company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Later discovery of previously unknown problems with any approved therapeutic candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">restrictions on the labeling, distribution, marketing or manufacturing of COMP360 or any future therapeutic candidates, withdrawal of the product from the market, or product recalls;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">untitled and warning letters, or holds on clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">refusal by the FDA, the EMA, the MHRA or other foreign regulatory body to approve pending applications or supplements to approved applications we filed or suspension or revocation of license approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">58</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">restrictions on coverage by third-party payors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of the product; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, any regulatory approvals that we receive for COMP360 or any future therapeutic candidates may also be subject to limitations on the approved indicated uses for which our COMP360 psilocybin treatment may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of such therapeutic candidates. For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations. REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin treatment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If there are changes in the application of legislation, regulations or regulatory policies, or if problems are discovered with our investigational COMP360 psilocybin treatment or our manufacture of an underlying therapeutic substance, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on us, imposing restrictions on the therapeutic or its manufacture and requiring us to recall or remove the therapeutic from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our therapeutic labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such COMP360 psilocybin treatment may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">COMP360 and any future therapeutic candidates we may develop may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of COMP360 or any future therapeutic candidates or following approval, if any, we may need to abandon our development of such therapeutic candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Undesirable side effects that may be caused by COMP360 or any future therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials or result in clinical holds and could result in a more restrictive label, a requirement that we implement a REMS plan to ensure that the benefits of the treatment outweigh its risks, or the delay or denial of regulatory approval by the FDA, the EMA, the MHRA or other comparable foreign authorities. We or regulatory authorities may also learn of and take similar actions based on side effects related to COMP360 or compounds similar to COMP360 or any future therapeutic candidates in studies not conducted by us, including in IISs or studies conducted by other sponsors, from spontaneous reports of use of psilocybin outside of the clinical trial setting or from safety reports in literature.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">59</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The results of future clinical studies may show that COMP360 or any future therapeutic candidates cause undesirable or unacceptable side effects or even death. For example, there were a number of serious treatment emergent adverse events reported with the results of our Phase 2b clinical trial in TRD. In addition, there may be serious adverse events reported in healthy volunteer studies. There can be no assurance that deaths or serious side effects will not occur, even in a clinical setting. In the event serious side effects occur, our trials could be suspended or terminated and the FDA, the EMA, the MHRA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of COMP360 or any future therapeutic candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, because of the high variability in how different individuals react to psilocybin, certain clinical trial participants, including healthy volunteers, may have negative experiences with the treatment that could subject us to liability or, if publicized, reputational harm. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Even if we receive regulatory approval for COMP360 or any future therapeutic candidates, we will have tested them in only a limited number of patients during our clinical trials. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the treatment used to determine whether, on a potentially statistically significant basis, the target safety and efficacy profile of any such therapeutic candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of COMP360 or any future therapeutic candidates may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to such therapeutic candidate for a longer duration, may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. If our applications for marketing are approved and more patients begin to use our COMP360 psilocybin treatment, new risks and side effects associated with our treatments may be discovered. There have been other products and treatments that have been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of treatments from the market, and our investigational COMP360 psilocybin treatment and any future therapeutic candidates may be subject to similar risks. We might have to withdraw or recall our investigational COMP360 psilocybin treatment and any future therapeutic candidates from the marketplace. We may also experience a significant drop in the potential future sales of our investigational COMP360 psilocybin treatment or any future therapeutic candidates if and when regulatory approvals for such treatment are obtained, experience harm to our reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved therapeutic candidates, if any, or substantially increase the costs and expenses of commercializing and marketing our investigational COMP360 psilocybin treatment and any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, if our investigational COMP360 psilocybin treatment or any future therapeutic candidates receive marketing approval and we or others later identify undesirable or unacceptable side effects caused by such therapeutic candidates, a number of potentially significant negative consequences could result, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such treatments and require us to take our approved therapeutic candidates, if any, off the market;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">60</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan to ensure that the benefits of the therapeutic candidate outweigh its risks;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may be required to change the way the COMP360 psilocybin treatment is administered, conduct additional clinical trials or change the labeling of the therapeutic candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may be subject to limitations on how we may promote the therapeutic candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">sales of the COMP360 psilocybin treatment may decrease significantly;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Any of these events could prevent us or our potential future collaborators from achieving or maintaining market acceptance of the affected therapeutic candidate or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Even if we obtain FDA, EMA or MHRA approval for COMP360 or any future therapeutic candidates that we may identify and pursue in the U.S., Europe or the UK, we may never obtain approval to commercialize any such therapeutic candidates outside of those jurisdictions, which would limit our ability to realize their full market potential.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a therapeutic candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Seeking foreign regulatory approval could result in difficulties and costs and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our investigational COMP360 psilocybin treatment and any future therapeutic candidates in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA, EMA or MHRA approval. We do not have any therapeutic candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets for COMP360 or any future therapeutic candidates. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">61</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">reduced and our ability to realize the full market potential of our investigational COMP360 psilocybin treatment and any future therapeutic candidates will be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The results of preclinical studies and early-stage clinical trials of our investigational COMP360 psilocybin treatment or any future therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of COMP360 or any future therapeutic candidates. There is a high failure rate for drugs proceeding through clinical trials, including in Phase 3 pivotal trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, several of our past clinical trials utilized, and in the future we may conduct clinical trials that utilize, an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Discovery and development of new drugs targeting central nervous system, or CNS, disorders are particularly difficult and time-consuming, evidenced by the higher failure rate for new drugs for CNS disorders compared with most other areas of drug discovery. Any such setbacks in our clinical development could have a material adverse effect on our business and operating results. In addition, our later stage clinical trials may present challenges related to conducting adequate and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related to maintaining the blinding during the trial or placebo or nocebo effects.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Due to the complexity of the human brain and the central nervous system, it can be difficult to predict and understand why a drug, including COMP360, may have a positive effect on some patients but not others and why some individuals may react to the drug differently from others. For example, the population of those suffering with TRD is large and heterogenous and individuals may have different levels of severity of TRD. These differences may further result in different reactions impacting the effectiveness of our investigational COMP360 psilocybin treatment which may cause the percentage of patients, if any, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">62</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">that go into remission to fluctuate. All of these factors may make it difficult to assess the prior use or the overall efficacy of our investigational COMP360 psilocybin treatment. In addition, certain diseases or conditions that we target or may decide to target have in the past and may in the future present increased or unique challenges in clinical development. For example, drug development for anorexia nervosa is not well understood, and we experienced challenges in recruiting and screening participants for our Phase 2 study in anorexia nervosa.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In the second half of 2024, we closed enrollment in our Phase 2 trial in anorexia nervosa and have enrolled 32 patients in the study. Given the challenges in designing and executing clinical trials for this highly vulnerable patient population, we are considering whether to proceed with future development in anorexia nervosa. We have experienced and expect to continue to experience some recruitment challenges based on the patient populations for our clinical trials and the challenges with clinical study conduct. Moreover, these increased or unique challenges could ultimately impact our ability to seek and obtain regulatory approval in these conditions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We depend on the enrollment of patients in our clinical trials for COMP360 and any future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Identifying and qualifying patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors, including:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">identifying and enrolling eligible patients, including those willing to discontinue use of their existing medications; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the design of the clinical protocol and the patient eligibility and exclusion criteria for the trial;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">safety profile, to date, of the therapeutic candidate under study;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the willingness or availability of patients to participate in our trials due to a number of factors, including due to the perceived risks and benefits, stigma or other side effects of use of a controlled substance, any public health crisis or other factors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">perceived risks and benefits of our approach to treatment of indication;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the proximity of patients to clinical sites;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the availability of competing clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the availability of new drugs approved for the indication the clinical trial is investigating;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions of the potential advantages of the drug being studied in relation to other available treatments, including any new treatments that may be approved for the indications we are investigating; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our ability to obtain and maintain patient informed consents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">63</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, any negative results we may report in clinical trials of COMP360 or any future therapeutic candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same therapeutic candidate. Delays in the enrollment for any clinical trial of COMP360 or any future therapeutic candidates have in the past and will in the future likely increase our costs, delay the timeframe in which the results of our clinical trials will become available, slow down the COMP360 approval process and delay or potentially jeopardize our ability to commence sales of our investigational COMP 360 psilocybin treatment, if approved, and generate revenue. For example, in our clinical trials for TRD, reviewing and verifying a participant&#8217;s medical records to confirm such participant meets the inclusion criteria for TRD is time-consuming and administratively burdensome, which can delay the screening process for our clinical trials. The steps we have taken to make this process more efficient may not be successful. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of COMP360 or any future therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Further, timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, pandemics. For example, our clinical trial sites may be located in regions which may in the future be impacted by pandemics or public health crises. In addition, in the past, enrollment in our trials was adversely affected as a result of the COVID-19 pandemic due to limited availability of participants, the inability of patients, healthcare professionals to participate in our trials, interruptions in supply chains and delays with regulators and other similar bodies. The conduct of our trials may continue to be adversely affected by future public health crises or pandemics, despite efforts to mitigate this impact.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our treatments on our own or with suitable collaborators. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">While we are currently engaged in commercial preparedness planning and activities, we have limited organizational experience in the sale or marketing of therapeutic candidates. To achieve commercial success for any approved treatment, we must develop or acquire a sales and marketing organization, outsource these functions to third parties or enter into partnerships. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If our investigational COMP360 psilocybin treatment is approved for commercial sale, we plan on establishing our own market access and commercialization capabilities in primary markets in North America. In select geographies, we might also consider relying on the support of a Contract Sales Organization, or CSO, or enter into commercialization arrangements with companies with relevant commercialization capabilities. There are risks involved in establishing our own sales and marketing capabilities, as well as with entering into arrangements with third parties to perform these services. Even if we establish sales and marketing capabilities, we may fail to launch our treatments effectively or to market our treatments effectively since we have limited organizational experience in the sales and marketing of therapeutic substances. In addition, recruiting and training a sales force is expensive and time-consuming, and could delay any therapeutic launch. In the event that any such launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize our treatments on our own include: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">64</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our inability to train an adequate number of healthcare professionals to meet the demand for COMP360 psilocybin treatment;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the ability of healthcare professionals at third-party treatment sites to perform their roles consistently with our training and our guidelines for the administration of our investigational COMP360 psilocybin treatment;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our inability to recruit, train and retain effective market access and commercial personnel;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the inability of commercial personnel to obtain access to or educate adequate numbers of physicians on the benefits of prescribing any future treatments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our inability to identify a sufficient number of treatment centers in third-party treatment sites to meet the demands of our treatments;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the lack of complementary treatments to be offered by our commercial personnel, which may put us at a competitive disadvantage relative to companies with more extensive therapeutic lines; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent market access and commercial organization; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">costs of market access and commercialization above those anticipated by us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we enter into arrangements with third parties to perform market access and commercial services for any approved treatments, the revenue or the profitability of these revenues to us could be lower than if we were to commercialize any treatments that we develop ourselves. Such collaborative arrangements may place the commercialization of any approved treatments outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our treatments or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy. Our business may be adversely affected by business combinations, restructurings or other corporate transactions, worsening of our collaboration partner&#8217;s financial position or significant changes in its strategy. For example, in December 2023, we entered into an agreement with Greenbrook TMS to research and investigate models for the delivery of COMP360 treatment, if approved, within healthcare systems. In December 2024, Neuronetics, Inc. acquired Greenbrook TMS in an all stock acquisition, which may negatively impact Neuronetics&#8217; willingness or ability to complete its obligations under our agreement. We may not be successful in entering into arrangements with third parties to commercialize our treatments or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention to commercialize our treatments effectively, to set up a sufficient number of treatment centers in third-party treatment sites, or to recruit, train and retain an adequate number of healthcare professionals to administer our treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we do not establish commercial capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our treatments, which in turn would have a material adverse effect on our business, prospects, financial condition and results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">65</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The future commercial success of our investigational COMP360 psilocybin treatment or any future therapeutic candidates will depend on the degree of market access and acceptance of our potential treatments among healthcare professionals, patients, healthcare payors, health technology assessment bodies and the medical community at large. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may never have a product that is commercially successful. To date, we have no product authorized for marketing. Our investigational COMP360 psilocybin treatment requires further clinical investigation, regulatory review, significant market access and marketing efforts and substantial investment before it can produce any revenue. Furthermore, if approved, our COMP360 psilocybin treatment may not achieve an adequate level of acceptance by payors, health technology assessment bodies, healthcare professionals, patients and the medical community at large, and we may not become profitable. The level of acceptance we ultimately achieve may be affected by negative public perceptions and negative media coverage of psychedelic substances, including psilocybin. As a result, efforts to educate the medical community and third-party payors and health technologies assessment bodies on the benefits of our investigational COMP360 psilocybin treatment may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Market acceptance of any of our future treatments by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on a number of factors, many of which are beyond our control, including, but not limited to, the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">acceptance by healthcare professionals, patients and healthcare payors of each treatment as safe, effective and cost-effective; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in the standard of care for the targeted indications for any therapeutic candidate; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the strength of sales, marketing and distribution support; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">potential product liability claims; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the therapeutic candidate&#8217;s relative convenience, ease of use, ease of administration and other perceived advantages over alternative treatments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the prevalence and severity of adverse events or publicity; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of therapeutic characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the cost of treatment with COMP360 in relation to alternative treatments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the steps that prescribers and dispensers must take, given that COMP360 includes a controlled substance, as well as the perceived risks based upon its controlled substance status;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the ability to manufacture our product in sufficient quantities and yields;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">66</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the availability and amount of coverage and reimbursement from healthcare payors, and the willingness of patients to pay out of pocket in the absence of healthcare payor coverage or adequate reimbursement;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the willingness of the target patient population to try, and of healthcare professionals to prescribe, our COMP360 psilocybin treatment;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">any potential unfavorable publicity, including negative publicity associated with recreational, spiritual or medical use or abuse of psilocybin or other psychedelic drugs or with adverse outcomes or side effects from the use of psilocybin or other psychedelic drugs such as unfavorable publicity related to use of psilocybin at Oregon state-licensed psilocybin service centers under the supervision of a state-licensed facilitator;</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">any restrictions on the use, sale or distribution of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, including through REMS;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the extent to which treatments are approved for inclusion and reimbursed on formularies of hospitals and managed care organizations; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">whether our treatments are designated under physician treatment guidelines or under reimbursement guidelines as a first-line, second-line, third-line or last-line treatment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If our investigational COMP360 psilocybin treatment or any future therapeutic candidates fail to gain market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory, or any, return on our investments. Even if some treatments achieve market access and acceptance, the market may prove not to be large enough to allow us to generate significant revenue. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our business and commercialization strategy for our investigational COMP360 psilocybin treatment depends on our ability to identify, qualify, prepare and support third-party treatment sites which will administer COMP360 psilocybin treatment. If we are unable to do so, our commercialization prospects would be limited and our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we are able to commercialize our investigational COMP360 psilocybin treatment or future treatments, our success will be dependent upon our ability to identify, qualify, prepare, certify and support third-party treatment sites that offer and administer our treatments. Our commercial model of delivering our investigational COMP360 psilocybin treatment will also involve third-party healthcare professionals before, during and after the COMP360 psilocybin administration session, which will be hosted in one of the third-party treatment sites. We intend to commercialize our investigational COMP360 psilocybin treatment and any future therapeutic candidates by building close relationships with qualified third-party treatment sites where these healthcare professionals will administer our investigational COMP360 psilocybin treatment. Because we expect our COMP360 psilocybin treatment to be subject to a REMS program and because we intend to work only with third-party sites and providers who agree to adhere strictly to our treatment protocols, we may face limitations on the number of sites available to administer our investigational COMP360 psilocybin treatment. Any such limitations could make it impracticable or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">67</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">impossible for some potential patients to access our investigational COMP360 psilocybin treatment, if approved, which could limit the overall size of our potential patient population and harm our future results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we are unable to establish a sufficient network of third-party treatment sites certified under applicable standards, including regional, national, state or other applicable standards as needed to administer our COMP360 psilocybin treatment if regulatory approval is obtained, including the certifications that such third-party treatment sites may require, it would have a material adverse effect on our business and ability to grow and would adversely affect our results of operations and commercialization efforts. We expect the healthcare professionals to be employed by the third-party treatment sites where the healthcare professionals administer our treatments. Third-party treatment sites could, for a number of reasons, demand higher payments for our treatments or take other actions to increase their income from selling our treatments, which could result in higher costs for payors and for our patients to get access to our treatments. For example, legal regimes may have higher levels of licensure which force us to contract with third-party treatment sites that demand higher payment rates to administer our COMP360 psilocybin treatment, if regulatory approval is obtained. In addition, third-party treatment sites may have difficulty meeting any applicable regulatory or accreditation requirements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Given the novel nature of our treatment, third-party treatment sites may face additional financial and administrative burdens in order to deliver any approved treatment, including adhering to a REMS plan in the U.S. or a Risk Management Program, or RMP, in Europe. The process for a third-party treatment site to obtain a certificate under a REMS plan can be very costly and time-consuming, which could delay a third-party treatment site&#8217;s ability to provide our treatments and materially adversely affect our commercialization trajectory. Furthermore, third-party treatment sites will need to ensure that they have the necessary infrastructure and equipment in order to deliver our investigational COMP360 psilocybin treatment, such as adequate audio-visual equipment, ancillary equipment and sufficient treatment rooms. This may deter third-party treatment sites from providing our therapeutic candidate and reduce our ability to expand our network and generate revenue. Our ability to develop and maintain satisfactory relationships with third-party treatment sites may otherwise be negatively impacted by other factors not associated with our operations and, in some instances, outside of our direct or indirect control, such as negative perceptions regarding the medical use of psilocybin or other psychedelic drugs, changes in Medicare and/or Medicaid or commercial payors reimbursement levels and other pressures on healthcare providers and consolidation activity among hospitals, physician groups and the providers. Reimbursement levels may be inadequate to cover third-party treatment sites&#8217; costs of delivering our investigational COMP360 psilocybin treatment. The failure to maintain or to secure new cost-effective contracts with third-party treatment sites may result in a loss of or inability to grow our network of third-party treatment sites, patient base, higher costs to our patients and us, healthcare provider network disruptions and/or difficulty in meeting regulatory or accreditation requirements, any of which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We currently rely on specially trained, qualified healthcare professionals working at third-party clinical trial sites to administer our investigational COMP360 psilocybin treatment in our clinical trials and we expect this to continue upon approval, if any, of COMP360 or any future psychedelic-based drug candidates. If third-party sites fail to recruit and retain a sufficient number of healthcare professionals or effectively manage their healthcare professionals, our business, financial condition and results of operations would be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">68</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We currently administer our investigational COMP360 psilocybin treatment in our clinical trials through qualified third-party healthcare professionals working at third-party clinical trial sites. However, there are currently not enough trained healthcare professionals to support administration of our investigational COMP360 psilocybin treatment at a commercial scale, and our efforts to facilitate training programs may be unsuccessful.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">While we currently provide training to healthcare professionals working at third-party clinical trial sites and expect to continue providing training in the future (either directly or indirectly through third-party providers), we do not currently employ the healthcare professionals who deliver our treatments in our clinical trials and do not intend to do so in the future. Such healthcare professionals are typically employed by the third-party treatment sites. If our investigational COMP360 psilocybin treatment or any future therapeutic candidates are approved for commercialization, third-party treatment sites may demand substantial financial resources from us to recruit and retain a team of specially trained, qualified healthcare professionals to administer our investigational COMP360 psilocybin treatment or any future therapeutic candidates. If the third-party treatment sites fail to recruit, train and retain a sufficient number of healthcare professionals or if a competitor develops a similar treatment that is effective without the requirement of engaging healthcare professionals to monitor and safeguard patients receiving such treatments, our ability to offer and administer our treatments will be greatly harmed, which may in turn reduce the market acceptance rate of our treatments or limit our ability to grow our business. If this occurs, our commercialization prospects would be negatively affected and our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Although we currently provide training and expect to continue providing training to the healthcare professionals (directly or through third-party providers), we generally rely on qualified and certified third-party treatment sites to manage the healthcare professionals and monitor the administration of our treatments and ensure that the administration process of our treatments comply with our established protocols. However, if not properly managed and supervised, there is a risk that healthcare professionals may deviate from our training protocols, fail to follow the guidelines we have established, or abuse patients during psilocybin administration sessions. The healthcare professionals might also administer unauthorized treatments to patients using illegal psilocybin compounds in &#8220;underground&#8221; clinics. Such illegal activities would put the patients at risk and subject us to potential liabilities, litigations, regulatory proceedings and reputational harm. If this were to occur, we may face serious setbacks for our commercialization process and our financial condition and results of operations would be materially harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Commercialization of our COMP360 psilocybin treatment or other psychedelic-based drug candidates is dependent on our relationships with affiliated professional entities, which we do not own, to provide physician services, and our business would be adversely affected if those relationships were disrupted.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">There is a risk that U.S. state authorities in some jurisdictions may find that our contractual relationships with our affiliated providers and our Centers of Excellence violate laws prohibiting the corporate practice of medicine and certain other health professions. These laws generally prohibit the practice of medicine and certain other health professions by lay persons or entities and are intended to prevent unlicensed persons or entities from interfering with or inappropriately influencing the professional judgment of clinicians and other health care practitioners. The professions subject to corporate practice restrictions and the extent to which each jurisdiction considers particular actions or contractual relationships to constitute improper influence of professional judgment vary across jurisdictions and are subject to change and evolving interpretations </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">69</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">by state boards of medicine and other health professions and enforcement agencies, among others. As such, we must monitor our compliance with laws in every jurisdiction in which we operate on an ongoing basis and we cannot guarantee that subsequent interpretation of the corporate practice laws will not further circumscribe our business operations. State corporate practice restrictions also often impose penalties on health professionals for aiding a corporate practice violation, which could discourage clinicians or other licensed professionals from participating in our network of providers or Centers of Excellence. Any difficulty securing clinicians to participate in our network could impair our ability to provide treatments and could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Corporate practice restrictions exist in some form, whether by statute, regulation, professional board or attorney general guidance, or case law, in at least 42 U.S. states, though the broad variation between jurisdictions with respect to the application and enforcement of the doctrine makes establishing an exact count difficult. Because of the prevalence of corporate practice restrictions on medicine, we contract for provider services and other services provided by the Centers for Excellence through various agreements, such as service agreements, rather than employ providers. We expect that these relationships will continue, but we cannot guarantee that they will. The arrangement in which we have entered to comply with state corporate practice of medicine doctrines could subject us to additional scrutiny by federal and state regulatory bodies regarding federal and state fraud and abuse laws. In addition, a material change in our relationship with providers, whether resulting from a dispute among the entities, a change in government regulation, or the loss of these affiliations, could impair our ability to provide treatments and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Changes in methods of therapeutic candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As therapeutic candidates are developed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, may be altered along the way in an effort to optimize processes and results. Any of these changes could cause our investigational COMP360 drug product or any future drug candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of COMP360 or any future therapeutic candidates and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Breakthrough Therapy designation by the FDA for COMP360 or any future therapeutic candidates may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our investigational COMP360 psilocybin treatment or any future therapeutic candidates will receive marketing approval.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have received Breakthrough Therapy designation for COMP360 for the treatment of TRD and may seek it for any future therapeutic candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing treatments on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">70</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if in the future we have therapeutic candidates that we believe meet the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for COMP360 and any future therapeutic candidates may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even though COMP360 has been designated as a breakthrough therapy, the FDA may later decide that it, or any future therapeutic candidates that are designated by the FDA as breakthrough therapies, no longer meet the conditions for qualification. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Fast Track designation, if granted by the FDA, may not actually lead to a faster development or regulatory review or approval process. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may seek Fast Track designation for any of our therapeutic candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular therapeutic candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we receive Fast Track designation for any future therapeutic candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw Fast Track designation for any therapeutic candidate that is granted Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may in the future enter into collaborations for the discovery, development and/or commercialization of additional therapeutic candidates or research programs. Such collaborations may not result in the development of commercially viable therapeutic candidates or the generation of significant future revenue, or we may fail to enter into profitable relationships.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may enter into collaborations with pharmaceutical companies or others for the discovery, development and/or commercialization of future therapeutic candidates or research programs. For example, we established a Discovery Center under a sponsored research agreement with University of the Sciences Philadelphia (which merged into Saint Joseph&#8217;s University in 2022), or USciences. If we fail to enter into or maintain collaborations on reasonable terms, our ability to discover and develop future therapeutic candidates and research programs could be delayed or become more costly. Any future collaborations may subject us to a number of risks, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the inability to control the amount and timing of resources that our collaboration partner devotes to our future research programs and therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">for collaboration agreements where we may be solely or partially responsible for funding development expenses through a defined milestone event, we may never recoup the costs of these investments if the therapeutic candidate fails to achieve regulatory approval or commercial success; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">71</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may rely on the information and data received from third parties regarding their research programs and therapeutic candidates without independent verification; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may not have control of the process conducted by the third party in gathering and composing data regarding their research programs and therapeutic candidates and we may not have formal or appropriate guarantees with respect to the quality and the completeness of such data; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may not have sufficient funds to satisfy any milestone, royalty or other payments we may owe to any third party collaborator;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our collaboration agreements may contain non-competition provisions which place restrictions on our business operations and the therapeutic candidates and/or indications we may pursue; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">a collaborative partner may develop or commercialize a competing therapeutic candidate either by itself or in collaboration with others, including one or more of our competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our collaborative partners&#8217; willingness or ability to complete their obligations under our collaboration arrangements may be adversely affected by business combinations or significant changes in a collaborative partner&#8217;s strategy; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our collaborative partners may experience delays in, or increases in the costs of, the discovery and development of our future therapeutic candidates and research programs and we may be required to pay for any cost increases; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may have disagreements with collaborative partners, including disagreements over proprietary rights, selection of lead therapeutic candidates, contract interpretation or the preferred course of development that might cause delays or termination of the research, development or commercialization of therapeutic candidates, might lead to additional responsibilities for us with respect to therapeutic candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our collaborative partners may not properly obtain, maintain, defend or enforce intellectual property rights; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our collaborative partners may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a collaborative partnership depends, among other things, upon our assessment of a potential collaborator&#8217;s resources and expertise, the terms and conditions of the proposed partnership and the potential collaborator&#8217;s evaluation of a number of factors. Proposing, negotiating, and implementing collaborations, licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. We have limited institutional knowledge and experience with respect to such activities and we may also not realize the anticipated benefits of any such transaction or arrangement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Should any of the foregoing risks materialize, any collaborations we enter into could fail to result in the development of commercially viable therapeutic candidates or the generation of future revenue, which could have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">72</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Developing Centers of Excellence has in the past and may in the future involve significant costs, time and resources. If our efforts are unsuccessful, our business, prospects and financial condition would be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have, and may in the future, set up research facilities and innovation labs, which we refer to as Centers of Excellence, in key markets. We announced the establishment of our first Center of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, in January 2021. In March 2022, we announced a strategic collaboration with King&#8217;s College London and South London and Maudsley NHS Foundation Trust, or SLaM, to establish The Center for Mental Health Research and Innovation with an overarching goal of accelerating patient access to evidence-based innovation in mental health care by driving forward research in psychedelic treatments through, among other things, the development of working model psychedelic treatment clinics, our training programs, conducting clinical trials, and data analysis.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We intend to use these Centers of Excellence to gather evidence to optimize our treatment delivery and psychological support model, and train qualified healthcare professionals, conduct clinical trials, including proof of concept studies, test digital technology solutions to improve patient experience and outcomes and pursue other activities to refine our approach to delivering our investigational COMP360 psilocybin treatment safely and cost-effectively. Our efforts to design, build and staff these Centers of Excellence, or identify suitable third parties with whom we may collaborate to open these centers, will involve significant time, costs, including potential capital expenditures to acquire and develop facilities, and other resources, and may divert our management team&#8217;s focus from executing on other key elements of our business strategy. If we fail to enter into or maintain agreements with third parties to develop and operate these Centers of Excellence on reasonable terms, or at all, our ability to develop our future research programs and therapeutic candidates could be delayed, the commercial potential of our treatments could change and our costs of development and commercialization could increase. If our efforts to develop these Centers of Excellence are unsuccessful, it will have a materially adverse impact on our business, future prospects and financial position.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may become exposed to costly and damaging liability claims, either when testing our investigational COMP360 psilocybin treatment or any future therapeutic candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of therapeutic substances. Currently, we have no treatments that have been approved for commercial sale; however, the current and future use of our investigational COMP360 psilocybin treatment or any future therapeutic candidates by us and our corporate collaborators in clinical trials, and the potential sale of any approved treatments in the future, may expose us to liability claims. These claims might be made by patients or healthy volunteers who receive our investigational COMP360 psilocybin treatment in clinical trials and if regulatory approval is obtained, by patients who receive it under prescription and by healthcare providers, pharmaceutical companies, our corporate collaborators or other third parties that sell COMP360 psilocybin treatment or any future therapeutic candidates. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our investigational COMP360 psilocybin treatment or any future therapeutic candidates or any prospects for commercialization of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">73</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">investigational COMP360 psilocybin treatment or any future therapeutic candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If COMP360 or any future therapeutic candidates cause adverse side effects during clinical trials or after regulatory approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with warnings that identify known potential adverse effects and describe which patients should not use COMP360 or any future therapeutic candidates. Regardless of the merits or eventual outcome, liability claims may cause, among other things, the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">decreased demand for our treatments due to negative public perception; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">injury to our reputation; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">initiation of investigations by regulators; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">costs to defend or settle the related litigation; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">loss of revenue from therapeutic sales; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the inability to commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates, if approved.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">It is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial treatments if we obtain marketing approval for our investigational COMP360 psilocybin treatment or any future therapeutic candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business, financial condition and results of operations could be materially adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Liability claims resulting from any of the events described above could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Psilocybin and psilocin are listed as Schedule I controlled substances under the CSA in the U.S., and similar controlled substance legislation in other countries and any significant breaches in our compliance with these laws and regulations, or changes in the laws and regulations, may result in interruptions to our development activity or business continuity. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">74</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Psilocybin and psilocin are categorized as Schedule I controlled substances under the CSA, Schedule 1 drugs under the UK&#8217;s Misuse of Drugs Regulations 2001 and are similarly categorized by most states and foreign governments. Even assuming that COMP360 or any future therapeutic candidates containing psilocybin or psilocin are approved and scheduled by regulatory authorities to allow their commercial marketing, the ingredients in such therapeutic candidates would likely continue to be Schedule I, or the state or foreign equivalent. Violations of any federal, state or foreign laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges and penalties, including, but not limited to, disgorgement of profits, cessation of business activities, divestiture, or prison time. This could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial position, operating results, profitability or liquidity or the market price of our publicly traded ADSs. In addition, it is difficult for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or our final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet such activities or to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities may result in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment, fines and/or imprisonment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Various federal, state, provincial and local laws govern our business in the jurisdictions in which we operate or currently plan to operate, and to which we export or currently plan to export our products, including laws relating to health and safety, the conduct of our operations, and the production, storage, sale and distribution of our products. Complying with these laws requires that we comply concurrently with complex federal, state, provincial and/or local laws. These laws change frequently and may be difficult to interpret and apply. To ensure our compliance with these laws, we will need to invest significant financial and managerial resources. It is impossible for us to predict the cost of such laws or the effect they may have on our future operations. A failure to comply with these laws could negatively affect our business and harm our reputation. Changes to these laws could negatively affect our competitive position and the markets in which we operate, and there is no assurance that various levels of government in the jurisdictions in which we operate will not pass legislation or regulation that adversely impacts our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, even if we or third parties were to conduct activities in compliance with U.S. state or local laws or the laws of other countries and regions in which we conduct activities, potential enforcement proceedings could involve significant restrictions being imposed upon us or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on our business, revenue, operating results and financial condition as well as on our reputation and prospects, even if such proceedings conclude successfully in our favor. In the extreme case, such proceedings could ultimately involve the criminal prosecution of our key executives, the seizure of corporate assets, and consequently, our inability to continue business operations. Strict compliance with state and local laws with respect to psilocybin and psilocin does not absolve us of potential liability under U.S. federal law, EU law or English law, nor provide a defense to any proceeding which may be brought against us. Any such proceedings brought against us may adversely affect our operations and financial performance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Despite the current status of psilocybin and psilocin as Schedule I controlled substances in the U.S., there may be changes in the status of psilocybin or psilocin under the laws of certain U.S. cities or states. For instance, the city of Denver voted to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">75</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">decriminalize the possession of psilocybin in 2019, and in Oregon, Measure 109 was passed in November 2020 to pave the way for the legal use of &#8220;psilocybin products,&#8221; including naturally-derived psilocybin substances, in licensed facilities with supervision by licensed facilitators. Oregon psilocybin service centers opened and licensed facilitators began offering psilocybin services to adults over the age of 21 in January 2023. In November 2022, voters in Colorado approved a ballot measure legalizing the use of naturally-derived psilocybin and psilocin in state-regulated centers under the supervision of state-licensed facilitators and Colorado began accepting licensing applications on December 31, 2024. In April 2025, New Mexico&#8217;s governor signed SB 219, the Medical Psilocybin Act, which provides for a medical program for naturally-derived psilocybin. This bill creates a regulated medical psilocybin program overseen by the New Mexico Department of Health, allowing licensed healthcare providers to prescribe naturally-occurring psilocybin to patients with qualifying conditions, including, among others, TRD and PTSD. The program is expected take effect in 2028. Some cities have also passed measures that decriminalizes or minimizes enforcement actions for psilocybin, including, for example, Washington, D.C. (November 2020), Somerville, Massachusetts (January 2021), Cambridge, Massachusetts (February 2021), Northampton, Massachusetts (April 2021), Seattle, Washington (October 2021), San Francisco, California (September 2022), Minneapolis, Minnesota (July 2023) and Portland, Maine (October 2023). The legalization of psilocybin without regulatory oversight or with minimal regulatory oversight may lead to the setup of clinics without proper therapeutic infrastructure or adequate clinical research, which could put patients at risk and bring reputational and regulatory risk to the entire industry, making it harder for us to achieve regulatory approval. Furthermore, the legalization of psilocybin could also impact our commercial sales if we receive regulatory approval as it would reduce the barrier to entry and could increase competition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from manufacturing COMP360 and developing and selling our investigational COMP360 psilocybin treatment or any future therapeutic candidates outside the U.S. or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our operations are subject to anti-corruption laws, including the UK Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, a financial or other advantage to government officials or other persons to induce them to improperly perform a relevant function or activity (or reward them for such behavior).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We, along with those acting on our behalf and our commercial partners, operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">76</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the UK and the U.S., and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from manufacturing COMP360 and developing and selling our investigational COMP360 psilocybin treatment or any future therapeutic candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by UK, U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may become subject to U.S. federal and state forfeiture laws which could negatively impact our business operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, seizure of assets, disgorgement of profits, cessation of business activities or divestiture. As an entity that conducts business involving psilocybin and psilocin, we are potentially subject to federal and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">77</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">state forfeiture laws (criminal and civil) that permit the government to seize the proceeds of criminal activity. Civil forfeiture laws could provide an alternative for the federal government or any state (or local police force) that wants to discourage residents from conducting transactions with psilocybin- and psilocin-related businesses but believes criminal liability is too difficult to prove beyond a reasonable doubt. Also, an individual can be required to forfeit property considered to be the proceeds of a crime even if the individual is not convicted of the crime, and the standard of proof in a civil forfeiture matter is lower than the standard in a criminal matter. Depending on the applicable law, whether federal or state, rather than having to establish liability beyond a reasonable doubt, the federal government or the state, as applicable, may be required to prove that the money or property at issue is proceeds of a crime only by either clear and convincing evidence or a mere preponderance of the evidence.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Investors located in jurisdictions where psilocybin and psilocin remains illegal may be at risk of prosecution under conspiracy, aiding and abetting, and money laundering statutes, and be at further risk of losing their investments or proceeds under forfeiture statutes. Many jurisdictions remain fully able to take action to prevent the proceeds of psilocybin and psilocin businesses from entering their state. Our investors and prospective investors should be aware of these potentially relevant laws in considering whether to invest in us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We are subject to certain tax risks and treatments that could negatively impact our results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Section 280E of the Internal Revenue Code of 1986, as amended, or the Code, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the CSA). The U.S. Internal Revenue Service, or IRS, has invoked Section 280E in tax audits against various businesses in the U.S. that are permitted under applicable state laws. Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. There is no guarantee that any federal court will issue an interpretation of Section 280E favorable to psilocybin and psilocin businesses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable UK tax legislation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As a UK incorporated and tax resident entity, we are subject to UK corporation tax on tax-adjusted trading profits. Due to the nature of our business, we have generated losses since inception and therefore have not paid any UK corporation tax. We had accumulated trading losses for carry forward in the UK of $339.7 million and $252.3 million as of December&#160;31, 2024 and 2023, respectively. Subject to any relevant utilization criteria and restrictions (including, but not limited to, those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half of our ordinary shares and a major change in the nature, conduct or scale of the trade), we expect these to be eligible for carry forward and utilization against future operating profits. The use of loss carryforwards in relation to UK profits incurred on or after April 1, 2017 is limited each year to &#163;5.0 million per group plus, broadly, an incremental 50% of the remaining UK taxable profits. In addition, if we were to have a major change in the nature of the conduct of our trade, loss carryforwards may be restricted or extinguished.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As a company that carries out extensive R&amp;D activities, we seek to benefit from the UK R&amp;D tax relief programs, which historically consisted of the Small and Medium-sized Enterprises, or SME, R&amp;D tax relief program, and, to the extent that our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">78</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. For accounting periods starting on or after April 1, 2023 and before April 1, 2024, under the SME Program, we may be able to surrender the trading losses that arise from our qualifying R&amp;D activities for a cash rebate of an amount up to an effective rate of 18.6% of such qualifying R&amp;D expenditures or 12.1% for any work that is contracted out. The majority of our research, clinical trials management and clinical manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. For accounting periods starting on or after April 1, 2024, the SME and RDEC regimes have been merged, which will impact us for the first time from January 1, 2025. Under this new merged scheme, for non-research intensive companies, the effective net credit will be 16.2% for in-house expenditure and 10.5% for any work that is contracted out. This merged regime will apply to both SME and large companies.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The SME Program, and the new merged scheme, incorporate a cap on repayable credits to a multiple of payroll taxes (broadly, to a maximum payable credit equal to &#163;20,000 plus three times the total PAYE and NICs liability of the company) subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying R&amp;D expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If the exception does not apply, this could restrict the amount of payable credit that we claim. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The rates described above relate to non-research intensive companies. However, new rules were introduced by the Finance Act 2024 for an enhanced rate of relief for research intensive companies from April 1, 2023 onwards, which are approximately 27.0% for qualifying expenditure and approximately 17.5% for qualifying subcontracted expenditure (paid to an unconnected subcontractor) under the SME program. To be eligible as a research intensive company, the qualifying R&amp;D expenditure for tax purposes must be at least 40% of the aggregate expenditure across the consolidated group. The threshold has decreased from 40% to 30% from January 1, 2025.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">For the year ended December 31, 2023, the Company was uncertain whether it would meet the R&amp;D intensity condition and therefore be eligible for the enhanced effective rate due to uncertainties over the ability to net off an exchange gain and loss arising on an intercompany loan when calculating aggregate expenditure, which was not covered by HMRC guidance. It sought clarity from HMRC in the form of a non-statutory clearance and received a positive response in April 2025. Therefore for the year ended December 31, 2023 the company intends to file a resubmission to claim at the enhanced rate, which will result in an increase in its R&amp;D tax relief claim of $3.9 million. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">For the year ended December 31, 2024 the Company believes that it meets the R&amp;D intensity condition and has therefore calculated its R&amp;D tax credit at the enhanced rate on the basis that it is research intensive.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As the Company believes that it meets the R&amp;D intensity condition for the year ended December 31, 2024 and is intending to claim the enhanced rate for that period, it should automatically fulfil the expenditure conditions to be eligible for the enhanced rate in the year ended December 31, 2025 as a company remains research intensive unless it fails to meet the eligibility requirement for two consecutive years. However to continue to be able to claim at the enhanced rate in that year, it must also be loss making and qualify as a small or medium sized enterprise (SME).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Restrictions have also been introduced on relief that may be claimed for expenditure on contracted out R&amp;D activity where the work is undertaken outside the UK, save for certain exceptions. These changes may impact the quantum of R&amp;D </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">79</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">relief that we are able to claim in the future and took effect for accounting periods starting from April 1, 2024, which will therefore impact us for the first time from January 1, 2025. These restrictions and the application of the exceptions have been taken into account in the assessment of qualifying expenditures. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may benefit in the future from the UK&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenue from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. We own two UK patents which cover our investigational COMP360 psilocybin treatment, and accordingly, future upfront fees, milestone fees, product revenue and royalties could be eligible for this deduction. When taken in combination with the enhanced relief available on our R&amp;D expenditures, we expect a long-term rate of corporation tax lower than the statutory rate to apply to us. If, however, there are unexpected adverse changes to the UK R&amp;D tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The UK tax authority, His Majesty&#8217;s Revenue &amp; Customs, or HMRC, has an increased focus on claims for R&amp;D tax reliefs and we may be subject to increased scrutiny in respect of any claims it makes. In addition, the legislation on the UK R&amp;D tax reliefs regime is updated and changed frequently, so there can be no guarantee of our ability to make use of reliefs as it might currently expect to in future.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates and could have a material adverse effect on our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In the U.S., the EU and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and there may continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. For more information regarding the risks related to these laws and regulations, please see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">Business&#8213;Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We expect that changes and challenges to the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, and additional downward pressure on the price that we receive for any future approved product. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">New laws and additional health reform measures may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and affordability for our investigational COMP360 psilocybin treatment and any future therapeutic candidates and, accordingly, the results of our financial operations. These continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">80</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:13.8pt">the demand for our investigational COMP360 psilocybin treatment or any future therapeutic candidates, if we obtain regulatory approval;</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:13.8pt">our ability to set a price that we believe is fair for our products;</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:13.8pt">our ability to obtain coverage and reimbursement approval for a product;</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:13.8pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:13.8pt">the level of taxes that we are required to pay; and</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:13.8pt">the availability of capital.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:16.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and there may be ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from one or more of our approved products or other therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Although we do not currently have any treatments on the market, our current and future operations may be directly, or indirectly through our relationships with investigators, health care professionals, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute or the federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any treatments for which we obtain marketing approval. These laws impact, among other things, our research activities and proposed sales, marketing and education programs and constrain our business and financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">81</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">arrangements and relationships with third-party payors, healthcare professionals who participate in our clinical research program, healthcare professionals and others who recommend, purchase, or provide our approved treatments, and other parties through which we market, sell and distribute our treatments for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business, along with foreign regulators (including European data protection authorities). Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. For more information regarding the risks related to these laws and regulations, please see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">Business&#8213;Other Healthcare Laws and Compliance Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The distribution of pharmaceutical products is subject to additional requirements and regulations, including licensing, extensive record-keeping, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Further, if any of our Centers for Excellence conduct clinical studies, we may face risks relating to operating a clinical trial site. Such risks may include, but are not limited to, research misconduct and patient injury. In addition, we may end up possessing a large amount of individually identifiable health information. Such activities are subject to a wide variety of laws, such as the Health Insurance Portability and Accountability Act, or HIPAA.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">82</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Failure to comply with health and data protection laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We and any potential collaborators may be subject to U.S. federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, which are subject to privacy and security requirements under HIPAA, as amended by the Health Information Technology for Economics and Clinical Health, or HITECH. To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Depending on the facts and circumstances, we could be subject to significant civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, in June 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which came into effect on January 1, 2020 and became enforceable by the California Attorney General on July 1, 2020. The CCPA provides additional data privacy rights for consumers (as that term is broadly defined) and operational requirements for companies. The CCPA required covered companies to provide certain disclosures to consumers about their data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. In particular, the CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has resulted in an increase in data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities, exemplifying the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, a California ballot initiative, the California Privacy Rights Act, or CPRA, was passed in November 2020. Effective starting on January 1, 2023, the CPRA imposed additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA creates a new state agency vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">83</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Certain other state laws impose similar privacy obligations, and we anticipate that more states may enact legislation similar to the CCPA, which provides consumers with new privacy rights and increases the privacy and security obligations of entities handling certain personal information of such consumers. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">At the federal level, a comprehensive federal data privacy bill, the American Privacy Rights Act of 2024 has been proposed and, if passed, will further change the privacy and data security compliance landscape. This proposed legislation, if passed, would also introduce new stringent privacy and data security obligations that would apply to personal data collected from throughout the U.S.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Compliance with U.S. and foreign privacy and data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">European data collection is governed by restrictive privacy and security regulations governing the use, processing and cross-border transfer of personal information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are subject to European data protection regulations, where we collect and use personal data relating to Europe, including to conduct and enroll subjects in clinical trials in the UK or the European Economic Area (EEA). This includes the EU General Data Protection Regulation, or EU GDPR, and the UK equivalent of the same, the UK GDPR (collectively referred to as the GDPR), as well as other national data protection legislation in force in the UK and relevant EEA Member States (including the UK Data Protection Act 2018 in the UK), which govern the collection, use, storage, disclosure, transfer, or other processing of personal data (including health data processed in the context of clinical trials) (i) regarding individuals in the UK and EEA, and/or (ii) carried out in the context of the activities of our establishment in the UK and any EEA Member State. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The GDPR is wide-ranging in scope and imposes numerous additional requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, increasing requirements pertaining to health data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">84</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">and pseudonymized (i.e., key-coded) data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the UK and EEA, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenue, whichever is greater. The GDPR provides individuals with various rights in respect of their personal data, including rights of access, erasure, portability, rectification, restriction and objection. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The GDPR provides that EEA Member States may make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between EEA Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, we are subject to evolving and strict rules on the transfer of personal data out of the UK and EEA to third countries such as the U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">n certain circumstances, unless a derogation exists or a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses, or SCCs, and the UK International Data Transfer Agreement/Addendum, or UK IDTA) have been put in place. Where relying on the SCCs or the UK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. Any inability to transfer personal data from the UK and EEA to third countries in compliance with data protection laws may adversely affect our operations and our business and financial position. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition, and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR. While we have taken steps to comply with the GDPR, and implementing legislation in the UK and applicable EEA Member States, including by seeking to establish appropriate lawful bases for the various processing activities we carry out as a controller or joint controller, reviewing our security procedures and those of our vendors and collaborators, and entering into data processing agreements with relevant vendors and collaborators, we cannot be certain that our efforts to achieve and remain in compliance have been, and/or will continue to be, fully successful. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The UK data protection regime is independent from but currently still aligned to the EEA&#8217;s data protection regime. However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the UK and EEA. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">85</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The UK Government has also now introduced a Data (Use and Access) Bill into the UK legislative process to reform the UK&#8217;s data protection regime following Brexit. If passed, the final version of the Data (Use and Access) Bill may have the effect of further altering the similarities between the UK and EEA data protection regimes and threaten the UK adequacy decision from the European Commission. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, complexity and cost to our handling of personal data and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EEA. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The successful commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our investigational COMP360 psilocybin treatment or any future therapeutic candidates, if approved, could limit our ability to market those treatments and decrease our ability to generate revenue. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford treatments such as our investigational COMP360 psilocybin treatment or any future therapeutic candidates, if approved. As Schedule I substances under the CSA, psilocybin and psilocin are deemed to have no accepted medical use and treatments that use psilocybin or psilocin are precluded from reimbursement in the U.S. Our products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially marketed. Our ability to achieve acceptable levels of coverage and reimbursement for treatments by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, and attract additional collaboration partners to invest in the development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. There is limited clinical data on the long-term efficacy of psilocybin on treating TRD. Certain patients may need repeated treatments over their lifetime to avoid relapse. This may increase treatment costs, making it more difficult for us to secure reimbursement. Even if we obtain coverage for a given treatment by third-party payors, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients may find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., Europe or elsewhere will be available for any treatment that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. For more information regarding the risks related to these laws and regulations, please see the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">Business&#8213;Coverage, Pricing and Reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We intend to seek approval to market our investigational COMP360 psilocybin treatment or future therapeutic candidates in both the U.S. and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for COMP360 or our future therapeutic candidates, we will be subject to rules and regulations in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In some foreign countries, particularly certain countries in Europe, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our investigational COMP360 psilocybin treatment or our future therapeutic candidates. In these countries, pricing negotiations with governmental authorities can take </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">86</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">considerable time after obtaining marketing approval of a therapeutic candidate. In addition, market acceptance and sales of our investigational COMP360 psilocybin treatment or future therapeutic candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our investigational COMP360 psilocybin treatment or future therapeutic candidates and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Third-party payors are increasingly challenging prices charged for therapeutic substances and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive drug is available. It is possible that a third-party payor may consider our investigational COMP360 psilocybin treatment or any future therapeutic candidates as substitutable and only offer to reimburse patients for the less expensive drug. Even if we show improved efficacy or improved convenience of administration with our investigational COMP360 psilocybin treatment or any future therapeutic candidates, pricing of existing drugs may limit the amount we will be able to charge. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed treatments at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates, and may not be able to obtain a satisfactory financial return on therapeutic candidates that we may develop. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved treatments. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug products before they will reimburse health care providers who use such treatments. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our treatments to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">On the state level, local governments have been very aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">87</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">could reduce the ultimate demand for our treatments or put pressure on our therapeutic pricing, which could negatively affect our business, results of operations, financial condition and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, and other countries has and will continue to put pressure on the pricing and usage of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. In many countries, the prices of medical treatments are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical treatments, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulations could restrict the amount that we are able to charge for our investigational COMP360 psilocybin treatment or any future therapeutic candidates. Accordingly, in markets outside the U.S., the reimbursement for our treatments may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU-wide, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of treatments in that context. In general, however, the healthcare budgetary constraints in many EU Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with increasing EU and national regulatory burdens on those wishing to develop and market treatments, this could prevent or delay marketing approval of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, restrict or regulate post-approval activities and affect our ability to commercialize any treatments for which we obtain marketing approval. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">EU drug marketing regulation may materially affect our ability to market and receive coverage for our treatments in the EU Member States. Much like the federal Anti-Kickback Statute prohibition in the U.S., the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal treatments is also prohibited in most countries within the EU. The provision of benefits or advantages to induce or reward improper performance generally is typically governed by the national anti-bribery laws of EU Member States, and in respect of the UK, the Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Payments made to physicians and other healthcare professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in individual EU Member States and the particular requirements can therefore vary widely amongst the EU Member States. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">88</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, in most foreign countries, including many EU Member States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, individual Member States in the EU have the ability to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced Member States, can further reduce prices. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our investigational COMP360 psilocybin treatment or any of our future therapeutic candidates to other available treatments in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our treatments. Historically, drug products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our treatments is unavailable or limited in scope or amount, our revenue from sales and the potential profitability of our investigational COMP360 psilocybin treatment or any of our future therapeutic candidates in those countries would be negatively affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Moreover, efforts by governmental and third-party payors in the EU, the U.S. and elsewhere to cap or reduce healthcare costs may cause such organizations to limit coverage and the level of reimbursement for newly approved treatments and, as a result, they may not cover or provide adequate payment for our investigational COMP360 psilocybin treatment or any future therapeutic candidates. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific treatments. We expect to experience pricing pressures in connection with the sale of our investigational COMP360 psilocybin treatment or any future therapeutic candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We could experience difficulty enforcing our contracts.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Due to the nature of our business and the fact that some of our contracts involve psychedelics including psilocybin and psilocin, the use of which is not legal under U.S. federal law and in certain other jurisdictions, we may face difficulties in enforcing our contracts in U.S. federal and state courts. The inability to enforce any of our contracts could have a material adverse effect on our business, operating results, financial condition or prospects.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In order to manage our contracts with contractors, we ensure that such contractors are appropriately licensed at the state and federal level in the U.S., and at the appropriate level in other territories. Were such contractors to operate outside the terms </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">89</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">of these licenses, we may experience an adverse effect on our business, including the pace of development of our investigational COMP360 psilocybin treatment or any future psychedelic-based drug candidate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We rely on patents and other intellectual property rights to protect our investigational COMP360 psilocybin treatment, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for COMP360, any future therapeutic candidates, any associated psychological support, digital tools, methods used to manufacture the underlying drug substances, and the methods for treating patients using those substances, or on licensing in such rights. Failure to obtain, maintain, protect, enforce or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our investigational COMP360 psilocybin treatment and any future therapeutic candidates. We also rely on trade secrets and know-how to develop and maintain our proprietary and intellectual property position. Any failure to protect our trade secrets and know-how could adversely affect our operations and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We cannot be certain that patents will be issued or granted with respect to patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid or unenforceable. The patent position of companies like ours is generally uncertain because it involves complex legal and factual considerations. The standards applied by the European Patent Office, the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in pharmaceutical patents. Consequently, patents may not issue from our pending patent applications, and even if they do issue, such patents may not issue in a form that effectively prevents others from developing or commercializing competing treatments. As such, we do not know the degree of future protection that we will have on our proprietary treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The patent prosecution process is expensive, complex and time-consuming, and we and our current or future third party partners, licensors, licensees, or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaboration partners will fail to identify patentable aspects of inventions made in the course of research, development or commercialization activities before it is too late to pursue patent protection on them. In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not published until and unless granted. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly we cannot be certain that for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">90</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">any licensed patents or pending patent applications, the named applicant(s) were the first to make the inventions claimed in such patents or pending patent applications or that the named applicant(s) were the first to file for patent protection for such inventions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued that protect our treatments, in whole or in part, or that effectively prevent others from commercializing competitive technologies and treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaboration partners. If our current or future licensors, licensees or collaboration partners fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaboration partners are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The patent examination process may require us or our licensors, licensees or collaboration partners to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. Even if patents do successfully issue and even if such patents cover COMP360 and any future therapeutic candidates, third parties may initiate an opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> review, nullification or derivation proceedings in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">For example, in December 2021, a third party filed two petitions requesting post grant review of two of our patents (U.S. Patent 10,947,257 and U.S. Patent 10,954,259) before the Patent Trial &amp; Appeal Board of the U.S. Patent and Trademark Office, or the USPTO Board. On June 22, 2022, the USPTO Board issued decisions in both cases denying institution of post grant review on the merits of the arguments presented in each of the challenges. On July 22, 2022, the third-party challenger filed a request with the USPTO Board for rehearing of the USPTO Board&#8217;s decision, as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">well as a request for Precedential Opinion Panel on August 16, 2022 in each of the challenges. On February 10, 2023, the USPTO Board denied the request for Precedential Opinion Panel in each of the challenges. On May 23, 2023, the USPTO Board denied the requests for rehearing in each of the challenges. We cannot provide any assurances that we will successfully defend ourselves against any future patent challenges. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our and our licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In addition, patents and other intellectual property rights also will not protect our technology, COMP360 and any future therapeutic candidates if third parties, including our competitors, design </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">91</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">around our protected technology and our investigational COMP360 psilocybin treatment and any future therapeutic candidates without infringing, misappropriating or otherwise violating our patents or other intellectual property rights. Moreover, some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing treatments and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our current or future licensors, licensees or collaborators were or will be the first to file any patent application related to a therapeutic candidate. Furthermore, if patent applications of third parties have an effective filing date before March 16, 2013, an interference proceeding can be initiated by such third parties at the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If patent applications of third parties have an effective filing date on or after March 16, 2013, a derivation proceeding can be initiated by such third parties at the USPTO to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, we may be subject to third-party challenges regarding our exclusive ownership of our intellectual property. If a third party were successful in challenging our exclusive ownership of any of our intellectual property, we may lose our right to use such intellectual property, such third party may be able to license such intellectual property to other third parties, including our competitors, and our competitors could market competing treatments and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Issued patents covering one or more of our investigational therapeutics could be found invalid or unenforceable if challenged in court. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of our or our licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors&#8217; or collaboration partners&#8217; efforts, we or our licensors or collaboration partners may not prevent third parties from infringing upon, misappropriating or otherwise violating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the UK, EU and the U.S.. We may fail in enforcing our rights, in which case our competitors and other third parties may be permitted to use our treatments without payment to us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, litigation involving our patents carries the risk that one or more of our patents will be held unenforceable, one or more claims narrowed or held invalid (in whole or in part, on a claim-by-claim basis). Such an adverse court ruling could allow third parties to commercialize our treatments, and then compete directly with us, without payment to us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">92</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our investigational treatments, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S. or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise challenges to the validity of our patent claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover COMP360 or any future therapeutic candidates. For example, on July 22, 2022, a third-party challenger filed with the USPTO Board requests for rehearing of the USPTO Board&#8217;s decisions to deny institution of post-grant reviews of U.S. Patent 10,947,257 and U.S. Patent 10,954,259, and on August 16, 2022, the third-party challenger also filed requests for a Precedential Opinion Panel in each of the patents. On February 10, 2023, the USPTO Board denied the request for a Precedential Opinion Panel in each of the challenges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">On May 23, 2023, the USPTO Board denied the requests for rehearing in each of the challenges. The outcome following legal assertions of invalidity and unenforceability during patent litigation or other proceedings is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on COMP360 or one or more of any future therapeutic candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations, and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm our business and financial results. </span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the European Patent Office, the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The European Patent Office, the USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our collaboration partners to pay these fees due to the U.S. and comparable foreign patent agencies and take the necessary action to comply with such requirements with respect to our intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">93</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our investigational treatments, third parties, including our competitors might be able to enter the market with similar or identical treatments or technologies, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our investigational treatments, our business may be materially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In the U.S., if all maintenance fees are paid on time, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our investigational treatments, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive treatments. Given the amount of time required for the development, testing and regulatory review of new investigational treatments, patents protecting such candidates and concomitant treatments might expire before or shortly after such candidates and concomitant treatments are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing treatments similar or identical to ours. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Depending upon the timing, duration and conditions of FDA marketing approval of COMP360 and any future therapeutic candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar legislation in the EU. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term loss during product development, the FDA regulatory review process and the issuance of a final decision controlling the product under the Controlled Substance Act. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method of manufacturing it may be extended. However, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will not be lengthened and third parties, including our competitors, may obtain approval to market competing treatments sooner than we expect. As a result, our revenue from applicable treatments could be materially reduced and our business, financial condition, results of operations, and prospects could be materially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">94</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">others may be able to make compounds or develop digital assets that are the same as or similar to our investigational COMP360 psilocybin treatment, any future therapeutic candidates and digital assets but that are not covered by the claims of the patents that we own or control; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the patents of third parties may have an adverse effect on our business; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we or our licensors or any current or future collaboration partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or control; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we or our licensors or any current or future collaboration partners might not have been the first to file patent applications covering certain of our inventions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">it is possible that our current and future pending patent applications will not lead to issued patents; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by third parties; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive treatments for sale in our major commercial markets; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">third parties performing manufacturing or testing for us using our treatments or technologies could unknowingly use the intellectual property of others without obtaining a proper license; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may not develop additional technologies that are patentable; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property, or otherwise develop similar know-how.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Many of our consultants, advisors and employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Some of these individuals executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we intend that our consultants, advisors and employees do not use proprietary information or know-how of their former employers while working for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s former employer. Litigation may be necessary to defend against these claims. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">95</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our treatments. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract our management from its day-to-day activities. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Intellectual property rights of third parties could adversely affect our ability to compete or commercialize our investigational treatments, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational treatments. Such litigation or licenses could be costly or not available on commercially reasonable terms. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market, and sell any investigational treatments that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In the past, we have been subject to, and in the future we may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to COMP360 or any future therapeutic candidates. If the outcome of any such proceeding or litigation is adverse to us, it may affect our ability to compete effectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our treatments or elements thereof, our manufacture or uses relevant to our development plans, the targets of COMP360 or any future therapeutic candidates, or other attributes of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. In such cases, we may not be in a position to develop or commercialize such therapeutic candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms or at all. In the event that a patent has not expired at the time of approval of such investigational treatments or therapeutic candidate and the patent owner were to bring an infringement action against us, we may have to argue that our investigational treatments or the manufacture or use of the underlying therapeutic substances do not infringe a valid claim of the patent in question. Alternatively, if we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would need to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. The same applies to other jurisdictions. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. In the event that a third party </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">96</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">successfully asserts its patent against us such that such third party&#8217;s patent is found to be valid and enforceable and infringed by COMP360 or further therapeutic products, unless we obtain a license to such patent, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to commercialize COMP360 or further therapeutic products. Similarly, the targets for our investigational COMP360 psilocybin treatment have also been the subject of research by other companies, which have filed patent applications or have patents on aspects of the targets or their uses. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, or at all, and any such litigation would be costly and time-consuming. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">It is possible that we have failed, and in the future may fail, to identify relevant patents or applications that may be asserted against us. For example, certain U.S. applications filed after November 29, 2000 can remain confidential until and unless issued as patents, provided that inventions disclosed in the applications have not and will not be the subject of a corresponding application filed outside the U.S. In general, patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our treatments could have been filed by others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications in the areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our treatments or the use of our treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Third-party intellectual property right holders, including our competitors, may actively bring infringement, misappropriation or violation claims against us based on existing or future intellectual property rights, regardless of their merit. We may not be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we are unsuccessful defending in any such claim, in addition to being forced to pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing any of our investigational treatments that were held to be infringing. If possible, we might be forced to redesign our investigational COMP360 psilocybin treatment or any future therapeutic candidates so that we no longer infringe the intellectual property rights of third parties, or we may be required to seek a license to any such technology that we are found to infringe, which license may not be available on commercially reasonable terms or at all. Even if we or our licensors or collaboration partners obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaboration partners and it could require us to make significant licensing and royalty payments. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">97</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaboration partners&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future investigational treatments. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Intellectual property litigation could cause us to spend substantial resources, distract our personnel from their normal responsibilities, harming our reputation and our business operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development and commercialization activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may not be successful in obtaining or maintaining necessary rights to COMP360 or any future therapeutic candidates through acquisitions and in-licenses. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In the future, our programs may require the use of proprietary rights held by third parties, and the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, with respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest in such patents. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for COMP360 or any future therapeutic candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of an investigational treatment or program, we may have to abandon development of that investigational treatment or program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">98</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our applicable investigational treatment or program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights to or from third parties, or otherwise experience disruptions to our business relationships with our licensors, licensees or collaborators, we could lose the rights to intellectual property that are important to our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are or may become a party to third-party agreements under which we grant or are granted rights to intellectual property that are potentially important to our business and we expect that we may need to enter into additional license or collaboration agreements in the future. Our existing third-party agreements impose, and we expect that future license agreements will impose, various obligations related to, among other things, therapeutic development and payment of royalties and fees based on achieving certain milestones. In addition, under several of our collaboration agreements, we are prohibited from developing and commercializing treatments that would compete with the treatments licensed under such agreements. If we fail to comply with our obligations under these agreements, our licensor or collaboration partner may have the right to terminate the agreement, including any licenses included in such agreement. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The termination of any license or collaboration agreements or failure to adequately protect such license agreements or collaboration could prevent us from commercializing our investigational COMP360 psilocybin treatment or any future therapeutic candidates covered by the agreement or licensed intellectual property. For example, we may rely on license agreements which grant us rights to certain intellectual property and proprietary materials that we use in connection with the development of our treatments. If this agreement were to terminate, we would be unable to timely license similar intellectual property and proprietary materials from an alternate source, on commercially reasonable terms or at all, and may be required to conduct additional bridging studies on our investigational COMP360 psilocybin treatment or any future therapeutic candidates, which could delay or otherwise have a material adverse effect on the development and commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Several of our existing license agreements are sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we must rely on our licensor to comply with its obligations under the primary license agreements under which such third party obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which it may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates incorporating the relevant intellectual property. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Disputes may arise regarding intellectual property subject to a license or collaboration agreement, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the scope of rights granted under the agreement and other interpretation-related issues; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">99</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor or collaboration partner that is not subject to the agreement; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the sublicensing of patent and other rights under any current or future collaboration relationships; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaboration partners; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, our third-party agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidate, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We consider proprietary trade secrets, confidential know-how and unpatented know-how to be important to our business. We rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to maintain as confidential. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">To protect this type of information against disclosure or appropriation by third parties and our competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or confidential know-how. Also, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our trade secrets and confidential know-how to our competitors and other third parties or breach such agreements, and we may not be able to obtain an adequate remedy for such breaches. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is difficult, expensive, time-consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor or other third party lawfully obtained or independently developed any of our trade secrets or confidential know-how, we would have no right to prevent such competitor or other third party from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">100</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Failure to obtain or maintain trade secrets or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We may not be able to protect our intellectual property rights throughout the world and may face difficulties in certain jurisdictions, which may diminish the value of intellectual property rights in those jurisdictions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Filing, prosecuting and defending patents on therapeutic candidates in all countries and jurisdictions throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside of the UK and the U.S., could be less extensive than those in the UK and the U.S., assuming that rights are obtained in the UK and the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the UK and the U.S., or from selling treatments or importing drug substances made using our inventions in and into the UK and the U.S., or other jurisdictions. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. It is also quite common that depending on the country, the scope of patent protection may vary for the same therapeutic candidate or technology. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Competitors may use our and our licensors&#8217; or collaboration partners&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own treatments and, further, may export otherwise infringing treatments to territories where we and our licensors or collaboration partners have patent protection, but enforcement is not as strong as that in the UK and the U.S. These treatments may compete with COMP360 or any future therapeutic candidates, and our and our licensors&#8217; or collaboration partners&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the UK and the U.S., and companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">101</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors or collaboration partners is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Proceedings to enforce our and our licensors&#8217; or collaboration partners&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#8217; or collaboration partners&#8217; efforts and attention from other aspects of our business, regardless of whether we or our licensors or collaboration partners are successful, and could put our and our licensors&#8217; or collaboration partners&#8217; patents at risk of being invalidated or interpreted narrowly. In addition, such proceedings could put our and our licensors&#8217; or collaboration partners&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaboration partners. We or our licensors or collaboration partners may not prevail in any lawsuits that we or our licensors or collaboration partners initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our future product candidates. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We rely on the protection of our intellectual property in various jurisdictions. Changes in patent laws in the U.S. and other jurisdictions could cause us to lose protection over certain of our patents and therefore impair our ability to protect our future product candidates. For example, in the U.S., recent decisions raise questions regarding the award of patent term adjustment for patents in families where related patents have been issued without a patent term adjustment. Thus, it cannot be said with certainty how a patent term adjustment award will or will not be viewed in future and whether patent expiration dates may be impacted. The complexity and uncertainty of European patent laws have also increased in recent years. For example, in Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We may decide to opt out of our future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Our Dependence on Third Parties</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">102</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We rely on third parties to supply drug substance and manufacture, package and distribute COMP360 and expect to continue to rely on third parties to supply and manufacture any future therapeutic candidates, and if COMP360 is approved, we will rely on third parties to manufacture these substances for commercial supply. If any third-party provider fails to meet its obligations to supply drug substance or manufacture COMP360 or our future therapeutic candidates, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substance and the commercialization of any treatments, if approved, could be stopped, delayed or made commercially unviable, less profitable or may result in enforcement actions against us. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We do not currently have, nor do we plan to acquire, the infrastructure or capability necessary to manufacture COMP360 or any future therapeutic candidates, including the psilocybin incorporated into such therapeutic candidates. We rely on, and expect to continue to rely on, contract manufacturers, or CMOs, for the development, manufacture and production of the psilocybin used in our investigational treatments administered in our clinical trials and will continue to rely on such CMOs for the development, manufacture and production of any commercial supply, if our investigational treatments are approved. Currently, we engage with multiple different CMOs in the UK for all activities relating to the development, manufacture and production of all components incorporated in COMP360. Reliance on third-party providers, such as CMOs, exposes us to more risk than if we were to manufacture COMP360, or any future therapeutic candidates. We do not control the manufacturing processes of the CMOs we contract with and are dependent on those third parties for the production of COMP360 or any future therapeutic candidates in accordance with relevant regulations (such as the FDA&#8217;s good laboratory practices, or GLP, cGMPs or similar regulatory requirements outside the US) for the manufacture of drug substances, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Some of the suppliers currently engaged in the production process of COMP360, including our current supplier of API, have not in the past been subject to inspection by the FDA and/or EMA and there can be no assurance that they are in compliance with all applicable regulations. Our failure, or the failure of third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of COMP360 or any future therapeutic candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of COMP360 or any future therapeutic candidates and harm our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for COMP360 or any future therapeutic candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">including as a result of trade tensions, supply chain delays or increasing costs, we could experience delays in our research or planned clinical studies or commercialization. In addition, quality issues may arise during scale-up activities. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. For example, the COVID-19 pandemic created supply constraints generally globally. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, may significantly delay our clinical studies and the commercialization of our treatments, if approved, which would materially adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">103</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In complying with the manufacturing regulations of the FDA, the DEA, the EMA, the MHRA and other comparable foreign authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the drug product meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of drug product and shutting down of production, any of which could materially adversely affect our business, prospects, financial condition and results of operations. We and any of these third-party suppliers may also be subject to audits by the FDA, the DEA, the EMA, the MHRA or other comparable foreign authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the treatments could suffer significant interruptions. We face risks inherent in relying on a limited number of CMOs, as any disruption, such as a fire, natural hazards or vandalism at the CMO could significantly interrupt our manufacturing capability. We currently do not have disaster recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all, and we would likely experience months of manufacturing delays as we build or locate replacement facilities and seek and obtain necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis or at all. In addition, operating any new facilities may be more expensive than operating our current facility, and business interruption insurance may not adequately compensate us for any losses that may occur, in which case we would have to bear the additional cost of any disruption. In such a scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">For these reasons, a significant disruptive event of the manufacturing facility could have a material adverse effect on our business, including placing our financial stability at risk. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, academic collaborators and contract research organizations, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">104</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">regulatory approval for or commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates and our business could be substantially harmed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, academic collaborators and third-party contract research organizations, or CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the EMA, the MHRA and comparable foreign regulatory authorities for all of our treatments in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we, our investigators, academic collaborators or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, the MHRA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure, or the failure of our third-party contractors and CROs, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Further, these investigators, academic collaborators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our investigational COMP360 psilocybin treatment or any future therapeutic candidates and clinical trials. If independent investigators, academic collaborators or CROs fail to devote sufficient resources to the development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. In addition, investigators, academic collaborators and CROs may have difficulty staffing, undergo changes in priorities or become financially distressed or form relationships with other entities, some of which may be our competitors, any of which materially adversely affect our business. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">There is a limited number of third-party service providers that specialize in or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs, academic collaborators or investigators on commercially reasonable terms or at all. If CROs, academic collaborators or clinical investigators do not successfully carry out their contractual duties </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">105</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">or obligations or meet expected deadlines, or if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates. As a result, our results of operations and the commercial prospects for our investigational COMP360 psilocybin treatment or any future therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Switching or adding additional CROs (or investigators) involves additional cost and requires management time and focus. In addition, delays occur during the natural transition period when a new CRO commences work, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on our business or financial condition and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">There are a number of third parties that conduct IISs using COMP360 provided by us. Generally, we do not sponsor these IISs, and encourage the open publication of all IIS findings. Any failure by a third party to meet its obligations with respect to the clinical development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates may delay or impair our ability to obtain regulatory approval for COMP360. IISs of COMP360 or any future therapeutic candidates may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360 and any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">There are a number of academic and private non-academic institutions that conduct and sponsor clinical trials relating to COMP360. We do not control the design or conduct of the IISs sponsored by third-parties, and the FDA or comparable foreign regulatory authorities could determine that these IISs do not provide adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the studies, safety concerns or other study results. Third-party investigators may design IISs that are underpowered, use clinical endpoints that are not widely accepted, questionable, or more difficult to achieve, or in other ways increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. In addition, these IISs may be conducted using different populations or indications than are used in our clinical trials or IISs which we sponsor, including milder or more severe patient populations. We also do not have control over academic or private non-academic institutions&#8217; disclosure of information, and these parties may disclose sensitive information or results of studies without our approval or consent.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As a result of these IISs sponsored by third-parties, we will receive certain information rights with respect to the IISs, including access to and the ability to use and reference the resulting data, including for our own regulatory filings. However, we do not have control over the timing and reporting of the data from IISs, nor do we necessarily own or control the data from the IISs. If we are unable to confirm or replicate the results from the IISs or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of COMP360 or any future therapeutic candidates. Any data generated in IISs may not be predictive of the results in populations or indications in which we are conducting, or plan to conduct, clinical trials. Any data perceived to be negative, however, could harm our ability to advance the clinical development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, and we may not be able to investigate whether such negatively perceived data reflects issues with the design and/or conduct of the IIS or if it </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">106</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">actually reflects characteristics of our therapeutic approach. Moreover, we rely on our investigators and institutions to provide us timely information. We have in the past, and may in the future, experience delays in receiving notice of reportable adverse events or SUSARs from IISs. For example, we were informed in September 2020 of a SUSAR in an IIS at the University of Zurich that had occurred a few weeks earlier, despite an obligation by the site investigator to report such an event to us immediately. Such delays, or any failures to provide contractually required information, could negatively impact us or cause delays in our reporting requirements to applicable regulatory authorities. Further, if investigators or institutions breach their obligations with respect to the clinical development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the IISs been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, the FDA or comparable foreign regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these IISs, or our interpretation of preclinical, manufacturing or clinical data from these IISs. If so, the FDA or other comparable foreign regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Our Business Operations, Managing Growth and Employee Matters</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our future growth and ability to compete effectively depends on our ability to manage senior management changes and our ability to retain our key personnel and recruit additional qualified personnel, and on the key personnel employed by our collaborative partners. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our success depends upon the continued contributions of our key executives, managers, scientific and medical personnel, many of whom have been instrumental for us and have substantial experience with our treatments and related technologies. These key management individuals include the members of our board of directors and certain executive officers. We do not currently maintain any key person insurance. The loss of key executives, managers and senior scientists or medical personnel could delay our research and development activities. In addition, we may experience increased employee turnover as a result of general market conditions and a competitive talent market, as well as Company-specific factors, such as a decline in the price of our ADSs, business performance, and leadership changes. For example, on October 28, 2024, our board of directors authorized a strategic reorganization, which included a reduction in workforce, including some senior management roles. In addition, we are exploring a potential externalization of our digital technologies, intellectual property and associated employees. This reorganization and the potential externalization of our digital technologies and associated employees has caused and may in the future cause additional attrition and affect employee morale. Additionally, as we are operating with fewer employees than we have in prior periods, we face additional risk that we might not be able to execute on our strategic plans which may have an adverse effect on our business, financial condition, and operating results. If we are not successful in managing these transitions or any future changes in senior management, it could negatively impact our corporate culture, negatively impact our relationships with employees, investors, suppliers, CROs, principal investigators, key opinion leaders, regulators and other key stakeholders, or otherwise disrupt our business operations, which could have a material adverse effect on our business and prospects. In addition, our ability to compete in the highly competitive pharmaceutical and biotechnology industry depends upon our ability to attract and retain highly qualified management, scientific and medical personnel. Many </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">107</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">other companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Therefore, we might not be able to attract or retain these key persons on conditions that are economically acceptable. Moreover, some qualified prospective employees may choose not to work for us due to negative perceptions regarding the therapeutic use of psilocybin or other objections to the therapeutic use of a controlled substance. Furthermore, we will need to recruit new managers and qualified scientific and medical personnel to develop our business if we expand into fields that will require additional skills. Our inability to attract and retain these key persons could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As part of our long-term plans, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the area of sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth or raise funds to support our growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, certain key academic and scientific personnel play a pivotal role in our collaborative partners&#8217; research and development activities. If any of those key academic and scientific personnel who work on the development of our research programs, our investigational COMP360 psilocybin treatment and any future therapeutic candidates leave our collaborative partners, the development of our research programs, our investigational COMP360 psilocybin treatment and any future therapeutic candidates may be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our employees, independent contractors, principal investigators, institutions and researchers of IISs, CROs, consultants, vendors, third-party treatment sites, healthcare professionals and collaboration partners and third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are exposed to the risk that our employees, independent contractors, principal investigators, institutions and researchers of IISs, CROs, consultants, vendors, third-party treatment sites, healthcare professionals or other qualified professionals and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and negligent conduct or unauthorized activities that violate, among other things: (i) the regulations of the FDA, the EMA, the MHRA and other comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">108</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our commercialization model also entails the risk of malpractice and professional liability claims against both our third-party treatment sites and us as a result of actual or alleged misconduct by healthcare professionals administering our treatments. Although we, and the third-party treatment sites with which we engage, carry insurance covering malpractice and professional liability claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful malpractice or professional liability claims could result in substantial damage awards that exceed the limits of our insurance coverage and our third-party treatment sites&#8217; insurance coverage. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our services. As a result, adequate professional liability insurance may not be available to our providers or to us in the future at acceptable costs or at all. Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our third-party treatment sites from our operations, which could have a material adverse effect on our business, financial condition and results of operations. In addition, any such claims may materially and adversely affect our business or reputation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">It is not always possible to identify and deter misconduct by employees and other third parties, including healthcare professionals who monitor and safeguard participants receiving investigational COMP360 psilocybin treatment in our clinical trials, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We face substantial competition and our competitors may discover, develop or commercialize treatments before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The pharmaceutical and psychedelic industry is intensely competitive and subject to rapid and significant technological change. Our competitors include multinational pharmaceutical companies, universities and other research institutions. We also face competition from 501(c)(3) non-profit medical research organizations, including the Usona Institute, which, in August 2023, published results from its Phase 2, double-blind, placebo-controlled study evaluating a single dose of psilocybin to treat major depressive disorder. In March 2024, Usona Institute announced the launch of its Phase 3 trial evaluating the efficacy and safety of psilocybin 25 mg in as a treatment for major depressive disorder, which is expected to enroll approximately 240 adult patients. Such non-profits may be willing to provide psilocybin-based products at cost or for free, undermining our potential market for COMP360. In addition, a number of for-profit biotechnology companies or institutions are specifically pursuing the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">109</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">development of psilocybin, including Cybin Inc., and other psychedelic compounds to treat mental health illnesses, including TRD. Cybin is conducting a Phase 3 program for its deuterated psilocybin analog for the adjunctive treatment of major depressive disorder, which includes two Phase 3 trials and is expected to enroll approximately 550 adult patients. In addition, an increasing number of companies are stepping up their efforts in discovery of new psychedelic compounds. It is also probable that the number of companies seeking to develop psychedelic products and treatments for mental health illnesses, such as depression, will increase. If any of our competitors is granted an NDA for their psychedelic treatments before us and manages to obtain approval for a broader indication, such as major depressive disorder, and thus access a wider patient population, we may face more intensified competition from such potential psychedelic treatments and increased difficulties in winning market acceptance of our investigational COMP360 psilocybin treatment or any future therapeutic candidates. All of these risks are heightened because psilocybin, which is a naturally occurring substance and therefore not subject to patent protection, may be deemed an appropriate substitute for COMP360.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We also face competition from major pharmaceutical, biopharmaceutical and biotechnology companies who have developed or are developing non-psilocybin or psychedelic based treatments for the treatment of MDD and TRD, and will face future competition for any other indications we may seek to treat with our investigational COMP360 psilocybin treatment. There are a number of companies that currently market and sell products or treatments, or are pursuing the development of products or treatments, for the treatment of depression, including antidepressants such as SSRIs and serotonergic norepinephrine reuptake inhibitors, or SNRIs, antipsychotics, cognitive behavioral therapy, or CBT, esketamine and ketamine, repeat transcranial magnetic stimulation, or rTMS, electroconvulsive therapy, or ECT, vagus nerve stimulation, or VNS, and deep brain stimulation, or DBS, among others. Many of these pharmaceutical, biopharmaceutical and biotechnology competitors have established markets for their treatments and have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market superior products or treatments. In addition, many of these competitors have significantly greater experience than we have in undertaking preclinical studies and human clinical trials of new therapeutic substances and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA, EMA or MHRA approval for alternative or superior products. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Smaller and earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The field in which we operate is characterized by a growing and shifting understanding of disease biology, changing technologies, and strong intellectual property barriers to entry, and many companies are involved in the creation, development and commercialization of novel therapeutics and technology platforms. Our competitors may develop treatments that are more effective, more convenient, more widely used and less costly or have a better safety profile than our treatments and these competitors may also be more successful than we are in manufacturing and marketing their treatments. Additionally, there can be no assurance that our competitors are not currently developing, or will not in the future develop, technologies and treatments that are equally or more economically attractive as our investigational COMP360 psilocybin treatment or any future therapeutic candidates. Competing alternative treatments or technology platforms may gain faster or greater market acceptance than our treatments or technology platforms and medical advances or rapid technological development by competitors may result in our investigational COMP360 psilocybin treatment or any future therapeutic candidates or technology platforms becoming non-competitive or obsolete before we are able to recover our research and development and commercialization </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">110</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">expenses. If we are unable to compete effectively against these companies, then we may not be able to commercialize our investigational COMP360 psilocybin treatment or any future therapeutic candidates or achieve a competitive position in the market. This would materially and adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We anticipate that we will face intense and increasing competition as new treatments enter the market. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Acquisitions and investments could result in operating difficulties, dilution and other harmful consequences that may adversely impact our business, financial condition and results of operations. Additionally, if we are not able to identify and successfully acquire suitable businesses, our operating results and prospects could be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may in the future make additional acquisitions or investments to add employees, complementary companies, treatments, products, solutions, technologies, or revenue. These transactions could be material to our business, financial condition and results of operations. We also expect to continue to evaluate and enter into discussions regarding a wide array of potential strategic transactions. The identification of suitable acquisition or investment candidates can be difficult, time-consuming and costly, and we may not be able to complete acquisitions or investment on favorable terms, if at all. The process of integrating an acquired company, business or technology and managing our future investments may create unforeseen operating difficulties and expenditures. The areas where we face risks include:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">loss of key employees of the acquired company and other challenges associated with integrating new employees into our culture, as well as reputational harm if integration is not successful;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">diversion of management time and focus from operating our business to addressing acquisition integration and investment management challenges;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">high uncertainty with respect to any investment in companies engaging in early stage drug discovery and development with limited proof of concept, which might result in significant investment loss;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">challenges in identifying suitable investment opportunities in the digital health market and diversion of management time and resources to integrate such investments into our business due to our lack of experience in such market; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">implementation or remediation of controls, procedures, and policies at any acquired company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">difficulties in integrating and managing the combined operations, technologies, technology platforms and products of any acquired companies and realizing the anticipated economic, operational and other benefits in a timely manner, which could result in substantial costs and delays or other operational, technical or financial problems;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">integration of the acquired company&#8217;s accounting, human resource and other administrative systems, and coordination of product, engineering and sales and marketing function;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">assumption of contractual obligations that contain terms that are not beneficial to us, require us to license or waive intellectual property rights, or increase our risk for liabilities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">111</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">failure to successfully further develop the acquired technology or realize our intended business strategy;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">our dependence on unfamiliar affiliates and partners of acquired businesses;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">uncertainty of entry into markets in which we have limited or no prior experience or in which competitors have stronger market positions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">unanticipated costs associated with pursuing investments or acquisitions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">failure to find commercial success with the products or services of the acquired company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">difficulty of transitioning the acquired technology onto our existing platforms and maintaining the security standards for such technology consistent with our other solutions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">responsibility for the liabilities of acquired businesses, including those that were not disclosed to us or exceed our estimates, as well as, without limitation, liabilities arising out of their failure to maintain effective data protection and privacy controls and comply with applicable regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">inability to maintain our internal standards, controls, procedures, and policies;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">failure to generate the expected financial results related to an acquisition in a timely manner or at all;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">difficulties in complying with antitrust and other government regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">challenges in integrating and auditing the financial statements of acquired companies that have not historically prepared financial statements in accordance with U.S. GAAP;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">potential accounting charges to the extent intangibles recorded in connection with an acquisition, such as goodwill;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">trademarks, client relationships or intellectual property, are later determined to be impaired and written down in value; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">failure to accurately forecast the impact of an acquisition transaction.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Moreover, we may rely heavily on the representations and warranties provided to us by the sellers of acquired companies or strategic partners, including as they relate to creation of, and ownership and rights in, intellectual property, existence of open source and compliance with laws and contractual requirements. If any of these representations and warranties are inaccurate or breached, such inaccuracy or breach could result in costly litigation and assessment of liability for which there may not be adequate recourse against such sellers, in part due to contractual time limitations and limitations of liability.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Future acquisitions and investments could also result in expenditures of significant cash, dilutive issuances of our equity securities, the incurrence of debt, restrictions on our business, contingent liabilities, amortization expenses or write-offs of goodwill, any of which could harm our financial condition. In addition, any acquisitions or investments we announce could be viewed negatively by collaborative partners, employees, vendors, patients, shareholders, or investors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">112</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, competition within our industry for acquisitions of business, technologies and assets may become heightened. Even if we are able to identify an acquisition or investment that we would like to consummate, we may not be able to complete the acquisition or investment on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions or investments that are not ultimately consummated. Those negotiations could result in diversion of management time and significant out-of-pocket costs. If we fail to evaluate and execute acquisitions or investments successfully, we may not be able to realize the benefits of these acquisitions or investments, and our operating results could be harmed. If we are unable to successfully address any of these risks, our business, financial condition and results of operations could be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If we are not able to maintain and enhance our reputation and brand recognition, our business, financial condition and results of operations will be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing and future third-party treatment sites, healthcare professionals, patients and collaborators, and to our ability to attract clinics to become our third-party treatment sites offering our treatments. The promotion of our brand has required and may continue to require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing and other initiatives may become increasingly difficult and expensive. Brand promotion and marketing activities may not be successful or yield increased revenue, to the extent we generate any future revenue, and to the extent that these activities yield increased future revenue, the increased revenue may not offset the expenses we incur and our business, financial condition and results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our network of third-party treatment sites, healthcare professionals and patients, could harm our reputation and brand and make it substantially more difficult for us to attract new third-party treatment sites, healthcare professionals and patients. If we do not successfully maintain, protect or enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with third-party treatment sites, healthcare professionals and patients, which would harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our current and potential future digital technologies may not be successful, which may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We currently employ or are developing digital technologies to collect data, educate patients and healthcare professionals in our clinical trials, collect digital phenotyping information, and harness artificial intelligence. We use certain internally developed digital technologies in the conduct of our clinical trials and we continuously maintain, evaluate and improve the performance, security and reliability. In addition, we are exploring a potential externalization of our digital technologies and may rely significantly on third-parties in the future to provide us with digital technology services. There can be no assurance that these digital technologies do not or will not have inaccuracies or errors. As with any digital technology, poor performance, unreliability or errors or inaccuracies may adversely impact the conduct of our clinical trials, our reputation and our plans to use digital technologies to complement our investigational treatments.</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our efforts to maintain and optimize the digital technologies used in the conduct of our clinical trials, either internally or through a third-party service provider, or to develop or acquire alternate technologies if required for the conduct of our clinical trials may involve significant time, costs, and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">113</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">resources, and may divert our management team&#8217;s attention and focus from executing our clinical trials or other key elements of our strategy. If our efforts to maintain or optimize our current digital technologies, either internally or through a third-party service provider, or, if needed, develop or acquire these digital technologies are unsuccessful, it may have a materially adverse impact on the conduct of our trials, future prospects and financial position.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our current or future digital technology solutions, including those provided by third parties, could compromise sensitive information related to our business, patients, healthcare professionals, third-party treatment sites and collaborators, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our current and future digital technology solutions, including those provided by third parties, may involve the collection, storage, usage or disclosure of confidential and sensitive data, including protected health information, or PHI, and other types of personal data or personally identifiable information, or PII. For example, as part of our clinical trials, we may use digital technology solutions to record and analyze therapeutic sessions. We may also process and store, and use additional third parties to process and store, confidential or sensitive information, including intellectual property and other proprietary business information of ours and our third-party collaborators.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are highly dependent on information technology networks and systems, including the internet and external cloud providers, to securely process, transmit and store this critical information. Security incidents or breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, and employee or contractor error, negligence or malfeasance, could create system disruptions, shutdowns or unauthorized disclosure or modifications of confidential information, causing patient health information to be accessed, acquired or altered without authorization or to become publicly available. In addition, we use certain systems that rely on machine learning systems, which are complex and may have errors or inadequacies that are not easily detectable. These machine learning systems may inadvertently reduce the efficiency of our systems, or may cause unintentional or unexpected outputs that are incorrect, do not match our business goals, do not comply with our policies, or otherwise are inconsistent with our guiding principles, and mission. Any errors or vulnerabilities discovered in our systems or data could also result in damage to our reputation or liability for damages, any of which could adversely affect our growth prospects and our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We utilize third-party service providers for important aspects of the collection, storage and transmission of patient information, and other confidential and sensitive information as well as encryption of data at rest and in transit, along with appropriate system logging and access controls, and therefore rely on third parties to manage functions that have material cybersecurity risks. We and our third party service providers are at constant risk of cyber-attacks or cyber intrusions via viruses, worms, break-ins, malware, ransomware, phishing attacks, hacking, denial-of-service attacks or other attacks and similar disruptions from the unauthorized use of or access to computer systems (including from internal and external sources) that attack or otherwise exploit any vulnerabilities in our systems or those of our third party service providers, or attempt to fraudulently induce our employees, consumers, third party service providers or others to disclose passwords or other sensitive information or unwittingly provide access to our systems or data. These types of incidents continue to be prevalent and pervasive across industries, including in our industry. We take certain administrative and technological safeguards designed to address these risks, such as by requiring outsourcing contractors who handle or subcontract the handling of patient information for us to enter into agreements that contractually obligate those contractors and any subcontractors to use reasonable efforts to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">114</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">safeguard PHI, other PII, and other sensitive information. Measures taken to protect our systems, those of our subcontractors, or the PHI, other PII, or other sensitive data we or our subcontractors process or maintain, may not adequately protect us from the risks associated with the collection, storage and transmission of such information. Although we take steps to help protect confidential and other sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses, failures or breaches due to third-party action, employee negligence or error, malfeasance or other disruptions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">A security breach or privacy violation that leads to disclosure or unauthorized use, loss of, or modification of, or that prevents access to or otherwise impacts the confidentiality, security, or integrity of, patient information, including PHI or other PII, or other sensitive information we or our subcontractors maintain or otherwise process, could harm our reputation, compel us to comply with breach notification laws, require us to verify the accuracy of database contents, and cause us to incur significant costs for remediation, including measures intended to repair or replace systems or technologies or upgrade systems to prevent future occurrences, fines, penalties, and potential increases in insurance premiums. If we are unable to prevent such security incidents or breaches or privacy violations or implement satisfactory remedial measures, or if it is perceived that we have been unable to do so, our operations could be disrupted, we may be unable to provide access to our digital technology solutions and tools, and our ability to conduct our clinical trials may be negatively impacted, including patient enrollment in clinical trials and to train healthcare professionals for our clinical trials, and we may suffer loss of reputation, adverse impacts on patients, physicians, clinical trial sites and investor confidence, financial loss, governmental investigations or other actions, regulatory or contractual penalties, and other claims and liability. In addition, security breaches and other inappropriate access to, or acquisition or processing of, information can be difficult to detect, and any delay in identifying such incidents or in providing any notification of such incidents may lead to increased harm.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Any such breach or interruption of our systems or any of our third-party information technology partners, could compromise our networks or data security processes and confidential or sensitive information could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost, misused, or stolen. Any such interruption of access, improper or unauthorized access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws and regulations that protect the privacy and security of patient information or other personal information, such as HIPAA, and the GDPR, the CCPA, and regulatory penalties.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct clinical trials for COMP360 psilocybin treatment or any future therapeutic candidates, obtain regulatory approval of and commercialize COMP360 psilocybin treatment or any future therapeutic candidates, conduct research and development activities, collect, process, and prepare company financial information, provide information about our current and future therapeutic candidates. Any such breach could also result in the compromise of our trade secrets and other proprietary information or that of third parties whose information we maintain, which could adversely affect our business and competitive position. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">115</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">A pandemic, epidemic, or outbreak of an infectious disease or other public health crises may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The future extent of the impact of any public health crisis on our preclinical studies or clinical trial operations, our supply chain and manufacturing and our office-based business operations, will depend on future developments, which remain highly uncertain and cannot be predicted with confidence. For example, at the onset of the COVID-19 pandemic, we paused the enrollment of new patients into our clinical trials. In the future, we could also experience significant and material disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of COMP360 and any future therapeutic candidates due to a public health crisis. Future developments are inherently hard to predict and there can be no guarantee we will not face difficulties or additional costs in enrolling patients in our clinical trials, that we will be able to achieve full enrollment of our studies within the timeframes we anticipate, or at all, or that supply disruptions would not adversely impact our ability to initiate and complete preclinical studies or clinical trials. Any public health crisis may in the future affect employees of third-party CROs that we rely upon to carry out our clinical trials and may cause disruptions that could severely impact our business and clinical trials, including the diversion of healthcare resources away from our clinical trials, the interruption of key clinical trial activities, delays in receiving authorizations from regulatory authorities, changes in local regulations, supply chain disruptions and continued volatility in the public equity markets and global economic disruptions, among other things.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Any public health crisis in the future may cause significant volatility in public equity markets and disruptions to the U.S. and global economies. Increased volatility and economic dislocation may make it more difficult for us to raise capital on favorable terms, or at all. To the extent that any future public health crisis adversely affects our business and financial results, it may also heighten many of the other risks described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section, such as those relating to the timing and completion of our clinical trials and our ability to obtain future financing.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our current operations are headquartered in one location, and we or the third parties upon whom we depend may be adversely affected by natural disasters, as well as occurrences of civil unrest, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our current business operations are headquartered in our offices in London, UK, with additional offices in New York and San Francisco in the U.S. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents, including events of civil unrest that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our investigational COMP360 psilocybin treatment or any future therapeutic candidates or interruption of our business operations. Such natural disasters could further disrupt our operations, and have a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">116</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot ensure that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our investigational COMP360 psilocybin treatment or any future therapeutic candidates are being developed to treat, and we may use appropriate social media in connection with our commercialization efforts of our investigational COMP360 psilocybin treatment following approval of COMP360 or future therapeutic candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve, and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to certain prohibited activities. For example, patients may use social media channels to comment on their experience in an ongoing clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment may be adversely impacted, we fail to monitor and comply with applicable adverse event reporting obligations, or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational COMP360 psilocybin treatment or any future therapeutic candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to the Ownership of Our ADSs</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The market price of our ADSs has been and will likely continue to be volatile and you could lose all or part of your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The market price of our ADSs has been and may continue to be highly volatile and could be subject to large fluctuations in response to the risk factors discussed in this section, and others beyond our control, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">positive or negative results of testing and clinical trials by us, strategic partners or competitors; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">117</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">positive or negative developments in the regulatory approval process for psychedelic-based compounds developed by us, strategic partners or competitors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">timing of completion of our Phase 3 program and the time period during which results of our Phase 3 trials will become available;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">delays in entering into strategic relationships with respect to development or commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in our strategic focus and research and development priorities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">entry into strategic relationships on terms that are not deemed to be favorable to us; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">technological innovations or commercial therapeutic introductions by competitors; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in government regulations and healthcare payment systems; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">developments concerning proprietary rights, including patent and litigation matters; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">public concern relating to the commercial value or safety of our investigational COMP360 psilocybin treatment or any future therapeutic candidates; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">negative publicity or public perception of the use of psilocybin as a treatment for mental health conditions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">reorganizations, restructurings, financings or other corporate transactions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">the trading volume of our ADSs on Nasdaq, including the sale of ADSs held by holders from our PIPE offering or the exercise of the 2025 ADS Warrants and/or the PIPE Warrants;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">sales of our ADSs by us (including through our ATM Facility), members of our senior management and directors or our significant shareholders or the anticipation that such sales may occur in the future;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.68pt">general economic, political, geopolitical and market conditions, including the recent fluctuations in inflation in the U.S., UK and Europe, the effects of announced or future tariff increases, and overall market volatility in the U.S. or the UK as a result of, among other factors, macroeconomic conditions and the ongoing war between Russia and Ukraine, conflict in the Middle East, significant changes in U.S. policies or regulatory environment or similar events; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">other events and factors, many of which are beyond our control.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In recent years, the stock markets, and particularly the stock of pharmaceutical and biotechnology companies, at times have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of affected companies. In addition, if the market for pharmaceutical and biotechnology stocks or the broader </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">118</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">stock market continues to experience a loss of investor confidence, the trading price of our ADSs could decline for reasons unrelated to our business, financial condition or results of operations. Since our ADSs were sold in our IPO at a price of $17.00 per ADS, our ADS price has fluctuated significantly, ranging from an intraday low of $2.49 to an intraday high of $61.69 for the period beginning September 18, 2020, our first day of trading on The Nasdaq Global Select Market, through May 6, 2025. If the market price of our ADSs does not exceed the price at which you acquired them, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Because we have no present intention to pay dividends on our ordinary shares for the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs will be your sole source of gains for the foreseeable future, and you will suffer a loss on your investment if you are unable to sell your ADSs at or above the price at which you purchased them. Any recommendation by our board of directors to pay dividends will depend on many factors, including our financial condition (including losses carried forward), results of operations, legal requirements and other factors. In addition, our Loan Agreement with Hercules currently prohibits, and any future debt financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our ordinary shares. We are unlikely to pay dividends or other distributions in the foreseeable future. If the price of our ADSs declines before we pay dividends, you will incur a loss on your investment, without the likelihood that this loss will be offset in part or at all by potential future cash dividends.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If securities or industry analysts do not continue to publish research or publish inaccurate research or unfavorable research about our business, the price of our ADSs and trading volume could decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The trading market of our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have control over these analysts. If one or more of the analysts who covers us downgrades our ADSs or publishes incorrect or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our ADSs could decrease, which could cause the price of our ADSs or trading volume to decline. <br/><br/>        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Holders of our ADSs do not have the same voting rights as the holders of our ordinary shares, and may not receive voting materials or any other documents that would need to be provided to our shareholders pursuant to English corporate law, including the UK Companies Act 2006, or Companies Act 2006, in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Except as described in the deposit agreement, holders of the ADSs are not able to exercise voting rights attached to the ordinary shares represented by the ADSs. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon our request, the depositary shall distribute to the holders as of the record date (i) the notice of the meeting or solicitation of consent or proxy sent by us and (ii) a statement as to the manner in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">119</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">which instructions may be given by the holders. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. As a result, ADS holders may not be able to exercise their right to vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested or if their shares cannot be voted. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Many members of our senior management and certain members of our board of directors are non-residents of the U.S., and all or a substantial portion of our assets and the assets of such persons are located outside the U.S. As a result, it may not be possible to serve process on such persons or us in the U.S. or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The U.S. and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the U.S., whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether the courts of England and Wales would entertain original actions brought in the UK against us or our directors or senior management predicated upon securities laws of the U.S. or any state in the U.S. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decisions. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As a result, U.S. investors may not be able to enforce against us or certain of our directors any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may increase the risk of holding our ADSs. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our ADSs trade on the Nasdaq Global Select Market in U.S. dollars. Fluctuations in the exchange rate between the U.S. dollar and the pound sterling have occurred in the past and may continue in the future. Such fluctuations may result in temporary differences between the value of our ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit such differences. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">120</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the pound sterling, the U.S. dollar equivalent of the proceeds that a holder of ADSs would receive upon the sale in the UK of any ordinary shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in pound sterling on our ordinary shares represented by ADSs could also decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The deposit agreement governing our ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ADSs or the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the U.S. Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and our ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or our ADSs, including claims under federal securities laws, you or such other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">121</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our articles of association, or Articles, provide that the courts of England and Wales are the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act or the Exchange Act, and that the U.S. District Court for the Southern District of New York is the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our Articles provide that, unless we consent by ordinary resolution to the selection of an alternative forum, the courts of England and Wales shall, to the fullest extent permitted by law, be the exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us; (c) any action or proceeding asserting a claim arising out of any provision of the Companies Act 2006 or our Articles (as may be amended from time to time); or (d) any action or proceeding asserting a claim or otherwise related to our affairs, or the England and Wales Forum Provision. The England and Wales Forum Provision does not apply to any causes of action arising under the Securities Act or the Exchange Act. Our Articles further provide that unless we consent by ordinary resolution to the selection of an alternative forum, the U.S. District Court for the Southern District of New York is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act, or the U.S. Federal Forum Provision. In addition, our Articles provide that any person or entity purchasing or otherwise acquiring any interest in our shares is deemed to have notice of and consented to the England and Wales Forum Provision and the U.S. Federal Forum Provision; provided, however, that our shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The England and Wales Forum Provision and the U.S. Federal Forum Provision in our Articles may impose additional litigation costs on our shareholders in pursuing any such claims. Additionally, the forum selection clauses in our Articles may limit the ability of our shareholders to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including the courts of England and Wales and other courts within the U.S., will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. The U.S. Federal Forum Provision may also impose additional litigation costs on our shareholders who assert that the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">122</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">provision is not enforceable or invalid. The courts of England and Wales and the U.S. District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.<br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our classification as a passive foreign investment company in any period would result in adverse U.S. federal income tax consequences to U.S. holders. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Under the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a U.S. Holder (as defined below in the section entitled &#8220;U.S. Federal Income Tax Considerations for U.S. holders&#8221; in Part II, Item 9B. &#8220;Other Information&#8221;) holds our ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements. Based on the composition of our income and assets and the value of our assets, we believe that we were a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2023 and we believe that we were not a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2024. However, no assurances regarding the determination of our PFIC status can be provided for the 2023 taxable year, the 2024 taxable year or any future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering. Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. Holders</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. In addition, if a non-U.S. corporation owns at least one U.S. subsidiary, under current law, any current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries of the non-U.S. corporation will generally be treated as CFCs of such U.S. subsidiary, regardless of whether the non-U.S. corporation is treated as a CFC. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">123</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the value or total combined voting power of all classes of stock entitled to vote of such corporation. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Based on our review of beneficial ownership reports filed with the SEC, we do not believe that we were classified as a CFC for the 2024 taxable year. However, the determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. Failure to comply with CFC reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any Ten Percent Shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the CFC rules of the Code. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We have incurred and will continue to incur increased costs as a result of operating as an English-domiciled public company listed in the U.S., and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As an English domiciled public company listed in the U.S., we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">requirements on foreign reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our board of directors, management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">regulations have increased and will continue to increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, each year in our annual reports on Form 10-K, we are required to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. However, we will not require an attestation report on internal control over financial reporting issued by our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">124</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">independent registered public accounting firm for so long as we do not qualify as an accelerated filer or large accelerated filer. In order to achieve and maintain compliance with Section 404, we have documented and evaluated our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources, have engaged outside consultants and adopted a detailed work plan to continually assess and document the adequacy of internal control over financial reporting, taken steps to improve control processes as appropriate, validated through testing that controls are functioning as documented and have implemented a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk in any given year that we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. Moreover, if in future years an attestation report on internal control over financial reporting issued by our independent registered public accounting firm may be required and if our independent registered public accounting firm were to be unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our ADSs could be negatively affected, and we could become subject to investigations by the SEC or other regulatory authorities or to stockholder litigation, which could have an adverse impact on the market price or our ADSs and cause us to incur additional expenses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our securities less attractive to investors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. As a result, we may take advantage of certain of the scaled disclosures available to smaller reporting companies. These include, but are not limited to, reduced disclosure obligations regarding executive compensation and an exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures. As a smaller reporting company with annual revenues of less than $100.0 million and a non-accelerated filer, we are also not required to provide an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will be able to take advantage of these scaled disclosures and exemptions for so long as (i) our voting and non-voting shares held by non-affiliates is less than $250.0 million measured on the last business day of our most recent second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting shares held by non-affiliates is less than $700.0 million measured on the last business day of our most recent second fiscal quarter. We cannot predict if investors will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">You may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited, because we are incorporated under the laws of England and Wales, conduct most of our operations outside the U.S. and many members of our senior management and certain members of our board of directors reside outside the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">125</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are incorporated and have our registered office in, and are currently existing under the laws of, England and Wales. In addition, most of our tangible assets are located, and many members of our senior management and certain of our directors reside, outside of the U.S. As a result, it may not be possible to serve process within the U.S. on certain directors or us or to enforce judgments obtained in U.S. courts against such directors or us based on civil liability provisions of the securities laws of the U.S. As a result, it may not be possible for investors to effect service of process within the U.S. upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The U.S. and the UK do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the U.S., whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the UK. In addition, uncertainty exists as to whether courts of England and Wales would entertain original actions brought in England and Wales against us or our directors or senior management predicated upon the securities laws of the U.S. or any state in the U.S. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is subject to determination by the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As a result, U.S. investors may not be able to enforce against us or certain of our directors any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%"> </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">As an English domiciled public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">English law provides that a board of directors may only allot shares (or grant rights to subscribe for or to convert any security into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five years, each as specified in the articles of association or relevant ordinary resolution passed by shareholders at a general meeting. Such authority from our shareholders to allot additional shares for a period of five years from May 9, 2024 was included in the ordinary resolution passed by our shareholders on May 9, 2024, and is included as a proposal in our proxy statement for the 2025 annual general meeting of shareholders, which authorization, if approved, will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">126</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">is contained in the articles of association, but not longer than the duration of the authority to allot shares to which this disapplication relates or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). Such authority from our shareholders to disapply preemptive rights for a period of five years was included in the special resolution passed by our shareholders on May 9, 2024, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years.<br/><br/>        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Shareholder protections found in provisions under the UK City Code on Takeovers and Mergers, or the Takeover Code, do not apply to us while our securities are not quoted on a UK regulated market. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As the Company&#8217;s securities are not quoted on a UK regulated market (or UK multilateral trading facility or certain exchanges in the Channel Islands or the Isle of Man), the Takeover Code does not apply to the Company. As a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code, including the rules regarding mandatory takeover bids (a summary of which is set out below).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> In the event that this changes, or if the interpretation and application of the Takeover Code by the Panel on Takeovers and Mergers, or Takeover Panel, changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside of the UK), the Takeover Code may apply to us in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The Takeover Code provides a framework within which takeovers of companies which are subject to the Takeover Code are regulated and conducted. The following is a brief summary of some of the most important rules of the Takeover Code:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">When any person acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares already held by that person and an interest in shares held or acquired by persons acting in concert with him or her) carry 30% or more of the voting rights of a company that is subject to the Takeover Code, that person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights in that company to acquire the balance of their interests in the company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">When any person who, together with persons acting in concert with him or her, is interested in shares representing not less than 30% but does not hold more than 50% of the voting rights of a company that is subject to the Takeover Code, and such person, or any person acting in concert with him or her, acquires an additional interest in shares which increases the percentage of shares carrying voting rights in which he or she is interested, then such person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights of that company to acquire the balance of their interests in the company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">127</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">A mandatory offer triggered in the circumstances described in the two paragraphs above must be in cash (or be accompanied by a cash alternative) and at not less than the highest price paid within the preceding 12 months to acquire any interest in shares in the company by the person required to make the offer or any person acting in concert with him or her.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">In relation to a voluntary offer (i.e., any offer which is not a mandatory offer), when interests in shares representing 10% or more of the shares of a class have been acquired for cash by an offeror (i.e., a bidder) and any person acting in concert with it in the offer period and the previous 12 months, the offer must be in cash or include a cash alternative for all shareholders of that class at not less than the highest price paid for any interest in shares of that class by the offeror and by any person acting in concert with it in that period. Further, if an offeror acquires for cash any interest in shares during the offer period, a cash alternative must be made available at not less than the highest price paid for any interest in the shares of that class.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">If, after making an offer for a company, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (i.e., a target) at a price higher than the value of the offer, the offer must be increased to not less than the highest price paid for the interest in shares so acquired.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">An offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Special or favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">All shareholders must be given the same information.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Each document published in connection with an offer by or on behalf of the offeror or offeree must state that the directors of the offeror or the offeree, as the case may be, accept responsibility for the information contained therein.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Stringent requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">128</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are incorporated under the laws of England and Wales. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by the laws of England and Wales, including the provisions of the Companies Act 2006, and by our Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See the information under the heading &#8220;Description of Share Capital and Articles of Association&#8212;Differences in Corporate Law&#8221; in our prospectus dated October 17, 2024, filed with the SEC pursuant to Rule 424(b), which information is incorporated herein by reference, for a description of the principal differences between the provisions of the Companies Act 2006 applicable to us and, for example, the Delaware General Corporation Law relating to shareholders&#8217; rights and protections.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The principal differences include the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Under English law and our Articles, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Under English law and our Articles, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">In the UK, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares (including those represented by ADSs) will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">129</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares (including those represented by ADSs) voting at the meeting for approval.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">Under English law and our Articles, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">The quorum requirement for a shareholders&#8217; meeting is one or more qualifying persons present at a meeting and between them holding (or being the proxy or corporate representative of the holders of) at least thirty-three and one-third percent (33 &#8531;%) in number of the issued shares (excluding any shares held as treasury shares) entitled to attend and vote on the business to be transacted. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#8217; meeting in order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#8217;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">Risks Related to Our Controls Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, testing required to be conducted by us in connection with Section 404, and subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">If we fail to maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#8217; confidence and our ADS price.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures and that we furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">130</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. We cannot assure you that we will not identify other material weaknesses or deficiencies, which could negatively impact our results of operations in future periods. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">More generally, if we are unable to meet the demands that have been placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by law or stock exchange regulations. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose confidence in our reported financial information. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">Risks Related to the Ownership of Our ADSs&#8212;We have incurred and will continue to incur increased costs as a result of operating as an English public company listed in the U.S., and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8221;</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information, and the trading price of our stock may decline. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:175%">General Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Exchange rate fluctuations may materially affect our results of operations and financial condition.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Due to the international scope of our operations, our assets, earnings, expenses and cash flows are influenced by movements in exchange rates of several currencies, particularly the U.S. dollar, the Pound Sterling and the Euro. Our reporting currency is denominated in U.S. dollars and our functional currency is the U.S. dollar (except that the functional currency of our UK subsidiary is the Pound Sterling) and the majority of our operating expenses are paid in both Pound Sterling and U.S. dollars. We also regularly acquire services, consumables and materials in U.S. dollars, Pound Sterling and the Euro. Further potential future revenue may be derived from abroad, particularly from the U.S. As a result, our business and the price of our ADSs has been affected and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">may in the future be affected by fluctuations in foreign exchange rates between the Pound Sterling and these other currencies, which may also have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. See Note 2 in the notes to our annual consolidated financial statements for a description of foreign exchange risks. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">In addition, the possible abandonment of the Euro by one or more members of the European Union, or the EU, could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the Euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">131</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the Euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Unfavorable global economic and geopolitical conditions have in the past and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">could in the future adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our results of operations have in the past and could in the future be adversely affected by general conditions in the global economy, geopolitics and in the global financial markets. Key national economies, including the U.S. and UK, have been affected from time to time by economic downturns or recessions, government shutdowns, supply chain constraints, fluctuating inflation and interest rates, international tariffs, changes in international trade relationships, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies and overall uncertainty with respect to the economy. For example, while we do not have activities in Russia and Ukraine or the Middle East, the ongoing conflicts and any further escalation of geopolitical tensions related to these conflicts, including the imposition of sanctions by the U.S. and other countries, has and could result in, among other things, supply disruptions, fluctuations in foreign exchange rates, increased probability of a recession and increased volatility in financial markets. In addition, in the past, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the U.S. Although U.S. lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the U.S. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Furthermore, the global markets have experienced volatility from the effects of announced or future tariff increases by the U.S. and such tariffs or increasing international tension have in the past and may in the future lead to increased economic uncertainty, raise the possibility of an economic slowdown, impact supply chains or have other adverse consequences on our business. In addition, additional tariffs may specifically be placed on pharmaceuticals and pharmaceutical ingredients in the future. For example, on April 16, 2025, the U.S. Department of Commerce announced an investigation under Section 232 of the Trade Expansion Act of 1962 into imports of pharmaceuticals and pharmaceutical ingredients and the impact of these imports on U.S. national security culminating in a decision by the President whether to take action to remedy any identified threats, including by imposing additional tariffs. The statute provides that the Commerce Department report must be completed within 270 days of initiation and that the President must decide whether to act within 90 days of receiving the report. Any of these disruptions could adversely affect our businesses, results of operations and financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">A deterioration in the global economy and financial markets could result in a variety of risks to our business. In addition, due to the international scope of our operations, our financial condition is and will continue to be influenced by movements in exchange rates of several currencies because our functional currency for our wholly-owned UK operating subsidiary is the Pound Sterling, and we report our financial results in U.S. dollars. For example, inflation rates, particularly in the U.S., have seen increased levels for the last few years compared to recent history. Elevated inflation has in the past and may in the future result in further currency fluctuations, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. Although the U.S. Federal Reserve lowered interest </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">132</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">rates in 2024, the U.S. Federal Reserve had previously raised, and may again raise, interest rates in response to concerns about inflation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets and geopolitics, may have the effect of further increasing economic uncertainty and heightening these risks. In addition, fluctuating interest rates or a general economic downturn or recession could reduce our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy, supply disruptions or international trade disputes could also strain our third-party suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current and future economic climate and financial market conditions could adversely impact our business. Moreover, the turmoil in the banking system, such as the turmoil seen in early 2023 with the appointment of the FDIC as a receiver for several U.S. banks, and the announcement of the imposition of tariffs by the U.S. and other countries has in the past and may in the future increase market volatility. Due to these and other macroeconomic factors, there is a risk of a recession occurring in the U.S., and perhaps in other major global economies. These developments may adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">The U.S. Congress, the Trump administration, or any new administration have in the past and may in the future make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Since the start of the Trump administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation, the operation of governmental agencies that regulate our business and other areas. For example, increasing international trade tensions has resulted in increased volatility in the financial markets and increased economic uncertainty. Although we cannot predict the impact, if any, of these changes to our business, they have resulted in increased market volatility in the past and could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Disruptions at the FDA, the SEC, the DEA, the U.S. Patent and Trademark Office and other government agencies, including any disruption caused by changes in policy of the Trump administration and decisions to reduce the number of federal employees, and any funding shortages or potential funding shortages could hinder their ability to hire and retain key leadership and other personnel, prevent new drugs from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions, which could negatively impact our business and our timelines. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The ability of the FDA to review and clear or approve new products can be affected by a variety of factors, including changes in government budget and funding levels, the ability to hire and retain key personnel, shifting policy priorities as a result of changes in the presidential administration and political appointees tasked to oversee the agency, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years and recently other companies have reported delays in the FDA providing guidance, and additional delays in review by the FDA may in the future increase as a result. In addition, government funding of the SEC, the DEA, the U.S. Patent and Trademark Office and other government agencies on which our operations may rely is subject to the impacts of political events, which are inherently fluid and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">133</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">unpredictable. Currently, federal agencies in the United States are operating under a continuing resolution that is set to expire on September 30, 2025 and the current administration is focused on reducing costs of the federal government generally, including significantly reducing the number of government employees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Disruptions at the FDA, DEA and other agencies may slow conduct of our clinical trials, including without limitation due to delays in obtaining DEA licenses required for conduct of our clinical trials, and the time necessary for review and approval of COMP360 and related rescheduling decisions, which could adversely affect our business. For example, if the FDA or DEA experiences significant decreases in funding or personnel, it could significantly impact the ability of the FDA and DEA to issue licenses needed for the conduct of our clinical trials and timely review and process our applications or submissions, which could have a material adverse effect on our business and our timelines.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">With the change in the U.S. presidential administration in 2025, there is substantial uncertainty as to whether and how the Trump administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges and/or opportunities as we navigate development and approval of our product candidate. Additionally, the new administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic candidates,</span></div><div style="margin-bottom:10pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Changes and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We conduct business globally and file tax returns in multiple jurisdictions. Our consolidated effective corporate income tax rate could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms being implemented or under consideration (such as, without limitation, those related to the Organization for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project, the European Commission&#8217;s state aid investigations and other anti-tax avoidance legislative efforts and other initiatives); the practices (published or otherwise) of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes (which may have retroactive effect), to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and paid or accrued on our balance sheets, and otherwise affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">134</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, HMRC, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8216;&#8216;permanent establishment&#8217;&#8217; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. If we are assessed with additional taxes, this may result in a material adverse effect on our results of operations and/or financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">A tax authority may take the position that material tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable, or result in other liabilities (including, without limitation, in relation to penalties and interest), which in turn could affect our results and the returns available to investors.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new treatments from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">The ability of the FDA to review and approve new treatments can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on September 30, 2025. Without appropriation of additional funding to federal agencies, our business operations relating to our product development activities for the U.S. market could be impacted. . </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">135</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, manufacture, handling, release and disposal of and the maintenance of a registry for, hazardous materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. Furthermore, if we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous materials and, as a result, may incur material liability as a result of such release or exposure. Environmental, health and safety laws and regulations are becoming more stringent. We may incur substantial expenses in connection with any current or future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely affected. In the event of an accident involving such hazardous materials, an injured party may seek to hold us liable for damages that result.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general or prevent us from obtaining patents and thereby impair our ability to protect our investigational treatments. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">As is the case with other companies in our industry, our success is heavily dependent on our intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve technological and legal complexity. Therefore, obtaining and enforcing patents for therapeutics is costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the U.S. or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, the America Invents Act, or the AIA, enacted in the U.S. in 2012 and 2013, has resulted in significant changes to the U.S. patent system. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Prior to the enactment of the AIA, assuming that other requirements for patentability are met, the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March 16, 2013, under the AIA, the U.S. transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention regardless of whether a third party was the first to invent the claimed invention. On or after that date, a third party that files a patent application in the USPTO before us could be awarded a patent covering an invention of ours even if we made the invention before the third party. The AIA will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">136</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide additional opportunities for third parties to challenge any pending patent application or issued patent in the USPTO. Such opportunities include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:175%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%"> review and derivation proceeding. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim in our patents invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our business is subject to economic, political, regulatory and other risks associated with international operations. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including the following: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">economic weakness, including fluctuating inflation and interest rates, political instability, including foreign conflicts, and the emergence of any future public health crisis or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:175%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">any future mitigation efforts and current or future economic effects;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">differing regulatory requirements for drug approvals; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">differing jurisdictions potentially presenting different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">potentially reduced protection for intellectual property rights; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in regulations and customs, tariffs and trade barriers; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in currency exchange rates of the Euro, U.S. dollar, Pound Sterling and currency controls; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">137</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain international markets; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">negative consequences from changes in tax laws or practice; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S., UK and European Union; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war, terrorism, pandemics, or natural disasters including earthquakes, typhoons, floods and fires.<br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:175%">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber security or cyber security of our collaborators, vendors and other partners.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Given our reliance on technological infrastructure, we continue to evaluate internal security measures and policies. Our internal computer systems, which are managed partially by a third party, and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, pandemics and telecommunications and electrical failure. Any system failure, accident or security compromise or breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our therapeutic development programs. In addition, our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. Cyber incidents have been increasing in sophistication and frequency and can include third parties gaining access to employee or clinical trial data using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks, ransomware, card skimming code, inadvertent or wrongful conduct by our employees or vendors, and other deliberate attacks and attempts to gain unauthorized access. While we conduct periodic penetration testing and perform security monitoring, as the techniques used by adversaries who may attempt to penetrate and sabotage our network security or our website change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques, and the costs to protect our network and systems may increase.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">Additionally, it is also possible that unauthorized access to employee or clinical trial data may be obtained through inadequate use or circumvention of security controls by customers, suppliers or other vendors. While we continue to expend time and resources on the mitigation of such risks, there is the possibility of a material impact from such an attack in the future.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">While we have not, to our knowledge, experienced any such material system failure or security breach that caused interruptions to our operations to date, if such an event were to occur and cause interruptions in our operations, it could result </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">138</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:175%">in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of COMP360 or any future therapeutic candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security compromise or breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our investigational COMP360 psilocybin treatment or any future therapeutic candidates could be hindered or delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security compromises or breaches, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Although we maintain cyber liability insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">139</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_139"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES, USE OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following table summarizes the surrenders of our equity securities during the three months ended March 31, 2025:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.870%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 to January 31, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 to February 28, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,095</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 to March 31, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,468</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.67</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,563</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><br/>(a) Represents ordinary shares surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of equity awards under our equity incentive plans.</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_142"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_145"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_148"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ITEM 5. OTHER INFORMATION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Rule 10b5-1 Trading Plans</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the three months ended March 31, 2025, none of our directors or executive officers <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-529"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-530">adopted</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-531"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-532">terminated</ix:nonNumeric></ix:nonNumeric> or modified the amount, pricing or timing provisions in any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">140</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_151"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="-sec-extract:summary;padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="-sec-extract:summary;margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed in the Exhibit Index of this Quarterly Report on Form 10-Q are incorporated by reference or are filed with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></div><div style="margin-bottom:4pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.242%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporation by reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Schedule/Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000162828020013522/exhibit32f-1a1xformofa.htm">Articles of Association of COMPASS Pathways plc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-248484</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9/14/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1472033/000119380520001149/e619934_ex99-a.htm">Deposit Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form F-6/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-248514</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.(A)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9/17/2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of American Depositary Receipt (included in exhibit 4.1).</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000181659025000008/formofpre-fundedwarrant.htm">F</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000181659025000008/formofpre-fundedwarrant.htm">orm of Pre-funded Warrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39522</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">01/10/2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000181659025000008/formofwarrant.htm">F</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1816590/000181659025000008/formofwarrant.htm">orm of ADS Warrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39522</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">01/10/2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1#*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">mended and Resta</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">ted Employ</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">ment </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">May 7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">, 2025 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">between Compass Pathfinder L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">i</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-kabir.htm">mited and Kabir Nath</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2#*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">mendment </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">May 7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">, 2025 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">to Employment Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">dated December 6, 2023 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">between Compass Pathways</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-teri.htm">, Inc. and Teri Loxam</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3#*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="guyaragreement.htm">Amended and Restated Employment Agreement dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="guyaragreement.htm">May 7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="guyaragreement.htm">, 2025 between Compass Pathfinder L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="guyaragreement.htm">i</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="guyaragreement.htm">mited and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="guyaragreement.htm">Guy Goodwin</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex104-slam.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex104-slam.htm">mendment No. 1 dated April 30, 2025 to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex104-slam.htm">Master Research Collaboration Agreement by and among COMPASS Pathfinder Limited, King&#8217;s College London and South London and Maudsley NHS Foundation Trust, dated March 22, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x25xex311ceo302cert.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Principal Executive Officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x25xex312cfo302cert.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Principal Finance Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cmps-q1x25xex321ceoxcfosec.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">_________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">#    &#160;&#160;&#160;&#160;Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224; &#160;&#160;&#160;&#160;Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit pursuant to Item 601(b)(10)(iv). The Company undertakes to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">141</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div><div id="i387913fc30d8481bbd7cf8b08db88d3a_154"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:393%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:4pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934 the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COMPASS PATHWAYS PLC</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;8, 2025</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kabir Nath</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kabir Nath</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;8, 2025</span></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Teri Loxam</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teri Loxam</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="12" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">142</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:339%"> </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-kabir.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id73e3d776a744d5e834658cd60fec73e_78"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:112.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">STRICTLY PRIVATE AND CONFIDENTIAL</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.218%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:125.47pt;padding-right:125.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:13.40pt">Dated 15 April 2024 (as amended and restated on 7 May 2025)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="margin-top:0.3pt;padding-right:-2.63pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:125.49pt;padding-right:125.49pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPASS PATHFINDER LIMITED</font></div><div style="margin-top:0.05pt;padding-right:-2.63pt;text-align:center"><font><br></font></div><div style="padding-left:175.79pt;padding-right:175.79pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:267%">and</font></div><div style="padding-left:175.79pt;padding-right:175.79pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:267%">Kabir Nath</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="margin-top:10.7pt;padding-left:125.39pt;padding-right:125.39pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:17.40pt">SERVICE AGREEMENT</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:601px"></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.084%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4135-1945-7548, v. 3</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_81"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIS AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is entered into between the parties with retroactive effect to 6 April 2024 and is amended and restated as of 7 May 2025.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PARTIES</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:32.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:16.13pt">COMPASS PATHFINDER LIMITED </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">a company incorporated and registered in England and Wales with company number 10229259 and whose registered office is at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;)&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.13pt">Kabir Nath</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGREED TERMS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Definitions</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.05pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The following terms shall have the following meanings unless the context requires otherwise&#58;</font></div><div style="margin-top:7pt;padding-left:61.65pt;padding-right:33.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:132%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:132%">&#34; means the board of directors of COMPASS Pathways plc, the indirect parent of the Company, or any person or committee of the board duly appointed by it&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:131%">Capacity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34; means as agent, consultant, director, employee, owner, partner, shareholder or otherwise&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:131%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34; means trade secrets, knowhow and information (whether or not recorded in documentary form, or stored on any magnetic or optical disk or memory) relating to the business, products, affairs and finances of any Group Company or any of their suppliers, customers, agents, shareholders or management, including (but not limited to)&#58; (a) business, financial or strategic information or plans&#59; (b) technical data, research data and know-how&#59; (c) litigation, potential litigation or legal advice&#59; (d) employment terms or pay of the Executive or others&#59; (e) commercial terms with business partners&#59; (f) products or services in the course of development&#59; (g) processes, techniques or know-how&#59; (h) details of any joint ventures, which (in each case) the Executive creates, develops, learns, receives or obtains in connection with the Executive&#8217;s employment before or after the date of this agreement, whether or not such information is marked confidential&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:131%">Copies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34; means copies or records of any Confidential Information in whatever form (including, without limitation, in written, oral, visual or electronic form or on any magnetic or optical disk or memory and wherever located) including, without limitation, extracts, analysis, studies, plans, compilations or any other way of representing or recording and recalling information which contains, reflects or is derived or generated from Confidential Information&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:63.55pt;padding-right:33.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Garden Leave</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#34; means any period during which the Company has exercised its rights under clause <a href="#id73e3d776a744d5e834658cd60fec73e_90" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;text-decoration:none">22&#59;</a></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:63.55pt;padding-right:32.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Group Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; means the Company and any group undertaking (as such term is defined in section 1161(5) of the Companies Act 2006) of the Company in any jurisdiction from time to time&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:63.55pt;padding-right:32.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; means patents, rights to Inventions, copyright and related rights, trade marks, trade names and domain names, rights in get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, rights in confidential information </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:63.55pt;padding-right:32.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:63.55pt;padding-right:32.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; means any invention, idea, discovery, development, notation, formula, improvement or innovation, whether or not patentable or capable of registration, and whether or not recorded in any medium&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:63.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Permitted Investment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34; has the meaning given to it in clause 16.2&#59;</font></div><div><font><br></font></div><div style="padding-left:63.55pt;padding-right:33.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Quoted Company Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; means (a) all legal and regulatory obligations, codes of practice and recommendations which apply to the Executive or any Group Company relating to transactions in securities, related party transactions and inside information (including the Company's share dealing policy)&#59; and (b) the Financial Services and Markets Act 2000 and the Criminal Justice Act 1993, in each case as amended or superseded from time to time&#59; and as applicable, the securities laws of the United States, including but not limited to the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, and the Listing Rules of The Nasdaq Stock Market, each as amended from time to time&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:63.55pt;padding-right:32.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; means the termination of the Executive&#8217;s employment under this Agreement however caused, whether lawful or not, and &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Termination Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; means the date of Termination.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">In this Agreement, unless the context otherwise requires&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">words in the singular include the plural and in the plural include the singular&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">any phrase introduced by the terms &#34;including&#34;, &#34;include&#34;, &#34;in particular&#34; or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">the headings are inserted for convenience only and shall not affect its construction&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.7pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension or re-enactment and includes any subordinate legislation for the time being in force made under it&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.25pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">the Schedules shall form part of this Agreement, shall have effect as if set out in full in the body of this Agreement and any reference to this Agreement includes the Schedules&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">reference to any regulator or other body includes a reference to any successor.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Term of Employment</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.4pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Executive&#8217;s employment with Compass Pathways, Inc., a Group Company, began on 1 August 2022 under the terms of an Employment Agreement dated as of 1 August 2022 between the Executive and Compass Pathways, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Prior Employment Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;). In connection with the Executive&#8217;s relocation to the United Kingdom, this Agreement shall commence retroactively as of 6 April 2024 and shall continue, subject to </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61.65pt;padding-right:33.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">the remaining terms of this A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">greement, until terminated by the Executive on nine months&#8217; prior notice in writing or by the Company giving the Executive not less than fifteen months' prior notice in writing. </font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Executive&#8217;s period of continuous employment for the purposes of the Employment Rights Act 1996 commenced on 1 August 2022.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Conditions and Warranties</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">The Executive warrants that&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">the Executive is entitled to work in the United Kingdom without any additional approvals&#59; and</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.95pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">the Executive is not prevented by the terms of any agreement or court order from continuing employment with the Company from the date of this Agreement and that there are no express or implied terms of any contract with (or other obligation to) any third party that could prevent or hinder the performance of the Executive&#8217;s duties to any Group Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">It is a condition of this employment that the Executive has and maintains during the course of this employment, valid United Kingdom immigration permission which permits the Executive to be employed by the Company in the role for which the Executive is employed. The Executive must notify the Company immediately if at any time the Executive does not meet this condition. The Executive must produce to the Company for inspection the documents proving this right to the Company&#8217;s satisfaction upon request.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">If the Executive is in breach of any of the warranties or fails to satisfy the conditions set out in this clause <a href="#id73e3d776a744d5e834658cd60fec73e_81" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">3</a> then the Company shall be entitled to terminate the Executive&#8217;s employment summarily.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Duties</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">The Executive shall serve the Company as the Chief Executive Officer of the Group Companies and a member of the board of directors of each Group Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">During the employment the Executive shall&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:33.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">devote the whole of their working time, attention and abilities to the business of the Company and any other Group Company for which the Executive is required to work from time to time&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:32.75pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">faithfully and diligently exercise such powers and perform such duties for each Group Company as may from time to time be assigned by the Company&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">comply with all reasonable and lawful directions given by the Board&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.05pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">promptly make such reports to the Board in connection with the affairs of each Group Company on such matters and at such times as are reasonably required&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">report their own wrongdoing and any wrongdoing or proposed or potential wrongdoing of any other employee, officer or consultant of any Group Company to the Board immediately on becoming aware of it&#59;</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_84"></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5.15pt;padding-left:97.2pt;padding-right:33.25pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">use their utmost endeavours to promote, protect, develop and extend the business of each Group Company&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">comply with their common law, statutory, regulatory and fiduciary duties&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.75pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">exercise the Executive&#8217;s powers jointly with such other person that the Company may appoint&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.3pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">at all times conduct the business of each Group Company for which the Executive is responsible in a lawful and ethical manner.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Regulatory Compliance and Policies and Procedures</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">The Executive will read and comply strictly with&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">any rules, policies and procedures that apply to each Group Company at all times&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.38pt">the Quoted Company Requirements&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.3pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:13.33pt">any other laws and regulations material to the conduct of the business of the Company or any Group Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">Although the Company&#8217;s rules, policies and procedures do not form part of this Agreement, failure to comply with them may result in disciplinary action up to and including dismissal.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Executive is aware of the Quoted Company Requirements and that a breach of the Quoted Company Requirements carries sanctions including criminal liability, disciplinary action by the Company (up to and including summary dismissal) and disciplinary action by the relevant regulatory authority. Due to the Executive's position the Executive shall be named on the Company's list of persons with access to inside information relating to the Company which may be made available to relevant authorities.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Place of Work</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The normal place of work of the Executive is the Company's offices at 33 Broadwick Street</font></div><div style="padding-left:61.65pt;padding-right:32.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">London W1F 0DQ United Kingdom or such other location as the Company may require.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">As Chief Executive Officer of the Group Companies, significant international travel, particularly between the United Kingdom and the United States of America, will be required. The Executive agrees to travel on any business of any Group Company (both within the United Kingdom and abroad) as may be required for the proper performance of the Executive&#8217;s duties.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">If the Executive is required to work outside of the United Kingdom for a continuous period of more than a month the terms that apply will be separately communicated to the Executive.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Hours of Work</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61.65pt;padding-right:33.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Executive shall work such hours as are required for the proper and efficient performance of their duties including the Company&#8217;s normal business hours which are 9am until 5&#58;30pm from Monday to Friday.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:5.15pt;padding-left:61.65pt;padding-right:33pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Executive agrees that the limit on weekly working time contained in Regulation 4 of The Working Time Regulations 1998 does not apply because Regulation 20 applies to the Executive.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Salary</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Executive shall be paid a basic salary of &#163;491,600 per annum subject to deductions required by law. The Executive&#8217;s salary shall accrue from day to day, shall be payable in equal monthly instalments in arrears on or about the last Friday of each month and shall include any directors&#8217; fees.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.4pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The salary paid to the Executive may be reviewed annually. The Company is under no obligation to award an increase following a salary review.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.46pt">The Company may deduct from the salary or any other sums payable to the Executive any money owed to any Group Company by the Executive. The Executive will reimburse the Company upon demand for the personal use of any Company credit card, any other unauthorised transactions entered into by the Executive or any overpayments made to the Executive.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.02pt">Expenses</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:33.3pt;padding-right:33pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company shall reimburse any expenses wholly, exclusively and necessarily incurred by the Executive in the proper performance of the Executive&#8217;s duties under this Agreement subject always to the rules and policies of the Company from time to time and subject to the Executive providing receipts or other evidence of payment as the Company may require.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Annual Bonus</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall be eligible to earn an annual incentive bonus, with a target bonus amount of 60% of the Executive&#8217;s basic salary (and the ability to earn up to 100% of the Executive&#8217;s basic salary in certain circumstances as determined by the Compensation and Leadership Development Committee of the Board), subject to such terms and with such individual, team or corporate targets as the Board may communicate from time to time. The Board shall be entitled to determine whether such targets have been met and where such targets have been met in full or part shall have a discretion to determine whether to make payments and, if so, in what amount and when.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Board may suspend, alter or discontinue any bonus payment(s) or any bonus plan and its eligibility requirements at any time (whether generally or in relation to the Executive only) at its absolute discretion. If the Executive receives any bonus payment the Company is not obliged to make any further bonus payments and any bonus payment will not become part of the Executive's contractual remuneration or fixed salary. </font></div><div style="padding-left:61.65pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive will not be entitled to receive any bonus (or pro rata portion of it) if&#58;</font></div><div style="padding-left:61.65pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:32.9pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">he has resigned&#59; or </font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:32.9pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:32.9pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company has dismissed him, or would have been entitled to dismiss him, summarily pursuant to clause 21,</font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:32.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;on or prior to the date when the bonus would otherwise have been payable. </font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Subject to clause 10.4 and clause 20.1, if the Executive is terminated by the Company on notice in circumstances which do not warrant summary dismissal, he will remain eligible for a target bonus in respect of the year in which the employment terminates. </font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall not be eligible to be considered for any bonus nor shall any bonus be paid if the Executive is subject to any disciplinary action or investigation at the date any bonus is being considered and&#47;or at the bonus payment date (as applicable) although the </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_87"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:61.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Company may reconsider the matter upon the conclusion of the disciplinary action or investigation in question.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Allowances</font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:61.2pt;padding-right:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11.1  The Company will provide, at its sole discretion, assistance to the Executive in dealing with certain US and UK tax compliance matters in connection with Executive&#8217;s relocation to the UK through the provision of a tax advisor, who has agreed to provide the specific scope of services for &#163;7,500 plus VAT and disbursements (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Scope of Work</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;). For the avoidance of doubt, the Company shall not be obliged to pay for any tax assistance beyond this Scope of Work, nor to provide any assistance with any tax implications of non-Company income beyond this Scope of Work.</font></div><div style="padding-left:4.95pt"><font><br></font></div><div style="padding-left:61.2pt;padding-right:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;11.2&#160;&#160;&#160;&#160;The Company will pay the fees for a visa for the Executive&#8217;s spouse in connection with Executive&#8217;s relocation to the UK.</font></div><div style="padding-left:61.2pt;padding-right:33.1pt;text-indent:-28.1pt"><font><br></font></div><div style="padding-left:61.2pt;padding-right:33.1pt;text-indent:-28.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11.3&#160;&#160;&#160;&#160;If the provision of tax assistance, as outlined in clause 11.1, and payment of visa fees, as outlined in clause 11.2, creates any additional tax liabilities for the Executive, he will be required to pay the related taxes personally.</font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Pensions</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.2pt;padding-right:33.1pt;text-align:justify;text-indent:-28.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.65pt">The Company intends to comply with the employer pension duties in respect of the Executive in accordance with Part 1 of the Pensions Act 2008. Unless the Executive opts out, the Company will make a pension contribution equivalent to the level as is available to the general workforce (which is currently set at 3% of basic salary each month during employment). In the event the contribution level is increased for the general workforce, Executive&#8217;s contribution level will be increased to match the same.  Any pension contribution or cash supplement amount will not be considered part of the Executive&#8217;s basic salary. The Executive may be required to periodically renew any opt out.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive&#8217;s participation in the Company&#8217;s pension arrangements is subject to the rules of the relevant scheme and the statutory requirement as each are varied from time to time. In particular the Company reserves the right to change the scheme provider, the funds available, the charging structure and the default fund from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Benefit Plans</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.5pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">13.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;padding-left:8.9pt">The Executive shall, during employment, be eligible to participate in the following benefit plans operated by the Company&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">health insurance for the Executive&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">life assurance&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">permanent insurance cover.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.95pt">The Executive&#8217;s participation in the benefit plans referred to in this clause are subject to&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">the terms of that benefit plan, as amended from time to time&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the rules or the insurance policy of the relevant benefit provider, as amended from time to time&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:97.2pt;padding-right:33.1pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Executive satisfying the normal underwriting requirements of the relevant benefits provider (which may involve a medical and&#47;or a medical questionnaire) and the premium being at a rate which the Company considers reasonable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company&#8217;s obligation under this clause is limited to paying premiums to the relevant benefits provider. If the benefit provider refuses to accept a claim under the relevant benefit plan the Company shall have no obligation or responsibility to challenge that decision or to compensate the Executive.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">13.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;padding-left:8.9pt">The Company reserves the right to discontinue, vary or amend each benefit plan (including the level of cover) at any time on reasonable notice to the Executive.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Holidays</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall be entitled to 25 days' paid holiday in each holiday year together with the usual public holidays in England to be taken at times convenient to the Company and  authorised in advance. In addition to this, the Executive shall be entitled to one day&#8217;s paid annual leave to be taken on or around their birthday. Finally, the Executive may be entitled</font></div><div style="margin-top:3.95pt;padding-left:61.65pt;padding-right:22pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">to additional paid leave, based on service, as per the Holiday Policy (UK) available from the Board.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company's holiday year runs between 1 January and 31 December. If the Executive&#8217;s employment commences or terminates part way through a holiday year, the Executive's entitlement during that holiday year shall be calculated on a pro rata basis rounded up to the nearest whole day.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall have no entitlement to any payment in lieu of accrued but untaken holiday except on Termination. The amount of such payment in lieu shall be 1&#47;260</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">of the Executive's salary for each untaken day of entitlement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">If on Termination the Executive has taken in excess of their accrued holiday entitlement, the Company shall be entitled to recover from the Executive by way of deduction from any payments due to the Executive or otherwise, one day's pay for each excess day calculated at 1&#47;260</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">of the Executive&#8217;s salary.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">If either party has served notice to terminate the employment, the Company may require the Executive to take any accrued but unused holiday entitlement during the notice period. Any accrued but unused holiday entitlement shall be deemed to be taken during any period of Garden Leave.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Sickness</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company may in its absolute discretion pay the Executive an amount equal to the Executive&#8217;s normal basic pay (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Company Sick Pay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;) for the first 20 working days of sickness absence in any rolling 12 month period, subject to such conditions as set out in the Sick Leave Policy (UK) and&#47;or as the Board may specify. Company Sick Pay will include any entitlement to statutory sick pay or any benefits provided by virtue of any permanent health insurance scheme. Company Sick Pay is also subject to the Executive&#8217;s compliance with this Agreement and will not be paid in respect of any period of illness that commences during the first 6 months of the Executive&#8217;s employment or whilst the Company is addressing performance or disciplinary issues.</font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive must comply with the Company&#8217;s sickness absence notification procedures as set out in the Sick Leave Policy (UK). Any period of absence of up to seven calendar days may be self-certified and any period of absence of more than five days must be supported by doctor&#8217;s certificate.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive consents to undergo a medical examination by a doctor nominated by the Company at the Company&#8217;s request and expense.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The rights of the Company to terminate the Executive&#8217;s employment under the terms of this Agreement apply even when such termination would or might cause the Executive to forfeit any entitlement to sick pay, permanent health insurance or other benefits.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Outside Activities and Interests</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall not during the employment except as a representative of the Company or with the Board&#8217;s prior written consent (whether directly or indirectly, paid or unpaid) be employed, engaged, concerned or interested in any other actual or prospective business, organisation, occupation or profession. Any such permission granted by the Board or the Company prior to the date of this Agreement shall continue to apply during the term of this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Nothing in this Agreement shall prevent the Executive from holding an investment by way of shares or other securities to in any entity listed or dealt on a recognised stock exchange (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Permitted Investment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;) provided always that during the term of the employment&#58; (i) the Permitted Investment shall not constitute more than 3% of the issued share capital of the entity concerned, (ii) the Executive makes full disclosure of such Permitted Investments and any actual or apparent conflicts of interest resulting therefrom, so that the Company can make appropriate determinations on the propriety of any investment&#59; and (iii) the Executive complies with the Quoted Company Requirements.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Confidential Information</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Without prejudice to the Executive&#8217;s common law and fiduciary duties, the Executive shall not during employment or at any time after Termination and whether for their own benefit or for the benefit of any third party&#58;</font></div><div><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">use any Confidential Information&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.2pt;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">disclose any Confidential Information to any person, company or other organisation whatsoever,</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:28.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">except in the proper course of their duties, as required by law or as authorised by the Board in writing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall be responsible for protecting the confidentiality of the Confidential Information and shall use best endeavours to prevent the misuse of Confidential Information by others.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">All Confidential Information and Copies shall be the property of the Company and the Executive shall not make any Copies save in the proper course of their employment.</font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Save as authorised by the Board, the Executive shall not make or publish any comment regarding to the business of any Group Company or any of its current or former employees or directors to the media (including on social media).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Whistleblowing</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">It is the duty of the Executive to report to the Board any material breach by any Group Company of their legal obligations of which the Executive is aware. Concerns should be reported, in writing, to the Board.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Whilst it is the Company&#8217;s clear policy to operate in an ethical and lawful manner and to foster an environment which facilitates the internal reporting of matters of concern for the avoidance doubt nothing in this Agreement prevents the Executive from making a &#34;protected disclosure&#34; within the meaning of Part 4A (Protected Disclosures) of the Employment Rights Act 1996 nor from reporting any regulatory breaches to any regulator or from reporting any criminal conduct to the relevant authorities.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:3.8pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Intellectual Property</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.9pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall disclose (voluntarily) to the Company details of all Inventions and of all works embodying Intellectual Property Rights made solely or jointly with others at any time in the course of employment which relate to, or are capable of being used in, the business of any Group Company whether or not in the course of their ordinary duties and whether or not made in working time (together, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Company IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;). The Executive acknowledges that all Intellectual Property Rights subsisting (or which may in the future subsist) in such Company IP shall automatically, on creation, vest in the Company absolutely. To the extent that the Company IP does not vest automatically in the Company the Executive hereby assigns all right, title and interest in the Company IP to the Company with full title guarantee by way of a present assignment of all future rights and shall otherwise hold them on trust for the Company. The Executive agrees promptly to execute all documents and to do all acts as may, in the opinion of the Company, be necessary or desirable to give the Company full benefit of this clause.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.4pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Nothing in this Agreement obliges the Company to seek patent or other protection or to exploit any Invention disclosed by the Executive in accordance with clause 19.1</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive acknowledges that, save as provided by s40 Patents Act 1977, no further remuneration or compensation is or may become due to you as a result of the performance of your obligations under this clause 19.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.4pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive irrevocably waives all &#8220;moral rights&#8221; under the Copyright, Designs and Patents Act 1988 (and, to the fullest extent permitted by law, all similar rights in other jurisdictions) which the Executive has or will have in any Company IP.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">By way of security for the Executive&#8217;s obligations under this Agreement, the Executive irrevocably appoints the Company to be the Executive&#8217;s attorney to execute any instrument or to do anything and generally to use the Executive&#8217;s name for the purpose of giving the Company or its nominee the benefit of this clause. The Executive acknowledges in favour of a third party that a certificate in writing signed by the Company that any instrument or act falls within the authority conferred by this clause shall be conclusive evidence that such is the case.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Payment in Lieu of Notice</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company may, in its sole and absolute discretion, terminate the Executive&#8217;s employment under this Agreement at any time and with immediate effect by notifying the Executive that the Company is exercising its right under this clause <a href="#id73e3d776a744d5e834658cd60fec73e_87" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">19 </a>and that it will make a payment in lieu of notice (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">PILON&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">) to the Executive. The Executive&#8217;s employment will terminate immediately and any PILON due to the Executive in accordance with the provisions of this clause <a href="#id73e3d776a744d5e834658cd60fec73e_87" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">20</a> will be paid within 28 days. The PILON will be equal to the basic salary (as at the Termination Date) which the Executive would have been entitled to receive under this Agreement during the notice period referred to at clause <a href="#id73e3d776a744d5e834658cd60fec73e_81" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">2 </a>(or, if notice has already been given, during the remainder of the notice period) and (ii) the target annual bonus of 60% of basic salary (or the target percentage then in effect as determined by the Board for the applicable year in which the termination occurs) for the year in which the termination occurs, less deductions required by law.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">20.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;padding-left:8.9pt">The Executive shall have no right to receive a PILON unless the Company has exercised its discretion in clause 20.1</font></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Notwithstanding clause <a href="#id73e3d776a744d5e834658cd60fec73e_87" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">20.1,</a> the Executive shall not be entitled to any PILON if the Company would otherwise have been entitled to terminate the Executive&#8217;s employment under this Agreement without notice in accordance with clause 21. In that case the Company shall also be entitled to recover from the Executive any PILON already made.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.7pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Notwithstanding anything to the contrary herein, the following provisions apply to the extent the Executive is subject to U.S. income tax and the PILON provided herein is subject to Section 409A of the U.S. Internal Revenue Code (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;) and the regulations and other guidance thereunder and any state law of similar effect (collectively &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;). The PILON shall not commence until the Executive has had a &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#8220;separation from service&#8221;). Each instalment of the PILON is a separate &#8220;payment&#8221; for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i), and the PILON is intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and the Executive is, upon separation from service, a &#8220;specified employee&#8221; for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the PILON shall be delayed until the earlier of (i) six (6) months and one day after your separation from service, (ii) your death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Section 409A period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to the Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. The parties acknowledge that the exemptions from application of Section 409A to the PILON are fact specific, and any later amendment of this Agreement to alter the timing, amount or conditions that will trigger payment of the PILON may preclude the ability of the PILON provided under this Agreement to qualify for an exemption. To the extent that the PILON or other benefits are deferred compensation under Section 409A, and are not otherwise exempt from the application of Section 409A, then, if the period during which the Executive may consider and sign the Release spans two calendar years, the payment of such severance payments and benefits will not be made or begin until the later calendar year. It is intended that this Agreement shall comply with the requirements of Section 409A, and any ambiguity contained herein shall be interpreted in such manner so as to avoid adverse personal tax consequences under Section 409A. </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61.65pt;padding-right:32.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Notwithstanding the foregoing, the Company shall in no event be obligated to indemnify the Executive for any taxes or interest that may be assessed by the Internal Revenue Service pursuant to Section 409A of the Code to payments made pursuant to this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Termination Without Notice</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.05pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company may terminate the Executive&#8217;s employment under this Agreement with immediate effect without notice and with no liability to make any further payment to the Executive (other than in respect of amounts accrued at the Termination Date) if in the reasonable opinion of the Board the Executive&#58;</font></div><div><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">is guilty of gross misconduct&#59; or</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.95pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">commits any serious or repeated breach or non-observance of any of the provisions of this Agreement or refuses to comply with any reasonable and lawful directions of the Company&#59; or</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_90"></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5.15pt;padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">is grossly negligent or grossly incompetent in the performance of their duties&#59; or</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.15pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">is declared bankrupt or makes any arrangement with or for the benefit of their creditors or has a county court administration order made under the County Court Act 1984&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.75pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">is convicted of any criminal offence (other than an offence under any road traffic legislation in the United Kingdom or elsewhere for which a fine or non-custodial penalty is imposed)&#59; or</font></div><div><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">has breached the Quoted Company Requirements&#59; or</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.9pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">is disqualified from acting as a director or resigns as a director from the Company or any Group Company without the prior written approval of the Board&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:33.35pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">is no longer eligible to work in the country in which the Executive&#8217;s usual place of work is located&#59; or</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:33pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">is guilty of any fraud or dishonesty or acts in any manner which brings or is likely to bring the Executive or any Group Company into disrepute or is materially adverse to the interests of any Group Company.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The rights of the Company under clause <a href="#id73e3d776a744d5e834658cd60fec73e_87" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">21.1 </a>are without prejudice to any other rights that it might have at law to terminate the Executive&#8217;s employment or to accept any breach of this Agreement by the Executive as having brought the Agreement to an end. Any delay by the Company in exercising it rights to terminate shall not constitute a waiver thereof.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company may suspend the Executive from any or all of the Executive&#8217;s duties during any period in which the Company is investigating any disciplinary matter involving the Executive or while any disciplinary procedure or regulatory investigation is outstanding. Any such suspension shall not constitute disciplinary action. During any period of suspension, the Company may impose the same conditions that apply to Garden Leave.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Garden Leave</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Following service of notice to terminate the employment by either party, or if the Executive purports to terminate the employment in breach of contract, the Company may by written notice place the Executive on Garden Leave for the whole or part of the remainder of the employment.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.95pt">During any period of Garden Leave&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.8pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company shall be under no obligation to provide any work to the Executive and may revoke any powers the Executive holds on behalf of any Group Company&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.05pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company may require the Executive to carry out alternative duties or to only perform such specific duties as are expressly assigned to the Executive, at such location (including the home of the Executive) as the Board may reasonably decide&#59;</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_93"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:97.2pt;padding-right:33.05pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company may appoint another person to carry out the Executive&#8217;s normal duties&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.25pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Executive shall continue to receive their basic salary but shall not be entitled to receive any bonus or other incentive in respect of the period of Garden Leave&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.15pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Executive shall remain an employee of the Company and bound by the terms of this Agreement (including any implied duties of good faith and fidelity)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Executive shall be contactable during each working day (except during any periods taken as holiday in the usual way)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company may exclude the Executive from any premises of any Group Company, require the Executive to return any Group Company property and remove the Executive&#8217;s access from some or all of its information systems&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.15pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">22.2.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client or other business contact of any Group Company as it may reasonably determine.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Change in Control</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.95pt">In this clause 23, the following terms shall have the following meaning&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.82pt">&#8220;Agreed Sum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an amount equivalent to the gross value of&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:128.25pt;text-indent:-31.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.88pt">15 months&#8217; basic salary as specified in clause <a href="#id73e3d776a744d5e834658cd60fec73e_84" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">8.1&#59;</a></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:125.5pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:16.13pt">a sum equivalent to the target bonus the Executive would have received for the financial year in which their employment was terminated had they not been dismissed&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:125.5pt;padding-right:32.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:16.69pt">an amount equivalent to the cost to the Company of providing the Executive&#8217;s other employment benefits for 12 months,</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:97.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">less any sums paid to the Executive by way of notice or payment in lieu of notice (inclusive of salary and bonus).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.1pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221; means in relation to a body corporate, the power of a person to secure that the affairs of the body corporate are conducted in accordance with the wishes of that person&#58;</font></div><div><font><br></font></div><div style="padding-left:125.5pt;padding-right:33.4pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:16.13pt">by means of the holding of shares, or the possession of voting power, in or in relation to that or any other body corporate&#59; or</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:125.5pt;padding-right:32.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:16.13pt">as a result of any powers conferred by the articles of association or any other document regulating that or any other body corporate,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">and a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221; occurs if a person who controls any body corporate ceases to do so or if another person acquires Control of it, but does not occur in the circumstances described in clause <a href="#id73e3d776a744d5e834658cd60fec73e_99" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">29.2.</a></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_96"></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5.15pt;padding-left:61.65pt;padding-right:33.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">If there is a Change of Control of the Company and, within 12 months following the Change of Control of the Company, directly or indirectly in connection with it&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.95pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Company serves notice to terminate the Executive&#8217;s employment (other than for misconduct, lack of capability or poor performance, provided that such dismissal is not subsequently found to be unfair contrary to s98 Employment Rights Act 1996 by an Employment Tribunal)&#59; or</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Executive terminates the Appointment in response to a fundamental breach of   contract by the Company,</font></div><div style="padding-left:61.65pt;padding-right:33.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">the Company shall, subject to clause <a href="#id73e3d776a744d5e834658cd60fec73e_96" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none">23.3 </a>below, pay the Agreed Sum to the Executive within three months following Termination. The Agreed Sum shall be payable less any applicable tax or other statutory deductions.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;text-indent:-28.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.95pt">The payment of the Agreed Sum shall be conditional on and in consideration of&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">the Executive complying with the obligations in clause <a href="#id73e3d776a744d5e834658cd60fec73e_96" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">23&#59;</a></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97.2pt;padding-right:33pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">the Executive complying with (and continuing to comply with) the obligations relating to confidentiality, intellectual property and restrictive covenants as set out in clauses 17, 19 and 26 respectively&#59;</font></div><div><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.15pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">clause 26 applying notwithstanding that the Appointment may, or without the payment of the Agreed Sum might, otherwise have been repudiated by the Company&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.1pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">23.3.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;padding-left:7.77pt">the Executive executing a settlement agreement waiving their claims against the Company in a form reasonably acceptable to the Company.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.35pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">For the avoidance of doubt, the payment of the Agreed Sum shall not affect the Executive&#8217;s entitlement to any of the following&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">any accrued but unpaid salary&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;text-indent:-35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.82pt">any payment in lieu of accrued but unused holiday&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.15pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">23.4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;padding-left:7.77pt">the reimbursement of expenses, provided that all claims for reimbursement are submitted within four weeks after the Termination Date,</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in relation, in each case, to the period before the Termination Date.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">To the extent that the Agreed Sum is damages (which is not admitted), the parties agree that the terms of this clause 23 represent a genuine pre-estimate of the loss to the Executive that would arise on termination of their employment in the circumstances described and does not constitute a penalty. The Executive shall, subject to clause 23.4 accept the Agreed Sum in full and final settlement of all and any claims that they may have arising out of the Employment or its termination excluding any personal injury claims of which they are not aware at the Termination Date or any claims in relation to accrued entitlements under the relevant pension scheme.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:61.65pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">In the event of CIC Qualifying Termination (as defined below), each of Executive&#8217;s then outstanding unvested Time-Based Equity Awards shall accelerate and immediately become fully </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="padding-left:61.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">vested (and, if applicable, exercisable) with respect to 100% of the shares subject thereto, effective as of the Termination Date.   </font></div><div style="padding-left:61.65pt"><font><br></font></div><div style="padding-left:97.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">&#8220;Time-Based Equity Awards&#8221; means all options to purchase ordinary shares (or American Depositary Shares) of the Company, restricted share units, and all other share-based awards granted to Executive, including but not limited to share bonus awards, restricted share and share appreciation rights, but in each case, excluding awards that vest based upon the satisfaction of performance criteria. </font></div><div style="padding-left:97.2pt"><font><br></font></div><div style="padding-left:97.2pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">23.6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">&#8220;CIC Qualifying Termination&#8221; means the Termination Date occurring within twelve (12) months following a Sale Event (as defined in the Compass Pathways plc 2020 Share Option and Incentive Plan) resulting from (i) the Company or any Associated Company terminating the Executive&#8217;s employment (other than for misconduct, illegality, or performance based reasons, provided that such dismissal is not subsequently found to be unfair or contrary to s98 Employment Rights Act 1996 by an Employment Tribunal) or (ii) the Executive terminating his or her employment in response to a fundamental breach of contract by the Company or any Associated Company (unless such dismissal is subsequently deemed by an Employment Tribunal to not amount to a constructive dismissal). A termination or resignation due to Executive&#8217;s death or disability (whether permanent or not) shall not constitute a CIC Qualifying Termination.</font></div><div style="margin-top:5.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Obligations Upon Termination</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">On Termination or, if earlier, at the start of a period of Garden Leave following the service of notice or purported Termination by the Executive, the Executive shall&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.95pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">immediately deliver to the Company all documents, books, materials, records, correspondence, papers, Copies, Confidential Information and other business information (on whatever media and wherever located) relating to the business or affairs of any Group Company or its business contacts, any keys and any other property of any Group Company, which is in the Executive&#8217;s possession or control&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:97.2pt;padding-right:32.85pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">irretrievably delete any information relating to the business of any Group Company stored on any magnetic or optical disk or memory (including on any personal computer, personal device, personal email account or web account), and all matter derived from such sources which is in their possession or under their control outside the premises of the Company&#59;</font></div><div style="padding-left:61.65pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:97.2pt;padding-right:33.05pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:7.77pt">provide a signed statement confirming full compliance with the obligations under clauses 24.1.1 and 24.1.2 together with such reasonable evidence of compliance as the Company may request.</font></div><div style="padding-left:61.65pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Shares</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive may at the absolute discretion of the Company be granted an option or other award over shares in the COMPASS Pathways plc. Any such option or award shall be governed by rules set by the Company and COMPASS Pathways plc and which may be varied from time to time by the Company or COMPASS Pathways plc. Any such options or awards are not benefits conferred by this contract of employment.</font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">If on termination of this Agreement, whether lawfully or in breach of contract, the Executive loses any rights or benefits in relation to any awards or options the Executive held immediately prior to such termination of this Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Other Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221;) which the Executive would not have lost had the Agreement not been terminated (for example, the Executive is not employed as at a vesting date and therefore options which would have vested on that date lapse) the Executive shall not be entitled to be compensated for any such loss.</font></div><div style="padding-left:61.65pt;text-align:justify;text-indent:-28.35pt"><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Post Termination Restrictions</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In consideration for (i) a payment of &#163;1,000, and (ii) the Company&#8217;s agreement to support the Executive&#8217;s relocation to the UK, and consistent with the post termination restrictions to which the Executive is currently subject under his Prior Employment Agreement, the Executive agrees to be bound by the restrictive covenants contained in Schedule 1. The Company shall deduct income tax and National Insurance contributions from the payment made under this clause.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Statutory Particulars</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive is subject to the Company's disciplinary and grievance procedures, copies of which are available upon request although the Board reserves the right to deviate from these procedures in light of the Executive&#8217;s seniority. These procedures do not form part of the Executive's contract of employment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">If the Executive wishes to raise a grievance or appeal a disciplinary decision the matter should be raised in writing with the Board.</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_99"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:61.65pt;padding-right:33.55pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">There is no collective agreement which affects the Executive&#8217;s employment or this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.25pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">27.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%;padding-left:8.9pt">The Company does not impose any mandatory training requirements in relation to the Executive.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Company intends to comply with its statutory obligations regarding time off of work for example relating to family-related leave, domestic incident leave, jury and military service. There is no right to paid time off beyond the statutory entitlements but the Company may exercise its discretion in relation to short term absences.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Workplace Privacy</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">Information about the Company&#8217;s processing of the Executive&#8217;s personal data is set out in the Company&#8217;s Privacy Notice which is available from the Company&#8217;s Human Resources department.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.85pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive consents to the Company monitoring their communication and electronic equipment including, without limitation, the Company's telephone, chat and e-mail systems, information stored on the Company's computer equipment (including all electronically stored information that is the property of the Company), recordings from the Company's closed circuit television cameras and any other computer equipment or other device used by the Executive in the performance of their duties.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:33.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">General</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive will, at the request of the Company at any time after the Termination Date, co-operate and provide assistance to any Group Company in any internal investigation, administrative, regulatory, quasi-judicial proceedings or any threatened or actual litigation concerning any Group Company where the Executive is aware of any facts or other matters which the Company reasonably considers is relevant to such process or legal proceedings (including, but not limited to, giving a candid and accurate account of events, giving statements&#47;affidavits, meeting with their legal and other professional advisers, attending any legal hearing and giving evidence) and shall not cooperate with or otherwise give any information to any other party unless legally required to do so in which case the Executive will (so far as they are legally permitted to do so) give advance notice to the Company. The Company will pay any reasonable expenses for which receipts and other supporting documents are provided to the reasonable satisfaction of the Company and provided any expense is authorised in advance by the Company).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.75pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">If the Executive&#8217;s employment is terminated at any time by reason of any reconstruction or amalgamation of any Group Company, whether by winding up or otherwise, and the Executive is offered employment with any concern or undertaking involved in or resulting from the reconstruction or amalgamation on terms which (considered in their entirety) are no less favourable to any material extent than the terms of this Agreement, the Executive acknowledges and agrees that there shall be no claim against the Company or any undertaking arising out of or connected with such termination.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">This clause applies if the Executive subscribes for or is awarded shares in the Company or any Group Company or participates in any share option, restricted share, restricted share unit, long term incentive, carried interest, co-invest or any other form of profit sharing, incentive, bonus or equity plan or arrangement (each, an &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Incentive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;) or may do so. Upon</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:61.65pt;padding-right:32.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Termination, the Executive's rights (if any) in respect of each Incentive shall be solely determined by the articles of association, rules or other documents governing each Incentive which are in force on the Termination Date and the Executive hereby irrevocably waives all claims or rights of action in respect of the loss of any rights or benefits under or in respect of any Incentive granted or not yet granted to the Executive (including any loss relating to the lapse of, or their ineligibility to exercise, any share options, the value of any shares, the operation of any compulsory transfer provisions or the operation of any vesting criteria).</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:32.95pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">A notice given to a party under this Agreement shall be in writing in the English language and signed by or on behalf of the party giving it. It shall be delivered by hand or sent to the party at the address given for that party in this Agreement, in the case of the Executive to their personal email address or as otherwise notified in writing to the other party. A notice given by email shall be deemed to take effect one hour after it is sent, a notice sent by first class post shall be deemed to take effect on the next working day and notice sent by courier upon delivery at the address in question. A notice required to be given to the Company under this Agreement shall not be validly given if sent by email.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61.65pt;padding-right:32.8pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">This Agreement and any document referred to in it constitutes the entire agreement between the parties and supersedes and extinguishes all previous discussions, correspondence, negotiations, drafts, agreements including the Prior Employment Agreement (but excluding Sections 15 (Confidential Information) and 17 (Intellectual Property) of the Prior Employment Agreement), promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter. Notwithstanding the foregoing, the Executive and the Company agree that Section 15 (Confidential Information) and Section 17 (Intellectual Property) of the Prior Employment Agreement remain in full force and effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive agrees that in entering into this Agreement the Executive does not rely on and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not expressly set out in this Agreement. The Executive waives any claim for innocent or negligent misrepresentation or negligent misstatement including in respect of any statement set out in this Agreement.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.15pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">No variation or agreed termination of this Agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.2pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">The Executive shall not be contractually entitled to receive any benefit from the Company which is not expressly provided for by this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.4pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:8.9pt">This Agreement may be executed in any number of counterparts, each of which, when executed and delivered, shall be an original, and all the counterparts together shall constitute one and the same agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61.65pt;padding-right:33.1pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:3.34pt">The Contracts (Rights of Third Parties) Act 1999 shall only apply to this Agreement in relation to any Group Company. No person other than the parties to this Agreement and any Group Company shall have any rights under it and it will not be enforceable by any person other than those parties.</font></div><div><font><br></font></div><div style="padding-left:61.65pt;padding-right:33pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:3.34pt">This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England.</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:61.65pt;padding-right:33.3pt;text-align:justify;text-indent:-28.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">29.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:3.34pt">Each party irrevocably agrees that the courts of England shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this Agreement or its subject matter or formation (including non-contractual disputes or claims).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.8pt;padding-left:5pt;padding-right:33.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Executed and delivered as a Deed by the Executive and executed as an Agreement under hand by the Company on the date stated at the beginning of this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><img alt="image_1a.jpg" src="image_1a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHFINDER LIMITED</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">By&#58; ____&#47;s&#47; Anne Benedict________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title&#58; Anne Benedict, Chief People Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date&#58; __________7 May 2025_________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KABIR NATH</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">By&#58; ________&#47;s&#47; Kabir Nath_____________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date&#58; __________7 May 2025_________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.8pt;padding-left:155.45pt;padding-right:155.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE 1</font></div><div style="margin-top:1.75pt;padding-left:155.52pt;padding-right:155.52pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POST TERMINATION RESTRICTIONS</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:47.75pt;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:23.18pt">In this Schedule, the following terms not otherwise defined in the Agreement shall have the following meanings unless the context requires otherwise&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:40.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Look Back Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34; the period of 12 months before the Termination Date&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:35.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Restricted Business</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#34; those parts of the business of the Company and any Group Company with which the Executive was either&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90.1pt;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.28pt">involved to a material extent&#59; or</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:255.9pt;text-align:justify;text-indent:6.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:241%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:241%;padding-left:12.18pt">privy to Confidential Information, in each case during the Look Back Period.</font></div><div style="margin-top:2.35pt;padding-left:41pt;padding-right:33.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Restricted Client</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#34; any firm, company or person who, during the Look Back Period was either a client or customer of or was otherwise in the habit of dealing with the Company or any Group Company and with whom or which the Executive either&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90.1pt;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.28pt">had material personal contact&#59; or</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:41pt;padding-right:235.25pt;text-align:justify;text-indent:6.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:250%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:250%;padding-left:12.18pt">was privy to Confidential Information, in each case during the Look Back Period.</font></div><div style="margin-top:1.45pt;padding-left:41pt;padding-right:33.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Restricted Prospective Client</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#34; any firm, company or person who was a prospective client or customer of the Company or any Group Company with whom or which the Company or any Group Company has been in negotiations during the Look Back Period or had expended significant time or resources and with whom or which the Executive&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:90.1pt;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.28pt">had material personal contact&#59; or</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:41pt;padding-right:235.3pt;text-align:justify;text-indent:6.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:249%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:249%;padding-left:12.18pt">was privy to Confidential Information, in each case during the Look Back Period.</font></div><div style="margin-top:1.7pt;padding-left:40.4pt;padding-right:33.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Restricted Subject Matter Expert</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221; means anyone employed or engaged by the Company or any Group Company who holds a high degree of technical experience in their area (such that their replacement would be costly and&#47;or disruptive to the Company or any Group Company&#8217;s business) and with whom the Executive had material dealings during the period of 12 months immediately preceding the Termination Date in the course of the Executive&#8217;s employment.</font></div><div><font><br></font></div><div style="padding-left:40.4pt;padding-right:33.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Supplier</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221; means any person, firm, company or entity who during the period of 12 months immediately preceding the Termination Date was a supplier of services to the Company or any Group Company and with whom the Executive had material contact during the period of 12 months immediately preceding the Termination Date in the course of their employment.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:40.4pt;padding-right:36.2pt;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:23.18pt">In order to protect the Confidential Information, trade secrets and business connections of the Company and each Group Company to which the Executive has access as a result of the</font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:40.4pt;padding-right:42.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">employment, the Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that the Executive shall not&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:32.65pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.28pt">for twelve (12) months after the Termination Date, solicit or endeavour to entice away from the Company or any other Group Company the business or custom of a Restricted Client in competition with any Restricted Business&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:33.05pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.28pt">for twelve (12) months after the Termination Date, be involved with the provision of products or services to (or otherwise have any business dealings with) any Restricted Client in the course of any business concern which is in competition with any Restricted Business&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:33.05pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.84pt">for twelve (12) months after the Termination Date, solicit or endeavour to entice away from the Company or any other Group Company the business or custom of a Restricted Prospective Client in competition with any Restricted Business&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:33.1pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.28pt">for twelve (12) months after the Termination Date, be involved with the provision of products or services to (or otherwise have any business dealings with) any Restricted Prospective Client in the course of any business concern which is in competition with any Restricted Business&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:32.8pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.28pt">for twelve (12) months after the Termination Date, in the course of any business concern which is in competition with any Restricted Subject Matter Expert, employ or engage or otherwise facilitate the employment or engagement of any Restricted Person, whether or not such person would be in breach of contract as a result of such employment or engagement&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:32.95pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:33.07pt">for twelve (12) months after the Termination Date, solicit, entice away or interfere with the Company&#8217;s or any Group Company&#8217;s relationship with or endeavour to solicit, entice away or interfere with the Company&#8217;s or any Group Company&#8217;s relationship with any Supplier&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:32.7pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.28pt">for twelve (12) months after the Termination Date, be employed by, work for the benefit of, engaged by, interested in or concerned with any business concern which is (or intends to be) in competition with any Restricted Business for the purposes of providing services the same as or similar to those he&#47;she provided to the Company or any Group Company.</font></div><div><font><br></font></div><div style="padding-left:47.6pt;padding-right:33.05pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.38pt">The Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that the Executive shall not at any time after the Termination Date, represent any connection with any Group Company in any Capacity, other than as a former employee, or use any registered business names or trading names associated with any Group Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:47.6pt;padding-right:32.65pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:30.38pt">None of the restrictions in this Schedule shall prevent the Executive from holding a Permitted Investment.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:47.6pt;text-indent:-42.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.43pt">The restrictions imposed on the Executive by this Schedule apply to the Executive acting&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:90.1pt;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.28pt">directly or indirectly&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:90.1pt;padding-right:33.05pt;text-align:justify;text-indent:-42.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.28pt">in any Capacity, on their own behalf or on behalf of, or in conjunction with, any firm, company or person.</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></td></tr></table></div></div></div><div id="id73e3d776a744d5e834658cd60fec73e_102"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:47.6pt;padding-right:32.8pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(6)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.38pt">The periods for which the restrictions in paragraph <a href="#id73e3d776a744d5e834658cd60fec73e_99" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;text-decoration:none">(2)</a>(g) above apply shall be reduced by any period that the Executive spends on Garden Leave immediately before the Termination Date.</font></div><div><font><br></font></div><div style="padding-left:47.6pt;padding-right:32.75pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(7)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.38pt">If the Executive receives an offer to be involved in a business concern in any Capacity during employment, or before the expiry of the restrictions set out in paragraph <a href="#id73e3d776a744d5e834658cd60fec73e_99" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;text-decoration:none">(2)</a> above, the Executive shall give the person making the offer a copy of this Schedule and shall tell the Company the identity of that person as soon as possible after accepting the offer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47.6pt;padding-right:32.7pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(8)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.38pt">Each sub-paragraph <a href="#id73e3d776a744d5e834658cd60fec73e_99" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;text-decoration:none">(2)(a) </a>to <a href="#id73e3d776a744d5e834658cd60fec73e_99" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;text-decoration:none">(2)(g), </a>each definition set out in this Schedule, each limb of each such definition and each operative word within each sub-paragraph or definition is agreed to be a separate and severable restriction, notwithstanding that they are combined together for the sake of brevity. The parties agree that if any such restrictions shall be held to be void but would be valid if part of&#58; (a) the wording of such restriction were deleted, such restriction shall apply with such deletion (including but not limited to a single word or words) as may be necessary to make it valid or effective&#59; and (b) the wording of any definition were deleted, such restriction shall apply with such deletion as may be necessary to make it valid or effective but the deletion in that definition shall not apply to any other restriction, so that each definition is deemed to be repeated each time it is used. The parties agree that if any such restrictions shall be held to be void on account of its duration, the duration of each restriction shall take effect as if reduced by a month, until the resulting period shall be valid and enforceable.</font></div><div><font><br></font></div><div style="padding-left:47.6pt;padding-right:32.9pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(9)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:30.38pt">If the employment of the Executive is transferred to any firm, company, person or entity other than a Group Company (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:131%">New Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#34;) pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, the Executive will, if required, enter into an agreement with the New Employer containing post termination restrictions corresponding to those restrictions in this Schedule, protecting the confidential information, trade secrets and business connections of the New Employer.</font></div><div><font><br></font></div><div style="padding-left:47.6pt;padding-right:32.7pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(10)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:24.82pt">If the Executive breaches any of the provisions in this Schedule the Company may elect to extend the period during which the relevant breached provisions apply by a length of time equal to the period during which the breach continues, such additional period to commence on the date on which the original period would have expired. The Executive agrees that the Company's right to apply for injunctive relief or damages is not prejudiced by this clause.</font></div><div><font><br></font></div><div style="padding-left:47.6pt;padding-right:32.95pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(11)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:24.82pt">The Executive enters into each of the restrictions in this Schedule for the benefit of the Company on its own behalf and as trustee for each Group Company. The Executive will, at the request and expense of the Company, enter into a separate agreement with any Group Company in which the Executive agrees to be bound by restrictions corresponding to those restrictions in this Schedule in relation to that Group Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:47.6pt;padding-right:32.6pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">(12)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%;padding-left:24.82pt">The Executive acknowledges that if the Executive breaches the restrictions set out in this Schedule the Company will suffer irreparable loss, damages will not be an adequate remedy and the Company should be entitled to injunctive relief.</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.829%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-teri.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie06450659d434607a1706337d103af6b_78"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:133%">AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT</font></div><div><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS AMENDMENT NO. 1 (this &#8220;Amendment&#8221;) is dated May 7, 2025 and amends that certain Employment Agreement entered into as of December 6, 2023 (the &#8220;Employment</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;), by and COMPASS Pathways, Inc. (the &#8220;Company&#8221;), a Delaware corporation with a principal place of business at 44 West 37</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Street, 7th Floor New York, NY 10018, and Teri Loxam, residing at xxxxxxx (the &#8220;Employee&#8221; or &#8220;you&#8221;&#59; collectively with the Company, the &#8220;Parties&#8221;&#59; each of the Parties referred individually as &#8220;Party&#8221;).</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company and the Employee previously entered into the Employment Agreement&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuant to Section 12 of the Employment Agreement, the Employment Agreement can be amended or modified by a written instrument signed by the Company and the Employee&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company and the Employee desire to amend the Employment Agreement, as set forth herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment to Employment Agreement</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.66pt">Section 3 of the Employment Agreement is hereby amended by adding the following paragraphs at the end thereof&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;In the event of a CIC Qualifying Termination, each of Employee&#8217;s then outstanding unvested Time-Based Equity Awards shall accelerate and immediately become fully vested (and, if applicable, exercisable) with respect to 100% of the shares subject thereto, effective as of the Termination Date. </font></div><div style="margin-bottom:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:133%">&#8220;Time-Based Equity Awards</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221; means all options to purchase ordinary shares (or American Depositary Shares) of the Company, restricted share units, and all other share-based awards granted to Employee, including but not limited to share bonus awards, restricted share and share appreciation rights, but in each case, excluding awards that vest based upon the satisfaction of performance criteria.</font></div><div style="margin-bottom:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CIC Qualifying Termination</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8221; means a termination of Employee&#8217;s employment on or within twelve (12)&#160;months following a Sale Event (as defined in the Compass Pathways plc 2020 Share Option and Incentive Plan) resulting from (i)&#160;the Company (or its successor thereto) terminating the Employee&#8217;s employment without Cause or (ii)&#160;Employee terminating his or her employment with the Company (or its successor) for Good Reason.  For the avoidance of doubt, a termination or resignation due to Employee&#8217;s death or Disability shall not constitute a CIC Qualifying Termination.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment&#59; Entire Agreement</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as herein modified or amended, no other term or provision of the Employment Agreement is amended or modified in any respect and, to the extent the terms of the Amendment conflict with the terms of the Employment Agreement, this Amendment shall control. The Employment Agreement, as amended by this Amendment, constitutes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">ACTIVE&#47;137187941.1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the entire agreement between the parties hereto relating to the subject matter hereof and supersedes all prior oral and written agreements, understandings, negotiations, and discussions relating to the subject matter hereof. The Employment Agreement, as amended by this Amendment, cannot be further modified or amended except as set forth in Section 12 of the Employment Agreement.  The waiver of any provision of this Amendment shall not constitute a waiver of any other provisions and, unless otherwise stated, shall not constitute a continuing waiver.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Amendment will be governed by the laws of the Commonwealth of Pennsylvania (with the exception of its conflict of law provisions).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  This Amendment may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Amendment and all of which, when taken together, will be deemed to constitute one and the same agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">ACTIVE&#47;137187941.1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, the Parties have executed this Agreement as of the day and year first above written.</font></div><div style="margin-bottom:10pt;margin-top:11.25pt;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.62pt;padding-right:2.62pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">EMPLOYEE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.62pt;padding-right:2.62pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">COMPASS PATHWAYS, INC.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.62pt;padding-right:2.62pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;s&#47; Kabir Nath</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.62pt;padding-right:2.62pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;s&#47; Teri Loxam</font></div><div style="margin-bottom:12pt;padding-left:2.62pt;padding-right:2.62pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.62pt;padding-right:2.62pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:24.22pt;padding-right:2.62pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58; KABIR NATH</font></div><div style="margin-bottom:10pt;padding-left:24.22pt;padding-right:2.62pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Title&#58;  Chief Executive Officer&#160;&#160;&#160;&#160;<br></font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">ACTIVE&#47;137187941.1</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>guyaragreement.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>guyaragreement</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- guyaragreement001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  4135-1945-7548, v. 3  STRICTLY PRIVATE AND CONFIDENTIAL    Dated 26 July 2021 (as amended and restated on 7 May 2025)  COMPASS PATHFINDER LIMITED     and    GUY GOODWIN  SERVICE AGREEMENT                  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  1  4135-1945-7548, v. 3  THIS AGREEMENT is entered into between the parties on 26 July 2021 and is amended and restated  as of 7 May 2025.    PARTIES    (1) COMPASS PATHFINDER LIMITED a company incorporated and registered in England and  Wales with company number 10229259 and whose registered office is at 3rd Floor, 1 Ashley  Road, Altrincham, Cheshire, United Kingdom, WA14 2DT (the &quot;Company&quot;); and    (2) Guy Goodwin of xxxxxxx (the &quot;Executive&quot;).    AGREED TERMS    1. Definitions    1.1 The following terms shall have the following meanings unless the context requires  otherwise:  &quot;Board&quot; means the board of directors of the Company or any person or committee of the  board duly appointed by it;  &quot;Capacity&quot; means as agent, consultant, director, employee, owner, partner, shareholder  or otherwise;  &#8220;Commencement Date&#8221; shall mean 16 August 2021;  &quot;Confidential Information&quot; means trade secrets, knowhow and information (whether or  not recorded in documentary form, or stored on any magnetic or optical disk or memory)  relating to the business, products, affairs and finances of any Group Company or any of  their suppliers, customers, agents, shareholders or management, including (but not limited  to): (a) business, financial or strategic information or plans; (b) technical data, research  data and know-how; (c) litigation, potential litigation or legal advice; (d) employment terms  or pay of the Executive or others; (e) commercial terms with business partners; (f) products  or services in the course of development; (g) processes, techniques or know-how; (h)  details of any joint ventures, which (in each case) the Executive creates, develops, learns,  receives or obtains in connection with the Executive&#8217;s employment before or after the date  of this agreement, whether or not such information is marked confidential;   &quot;Copies&quot; means copies or records of any Confidential Information in whatever form  (including, without limitation, in written, oral, visual or electronic form or on any magnetic  or optical disk or memory and wherever located) including, without limitation, extracts,  analysis, studies, plans, compilations or any other way of representing or recording and  recalling information which contains, reflects or is derived or generated from Confidential  Information;  &quot;Garden Leave&quot; means any period during which the Company has exercised its rights  under clause 21;    &quot;Group Company&quot; means the Company and any group undertaking (as such term is  defined in section 1161(5) of the Companies Act 2006) of the Company in any jurisdiction  from time to time;      &quot;Intellectual Property Rights&quot; means patents, rights to Inventions, copyright and related  rights, trade marks, trade names and domain names, rights in get-up, rights in goodwill or  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  2  4135-1945-7548, v. 3  to sue for passing off, unfair competition rights, rights in designs, rights in computer  software, database rights, topography rights, rights in confidential information (including  know-how and trade secrets) and any other intellectual property rights, in each case  whether registered or unregistered and including all applications (or rights to apply) for,  and renewals or extensions of, such rights and all similar or equivalent rights or forms of  protection which subsist or will subsist now or in the future in any part of the world;    &quot;Invention&quot; means any invention, idea, discovery, development, notation, formula,  improvement or innovation, whether or not patentable or capable of registration, and  whether or not recorded in any medium;    &quot;Permitted Investment&quot; has the meaning given to it in clause 15.2;    &quot;Quoted Company Requirements&quot; means (a) all legal and regulatory obligations, codes  of practice and recommendations which apply to the Executive or any Group Company  relating to transactions in securities, related party transactions and inside information  (including the Company's share dealing policy); and (b) the Financial Services and  Markets Act 2000 and the Criminal Justice Act 1993, in each case as amended or  superseded from time to time; and as applicable, the securities laws of the United States,  including but not limited to the Securities Act of 1933, as amended, the Securities  Exchange Act of 1934, as amended, and the rules and regulations promulgated  thereunder, and the Listing Rules of The Nasdaq Stock Market, each as amended from  time to time; and  &quot;Termination&quot; means the termination of the Executive&#8217;s employment under this  Agreement however caused, whether lawful or not, and &quot;Termination Date&quot; means the  date of Termination.    1.2 In this Agreement, unless the context otherwise requires:    1.2.1 words in the singular include the plural and in the plural include the singular;    1.2.2 any phrase introduced by the terms &quot;including&quot;, &quot;include&quot;, &quot;in particular&quot; or any  similar expression shall be construed as illustrative and shall not limit the sense of  the words preceding those terms;     1.2.3 the headings are inserted for convenience only and shall not affect its construction;    1.2.4 reference to a particular law is a reference to it as it is in force for the time being  taking account of any amendment, extension or re-enactment and includes any  subordinate legislation for the time being in force made under it;     1.2.5 the Schedules shall form part of this Agreement, shall have effect as if set out in  full in the body of this Agreement and any reference to this Agreement includes  the Schedules; and     1.2.6 reference to any regulator or other body includes a reference to any successor.    2. Term of Employment    2.1 The Executive&#8217;s employment under the terms of this Agreement shall commence on the  Commencement Date, and shall continue, subject to the remaining terms of this  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  3  4135-1945-7548, v. 3  Agreement, until terminated by either party giving the other not less than 3 months' prior  notice in writing.     2.2 No previous employment with the Company or any other employer counts as part of the  Executive's period of continuous employment with the Company.    3. Conditions and Warranties    3.1 The Executive warrants that:    3.1.1 the Executive is entitled to work in the United Kingdom without any additional  approvals; and    3.1.2 the Executive is not prevented by the terms of any agreement or court order from  continuing employment with the Company from the date of this Agreement and  that there are no express or implied terms of any contract with (or other obligation  to) any third party that could prevent or hinder the performance of the Executive&#8217;s  duties to any Group Company.    3.2 It is a condition of this employment that the Executive has and maintains during the course  of this employment, valid United Kingdom immigration permission which permits the  Executive to be employed by the Company in the role for which the Executive is employed.  The Executive must notify the Company immediately if at any time the Executive does not  meet this condition. The Executive must produce to the Company for inspection the  documents proving this right to the Company&#8217;s satisfaction upon request.    3.3 If the Executive is in breach of any of the warranties or fails to satisfy the conditions set  out in this clause 3 then the Company shall be entitled to terminate the Executive&#8217;s  employment summarily.     4. Duties    4.1 The Executive shall serve the Company as Chief Medical Officer reporting to the Chief  Executive Officer (currently George Goldsmith) or such other role and reporting line as the  Company may determine from time to time.     4.2 During the employment the Executive shall:    4.2.1 devote the whole of their working time, attention and abilities to the business of  the Company and any other Group Company for which the Executive is required  to work from time to time;    4.2.2 faithfully and diligently exercise such powers and perform such duties for each  Group Company as may from time to time be assigned by the Company;    4.2.3 comply with all reasonable and lawful directions given by the Board;    4.2.4 promptly make such reports to the Board in connection with the affairs of each  Group Company on such matters and at such times as are reasonably required;    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  4  4135-1945-7548, v. 3  4.2.5 report their own wrongdoing and any wrongdoing or proposed or potential  wrongdoing of any other employee, officer or consultant of any Group Company  to the Board immediately on becoming aware of it;    4.2.6 use their utmost endeavours to promote, protect, develop and extend the business  of each Group Company;     4.2.7 comply with their common law, statutory, regulatory and fiduciary duties;     4.2.8 exercise the Executive&#8217;s powers jointly with such other person that the Company  may appoint; and    4.2.9 at all times conduct the business of each Group Company for which the Executive  is responsible in a lawful and ethical manner.    5. Regulatory Compliance and Policies and Procedures    5.1 The Executive will read and comply strictly with:    5.1.1 any rules, policies and procedures that apply to each Group Company at all times;     5.1.2 the Quoted Company Requirements;    5.1.3 any other laws and regulations material to the conduct of the business of the  Company or any Group Company.      5.2 Although the Company&#8217;s rules, policies and procedures do not form part of this Agreement,  failure to comply with them may result in disciplinary action up to and including dismissal.     5.3 The Executive is aware of the Quoted Company Requirements and that a breach of the  Quoted Company Requirements carries sanctions including criminal liability, disciplinary  action by the Company (up to and including summary dismissal) and disciplinary action by  the relevant regulatory authority. Due to the Executive's position the Executive shall be  named on the Company's list of persons with access to inside information relating to the  Company which may be made available to relevant authorities.    6. Place of Work    6.1 Your normal place of work will be your home address, as stated at the top of this  Agreement and which may be amended from time to time as agreed in advance between  you and the Company.    6.2 The Executive agrees to travel on any business of any Group Company (both within the  United Kingdom and abroad) as may be required for the proper performance of the  Executive&#8217;s duties.    6.3 If the Executive is required to work outside of the United Kingdom for a continuous period  of more than a month the terms that apply will be separately communicated to the  Executive.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  5  4135-1945-7548, v. 3  7. Hours of Work    7.1 The Executive shall work such hours as are required for the proper and efficient  performance of their duties including the Company&#8217;s normal business hours which are 9am  until 6 pm from Monday to Friday.    7.2 The Executive agrees that the limit on weekly working time contained in Regulation 4 of  The Working Time Regulations 1998 does not apply because Regulation 20 applies to the  Executive.    8. Salary    8.1 The Executive shall be paid a basic salary of &pound;340,939 per annum subject to deductions  required by law. The Executive&#8217;s salary shall accrue from day to day, shall be payable in  equal monthly instalments in arrears on or about the last Friday of each month and shall  include any directors&#8217; fees.    8.2 The salary paid to the Executive may be reviewed annually. The Company is under no  obligation to award an increase following a salary review.     8.3 The Company may deduct from the salary or any other sums payable to the Executive any  money owed to any Group Company by the Executive. The Executive will reimburse the  Company upon demand for the personal use of any Company credit card, any other  unauthorised transactions entered into by the Executive or any overpayments made to the  Executive.      9. Expenses    The Company shall reimburse any expenses wholly, exclusively and necessarily incurred by the  Executive in the proper performance of the Executive&#8217;s duties under this Agreement subject  always to the rules and policies of the Company from time to time and subject to the Executive  providing receipts or other evidence of payment as the Company may require.      10. Annual Bonus    10.1 The Executive shall be eligible to earn an annual incentive bonus, with a target bonus  amount of 35% of the Executive&#8217;s basic salary (and the ability to earn up to 125% of that  target bonus amount in certain circumstances), subject to such terms and with such  individual, team or corporate targets as the Board may communicate from time to time.  The Board shall be entitled to determine whether such targets have been met and where  such targets have been met in full or part shall have a discretion to determine whether to  make payments and, if so, in what amount and when.    10.2 The Board may suspend, alter or discontinue any bonus payment(s) or any bonus plan  and its eligibility requirements at any time (whether generally or in relation to the Executive  only) at its absolute discretion.  If the Executive receives any bonus payment the Company  is not obliged to make any further bonus payments and any bonus payment will not  become part of the Executive's contractual remuneration or fixed salary. In order to be  eligible to receive a bonus payment, the Executive must be in the Company's employment  and not under notice, given or received on the date that the bonus is paid. Bonus  entitlement does not accrue in the course of a year, and the Executive is not entitled to  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  6  4135-1945-7548, v. 3  payment of a bonus, or any pro rata portion of it, if the Executive leaves employment prior  to the date that the bonus is paid.    10.3 The Executive shall not be eligible to be considered for any bonus nor shall any bonus be  paid if the Executive is subject to any disciplinary action or investigation at the date any  bonus is being considered and/or at the bonus payment date (as applicable) although the  Company may reconsider the matter upon the conclusion of the disciplinary action or  investigation in question.      11. Pensions    11.1 The Company intends to comply with the employer pension duties in respect of the  Executive in accordance with Part 1 of the Pensions Act 2008.    11.2 The Executive&#8217;s participation in the Company&#8217;s pension arrangements is subject to the  rules of the relevant scheme and the statutory requirement as each are varied from time  to time.  In particular the Company reserves the right to change the scheme provider, the  funds available, the charging structure and the default fund from time to time.      12. Benefit Plans    12.1 The Executive shall, during employment, be eligible to participate in the following benefit  plans operated by the Company:    12.1.1 health insurance for the Executive;    12.1.2 life assurance;    12.1.3 permanent insurance cover.    12.2 The Executive&#8217;s participation in the benefit plans referred to in this clause are subject to:    12.2.1 the terms of that benefit plan, as amended from time to time;    12.2.2 the rules or the insurance policy of the relevant benefit provider, as amended from  time to time; and    12.2.3 the Executive satisfying the normal underwriting requirements of the relevant  benefits provider (which may involve a medical and/or a medical questionnaire)  and the premium being at a rate which the Company considers reasonable.    12.3 The Company&#8217;s obligation under this clause is limited to paying premiums to the relevant  benefits provider. If the benefit provider refuses to accept a claim under the relevant benefit  plan the Company shall have no obligation or responsibility to challenge that decision or  to compensate the Executive.       12.4 The Company reserves the right to discontinue, vary or amend each benefit plan (including  the level of cover) at any time on reasonable notice to the Executive.      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  7  4135-1945-7548, v. 3  13. Holidays     13.1 The Executive shall be entitled to 25 days' paid holiday in each holiday year together with  the usual public holidays in England to be taken at times convenient to the Company and  authorised in advance. In addition to this, the Executive shall be entitled to one day&#8217;s paid  annual leave to be taken on or around their birthday. Finally, the Executive may be entitled  to additional paid leave, based on service, as per the Holiday Policy (UK) available from  the Board.    13.2 The Company's holiday year runs between 1 January and 31 December. If the Executive&#8217;s  employment commences or terminates part way through a holiday year, the Executive's  entitlement during that holiday year shall be calculated on a pro rata basis rounded up to  the nearest whole day.    13.3 The Executive shall have no entitlement to any payment in lieu of accrued but untaken  holiday except on Termination. The amount of such payment in lieu shall be 1/260th of the  Executive's salary for each untaken day of entitlement.    13.4 If on Termination the Executive has taken in excess of their accrued holiday entitlement,  the Company shall be entitled to recover from the Executive by way of deduction from any  payments due to the Executive or otherwise, one day's pay for each excess day calculated  at 1/260th of the Executive&#8217;s salary.    13.5 If either party has served notice to terminate the employment, the Company may require  the Executive to take any accrued but unused holiday entitlement during the notice period.  Any accrued but unused holiday entitlement shall be deemed to be taken during any period  of Garden Leave.    14. Sickness    14.1 The Company may in its absolute discretion pay the Executive an amount equal to the  Executive&#8217;s normal basic pay (&#8220;Company Sick Pay&#8221;) for the first 10 working days of  sickness absence in any rolling 12 month period, subject to such conditions as set out in  the Sick Leave Policy (UK) and/or as the Board may specify. Company Sick Pay will  include any entitlement to statutory sick pay or any benefits provided by virtue of any  permanent health insurance scheme. Company Sick Pay is also subject to the Executive&#8217;s  compliance with this Agreement and will not be paid in respect of any period of illness that  commences during the first 6 months of the Executive&#8217;s employment or whilst the  Company is addressing performance or disciplinary issues.    14.2 The Executive must comply with the Company&#8217;s sickness absence notification procedures  as set out in the Sick Leave Policy (UK). Any period of absence of up to seven calendar  days may be self-certified and any period of absence of more than five days must be  supported by doctor&#8217;s certificate.     14.3 The Executive consents to undergo a medical examination by a doctor nominated by the  Company at the Company&#8217;s request and expense.     14.4 The rights of the Company to terminate the Executive&#8217;s employment under the terms of  this Agreement apply even when such termination would or might cause the Executive to  forfeit any entitlement to sick pay, permanent health insurance or other benefits.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  8  4135-1945-7548, v. 3  15. Outside Activities and Interests    15.1 The Executive shall not during the employment except as a representative of the Company  or with the Board&#8217;s prior written consent (whether directly or indirectly, paid or unpaid) be  employed, engaged, concerned or interested in any other actual or prospective business,  organisation, occupation or profession. Any such permission granted by the Board or the  Company prior to the date of this Agreement shall continue to apply during the term of this  Agreement.    15.2 Nothing in this Agreement shall prevent the Executive from holding an investment by way  of shares or other securities to in any entity listed or dealt on a recognised stock exchange  (a &#8220;Permitted Investment&#8221;) provided always that during the term of the employment: (i)  the Permitted Investment shall not constitute more than 3% of the issued share capital of  the entity concerned, (ii) the Executive makes full disclosure of such Permitted Investments  and any actual or apparent conflicts of interest resulting therefrom, so that the Company  can make appropriate determinations on the propriety of any investment; and (iii) the  Executive complies with the Quoted Company Requirements.    16. Confidential Information    16.1 Without prejudice to the Executive&#8217;s common law and fiduciary duties, the Executive shall  not during employment or at any time after Termination and whether for their own benefit  or for the benefit of any third party:      16.1.1 use any Confidential Information; or    16.1.2 disclose any Confidential Information to any person, company or other  organisation whatsoever,     except in the proper course of their duties, as required by law or as authorised by the Board  in writing.    16.2 The Executive shall be responsible for protecting the confidentiality of the Confidential  Information and shall use best endeavours to prevent the misuse of Confidential  Information by others.    16.3 All Confidential Information and Copies shall be the property of the Company and the  Executive shall not make any Copies save in the proper course of their employment.      16.4 Save as authorised by the Board, the Executive shall not make or publish any comment  regarding to the business of any Group Company or any of its current or former employees  or directors to the media (including on social media).     17. Whistleblowing    17.1 It is the duty of the Executive to report to the Board any material breach by any Group  Company of their legal obligations of which the Executive is aware. Concerns should be  reported, in writing, to the Board.    17.2 Whilst it is the Company&#8217;s clear policy to operate in an ethical and lawful manner and to  foster an environment which facilitates the internal reporting of matters of concern for the  avoidance doubt nothing in this Agreement prevents the Executive from making a  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  9  4135-1945-7548, v. 3  &quot;protected disclosure&quot; within the meaning of Part 4A (Protected Disclosures) of the  Employment Rights Act 1996 nor from reporting any regulatory breaches to any regulator  or from reporting any criminal conduct to the relevant authorities.     18. Intellectual Property    18.1 The Executive shall disclose (voluntarily) to the Company details of all Inventions and of  all works embodying Intellectual Property Rights made solely or jointly with others at any  time in the course of employment which relate to, or are capable of being used in, the  business of any Group Company whether or not in the course of their ordinary duties and  whether or not made in working time (together, the &#8220;Company IP&#8221;). The Executive  acknowledges that all Intellectual Property Rights subsisting (or which may in the future  subsist) in such Company IP shall automatically, on creation, vest in the Company  absolutely. To the extent that the Company IP does not vest automatically in the Company  the Executive hereby assigns all right, title and interest in the Company IP to the Company  with full title guarantee by way of a present assignment of all future rights and shall  otherwise hold them on trust for the Company. The Executive agrees promptly to execute  all documents and to do all acts as may, in the opinion of the Company, be necessary or  desirable to give the Company full benefit of this clause.    18.2 Nothing in this Agreement obliges the Company to seek patent or other protection or to  exploit any Invention disclosed by the Executive in accordance with clause 18.1.    18.3 The Executive acknowledges that, save as provided by s40 Patents Act 1977, no further  remuneration or compensation is or may become due to you as a result of the performance  of your obligations under this clause 18.    18.4 The Executive irrevocably waives all &#8220;moral rights&#8221; under the Copyright, Designs and  Patents Act 1988 (and, to the fullest extent permitted by law, all similar rights in other  jurisdictions) which the Executive has or will have in any Company IP.    18.5 By way of security for the Executive&#8217;s obligations under this Agreement, the Executive  irrevocably appoints the Company to be the Executive&#8217;s attorney to execute any instrument  or to do anything and generally to use the Executive&#8217;s name for the purpose of giving the  Company or its nominee the benefit of this clause. The Executive acknowledges in favour  of a third party that a certificate in writing signed by the Company that any instrument or  act falls within the authority conferred by this clause shall be conclusive evidence that such  is the case.    19. Payment in Lieu of Notice    19.1 The Company may, in its sole and absolute discretion, terminate the Executive&#8217;s  employment under this Agreement at any time and with immediate effect by notifying the  Executive that the Company is exercising its right under this clause 19 and that it will make  a payment in lieu of notice (&quot;PILON&quot;) to the Executive.  The Executive&#8217;s employment will  terminate immediately and any PILON due to the Executive in accordance with the  provisions of this clause 19 will be paid within 28 days. The PILON will be equal to the  basic salary (as at the Termination Date) which the Executive would have been entitled to  receive under this Agreement during the notice period referred to at clause 2 (or, if notice  has already been given, during the remainder of the notice period) less deductions required  by law.     </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  10  4135-1945-7548, v. 3  19.2 The Executive shall have no right to receive a PILON unless the Company has exercised  its discretion in clause 19.1.     19.3 Notwithstanding clause 19.1, the Executive shall not be entitled to any PILON if the  Company would otherwise have been entitled to terminate the Executive&#8217;s employment  under this Agreement without notice in accordance with clause 20. In that case the  Company shall also be entitled to recover from the Executive any PILON already made.    19.4 Notwithstanding anything to the contrary herein, the following provisions apply to the extent  the Executive is subject to U.S. income tax and the PILON provided herein is subject to  Section 409A of the U.S. Internal Revenue Code (the &#8220;Code&#8221;) and the regulations and  other guidance thereunder and any state law of similar effect (collectively &#8220;Section 409A&#8221;).  The PILON shall not commence until the Executive has had a &#8220;separation from service&#8221;  (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any  alternative definition thereunder, a &#8220;separation from service&#8221;). Each installment of the  PILON is a separate &#8220;payment&#8221; for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i), and  the PILON is intended to satisfy the exemptions from application of Section 409A provided  under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9).  However, if such exemptions are not available and the Executive is, upon separation from  service, a &#8220;specified employee&#8221; for purposes of Section 409A, then, solely to the extent  necessary to avoid adverse personal tax consequences under Section 409A, the timing of  the PILON shall be delayed until the earlier of (i) six (6) months and one day after your  separation from service, (ii) your death or (iii) such earlier date as permitted under  Section 409A without the imposition of adverse taxation. Upon the first business day  following the expiration of such applicable Section 409A period, all payments deferred  pursuant to this paragraph shall be paid in a lump sum to the Executive, and any remaining  payments due shall be paid as otherwise provided herein or in the applicable agreement.  No interest shall be due on any amounts so deferred. The parties acknowledge that the  exemptions from application of Section 409A to the PILON are fact specific, and any later  amendment of this Agreement to alter the timing, amount or conditions that will trigger  payment of the PILON may preclude the ability of the PILON provided under this  Agreement to qualify for an exemption. To the extent that the PILON or other benefits are  deferred compensation under Section 409A, and are not otherwise exempt from the  application of Section 409A, then, if the period during which the Executive may consider  and sign the Release spans two calendar years, the payment of such severance payments  and benefits will not be made or begin until the later calendar year. It is intended that this  Agreement shall comply with the requirements of Section 409A, and any ambiguity  contained herein shall be interpreted in such manner so as to avoid adverse personal tax  consequences under Section 409A. Notwithstanding the foregoing, the Company shall in  no event be obligated to indemnify the Executive for any taxes or interest that may be  assessed by the Internal Revenue Service pursuant to Section 409A of the Code to  payments made pursuant to this Agreement.    20. Termination Without Notice    20.1 The Company may terminate the Executive&#8217;s employment under this Agreement with  immediate effect without notice and with no liability to make any further payment to the  Executive (other than in respect of amounts accrued at the Termination Date) if in the  reasonable opinion of the Board the Executive:    20.1.1 is guilty of gross misconduct; or    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  11  4135-1945-7548, v. 3  20.1.2 commits any serious or repeated breach or non-observance of any of the  provisions of this Agreement or refuses to comply with any reasonable and lawful  directions of the Company; or     20.1.3 is grossly negligent or grossly incompetent in the performance of their duties; or    20.1.4 is declared bankrupt or makes any arrangement with or for the benefit of their  creditors or has a county court administration order made under the County Court  Act 1984; or    20.1.5 is convicted of any criminal offence (other than an offence under any road traffic  legislation in the United Kingdom or elsewhere for which a fine or non-custodial  penalty is imposed); or    20.1.6 has breached the Quoted Company Requirements; or    20.1.7 is disqualified from acting as a director or resigns as a director from the Company  or any Group Company without the prior written approval of the Board; or    20.1.8 is no longer eligible to work in the country in which the Executive&#8217;s usual place of  work is located; or    20.1.9 is guilty of any fraud or dishonesty or acts in any manner which brings or is likely  to bring the Executive or any Group Company into disrepute or is materially  adverse to the interests of any Group Company.    20.2 The rights of the Company under clause 20.1 are without prejudice to any other rights that  it might have at law to terminate the Executive&#8217;s employment or to accept any breach of  this Agreement by the Executive as having brought the Agreement to an end. Any delay  by the Company in exercising it rights to terminate shall not constitute a waiver thereof.    20.3 The Company may suspend the Executive from any or all of the Executive&#8217;s duties during  any period in which the Company is investigating any disciplinary matter involving the  Executive or while any disciplinary procedure or regulatory investigation is outstanding.  Any such suspension shall not constitute disciplinary action. During any period of  suspension, the Company may impose the same conditions that apply to Garden Leave.      21. Garden Leave    21.1 Following service of notice to terminate the employment by either party, or if the Executive  purports to terminate the employment in breach of contract, the Company may by written  notice place the Executive on Garden Leave for the whole or part of the remainder of the  employment.    21.2 During any period of Garden Leave:    21.2.1 the Company shall be under no obligation to provide any work to the Executive  and may revoke any powers the Executive holds on behalf of any Group Company;    21.2.2 the Company may require the Executive to carry out alternative duties or to only  perform such specific duties as are expressly assigned to the Executive, at such  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement013.jpg" title="slide13" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  12  4135-1945-7548, v. 3  location (including the home of the Executive) as the Board may reasonably  decide;    21.2.3 the Company may appoint another person to carry out the Executive&#8217;s normal  duties;    21.2.4 the Executive shall continue to receive their basic salary but shall not be entitled  to receive any bonus or other incentive in respect of the period of Garden Leave;    21.2.5 the Executive shall remain an employee of the Company and bound by the terms  of this Agreement (including any implied duties of good faith and fidelity);    21.2.6 the Executive shall be contactable during each working day (except during any  periods taken as holiday in the usual way);    21.2.7 the Company may exclude the Executive from any premises of any Group  Company, require the Executive to return any Group Company property and  remove the Executive&#8217;s access from some or all of its information systems; and    21.2.8 the Company may require the Executive not to contact or deal with (or attempt to  contact or deal with) any officer, employee, consultant, client or other business  contact of any Group Company as it may reasonably determine.    22. Change in Control    22.1 In this clause 22, the following terms shall have the following meaning:    22.1.1 &#8220;Agreed Sum&#8221; means an amount equivalent to the gross value of:    (a) 12 months&#8217; basic salary as specified in clause 8.1;  (b) a sum equivalent to the pro rata bonus the Executive would have received  for the financial year in which their employment was terminated had they  not been dismissed, but not including any pro rata bonus in respect of any  part of the Executive&#8217;s notice period which is not worked (whether the  Executive receives pay in lieu of such notice period or is placed on Garden  Leave);  (c) an amount equivalent to the cost to the Company of providing the  Executive&#8217;s other employment benefits for 12 months,  less any sums paid to the Executive by way of notice or payment in lieu of notice.  22.1.2 &#8220;Control&#8221; means in relation to a body corporate, the power of a person to secure  that the affairs of the body corporate are conducted in accordance with the wishes  of that person:  (a) by means of the holding of shares, or the possession of voting power, in or  in relation to that or any other body corporate; or  (b) as a result of any powers conferred by the articles of association or any  other document regulating that or any other body corporate,  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement014.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement014.jpg" title="slide14" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  13  4135-1945-7548, v. 3  and a &#8220;Change of Control&#8221; occurs if a person who controls any body corporate  ceases to do so or if another person acquires Control of it, but does not occur in  the circumstances described in clause 27.2.    22.2 If there is a Change of Control of the Company and, within 12 months following the Change  of Control of the Company, directly or indirectly in connection with it:    22.2.1 the Company serves notice to terminate the Executive&#8217;s employment (other than  for misconduct, lack of capability or poor performance, provided that such  dismissal is not subsequently found to be unfair contrary to s98 Employment  Rights Act 1996 by an Employment Tribunal); or    22.2.2 the Executive terminates the Appointment in response to a fundamental breach of  contract by the Company,    the Company shall, subject to clause 22.3 below, pay the Agreed Sum to the Executive  within three months following Termination. The Agreed Sum shall be payable less any  applicable tax or other statutory deductions.    22.3 The payment of the Agreed Sum shall be conditional on and in consideration of:  22.3.1 the Executive complying with the obligations in clause 22;  22.3.2 the Executive complying with (and continuing to comply with) the obligations  relating to confidentiality, intellectual property and restrictive covenants as set out  in clauses 16, 18 and 24 respectively;  22.3.3 clause 24 applying notwithstanding that the Appointment may, or without the  payment of the Agreed Sum might, otherwise have been repudiated by the  Company; and  22.3.4 the Executive executing a settlement agreement waiving their claims against the  Company in a form reasonably acceptable to the Company.    22.4 For the avoidance of doubt, the payment of the Agreed Sum shall not affect the Executive&#8217;s  entitlement to any of the following:  22.4.1 any accrued but unpaid salary;  22.4.2 any payment in lieu of accrued but unused holiday; or  22.4.3 the reimbursement of expenses, provided that all claims for reimbursement are  submitted within four weeks after the Termination Date,  in relation, in each case, to the period before the Termination Date.    22.5 To the extent that the Agreed Sum is damages (which is not admitted), the parties agree  that the terms of this clause 22 represent a genuine pre-estimate of the loss to the  Executive that would arise on termination of their employment in the circumstances  described and does not constitute a penalty. The Executive shall, subject to clause 22.4,  accept the Agreed Sum in full and final settlement of all and any claims that they may have  arising out of the Employment or its termination excluding any personal injury claims of  which they are not aware at the Termination Date or any claims in relation to accrued  entitlements under the relevant pension scheme.    22.6 In the event of CIC Qualifying Termination (as defined below), each of Executive&#8217;s then  outstanding unvested Time-Based Equity Awards shall accelerate and immediately  become fully vested (and, if applicable, exercisable) with respect to 100% of the shares  subject thereto, effective as of the Termination Date.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement015.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement015.jpg" title="slide15" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  14  4135-1945-7548, v. 3  22.6.1 &#8220;Time-Based Equity Awards&#8221; means all options to purchase ordinary shares (or  American Depositary Shares) of the Company, restricted share units, and all other share- based awards granted to Executive, including but not limited to share bonus awards,  restricted share and share appreciation rights, but in each case, excluding awards that  vest based upon the satisfaction of performance criteria.      22.6.2 &#8220;CIC Qualifying Termination&#8221; means the Termination Date occurring within twelve  (12) months following a Sale Event (as defined in the Compass Pathways plc 2020 Share  Option and Incentive Plan) resulting from (i) the Company or any Associated Company  terminating the Executive&#8217;s employment (other than for misconduct, illegality, or  performance based reasons, provided that such dismissal is not subsequently found to be  unfair or contrary to s98 Employment Rights Act 1996 by an Employment Tribunal) or (ii)  the Executive terminating his or her employment in response to a fundamental breach of  contract by the Company or any Associated Company (unless such dismissal is  subsequently deemed by an Employment Tribunal to not amount to a constructive  dismissal). A termination or resignation due to Executive&#8217;s death or disability (whether  permanent or not) shall not constitute a CIC Qualifying Termination.      23. Obligations Upon Termination    23.1 On Termination or, if earlier, at the start of a period of Garden Leave following the service  of notice or purported Termination by the Executive, the Executive shall:    23.1.1 immediately deliver to the Company all documents, books, materials, records,  correspondence, papers, Copies, Confidential Information and other business  information (on whatever media and wherever located) relating to the business or  affairs of any Group Company or its business contacts, any keys and any other  property of any Group Company, which is in the Executive&#8217;s possession or control;    23.1.2 irretrievably delete any information relating to the business of any Group Company  stored on any magnetic or optical disk or memory (including on any personal  computer, personal device, personal email account or web account), and all matter  derived from such sources which is in their possession or under their control  outside the premises of the Company;     23.1.3 provide a signed statement confirming full compliance with the obligations under  clauses 23.1.1 to 22.1.3 together with such reasonable evidence of compliance as  the Company may request.    24. Post Termination Restrictions    In consideration for the increase in basic salary the Executive shall be entitled to under this  Agreement, the Executive agrees that Schedule 1 shall take effect.    25. Statutory Particulars    25.1 The Executive is subject to the Company's disciplinary and grievance procedures, copies  of which are available upon request although the Board reserves the right to deviate from  these procedures in light of the Executive&#8217;s seniority. These procedures do not form part  of the Executive's contract of employment.       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement016.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement016.jpg" title="slide16" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  15  4135-1945-7548, v. 3  25.2 If the Executive wishes to raise a grievance or appeal a disciplinary decision the matter  should be raised in writing with the Board.       25.3 There is no collective agreement which affects the Executive&#8217;s employment or this  Agreement.    25.4 The Company does not impose any mandatory training requirements in relation to the  Executive.    25.5 The Company intends to comply with its statutory obligations regarding time off of work for  example relating to family leave, domestic incident leave, jury and military service.  There  is no right to paid time off but the Company may exercise its discretion in relation to short  term absences.     26. Workplace Privacy    26.1 Information about the Company&#8217;s processing of the Executive&#8217;s personal data is set out in  the Company&#8217;s Privacy Notice which is available from the Company&#8217;s Human Resources  department.     26.2 The Executive consents to the Company monitoring their communication and electronic  equipment including, without limitation, the Company's telephone, chat and e-mail  systems, information stored on the Company's computer equipment (including all  electronically stored information that is the property of the Company), recordings from the  Company's closed circuit television cameras and any other computer equipment or other  device used by the Executive in the performance of their duties.     27. General    27.1 The Executive will, at the request of the Company at any time after the Termination Date,  co-operate and provide assistance to any Group Company in any internal investigation,  administrative, regulatory, quasi-judicial proceedings or any threatened or actual litigation  concerning any Group Company where the Executive is aware of any facts or other matters  which the Company reasonably considers is relevant to such process or legal proceedings  (including, but not limited to, giving a candid and accurate account of events, giving  statements/affidavits, meeting with their legal and other professional advisers, attending  any legal hearing and giving evidence) and shall not cooperate with or otherwise give any  information to any other party unless legally required to do so in which case the Executive  will (so far as they are legally permitted to do so) give advance notice to the Company.    The Company will pay any reasonable expenses for which receipts and other supporting  documents are provided to the reasonable satisfaction of the Company and provided any  expense is authorised in advance by the Company).    27.2 If the Executive&#8217;s employment is terminated at any time by reason of any reconstruction or  amalgamation of any Group Company, whether by winding up or otherwise, and the  Executive is offered employment with any concern or undertaking involved in or resulting  from the reconstruction or amalgamation on terms which (considered in their entirety) are  no less favourable to any material extent than the terms of this Agreement, the Executive  acknowledges and agrees that there shall be no claim against the Company or any  undertaking arising out of or connected with such termination.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement017.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement017.jpg" title="slide17" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  16  4135-1945-7548, v. 3  27.3 This clause applies if the Executive subscribes for or is awarded shares in the Company  or any Group Company or participates in any share option, restricted share, restricted  share unit, long term incentive, carried interest, co-invest or any other form of profit sharing,  incentive, bonus or equity plan or arrangement (each, an &quot;Incentive&quot;) or may do so. Upon  Termination, the Executive's rights (if any) in respect of each Incentive shall be solely  determined by the articles of association, rules or other documents governing each  Incentive which are in force on the Termination Date and the Executive hereby irrevocably  waives all claims or rights of action in respect of the loss of any rights or benefits under or  in respect of any Incentive granted or not yet granted to the Executive (including any loss  relating to the lapse of, or their ineligibility to exercise, any share options, the value of any  shares, the operation of any compulsory transfer provisions or the operation of any vesting  criteria).    27.4 A notice given to a party under this Agreement shall be in writing in the English language  and signed by or on behalf of the party giving it. It shall be delivered by hand or sent to the  party at the address given for that party in this Agreement, in the case of the Executive to  their personal email address or as otherwise notified in writing to the other party. A notice  given by email shall be deemed to take effect one hour after it is sent, a notice sent by first  class post shall be deemed to take effect on the next working day and notice sent by  courier upon delivery at the address in question. A notice required to be given to the  Company under this Agreement shall not be validly given if sent by email.     27.5 This Agreement and any document referred to in it constitutes the entire agreement  between the parties and supersedes and extinguishes all previous discussions,  correspondence, negotiations, drafts, agreements, promises, assurances, warranties,  representations and understandings between them, whether written or oral, relating to its  subject matter.    27.6 The Executive agrees that in entering into this Agreement the Executive does not rely on  and shall have no remedies in respect of, any statement, representation, assurance or  warranty (whether made innocently or negligently) that is not expressly set out in this  Agreement. The Executive waives any claim for innocent or negligent misrepresentation  or negligent misstatement including in respect of any statement set out in this Agreement.      27.7 No variation or agreed termination of this Agreement shall be effective unless it is in writing  and signed by the parties (or their authorised representatives).    27.8 The Executive shall not be contractually entitled to receive any benefit from the Company  which is not expressly provided for by this Agreement.       27.9 This Agreement may be executed in any number of counterparts, each of which, when  executed and delivered, shall be an original, and all the counterparts together shall  constitute one and the same agreement.    27.10 The Contracts (Rights of Third Parties) Act 1999 shall only apply to this Agreement in  relation to any Group Company.  No person other than the parties to this Agreement and  any Group Company shall have any rights under it and it will not be enforceable by any  person other than those parties.    27.11 This Agreement and any dispute or claim arising out of or in connection with it or its subject  matter or formation (including non-contractual disputes or claims) shall be governed by  and construed in accordance with the law of England.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement018.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement018.jpg" title="slide18" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  17  4135-1945-7548, v. 3    27.12 Each party irrevocably agrees that the courts of England shall have exclusive jurisdiction  to settle any dispute or claim arising out of or in connection with this Agreement or its  subject matter or formation (including non-contractual disputes or claims).  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement019.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement019.jpg" title="slide19" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  18  4135-1945-7548, v. 3  Executed and delivered as a Deed by the Executive and executed as an Agreement under hand  by the Company on the date stated at the beginning of this Agreement.        Signed by Anne Benedict  for and on behalf of COMPASS  PATHFINDER LIMITED    ...../s/ Anne Benedict..................  Signature         Signed as a deed by GUY GOODWIN  in the presence of:       ../s/ Guy Goodwin....................  Signature  .....................................  Witness&#8217;s Signature     Name of witness    Address of witness        Occupation of witness  .......................................    .......................................  .......................................  .......................................    .......................................               </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement020.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement020.jpg" title="slide20" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  19  4135-1945-7548, v. 3  SCHEDULE 1  POST TERMINATION RESTRICTIONS      (1) In this Schedule, the following terms not otherwise defined in the Agreement shall have the  following meanings unless the context requires otherwise:    &quot;Look Back Period&quot; the period of 12 months before the Termination Date;    &quot;Restricted Business&quot; those parts of the business of the Company and any Group Company  with which the Executive was either:     (a) involved to a material extent; or   (b) privy to Confidential Information,   in each case during the Look Back Period.    &quot;Restricted Client&quot; any firm, company or person who, during the Look Back Period was either  a client or customer of or was otherwise in the habit of dealing with the Company or any Group  Company and with whom or which the Executive either:    (a) had material personal contact; or  (b) was privy to Confidential Information,    in each case during the Look Back Period.    &quot;Restricted Prospective Client&quot; any firm, company or person who was a prospective client or  customer of the Company or any Group Company with whom or which the Company or any  Group Company has been in negotiations during the Look Back Period or had expended  significant time or resources and with whom or which the Executive:    (a) had material personal contact; or  (b) was privy to Confidential Information,    in each case during the Look Back Period.    &#8220;Restricted Subject Matter Expert&#8221; means anyone employed or engaged by the Company or  any Group Company who holds a high degree of technical experience in their area (such that  their replacement would be costly and/or disruptive to the Company or any Group Company&#8217;s  business) and with whom the Executive had material dealings during the period of 12 months  immediately preceding the Termination Date in the course of the Executive&#8217;s employment.    &#8220;Supplier&#8221; means any person, firm, company or entity who during the period of 12 months  immediately preceding the Termination Date was a supplier of services to the Company or any  Group Company and with whom the Executive had material contact during the period of 12  months immediately preceding the Termination Date in the course of their employment.    (2) In order to protect the Confidential Information, trade secrets and business connections of the  Company and each Group Company to which the Executive has access as a result of the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement021.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement021.jpg" title="slide21" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  20  4135-1945-7548, v. 3  employment, the Executive covenants with the Company (for itself and as trustee and agent  for each Group Company) that the Executive shall not:    (a) for twelve (12) months after the Termination Date, solicit or endeavour to entice  away from the Company or any other Group Company the business or custom of a  Restricted Client in competition with any Restricted Business; or  (b) for twelve (12) months after the Termination Date, be involved with the provision of  products or services to (or otherwise have any business dealings with) any  Restricted Client in the course of any business concern which is in competition with  any Restricted Business; or  (c) for twelve (12) months after the Termination Date, solicit or endeavour to entice  away from the Company or any other Group Company the business or custom of a  Restricted Prospective Client in competition with any Restricted Business; or  (d) for twelve (12) months after the Termination Date, be involved with the provision of  products or services to (or otherwise have any business dealings with) any  Restricted Prospective Client in the course of any business concern which is in  competition with any Restricted Business; or  (e) for twelve (12) months after the Termination Date, in the course of any business  concern which is in competition with any Restricted Subject Matter Expert, employ  or engage or otherwise facilitate the employment or engagement of any Restricted  Person, whether or not such person would be in breach of contract as a result of  such employment or engagement; or  (f) for twelve (12) months after the Termination Date, solicit, entice away or interfere  with the Company&#8217;s or any Group Company&#8217;s relationship with or endeavour to  solicit, entice away or interfere with the Company&#8217;s or any Group Company&#8217;s  relationship with any Supplier;   (g) for twelve (12) months after the Termination Date, be employed by, work for the  benefit of, engaged by, interested in or concerned with any business concern which  is (or intends to be) in competition with any Restricted Business for the purposes of  providing services the same as or similar to those he/she provided to the Company  or any Group Company.  (3) The Executive covenants with the Company (for itself and as trustee and agent for each Group  Company) that the Executive shall not at any time after the Termination Date, represent any  connection with any Group Company in any Capacity, other than as a former employee, or  use any registered business names or trading names associated with any Group Company.  (4) None of the restrictions in this Schedule shall prevent the Executive from holding a Permitted  Investment.   (5) The restrictions imposed on the Executive by this Schedule apply to the Executive acting:  (a) directly or indirectly; and  (b) in any Capacity, on their own behalf or on behalf of, or in conjunction with, any firm,  company or person.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- guyaragreement022.jpg -->
<DIV style="padding-top:2em;">
<IMG src="guyaragreement022.jpg" title="slide22" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  21  4135-1945-7548, v. 3  (6) The periods for which the restrictions in paragraph (2)(g) above apply shall be reduced by any  period that the Executive spends on Garden Leave immediately before the Termination Date.  (7) If the Executive receives an offer to be involved in a business concern in any Capacity during  employment, or before the expiry of the restrictions set out in paragraph (2) above, the  Executive shall give the person making the offer a copy of this Schedule and shall tell the  Company the identity of that person as soon as possible after accepting the offer.  (8) Each sub-paragraph (2)(a) to (2)(g), each definition set out in this Schedule, each limb of each  such definition and each operative word within each sub-paragraph or definition is agreed to  be a separate and severable restriction, notwithstanding that they are combined together for  the sake of brevity. The parties agree that if any such restrictions shall be held to be void but  would be valid if part of: (a) the wording of such restriction were deleted, such restriction shall  apply with such deletion (including but not limited to a single word or words) as may be  necessary to make it valid or effective; and (b) the wording of any definition were deleted,  such restriction shall apply with such deletion as may be necessary to make it valid or effective  but the deletion in that definition shall not apply to any other restriction, so that each definition  is deemed to be repeated each time it is used.  The parties agree that if any such restrictions  shall be held to be void on account of its duration, the duration of each restriction shall take  effect as if reduced by a month, until the resulting period shall be valid and enforceable.  (9) If the employment of the Executive is transferred to any firm, company, person or entity other  than a Group Company (the &quot;New Employer&quot;) pursuant to the Transfer of Undertakings  (Protection of Employment) Regulations 2006, the Executive will, if required, enter into an  agreement with the New Employer containing post termination restrictions corresponding to  those restrictions in this Schedule, protecting the confidential information, trade secrets and  business connections of the New Employer.  (10) If the Executive breaches any of the provisions in this Schedule the Company may elect to  extend the period during which the relevant breached provisions apply by a length of time  equal to the period during which the breach continues, such additional period to commence  on the date on which the original period would have expired. The Executive agrees that the  Company's right to apply for injunctive relief or damages is not prejudiced by this clause.     (11) The Executive enters into each of the restrictions in this Schedule for the benefit of the  Company on its own behalf and as trustee for each Group Company. The Executive will, at  the request and expense of the Company, enter into a separate agreement with any Group  Company in which the Executive agrees to be bound by restrictions corresponding to those  restrictions in this Schedule in relation to that Group Company.  (12) The Executive acknowledges that if the Executive breaches the restrictions set out in this  Schedule the Company will suffer irreparable loss, damages will not be an adequate remedy  and the Company should be entitled to injunctive relief.   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex104-slam.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="idf5657794ad04b43b9b8b6d31cdf54cc_78"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5.8pt;text-align:right"><font style="color:#444444;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Exhibit 10.4</font></div><div style="margin-bottom:5.8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Certain confidential information in this document has been omitted from this exhibit and replaced with &#8220;&#91;***&#93;&#8221; because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.</font></div><div style="margin-bottom:5.8pt;text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">AMENDMENT No. 1</font></div><div style="margin-bottom:5.8pt;text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">to </font></div><div style="margin-bottom:5.8pt;text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">MASTER RESEARCH COLLABORATION AGREEMENT</font></div><div><font><br></font></div><div style="margin-bottom:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">This Amendment No. 1 (the &#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">Amendment</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;), effective as of 30 April 2025 (the &#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">Amendment</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%"> </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">Effective Date</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;), is made by and between&#58;</font></div><div style="margin-bottom:5.8pt;padding-left:93.25pt;text-align:justify;text-indent:-35.15pt"><font style="color:#1c1c1c;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:700;line-height:119%">(1)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%;padding-left:24.64pt">COMPASS PATHFINDER LIMITED, </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">a company registered in England under number 10229259, whose registered office is at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">COMPASS</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;)&#59; and</font></div><div style="margin-bottom:5.8pt;padding-left:93.25pt;text-align:justify;text-indent:-35.15pt"><font style="color:#1c1c1c;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:700;line-height:119%">(2)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%;padding-left:22.76pt">KING&#8217;S COLLEGE LONDON, </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">with its registered offices at Strand Building, Strand Campus, Strand, London, WC2R 2LS, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">KCL</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;)&#59; and</font></div><div style="margin-bottom:5.8pt;padding-left:93.25pt;text-align:justify;text-indent:-35.15pt"><font style="color:#1c1c1c;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:700;line-height:119%">(3)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%;padding-left:22.74pt">SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST, </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">with its registered offices at Bethlem Royal Hospital, Monks Orchard Road, Beckenham BR3 3BX, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">SLaM</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">COMPASS, KCL, and SLaM are referred to herein collectively as the &#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">Parties</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221; and individually as a &#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">Party</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">WHEREAS, </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">COMPASS, KCL, and SLaM are parties to that certain Master Research Collaboration Agreement dated 22 March 2022 (the &#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">MRCA</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">WHEREAS, </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">the Parties now desire to amend the MRCA in order to outline the terms and process for COMPASS&#8217;s review of requests by the Academic Parties to conduct non-Compass sponsored studies using the facilities at 5 Windsor Walk, a property owned by SLaM and leased to COMPASS. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">in consideration of the foregoing premises and the terms and conditions set forth below, the Parties agree as follows&#58;</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#625d5a;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:119%">1.</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%;padding-left:10.8pt">Section 10.5.1 of the MRCA shall be deleted in its entirety and replaced with the following&#58;</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">&#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:119%">10.5.1   Maudsley Hospital or 5 Windsor Walk. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Notwithstanding anything to the contrary in this Agreement, during the term of the Maudsley Hospital (5 Windsor Walk) Lease, none of the Academic Parties shall, directly or indirectly, use such leased premises for any purpose outside of those contemplated by this collaboration without COMPASS&#8217;s express written permission&#59; provided however, COMPASS shall act reasonably when determining whether or not to grant the aforementioned express written permission, taking into account idle capacity and reasonable rental returns&#59; further provided that as between the parties, such permission shall remain within COMPASS&#8217;s sole discretion. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">If the Academic Parties desire to use the facilities at 5 Windsor Walk for non-Compass sponsored studies, the following request process shall be followed&#58;</font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-28.6pt;text-align:right;text-indent:28pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</font></div><div style="padding-right:43.4pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#169; Compass Pathways</font></div><div style="padding-right:43.4pt"><font><br></font></div><div style="margin-bottom:5.8pt;padding-right:43.4pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:7.5pt;font-weight:400;line-height:119%">COMPASS Pathfinder Limited is a UK company registered in England and Wales with company #10229259 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">(1) a request form template in the form attached hereto as Schedule 10 must be completed and submitted by the Academic Parties to COMPASS&#59; and </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">(2) all requests must be submitted as soon as practicable to allow COMPASS ample time to review, in any event no less than two (2) weeks notice, it being understood that COMPASS may require additional time to review based on the complexity or nature of the request. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">If a request is granted by COMPASS, the Academic Parties agree that&#58; </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">(a)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%"> COMPASS-sponsored studies retain priority for use of the facilities at 5 Windsor Walk&#59; </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">(b)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%"> the conduct of non-Compass sponsored studies at 5 Windsor Walk must not negatively impact COMPASS-sponsored studies, and Academic Parties will take appropriate steps to model capacity at 5 Windsor Walk accordingly&#59; </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">(c)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%"> the costing template in Schedule 10 shall be used to charge non-Compass sponsors for use of the facilities at 5 Windsor Walk&#59; and </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">(d)</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%"> any and all funds which SLaM receives from non-Compass sponsors for use of the facilities at 5 Windsor Walk must be used to offset the annual costs incurred by COMPASS. Offset costs, less management fee of &#91;***&#93; to SLaM, should be recognised by reducing the next invoice to Compass for its quarterly rent payments, as summarized in Schedule 5, by the corresponding amount.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">When (i) the Bethlem Hospital facility is available for use for trials or research and (ii) the Maudsley Hospital Lease has expired or terminated (in whole or in part)&#59; then SLaM shall be free to utilize the Maudsley Hospital premises for any purposes without the requirement of COMPASS&#8217;s express written permission.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#625d5a;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:119%">2.</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%;padding-left:10.8pt">A new Schedule 10 entitled &#8220;SCHEDULE 10 &#8211; FACILITIES USE REQUEST FORM (5 WINDSOR WALK&#8221; </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:119%">shall be incorporated into the MRCA </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">in the form attached hereto as Appendix 1.</font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:53.45pt;text-align:justify;text-indent:-18pt"><font style="color:#625d5a;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:119%">3.</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%;padding-left:10.8pt">Section 17.1 of the MRCA shall be updated to list the following notice address(es) for COMPASS&#58;</font></div><div style="padding-left:53.45pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">&#8220;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:119%">If to COMPASS&#58;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%"> </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">Fora SoHo, 2nd floor </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">33 Broadwick St, </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">London W1F 0DQ </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">United Kingdom </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">Attn&#58; Sarah Maxwell, Guy Goodwin, Laurie Medhurst </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">E-mail&#58; </font><font style="color:#0563c1;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%;text-decoration:underline">guy.goodwin&#64;compasspathways.com</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%"> ,</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#0563c1;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%;text-decoration:underline">laurie&#64;compasspathways.com</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">, </font><font style="color:#0563c1;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%;text-decoration:underline">sarah.maxwell&#64;compasspathways.com</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%"> </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">with a copy to&#58; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">Compass Pathfinder Limited</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">Attn&#58; Legal Dept.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">3rd Floor, 1 Ashley Road</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">Altrincham, Cheshire, WA14 2DT</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">United Kingdom </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%">E-mail&#58; </font><font style="color:#0563c1;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%;text-decoration:underline">LegalNotices&#64;compasspathways.com</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:119%"> &#8221;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-28.6pt;text-align:right;text-indent:28pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</font></div><div style="padding-right:43.4pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#169; Compass Pathways</font></div><div style="padding-right:43.4pt"><font><br></font></div><div style="margin-bottom:5.8pt;padding-right:43.4pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:7.5pt;font-weight:400;line-height:119%">COMPASS Pathfinder Limited is a UK company registered in England and Wales with company #10229259 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">To the extent there are any inconsistencies between this Amendment and the MRCA, this Amendment will control but solely as to the subject matter herein. Capitalized terms not otherwise defined herein shall have the same meaning given those terms in the MRCA, it being the intent of the Parties that the MRCA and this Amendment will be applied and construed as a single instrument. The MRCA, as modified by this Amendment as well as any existing riders, constitutes the entire agreement between the Parties regarding the subject matter of this Amendment and supersedes all prior or contemporaneous writings and understandings between the Parties regarding the same.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">This Amendment may be executed in counterparts, each of which, when executed and delivered, shall be deemed to be an original and all of which together shall constitute one and the same document. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5.8pt;text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-28.6pt;text-align:right;text-indent:28pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></div><div style="padding-right:43.4pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#169; Compass Pathways</font></div><div style="padding-right:43.4pt"><font><br></font></div><div style="margin-bottom:5.8pt;padding-right:43.4pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:7.5pt;font-weight:400;line-height:119%">COMPASS Pathfinder Limited is a UK company registered in England and Wales with company #10229259 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5.8pt;padding-left:32.1pt;text-align:justify;text-indent:-0.5pt"><font><br></font></div><div style="margin-bottom:5.8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">, the Parties have caused this Amendment to be duly executed as of the Amendment Effective Date. </font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">COMPASS Pathfinder Limited &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;King&#8217;s College London</font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#47;s&#47; Kabir Nath&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Laura Weiss</font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">_______________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Name&#58;&#160;&#160;&#160;&#160;   Kabir Nath&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; &#160;&#160;&#160;&#160;   Laura Weiss </font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Title&#58; &#160;&#160;&#160;&#160;   CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;   Head of Contracts</font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Date&#58;&#160;&#160;&#160;&#160;________April 30, 2025_______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;&#160;&#160;&#160;&#160;_________April 30, 2025_______________</font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:119%">South London and Maudsley NHS Foundation Trust</font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">___&#47;s&#47; Danny Bosch____________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Name&#58;&#160;&#160;&#160;&#160;   Danny Bosch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Title&#58; &#160;&#160;&#160;&#160;   Dr.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5.8pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:119%">Date&#58;&#160;&#160;&#160;&#160;_____April 30, 2025___________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div style="margin-bottom:5.8pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:5.8pt;padding-left:32.1pt;padding-right:43.4pt;text-indent:-0.5pt"><font><br></font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-28.6pt;text-align:right;text-indent:28pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</font></div><div style="padding-right:43.4pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#169; Compass Pathways</font></div><div style="padding-right:43.4pt"><font><br></font></div><div style="margin-bottom:5.8pt;padding-right:43.4pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:7.5pt;font-weight:400;line-height:119%">COMPASS Pathfinder Limited is a UK company registered in England and Wales with company #10229259 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPENDIX 1</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE 10 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FACILITIES USE REQUEST FORM (5 WINDSOR WALK)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Please complete the form below and submit to the following Compass contacts via email&#58; *****, </font></div><div style="text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*****,</font></div><div style="text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*****, and </font></div><div style="text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">***** </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Request Template</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsor Name&#58; ____________________________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial (clinicaltrials.gov identifier)&#58;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> ____________________________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investigational product&#58;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> ____________________________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indication&#58;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> ____________________________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of in person visits&#47; in person hours per patient&#58; </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">__________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrolment target&#58;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> ____________________________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First patient in date&#58; </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">______________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Last patient in date&#58;</font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> ______________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date decision needed by (at least 2 weeks from request submission date)&#58; </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">________________</font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Notes&#58; </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">____________________________________________________________________________________________________________________________________________________________________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Costing template</font></div><div><font><br></font></div><div style="text-indent:-0.5pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the above request is approved, the rate charged to Sponsor for use of the facilities will be&#58;  </font><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#163;&#91;****&#93; per room, per half-day (4-hour block) </font></div><div><font><br></font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-28.6pt;text-align:right;text-indent:28pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></div><div style="padding-right:43.4pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#169; Compass Pathways</font></div><div style="padding-right:43.4pt"><font><br></font></div><div style="margin-bottom:5.8pt;padding-right:43.4pt"><font style="color:#000000;font-family:'Montserrat',sans-serif;font-size:7.5pt;font-weight:400;line-height:119%">COMPASS Pathfinder Limited is a UK company registered in England and Wales with company #10229259 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>cmps-q1x25xex311ceo302cert.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib5f364a786c445a0842d326b603f9793_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">I, Kabir Nath, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of COMPASS Pathways plc (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>cmps-q1x25xex312cfo302cert.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7432f9995e6c42448a66c147c3c18896_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">I, Teri Loxam, certify that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of COMPASS Pathways plc (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:28.5pt">The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:151%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Teri Loxam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teri Loxam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>cmps-q1x25xex321ceoxcfosec.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic860ec821bc04cd7818a1f104e491d05_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Kabir Nath, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on&#160;Form 10-Q&#160;of COMPASS Pathways plc for the period ended March&#160;31, 2025 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on&#160;Form 10-Q&#160;fairly presents, in all material respects, the financial condition and results of operations of COMPASS Pathways plc.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:4.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May&#160;8, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kabir Nath</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is not to be incorporated by reference into any filing of COMPASS Pathways plc under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Teri Loxam, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on&#160;Form 10-Q&#160;of COMPASS Pathways plc for the period ended March&#160;31, 2025 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on&#160;Form 10-Q&#160;fairly presents, in all material respects, the financial condition and results of operations of COMPASS Pathways plc.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:4.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Teri Loxam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Teri Loxam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and it is not to be incorporated by reference into any filing of COMPASS Pathways plc under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cmps-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ecce3bbb-f5c6-429b-99e4-462edd6def85,g:b4bd98cb-b7e6-4e40-b9b6-c78a12b28ef2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cmps="http://compasspathways.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://compasspathways.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://compasspathways.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Shareholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://compasspathways.com/role/NatureofBusiness">
        <link:definition>9952157 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>9952159 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://compasspathways.com/role/Debt">
        <link:definition>9952160 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://compasspathways.com/role/FairValueMeasurements">
        <link:definition>9952161 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://compasspathways.com/role/ShareholdersEquity">
        <link:definition>9952162 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://compasspathways.com/role/ShareBasedCompensation">
        <link:definition>9952163 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://compasspathways.com/role/NetLossPerShare">
        <link:definition>9952164 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://compasspathways.com/role/CommitmentsandContingencies">
        <link:definition>9952165 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://compasspathways.com/role/SegmentReporting">
        <link:definition>9952166 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://compasspathways.com/role/RelatedPartyTransactions">
        <link:definition>9952167 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>9955512 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://compasspathways.com/role/DebtTables">
        <link:definition>9955513 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://compasspathways.com/role/FairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://compasspathways.com/role/ShareBasedCompensationTables">
        <link:definition>9955515 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://compasspathways.com/role/NetLossPerShareTables">
        <link:definition>9955516 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://compasspathways.com/role/SegmentReportingTables">
        <link:definition>9955517 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://compasspathways.com/role/NatureofBusinessDetails">
        <link:definition>9955518 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955519 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://compasspathways.com/role/DebtNarrativeDetails">
        <link:definition>9955520 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofDebtDetails" roleURI="http://compasspathways.com/role/DebtComponentsofDebtDetails">
        <link:definition>9955521 - Disclosure - Debt - Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofDebtDetails_1" roleURI="http://compasspathways.com/role/DebtComponentsofDebtDetails_1">
        <link:definition>9955521 - Disclosure - Debt - Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofPrincipalPaymentsDetails" roleURI="http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails">
        <link:definition>9955522 - Disclosure - Debt - Schedule of Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9955523 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>9955524 - Disclosure - Fair Value Measurements - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails" roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails">
        <link:definition>9955525 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955526 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://compasspathways.com/role/ShareholdersEquityDetails">
        <link:definition>9955527 - Disclosure - Shareholder's Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2017EquityIncentivePlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails">
        <link:definition>9955528 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails">
        <link:definition>9955529 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2020ShareOptionPlanDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails">
        <link:definition>9955530 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2022InducementGrantOptionAwardDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails">
        <link:definition>9955531 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>9955532 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>9955533 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9955534 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://compasspathways.com/role/SegmentReportingDetails">
        <link:definition>9955535 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://compasspathways.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955536 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cmps_WarrantLiabilityNoncurrent" abstract="false" name="WarrantLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_OrdinarySharesMember" abstract="true" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" abstract="false" name="ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_TransactionCostsIncurredInConnectionWithWarrants" abstract="false" name="TransactionCostsIncurredInConnectionWithWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_UnderwrittenOfferingMember" abstract="true" name="UnderwrittenOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_LoanAgreementMember" abstract="true" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_LoanAgreementTermLoanOneMember" abstract="true" name="LoanAgreementTermLoanOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_PIPEWarrantsMember" abstract="true" name="PIPEWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_A2025ADSWarrantsMember" abstract="true" name="A2025ADSWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_PrefundedWarrantsMember" abstract="true" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_SaleOfStockMaximumAmountAllowableForSale" abstract="false" name="SaleOfStockMaximumAmountAllowableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_NumberOfOrdinarySharesConversionRatio" abstract="false" name="NumberOfOrdinarySharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cmps_SaleOfStockAmountAuthorized" abstract="false" name="SaleOfStockAmountAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ProceedsFromWarrantExercisesFullyExercised" abstract="false" name="ProceedsFromWarrantExercisesFullyExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" abstract="false" name="ClassOfWarrantOrRightThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_PrepaidExpenseResearchAndDevelopmentCurrent" abstract="false" name="PrepaidExpenseResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_ResearchAndDevelopmentTaxCreditPayable" abstract="false" name="ResearchAndDevelopmentTaxCreditPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_PrepaidResearchAndDevelopmentTaxCredit" abstract="false" name="PrepaidResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_LoanAgreementTermLoanTwoMember" abstract="true" name="LoanAgreementTermLoanTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_LoanAgreementTermLoanThreeMember" abstract="true" name="LoanAgreementTermLoanThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_FacilityFeesMember" abstract="true" name="FacilityFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_CompanyFeesMember" abstract="true" name="CompanyFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_EndOfTermChargeMember" abstract="true" name="EndOfTermChargeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_PaidInKindInterestRate" abstract="false" name="PaidInKindInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" abstract="false" name="OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cmps_OptionsExercisableNumber" abstract="false" name="OptionsExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_OptionsExercisableFairValue" abstract="false" name="OptionsExercisableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" abstract="false" name="DebtInstrumentCovenantMinimumCashOnHandAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_DebtInstrumentMarketCapitalization" abstract="false" name="DebtInstrumentMarketCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_LongTermDebtEndOfTermCharge" abstract="false" name="LongTermDebtEndOfTermCharge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_LongTermDebtIncludingEndOfTermCharge" abstract="false" name="LongTermDebtIncludingEndOfTermCharge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_DebtInstrumentPaidInKindInterestPayable" abstract="false" name="DebtInstrumentPaidInKindInterestPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_GainLossOnIssuanceOfWarrant" abstract="false" name="GainLossOnIssuanceOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_GainLossOnFairValueOfWarrants" abstract="false" name="GainLossOnFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_HerculesCapitalInc.Member" abstract="true" name="HerculesCapitalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_A2017EquityIncentivePlanMember" abstract="true" name="A2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_OptionsGrantedBeforeJune302020Member" abstract="true" name="OptionsGrantedBeforeJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_GrantDateJune302020Member" abstract="true" name="GrantDateJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cmps_A2020ShareOptionPlanMember" abstract="true" name="A2020ShareOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionOneMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionFourMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" abstract="true" name="ShareBasedPaymentArrangementVestingConditionFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cmps_NumberOfVestingConditions" abstract="false" name="NumberOfVestingConditions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cmps_A2022InducementGrantOptionAwardMember" abstract="true" name="A2022InducementGrantOptionAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_FairValueChangeOfPreFundedWarrantLiabilities" abstract="false" name="FairValueChangeOfPreFundedWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cmps_UnvestedRestrictedShareUnitsMember" abstract="true" name="UnvestedRestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_ShareOptionsMember" abstract="true" name="ShareOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cmps_DevelopmentExpensesMember" abstract="true" name="DevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_PersonnelExpensesMember" abstract="true" name="PersonnelExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_LegalAndProfessionalFeesMember" abstract="true" name="LegalAndProfessionalFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_NonCashShareBasedCompensationExpenseMember" abstract="true" name="NonCashShareBasedCompensationExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_FacilitiesAndOtherExpensesMember" abstract="true" name="FacilitiesAndOtherExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cmps_SingleOperatingSegmentMember" abstract="true" name="SingleOperatingSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cmps-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ecce3bbb-f5c6-429b-99e4-462edd6def85,g:b4bd98cb-b7e6-4e40-b9b6-c78a12b28ef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3aeacd21-b007-4098-b489-da700103707f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b1c5bde8-3978-4335-9cfc-7c9e5232d12d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3aeacd21-b007-4098-b489-da700103707f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b1c5bde8-3978-4335-9cfc-7c9e5232d12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_830adca1-37bf-444a-81bc-8b6a3256e577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3aeacd21-b007-4098-b489-da700103707f" xlink:to="loc_us-gaap_AssetsCurrent_830adca1-37bf-444a-81bc-8b6a3256e577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2631f415-2bd1-4a13-926f-38424e639f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3aeacd21-b007-4098-b489-da700103707f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2631f415-2bd1-4a13-926f-38424e639f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ebd008fc-03f8-4bd6-93b4-aff9ad2b1c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3aeacd21-b007-4098-b489-da700103707f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ebd008fc-03f8-4bd6-93b4-aff9ad2b1c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_62a9bece-7e42-4dc7-aafc-88d57804d9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4809c7d8-b516-45db-9526-34a640f7db87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_62a9bece-7e42-4dc7-aafc-88d57804d9f0" xlink:to="loc_us-gaap_AccountsPayableCurrent_4809c7d8-b516-45db-9526-34a640f7db87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9ed00c03-9e26-4227-b1ba-a83d5fa6be19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_62a9bece-7e42-4dc7-aafc-88d57804d9f0" xlink:to="loc_us-gaap_LongTermDebtCurrent_9ed00c03-9e26-4227-b1ba-a83d5fa6be19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5c702ab-bd99-41a5-9ac1-a8191c1399f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_62a9bece-7e42-4dc7-aafc-88d57804d9f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5c702ab-bd99-41a5-9ac1-a8191c1399f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_da65ddfd-5636-4f92-8fec-3382cf184153" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_62a9bece-7e42-4dc7-aafc-88d57804d9f0" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_da65ddfd-5636-4f92-8fec-3382cf184153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cebf6669-5f3e-4038-80d3-f59625f1357c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_48f26652-6f32-49ae-8ade-83e2fd019ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cebf6669-5f3e-4038-80d3-f59625f1357c" xlink:to="loc_us-gaap_LiabilitiesCurrent_48f26652-6f32-49ae-8ade-83e2fd019ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_68c46117-5342-4691-b565-171690fc59d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cebf6669-5f3e-4038-80d3-f59625f1357c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_68c46117-5342-4691-b565-171690fc59d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e7429315-6c06-4f8c-a4be-0b8b0dc9d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cebf6669-5f3e-4038-80d3-f59625f1357c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e7429315-6c06-4f8c-a4be-0b8b0dc9d95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WarrantLiabilityNoncurrent_17f8d97f-738a-4d85-9b08-3d674264656c" xlink:href="cmps-20250331.xsd#cmps_WarrantLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cebf6669-5f3e-4038-80d3-f59625f1357c" xlink:to="loc_cmps_WarrantLiabilityNoncurrent_17f8d97f-738a-4d85-9b08-3d674264656c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d48222f-bbb5-4f8e-af7b-dcfee4842298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d640c0ab-696c-4f2d-86ed-3af556d91891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d48222f-bbb5-4f8e-af7b-dcfee4842298" xlink:to="loc_us-gaap_CommonStockValue_d640c0ab-696c-4f2d-86ed-3af556d91891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4e178a9-47b7-4333-adf6-f7e74a43c2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d48222f-bbb5-4f8e-af7b-dcfee4842298" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4e178a9-47b7-4333-adf6-f7e74a43c2b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa6ccd8a-5c93-47b9-9407-e6c5e89a6bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d48222f-bbb5-4f8e-af7b-dcfee4842298" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa6ccd8a-5c93-47b9-9407-e6c5e89a6bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ba1876a5-f05d-4fd0-b250-6366aaf0331a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4d48222f-bbb5-4f8e-af7b-dcfee4842298" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ba1876a5-f05d-4fd0-b250-6366aaf0331a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4239138-1eff-419a-ad9c-2e9fff7f853f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4aa7404b-d910-4707-a201-40fadc716e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4239138-1eff-419a-ad9c-2e9fff7f853f" xlink:to="loc_us-gaap_Liabilities_4aa7404b-d910-4707-a201-40fadc716e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0172b8b2-e415-47a0-9f5a-b35c90df39e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4239138-1eff-419a-ad9c-2e9fff7f853f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0172b8b2-e415-47a0-9f5a-b35c90df39e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26a712f5-04f6-4510-aa63-9849a7433340" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4239138-1eff-419a-ad9c-2e9fff7f853f" xlink:to="loc_us-gaap_StockholdersEquity_26a712f5-04f6-4510-aa63-9849a7433340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4704058e-8a29-4815-8d7a-86bf7fe5eadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d99c8d1c-7751-4abf-8e84-4ad6e8ff49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4704058e-8a29-4815-8d7a-86bf7fe5eadc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d99c8d1c-7751-4abf-8e84-4ad6e8ff49d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4718d61-b704-4d09-91f0-bc93c900479c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4704058e-8a29-4815-8d7a-86bf7fe5eadc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f4718d61-b704-4d09-91f0-bc93c900479c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_11a61ec5-2dbb-4626-93ba-bf356f46ddec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4704058e-8a29-4815-8d7a-86bf7fe5eadc" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_11a61ec5-2dbb-4626-93ba-bf356f46ddec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dca43c10-9baf-48b7-842b-530821317d53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d231fb45-0b34-48b5-8a66-e996ab30b791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dca43c10-9baf-48b7-842b-530821317d53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d231fb45-0b34-48b5-8a66-e996ab30b791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_056f20b0-ddcd-4dc8-b7f4-9fff735fd12b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dca43c10-9baf-48b7-842b-530821317d53" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_056f20b0-ddcd-4dc8-b7f4-9fff735fd12b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6969854d-ad86-4b44-941d-71deccb20426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6969854d-ad86-4b44-941d-71deccb20426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_3d6335f5-4cab-4d05-a4c5-f4870f5ae6fe" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_3d6335f5-4cab-4d05-a4c5-f4870f5ae6fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_599e2c48-cf61-413e-b455-412be8c0ea17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:to="loc_us-gaap_InterestExpenseNonoperating_599e2c48-cf61-413e-b455-412be8c0ea17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fbd49496-f181-46e0-9b06-e50ec5b8fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fbd49496-f181-46e0-9b06-e50ec5b8fa8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b6cb6504-4e02-44fc-8683-0d61c0fcb8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b6cb6504-4e02-44fc-8683-0d61c0fcb8c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f2bd7154-1f5b-421c-aa59-410ec62c4968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1d5a64af-224e-47bb-b131-54db72868fb9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f2bd7154-1f5b-421c-aa59-410ec62c4968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ff8bdad-2b27-4541-952d-b37a56350497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2c2fc85-e0d2-4446-bb88-c39fee7fd7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ff8bdad-2b27-4541-952d-b37a56350497" xlink:to="loc_us-gaap_NetIncomeLoss_a2c2fc85-e0d2-4446-bb88-c39fee7fd7b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4ce02783-2038-4bba-bf93-105489ffcfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5ff8bdad-2b27-4541-952d-b37a56350497" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4ce02783-2038-4bba-bf93-105489ffcfd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e08d5a3-e2a0-4e03-81c8-39414af1fb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e48fe0c4-8c76-420e-9638-9f49c20ba869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3e08d5a3-e2a0-4e03-81c8-39414af1fb0d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e48fe0c4-8c76-420e-9638-9f49c20ba869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c98eeb5-10bc-4653-80cf-b565ce98eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3e08d5a3-e2a0-4e03-81c8-39414af1fb0d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c98eeb5-10bc-4653-80cf-b565ce98eba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e3bcd9f7-3de5-436f-b833-b31afbcd9b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1ffb3dae-078d-4efd-a130-fe0ddbe51ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e3bcd9f7-3de5-436f-b833-b31afbcd9b44" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1ffb3dae-078d-4efd-a130-fe0ddbe51ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_518c030c-4884-48c6-83c3-886974c37b69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e3bcd9f7-3de5-436f-b833-b31afbcd9b44" xlink:to="loc_us-gaap_OperatingIncomeLoss_518c030c-4884-48c6-83c3-886974c37b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bfc13f50-2d3b-4851-86f5-9f72b54fd7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5fba14b8-6953-4e8d-875d-df6d69926dea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bfc13f50-2d3b-4851-86f5-9f72b54fd7d7" xlink:to="loc_us-gaap_OperatingExpenses_5fba14b8-6953-4e8d-875d-df6d69926dea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99412668-eadf-4504-9238-ad2effe9f455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0549ac6b-b5f9-47fb-9e18-71719a36833b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99412668-eadf-4504-9238-ad2effe9f455" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0549ac6b-b5f9-47fb-9e18-71719a36833b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e5656e92-1b36-47c6-93e4-2141ca01c538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99412668-eadf-4504-9238-ad2effe9f455" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e5656e92-1b36-47c6-93e4-2141ca01c538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed106fa-b086-478f-bf19-033792e51921" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_74502ca8-576c-4b1f-9762-7a7b2418cdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed106fa-b086-478f-bf19-033792e51921" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_74502ca8-576c-4b1f-9762-7a7b2418cdbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c8ed78ce-34fd-4bb5-9400-00f392d442da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed106fa-b086-478f-bf19-033792e51921" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c8ed78ce-34fd-4bb5-9400-00f392d442da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_943bfef4-9b83-41d4-9048-fd030a41423e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed106fa-b086-478f-bf19-033792e51921" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_943bfef4-9b83-41d4-9048-fd030a41423e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0db14942-17cf-415d-b1bd-24d11310785d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed106fa-b086-478f-bf19-033792e51921" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0db14942-17cf-415d-b1bd-24d11310785d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9c9b1c7f-3fe1-4c82-bc06-988872b743c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12f0bb5c-1f6e-49b6-ada4-0ce718383a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9c9b1c7f-3fe1-4c82-bc06-988872b743c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12f0bb5c-1f6e-49b6-ada4-0ce718383a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0fac875-6e54-46e6-aa7d-6898ca1114db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9c9b1c7f-3fe1-4c82-bc06-988872b743c0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0fac875-6e54-46e6-aa7d-6898ca1114db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0b6e8bd-630f-4dcf-9ea9-2c14f8e976b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9c9b1c7f-3fe1-4c82-bc06-988872b743c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0b6e8bd-630f-4dcf-9ea9-2c14f8e976b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c125267b-2e7a-4cf6-a49b-3dc6d1c44779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c125267b-2e7a-4cf6-a49b-3dc6d1c44779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0cf931e4-60b1-419a-be84-ded36e1188d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0cf931e4-60b1-419a-be84-ded36e1188d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_TransactionCostsIncurredInConnectionWithWarrants_d8007c89-5684-4b8f-8ebc-d9f36b3c6b21" xlink:href="cmps-20250331.xsd#cmps_TransactionCostsIncurredInConnectionWithWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_cmps_TransactionCostsIncurredInConnectionWithWarrants_d8007c89-5684-4b8f-8ebc-d9f36b3c6b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_200e1e10-8790-474f-87de-ac0c8cc9209f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_200e1e10-8790-474f-87de-ac0c8cc9209f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc70f9f9-02f9-4357-9b71-fbf5def2ae0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_NetIncomeLoss_bc70f9f9-02f9-4357-9b71-fbf5def2ae0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_50a51bad-ce63-4e51-a5fe-9f6a95dd380b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_50a51bad-ce63-4e51-a5fe-9f6a95dd380b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5d7ab10d-0709-47a2-ac0a-ed89cc91ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5d7ab10d-0709-47a2-ac0a-ed89cc91ab96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_30573dc9-46fc-433f-b378-adfeb4cdd692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_30573dc9-46fc-433f-b378-adfeb4cdd692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_af3687bd-ec12-4455-addc-6785afe317fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_Depreciation_af3687bd-ec12-4455-addc-6785afe317fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c58c81e2-f7c9-4c3a-82b7-1753d251ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c58c81e2-f7c9-4c3a-82b7-1753d251ba7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_3b99bcb5-b803-499d-9500-9c03a2ad0053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_3b99bcb5-b803-499d-9500-9c03a2ad0053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e626444f-dc09-4564-9dc2-3d6698e01d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e626444f-dc09-4564-9dc2-3d6698e01d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1e6d7d82-d877-4ab0-ba41-af8a4ae5a825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1e6d7d82-d877-4ab0-ba41-af8a4ae5a825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4af80436-cbf8-46c4-afc5-2ecdd2d8b975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbc6a14f-f7dc-496a-a0c4-5a220378db1f" xlink:to="loc_us-gaap_ShareBasedCompensation_4af80436-cbf8-46c4-afc5-2ecdd2d8b975" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f186ac1-8008-423b-91d1-da21f451b77a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_522c7fb2-c6c9-4a67-b9eb-dff17af0a095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f186ac1-8008-423b-91d1-da21f451b77a" xlink:to="loc_us-gaap_OtherAssetsCurrent_522c7fb2-c6c9-4a67-b9eb-dff17af0a095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_56fbf2de-d3d1-4f53-a31c-10840153e98c" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f186ac1-8008-423b-91d1-da21f451b77a" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_56fbf2de-d3d1-4f53-a31c-10840153e98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_b1047127-6a13-4665-bcfc-4e484ac5f0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f186ac1-8008-423b-91d1-da21f451b77a" xlink:to="loc_us-gaap_PrepaidInsurance_b1047127-6a13-4665-bcfc-4e484ac5f0eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_61f28935-7bf7-42c7-b45a-ff2b1eb176b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f186ac1-8008-423b-91d1-da21f451b77a" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_61f28935-7bf7-42c7-b45a-ff2b1eb176b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_2e8d6019-073a-43a1-be8a-9a1d1f5c5203" xlink:href="cmps-20250331.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f186ac1-8008-423b-91d1-da21f451b77a" xlink:to="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_2e8d6019-073a-43a1-be8a-9a1d1f5c5203" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtComponentsofDebtDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/DebtComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e0dad467-906d-4458-9789-dfda8f42b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_f3f8d196-db2c-4c4a-a085-aeb6c31eef06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0dad467-906d-4458-9789-dfda8f42b73d" xlink:to="loc_us-gaap_DebtCurrent_f3f8d196-db2c-4c4a-a085-aeb6c31eef06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ccf22d5a-7a97-4d8f-b402-12909c03946c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0dad467-906d-4458-9789-dfda8f42b73d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ccf22d5a-7a97-4d8f-b402-12909c03946c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtIncludingEndOfTermCharge_baa38d6b-8432-43c6-a0c3-4ebc967bc1f3" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtIncludingEndOfTermCharge"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_53dd6166-978b-449f-b22a-eb8749cdffee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmps_LongTermDebtIncludingEndOfTermCharge_baa38d6b-8432-43c6-a0c3-4ebc967bc1f3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_53dd6166-978b-449f-b22a-eb8749cdffee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtEndOfTermCharge_dc7cee65-49dc-434a-b2ed-0a9d0c1ce506" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtEndOfTermCharge"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmps_LongTermDebtIncludingEndOfTermCharge_baa38d6b-8432-43c6-a0c3-4ebc967bc1f3" xlink:to="loc_cmps_LongTermDebtEndOfTermCharge_dc7cee65-49dc-434a-b2ed-0a9d0c1ce506" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtComponentsofDebtDetails_1" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtComponentsofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/DebtComponentsofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5b400e73-7a85-4739-bed3-afb6f8f75a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7d4b84c6-6398-48d7-ab0f-3449358a678f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5b400e73-7a85-4739-bed3-afb6f8f75a0d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7d4b84c6-6398-48d7-ab0f-3449358a678f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtIncludingEndOfTermCharge_b4075b22-2885-4ed5-905f-08e5b782f2d7" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtIncludingEndOfTermCharge"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5b400e73-7a85-4739-bed3-afb6f8f75a0d" xlink:to="loc_cmps_LongTermDebtIncludingEndOfTermCharge_b4075b22-2885-4ed5-905f-08e5b782f2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentPaidInKindInterestPayable_b63db606-7aff-4bb5-be3e-08a3c8f6dd5c" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentPaidInKindInterestPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5b400e73-7a85-4739-bed3-afb6f8f75a0d" xlink:to="loc_cmps_DebtInstrumentPaidInKindInterestPayable_b63db606-7aff-4bb5-be3e-08a3c8f6dd5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtScheduleofPrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtIncludingEndOfTermCharge_04e76c9f-b790-4bed-9257-1dcc67cc391f" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtIncludingEndOfTermCharge"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8aa96903-3157-467e-aa7f-764a4bfc4620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmps_LongTermDebtIncludingEndOfTermCharge_04e76c9f-b790-4bed-9257-1dcc67cc391f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8aa96903-3157-467e-aa7f-764a4bfc4620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b3b5448e-26d3-48d8-bf53-91b5f84f35fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmps_LongTermDebtIncludingEndOfTermCharge_04e76c9f-b790-4bed-9257-1dcc67cc391f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b3b5448e-26d3-48d8-bf53-91b5f84f35fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_27958d09-5526-40e3-9051-858023201378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmps_LongTermDebtIncludingEndOfTermCharge_04e76c9f-b790-4bed-9257-1dcc67cc391f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_27958d09-5526-40e3-9051-858023201378" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_18c5a217-87cb-4a5d-aa0d-ce4607935e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_df9795a9-6b89-4bec-b23a-c9f34972410c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_18c5a217-87cb-4a5d-aa0d-ce4607935e5e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_df9795a9-6b89-4bec-b23a-c9f34972410c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FairValueChangeOfPreFundedWarrantLiabilities_fdf9386b-94d3-4106-97dc-83c65b5ab5df" xlink:href="cmps-20250331.xsd#cmps_FairValueChangeOfPreFundedWarrantLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_18c5a217-87cb-4a5d-aa0d-ce4607935e5e" xlink:to="loc_cmps_FairValueChangeOfPreFundedWarrantLiabilities_fdf9386b-94d3-4106-97dc-83c65b5ab5df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_164c38ec-b18c-4070-af85-1b8bd57c8018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cda2d7b1-4d88-4f1c-b4c1-4477cf5fed14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_164c38ec-b18c-4070-af85-1b8bd57c8018" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cda2d7b1-4d88-4f1c-b4c1-4477cf5fed14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_0bcf1fa0-f21d-4674-a510-cce803856a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_164c38ec-b18c-4070-af85-1b8bd57c8018" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_0bcf1fa0-f21d-4674-a510-cce803856a55" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cmps-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ecce3bbb-f5c6-429b-99e4-462edd6def85,g:b4bd98cb-b7e6-4e40-b9b6-c78a12b28ef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b214887a-1733-4f33-ae7d-6d49f45d1f80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:to="loc_us-gaap_ClassOfStockDomain_b214887a-1733-4f33-ae7d-6d49f45d1f80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc55e35c-3f28-4339-a23f-23c78892308a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:to="loc_us-gaap_ClassOfStockDomain_dc55e35c-3f28-4339-a23f-23c78892308a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_7330d1e0-9a1e-4041-831c-019d034dedd7" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc55e35c-3f28-4339-a23f-23c78892308a" xlink:to="loc_cmps_OrdinarySharesMember_7330d1e0-9a1e-4041-831c-019d034dedd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6b3e1f2-09ce-4d2b-81f3-89e8ffacbf14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6b3e1f2-09ce-4d2b-81f3-89e8ffacbf14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7f009f63-2464-4e26-88fc-453838387297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7f009f63-2464-4e26-88fc-453838387297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_72815002-d17b-4e27-801f-06e79f428d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockSharesIssued_72815002-d17b-4e27-801f-06e79f428d6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_336ba5bf-ceac-4a9b-be2a-3b139d99c176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_336ba5bf-ceac-4a9b-be2a-3b139d99c176" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4b574f23-c197-462a-814e-935fbac8b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4b574f23-c197-462a-814e-935fbac8b85d" xlink:to="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5de8569c-01b8-4349-98a7-6c16726460c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:to="loc_us-gaap_ClassOfStockDomain_5de8569c-01b8-4349-98a7-6c16726460c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1e0ad57b-e411-4e99-aa89-dff5bb46a726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:to="loc_us-gaap_ClassOfStockDomain_1e0ad57b-e411-4e99-aa89-dff5bb46a726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_db4cb3fd-9938-46f7-ad40-8975704d3160" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1e0ad57b-e411-4e99-aa89-dff5bb46a726" xlink:to="loc_cmps_OrdinarySharesMember_db4cb3fd-9938-46f7-ad40-8975704d3160" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:to="loc_us-gaap_EquityComponentDomain_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:to="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e3d2083f-cd78-4f24-bf99-a13b25db3235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_CommonStockMember_e3d2083f-cd78-4f24-bf99-a13b25db3235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_48d15aa6-afb0-4cc3-b7d8-a092998402bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_48d15aa6-afb0-4cc3-b7d8-a092998402bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7b59455c-a430-4d25-b2be-2a7ab7acbf73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7b59455c-a430-4d25-b2be-2a7ab7acbf73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_130ee456-d214-4137-bcfc-4bede6323ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_RetainedEarningsMember_130ee456-d214-4137-bcfc-4bede6323ed5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008ad069-e001-4dea-92f1-b2dbdf0255d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_008ad069-e001-4dea-92f1-b2dbdf0255d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47a7e684-4594-4a18-9886-f326dad671c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47a7e684-4594-4a18-9886-f326dad671c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_d55c66f3-fa7f-41b0-b08c-4aa20057a45f" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47a7e684-4594-4a18-9886-f326dad671c2" xlink:to="loc_cmps_AtTheMarketOfferingMember_d55c66f3-fa7f-41b0-b08c-4aa20057a45f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4b574f23-c197-462a-814e-935fbac8b85d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5e8f2c10-aa4b-469d-91f6-4eb2b2e5d1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5e8f2c10-aa4b-469d-91f6-4eb2b2e5d1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b4637ee-3b6d-4eb0-86c8-b24779ac2de9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockholdersEquity_6b4637ee-3b6d-4eb0-86c8-b24779ac2de9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0b92ef59-e206-4517-ba8d-f58d8de19f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0b92ef59-e206-4517-ba8d-f58d8de19f72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_88574d3b-8b02-42da-8dd6-c48ceed9bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_88574d3b-8b02-42da-8dd6-c48ceed9bde6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f222397b-588a-4cae-812c-7a3a8a7d1035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f222397b-588a-4cae-812c-7a3a8a7d1035" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fe190c2-f14b-4178-981e-31b8c92bea84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fe190c2-f14b-4178-981e-31b8c92bea84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0d67530d-b967-467d-b1d7-412de0523241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0d67530d-b967-467d-b1d7-412de0523241" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_6b64797a-ed64-4ae1-ad02-2b0d146185e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_6b64797a-ed64-4ae1-ad02-2b0d146185e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_1eb2c522-4c40-4f9c-a171-185f09327603" xlink:href="cmps-20250331.xsd#cmps_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_1eb2c522-4c40-4f9c-a171-185f09327603" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodValueWarrantsExercised_50bb8cda-1aa2-46ba-85bb-0f43b518fe99" xlink:href="cmps-20250331.xsd#cmps_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_cmps_StockIssuedDuringPeriodValueWarrantsExercised_50bb8cda-1aa2-46ba-85bb-0f43b518fe99" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8f8e5893-faf2-41a4-b157-c56b1a5d85bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8f8e5893-faf2-41a4-b157-c56b1a5d85bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9109865-86b3-4cdf-b7e4-b46e674f6ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9109865-86b3-4cdf-b7e4-b46e674f6ce3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5b5356e5-99f7-45f0-b37b-ead1d9b61ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5b5356e5-99f7-45f0-b37b-ead1d9b61ce1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9fa2e95a-1ffd-4e14-bbcb-65d8d9c9b7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_NetIncomeLoss_9fa2e95a-1ffd-4e14-bbcb-65d8d9c9b7e7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2809c9dd-3f39-4a76-bbcc-d6283aa92f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52544a60-09ee-4003-b347-44c8a65ea8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d3330fd-e44d-4371-b97b-c61b6633f4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7d3330fd-e44d-4371-b97b-c61b6633f4b3" xlink:to="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a337ad97-f9c6-40e1-91d2-b501846a5b8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:to="loc_us-gaap_ClassOfStockDomain_a337ad97-f9c6-40e1-91d2-b501846a5b8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e825a19-0554-4a11-aa59-60ea0e2188ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:to="loc_us-gaap_ClassOfStockDomain_9e825a19-0554-4a11-aa59-60ea0e2188ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_ccd49ad2-b19a-4f15-baba-d59475a50d71" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9e825a19-0554-4a11-aa59-60ea0e2188ab" xlink:to="loc_cmps_OrdinarySharesMember_ccd49ad2-b19a-4f15-baba-d59475a50d71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_825ebab5-374d-4b78-9d0a-ece690cd23a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d3330fd-e44d-4371-b97b-c61b6633f4b3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_825ebab5-374d-4b78-9d0a-ece690cd23a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49ff591b-caf9-498e-9bee-5ec7222b2e28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49ff591b-caf9-498e-9bee-5ec7222b2e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6527fbc3-e766-48d9-9f4d-dd0088c2c7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_us-gaap_IPOMember_6527fbc3-e766-48d9-9f4d-dd0088c2c7ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_5b9ea585-4810-44a7-8383-5a86914576d0" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_cmps_AtTheMarketOfferingMember_5b9ea585-4810-44a7-8383-5a86914576d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b6f43732-0354-4ae1-8f76-7c66bf741ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_us-gaap_PrivatePlacementMember_b6f43732-0354-4ae1-8f76-7c66bf741ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnderwrittenOfferingMember_f46c38d8-5c63-4586-9078-8f80ff40ca13" xlink:href="cmps-20250331.xsd#cmps_UnderwrittenOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_cmps_UnderwrittenOfferingMember_f46c38d8-5c63-4586-9078-8f80ff40ca13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c268b979-17ea-45f0-b42c-a65ccbe71c9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:to="loc_us-gaap_ClassOfStockDomain_c268b979-17ea-45f0-b42c-a65ccbe71c9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_48b36a75-1086-4ce8-84a6-3ad32fc8f6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:to="loc_us-gaap_ClassOfStockDomain_48b36a75-1086-4ce8-84a6-3ad32fc8f6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_a8992012-9942-4eca-8f53-71183e402d7d" xlink:href="cmps-20250331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_48b36a75-1086-4ce8-84a6-3ad32fc8f6b4" xlink:to="loc_cmps_AmericanDepositarySharesMember_a8992012-9942-4eca-8f53-71183e402d7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d4d2b2d-064e-41c9-9978-cb2e361b9124_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d4d2b2d-064e-41c9-9978-cb2e361b9124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementMember_9e24e441-f35e-4399-92f2-a8ab9175041e" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:to="loc_cmps_LoanAgreementMember_9e24e441-f35e-4399-92f2-a8ab9175041e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanOneMember_18f0eaaa-20ec-4dcd-b37c-f5525e438e34" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:to="loc_cmps_LoanAgreementTermLoanOneMember_18f0eaaa-20ec-4dcd-b37c-f5525e438e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_565a10da-2e7c-480d-a723-2d20ff445f8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_565a10da-2e7c-480d-a723-2d20ff445f8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PIPEWarrantsMember_cc56b123-47dc-4d7b-bcd7-b7bbb5d65773" xlink:href="cmps-20250331.xsd#cmps_PIPEWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:to="loc_cmps_PIPEWarrantsMember_cc56b123-47dc-4d7b-bcd7-b7bbb5d65773" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_2869610f-8b1a-411b-b7ec-f60fd59841a7" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:to="loc_cmps_A2025ADSWarrantsMember_2869610f-8b1a-411b-b7ec-f60fd59841a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_db02a0f4-ffe2-46e5-a515-dfefa89f0d3d" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:to="loc_cmps_PrefundedWarrantsMember_db02a0f4-ffe2-46e5-a515-dfefa89f0d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_5ffc360d-79b2-457d-b9e3-b13b960a5751" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_5ffc360d-79b2-457d-b9e3-b13b960a5751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_41feb11e-b193-4e47-b00e-1b4774d12824" xlink:href="cmps-20250331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_41feb11e-b193-4e47-b00e-1b4774d12824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79f015ec-3f15-4a9a-84e2-155a023d5209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79f015ec-3f15-4a9a-84e2-155a023d5209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2b467d93-6fa4-4150-9f1a-e7e745eab061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2b467d93-6fa4-4150-9f1a-e7e745eab061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized_9cc62fee-3190-4887-be36-b034188fe86c" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_SaleOfStockAmountAuthorized_9cc62fee-3190-4887-be36-b034188fe86c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_50e52929-44de-4f1d-8233-9d56faf0224b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_50e52929-44de-4f1d-8233-9d56faf0224b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_985973a3-cee7-448b-838e-bc1535c59847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_985973a3-cee7-448b-838e-bc1535c59847" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cf662480-1f63-4f8e-a26a-d9b70363ae89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cf662480-1f63-4f8e-a26a-d9b70363ae89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_189ca664-abcd-4dbe-ac1d-70403837878a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_189ca664-abcd-4dbe-ac1d-70403837878a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_98ec9a1a-b4c0-4837-b308-28f9b09cc470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_98ec9a1a-b4c0-4837-b308-28f9b09cc470" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromWarrantExercisesFullyExercised_b4c94794-1cd7-400c-9dee-82a789aa4a22" xlink:href="cmps-20250331.xsd#cmps_ProceedsFromWarrantExercisesFullyExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_ProceedsFromWarrantExercisesFullyExercised_b4c94794-1cd7-400c-9dee-82a789aa4a22" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ef62ce9f-9e7d-41b4-8928-342a050760d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ef62ce9f-9e7d-41b4-8928-342a050760d8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_7022b41f-a360-4881-8c02-14c3235c5f4b" xlink:href="cmps-20250331.xsd#cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_7022b41f-a360-4881-8c02-14c3235c5f4b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b9a1eff-44a4-451e-80e5-5865bbc453fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_NetIncomeLoss_0b9a1eff-44a4-451e-80e5-5865bbc453fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eca0db01-e8e9-48c0-93f4-72b32c7e7209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eca0db01-e8e9-48c0-93f4-72b32c7e7209" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a39c3e-7446-4a45-aea8-319887cfafd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a39c3e-7446-4a45-aea8-319887cfafd6" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2c5c3757-ad15-4fc7-8c5f-40b024775b05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2c5c3757-ad15-4fc7-8c5f-40b024775b05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementMember_c7689fd5-f6fc-48e8-afda-94b29e2f00cc" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementMember_c7689fd5-f6fc-48e8-afda-94b29e2f00cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanOneMember_b36e1bb6-0985-4dd6-964f-c497640943ef" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementTermLoanOneMember_b36e1bb6-0985-4dd6-964f-c497640943ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanTwoMember_a6e4f8eb-50af-41ef-9b1f-ea236ecffadd" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementTermLoanTwoMember_a6e4f8eb-50af-41ef-9b1f-ea236ecffadd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanThreeMember_3e238413-59b4-4317-8622-bf76b70e0156" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementTermLoanThreeMember_3e238413-59b4-4317-8622-bf76b70e0156" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:to="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FacilityFeesMember_fe26d43c-08a2-4b0d-ad7f-80272c0f850e" xlink:href="cmps-20250331.xsd#cmps_FacilityFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_cmps_FacilityFeesMember_fe26d43c-08a2-4b0d-ad7f-80272c0f850e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CompanyFeesMember_03047b2d-5620-4b4c-bb67-87129c9d8350" xlink:href="cmps-20250331.xsd#cmps_CompanyFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_cmps_CompanyFeesMember_03047b2d-5620-4b4c-bb67-87129c9d8350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_79f28ae5-b60d-41d1-b9f3-1b0bd0d0a1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_us-gaap_WarrantMember_79f28ae5-b60d-41d1-b9f3-1b0bd0d0a1bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_EndOfTermChargeMember_b29b8f45-301b-4aa0-a320-83e7d7e60b06" xlink:href="cmps-20250331.xsd#cmps_EndOfTermChargeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_cmps_EndOfTermChargeMember_b29b8f45-301b-4aa0-a320-83e7d7e60b06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_23d6869b-fe5d-40ed-a7e9-2922512dd39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_23d6869b-fe5d-40ed-a7e9-2922512dd39f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_500066a4-4817-4ff8-b8c6-9042056d5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_500066a4-4817-4ff8-b8c6-9042056d5e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7a5bdad-49ad-4639-91c6-565d2768ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7a5bdad-49ad-4639-91c6-565d2768ae58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PaidInKindInterestRate_6ee11d04-3354-4f69-b070-167c62132f97" xlink:href="cmps-20250331.xsd#cmps_PaidInKindInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_PaidInKindInterestRate_6ee11d04-3354-4f69-b070-167c62132f97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_002bffb7-8761-4ed9-996d-70d3d42ca06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_002bffb7-8761-4ed9-996d-70d3d42ca06b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8c21c4c1-a36b-4658-962e-c757314ad6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8c21c4c1-a36b-4658-962e-c757314ad6fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_849dd61f-80ae-48f7-86b6-52e6d01f5816" xlink:href="cmps-20250331.xsd#cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_849dd61f-80ae-48f7-86b6-52e6d01f5816" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableNumber_355bdbb1-e169-4a8e-b657-ff7165e1fb77" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_OptionsExercisableNumber_355bdbb1-e169-4a8e-b657-ff7165e1fb77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableFairValue_754f6135-70f6-42c4-b66a-4ceba12eda7a" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_OptionsExercisableFairValue_754f6135-70f6-42c4-b66a-4ceba12eda7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_ac9d4473-429b-48f4-9089-26a4558ef4f4" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentCovenantMinimumCashOnHandAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_ac9d4473-429b-48f4-9089-26a4558ef4f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentMarketCapitalization_2d3b86a7-93d1-4649-96be-cc7243aa00ac" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentMarketCapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_DebtInstrumentMarketCapitalization_2d3b86a7-93d1-4649-96be-cc7243aa00ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1a60d44d-4c83-48ca-afca-92b901a59f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_InterestExpenseDebt_1a60d44d-4c83-48ca-afca-92b901a59f32" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d74704f-e4c5-419b-a182-ff7849027439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d74704f-e4c5-419b-a182-ff7849027439" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e6fa763b-74a8-41f4-9261-67f3c39e1ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e6fa763b-74a8-41f4-9261-67f3c39e1ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_b080a2b9-dd17-49d1-b13c-c40e67215161" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:to="loc_cmps_PrefundedWarrantsMember_b080a2b9-dd17-49d1-b13c-c40e67215161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_8ed87021-bd7d-4232-ba50-b23f56038a4a" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:to="loc_cmps_A2025ADSWarrantsMember_8ed87021-bd7d-4232-ba50-b23f56038a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93fb913c-0483-40b2-b6d9-1c58c7b81269_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93fb913c-0483-40b2-b6d9-1c58c7b81269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_efff3732-e95f-4b16-96f7-56bae7229266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_efff3732-e95f-4b16-96f7-56bae7229266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e007cefd-0ee3-43c5-8884-d74d770ccf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_efff3732-e95f-4b16-96f7-56bae7229266" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e007cefd-0ee3-43c5-8884-d74d770ccf8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eefe0941-0d18-4bb2-a26c-474b329e2653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eefe0941-0d18-4bb2-a26c-474b329e2653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cc39ee32-80be-4d0b-9c0d-7032d0e6aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cc39ee32-80be-4d0b-9c0d-7032d0e6aa4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_26e6ef7b-0229-48fd-8ade-359343d01b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_26e6ef7b-0229-48fd-8ade-359343d01b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WarrantLiabilityNoncurrent_90beb9f6-dcd5-41a3-8543-5f578cf7b587" xlink:href="cmps-20250331.xsd#cmps_WarrantLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d74704f-e4c5-419b-a182-ff7849027439" xlink:to="loc_cmps_WarrantLiabilityNoncurrent_90beb9f6-dcd5-41a3-8543-5f578cf7b587" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_de66a4d5-1b92-4c3f-aa23-104f96f54a53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_de66a4d5-1b92-4c3f-aa23-104f96f54a53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ef51b848-5bb8-40f9-a853-a0e1473c9843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ef51b848-5bb8-40f9-a853-a0e1473c9843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_a0d6f20a-d712-42ce-8432-5b834ca3fae3" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ef51b848-5bb8-40f9-a853-a0e1473c9843" xlink:to="loc_cmps_A2025ADSWarrantsMember_a0d6f20a-d712-42ce-8432-5b834ca3fae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9135a4af-e4f9-4320-8bee-e9186340df5a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:to="loc_srt_RangeMember_9135a4af-e4f9-4320-8bee-e9186340df5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:to="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ad7a9d4-f942-41b2-ab26-f48e8a29e082" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:to="loc_srt_MinimumMember_6ad7a9d4-f942-41b2-ab26-f48e8a29e082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ebe7f68-00c3-4fd8-886b-5b642e0a8c5b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:to="loc_srt_MaximumMember_4ebe7f68-00c3-4fd8-886b-5b642e0a8c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_737f12d1-fae7-4897-94a3-322892cc7d9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_737f12d1-fae7-4897-94a3-322892cc7d9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputCommodityMarketPriceMember_13c2af80-40f6-43a5-90ac-88aac5026d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCommodityMarketPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputCommodityMarketPriceMember_13c2af80-40f6-43a5-90ac-88aac5026d35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_ede4c1fe-17eb-4223-9a27-e3c9f552b524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_ede4c1fe-17eb-4223-9a27-e3c9f552b524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_304b8646-fe8a-4887-8bba-c9cdbebe163e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_304b8646-fe8a-4887-8bba-c9cdbebe163e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_85adecc9-9071-4d49-86f9-1dc258303c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_85adecc9-9071-4d49-86f9-1dc258303c49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8e884664-0d95-48e4-b067-c33fdd9774ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8e884664-0d95-48e4-b067-c33fdd9774ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1d361e71-e48b-4092-a176-c71eab29a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1d361e71-e48b-4092-a176-c71eab29a73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_34488898-814f-44f0-b4d1-a0a04a174df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_34488898-814f-44f0-b4d1-a0a04a174df5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c2d0273-4ccf-4428-a36a-de5400e63c33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c2d0273-4ccf-4428-a36a-de5400e63c33" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b444c0fd-401d-44d5-9a90-b8da939ccb4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b444c0fd-401d-44d5-9a90-b8da939ccb4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_c775ace7-86ce-46f9-9b79-774f336b81b6" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:to="loc_cmps_PrefundedWarrantsMember_c775ace7-86ce-46f9-9b79-774f336b81b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_de7277e3-3806-4091-a59d-f268268f7ccf" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:to="loc_cmps_A2025ADSWarrantsMember_de7277e3-3806-4091-a59d-f268268f7ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c2d0273-4ccf-4428-a36a-de5400e63c33" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_578aaf14-07a9-4029-89eb-a549ec697a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_578aaf14-07a9-4029-89eb-a549ec697a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7e52faa5-8817-4a41-ac21-2bba4de95d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_32aea2c5-a49b-4ba5-8940-9a830de3a2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_32aea2c5-a49b-4ba5-8940-9a830de3a2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7cca65ff-0244-43cb-9e3b-8fbd9f481240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6c27b740-5a6e-483c-aae1-c4b375073ea8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6c27b740-5a6e-483c-aae1-c4b375073ea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_361d989c-51c1-45c0-b977-d7ad09bd3511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_361d989c-51c1-45c0-b977-d7ad09bd3511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_4dabf769-36da-4119-999c-3297640e55da" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_361d989c-51c1-45c0-b977-d7ad09bd3511" xlink:to="loc_cmps_PrefundedWarrantsMember_4dabf769-36da-4119-999c-3297640e55da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_fb7898e5-d3cb-4b48-8b31-c68be0a1e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_fb7898e5-d3cb-4b48-8b31-c68be0a1e2f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GainLossOnIssuanceOfWarrant_e3730471-5bef-490b-b919-e0e9aea4475d" xlink:href="cmps-20250331.xsd#cmps_GainLossOnIssuanceOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_cmps_GainLossOnIssuanceOfWarrant_e3730471-5bef-490b-b919-e0e9aea4475d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GainLossOnFairValueOfWarrants_57dca6d3-3cd2-4019-b136-c3fcdd9d44ee" xlink:href="cmps-20250331.xsd#cmps_GainLossOnFairValueOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_cmps_GainLossOnFairValueOfWarrants_57dca6d3-3cd2-4019-b136-c3fcdd9d44ee" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ad1ad4c5-f589-4e1b-826d-2f3e837861e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:to="loc_us-gaap_ClassOfStockDomain_ad1ad4c5-f589-4e1b-826d-2f3e837861e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3bf0bbc8-8dd6-4cb5-9ca1-ba3ca98e9ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:to="loc_us-gaap_ClassOfStockDomain_3bf0bbc8-8dd6-4cb5-9ca1-ba3ca98e9ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_54ba85f9-9acc-4f29-b018-e1fe1b86cc00" xlink:href="cmps-20250331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3bf0bbc8-8dd6-4cb5-9ca1-ba3ca98e9ba7" xlink:to="loc_cmps_AmericanDepositarySharesMember_54ba85f9-9acc-4f29-b018-e1fe1b86cc00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cb50ce-5e52-4a0c-b763-04649bb81002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90cb50ce-5e52-4a0c-b763-04649bb81002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7168ac29-2dd9-4071-a99c-c73cc9556f83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_us-gaap_IPOMember_7168ac29-2dd9-4071-a99c-c73cc9556f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_6eb151df-b80b-405e-a66e-fc03a4958d92" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_cmps_AtTheMarketOfferingMember_6eb151df-b80b-405e-a66e-fc03a4958d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b574c199-4e28-462a-b117-4e295d7ac937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_us-gaap_PrivatePlacementMember_b574c199-4e28-462a-b117-4e295d7ac937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnderwrittenOfferingMember_e344bc0a-2594-48d6-9c31-dfb06fefac3e" xlink:href="cmps-20250331.xsd#cmps_UnderwrittenOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_cmps_UnderwrittenOfferingMember_e344bc0a-2594-48d6-9c31-dfb06fefac3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65a0f4e3-afea-4fbf-97a9-48b183fd8d09_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65a0f4e3-afea-4fbf-97a9-48b183fd8d09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b63a7c89-0795-4f8d-969b-fbc9a185a110" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b63a7c89-0795-4f8d-969b-fbc9a185a110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_HerculesCapitalInc.Member_5a58c592-bd29-437f-85cd-adadcf59e8f7" xlink:href="cmps-20250331.xsd#cmps_HerculesCapitalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b63a7c89-0795-4f8d-969b-fbc9a185a110" xlink:to="loc_cmps_HerculesCapitalInc.Member_5a58c592-bd29-437f-85cd-adadcf59e8f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PIPEWarrantsMember_a3ba00f6-af3f-4361-9aa7-0264154dfa24" xlink:href="cmps-20250331.xsd#cmps_PIPEWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:to="loc_cmps_PIPEWarrantsMember_a3ba00f6-af3f-4361-9aa7-0264154dfa24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_61809a16-5db9-45ba-a557-76e1c4461304" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:to="loc_cmps_A2025ADSWarrantsMember_61809a16-5db9-45ba-a557-76e1c4461304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_391b1167-987b-47eb-a88e-7fa477e3a28b" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:to="loc_cmps_PrefundedWarrantsMember_391b1167-987b-47eb-a88e-7fa477e3a28b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized_8876cec0-1c76-45a1-8a32-1d9261280fc9" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_SaleOfStockAmountAuthorized_8876cec0-1c76-45a1-8a32-1d9261280fc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_b812f563-4658-4a55-afbd-c5100543f950" xlink:href="cmps-20250331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_b812f563-4658-4a55-afbd-c5100543f950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a488f72b-98a9-4327-9d65-c0dae2d9f59f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a488f72b-98a9-4327-9d65-c0dae2d9f59f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_435b725a-653c-458a-84bb-761476a3272d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_435b725a-653c-458a-84bb-761476a3272d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_7616405f-23a4-49c4-9400-a01090fb672e" xlink:href="cmps-20250331.xsd#cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_7616405f-23a4-49c4-9400-a01090fb672e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_60c404df-f03c-4ea7-8fd6-af226183c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_60c404df-f03c-4ea7-8fd6-af226183c2fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableNumber_ee16f198-8f26-4f2c-85ac-35840993634b" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_OptionsExercisableNumber_ee16f198-8f26-4f2c-85ac-35840993634b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableFairValue_c42bf4a0-5974-43a5-8406-9f11b99250ab" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_OptionsExercisableFairValue_c42bf4a0-5974-43a5-8406-9f11b99250ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29183def-926f-450a-ab7a-cfcd3a86ee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29183def-926f-450a-ab7a-cfcd3a86ee9b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8615f4aa-73a1-429e-8340-133a02d2434d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8615f4aa-73a1-429e-8340-133a02d2434d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb7670bc-c4dc-4e0d-9f00-33141caaaa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb7670bc-c4dc-4e0d-9f00-33141caaaa3a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_c2b5e623-0572-49a4-94d3-100ea84620a1" xlink:href="cmps-20250331.xsd#cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_c2b5e623-0572-49a4-94d3-100ea84620a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6720ffea-aad6-4c63-b86a-363d4c500efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6720ffea-aad6-4c63-b86a-363d4c500efe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ee3e2455-81fa-44ed-95ef-502bce31e87c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ee3e2455-81fa-44ed-95ef-502bce31e87c" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2017EquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c6a582e-efcd-403e-b8f5-6b29b0052780_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c6a582e-efcd-403e-b8f5-6b29b0052780_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29207d7d-c74a-44a7-928e-6210006953fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29207d7d-c74a-44a7-928e-6210006953fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ab616010-6e36-4ecf-a1ff-38e10a39d939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ab616010-6e36-4ecf-a1ff-38e10a39d939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:to="loc_us-gaap_PlanNameDomain_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_03bb7384-167f-4177-befc-a9a497ab492c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:to="loc_us-gaap_PlanNameDomain_03bb7384-167f-4177-befc-a9a497ab492c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember_0cdd6f1d-361c-41f0-9946-0cdae0d2c203" xlink:href="cmps-20250331.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_03bb7384-167f-4177-befc-a9a497ab492c" xlink:to="loc_cmps_A2017EquityIncentivePlanMember_0cdd6f1d-361c-41f0-9946-0cdae0d2c203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e216fec-ebb6-415c-a726-1df59b4d68e6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:to="loc_srt_RangeMember_0e216fec-ebb6-415c-a726-1df59b4d68e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:to="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8d3ecbb9-305b-453f-b71f-ceb5fe25a8a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:to="loc_srt_MinimumMember_8d3ecbb9-305b-453f-b71f-ceb5fe25a8a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2834aba-f844-451b-bf60-c9270374ae6b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:to="loc_srt_MaximumMember_e2834aba-f844-451b-bf60-c9270374ae6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ed4d4d63-2119-44b9-9c6a-4af17b1a2583_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:to="loc_us-gaap_VestingDomain_ed4d4d63-2119-44b9-9c6a-4af17b1a2583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:to="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9f1785e-2442-466a-8d25-f7efeaa5dfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9f1785e-2442-466a-8d25-f7efeaa5dfcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_863de968-20d3-48cd-bcf5-ac639a85c97b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_863de968-20d3-48cd-bcf5-ac639a85c97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_ffa2324f-cd02-4aac-81d2-d4164878f512_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:to="loc_us-gaap_AwardDateDomain_ffa2324f-cd02-4aac-81d2-d4164878f512_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:to="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member_1a44e773-2312-4128-9426-f72e0aec3780" xlink:href="cmps-20250331.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:to="loc_cmps_OptionsGrantedBeforeJune302020Member_1a44e773-2312-4128-9426-f72e0aec3780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member_6ef9c92b-0ade-4fa4-a81d-d9d2be153546" xlink:href="cmps-20250331.xsd#cmps_GrantDateJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:to="loc_cmps_GrantDateJune302020Member_6ef9c92b-0ade-4fa4-a81d-d9d2be153546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b7474fa4-7151-468c-b61d-f4088ee53694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b7474fa4-7151-468c-b61d-f4088ee53694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e1109d32-5a49-4f8f-b8a3-247daa1a3d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e1109d32-5a49-4f8f-b8a3-247daa1a3d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76eec57e-85cf-41a1-9ee1-5af1c5c81319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76eec57e-85cf-41a1-9ee1-5af1c5c81319" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_1628aa33-b130-4afc-bbef-e456ce79b7c8" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_1628aa33-b130-4afc-bbef-e456ce79b7c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_57b249aa-3bf9-41ad-88a6-2f684356a072" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_57b249aa-3bf9-41ad-88a6-2f684356a072" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05376e9d-faf9-4fdd-8966-e8f4a7f45f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05376e9d-faf9-4fdd-8966-e8f4a7f45f4b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:to="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce801791-2254-4aa1-9d4d-89834761b0eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce801791-2254-4aa1-9d4d-89834761b0eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50002c83-1bbe-45ca-97d3-8c79058a8413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50002c83-1bbe-45ca-97d3-8c79058a8413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b69c8b3c-d98d-4f59-a95b-77582c2aa91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50002c83-1bbe-45ca-97d3-8c79058a8413" xlink:to="loc_us-gaap_EmployeeStockMember_b69c8b3c-d98d-4f59-a95b-77582c2aa91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_844dd9e7-6b1f-4a75-a74c-ec661cab2f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_844dd9e7-6b1f-4a75-a74c-ec661cab2f33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_5f437774-fd35-4c7f-b23f-2d366d213b21" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_5f437774-fd35-4c7f-b23f-2d366d213b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_c9fdb33f-f12d-42d9-8125-a6ceb09a1f12" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_c9fdb33f-f12d-42d9-8125-a6ceb09a1f12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_7a9a9eb5-8cda-45d5-a524-56d1bade6ff6" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_7a9a9eb5-8cda-45d5-a524-56d1bade6ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48a00214-4bf4-4956-a35d-e449f1db525d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48a00214-4bf4-4956-a35d-e449f1db525d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2020ShareOptionPlanDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b629c88e-d2e4-43df-96d7-3eb835e09dd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:to="loc_us-gaap_PlanNameDomain_b629c88e-d2e4-43df-96d7-3eb835e09dd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a2510785-d1d8-4988-a1e2-d11eb558000b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:to="loc_us-gaap_PlanNameDomain_a2510785-d1d8-4988-a1e2-d11eb558000b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember_ccb482ad-475d-4090-a654-390183c9b2ea" xlink:href="cmps-20250331.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a2510785-d1d8-4988-a1e2-d11eb558000b" xlink:to="loc_cmps_A2020ShareOptionPlanMember_ccb482ad-475d-4090-a654-390183c9b2ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c528bc55-9e2b-4f40-a29d-38249ff0d39a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:to="loc_us-gaap_ClassOfStockDomain_c528bc55-9e2b-4f40-a29d-38249ff0d39a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a4ab82e-baaa-48a5-938e-4146a9ed2d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:to="loc_us-gaap_ClassOfStockDomain_8a4ab82e-baaa-48a5-938e-4146a9ed2d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_25e7be9f-8ac1-4a07-9e37-96a84723d319" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a4ab82e-baaa-48a5-938e-4146a9ed2d24" xlink:to="loc_cmps_OrdinarySharesMember_25e7be9f-8ac1-4a07-9e37-96a84723d319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db9ac54d-e9ff-4065-b97d-0be27b263f48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db9ac54d-e9ff-4065-b97d-0be27b263f48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_813e519e-dff0-4321-b98d-45833a68e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_813e519e-dff0-4321-b98d-45833a68e4b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3478686c-4e5b-4226-b9bc-26530266d281" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_813e519e-dff0-4321-b98d-45833a68e4b0" xlink:to="loc_us-gaap_EmployeeStockMember_3478686c-4e5b-4226-b9bc-26530266d281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:to="loc_us-gaap_VestingDomain_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:to="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_135ecf37-c5c3-47ae-b551-e751deab0225" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_135ecf37-c5c3-47ae-b551-e751deab0225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_e79e086d-dcbf-48d7-8fe7-1d723991b658" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_e79e086d-dcbf-48d7-8fe7-1d723991b658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_cd09e687-5eb8-46d7-b6b3-18af29c025af" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_cd09e687-5eb8-46d7-b6b3-18af29c025af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_773efb93-403d-495b-969e-a32192890c38" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_773efb93-403d-495b-969e-a32192890c38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_9b2b357d-6e69-4fa2-aa21-ac21e3726ce1" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_9b2b357d-6e69-4fa2-aa21-ac21e3726ce1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2b4b4c5a-e0cd-4246-b377-677465e875b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2b4b4c5a-e0cd-4246-b377-677465e875b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfdf6e00-22e3-4a6c-b4e7-24d8213d84e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfdf6e00-22e3-4a6c-b4e7-24d8213d84e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ad309dcd-e474-4864-9b05-b5ddb929cf82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ad309dcd-e474-4864-9b05-b5ddb929cf82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e8d90159-cce5-49fe-a00f-9530bbbf4960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e8d90159-cce5-49fe-a00f-9530bbbf4960" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_ffbf9e53-b8ab-438b-804d-6ad19f7efa93" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_ffbf9e53-b8ab-438b-804d-6ad19f7efa93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_fbadacbe-622f-450e-a080-0516923e922f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_SharesIssued_fbadacbe-622f-450e-a080-0516923e922f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_61fbfcc7-e794-43c7-ae3b-0b78c66f4665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_61fbfcc7-e794-43c7-ae3b-0b78c66f4665" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfVestingConditions_18a8047c-61ec-4786-bfec-5c79e62d62a6" xlink:href="cmps-20250331.xsd#cmps_NumberOfVestingConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_cmps_NumberOfVestingConditions_18a8047c-61ec-4786-bfec-5c79e62d62a6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2022InducementGrantOptionAwardDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c35cc49a-e6e9-45c4-a655-ab69d53a5255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:to="loc_us-gaap_PlanNameDomain_c35cc49a-e6e9-45c4-a655-ab69d53a5255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74ce166b-ac5b-44e8-a6c6-654a96b84243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:to="loc_us-gaap_PlanNameDomain_74ce166b-ac5b-44e8-a6c6-654a96b84243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember_4076b21e-1b39-457f-a407-80b3c91d6f3c" xlink:href="cmps-20250331.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74ce166b-ac5b-44e8-a6c6-654a96b84243" xlink:to="loc_cmps_A2022InducementGrantOptionAwardMember_4076b21e-1b39-457f-a407-80b3c91d6f3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4512725b-844c-4c3a-95c6-6f5f90a1866e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:to="loc_us-gaap_ClassOfStockDomain_4512725b-844c-4c3a-95c6-6f5f90a1866e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_492d1dd7-d551-473d-a3bf-cde1fcad7a99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:to="loc_us-gaap_ClassOfStockDomain_492d1dd7-d551-473d-a3bf-cde1fcad7a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_ede0c2c6-cfc9-4a76-9d1a-dadbf3249d88" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_492d1dd7-d551-473d-a3bf-cde1fcad7a99" xlink:to="loc_cmps_OrdinarySharesMember_ede0c2c6-cfc9-4a76-9d1a-dadbf3249d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:to="loc_us-gaap_VestingDomain_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:to="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2ba3fbb2-8784-41df-b527-9b9f8621caf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2ba3fbb2-8784-41df-b527-9b9f8621caf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482d665f-339d-444c-b611-8bbd78e351c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482d665f-339d-444c-b611-8bbd78e351c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d51f3949-03cc-47ac-a54a-0cf7b78931b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d51f3949-03cc-47ac-a54a-0cf7b78931b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d950858f-5f97-4e04-84e6-8e9de1cc112a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d950858f-5f97-4e04-84e6-8e9de1cc112a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed89a632-b856-4285-961b-c1279187e42a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed89a632-b856-4285-961b-c1279187e42a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cbb58c34-ec45-4272-b1b3-736d874956f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cbb58c34-ec45-4272-b1b3-736d874956f3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b07fae-c890-431f-90c7-53347bb9e526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b07fae-c890-431f-90c7-53347bb9e526" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_547ae216-58e8-4955-967a-1d2f87f2acba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_547ae216-58e8-4955-967a-1d2f87f2acba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2beba2d5-6a99-4d67-a2f9-0d416c4fdd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2beba2d5-6a99-4d67-a2f9-0d416c4fdd7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac4a690d-7c3f-4ca9-9c62-36b57d43fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac4a690d-7c3f-4ca9-9c62-36b57d43fb5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1d27c3f-dfff-4c16-bfc6-fb1eaa47153f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b07fae-c890-431f-90c7-53347bb9e526" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1d27c3f-dfff-4c16-bfc6-fb1eaa47153f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd67eb11-e9cb-40ff-97a1-c5b57b054cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd67eb11-e9cb-40ff-97a1-c5b57b054cc4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14f671fa-b6da-4757-94bb-16af7f8b9c99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_14f671fa-b6da-4757-94bb-16af7f8b9c99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember_d266a5d0-e026-4145-a739-f77c03330f84" xlink:href="cmps-20250331.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:to="loc_cmps_UnvestedRestrictedShareUnitsMember_d266a5d0-e026-4145-a739-f77c03330f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember_53c22a65-17ac-419b-8b6d-5b7d72908f63" xlink:href="cmps-20250331.xsd#cmps_ShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:to="loc_cmps_ShareOptionsMember_53c22a65-17ac-419b-8b6d-5b7d72908f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1f5b25c6-6966-4e0d-9e2e-02d5696bd475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:to="loc_us-gaap_WarrantMember_1f5b25c6-6966-4e0d-9e2e-02d5696bd475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f568e03f-2273-4e6c-a2a1-d44852d0980e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd67eb11-e9cb-40ff-97a1-c5b57b054cc4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f568e03f-2273-4e6c-a2a1-d44852d0980e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://compasspathways.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:to="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DevelopmentExpensesMember_ff2ae086-9c61-4a58-865e-a5182fd2c1b8" xlink:href="cmps-20250331.xsd#cmps_DevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_DevelopmentExpensesMember_ff2ae086-9c61-4a58-865e-a5182fd2c1b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PersonnelExpensesMember_5f843b1e-962d-4ad8-abf3-50fb7e77057d" xlink:href="cmps-20250331.xsd#cmps_PersonnelExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_PersonnelExpensesMember_5f843b1e-962d-4ad8-abf3-50fb7e77057d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LegalAndProfessionalFeesMember_786a6a86-22a2-4bd9-8b76-4bbd1d7afef4" xlink:href="cmps-20250331.xsd#cmps_LegalAndProfessionalFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_LegalAndProfessionalFeesMember_786a6a86-22a2-4bd9-8b76-4bbd1d7afef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NonCashShareBasedCompensationExpenseMember_f76820c8-9f46-419b-8fc8-288e1141fd6e" xlink:href="cmps-20250331.xsd#cmps_NonCashShareBasedCompensationExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_NonCashShareBasedCompensationExpenseMember_f76820c8-9f46-419b-8fc8-288e1141fd6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FacilitiesAndOtherExpensesMember_69730768-fb0e-4a66-9dc8-72ff68e225c6" xlink:href="cmps-20250331.xsd#cmps_FacilitiesAndOtherExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_FacilitiesAndOtherExpensesMember_69730768-fb0e-4a66-9dc8-72ff68e225c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c09f6f04-433b-48e4-a940-695877e924e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:to="loc_us-gaap_SegmentDomain_c09f6f04-433b-48e4-a940-695877e924e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b02e0ab1-756d-43fe-a2dd-d41ec66a942d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:to="loc_us-gaap_SegmentDomain_b02e0ab1-756d-43fe-a2dd-d41ec66a942d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SingleOperatingSegmentMember_9ba5ee7f-897b-4da1-8dc4-22989259a7f7" xlink:href="cmps-20250331.xsd#cmps_SingleOperatingSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b02e0ab1-756d-43fe-a2dd-d41ec66a942d" xlink:to="loc_cmps_SingleOperatingSegmentMember_9ba5ee7f-897b-4da1-8dc4-22989259a7f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ea01430b-a69d-47b9-a0c0-50d771cbb813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ea01430b-a69d-47b9-a0c0-50d771cbb813" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0bbda10-9735-423f-8d04-c201f57eeeed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0bbda10-9735-423f-8d04-c201f57eeeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_655acd56-5dc4-4b85-b6e8-55a90874d212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_OperatingExpenses_655acd56-5dc4-4b85-b6e8-55a90874d212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1aeb599a-0478-4d81-8126-b0cb27b7f049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_OperatingIncomeLoss_1aeb599a-0478-4d81-8126-b0cb27b7f049" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1c5b5213-e9bc-4fcc-9b14-d615afe421f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1c5b5213-e9bc-4fcc-9b14-d615afe421f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_448171ec-2844-46ee-b2eb-384b2f66bccd" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_448171ec-2844-46ee-b2eb-384b2f66bccd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3fdfe845-e6e3-492d-ab1e-ede00bf8d817" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3fdfe845-e6e3-492d-ab1e-ede00bf8d817" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_439f2cb5-db4b-4384-845b-0feff5f25ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_439f2cb5-db4b-4384-845b-0feff5f25ca9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_886e374f-9911-42f8-aa58-ed154050c4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_886e374f-9911-42f8-aa58-ed154050c4eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5b9e1a72-0c9c-42c2-9d42-9645fdf6a361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5b9e1a72-0c9c-42c2-9d42-9645fdf6a361" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_539a6978-2379-4ce8-ad6b-296b0f3bc5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_539a6978-2379-4ce8-ad6b-296b0f3bc5d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5050833e-132e-4550-90f4-1ccd6640fcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_NetIncomeLoss_5050833e-132e-4550-90f4-1ccd6640fcdd" xlink:type="arc" order="11"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cmps-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ecce3bbb-f5c6-429b-99e4-462edd6def85,g:b4bd98cb-b7e6-4e40-b9b6-c78a12b28ef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_e7e51d5e-1dd4-4d81-b38b-32291b1b4c87_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_ea02f4ba-9235-43b2-a0fc-8f1a0ebe4084_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bd188dd6-ca03-47c1-a11d-7f218ab26931_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be659525-204e-4193-9dbf-27e5a031de76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e2ebb783-f449-416b-829e-b3fefdd12c60_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d998ac70-ae44-432c-9834-3f86f1c5315f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_8c461f7f-026f-4a74-acb9-4a962e567587_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_e71a4798-a196-4b37-82d1-0b1deaabc49c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91b27ddb-1761-45bb-8ed9-364d88814ecb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c267d223-213e-407e-aae9-fe31eee3672d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SingleOperatingSegmentMember_8680343a-ae78-4dae-aa9c-3b6537e88fa4_terseLabel_en-US" xlink:label="lab_cmps_SingleOperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Single Operating Segment</link:label>
    <link:label id="lab_cmps_SingleOperatingSegmentMember_label_en-US" xlink:label="lab_cmps_SingleOperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Single Operating Segment [Member]</link:label>
    <link:label id="lab_cmps_SingleOperatingSegmentMember_documentation_en-US" xlink:label="lab_cmps_SingleOperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Single Operating Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SingleOperatingSegmentMember" xlink:href="cmps-20250331.xsd#cmps_SingleOperatingSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SingleOperatingSegmentMember" xlink:to="lab_cmps_SingleOperatingSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_64ffcb6a-9599-47ba-a138-2202ec767104_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_20df4d56-8ced-4717-bc09-9dc66d5cffc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_833538e4-a9ab-4702-bb56-f910ddda70cc_terseLabel_en-US" xlink:label="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:href="cmps-20250331.xsd#cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:to="lab_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ef9c2b4a-dcf7-4357-958d-847c32f4f97d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LegalAndProfessionalFeesMember_ba25cde7-7409-4179-a350-abb4323e9670_terseLabel_en-US" xlink:label="lab_cmps_LegalAndProfessionalFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and professional fees</link:label>
    <link:label id="lab_cmps_LegalAndProfessionalFeesMember_label_en-US" xlink:label="lab_cmps_LegalAndProfessionalFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal and Professional Fees [Member]</link:label>
    <link:label id="lab_cmps_LegalAndProfessionalFeesMember_documentation_en-US" xlink:label="lab_cmps_LegalAndProfessionalFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal and Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LegalAndProfessionalFeesMember" xlink:href="cmps-20250331.xsd#cmps_LegalAndProfessionalFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LegalAndProfessionalFeesMember" xlink:to="lab_cmps_LegalAndProfessionalFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LongTermDebtIncludingEndOfTermCharge_fa2b358e-7317-47a8-96be-0583ef37b527_totalLabel_en-US" xlink:label="lab_cmps_LongTermDebtIncludingEndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Future principal payments and end of term charge</link:label>
    <link:label id="lab_cmps_LongTermDebtIncludingEndOfTermCharge_label_en-US" xlink:label="lab_cmps_LongTermDebtIncludingEndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Including End of Term Charge</link:label>
    <link:label id="lab_cmps_LongTermDebtIncludingEndOfTermCharge_documentation_en-US" xlink:label="lab_cmps_LongTermDebtIncludingEndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Including End of Term Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtIncludingEndOfTermCharge" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtIncludingEndOfTermCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LongTermDebtIncludingEndOfTermCharge" xlink:to="lab_cmps_LongTermDebtIncludingEndOfTermCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f10e19eb-381c-453b-894e-f304ee7a5a36_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e861017f-a6fb-4137-bbee-52bd16dc3df9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_cfc0682e-739a-463d-b9e9-1c45eef23e59_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares to settle vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_314c53a3-6eb5-465e-bcd4-7add13e0336e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_39b1f516-80f1-498c-be03-18715d41e79b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_ae64699a-83ed-48a9-a5be-8d28aa44bc77_terseLabel_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary share conversion ratio (in shares)</link:label>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_label_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Conversion Ratio</link:label>
    <link:label id="lab_cmps_NumberOfOrdinarySharesConversionRatio_documentation_en-US" xlink:label="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio" xlink:href="cmps-20250331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfOrdinarySharesConversionRatio" xlink:to="lab_cmps_NumberOfOrdinarySharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_882d33c9-5a5d-495a-b1db-1d3854bcf366_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of underlying ordinary shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_349d323f-21d4-4e7d-a618-4aa1ecb79252_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_aa874ece-ecff-4a80-969b-2430a63133a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_00a8b082-c1e8-490a-a26d-735eb6af3320_terseLabel_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Research And Development, Current</link:label>
    <link:label id="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:href="cmps-20250331.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:to="lab_cmps_PrepaidExpenseResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_85b54919-fe41-42fb-8a65-8ff2f0110c05_terseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares to settle warrants exercised (in shares)</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="cmps-20250331.xsd#cmps_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_cmps_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_c661fd40-1bdd-4373-ba7d-a7926e0837cf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c144654a-55a9-4ee9-a29b-70eb927e8230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_64375b76-99ab-4b23-9a5a-7f8e8ba36a99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_65c47a58-0161-44c0-9562-ff6fb6b9efbb_terseLabel_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cmps_A2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cmps_A2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember" xlink:href="cmps-20250331.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2017EquityIncentivePlanMember" xlink:to="lab_cmps_A2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_30903622-d9f7-4591-a5da-06715cbddd6d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cf1e3d74-7387-4350-810d-78737bac5454_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_bf245053-4659-41bd-9d38-2402317f8a84_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6a48228f-da37-47f7-85a9-a0cc3ba8142c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1331efe2-4a13-4800-aa87-a446ebf2e629_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_47c71cd9-ab32-4b0c-a225-8635f1d28ff9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_032a3974-a5ec-4bd5-a642-3ddf7f357fcf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e24a65f6-9af8-4d36-b4d9-ab8eaf37139f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d8abe594-22ef-4f10-b3ec-6124514c14df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9c0f130d-fb44-4a79-83ac-2e55ba8518dc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f63ee93a-2e96-4d2e-929f-44d9681a690a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f6e450a9-0ce6-4990-bbc0-dcd83205eef4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_76d2cdd1-c3e1-4f24-a0be-ff632c30e6b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_86102d72-59ad-45a7-aa17-9979e8253a41_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockTable_9feec409-2002-4b67-88be-7e7238931018_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockTable_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockTable" xlink:to="lab_us-gaap_ConversionOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_154bdc85-fb8b-4f03-b5a3-a208a18b5c75_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5e49f53e-4f54-4bb4-b29f-15791cbb7140_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditPayable_40609bb1-12ff-497d-a0c3-faf327d76208_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax relief claim</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditPayable_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Tax Credit Payable</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditPayable_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Tax Credit Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditPayable" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditPayable" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_GainLossOnFairValueOfWarrants_dceab098-281e-415a-aad2-4dc09652e3d4_terseLabel_en-US" xlink:label="lab_cmps_GainLossOnFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain in fair value between initial fair value and balance sheet fair value</link:label>
    <link:label id="lab_cmps_GainLossOnFairValueOfWarrants_label_en-US" xlink:label="lab_cmps_GainLossOnFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss ) on Fair Value Of Warrants</link:label>
    <link:label id="lab_cmps_GainLossOnFairValueOfWarrants_documentation_en-US" xlink:label="lab_cmps_GainLossOnFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss ) on Fair Value Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GainLossOnFairValueOfWarrants" xlink:href="cmps-20250331.xsd#cmps_GainLossOnFairValueOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_GainLossOnFairValueOfWarrants" xlink:to="lab_cmps_GainLossOnFairValueOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f94dda5f-37e3-468e-b653-1e9e2f0f0afc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ff756d5-d5f3-477f-a040-996936f7313d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_48bae165-7825-4da7-ab72-d5ec8bd78f0f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_15edb8ae-a4e9-4287-a242-700d95aa7433_terseLabel_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted share units</link:label>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_label_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Restricted Share Units [Member]</link:label>
    <link:label id="lab_cmps_UnvestedRestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unvested Restricted Share Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember" xlink:href="cmps-20250331.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnvestedRestrictedShareUnitsMember" xlink:to="lab_cmps_UnvestedRestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_935574b5-5e8b-4fe2-a502-1fc5e341773a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NonCashShareBasedCompensationExpenseMember_ece97224-554c-4f2e-9403-069be617ac4a_terseLabel_en-US" xlink:label="lab_cmps_NonCashShareBasedCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash share-based compensation expense</link:label>
    <link:label id="lab_cmps_NonCashShareBasedCompensationExpenseMember_label_en-US" xlink:label="lab_cmps_NonCashShareBasedCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Share-Based Compensation Expense [Member]</link:label>
    <link:label id="lab_cmps_NonCashShareBasedCompensationExpenseMember_documentation_en-US" xlink:label="lab_cmps_NonCashShareBasedCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Share-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NonCashShareBasedCompensationExpenseMember" xlink:href="cmps-20250331.xsd#cmps_NonCashShareBasedCompensationExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NonCashShareBasedCompensationExpenseMember" xlink:to="lab_cmps_NonCashShareBasedCompensationExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_680459a3-ea23-42e9-b52d-7f424c525fbe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f9dcd0e4-1a64-4325-872a-6bc203cb483f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_a63c675b-d00f-4a2c-b3ec-92975f18763c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21cf42f7-3000-43bf-a447-47a77feefe9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e47d50e1-65b5-4b7a-b634-cd598404110d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40526f06-3886-43f5-ae6b-6868e876a4b2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_FacilityFeesMember_166c1383-5b1a-4519-bfde-eb43a0cbc751_terseLabel_en-US" xlink:label="lab_cmps_FacilityFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Fees</link:label>
    <link:label id="lab_cmps_FacilityFeesMember_label_en-US" xlink:label="lab_cmps_FacilityFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Fees [Member]</link:label>
    <link:label id="lab_cmps_FacilityFeesMember_documentation_en-US" xlink:label="lab_cmps_FacilityFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FacilityFeesMember" xlink:href="cmps-20250331.xsd#cmps_FacilityFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_FacilityFeesMember" xlink:to="lab_cmps_FacilityFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1ba77ecb-1a0d-4763-a363-d11b2607214c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a5230b77-12c5-4247-8502-b3729aa9bd9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of withholding tax on stock award</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ecda1395-65e7-47b2-aece-c6884a3cf4c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants_47c5d925-fb88-49f5-b554-63863ac00958_terseLabel_en-US" xlink:label="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs allocated to warrants</link:label>
    <link:label id="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants_label_en-US" xlink:label="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs Incurred In Connection With Warrants</link:label>
    <link:label id="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants_documentation_en-US" xlink:label="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Costs Incurred In Connection With Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_TransactionCostsIncurredInConnectionWithWarrants" xlink:href="cmps-20250331.xsd#cmps_TransactionCostsIncurredInConnectionWithWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_TransactionCostsIncurredInConnectionWithWarrants" xlink:to="lab_cmps_TransactionCostsIncurredInConnectionWithWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_10c6b7a1-7041-45d5-891c-c602f27b6bc5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f4a9e92d-479a-4c10-a9ba-fc1ba55a7fd9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ea5d90-e3d9-40de-88a7-31ad944679d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_903b8af2-e1cd-4844-97fe-823c3b2c99ae_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OrdinarySharesMember_d394e698-8a4a-4215-b01c-f2991e627144_terseLabel_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_cmps_OrdinarySharesMember_label_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares [Member]</link:label>
    <link:label id="lab_cmps_OrdinarySharesMember_documentation_en-US" xlink:label="lab_cmps_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OrdinarySharesMember" xlink:to="lab_cmps_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_FacilitiesAndOtherExpensesMember_f5d8bb3b-cfb6-4987-a999-11f6568ac608_terseLabel_en-US" xlink:label="lab_cmps_FacilitiesAndOtherExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities and other expenses</link:label>
    <link:label id="lab_cmps_FacilitiesAndOtherExpensesMember_label_en-US" xlink:label="lab_cmps_FacilitiesAndOtherExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities and Other Expenses [Member]</link:label>
    <link:label id="lab_cmps_FacilitiesAndOtherExpensesMember_documentation_en-US" xlink:label="lab_cmps_FacilitiesAndOtherExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facilities and Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FacilitiesAndOtherExpensesMember" xlink:href="cmps-20250331.xsd#cmps_FacilitiesAndOtherExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_FacilitiesAndOtherExpensesMember" xlink:to="lab_cmps_FacilitiesAndOtherExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_a3e6f9f3-dcae-4cba-8d57-bcdf70abe735_terseLabel_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Share Option Plan</link:label>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_label_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Share Option Plan [Member]</link:label>
    <link:label id="lab_cmps_A2020ShareOptionPlanMember_documentation_en-US" xlink:label="lab_cmps_A2020ShareOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Share Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember" xlink:href="cmps-20250331.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2020ShareOptionPlanMember" xlink:to="lab_cmps_A2020ShareOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b7a6024d-1786-42fa-b860-1283f778deb1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c65c01f7-78c9-4494-9357-97b24ef4cb55_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7a1058c4-879f-43a8-bd5f-3c5cbdc43ebe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, prime margin (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6b706d1c-e6c2-4753-8434-ba47ae6c1abe_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_a557e05e-1f09-467e-84b4-1fea182f7a17_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan, offering period</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3ee5a544-c0b6-499c-9874-56067340e254_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit_38c6f72a-2e73-40e8-a7f7-3470acc48a01_terseLabel_en-US" xlink:label="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development tax</link:label>
    <link:label id="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Tax Credit</link:label>
    <link:label id="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidResearchAndDevelopmentTaxCredit" xlink:href="cmps-20250331.xsd#cmps_PrepaidResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PrepaidResearchAndDevelopmentTaxCredit" xlink:to="lab_cmps_PrepaidResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0d2493a1-3f39-40aa-8537-8c12fea9663f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in GBP per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8cb17387-b5e7-4da0-918e-6457e937cdf4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a82e5514-3a2d-4d7c-9caa-feebedf9111b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_0d8ee4bb-56cb-4fb4-addc-68605df5ac09_terseLabel_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Granted Before June 30, 2020</link:label>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_label_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Granted Before June 30, 2020 [Member]</link:label>
    <link:label id="lab_cmps_OptionsGrantedBeforeJune302020Member_documentation_en-US" xlink:label="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Granted Before June 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member" xlink:href="cmps-20250331.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OptionsGrantedBeforeJune302020Member" xlink:to="lab_cmps_OptionsGrantedBeforeJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_17d4aae2-9c52-4047-99ca-d25883d96fd1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_86c49970-5308-475f-b81b-90440d7cf7e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_bde24e88-c528-4096-b9f7-6062598a3a71_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance premium</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62fb9ad0-129d-4452-bbc2-f34db50e0408_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e8e65afb-747b-4f4f-a9a0-b21b755b7b0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9a269531-234a-4cf8-a0dd-116b327ff54d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b96b2361-fc38-475f-ab71-6097b4b179bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DebtInstrumentPaidInKindInterestPayable_a1120d64-8ab4-4e08-becd-bc62fa2e8fd0_terseLabel_en-US" xlink:label="lab_cmps_DebtInstrumentPaidInKindInterestPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PIK interest payable</link:label>
    <link:label id="lab_cmps_DebtInstrumentPaidInKindInterestPayable_label_en-US" xlink:label="lab_cmps_DebtInstrumentPaidInKindInterestPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Paid-In-Kind Interest Payable</link:label>
    <link:label id="lab_cmps_DebtInstrumentPaidInKindInterestPayable_documentation_en-US" xlink:label="lab_cmps_DebtInstrumentPaidInKindInterestPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Paid-In-Kind Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentPaidInKindInterestPayable" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentPaidInKindInterestPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DebtInstrumentPaidInKindInterestPayable" xlink:to="lab_cmps_DebtInstrumentPaidInKindInterestPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7d429144-535e-49cd-b84e-40b06ba4830b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8663977d-0046-459e-b100-4617c12f62d9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_327ba7d0-9201-4915-99b0-f0e8efed9f12_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cc46d1ea-277b-4b6d-ad08-b4099b4ee44d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6ddcdafb-5af9-4f03-a452-1e2a3b348add_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_41c35db5-dd4f-4857-a5a2-c44318406e63_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AtTheMarketOfferingMember_9f3d9af5-c20b-42c2-9282-d58299293c0e_terseLabel_en-US" xlink:label="lab_cmps_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_cmps_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_cmps_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_cmps_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_cmps_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AtTheMarketOfferingMember" xlink:to="lab_cmps_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_b581314d-34e8-4b88-9340-aa727ed4642f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_fc4268c1-d241-469d-885b-f0f7132b9050_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_08a4e715-589f-4db3-a529-969da3083d34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_cd14d731-9446-459e-a427-70fa94554b4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_fcb9ce37-f1a6-427e-a70e-634b1df300f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7261557d-ccb3-4529-9913-a88404f98903_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_08a502f9-f3a2-403d-8735-fa6bffded587_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_735f96c6-46d4-4517-a664-9ed2e2b8329f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ee804330-0e21-4c57-b381-87ba97dcd851_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Carrying value of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_dfb4a5c8-39a3-434b-a8a8-5e262208a77c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SaleOfStockAmountAuthorized_5fb0e742-687d-4bdd-8549-366513b4c72d_terseLabel_en-US" xlink:label="lab_cmps_SaleOfStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount authorized</link:label>
    <link:label id="lab_cmps_SaleOfStockAmountAuthorized_label_en-US" xlink:label="lab_cmps_SaleOfStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Amount Authorized</link:label>
    <link:label id="lab_cmps_SaleOfStockAmountAuthorized_documentation_en-US" xlink:label="lab_cmps_SaleOfStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Amount Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SaleOfStockAmountAuthorized" xlink:to="lab_cmps_SaleOfStockAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c73aa7e5-f938-4220-ad03-ad6e588c414e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_fd1a7039-871f-4b9d-a027-62619812595f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_df60e36b-b847-4974-a247-2e4a0e588984_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_158b0c9b-2f5d-4c2a-b868-4b0290f9cca3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ca96dddb-c4a4-471c-96ac-cf455ccdcd56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_94492f91-f152-4f2f-b145-7e0242f1da9d_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting condition five</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Five [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_a2aee9a3-35a5-4202-969f-6d43cbce9c03_terseLabel_en-US" xlink:label="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for purchase, percent of principal amount of term loan (as a percent)</link:label>
    <link:label id="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_label_en-US" xlink:label="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, Number Of Shares Available For Purchase, Percent Of Principal Amount Of Term Loan Advances</link:label>
    <link:label id="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_documentation_en-US" xlink:label="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options, Number Of Shares Available For Purchase, Percent Of Principal Amount Of Term Loan Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" xlink:href="cmps-20250331.xsd#cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" xlink:to="lab_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_a0949637-9eab-46a1-8bdc-45ce8c761fbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSE), NET:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_163f8651-2962-46b4-8c19-36df8f7f40ef_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_458f767b-c6cf-4ab4-81ec-163db0304ac0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9a0575f0-0b99-4bf3-81d5-3c1a5ff34b80_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LoanAgreementTermLoanOneMember_569af464-b5e1-4810-a9fb-1cf7af52ec64_terseLabel_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan One</link:label>
    <link:label id="lab_cmps_LoanAgreementTermLoanOneMember_label_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan One [Member]</link:label>
    <link:label id="lab_cmps_LoanAgreementTermLoanOneMember_documentation_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanOneMember" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LoanAgreementTermLoanOneMember" xlink:to="lab_cmps_LoanAgreementTermLoanOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_63067ab0-4fef-46a9-a955-571154bf509d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e03eea8a-8ede-4e79-9271-0960150da0ce_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_6ebc969e-c1f3-4ecf-9579-587383767083_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, amounts of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_fce4372d-82e3-4886-87aa-b0e132af0ecf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Saving period (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_8b9309ae-4d8c-444a-b9e7-214c8cc22069_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_52538334-79a7-407d-8689-2d751bf19909_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0a875c06-101b-4ea8-abc2-03242e01067d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c3b2af34-ee04-471c-9e7e-2fb265ddc5d7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c6ce34fc-6797-4c51-8ac2-c80f618a1f7e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3f46488-9ee0-4339-826e-9929e15ad305_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a0a2edf6-1ceb-40a9-8bd5-996c8b4f90cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_e57f7a7e-1bfe-4842-a8b6-1e6de02ea0d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_GrantDateJune302020Member_02417350-28b6-4d61-8534-79972e46b2ac_terseLabel_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Date June 30, 2020</link:label>
    <link:label id="lab_cmps_GrantDateJune302020Member_label_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Date June 30, 2020 [Member]</link:label>
    <link:label id="lab_cmps_GrantDateJune302020Member_documentation_en-US" xlink:label="lab_cmps_GrantDateJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Date June 30, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member" xlink:href="cmps-20250331.xsd#cmps_GrantDateJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_GrantDateJune302020Member" xlink:to="lab_cmps_GrantDateJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d9c03fcb-5c79-4adb-8ab0-6a65df178844_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0a1cd00e-85ca-4747-8d7b-be954db0cf79_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b94969e5-d45e-40ab-a17d-9a2a65dd4fec_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d26c32f0-7815-4632-9f68-05188bfb7963_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a39237bb-4d7a-4f79-9864-5e7442b1204c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e50ce9a7-9e03-4283-9bf8-7049048a497b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_160a0162-6c68-474e-a706-2b589aa40810_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f52c9344-5b08-46fd-8d22-1ae02696cb65_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_91af445d-d2c3-4c35-af16-09874df910b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_89aad700-593e-4e1f-a027-8e749a80f0fc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_481d4d5e-15a1-4baf-b19f-72adb534c777_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT recoverable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7caa00d4-bfcd-4c18-baf2-d9a85b32d76c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting percentage (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b8f98243-910c-4b5a-8ec3-968fa8aa3c4a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_a0ac4243-20c8-48bc-b875-73a0069e015d_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting condition one</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition One [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_405a160f-00e6-4e21-b11e-e4baa9ca325c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value change of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_d953ab7e-127d-40cf-a50f-2d2c496f0d30_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value change of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_d7d1465e-6094-4537-81d2-5b16914446b5_negatedNetLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Fair value change of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0459467-2d93-4778-9c7e-e082d86dda16_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_CompanyFeesMember_5fbeba99-0fce-491c-b41d-2c1ee6f3ee64_terseLabel_en-US" xlink:label="lab_cmps_CompanyFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Fees</link:label>
    <link:label id="lab_cmps_CompanyFeesMember_label_en-US" xlink:label="lab_cmps_CompanyFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Fees [Member]</link:label>
    <link:label id="lab_cmps_CompanyFeesMember_documentation_en-US" xlink:label="lab_cmps_CompanyFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CompanyFeesMember" xlink:href="cmps-20250331.xsd#cmps_CompanyFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_CompanyFeesMember" xlink:to="lab_cmps_CompanyFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_24021ff8-7b5e-4589-bd54-15764a41f827_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash (gain)/loss on foreign currency remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_c861e893-2ccb-4aab-9378-9810cd0d17e9_terseLabel_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Grant Option Award</link:label>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_label_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Inducement Grant Option Award [Member]</link:label>
    <link:label id="lab_cmps_A2022InducementGrantOptionAwardMember_documentation_en-US" xlink:label="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Inducement Grant Option Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember" xlink:href="cmps-20250331.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2022InducementGrantOptionAwardMember" xlink:to="lab_cmps_A2022InducementGrantOptionAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4a01b286-8869-44d9-8a08-21bc62286a29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_446a2457-d0bd-4b8a-a669-19cb939250ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c333c373-827d-4da9-9c95-4a818b791378_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_03e0fcc4-aa26-4e02-b73d-8f147e5936c6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ea3e143-2b99-4dc0-beba-c550fb439c07_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ae11838d-61ae-4353-b1e6-a37521aac49c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to ordinary shareholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5f15ed88-6b0d-4541-a79f-ee0d9a0b3420_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_91005e72-bb76-478f-9ad5-d590fc264056_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting condition four</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Four [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionFourMember" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionFourMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_da995b6a-2571-4dc4-a414-6e022976cf3a_terseLabel_en-US" xlink:label="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument covenant, cash on hand</link:label>
    <link:label id="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_label_en-US" xlink:label="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash On Hand, Amount</link:label>
    <link:label id="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_documentation_en-US" xlink:label="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash On Hand, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentCovenantMinimumCashOnHandAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" xlink:to="lab_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_16864db4-cf01-4038-aaac-abdbbde22eae_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations:</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_30fbf8a4-383b-431a-bcbd-92c29fec032f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9f930176-0751-42cb-acf2-8b1540130052_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e8282d1-b8e0-4921-bfc9-1a5fb34f20a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0a2939b8-e049-4566-8a2f-6ac6f06903fe_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_03dbcd5b-bef3-43f9-9b7b-1081495dc577_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareOptionsMember_9eb019e0-9a55-4b5c-b650-7ee022f543e5_terseLabel_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share options</link:label>
    <link:label id="lab_cmps_ShareOptionsMember_label_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options [Member]</link:label>
    <link:label id="lab_cmps_ShareOptionsMember_documentation_en-US" xlink:label="lab_cmps_ShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember" xlink:href="cmps-20250331.xsd#cmps_ShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareOptionsMember" xlink:to="lab_cmps_ShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_EndOfTermChargeMember_832f353d-9808-42b7-96ac-3df444a6cdbf_terseLabel_en-US" xlink:label="lab_cmps_EndOfTermChargeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End of Term Charge</link:label>
    <link:label id="lab_cmps_EndOfTermChargeMember_label_en-US" xlink:label="lab_cmps_EndOfTermChargeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">End of Term Charge [Member]</link:label>
    <link:label id="lab_cmps_EndOfTermChargeMember_documentation_en-US" xlink:label="lab_cmps_EndOfTermChargeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">End of Term Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_EndOfTermChargeMember" xlink:href="cmps-20250331.xsd#cmps_EndOfTermChargeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_EndOfTermChargeMember" xlink:to="lab_cmps_EndOfTermChargeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5c7fbe5b-5916-4677-8ebf-954cd01b9c71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a91a3c2a-62e9-495d-b545-20a2e84b328a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a73f254b-79ae-4f14-9cc0-b4bdf51e1bc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares tendered for withholding taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7d0763db-c4c5-46a2-a64a-45e620636c0e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares to settle vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747d7a49-6ded-4655-8feb-1a8dbd4cd003_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PIPEWarrantsMember_9fcca5a0-ee39-4e46-8f04-a721790cf5e4_terseLabel_en-US" xlink:label="lab_cmps_PIPEWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PIPE Warrants</link:label>
    <link:label id="lab_cmps_PIPEWarrantsMember_label_en-US" xlink:label="lab_cmps_PIPEWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PIPE Warrants [Member]</link:label>
    <link:label id="lab_cmps_PIPEWarrantsMember_documentation_en-US" xlink:label="lab_cmps_PIPEWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PIPE Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PIPEWarrantsMember" xlink:href="cmps-20250331.xsd#cmps_PIPEWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PIPEWarrantsMember" xlink:to="lab_cmps_PIPEWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LoanAgreementTermLoanTwoMember_08d53105-c853-4e39-b77e-ce334d36d4eb_terseLabel_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan Two</link:label>
    <link:label id="lab_cmps_LoanAgreementTermLoanTwoMember_label_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan Two [Member]</link:label>
    <link:label id="lab_cmps_LoanAgreementTermLoanTwoMember_documentation_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanTwoMember" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LoanAgreementTermLoanTwoMember" xlink:to="lab_cmps_LoanAgreementTermLoanTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ba0d5a1c-ae58-4425-96eb-805bd32ff109_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6abaf3ca-d6a8-438c-8a85-f11b65b82b41_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_21e6d17f-7bb3-4f9f-a24c-0c920fee1408_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_73fe8d18-2d68-4e0d-9e4c-c27fdba3434a_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_aac45f4b-91eb-4f73-8c62-9845bf3c26ee_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1698f694-dbe1-4e61-83af-3ef37d558367_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PaidInKindInterestRate_96c67c74-3394-476f-8876-7f7a33beb51e_terseLabel_en-US" xlink:label="lab_cmps_PaidInKindInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in-kind interest rate</link:label>
    <link:label id="lab_cmps_PaidInKindInterestRate_label_en-US" xlink:label="lab_cmps_PaidInKindInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-In-Kind Interest Rate</link:label>
    <link:label id="lab_cmps_PaidInKindInterestRate_documentation_en-US" xlink:label="lab_cmps_PaidInKindInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paid-In-Kind Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PaidInKindInterestRate" xlink:href="cmps-20250331.xsd#cmps_PaidInKindInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PaidInKindInterestRate" xlink:to="lab_cmps_PaidInKindInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cf818f15-0fd3-4811-8be3-5f4027adec74_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c55cfab2-e889-43bd-abf2-66b9adacf98f_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_3ae4551f-6c3a-4a7c-b890-fe6690e3eadb_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockLineItems" xlink:to="lab_us-gaap_ConversionOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5393b115-44a7-4d44-a698-1a49d2d24651_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_deccee7e-2303-4ad0-9d0a-b7f523d7c6c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_683cb227-5889-49c6-acd4-21762c483fe3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9ef948e7-28b1-40ca-82fd-49399fe5d753_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan payable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1b053510-702e-415f-8a89-6d8b66473573_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PersonnelExpensesMember_fc0b32cc-35de-42bd-b849-dcdffe4e9127_terseLabel_en-US" xlink:label="lab_cmps_PersonnelExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel expenses</link:label>
    <link:label id="lab_cmps_PersonnelExpensesMember_label_en-US" xlink:label="lab_cmps_PersonnelExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel Expenses [Member]</link:label>
    <link:label id="lab_cmps_PersonnelExpensesMember_documentation_en-US" xlink:label="lab_cmps_PersonnelExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personnel Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PersonnelExpensesMember" xlink:href="cmps-20250331.xsd#cmps_PersonnelExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PersonnelExpensesMember" xlink:to="lab_cmps_PersonnelExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ecdbb514-3f46-4e71-8d76-f72ee4f4bc51_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_293d2512-9ec4-47be-9433-0105dc020e0e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_c7f497eb-5677-461e-b562-6e3af1fbfa2a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8afc5302-4a85-44ad-a1fc-098a9706d93f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHAREHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_c076e6e2-9fd2-4f16-88cf-306ae0c936b6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5a1cb92d-ce38-468e-9882-beca718dcd9d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_eed9b0f4-f21b-4a96-9eb8-6a93a6758ab2_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting condition three</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Three [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_50b06c7a-2fca-4b20-beb6-2e081b63dde2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_174bde0c-3aee-4dd0-b5ee-11cc0f1d6f29_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised_ae302468-167a-4906-918f-c5ab0627d96b_terseLabel_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares to settle warrants exercised</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="cmps-20250331.xsd#cmps_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_cmps_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_23d15c43-04ab-47c4-a971-29afb5711dd5_terseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK R&amp;D tax credit</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Tax Credit, Current</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Tax Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cce4fccc-599c-4f30-b0c1-c697b45336c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_ebe4500d-fe07-4e05-b297-1a0583484299_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_90aba3f9-c88b-42be-ad16-f08e9d6ad15d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_a94bf96b-c8a1-4053-b8b1-d1ff5fc3983d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_5689feb8-9604-434e-9031-f2e2c063e125_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_dfc3cd48-1888-4722-9c8d-3b7b839d2796_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ProceedsFromWarrantExercisesFullyExercised_a1ab0a3f-abfb-452d-a45c-c3ebdfbc8751_terseLabel_en-US" xlink:label="lab_cmps_ProceedsFromWarrantExercisesFullyExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercises, fully exercised</link:label>
    <link:label id="lab_cmps_ProceedsFromWarrantExercisesFullyExercised_label_en-US" xlink:label="lab_cmps_ProceedsFromWarrantExercisesFullyExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises, Fully Exercised</link:label>
    <link:label id="lab_cmps_ProceedsFromWarrantExercisesFullyExercised_documentation_en-US" xlink:label="lab_cmps_ProceedsFromWarrantExercisesFullyExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises, Fully Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromWarrantExercisesFullyExercised" xlink:href="cmps-20250331.xsd#cmps_ProceedsFromWarrantExercisesFullyExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ProceedsFromWarrantExercisesFullyExercised" xlink:to="lab_cmps_ProceedsFromWarrantExercisesFullyExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_0eafb319-71f1-4061-a1e6-fe72a2bb434b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_41b7b6c3-3c38-4f40-b92e-b1ffda618f9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_HerculesCapitalInc.Member_ba0a5d10-9226-409e-b05c-01e4ecc8eea1_terseLabel_en-US" xlink:label="lab_cmps_HerculesCapitalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hercules Capital, Inc.</link:label>
    <link:label id="lab_cmps_HerculesCapitalInc.Member_label_en-US" xlink:label="lab_cmps_HerculesCapitalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hercules Capital, Inc. [Member]</link:label>
    <link:label id="lab_cmps_HerculesCapitalInc.Member_documentation_en-US" xlink:label="lab_cmps_HerculesCapitalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hercules Capital, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_HerculesCapitalInc.Member" xlink:href="cmps-20250331.xsd#cmps_HerculesCapitalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_HerculesCapitalInc.Member" xlink:to="lab_cmps_HerculesCapitalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_1f60eead-204d-4325-b47d-a9d96aebe546_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage amount closing price is higher than listing price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_981381ac-6c6b-496c-bb1d-76250b77ea60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1f79d775-e7fb-49cc-a69d-c5c176068527_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6566bef7-aaef-44a6-9aca-2e43faa8164d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">COMMON STOCK</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b143b4ab-1255-4577-8a5f-6063c019e0fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_1194af06-0055-4a97-8d7c-20ff894afc91_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_df3e9d5a-2134-496b-a0cd-cee58d0b9dcc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_f77b18ef-bdee-444a-947a-08c77876c5db_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_76a4658e-05e9-4933-a438-1ffdfd89c14c_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance of fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6914f354-6a57-491c-a78f-af0d8946850b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial fair value as of January 13, 2025</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d6f2a06e-c0d0-4668-be91-380807d4c429_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance of fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_31aa8330-fde4-49ea-8fe6-da5b90ccf9b1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_53847d8a-e55b-44c3-a29f-ef0d8ada0930_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_5420c23d-3461-4158-8a65-27f3afee6667_terseLabel_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount of stock that may be sold</link:label>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_label_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Amount Allowable For Sale</link:label>
    <link:label id="lab_cmps_SaleOfStockMaximumAmountAllowableForSale_documentation_en-US" xlink:label="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Amount Allowable For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:to="lab_cmps_SaleOfStockMaximumAmountAllowableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputCommodityMarketPriceMember_ea933587-1d71-4aeb-a83f-d2a18019eaff_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputCommodityMarketPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputCommodityMarketPriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputCommodityMarketPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Commodity Market Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputCommodityMarketPriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCommodityMarketPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputCommodityMarketPriceMember" xlink:to="lab_us-gaap_MeasurementInputCommodityMarketPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1089c3c6-f37d-4029-a34d-815b88610e4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cea95c9c-8fc4-4a78-86ea-17b7fa287b04_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_9b722078-fd90-4927-97c6-5cf6be45a9d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e9da4397-7494-4819-af4f-c0b3f718c6a0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_UnderwrittenOfferingMember_80237d38-d48c-4fd8-95f0-f45e33b7cbe8_terseLabel_en-US" xlink:label="lab_cmps_UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Offering</link:label>
    <link:label id="lab_cmps_UnderwrittenOfferingMember_label_en-US" xlink:label="lab_cmps_UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Offering [Member]</link:label>
    <link:label id="lab_cmps_UnderwrittenOfferingMember_documentation_en-US" xlink:label="lab_cmps_UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnderwrittenOfferingMember" xlink:href="cmps-20250331.xsd#cmps_UnderwrittenOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_UnderwrittenOfferingMember" xlink:to="lab_cmps_UnderwrittenOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d904e9f-3475-464b-9833-ad96911a7229_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_04b2d941-a5c6-4296-831d-40f6af1ddfcf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b3d0f001-f263-4670-8e6b-8a2da699078d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_031883d8-5c25-408f-8b58-84d91f8e324f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2f29f338-cfda-4ccf-b730-14e038fca758_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_4cf87aed-53b7-4273-99e4-b17f7dac9602_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting condition two</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_label_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Two [Member]</link:label>
    <link:label id="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_documentation_en-US" xlink:label="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Vesting Condition Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:to="lab_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_b9788912-f41f-4475-b6b9-b092c22f7c88_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d2685344-a843-4485-aea5-1ff324df42f4_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b82e3da4-6186-459b-902e-cbd2029cf0eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7125cf04-4343-4ead-9ea9-fa349a4a6d57_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e9fcd7a2-c728-413f-b02f-23adb868d63e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_80d256bb-a7d1-43f2-b0d5-02572c079da3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_08ad17a3-7c9f-44a0-997c-fe486c056721_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LongTermDebtEndOfTermCharge_c80965e6-23fe-422c-9c49-ace644126810_terseLabel_en-US" xlink:label="lab_cmps_LongTermDebtEndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">End of term charge</link:label>
    <link:label id="lab_cmps_LongTermDebtEndOfTermCharge_label_en-US" xlink:label="lab_cmps_LongTermDebtEndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, End Of Term Charge</link:label>
    <link:label id="lab_cmps_LongTermDebtEndOfTermCharge_documentation_en-US" xlink:label="lab_cmps_LongTermDebtEndOfTermCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, End Of Term Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtEndOfTermCharge" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtEndOfTermCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LongTermDebtEndOfTermCharge" xlink:to="lab_cmps_LongTermDebtEndOfTermCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_f3f1d0a5-5c28-48e5-a452-43fffd022cbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Warrant Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Option, Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_abc53286-f66f-4ffb-ad0a-69c39003c388_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6c16d1c6-8dd3-4bff-a3ff-6993e4597d70_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3bac7b6d-7146-41e3-990f-88caa51191e2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, non-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4caa406a-256f-4793-ab9b-148fb14d8e74_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_329f0a84-cea8-4229-a178-701764bc5202_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bc3962ae-5cc8-4aad-a599-b03e1b40339b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5a88afc6-52f5-4255-a3d5-2b3c1a4c391b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_A2025ADSWarrantsMember_748c8e3f-5231-4e94-99e2-30b1bfec17e5_terseLabel_en-US" xlink:label="lab_cmps_A2025ADSWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 ADS Warrants</link:label>
    <link:label id="lab_cmps_A2025ADSWarrantsMember_label_en-US" xlink:label="lab_cmps_A2025ADSWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 ADS Warrants [Member]</link:label>
    <link:label id="lab_cmps_A2025ADSWarrantsMember_documentation_en-US" xlink:label="lab_cmps_A2025ADSWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 ADS Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_A2025ADSWarrantsMember" xlink:to="lab_cmps_A2025ADSWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_770672a6-df85-46d1-9a9c-5b23414d5419_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_fcaa347d-f1e1-406a-90ea-e531eca70e0a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OptionsExercisableFairValue_6c646d30-3f14-4770-8078-ed5f9f8ba586_terseLabel_en-US" xlink:label="lab_cmps_OptionsExercisableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of exercisable options</link:label>
    <link:label id="lab_cmps_OptionsExercisableFairValue_label_en-US" xlink:label="lab_cmps_OptionsExercisableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, Exercisable, Fair Value</link:label>
    <link:label id="lab_cmps_OptionsExercisableFairValue_documentation_en-US" xlink:label="lab_cmps_OptionsExercisableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options, Exercisable, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableFairValue" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OptionsExercisableFairValue" xlink:to="lab_cmps_OptionsExercisableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_c40a7dbf-2e5a-4e97-b320-d98218f39120_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees and transaction costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9c86cb00-1ae2-4dde-8f79-74d18a6d4132_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_288a07c4-05bf-490d-8e24-34d5e5aa12f6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities_fef3ce2b-83c2-4439-94e2-630a45193f80_terseLabel_en-US" xlink:label="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value change of warrant liabilities</link:label>
    <link:label id="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities_label_en-US" xlink:label="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Change Of Pre-funded Warrant Liabilities</link:label>
    <link:label id="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities_documentation_en-US" xlink:label="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Change Of Pre-funded Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FairValueChangeOfPreFundedWarrantLiabilities" xlink:href="cmps-20250331.xsd#cmps_FairValueChangeOfPreFundedWarrantLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_FairValueChangeOfPreFundedWarrantLiabilities" xlink:to="lab_cmps_FairValueChangeOfPreFundedWarrantLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_93d3d931-6d7a-44c8-9c8d-b7119fb10224_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_WarrantLiabilityNoncurrent_81134092-eeac-4416-8f95-7e1c6eb3ee79_terseLabel_en-US" xlink:label="lab_cmps_WarrantLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_cmps_WarrantLiabilityNoncurrent_label_en-US" xlink:label="lab_cmps_WarrantLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability Noncurrent</link:label>
    <link:label id="lab_cmps_WarrantLiabilityNoncurrent_documentation_en-US" xlink:label="lab_cmps_WarrantLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WarrantLiabilityNoncurrent" xlink:href="cmps-20250331.xsd#cmps_WarrantLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_WarrantLiabilityNoncurrent" xlink:to="lab_cmps_WarrantLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_NumberOfVestingConditions_898e352f-f731-432a-86e6-c005b26732ae_terseLabel_en-US" xlink:label="lab_cmps_NumberOfVestingConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of vesting conditions</link:label>
    <link:label id="lab_cmps_NumberOfVestingConditions_label_en-US" xlink:label="lab_cmps_NumberOfVestingConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Vesting Conditions</link:label>
    <link:label id="lab_cmps_NumberOfVestingConditions_documentation_en-US" xlink:label="lab_cmps_NumberOfVestingConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Vesting Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfVestingConditions" xlink:href="cmps-20250331.xsd#cmps_NumberOfVestingConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_NumberOfVestingConditions" xlink:to="lab_cmps_NumberOfVestingConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_01815a9d-1fb4-41ab-b23b-ac3bb63dc695_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5d7aa914-75d9-4f3e-96a3-a0e75c7fd2c3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_d69f2293-abaf-4454-9ba5-d13a124fa646_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Add: Weighted-average pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_888bdd49-a8d9-453b-921f-11c3eb27e04e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_db1644be-9e46-42d0-8e2b-e98b4e8263c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_80395f8c-6ed2-458a-9ea5-1fa59de0e1de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_0b985c55-a1c3-4cd8-82ab-7bdd6e8e7d5e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_911c8a0d-672e-41b8-825e-d1467477be7d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_12276cb0-b9a8-4a7b-9897-79dd86d3003e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1126b336-a865-4e6d-8164-363fc612f96c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_41de1b8d-2ad0-43a6-b217-1f7170d56e9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_35874c2c-80e3-405b-9060-46220f3ceef7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c3f416fd-425f-4a89-953e-ed5f13646c81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_75608c07-115d-4ad8-a145-a528a14e5f30_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8081dd9c-7725-4a10-8220-41bd04046c95_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a3975738-1288-46d8-994e-b4023fb3d5b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, &#163;0.008 par value; 92,848,326 and 68,552,215 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LoanAgreementMember_8a1dd81e-6b2c-4b47-8147-1ebd4c57d458_terseLabel_en-US" xlink:label="lab_cmps_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_cmps_LoanAgreementMember_label_en-US" xlink:label="lab_cmps_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:label id="lab_cmps_LoanAgreementMember_documentation_en-US" xlink:label="lab_cmps_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementMember" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LoanAgreementMember" xlink:to="lab_cmps_LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3668c5d2-d5e0-4c0a-9306-6267ce49f96a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_110ee148-dce8-42e0-b472-b2ac37d89583_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DebtInstrumentMarketCapitalization_838dc045-39fd-4b50-b964-0db86c5ea4e8_terseLabel_en-US" xlink:label="lab_cmps_DebtInstrumentMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market capitalization</link:label>
    <link:label id="lab_cmps_DebtInstrumentMarketCapitalization_label_en-US" xlink:label="lab_cmps_DebtInstrumentMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Market Capitalization</link:label>
    <link:label id="lab_cmps_DebtInstrumentMarketCapitalization_documentation_en-US" xlink:label="lab_cmps_DebtInstrumentMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Market Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentMarketCapitalization" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentMarketCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DebtInstrumentMarketCapitalization" xlink:to="lab_cmps_DebtInstrumentMarketCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e96d88fb-936b-44cf-8031-3ada15ba26c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f2b320d2-65cc-47e2-b230-250c0d57360a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f9f357d7-60a2-4caa-b601-afccbb9a81ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to ordinary shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e0c7920e-8b74-4bfe-9f5d-e55ce508413b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_491933c7-14cb-4a2d-a648-a2a464143905_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_17dd450c-7c1f-4379-a501-f0c5846474b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of ordinary shares and Pre-funded Warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0bfef72e-9e65-48ac-900c-7611c2904006_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_6543478f-912f-4d4b-9665-6f6509fc2f8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d4222364-f293-4144-9069-be224cacfe94_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to ordinary shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_cf600753-6c75-4f20-a0ea-f1101055cf5d_terseLabel_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum increase in shares available for issuance (in shares)</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_label_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</link:label>
    <link:label id="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:to="lab_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d74fbee4-7ef9-4ef8-aead-f11e2c045027_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b92e9dea-002a-4797-a6d8-837ed59a0572_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d2f37118-6952-4ec0-8c8a-4c5c5413ee57_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_42bc671b-54b4-4686-b1eb-b592901363eb_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs of warrant</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ab4e2246-3411-4399-be3d-c402b41ef6ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e51db97f-23df-4b4e-ab38-1ee3d21510ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_466f1cf8-2240-4b22-b3e4-a643140f1223_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9aaef2cf-686d-4634-a655-5f17128bc848_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fcfefabd-4f93-41cc-87b1-a8542cea2a1f_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e1e580c6-657a-4f6f-b204-4c27048d5472_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0ac47510-21fe-4c63-af0b-157f2dc40384_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_32e9867c-d400-4524-a912-c0141e777a2a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_92181f8c-a92b-4d61-853e-0e915de6d1df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7f325944-53ee-4e2d-aa9c-6d2b250efc64_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bacfbbfc-d730-4411-9113-14e739dde787_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b9c109dc-afb9-4474-a7de-dcd36c2880e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a5f76e69-178c-4bbe-a345-7e0342bb2314_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_4bff06b5-bab2-43a3-931f-236d9feda224_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_PrefundedWarrantsMember_56581721-8ced-4cd8-9fa6-7cda8552caf3_terseLabel_en-US" xlink:label="lab_cmps_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded Warrants</link:label>
    <link:label id="lab_cmps_PrefundedWarrantsMember_label_en-US" xlink:label="lab_cmps_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
    <link:label id="lab_cmps_PrefundedWarrantsMember_documentation_en-US" xlink:label="lab_cmps_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_PrefundedWarrantsMember" xlink:to="lab_cmps_PrefundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6920162e-4dab-4df9-97c8-20c71eddda1e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4c56b3bd-3ca2-4c68-afad-3a33a6688a1b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3f1aa615-b6d2-48ab-adb0-9a43c91793e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a1f14bd4-3438-4b57-a163-8eec71686faf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_074286c3-f9a5-4ed4-84c3-1c12f3a95336_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_221a6e73-cb0b-4d93-b3fb-b403f7694d97_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_a00fe4b7-c0e8-41c4-ad93-6793fa9b4fa7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_LoanAgreementTermLoanThreeMember_5762e506-1c30-4d2a-a044-bd0e29955e17_terseLabel_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan Three</link:label>
    <link:label id="lab_cmps_LoanAgreementTermLoanThreeMember_label_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan Three [Member]</link:label>
    <link:label id="lab_cmps_LoanAgreementTermLoanThreeMember_documentation_en-US" xlink:label="lab_cmps_LoanAgreementTermLoanThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement, Term Loan Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanThreeMember" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_LoanAgreementTermLoanThreeMember" xlink:to="lab_cmps_LoanAgreementTermLoanThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0bff1ff2-3be3-4e5a-9ee5-8a8dba312407_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_4a875343-c75e-4235-a885-6ec71ea92c45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_840529a1-e6ad-4dd1-964c-2a232a370b73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred and prepaid tax assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_GainLossOnIssuanceOfWarrant_ba2c6c83-5894-4188-880b-b4d35746ac58_negatedTerseLabel_en-US" xlink:label="lab_cmps_GainLossOnIssuanceOfWarrant" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on issuance of warrants</link:label>
    <link:label id="lab_cmps_GainLossOnIssuanceOfWarrant_label_en-US" xlink:label="lab_cmps_GainLossOnIssuanceOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Issuance Of Warrant</link:label>
    <link:label id="lab_cmps_GainLossOnIssuanceOfWarrant_documentation_en-US" xlink:label="lab_cmps_GainLossOnIssuanceOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Issuance Of Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GainLossOnIssuanceOfWarrant" xlink:href="cmps-20250331.xsd#cmps_GainLossOnIssuanceOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_GainLossOnIssuanceOfWarrant" xlink:to="lab_cmps_GainLossOnIssuanceOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b054294-333c-4e3a-af4b-e93d2f5e2586_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_56eed14d-4cfb-4274-86a1-ce6beb6e9bd9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b1d9f3ce-e372-48ea-bf43-0b6e983c03dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_efaa4a84-154d-4e1b-997d-5c0e16449096_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_093b4b65-6d88-44b6-8049-7967b49eca28_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a951ba1a-58e8-467f-9993-eed0b8eb032b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9c1bd173-88f0-45f8-9a73-5da975e85b9e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_279470fe-9952-4b25-a869-08478d14d18f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average ordinary shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_1494a587-bd51-4097-b857-9b749858c016_terseLabel_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:label id="lab_cmps_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_cmps_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depositary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember" xlink:href="cmps-20250331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_AmericanDepositarySharesMember" xlink:to="lab_cmps_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_DevelopmentExpensesMember_96b60a05-408b-4d08-90d4-c7830b224917_terseLabel_en-US" xlink:label="lab_cmps_DevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development expenses</link:label>
    <link:label id="lab_cmps_DevelopmentExpensesMember_label_en-US" xlink:label="lab_cmps_DevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Expenses [Member]</link:label>
    <link:label id="lab_cmps_DevelopmentExpensesMember_documentation_en-US" xlink:label="lab_cmps_DevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DevelopmentExpensesMember" xlink:href="cmps-20250331.xsd#cmps_DevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_DevelopmentExpensesMember" xlink:to="lab_cmps_DevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d8631fa0-6853-4d78-8cc2-9c17c3e16a59_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_063e0560-851b-405d-8585-a8a4e9720bcf_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_31fc7c7a-bad4-4667-a785-659105deeaff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_OptionsExercisableNumber_8e305fc4-580e-4c0b-b0d9-5e1d485ef0b4_terseLabel_en-US" xlink:label="lab_cmps_OptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options exercisable (in shares)</link:label>
    <link:label id="lab_cmps_OptionsExercisableNumber_label_en-US" xlink:label="lab_cmps_OptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, Exercisable, Number</link:label>
    <link:label id="lab_cmps_OptionsExercisableNumber_documentation_en-US" xlink:label="lab_cmps_OptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableNumber" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_OptionsExercisableNumber" xlink:to="lab_cmps_OptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_b8e7e4d0-2ec6-4d9a-ad1c-7771b7c2f081_negatedTerseLabel_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit from R&amp;D tax credit</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Tax Credit, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Tax Credit, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:to="lab_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f44fed9f-469d-405b-b460-5a8ee37fd272_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_cab8afda-b204-460c-bf55-bf028d74806e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74130c14-2017-4d16-b3f5-95bc4cbdd150_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_e102de6b-0b40-4312-9118-5a9768a99ede_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cmps-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ecce3bbb-f5c6-429b-99e4-462edd6def85,g:b4bd98cb-b7e6-4e40-b9b6-c78a12b28ef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/Cover" xlink:type="simple" xlink:href="cmps-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_72c1eb77-9960-4c1f-91f8-0ef30a6f38ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_DocumentType_72c1eb77-9960-4c1f-91f8-0ef30a6f38ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a72222eb-9fd9-4876-82af-9d936d0503ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_DocumentQuarterlyReport_a72222eb-9fd9-4876-82af-9d936d0503ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e8dacb10-87c9-4db8-8119-43fd3b8e3c45" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_DocumentPeriodEndDate_e8dacb10-87c9-4db8-8119-43fd3b8e3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_59e98aa6-0d71-437d-85ad-44e4d0b745d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_DocumentTransitionReport_59e98aa6-0d71-437d-85ad-44e4d0b745d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c4b73405-429a-4ed6-b26a-07858d68303f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityFileNumber_c4b73405-429a-4ed6-b26a-07858d68303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dcde0c96-a0f4-4081-bd02-8837274e7ba3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityRegistrantName_dcde0c96-a0f4-4081-bd02-8837274e7ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a75b0364-b9f2-4cbf-9dfc-037b5a88ef50" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a75b0364-b9f2-4cbf-9dfc-037b5a88ef50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_40344359-53c0-48c6-8c0b-359e1190876b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityAddressAddressLine1_40344359-53c0-48c6-8c0b-359e1190876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4ec96883-fabc-47f4-84df-962ee1ddfcda" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityAddressCityOrTown_4ec96883-fabc-47f4-84df-962ee1ddfcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_732797d7-def6-4240-a1d8-c7b273e269c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityAddressPostalZipCode_732797d7-def6-4240-a1d8-c7b273e269c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_351afb48-4f32-478e-9e3b-b5baed392854" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityAddressCountry_351afb48-4f32-478e-9e3b-b5baed392854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5de91336-006d-4646-9504-9e724097eb97" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_CityAreaCode_5de91336-006d-4646-9504-9e724097eb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_405709e4-4c3b-444d-a3da-0a90aad56a7a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_LocalPhoneNumber_405709e4-4c3b-444d-a3da-0a90aad56a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4e35bc5b-36b4-4abc-95ba-21c32cd21ae1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_Security12bTitle_4e35bc5b-36b4-4abc-95ba-21c32cd21ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0c33333f-6d46-44d5-a274-429665443d14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_TradingSymbol_0c33333f-6d46-44d5-a274-429665443d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5ca4d439-1503-496a-b1f9-cd6d8611017e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_SecurityExchangeName_5ca4d439-1503-496a-b1f9-cd6d8611017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7699de56-3ece-4c2e-afa5-853b23c5c598" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityCurrentReportingStatus_7699de56-3ece-4c2e-afa5-853b23c5c598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ce10b5d9-a677-4557-9c1e-ebff08f66717" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityInteractiveDataCurrent_ce10b5d9-a677-4557-9c1e-ebff08f66717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e939af3b-b7f2-4229-8034-24364cf4d857" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityFilerCategory_e939af3b-b7f2-4229-8034-24364cf4d857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_32fd63f6-eb3f-40f8-8d24-2c08a0a6b996" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntitySmallBusiness_32fd63f6-eb3f-40f8-8d24-2c08a0a6b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f671d460-0d04-4f47-b807-aa1a32388e9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityEmergingGrowthCompany_f671d460-0d04-4f47-b807-aa1a32388e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_366ffcd8-0cdd-494e-8a3c-82454099cca5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityShellCompany_366ffcd8-0cdd-494e-8a3c-82454099cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3ab13a6a-f59f-4e62-ab7d-e77a51ffb3d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3ab13a6a-f59f-4e62-ab7d-e77a51ffb3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4d03c0ab-e162-4d6e-8a49-4bd5caa08db6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_EntityCentralIndexKey_4d03c0ab-e162-4d6e-8a49-4bd5caa08db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e42a41a2-7a25-4227-86fe-8eaa8d0742cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_DocumentFiscalYearFocus_e42a41a2-7a25-4227-86fe-8eaa8d0742cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_25d53b31-ace1-4d3a-be57-fc15f2b8e623" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_DocumentFiscalPeriodFocus_25d53b31-ace1-4d3a-be57-fc15f2b8e623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7925b14f-7bfe-4b3d-8815-9207ad7eb10c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_AmendmentFlag_7925b14f-7bfe-4b3d-8815-9207ad7eb10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e59c1f2a-82b9-405c-9b49-00614128d580" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51d50ec5-d8fd-4cd5-96e1-a30270472ddc" xlink:to="loc_dei_CurrentFiscalYearEndDate_e59c1f2a-82b9-405c-9b49-00614128d580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_146ca2c0-421c-4866-bad0-cf27f7fe40f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7e9494ce-5ae7-4d63-971c-a432a5a1ad3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146ca2c0-421c-4866-bad0-cf27f7fe40f5" xlink:to="loc_us-gaap_AssetsAbstract_7e9494ce-5ae7-4d63-971c-a432a5a1ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_232414cb-5a31-4cb5-af12-6eb22e9fc3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7e9494ce-5ae7-4d63-971c-a432a5a1ad3e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_232414cb-5a31-4cb5-af12-6eb22e9fc3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff3e97df-2a2b-4ee0-ad04-ae108addc21d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_232414cb-5a31-4cb5-af12-6eb22e9fc3ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff3e97df-2a2b-4ee0-ad04-ae108addc21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f323191f-df94-4e4c-a14c-6b39d13323e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_232414cb-5a31-4cb5-af12-6eb22e9fc3ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f323191f-df94-4e4c-a14c-6b39d13323e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_3cd2e266-ba06-47ff-94c1-2be03f56dd95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_232414cb-5a31-4cb5-af12-6eb22e9fc3ff" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_3cd2e266-ba06-47ff-94c1-2be03f56dd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a6444d23-211f-47d1-8399-4539d318d766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_232414cb-5a31-4cb5-af12-6eb22e9fc3ff" xlink:to="loc_us-gaap_AssetsCurrent_a6444d23-211f-47d1-8399-4539d318d766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_290647f3-4d4a-442b-970a-9835f0db7efb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7e9494ce-5ae7-4d63-971c-a432a5a1ad3e" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_290647f3-4d4a-442b-970a-9835f0db7efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1a9553b-6dfa-44c7-97db-2e9aa097a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_290647f3-4d4a-442b-970a-9835f0db7efb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1a9553b-6dfa-44c7-97db-2e9aa097a9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a3fc6bc1-b479-48a4-aba7-e97aabc20591" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_290647f3-4d4a-442b-970a-9835f0db7efb" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a3fc6bc1-b479-48a4-aba7-e97aabc20591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019a15f9-71c6-4391-9969-ab432151ed24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_290647f3-4d4a-442b-970a-9835f0db7efb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019a15f9-71c6-4391-9969-ab432151ed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d0339cd2-003d-4e88-9037-c81a673df781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7e9494ce-5ae7-4d63-971c-a432a5a1ad3e" xlink:to="loc_us-gaap_Assets_d0339cd2-003d-4e88-9037-c81a673df781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146ca2c0-421c-4866-bad0-cf27f7fe40f5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3ae60ab6-e506-47d4-a2b9-65d33fd5ef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:to="loc_us-gaap_AccountsPayableCurrent_3ae60ab6-e506-47d4-a2b9-65d33fd5ef4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_41814375-0860-4de8-bbbe-cf2b5d51d634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_41814375-0860-4de8-bbbe-cf2b5d51d634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_37b8e74d-65fb-4210-b005-f8e1b745f82d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:to="loc_us-gaap_LongTermDebtCurrent_37b8e74d-65fb-4210-b005-f8e1b745f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cdc3f066-ac27-4be0-859b-a0fe6cd46788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cdc3f066-ac27-4be0-859b-a0fe6cd46788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e6adc5e-008f-449c-8536-582f7f6e02fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_85feae41-b39d-4799-a563-f9ec49f9b88a" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e6adc5e-008f-449c-8536-582f7f6e02fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ef0e8af-fb5e-4925-88f1-accda7fd93da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ef0e8af-fb5e-4925-88f1-accda7fd93da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6786fa02-3a62-4895-8d96-7a5dfeb0fa74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ef0e8af-fb5e-4925-88f1-accda7fd93da" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6786fa02-3a62-4895-8d96-7a5dfeb0fa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90563e55-2b8f-4bec-a2bc-886b2e5f6178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ef0e8af-fb5e-4925-88f1-accda7fd93da" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90563e55-2b8f-4bec-a2bc-886b2e5f6178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WarrantLiabilityNoncurrent_2ab6baea-0672-44ca-b8af-1c3376bf42c7" xlink:href="cmps-20250331.xsd#cmps_WarrantLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7ef0e8af-fb5e-4925-88f1-accda7fd93da" xlink:to="loc_cmps_WarrantLiabilityNoncurrent_2ab6baea-0672-44ca-b8af-1c3376bf42c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d9b26d03-1802-405d-a25a-5141cd36343f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:to="loc_us-gaap_Liabilities_d9b26d03-1802-405d-a25a-5141cd36343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f9c447f6-d59a-42f5-85ce-2bcd0823f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f9c447f6-d59a-42f5-85ce-2bcd0823f7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_762ad8e7-efbf-4ef8-a7e8-201640774314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:to="loc_us-gaap_CommonStockValue_762ad8e7-efbf-4ef8-a7e8-201640774314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7c83f562-8c1d-4def-8666-7c06115f4950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7c83f562-8c1d-4def-8666-7c06115f4950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41b436ab-4219-4e70-9996-eb20aad4c675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41b436ab-4219-4e70-9996-eb20aad4c675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3e4e22f-a7f1-4f2d-b0c8-3545d5239645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3e4e22f-a7f1-4f2d-b0c8-3545d5239645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d4b5a8d-35aa-4b8a-8c43-609e0eb1e362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4117c85f-18a0-4c72-8ec7-ba0c595b7c95" xlink:to="loc_us-gaap_StockholdersEquity_0d4b5a8d-35aa-4b8a-8c43-609e0eb1e362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_02306692-f71b-427b-b12f-38695d52df60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d55ba8e1-e92d-4181-9f9a-ca59fad31927" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_02306692-f71b-427b-b12f-38695d52df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e1538b62-6f0b-4b95-833b-b6053cc0c50e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1538b62-6f0b-4b95-833b-b6053cc0c50e" xlink:to="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc55e35c-3f28-4339-a23f-23c78892308a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b214887a-1733-4f33-ae7d-6d49f45d1f80" xlink:to="loc_us-gaap_ClassOfStockDomain_dc55e35c-3f28-4339-a23f-23c78892308a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_7330d1e0-9a1e-4041-831c-019d034dedd7" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc55e35c-3f28-4339-a23f-23c78892308a" xlink:to="loc_cmps_OrdinarySharesMember_7330d1e0-9a1e-4041-831c-019d034dedd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e9455e4e-ce9a-4597-a5d1-95d12c26eb6f" xlink:to="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6b3e1f2-09ce-4d2b-81f3-89e8ffacbf14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e6b3e1f2-09ce-4d2b-81f3-89e8ffacbf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7f009f63-2464-4e26-88fc-453838387297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7f009f63-2464-4e26-88fc-453838387297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_72815002-d17b-4e27-801f-06e79f428d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockSharesIssued_72815002-d17b-4e27-801f-06e79f428d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_336ba5bf-ceac-4a9b-be2a-3b139d99c176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a45f66d-3459-4fa7-86af-3ace3131489b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_336ba5bf-ceac-4a9b-be2a-3b139d99c176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_459de1f5-cc58-47e1-a0a3-9cd951b2908c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_459de1f5-cc58-47e1-a0a3-9cd951b2908c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_933804e3-3294-4520-af87-6e09f0d780f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_459de1f5-cc58-47e1-a0a3-9cd951b2908c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_933804e3-3294-4520-af87-6e09f0d780f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fa282688-0911-4599-8e55-5019be0eb6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_459de1f5-cc58-47e1-a0a3-9cd951b2908c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fa282688-0911-4599-8e55-5019be0eb6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_112fd3d5-f40a-462f-8e3a-262cf6988a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_459de1f5-cc58-47e1-a0a3-9cd951b2908c" xlink:to="loc_us-gaap_OperatingExpenses_112fd3d5-f40a-462f-8e3a-262cf6988a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7dd495cc-e668-44d0-bfaa-30fc25f90999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_OperatingIncomeLoss_7dd495cc-e668-44d0-bfaa-30fc25f90999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2d767ecf-b71d-435f-b464-32fddbbfe58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2d767ecf-b71d-435f-b464-32fddbbfe58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_e00a2191-4e41-4291-8b0d-6e8e49384e39" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_e00a2191-4e41-4291-8b0d-6e8e49384e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a8c2dc24-01c6-4df3-bfb8-0e779bf91f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a8c2dc24-01c6-4df3-bfb8-0e779bf91f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e08608a9-e356-4847-8a19-2674dd365100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e08608a9-e356-4847-8a19-2674dd365100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_775206f6-af2b-4554-ab09-8b2b131cad19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_us-gaap_InterestExpenseNonoperating_775206f6-af2b-4554-ab09-8b2b131cad19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_beb006c5-0e49-44a2-a510-a6dab1c29a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_beb006c5-0e49-44a2-a510-a6dab1c29a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6517528c-0ff4-4b78-b893-0684df66fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_83d73381-fb01-4481-b750-7e948a99e77e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6517528c-0ff4-4b78-b893-0684df66fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_21bba6c5-ab40-49d9-acd6-3a11f329c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_21bba6c5-ab40-49d9-acd6-3a11f329c81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e44e0f18-cd8c-4fb2-9120-1f73330f24bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e44e0f18-cd8c-4fb2-9120-1f73330f24bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4368b8d-f9c9-406a-9ede-f375117a58c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_NetIncomeLoss_f4368b8d-f9c9-406a-9ede-f375117a58c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c1c76ea2-4faf-4d60-80af-d9c6e583b171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_c1c76ea2-4faf-4d60-80af-d9c6e583b171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5bdcfafb-26ff-49e2-8b30-f52361c0efab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5bdcfafb-26ff-49e2-8b30-f52361c0efab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_25eebb7f-a973-4972-bf57-05fb73448b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_25eebb7f-a973-4972-bf57-05fb73448b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cb44f09-0775-40b5-bc8c-d7b878a2a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cb44f09-0775-40b5-bc8c-d7b878a2a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8f6318ec-e9eb-4ac4-8e0b-f1e2817c98e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8f6318ec-e9eb-4ac4-8e0b-f1e2817c98e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_fe4539ee-72ac-4e65-abb4-d2ec58dbbe61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8f6318ec-e9eb-4ac4-8e0b-f1e2817c98e1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_fe4539ee-72ac-4e65-abb4-d2ec58dbbe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_de62a95a-a556-4171-a8fc-d3a72474e7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_13116fa0-977e-4643-8b59-e0110076e4c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_de62a95a-a556-4171-a8fc-d3a72474e7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9b511925-605a-4de7-89de-8fd851d29c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9b511925-605a-4de7-89de-8fd851d29c6e" xlink:to="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1e0ad57b-e411-4e99-aa89-dff5bb46a726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5de8569c-01b8-4349-98a7-6c16726460c5" xlink:to="loc_us-gaap_ClassOfStockDomain_1e0ad57b-e411-4e99-aa89-dff5bb46a726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_db4cb3fd-9938-46f7-ad40-8975704d3160" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1e0ad57b-e411-4e99-aa89-dff5bb46a726" xlink:to="loc_cmps_OrdinarySharesMember_db4cb3fd-9938-46f7-ad40-8975704d3160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a7ff5e7e-bc4f-4e8b-8bd2-a3d54ef21f5a" xlink:to="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e3d2083f-cd78-4f24-bf99-a13b25db3235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_CommonStockMember_e3d2083f-cd78-4f24-bf99-a13b25db3235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_48d15aa6-afb0-4cc3-b7d8-a092998402bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_48d15aa6-afb0-4cc3-b7d8-a092998402bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7b59455c-a430-4d25-b2be-2a7ab7acbf73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7b59455c-a430-4d25-b2be-2a7ab7acbf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_130ee456-d214-4137-bcfc-4bede6323ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d398210-4047-4797-a1f3-4d04ee8bc71f" xlink:to="loc_us-gaap_RetainedEarningsMember_130ee456-d214-4137-bcfc-4bede6323ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47a7e684-4594-4a18-9886-f326dad671c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_008ad069-e001-4dea-92f1-b2dbdf0255d2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47a7e684-4594-4a18-9886-f326dad671c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_d55c66f3-fa7f-41b0-b08c-4aa20057a45f" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47a7e684-4594-4a18-9886-f326dad671c2" xlink:to="loc_cmps_AtTheMarketOfferingMember_d55c66f3-fa7f-41b0-b08c-4aa20057a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4b574f23-c197-462a-814e-935fbac8b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_257db1ff-37a4-4ed1-8506-fc5042e9385f" xlink:to="loc_us-gaap_StatementLineItems_4b574f23-c197-462a-814e-935fbac8b85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4b574f23-c197-462a-814e-935fbac8b85d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5e8f2c10-aa4b-469d-91f6-4eb2b2e5d1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5e8f2c10-aa4b-469d-91f6-4eb2b2e5d1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b4637ee-3b6d-4eb0-86c8-b24779ac2de9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockholdersEquity_6b4637ee-3b6d-4eb0-86c8-b24779ac2de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0b92ef59-e206-4517-ba8d-f58d8de19f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0b92ef59-e206-4517-ba8d-f58d8de19f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_88574d3b-8b02-42da-8dd6-c48ceed9bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_88574d3b-8b02-42da-8dd6-c48ceed9bde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f222397b-588a-4cae-812c-7a3a8a7d1035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f222397b-588a-4cae-812c-7a3a8a7d1035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fe190c2-f14b-4178-981e-31b8c92bea84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8fe190c2-f14b-4178-981e-31b8c92bea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0d67530d-b967-467d-b1d7-412de0523241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0d67530d-b967-467d-b1d7-412de0523241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_6b64797a-ed64-4ae1-ad02-2b0d146185e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_6b64797a-ed64-4ae1-ad02-2b0d146185e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_1eb2c522-4c40-4f9c-a171-185f09327603" xlink:href="cmps-20250331.xsd#cmps_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_cmps_StockIssuedDuringPeriodSharesWarrantsExercised_1eb2c522-4c40-4f9c-a171-185f09327603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_StockIssuedDuringPeriodValueWarrantsExercised_50bb8cda-1aa2-46ba-85bb-0f43b518fe99" xlink:href="cmps-20250331.xsd#cmps_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_cmps_StockIssuedDuringPeriodValueWarrantsExercised_50bb8cda-1aa2-46ba-85bb-0f43b518fe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8f8e5893-faf2-41a4-b157-c56b1a5d85bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8f8e5893-faf2-41a4-b157-c56b1a5d85bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9109865-86b3-4cdf-b7e4-b46e674f6ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9109865-86b3-4cdf-b7e4-b46e674f6ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5b5356e5-99f7-45f0-b37b-ead1d9b61ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5b5356e5-99f7-45f0-b37b-ead1d9b61ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9fa2e95a-1ffd-4e14-bbcb-65d8d9c9b7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_NetIncomeLoss_9fa2e95a-1ffd-4e14-bbcb-65d8d9c9b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2809c9dd-3f39-4a76-bbcc-d6283aa92f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2809c9dd-3f39-4a76-bbcc-d6283aa92f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52544a60-09ee-4003-b347-44c8a65ea8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e94b931d-4bec-4e7a-9bb8-bc4cc0e84af2" xlink:to="loc_us-gaap_StockholdersEquity_52544a60-09ee-4003-b347-44c8a65ea8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6194d182-39e6-49cb-af40-515167ee0ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6194d182-39e6-49cb-af40-515167ee0ed5" xlink:to="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e825a19-0554-4a11-aa59-60ea0e2188ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a337ad97-f9c6-40e1-91d2-b501846a5b8b" xlink:to="loc_us-gaap_ClassOfStockDomain_9e825a19-0554-4a11-aa59-60ea0e2188ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_ccd49ad2-b19a-4f15-baba-d59475a50d71" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9e825a19-0554-4a11-aa59-60ea0e2188ab" xlink:to="loc_cmps_OrdinarySharesMember_ccd49ad2-b19a-4f15-baba-d59475a50d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d3330fd-e44d-4371-b97b-c61b6633f4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3ac1bfc-8670-47e2-8205-99f02c482a49" xlink:to="loc_us-gaap_StatementLineItems_7d3330fd-e44d-4371-b97b-c61b6633f4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_825ebab5-374d-4b78-9d0a-ece690cd23a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d3330fd-e44d-4371-b97b-c61b6633f4b3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_825ebab5-374d-4b78-9d0a-ece690cd23a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cmps-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15a20e64-4486-4ed4-93e9-ac71138bd5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15a20e64-4486-4ed4-93e9-ac71138bd5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4a870f1d-f973-4fde-868e-7d703ddaedca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15a20e64-4486-4ed4-93e9-ac71138bd5d4" xlink:to="loc_us-gaap_NetIncomeLoss_4a870f1d-f973-4fde-868e-7d703ddaedca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15a20e64-4486-4ed4-93e9-ac71138bd5d4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1e695211-e605-4cc7-b7a6-d193ffe65a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_us-gaap_Depreciation_1e695211-e605-4cc7-b7a6-d193ffe65a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8002212d-dee5-4e1d-99e1-d549cc518d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8002212d-dee5-4e1d-99e1-d549cc518d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_71d48af5-4a55-4ecd-9674-112312d03ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_71d48af5-4a55-4ecd-9674-112312d03ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_98d3c9a0-a18d-4251-9690-35a924bba173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_us-gaap_ShareBasedCompensation_98d3c9a0-a18d-4251-9690-35a924bba173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_12cccbdf-b5de-4405-a309-8d2e870f8cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_12cccbdf-b5de-4405-a309-8d2e870f8cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_TransactionCostsIncurredInConnectionWithWarrants_0da517e7-b359-4663-b24f-5180769c434d" xlink:href="cmps-20250331.xsd#cmps_TransactionCostsIncurredInConnectionWithWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_cmps_TransactionCostsIncurredInConnectionWithWarrants_0da517e7-b359-4663-b24f-5180769c434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ab2c666e-3bc8-4e75-a990-fdc04fb5d594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5924083f-c53e-41d3-801f-54f6e782e07d" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ab2c666e-3bc8-4e75-a990-fdc04fb5d594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15a20e64-4486-4ed4-93e9-ac71138bd5d4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d1be058c-2b33-4262-9e6d-5fba61d0844c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d1be058c-2b33-4262-9e6d-5fba61d0844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2af41e5c-85e9-4e44-b7a3-575570f4de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2af41e5c-85e9-4e44-b7a3-575570f4de1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a8089a4c-f719-4099-8051-2a4eb98d2b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a8089a4c-f719-4099-8051-2a4eb98d2b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1c55ae10-bc4b-462b-8467-8d97e338ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1c55ae10-bc4b-462b-8467-8d97e338ad74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d16001e5-6e21-4422-9461-3aed7f061734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d16001e5-6e21-4422-9461-3aed7f061734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cefce911-fb96-4abd-850e-1eabdbb81b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_3be71416-d066-4652-96fc-8194b3956bdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cefce911-fb96-4abd-850e-1eabdbb81b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_445dd90a-bbfb-40df-bd01-d86a9bd861a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15a20e64-4486-4ed4-93e9-ac71138bd5d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_445dd90a-bbfb-40df-bd01-d86a9bd861a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1fcc9afa-68f0-46fa-a05a-5143aeb1fc64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1fcc9afa-68f0-46fa-a05a-5143aeb1fc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7519f36d-efbd-43cf-9649-3a60aee7a467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7519f36d-efbd-43cf-9649-3a60aee7a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_71adb914-82dd-44d2-933b-61aa6f513f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_71adb914-82dd-44d2-933b-61aa6f513f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4b0f3b25-4dd9-49e8-8e28-f10554674433" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4b0f3b25-4dd9-49e8-8e28-f10554674433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22ef1395-41bf-40fb-86d2-5bfcea8ae393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6de588f-3a3a-431e-8bd0-b71efea31222" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22ef1395-41bf-40fb-86d2-5bfcea8ae393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f353e735-2d21-440d-a73f-6e935b5db108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f353e735-2d21-440d-a73f-6e935b5db108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4bb1fa7e-f0dd-4260-914f-1951b58194a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4bb1fa7e-f0dd-4260-914f-1951b58194a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b85ae293-40ef-428c-9225-95c118efcf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b85ae293-40ef-428c-9225-95c118efcf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c601dc05-d64a-426a-beb1-671bcf265e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c601dc05-d64a-426a-beb1-671bcf265e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_ed1b955b-a596-41b3-ab14-9c054ee5307d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_84fd24dc-213b-4e2c-b291-bc8689443b0b" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_ed1b955b-a596-41b3-ab14-9c054ee5307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a46d24f-770f-4153-9603-dfeb6faedfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ed1b955b-a596-41b3-ab14-9c054ee5307d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a46d24f-770f-4153-9603-dfeb6faedfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0cc1cf57-97b0-4766-999d-bc4ce1af399b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ed1b955b-a596-41b3-ab14-9c054ee5307d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0cc1cf57-97b0-4766-999d-bc4ce1af399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6013edf1-da42-4663-ab86-a00f2b40dac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ed1b955b-a596-41b3-ab14-9c054ee5307d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6013edf1-da42-4663-ab86-a00f2b40dac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusiness" xlink:type="simple" xlink:href="cmps-20250331.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae48874a-b179-46cc-a1ee-2b205a65eebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1e7ecc14-cf27-459a-9708-9fc6717e7fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae48874a-b179-46cc-a1ee-2b205a65eebd" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1e7ecc14-cf27-459a-9708-9fc6717e7fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cmps-20250331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_09a531ca-d344-4e29-8791-5df4e7331ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_eaf090a1-b28f-4d80-820c-f75a683f24de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_09a531ca-d344-4e29-8791-5df4e7331ba6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_eaf090a1-b28f-4d80-820c-f75a683f24de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="cmps-20250331.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_1bf5d5d1-6112-490e-a492-92c1a59125ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_a68f8f3d-c4da-42c1-bcc8-6eb1678a4cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_1bf5d5d1-6112-490e-a492-92c1a59125ec" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_a68f8f3d-c4da-42c1-bcc8-6eb1678a4cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/Debt" xlink:type="simple" xlink:href="cmps-20250331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_635f80ab-3b19-4236-9757-d18f19940a79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4938f086-b182-460f-83bd-9db6979dcb39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_635f80ab-3b19-4236-9757-d18f19940a79" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4938f086-b182-460f-83bd-9db6979dcb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4430a45a-e2dd-4992-a2a3-783e1ca57e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a86751c6-86bd-4825-8d54-998e9bde3a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4430a45a-e2dd-4992-a2a3-783e1ca57e4e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a86751c6-86bd-4825-8d54-998e9bde3a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4160e5e6-5fd0-404a-a6f1-4bbc79d7b455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fe0be216-46aa-4f2d-8568-339310e03d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4160e5e6-5fd0-404a-a6f1-4bbc79d7b455" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fe0be216-46aa-4f2d-8568-339310e03d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95acf96a-421a-4af1-9a3d-5e29801c50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_143fb31a-20dd-4baa-ad3b-e8553d857b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95acf96a-421a-4af1-9a3d-5e29801c50a6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_143fb31a-20dd-4baa-ad3b-e8553d857b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cmps-20250331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1fe95af8-608e-47da-a4e9-d62cd05ce1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_390fe95b-1377-42c1-ad6e-3b104245b808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1fe95af8-608e-47da-a4e9-d62cd05ce1c2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_390fe95b-1377-42c1-ad6e-3b104245b808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cmps-20250331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f5d9642-07f6-44ce-8104-4735277d88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_01aa6ffa-8e47-4d69-8a7a-510f61937b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f5d9642-07f6-44ce-8104-4735277d88b1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_01aa6ffa-8e47-4d69-8a7a-510f61937b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SegmentReporting" xlink:type="simple" xlink:href="cmps-20250331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c33a7667-31e3-4761-b327-27c31b7ce55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_14ad3a89-032a-49d2-b6d7-5727e4b33d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c33a7667-31e3-4761-b327-27c31b7ce55b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_14ad3a89-032a-49d2-b6d7-5727e4b33d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="cmps-20250331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2e4b141f-aed3-4ace-b736-bf15ff66df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ad34e9f3-79bb-44d4-a2aa-cc7aaf7095c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2e4b141f-aed3-4ace-b736-bf15ff66df0b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ad34e9f3-79bb-44d4-a2aa-cc7aaf7095c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cmps-20250331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89152106-3c82-40d1-8269-e380ff792118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9f60a509-f7ed-4160-9347-a0e9bd7edaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89152106-3c82-40d1-8269-e380ff792118" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9f60a509-f7ed-4160-9347-a0e9bd7edaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_649b5fc1-5fe2-42ef-ab17-24c9d2d52d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89152106-3c82-40d1-8269-e380ff792118" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_649b5fc1-5fe2-42ef-ab17-24c9d2d52d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_52eb6ecf-4ed1-4a5a-ad3e-8977ea18f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89152106-3c82-40d1-8269-e380ff792118" xlink:to="loc_us-gaap_UseOfEstimates_52eb6ecf-4ed1-4a5a-ad3e-8977ea18f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c299dd5-fbc3-4576-844d-48c6717fc73e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89152106-3c82-40d1-8269-e380ff792118" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c299dd5-fbc3-4576-844d-48c6717fc73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="cmps-20250331.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_28a93dfc-15f3-47f0-b025-5779000be54f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_151233ce-bb59-4e37-8fe6-7668cc54e0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_28a93dfc-15f3-47f0-b025-5779000be54f" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_151233ce-bb59-4e37-8fe6-7668cc54e0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtTables" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e3578ad4-9e9f-46fb-a796-06b71f324a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_781fb0d0-3278-442a-8e5c-9445c918bc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3578ad4-9e9f-46fb-a796-06b71f324a27" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_781fb0d0-3278-442a-8e5c-9445c918bc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ecc9dca1-5c27-46e6-99e6-7439212cbf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3578ad4-9e9f-46fb-a796-06b71f324a27" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ecc9dca1-5c27-46e6-99e6-7439212cbf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_678811e5-3ff8-4953-af8e-60d12cda6557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_d5b7c15e-df8f-4874-aec0-2ee8520227ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_678811e5-3ff8-4953-af8e-60d12cda6557" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_d5b7c15e-df8f-4874-aec0-2ee8520227ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d3771c22-0e0f-40c1-b605-7c05118da81c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_678811e5-3ff8-4953-af8e-60d12cda6557" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d3771c22-0e0f-40c1-b605-7c05118da81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_bf4d75cf-3481-43bb-b1b7-99626652a434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_678811e5-3ff8-4953-af8e-60d12cda6557" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock_bf4d75cf-3481-43bb-b1b7-99626652a434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_621342cc-6e18-4e5b-b491-d704298e462a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6e856a42-b2ff-41d5-8be9-1b4ae8b83767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_621342cc-6e18-4e5b-b491-d704298e462a" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6e856a42-b2ff-41d5-8be9-1b4ae8b83767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cmps-20250331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_764633da-42ef-48c4-9357-19eb7d5547b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_198af9ce-9131-42ea-bed6-1a226065fffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_764633da-42ef-48c4-9357-19eb7d5547b0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_198af9ce-9131-42ea-bed6-1a226065fffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4e3b0367-d26d-4f95-82a1-5feff26b4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_764633da-42ef-48c4-9357-19eb7d5547b0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4e3b0367-d26d-4f95-82a1-5feff26b4a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="cmps-20250331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f24d4773-6d4c-41fd-aae1-78ac14bb8fad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d077e5bd-b08a-40fc-8afd-eb49a4cd3999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f24d4773-6d4c-41fd-aae1-78ac14bb8fad" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d077e5bd-b08a-40fc-8afd-eb49a4cd3999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d1af0aa-9992-482f-95aa-e48c0672240f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d1af0aa-9992-482f-95aa-e48c0672240f" xlink:to="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_49ff591b-caf9-498e-9bee-5ec7222b2e28" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6527fbc3-e766-48d9-9f4d-dd0088c2c7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_us-gaap_IPOMember_6527fbc3-e766-48d9-9f4d-dd0088c2c7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_5b9ea585-4810-44a7-8383-5a86914576d0" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_cmps_AtTheMarketOfferingMember_5b9ea585-4810-44a7-8383-5a86914576d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b6f43732-0354-4ae1-8f76-7c66bf741ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_us-gaap_PrivatePlacementMember_b6f43732-0354-4ae1-8f76-7c66bf741ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnderwrittenOfferingMember_f46c38d8-5c63-4586-9078-8f80ff40ca13" xlink:href="cmps-20250331.xsd#cmps_UnderwrittenOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63178508-730d-48f7-947e-fa47cea3336c" xlink:to="loc_cmps_UnderwrittenOfferingMember_f46c38d8-5c63-4586-9078-8f80ff40ca13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_48b36a75-1086-4ce8-84a6-3ad32fc8f6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c268b979-17ea-45f0-b42c-a65ccbe71c9e" xlink:to="loc_us-gaap_ClassOfStockDomain_48b36a75-1086-4ce8-84a6-3ad32fc8f6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_a8992012-9942-4eca-8f53-71183e402d7d" xlink:href="cmps-20250331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_48b36a75-1086-4ce8-84a6-3ad32fc8f6b4" xlink:to="loc_cmps_AmericanDepositarySharesMember_a8992012-9942-4eca-8f53-71183e402d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d4d2b2d-064e-41c9-9978-cb2e361b9124" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementMember_9e24e441-f35e-4399-92f2-a8ab9175041e" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:to="loc_cmps_LoanAgreementMember_9e24e441-f35e-4399-92f2-a8ab9175041e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanOneMember_18f0eaaa-20ec-4dcd-b37c-f5525e438e34" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_37586fea-8e1d-4d5a-8c66-762113b6403d" xlink:to="loc_cmps_LoanAgreementTermLoanOneMember_18f0eaaa-20ec-4dcd-b37c-f5525e438e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_565a10da-2e7c-480d-a723-2d20ff445f8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PIPEWarrantsMember_cc56b123-47dc-4d7b-bcd7-b7bbb5d65773" xlink:href="cmps-20250331.xsd#cmps_PIPEWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:to="loc_cmps_PIPEWarrantsMember_cc56b123-47dc-4d7b-bcd7-b7bbb5d65773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_2869610f-8b1a-411b-b7ec-f60fd59841a7" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:to="loc_cmps_A2025ADSWarrantsMember_2869610f-8b1a-411b-b7ec-f60fd59841a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_db02a0f4-ffe2-46e5-a515-dfefa89f0d3d" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_81f5ba83-7e1c-4cef-b449-b2c2d2249c1d" xlink:to="loc_cmps_PrefundedWarrantsMember_db02a0f4-ffe2-46e5-a515-dfefa89f0d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_6f581e5f-5f6c-43d9-aa80-7236763fe670" xlink:to="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_5ffc360d-79b2-457d-b9e3-b13b960a5751" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockMaximumAmountAllowableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_SaleOfStockMaximumAmountAllowableForSale_5ffc360d-79b2-457d-b9e3-b13b960a5751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_41feb11e-b193-4e47-b00e-1b4774d12824" xlink:href="cmps-20250331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_41feb11e-b193-4e47-b00e-1b4774d12824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79f015ec-3f15-4a9a-84e2-155a023d5209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_79f015ec-3f15-4a9a-84e2-155a023d5209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2b467d93-6fa4-4150-9f1a-e7e745eab061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2b467d93-6fa4-4150-9f1a-e7e745eab061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized_9cc62fee-3190-4887-be36-b034188fe86c" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_SaleOfStockAmountAuthorized_9cc62fee-3190-4887-be36-b034188fe86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_50e52929-44de-4f1d-8233-9d56faf0224b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_50e52929-44de-4f1d-8233-9d56faf0224b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_985973a3-cee7-448b-838e-bc1535c59847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_985973a3-cee7-448b-838e-bc1535c59847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cf662480-1f63-4f8e-a26a-d9b70363ae89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cf662480-1f63-4f8e-a26a-d9b70363ae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_189ca664-abcd-4dbe-ac1d-70403837878a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_189ca664-abcd-4dbe-ac1d-70403837878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_98ec9a1a-b4c0-4837-b308-28f9b09cc470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_98ec9a1a-b4c0-4837-b308-28f9b09cc470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ProceedsFromWarrantExercisesFullyExercised_b4c94794-1cd7-400c-9dee-82a789aa4a22" xlink:href="cmps-20250331.xsd#cmps_ProceedsFromWarrantExercisesFullyExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_ProceedsFromWarrantExercisesFullyExercised_b4c94794-1cd7-400c-9dee-82a789aa4a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ef62ce9f-9e7d-41b4-8928-342a050760d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ef62ce9f-9e7d-41b4-8928-342a050760d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_7022b41f-a360-4881-8c02-14c3235c5f4b" xlink:href="cmps-20250331.xsd#cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_7022b41f-a360-4881-8c02-14c3235c5f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b9a1eff-44a4-451e-80e5-5865bbc453fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_NetIncomeLoss_0b9a1eff-44a4-451e-80e5-5865bbc453fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eca0db01-e8e9-48c0-93f4-72b32c7e7209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eca0db01-e8e9-48c0-93f4-72b32c7e7209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a39c3e-7446-4a45-aea8-319887cfafd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_74de3f2b-02ad-45d2-baf3-b2bdcc0e0259" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a39c3e-7446-4a45-aea8-319887cfafd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_4f9b9fef-e642-4a82-9d42-2d50736d71da" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditCurrent_4f9b9fef-e642-4a82-9d42-2d50736d71da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_30e7bd87-f678-491b-ac63-a7e4a3938b95" xlink:href="cmps-20250331.xsd#cmps_PrepaidExpenseResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_cmps_PrepaidExpenseResearchAndDevelopmentCurrent_30e7bd87-f678-491b-ac63-a7e4a3938b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_3bcdb577-1d21-475d-b468-368c1616cade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_3bcdb577-1d21-475d-b468-368c1616cade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_b92da556-3686-4d42-8296-06a76056661c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_us-gaap_PrepaidInsurance_b92da556-3686-4d42-8296-06a76056661c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c3a66ffd-8497-4c07-88f1-56d5c899527e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_us-gaap_OtherAssetsCurrent_c3a66ffd-8497-4c07-88f1-56d5c899527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2974b769-e0dd-41e0-a9ac-1106c42092d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2974b769-e0dd-41e0-a9ac-1106c42092d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditPayable_20c75efe-aa65-4bc5-9dc2-48d87fac0fea" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditPayable_20c75efe-aa65-4bc5-9dc2-48d87fac0fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrepaidResearchAndDevelopmentTaxCredit_5b2b1f19-5172-44c8-aeed-7c367f686635" xlink:href="cmps-20250331.xsd#cmps_PrepaidResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dd667f27-e5e6-450e-a788-28f975555cb9" xlink:to="loc_cmps_PrepaidResearchAndDevelopmentTaxCredit_5b2b1f19-5172-44c8-aeed-7c367f686635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_49c2fe08-b0cc-492f-8c87-a660902e1b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_49c2fe08-b0cc-492f-8c87-a660902e1b6e" xlink:to="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:to="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2c5c3757-ad15-4fc7-8c5f-40b024775b05" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementMember_c7689fd5-f6fc-48e8-afda-94b29e2f00cc" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementMember_c7689fd5-f6fc-48e8-afda-94b29e2f00cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanOneMember_b36e1bb6-0985-4dd6-964f-c497640943ef" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementTermLoanOneMember_b36e1bb6-0985-4dd6-964f-c497640943ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanTwoMember_a6e4f8eb-50af-41ef-9b1f-ea236ecffadd" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementTermLoanTwoMember_a6e4f8eb-50af-41ef-9b1f-ea236ecffadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LoanAgreementTermLoanThreeMember_3e238413-59b4-4317-8622-bf76b70e0156" xlink:href="cmps-20250331.xsd#cmps_LoanAgreementTermLoanThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b94ca09b-1812-4d4f-bf83-441ddee1a470" xlink:to="loc_cmps_LoanAgreementTermLoanThreeMember_3e238413-59b4-4317-8622-bf76b70e0156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:to="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_dcd7d8fd-1375-4a25-9b02-cb7960e5fdc4" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FacilityFeesMember_fe26d43c-08a2-4b0d-ad7f-80272c0f850e" xlink:href="cmps-20250331.xsd#cmps_FacilityFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_cmps_FacilityFeesMember_fe26d43c-08a2-4b0d-ad7f-80272c0f850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_CompanyFeesMember_03047b2d-5620-4b4c-bb67-87129c9d8350" xlink:href="cmps-20250331.xsd#cmps_CompanyFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_cmps_CompanyFeesMember_03047b2d-5620-4b4c-bb67-87129c9d8350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_79f28ae5-b60d-41d1-b9f3-1b0bd0d0a1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_us-gaap_WarrantMember_79f28ae5-b60d-41d1-b9f3-1b0bd0d0a1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_EndOfTermChargeMember_b29b8f45-301b-4aa0-a320-83e7d7e60b06" xlink:href="cmps-20250331.xsd#cmps_EndOfTermChargeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8d788f17-f99f-4761-8ef5-2a464749d2ba" xlink:to="loc_cmps_EndOfTermChargeMember_b29b8f45-301b-4aa0-a320-83e7d7e60b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_42321c5e-a889-4366-8e9f-549da93fe4e4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_23d6869b-fe5d-40ed-a7e9-2922512dd39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_23d6869b-fe5d-40ed-a7e9-2922512dd39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_500066a4-4817-4ff8-b8c6-9042056d5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_500066a4-4817-4ff8-b8c6-9042056d5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7a5bdad-49ad-4639-91c6-565d2768ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c7a5bdad-49ad-4639-91c6-565d2768ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PaidInKindInterestRate_6ee11d04-3354-4f69-b070-167c62132f97" xlink:href="cmps-20250331.xsd#cmps_PaidInKindInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_PaidInKindInterestRate_6ee11d04-3354-4f69-b070-167c62132f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_002bffb7-8761-4ed9-996d-70d3d42ca06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_002bffb7-8761-4ed9-996d-70d3d42ca06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8c21c4c1-a36b-4658-962e-c757314ad6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8c21c4c1-a36b-4658-962e-c757314ad6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_849dd61f-80ae-48f7-86b6-52e6d01f5816" xlink:href="cmps-20250331.xsd#cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_849dd61f-80ae-48f7-86b6-52e6d01f5816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableNumber_355bdbb1-e169-4a8e-b657-ff7165e1fb77" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_OptionsExercisableNumber_355bdbb1-e169-4a8e-b657-ff7165e1fb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableFairValue_754f6135-70f6-42c4-b66a-4ceba12eda7a" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_OptionsExercisableFairValue_754f6135-70f6-42c4-b66a-4ceba12eda7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_ac9d4473-429b-48f4-9089-26a4558ef4f4" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentCovenantMinimumCashOnHandAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount_ac9d4473-429b-48f4-9089-26a4558ef4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentMarketCapitalization_2d3b86a7-93d1-4649-96be-cc7243aa00ac" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentMarketCapitalization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_cmps_DebtInstrumentMarketCapitalization_2d3b86a7-93d1-4649-96be-cc7243aa00ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1a60d44d-4c83-48ca-afca-92b901a59f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_642c7587-4f90-4b40-a675-c69daa491862" xlink:to="loc_us-gaap_InterestExpenseDebt_1a60d44d-4c83-48ca-afca-92b901a59f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtComponentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/DebtComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c2c79636-cdcb-427d-951c-9c3b2e9f92e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c2c79636-cdcb-427d-951c-9c3b2e9f92e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtEndOfTermCharge_8cbb7989-bb4b-42d8-93ea-7fdca2bf7e10" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtEndOfTermCharge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_cmps_LongTermDebtEndOfTermCharge_8cbb7989-bb4b-42d8-93ea-7fdca2bf7e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtIncludingEndOfTermCharge_96342aba-613c-4455-9bd0-3cc3f61eef08" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtIncludingEndOfTermCharge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_cmps_LongTermDebtIncludingEndOfTermCharge_96342aba-613c-4455-9bd0-3cc3f61eef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DebtInstrumentPaidInKindInterestPayable_a7f4c4eb-f4f5-4a00-b7ae-55bae03f059d" xlink:href="cmps-20250331.xsd#cmps_DebtInstrumentPaidInKindInterestPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_cmps_DebtInstrumentPaidInKindInterestPayable_a7f4c4eb-f4f5-4a00-b7ae-55bae03f059d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3625e5dd-71b3-40f1-957c-e08d906e9241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3625e5dd-71b3-40f1-957c-e08d906e9241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d16cee0f-2deb-44fe-929e-e098acc7110a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_us-gaap_LongTermDebt_d16cee0f-2deb-44fe-929e-e098acc7110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_689ebcd2-7829-4ca0-88fe-5571d6da7e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_us-gaap_DebtCurrent_689ebcd2-7829-4ca0-88fe-5571d6da7e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e0f213b7-da17-4a77-bd26-11f8c609b371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_942f67d1-8247-4fb5-a104-d02008694a42" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e0f213b7-da17-4a77-bd26-11f8c609b371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#DebtScheduleofPrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c5196c68-4cce-42a5-b226-3dcfba5b8abf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a13a2f92-6114-4e93-ae02-4559d7c9aa99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5196c68-4cce-42a5-b226-3dcfba5b8abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a13a2f92-6114-4e93-ae02-4559d7c9aa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_458d6042-df79-4a0e-93cf-1ec88f6d3a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5196c68-4cce-42a5-b226-3dcfba5b8abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_458d6042-df79-4a0e-93cf-1ec88f6d3a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98465097-3b0b-4993-b223-a1c57fe15ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5196c68-4cce-42a5-b226-3dcfba5b8abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98465097-3b0b-4993-b223-a1c57fe15ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LongTermDebtIncludingEndOfTermCharge_b7f62ab0-d796-411c-87b2-4f60ef936e7a" xlink:href="cmps-20250331.xsd#cmps_LongTermDebtIncludingEndOfTermCharge"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5196c68-4cce-42a5-b226-3dcfba5b8abf" xlink:to="loc_cmps_LongTermDebtIncludingEndOfTermCharge_b7f62ab0-d796-411c-87b2-4f60ef936e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_94784373-3cb8-44f2-8605-09451b2d1fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_94784373-3cb8-44f2-8605-09451b2d1fd8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e6fa763b-74a8-41f4-9261-67f3c39e1ceb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_b080a2b9-dd17-49d1-b13c-c40e67215161" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:to="loc_cmps_PrefundedWarrantsMember_b080a2b9-dd17-49d1-b13c-c40e67215161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_8ed87021-bd7d-4232-ba50-b23f56038a4a" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_41286890-d8d7-421e-b881-214df2e1f95c" xlink:to="loc_cmps_A2025ADSWarrantsMember_8ed87021-bd7d-4232-ba50-b23f56038a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_efff3732-e95f-4b16-96f7-56bae7229266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_93fb913c-0483-40b2-b6d9-1c58c7b81269" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_efff3732-e95f-4b16-96f7-56bae7229266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e007cefd-0ee3-43c5-8884-d74d770ccf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_efff3732-e95f-4b16-96f7-56bae7229266" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e007cefd-0ee3-43c5-8884-d74d770ccf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eefe0941-0d18-4bb2-a26c-474b329e2653" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cc39ee32-80be-4d0b-9c0d-7032d0e6aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cc39ee32-80be-4d0b-9c0d-7032d0e6aa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_26e6ef7b-0229-48fd-8ade-359343d01b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78a9fb7b-f62a-4ff8-8a70-475f769dd46a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_26e6ef7b-0229-48fd-8ade-359343d01b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d74704f-e4c5-419b-a182-ff7849027439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98798ab7-cc70-454e-8e32-263150a89ea4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d74704f-e4c5-419b-a182-ff7849027439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_WarrantLiabilityNoncurrent_90beb9f6-dcd5-41a3-8543-5f578cf7b587" xlink:href="cmps-20250331.xsd#cmps_WarrantLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d74704f-e4c5-419b-a182-ff7849027439" xlink:to="loc_cmps_WarrantLiabilityNoncurrent_90beb9f6-dcd5-41a3-8543-5f578cf7b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a238aea9-aff5-44f6-a008-bd6cbe575870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a238aea9-aff5-44f6-a008-bd6cbe575870" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ef51b848-5bb8-40f9-a853-a0e1473c9843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_de66a4d5-1b92-4c3f-aa23-104f96f54a53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ef51b848-5bb8-40f9-a853-a0e1473c9843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_a0d6f20a-d712-42ce-8432-5b834ca3fae3" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ef51b848-5bb8-40f9-a853-a0e1473c9843" xlink:to="loc_cmps_A2025ADSWarrantsMember_a0d6f20a-d712-42ce-8432-5b834ca3fae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9135a4af-e4f9-4320-8bee-e9186340df5a" xlink:to="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ad7a9d4-f942-41b2-ab26-f48e8a29e082" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:to="loc_srt_MinimumMember_6ad7a9d4-f942-41b2-ab26-f48e8a29e082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ebe7f68-00c3-4fd8-886b-5b642e0a8c5b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a7c14bf-c6e9-45f0-a62c-b4437a1457dd" xlink:to="loc_srt_MaximumMember_4ebe7f68-00c3-4fd8-886b-5b642e0a8c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_737f12d1-fae7-4897-94a3-322892cc7d9f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputCommodityMarketPriceMember_13c2af80-40f6-43a5-90ac-88aac5026d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCommodityMarketPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputCommodityMarketPriceMember_13c2af80-40f6-43a5-90ac-88aac5026d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_ede4c1fe-17eb-4223-9a27-e3c9f552b524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_ede4c1fe-17eb-4223-9a27-e3c9f552b524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_304b8646-fe8a-4887-8bba-c9cdbebe163e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_304b8646-fe8a-4887-8bba-c9cdbebe163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_85adecc9-9071-4d49-86f9-1dc258303c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c4eb4453-9103-4ffc-b132-b3be523fa650" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_85adecc9-9071-4d49-86f9-1dc258303c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a0d194fe-be11-4587-8f1e-25812028bd95" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8e884664-0d95-48e4-b067-c33fdd9774ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8e884664-0d95-48e4-b067-c33fdd9774ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1d361e71-e48b-4092-a176-c71eab29a73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1d361e71-e48b-4092-a176-c71eab29a73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_34488898-814f-44f0-b4d1-a0a04a174df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_96276faa-84fa-4b66-8fbb-fab1f386524e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_34488898-814f-44f0-b4d1-a0a04a174df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b6017d54-7a16-4389-bc96-df11c9ca04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b6017d54-7a16-4389-bc96-df11c9ca04dd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b444c0fd-401d-44d5-9a90-b8da939ccb4e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_c775ace7-86ce-46f9-9b79-774f336b81b6" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:to="loc_cmps_PrefundedWarrantsMember_c775ace7-86ce-46f9-9b79-774f336b81b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_de7277e3-3806-4091-a59d-f268268f7ccf" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3083d127-a572-4313-962d-e5d06dea6e99" xlink:to="loc_cmps_A2025ADSWarrantsMember_de7277e3-3806-4091-a59d-f268268f7ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c2d0273-4ccf-4428-a36a-de5400e63c33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a8c0e207-560c-4e26-bb7c-f0626332af65" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c2d0273-4ccf-4428-a36a-de5400e63c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c2d0273-4ccf-4428-a36a-de5400e63c33" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_578aaf14-07a9-4029-89eb-a549ec697a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_578aaf14-07a9-4029-89eb-a549ec697a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7e52faa5-8817-4a41-ac21-2bba4de95d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_7e52faa5-8817-4a41-ac21-2bba4de95d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_32aea2c5-a49b-4ba5-8940-9a830de3a2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_32aea2c5-a49b-4ba5-8940-9a830de3a2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7cca65ff-0244-43cb-9e3b-8fbd9f481240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b6f160b-cb50-4d13-abcc-d6e3deff859e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_7cca65ff-0244-43cb-9e3b-8fbd9f481240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_604dcf40-a17d-49d0-80d6-f5b2a6557c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_604dcf40-a17d-49d0-80d6-f5b2a6557c9e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_361d989c-51c1-45c0-b977-d7ad09bd3511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6c27b740-5a6e-483c-aae1-c4b375073ea8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_361d989c-51c1-45c0-b977-d7ad09bd3511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_4dabf769-36da-4119-999c-3297640e55da" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_361d989c-51c1-45c0-b977-d7ad09bd3511" xlink:to="loc_cmps_PrefundedWarrantsMember_4dabf769-36da-4119-999c-3297640e55da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2d994392-530a-41f7-8e9f-9c09459e1982" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_fb7898e5-d3cb-4b48-8b31-c68be0a1e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_fb7898e5-d3cb-4b48-8b31-c68be0a1e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GainLossOnIssuanceOfWarrant_e3730471-5bef-490b-b919-e0e9aea4475d" xlink:href="cmps-20250331.xsd#cmps_GainLossOnIssuanceOfWarrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_cmps_GainLossOnIssuanceOfWarrant_e3730471-5bef-490b-b919-e0e9aea4475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GainLossOnFairValueOfWarrants_57dca6d3-3cd2-4019-b136-c3fcdd9d44ee" xlink:href="cmps-20250331.xsd#cmps_GainLossOnFairValueOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c3101af1-1d03-4127-b1c1-70e32eda33dd" xlink:to="loc_cmps_GainLossOnFairValueOfWarrants_57dca6d3-3cd2-4019-b136-c3fcdd9d44ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d91182bb-1af8-4b83-bb3d-019d87cef959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d91182bb-1af8-4b83-bb3d-019d87cef959" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3bf0bbc8-8dd6-4cb5-9ca1-ba3ca98e9ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ad1ad4c5-f589-4e1b-826d-2f3e837861e6" xlink:to="loc_us-gaap_ClassOfStockDomain_3bf0bbc8-8dd6-4cb5-9ca1-ba3ca98e9ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AmericanDepositarySharesMember_54ba85f9-9acc-4f29-b018-e1fe1b86cc00" xlink:href="cmps-20250331.xsd#cmps_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3bf0bbc8-8dd6-4cb5-9ca1-ba3ca98e9ba7" xlink:to="loc_cmps_AmericanDepositarySharesMember_54ba85f9-9acc-4f29-b018-e1fe1b86cc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90cb50ce-5e52-4a0c-b763-04649bb81002" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7168ac29-2dd9-4071-a99c-c73cc9556f83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_us-gaap_IPOMember_7168ac29-2dd9-4071-a99c-c73cc9556f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_AtTheMarketOfferingMember_6eb151df-b80b-405e-a66e-fc03a4958d92" xlink:href="cmps-20250331.xsd#cmps_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_cmps_AtTheMarketOfferingMember_6eb151df-b80b-405e-a66e-fc03a4958d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b574c199-4e28-462a-b117-4e295d7ac937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_us-gaap_PrivatePlacementMember_b574c199-4e28-462a-b117-4e295d7ac937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnderwrittenOfferingMember_e344bc0a-2594-48d6-9c31-dfb06fefac3e" xlink:href="cmps-20250331.xsd#cmps_UnderwrittenOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad9bfb37-fb5a-48b9-ad6b-4ace6d8b5596" xlink:to="loc_cmps_UnderwrittenOfferingMember_e344bc0a-2594-48d6-9c31-dfb06fefac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b63a7c89-0795-4f8d-969b-fbc9a185a110" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_65a0f4e3-afea-4fbf-97a9-48b183fd8d09" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b63a7c89-0795-4f8d-969b-fbc9a185a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_HerculesCapitalInc.Member_5a58c592-bd29-437f-85cd-adadcf59e8f7" xlink:href="cmps-20250331.xsd#cmps_HerculesCapitalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b63a7c89-0795-4f8d-969b-fbc9a185a110" xlink:to="loc_cmps_HerculesCapitalInc.Member_5a58c592-bd29-437f-85cd-adadcf59e8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13b3eb8f-1d58-43b0-9d8a-1d8be9f92aff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PIPEWarrantsMember_a3ba00f6-af3f-4361-9aa7-0264154dfa24" xlink:href="cmps-20250331.xsd#cmps_PIPEWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:to="loc_cmps_PIPEWarrantsMember_a3ba00f6-af3f-4361-9aa7-0264154dfa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2025ADSWarrantsMember_61809a16-5db9-45ba-a557-76e1c4461304" xlink:href="cmps-20250331.xsd#cmps_A2025ADSWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:to="loc_cmps_A2025ADSWarrantsMember_61809a16-5db9-45ba-a557-76e1c4461304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PrefundedWarrantsMember_391b1167-987b-47eb-a88e-7fa477e3a28b" xlink:href="cmps-20250331.xsd#cmps_PrefundedWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_884f5c10-3553-4e77-a04e-d3600e929272" xlink:to="loc_cmps_PrefundedWarrantsMember_391b1167-987b-47eb-a88e-7fa477e3a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5524a259-a317-4c4a-b880-e355a81be896" xlink:to="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SaleOfStockAmountAuthorized_8876cec0-1c76-45a1-8a32-1d9261280fc9" xlink:href="cmps-20250331.xsd#cmps_SaleOfStockAmountAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_SaleOfStockAmountAuthorized_8876cec0-1c76-45a1-8a32-1d9261280fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfOrdinarySharesConversionRatio_b812f563-4658-4a55-afbd-c5100543f950" xlink:href="cmps-20250331.xsd#cmps_NumberOfOrdinarySharesConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_NumberOfOrdinarySharesConversionRatio_b812f563-4658-4a55-afbd-c5100543f950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a488f72b-98a9-4327-9d65-c0dae2d9f59f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a488f72b-98a9-4327-9d65-c0dae2d9f59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_435b725a-653c-458a-84bb-761476a3272d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_435b725a-653c-458a-84bb-761476a3272d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_7616405f-23a4-49c4-9400-a01090fb672e" xlink:href="cmps-20250331.xsd#cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances_7616405f-23a4-49c4-9400-a01090fb672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_60c404df-f03c-4ea7-8fd6-af226183c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_60c404df-f03c-4ea7-8fd6-af226183c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableNumber_ee16f198-8f26-4f2c-85ac-35840993634b" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_OptionsExercisableNumber_ee16f198-8f26-4f2c-85ac-35840993634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsExercisableFairValue_c42bf4a0-5974-43a5-8406-9f11b99250ab" xlink:href="cmps-20250331.xsd#cmps_OptionsExercisableFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_OptionsExercisableFairValue_c42bf4a0-5974-43a5-8406-9f11b99250ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29183def-926f-450a-ab7a-cfcd3a86ee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29183def-926f-450a-ab7a-cfcd3a86ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8615f4aa-73a1-429e-8340-133a02d2434d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8615f4aa-73a1-429e-8340-133a02d2434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb7670bc-c4dc-4e0d-9f00-33141caaaa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bb7670bc-c4dc-4e0d-9f00-33141caaaa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_c2b5e623-0572-49a4-94d3-100ea84620a1" xlink:href="cmps-20250331.xsd#cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_c2b5e623-0572-49a4-94d3-100ea84620a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6720ffea-aad6-4c63-b86a-363d4c500efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6720ffea-aad6-4c63-b86a-363d4c500efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ee3e2455-81fa-44ed-95ef-502bce31e87c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f03a70cb-9622-4f40-86c8-18d42a300af3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ee3e2455-81fa-44ed-95ef-502bce31e87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2017EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00abf924-c80f-4ad4-8d3d-d56a416fab61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00abf924-c80f-4ad4-8d3d-d56a416fab61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0c6a582e-efcd-403e-b8f5-6b29b0052780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29207d7d-c74a-44a7-928e-6210006953fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29207d7d-c74a-44a7-928e-6210006953fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ab616010-6e36-4ecf-a1ff-38e10a39d939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f66075f6-b997-44ab-9450-708a4d2b63c4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ab616010-6e36-4ecf-a1ff-38e10a39d939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_03bb7384-167f-4177-befc-a9a497ab492c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e39e9cfb-2ad4-46c8-aca6-e2c9735ce2f6" xlink:to="loc_us-gaap_PlanNameDomain_03bb7384-167f-4177-befc-a9a497ab492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2017EquityIncentivePlanMember_0cdd6f1d-361c-41f0-9946-0cdae0d2c203" xlink:href="cmps-20250331.xsd#cmps_A2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_03bb7384-167f-4177-befc-a9a497ab492c" xlink:to="loc_cmps_A2017EquityIncentivePlanMember_0cdd6f1d-361c-41f0-9946-0cdae0d2c203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0e216fec-ebb6-415c-a726-1df59b4d68e6" xlink:to="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8d3ecbb9-305b-453f-b71f-ceb5fe25a8a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:to="loc_srt_MinimumMember_8d3ecbb9-305b-453f-b71f-ceb5fe25a8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2834aba-f844-451b-bf60-c9270374ae6b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f4d3aafe-ca11-4624-b47e-2514be9139d9" xlink:to="loc_srt_MaximumMember_e2834aba-f844-451b-bf60-c9270374ae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_ed4d4d63-2119-44b9-9c6a-4af17b1a2583" xlink:to="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9f1785e-2442-466a-8d25-f7efeaa5dfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9f1785e-2442-466a-8d25-f7efeaa5dfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_863de968-20d3-48cd-bcf5-ac639a85c97b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_844ee42a-fa63-4f9c-9063-dc56ab6eb802" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_863de968-20d3-48cd-bcf5-ac639a85c97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_ffa2324f-cd02-4aac-81d2-d4164878f512" xlink:to="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OptionsGrantedBeforeJune302020Member_1a44e773-2312-4128-9426-f72e0aec3780" xlink:href="cmps-20250331.xsd#cmps_OptionsGrantedBeforeJune302020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:to="loc_cmps_OptionsGrantedBeforeJune302020Member_1a44e773-2312-4128-9426-f72e0aec3780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_GrantDateJune302020Member_6ef9c92b-0ade-4fa4-a81d-d9d2be153546" xlink:href="cmps-20250331.xsd#cmps_GrantDateJune302020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_7b56d3e0-065a-40e4-96df-cab041d3bd6c" xlink:to="loc_cmps_GrantDateJune302020Member_6ef9c92b-0ade-4fa4-a81d-d9d2be153546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5807d3aa-9b8c-4628-b642-f3425c5d021c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b7474fa4-7151-468c-b61d-f4088ee53694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b7474fa4-7151-468c-b61d-f4088ee53694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e1109d32-5a49-4f8f-b8a3-247daa1a3d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e1109d32-5a49-4f8f-b8a3-247daa1a3d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76eec57e-85cf-41a1-9ee1-5af1c5c81319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_76eec57e-85cf-41a1-9ee1-5af1c5c81319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_1628aa33-b130-4afc-bbef-e456ce79b7c8" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice_1628aa33-b130-4afc-bbef-e456ce79b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_57b249aa-3bf9-41ad-88a6-2f684356a072" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_57b249aa-3bf9-41ad-88a6-2f684356a072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05376e9d-faf9-4fdd-8966-e8f4a7f45f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07239b52-e96b-481e-b6b8-4c7c8fcd2f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_05376e9d-faf9-4fdd-8966-e8f4a7f45f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9511d3ea-27e4-45a5-9db2-756128ee99a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9511d3ea-27e4-45a5-9db2-756128ee99a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:to="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50002c83-1bbe-45ca-97d3-8c79058a8413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ce801791-2254-4aa1-9d4d-89834761b0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50002c83-1bbe-45ca-97d3-8c79058a8413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b69c8b3c-d98d-4f59-a95b-77582c2aa91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50002c83-1bbe-45ca-97d3-8c79058a8413" xlink:to="loc_us-gaap_EmployeeStockMember_b69c8b3c-d98d-4f59-a95b-77582c2aa91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6686ebb9-0c0e-46a9-9776-9ae6667704f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_844dd9e7-6b1f-4a75-a74c-ec661cab2f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_844dd9e7-6b1f-4a75-a74c-ec661cab2f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_5f437774-fd35-4c7f-b23f-2d366d213b21" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum_5f437774-fd35-4c7f-b23f-2d366d213b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_c9fdb33f-f12d-42d9-8125-a6ceb09a1f12" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance_c9fdb33f-f12d-42d9-8125-a6ceb09a1f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_7a9a9eb5-8cda-45d5-a524-56d1bade6ff6" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod_7a9a9eb5-8cda-45d5-a524-56d1bade6ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48a00214-4bf4-4956-a35d-e449f1db525d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ba92696-e8b6-40c1-bcea-226ce47eb229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48a00214-4bf4-4956-a35d-e449f1db525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2020ShareOptionPlanDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0fe748f-07e9-4d14-b904-305c0cc45b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0fe748f-07e9-4d14-b904-305c0cc45b3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a2510785-d1d8-4988-a1e2-d11eb558000b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b629c88e-d2e4-43df-96d7-3eb835e09dd6" xlink:to="loc_us-gaap_PlanNameDomain_a2510785-d1d8-4988-a1e2-d11eb558000b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2020ShareOptionPlanMember_ccb482ad-475d-4090-a654-390183c9b2ea" xlink:href="cmps-20250331.xsd#cmps_A2020ShareOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a2510785-d1d8-4988-a1e2-d11eb558000b" xlink:to="loc_cmps_A2020ShareOptionPlanMember_ccb482ad-475d-4090-a654-390183c9b2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a4ab82e-baaa-48a5-938e-4146a9ed2d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c528bc55-9e2b-4f40-a29d-38249ff0d39a" xlink:to="loc_us-gaap_ClassOfStockDomain_8a4ab82e-baaa-48a5-938e-4146a9ed2d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_25e7be9f-8ac1-4a07-9e37-96a84723d319" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a4ab82e-baaa-48a5-938e-4146a9ed2d24" xlink:to="loc_cmps_OrdinarySharesMember_25e7be9f-8ac1-4a07-9e37-96a84723d319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_813e519e-dff0-4321-b98d-45833a68e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_db9ac54d-e9ff-4065-b97d-0be27b263f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_813e519e-dff0-4321-b98d-45833a68e4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3478686c-4e5b-4226-b9bc-26530266d281" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_813e519e-dff0-4321-b98d-45833a68e4b0" xlink:to="loc_us-gaap_EmployeeStockMember_3478686c-4e5b-4226-b9bc-26530266d281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9fdb08aa-bb27-499b-ab8c-2b2aa3491eea" xlink:to="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_135ecf37-c5c3-47ae-b551-e751deab0225" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionOneMember_135ecf37-c5c3-47ae-b551-e751deab0225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_e79e086d-dcbf-48d7-8fe7-1d723991b658" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionTwoMember_e79e086d-dcbf-48d7-8fe7-1d723991b658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_cd09e687-5eb8-46d7-b6b3-18af29c025af" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionThreeMember_cd09e687-5eb8-46d7-b6b3-18af29c025af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_773efb93-403d-495b-969e-a32192890c38" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionFourMember_773efb93-403d-495b-969e-a32192890c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_9b2b357d-6e69-4fa2-aa21-ac21e3726ce1" xlink:href="cmps-20250331.xsd#cmps_ShareBasedPaymentArrangementVestingConditionFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7d3582c4-987d-449b-b667-ebb5f5de05ce" xlink:to="loc_cmps_ShareBasedPaymentArrangementVestingConditionFiveMember_9b2b357d-6e69-4fa2-aa21-ac21e3726ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85ec0a59-b983-463d-a857-8877ff6f7a52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2b4b4c5a-e0cd-4246-b377-677465e875b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2b4b4c5a-e0cd-4246-b377-677465e875b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfdf6e00-22e3-4a6c-b4e7-24d8213d84e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfdf6e00-22e3-4a6c-b4e7-24d8213d84e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ad309dcd-e474-4864-9b05-b5ddb929cf82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ad309dcd-e474-4864-9b05-b5ddb929cf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e8d90159-cce5-49fe-a00f-9530bbbf4960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e8d90159-cce5-49fe-a00f-9530bbbf4960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_ffbf9e53-b8ab-438b-804d-6ad19f7efa93" xlink:href="cmps-20250331.xsd#cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease_ffbf9e53-b8ab-438b-804d-6ad19f7efa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_fbadacbe-622f-450e-a080-0516923e922f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_SharesIssued_fbadacbe-622f-450e-a080-0516923e922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_61fbfcc7-e794-43c7-ae3b-0b78c66f4665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_61fbfcc7-e794-43c7-ae3b-0b78c66f4665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NumberOfVestingConditions_18a8047c-61ec-4786-bfec-5c79e62d62a6" xlink:href="cmps-20250331.xsd#cmps_NumberOfVestingConditions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140b1bd2-139f-4aa8-9978-434a1e702578" xlink:to="loc_cmps_NumberOfVestingConditions_18a8047c-61ec-4786-bfec-5c79e62d62a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensation2022InducementGrantOptionAwardDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ce61009-2431-4116-a66c-b2bf457f84a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ce61009-2431-4116-a66c-b2bf457f84a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74ce166b-ac5b-44e8-a6c6-654a96b84243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c35cc49a-e6e9-45c4-a655-ab69d53a5255" xlink:to="loc_us-gaap_PlanNameDomain_74ce166b-ac5b-44e8-a6c6-654a96b84243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_A2022InducementGrantOptionAwardMember_4076b21e-1b39-457f-a407-80b3c91d6f3c" xlink:href="cmps-20250331.xsd#cmps_A2022InducementGrantOptionAwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74ce166b-ac5b-44e8-a6c6-654a96b84243" xlink:to="loc_cmps_A2022InducementGrantOptionAwardMember_4076b21e-1b39-457f-a407-80b3c91d6f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_492d1dd7-d551-473d-a3bf-cde1fcad7a99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4512725b-844c-4c3a-95c6-6f5f90a1866e" xlink:to="loc_us-gaap_ClassOfStockDomain_492d1dd7-d551-473d-a3bf-cde1fcad7a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_OrdinarySharesMember_ede0c2c6-cfc9-4a76-9d1a-dadbf3249d88" xlink:href="cmps-20250331.xsd#cmps_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_492d1dd7-d551-473d-a3bf-cde1fcad7a99" xlink:to="loc_cmps_OrdinarySharesMember_ede0c2c6-cfc9-4a76-9d1a-dadbf3249d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_01aaf8bb-39ff-4c76-94f3-2c7b0c15c9c7" xlink:to="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2ba3fbb2-8784-41df-b527-9b9f8621caf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2ba3fbb2-8784-41df-b527-9b9f8621caf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482d665f-339d-444c-b611-8bbd78e351c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_986817ad-e87f-4cdb-b802-54d9f5a0cc4d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482d665f-339d-444c-b611-8bbd78e351c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc37fc88-d58f-4152-9e5a-16634339f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d51f3949-03cc-47ac-a54a-0cf7b78931b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d51f3949-03cc-47ac-a54a-0cf7b78931b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d950858f-5f97-4e04-84e6-8e9de1cc112a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d950858f-5f97-4e04-84e6-8e9de1cc112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed89a632-b856-4285-961b-c1279187e42a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ed89a632-b856-4285-961b-c1279187e42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cbb58c34-ec45-4272-b1b3-736d874956f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf47053-2790-43b6-9677-96ae235c553d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cbb58c34-ec45-4272-b1b3-736d874956f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b17a1de9-013f-4b58-87bf-dfb358a7644b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b17a1de9-013f-4b58-87bf-dfb358a7644b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_547ae216-58e8-4955-967a-1d2f87f2acba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2beba2d5-6a99-4d67-a2f9-0d416c4fdd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2beba2d5-6a99-4d67-a2f9-0d416c4fdd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac4a690d-7c3f-4ca9-9c62-36b57d43fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a0b71ff-4b51-424e-847a-bc270a25a114" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac4a690d-7c3f-4ca9-9c62-36b57d43fb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b07fae-c890-431f-90c7-53347bb9e526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37ce4553-7118-4d4b-9eb2-ed555eac5d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b07fae-c890-431f-90c7-53347bb9e526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1d27c3f-dfff-4c16-bfc6-fb1eaa47153f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b07fae-c890-431f-90c7-53347bb9e526" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1d27c3f-dfff-4c16-bfc6-fb1eaa47153f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_479987b6-ac86-4f01-8e04-61c39c0235d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_479987b6-ac86-4f01-8e04-61c39c0235d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FairValueChangeOfPreFundedWarrantLiabilities_bdb8d55c-add8-4162-912d-722b5923f6f4" xlink:href="cmps-20250331.xsd#cmps_FairValueChangeOfPreFundedWarrantLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_cmps_FairValueChangeOfPreFundedWarrantLiabilities_bdb8d55c-add8-4162-912d-722b5923f6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_36ac981a-fd88-43a2-9d50-be31258bc5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_36ac981a-fd88-43a2-9d50-be31258bc5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee6cb8c8-b489-4e9a-af4e-b01f501d2ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee6cb8c8-b489-4e9a-af4e-b01f501d2ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_44b483e6-ae6e-4d29-9ed2-4a0e85f4aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_44b483e6-ae6e-4d29-9ed2-4a0e85f4aed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e35b448b-87c6-4727-8b82-94fcd88496ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e35b448b-87c6-4727-8b82-94fcd88496ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fab55d84-2e89-4962-b26c-e183167c631c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_EarningsPerShareBasic_fab55d84-2e89-4962-b26c-e183167c631c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d32e97c7-792b-4854-825c-827d80148743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8687883d-34a1-48d7-a95e-b854c0e336dd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d32e97c7-792b-4854-825c-827d80148743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4d8d6455-dccb-436b-b585-97b53186bbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4d8d6455-dccb-436b-b585-97b53186bbf7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_14f671fa-b6da-4757-94bb-16af7f8b9c99" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_UnvestedRestrictedShareUnitsMember_d266a5d0-e026-4145-a739-f77c03330f84" xlink:href="cmps-20250331.xsd#cmps_UnvestedRestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:to="loc_cmps_UnvestedRestrictedShareUnitsMember_d266a5d0-e026-4145-a739-f77c03330f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ShareOptionsMember_53c22a65-17ac-419b-8b6d-5b7d72908f63" xlink:href="cmps-20250331.xsd#cmps_ShareOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:to="loc_cmps_ShareOptionsMember_53c22a65-17ac-419b-8b6d-5b7d72908f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1f5b25c6-6966-4e0d-9e2e-02d5696bd475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4a2f0e-f1a0-42ec-8ca5-c3d52ca07d37" xlink:to="loc_us-gaap_WarrantMember_1f5b25c6-6966-4e0d-9e2e-02d5696bd475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd67eb11-e9cb-40ff-97a1-c5b57b054cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e7d157e9-45d8-45e2-a46c-6f37a1c1c314" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd67eb11-e9cb-40ff-97a1-c5b57b054cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f568e03f-2273-4e6c-a2a1-d44852d0980e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bd67eb11-e9cb-40ff-97a1-c5b57b054cc4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f568e03f-2273-4e6c-a2a1-d44852d0980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_567c6f9c-4f51-48a9-827c-f2ecf2aa5172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_18e82902-d44c-4baa-b747-133ef4aab596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_567c6f9c-4f51-48a9-827c-f2ecf2aa5172" xlink:to="loc_us-gaap_NumberOfOperatingSegments_18e82902-d44c-4baa-b747-133ef4aab596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_567c6f9c-4f51-48a9-827c-f2ecf2aa5172" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:to="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_ba4550d2-ac16-40ed-9d34-bfb7b5eec00a" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_DevelopmentExpensesMember_ff2ae086-9c61-4a58-865e-a5182fd2c1b8" xlink:href="cmps-20250331.xsd#cmps_DevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_DevelopmentExpensesMember_ff2ae086-9c61-4a58-865e-a5182fd2c1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_PersonnelExpensesMember_5f843b1e-962d-4ad8-abf3-50fb7e77057d" xlink:href="cmps-20250331.xsd#cmps_PersonnelExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_PersonnelExpensesMember_5f843b1e-962d-4ad8-abf3-50fb7e77057d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_LegalAndProfessionalFeesMember_786a6a86-22a2-4bd9-8b76-4bbd1d7afef4" xlink:href="cmps-20250331.xsd#cmps_LegalAndProfessionalFeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_LegalAndProfessionalFeesMember_786a6a86-22a2-4bd9-8b76-4bbd1d7afef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_NonCashShareBasedCompensationExpenseMember_f76820c8-9f46-419b-8fc8-288e1141fd6e" xlink:href="cmps-20250331.xsd#cmps_NonCashShareBasedCompensationExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_NonCashShareBasedCompensationExpenseMember_f76820c8-9f46-419b-8fc8-288e1141fd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_FacilitiesAndOtherExpensesMember_69730768-fb0e-4a66-9dc8-72ff68e225c6" xlink:href="cmps-20250331.xsd#cmps_FacilitiesAndOtherExpensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_b60fbd73-5750-45ad-84ce-34c8b7285909" xlink:to="loc_cmps_FacilitiesAndOtherExpensesMember_69730768-fb0e-4a66-9dc8-72ff68e225c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b02e0ab1-756d-43fe-a2dd-d41ec66a942d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c09f6f04-433b-48e4-a940-695877e924e9" xlink:to="loc_us-gaap_SegmentDomain_b02e0ab1-756d-43fe-a2dd-d41ec66a942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_SingleOperatingSegmentMember_9ba5ee7f-897b-4da1-8dc4-22989259a7f7" xlink:href="cmps-20250331.xsd#cmps_SingleOperatingSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b02e0ab1-756d-43fe-a2dd-d41ec66a942d" xlink:to="loc_cmps_SingleOperatingSegmentMember_9ba5ee7f-897b-4da1-8dc4-22989259a7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a12c90fc-6d4b-49b1-b0a6-226cd70ce3cd" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ea01430b-a69d-47b9-a0c0-50d771cbb813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ea01430b-a69d-47b9-a0c0-50d771cbb813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0bbda10-9735-423f-8d04-c201f57eeeed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0bbda10-9735-423f-8d04-c201f57eeeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_655acd56-5dc4-4b85-b6e8-55a90874d212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_OperatingExpenses_655acd56-5dc4-4b85-b6e8-55a90874d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1aeb599a-0478-4d81-8126-b0cb27b7f049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_OperatingIncomeLoss_1aeb599a-0478-4d81-8126-b0cb27b7f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1c5b5213-e9bc-4fcc-9b14-d615afe421f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1c5b5213-e9bc-4fcc-9b14-d615afe421f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_448171ec-2844-46ee-b2eb-384b2f66bccd" xlink:href="cmps-20250331.xsd#cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit_448171ec-2844-46ee-b2eb-384b2f66bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3fdfe845-e6e3-492d-ab1e-ede00bf8d817" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3fdfe845-e6e3-492d-ab1e-ede00bf8d817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_439f2cb5-db4b-4384-845b-0feff5f25ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_439f2cb5-db4b-4384-845b-0feff5f25ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_886e374f-9911-42f8-aa58-ed154050c4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_886e374f-9911-42f8-aa58-ed154050c4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5b9e1a72-0c9c-42c2-9d42-9645fdf6a361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5b9e1a72-0c9c-42c2-9d42-9645fdf6a361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_539a6978-2379-4ce8-ad6b-296b0f3bc5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_539a6978-2379-4ce8-ad6b-296b0f3bc5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5050833e-132e-4550-90f4-1ccd6640fcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_198ba8b3-fdc3-48c4-8ee0-fa9e805b064f" xlink:to="loc_us-gaap_NetIncomeLoss_5050833e-132e-4550-90f4-1ccd6640fcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://compasspathways.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="cmps-20250331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bbe6fbd7-8eab-424a-874c-130a8400fab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c087a62f-87fc-4df8-b368-462f649d289f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bbe6fbd7-8eab-424a-874c-130a8400fab6" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c087a62f-87fc-4df8-b368-462f649d289f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>guyaragreement001.jpg
<TEXT>
begin 644 guyaragreement001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOGC6=:2^^(
MNOV'C7Q;KOAY()RFF1V3-'"8\G:QV@YR-ISQU//:N[\.^'==\1> (K#4O&LD
MQ2[\VVU71KLF26(*0$=\#)R3GKT'I0!Z917@'@[PSK'B3Q9XKTBX\<^)XHM&
MN5AA>._;=("SC+9/^P.GK4GB.Z-Y\:-:TC5/'&I:!I<%G%)$T6H&%3)LB^4
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MUM>.HM9TSXK>&/$5EX>U+5;:QT]DE6SA+?,PD7&<8!^8&NF_X5@?^A[\;?\
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M\'-<M/"*M8>*-1U272@LEC8&$  J1]S!)!QG&.N*[G_A6!_Z'OQM_P"#8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6-R)(761";IS@@Y'>NN\3>&-,\6Z0=+U>)Y+4R+(51RAR.G(^M &K#_J(_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,%Q+>7&QI'!((5<C'*G'7IVZ4 >I45S/@7Q7+XOT WMUID^FW<4IAGMY0>&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***I7^L:=I<UK#?7L%M)=R"*W65PIE<X
M&U?4\C\Z +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M0EN(--NIK5(
MGN$B9HEF?8A8#C<W89ZFK-9/BC1/^$C\+ZEHPN&MS>0-$)5&=I/MW'J/2@#Q
M^/XG^)-,\0Z)#>>(/#^K"_NT@NK'3TW?9@S 9$@X)&?4_CUKH'\3^-];^(?B
M7PQH=SIEK#IZQO'<7,)8H"H.W ZDD]3T /6J"_"OQ9/I>@65UJFAQPZ'=130
M16MNZ^>%/WI&_O\  ' [DGFNTT'P==:3\0_$?B26YA>WU58ECB4'<FT '/;M
M0!Q=K\7M4B^$%UXBO+6W?6(+XZ<@4$1O)@$,1GL"> >2.V:R/&,7C&W\3?#]
M/%-SI]T)-7AD1[6,HT3[X]R-V(Z8(]#[5TUG\()&^&^J^%]0U"(SW6H-?6]Q
M"I(B;"A<@XST(/L:;<?#SQKKFI^'+_Q#XATZ=M&O(YEB@A90Z*REF)QRYV@=
M !^- 'K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6-U;:W:17-O]D:W?<[NSD<XP/O8.2.AH VK?QAXXO_@Y9>+["\BFOK6>5[V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<?\ Q%;=% &)_P )7I7_ $__ /@NN/\ XBC_ (2O2O\ I_\ _!=<?_$5MT4
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MZ5_T_P#_ (+KC_XBC_A*]*_Z?_\ P77'_P 16W10!B?\)7I7_3__ ."ZX_\
MB*/^$KTK_I__ /!=<?\ Q%;=% &)_P )7I7_ $__ /@NN/\ XBC_ (2O2O\
MI_\ _!=<?_$5MT4 8G_"5Z5_T_\ _@NN/_B*/^$KTK_I_P#_  77'_Q%;=%
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M*/\ A*]*_P"G_P#\%UQ_\16W10!B?\)7I7_3_P#^"ZX_^(H_X2O2O^G_ /\
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M^(H_X2O2O^G_ /\ !=<?_$5MT4 8G_"5Z5_T_P#_ (+KC_XBC_A*]*_Z?_\
MP77'_P 16W10!B?\)7I7_3__ ."ZX_\ B*NZ?J]IJ9D%M]HS'C=YMM)%U]-Z
MC/3M5ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **"0!D
MG I%96&5((/<&@!:*** "BBB@ HHHH **** "BD+!02Q  [F@$$9!R#W% "T
M444 %%%% !1110 44A=0P4L QZ#/)I: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/Q;X&T3QJMD-8BE?[&Y>,QOM/.,J?4' X]JZ2B@!  J@   < #M6-HGA?3M
MO]6O;+SO-U6X-S<>8^1OY^[QP.36U10!Q>N_##0-;U=]7CDO]*U*3_6W6F7)
M@>3_ 'N""??&35GPQ\/-"\+7TNH6RW-WJ4HVO?7TQFF(],G@?@*ZNB@#C/$?
MPRT/Q-KIUF\GU&&\,*PEK6Y\L;1VX%9O_"F/#_\ T%/$'_@Q;_"O1:* (X(E
M@MXX5+%8U"@L<D@#'-9&D>%=.T76M6U>V\Y[W59%>XDE?=]W.%7C@#/3V%;=
M% %35--M=9TJ[TV]3?;7430RKT)5A@X]#[UGV'A72K'PK'X:>)KS3$C,7EW9
M$A*9R >.W;TP*VZ* /.&^"OAY-T=GJ>OV5FQ)-G;:@1%],$$_K75^&O"&A>$
M;-K;1=/CM@^/,DY:20_[3'D_3I6Y10!B^&?"^G>$M-EL-,\[R99WN&\U]QW-
MC/..G%1>*?!VE>+H;-=269);.83V\]O)LDC;V;\OR'I6_10!Q_B;X;Z+XLU6
MWU/4)]0CN[> 6Z26UQY9VY)YP.N6-97_  ICP_\ ]!3Q!_X,6_PKT6B@#D]>
M^'FC>(]*TG3[Z6^$>EJ!;R13[9.%"Y+8Y/ YK&_X4QX?_P"@IX@_\&+?X5Z+
M10!R<_P]T:Z\(0^&;B6^EL89A,KR3[I2P8MRQ'(R:N>+/!FC>-+2UMM8BD>.
MVF$T?EMM.<8(/L>X]A7044 8VO>&-.\1/IC7PE!TV[2\MQ$VT>8G3/'(]JRO
M%/PZT7Q=JMOJ6H37\5U;Q>3&]K<>7A<D^GN:ZZB@#SK_ (4QX?\ ^@IX@_\
M!BW^%='<^"]+NT\/K.]TYT)T>T8RY8E0 "YQ\W05T5% $5S;07EK-:W,2RP3
M(8Y(W&0RD8(/X5B^$O!^E>"M*ETW2!,+>6=IR)GWD,0HX/IA16_10!BZMX7T
M[6=<TC5[OSOM6DN[VVQ\+EP =PQST%;5%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!0N-#TF\G:>YTNRGF;&Z26W1F/;DD5%_PC6A?] 33?\ P%3_
M  K4HH R_P#A&M"_Z FF_P#@*G^%'_"-:%_T!--_\!4_PK4HH R_^$:T+_H"
M:;_X"I_A1_PC6A?] 33?_ 5/\*U** ,O_A&M"_Z FF_^ J?X4?\ "-:%_P!
M33?_  %3_"M2B@#+_P"$:T+_ * FF_\ @*G^%'_"-:%_T!--_P# 5/\ "M2B
M@#+_ .$:T+_H":;_ . J?X4?\(UH7_0$TW_P%3_"M2B@#+_X1K0O^@)IO_@*
MG^%'_"-:%_T!--_\!4_PK4HH R_^$:T+_H":;_X"I_A1_P (UH7_ $!--_\
M 5/\*U** ,O_ (1K0O\ H":;_P" J?X4?\(UH7_0$TW_ ,!4_P *U** ,O\
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M_A&M"_Z FF_^ J?X4?\ "-:%_P! 33?_  %3_"M2B@#+_P"$:T+_ * FF_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16#KOBBWT74M+T_
MR'N+F_N$BVH<"%&;;YC'TR0 ._/H<++XFB3Q=;>'TL[AGECD=[ED*QJ556V@
MD?.<,,XX'UXH W:*YN+Q/<C6[6RO=):T@O9)H[:1IP9#Y89BSQX^12%)!R>H
MR!FH_"GBN?Q.!.MC:PVCPB562_664!L%0\84%<@YY- '445A>)/$T7AV.UW6
M=Q<R7$\<0$2':@:14W.^,* 7''4GIW(J:MXNETZ[U3R=,-Q9:1$LNH3F<(R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 </KW@G4+S4_M]AKEVCS:A;W$L;)"1&D?3:2A/RC)
M"DXR3ZFM^_TVXN/%&C:A&%\BTCN%E)/.7"!<#O\ =-;-% '$7&AZWJ6O6=U<
M:?IMK=6DLGF:G$V?M,!5PD13[Q!W*65C@%3C/&([#PQJ%UJ-A+/I]KH*V5E)
M:O)I<H!F9]GW,+\J#:2-W.2..I/=T4 <[K&@W,_A5-+MKF:ZE2YMY?-NY,NR
MI<)(V6QV52!QV%8OB[PG>:Y?:A';V*>7J%LMNUTE[)$%Z@F:('$I4'*\<]#@
M5WE% '"/X$OK77=+N['7+MH(M2>\G25(25!A=!@[,G@JF">%Z<@&E_X1O4;O
M4;"*32M.T];._DNVU&Q(1I58. %7&X,V\;LG'!ZY&.ZHH Y;4_#-S-H*Z1%?
M75[#<7L+W;WLP9O(#*70$ <$+C'^T:=XATZ]GU%IH- TO5(I;-K?,Y"2QL23
MAF(.8SGD#D$=\\=/10!YO<?#G5(M)M([7Q#=O=H=/27<D17;;O&25+(6&-K.
M%S@L><Y-3:AX1U*?6+R465M/=SWL4]MK;R@36D2[,H!C(QM<!5.UMYSC)KT*
MB@"G87<]W]J\ZT:W\FX:*,EL^:HQAQP.N3^74US6A>&K_1M7U&Z=8I[>UBDB
MT>$/MPDCF5U8X^7YMB#KA8Q78T4 4;YM4.CL^GQVRZCL5EBG8F/.064L.>1D
M!L<'!P>E8OA;1KG3]3U6]:P@TNTN_*\O3X'#*KKNWRG: H9MRCC^X">37444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>guyaragreement002.jpg
<TEXT>
begin 644 guyaragreement002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:WC5O[1F=C+AN"N6.,9.?J* /;Z*^;[GQ+J$7@6S\):U*RZMI^H64MO)N/\
MI%HYRC ]\9"G\.X-=+\3O!6B6_B;PW<Q0W"R:SKB17I%U)B17/S #=A>O;%
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M36J74:&+,+NRALR*.JD'C.?PK'U+Q5XD_M#Q-'I=EIAMM"VLS7+ONG!A64J
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MLP(W9.[.>E7_  _X>N=)U#5-0O=3-_=:BT;2$0B)4V+M 503@8]23[FM^B@
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MZ[&D,2EF7I@G&<>U9[: 9O$\.L7-Z\L5K&R6=IY:JD#, K/D<L2!@9Z GUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH;5GAM20"0[#N 03C..^*?JWC33M.N)[6..\NY88!/.]G;F9+=&!*LY'K@G
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MS(09L;?WF.QX.> #VA65E#*00>X-+7FOAOQ%J>HZ9H.C:'!ING3W%E->S2-
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MW7V2V< [I'11YI)SC <[1@?PF@#<HHHH **** "BBB@ HHHH **** "BBB@
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M%U):0C!4QXV>7@XV8P.O7FKOA_PZFB/?W,EW+>7VH3":YN)$5-Q"A5 50
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MB]U1I[4VB%@D(B0L&W*$ &_<JG<?[HQBNMK/U#6+;3;[3+.=9#)J,[00E "
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MUMM'+#:PQS3F>5$"O,RA3(0.6(' SUP.*YZU\<:9=VLMTL-W';P7L=E-)(@
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MAG1O[ \-V&F%_,D@B'G2?\])3\SM^+%C^-:U% !1110 4444 %%%% !1110
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M;2=-N;%;&?3[66S3&VW>%6C&.F%(Q3X]-L88WCBLK=(Y$$;JL2@,H& I&.0
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MIUC-;36TME;R03,7EB:)2LC'J6&,$_6B'3K&WB@B@LK>*.W),*)$JB,D$94
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MDD_B: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+>QS;5W2,KNVTCICYS^5=/KVBVWB#1YM.NGDC1RKK+$</&ZL&5U/J& -:5%
M'*Q^#9;BXN+O6-9GU&[>RDLH9#"D2P1R8WE57JQP,D^F.*W;#3_[-T.UTV"8
M_P"C6R6\<K*"?E4*&(_#.*NT4 <EI_@.UTF?3[RPO9H]1M_,%S=,H9KWS.7\
MWU^;##TQ@<4ECX#MM-GL+VSOITU2"262XO64,UYYG+B4<9&0I']W:,5UU% '
M)6/@.UTVXL+ZUO9UU2":26YO64%[SS/OK(.X)"X_N[1BBT\!VME<65_#?3_V
MO#=27$]^5!>Z\S[Z..FP@* !]W8N.E=;10!R,'@.VM[BVU!+Z?\ MF.]:[EU
M J-\^_AHV'3RRH50HZ;01S0G@*V2=-1%]/\ VTM\;UM1VC>^?E,1'_//9A=O
ML#UKKJ* .1B\!VT,\.H+?3_VTEZUX^HE1OEW?*T1'3R]@"[>VT$<U>\9:5<:
MIH.;) ]_93Q7UJA.-\D3A@O_  ( K_P*N@HH Y/6?"B^);G^TDO[JQ%YI<EA
M<0M"N7BD!(R&&592V?PQ6E+X;@EO-"N&F?.D*ZHN!B0-'Y9S^'-;5% '(6'@
MB?3UM;*#Q#?KHMI,)8;% JL #N$9E'S&,'^'TX)(KKZ** ./\6>!#XEUW3=9
MM];O-+O;"-XXI+95)P_7K[9'XU5D\ :K<Z+J&EWGC;5KF*^18W:1$W(F3N"X
M'&X<'VKNJ* .)TSX9:/HUWJ:6$DL6DZG:"UNM,ZQMA=N\'J&QG)[Y)^CO#W@
M&XT*\LC+XIU:]T_3XVBM+%RJ1JI&,2;0/,P.F>E=I10!YY9?"F"PN;>"#Q#J
MBZ%;W?VR'2E90BODG&\#<4R3\O\ 7FDU/X4Q7]SKHA\0:A::?K3F:ZLHE0JT
MO][<1G&><#&>YQQ7HE% '&3_  _0ZSX=U6SU>YM+C1[5+,[8U87$*XRK9Z9P
M<D>M+:?#K3K?P?K/AN6XEGMM4GFG=V4!HV?!&/\ =(!'TKLJ* .-A^&VCI\/
M#X-E>:2T;+-<9 E,F_?YF?7./P&*N>'?"U_H^H37VI>)M2U>9X1 B3D1Q(H.
M<[%X+?[1YKIJ* ,#QG!=W_AFYTJQC=I]2'V/>JY$2/P[L>P";C[G ZFM"TTZ
M2SNP8[R3[$ELD$5H57;&5S\P.,DD8&,XXJ_10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <1\2O&6H>$],L8M$M8KO6;^<QV\$JE@552SM@$$X&
M!U[T]/B)8I\+(_&TJ;H_LRN\,9QF;.PH#V^?C/IS7/ZSX6\4>*OBC/JEM?RZ
M%::/;K!8736J3^<S@^8RJQP.I&?0"L:P^'6O#POXN\!W+-):2.EYIFHM&$BD
MDRK,N 3MY &.WS&@#H$UKXJPV5KK,NC:+=VDS(SZ9;-(+F.-O]ICMW#//^<3
M>)/%GBM/B)#X8\/#18@^F"^:34UDX.]E(RA]AV]>:X[Q79>*/&6DVFG3^!]4
MM_$5O$L OEO1':I@C<_!PV<'CMGJ<5N:C\.O[?\ B38#7M+:[TF'PZEL\X<A
M1<*YZ$$'."3^- $D'Q+U^'1O&46H6NEOJWAZ-'6:S+O;2[N@Y.<C'K^6*M>'
M/$?CG5VTJYFU3P3]EN_*DD@BDF^T"-L$J!DC?@D8Z9K L_"FOZ)X&\8^"ET8
MSIY;/IU_!$J_:U)'RN1U<>_N.@%2^%-/M]+?1E?X47D6H6XA234,1_+(  TG
M7/7)H NKXY\9:GXF\06&FWGA.SMM+O6MD_M-I4=QDX/#8/3GI5W7?%OC*PO/
M"6CV3>'IM5UE;CS9\2M;93#*4(.[&T^AYKE_^$=DL_&/BBYU?X<W6O1WFH-+
M:SJ$P$R>F3WX-:NN6VKKJO@/7-*\&W\=MI0NUDTV/8'@! 11UQSC(]J .E\-
M>+M=_P"$QG\)>++.PAU+[+]LMKC3V8PSQYP1AN00<_D?;-CQ_JGB[0]-N-6T
M'^Q386=JTUPE\LIE8KD_)M('3U/6LOP_IFN^(?B6?&.L:.^CVMI8?8K2VFE5
MY9"6)+MMZ#DC'TKJ/'-E<ZEX$UVRLX6FN9[*6.*->K,5. * .&N/&OCG3/AG
M=>,-03P^Z/:V\]G%;QS9'F.@(D!;^ZW8]:U?#VM>-K_4K'[;JO@N6TE(:6*S
MEE,Y7&2%!.,U3\2>'M6N_P!GV#0K>PEDU1;"SC-L,;PR-&6'X8/Y55\*6MG8
M:SIC1?"J[TZZ5EC.H$1@19&UG.#G&": (['QMX^UD:]>:<WA6&RTN^GM=E[Y
MR2.(^<Y#8Y!'/'.>E5]=^+VN0_#SP[XBTK3;1;K4GF2:&=6=1Y>[)7# X.TG
MO5"U^#_]O:+XJFO].-IKKZO<3Z=<RGAX\AE!&<%&.X<CO6O<:5K?B/3/ :WO
MAQ[)["^,>H6R1JD<:!=NY0. A'8=.1VH 7QI\6[_ $FY\.)H5O:31ZC:17ER
M9U9O+CD953&&&#DMUSVJYX@\>:^?'FH>&M&NO#^F&QBC</K#NINV=0V(\$#
MSCU_IP-E\./%,.@:BMWI]Q/=07]I:68XR;6*1F+#G[O*_E7;^,[.^N/$=]%K
M_@0>)=)D1?[.N;% L\/'S([9##D]<X^N> #O_"VHZKJGAZVNM:TS^SM08$36
MX<,N0>&4@G@C!K9KB?A3H>K^'_ T-EK*M%-YTDD5N\GF&WB)^5"?;D_C7;4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,9(.!Z4^Y\):LME9VUKK%M=11VWD7$&JV0GAF;.?-VJR[6R2,<C&!VS7844
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4)?VDEX+1+F)K@PB<1A@6,9. V/3/&: +%%%% !1110 4444 %%%% !1110
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M"U2"0K%>K?F1YF:22=3D.[$Y8_7T K5U'3[35M/GL+Z!9[6="DD;=&!_E]:
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M66) <LDGED@?4&JU]X$T34+NYFE6[2*\<27=K%=2)!<-QR\8."3@9]<<YKI
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MA;V5L@2"WB6*-1V51@#\A6%J'@;1=2O+JXF6[C6\(-Y;P74D<-R0,9D12 >
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M'1TG<L68,#D9W,,=,&DE\%:).-466&9XM3D$UQ";A]@E&#YB#/R/D Y7!X%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Q_%&N'PYX=NM6$ G\@I^[+[<[G5>N#_ 'L_A6Q7)?$R
M![KX>ZK"EM)=%O*S!$I9G'FID #VS0!NZ=KND:P9AIFIV=X8#B46\ZR;#[X/
M%-T_Q#HNK7,MMIVKV-Y/#_K([>X5V7MR :\Y\1POXKO+AO"-K/$8-!N[6:7[
M.UN&9]GE0#<!\PVMQ_#GMFK<EY9ZQJ/A5?#>E7*7&EL\EPIM7@^S0B!U,#,P
M !9BHP,],]LT =Q!XFT&ZU1M,M]:T^6_4D&V2Y1I 1U&T'.14D?B#1IKU[.+
M5K%[J-7=X5N%+JJDJQ(SD $$'T(KR&TFNKR'P@B;D^SZI;R2Z9::0\,>G@DA
M@\CY.03CJ,Y)QBMG_A'IYOASXK6TTUC?W.JW<C*(\2SQ"YRR@]3NC4@#OD4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M17\WEF:.50L2XSNY^\/I5?2/&FBZU>:I;6UTJG3KC[/*\K*JLW?;SR,\9]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=HSC.X9+ 8KI/ $>B>'O S>(+N&WMI6GN?M-ZT>9"OVEU + 9QPHQTX%>A@
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M=P^M=K\,M(L-.\ Z)/:6<,-Q=6$$EQ*D8#RMMSECU."QQGIFNO  S@ 9ZTM
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME9L=>3P#SWZ<^AT4 >00>#?&6JZ9X<\+ZO9:=::5HES%,^H07&]KA8@0@1,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]<U@3VVG:H]H@2U*,AZ"( ??;WK-T_P?KD&J_#2>2T41Z)93Q7Y\U#Y3-"%
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MFZ>737N$42I*Q^Z^2H8#!'U]L4 =_;?$?P]=:!J>KK+<1QZ9@7MO+ R3P$G
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MH)/!]<57\2>&;S_A,Y];CT[4M2M;NSC@:/3M3:SEBDC+8SB1 RD-ZD@@\<T
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MUW+:,D,DA!.P,?XN"/3((S5GQ)I5YJ&M>&[BVB#Q65[)-.=P&U3!(@//7YF
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>(=/CTV\\;66DVOV:Q-OIDUS;V:;!Y1E<3E57N8U.<=0*]>VCT'Y4N!G..:
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MXWC\MD4IC&TCC\J /!]EO=67BJSCEL);275=(/\ Q+83!;MNE56:,;CUVX+
M\D$UVDWA?2I/'.L:#:V<%G8ZCX>4316\812WFNH?:.-P!X/M7HNQ0,;1^517
M<,L]I-'!<-;3.A5)T56,9(X8!@0<=<'B@#S_ ,"W5[XFUM=1U.-EET&T_LMP
MPZWA/[]Q^"1X_P!XU<\;_85\4>&I->\K^P%-QYIN0/(6XVKY1DS\O3S,9XS[
MXKI]!T6+0=,%I'-+<2-(\T]Q+C?-*[%F=L #DGH.@P.U:3(KJ5=0RG@@C(-
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M<XS0!?N/B7IUO]IF;2=6-A:7SV%Q>K"ICCF63R\8W;F!..54_>&>>*O0>.+
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M2VMD3S'6.5P!R54*JJ,L2/S-1:5XZ99O$=UJ4-\L<&HPV=G8-"OGB1H4_=*
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MSQN6=20$ !4[1PPSD'M707 UZWU71/#K^([II=2%Q=W%\(8A(BQK'^ZB&W:
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M151/%OAR1K-4U[36:\_X]@+I,S<X^7GGGCCOQ4U_XBT72KN*TU#5[&TN9O\
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MVO[3S[B6RMH3,\>?.Q;88*2.1N].]:EG9:C=?!JVL+821ZE)H"0QAOE993
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MM W*/FQG'&.]2:E\,=1O;+6K%+C1Q_:,\LPU*6T+WF&;<(RV< #A<C^$< 4
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MQK<R=(P<L2%4?-C/+ >E4KKP/J=Q;:///>6&H:EI(E@1K^W,D=U ^,"0=1(
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M[T )<>.Y=&_M"#Q#I/V2\M;07D4=K<>>ERA<1@*Q52&WLJD$?Q YJF=;U_\
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M_P!EL8S';V_RA<(I/?&2>,D]!0!TU%%% !1110 4444 %%%% !1110 4444
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M#+LO!_A_3X+N&VTR)5NX3!.6+.SQD8V;F)(7D\ XK9AACMX(X8E"1QJ$11T
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M;+QRRMD8/&'/H,V=8US3M"MXYM0G,8E<1Q(D;222OUVJB@LQP#T%4?\ A--
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MT7+R!=NUXY=KJ03E3O49]:]/HH \ZT'PMJ<'BN:TN8C%HFCFXDTJ4'[S7//
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L/QAKDWAOPM>ZM;VZW$UOLVQ,<!
M]SJN,_C6Y65XDT1?$6@W.E/.8%F*$R!=Q&UU;I_P'% '(ZMXXU71+ZST;5+C
MP_8ZG-"]U)<3RR"WCBW;54 X9W)W=P %S[4[3_B%=ZY:Z=::5;V+ZM=W5Q;/
M(96>V00 %Y%(^9U(9-HX^]R>*Z'6?#EQ>:S;ZUI>I?V?J44#6S.\ FCEB)#;
M63(.0PR"".IZYJG)X-NFM]/G77[EM:LII9DOYXQ(K>:,.ACR (\8PH(QM'-
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MYOD,9,@E79C.?F)8@*1C(KJ_A7HUE!X6MM8".^HW8D6:XDD9F91*P5>3@
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M32,%5G27+X!^]\HP>HYQUH [;5?$<6EZOI^E+8WEY>7P=U2V5?W<:E0SL68
M ;QTR?:MJO&_#=HNI:EX+U*>$76I-X<FF$LI)9Y8VA$9)[D9_6F68TN+PEX;
MUG3[LOXON;RU69_.)GFE:0"XCD7.=H'F9!&%"CI0![/17B]WI-LO@#QGKH\W
M^U/[0OH$N#*VZ*,77W5&< 9&>G4FMT^#=#7XD#2?LKG3IM'-Q/;-,Y2:590H
MD<9^9L,W)]<]10!Z75._U2TTQ[-;J0JUY<+;0 *3ND() ]N%)R?2O(M/N8M2
MT3PMI-U;Q:A.MI=2*FJ7YAM-B3>6"WRL9'   '89-4[*+3K[P[H9U%K66RM?
M%LMM&XE+0QP%7.U&8YV9"XSVQ0![9:7ANVN5^S7$'D3&+,R;1)@ [DYY7G&?
M4&K->07,PEU&ZM-2N'CT2?Q;-%?,9"JE?LRF-&.>$,FT$=#P.]5M>2VM8/%.
MF:!</'HL;:8<6TQV6]P]R ZQD'Y3LV$@="?>@#VBJQO"-32R^S7!#0M+]H"?
MNA@@;2V?O'.0,= :X[2=*L_#_P 3WL-*B-M:7&C&>6%78J\BS!0Y!/WL,1GO
M4'BZ7;XPN5?4)K"+_A%[TM<Q*SF'][$/,"KR2.O'- 'H-%>7>!C!I7BRVT_[
M'IPEN]/>1;K1KUI()D5D^>6)N5<YX;)SDC-;'B?3+76?B+X=L;Y6ELVL+UY(
M-Y"28:' 8 _,.<X/<"@#N:*\6M-(M;/PK:ZO%YW]H6?B5;2WG:9V:* 7OE")
M<G[FS(QTYJCXRNK:YTOQ-K5M!9Q7%K>RQ1WU[J#&]26-@H6&-5^101P-W3DB
M@#W.XF6VMI9W!*1(7;'7 &:KZ3J4.LZ/9:G;*ZP7D"3QB0 ,%90PR!GG!K@8
MM(LM3\9>,]1O$>>>R6 VNZ1ML):U&XJH.,GC\JQ? DVH6]M8#5@LFI/H$<GA
MX(Q,/EK$-R!3_P MONECSD' P : /9*S];UBVT'3&U"[61H5DCC(C +9=U0=
M2.[#\*\>\-)+Y?A74XKW1H-1NKJ(3W*7D\MY=D_ZZ.5-AY^]G/RH0.1BDO(-
M%N/ J:GJ%PO_  E4FKQI<%ISYQE%V 8BN?N!!D+C  !]Z /<J*Y7XBW%Q;>"
M;R2"66%?,A6XEB)#1P&5!*P(Y&$+<]ADUR'B1/#^B:?J,7AB\FMFDM[=KY+"
M4M%';&=%>7(SMDV%^<Y*Y/;- 'K-%>2ZQ#I.D:G<6OA26-;:?0+Z74(;6;?&
M J+Y,AY(#DEAGJ1FI]/T2QTO4? 5S:I(L^IQ217\C2LQNE-HSGS,GYOF (].
MU '8:9XOBU:_>"UTC5&MENGM!>^4GDETW!C][<%!0KD@<D5IZQK%MHEM!/=+
M(R37,-JOE@$[Y'"+G)'&2,UY7X=L+?35\--8PK"\WB6_1]I(WA!=! ?8#%4D
M@T27PIX9U.XN5/B>XUJT%XS3'SI)OM \R-UST7!P",#:N* /<:*\/U99[V\\
M77FI7&CP7EG>RI!=7M]-'<V40 \EHD13P1AAM^\20<]*WK;0;7Q%XB\2_P!N
MJ;R2#3[(J-SHB2-"Q9U7C#9 P2 1[<T >C/JEHFLQ:29#]LEMWN53:<>6K*I
M.>G5QQ3]/O#?V$-V;:XMO-7=Y-RFR1/9ADX->6>%TM+SQ/X)U'4C&][<>&=Z
MS3/\TDP:$ Y)Y;!;\S67I$UMJFB^&--N;2UO9HM%^TL-6OS#:(K2%=X4*Q>3
MY>O  [\T >P:AK-MIM_IEG,LAEU&=H(2@! 949SNYX&$/KS6A7COA6Y:ZTSP
M"6G$RQZW?1QL'+#8J7(4 MS@# &>V*]1T:'2X+*1=)DC>W,\C,8YC(/,+$N,
MDGG=GCMTH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I&4,I5@"I&""."*6B@"G::3IUA%+%9Z?:VT<O^L2&%4#_4 <U:CC2&)(HD
M5(T 5548"@= !V%.HH JQ:9803&:&QMHY3(9=Z1*#O(P6R!U(XS3VLK1RY:U
MA8NZR.3&#N9<;6/J1@8/; J>B@"FVDZ:^H#4&T^T:]'2Y,*F0?\  L9J>XMX
M+NW>WN88YH7&'CD4,K#T(/!J6B@#+N-!LSIDUIIZ)IDC0M%%/9Q*CP@\_+QC
MJ <=#6/I'@V6UUF+4]3O;2ZD@ADB@BM;!;:,>9MWNP#-N8A0.H'7BNLHH A:
MTMFL_LC6\1MMGE^24&S;TV[>F/:F6FG6-A:FVL[.WM[<YS%#$J(<]> ,59HH
M I6NCZ990S0VFG6EO%-GS4B@5%DS_> '/XU8^S6X>)_(CW0J5B;8,H#C(7T'
M Z>E2T4 5I=.L9K:6VEL[>2"5B\D31*5=B<DD8P23S21:;8P6T5M#96T=O$P
M>.)(E"HP.00 , YYS5JB@"(VT#2O*88S(Z>6[E!EEY^4GN.3Q[U3@T/3[74(
M+RVMHX'@@>WB2)%1$1V#-@ =RH_7U.=&B@".:WAN%59X8Y0C!U#J&PPY!&>X
M]:%MX$FEF2&-990!(X4!GQTR>^*DHH @%E:K##"+:$10D-$@C&V,CH5';'M4
M3:3IKZ@NH-I]JUZO N#"ID'_  +&:N44 59=,L)YI)IK&VDEDC\J1WB4LZ==
MI)'(]JF:"%IDF:)#+&"J.5&Y0<9 /;.!^5244 4[?2=-M+N6[MM/M8;F7_63
M1PJKO]6 R:L0P16T2Q01)%&O1$4*!WZ"I** *EYI6G:B\3WMA:W+1',;3PJY
M0^V1Q4_D0B?S_*3SMFSS-HW;<YQGKC/:I** (Y8(I]GFQ))L8.F]0=K#H1Z'
MWI/LT'F22>3'OE4+(VT9<#. 3W')_,U+10!5LM,T_34=+"QMK5'.76")4#'U
M.!S4EK9VMC#Y-I;0V\62=D2!%R>IP*FHH IV^DZ;:7<EW;:?:0W,O^LFCA57
M?ZL!DTG]CZ6+J2Z_LVS^T2$-)+Y"[W((().,G! /X5=HH J2:7I\U^E]+86K
MWD8PEPT*F1?HV,BI#96K0S0FVA,4Q+2H8QMD)ZEAWS[U/10 R2*.:%X98T>)
MU*LC#*L#P01W%-CMH(I&DC@C1W559E0 L%Z GT&3CZU+10!!%96L!B,5M#&8
MD,<>R,#8IQE1Z#@<>U1QZ5IT5^]_'86J7C\/<+"HD;ZMC)JW10! ;*T-O) ;
M6$PR,6>,QC:Q)R21T))YI_D1?://\I/.V[/,VC=MSG&>N,]JDHH HSZ+I5U!
M%!<:99S0Q,6CCD@5E0GDD C@T^32]/FMY+>6PM7@D?>\;0J59N.2,8)X'/M5
MNB@"N]A9R030/:0-%.2TL9C!60G'+#OT'7TID6EZ?!9BSAL;:.U!#"!(5" @
MY!V@8Z@&K=% $?D1?://\I/.V[/,VC=MSG&>N,]J#!"TXG,49E"%!(5&[:3D
MC/ID#CVJ2B@"G9:5IVFM(UAI]K:F0Y<P0JF\^^!S5AH(FG2=HD,J JLA4;E!
MQD ]@<#\JDHH @^Q6GE>5]EA\OS/-V>6,;\[MV/7/.?7FH'T72I+J6Z?3+-K
MB52DDK0*7=2,$$XR1CC%7J* (DM;>,R%((E,H D(0#> ,#/KQQ3?L5H%@46L
M.+?_ %(\L?NN,?+Z<<<5/10!3BTG38+Y[Z'3[6.[D^_<)"HD;ZL!DTDFCZ9+
M=M=R:=:/<N &F:!2[ $$9;&>"!^57:* $95=2K %2,$$<$55L]+T_3X9(K*Q
MM;:*0Y=(850,?< <U;HH IVND:;8PRPVFGVEO%-GS4BA5%?/]X <_C4_V6WS
M"?(BS!_JOD'[OC'R^G''':I:* (%LK1/+VVL(\MS(F(P-KG.6'H3DY/N:A.C
MZ8;Q[LZ=:&Y<@M,8%WL001EL9." 1]*NT4 4[C2=-N[N*[N=/M9KF+_5S20J
MSI]&(R*L"WA62200QB24 2,%&7 Z9/?%244 53IMB?LV;*V/V7_CWS$O[G_<
MX^7\*CFT32;B.".?3+*5+?\ U*O;HPB_W01Q^%7J* (%L;1&5EM8%*R-*I$8
M&'.<L/<Y.3[U%INFV^E6[P6P(5YI)FSCEG8L>F!U-7** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCG"HH&22:YF'X@Z3));--9ZK:V5TZQP7]S9M'!(6X7YCRH;L6 !S0!UE%%%
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M8S3+;PPV\>^261LX51^!//I0!J44R&3SH(Y3&\>]0VQQAER.A'K3Z "BBB@
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M[.W:ZMU*0S&)2\:D8(5L9 (]*JP>'-#MM4?5(-'L(M0<DM=);H)"3U.X#/-
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M'3I7K+6ELUU]J:WB-QY9B\TH-^PG)7/7&><54M- T>Q4+::38VZJCQ@16Z*
MKD%EX'0D D=\"@#S'1_/TWQOX/$=M]@745F\P/J[W4UV@@9P\JXVCY@IR">3
MQQ79?#'_ ))QHW_7)O\ T-JU['POH&F.KV.B:=;,LGF*T-JB$/@C<"!P<$CZ
M$UHVUK;V5LEM:0100(,)%$@55^@' H Y3Q/_ ,C]X'_Z^;O_ -)GKBY;+9X*
MU7Q+]LOCJMIK<PMYC=28B07NS8%SMVD$Y!'.?I7KTMI;3SP3RV\4DT!)AD=
M6C)&"5/;(XX[5$=+T\V<EH;&V-M(YD>$Q+L9RVXL5Q@G=SGUYH \GU:V32-1
M\<7EE+<6C-J5C;SW23ON@@E6$S,,G .">?X1TP!5WQ#%!X<O[^P\/W4ZV]QX
M=OKBZ@%R\HB9%7RI@6)*L2S#(/./:O3OL%GFY/V2#-U_Q\'RQ^^XV_/_ 'N.
M.>W%5++PYH>FVMQ;6.CV%M;W(*SQ0VZ*LH(P0P Y&"1SZT >>GP_;QS^"+(7
M>H;-5:2;4&-[+NN&%J6.3NX!(Y P*S+O2TL_"GBS4(;N_%QHNK-%II-Y*1;(
MIB;:HW8(R[ YSQ@=J]@-C:%[9S:P[K7/V<^6,Q9&T[?[O''':F/I>GR07$#V
M-LT-RYDGC,2E96X^9ACYCP.3Z"@#S+Q=)'J6I^)Y8K:6X&F0JDES>:LUK%9-
MY6\&%$!)/(.6ZG@' JOIZQ7>MZ=JUU-(VH3>#$N?-,[ O+@ MC."<$_SZ\UZ
M;<^'=$O=274;K2+">]0 +<2VZ-(,=/F(S3FT#1W-J6TJQ/V1#';9MT_<J1@J
MG'RC'&!0!YWH:1^(+[P]IFNW,[60\,VUU!";AXQ/,>)'8J0690%ZGC<3WJGI
MGFZYJ7A[3+C4+VXTH:AJD$4BW+@W5O%CR]S@@N >,YY"^YKT^]\/:+J5E!97
MND6-S:VX AAEMT9(P!@!01@<#'%64TZQC-L4L[=3:J5MRL2CR01@A./E! QQ
M0!S/@)6MO^$CTU99GM;'5Y(+999&<QQF*)]H+$G +MCZU+\09I8/#D#PRO&Q
MU.Q4LC$'!N8P1QV(XKI8;6WMFF:""*)IW\R4H@4R/@#<V.IP ,GT%%Q:V]Y$
M(KF"*>,,KA9$# ,I!4X/<$ @]B* /)-4T\7'AOQYKLEY??VAIM_<FQD6[D46
M^Q$8;5!QU)SD<CBO7(',EO$[=60$_E4+:98-;W-NUE;&"Z9FN(S$NV8L,$N,
M88D 9S5D *    . !0!YAXNDOH?$M_X;M[R>$^)Q;&UD1SF$HVVXV^G[M5/'
M<USU]J=YXE\!>(=0N995_LW1X=,D7<<&[W!IVQZC$8_.O:I;.UGNH+J6VADN
M+?=Y,KH"\>X8;:>HR.#CK47]D:;]EN+7^S[3[/<NTD\7DKLE9CEF88PQ)ZDT
M <'?V]KX,\5Q/;76H1VDVBWL]Z?M#S.[0^61( Y(\P!FY]ZPM-$MGXE\'.EN
MUDFILZR-+K#W-Q>Q&!VW2IC:.=IR"<$\8KUZ2SM9KA+B6VA>9$:-9&0%E5L;
ME![ X&1WP*H6?A;P_ISA[+0]-MW$@E#16J*0X! 8$#K@GGW- 'D5FCV7A?1-
M/T\#[/?Z]>PWJ2:A);K)LDF\N)I &*!MHX ^;&#US6Q%;:S;Z=XD2TE@B?1Y
MK:_M=/M=0ENO)= 6DB+LB_*ZC[G."QZ9%>DMX>T5XKR)M(L#'>OOND-NF)V]
M7&/F/N:GT[2M/TBT^R:;8VUG;Y)\JWB5%R>IP!UH \MUG7;_ %+PYKWBO3+J
M5+&ZNK;3[63SC$L=JL@664, =FYW<%P"0%![4HCU#2)]<MHOL>GP-H%S.UE;
MZM->-O ^28;T79U()S\W![5ZG#IUC;Z>+"&SMX[(*4%ND2B/:>HV@8QR>*JV
M/AS1-+MKBWL-'L+6"Y!$\<-NB+*",88 <C!/7UH SO!&D6^F>&K.>.2XEN+V
MWBGN99YWD,DA09;YB0.O08%97Q&TNTU&X\*_:4=LZU%%\LK)\K(Y/W2/[HYZ
MC\37;Q11PQ)%$BI&BA511@*!T '84R>UM[DQ&X@BE,,@EC,B!MCC(##/0\GG
MWH \KN8[2]T7QEK.IZG<V^K:9=W,=LZW;QFT6,?N J @?,-IY!W;CUK0\-V4
MFN^,M3O]8DNOM-E;6$T=N)W2.*9X<N=@(!.1C!R.OK7;W7AW1;[48]1N](L9
M[V+&RXEMT:1<=,,1GBKB6EO%<37$<$233[?-D5 &DP,#<>IP.F: /&])TA9/
M#/@*_:_U(WFJW*V][-]MES-"T4C&,_-@#Y%'&#[YYKN?!$0L-5\4Z5#)*;*R
MU!!;QR2-)Y2O!&Y4%B3C<Q./>NF32]/CAM84L;98K1@UNBQ*%A(!&4&/E."1
MQZFIHK6W@EFEA@BCDG8/*Z( 9&  !8]S@ <]@* ):*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX60NL4[2A),%@"/F!/.0.U &GHOQ&L)!<Q:O))'+%J<]EYL=I(8(\3,D8>0
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MW1_9C%)*S^:QW;@P#<KM)R..N: .MO\ Q_X>TVZO+:XN+@O8N$NS%9RR+;Y
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M% +2;20.> ,YP.: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHK%\5ZY)X?T"6]MX%GN6DBM[>)VV
MJTDCJB[CV&6R?84 :=E96^GVD=I:1+%;QY"1KT49S@>@YZ=JGK@M3\3>(?#$
MEQ;:LVFWDDNEW5[9S6T#Q*LL"!FC=2[97Y@001T(QWKHO"UQK=[I,=[K36.^
MY1)H8K2-E\I64':Q8G<1GJ,?2@#;HKEM4U?6;KQ4?#^B/96SP6:WES=7<+3
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MB*<OL!Z+CBLG6_%)U+P1->W6J:9J%M9ZO8,+G3T=&V">-B'A)9D88/&3GT%
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M^O:UXQO+.R%A!I-BMM+(9XG,TBRQ[MHPP"D<\D'MQUJ[\0_^2<>)/^P;/_Z
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M P;."#@X.#T->3Z]J_B#Q%X*@UL_V>FC76I6OEVPC?STB%V@1R^[!)(&5VC
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MD$T1E,0D0R 9*;AD#Z5DP^(X+V*=["WGNOL]_P#890FT%6#!6?D\JN<^IP<
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MYY.:OW7B:&'5+K3K>TFO+B#3Q?J(67$JEV0(I)'S94]>*V3-&D8:1ECSCAF
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MUE#=7=OHEF<2J&$<IBEW,HZ!LJ.1R,<4NBZ99:?=_#N_M;=([S4+&4WEP/\
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MG,5JK!68&8@'<O'"G@G'I7G#B"32/'%E;RZ=]E-SI3!=)4Q6X9I@&,?)Y^4
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M]NTX8A\<@>8$"=><9QWKW5(HX_N1JO 'RC' Z"FR6MO+"(9((GB'1&0%1^%
M'CNDZ19ZO<>#K&_DAU/2VN=2:%!&ZPM$ "J*')+1J1\N<@@+Z5ZOJ6CVNH^'
MKK16C5+6>V:VVJ.%4KM&![?TJ]Y:94[%RG"\=/I3J /!U\1:E;F'QO/',\NC
MHN@SP@'YY?)<R''O.8A^%:UY8Z=I5]IF@7]OHAGL-'1Y;G7I2T#,[L9#%%T9
MRP)9L@X(%>O^3$5*^6FTMN(VC!/7/UILMO!.R-+#'(T9RA=02I]1Z4 >.:'>
M#0_ /A?QBQ9X]+GNK.\VJ0?LLD[H!@Y("LL1 /0 UZ-X)TZ>P\,027JXU"^=
M[Z\]1+*=Q7_@((7Z**GU[P[_ &\EM:O>O!IRRB2ZM8XUQ=88,%9B,@97G'4$
MBMN@#RB^7PP^K>,CXR-I]O27_1/M9'F+:^4OEFWSSG?O^YSN]ZE\'Z6)/&VD
MWFKV$)UC_A&;>:>:6$>;YV\H68XSOVC:3U[5Z=);P32))+#&[QG*,R@E3['M
M3]B[]^T;L8W8YQZ4 <5\1+&WU.7PK97<8DMYM;19(ST=?)FRI]0>A'<5Q^M6
M%C:^--9LM07PW:Z=;V<"Z=#K,3;$M]GS^1A@ =^[./F^[[5[*R*Q4LH.TY&1
MT-1S6T%QM\^&.78<KO4-@^HS0!X_IZZ)_;_A=/%MY;W47_"/N8I=239'*WFC
M:763^+9TW>YZTW3=,L]9O/"UC=0?:-"?5=3-C#+DI):A28Q@]4R,@'L%[5ZA
M/X?MKGQ(NLS'S&6R:S\AU!0J75]W/?*BM7RTRIV+E?NG'3Z4 >&ZM:VL>I>*
MX-5F\/6DD$OEV@U")S<0VPC40FVPPP!SC8,[LYJSXB@MENI+C4[W1+Z]71[8
M75KKT30.P"$E[:0\HS'.0 2&QSFO9I+:":1))88WDC.49D!*_0]J);:"=D::
M".1D.4+H"5/MGI0!X[J,RZEXFMYM831K2RDT2VDL;?Q&&D1 03*%)8 R#Y0Q
M/S8Q[U/HFDVNK:AX'M=49=4M18:B\?G1,$DC$L7E@H_+* 1C=G.%/I7K<]O!
M<J%GACE4'($BA@#Z\T_8NX-M&Y1@''(% 'BMS8:-;Z;:QZA;V:Z9I_C.6!?M
M*KY5O 58E/FX5-V..G2K=W:0:A%):W"[[>;QT5D3. ZF/D'V(X/L:]=:"%XV
MC>*-D8Y92H()]2*7R8O^>:?>W?='7U^M 'D&NV$&DZAXMT_3K;[+HP?29KZW
MM%V*L#2.)RJKTRBC=CL#6MX;/A<_%H_\(N;+[/\ V&_F_8-OD;O.CQC;\N[&
M,X]LUWNK:8=3T^:WBN[BQFDVE;FU8+(I4@CZCC!!X()'>LW1?#+Z=JTNK7VI
M27]^\ MD;R4A2*+=N(5%[EN223T'2@#*\?\ V8WWAM=8*CP^UZPO_-/[HMY;
M>4)>VS?CKQG&:XG5K?3;EM<L]%\O_A')-4TF-1:MB 3M,!,(BO ^7R\[>_O7
MM3HDJ,DBJZ,,%6&0135MX4B6)(8UC7[J!0 /H* (=.TRQTBQCL=.M(;6UCR4
MAA0*JY))P![DUY!)HT</PY\3ZSI]L!JLFIW<4MTJDR+;?;,2*".0NP,2![GJ
M:]II%14!"J%!). ,<T >*QQ20W&H-X6OM"^U?V%<G[/X>@<*YVCRF<ABHD!S
MM_B.35Z7_A%XM!B/@I5;Q"^CW'DMII!D_P!5DFXVG.[=C&[G?^->L0VT%L&$
M$,<08Y;8H7)]3BECMX(7=XH8T:0Y=E4 L??UH \LL1X835/!K>#3:?V@\O\
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M8(1%4'DA1B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7C;U9 LAW?<;EAP3G\*]5N[.VO[26TO+>*XMY5VR12H&5AZ$'@UGV7A?0=.
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ML6IO=R6DC.06#LH*JP .W)Y!/>O59]$TJY6\6?3;25;W;]J#PJ1/M&!OX^;
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M-Q&6^?)X'RD<9K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!CQ1R/&[QHSQDE&*@E3C&1Z<$C\:?110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI:7-QQ+)#& 2,YQ[#/8<5LD9&#0!YA%K_@*'X5:"FJ?8[O3C#;QI9HHE?SL
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M+:65)GB2/:I=.%; XR*MWND1_:KG5]/MK1==-HUO#<SJ2,9W*K8YV[L$XYH
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M*Y$$HFBWCE''1@>QH \HM[.?3?!&H>([75=1BO+?7)O*B2Y98 AOBC(8P=K
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M[$YZ5FWO@SPYJ+PO=Z1;2M%$L*D@\QKT1O[RCT.:VT18T5$4*BC"JHP /04
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MK$R&)68 /N+ ?(2,#-;_ ,/[2YLO"$,%W!+!,+J[8QRH5;#7$A!P?4$$>QH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2Z'+H[:O'J]BVG(=K70G7RU/3!;. >1Q[U8TS5M.UFT^U:9?6]Y!N*F2"0.
M1U!QT/M7F^KZ:$O?%$DUMJ<$"ZY:74%S80;V@86\>9@A!\Q0V0P /4^G&GX6
MUR73K/Q!JFJK]HL8I8F758M,:VDO,J%8M'U.SY1N QC/I0!W\DB11M)(ZI&@
M+,S' 4#J2:S=.\2:'J\<[Z=J]C=);C,S0SJPC'J<'@<'GI6;\0+"[U+P-J5K
M90O/,PC8PI]Z5%D5G0>I90PQWS7+>*9K;Q9I=_'X?T&ZGECL466Y:V> F-9H
MW:U574%BRJW X'3O0!W>F^)-#UD3'3=7LKOR!F7R)U?8/4X/3WIMEXHT#4KP
M6=CK5A<W)3S!%#<*S%<9R #SP0?QKCKNZM_$/BC3;[1;.YCM]/TZ[2\GDM'M
MU"N@"0_.HW$,-V!TQ[UC>'9[;6/"G@+2])TZZCOK*:UNIW:T>-(8U4F1_,("
MD2 G&"=V_P"M 'JBZOIK6$-^M_;&SG*K%.)5V.6.U0&S@DD@#WK*O?%^E+%/
M'IVJZ5<7L.PM#)>*@53*(R21G')P/? [UR&E:;<CQV/"K1'^R=(NY-9B;^$K
M*/W,?_ 9&G/_ &S6JZ:++%\(;F./3I%OI=4,CJ(3YC#^T <D8R1M /T H ]#
MO_$NA:5>I9:AK%C:W3KN6*:=48CUP363-X\TBR\07-C?WUE:V26=O=0W<MPJ
MB;S3(,#/!&$!R/6N7U>:+1;;QW::MI5Y=3ZFTD]O+'9O*D\7D*JJ9 "J;"K9
MW$8ZCK5WP3IN_P 0Q7D]GN3_ (1G3H8YGCX.?,WJ"?\ @.1]* .DNO&>D6WB
M72=$^UV[2ZE T\4@G7& 5"8'??N.W'7::UM2U73]'M#=:G>V]G;Y"^9/($7)
MZ#)[^U>9>%X9]+D^'\EY9W4<:V=Y:,?L[MY<CR1^6K8'R@A3@G XKI/'=U<6
MNHZ"\<20PB64OJ;6371M#LPH5%Z%\D;CP,>] '10^(M$N--74H=6LGL6D$0N
M!.NS>3@+NSC.2!BC3O$6BZO;SW&G:M974-O_ *Z2&=6$?&<L0>!@'K7E4.FW
ME]IFLQ7%K?74=SXGL)BUS9>49XB8=SF,* %P#GCIUYS6QXWT2^OM=\0KI]C+
M(LVAVFY8TP)]ET[/&#T+&,$8]"* .IM/&VF:IXGL=*TFZM+^&XMYYI)[></Y
M;1F,!<#U\S/X5L:IKFE:)&LFJ:C:V2,"5-Q*J;@,9QD\XW#\Q7&V=]9:U\3-
M'O\ 2]/NT@ATNYAFN9+*2%02T16/+*.5^;CW^M:?B'3OMOC_ ,)2R6AG@@2]
M9F,>Y48H@7/8'KB@#8N/%.@6MY!9W&M:?%<SA6BB>X4,X;[I SW[>M06_B.)
MM=UVQNQ%;6VE1P2-<R284B168EL\ #;ZUYIJ-C=6<OBW3-0N=3C;4KR5XK2V
MTD7'VV)U C"2[2 0,+@D;=N>*O:C:ZCIJ^),Z9)>@II,;275NTX 48>4HO\
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M$VXVYBDR(3U& F[&#CY#5_1?B);ZYI>EW5OI\JS7^H&R6W>3YD 4R&0\=/+
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MY10!R#^'-:TC6+Z\\-W.GK#?Q1++#?(Y\IXTV*Z%>ORA05./N]>:JV?@B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117,^.=4UO2?#5Y<:':Q//';32O<S2 );JB%MV
MWDNQ[#IGKQU .FHJEH\\EUHEA<3-NEEMHW=L8RQ4$FKM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !16#KOBBWT74M+T_P A[BYO[A(MJ' A
M1FV^8Q],D #OSZ'"R^)HD\76WA]+.X9Y8Y'>Y9"L:E55MH)'SG##..!]>* -
MVBN;B\3W(UNULKW26M(+V2:.VD:<&0^6&8L\>/D4A20<GJ,@9J/PIXKG\3@3
MK8VL-H\(E5DOUEE ;!4/&%!7(.>30!U%%87B3Q-%X=CM=UG<7,EQ/'$!$AVH
M&D5-SOC"@%QQU)Z=R*FK>+I=.N]4\G3#<66D1++J$YG",@*[R(TP=Y"?,<E>
MN!DT =116!>^*K:U\3:3HD4+7$M^S;Y4/RP#RW==WJ6\ML#T!/IFMI/BV;6-
M=GL;>RM/L\,\L+2&_7SL1L4+>3MSC<I'6@#J**R==U*_TNU^TVEA;W,,:.]P
M\]WY B51G.=K9&,^F,5SS>/;H6^D[M'M[>[U"V>Z,-YJ"PB) RJ@W%>6;=G;
M@$8- ';T5SVN>*H]!32XY[5I;R^GAA,$;Y$(>1(V<MC[JLZCIR2!QVJWOC,V
MFM7%H-/#VEM>6]C-,;@++YDP3:4BQ\RCS%R<@_>P#B@#JZ*1B%4L>@&352'5
M;"X%F8;N&07J&2V*MGS5 !)7U&"#^- %RBJNI7<MCITUS!:2W<J#Y((L;G8G
M '/3KR>PR:H:'K<NJ7&H6=U:);7EA(J2K%-YT9W*&&'VJ<X/((!'X@T ;-%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5F>)+&;4_"^KV%L%,]U930QAC@;F0@9/U-:=% %/2;>2ST:Q
MMI0!)#;QQO@Y&0H!_E5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#A]>\$ZA>:G]OL-<NT>;4+>XEC9(2(TCZ;24)^49(4G&2?4UOW^FW
M%QXHT;4(POD6D=PLI)YRX0+@=_NFMFB@#B+C0];U+7K.ZN-/TVUNK263S-3B
M;/VF JX2(I]X@[E+*QP"IQGC$=AX8U"ZU&PEGT^UT%;*RDM7DTN4 S,^S[F%
M^5!M)&[G)''4GNZ* .=UC0;F?PJFEVUS-=2I<V\OFW<F794N$D;+8[*I X["
ML7Q=X3O-<OM0CM[%/+U"V6W:Z2]DB"]03-$#B4J#E>.>AP*[RB@#A'\"7UKK
MNEW=CKEVT$6I/>3I*D)*@PN@P=F3P53!/"].0#2_\(WJ-WJ-A%)I6G:>MG?R
M7;:C8D(TJL' "KC<&;>-V3C@]<C'=44 <MJ?AFYFT%=(BOKJ]AN+V%[M[V8,
MWD!E+H" ."%QC_:-.\0Z=>SZBTT&@:7JD4MFUOF<A)8V))PS$',9SR!R".^>
M.GHH \WN/ASJD6DVD=KXANWNT.GI+N2(KMMWC)*ED+#&UG"YP6/.<FIM0\(Z
ME/K%Y*+*VGNY[V*>VUMY0)K2)=F4 QD8VN JG:V\YQDUZ%10!3L+N>[^U>=:
M-;^3<-%&2V?-48PXX'7)_+J:YK0O#5_HVKZC=.L4]O:Q21:/"'VX21S*ZL<?
M+\VQ!UPL8KL:* *-\VJ'1V?3X[9=1V*RQ3L3'G(+*6'/(R V.#@X/2L7PMHU
MSI^IZK>M80:7:7?E>7I\#AE5UW;Y3M 4,VY1Q_<!/)KJ** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>guyaragreement003.jpg
<TEXT>
begin 644 guyaragreement003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HKS&Q\2Z[I5SXD,PM[V:;7TT^QA:1P%D>./ ).
M=L87YB ,YW>M=1I&MZJOB63P_KD-G]I:T^V6]Q9E@DB!@C*5;)# E>Y!![4
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M%% !1110 4444 %%%% '&W?@,W-UJDBZO+#'=WL>HVX6%2]K=(% <,3\RD(
M5(Z$\UHZ1X<N;76Y=;U;4_[0U%K<6L;) (8XHMVXA5RQR3@DDGH.E=#10!0U
MG3YM4TN6UM[^XL)V*M'<P'YD92"..A!Q@@]02*YA_AZ-0369-7U)9[O5+1;1
MY;2U6W5%4E@VW+;FW'.23T XK;O_ !7I>G:PVF3M.9H[<W4[I S1V\7S?-(X
M&%!V-C/I6O!/'<V\4\+;HI4#HV,9!&0: .23P3=7FJ?;M?UHZF383Z>\26H@
M1HY=N3@$D-\IR<\Y& ,<V-*\+ZM8SZ?'=>)KBYL-/&(;=(!"\@"[5$S@_O !
MV 4$@$YKJ:* "N.B\"-9Z;I*6&JO;ZCI<MP]O=F .K+,Y9T=,\J<CH0<J#FN
MQHH X\>!?-ADDO-4DN-1N-2MM0N;KR0H<PLI2-4!^5<+CJ3R3S78452U35;3
M1K+[9>N4A\V.+(4M\SN$7@?[3"@#DKS1]=N?B5J-YIM_)IL1TJWB\Z2T\Z*4
M^9*2!DCYUR#UXW<@YJ2+X?'3;G3+K1M5^SW%E:R6S/=VPN/,#R>8SXW+M<L2
M<CCG&*[:JT>H6LNHSZ?'.K74$:22Q#JBN6"D_7:WY4 <K9^"+_2[$1Z?XEN$
MN1>SW323P"2.;S>666,%0W/((QC-.L_!%SIFF"+3=<DM;YKZ2^EE2W'D2LZ[
M61H00-F,8&<@C.<UV-4M)U6TUO2K?4K%R]K<+OC8J5)&<=#]* .9L? $=JUO
M/)?A[I=6&JS-%;B*-W$1CVJ@/R#!!SDDD<YS5F/P5''X2L=!^W.5M;U+L3>7
MRQ6?SMN,\>F?QKJJ* /(?%-CJ'E^)]&TI=<MSJ<DA6RBT_S8;B210#(MQC;&
MC'EPQR/FQC->KV4!M;"WMV(+11*A([X %3T4 <O>^%;\:OJ%_HNN-IIU(+]K
MC:V68%U7:)$)(V-M '.1P.*DTGP;9Z+J&GW%G,ZPV.F-IT<3#)8%U?>6]<KZ
M=ZV]0OHM-L9;R=96BCP6$49=N2!PHY/6K- ',Z=H6HZ!I/AS2--O"]M9/Y=V
M[1J/-B"-ZDD'=M^[_*NFJE%JMI-K%SI2.3=V\,<\B;3@(Y8*<].J-4DVH6MO
M>VMG+.JW-UO\B,]7VC+8^@H XUOAY=&T&F+XAD71XK\7T-J+5=RMYWG%&DS\
MR[LXX!&1R<8K3F\&QS>'_$FE?;6"ZW--,TGE\P^8H7 &><;?:NHHH Y>\\%P
M7QU\2WDH36;"&R<(N#&(PXW ]\^9T]O>JUIX+OEU71K^^UQ)O[)$BPP6]BL$
M15XRAR Q.[D'.<<=!FNH74+5]2DTY9U-W'$LSQ#JJ,2 3]2I_*K- '*^'?!4
M?A^XTJ9+YIO[/TLZ: 8]N\%U??UX^[C'O75444 <?8^"KNP%M80:_.FA6US]
MHBLDA"R !MXC,H.3&&[;<D<$XJ!?A_,+%-$.MR'PVDXE6P^SKYFT/O$1ES_J
M]W;;G'&:[>B@#F+OP='=V/BFV-ZRC7\[F\O/DYA6+CGYONY[=:J>,/#+W6EW
MM_;O++<6^@WMC%;QQ[C*9$7&,<YR@ &.<UV5% '&:%X3OF&B7>MZM)>IIT -
MK:M;"(H[1["9#D[V"E@.%ZGC-/T[P7J&FQVFG6_B2X31+28216L<(6;8#D1&
M8-DIVQM!(XS71P:K:7.K7FF1.3=6:1R3+M( $F[;ST/W35V@#CG\"N]U=G^U
MF^R3ZO#JRP&W&8Y4968;L\AM@[<>]$_@5YCJL7]K,+.^U*'4A";<%HI4=&8;
ML\AO+ Z<>]=C4%[=QZ?8SWDPD,4$;2.(T+L0!DX4<D^PH Y2[\#W4BZI966O
M26>D:K*\MU:BV5W!D_U@CD)^0-SG*MC)QBM.Q\+0:?=ZQ+!,5CU&&&%8@O$*
MQQ^6,'//%;J.)(U<9PP!&1@U4.JVBZVFD%S]M>V:Z5-IQY:L%)STZL.* &:%
MI:Z'X?T[25E,RV5M';B0K@OL4+G';.*B31%3Q7/KOGDM+91V?D[> %=WW9_X
M'C'M5RXU"UM+FTMIYU2:[<QP(>LC!2Q _P" J3^%6: /-=0T%O":Z(;.?4TF
MMDN8SJ5I8&Z79))YACEA7+8)/##H5YZU+X1\)WEQ807VHS7<4J:]-JT8NH@L
MLJE&C&]1C83DMC'' Q7HM% '*ZKX)BU5?$@:^DC_ +;C@0E8P?),0P".?FYP
M<<57U/P=K&J6]S;S>)1);WL"Q7<4UBLJ[@NTO""V(B1SCYAGFNIL+Z+4;1;F
M!95C+,H$L91LJQ4\'GJ#CU'-1ZAJMIICV273E3>7"VL.%)W2$$@<=.%/- %*
MPL+[3]5@M89F_L2VTZ.".-PI/FJV V[[Q.P '.!TQDYQ/XBT=?$'AS4=(:8P
MK>P/ 90NXIN&,X[U:O\ 4+72[&6]O9EAMHAEY&Z#G'\R*LT 86I^'(M0U'3;
MZ1_,%A;7$'V<KQ.)552"<\?=_6O/-.L-4O[SPMIL,NNFVTN]CF>UOM.\E;2.
M-& 5YL 3,.%7:>023GK7L%5K"^BU&T%S LJQEG4"6,HV58J>#SU!QZCF@#GF
M\$QMX/F\/?;FV27AN_.\OD$W/G[<9]?ESGWHO?"%U/K.K7]GKMS8C4HH@ZPQ
MC?'+%C8ZOGI@8*D8()YKJJ* .:T3PM-I^OW6N:A?Q7>H3VZVVZ"T%N@0,6R5
M#,68D]2>W %:'B/1%\0Z*^G/.8 TT,N\+N_U<JR8Q[[<?C6K10!S3^$8WT?Q
M1I_VQ@->EFD9_+_U/F0K%@#/.-N>W6M^U@%K9P6X;<(HU3=C&<#%4M<UVR\/
MV275[YS"658(HX(FDDED;HJJO)/!_*IM-U.'58))88[B,1R&-EGA:-@P )X8
M>_6@#"U'PE>3:IJ-WI6MOIR:HBK>Q_9UEW%5V!XR2-C;<#.&' XS5>W\#7.E
MIILNBZU]DO+33HM.FDEM1+'<1Q_=)3<,,"6P0>^.:Z6UU6TO-2OM/A<FXL2@
MG4J0%WKN7GOQ5V@#F'\,:I'86$=IXENQ>6WF>;-=IY\=UO.6#QY48!^[@C:.
M*JZ;X M].;3)/MGFO:7MQ?2@0JB3/-&R, HX10&X'/3WS78UFV^O:?>+I\EK
M*\\6H;OL\L4;%"%!))., <'!/7M0!Y;;:;J=V?#^B6IUV.VL-3@G-A=Z?L2U
MBB?<0UQC;*H P@4Y.1G.*[J?P5'/X7UG1#?,%U.\FNC+Y?,9DE\S;C/..F:Z
MJJ6G:K::JMT;1RXMKF2UERI&)$.&'/7ZT <WKW@F\UT7]G+KS?V3?N'EM9[5
M9GBX (AD8_NP<9^Z<$DC%;MK#J4>O76^7.E"VB6WC*KD2 MO.?O'C9U_#O5N
M"^BN+VZM$6426VSS"T9"G<,C:QX;WQTI]U=0V5G/=W,@C@@C:21ST55&2?R%
M %#Q)HB^(O#]UI3SF!9]N9 NXKM8-T_"J7B#PW#JEZ=1F1KE8M-NK,V2X'GB
M7:2-Q/!^3'X^U:.BZQ!KNFI?VT-U%!(?D^TP-$S# (8!N<$'@UHT >3Z-::K
MJGB3PLOVG6Y[727>25=0TTVH@7R6159R!YLF6 RO&-Q[YKKH_!4<?A/3]!^W
M,5L[R.[$WE\L4G\[;C/&>F:ZJB@#DYO!]Z-1U>ZL?$%Q9+J$\5VJ1P@F*9%1
M<DY^=&5 "A'?K5KP]X8?1]4U'5;N\CNK^_$:2M!;"WC"INQA 3D_,<DDGITQ
M715FPZ]I]R+1K:5YTNIY+>.2*-F7?'N#9.. "C#)X)^M #/$.B+K^FQV;3F$
M)<P7&X+NSY4BR8_';C\:RKCP5'<>&=?T4WS*NKW,]PTOE\Q>80< 9YQCVKJJ
M* $ P *Y.\\'7K76J?V7K\NG66JR>;>0I '<.5"LT4F1Y98*.H;!Y&*ZVLL^
M(+'?,J>=((;M+)VCB9@)6QQQV&X9/0<YZ&@#$N/!E[#<ZA_8NO2Z=:ZE@W43
M6XF;?L"%XW)&UBJC)(;D9J_I7A.TT;5[:\LY66"VTN/38H",X1&+!BW<\XZ5
MT%% '*VG@J.UT+P]I@OF9=&NUNED\O!E(#C!&>/O^_2N=\->#=5U#PV+'5=2
MN(-*DU">>739+4+(P%R[*OF$Y$;85L8R<G!P:[^WU6TNM5O=-B<FZLEC>92I
M 42 E>>_W35V@#A]6\ 7=_'KMG;>()+33-9=I;BW%JKNLC(%)5R>%.T97'K@
MC-7KGP7'=:KJ,TMZS6&IZ>EC>6AB&7"A@K*^<J<.>,&MR[U>SLM1L["=V%Q>
M"0PJ%)W;%W-SVX-36-Y%J-A!>0B013H)$$B%& /JIY!]C0!@:9X;UBUN[-K_
M ,33WEK9(5B@C@$)ERNT&9@Q\S ]E&><5I^&]%7P[X<L-'2<SK:1"(2E=I;'
M?':M2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ]X'T/7\:-4\+:#K=REQJ>D6=W,B[0\L08[<YVGU&>QXK61%C1410JJ,!0,
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M!.LQ !S@ +M!;C+GM0-)O-6NY+E+/Q-*]OIET@DU:2- DDB;1&B*N9"<<G(
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MX;4IE::4*BJ'9%4!,XQCDX )Q0!UU%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45P&H?$@Z;IL$
MT^G W(U>33[N)9.(8HV.Z;..1L*-C_;%5/%/B/4;O5+!-+M5<6?B.*RBS.8U
MN'^S2,X8@'"JS '@_=/% 'I5%<%=?$&YT6SUB/6K&TCU'3Y[>!!#<X@F,_\
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M/?TH Z35]'L==T][#483-;.0602,F<>I4@X]N]6XHHX(4BB14C10J(HP% X
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MF691R1E77A@1R/8\X-<XNKH?$_B75;QW%AX>MEA15Z9,8FF?'<[3&H],'U-
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MODMA=PR6DK/%+%NVG[P!5@V,CW!H Z.BL+Q-K-[I$5M]DAL@LS,)+J_NA!!
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MZ49O]-> W*Q;3S&&"ELXQU8#&<U;H R&T0MXPCU[[1PE@]EY&SKND5]V[/\
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M\6_D\D8.!6E679>(=-U'6+S2K2666YL^)R('\M&XROF8VEOF'R@YH U****
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M, ./ESC=NYS7K0T735MM/MQ:1B'3F5K1.<0E5**1]%)'XU1_X0WPZ=5_M/\
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M%Y-NUM'@'"Q,VXISVR :K:9X/\/Z/?"\L-+AAG566-@21$#U" DA ?\ 9 H
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M9?0M/?:<+9$=T7:B((U89V]6R"< $\T =]8>-/#FIWR65EK%M/<2(7C1"3O
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M%FK6&EWT-M+X=DL(EGMGAENYOG8;8V 8X!V@D#);B@#K= UV6Z\()K>J3V;
MQM,SVB.L:J.HPV3D8(S6!:?%"PN(?#=Y,8+6RU6WGDG+L2T,B",B->!N/[S'
M Y[5V5E%(-"MH64K(+95*MP0=H&#7G?A*PO))? 'VC2KV!M)L;NVN3<6S)Y4
MNR( Y(Z'Y@#T.#B@#NU\4Z$VA_VT-4MO[.W;//+X&[.-N.N[/&WK5C2M:TW7
M+=Y]-O([B-'V/MX*-Z,#R#[$5YCJ>@:OYES>QP:E#!:^*9KQA9PJTQB:!5$T
M:.K!\,3T!/7'(KI_!%E)_;6M:JS:W*MRL,0N=5B2!I]@;E8EC0J!NQEAS^%
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MCB@AA:1HHD0ROOD*J!N; &3ZG  S[5)10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !16"/&?A]KBY@&HKYML+AIE\M_E$! E[?PDCZ]LUIZ7J=GK.F6^H
MZ?.)[2X7?%(%(W#UP0#0!;HHHH **** "BLZXUW2[6+49);Z';IL?FWFT[C
MN"?F R1P"<=:LV%];:GI]O?V<HEM;F-98I "-RL,@X//2@"Q115;4+^VTO3[
MB_O91%:VT;2RR$$[5 R3@<T 6:*H:7K6GZTEP^GW(G6WE\F4A2-K[0V.0.S
M_C5^@ HHHH **** "BBB@ HHHH **** "BBJVH:A:Z7837U[)Y5M"NZ1]I;
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M*;)(D,3RRNJ1HI9G8X"@=23Z4VWGBNK:*X@D62&5 \;J<AE(R"/PH DHHHH
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MZA,FG>+XK."9IR)?+9$8;F'+,I8X8\UIW.M:J\M]IJZG<0)=>*ETW[2&&^"
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M1V\H$$%5R2%7!/RCCVI;7P5X=LM22_M]+C2>.0RQC>QCC<]62,G8IY/( /-
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M;6-4,VFQ6IFET\6RS$2A@JH$5G91GYL8 ;%>R0P16\2Q0Q)'&HP%10 .W04
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M9V32Y*+/,$+ =3@]O>J%WXRTJT\4:5H37,#2ZC \T;B9<8!4( .^_<<?[IK
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M2W\):QH=UI^H:-/ILUW%IXL;J*>'[-#( YD#H(EPA#,_&#D'KGFNWHH XO\
MX1KQ%:7UAK5OJ5G>ZQ';26UVMTK1Q2H\GF (5!*[#P,@Y'7FH]/\$WUOJ>G:
MG=7EO)>+JD^I7NQ2J$R0&()&#SA1MY/7!/M7<44 <3J'AC7X9]>BT2ZT];+6
MR9)3=!_,MI6C$;,@7AP0H."1@^O2LZ3X=W%O<VMY!9:#J<O]FV]E<0ZK 657
MB7:)(VVL1D'!7 S@<BO1Z* .(C\'ZGID.AWFESZ<VJ:;%-#+&UN+>WG24AF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEZ$\8&<9IOA1Q9ZUX=L=./\ :-O!(Z?9+W3##>:4A1MQ:5<*?[IR/FSP3UH
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M# 8&,F@#27Q-H#/,BZWII:&/S90+I,HG'S'G@<CGW%6(]7TR;3/[3CU&T>P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ=IG6/\ N*6/"_2J,'PL\+6^BSZ0MM<&REG6X1&N7)MY%S@Q'.4^\>G7/.:
M.)NO'GB_0/"'B62ZCO)7M)8(].U'4+$6[D2G#;T'RY3MZY&:LQ:?J^F_&WPK
M;ZOKG]KR'3[AUF:!(F7*MD87@C(R#UZUW%G\/?#EIHVI:8UG)<PZF0;V2ZF:
M66<C[I9R<\=L=#S4>B_#?P[H6JVFJ6D5T]]:HT<<\]T\C;6&W;R>@'0=J .<
M^**1WOC/P'IFH@-HUS?2FXC?[DDBA?+5NQY)&.^36Y-IW@S0_&B7D$,%MX@%
MA(T=M;9C\V$9))1<*QX/7T]JW_$'AS2O%.EMIVL6BW-L6#@$E61AT96'(/TK
M-\-> /#_ (5O)KW3[>9[V9?+>YN9FEDV?W06Z#@=/2@#S3_A,/&5OX$MOB-)
MKT$MM+<@-HHM4$?E&4Q[5?[V[C.?\*GUGQ-XPGE\>75EXA-E;>'Y4>W@%I&Q
M<$9*L2.G'UR>O%=O#\*O"4&J)?)82[4G^T):&X<VZR_WQ'G;G]/:M*3P3H<L
M>NQO!(5UP@WW[UOGP,#']WKVH XO0/$/BB'QQX7M]3UA+VT\0Z:]V]L+98UM
MF";P$(^8CH.2<\_AS5MXP\;K\-3XZD\2Q2BRN_*?3S:1A9T\T(0S 9#?-VQP
M/7FO7X_"6D1ZEH^H+#)]HTBW-M:-YAPL97:01WX[FN$\%?![3[30[0>)+5GO
MHKEYW@CNF,$AW$HS(#M8@8[>QS0!2\=>+]<AU#6)-#U^^7^S;6.8V=EIB2);
ML5W'[1+)QSZ+V[9'-I/$7BGQ'XOT'2;+6AI<&H^&8=2N#';)(5E9CDIN'!Z#
MG(QGC/-=9JOPU\-ZQJE]?W4-T'OT"W<4-U)'%.0,*752 2.WOS5_3_!VCZ9J
MEEJ5M%*+JRT]=-A9I2<0*<A2.Y]^M 'FEGXY\41> =-\1W5^)4TW66L]6*P(
M//M]X7>>/E()'W<=>:[7P/KNI>)=:\2ZB]UOT2&\^QZ=$J+@^6,22!@,L&.,
M<^M5?$?A*XT[P-?^'?"FCPW2:F\OG_:KO:(3(.9.<[L'& ,5T?@[P['X4\):
M;HD95C;1 2.O1Y#R[?BQ- 'D^O'4(_C+XIGL/#-CK[0Z= [V]T5RJA%Y0$'+
M>PYJCH>N7/A;X7:KXGT6:S%UKNJJD=M:1%HM/9LY780,L!VQC[O45[9;>'--
MM?$M[X@BB<:A>1)#,Y<D%5QC Z#H*RS\.?#)AUBW-@3;:O();N#S6V%P<AU&
M?D.><C% '#VWC/Q9H-EXD>]CU+4+6ST[[5:7FI:<+5EFR%*,%X(^;=ZX!IUM
MK'C#2=5\"_;?%"ZA!X@D$EQ$;2)"@*!MJD#E?F'/!X]\5W.D?#_P_HZ7X2WF
MNY+^+R+F6]G:=Y(L8V98\+CL/;T%<K<?"JWTOQ1X6OM CE-OI]TSW!N;MI#'
M%CY50,3@ YX% &=)XX\0)\,/&^L?VCB_TS6I;6TE\I/W<8DB 7&W!X9N2">:
M?JGB34[3Q;XAE@EA2:W\'F]BE%M'Y@E&""6VY(S_  D[?:NIOOA1X4U&ZU":
M>UN=M_(9IX$NI%B,A.2^P'&[W]^*U+CP1H=U>7EU+!(9;S3O[,F(E89@]/8^
M_6@#S:\\4>,M%^'ND:U<:ZUY>^(IK2" 1V"?Z$'5BS*H_P!8Y 7@\9S@4EYX
MQ\9Z1X2\6-++J)^PQ02Z?J5]IRP29:15=&3&T]>..GZ>G7G@[1+_ ,*P>&[J
MT,FFV\:1PH7(:/8,*0PY!'K6=%\-/#<>CZGIKP7,ZZGL^V3SW+R32A""H+DY
MP,#I0!QZ7GC=_'5CX=;Q: FJ:4+]YEL(LVS D%8QZ< 9;/&>_-92?$CQ-<>!
M_#40N9!J>I:A-:3WUM:+++LB/5(_NER".W8UZX/#.F+K]KK8B?[=:VGV.)]Y
MP(LYQCH3[UEM\-_#3>'8]$^R2BUAN#=0NL["6*4G.Y7!R#S0!Y]J/C;QII7@
M/79IGNX[FQOK>.RO[VQ6%YXG;!5D(VY&,$CU%;!O?%5CXZU#PK>>)#=I>:&]
M[%<?8XT-M+N*_*!U7@\'/;\>G7X:^&AH%SH[6T\D%W.MS<RR7#M+-(IR&9R<
MG_/K6Q+X<TV;Q*OB"2)CJ"VALPV\[?*+%B-O3J>M 'C?A.?Q;I7P,TB[T&[F
MN3<7C PPV\;36T'FR!Q$&_UC%@#SDC=Q[=7X*O8_&^FZKHVLZM?7KVES;S_9
M[ZQ6TNK<*PD4/M^5@63L <9]1C;@^%?A:WT9])2WNOLOV@7,(-T^ZWD&<&)L
MY3J>G7OFM?P]X2TKPRUU+8K<275VRM<75U.TTLNT87+,2< 4 7M&T>TT+3%T
M^R#"!9)) &.3EW9S^K&O,['5?%D_A[PSK+>)9/.U>_%C+";6'RHXV\P!U&W/
MF#8#DG&>V.*];K%A\*:5!IFF:?'"XM]-N!<VR^8<JXW8)/?[QXH X;4?%&O:
M!#K>DK?W&H7,.J6EE:W<D$;3(LZ*Q^50JNP^8+P,DC-6;;Q%K>F#6$N[K4(K
M"+3C<0ZAKEI&K03!@NTK$!O4[@0,9R".<UU]YX3T?4/[4^U6S2?VFT;W'[Q@
M=T:@(RD'*D;1@CN*J+X$T1K>_BNUNK][Z$03S7ER\LGE@Y"JQ.5 //&.>: .
M6T_Q#K-IXFMK-K[6[BUO-/NI2VK644!$D80AHPJJP'S<AAW'7FG:1JGB.#3_
M  5K5[KTMX-;EA@NK1K>)8E$D#N&3:H8,"HSR0<G@#BNIM_!&E0ZA%J$LM_=
M7L43PK/=7;R-Y;C!7DXQ]!UYJZOAG3$T_1[$1/Y&D/')9C><J40HN3W^5CUH
M XC2->URW\06,>OZCJ5G-<W;0M%-9Q/I]P"6V)!+&-RM]W&]LG!!%=%XY<R_
M\(_IA_U&H:O#%..S(BO+M/L3&H]QFI[3P)HMG=P2Q"\,%M,;BWLWNG:WADR3
MN6,G P22!T&> *L^*M(GU;2HS9[?M]E<1WEIO.%,D9SM)[!AN4GMNH YSQ-J
M]\_B&\L;'5]61K:W1A;:/8QRF-V!.Z:252H!&,*"O )-5IM9NM0\%^!_$\Q4
M:@UY9B1D&-XG/E2#'H0^<>H'I73WG@_3-2U&?49?MMO+>1HEW%!=O&DX48 D
M"G!P...HXY%5I/"J1OX=TFTB,>B:3)]J.Y]S,Z B).>< L6S_L*.] %CQGJ<
MFF:-$8=1:QEGN8X5>*V,\SYR2D28.7(!QD$#DGI7G6K:SJ5SH7BO2;V?4IK>
MV33Y[=M3ACCN!YD^&!$8 (^0$9 /7VKU36]"LM?M88+SS5,$RSP2P2F.2*09
M 96'0X)'XUECP#H>V^\Q;N9[](DNI9KIW>7RWWH22>H/IVXZ4 0^%?\ D;_&
MO_80@_\ 26*N3O-=OM$D\1)IPE%SJ'BF.S$D,0EDC5K6-F9%;@MA"!GC)KTR
MSTJTL+Z_O($99K^599R6)#,J*@P.WRJ*H7/A'1[RWU"":W<K?72WDK"5E99E
M555T8'*D!%QC^M '$3>*?$FCV.K1[=1>+9;"RO-7MHXY(I)9A$VX1X#*-P8'
M Z$'-:DUYK/AOQ7%97?B5KO3WTB[O&>^AC!BDC,?S,8U7Y!N)QUZ\GC&E>>#
M+>WT35TL8%U+4+^)8Y'U:>27SE4\(6SE1@G&.A.>:Q=#\#RW/B":_P!5TV:W
MLVTV33VAO-2>\EG$C+G+$G:@"D  Y^8GB@"KH_B+6$\3^'(VU'6;RUU1I([A
MK^PCMX'(A:0-" JR 97OG@]<UTGPT_Y$2T_Z^+O_ -*9:GM/ ND6EYI]X9=0
MN+C3VS:/<WCR>2-I4J 3C!!YXR<#G@5LZ3I5IHFG)862,ENC.ZAF+'+N7;D^
M[&@#S&]\6:M%Y6K6>L:I>QG4HX6\NPC33C$TXCVJ[*)&(!QN5CEAZ5:U'5/$
MKZ3XQUN'Q!+;KH=Y.MK:I;Q&-UC17*R$J6(.2."".N372?\ "N= ,"VQ^W&S
MCF$\%J;R3RH'#;\HN<#GZXR<5JOX8TN33-7T]HG^SZM)))=KYARS.H5L'MP!
MTH Y6YNM9\377B5;;69-,M],B2&&WCBC997: 2,TI922OSA0%*\ G.:W?!;M
M'\--!=3AETF @^_E"GZCX)T?4[J2XD^UPM-"L%RMM=/$MS&HP%D"D;L D>N#
MCIQ6O8Z;;:=I%OI=LI6UMX%MXU+$D(J[0,_04 >70^(/%%KX,\/:C/K%W>7O
MB&2"/$%G$3;+Y;NQB7 #.P4#YLC.2!VJR_B?Q+I]O>V.=0"S7%G;V-_JMM&D
ML)FD\M]RIA6"\%3@<G!SBNWE\):1+X<M-":&06=F(_LQ65EDA9/NLK@Y##US
M69J/@RW@T#5(;"U74[Z^\OSSJES([7"HPPOF9RA SM(X#8- &%K.H^(?#6HZ
MS9KX@GOH8?#=SJ%NUQ##YL<R, "2J $=< CN<YXKH)]9ODU[P=;+<8BU&*=K
ME=J_O"L(8=N,$YXQ65X<\&3'Q!?ZGJEA+!;3Z<=/,%WJ#7DTRLV6+.2<+@!0
MH/J>,UN:9X&T?2]0L[Z-[Z>XLE9+5KF[DE\E"NTHH8X Q_(>@H X;0-5GA\&
M^%M.M]4O[<RVDTKV^E68GNI ), Y965$!)R2.20 >M1I>ZMXAB\+->ZG>PW%
MKXDN;+?Y4*R,$CEVLXVLH< %3CCD\9P1W8\!Z-%%8K:M>V;V4+6\4MK=/&YB
M9MQ1B#R,\^W:@> ="CTR.P@CNH(HKTWT3Q73K)',006#YSR"<Y/<T <[/JGB
M"^T'Q#XHM]<>T&F3W2VVGB&,PLEN6!$I*[RS[#R&&,C%3V-WXA\4>(]86UUZ
M;3+2UM[:2W@CMXG.^:#<=Q922 ><>I/TK=O? FB7UW<S2K=K#=R"6ZM([ITM
M[A^/F>,'!)P,^N.<UJPZ5;:?>:CJ-I 3=WBH9%+X#F-=J =EXXH Y+P_XJU+
MQ!>^'K))/)N(K>6?6E"+D/&3#Y?(^7=*';C!PGO6EKUYJ-[XNT[PY8ZA)IL4
MMI->W%S"B-*P1D0(F\,HY?)."<#M2^#O#\VFW.LZS?6<5GJ&L77G2012>8(D
M4852W0DG<QQQES6IK/AVQUQ[:6X-Q#=6I8P7-M,T4L>X88!AV(QD'@X% 'G6
MJ7>L:E<Z=HTVI@WNF^*4M8]2\E-S(;220$KC;O <KTQD X[5)XHO-1M])\3>
M'[Z_DU&.S.G7,%S,B+(%DN "C[ JD@ID' X/M792^ ]!ETJWT]H;@1P79OEE
M%RXF:X((\UI,[BWS'G/8>E2)X*T==,O+&1;B<7LL<MS//.SS2LC IER<X&T8
M X_.@#E[SQ#JRZEJFFVMTEM)=>(XM-BN1"A,$;6RR,1QAFX8 MG[P],47>L:
MQX?U/Q%877B;S+>UTZVFM;J[M4=XGDD=/F6-1O;@  #GY>.N=WQ%X7273+[^
MSM.AO)KV]CN[F*:X>)F*A5W12*<QN BD'IP?6L?0_ *W5QKEQK=E+!!J,4$2
MPR7[W$^8F9A*TN<AMQ7&#P$% &4VK:O-?:KHLFHZX;.XT*YNEDU.T@BE61&4
M'8%0?*0Y!#+QVIIUZ_\ "GA?PK/'.UXJ>'+J[*S1IDLD4+(N54$*-V..2.I)
MYKN;7P5I-OJ!U"1KRZO&MGM7FNKIY6>)\90Y.,<=L=_4TMGX*T:S@L8?+GN(
M[*":VA6YG:4"*4*&0[NJX4  ]!0!B"XUWP_?^')[S7I=4BU:X%K<P2PQ*J.T
M;.'BV*" "F,,6R#ZUC66L>)1X9TKQ1/K\LIEU1+62Q^SQ"%H6N3#R0N[?CG(
M..V*[/3/!6D:5>VUU$;R=K12EFEU=/*ELI&"(U8D#CC/7''2K"^%-)30X-'$
M+_8H+A;F-?,.0ZR^:#GK]_F@#B[G7M<T_P 1RR:OJ.I:?;?VCY<$BV44VG/;
MEPJJSJ-Z2$<$LP ;VKTZN:D\":++>23,+SR);C[5)9"Z<6SR[MV\QYQ]X!L=
M"><5IZ;IDEC?ZI<O</(MY<"5(V<L(@$5<#)XR03@8'- '.3RZUX@\4Z[86>N
M3:3!I*0I$((8W\V5X]^^3>K909 P,=#S5:QN==\4:QJ5I%XB^P)ID-N@DTZ*
M-TN)I(A(9"9%;,?( 48SSS6_JW@_2]8OI+R5KRWGFB$-PUI=/#Y\8SA7VD9Q
MD\]>3S45WX'T:YD22$75@1;K:L+"Y> 20J,*C!2,@#(!Z@'K0!R^@>(M;\;7
M-A:#4WTGR],%W<26<<;-/*9GB&/,5@$_=%L 9.X#-8^EZWJVE^&]"T:VENC/
M?ZGJ?VFYT^W227;%/(6\M7RH+$CDYP :]$NO!>C3QV*VZ7%@UE#]G@DL9V@=
M8N,QDJ>5X!Y[\]:C7P+H4>BVNE00SP0VD[W%K)%.ZRP2,6)*OG/\1&.F#@T
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MXQCM\7,%N+%KR+>)+<1 -'%D'+>9ORHY.0: /1KK4+*R4M=WEO;A0&)EE5,
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M.Q 5%'=B2 /K6"WB[6+ V]QK7A::RTZ:5(C<1W:3O"7(53(@' R0"06Q4GQ
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M!\S=MVLK$,,)U]_7.*_C[6]0\/\ A9K[3(&EN/M,$65V?(KR*I/S$#G.T>[
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MX/2@#H9D,L,D:R-&S*5#IC*DCJ,\9K-T'0H=!LY84N)[J>XF:>XN;@@R32'
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M\MMLMY3/YTS@ .244HBX/ R3NYZ5V-M<P7EO'<6L\<\$@W))$X96'J".#4M
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M[I[6]US3+:XCQOBFNXT=<C(R"<C@@U:M]4T^\\C[-?VL_P!H1I(?*F5O,52
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >9WNH2_V!\1=?VQ/<V\DMG"LT8D18X(QA2IX(+.[$'KNJY/?>)=3USQ#
M:V&M1Z?;:7;6\L(6T20N[Q%B&+?PY';GGJ,5J-X6\Z^\2:;<1N=%UR,3.T;A
M6CE*B.1?7Y@J,#CKNSVSL0:!96]YJ5TGF>9J,<<<^6XPBE%QZ<&@#D=*\0:Y
MXON-/MK/4$TD?V+;:C<RQ0+(SRS;L*H?("#8<\9.0,BL[5M2U;2]7O\ 49[B
MT?5K3PC<2F:V&Z(R)+D, ?<#(^HKK&\"Z:D&GI97>H6$UC9K8QW%K.%D>!>B
M/D$-ZYQD$G&,U+!X(T*V3RH[9_(_LY]-:(R$JT+MN;/<L222<]S0!1U;Q)>:
M;J'AOY@T%W:W,]T@49?RX0XP>W.>E<S='7]0L/!6MZCJT4\-_JEI<-9K;JBP
M;U9E",/F. <'=G/7BNNT[P+IVGZA97SWNI7LUBCQ6WVRX\Q8XV7:5 P!C'?J
M<#).*C@^'NDV\]BRW>I-;:?<"XLK1[G,-NPS@*N,XY( ).!P,4 <Y::[KEU/
MIFG:?=6UBU]K6IV\LJVJ'"1-(00O +?+U/4G)S4O_"3>(+?[1H+7\4NH_P!N
MQZ7%J3VZC;&\ FWE!A2X&5'0$XXKK+7PCIEG=VES%YWF6MW<WD>7R/,GW;\\
M=/F.!VK-\2>%D:POIK#3WOKB\OXKR:,7/DRJR*J!X7X"N JD9.#R#UH =X?O
M-:A\::KHFIZFE_;VUE;W$$GD+&_SM(#OV\$_)V &,<=:VO$J2R>%]56&8PR&
MUDQ(%!(^4]CQ7.>"?#M]8:]K&M7MO=V_VR*"&..^NEN)VV;R7=E)49W !5/
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MW&;>)P<@A<9P"<A22!Z5U5 'EMLNHM\0/&7V+PSI^KK]KM]TEU=+$4/V:/@
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MQ70^(-5DTSPMJ&JV<1N)(+5YHE4 [B%R#R1QW//0&@#450HPH  ["EKA=/\
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MTA4$@D#(Z'TKE8?'VGS212BPU%=+FN!;1:JT:_9WD+;!_%O"EN Q7;GO75T
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ME$$[G.W&&+@-CY2R@'CU% '4A0"2  3U]Z6N8LO&UKJ%Y"D&EZH;&>X:UBU
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MY-.BN'VM%,@0CS7SF0!4.< '!''6O1J9'-%*TBQR([1MM<*P.TXS@^AP1^=
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M@C"E>J\'IUQBNW\(Z=J>E>&;:SU>Z:XO$+DLTIE**6)5"Y +E5(&X]<5N44
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M"9-WS0 @EP#C .,X.:OZUX0UJ[UR[N;#3+:RU&6Z5X=;LKUX,19!Q-"/]8P
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M=$.G!R?F+!XR./HAK+TCPEJEGK&D74RQ>7:ZGJ=U)A\G9.7,>/?YAGTKOJ*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'FC>(=6AEEMM)33[6>Z\4RZ
M>TAM\C9Y)8NP!&Y\J#G/. *EF\6:_I3ZKHTTUI>:E%?V=G9W;0&-/])'!D0-
M_#ANA&>.E=*O@W3ENDN!+<[TU5M6 W+CSFC*$=/NX)XZY[T7_@S3-2FU6:=[
MD2:BT#LZ2!3"\/\ JWC(&58'GG/Y<4 <UXM@U^UT-H=6O;2^M?[1TYH+B.+R
M9 WVI-RL@)&.A!![D8[U=NO%>I1>$O&FI*8?M&D7-S%:Y3C:B*R[AWY)J\?
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M+#"A8_+&WCCCUSS0!P/AZ6_N_%'A^\%Q;PV[^$DG-I'; 1J"4RBC.%&<$<<
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M6+;K>ZMF7>GR[2"&4JP(Z@@U0/@;36T=[%[B]:X>[%\=0,@^T?:!TDSC;D
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M7Q%HTVF7C2I%*58/"VUT96#*RGGD,H/(K)B\$P?VH=3O=7U.^O6LY;)I)FC
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M.&G1B1E(,08-DX ^;(Z]/:@#A+>>_P!1\2^&7MY[6R1==U6/RX;4;6V><"Q
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M06KVL.L6GFR7*J42,R /N+<!2.#GC'6N5N] T:^\._$G59+*WFNK>YN&M+C
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MS8_,\O>OF8SMSSCZ4ZO$[IM.TWQ%<WR_V1JTG]N F*3=;ZO#*90-J$9,B#/
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M &=X&^QFW_X23^T[7[=M/^E>9G]]Y_\ %]_^]WQB@#V_<,$Y&!UK-L=:@O\
M6-6TU(Y%DTUXTD=L;6WQAQC\#WKRO7-9TZQ\"_$'2[F\ABU"34KHI:,X$KA]
MK*P3J01SGI@'TJWK]W;6M_XP2[MUGAN=2TV K+.881NACP9G .(^/FXYZ=Z
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M2$:/$-/O'M)#)@ LJJ21[?,*T5=74,K!@1G(.>*\?N?L_P!KN_[6V_\ "/\
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M6.>",GBC6-'\2^)+W6+R3118I<>';G3H(9+J-W:9V!&=I( /;GMSC.*]*HH
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M/EQAF )VCEVQG"@C)P,U53PU=:?8VL%AJEX\_P#:*7EY<W$H+3KGYU8!<8(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9$9O-5PN2A"@],XSUJ2[\?:CI6G:LNI:=:)J&FWD%M)(D[&V59@&65FV[E4
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MDR3\Z_=XR?QJH_Q-/V#2XFCTRQU.\>Y28W][Y5M!Y$AC<[R,MEA\H SUSTH
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M6RDN+JY?R(R8$;S7.#L7HN ,9QTR375>&=6N]8TZ2XNXK(%92D<UC=">&=,
MAU(Y'4C!YXH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ?MGB"Y$8CA)VH[DB0^D?'WO>@#LJ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(@F;3S:"0YV[C'LSZXS5'P_X9N-(UEKV6>)T.E6ECM3.=T._+?0[QCZ5T]%
M'!:=X+U?0K/0KC3;JRDU/3;::TF2?>(9XI'#\, 2I!53G![U8;PAJVH7ME=Z
MOJD4\BP7T4XC0@(+@(%2/_94+U;D_H.UHH X'3_"7B3SO#$6I7FEFST%L*+=
M7WW"B%H@QSPIP1P,CD\]!42^"_$46D:;X>BOM._L?3KV">*5E?SY(HY0ZQL/
MN@@#&X$YP.!DUZ'10!YO=?#JZCN]42QM?#LL&H73W*WE_8B6YM3(<N%!4K(
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M,\94CDT[3_A_J%JS%Y].C5M;M]4$=K"8XT1$"F-5_#@]^IQ7HE% &:+C4?\
MA)C;>3'_ &6+,2>;L8.)MY&W.<$;>< 9&.>HK2HHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *A
MN[J&QLYKNY?9! C22/@G:H&2<#GI4U% '.>%/%7_  E#:JPL)[..RNQ;HMPI
M61U,:.&93RN=W0\XQG!XJ;6=6U>#4[?3=&TI+J:6)II+BZE:*WB4$  L%8ER
M3PH'0$U0\-)+9ZSXRN)X95C;4A*A\L_.HMHLE?[W((X[BLSQ;XTGC33;'38]
M0LTU&#SY=0&G32M;1'H BJ?WIYX;A<9/84 =-X9UX^(-,DN)+4VMS;W,MI<P
M[]X26-MK!6P-P]#@5A:CXSUC3K6[UF70$CT*TN##(\UPR7+('V&58BF-N>0"
MP)'/<5>\.7VAZ;H&G6VDP7XM)+@VR&6TE60R'+,\F]0>3DESQDUR5WXGM/$/
MB"1==AU6WT:PN?\ 1[!-+N7^UNAXEE94(V C*H/0%O2@#U6BBB@ K(L_%/A_
M4-2.G6>M:?<7HS^XBN%9^.N #SCOZ5=U)Y(]*O'AM_M,JP.4@SCS6VG"Y]^G
MXUY%827M[=>"MKW+K:7T9FL[?1VMH-/!B=2A=@6)!(7[V#R3VH ]/7Q7X>?4
M(K!-<TYKN9BL<(N4+L02, 9ZY!&/8U<_M;3OL5Q>_;[;[+;LZS3>:NR,H<,&
M.< @CG/2O,UT:5/A1*J:=(+UM<^T;1"?,S_: P^,9^X.O]WVJQJ^FW(\=R>%
MXHB=*UVYBU:<C[J+%_KT/^^R0?\ ?;4 >G@A@"#D'D&LFU\5>'[Z_2QM-;T^
M>ZD7<D,5RC,PQG@ \\<_2M>O%?#T]MJOP[\.:%I>GW2:LE_!<;_LCJL.R?>\
MYDQMP5##@Y.['M0!Z!I_CS2)K^^L=1OK&PNH-0DLX89;E0TP7&& ..I./PK9
MF\0:/;ZG'IDVJ6<=_(^Q+9IU$A; ;&W.<X(/XBO/+[1I&\!_$8#3G:ZNK^[>
M,>22\N%785XR>>F._2MO2+!XO%GC'46TTS7#1VOD%TP9=MO]U6/^UP<=Z .B
MM?%/A^]U,Z9:ZUI\]\"1]GCN%9\CJ, \D=_2G0^)M"N-6;2H=8L9-04E3;+.
MID!'4;<YR.X[5Y5927MZ?!JJ;C%KJ,#S:?;:.UO!IX*L"I=@6)!;;][GDFK>
MF_:+'5]-L--CO+B)-5+/HVIZ66:Q#.Q>9+D # !+ DMD$#.: /2V\2:&FKC2
M&U>Q&HDX%J9U\S/IMSG/MUK4KPV+3+Y-#N/#M]>ZN-2DU%W:SM]*5C(YF+K.
MLY7&,8;<6XQCMBO<J ,&#Q3IT.D0WNKZEI=F9#*05O%:-E1]I*L<9QE<^A.*
MK:MX]T#2K/2KS^T;.:VU*Z%O%,MR@0#G<^<]%P ?0D#BN0\,:3/_ &AX(:ZL
M)<6O]L.QDB/[IFG&PG(X)!./7M4=S;2Z=%/=R6-RMI;>-#=/Y=L[[83'@N%4
M$E=S=0* /2(_$.C3:F=-BU6R>^ 8FW6=3(-IPWRYSQ@Y^AINF^)-#UBYEMM,
MU>QO)XAEXX)U=E&<9P#TSWKAH] N[OP;X]BLK,QZE?7][Y+,FQY5(  !/8C(
M';FDO98_$M]X;M_#5A=V=SIZRF:66S> 6<9@=/*)90,ERGRC/W<]LT =+J7C
MK2;?4+&PT^]LKZ[FU".SFABN5+PALY8@9Z$8Q[UNG5M.%DUZ;^V^RI(8FG\U
M=@?=LVELXSN^7'KQ7EMM);2Z/X%T:+1KV/4]*O[87:M9.HMBJE9&+[=I#-SD
M$YSGM45Y<RP^"-2\,'3]0;51K+2&);.0KY1O1*)-^-NTJ?7K0!Z?>>)-#T[4
M8M/O=7L;>\EQL@EG57.>G!.>>WK1J/B30](NXK74=7L;2XE&4BGG5&89QG!/
M3-<-Y]KI#>+=-UG1+K4;S4K]YH(%M7=;Z)E41J) I4;<;3DC;C-9>I6]WIVN
M^*4U*ZU"V74BK0Q6^EB\%W%Y*J(E?:>00R[21USW)H ]0U/7]'T5H5U/5+.S
M:<XB%Q,J%_IDU!X6UMO$?ANTU9H5A-QO_=JVX#:[+U_#-<1I,:>%-9\S7;._
MG@N-$M+2UE>U:X<&,.)('\L-ACN4^C>IQ72?#6WDM/A[I4$MK):NBR?N)5*M
M&/,? (^F* 'S>.-+T_Q+J6E:M=V>GQVL=NT4UQ<!/-,@<D8..FT?G7017]G/
M<M;174,DZQK*8UD!8(V=K8]#@X/M7!W%]8:+\1?$=WJNFW<D5S8VL4,\=D\Z
MR8#[H@54\G*\=\>U8,UIK7@WPGX9UB"U?^U!:2:3);DY9?.):W4_[D@1?^!&
M@#URUN[:]@\ZTGBGBW,N^)PRY4E6&1W!!!]Q7)ZQ\0M.TZY\164)@FO=&L/M
MGE&=09CM=B@ Y&T*N?3<*Z'0-(BT'0+#2H3N2UA6/<>KD#EC[DY/XUY_XNCE
M35?'5M]DN6EU'P^@M#';NRRLBS[E# 8W?,O!.3D4 =UI/B;1M:E-O8ZI97%W
M&@>6"&=7>/UR <\'BGVGB30[_4I--M-7L9[V/.^WBG5G&.O .>._I7(ZYHUQ
M_:7A:'2K8V\B:;>VZR1IM$),"A 2.@W8Q[BN;\/64TT?A/2WN=7-UIMQ$\EB
M-)6$6912'+S%0"IY&0Q+[N] 'KNHW]OI>FW-_=2+'!;QF1V9@H  ]3Q6-I_C
M;0KOPM8Z_<ZE9V=K=QJ?WMPN$D(R8\]V'0CKQ6QJ<33Z3>1(NYW@=57U)4XK
MR"S^U1P^#=3,^H:?9V6C'3Y9AIC2M:W0$>X-&R$J&"D;P,<8S@T >K3>(]$M
MM/AU";5[&.SG!,4[7"A)  2=IS@\ GCTJO-XQ\,VPB,WB#3(_-V[-UT@W;E#
M*>O0AE.?0CUKS[2=$:6\\.2/;7UQ:2Z_=7A-Y:"(8-N^)/+ ^12XW#< <G..
M:T]0T<O-\3'&G%FN+&.*W(ASY@%IPJ<<X;L.] ';V?B#1M0O[BQL]5L[B[M@
M3-#%.K/& <'(!XP>/:FZ;XET/6;F6WTS5[&\GB&7C@G5V SC. >F>]<7=:/L
MNO"4<>ES/ FA7D$T4";"08H<1YX"DG=C..<U4\'RW2^(]%M+9[C4[&"UDC9M
M0THV]QI:A1A#+M56)("D8R<9SB@#O/$NKW&AZ(]];6?VN59H8A%NQD/*J$]#
MTW9_"L_1O$]SJ2:>]U:VMG]IEO(WCEN<2 0N5!12/FSC)],CK73UQ_BBVGE\
M9>')8X9'CCM[\.ZJ2%)C4#)[9[4 ;-GXI\/ZA?I866MZ?<7;H)$ABN49F7&<
M@ \\<_2G_P#"2:'_ &Q_9']KV/\ :.<?9?/7S,]<;<YSCMUK@M/T>2V\$?#=
M(]/>.>WO;5Y@(2&CS%)O+<9&2><T[P_/;6&A6?AS4-"NKS7(M3,DD1MG"E_/
M+?:?-V[=H4ALYS_#0!V/ASQ-!KEA#+-Y-M<SSW,<5OYH+.(96C+ '!/0$^FZ
MM";6M+M[2ZNYM1M8[>U<QW$K3*%B<8RK'/!Y'!]17F.D>;H4WAC5-0M+R.S@
MN=8BF=;9W,1EN-T995!(#!3@XQR/6FQ174MN^L3Z9?'3X?%DE]/;O;-YA@,.
MU)?+QN(5BK8QD8/&10!UJ>.[>]DUW^S)-.N+?3K>WFCNGO L,AD+@AGP0N-G
MYFMJ]\5^'M-N?LU[KFG6\_F>68Y;E%8-@'!!/'#*?Q'K7FFLJ-8A^(5YI>F7
M8AO+.Q$3FU>,W3JT@9E! )[#IVSTQ6W+I!EM?B:[Z>S2W998B8LF91:)M"\?
M-\V<8[T =MJ?B#1]%,(U35+.R,QQ$+B94W_3)KG/$/CF;39$.DV$6JVSV;7"
M3Q395F6>.(J" 1QYA/\ P'%9&FR?V#K@OM:TZ]N8;W1+.WMI(K.2X*,@;S(6
M"@E2Q93S@'UXK:^%84?#?2MD)A3,^V(_P#SI,#\* .QKF?%WB:\\."V-KIGV
MT2PW4C?.5VF*!I%'0_>*[?QK9M=4MKS4;ZQB\SS[)D68,A4?,NX%2?O#'<=\
MBKM &%8>(5D6YDU%[*SBABMW;-T"T;2KG;(#C9R0!GK5O3/$.BZR\Z:9JME>
M-!_K1;SJ^SZX/3WKSWQ;IEU=GQ[&+*:5+DZ8$ B)$H##=CUQWQTJYXTT2^O=
M?OH=(MF22?PO=6T;QIM4OYD>U-W0$C=@>YH ZB;QEHLNFZI<:7J=CJ%QI]M)
M</!!<*Q^12><9P,C&:OZ1J]OJEI;,)(ENI;6*ZDMUD!:-9!D$CKC((![X-</
M?:AIFLZ,UKI7AZ[-S;:-=1&1[1X38@Q8\KYE&YF( VKGIFF:3>_\(SXAM[G4
M;.^$5WX?L883#:22[I8S)NC^4'#?.O!Q0!V]UXET*RTZ'4+G6+&&SG.(IWN%
M"2'_ &3G!Z'I5#2/&-A?:1J&J7EQ:V=C:7TUJMP\X\MU1L*^XX'S5POA5)?#
MZ^%=5UNQNDLX])GM<_9GD-K.TP;YE4$KN48W8[8[U033KP6%AJ5O:WVFZ9;>
M(KVY=!8&1X$<$12^20>!GT^7=GM0!Z5?^*X1IVFWVB>1JL%WJ$5FTD$P*QAS
MAFR,\CTJ[X8U:?7?#.GZK<VGV2:ZB$C0;L[,]LX%<]X"MRVI:]J2W%_<Q7<L
M6+BYM%MDF95(+H@ /< L0,[>,XKJI=4MH=7MM,?S/M%S$\L>$.TA,9RW0'YA
MQ0!5\3ZO<:%X>N=2M;/[7-$4"P;MN[<ZJ><'H"3^%4-)\37>HRVJSVEM:^=>
MW=J4EN,2,L+,H9%(^?.W)'8<\UTU<KXAMYI?&WA&6.&1XXI;LR.JDA,P,!D]
MLGB@#2M?%?AZ^OX[&TUS3I[N5=\<,5RC,XQG( //'/TYK5EEC@B>65U2-%+.
M[' 4#DDGTKRO2M&EMOAQX"B33I([B#4[2651"0\>6;>S#&1UY)KT3Q'_ ,BO
MJ_\ UY3?^@&@!+'Q+H>J7K65AK%C=72KN,4-PKMCUP#3#XI\/C5AI)UK3_[0
M+[/LWVA?,W?W<9Z^W6O/]$GMM9TSP#8Z-I]U#<Z:\-Q<NUH\:V\0A8."Y !\
MPL,8)W9S6+>SZC?:##;^3<VT\>JQ3RZ-::0RK;8N0Q=YF!+<?-N4C)/IF@#T
M_6_'/AW0K:]>XU:Q-S:Q22&U%R@D8H.4 )^\3@8]34NE>)(=8N+)K6:QDM+F
MQ-T&2Z#2 A@I 4=5!)!;L1BN4AT61_#?Q%*Z>QO;NZO1"3%\\H,"A=O&2,D@
M8]369?6E]X@@!T>"Y#S>$+BUC9X7B_>^8@*'<!@G##GZ].: /1+3Q5X>OS=?
M9-;T^?[(ADG\NY1O+0=6;!X ]>E7GU"S0VZFZAWW0)MU\P9FPNX[?7CGCM7G
MU_=:?XBT1M-T7P]=->1Z-=0*\EJ\'V(M%M$/S* 69L# STS4=IJBZSKG@A+.
MRU#%C%.MV\UG)$L#FV*A"64<Y!Z9[>HR =1I?C73)O".E:]K%W::6M_"LBI-
M. ,D9P"<;JT9?$VA0:=#J,NLV"64P+13M<*$D Z[3G!Q[5YAI,U_I>D^#X9H
MGTH1Z,5.HMIDEU,LA9<P*H'R$@!N0<XP*7PSI-Q/=^&UO=/NFCBU[4IG%U:[
M"H,;LC,H 5<D@C  STH [&W\:W5WXLBTN#35ET^6[\A+Y)<JR&U$X<8&"#G'
M6NOEEC@B>65UCC12S.YP% ZDGL*<JJBA5 50,  8 %<Q\0K&ZU'P7>06EN]R
MPDADDMXQEIHDE1I$ [DJ&&._3O0!IV'B;0M5AN)K#6+&YBMEW3O%<*PC7KEL
M'@<'GI4^G:UI>L&<:;J-K>&!@DOD2J^PGH#@\5Y[KLT?B75C>Z#977D6FAWT
M-U.UI)"'WHHCA 906(()P!Q^-=MX2L8M/\(Z/!';+;LME"'0)M(;8,Y]\YZT
M 6=6U_1]"2-M6U.TLA(2$^T3*F['7&>M-N/$>AVEE#>W&L6$5K.ADBF>X4)(
MHQDJ<X(Y'3U%<EXIOKFU\;Q@$Z;$=/ 348M,>[EG)<YA4@$+C .""3GVK!\'
MZ3<EO RWFGW -G<:LT@N(-IB8R,4+ #"D@\8X]* /3K37M(OH;66TU.SGCNV
M9+=HYE82LH)(7GD@ DCM@U:CN[:6ZFMHYXGG@"F6)7!:,-]W<.V<'%>:7.D7
M,>C>+KVWMFBNM-U\ZK9 KM#F.*)FV^H8>8OU8UU'@.*2?1I]>N$9;G6[AKXA
MNJQ$!85_"-4_$F@#J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9A[I&<LJ%]DBCE"0#Z@'BL7PWXHU/4-.\,SZI'=?;+R^O(XO*N$6.?8DQ D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQU./,4X(P#NVL493R" >IK#TKP)?6%CI$)N+9!9ZTVI&WC9VB@B,;H(8BW)
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MV8*@C VA3R<D\4_7=>\0K<M>R76JV6FFQAFM[C2[2*YBBD*;G-PA!DVCC&W
MV]\UW<OAS39O[9WQ,?[8C$=Y\Y^=1'Y?'I\O'%9]YX%T:[E:0-?6_F0);SK:
MWDD2W$:#:HD"GYL#C/7'&: -/3_.O)+?5(]4$]C/9Q[(8X@(V8_-YH/WN00,
M9QBM*LBUT1;/7$O+>0Q6D5@EG':HQV*%8D';G P, 8&?R%:] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M XR65BH*Y!*'D@<9H [FBN'@\8164TEYK#7]L8=%BO)[=O+=!F1U!79DF1B
M,9Q@KT.:U-/\6//JL&FZGHU[I5Q=1/+:_:&C<3!0"RY1CM< YVGM]* .DHKB
MM+^(L6I1Z1=MH>HVVF:K*L%O>RF/;YK X4J&+ $@@-C&?8@UU=E=RW?VGS;.
M:V\F=HE\W'[U1C#K@GY3VSSQTH M4444 %%%% !1110 4444 %%%% !1110
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M# Y!'K7D/BV""2+Q[+<P))'#JNERDNFX(H6WWM]-N[/MFO2-1O+:/PA=7ME
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M&P#2ZCXVM;*\NK>UTS4M2%E&LMY+9QHRVZLNX9W,I8[?FVJ"<&@#I\4@  P
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M6.X;!90,,64L 2N\+F@#JJ,"N(\!ZMJNNZAKM]J!U**.*]EMH+:=81#&J.0
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MA)%<3%U*N.C#"G!X.2,U<LO!=^D=C.NFV-@ZZY%?200S/(RPI&R#>['YWY[
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MY[32G<5_X#D+]%%;5S9VMZL:W5M#.L;B1!+&&"L.C#/0CUJ>@ HHHH ****
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M\EK<+<P36T@1XW (R"01T8CD=ZK3>$--GT/5M(=I_LVJS2SW!#C=ND.6VG'
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M%[]B0O<22L^T;#\JJ G..23U%9=_XKU\ZTFBR7,MM-:6,4UW<:1ICWPEF<L
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M(STH Z6BN:TWQK9ZA>V=O+I^I6"WREK*:\A5$N,#=\N&)4[<G#!20#6'JGQ
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MA=OW=NS9MXV;<8[9YK0T+P_%HCWLYN[B]O;Z19;FZN-H:0JH51A J@ #  %
M&Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKXCBO+F)#),1,BA\0QH,Y\LQ[>!P02: /<0<@'UI:1/N+]*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[<"1@QE,KJ[NY[L67/IR:VK:UF@N[N:2]EGCG<-'$ZJ%@ 4 JN!D@D9YSUH
MM4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45P'C'6?&]A=:G<
MZ3#I=EHVF6?VG[5?9<W; 9**%;Y0.G(Z_6NH\+:P_B'PMIFKRV_V>2\MTF:+
M^Z2.WMZ>U &O1110 444R82&"00LJRE3L+#(#8XS0 ^BO(9=:^)<7CR'PF=5
MT$W,MA]N$WV1]@7>5V]<YXKL=3^(&A^&98=.UR_+:BD"27?V6WDD6(8&7;:#
ML4GIGG&* .MHKE-;^)'A?0)H(;[4#YEQ:K=P"&%Y?-B)P"I4$'H3]!FJU[\5
MO".GSW,-Q?SK):R^5< 6DI\D\<OA>!DXSZ_2@#M**YK1O'WAS7]:?2=/OFDN
MA&94#0NBS(#@LC$ ,/<?A5SQ%XIT?PK:17.KW7DB9_+AC1&>25O154$F@#9H
MK@->^*6D0^ =1U_1+@7$]NWD+%)"X,<Q!P)$P"HX)R<#CK6O\/\ 5KW7/"%K
MJ5_?)>3SDMO2U:W"]/EVGK@Y^;O0!U%%>(>'O'OB[Q!IK7K>+?".F$3/&+>]
M&R0!3C.-W0UZ#J'Q T/P[+'INLWQ?5$M$N)$M;:202 ]63:#QD$^PZT ==17
M'67Q1\(ZCJ%C9VNIM(]\P2"3[/((V<C(3>1@-R./?%,O/BOX0L;JYMY]1E#V
MERUM<[;65A"RG!+$+@#/ /?!QTH [2BN-G\4W?\ PM'2]!MW@?2[O2GO"X&2
MS!B 0V>F,4MO\4O"%UJZ:;%JF7DF\B.<PN('D_NB3&TG\<4 =C17/KXUT$V6
MM79O"D6BR-%?;XF!B9?8C)SV(SGM6;>_%'PK8-Y<]Y<>=]FCNQ$EI*S^4Z[@
MV O QR<].] '945R.G_$SPGJFJV>GV>I-)+>C_1Y/(D6.1L9V!R,;@.H['CK
MQ3KGXD^%;37'TF;42)HYA;R2B%S#'*>B-(!M!_'CO0!UE%<EJ_Q*\+Z'J-]I
M]Y>3?:[':;B**VDD**R[MW"XV@$9/09%9/B'XK:;I.M>&K6U'VFRU=#.]RL4
MC;82#M*@#EBPY'5<<CF@#T.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M39Z'- 'N551J5H=6;2Q,#>K +AHL'B,L5#9Z<D$?A7EVI::+[2?B'J\UY?\
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M7'AO0[O5$U.YT>PFOT(*W,ENC2 CH=Q&>.WI5O[#:&6XE-K!YER@2=_+&95
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M>#&<!>3QTJF1J?A^;Q38G0+W4FU:Y>YM)K=5:.3?$J;)"2-FTJ1SQCI7H5%
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MZH RJ?O ;,$#G!X[UZ'10!Y9:^'+Z1K&]33=3 E\1P7DAU"99)FC2%D\UU
M3G QR> 36IJ&B7\J_$@QV3LVI6JI:8'^O(M F!_P+(KOZ* /-+J#78M62&6W
MUJ*S&G6R6_\ 8\<0:>0 [UFE8;DP<8Y P2<UG:%X;UJWTG28I].G22#PWJ%G
M(IYVS-*A5<]R0"17KE% '"1Z-?)9?#M!9N#IS)]J '^I M'0Y_X$0*H>%- U
M.SOO"$EU821BSM=268L/]4TDR%,_4 UZ510!Y=)I6HZ;>)J;632FW\47-VEG
MO57N8I(F7=&&(#,,E@,\@&M;P?>2ZA\0/%UU)ITUCF*Q41S[?,.%DY8*2 <$
M<9SC&?2NMU;1M/URS%KJ-LL\2N)%^8JR..C*P(*GD\@@\TW2-#TW0K>2'3K8
M0K*_F2,69WD;IEF8EF. .IH T*\BN- UE[!$_L_5(VTKQ#<WKBV**\\,K2[9
M("20S*'!P<'DCK7KM% 'DMUX<OM1T?7KB#3M9D>[FT^-&U.53-<)%<*['RPH
MVJH+<DY(SP,<]IJ&G7,WQ&T34%MV:UM["[C>7'".S1;1]2 WY&NFHH \U7P_
MJ:^"EM!82"Y_X27[68P!GROMV_?]-G/TJI_9VLVFM[=&T_6;&X;5/,FM)&2?
M3'C,NYY59AE"5);"X(8XQWKU6B@ KD?$$-YI_C/2O$,>GW&H6<5G/9S1VRAY
M(2[(RR!<\@["IQSR*ZZB@#S%-#U>ZN$U5M-FMEO?$\%^+5L;X8$B$9=P#@$E
M<D=LBO3J** .4\307:>+/"VI0V-Q=6UM-/'.8%#&/S(PJL1D?+GJ>U<^GA_4
MU^%<&G"PD%\-66=H<#=M_M#S-W_?'/TKTNB@#S/4M#NRVO2W&CZA<12:^EU#
M+8S^5<0H+=$\Z+^\005*^A/7&*W_  ,FLI%J?]I&\>T,Z_8I=0B2.ZD38 QD
M" 9YX!(S@<]JZVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK!UJTUV^U*WBL=4_LO3$A
M9Y[B%$>9I,C:H$BLJKC))P3T'% &]17-^!M7O-:\/-<WDJ7)2ZF@BNT38MU&
MCE5E ' R!VXXXKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BL'7?%%OHNI:7I_D/<7-_<)%M0X$*,VWS&/ID@ =^?0X67Q-$GBZV\/I9W
M#/+'([W+(5C4JJMM!(^<X89QP/KQ0!NT5S<7B>Y&MVME>Z2UI!>R31VTC3@R
M'RPS%GCQ\BD*2#D]1D#-1^%/%<_B<"=;&UAM'A$JLE^LLH#8*AXPH*Y!SR:
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M%258IO.C.Y0PP^U3G!Y! (_$&@#9HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>guyaragreement004.jpg
<TEXT>
begin 644 guyaragreement004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS0N\;.K$G@@[3QU&1R:N?#VYU>ZBUYM5GAFV:O<1QE"Y*[7(*_,?NC@*.PH
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M(E_!H>GW$\%C8S2WMS97EW<>8]K;O"Q7^'!PY'&2,<Y- 'HU%<EIMO<^)I-
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M2)&B9.!D-DDDY;/M6CK/A&TUW59KJ]E9H)],ETV2!1C*R.K%@W8C;QQ70T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4A5\A(]VUF=CM;D]AWS0!Z'17'Z9XW;4KO1+8V'D37L]W;74;29-O+;@[E!
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M3?)UPX^[GGCIS4,WQ*:'2-/\^"PM-5N[RYLF%W>>7;1- Q61S(1DKP,#&26
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MB@ I#G:=I ..":6B@#@]!\&>)M"NIYU\3:?<2W4_G7<\NE,9I^?NE_.X '
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MSHK.!+)T.> 6Z;JZ'PD^L6?BRYTZZ6[AL'LA.MOJ&IQW<Z2!]NY<,7V,">O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZX/'<$=_K@ Z6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVDG$;' 8JI.,]J\FGTR^BTS7- O[G6OM=YJ$SBSM=+1Q=!Y-R2K.4('&TY+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBHKBXAM+:2YN9DA@B4O))(P554=22>@H EHK,TCQ%H^O"7^R]0@NC
M%CS%1OF4'H2#S@]CT-7;N[M[&TFN[J9(;>%"\DCG"JHY))H FHID,T=Q!'/$
MP>*10Z,.A!&0:AGU"SMKVULYKB-+F[+""(GYI-HW-@>PH LT444 %%%4EU?3
MGELHTO(7:]#&VV-N$H49;:1P<#F@"[1110 451U?6=.T&Q-[JEW':VP8)YCY
MQN/0<5FZ9XW\-:S?QV.G:M#<74F2D:ALG R>H] : .@HHHH **** "BJEUJE
MA917<EQ=PQK9Q>=<Y;F),$[F'4#"M^1JRCK+&LB$,C ,I'<&@!U%%% !15:&
M_M9[ZYLHIU:YM@AFC'5 X)7/UP?RJS0 4444 %%([K&C.[!549+$X 'K5,:M
MI[7%M MY$TES UQ" V1)&-N7!Z8^9>?>@"[15*/5M/EN+6WBO(I)+N%I[<(V
MX2QC;EE(X(^9?SJ[0 456O;^UTZ%)KR=88WD2)6;N[L%4?B2!5F@ HJ*"Y@N
MD9[>:.55=D+(P8!E."..X((-2T %%%% !1145U<PV5I-=W,@C@@C:21VZ*JC
M))^@% $M%,AFCN((YHF#QR*'1AT((R#4-_?VNEV,M[>SK!;1#+R/T49Q_6@"
MS1110 452O-8T[3X;J6ZO88DM55I\MDQ!ONE@.1GM5V@ HHI"0 2>@H 6BJ=
MMJMC>:2NJV]RDEB\1F6=?NE ,YJ:TNH+ZS@O+659;>>-98I%Z,K#((^H- $U
M%5IK^UM[RVLYIU2XNMWD1GJ^T9;'T'-26]S!=P+/;31S1-G;)&P93@X."/<4
M 2T4562_M9=0FL$G5KJ&-)9(AU56)"D_7:WY4 6:*K7VH6FFPI+>3I#&\J0J
MS=W<A5'U)(%,NM6L+*^M+*XND2ZNR1!#U>3 R2 .P[GH* +E%5K"_M=3LH[R
MRG6>WDSLD7H<$@_J#5F@ HHJM]OM3J1T[SU^V"$3F+OY9.W=],@B@"S1110
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M&!_&@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/Z7-JFLZ9/XFF\42::4U&6-;>01BUBACG,?ENI )9@OWMP.6&/2F7WB'4X?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJXQ(N#\C\ Y&#D U';>"M&A2^%REQJ$E]!]FGEOYVF=HN?D!)X7))XQSSUH
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M2YDA,Q#,P7Y8U'S.<\#'4CC%<(/$^MZ?<Z_:K>ZN\<7A^?4;:35K6&.5)D.
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M3-.H1SZ YP:\IU'1[.33O$4/V&()-XNM86"Q@;HBUOE>/X>3^M;5Y#X<\/\
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M5W;6,!GN[B*WA!P9)7"*/Q-9FC^(K;5EU60!88=/O&MFE:0%7"HC;\] ,/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!H21K+$\;@E7!4X..#7,V7@M+>\L);O6M4U&#3FWV=O=O&5B;:5#$J@9R 2
M6)Z^O--MO&<KW=O:WGA_4K&:]B>2P6=HO](*KN\OAR$<CG#8[\\5R6E>.-?N
MH/!EU/8W<\VHI=B2V@\H?:BJJ4<?-A5&3U(/!X/&0#U>BN5C\=V9T2:^FL+V
M*[AOO[.;3\*TS7/&(U(;:<A@<YQCFHKGQ];Z;8ZG)J^EWMA=:="EQ+:N4=GB
M=MH=&5BK#.0><@CZ4 =?16=I&I7&I6!NKO3+G36W$"&Z9"VWJ&^4D#/H3D8-
M8%O\0+>=;6];2+^+1+N=8+?4WV>6S,VU6*[MZHQX#$=QG&: .PHKSG3/'5Y8
M)K\^HZ;J-WIUAJUS%-?)Y>RWB#X "E@S!1R2 <#UYJ:\\13PZKXE$]]=K:6V
MHZ;#;_9MA*B58L@9XVLS<]\$XH ] HKC=4^(,6G1:K>1:)J-YIFEN\5U>0>7
MM$BCYE52P9@#P2!@'/H35W4O%D]K+,EEX?U'4$MX%GGEC,<:*K D!2[#>V!D
MA<XXYS0!TM%<-'XRN]0\7:5!8VEP^C7VBO?B0>6",M'ASELC:&P1ZMT.,B33
M/&:MH^AV^GV>I:SJ%YIZWFQFB201<#?*Q(0$GC ZG- ':T5R#?$&S:WTXVVF
M:A<7=]<36BV:JBRQ3Q ET?+ #&#SG&.:UO#WB!->BO%:SGLKNRN#;W-M.5+(
M^T,,%2000P((- &S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?^&?".MZ
M;_PBL=^+)4T);F!FAF9O.1T4(P!48.<Y';'4YKT"D5E==RL&'J#F@#SW4_!V
MMRKJ36[P2PW6N"_DL_M3PBY@\E$\MG494[EW8Y!P,U07X>:I_9_BJ*"TTG3Q
MJUO;"VM[>1BD;Q,Q(=MH))R/FQWZ<9/ILUQ!;^7Y\T<?F.(TWL!N8]%'J3Z5
M+0!DZA9WFL>%+RQN$AMKR\LI(759"Z1NZ%?O8!(!/7 K#T#0-8@UG1M1U*.T
MA-GH\FGRI!,TF7\R,JP)4<%8R3Z$XYZUV5% 'F5[\.KR807<EKIVH36VJ7UR
M+.YD98YH;A]V-VT[7&%/0CJ*LV?@:]C@M9$L=)TYQK-O?-;6>=J0Q@C!?:"[
M\D] .<5Z)2,RH,LP49 R3B@#@_$_@N2]\5MKL.CZ9K"36JV\MK?2F(QLC,5=
M&"MP0Q!&.P-=%X5T:30O#D%A*EG%."[R+91[(E9F)PH/)QG&3UQGO6M'<P2S
MRP1SQO-#CS8U<%DR,C<.V1TS1]I@-T;7SX_M 02&+>-X0G&['7&01F@#RJ/X
M>:[)%IOVJRTN74;*_ANI]6FO))IKH)*&.T,G[O('KCC'0Y'2MX*GO/"7B?1+
MN>.,ZM>W-Q%(F6"!V#)N!QT(&1^M=K44-S!<F003QR^4YCDV.&V..JG'0\CB
M@#A?#O@ZYL_$%C?S^'M TM;.-]\EF[323R,NW*Y5?+7!/J3G'O71:CH]S=>,
MM#U:-HQ;V,%U'*&)W$R>7MP,?[!S^%;M% ' R^#=6BDGU"TDM#?PZ])JMK'(
M[!)(WB$91R!E206Y ."!6QH>DZH_B6^\1:S';6]Q/;1V<%K;RF41QHS,2SE5
MRQ9ST&  .M=-2!E8L%8$J<$ ]#U_K0!Y[KW@::;Q7J.LP:)I&LKJ$<8*7\S1
M-;R(NT$$(VY" N1P<CWI;SX?WFK:3I6@7EQ;6NDV-N96-@IC+WASM95QA40D
ML.?F.,C Y]"J&XO+:TBDEN;B&&.(!I'D<*$!Z$D]!0!YW<2^*+?QOX<+V^GW
M6K)H]TMU'Y[1QS 2PC<K;#M).UL$8ZCWJ_IO@W4X-6TK5+J6U-R-4NM1ODC9
MMJ&6 Q*D>1\V!LY.,\GVKN3&AD$A1=X& V.0/3-.H \UUCP#<'7]8OK71-%U
M5=3<2QRW\K(]K)L"G("-O3Y0V 0>H]ZDUGP1>30V5L-%T35(+>RC@A=I&LI;
M65<Y9&16.PY!V@C&.]>BJRMG:P.#@X/0TM 'G.I>#-6N++2[:_L-+\1&VL4@
M,]W.]M<1SCK(LJJS%3QQP>,\YKI[#0+@>!4\/ZK?/=SO8M:W%SDDMN4J2">3
MC/4\G'-;]% '!P>'O$M_#H.E:M'IT-CH]Q#.]U;SL[W1A'[L!"H"9(!;YCTP
M*W_!^CW.@>&8-.NVC::.6=R8R2N'F=QU [,*V&N8$N8[9IXUN)%+I$7 9E&,
MD#J0,C/U%$MS!;O$DT\<;3/Y<0=P"[8)VKGJ< G ]#0!Q6O^#M2U2X\3O!);
M :HE@L&]R,>1(6?=QQP>.OX5NKH]R/'DNM[H_LK:8EH%R=^\2L_3&,8([UNT
M4 >3Z7INO>&?$?AG3;2"RN[VUT*X2>)YVC1U\^/[K[3@Y*GE?6MW2O!NIVNL
M:3JEU-:M<+J%Y?WRQLVU6FBV*L>1R!A1DXS@GVKN?+0R"38N\#:&QSCTS3J
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MR:\NK6L,Y8Q2J(D3RY,#(R _3..#523P!?7>D:VD&CZ)H\MY;QP00VSM(>)
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M<F.X-K'');RQ*&) 48*$$C!!(..35[X:V4MO\,]%07.7FL8Y$<1*OE[HQ@8
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M/NS* ]TP'^\%7_@!H ]$HJ"RO+?4+&"]M)1+;7$:RQ2#HRL,@\^U3T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ?1110 444$X&30 44Q9HGEDC21&DCQO4,"5SR,CM3Z "BBF+-$TKQ+(AD0
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M2$!6'G1K@*#\HR0<>@QWK2C\#Z<MDT,MS>3SR7\.H3W<KJ99I8F5EW87 7Y
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MI4U\TCN6VKB,$*H"Y)/)SQT-;^E>%4L-675+O5;_ %2]C@-M#)>&,>5&2"0
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M_,X.S<P#<@,2/TH S=1U_P 5/!XOU"RO[&"U\/S2>5 ]J7-P$A25E9MPP.<
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M[602I"C0E%W,N0"688'6@#O?-CWA-Z[R,A<\D5D7'B."Q*B^MI[?S=06P@W
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MD"3RBO .WR\[>AQWKL](TJPT+XI7-GI-G#96LVBI+)!;H$1G$S*&*CC.#C-
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MP5:/S%*GO\IKG'\=M<^(8+.UM[A-.N=$.HI=?9]Q4G!5CSC:%/(_O$"@#N2
M001D&H8K2VAA:&*WBCB;.Y$0!3]16+X?\2V>I6\-NUU))<IIUO>O-+$(A+'(
MI(D S@<J<CL>*@_X3O3)+:PDM+74+R:^MS=0VUM;[I?)S@2,"0%4\8R><\4
M=+L3<&VKN P#CD#TK*O_  ]:W^LZ9J$F +%9U$.P%)/- !S^53Z=K5GJVC+J
MEB9)H&5B%"$/N4D,A4X(8$$8/>N6T#XA)=^%K+4=2L[I;Z\N98(+6WMR7G*L
MW^K7)R HY)( (- ';"&)41!&@1,;%"C"X]/2F_9H#<"X\B/SP-OF;!NQZ9ZU
M0T37[/78[C[.L\,]M)Y5Q;7,9CEA; (#+[@@@C((Z&N5LOB MG>^(8]5AOI;
M?3M2>)KF"T+16T&U""[#KR6)QD@<G Q0!TEMH#)XFFUR[OY+N3RC!:1-&JK;
M1L06 QRQ)5>3V %:YBC(<&-"'^^,?>^OK6!J/C/3K"]EM(K:^OY((EFN#8VY
ME$",,J6(]0"0!DXYQ6M'JMA+HZZLEU&=/:#[0+C/R^7C=NSZ8YH M;$WA]J[
M@, XY ]*9':V\4KRQP1)))]]U0 M]3WK!TOQIIVIWUK:BVU"T-XI>SDN[8QI
M<@#)V$]\<X.#CG%9T/Q/T*>&TN%MM5^RWC&.VN/L3%)I<']TN.2W! XQD$9H
M ['R8MFSRTV9SMVC&<Y_G5:_TJSU*VF@N859)@%D(X+J"#M)ZXXK!;X@:/%I
M5U?W45];?9+I+2XMY;<^='(^-N5&<@A@01G.:H>(?'/E^%]<DL(KK3]7L+99
MQ!>P!7V,V X!R&7J/8]<4 =S3617V[E!VG(R.A]:Y[4_&>GZ9?W-F+74+V6T
M19+LV=L95ME(R-Y]<<X&3CG%7+#Q+IFIWYM+6?>WV2.]1\826%\@.I[C(Y],
MB@#2EMH)I(Y)8(Y'C.49D!*GV/:G"&)<8B08SC"CC/7\ZYO_ (3O2Y;:PDL[
M:_O9;Z)KB"WMK?=(80V/,(R JDXP2><C%/D\;Z0-.L;NW%U=R7TCQ6]K! 3.
MSIGS%*'&W;@[LXQ^5 &^]K;RQI')!$Z(045D!"D=,#M4BHJ+M10H] ,5R_@O
MQ%/XBDU^63S!#:ZD;>".6'RWC411DJPZY#,W6LG3/B%'!)K0U>*]>"QU6>V>
M\BM<P6T8?"!V'H.I .,@G% '?$!E*L 0>"#WJ*WM;>T4K;6\4*DY(C0*"?PK
M,/BC3$AUJ661XET;/VO>N"J[!(&'J"IX]>:H^+_$T^A^!+G7K*UD>80J\<<D
M>=A;&"XR,8SSSUH Z3R8M@3RTV Y"[1C.<_SI'MX9(WC>&-D<Y92H(8^X[UP
MZ^.YK;Q7JUI<:?J<\$5G:W$-K;V>Z6$,)/,+XZ=$X)SZ \ULS>-M*$.GO91W
M>I2:A;_:H(+*$NYAX^=@<!1R!R1SQUH WGM;>62.22")Y(_N,R E?H>U++;P
MS,C2PQR-&=R%E!*GU'I572-7L]<TV._L79H7+*0ZE61E)#*RGD,"""#Z5R.D
M7'B;QEISZY8Z\FD64TD@L;9+-)=T:L5#RE^26QG"XP".: .[5510J*%4#  &
M *0HI=7*@LN<$CD9KF_^$GGTK3-,BURRD;7;M6'V'3E\XN4^\R\X"XP<D\;@
M,YIDGC_18].M[PB\)FO#8?9A;,9DN I;RV3J#@?3D=CF@#IGABD;<\:,=I7)
M4'@]1]*41HI)5%!8 ' ZXKCG^)>CQP74LECJZ?8GVWZFR;-F."&DYQ@@Y^4G
MCFK]_P"-+"RU:?2X[/4;V\@A2XD2SMS)B-LX;.0.W3J>P- $VK^'[R]O(;G3
MM:FT\I%Y30^2DT) .0P1N%<?WAVX.:LZ-X?LM&T&+2$#7$";F=K@!C*[,79F
MXQDL2>E49O&VE^58M81WFIO?0&YABL8=[&(8!=LX"C) Y(.>,5"WQ T;[%IM
MS''?3-J+RQ6]O%;,93)&<.A7J&!!Z\<$YQS0!TRPQ*C(L2!&ZJ%&#QC^5-CM
M;>*#R(X(DA_YYJ@"_E6!:^-])N;:&8I=P&34!ILD<\.UX)R,A7';.1@C(^8>
MM:UOJ]K=:Q>Z9"7:>R2-ISM^5=X)5<^N!G'H1ZT 7-B[]^T;\8W8YQZ4(BQJ
M%10JCH ,"N3/C.QTM+V2^NKFZ!UAM.A2*T^9)/+#B(!<E^APW<MBM;0_$=IK
MSWD44%U;75FZI<6UW%Y<D>X94XY!!'0@T :Q12RL5!9>A(Y%((8@JJ(T"H<J
M-HPI]J\XU_Q_J-HGB^.&WEM1HTELL-PT&5VLT>_=DG)(<E>/N\]:ZK3?%^GZ
MC?SV4EO>V%Q%;_:MM] 8=\.<%QGL#C.<$9Y% &Z88B23&A)(8G:.2.AI?+3+
M'8N6&&..H]ZYS3O'&EZE=VD*V]_!#?$BRNKBV,<5R<%L(Q]0"1N R!QFK'B#
MQ78^';FRM;BWO;FZO1(;>"S@,KR;-NX #V;/T!H OZGIBZAIL]I'<363R1A%
MN+5MDD>#D;3['MT[5DZ3X5DM-8_M74M3?4;M;=K:(>0D,<:,P9_E7JS%5R3Z
M=JANO'^DVDESNMM1DMK,A;RZBM2T5JV 2KGKE01NP#M[XJ-/%B6>N>)WU&[0
M:5IT-I)"RID_O5;.,#+%CM '/7B@#J9+>":#R988Y(N!L905X]J7[/#L9/)C
MVLH4C:,$#M]*R-(\46FK7[Z>;6^L;U8O/%O>P>6SQYQO7D@@$@'G(R,@9K!U
M'Q'J'_"RX]'6>ZLM+L[(7=PXMD9)?F.2SMDK& N,C!SF@#MDABC^Y&B\!?E4
M#@=!3(K2W@C:.&WBC1R2RH@ ;/7(KG].\<Z7J-Y9P"WU"VCO\_8KFZMC'%<\
M;L(3W(!(# 9'2I_#_BZQ\2S2KI]K?^3&&_TF6W*0LRMM958]2#Z>_H: -WRT
MRIV+E/N\?=^E.KF[KQSHEEIOV^YEECB_M$Z:P9/F68,5((]."<^G-9WBWQJN
MDRQPV;R[[74[2WO=L'F924%MB@9);;C@#/S#UH W=!\.VN@V?D1XF<332B9T
M&\>;(TA7/H"Q%:<EK;S2I+)!$\D?W'9 2OT/:N3O?&UI/HVJM&]]I%Y8&'SE
MN;,&2-9' 5@A.&#<C.>.?2KFI^.=+TN\O('@O[B.QP;ZXMK8R16N1N^=O92"
M0,X'6@#HPBAF8* S=3CDT@BC 0"- $^X-H^7Z>E<)'\05L=;\2PWL-]=V>GS
MQLDEG:[TMX# CEG8=1DL>YP.F*Z'Q-K[:/X+U'7;&/[4T-HUQ %7<K?+E21D
M?+T)]LT ;1AB)),:<L&/RCDCH?K3?LMO]I^T^1%Y^,>;L&['IGK7")X[NH_$
MUI;RV&HS17&C)=K906FZ42>:RLQ]%P!U..1W-;K>-](.D:=J%N+JZ_M%F6TM
MH(2TTC+G>-IQC;@Y)P!CK0!O&UMS<"X,$1G P)2@W ?7K3C#$R.AC0J^=ZE1
MAOKZU0T77+37;>:6V$T<D$IAG@GC*20N #M93[$'T((Q7 0>(KZ^U;7$N_B!
M8Z*+34YK:&UFBM]WEKC!^<@GJ1^% 'IB6T$<*PI#&L2_=15 4=^E/V+OW[1O
MQC=CG'I6!!XBLM,33+/4M5%T]Y \L6I%%2"?:-Q^93M!V\^A )J,^.---CI]
MS!;7]Q)J(9[2UBMR9I8UZR;21M3D'+$?>'K0!TM,\F+;M\I-N[=C:,9ZY^M<
M^WC?1QI,5^OVIWEN3:)9K WV@SC.8_+ZA@ 2<\8YSBBV\:Z7<F"-DNX+F6^%
M@UM/#MDBF*&0!AZ%1D$9!S0!T.Q=Y?:-Y&-V.<>E(L,2%2L:#;G;A1QGKBN1
M\7^-QH>FZM_9]O+/?Z>]LDBF+<BB9N#U';/XD5,WBZULM4OFO;BY6"-+'=;/
M:A?LIG9E!9LY.3@'^[COF@#IDMH(Y9)8X(UDD^^RH 6^I[T[RH]J+Y:[4Y48
MX7Z>E8^I^+-)TBZN[>\F=&M+9+F9E0L%5W*(O')9F! 4<FC2/$]IJU_)8&UO
M;&^2(3?9[V'RW>/.-Z\D$9X/.1D9Q0!MUCZ/X=M=':[=<327%[-=B1T&Z,R-
MDJ#Z53U'Q+::/KFHB^OY%MK33XKE[<6^=NZ1T#!ARS,0%VX[#UJYH_B*#5[J
M>T^Q7]E=0HLC0WD'EL48D!@02",@C@Y'>@#3FM;>X*&>"*4H<H70-M/J,]*?
ML7?OVC?C&['./2L'5/%UCIFHRV"VFH7UQ!&);A;*W,OD(<X+^YP2 ,G Z5%=
M^.=)@DL([9+O4)-0MC=6B64!D,L8QD]L?>!YQ^?% '1>3%M"^6FT-N VC .<
MY^N:&AB;=NC0[L;LJ.<=,URME\1=%OWL3##J(MKR86R73VK+$LYX\IB>C9XZ
M$9XS2R_$/1XI;S=!J!MK&Y:UO+P6Q,-NZMM.YO3H<@' ()Q0!U#00O(7:*-G
M9=A8J"2OI]/:B"WAMH_+@ACBC'.V-0H_(5R4?B];#5/$YU2<FTL;RWM[2.*+
M<[F2&-@BA1EF+,<?X58/CW28;:\DO(+ZRELA&]Q;W,&V1(W;:LF,D%,]2"<8
M.: .I(!!!&0>U1QP0PA1%%&@4;1M4# ZXK+U/Q1I6D7DUM>SF(P6;7LS[<K'
M$&"Y)]23@ <G!J#3/%UCJ-]]BEM;[3[EH3/%'?P>5YL8QN93DCC(R#@C(R*
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M='TB/4(M2G%S:W#7"HL$AB2,K*&.XJ"@(V[B0<=:[NF2RQPQM)*ZQQJ,LS'
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M<*@8%E0CU"D ^X-<QK_@Y+O3_#7@^VL+R:QL)(I)-0D9 B0HK*\9(()9U^7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$#EI[%D6<;2 I==P&>_!!X]:\DUYK33]=UC69#8:LL&I+O87,EMJ5HP* 1Q
MC#IZ 8# GKUKK/"MGIEM\3/&9BC@COFD@< 'YRC1(SG'7!?DGUH [RBN2^)[
M^5\.-9?S7B"QH3(APRCS%Y'O7-31:/I_B**+PI+$;>XT:[DU!;:;>C*%7RI'
MY/SEBP#'DC- 'J5%>.6FC:78>&_ YNMT6FZP(7UB>29@+B3[.S1+(Q/W2YQC
MIPHJ/4WMK*[UG3M)N#'X26^TY+TP2GRK<.S>>JL#\JD>5N .!N/3)H ]776;
M9O$4FAA)?M26BW9; V;&=D SG.<J>U:%>(^(K/1K*[\9P>&VC$2>&E9X[63<
MD3>8Q.W!PORX) ]<]ZZO5]<@O_'6B#1+V&[N(](OY56&0.-S"+R\XXY*F@#T
M.BO)M!3P[!H/A[5+"ZD?Q3=0$[H92\US<&%C(LXY)4,#G/W2!TK&\-))Y7A;
M4H[W18-3N;N(3W"74\M[=,?]=%*@0_[6=WRH0.0!0![E5+3M5M-4^U&T<N+6
MX>VE)4C$B8W#GK@GK5VO$HK?2["SU"U1H[6RE\6M;ZMY4FPK:Y?RU<@Y5"^T
M9XX)H ]MJMJ-_;:5IEUJ-XY2VM8FFE< G:BC).!R>!7&>&(["Q^(&J:=X>:,
M:,NGQ2SPV[[H8;DNP&WLI*#) ] :U?B+;177PX\1QS1B15T^:101T94+*?P(
M!_"@#3M]>M+G7!I,:R^>;)+X,5&SRV8J!G.<Y![?C6I7E>G>'?#^M>-+*V:W
M@NM-C\-PM'"CYA+&=\G ."0<_0D]ZP89+R\TWPAIUT]I/IA^WQB/5+AT@FDC
MG*1H[ '<0@.T'@X/<4 >Y51UC5[+0M+FU'4)O*MH@,D*6)). H Y))(  ]:Y
MGX;B1-,U2$7EI<6L5^Z6Z6CR216XVKNC5W4;E#9(QD#.,\8#OB.K1:3I.I.C
M/::;J]M>7852V(5)#-@=0I8-_P !H M6WC:%M0M+34=%U;21>OY=K->Q($E?
M&0F5=MK'!P& S]:ZBN:OO&.@_:-+MK6>#5;F^N$6"&TD25E'4RGGA5')->=7
M0TQ_!6M:U=W.WQK#>SK&_G'[3'.)B(8D7.=I78 H&"#0![517CNNZ1;7\/Q(
MU.]C9KZP5);5O,8?9I%LXWW)@_*=V.1Z"KUUIEKH>N6QT]7B:_\ #E[)>-YC
M,9W41%7<D\M\S<]>: /5**\>T-=%M+'P)>^'[A9=9NI(EO&CF+RSP^2QF\T9
MR0I QG[I  Q6/]JM9$\.Z[906%K+=ZS!LN9-0:;49E:;#B0!0%&"05R0!@4
M>\T5XQJFCV<WA/QUKLBR-JECJ=T]G<^8VZW*%2-G/R\Y)QUSS6SXKO+[P]KM
M_;V)?S/%-I'#9D9Q'> K$S#T_=NK_P#;(T >G5BW7B.*W\3V^@Q6-W<W,D(N
M)9(@GEP1%BH9RS \D'@ GBM'3K&'3--M;"WSY-M$L29.3A0 ,_E7F'C&P^R^
M,O$NIZ5:@:M%X:%Q!+&/G64O*A=?]K8,?@* /6**\PM8/#^G>(_"3>$+B-Y[
MQW%WY$Q<W%MY+$R3<G)#[,,><G'M6E\*M%L;?PG::NL3-J-VCK/<.[,S*)&V
MKR<     >E ':7UX;**.06MQ<;Y4BVP(&*[F W')'RC.2>P!JS7)_$%F31M-
M*L5)UFP'!QQ]H2N$U31[.7PEXZUZ19&U2QU2Z>SN?,;=;E&4C9S\O.2<=<\T
M >ST5XWXQ2U37=?U6:33=36U2)Y8+BZDM+VQQ&I'V9R""#]X8 RQ(R:NLGA;
M5?&/BJ7Q',B!+6UFABO)MAA0PY9U&>'!QDCD<>O(!ZO17AML^JZS>Z+;^(DT
MV<#08)H8M:N'B21RS;Y, $-( $SGD9SW-:5@8[RT\'V.O:C#>Z#,]Z/,,D@@
MF=6'D1NT@4N N\#/#;0>: /4[W5;33[JQMKARLM],8(%"D[G",Y^G"FI+.\-
MX)R;6XM_*F:+]^@7?M_C7DY4]C7E>H6/A1K[PU]D<3:9;Z_-!YER^8HB8'8Q
MQL>/+#@8Y/(('3%01&WN_$<=CK4N-"GU[5!,DLA6*69=GE(YS@C'F$*>"10!
M[)17C-Y' ]MJFEZ9<2?V GB/3H+4P3-MC+LGG)&X.0H)Z \$G%==X?TVTT'X
MD:MIFEPBVL9-+M[DVZ$[!*9)5+ =B0HSCKB@#K=3U*UT?2[K4KUREK:Q-+*P
M4DA5&3P.M5X=<M9]>DT=$E^T)9QWA8@;-CLR@9SG.4/;TK'^)EM%=?#7Q"LL
M8D"6,DB@CHRJ2#^!&:YJR\.>'M;\>"W>V@NM,B\/6YAA1R823--S@'!(YP>V
M30!ZA17A\<U[>Z+X)L;M[2?39%O49-4N'2":6.3;$DC '<0@;:#P<>HKN_AN
M)([#5H%O+.>TBOV2".S>22*W^5=T:.ZC<H;)XR!DCMB@#M:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MF30Q7$1BFC22-NJ.H(/?H:?534M2L]'TV?4+^=8+6!=TDC9.!]!R3V ')- %
MCR8O/\_RT\[;L\S:-VW.<9],]JKS:5IUS9K9SV%K+:J<K#)"K(/HI&*Y6T\=
M17GC(6&)K.PBTF:]N%OK9X'0K)& WS@?+M9OR]JU-+\::/JU]!:0F[ADN4,E
MJUU:20K<J!DF,L &XYQUQSTH V9+"SELOL4EI ]IM"^0T8*8'0;<8Q31IE@M
MA]@6QMA9XQ]G$2^7CK]W&*QK+QSH>H7]O;027.RYD:*VNGMI%@N'&<JDA&UC
MP<<\X.,U:3Q3I,FC6FK+.WV.ZN$MHG\MLF1I/+ QC(^;C- &NB+&BHBA44 *
MJC  ]!4$^G6-S,9I[*WEE*&,O)$K,4_NY(Z>U<[=?$7P[9W%Q'-/=".UN3:W
M5R+20PV\F[;AY,;5R<=^X]15JS\::+=B_+RW%G]AA%Q.+VW> B$YQ( X!*G:
M?RH W7@ADE25XD:1 55BH)4'&0#VS@?E5:XT?2[N"&"YTVSFAA_U4<D"LL?^
MZ"./PK.TSQAI6J77V9!>6\YA,\:7=K) 9HQC+)N W 9'3D9'%5-.^(.@:I/8
MI;/>>5?_ "VMQ)9R)#,^TML5RN"V >/4$=10!U"J%4*H 4#  Z"H+RPL]1A\
MF^M(+J+.=D\8=<^N#7(Z-\1+6\TNZO+^UNX774I;&WA2SE+S%6<*JKC+/M0E
MA_#@YQ72:-KEEKMM+-9F4&&4PS131-%)$X )5E8 @X(/XT 6+G3+"\M%M;JR
MMI[9,;898E9!CI@$8J06ELHA"V\0$'^J 0?N^,?+Z<<<5SUYX^T*RO+ZVD:\
M<Z>^R]DBLY'2VX!W.P& ,'K['TJQ<>,M'@UR/1@]Q/>N(WVV]N\BJDF0KLR@
M@+QU)P,B@#9:TMF$P:WB(G_UV4'[SC'S>O''-01:1ID$#00Z=:1PLFQHT@4*
M5R3C '3))Q[UCVGCO0KV\MX(I;D17,IAMKM[61;>>3GY4D(VDG!QSSCC-6SX
MJTA=$FU8SN+6&<VS_NVWB42>7LVXSG=Q^- &C/IUC<S>=/9V\LNPQ[Y(E9MA
MZKDCI[4VZTO3[YXGN["UN&A.8VFA5RGTR.*P!XRT[3;>YFU+4#,IU66PA$-H
M^X2 $B+:,EFPI&1U. *GB\<:')IE]?2RW%LMC(L5S#<6[QS([8V+Y9&XELC&
M <YH Z#R8O/\_P I/.V[/,VC=MSG&?3/:HULK1?+VVT(\IR\>(Q\C'.2/0G)
MY]S63I'BW3-9U.738!=PW\,0FDM[JV>%T0G )# =?:JMWXK>W\>P^'1:3&.2
MP>Y,P@=@'#*!\PX"X)R?7 R.X!T]1M!$\R3-$AE0$(Y4;E!Z@'MG KB?!_Q$
ML]8T?0QJ!N$O=0C5//\ L<B6\D^"3&LA&W/!XSV(ZUH6_C&RMK/=<W4U_<37
MUS;P16=DYD;RG(90@R3L P6X!Z]Q0!TXAB69IA&@E90K.%&X@9P"?3D_G5>?
M2M.N;-;.>PM9;53E89(59 ?92,4S2-7L]<T];VQD9HBS(0Z,CHZDAE96 (((
M((-<UJ7C[2WM-3CL+R>&:Q9HYKM["22&%TD",A. "W/3/0@T =A%%'!$D4,:
M1QH,*B* %'H .E,NK.UOHO*N[:&XCSG9*@<9]<&L/5/&VC:1>W-K<-=.UH@>
M[D@M9)8[8$9'F,H(7(Y^G)P*R'^($$7BDVX2ZNM/GTBWO[6.TLY)96WM)EB%
M!(7:$ZXY/J: .I30=&B),>DV"$@J2ML@R",$=.A%6S:V[-"S01%H?]42@_=\
M8^7TXXXKE+WQY;+J/A=-.BEO+'6F<^?%;R/A!&Q&,#@[@,@] #D#J+?C#Q0_
MAB+2V2UEN#>7\5LWEP/)M0GYL!?XL=!W]\4 ;4>EZ?#?/?16%JEV_P!^=85$
MC?5L9-*=,L#?_;S8VWVP#'VCRE\S'INQFL2]\=Z'87=Q#,]T8[5@EU<QVDCP
MVS'!Q)(!A3R,^F><5H^(-7_L7PWJ&K)$TYMK=ID1%+[B!D=.<>I[#)H L2:3
MILMT]U)I]H]PZ[7E:%2[#T)QDBGS:;8W$[3365O)*R>6SO$I8KG.TDCIGG%<
M/;_$-_[6TA;FVNC!?:.;K[/!8R-,TP=0=JX)VXW')XQ@YY%="?&FB?V)::M'
M<2RP7DAAMXHH'::20$@H(P-VX%6R,<8.: -QH(GF29HD:6,$(Y4%E!ZX/;.!
M4%UI>GWTT4UW86MQ+%S&\T*NR?0D<5!HVNV.NP326;2AX)/*GAGB:*6)\ X9
M& (X(/N#Q6#/J>N:_P")=2TG1+RWTVTTORX[B[DM_/>69UW[$4D  *1DG)R<
M"@#L*9Y,7G^?Y:>=MV>9M&[;G.,^F>U<[9ZSJ&B:1?S^+FMXX[.4)'>P+A;I
M#C:1&"S*^3MV]STSFG1>.-&>VU":<W=H^GVYNKB"[M7BE6+GYPK#+#@],\\4
M ;BV=JL442VT(CB;=&H081O4#L>3^=1-I.FM=273:?:&XDP'E,*[VP01DXR<
M$#\JY]?B+H+SB!%U)IY$\VVB&GS;KI/[T0V_..^?3GI4S^/=!6QTVZ2:XE&I
M&1;6**VD:21T.'38!D,#P0?0^E &W)I6G37R7TMA:O>)]VX:%3(OT;&14HL[
M87AO!;P_:BGEF;8-^WKMW=<>U8R^,]$.C/J9GF6..X^RO"T#^>)\@"+R\;MY
MR.,=\].:A7QWH8L=1NKE[JS&G"-KN*ZMGBDC5SA&VD<@G/(]#0!H>)=$7Q'X
M>N]):<P+<JH,@7<5PP;ID>E6[;3;"S69;6RMH!,291%$J^8?5L#G\:PH_'NB
M,MZ9/MT!L[4WCI<64L;/ #@R(&4%E'M6E>ZS;(]M903YO+^"62SV)O!"J#N[
M#'S+U(SD"@"])9VLMG]CDMH7M=H3R60%-HZ#;TQ[4D-A9VUG]C@M((K7!'DI
M&%3!ZC:.*YUO&-OHUI!:ZT+J;4K>SBFU(V=H\J6Y*\LY0$*,ACCT&>E=']LM
MOL/V[SD^R^5YWFY^79C.[/ICF@".UTO3[%-EI8VUNNW;B*%4&,YQP.F31:Z5
MIUAC['86MO@DCR853!.,]!WP,_2LG3/&FCZI=1V\9N[=IH6N(&N[62%)XUP2
MR,P ( (/K@YJ*R\=Z+?7=K!$+Y4O<BTN);*5(KDA2V$<K@Y )'KCC- &Y#IE
MA;WDMY#8VT5U+_K)DB57?ZL!DTD6EZ?#?/>Q6%K'=R??G6%1(WU;&37(:1XX
M?6=*M[MRVG,VLFQQ+928E7S754&<88A1D_PG((K73QQHLFH):*UWLDN#:1W1
MM)/L[S D%%DQM)R"/0D8S0!T=5CIUB7N'-G;EKD!9V\I<R@= W'S?C7#:!XZ
M>YFUS5-6N+B#3K>]:RM;0Z;(K%MP5 #C<\A.<H!D9[5T-MXUT6:WU&:>2XL3
MIR++=1WMN\+QHV=K;6'(.#C&>1B@#9L[&TT^#R+*U@MH<Y\N&,(N?H*G95=2
MK*&5A@@C((KB]6^(MC:>']7N[2VO!?V5FUU':W=G+$SKT5\$ E,XR1T[XJY;
M>*[4W<D]Y?"UM8]*2]E@N+5XFB!=P7+-V.W 7&>,]Z .AMK"SLPHM;2" *NQ
M?*C"X7).!@=,DG'J:;+IEA/9FSFLK:2U)R87B4IG.<[2,=236/9>-='O99(C
M]LM95MVND2\M)(3+$O5T# ;@..!SSTIFF>.]#U:]L[:V>[ OE)M)I;22.*X(
M7<0CL "0 ?R.* .A@MX;6!(+>&.&%!A8XU"JH]@.E2$ @@C(-4M0U6TTQ[-;
MJ0H;RX6UAPI.Z0@D#CIPIYJAJ7B[1M)&IF]NC$NF"%KH^6Q""4[4/ YR?3I0
M!H6>D:9I\KRV6G6EM))]]X8%0M]2!S3FTS3WOUOWL;9KQ1A;@Q*9 /9L9K+L
M?&&D7LES&SW%G);0?:I$OK=[<^3_ ,]!O ROJ>W?%-TKQGI&KWT%G#]KAEN4
M,EJ;JTDA6Y0#),98 -QSCKCG&* -IK2V99U:WB(G_P!<"@_><8^;UXXY[5#?
MZ;!?6<\!1$>2!X%EV E%88./;IQ[5@V?Q#\/W\]HD$EWY-W*+>&Z:SD6!I2<
M"/S"NW=D8QZ\=:V=;US3_#NFMJ&IS&&U5TC+A"V"S!1P.>I% $6A>'K'0=/M
M8(((#<0VT=O)=+"J/,$4+EB.>WJ:L)HVEQRRRIIMFLDS!I76!07(.06..3D
M\]ZR'\<Z4L5L1;ZF]S<(TJV:6$IN%16VEVCVY5<C )Z]LU--XST6.PL+N&>6
M[&H;OLD5K \DLNW[V$ R-O?.,=#S0!LFSM6AEB-M"8IB6D0H,.3U)'?/O63<
M>'Y;WQ3::K=WPDM+$,UI9"$*(Y67:79\Y;@L ,#&X]:CLO&NAZA#!+;W$A6:
M^_LY0T#H1/LWE"" 1@ YST(Q5B[\4:18MJ@NKORO[,2-[HLAPHDSLQQ\Q.,8
M&3G H V*9Y,0G,_EIYQ4(9-HW%<YQGTR3Q6#;>-=&FBO7G>YL6LH/M,\=];/
M XA_YZ!6&67C'&>>.M5+CQ[IZZ9J<L-M?I>6=FUVMK<V4L;R(. P!&2N< D=
M.^* .BM=,T^QEEEM+&VMY)3F1X8E0N?<@<U/##%;Q+%#&D<:]$10 /P%9WAS
M56USPYI^IO$\3W$"NZ/$T>&(YP&YQGH>XP:U* &2PQ3J%EC2158, Z@X(.0?
MJ#3#9VK0RPFVA,4Q+2(4&')ZDCOFIJ* *EQI6G7=S%<W-A:S7$7^KEDA5F3Z
M$C(K,B\*6'_"0:GJUW%!=M>M"Z1S0*WDF--N5)SR>O:MZB@"M>Z=8ZE&L=]9
M6]TBG<JSQ*X!]0"*6>QL[JT^R7%K!-;8 \F2,,F!T^4\58HH JOIEA)9I9O8
MVS6L>"D)B4HN.F%Q@4LNG6,]O+;S6=O)!*Q>2-XE*NQZD@C!-6:* *Z6%G';
M1VT=I D$1#1Q+& J$'(('08-2B&(3F<1H)2H0R;1N*CD#/IR?SI]% #719$9
M'4,C##*PR"/0U#;6%G9@"UM(( J;!Y487"Y)QQVR2<>YJQ10!5ETVPGL_L<U
ME;26I.?(>)2G7/W2,=:FM[>"T@2"VACAA086.-0JJ/8#@5)10 4444 %%%%
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M>26,^0T:JHR%8[@W)!'8<XKI*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.7MO'FE75Y!&D%\MI<W!M;?4'@Q;S2@D;5;.>2" 2 "1P:V-9UFTT'37OKTO
MY898U2-"[R.Q"JBJ.K$D "O/_$NK6.J0Z%KNEZF9TAU.".+0Y%51)+YNQB5
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M=,' ;..>X JO<O>:[XENDU5=*N(H=+M)K9-4U"2V"J\>9)8PBD$[\@MU&T4
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M#?<W<TD N1'8VLEP1$>CG8#A3@X)ZXXH U[NQM+^-([RU@N$1PZK-&'"L.A
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M(-%U.[LA%OU#4;ZXB#JWV43* BD@\GCG&1DFG7GAO5I/!OBFRCLF-S>ZVUU
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M/!K4%C?+JKWIMS<YL1J#1M<B+:O^L*<$[MV.^,9KJ:* "BBB@ HHHH ****
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M5_/C52NTD_=R<'(YX]ZUZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MASL _AX&01G-8-QJEY]FTOQ%8/K!CNM6A1-1N]3V)<QO/M*+:JQ7;MR "%(
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M#6B7^G6^GW.EVKVEMCR(O+ $6!@;,?=XXXI=%UJVU2VB07=K->+:PSSK;DE
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MTS(L<!)+,7)"\#L2.O3\Z-?UB33%L;:U1)+_ %"Y6WMT?)4<%G<@<X5%8^^
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M +)]*]-HH \X22?0_P#A)]+N_#=YJMQJ5_+<VR+;%[>[20*%5Y,%4"XVG?C
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MZ";=C'+ TT1+*V,, %;/IWKU6B@#ETLYT^*%S?F!UM&T6.(S[?D+B9SMSTR
M<X]#57P%!+/X%D>-C$M]<WEQ;'^Y'+-(R$?@0WXUU=[:17]C/9S[_)GC:-]C
M%25(P<$<CCTJ2&&.W@CAA18XHU"(BC 50,  >E 'E=O;WMUX,\/>$(]"O[;5
M+"YM/.F>V98(/)D5GF67[K;@K8VDD[^G6NN\#Z?-86NM>?:O \^M7DXWIM+J
MTAVM[@C&#Z5U-% 'FGC"VN8/$6HW-C%KMG=7%JB+)96?VVVO\!ALEC*$(1G&
M25!!ZU-8W6IZ!XF^WZGH=X[W^BV<6S3;8RQI<1F3?%\O"#YQ@DA<=^*]%HH
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MP1V)KMO 5@]M;ZM>.FJJ+Z],P;4PB2RX15\SRT1/+SMZ$9.,GK7744 %%%%
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MO<PEX9 D2Q^5*,_,"5W?4#BBS\/)X;N-:UO7;BP73[NRBMYK:SM&2*%5+C
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M+**TA4J3Y(2%HP3Z]0?PH CTKQC?7NL:5;WFC+:6>L6[W%C*+G?)A55L2)M
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MPO4GKCB@#LJ*JZ<E]'8QKJ4T,UV"V]X(RB$;CC )/; Z]:M4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]RKSF19FFVE%"J5SDY!7&.E96L&_@\)^+?#B:)JL^H7>IW%Q!Y-F[1O#),)
MXD V],\9SD8Q7K]% 'E7BNSOY)_'UE%IE_+)J%O:RVKQ6SNDH155@& QN!_A
MZXYJ]XHT'4IO%CZ;9VDKZ1XD,)U&9%.V#R#F3<>@\R,(G/7%>CT4 >3:I8:A
MIGB/Q1]HGU^.'4W62W33-.CN8[I/*5/++&)]A!!&&*K@Y]:[W2=-:R\#VFF2
M6TTK1:>L)MYI@7;"8V,X &>V1Q6Y10!Y9X4748-<T6TLX]6N-/@AD2:#6--V
M/IJ^7@+'<;%WY(5<#=E><T[3-%O8/ASX"M1IMQ'<6NH6DL\7D,'AY;>S#&5Z
MG)/K7J-% 'B>LKKFH>'KZS-IJT-T-0\UM(L=("6R*+@-YAEV$R$J-V4;)8],
M9K=U72M1DU_5Y4L+IHY/$NESHRPL0T:)"'<''*K@Y/08->GT4 4["\2[:["6
MMQ;^3<-$QFA,?FD '>O]Y3G[WL?2KE%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$0-V9T&#D'CG/U H ZJ._M9=0GL$G5KJ!$DEB'55;.TGZ[6_*K-><KHEU?\
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MU)(S&0T>U1M!WD8Z=*U?&FHMIVA(8]0GLI;BYB@1K:W$TTA9N4C4\!R <$Y
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M,H"@+T7J6YK1;4_%MYHVEK,+]_*N+J.\BL;BV2^FC0@1OC)7(SAU4@YQVXH
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M99HM,U6SO9(#B5;>=7*?7!IMGXDT/4-1DTZSU>QN+V/.^"*=6<8Z\ YX[^E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*']]YQ=P4]<1K"G'J172)I9MM2^'?V>Q,:6T4J2%(L")3:GAN.,L!U[UWU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MESY<(N$WO@D'"YR<$$?@:Y_4_B%IMD=<BMU2YN=(E@CEB$Z@N9&121C)PI<
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M2KO:&*=6<+Z[0<XY%9?B#QAINAP2!+BUNKV.:"-[-;E1*HDE2/<5Y( WYZ4
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MYS!J2V$H>[1" 3CS%Z[@>=HZMCBMJ36-+BU%-.DU*S2^?E;9IU$K?1<Y/Y4
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MM-PHCC6- V<]"#G&<BMBSO;74+9+FRN8;FW?[LL,@=6^A'!H GHHHH ****
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MI(3Y3)DJSA<GY?ICI7M=% 'ENLZJ/%7B=G\-O-,__".:A%#<K&R()F,6U0Q
M^8''TR*?IUWX:N=,TFRTO1Y&U*TT^5',<#1-8_N2'$O Y+?+@YR>>V:]/HH
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MC$KD2A&^ZK-EE! [$ 5T/@FV%GJ/BR&.#R8/[99HT"[5P8(22![G/XYKKJ*
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MD!549(&>364FD^(_#>JZG)H-MI]_IVHW#79@NKAH'MYF WD,$8,I(SC@@DT
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M+C*/L/0^HY!H ZU/&B7FG64^EZ/J%[<W3RQ_9E54,#Q'$@E9B%0@\=3D],U
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M,CJ6RI.,@%7(SC@]JKZWX1\0>*(=:O+Y+"SO+G2SIUG;1SM*J@N'9W?8.20
M %X ]Z -(>.[EM2&F+X5U7[?+!]IMH&>$>;#G!8MOPF#C(8Y^85O:'KD.O\
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M',4JOM) )&0N,X-8-SX/U>\U&\O7-I&;G6=.U'8)6;:D"1B1<[>3E&QZ\=*
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MD 9^<(Q,>1TW=^.#Q7-Z5X$U.W\0Z#JBZ7I.G-IYE%Q+'=27,\Y>%DW;V0'
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MVR;,=L$CVQ!68 LX(W=!D\ <4 =?:ZS#>:[J&E0QR%[!(FFEXV!I 2$'?(4
MGV85P7BCQ?KMLWCFWAAFMHM,LH)+6X4Q_NV;=D]2QW=N.-O.,\]+\/;"\MO"
ML5[J@_XFFJ.;Z\)&"'?&U<=MJ!%Q[5D^)?".MZG=^*4LA9&UUNQAB6269E:*
M2/<,%0IRI#=<\8Z4 ;6G^+Q<:NNG:CI-[I;RVSW=N]TT966-" V=K':PW*2#
MV-067CN*Z?3YY=(O[;2M2E6&RU"79LE9ON90,74/_"2.<C.,U9UKP[-JWB;3
MKTN@LX;"\M)QN(?,WE@;>,=$;]*Y/0_AW=:=-I%K+H?AY%T^5'DU1=SS7"I]
MTB,J CD@9;<<'.,T =5XSU>^TZTTVRTN1(;_ %6^2RBG= X@!#,S[3P2%4X!
MXSBF6_A[7-*U2RN++Q%>7]L7VWUOJ;JP9"#\T95 58'''W2/2K?BO09]=TZW
M^Q7"6^HV-TEY9RR*602)GA@.=I!93CUJA';^,=6U.P.I"QTFQM)1-,+&[>:2
M[(!PG**%CR<D'). * (Y?B#;QQS7XTF_?0H)S;RZJOE^6"&V,P3=O*!N"P'8
M]N:-5\?QZ;>ZS!%HFHWD6C!7OIXC&$CC:,2;AN8%C@G@#/RGVSE2>$?$0\,W
M7@V$:?\ V//+(%U!IF\Y+=Y"[)Y6W!<;BH.X#H?:M.[\)WTUMXWBC>W']N0B
M.TRQ^7_1A%\_''S#MGB@">W\=1/=M#=:1?6B26,E_:23;,7,4>"V &)5L,IP
MV#@\X/%)I?CJ/4)-*>XT:_L;+5L"QNIS'MD8J6"D*Q*Y )7(YQ57Q!H%V$LM
M0WP^3IVB7EM,-QW%G2/&WCD?NSZ=JSO#NE>(-?T'P@NHI86^G:?%;WJSP3,\
MEPRQ8C&PJ F-V6Y.2..#0!MGQR8Y[22XT#4K?3+N[6SAO9O+7+LVQ28]V]5+
M="1W!Q5>[^(L5J-2N%T/4I=.TNZ:VOKQ3&%B*D D*6W.!D$X' /X5S47P[UQ
MXM-^TV6E2:C97\-U/JTUW)--=!)0QVAD_=Y'N1QCH<CHKKP?J,_@[Q;I*R6W
MVC5[NYFMR7.T+)C;N..#QS@&@#;?Q58PW&NQ7*R0?V-"MQ,SXP\3(6#KSR/E
M8?535K3=6FU!X=VF75M'+:1W(DEVX!;_ )9G!SN'?MSUKB/&.FP:SXYT73+.
M\B-Q<1&#5[9&#-]D1DF&X#[H+#8,]1*:[B.\O6\236)MD^PI:)*LXW9\PLP*
MGC'09X.?7'&0#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD=#S4E% !1110 4444 %%%% !1110 A 92" 0>"#WH5510J@*H&  , "EHH
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MQUH VZ*Y^+Q?ITFL+9.\<4+:>E\+F250F&<H%SZY'K6^K*Z!T8,K#((.010
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M>V$(_&@#6HJ".]M9HHI8KF&2.4XC=9 0Y] >_0U*)$,IB#KY@ 8IGD#UQ^%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF;5C^5>YT4 >/^(M)MHQ\1Y+33XA+&;)P881N"[(W?&!GL2?7%:&HZ]IFO\
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MBNM(!&" 0>QI: /#?$S:#;^#O&=IKMM&WB62ZN94+PDS.I;,+HV,^6$VC@X
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M5LL22S$DG)]S^'2@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJP^(M5TW4[>RM](N)K>"S>V#K.81EC(Q.1N.0-N,#!YH [^D#!AE2",D<&N
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M-(S0[RK$G[N1VYYZC% '?45Y:_CK5=7N["WMI+RQ0Z3;7T\EAI;WK-+,"0N
M"%0 'KR<\'@U>T[Q)XD\03Z/HYW:+?2VMQ=7D\EF0Y6.41KY<<GW=^X-\P.!
MQ[T >AE@" 2 2<#)ZTR"X@NH1-;S1S1$D!XV#*2#@\CT((_"O.[^VU]O&7@Q
M-0U:W:XCGO%+VT(VR*J$@D'[K,F 0,@')%1:%KVKZK:Z%H^GS6VFRW8OKFXN
M8K9?DCBN"@5$^[N8L"20>A/4T >FT5YI=>*/$D#_ -B+>6IU*#78=->]-O\
M+)#+ 90Q3/#@8R 0,CL#71>&+_51XAUW0]4O5OOL MY8;GR5B9EE5B58+QP4
MZCUH ZFBN8\2>(9O#NMZ;-<2*-'GAN4FRHRDJ)YJ'/NJ2#'TKG/#7C'7M471
MM+OO*BUE[^3[>%C&%MUB$W [9$L*9]S0!Z+!=6]S#'-;SQ2Q2?<>-PRM]".O
M2EM[B"[@2>VFCFA<962-@RL/8CK7D^@2W^J:WX O1=16RR65\S006R*GRR)N
M  Z;A@>V,CJ:;X0O-?T3P7X2O_[3ADL;J\ALFL/LP 6.20H&WYW;@<'T[8H
M]>J+[5;^='#Y\7FRJ7C3>-SJ,9('<#(Y]Q537DED\/ZBL$QAE-O)MD"AMORG
ML:\MT*SU>6;X>PVFK+!,_A^9C<-;JS1Q$6Y"JO0D<#)SQGB@#V*BO+Y_&^M6
MNCP6#RF74GUJ?3&O;>R:5O+B#,9%A7.7*@#'0<GH*Z+P;K.K7]YJ5EJ,5]+;
MV_EO;7UWISVC2AL[D*L "5('('(8<4 ==4%W>6NGVLEU>W,-M;QC+RS.$1?J
M3P*YWQEK,^F'3H(-533_ +3(X8QVCW5S(%7.(HE5L\D9)& /K7!:AJ6K^)M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBN J[1N&"1\N!P1D#G-.G\$6+-;R6=_J6G30VB6336<P5IHD'RA\J02,G#
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MFH/J27$4NV6&=NK(<<=Q@@C!.<U<T3P[;Z++=W NKN\O+LJ9[J[D#.X484<
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MH49I#CGY>!C &!Z5IV&CVVG7^I7D!D\W49EFFW'(W*BH,>@PHJ_UHH ****
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ME!*GU'I67<>';2Y\06VJR8/D6DMH+<H"C*[HQ)'L4'YT 8WPXV_V+J/V3/\
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M)]371?#662;X<:$TKL["V"[F.3@$@?H!75!%#EPHW$8)QR:%144*BA5'0 8
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M#9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L+69?$-IJ=O<Z7:0ZA8&)HY[,R+%('R"LBL1@C&00<=
MB,UNT4 <[X,T2ZT/1[A+T0QSW=Y->-;P',=OYC9\M3@9 ]<#DFNBHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>guyaragreement005.jpg
<TEXT>
begin 644 guyaragreement005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI'3C.:W/";,WB;QD"Q(74XP 3T_T:&@#K**** "BBB@ HHHH **** "BBB@
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MQR*]+U7POH6N7$=QJFDVEW,B[5>6(,=N<[2>XSV/%.U3PUHFM101ZEI=K<K
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ME-A; (RX 7&>..:T]+TVWT?2;33;1=MO:PK#&/\ 948&??B@"W1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 1W$\=K;2W$I81Q(78JI8X R< 9)^@KD]$^(>
ME7_A+3]<OW-HUX=BVZQ2.YDQG:BA=TF!W4$5V%>3>'++5M&L_"=_=:%J+C1[
M6XTZ[MUB#2(S[")HUS\Z_*5R.>>E 'I>DZQI^N67VO3;E9X=Y1B 5*,.JLI
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MO$+^&-%BU%3 $^V6\,K3YVI&\JJ[<$<A234^G^*]$U.*[DM[X*+-/,N!<1O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9W]A:;_;O]M&V#:CY7E"9G8[5[[5)PN<#) R:T:** "BBB@ HHHH ****
M "BBB@ HHHH Q=6\):)KEV+J_LV>?R_*:2.>2(NF<[6V,-R\G@Y')K5MK:"S
MM8K:VB2&") D<:+A44#  '85+10 4444 %%%% !1110 4444 %,\J/SO-\M?
M,V[=^.<=<9]*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%4;/6=.O\
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M110 4444 %%%% !14%U>VUBD;W4Z0K)*D*%SC<['"J/4DFIZ "BBB@ HHHH
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MKRTANH&+0S(LB,5*DJ1D<'D<'O0!+1110 4444 %%%% !1110 4444 %%%%
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ME2JGJN5(^4X''2@#SG3+K4O$:^%+1]=U&&"]FU<W$MK<%'E2.?\ =C?U&!@
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M9B>6/ Y)[4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4MO!<7UD(6EEW$[$C5%(^]P&&3SC(KL[S2I6\3^#62R8VMM:W44Q$?R1AHD
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M>.UMY;B9MD42%W;&<*!DFFV=W!?V4%Y:R>9;W$:RQ. 1N5AD'GGH: )J***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC=&ZL593CC(8$<5YQ<>+/$;6<\\UO.&A\51VD4=O.NZ2/=@P=ACIR3@[N>E
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M=C44TZ[B:0,('D0O&X(^\C?* >.3TH ZZBN+C^(MG/;:U)#92O+IM\EC'%O
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M)-@9@!_L[@#[Y]* -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH4J5DP2=I8C&>0<5Z510!SNG^'KFPU7Q%=1721#4A"+=HT!:'9"(\E2-O49
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MNC-=A]T3&V0;UV\-Q_"<=!S7H]% 'G#?#FXL[ZU^S0Z1JEG;Z?!9VZZNC/\
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M1110 4444 %%%% !1110 4444 %%%5-3U*UTC3;C4+V3R[>!"[MC)^@'<D\
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M[;V6C:<^HW$MFEZX:=($CB?[F6;^)L' 'H<XK8T'6[;Q#H\.I6JR(DA96CD
M#QNK%65L<9# B@#2HKS7P;XWU&/PIH=SK.FWC6=S(ML=4EF5B9&<JK,F=P0M
MA=WTXQS713^-;>#PUK&M&SE,>F7<UJ\>X9<QR;"0>P)YH ZBBN1N_&TJ:WJ&
MGV&BSWXTUT2Z\J=!-\RJV8XC\S@!ASQGG&<5#J/BZWT&]\2W3Q:A="QDLHW@
M$@*_OL*/*7 Q][)!/)]* .THKD5\<BRGU&'7]+FTI[*Q_M#F5)A)""5."O\
M$#QM]Q@FBT\;N+VVM]7T>;3A>122VK>>DQ?8N]D8+RK[03CD<'G- '745R?A
M_P 9S:Z+:Y_L6:+3KJ%IH;N*=)PH !VR!/N,0>G//'6CPWXTF\1/9S1:+,FG
M7JLT-W'<)*$P,@2JO^K)';GG@X- '645AZ[XA;2KVQTZSL)-0U*^WM#;HXC
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MO$$>NQ7:M;/:7EE-Y%U;.X8HV P(8<,I5@0: -FBBB@ HHHH **** "BBB@
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MITVFW-Y8::^G7,=R[I&X+JX=&52<@KT(Y![5W\<B2QK)&P9' 96!R"#T-.H
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M357\01M#HES)J3RM;ZG>[Y+BV1EP(E0J0H'0,&&!S@FO4,8HH YW1M NM/\
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M?P[0"201G)Z],=*Z^LF+P[86^AV.D0&>*TLO*\D1S,K 1D%06!R1QR#UK6H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI&S"&*./.$4X))PQZC_$V?C?=VUOHVF26EZL/B2VNTETV).99=QV,%'H<_\
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M$NH2RJ]JQ^^-J<.#SBME_!GB/P_XL&K^%FTIXKG3H;"XAN]Z+$8P%5T"Y)&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% ";1NW8&[IG%+110 4444
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M.<T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444C,J(SNP55&22< "@!:*KP7]G=.4M[N"9P,E8Y Q ]>*G=UC1G=@JJ,E
MB< "@!:*165T5T8,K#((.0136EC1T1Y%5Y"0BDX+$#.!Z\ F@!]%%% !1110
M 4444 %%%% !13&FB25(FD19),[$+ %L=<#OBGT %%%% !1110 45%+=6\+%
M99XHV5#(0[@$(.K?09ZU(K!U#*05(R"#P10 M%,$T1G,(D0RA0Q3<-P4\ X]
M.#^5/H **** "BBB@ HI@FB:9H1(AE4!F0,-P!S@D>^#^5/H **** "BBB@
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M* "BBB@ HH)P,FB@ HILDB0Q/+*ZI&@+,S' 4#J2>PIJ7$,DACCFC9PH<JK
MD*>AQZ'!_*@"2BF2S101/+-(D<:#<S.P 4>I)Z4\'(R.E !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<\GE02290;%+9=MJ\#N>P]Z\STWQOJC:SH(?5K?4H=2N?L]Q';Z9+';Q$HS
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M#B@#!TOQ=K+>);>SU:_@T^XFO'A;3+RPDB5H\L$,-QRLCG"GT.3P*](KE(O
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MK)LQQESYTL[Q[=P&YHU)R!C/7')I^G>+-?\ MMQ:0+/K1>PFG@DDTB>Q"7"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUSUKLJ* ./O].UG0_%=YKVC6"ZE;ZE#''>6@F6.5)(\A)$+84C:<%21T!!K
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MM+*W@GNGWW$D485I6]6(ZGZT 8WCW1[O7O!=_IEC$LMQ,8MJ,P4$"56/)XZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=A+*DUE=3^(("I/,0C#HGT^T.PQ_LU:N98O$OAF\\0R:A%9PZQJ\*VBWJO\
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MWMO)4QO#R,$L7.5Y)XH\)Z>+SQQHNI:M:*=6?PS#<3R2+A_.WA=Q_P!K;P:
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MMO/)OOWFBA22%D821#+HP(^5A@\'T.*T+'5;34;B]AM9"[64WD3':0!)M#$
M]\!AG'TH M20Q2E#)&CF-MZ%E!VMTR/0\G\ZJ#1M+$\TPTVS\V?_ %K^0NZ3
MG/S''/(SS63?>.M#T^\N8)I+IH[1Q'=745K(\%NQQP\@&U3R,^F><5,_B_21
MXB_L*,W,U\I02"&V=TB#KN5G<#"J0>I/\C0!M?9X?/,_DQ^<4V&3:-Q7.<9Z
MXSVJ,V-FUE]B-K ;3;M\@QC9CTV],52UGQ#8Z&UM%<BXEN;HL(+:V@::63:,
ML0J@\ $9)X&15$^.M!71!JTEQ-%;"Z^QNKV[B2.;.-C)C<&]L=QZT ;EI96M
MA;BWL[:&VA!R(X8PBC\!Q1>6-IJ$!@O;6"YA)R8YHPZY^AXK!B\=Z(]O=RS-
M=VILY(H[B*ZM9(GB\UML;%6&=I/?IZUL?VK:?VU_9 D)O/L_VDH%.!'NV@D]
M!DYP.^#Z4 /33;%%"I96Z@;.!$H^[]WMV[>E3>1"9C-Y2>:R["^T;BO7&?3D
M\>]<SK6L:M=>)X?#6A26]M.+7[9=WL\1E$,98JBJF1EV(;J< #O4FGR^(](O
MKF/6Y[?4-+2V:==0BA$+QLIYC>,,=V1R"OH0>U &W:Z5IUBVZSL+6W.6.885
M3KC/0=\#/T%6)8HYXGBFC22-QM9'&0P]"#UKF8/B%H%SIIU"-[PVS/'' QLI
M0;IW!VK"-N9#P?NYQCTJQ%XUT62PN+IY9X#;3Q6]Q!/;O'+$\C!4#(1G!+#!
MZ>_!H V[FTMKRV:VNK>*>!A@Q2H&4_@>*S-5T$W6CQV&EW":6(I Z"*!6B8<
MY1X^ R')R..QS3]2\2Z7I,]U#>3,CVMBVH2@1DXA4D%N.IR.G6JVE^,=(U>^
MAL[=KF.2XC,MLUQ;/$MR@QEHV8 ,!D'CL<].: &>'O"PT>:_NKNYBN[J^6..
M3RK80PI&@8*BQ@G ^9B<DYS6M;Z1IEI$8K;3K2&,JR%(X%4%6QN& .AP,^N*
MR?%6N7FF-IFG:5'"^JZK<&"W,X)CB"J7>1@,$A5'0$9)%16,/BW3M9M8KV\M
MM8TV<,)Y5MUMY+5@,J0-Q#J3QCJ,@\\T ;<VDZ;<3033:?:R2P "%WA4M&!T
MVDCC\*<VFV+Q11/96S1Q/YD:&)2$;.=P&.#DYS6)!X\T*YO8H(Y;GR9Y_L\-
MXUK(+:67.-BRD;2<@@<X)& 34-S\1?#MG/<1S3W0BM;DVMS<BTD,-O(&VX>3
M&U<G'?N/44 =#-IEA<6?V.:QMI;7.?)>)63.<YVD8ZDFGK9VJ1PQI;0JD!S"
MHC $9QCY1VX)Z>M8,7CK1'M]2FE:[MO[.@%S.ES:21/Y)SB158 LIVGIZ5-I
MWC+1]2NQ;))<0.\+7$+75N\*SQ+U=&8 ,!D'Z$'I0!L265K*)A);0N)P!,&C
M!\P#@!O7\:2SL;33H/(LK6"VASGRX8PBY^@K#T_QSHVHWUG;1?;8Q?9%G//9
MR1Q7. 6^1V !X!(]1TJ&'XA^'YYX4CDNS%+<?91=&SD$"S;MH0R;=H)/'7N*
M .GEABF"B6-) K!U#J#AAR"/<4W[/ 7E?R8]TJA9#M&7 Z ^HY/YUEOXJTB/
M2=1U-[AEMM.F>"Y)C;<DB$ KMQDDY&,=<C'6M@'(!P1GL: *DFD:;-+!++IU
MH\EN L+M"I,0'0*<<?A3CIMBRPJUE;%8'\R$&)<1MG.Y>.#GN*M44 5%TO3T
MOVOTL+5;QA@W A42'_@6,U*;2V,,L)MXO*E),B;!M<GJ2.^>]344 5)=+T^>
M[BNY;"UDN8AB.9X5+H/9L9%20V=K;E3#;0Q%$\M2B!<+G.T8[9[5/10 V6*.
M:)XI462-P59&&0P/4$=ZIRZ+I4\4$4VF6<D=O_J5>!2(O]T$<?A5ZB@ JO+8
MVD]PD\UK!),BE%D>,%E4\$ GD U8HH B^RV^V%?(BQ!_JAL'[OC'R^G''%0K
MI>GK?F_6PM1>$8-P(5\P_P# L9JW10 5573+!+]K];&V%XPP;@1+YA'INQFK
M5% %4Z9IYOQ?FQMC> 8%P8E\P#_>QFI?LMOMF7R(ML^?-&P8DR,'=Z\<<U+1
M0!5N-,L+KR/M%C;3>0<P^9$K>6?]G(X_"FSZ3IUS;1VUQI]K+;Q',<4D*LJ'
MU (P*N44 5I-/LI;62UDL[=[>0DO$T2E&).22,8/--.EZ>U@+!K"U-FO2W,*
M^6._W<8JW10 =*JC3-/6_-^MC;"\(P;@1+YA'^]C-6J* &)#%'))(D:*\A!=
ME4 L0, D]^ !3;FVM[R!H+J"*>%_O1RH&4_4'BI:* (%L[5(I8EMH1'+_K$"
M##\8Y'?@ ?2H[O2].OXHXKRPM;F.+_5I-"KA/H".*MT4 (JA5"J % P !P!5
M6[TO3K\YO+"UN>G^NA5^F<=1VR?S-6Z* *UWI]E?VZV]Y9V]Q"I!$<T2NH(Z
M<$8I)-,L)K5[66QMGMY#N>)HE*,?4C&#TJU10!7CL+.&WB@BM($AA8-%&L8"
MH1T*C& ?I2_8[7[.;?[-#Y);?Y>P;=V=V<=,YY^O-3T4 5+C2]/N[J*ZN;"U
MFN(O]7+)"K.GT)&11=:5IU]/%/=V%K<31?ZN26%79/H2.*MT4 5+O2M.OY8Y
M;RPM;F2+_5O-"KE/H2.*MT44 5;G3-/O9XI[JQMIYHN8Y)8E9D^A(R*G\F+S
M_/\ +3SMNSS-HW;<YQGTSVI]% ",JNI5@&4C!!&014%MI]E9A1:VEO %78OE
M1A<+G.!@=,DG'J:L44 59=-L)[,V<UE;26I))A>)2A).2=I&.I)J:WMX+2!(
M+:&.&%!A8XU"JH]@.E244 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'<0
M)<VTL$HS'*A1AZ@C!K@]'NO%/A?P_#X>7PS/J-Q91_9[.]AN(EMY47A&DW,&
M0@8R,'IQ7H%% '!QV7B+0?$%KK=W:2Z[+/I4=E>-9>6CI,CL^Y5<J"AWD<'/
MR@XJKHOA?6+?7-$U.[LUC+:EJ-_=1K(K"U$Z$(F<_,>F2N1DGMS7HU% 'G5[
MX:U:7P?XML8[,FYO]8:YMTWK^\C,D1#9S@<*>O/%58;W55U?QYI^GZ#-?FZO
M?+CG26-41VMHAB3<P(4#!R >XQZ^GU!;V5M:S7$L$"1R7,GF3,HP9&P%R?4X
M 'X4 >=2Z%K^G7-EILD6L7NF6NEV]M;G2;M+8/,@*N9G+*X!^7&#@#/&:?X+
M\,:SI=QX5:_L?*^P6%]!<'S5<([S(R8.<G*@G/YX->DT4 >8ZMI-YH_@_7M5
MGB6"[T_7)M9LMSC]XH<$#C^^A9<=?FKL?!VE3:1X8M8KSF_GW75XWK/(2[_D
M6(^@%7]1T;3=6>V;4+*&Y-K*)H?-7=L<="/>KU 'F\VG:_IVC^)?#EOH4MZ=
M5N+J2UOEEC$ 6X)),N6# IN/ 4Y &*V_">@7>B:[K33H3!)#90P3DC][Y4.Q
MCC.1SZUUM% ''>,;?6IM6TQK6+4I=)"2BY72I8X[CS#MV99RIV8W9VD'.,US
MFE^%-;BTKR9M-FC;_A*X=1"378G<6X\LEF<L2Q&#GDG(XR,5ZI10!QU]X9DU
M;Q/XC%[#C3-1TB"S$VX??#3;L#.01O4YJK\,8KZ]TFX\1:LRO?:@4A#J<@Q0
M+Y:D>S,)'_X'78ZCIMGJ]A+8:A;I<6LP DBD&5;!R,_B!4UO!#:V\=O;Q)%#
M$H2.-%PJJ!@  =!0!RFM:?JVE^+D\3:18?VE'-9BSO;-)5CDPK%DD0L0I(W,
M""1P1BN<M?"UW>^(9]7L?#$FAVXL;N)TN+E6ENY90-OR*S*H!!Y)_BZ5ZE10
M!P+:%JUCX>\$74%@;B[T**,7-@LB!F!MS$^TD[2RDY'(!P>:S]7T#7=?77]9
MCTI[6:<6"VEC/*@EE6WF\UBY4E5+9*CGMSBO3J* /*O%$>KZC%XHURZT:XTZ
MP_X1>XM8Q<R1F0ODL<JC-@8/'/;M6S81:OX@U;PQ<7&BRZ9;:0K3RRRR1D2N
MT)C5(MK$E?F)R0O0#&:[:ZM8+ZTFM+J))K>9#')&XRKJ1@@CT(J1$6.-410J
M* % Z "@#FO%VDZA<S:1K.D0I<:AI%RTR6[N$$\;H4D0,> Q!R">,BH(K_Q+
MKVJ6L2:3<Z)I<8<WDEXT32SDJ0L<81FP,D$MD=,"NNHH \PBT;Q!/X-TSP3)
MH<D+6DMNDVI^;']G\J&57\Q,-O+,$'RE1@DY-6;SPSJTO@SQ-8)99N;W6VNH
M8]Z_O(C/&V[.<#Y5)P>>*]&HH \U^(NFW:KXJU4P_P"A-X9-N)=PYD$DC%<9
MST(/3'-6KB'Q#XAU'2[R'16TN32K6X='NI(V26XDA,:*@1B3&"<DD#H.*[F\
ML[;4+.:SNX4GMID*21.,JZGJ"*F "J% P , 4 >46.@^(+G4_"]U<Z=KC36-
MVLE_+J%_&8U/E.I\J)'V[<MUV@@8 SDUIKX9U8?#&+2?L1%^NJBX,6]?N?;_
M #=V<X^YSUSVZ\5Z+10!YMJVCSS_ !1BTR J=,U#R=6OX\\J]OE5R/1V\CZ^
M6:[^VN;F:]O(9;)X88640SLZD3@J"2 #D8/'/I4=GHVFZ?>WEY:64,-S>,'N
M)47#2D=,G\3^=7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+V60PR1E=CAV8L V6!7.&V].M=UX.M(K+P=I$4)E*FTB?][*TAR5!/+$G'/
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MQ/@9PA8 $X[=?:NDKS[XD:OI]YID6A6MPKZ])>V<EE" =^[S5;S%/<!0V6'
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M=K?.W ^]GI[FKE[>2^(+S2[7R=1U&Y71X;NXMXM0-C;QF3_EHSJ0S,<$8 (
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M(D)+$#(QDG&[VJYJUI??\)G#X9M(+R\TVSTQ9X;=M9EMGD9I'#.T@R\FW"@
MGC/N* /4J*\DMK^^U/3M#TB[FO=6O"UVX@L=2$:30QN$4S7 *EBF0N%^\<DB
MJVC:E?WMM9:'=W]S!82^);BQE>._>1UC2'S$@$_#$%_ESP<#&: /5]2U6TTE
M+9[MR@N;F.UCPI.9'.%''3GO5VO+/$VGV<-E'HMCK5]*J>(;!61IF>2RWD':
MDC9/3YADG;FN@\.VYT?Q[K.C6]S=R6 L+:Z2*YN7G\N1GE5MK.20"$4XSUH
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MU"2__L2P^UR2"5Y?(7<7#!MWUW '/J*N_P!C::'#_8;?<+G[8#L'^NQCS/\
M>P<9K"_X32VGUS2TLYX)M(N["[NY+C:VY3"T8Q[8W-D$9R.U;8US33'ID@NE
MV:F0+,[3^]RA<8XX^4$\XH AU;PQH>NS1S:KI-I>2QKM5YH@Q"]=N>X]NE78
M].LX;I+F*UA2=(1;K(J %8P<A!Z+GM7)Z[\1--M#!;Z7=1W%V^HP69WPR>4V
MZ54D"R8"LR@DX!.,<C@UHKXMT^PM;RYU;4[1(8]1DLHVBCD&U@,B-L@Y? /(
MX/&* -9-&TV.UM;9+&W6"UD$L$80;8G&?F4=CR?SJK/X4\/W.K#59]'LI+X,
M'\]H06+#HQ]2.QZBHK;QEH%UIM[J"Z@L=O8D"Z,\;Q-"3TW(X##.>..>U.TG
MQ;HFMWS6-C=NUXD1F:WE@DBD5,@;BKJ"!DC'KVH T/[,L=MZOV2'%]_Q]#8/
MWWRA?F]?E 'T%02>'M&EN[:ZDTRT:XM83;PR&($I&004'^S@D8Z<FG:OK>G:
M%:I<:C<"%'<1Q@(SO(YZ*JJ"S'@\ 'I6=)XY\-PZ4FIRZFJ6KW!M06B<.)@I
M8QE-NX-A3P1GIZB@"WI7AC0]#FDFTO2;2TED7:SPQ!3MSG;GL/8<59U31].U
MNU%MJ=E#=PAPZI*F=K#H1Z'W%8<7C72D:_O+O5+6/38A;&,M#+')'YHX\S<.
MYQC@8'6D;XC>%ECE9M1D#0G]Y$;2;S$&,[BFS<$P1\V,>] &I#X7T&VMY((-
M'LHXI?+\Q$A4!]C;D)]2&Y!]:O/86DEX;M[:)K@PF R,@+&,G)7/IGM61/XE
MM+?4=[ZC9_V:NEMJ#81VD,8(_>!A\I3:>G7)%.TSQEH&L:@+&QO_ #)WC,D8
M:)T65!U9&8!7 S_"30!+IWA/P_I%T+G3M&LK6=<[9(H0K#/! /8>W2KVH:=9
M:M8RV.H6L5U:R@!X9D#*V#D9!]P#619^./#M_?P65M?EI+ABD#F"18IF&<A)
M"H1CP>A-2^%-9N-=TB:[N4B21+VYMP(P0-L<SHIY)YPHS[T 7H-%TRVMKBWA
ML;>.&Y4),BH ) $" -Z_* OT%5;WPIH&I-;->Z/9SFVC$47F1 [4'1/]WVZ5
MCW/BJZBUW5[%I;*WALKNPABDFC=MXGQN4[3]X]%/ !/-7[_QQX=TR\FM;N_*
M/ X2>18)'BA8XP'D52B'D=2.M %Q_#.AR6]O;OI-F8;:<W,">2,12D[BR^AR
M2>*NWUC::G92V=];17-M*-LD4JAE8>X-<K-X^LM,\5ZSI>K2K%!9QP20F*"2
M1RK*2[/M!PH..2 !FI?$WBM]+LKB[TZZL)E71KG48(G5V,Q0*58,IV[/FYYR
M<C'>@#8T[PUHFD3+-I^E6EM,JLHECC ?#8R"W4YVKU]!4VIZ+IFM1I'J=A;W
MB1DE!/&&VDC!(ST.*Y?6_'+:%IFK7TAMKAK2RMIDM8XY-ZO+NY=L$;3MXQTP
M<GD5TMAK^F:DURMM<Y>V1))EDC:,QJZ[E)# 'D _D?2@ MO#^CVEE!96^F6L
M5M!,)XHEC "R Y#C_:SWZT:OX?T?7EB75=-MKSRB3&98P2F>N#U&>_K5FPO[
M;5-/M[^SD\VVN(Q)%)M*[E(R#@@'D5%JVL6&AV7VO4;@0PEQ&OREF=ST554$
ML3Z $T 5KOPMH-_:6MI<Z19R6]H,6\?E "(="%QT'L.M._X1C0O[-GT[^Q[(
M64[AY+<0*$9@  =N,9 5>?85S4/CT7\^O&SN;.*TL);*.*:Y@E!S*VUU=>&#
M9X' P2,\5N3^,] MM3;3YK\K,LRP._DR&))#C"-*%V!N1P3GF@"W;>'=&L[*
M*SMM,M8K:*87"1K& !*#D/\ [V>_6KBV=LE])>K!&+J2-8GF"_,R*20I/H"Q
M_,UDZKXQT'1;Q[2_OMDT:"24)"\@A4]&D*J0@/JQ%02^+M.TZZU1]2U2RCLK
M:6"-"B/N0R(& =N0<YR"O&.M &KJNAZ7KD"0ZI86]W'&VY!,@;8?4'J#]*(M
M$TN"UL[:'3[:."R<26T:1 +"^"-R@=#AFY]S7/:SX[M(_">LZGHLJRWFG1JS
M074$D3+N(P61@K8(S@]#BK\_BBRTV]U<ZIJ5G#:64EO'PCAHC(HP)">#DD8(
MX ZT ;TL4<\+PS1K)%(I5T<9# \$$=Q5'3= TC2/+_L[3K:U\J(PIY487:A8
MN5'MN)./6J=CXQT#4(KV6&_"+8QB6Y%Q$\!C0@D.0X!V\'GI2:?XST'4[B2"
MWO)!+'";@I/;2PEHAU==ZC<.1R,T 6[CP[HUUIATV?2[22R,AE\AH@5#EBQ8
M#L<DG/7DU/IFE:?HUF+33;.&TMP2WEPH%!)ZDXZGWK)TWQUX;U>YA@L=2\UY
MW$<3>3(J2,59L!BH4G"MW[$=:V+?4K2ZOKNS@F#W%F46= #\A9=RC/3.,'CU
M% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K!\9Z'-XB\*7NFVLB1W3;)8&?[OF1NKKGV)4 _6MZB@
M#S+Q-XJ\57VBW&G6/@O4$FN+22&Z:49%NQ&-Z,N1*H!/ ^8\<=JGTZ.X\,:[
M'<V>D:EJ.GW.B6=K:R00X;?%O^60,04R'4Y; '.>E>C44 >5>&-,U?PLOAW5
M+W1[RX2/2'L+B&V022VTGG;P=N<E6'&1Z"G+I6KVHL]<DT>[VR>)I-3:RB"M
M-# \#1 E0<9)PQ )QN^M>IT4 >-3>&=3@L=8T*YM/$=W)>7L[QI:S1I9W$<L
MA8,TA4E, _-G)R.,\5NW-MJ6AKXMT[^P[[4SK!:6TGA571]T"Q>7(Q(V[2IY
M/4'CGBO2** ,OPU;RVGA71[:XC:.:&QACD1NJL$ (/XURNDW.H>"&U#2I]!U
M._LWO)KJQN-/C64,DK%RCC<"K!F(R>".]=]10!Y[/'XE%]X>\3:MI9G>UDNQ
M-8V0#RVT4P C/7#LH7#;?[QP#BJ%YHFJZO+J>K#2KB"+4-:TV2.UE4"3RH'0
M/*Z@_+D9X/.%&:]1HH XYM*NSXM\67?V5O*NM+MH8),<2,!-N4?]]+^8KE]"
MNKGPWXET>*YT:^N9HO"5G#,MM$'EA<.P*E<@X)&"1T(&?6O6:JC3K0:HVIB$
M?;6A%N9<G)C#%@N.G4D_C0!YE#IGB'2K;2%FMM0M+6>2]N;@Z7!%-<VS2R[T
MARP;:NTG)4=1UQS3=&\/:PJ67VG3;Y2GBUKX_:F6200& @2,P."<D XZ&O6:
M* .$OO"\^L:IXWMYHFA@U&VM!:W!X'FHC88'U5MI_"IOALUWJNDW/BG48Q'>
MZPZMM!R$BC78@'L2'?\ X'74ZKI5GK6G2V&H1-+;2XWH)&3.#GJI![>M6+>W
MAM+:*WMXUBAB0)'&@P%4#  'H!0!QWBCPO#XB\=>'WO]-6\TR"TNQ*77*([&
M+9GW.&_*L_2_"4OAG5M:T+2[!8]'UBUDDMKR.,;K6;:08Y&^\5YW*3G'(KT6
MB@#R/0M ORGAO2[NQ\2F;39X7G6XGC2SMS$/OHP4[P<8"CDAN2*AU$WNA_#^
MU\,WNBWAFM-3MPU[L7R&4WBLLH?/);(&,9!8YXKV*JNH:=::K:?9;V$30;TD
MV$D?,C!E/'HR@_A0!YIK5MK-KHOCC0H- U"[N-5GGGM)H54PLDD2#EB>&!5O
MEZDXQG-2^)?#VJ7O_"3K%I\LJW5AID40"Y$ACF8R ?0$9KU"B@#S_P 8:1?#
MQG8:Y'_;!LA8O:2-I)4S1,7#@E2"2K8P<<@J*HZ?X<O4BT"8:;?H&\12:A,M
MY,LLJH89%$C[0 A)VG:,X)ZYZ>G44 >=:IH6HS:/\28XK&1I=2)^R +S/_HL
M:C;Z_,"/K6?>:-J>E^)=9NY8_$;PZC'!) =(,95F2((8Y P.T@C()^7#5ZK1
M0!P/A/PY=:/XEL&>PD@MX/#T5KEY1+Y<GG,QCWX&X@$=ATK-T?2M5TE?!]Q-
MI5VZVE[J*3I$@+1+-(_EL1G[N"#GL*]0HH \JT?3]9L=8TV#2]/UFQC2])O-
M/O"D]A#%EMS0RL-P/.5"GO@@#-=GXZTJ[UGP?>V=C&);G=%*D)8 2^7*LA3)
MX^8*1SQS7144 <'K&I:UK6GZG+I'A5TFCT]DCEU.W02/(6'[M4).Y0 3S\I8
M*.:PTTS5[WQ-87JP^(;J!-/O(9+C5$CCQ(\:X58U VCY>N,$X )Q7K%% 'GW
M]A7W_"%^ ;+["_FV%U8R746WF+9&=Q/T;]:J>+?#&KZOJ'BIK.WE(FATV2#:
MP3SS#+([HK'@-C&,\9(KTRB@#RQ-%GU:[OKHZ/X@U%$TJ>WVZU=)!YQDVYA4
M*N>=N=^< @8]1H^$(-8B\2((AKC:,MHPE&N1IYL,FY=J1R#YV&-V<Y' YS7H
M5% '(^.K$W2:9-]@U.403LWVO2IMMS:$H1N5?XU/0CT/0US07Q:FB6C3PWY@
M&K2,;J.RA.H);>7A7,>"H<OD$@;MIZ=:]3HH \>_X1[6+JW\2YT[59$O+[2Y
M8&ORK2S1QRKO9MO P%)V\8&..U;WC3PUJ>NZUK"64)"W/AUK6.5CA&E\[<(R
M?<?H:]#HH X34+O4?$VG7=E;>%KBU;^R[F)IKZ-8VCE=-JQ1')W GJ1\N .:
MQ;K0=6\165O%%875DTGA6YTXFZ39LGW1 *W)P&VD_2O5:* . W:AXCU/PO$F
M@7VF#2KC[3=RW**BQXB9/*C()WY+=1Q@?A5.QT#4H?ASX0L#82+=6FIVLT\6
MWF-5F+,Q_ Y->ET4 >5-I^LVFMLNC:?K-E<OJGFRV<I2XTR2,R[GE#,,H2I+
M87!#'&.]=UXRM)[_ ,$:[9VL32W$^GSQQ1KU=BA  ^IK;HH X_P[I5W;>+M5
MN[BU9(I=+L(8Y&'#,@EWJ/IE<_45SGAS3-5\,P>%=4N](O+B.WT>33[B"",/
M+;2&17#;,Y((4@XZ<5ZG10!YQ)I>K:QK-I=MHBZ:D^G:G'L&!L,K1^69<<!V
M +'KWYJOIRZO?#P+8-H&I6O]CNJWLTZ*J(RVSQ_*03N!)^\..GK7I]% 'DR6
M6KP>#]$\*-X=OGN].U*U,UT$7R/+CN%8S*^>=PY(QD9;/2KW]@:FTL6ZPE*C
MQDU]RO2#8V)/IG%>ET4 >9>)M$U"37M>U".W!C$^DW$"2.J+>&&1RT0+'&XY
M &>^!5[2M2EU7XMF=])NK!4T(J/M059'S.O4*3@<$#/7FNUU+3;/5["6QU"W
M2XM90 \;]#@Y'T((!![$54TCPYI6A/-)I]J4EGP)99)7ED<#H"[DM@9.!G'-
M &3XKMKR+7?#VNP64U]!ITLXN(+<!I LD>T.JD_-@C! YPQQ67>6^HZ[>Z+?
M?\(^UE!'X@2XPZ 2M$MO(OG2@=#N( SSC;7?T4 >:>(- U.\U[7)8["66"XU
M'2)$(7(=(G!D/T4=:VSI5V?&/BF[^RMY-UI5O##)CAV'G;E'_?2_F*["B@#R
M4^'-9_X1^"#^SY_-7P,^GE<<BX(3$?\ O<&NCU'2M1^W^#Y;.R#FQM;A'##"
M1L;?:JMZ L *[>B@#QZUT_7[U_"K7%KK[SV>H02WL4\,4%I:@ J1$B ;@">"
M,@*#D\UWG@:QNM.T&XAO('AD;4;R4*XY*M.[*?H00?QKI:* /-==T+5+G7]:
MGAL97BFU32)HV X9(G4R$>RXYK(\4:?XDU33?%-@UGK1N9Y9Q:6EC%%%9R1'
M[KO)C<[$<D%LD\8KV&B@#SV"YU#0O%>O7C^&]1O(;ZVM%@DMXE;>Z1D%&R1M
M&3U/ YS[X5WX.UNT\.6>GBT>>:'PG?6;^5\RB=S&5C![]"!]*]?HH \NUSP[
MJ]U:>+D@L)7:ZT:QB@ P/,>/S2ZCW&1^8IWC2&^O-0TJYTR&>UD\2V_]CW<4
MPV2Q(3YGF%?5$$X_X$*]/K..A::==&M-;!M1$7E+,SL=J]]JDX!/<@9- #8;
MZWL]8MO#\5I+&!9&>*0*/*"(RILZYR-R]L8[UD^,+.\^W:!K%K9RWL>EWK2S
MVL(!=D>)X]R@]2I8''7KBNF\J,2F78OF%0I?')'7&?3DT^@#RK4-.U;6O^$J
MO(M#O+9;V[TM[=)D"R2K%*N]B >, 9P>< ?2C5]/UFWUC4CH>GZS9ZA/?"1(
M04N--NP67,K[Q^[) R0,$$<9KU6B@#@7;4/#NM>* = N]5&K2K/:/#&KQR?N
M5C\J4D_( 5ZGC#?A7/>(;/4--N;V]N-)#"76=':&WAP$E9$162,G P&&T9QV
MKU^JM]IUIJ20I>0B589DN(P21MD0Y5N/0T >:^)]-U7Q0GB'5+32+VWC?28[
M""&XC"2W$GG>82$SD!1P">N3BK.O:!J=WJOB%X["62*YU3298SMR'2,Q^8?H
M,'/TKTNB@#S[Q;IVMGQ!K%_I.G+<N^@QP1>9&KH\@G8E<-PS!3D \9Q65%IF
MK7GBFTO5A\0W5NNFWD#W&J*B$2.JX58U VCY>N.3CKBO5J* //;S1[BU^#>E
MYB%MJ6B6-M?1J_R^7- @9E/ID!E/^\:W? MG-#X<&H7:%+[597U"X4]5,G*K
M_P !38O_  &M76-#TW7[:.VU2V%Q!'()1&78*6&>H!&X<]#D'TK0Q@8% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,JJ[;WC27=PA);JI(!(S0!4U3QQKD)\276GZ=I\FG:"RO(\TKA[A#"DI"@#
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M*RKWX?75PNOVMOK:6]CK4DDL_P#H0:X4NN&42EL;..A7.. 1UH LS^)=>O\
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M:]N%AA@4YR[D\D#&,#DDCW-<WHVDIJ?Q/U+Q%';WD-G;PB%5N86B$MV?D>1
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M_P#79A:+U^7[V>])XB\.W6L:CI6HV.J?8+O36E>,F 2J^]=I##(XQGH<^XH
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MF6F4GV?9UE&)-K'(C)X&['!.>U;7A-=5T_QC/ITR26UC)8>?]CN=6-[*L@<
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MSU&"87Q<6VT_ZPH,N![CN#SQ574O$$D6JV%CID<=VQU!;2_QDFV4Q-)DXZ'
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MUO\ 5[>"XA($L;$DQY 8%L#@88<GCFI-3\7:!H\D<=_JD$321B91DMB,]'.
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M<MYD90(&%R\2.'6(MNVX! !8#) Z"M"7P=+)X9\4:3]L0/K4]S*DFPXB\U0
M",\XQ0!AW.OZNFK>+X[B'?I-GH<=PB1WS)(H,<QRI"<,VW!;/R[5(ST%N3Q\
MT4_]GZ9:V,DEI:0RW!U#4Q;DET#+&A*DNVW!).!R.>:MZCX.O[F]UEK>^MEM
MM6T<:=,LD3%T=4D574@XQ^\Y!':JLW@.]M=0FO-,DTB5[JVABN%U*R,H22-
M@DC((ZJ!E3Z#F@!)OB4ET^E)I%M9LVH6/VV,ZE??958;MOE(=K;I 0<C@#CG
MFNUT^YEO-.M[F>UDM998U=X)""T9(Y4D<''M7)WW@_4VL;*SANM+U&UBM1!-
M;:K8*T329SYRA,;2<D%>F,=#R=7P_H-]X>TO1M*@OXYK.SA>.Y,L1WRDX*;#
MGY0#G@YXP.U '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17G
M_B?Q[JEEXEN=!\/:9:7=S96RW%W)>7/DK\WW8D]78<CM7;:9=3WNEVMU<V<E
MG/+&K26\A!:)B.5)'!P>] %JBBB@ HHHH **\?M_B=XRNM!U+Q#;>'-+FTG3
MIY8YO]+9)2(S\Q (QT-=1IOC_P#M3Q;H^FPVJ)8ZCH@U7S9&PZ98C:>V,=Z
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MUVRU;3A'9M:6YF\BX"!,$#[I^7(;MGCO7=>"KG5M&TCPYX<U?3K^6\-AOFO
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M5R,@8X'/&1BO<** /!_'/@+6==\?ZY<Z;;316UGIUO-;0FW/V>\>,J1#_=/
M/R^N*]GT+4'U70K*]DL9[&2:(%[6>,QO$W0J5(!X/YCFM&B@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1LA&*C+
M8XH R!XKT ZS_9 U:U^W[_*\G?SOQG9GIN_V<Y]JV*\7\/2ZM9?#?0=9OO[-
MNM.^V0F;3VMB93(]P%\T2[N91(V[&W';MFO7]0L8M3L)K*9YDBF7:YAD,;X[
M@,O(STXH ++4;/45F:SN(YUAE:&0H<A77[R_459KB_AM9V^GZ;KEG:1+#;P:
MW=QQ1KT50P  KM* "JFI:I9:1:?:]0N$M[<.J&5_N@L<#)[<D#)JW5;4+"UU
M33KBPO85FM;B,QRQMT92,&@!NH:G9:5 DU]<)"DDJPH6ZN['"J .22>PJW7F
MW@S2KV]U^XAUF]%[#X6F-C8!AR[%0PFD]7$;(@_X$>IJF^K:V? <_CL:Y=+=
M1RO*NGX3[,(UF*>25VYR0,;LYW'\* /5:*X=M;OU@^(+F[=?[-R;7./W(^R(
M_'_ B3S5+1)M8U[Q5;Q2ZY>P6EMI&GWKPP;!YTK[]VXE2=I"\@8[=,4 >BT4
M5Y/<W^O)X:UOQ*/$%Z)M.UB>&WM0$\DQ+<[-CC;EN"1G/'&.G(!ZQ17GCRZM
MKI\4:BFOW>FG2;J6VM(( GEIY<:MOE#*2^XG."<8Z>M1>'-0U?Q;XECN)M5N
M[&TBTO3K\V=OM"O)*'+*Q92=AVXP,=1SQ0!Z117D-G=>(YO#GAS63XGOQ<ZG
MJ?V&5-D9B2%GD7*J5^^-H(8D\]L<5HSZM?Z./$>D2^(+\K;WMI#:7#0+<73>
M<@9HD  !8_,%)!QGGI0!Z+?W]KI=C-?7LRP6T*[I)&Z*/4U8ZUXIKNIZF-(\
M8:1<MJPM!HT=U%'JS1-,K&1E)!C)PIP.&YR.V:]J7[H^E "U6DO[6+4(;!YU
M6ZGC>2.(]652 Q'TW+^=<GJ*:CJWQ&GTA-<O+&PBTF*Y\JT*J[2-+*N[<02
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M+KQ>EC?-$;+3;*6W& 1%(\L@8_B M=SH^FS:78_9Y]3N]1D+ES/=%=W/8;0
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M[E>&#:VX2.@8LH([C:V?H:NUXGHVEW#Z)X(@AU6\BDGUJ^Q-E&:( 7 ;9E<
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M;?#OP^#<33>9I\$@,I!V9C4[1@#Y1V_G0!T4ES!#+#%+-&DD[%8D9@"Y +$
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M 9E$$ZOL'J<'I[T -C\,Z1#I]C81VF+:PN!<VR>8WR2 DALYR>6/!R.:CO\
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MIX=]S9%S;ON(V%UVMP#@Y''-4;KPIHM[#?17%D'%[.MS,?,8-YJJJJZD'*,
MJX*XZ5.?$.BKIT.HMJUB+*8D17!N%$;D D@-G!X5C^!]*J#QIX7,-O,/$.E^
M7<.8XF^U)AV'4#GKR/S% #8O!>A1:?=V1M))DO61[F2>XDDEF*$%=TC,6."!
M@9Q6H-,LQJYU7R?]-, MC+N/^K#%@N,XZDG.,U%KFL6V@:%>ZM>,JP6D+2ME
M@NX@<*">,DX ]R*S[#Q3:ZB+"YAN=/\ L%S8R7;R?:U+)L*AL#NJY8,V>" .
M] "R^"]"ETVQL%M)(8M/S]DD@N)(Y8,]=LBL'&>_/-:.DZ/8:'8BSTZ#R8=[
M.V6+,[DY+,S$EF/J235(>,O#)-P!X@TPFV3?-BZ3Y%R!D\^I ^I%63XAT8:.
M-8.JV0TUAQ=^>OE'G'WLXZ\?6@!VL:)8:]9I;:A$SI'(LT;1R-&\<B]&5E(*
MD9/(/>L^#P3X?@%[_H!F:^A$%V]Q/),TZ DC>78DD9//4<#/ K6T[4['5K-;
MO3KR"[MV) E@D#KD=1D=ZRK'Q?I=_P"*-5T&.X@%SIR([_OE);(.["]?EP ?
M0M0 FG^"M"TV\>\BM99;E[=K5I;JYEN&,+$$QGS&/R_*..W/J<MT_P #>']+
MU"UOK:UF^T6>X6K2W<L@@5E*E45F(5<$\ 8Z>@J_IGB/1-:FEATO5K*]DBYD
M2WG5RHZ9P#T]ZJ>(?%NF^&[W2;6_GAC;4;@PJ9)E0( I)<Y[9 7ZL* + \,Z
M/_PC[:";%&TP@Y@=F8<L6SDG.=QR#G@]*JVW@K0;:&]C:TDNOML7D7#WEQ)<
M.\?9-TC$A1GH"/6I8?$EC%:37&J7^FVBK<SPHPNU*D1D]2<88!267M@^E"^,
M?#+BU*Z_IA%V=MO_ *4G[PYQ@<\\\?6@"*T\%:%:+<@VLMU]H@-K(U[<RW!\
MD]8P9&.U?88[467@W1].,TEM%.\\ENULLEU=S3F.,_P*7<E5X'"D=!5W4O$>
MB:/<16^IZM96<TO,<<\ZHS#.,X)Z9[UI@@@$'(/>@"EI&GC2M%L=.$K3?9;=
M(?,;J^U0,GZXJMJ_AO3=;GMKB[2=;FV#"*>VN9()%#8W+NC8'!P./:BT\4Z!
M?ZD=.L]:L)[T9_<17"L_'7@'G'?TIT/B70[C5FTJ'6+&34%)4VR3J9 1U&W.
M<CN.U % > _#B6+6<5@T,9N?M8:&XD21)MH7S%<-N5B!R0>><YR:T](T2PT.
MVD@L(G42R&65Y)6DDE<@ LSL2S' ')/:K-Y>VNG6DEW>W,-M;1C+RS.$51[D
M\"JNG:_H^KVLUUIVJ6=U!#_K9(9E81\9^8@\<>M #]6TBQURP:RU"#S8"RN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LKQ%K:>'=&EU26!YH(73SMAP40L%9_<*#D^P-:M9VO2Z9%H-\=9FBAT
MUXC'</*VU0C?*<GWSC\: ,K6?&MEHM[>P2V\TRV=I'<2O#@DO+)LBB [LQ!Q
M_P#7JM)XVGTYKF'6M$FL+E+&:^MT$Z2K.D0RZAAT<9'&,<\$US_A?P?>:K\-
M9/M=XR:KJ$D-U%=2Q\J(2@MRR^FV-21_MM6Q=>%M:\27C7'B"6PMEBT^YL[>
M*Q9Y/FG4*\C%@O0#A<=SS0!MMXEB6Y\/0_9WSK08QG</W6(C)SZ\#%6-:U2Y
MTV*W%GI=QJ%S<2>6D<1"HG!):1SPB\=>Y( !KF=.\->)GU7PU/JLVE);Z(KI
MMM6D9I]T)C#G<!M/3Y>>IYZ"M#QGX<O/$!TQK=;2Z@M)F>?3[V1DAN05P-Q4
M-RIY ((H IM\1$@TV]FN=(G%[97\-C-:0S)(2TNW84<8#9##@XYX.*L+XY6R
M_M=->TN;3)M-M%O602K,)86+ %2O\6Y2N#WQS6+9_#W48%O1NTJV6XU6QOT@
MLXVCBB2 KN0#'7"<'C))) K9\0^"W\0:KJTTERL5M?:1'8*5!+QR+*\@?'0@
M%E[]C0!27Q!K=UX\\.6=[I=SI4,\%U(T1N%D28!4VAMO1E]#Z\$\U?\ $FM:
MOI_C'PQ86-OYEK>RS"X'F*N\+&3CD9&W[W'7&*9;:-XGO?%&CZKK,NE1PZ=%
M-&8[1I&,K2*!O^91CI]WG'/)J_XAT;4+[6=!U/37M?,TVXD:2.Y+*'CD0HV"
MH/S#.1VH Y7P]XVU.RT,7.I:7=W.GKJDUK+J+SJ2NZY9$(0\LBY5<\8QP#BM
MK4/'AMKC4VL](FO+#2G,=[<K.B$,H#.(T/+[0>>G.0,U$?!EZ? 4N@?:+?[0
M^H&Z$F6V;3=^?CIG.WCZUF:A\.K@:EJ\EEIOAN[34KAKA;O4K7S)[1W W8&P
MB09RP!*X)P<B@#M-5UR&P\)WFOPXG@@LGO(\=)%"%Q^=<Q9^%];U'P]!JC>*
MM4CUZX@6X5EFQ:QR,-P3R<;2@SCD$D<YS77-I5M+H1TB9%>U>V^RNJJ$!0KM
M( ' X[#@5R4>B>.;;1%\/0:EI0M$B^S1ZH1(+E(L8!\L#:9 /XMP&><4 :EW
MXFOX=2_L>PT@ZIJ5O;1SWOESK#%%NR  S=22K$#T')%5&\?QW$>BC2])N;RX
MU99_*A9UB,+PD!UD)X&"2"1G[O&<BG-X=UO1=9EU#P_-:70NK2&VN8]3FD#%
MH@0DN]0Q8D,=P(&<9S4>C>"KG2;WP].UY%.;!;U[MRI4RRW#*Y*CG !W=3TQ
M0!!#\19GM1>R^'+N&RAO1I][,T\9,$WF",[5!RZABN6&.O0X-6+GQW<Q2:S)
M;^'KJXL=&G:*\N%F0'"J&8HIY8A3DCCV)/%,F\&7LGA?5-+%Q;B6[UDZ@C$M
MM"&Y6;:>.N%QZ9K&L+'Q'JDGC73=.ET^.QO-5F@DFGW^;!NBC#,J@8?@\ E<
M$=Z .FU/Q;=V_FRZ9H4U]9PVZ7#W<DZV\;JPW 1EOOG'7H!D#.:K_P#"=O>7
M.G6VBZ+<7\VH::NI1!IDB5(R0,.3T/(Z9Y/XUDWOP\NVU6Z,5OI%_:26T-O:
M2ZF&DDT]4C"?)'M*MDC=U4Y)S6MX7\(WNB7NDSW,]NXLM#33'$98[G5P=PR!
MQ@?6@"?2O&]OJ<FBJ;&>W&J?:(U,C#]U/"2'B;'?Y7((Z[36MH>M1Z[!=7$,
M+)!#=RVT<A.1-Y9VLX]MP8?A7!>)-,;P]X%@TW[="/$!U62\TA8\DR3-<%@H
M!Y/RR[6[ $UVVGZ3=:%H6D:5I1MC':F..X:XW9>, [V7'\9///')H VZ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MELM4TTSP7X6,@+$RG>K#)! [D''>O:** /&O$$-W=Z7XJ>73I;:2?P_I@-L
M3Y;;Y"T8/<KG%='KNCM:^,+:/0;2.TFD\/7T$30($ <&+RP2.."3C\:]"HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9!#!&T0D5\ELL,$\ $\?2F6/CE+F?3FNM%U"QL=4<1V-Y/Y>V1B"5#*K%DW
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M4KM;A([5V=8U$2(%)(&2-O7'/7CI5CQ;H]SKNAK96K1K*+NVGS(2!MCF1VZ
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MKK/!N@2:%870FLM.LI+FX,OV?3U.R-< *I8@%VXY; ZXQQ0!TE%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4%Y>6NGVDMW>7$5O;1#=)+*X54'J2>!4]<?\ %/\ Y)AX@_Z]O_9A0!I6
MOC?PK>W45K:^)-*GN)6"1Q1W:,SL>@ !Y-;U<KI@\3&^M_MOA_08+;/SRV]Z
M[R*,=0IA )_$5A6/B/79O'Q\'2:I 3:SO=27P1-\\&%9;?;MVB0;QN( .T C
M!.: /1Z*\DD\7^)[Z/4]5TX:NSVUY-%:V,.GH]I(D3E-LDA&_<VTY(8;2>G%
M;\=WX@\27NOSV.MG1XM+G%M;V[01LC.(DD9IBRD[27Q\I7 &>M '>5%+<00Y
M\V:-"J&0AF PHZM]!D<UR5GKVHRWGB])+F-DTZ&%[8QJI5"UN')!Q\P+<\YK
ME[2XU*]\0:;K,NJ3&>7P=]KD3R8MCL=I((V="QW?48Z<4 >K6\\-U;17%O*D
ML$J!XY$;*NI&001U!%25YM8^,KS0].L+W5YEEL;SPY%?6ZK$J8N(T!DC7:!]
MX.A [8..*KW.O^)4U/3]!N[O5$N8M+CO+Z?2[&*65YI&8;,,I547:1P,GCF@
M#TJ6]M8+RWM);B-+BX#&&)FPTFT9; [X!&:?/!#<Q&*>*.6,]4D4,#^!KE_#
MCZCK&AV^I:M:%-7L6N(X#.GE!SDJLA4?=W*!D=LM6%X4U_6#KVGV6O:EJ4%[
M<Q.)K+4+"-899 N[_1IHQ@@8/#,Q(]Z /1XXTBC6.-%1%&%51@ >PJ."[MKJ
M2=()XY7@D\N948$QO@':WH<$''N*YSQ)?:C+XCT7P_I]\VGB]2>>>ZCC1Y D
M03Y$W@J"2XR2#P*Y'2KW5=#O-0A.H":>?Q?#:W$_E*/-B:WCX(Q@$@#)&.<X
MQ0!ZL[K&C.[!549+$X 'K4*7MK)=FT2YB:X$0F,0<%O+)(#8]"01GVKSWQKJ
M%_>V?Q TO[8T=K9Z)%-$J(F0668N"2"<,$ /H.F#S534_$NI^%8[XI,+U[3P
M[:31--"@8RR3O&"Q102HROR]./4DT >J45YOIVL^*H-3%M$-5ODGLYV,FK6,
M=LL-PJY0@H!\C'((.2..:D\(:]J;Z];6&L:GJB7<]L[26.J:?'%OD7!+6\L:
MA64<\$L<8/K0!Z)1110 4444 %%%% !1110 4444 -$:+(T@10[ !F Y..F3
M3J** "BBB@ HHHH *" 001D&BB@!D,,5O$L4,:1QKPJ(H 'T I]%% !1110
M4444 %-=$D7:ZJRY!PPSR.E.HH **** "BBB@ HHHH **** "BBB@ HHHH 1
ME5U*L RD8((R"*  JA5   P .U+10 4UT21"CJK*1@JPR#3J* "BBB@ IKHD
MB%'564]0PR*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8D9T9MP4Y"B-0#\S'..O-8__  A>L/XC@O8]/TZPNTOQ//J]C=/$;F$/N*/
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MKPWE[!"$FG))WM]3R?3)Y.,T 8.G?$6UO[:QOVT?4[;2KR=;:._F6,()2VT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBL'QCK5SH7AV2ZLDC:[DFAMH/-!V*\LBQAFQV&[/X4 ;W09-5
M;#4[#587FTZ^MKN)',;/;RK(%8=5)!.#R./>N$UVZ\0:5)+HEYK2WB:EIEU+
M#<_94CD@DA"EA@<%65L#N#W-;_P]LVLO .B(TBR%[*&0%8ECP#&I P.N/7J:
M .FHKD_$M_K/_"6:'HNE7T=E%?074D\S0"1E\OR]I4'C/S$<Y'/3BN:@\1>*
MXM%&LW.K6TB6>LC3);9+0*+E!<B$N6SE6YS\O''0YH ]1HK@)=6\2:K%XBU3
M3=3M[*WTBYFMX+1[82+.85!8R,3D;CD#;C P>:AL/$^MZYJ]S>P7J66D66G6
M>I26PMUDDE$L;.T>X]!A3SC.<4 >BT5Y7H?C+Q)>G1=0,>HW2:A+%]HLET25
M(((I/XTGV\[,@DDD,,XQQ7JE $4UU;VT;23SQ1(K!2SN% 8D #)[DD8^HJ6O
M%]2M]1C\,^-F^WK,_P#PDELL:R1 *)/-MB&..<<J,>WO76MK.N:#K6J:;J&L
M65VJ:0VHPW5U"($A=7*$/LSE.0?7MS0!W=%>9:5XMU4>)-.LVU.YU&UOK6X=
MI+C26M$62- P,195++U'.>W-.T?7_$XTSPAK>H:I;W$.M30V\]FMJJ*@DC9@
MZN#G=E1D'CDX H ]+HHKROQ5XTU;3?[;O+'6?-?396V6=II;S6X5<96><KA7
MZY 8;>.M 'JE%-1M\:MC&X UQ&K:AXBN_%FLZ9INJQ6%M8:=#=*QM5E=I&,O
M'/&T[.>_ QCF@#N:*\XTCQ)XAW^$]4U&^@FM->B=I;.*V"B#$#2J4;)8GY<'
M/'/&*9%XC\21>%-/\:3ZA;O9W4L#R:6MN J02R*@"R9W%P&!R>"<C H ](>.
M.4*)$5]K!AN&<$=#]:9-<P6T4DL\T<4<:[W>1@H5?4D]![UYI>^(O%,>B>(?
M$,>J6Z6^CZE/!'9?9%(GBCE P[YR#@X&,=,G.:I>+X+O^UOB'(;XF >'8CY/
ME+R")\#/7@@GWS[4 >N AE#*00>01WI:X;3+S7]*\1Z!8:CJ<-];:K:2L8UM
MA']G>-48;"#DKAB/FR>,YKMIE=X)$CD\N1E(5\9VG'!P>N* &O=6\;Q(\\2O
M*Q2-2X!=@"2!ZD 'CV-2UXIH]MJA\-^ 4@U)!<RZM<^5+) "(5\N<-P"-Q^\
M1GN1V%;]]XQUS0+'7;"XG2_O[/4;6RM;H6IR1<*C M$GWBNYN%QNP!0!Z917
M$>%-<UFX\0RZ=>#4KNP:U\Y+V\TE[,QR!@#&<J%8$'(QR,'.:WO%R2OX.UE8
M)C#)]BE(<*&QA23P?4<?C0!L*P90RD%2,@CH:6O*(/$6JZ=IOA;0(+R\4R:.
ME[-=VFF&ZE"?*J1JB@@ 9Y8@]!W-6D\3>*[^+1=/1VTZ\N]2N+-KNZT]HS+"
MD1D658GP02!TZ;@>W% 'IM%>8ZEK/BR!/%TL.MVZIX<BC= ;)2;IA;)*X?GY
M5)STY&[KQ5^/6/%%EK%M;R75MJ,FIZ3<7EO;>0(EAGC\LJ@;.2A\S'S<\9S0
M!W]%>?>#_$NHWFN16&J:K+]JDMF>73]0TTVLR2#',3 ;73EL\D]#FN^E5WA=
M8W\MRI"OC.T]CCO0 UKJW22*-YXE>9BD:EP"[ $D =R #^1J6O$]$M=5;2/
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M2![UECQIK-I+KT"7]U>1P:#<:E;3WVEFT=98R!PI5=R'<#R.W4T >J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>guyaragreement006.jpg
<TEXT>
begin 644 guyaragreement006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <_J?A=-3\8:)K\ETP_LE)A';[,AFD7:6
MSGC ]JN3Z;>R^([744U6:.SBA:.2P" I*QZ.3U!%:E% !1110 4444 <EX?\
M#1:#X3U705OWF74)+B0S&,*4\U<8QGG%99^%RP:+X>AT[7+BRU;0E=+744A5
MMROG<&C)P0<],_SKT&B@#SUOA3:77AC7=-U'5KF[U'6Y$FN]2:-58NARF$'
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MT?X>V^@ZYI6IZ;>F!K73ET^[B6$!;Q5 "NPS\K C.>?2NSHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%#8PHMP&)3: 9.!GJQR23C%=)/H>H-X2^(EN+&0W&HW-TUJFWF8-;HJD>OS
M@4 =)K?C'1=#DEMKF]5;I8?.*+$\@C7G:TA4$(I(ZL0*L^%]4FUOPII&JW*1
MI/>6<4\BQ@A0S*"0,DG'/K7(11:EX?U#7A)H5[J*ZO! UNUN@9=RP"(Q2$D;
M ",Y/&&/>NH\%6EQ8>!M!L[N)H;B"P@CEC8<HP0 @_C0!I:EJ=EH]A+?:A<)
M;VT6-\C]!DX ]R20 !R:YW5?'^E6WA76-6L)6GGT^$L;>6"6-PY4E-Z%0RJ2
M/O$ =>:3XAZ/?:MHEBU@MP\ECJ$-X\=JRK*Z+D'9NXW#=N /=:Y:XT.]U+3/
M%=U;V6OS2SZ*]E!+JLBB2=CN.Q8@H. 3]XGJQ '>@"2U\?ZO<ZI:Z=_:&G*Z
MV#7MS<2:3<HC')P@!;*@ $ESD'H!GBNPE\9:1IUCI[ZE?HUQ=6JW.VT@EDW(
M0,R!5!94R>K5BZCI&H2ZWJ$R6DK1R>%S:(P'!FW.=GUY%5-%AU'PIJ$5]=:-
M?WD5WHMC;C[)$)'@EA5@T;+G(!W@YZ9!S0!U<'B.TFU.8KJ=@VG)IT=\&&[<
M$9G_ 'A?[FPA>._!SQBG:5XNT/6IV@L;PM*L?G!)89(B\?\ ?4.HW+TY7(Y%
M<'JWA;7-:M]7B328M/ENO#UO"D$# 1+*L\DAA#=,X(![?-Z5=T?3;F_\2V%X
M]IXF;[%;SEI=7EC18F=-NQ55,R9]00!M!R>E '3Z?X\\,ZI=VMM9ZF)7NA_H
M[>3(J2G&=JN5"EL?PYR/2E\(^+(/%=M?S11/%]EO);?:T;KE58JK98#D@9([
M=#7,V.@ZC%X%\!69L9%N+&]M)+F/;S$%1]Q/XGGZUN^"(;NR&N6-W8W-NRZK
M<W"22*/+FCEE9U*'//&,^F: .KHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***QO%>N2>'/#-YJT5K]J
MD@V;8=VW>6=5QG_@5 &S17%W/C2]\/7$L?B>PMK=#837T#V4YE#"+&^([E7Y
MAN7!Z'VJGHWQ'^V:OIME>/HKC4PPA73M2%Q);N$+A)5P.H!&X<9&.^: /0**
M\CUSQ)XH\2?#,:H-.L;"QU"2T1-E[)YQ1YE1@=J<!B0.#G:Q[\5T%GK>M06U
M[9Z!H=A)::&!!<+)>.#+,$#O'"2I.!N W/C)/0=: .\HKB;+QKJ.O:[:6FA:
M;;264MC:ZA+<74Y0I%*S J%"G+@+QSC@\]*SX_B!K\FG6.JKH%FUC>WYT^)/
MMC"5I-[1JY^3 3<N#R3CG':@#T:BN-@\6:RD6NVMUI-H^J:6T/RP7>V!TE&0
MY=U!4*-V[@].,UFI\2)HH]?CF32;VXTO36U!)-,O3+$X&08V.,JV0/7@T >B
M45QEOXNU2TU6RAUW3;2UM-0M)KJ![>X:1XA&H=ED!4#.ULY4D9!'/6G:9XHU
MZYM;+6+S1+>+1+R(SAXKDM/;1;"ZO(I4 @@<A22"1UH [&BO-],^*:7ESI4L
MYT<6>J3I!%!;ZB)+R OQ&9(\8Y. 0#E<]\&NI\0Z]=:=>Z;I>FVD5SJ6HO((
MA/(4BC1%R[L0">,@  <D]J -^BO*_%_B'6M2T"]T62TMK74+;4;*VO1'=.$E
MBFD384<*&VMRK X(&>M;?C%]4T+PAH\&CK!;2+?64#J)W"@&5!L#8)*DG!)Y
MVD_2@#N:*\RCUOQ+IVO>-;BSL;.Z@L989YA<7;J.+6-FCB 4^A.3@<CCDXO:
MA\2(_M\%GI\ND6SM8Q7LDFKWPMUQ*"4C48)9L#)/0<=<T =_17G]IXTM-8N]
M$U6"S;?-IE_,/]))6-HFC5TP/E<%NC>@XZUO^#]9U?7](BU74M/M;*WNX8I[
M1(IVD<HRY^?*@ ]",$\'VH Z&BO+?$'B?7-;\*P:I:V$$&BW.I6R0S)<L+@1
MBZ10[+MQM;&, Y 8=>:ZI_%DBZ?XMNOLBYT%Y%1=_P#KML"R\\<?>QWZ4 =1
M17F-YK^KS:UX@EN(HGTE/#,=X;9;IU(W+*3MPO#$KM)!X 4CG@6KCXA+:W,.
MEV+Z-;/;V,$\S:MJ/D EURL:9!+' R6/3(ZYH ]$HKSN;XG+<V^BR6":=:+J
M=L\XGU6Z,4(='V&)752&;.>>.!GG-=-=ZC+-X$N]2O;'R9#I\DLMLMP&QA"2
MHD3L>S#US0!O45PUOXFUB:\T[1=#TNT9WT:"_P#-O+IPL88E=A(5F8\#GZD^
MY9>.;_6K;1H-)TN :IJ$,\TL=S.1%;+#)Y;DLJDME^!@#U.* .YHK@+K5M4;
MQ3X9DU&R:QN$BU(36Z3;XY"BIM8'C*GJ,@$9Z5IP^,))= \*:G]C0-KLT$3I
MO.(?,B9\@XYQMQVZT =917EOB'Q/KFM>%(]4M+""#1;C4K:.&9+EA<!!=(OF
M,NW&UL8P#G##KS6E)XKETIM4.GZ4)[F7Q&NG!)+I@'=XD(?)!V#H, 8X)ZT
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MAI+IEEF5 "Q10A (!SR>>E:4_B;6K_5-2MO#NEVES#IFQ9WNKEHS-(R!_+C
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MK;B$2&[U:_$"2-DC8@ ))&,DG Y'6LM/'NIZI:>&3HFD6TEUKEM/,%NKDK'
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MS'YL]L7BFBFE,A1D#@C!VX(;M[UJZ=XXT+5;^*RM)KQIY20@DTZXC7@9Y9D
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MPI'.:H^%/[2U;XA/K$]])?VD&E-:_:!I[V<0D:56VHKDLQPI+'..0.*]'HH
MY?5O"EU?^(+W4;?48X8+[2SIUQ"]N7/'F%75MPQ@R<@@Y [5(_A,/#X8B>[!
M71/O Q?Z\>0T/K\OWL]^F/>NDHH XC3/ ^I:8EEIT6M0#1[*57B5+("Z>-3E
M8FEW8*] 2%!('XUN^)/#Z^(+.W5+J2SO;2=;FTNXU#&&0 C.#PP()!!Z@UM4
M4 <I;>&M9O-9L=0\1:U!=II[&2VMK.U,$9D*E?,?+L6(!.!P!FJ'_" WW]E?
M\([_ &U%_P (UYWF?9_LO^D>7OW^3YN_&W/&=N<<>]=U10!R-YX)-WH/B?3/
M[0"_VY=-<"3R<^3E(UQC=\WW,YXZTSQEX?EN+?6=8AD:23_A'[JP2V2,EG9O
MF!!!Z_+C&.]=C10!PVE>$]5U"UT677=7$T-A;9MHH;8PR"1HBF^1BQRRJS 8
M"\G/M5:P^'5_:VFBV3ZM8)::1=0W$8MM.\M[CR_^>K;SEB">0!R<G/2O0J*
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M:D3KECM<OO+9ZG/3%5SX))\./I/]H#YM6_M+S?)_Z>?/V8W?\!SGWQVKKJ*
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MG5%U,P+]M6$VXF[B,L&*_3(!_"@"U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M14;'EK&555"X&& R<G(% '?4444 %%%% !1110 4444 %%%% !1110 4444
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M$T,WL9?3;V"Z:78<.(YO,( [9Z5:T_XA>&-5O4L[+4)99WE\H+]CF #^A)3
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M'3KB.2-BZD>84=2#CK)R".@IS>$W>V\*PO<H5T3'F_*?WP^SM%QZ?>S7444
M>?:7\/K[3%L=.CN-(&FV<RNEP-/4WDD:G(C9CE?0%P,D#H#S74>*]%?Q%X9O
M=)CF6%[A5 D9<A<,&Z?A6S10!QVH>"IKW4]2NUO8U%YJ=C?!2A.T6^S*]>IV
M=>V:T3X=D.NZ]J'VA=NIV4-JJ;>8R@DY/KGS!^5:D>K6$NKS:5'=(]]!$LTL
M*\E$8D GTSCIUK/@\8^'[K5?[,AU*-[GS3"/E;8T@ZH'QM+#!^4'/% &+;^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJ&>\M;5D6XN886D.$$CA2Q]!GK4U
M !1110 4444 %%5'U33XKU;.2_M4NFQB!IE#G_@.<U;H **C>XABECBDFC22
M7/EHS %\=<#O4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X)\2+)]3\=^)OL>BIK[
MV^BJLWG2!!IA(+!X\GYVQ\V!@^_6O7?!,\-QX&T.2WO)+R+[%$HN)!AI,* 2
M1V.0?7\:RO$/PWT_7M7N=3CU35-,N+V 6][]AF"+<Q@8 <$'G'&1VK4L?"5G
MIE[I<UC=7UO;:=:&UBLDF_<.O]YUQ\S>^: -^BBB@ H) &2< 444 ?-U_P"'
M#I.F:M<ZMX:M_$FCSW,ER?$FE7JFYC7=DGG/(P<C@=>>]=]XB\:7UI;:/'H.
MO645M-IBW40GM9;R]N#CY=T:#"J1U8]\^E79_@YI#_:K:VUK7++2;J0R3:7;
MW06W8DY( VY /I6E??#32KC58+^ROM1TLI9+I\D5E,%66W7HAR"1T R"#^/-
M '$0>(KCQ7XA^$NMW<4<5Q<G4?,6/(7*J%)&?7;G\:>?B9K]OXCTL'4])U"S
MO=52PEM[&TF:*%68@$7+ *[XYP/?C%=IIWPRT?34\.)'=7TBZ ;G[*)'0[Q-
M]X/A1G';&/QK/MOA!I-K%8VZZUK36>G7BWEE:M.AC@<-NX&SGDGKD\GU- %>
MT\0>-?$'C?Q'I.E7.EVMCH\Z)OG@9WD#H2%X..H))^E5-)^)&L:U;>%-.MX[
M>/7;Z_F@U-#&2((X,^;@9X)!4C/TKN=-\-VN@:IKVL6AN9[G576::)F7&Y%(
M 3@8SGN37'?#_P *78\>>(O&6HZ/)I7VYMEI:3.K.N[!D<X) +,H_,_B >GT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPT^]BU+3;6^ASY5S"DR9Z[6 (_0T 6**Y.P^(>BZ@;5XH[]+2ZF%O%>26K+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-@Q-O)&#$%.=N6[@'D<<$UB:1X$U"TLM,T2YT&ZF-I<1^9?2ZU*;-HT?<'6
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M=<D94Y''!IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8QN^[UJMK?C6_B\37^C6VH06/]FQ1;Y9-+GNOM$KKOQ^[.$4 CU//'2MV_\
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M!8W)M9)Q';0C#2%$.YV9@=O08()Z5I^'[Y_&,=YI^J@SKIMY;W$%ZEF]LMP
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M0Q\P,P()8HS( !SNY[UVES97AUC2Y;2X,-C;+*)X%("R J @QCL>1R,<]<\
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M-:[:(.5^8W#[WW<=B>,8]\UHZ3HL&D2ZE)!)(YO[QKR3>1\KLJK@8'3"#]:
M-*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\<Z$]^+59[C8UQ]E6[^S2?9FFSC8)<;,YXZXSQUH W%LK1$@1;6%5M_]2HC
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M0;5A4#"'*\8['D>E6(X(8GD>.)$:5MTC*H!<X R?4X 'X5)10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<YX[TV[U?P9?V-C"9KF4Q;(P0,XD4GD\= :Z.B@#B&T+43;>/U^RG=JA
M;[)\R_O1]E1!WX^8$<XJGI=IK7A34)KL:%=:DE_IUG'MMI(]T,T,90H^]A\I
MSG<,XYKT.B@#R_4_"WB+4K3Q"9+"VCN[S2+%(XX'"Q--%)([QKD\ 9 R>.:F
MU72];\9:S=2-H]UI-I-H%WIZ27;Q[A-(T9&51F^7@\]\'IQGTJB@#SZ%==U7
M7O"/G^&KBQBTJ20WDTLL156-N\8$>UB64DCG _AXZXYW3_!FI6NDVWARYTK6
M[EXKE0TYU4K8-$)=XEVA]V<8.S;][\Z]CHH YWQK'K$N@!=%61IQ<1&80;/.
M\D,-_E;_ )=^.F?YXKAV\-:U=7/B6>+3=6$-]X>EL[=M2O%EFDFRV 1O(0'<
M,#@<$G&:]:HH Y&?1[YM;\&3I;'R=/BF6Y.1^[W0!0.O//'%8G@K1YX_&6HV
MLA5],\./+;:=@Y -P1*P^J(53Z$UZ0Z+(C(X!5A@@]Q5/2M(T_0[%;+3+2*U
MME)81QC R>I/J?>@#"\2V=_!XDT/Q!9V,NH1V*7$$]M"RB0+*$PZ!B 2"@!&
M<X:N;30]=OHKVYET=[1[GQ39Z@L#2(6%N@AW.<,1G"'(R><XS7IU% 'G=QX1
MU._\"^+-)$0@NK_5+FYM]S@"13*'3)'0,%QZC-48_"]YKMTROINN6973[F W
M.KZGYWE2RQ^7B-5=MPY)+''08YKU*B@#BM(GU^>UTK2)?#ALA:6YBO+FY:-H
MP5C*#R-K$G)QR0,+GO6'H6FZ[H]GX4U&70+N232+"73+NS5XC+R(\31_/M89
M3'4'!Z5ZC10!YHOAS6;[6(=:FTUK?[5XBAOFM6="T$$=LT0=\$C<3@D G&1[
MT[Q9H^J-K^I7>F:5K$-_-$@M+_2;Q%CG8+@+<QR,%PI[[3E>^>*])HH KV"W
M2Z?;+>LC78B43M&,*7P-Q'MG-<AKWAG4-8UWQ*L:^3;ZCH"6,-P6&/-W39!
MYP ZYX[UV]% 'END^&[Z\O='@NM(UVW:R!:>>_U3S(87$90>2H=M^=QZ@ #W
MXJEHWA'4H++1M#N](UJ26QN(O.GDU4_80D; B2-0^2> 0FT8)YP!7K]% 'EQ
MT;7;772VCZ9JNF7;ZEYLS1W:2:9-"9,O(49BRLR9X50=WYUZ/:75Q/<7<<UE
M);I#)LBD=E(F7 .X8.0,DCGGBK5% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)8[J2-8)!;;MX"D#.0.O]34]E&FA:]X9OEN[TG4=)N9]1>2=Y?.9(XG#[6)
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M(],U+47N]MKILLD5VQC8&-T^\,8R>HQ@'.1C.:IIXILK6/6;K4-1B^S6=VL
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M]-&FW&E64MB&+BV>!3&&)))"XQG))S[FK-E8VFFVD=I8VL-K;1C"10QA$7Z
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MMPC2&5PFT!%;" XQG R?8 UO7FC:E;>'/!MS!8/<3Z&87N+%&4.R^0T3;<D
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MR<D#!/(KIO!NE31:UJ>J2V.JVZ31101RZI=^9/*%+$Y4$A5!;CG)R>!7:44
M<)XF\,ZCKFN^($@7RH;[PZ+**X8_+YOF2G:>_1AGV--V:OXBU'PS#)H%UI::
M3<BZNYIVCV@K$Z".+:Q+ E^O P/7BN]HH \B@\$ZW>>'=&TR2W:VD7P_?V4K
MNPQ%+(T>P-@]\'IVK?V:OXAO?#-O)H%UI:Z3<K=7<T[1[ 5B9!'%M8E@2W7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM8VB@?;S&K8R!Z [5_(5S&B?$/2-0\+6VM7TGV/SYFA6'RY'9G!.%0!=SG:
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M<']YSG</RJR?'/\ 8OB.YTCQ'/:HT-A!<![2WE8N[-('(4;CL 1><<9Y/(H
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M ([CP=X<NK>"WGT:S>*WC\N%3&/W2YSA3V&?2KT.C:9;K9+!86\2V((M0D8
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M44 %%%% !1110 4444 %<S\0=/N-4\#ZC96ENUQ-+Y0$2C)8"5">/H#7344
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MG4CY"IQR,BN>ETO5UD/B3^Q[M8G\2)J/V!%!G6 6YA+[ ?O$_,5ZX]Z]4HH
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MN\GC)ZXKJZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9KRM]D9;DO-&1$9!O7:!@JIQ@G'&:T-*\&P:-=W36MP1;2:7;Z=%$R9*+$'
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MH=IF^T2!\GG (QCIS[4 9/BGQ/KNH>%_%;:7IMO]BT^"XM)IS=LLQE6/YVC
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M8XXR<8R:UM8-_P"#-5@DT[4=1O7N=&OYY8KRX:99)H4C9&52<*<L1A<#'&*
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MX)?+/DC@+M[&K]K/KV@ZI:R0I=+%-97+R0W^LB\-VR1;T>-2<@[@ =N!ANG
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MW9.0.><UP$<>I2^&-.UO_A(=82^N?$!L=PNV*) UV\)4(?E.!R"02#CG  H
M]CHKRN]NWT"]\2Z*NK:RUN9-.6T5+@S7/F3EPT<<DC?+NV#DGY<DBJ$NLZWX
M<NO%,-M'?6Q@T'[;#:WFHF^>*3>R^9EBVWCG;DCY<T >KW.J6EIJ-E832E;F
M]+B!-I.[8NYN>@P/6KE>7WFF1:'XP\)W-EJE_J,DEO>2B.ZNVG\YA!D2+N)V
MYR!A<#D<5E:#>^(I;#PYKYEN5FO[F#[1<W6LJ;>X60_-&L!.U3@G:% 8%>_-
M 'KMW?6M@L374Z1":58(]Q^\['"J/<FK%<1\2;&.^M_#JR2W,8_MNU3,$[Q'
M#-@G*D<^AZCM6)-Y^HZ)XMUZXUW4;2^TFZNHK58KMDBMUA_U8:/.U]P )W Y
MW4 >EWM[;:=93WMY,D-M ADED<X"J.234,>K64NK2:6DN;R.W2Y9-IXC=F53
MG&.JMQUXKDO'#R:K\&=1NKH20SR:5]H=(W9,/L#%3@\C/!!X/>LZ/PY#?_$6
M:R;4-4CMX= M?]3?2)(Y,TV"T@.\XYXSCGG.!0!Z717CD&MZ]JVG>#]-=[V[
M6ZM[N2?R;W[++=-"X1091@\ [B 03^!KMO 4VI&TU.TU&7S!:WK10*]XMS+$
MFU3Y<CCJP)/7G!&: .MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#)U/PQHFM3PSZCIEM<RPKL1G3G;G.T^J^QXJ]965MIME#9V4"06T*[8XD&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2S$MC'8&KQ\,:,?[(S8I_P 2<;;#YF_<#:%XYYX '.:UJ* .7_X5SX0_M?\
MM3^P[?[5YOGYW-L\S^]Y>=F??%/U;X?^%==U7^T]2T6"XO#MW2$LHDQTWJ"
M_0?>!Z5TM% '.:UX"\+^(;M+K4](BFG6,1>8CO&2@Z*=A&X>QS6[9V=MI]G#
M:6<$<%M"@2.*-<*JCH *FHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7FD-H7G7T$W]F37SLR1E/,%P21A>BXSR*Z'PKHLGA_PGINCS2I+):0")I$!
M8CN,T <Q:?$FYF\.V^MW'A]K>VOGCAT]6O$W7$K$@@Y "*-K'<3T&<=J;JGC
ME9=#URVO[5K:]LH(K@KIVH!A)$[[0R3!0000005!^H-6)/ $DO@'1=">XM9+
MW29(YXGFA\R"1UW#:Z'DJ58CU&<]J@E\!W][HVLV\W]BV$M]#'###I]H$CC"
MN&+,^ [$^G &!QWH M:MX\O;"[U];7P^UU:Z$5:\G-VL>4,2R$HNT[F )X.!
MP.><42^+[Z?[38W>DOIQNM*GO;"=;D.S*@&0P &QQO4\$CWXJU>^$;BZM/&<
M*W42G7TVQ$@_NO\ 1UB^;UY&>*DU'PK/>W]A<+<QJ+;2KFP8$'YFE$8##V&P
M_G0!D^%O%VIQ:-X776M*DBMM2@AMX;][H22/,8L@R)C*[]I(.6ZC.,UJ)XV1
M_"-EK_V%@MS>I:"'S>5+7'D[LXY_O8Q[51TSPEKIB\/V&L:A8RZ?HC1RQFVC
M82W$D:%4WY.% SGC.2!TZ54'@?Q NEV^AKJ6GC2;34DO8G\I_/D47'G>6W.T
M8R>1UP.!S0!=E\?743:]<_V!*VEZ*\T5Q="Y7<SQJ& 1,9.<C)) &>^#5O3?
M&4LMC>W^IZ?!!I]M:-=_;+*]6[A95Y9=P"X<#G&"#ZU/9^&[ZRTWQ#!;ZBMO
M<ZG>S74$ZQ!_)WJH *MPWW>?8U@VGPZDN+W4I]1BTNPCOM.DL)H='B:-9B^,
MROGC<,<#!ZGDT 7]*\>O=ZCIEO?Z;#:0ZH2MH\=\DSJVTN%E0 ;"5!Z%AGC-
M;VNZI>:9% +'3&OIYI"GS2B**( $EI'(.T<8Z$DD5S6A>"]1L-1TZ2ZC\/Q0
MV .9K'3U6>Z.W:I8L/W?J=I))[@5H^,?#%SXAGTJ>$6-PEC*[R6.H*6@GW+@
M%@,\KU&0>IH SE^(Y&E7,[Z1YE];:G#IKVUK=K*KO)MVE), $?,."!@Y!Q4M
MQX\O--BU==5T'R+K3(8;N2.&Z$JO;.Y4R*VT<KM8E2.W!JG:?#Z_A-P9+JP3
MSM8L]3$=M 8HXUAV9C5?H@ /?J<5M:IIMG8:WJ_B'5[F%-*GTN*RF1P> 'D)
M)]B) * -&+74N/$[:-;P^:L5FMW-<*_RIO8B-<8Y+!7/7H/>LW7/%[Z?KBZ-
MI]G;W5ZMN+F8W-XMM'&A)"C<0Q+$@\ =N2*H_"[1Y].\+?;+QY9+F^8,KS+M
M?R$41P CM^[56QZL:D\0>#IKWQ+_ &[8V^D7<LMLMM/;:K;^8GRL2KHP!*D;
MB",8(QTQ0 G_  L:QCTG3=9N;5X-)N9)(+JY9P?L<R$C:X .064@,#C./44K
M^-=2(T.*#PY(;O61.]O!-<B/RD3:0TIVG;E6R0 2.!R:B?P'/?Z1INB:I=VT
MFDQ%YKZ"U@%N+F4G**%3 6-2<]R2JYK+OM-\2Z?XA\'6D=_;7=[:I?(MQ<(V
MV:$+'M$A'(?&,D9Y&><D4 :\WQ"2VL'2XTTQ:RE^-.-@UPH7S2GF!O-( \O9
M\V[&>V,U%+\1UL]+U:6[TQ3?Z8UN9+:UNEF25)I BM')@9YSP0.1[YJ&[^'E
MS?VKWUW<V,^N/J0U%O-MR]JQ$?E"$H3DIL&,]<\^U.;P)?76CZG!,=(LIKR6
MV:.&PM!'%$L4JN<M@,Y;!Z\#C ZT 7'\<76G3:G#KFAO:36>G/J2+;W G\V)
M3AAG"X8'''(YZTZP\;R/IUYJ>IZ=!!IMO9M=B\LKU;N,A>J$@+A\=N0?6KFJ
M^'+V]\12ZK9ZBMG(VDR6,;B,.T<C2*X?!X(&WH:YV/X;2W]U?2ZDFE:>MWI\
MME*FCQ-&)R^/WC@\97&0,'J<DT :FE>.I+K5=/L]1TV&S74@WV5H;Y9V#!2^
MR10!L8J">"PR,9H\->.+GQ)/;2P:1'_9UPS*)H;U9)8, X\Z+ \O.,<%L$@&
MH-#\':C9ZI8SW<>@6\=DC R:?IZK+<L5VAF+#]WCKA<Y/?'%06G@74V\0Z9J
M.H2Z2)K"<ROJ-G;&*ZO!A@%DQA0#D%NN<< 4 =5J&MC3M=TG3I8"8]1,J+/O
MP$D1-X4C'\2A^_\ #7/Z1\1K;6=+MKNVT^02W.JKIT<#28)!42"7..GE?/C'
MMGO6IXU\.7'B;P\UG97:V=]'*DUM<,,B-AP>!ZJ6'XUG:?X#33O&T&L07"C3
M[>R2**TV\B=4$0DS_P!<@%H Q/"OC+5[/PUIUSJ6ES7&G2Z@]F^HR7@:7<]P
MR*VP@DH"57.[/'3%;5UXZNXXM3U&ST%[K1-,FDBN;L7(61O+.)6CCQ\RJ0>K
M#.#BE3P7<IX&L] ^UQ>=;WZ71EVG:0MUYV/KCCZU7N?!^NI8:OH>GZC8QZ+J
MDTTC22Q,9[=9B3*B ':W+-@G&,]\4 9&LZW>MJ.OO:ZC<"!=3T80;)6 6.1H
M]P7G@,"<COGFNGF\;)!I&K7+V#?;=/O_ .SQ9B7YII&91%@XZ.'5NG )]*I7
M?@*62741;W44<-Q=:=-$K DHEL4R#[D)Q5+^S[77/B\;FQG:2SL(DEU&,(=G
MVR/?'"">[!78G']Q/:@#T49P,]:Y'5O&LMKKEYI6F:?;W<UC&CW37%\ML 7&
MY43(.YMO/8#(YYK<L9]2DUC5(KJ*-;&)XQ:.J%6;* ON).&PQX( ';J#7,:Q
MX(N9?$FH:OIUOH=T=12,3)JMKYAAD1=@=".H*@94XY'7F@"6X^).FVEEINJ7
M%M,FCZC:--!=CD^<!GR&0#AR <<G)!%6I_%6HH=*L8="W:W?P/<M9R701+:-
M< F23:><LHP%/)/IFJ-YX DU:TT_3-3U -IEC:D(MM&(&>Z.1YQ" *NW)*J.
MYR<XJQ)X>\0K/I&KQWUA+KEG:R6=R9480W4;%3GCE&RBG@$<D4 9U]XGU!/$
M&C7=S97=CY5AJ<ES8/)\LCP^5@@CAAUVMCHU= /%*E/##?9#_P 3T@+^\_U.
M8&EYX^;[N.W6LQO!VIWUY9W6K:LEQ*MM?0S[$*A?M&S"QCLJ!,<G)ZU7T[PE
MXB6Z\-#4M1TXVN@DK&+:)P\Z^2T09BQPI&1P,CKST% %GPWXYN/$=Q;R6^D1
MG3IW=!-%>K)-!C./.BP"F<8ZG!(S3?#'BJ.7^R;)K>Z$6HO?"&XN;GSF\V&9
M@8R2!U4,R^@7';-5+;P+J<GB#3=0U"72?.L+@S-J5I;&*[O!@@))C"@'(W=<
MXX J:?P)>MX%AT>VU&.#5+6]EO+6\521&SS.W3K]R1E/UH >_P 1$DBM19Z>
MDD]]<W$=F)[L11O#"VUIF<@[5)Z  DY'X4KKQ=+K$N@K!OLKJ'Q EG?017&]
M&_<2.!O7AT(VD<=NF15[5O ,3PZ"VF1:?(^CV[6J6^HP^9#-$P4$'NK J"&
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MX:%#AP< 889''(.>#6,/AU?O;Z\AGTRV_M466R&SMS'%;^1(6*@=\@]>.<\
M5T.M>$EUS7)[FXF L[C1Y],DC4?/^\=3N!Z<!3^- &%+XBUZ]\4>#Q=:5+I=
MG>W$KC9>>9YB?9Y&"2J ,-T;'S#CKD5TOB;Q%+H']F1V^G/?3ZA=_9(HUE$>
M&*.P))'3Y.?0<\XP<>U\-^)IM6\/3:KJ.G/;:,[$"")P]SF%XP[9.%/S=!D<
MGGH*W-<T675=0T.YCE1%TZ^^U.&!RX\J1,#WRX/X4 8;_$$V-EJ2ZII1M]3L
MKJ&T%I'<JZS/, 8]LA"@ @G)(&,&D7XBP6::DFL6<<%S96HNU2SNEN5G0ML
M5L+\V\JN"!]X<XI-<\ OK-WK5R;FW#W=S:7=JLL/F(CP+MQ(I^\K<@CT-0#P
M!<ZA9:I#?C2-.^UVRP0QZ39JHC97#B1G(#,=RK\O P.YYH TI/&%_I-K>77B
M/0)-/MK>T:Z$T$XN$."!Y;':NV3D8'(///%0V/CQSJ,%GJNFQ6K74$DUM]EO
M5NB3&N]D< #:^W)&,@X/-)?>%]?\36%[8^(M3M(K6:S:W6'3XVVM(2")6W]P
M5&%'')Y-1Z1X0U.WU*&ZN%T&P^SPR(LFEZ>BR2R,NT2$NOR8Y.U>I/)(XH F
M\/>.+G7(HKPZ1&-.FMVG6>TO5N6BP-VR5 !L8CL"W(Q3_"_C.Z\2/;3+I,2V
M%U$9$N+:^6<P\9"S* -C$=@6Y&*SM.\"ZFOB"RU6[ETFTNK2.1'O-,MC'->,
MR% TH/R\$[L?-\P'04FG^!-2'B"RU2]ETFVN+2.19+W3;<Q3WI9"F91]T==V
M.>0,8H M_P#"=WD&HZ9%J.AK9VNHW2VT.^]4W*,V=I>';\H..S$C/-4-4\;7
ME[HFO3G1;J#3-/GEM7O(=0$4KR1S!/D 7(!ZY^H]ZJZ?\-=1M8M&B;^PXCIM
M[#<R7<%LWVB^V-DF1SR"1DG[V3CD"MR?P7<S>#-;T,7<0EU"^GNDDVG:@DF\
MP ^X'% %0>)Y]&\2^))+H37%BFJV5J=TIVVB2PQC> <\;V&0,?>)KJ;'6Q?^
M(-4TR* ^7IPB62XW<&5P6* 8[+M).?XA7-Z_I6G:7I_C"\UV\1-/UK8J[4)9
M"(5C  '5MRY&.^*T_ .E7FE^$K9M3+-JMZ3>7S,,'S9.2#_NC:O_  &@#-U+
MQ<FA:EXBE6SO;Q[:ZL8##]IRK&8*H\M2,)][D9Y/<5,WCJ33'U:+Q#I)L)K"
MR6^"P7 N!-$S%0 <+AMPQ@^HYI-4\%W-_J&K7*7<2K?7UA=*"IRHMRI8'W.W
MBIO$/@O_ (2'5-2FFNA%!>:2M@-JY>-UE,@?T(!(X]J !_%>L6%G>W.K^&7M
M4@L);V-HKH3(?+&3&[!1L<]NH///%7Y/$RQW?AZ#[*3_ &PCL#O_ -5MB\ST
MY].U9[Z#XDUF"ZMM=U2SCM9;&:T\JPC;$K2+M,K[NF!G"CU/)JK8>%O$3ZKX
M?N=6O]-,.C))&D=K&X,P:(Q[V+'@].!QUY/& "K;_$C4I_#UCK7_  BTBV^H
MS0V]DGVU2\KR;AR-N% (ZD\@YXZ5>NO&U_!?1Z6NCVHU5+87-W#/J2QQ0!F(
M51)M.]CM)QM  ZFG6O@RY@\)^%]'-W$9-'NK>>20*<2"/.0/KFFZ]X-GNO$T
MFN6%OH]W)<6Z03V^JV_F*"A)5T8 D'#$$8P<#IB@!;?Q\=7CTR/0=+-Y?7L,
ML[P37 A6W2-_+?>X#<[_ )1@'.,]*E^'VH7NIZ9JT]^)TF&KW2"&>3>T(#<(
M#G&!T&./2JUOX.U;2'TO4-*O-/?4[:VDM;E9;80P3([B3Y5C'R%6''!R.O/-
M;'A+0[W0M/O(]0NXKJZNKV:[>2)"BY<YP 2<8^IH Y/3/%VLZ5;^)+VXTN>^
MTK3]7NA-=/=_O(XE?GRXR#N5!VRO<#.*Z*;QM:VL'B*2XMRAT9%E"J^[[3&Z
M;HV7C^(Y7'/(K)F\&^(GL]<T=-3L%TK6;R>:5S$_GPQRM\R)SM)([GH2>O%5
MM;TJRUGXE:/I]A,Q6R@']KPJI*B*)DEMU8],[SP.XW>E '2^+-3U.P^'NJ:G
M:0B#48M/>8(9!^Y;9DD'!#%>3TYQVS7,P:]XE'C"RA@TXW4\N@1S26K7^R!&
M\UAO+;3EB,#A<_@,UW&OZ6=;\.:GI0E\HWMK+;B0C.W>I7..^,UCZ'X>U*TU
MRWU;4I[1IDTI+!TM@VTLLC,&&[MM(_'- %'_ (6+'/IFCR6>GJ=0U/SL6US=
M+"D/DMLD+R8/ ;@8!)STK;\,^(X_$5K='R1;W5G.;>YA642*K@!@5<<,I# @
M\?08KES\.9X;+29(VTR[O=/DN\Q7T!>":.>9I,'NK+E<, >_K73^%M#GT2QN
M%NC8B>XG,ICL;588HA@ (N!EL8^\W)SV'% &[1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <M+\2/!T,SQ2>(;-9(V*,
MNX\$'!'2NDMKB&\M8;FWD$D$R+)&Z]&4C((_ UYIX";Q>/"__$JCT,V7VV\\
MLW4DHD_X^),YV@CKG\*M^/O$FL>%+NQN;:^@/]H0FVDMI02EJXP?M0P,[$S\
MP/'W?>@#T6BO,]5U+6?^$GC\.PW&O7-O9:;%/)/I@MQ-<2NS#>YD( 7Y.BCJ
M>> *-+U?Q%KUWHFA:A>W&F2O!=SW5Q!Y0FG$4JQH,C<J$A@S!>XP,4 >F5'-
M<0VRJT\T<2NZQJ78#+,<*HSW)( %<5#?ZE8>(_#FDOKJ:E')<WL,\BJ@9@D>
MY$DV\;UR,XQGTKGO$4][K4]S#+J=S'':>+[2V@\G8-BE83QE3R&9B/<\YZ4
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M>[2$# "=%&"2<]A0!Z317FFE:MXA\0W>BZ'J%]/IDK6EU<W4]OY0EN/*F6-
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M !1110 4444 %%%% !1110 4444 <D/AMX;0N8HM1A#NTA2'5+E%W,2Q(42
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ****    8 P**** "BBB@ HHHH *;Y<?F>9L7S,8W8YQ]:=10 4444
M%%%% !0 !T&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ (R,&CI110 4BHJ9VJ%R<G QD^M+10 4444 %%%% !1110 4444
M%%%% !1110 4444 %& 2#CITHHH ****  @$$$9!ZBD5510J@!0,  <"EHH
M**** "D"*'+A1N(P3CDTM% !1110 48&<XY]:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BN*\<?$O2O!<EO:.AO=2G= +2-]I1&.-['!VCT]
M?UJ;Q7XXDT'6+31M,T6?6-5N('N3;Q3+$$A7JQ9O4@@#OCZ9 .OHK(\,>(K/
MQ7X<L]:L0ZP7*DA'^\C D,I]P016O0 4444 %%<)XD^)]AX;\;Z=X;FM'E%S
MY8GNEDPML9&*IN&.^,]1P:[.YO[.S=$NKN"!G#,@ED"E@HRQ&>N!R?2@"Q15
M*/6=+EL#?QZE9O9@[?M"SJ8\YQC=G'6G6^JZ==SSP6U_:S30<31Q3*S1_P"\
M >/QH MT54&JZ<;6*Z%_:FWE?9'+YR[';., YP3D'CVIEUK>DV-TEK>:G96]
MQ)C9%-<(CMGT!.30!>HKG8O%2R_$&X\*?9"&AT\7WVGS.""X7;MQ[YSFL[Q=
MXXO/#WB'2=#TW0'U>^U-)7B1;I8<;!D\L,=,GJ.E '9T5R'A;QO-KNN7^A:G
MHEQH^K6<2S-!),LRM&W0AUX[C\_K716^L:9=WLEG;:C:374>?,@CG5G3ZJ#D
M4 7:*SY]=T>V8K<:K8Q$2>41)<(OS_W>3U]NM6C=VPNQ:&XB^TE/,$.\;RN<
M;MO7&>] $U%4VU?34LY+QM1M%M8V*O.9E"*?0MG -26=]9ZC;BXL;N"Z@)P)
M() ZD_4<4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)<W-O;64WV7,\1D8AR\48 < #*XY)X-9=SXO\1Z;I.OL/[1N(K;3&N[:_O\
M26M2DRL 8R"H5@001QG@YS0!ZG4)N[8310FXB$LP8Q(7&YPOWB!WQD9QTS7$
MO=>)+'Q!::5>ZU'<KJVGW,JLEHJ?998PARG]Y?GZ-D\=:P/"4NIPZ%X&L(+N
M%IKW2+MX9Y;9"T!$<>P XS@$\^O?I0!ZW17GEMXZO+VVTB2) LD.GW%_K$04
M97R08S$/0F4-^"&J.@^+O$EW-HEXZZE>)J$D8NK7^Q9(H+>.09#QS;>0I(R6
M)##)&* /3Y)$BC:21U1%!9F8X  ZDFDBECGA2:&1)(I%#(Z'*L#R"".HJAXB
M_P"19U7_ *\YO_0#7":'?Z[X:T#P==7FI17EA?I;V;V:VZKY(:$E&1AR2-H!
MSG.21B@#TVBO-(O$?B2/PE8>-9]1@>TN987DTL6ZA4@ED5 %D^\7 8')X)!&
M*BOO$/BF/1?$?B"+5H$@T?4IX8K+[(I$T4<@&'?J#@X&,=,G.: /4**Y>VUN
M]DU_Q7:-(ODZ=# ]N-H^4M$S')[\@5RDWBKQ(^D:%?SW-Y96%UH\-S)?V6FB
MZ7[2PRPE4 E$ VG@<Y/(Q0!ZG15#1+W^TM"L;W[1;W)F@1VFML^6Y(Y*YY S
MV/(JAXQU*]T;PU/JMDPS9/'/.I7=O@5QYH]ODW'/M0!O5"+NV:6:);B(R0X\
MU XS'GD;AVSVS7FUY\0=3M]4\2I'Y3VWDM'HF%'[R='2%P3_ !9EE3CT%4?&
M$NHW,?B"Q-W%$]I>Z.&FCMD#3%G3)8XYPV&'IC'0T >L1W,$TTT,4T;RPD+*
MBL"4)&0&';((/-2UY8(?$$.O^.KK3];2U-EY$K$VBN;B1;1"=V>%4XZ+@\GG
MBO1-#OWU70--U&1 CW=K%.RKT4LH; _.@"_17F?BSQ5JME=:X^GZTX?3D+16
MECI;7,8VQAB+B4KM0DYX## P>37H6F7;7^DV=XRA6G@24J.@+*#C]: +(96+
M $$J<'!Z'K2UY5IUYJ&B6OC"Z.O00%]?\@27%MOVDI#DHB L[E2 J=,C/K1_
MPF>MV=IXKB%Y=7)L-(&H6=Q?:=]EE#'S 04(&Y<H""5'?K0!ZK17 BZ\4'5=
M+T%]>C6ZOX)=0FNTLD'DQKY:B&-3D'YG)W-DX%9,WC/Q#86=UI]Q<K/J!U]M
M,CNK:Q,A2%8$E+")<[GQGCD D]AB@#U-F5%+,0J@9))P!2UX]XCU77=1\%>)
M+&ZDU#[-;K;RP7UWIAM7F#/AHF5@!D$*<J!P:]<M8Y8;6*.><SRJH#RE0N\]
MS@<"@ @N8+E7:":.4([1L8V#;64X*G'0@\$5+7DEE<:_HGASQ1XAL]3A6UL-
M8OYQ8-;J5F19V+AG^\&/.,8 P,YS71KJ'B#Q)JVMC2=5BTRVTR1((8VMED,\
MAB60F0MR%^<#"X/!.: .XHKS72/$GB#QCJ5C%8ZC'I-O<:'#?R%;99765I'0
MA=W&WY>^>@Z9S5OP_P"+-5U*3P>MR\(.H)?+>;$P': [0P_NY()Q[T =_17G
M5]XD\226VL&Q6:2.SUYK.22SM5FF@MA"C92,\.V]@.YP3P<5T'@K66UG2[EI
M-5347@N&CWFV:WE08!"RQD#:XR>@ (Q0!TM%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!0GTBUN-<M-7??\ :K2&6"/#
M?+MD*ELCU^05CWG@32[V^N)GN+Y+6ZG6XNM/CFQ;SR#'S,N,\[1D @''(-=/
M10!5AL1#J-S>?:;ES<*B^2\I,4>W/*+_  DYY]<"HK32+6RU;4=2BW_:+\QF
M;<V1\B[5P.W%7Z* "BB@D 9)P!0!GZ5HUKHYOC:^9_IMV]Y+O;/[QP <>@^4
M51B\(:9#H6FZ.IG^RZ?<1W,&7&[?&^]<G'(S6M#?V=S'))!=P2I']]DD#!?K
MCI2?VA9?O?\ 2[?]R,R_O!\@]6YX_&@#GKGP!I=S-<C[7J,5C=S_ &BYTZ*X
MVV\KDY8D8W $C) (!]*ZH# P.E1&ZMQ;?:3/$+?;N\TN-N/7/3%"75O)"DR3
MQ-%(0$=7!#$],'O0!RJ?#ZU@FN7M->U^T2XN)+AXK>]V('=BS8&WCDUH+X/T
MU[A9[Y[G4G6S:R7[;)Y@$;??[#YFX!/7  K;:>%"P>5%*@,P+ 8!Z$U"^I62
MPW,HNH66V!,VUP2F/7TH P6\#6*Q6'V?4=4M;JQMS:Q7D,X\YH<Y$;DJ0P'&
M,C(QUZU(W@?2AI5E9027EO+92M/!>Q3'[0LCYWN7.=Q;<<@@@YZ<"M71=7MM
M>T6SU6S)\BZB65 V-RA@#@X)P>>15E[NVCN4MGN(EG<96(N S#V'4T <VW@'
M2VLXT6ZU!+U+LWHU%9Q]I,Q786+$8(*_+MQC':D_X5_I/]F7]D;C4"U]<Q7<
MMRUQF831[=KJQ'!R@/3'H .*M1>*!=>,YO#]I9B5;6-7NKDSJHC+!BJA.K'Y
M>?3-3:SKT^GW]MI]AI-QJ5[/&TVR-UC2.-2 2SL< DD #DF@!8?"^GQ0ZM%(
M9KA=64+=^<P._$2Q>@ZJHS[YJ!?!>CKX5M_#JI.+2V820R"4B9) V\2!QR'W
M$G/N:J2^.H&T#3=2LM-N[J?4+LV<5D&1)1*N_>I+':-OEMDYQQ4TOBB_MM,B
MFO/#UQ:WMS=K:6UI+<Q'S&89W%T+!5 #>_R].E %S1_#5MI%[<7S7E[?WTZ+
M$]S>RAW"+DA   JC))X')/.:FUO0;;78;<337-O/;2^=;W-M)LDB?!&0<$'(
M)!!!!S5"T\6Q7MII;0VDGVJ^NI+8VQ<9B,3,LS$C@JI0\]R5'&:Z.@#FX/!.
MF1(ADFO+BX^WQZA)<S2AI)9D&U=QP!@  8  XJ35O!NE:S/?SW1N!+>QP(SQ
MR;3&879XV3CA@S$]ZVC=VPNA:FXB%P1D1;QO(]<=:Q(/% O/&5SH%I9B5+-%
M:ZNC.HV,P)"JG5NG)XQF@"&+P-8"^GOKF_U*\O)[*2PEFN)P2T+D$C 4*N",
MC '4YS6AI/ANPT:[:YM3+YC6<%F=[9'EPA@G;K\QR:=<^(+&U\06^BR.?MD]
MO)<(,C&U"H(/.<DL,#'8TSP[XCL_$6CV-]"R127=NLXMFD!D53Z@4 'B#PY9
M^(X;-+N6YB:SN!<P26TOEND@5E!S[;B?_K<517P-I+:;?6MU)=W<U](DL]Y/
M-^_+ICRV#*!MVXXV@ ?B:Z W=LMT+4W$0N&&1$7&\CUQUJ'5]032-%O]2>,R
M)9V\EPR*<%@BEL#\J *&C^&+?2=0FU![V^U"^EB$/VB]E#LL8.=BA0 !GD\9
M/>K6M:+9Z_IQLKU7V;UD22)RCQ2*<JZ,.0P/>L+3_%/B+4(K6X3P9<K;7"HZ
MRG4(.$;!W8SGH<XKJ?M$ C>3SH]D9(=MPPI'4$]J .;;P%IL]IJ$5]>:C?37
M\2037-S,#((U;<$7"A5&>>!SWIGB3PO'-8ZQ<6=@;^ZU"6WEF@:X\H_NMH!B
M?C8X R"3C(KII+RVAFCAEN(4EE_U:,X#/]!WHGN[:UV?:+B*'>=J>8X7<?09
MZT >>:/X*N-3U36;K5[?4[:TOM,&G$7]XDUS("Q+-E"RH "  /<D<UT-YX%L
M;G4;J_AU'5;*>ZBC@G-I<!!)&B[0I&#VSR,'DX(S73>8GF>7O7>!NVYYQZXK
M,NO$6G6FKZ;ICS!I]0\SR2K K\@YR<^O ]Z *H\&:&&"_9/]'&F_V7]GS^[^
MSYSC'7/OFH],\&V>FZA:WLFH:G?R6:-':+>W&];<,,': !DXXRV3CO6MIE^U
M_:))-"+:=MQ,!E5V #%0<J2,'&?QQUJ>2[MH8GEEN(DCC.UW9P I]">U $&K
MZ7:ZWI%WI=ZK-;7<312!3@[2,<'L:Q9?!%L\D,\6KZO;WJ0"VENX;@"6XC!)
M DRI!(R<, ",]:U=2U;[$FGO#!]J2\NH[?,<@&U6!^<?W@,=!VR>@-7%O+5[
MEK9+F%KA!EH@X+ >XZT 0Z3I5GHFEV^FV$7E6L"[47))ZY))/)))))/4FLK4
M_"%IJ.IS:A#?ZCIUS<1K%<M8SB/SU7.W<"#R 2 PP<=ZNZ[K<>A6EO<2PM*)
M[N"U 4XP97" _09S5^WN;>ZC,EO/%,@."T;AAGTR* .</@33(I[:;3;J_P!+
M:"T6R_T.8+YD*DE5;<#R"3\PPW)YJ;2O!6DZ,=,^R?: NFO</;*\N[;YQRX)
M/)Z\9.?K6W!>VET[I;W4,SQG#K'(&*_7'2B*\M;B62*&YAEDC.'1'!*GW Z4
M 9__  CECC6QF7_B<_\ 'U\W_3(1?+QQ\JCUYK0L;2+3["VLH=WE6\2Q)N.3
MM4 #/Y56L]5231X+^_5+#S%!9)9D(0^FX':?P-7U974,I!4C((/!% '(7GPY
MTJ^M]1LY+W5%TZ_D>::QCN L7F.<LPXW?>^;&=N>U;4/AVRAFU68-,7U1$2X
M+,.BQ^6,<<<?K6@EY:R7+VR7,+3H,M$K@LOU'44C7MHETMJUU"+AAD1&0;S^
M'6@!FF:?#I.E6>G6V[R+2!((]YR=JJ%&3ZX%<_>^ =-O9-35KW4HK/4W:2[L
MH;C;%([* S=-PS@9 ;![BM33M=@U"]UBW\LPC2[@022.PPV8TDW>PP^/PJ_%
M>VD\!GANH9(0<&1) 5SZ9% %#3/#MEI-\]Y;M,TSVD%FQ=@04BW;>W7YCFJ^
MF>$-,TE]):V,^=*MY;>WWOGY)"I;=QR?D%;$-W;7)(@N(I2.H1PV.<=O>I$D
M23.QU;:2IP<X(ZB@#G+KP1IES;R(LUY;RMJ+:DEQ!*%DBG88)4XQC!(P01S5
M?_A7FDFWN5-UJ+7,]U%>&\:XS,L\8PK@D8SC(QC&.,8K;L-8CU#4M2MH8SY-
M@ZPO.6X:7;N90/\ 9!7)]21V-6H;^SN4D>"[@E2/[[1R!@OUQTH YT^ -,E_
MM-KF[U&ZFU.S^Q74TTX+/'DXQQA2,GH /;-=1&@BB2-<[5 49]JCBN[::9X8
MKB*25 "Z*X++]1VK,UKQ)9Z,L )6>62[@M6BCD&Y#*X0,1Z#=F@"*U\(:99Z
MA;WL1G\V"[N;Q,N"/,GSOSQTY.!VI+KP=I5Y#J4<HGS?W:7KR))M>*9%55>,
MCE2-BG\_7%7=>UNT\.Z+<ZK?%OL]NNY@F-S<X &2.:K1>)[%]=O]-DDCB6TA
M@F^T/*H23S=^ /\ OV?SH I?\('I4MK>QWT]]?7%YY9DO+B;]\OEG,>QE ";
M221@#DG.:1O 6G3VNHQ7][J-_-?VWV26YN9@9%ASG8F%"J,\],D]<UTD]S!:
MPF:XFCBB'5Y'"K^9J1'61%=&#*PR&!R"* ,^XT6TNM7L=2EWF>RBEBB ;Y2L
MFW=D=_N"LS1_!.FZ*VF&"XO91IBS):+/*&$:2!04Z?=&P8].>M;LM[:03I!-
M=0QRR?<C>0!F^@/6LW_A)+-/$5YI$Y6 VUO#.9I9 JMYC. HSW_=G\Z $TWP
MKI6E:CJ]];0'S=5</<ASN4]> .P)9B1ZL:H6'@/3;"XLF%YJ4]I8/YEG8SW&
MZ&W8 @%1C)V@G&XG':M35=9;2S(YLVE@BLYKIY5E48\L [=I.3D$\@8&.>HK
M-N?&EO8Z))K-Y9RQV":=%?>8)$9F+Y_=A<@Y'')P#GV- '0W=M'>V4]I+GRY
MXVC?:<'##!Q^=<[I7@33=*N+!Q=ZC=0Z<N+*VNKC?';G;MW*, DX) R3@$XQ
M7213PSY\F6.3 !.Q@<9Z=*598WB\U9$,?)W \<=>: .7A^'^DP2PH+G4&TZ"
M?[3#IC3YMHY VX$+C. W(4DJ#VJ[-X1TR;1-5TAS/]FU2>6>XP_S;I#EMIQP
M,U8T?Q'IVM:-_:UO,$M=[H6E8+MVN5)//&<9'L16G%+'/$LL,B21L,JZ,""/
M8B@#G]3\%V&IZI<7YO-0M6NXEAO(K6XV)<HN0 XQGH2,J0<&H?\ A ["&.S6
MPU'5-/>VLX['S+6<*TL*?=#Y4@D9/S  \GFNCGN[:UV?:+B*'>=J>8X7<?09
MZT7-W;6<?F75Q%!'G&Z5PHS]30!D6?AT:7>:1'ILTEOI>GVLD'V42L5D)V[2
M5Z$C#'<3GGW-;%U;17MI-:SH'AFC:.13W4C!'Y&D>[MHHA+)<1)&PW!V< $8
MSG/TYICZA91A2]Y;J'("DRJ,DC( Y[@@T <_!\/M!@M=!MUCF9-#F::T+29)
M=CN)<X^;YL-]0*LZEX-TS5!JWGM<JVJ&!IGCDVE&AP8V0XX((![UT%1B>$QI
M()4*.0$;<,,3TQZT 9-KX8LK:/5%\ZYE;4T1+J25P6;;$(L\#J5&3[UHZ?8P
MZ9IEK86^[R;6%(8]QR=J@ 9/K@4[[;:>>L'VJ'SGR%C\P;CCK@>U,U+4+?2=
M,NM0NF*V]M$TLA'7"C)Q[T <_>> =-O9=3!O=2AL]3=I+NRAN-L4KE0I;IN&
M0!D!L''(KH[&TCL+"VLXBS1V\2Q(7.20H &??BJ]MK%C<:3;:F;B**VN$5T:
M615 W#."<XS5X$,H92"",@CO0!RUYX!TR\NKVX^UZA"US=I? 13@"&X0 "5
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M:IHUKX@?5)#L.FO+JGF^=^[:)O-!9=NW:0NT+QZU[#XSS_P@?B#/)_LRY_\
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MA^'E_J,$$:O-J,2R7,8!$AE8Q*21PV[.!ZYQS7M#*K8W*#@Y&1T-!4'J >]
M'CMA<GPUX+T#QBD+R+837MM>(@Y>"6>3'Y2K'^9IFJ:1=Z*_A,:M<:9!;O%<
MW-Y/JMN9K47\I5R7 =0#AG"LQP,$=:]FP,8Q2,JNI5@"#U!% '%?#2)4TG4G
MM[R"YLI-0D>W-K:M!;J,+N$(+-F/=DY!QDMBN*T:33M/\0Z5%:-I>JNVK.!
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M<PD8 GIC /3FO9++2(;#4M0NX'8+?LLDL/&T2!=I<>[*%!_W0>YJ\J*JA54
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MFM?W#::K@C%J7/EX!Y"]<>V*ZTQHR[2BE?0CBG4 <AXUC1=0\*,J*&?7XBQ
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M%4DA0"3DX'4TN "3@9/4T +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5S?CS6[WP[X*U+4]/A:2ZACR
MA 4A,G&XAB,@?C]#725A^,M'N-?\'ZKI5HT:W%S 4C,APN[J,D=!Q0!6NO%E
MQ!)Y,'AK5[JXC@6>XCC$(\@-G"EFD"LW!X0M563XA6+G2DT[3-2U*74[/[;!
M';1ID1@@'=N8 $9_I6/J/ASQ!J^L3W>I:3:7L-S;Q+;VTVIR"&Q< A]R!<2@
MG#9QGMQUJYX0\(ZGHEWH$MYY&VPT233Y?+?.9#*C CCIA30!8U'XC6>GV]]?
M?V/JMQI5G,T$M_ D9C,BMM( +AB WR[L8SW[U<U'QK#9WM_!;:3J.H1:=C[=
M<6JH4@.T-CYF!=@I!(4' /KQ7G.NWEU9>"=:\-:9=:3=6C7\L,+-<,MT&DN-
MQ@\@IDON8@-G!7FN@U7P'=IK>M7%MH>FZJNIR^?#/=7;Q&V<H%8.H!WID;AC
MGDCWH W;/Q7=7_Q!32[:UEETB72H[R*Y7R]K;V)$F=V[:0 H&,YSQC!KH=<N
M);7P_J5Q ^R:*UE=& Z,$)!_.N>T[P[J.C^+=-NK>"TDT]='CTZ8QN8S"T;,
MP*(0<J<@8W<>]='K%K)?:)?VD./-GMI(DW' RRD#/YT <MX7\;M>6&@1:IIV
MH6SZE;QK!?7"(([F;R]S !6)4MAB-RC('%3CX@V1 N_[,U'^Q3<?9AJVU/(W
M[]F<;M^S=QOVX_#FJ&GZ!XDO(O#.G:Q;6-M::&\<[SP7!D:Y>.,H@5=HVCYL
MG)/3 ]:J#PEXB_X1-?!)@LO[*$@3^T_M!WFW$F_'E;?]9CY?O8[^U &O>_$2
MTLVU-UT;59[/2IV@O[N-(_+AQ@D\N&8 $$[02!UK;A\16<][J]JB2EM+2.29
ML#:X="XV\\\#OBN?N/"FHR>%?&FFJ8?/UBYN9;7+\8DC55W'''*FH[C0_$=A
MJ^L/IEK8W,.KVD,1EFN#&;:1(S&25"G>,$$8(Y&..M %[_A/;>X2Q&FZ/J.H
M376G1ZF88?*5XH'^Z3O< MP1A2>GTKI;&[2_L+>\C25$GC614E0HZ@C.&4\@
M^U>=7/@K43H^@VEUH6FZK]ATN&U#"[:UGMYT7#%95&2AXX&",9P<UW/ANPO]
M,\-Z?8ZG>&\OH(52:X))WM]3R?3)Y.,T 0ZOK\FG7T5C::/?ZG=R1&8I;!%5
M$!QEGD95R3T )/M68WQ T_\ LG2KZ&PU&=M3N)+6&V2-?-69-^Y&!8 <HPSG
M'?..:K>*?#^JZGXEANA9QZII0M/*6RDOWMDCFW$F1@H(<%2!SG&.G-4?#_@K
M5=+LO#%O.MFO]E:I=W,P@8A/+D68+L!'K(O':@"X_P 2[:*UN[B;0-8CCTZ7
MRM28I%BS/'4[_G&"&^3=P<UH:AXVAM+R_AM=(U+48=-Q]NN+14*0':&*_,P+
ML%()"@XSZ\5F:EX1U.Z\.^-[&,P>=K5R\MKE^-IAB0;N..4/K3GT?Q+H]QKM
MOH]I8W=MJ\S7,<T]R8S;2.BHVY=IWK\H88.>WO0!T.G>)+#5=4:QLR\F+*&^
M68 >6\4I8+CG.?D)Z=Q61_PL&REM=%DL],U*[FUA)GM+>)$W'RB P8EPJ]<Y
MSC /? .?8^&-<\*:E:2:+;VFHPC2+?37-Q<&$H\)8B3A6RIWG('/%.\.>#]4
MTIO"!NF@8Z3:WD5R48\M*R%2HQR/E.?2@!NJ?$"Z:STF;2])OO-EUC^S[VV=
M8A)$R@EH^7"[FX(8$C&>1Q7?UY[>>$];CBN;BTBM9[A/$O\ :\,+SE!)%L"[
M2VT[6Z]CTKT$9(&1@^E ''?\)G::7;7DT_\ :5\6UM]-CB6%"ZR%<A$ (RG&
M 3SD\\<UKZ#XD36KJ_LI=/N]/O[$IY]M=;"0K@E&!1F4@X/0]C7/#PAJ?FAL
MP8'B@ZM]_P#Y8;2/3[V>U;VG:1=6OC/7-5DV?9KVWM8XL-\V8_,W9';[XH O
MZUK%IH.DS:E>E_)BP-L:[G=F(554=R20!]:Q#XYMK2WO9-7TK4M,DM8DF$4Z
M(YF5VVJ$,;,"Q;"[<@Y([<U>\7:+<:]H+6UG+''>13PW5NTN=ADBD5U#8YP=
MN#]:Y[7M!\3>,M)O;74(;'3H0L3VUIYQG$DR2!RTCA5(0A=N!D\D^@H U!XW
M@@6^74])U#3;FULI+\03B-FFA0?,4*.5R. 02",CMS6/>^/]1FG\/2:?X>U2
M.TU&^\O=,L*F>(Q,XV R9&< \XX4]R :L7@B]N(-69- TO2&FTJXLX%2Y>>1
MY9%QDN0 J=.,$GKQC%;FL:%JK:;X6>PAMY[K1[B.66&28QJZB%XVPVT\@OGI
MVH ?J'CJ+3FN9Y-$U5M+M9_L\^H!(Q&C;@I(4N'903@L%QZ9J.\\8V>B7VN/
M=-J-TMM>VMKY"0H=CRQIM$>#E@2P)SSDG%<GKG@'Q!J]AJUK/96=Y?SW#RPZ
MI=:A(P$>_<B)#M(0A<+QP.N370:CX1U.[U;4[J/R!'<ZSI]\@+\^7 (P^>.O
MR' [T ;^B>)EU;4KO3+C3;W3;^UC29H+K82T;DA64HS C*D'G@BM#5]5M-$T
MFYU.^D*6ULA=R!D_0#N2< #U-9T.D72>/;O6CL^R2Z;#:K\WS;UDD8\>F'%2
M>+-$D\1>&+W2X9EAFE"M$[C*AT8.N?;*C/M0!B:GXS*Z+JWVS3=9T6:&P>\C
MD:*)W,8X)3#,N\9'RL0>:NGQI;KK\VCQZ=J$[6B1O=W2J@B@1TW!V)8<=> "
M>#Q6;K6G^+_$^A:M8W-M8:?%/ITMO' EQYWG3MC#E]HVH #@=3GGI5^U\,7#
M:EXG-TR+:ZM;00(R-E@%A*,2/J>* ':;XWBU&:S)T;5+>ROPS6=[-&GES *6
M' 8LF5!(W 9JQ#XPL)M$T/55AN1!K,T4-NI5=R&0$C=S@#@YP36?HEGXM@M]
M*TB[BL+:RL(Q%<7<4QD:[14*J%0J-F3AB2>,8&<UBZ?X8\4IIGAC1;BUT^.T
MT*]AE>Z2Y+-<I&&4%4VC;P<G)ZT :C_$RQCC-R=&U<Z>EXUB]VL2%1,'*!0H
M?<V6  (!'('7(%K_ (3ZSM[35I=1TW4+"XTSR3+:S"-G<3';$5*N5.X\=1@]
M<507PAJ8\)0Z9F#[0FN_V@?G^7ROMGG=<==O;UJSJWAK4[G5O$EY;0Z=.FH6
M=I#%!>@M'+Y32%U<8X!#@ \X/..* (/$?C;4K'PAKMW!H>HV.I6$ D5;E(V3
M#9PX97*,!@Y .1QQ6M<^*KF&2.WM_#>K75W]G6XFAC\D>0I) #,T@4L<'Y5)
MKDD\!:M-HGB.QM;:+2+._L/L]MIIOGN(UFR29,D8C!&%POIFKNI>'_$.K:RU
M[J6D6M[!-:QI#9RZG(L-E(-V_<JKB4-E3G&>,>] &M_PL&QN%TH:;INHZA/J
MEHUU;10HBG:I 8.68!2"W<XXZYQEZ>/+";2K2Y@L;^6]N[F2SCTY443^='GS
M%.6V@+M))W8Q69X.\':IH5SX>>\-N5T[2KFRE,;YR[S(ZE1CIM4_2HX_"6M:
M==0ZM:):SWEKK%_=I;/*46:"X)XW8.UP-IZ8X(H V6\<6R62M)I>I)J+W9LD
MTTQKYSR[=V =VPKM^;?NVX[]J:_CRQ@L;N2ZL+ZWO[6XBMI-/<)YIDE.(\$-
ML(;LV['!SC%8^N>%M?\ $<5GJ6IV^GS7-G>M-#I33$1^0T>PH90N=^?GSC /
M'2F0>#;]-'U;R_#^@PF\EA_XELK-*LL,9Y624CACDE2%(7CKV .D74K_ %[2
M-3MK:SO]&U6W $8N44C?C<A#*65U)&#@^H.*O^'=9C\0>'-/U:--@NX%D*'^
M!B/F7\#D?A7+^'-.N/!MEKNJ7T7]GZ2L2R0::MX]R(=BL7(9NA8D *..!ZU9
M\(0ZEH&D>&=#FM%;S;26:[DW',$F0^W&,8S(1U[=Z .OFE2"&2:1ML<:EF/H
M ,FN=T/Q@NMSV>W1=3M[2^B,UI=RHC1RJ!GG8S%"0<@,!GZ\5T4RN\$BQ,JR
M%2%9EW ''!([UYUX=\':KI_B/3[U-,LM%6#>=0;3[QS#?$H0 L& J#<0V3R,
M8YZT =-!XRT^XT#1]96"Y%OJUQ%;P*57>K2-M!;G ''.":YS1O'T]K;:K-JU
MCJ,]E::O=6TNHJD?E0()BJ C<&*J-N6"G'<]:@L?"OBF'2/#V@26NGK9Z-J,
M,[7@N2S7$<;DC";?E.#SD]1@=<A\GACQ3-H>M>&FMM/6QU6_N9?MPN#NA@EF
M9R#'M^9\$XYQSSTY -Z;Q79Z5?\ B%[JXO9ELYK:);<1*<R2(NQ(<<L6+#[W
M<^E/3QQ96ZWXUBRO-(GLK7[9)#=!&+PYQN0QLP;G QG.2..17(W?A]?%NI>,
M+>PDMYC;ZC830^8Y,,CQ0IF-F7D C()'(S5@?#ZXU.UU9#I&FZ']HLOL]OY4
MS7$GF;U?<S< )E%^4 D]<CI0!NW?C:YCTS4&_P"$>U2SO8[&2\M4N4C(E51U
MRKD C()5B#CIFMKPMJ-SJ_A;3+^\@DAN)[9'D63;EB5'S?*2 #U'L>0.E9+6
M_BO7(;JVU&WL=-M7L9K<QQ3F<S3.,!L[1M1>>.IS[5J^%;>_L_#&G6>IV\4%
MU;0) RQ2^8IV *&!P.H&<8XS0!EZGXFO;#X@Z=I'V.4Z=+837$TP\L*"K(-Y
M)8$*H)SQGYAC.#@LO'MK=RV$DFE:E:Z=J,@BLM0G1!%,S?<X#%U#?PEE&>/6
MD\1^'[_4?$UA>6\44MF]A<Z==[IMCQI*4.]>#NQL/''45F0>'O$UYIV@Z!J-
MO80V.DSV\LM]%<%FN5@(*!8]HVEBJYR>.<9H ] KE].\;1:I=0?9]'U,Z?<7
M#V\.H!$:)G4L#E58NJY4C<R@>N,UU%>:0>#=97Q':WL6G6&FW4=\)[O5+"[>
M-;N$,25:W P688!R3@Y.30!U,OC+3X?#^J:TT%R;?3KJ6UE4*N]FCD\LE1G&
M,],D<5#J/C6&RO;^"VTC4M0BT['VZXM$0I 2H;&&8,Y"D$A0< ^O%<WJGA7Q
M3)HOB#P]9VNGO::C?RWD=[)<E2JR2"0H8]OWLY&<XQS[5KMI?B?1=0UU="M[
M&XAU:X^U17%Q.4-I*R*C;DVG>HVAA@CT/K0!23QS=V/B'Q4KZ=J6IV%A)#*K
M6R1A;>$VZ.3\S*6))8X&3].*[RTNH;VS@N[=]\,\:R1MZJPR#^1KEK?PWJ48
M\8>=+%*^KJ@@DSC<1:I$2PQ\N64],\5OZ#92Z;X=TRQGV^=;6D4,FTY&Y4 .
M/Q% &#+XIN[?XB7>D7%I+'I-OI:W;W)\L*IW-F0G=NVX7;C&<@G&,&I=/\;P
M7MS8+/I.HV-KJ1VV-W<J@CG.TL!@,60LH)&X#./7BJ^N>&K_ %+Q5>2JD1TS
M4]%?2[B7S=LD!S(0P7&&SO ZC%8F@>!KVTOM'6X\/Z/;?V>ZO-?I<O*TY5<*
M8XR!L)."22<<@9H U(_B;8R:4VJ_V+K"Z:)4@2X,*$2R-((]JJ'R<,?3L<9J
M1OB$4FO;4^&-:^WV48GN+8+"2D)!(DW>9M.<$;02V0>.*KP^$-3C\ Z1HI\C
M[7::C#<R?/\ +L6Z\TX..NW]:UCH5Y_PDWB+4/W?D:AI\%M#\W.]/-SD=A\Z
M_K0!%-X[MGDMX]+TO4-5>6QCU%EM1&I2!\[3AW7).#\HR>/I72V=TE[9074:
M2(DT:R*LJ%' (SAE/(/L:\WN/!.I'2=$M+K0M-U0V6EP6JRK=O:W%M,BX8K*
MHRR'CI@C'0YKN_#UC?:;X=T^RU*\-Y>P0*D]P23YC <G)Y/U/)H KZOX@DTZ
M_CL+31]0U.Z>(S%;8(JHF<9+R,JY)Z $GVK+_P"%A6$MMH\EGINI7<^K"?[/
M;1QH'#PD+(K[F 4@YYSCY3STS7\3^'M5U+Q,ET;*/5=+^RB*.SEOWMDAFW$E
MV500X(('.2,=.:I^%?!>JZ*_A@7(M NE?VB)O(8[2)Y R;!CICMVH V4\>6#
M:*;TV-\MT+XZ=_9Q1?/-S_SS'S;>GS;MV,<YJ'PQXAO]8\9>(+2ZM[JSBL[>
MTVVERJ;HW;S=Q#*2&! 7D$CZ<U0F\(:O&]UJ%K]F:]A\0-JUK%)(0DL;0B(H
MS8.TD%L'!P0*U?#FG:VOBG6M:U>VM;5+V"VB@@AF,I01^9G<=HR?G!X]<=LT
M ;.L:S;Z)%:RW,<K1W%U%:[T (C:1MJLV2,+N(&?<5CR^/M'B?Q&A6X+:"JF
MX 0?O2P.!'S\QW KSCYN*TO%&D-KWAC4-,C8)--"?)<]$E'S(WX,%/X5Q$7P
M]U9KOP_<7$UMEF>770&)$S>?]I0+QR!)D<]C0!<\1>,+[2K;6Y=.2^N;FWU*
MRMFB=(=MN)1$2%RPSD-C)SAF_NC(2/QQ?V.O^)TN-(U2]MK!H)3' L7^B1&W
M1V!)<;FR6.%+=#VQ4NM>$=6NXO%+VHMVEO\ 4+*\M$>0J&$(ARK'!VY,9 Z]
M15^TT#4V_P"$MGN(X8I=9C0PQK+O"-]F6,@G Z,#SCD<T =39W4-]907EN^^
M">-98VQC*L,@_D:PM6\6KIVK2Z9:Z3?ZG<P6ZW5PMIY?[J-BP!^=U+$[3PN3
MQ]*TO#]C-IGAO2["XV^=:V<4,FTY&Y4 .#Z9%<MXQ\,WFL:N+@:%I^I1" );
MS_:GM+FUDR<GS%!+(<@X'0@\'- '1V7B*TOM873(HKA9FL([_,L>P"-V90"#
MR&RIR".*RU\>6=Q8Z=+8:??7EUJ+3"WLX@@D*Q,5=V+,%500.2>X[UFVNA>*
M=#U33]1A^RZS<_V1%IUV]Q<M"?,1RPDSM;<#N(/?C-5='\)>(/#MMH-_!'9W
MNH6,-W;75L9C&LL<TWF!D;!P00O!'0D9XH GU'QO='6?#;65AJ6VZDO(+C3?
M*03-+&HPI).T ')W!MN.YKJ?#^OP^(+6XD2VN+2>UN&MKFVN H>*10"0=I((
MPP(()!!K&@T7Q!=Z_H.K:L]IOM)+QY8H6R(4D4+&BG WD8Y8@=:TO#ND7.EW
M_B":XV;+_4C=0[6R=GE1ISZ'*&@#>HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CGGAM86FN)8XHEQEY
M&"J,G'4U)7-^/KU]/\%:A=)%!*R&+"3QB1#F5!RIX/6@#I**\ZU+6/%$\_C"
M>QU6VM;;0GW01-:"0S8MTE*N2>!DGD<\]>*M6NM:_P"*=3NH=+O;?38K*SMI
MF5[?SO.EFC\S!)(P@&!QR<GGB@#JHDT6YOXKR%=/EO)8R\<Z!&D=!@$AAR1R
M!D>M7Y)$BC:21U1$!9F8X  ZDFO(_"=WJ:Z)X<L-+6U2^;PS<S02O"K,)5DC
M"KN/.TD\COP>U;=QXRN-;LHWTY8?LRZ#-J-^DL8<!F4K'$0?]I9,C_8QWH ]
M!CD26-9(W5T<!E93D,#T(--@GANH5FMY8Y8F^Z\;!E/T(K@M'U77O$$\=AI=
M]:Z9%8:79S2?Z('$LLR%@NW("Q@+T&#SP1BJ?@+5;VTTWP/I0,8@O+*]>X &
M<M&Z;<'T^=J /3:CFGAMHQ)/+'$A8+N=@HR3@#)[DD"N!N?%NH"PU,OJ=G8F
M+79+".5[=I9/*5 VV.-03))D]^,9/:L&^\0W^K:/JVGWL\URMAJVE&&>XLC:
MRNLDZ'#1D#&"#@X&0>E 'L%(2 0"0">![TM<1XM@O)?'W@O[/?>0GGW/R^4&
MY$+$]?497VSF@#MZ*\ELO'^OW]I%K=K'?SI+<_+I<6B3-&8/,V\7 7!?;\V<
M[<\8JSXK\9:KIKZY<6.LQL^FEC'96FF27,6U5#$7$V,(QYR 1M&.M 'J-%<#
M?:OXCU+Q!JMGIFI0:?;6>EP7JEK82L9'\SY>3C;\G/?CC%1:'XA\137?A&^O
M[VUEM?$,3%[.*WV"W/D&52KY))^7!SZ\8H ]#HK!\8:U<Z%H#7%DD;7DT\-K
M!YN=BO+(J!FQV&[/OBN:UO7O$/A-[NUN]2AU$S:/>7MI.;98FBF@0$AE!P4.
MX$=^,<T >AT5B>%QJ[Z1'=:SJ$5W-=*DRK%;B)80R@[!R2V#W/-8]Q?>(=;\
M1ZY8Z/J5OIT6D"*-?,MA*;B9XQ)\Y)^5 &4<<]3F@#LZ*XE-0\2:[KU[I=IJ
M-II9TRVMVN'B@^T":>52Q"EL?NQCT!.>HK)T[Q1XE\47NC65C>6NF27%C<S7
M<@M_. D@G$)V D<$^O0'UYH ],HKS.7Q!XIBT#7O$O\ :-K]FTF^ND2Q^S#$
MT$,K*0SYR&P"!CC@9SFM$:KXCU^;7KO2-2MK"VTJ<V\$$ML)/M#K&KL9"3E5
M)8 ;<$8S0!W=%>>:1XDU[Q7X@L5L+V'3M/?2;/4YHVMQ*[&1G#1@DC (7KU&
M!ZFLV3QOJT5Y8W46L1WT<VIQVLUO:Z9(;-8WE\OY;DJ-S $'.<$YXQ0!ZH""
M2 02.#[4M>2PZUJGA>S\97Z77VJ>7Q MI!&;8L%DD2%=^$^9L*1\HZ[1ZUT?
MA;7]7N?$3Z;=_;[VQ>V,RWMSI,ED8Y P!C.Y0K @Y&.1@YS0!VQ('4@=N:6N
M(^(<%Y-=^$Q:7WV7.LHO^J#_ #&.0AN?3!X[Y]JPO%/C;5M+&M7EEK$<SZ;*
MP2QM-,DGAV+C*S3[<*_7(!&W@<T >J45PSZUKDWBW7]M_%!I&B1PSM;K;!Y+
M@-#O9=Q/R].N">?:J,6L^*X;#PQK,^J6<MOK5W;)-9K:A1!'*-P"/G)('!)S
MGJ,4 >CTF020",CJ*\FB\?Z_>6SZS91W\ZBZ98M*AT29XY(5D*'_ $@+C>0"
MV0=H/&*LPR^(M.O_ ![>:7,U[<)J$"K ML&95,4)9U7(W,L9("Y&2OOB@#U&
MBN0\$Z_+JTVH6\VKK?-!Y9$<]DUI=0Y!R)(R ,9'! ]:F\9:S/IC:=!!JL.G
MBY=P[+:O<W+A1D"*)5.>3R2.!CUH ZFBO+[;Q=XFN_#%Y);I<SS66LFRGN8]
M./VA;;RU?S/LY/W\NJD8Z<XKJO!6M/K.G732:K!J+07!C$BV[6\JK@$++&P&
MU\D]!@C% '2EE!P2!QGDTR">*Y@2>"5)8G&Y)(V#*P]01UKB-7@O'^+6G-'?
M;(1HMRQB\H'*B2(,,^Y(.>VWWK \'WVOZ)X0\$74FHV\UA?2061L1;!=B.K;
M6$F<EAM!/;D\"@#UJD)"@DD #DDUY,OC[7[RWGUBQCOIE2Z=(=+AT6:2.6%)
M"A_?A<;R 3D':#P1UKU*\.=/N#_TR;^5 %:V\0:+>3K!:ZO83S-]V.*Y1F/T
M -:->!0VEXWPCTR9_"%E!:16T$\FLV\T;7,4:$,TRIM4[@ 3][\^E>DG4]:\
M1^(]4LM%U6'3K33HH")#;"9KB25/,!.XC"!2O Y))Y% '8RPQSILEC21,AMK
MJ",@Y!_ @&GUYI_PFU_J>E:+,=3ATN:Z@E:>&SLI+VYDDCD\L^7&%.(\JQW'
M/8>IJ&R\6^)=9L/#]I;7<%K>WNH7ME/<R6?(6$.0_E$_*V$^[G@_E0!Z?)(D
M4;22.J(H+,S'  '4DT1R)+&LD;J\;@,K*<A@>A!KS?4;KQ)K>D^*4M]6MHH-
M)B>Q:-K0'[7(L"M(['/R [\ +TZG/2NR\)_\B=H?_8/@_P#1:T ;%%>62^)/
M%W]CRZY%J5D(TUI]-CLWM,JZ&Y,*LS YR,CICA?>M;^WM;T>?Q/87^K:?/)I
M]G!=VU[=Q>1&GF&12'"9R 4XQR<X]Z .WMK2VLXS':V\4",Q8K$@4%CU.!WJ
M:O-]'\2ZS=>)1H\6JSWD=YIT\T%S=:2UIY4R% "@8#>GS\\'H.:OZ)XNOM>G
M\-6D(2*ZEAFGU==N3%Y7[ID'H3-T]E- '<T5@>+]9N]&T>%K 1?;;R\@LH'E
M!*1O*X7<P&,@ DX[UB:OJ'BCPU;&&34;'47OKBVM+&XEA\MX997V,71>&0#D
M8(.>#ZT =U17G^I:[K_AFXU/3[S4(M08Z+<ZC:7)MQ&T<D(&590<%3N4@\="
M#FH(M1\8-JOA^S?6[,#7+.2X=EL1_HA14;$?S?-G?CYO3/M0!Z/17F=IXF\3
M7\^CZ3'?VL5U-J&H6-S>?9@=RVY.'5,X#$#IG&3^%0MXB\6VVAZIJTVK6DBZ
M+JGV%X19@?;$$J*68Y^0X?@+QE>^> #U*BN+D\2ZBND>.KD/'YFC23+:'8,*
M%MDD&?7YF-5EU/Q)K7B1-+L=5@T^$:-;7SR_91*YE=I 0 3C:=HS]..M '<F
M>%;A+=I8Q,ZEEC+#<P&,D#J0,C\ZDKRZV\<79MM(UJ]M+629=!U"[G*1 ,7@
M= 0C'E5;!)'T]*WK*;Q7:V-OJU]K&E3VTUF\]Q%/%Y"6[>7O78XR2H/#;N<9
M(]* .SI 0>A![<5YEH_B[5IO$NA69U=]0M]4$J2N=)>WAC=8FD!A=@-XRN.<
MY!SFLK1]?U7P_P"%+"TBO))9]4UF]B$R6#3M B2RM(RQIDNQ(X'09/84 >QU
M5OM2L=,C22_O;:TC=@BM/*L89CT )/)]JYSP9K>J:E<ZG9ZA'=RPVQC:VOKG
M3Y+,SJP.5*,!\RD=1P0PXK/\6:?<7OQ*\(C[6BP;+IA$]NL@!54+'GN0<>V,
MCK0!WM%>7Z?XF\5/X6L=8FU"S>?6+Q-/M(#:82V9I63S6(;+G:I.W@9('ULZ
M[XC\0>%5UFQN+^&_FCT:74K.Z-N(V1HV"LCJ."/F4@\=P<T >CT5Y]]J\8?\
M)/9:*^NV@&H6#WC2K8C-L49 4C!;# ^8.6R>#ZUT/@K5KS6O"\%WJ#1M=K+/
M!*\:[5<QRO'N [9VYQ[T ;DUQ#;Q22SS1Q1QKN=W8*%7U)/04\$$ @Y!Z$5Y
M3KLE_8:Y\1;_ .TPSQ0:1 XMI[971OEE*A@>H&#QWW<UHZCK/B6>^\2IIVI6
MUE;:-90W,:FT$AE9HBY4DGA?E[<\\8QR >C45YU!XHUW3;G1K_5+N"ZL]5TV
M>\:TAM]GV<QQ+* C9);@D'/UXZ53T+QGXAO)M$O'6^NTU&6-;FS71)HHK:.0
M<.DY7!"Y&2201DC% 'J).!D]* 01D'(KEOB2LS?#;Q%Y,WDL+"5BVW.5"G(_
M$9&>V:SHKO7KO5[/PW9ZM';-;:7'>7-Z;57>4NS*B*I.T ;22>>W2@#NJCEG
MAMXI)9I4CCC7>[NP 5?4D]!P>:P_"&L7FL:7=+J B-[8WLUC/)"I5)6C;&\
MDXR,'&>#FN,U5[ZQUWXD7WVJ*>*#2(I!;36ZNC?NI2H;/4#!R.^[F@#U)6#*
M&4@J1D$=#2UYK=:YXFN)/$7]GZE:V5MHMA!<QI]D#F5F@,A0\C"_+VYY[8YG
MM_$NNZ=>Z/>:I>075GJNFSWC6L-OL^S&.-9 $;)+##$<]QGCI0!Z'17ENA^-
M/$-Y)HM\ZWUVFHRQBYLUT2:.*VCDZ.DY7#!,C))(89(QQ7J5 !1110 4444
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M-!']ADO (F0?PD*H)7VS6KJ/@^UO-1DO[34-0TJXFA6"<V$BH)D7.T,&4@$
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MD5VAB4<9*D@%G+N0#CYJZ\$, 5((/((JC::O:7NJ:AIT+,;BP,:S@C !==P
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M_P!GSR,GILZMG->L16=K ^Z&VAC;IE$ /Z426EM--'-+;Q/+']QV0%E^A[4
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MMQ+)<JI1(V)#;BW 4\9SQ7+7H\-26'C*?Q ]L-?BNI_L;2L!<1QA1]E^S_Q
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MQ6L,:+G"I& !GKQ[U0UO1YM3M8([+49M.E@?<C1J'C<8(*/&>&7!Z=B 1TH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ]222,U:U;P[J-QXF?Q!)H6I7*7]E%'):6>K&UFMI4+<,5D174ANN3@@X'-
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M&^SM($0#DG<4''?(]:Q-3\!:O=ZIXC$:1BR$<MUHYWC(NI3'(V1GC$D/4_\
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M8U#$<%B%R<9'/4T =-1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM 'IM%<3IVM>([;Q!H,&K7%A<6^M02N(K>W:-K5T0. &+'>,$@D@<C/M7;4
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M?:?(TEO<0!&*[E*L"K@@@@^E9<?P_L@;UY]2U"YFO+RVO9Y963<TD# KC"@
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MR!OE#*&0*H"\-TQC@<=<]910!E2Z''>>&)=#U&ZGO8I[=K>:=]JR.K @GY0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9ZI>03H(]-:WU);:U1?+ _?*KJ['=DGA@1@=* .XL?$6FZA?26EO/ND2UBO
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MFV'?@8C+'IRV3T.*[#3]>DU3Q5>V-H(7TZSM8GDG&2S32995!SC 0 GC^,4
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MU[J%Q82RRK)Y/[J-G\U!D,5*@'!^F1UJ&;QEXMM='UK4IH]&:+0;PVUTJQ2
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M<K ( <@#!SCJ,T =]17FE[\1;M]3>QMKS2M/>VM()IGO;>6432R('V($(VJ
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MTR.%[R81K//';Q\$[I'8*HX]2:-2U*TTFQ>\OIA%;HRJ7()Y9@JC ]68#\:
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MSI&&VAG!#$?*/<_B:]/O_#VBZK<PW.HZ38W<\(Q%)/;J[(.O!(XJ>+2M.MS
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M@ELQ"'?L>3S=H;C<%;C=QDB@#5G\<6$^GZJMC]IAU&TT^6\C@O;.6 NJJ<.
MZC<N< X]:NZ/XGL[Z&RMYKA3J+V$=Y<)&AV1*R@Y9NB9YP"<D"N#;0-9N]:N
MKN*PUR2WET*]LUEU6Y1I&F?85 0-A <8S@9.<\ &K6C>#=5T72+S0($E:QUW
M2B);B5PSV=YY(1MQZE&XQC."I' - '8:;XUT/5KV"UM9YPUR&-K)+:R1QW.!
MD^6[*%?CG@].>E=!7EFA>'[^2[\/6UWI.O(^FR))/)>ZB&M861"H,0#'?DG
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MRQQ727-M)%)"SD!-R,H8 [ASC'Y&FQ^/- :WOYI)[FW%C$L\Z7%G+$XB)P)
MK*"5]P..]<+_ ,(OK=Q'XD(TS4?+O;G2Y+?[?<K--(D4V9"QW$+@#.W/0COD
M5VMYH<E_X]GGN;4OIEQH;64KDC#,TN2GK]TF@#>DU6RBU.UTYILW5U&\L2*I
M.43;N8D< ?,O7KGBJ?BS4[C1?"&L:I:A#<6EG+-&'&5W*I(R/3BN4^&=E?2O
M?:CJ;B62Q']B6DH.0\5NQ#2 _P"TW7_<KIO&MC<ZGX'URQLXC+<W%C-%%&"
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M R/SQC&5Z$<XYXK<KR6^\%:W)?Z\(;7-OII>\T([Q\\TDJ7#*.?EP\>SGL]
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MS]X <^PH ])HKSUO&^N,+33XK&P&KG6'TJYWL_D@B$RB5>^,;3M//49[UO\
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M!VJ3@E5(.>,D9H ]4HKS[6M>UW7+'Q,NB16']G:="]O)]H#^;<.80[!"" F
MX R&R?2NH\(_\B7H7_8.M_\ T6M &S17GDGCK45\5SZ8\ND69BO1;QV%\)(I
M[F+('FQRDA#D$D* >F,YJ+Q7X_U'0+C5'2[T&,6/S)ITKM+=7"!02V4;]UGG
M 93TR: /2**\]CU6>R\2>--2M$MVD6TT^1!=3B*)<J_+N>  #D_2JMO\1KT/
MK<(NM'U0V>C3ZG!<6"2)'NCX,; LV[DCE6]: /1(["UBOYKY($6ZG1(Y)0.6
M5<E0?IN;\ZL5Q5GXC\0VLV@S:Y!IJ66KS>4/LH?=;L\>^)6+'!)(920 ,E:V
MO#6LSZ];7MZT<:68O)8;-ESF2)#LWGZL'QCMB@"YJ>B:;K/V<:E9Q7(MY1-$
M)!D*XZ''?\:OU#>?\>4__7-OY5YGX4UO6H/#G@G1-(CL=]]I#SO/=AV$7E^6
M,[5(W9WD8R.QSQ@@'J5%8/A+6KS6M,N3J$4,=[9WDUG/Y!/ENT;8W+GD C'!
MJMJVM:O+XH7P_H:V4<Z68O+BYO59T56<HBJJE222K<YX [YH Z>BO._^$W\0
M7TVF:986.G1:M/=W=C=&=G:&*2 !BZXP2I!R!UY SQFH/$&M>)-9\,^*Q91:
M8++3X)[*<.'\R>18<RLASA "Q"@ALXY(H ]+HKR]O'LME);Z+:7VDV)LM.MG
MEEU)9'\UWC!"($(P ,$L<_>'!J^/&^M:S'X830;.QBGUFVN99#?%V6!H2@.-
MN"P)9AV['VH ]!HJEJ1NUT6Z-O)$EV(&*NRDH&QUP"#C\:\_\*Z_XAE\/>%M
M%M'L9=2N]+%])=W2R,L<"A%&Y0V7D+/R=P'!- 'IM%8/A?7+K5H]1M=1@ABU
M'3;HVMQY!)C<[5=77/(!5AP>AS6!JPUIOBNJ:,;))#H8\R6\5G11YYP JD$D
MGW&.>O2@#O:*\UN?B9,EKIUHXT_3]4GGNK>ZENB[P0&W;8Y 7#/N)&T9'!.3
MQ71^"_%#>);2^$OV=Y[*X\AIK7=Y,P*AE=-W(X."#G!!Y- '3T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %9/B70H_$OA^ZTB6XDMTN-N98OO+M8-Q[\5K44 <G_ ,(0+^>XE\0ZI+JS
M26<EC&&B6%8XI,;SA>KMA<MQTX J73O"VH07-J=1\1WE_:6D;1Q6QC6(2 KM
MS,5_UA ^@SSC-;VH7T&F:;=:A<DBWM87FE*C)"J"3@=^!45EJL%_.8X8Y\""
M.<2/$51E?. &Z$\<CMD>M &!IG@J?3VT^U;7KN;2-.??:V7EJI& 0BO(.750
M>!QT&<XJ"+X?E+6#27UJX?P];SK-'IQB3.%?>L9DZE P'&,X &:Z^YG6UM9K
MAE=EB0N5C4LQ &< #J?:J5IKEG>:G_9T?FK=?8X[TI)&5(C<L%SGH<J<CM0!
MDS^"H)]!U;2C>2!-2U WS/L&4)D5]H]1\N/QJ76?!MCKNH7US>RRF.\TY;!X
MTX*A9"X=3_>!/'T%:LNK6L.M6VDNS?:[F&2>,;>"B%0W/U=:O4 <]I>@:I;:
ME#>:GXCNM0$$31Q0B)8$.<9:0+]]N.,X YP*K?$73KO5?!LUG9).T[W5J08!
MEU N(R6'T )_"N@N]1M+&6TBN9A')=S>1 I!.]]I; Q[*Q_"K5 '(2^!CJ:Z
MB^N:O/?W-Y8OIZRI$L(AA8Y;:HS\Q(!)/7 & .*+7P7=C5-'O[_7I+EM)#K!
M#':I#&5>,QG('.[!'.<<< 9-=?10!RK^"8_^$&L?#4.H2Q&Q,+P78C4L'B<.
MK%3P>1TKIHHW%LD<[B5P@5WVXWG')QVSZ5)10!Q<'@!H[:UTJ36[F7P_:3K-
M#IYB4'Y&WI&TG5D5@,#&> "370:5HL>E7^KW23-(=2NA<LI&-A$:)@>OW,_C
M5N^O4T^V$\D<TBF1(]L,9=LLP4' [#.2>PR:LT 8FNZ ^KWVDWT%\]G=:;.T
ML;B-7#JRE&4@^H/7M5)O!4#>$9O#_P!LD\J6\-V9=@R";CS\8],\?2NHHH Y
M*Y\&78N=1&E>(;O3;+4I3-=011*S!V #M%(>8RV/?!Y&*ZJ*,0PI$I8A%"@N
MQ8G'J3R3[T^J,FK6L6MV^D,S?:[B"2X0;>"B%0W/U=: .;B\&ZQ87FHRZ5XK
MGLX+Z\DO&A^PQ2!7?&<%AGL*M7'@X:O)8_\ "0Z@VK0VD4B^1)"J1RR/D>8R
MKQD(2H';)/6NHHH Y'_A"IXK323;:Y<QZCI2R0VU[)$LA:%L?NY%/#C"KSP<
MJ#ZT^3P9+/81&?7;V75H;PWT-^X!\N0J5*K']T1[21M'J3G/-=710!Q]QX'G
MN[8RW&OW3ZN+V.]CO/*4)$\:E%58N@3:S C.3DG-1R?#\W5GKR7NMW-Q=:P(
M#+<>4B^6\)RA51QCIQ[=<G-=I10!A6/AP0:K=ZC>79O)[RQALYPT057\O?EL
M#^]YAXK+T_X=:;8^#KGPZUU=2I/*)C=%@)59=OE$'U0(@'^[78T4 8.DZ'J5
MKJ?V_5-?N=0=8?)CB6,01*"02Q13AGX')Z<X S537/"=[J\]^(=?N+>RU"(1
MW-I)"LZ@!=I,6[_5DCKP1GG&:ZFB@"O8V<.G:?;6-N"(;:)88PQR=J@ 9/T%
M<Q'X'E@9K.WUVZAT1KLW9L$C4,&+^84$H^81E^<=<$C.*Z^B@#B[CP"TMO>:
M7%K=S#H%[,\T^GK$I/SMN=%DZJC$G(QGDX(K47PK D?B)%N'"ZW]\!1^Y_<K
M%\OKPN:UK[4;338X7O)A$LT\=O&2"=TCL%5>/4D5:H Y)O!&V\AF@U26-!I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7V41CR]A&"NWICVH \WE4>&[OP[/X<O;J\N+^QN'GCDNGG6Y5+<NDI4D@'S
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M7S(;.W-U.D]O)$RQ#JX5U!9?< T[3/&?A_6-02QL=166XD0R1 QNJRJ.I1F
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ML[RQ;%B09^;GDD<?*.: .ETWQOX<U>_@LK'4EEGN%+0?NG590!D[&*A6('4
MDC!]*Z"N!BT6^CT;X=1"RD5]/DA-TH7F$"TD4[O3YB!]37?4 >>3?$V)M+O+
MZ&..&.SUJ*PE:X20*(&E5#)DA<'&XX[8&1Z]3I_BW0M4BO9+:_4+9*'N1/&\
M)B4@D,0X!VX!YZ<5P\VDZG+!J6FMI-V2/%<%^',>8Y8&G1BRG/.%4Y':K7C?
MPQJNNZMX@2Q@;%SH5O#%)D*LDB7#N8\GC)7 YX^:@#K](\5Z+KMRUOI]X7G$
M?FB.2%XF=,XWJ'4;EZ<C(Y%;->=:!83WOB[3;][;Q,RV4$I:;5WCC6)G 78J
MJF9,]200HV@Y/2O0+F)I[6:%7*-(C*''521C- ''ZI\1-,2[TZTTFZAN9[G4
MX;-]\4FQE9]KF-\!68>Q..XK5N?''AVSOWLY]1"R1RB"1Q#(8HY"0-C2!=BG
M)'!(KB;>WU7_ (1_PCX<;PW?)=:1J%G]JG\L>0JQ-@RH^?FW#GCD G.*SO$5
MAXDU30]<L7LM;-Z]U(T=C9V\45D8_-W!]X&Z0E1D_,26/04 >@VOC.RF\6:U
MHLW[A-,@CE:=U8*00Q<EB JA0!SGGG'2KFD>+-$URY-MI]Z9)O+\U4DA>(NF
M<;TWJ-R\CE<CD5QGBG0M5U/4O&-A;65Q_P 3C3;;[+<  1,T6\M&S?PDY &1
MWJ;0=/N+[Q9I5[);>)F%C%*SRZM)'&D+.NW8JJF9,^H(4;0<GI0!Z)-*D$$D
MTA(2-2S84DX R>!R?PKSZW^)\-QI7A_4W2.VM;^_FM;KS(Y"8PJ2,NS@;F)5
M!P#DD@#->B5Y;H&DZG]D\'V=QI-W$^DZM<FY,L?RA3',5=3GE<NH!]: .UA\
M8Z!/I%QJBZBBVEM)Y,QD1T>.3C"%& ;<<C QDY&*S-5^(FCVGAG6-4L7>YGT
MV+>]K+#+"X8@[-RLH8*<?>QC@\UAZY8Z[:ZMXCN["PF,5SJ=C)YT5NDTBPK"
MH>2%6!!=6 '0XYXXK*N=!UK41XP:*TUFX6^T)8+6;4]@DGD5I"5"J $^\,*0
M#W[T >LV%Y%J%A#=P%C'*H9=R,A_)@"/QK$O/%D%GXXL/#;1/NNK62<RA'.&
M#*%7A<8.YB3GC SU%;&EW1O=+MK@V]Q;%T&8;A-DB=L$=JY[58;J#XCZ'J*V
M-S/:-97%H\L*;A$[O$RE^>%PC<T 5?"OQ&TO6;#3TU"[AAU.ZD:'RXXI!%Y@
M9@J!R"NX@ [=V>>E;%SXS\/6>IOI\^HJL\<BQ2'RW,<;MC"O(!L4G(X)!YKD
M;70-2B^&?AZP^P2K=V^K6\\L.WYD47>]F/\ P'FL>X\-ZE;VFN:)<VOB6[>]
MO9Y(XK22-+2YCE<L&:0H?+(!^;//'&>* /9*Y"\\=6FD^,-1TC5)$BMX+2"X
MA,<$DDC%C)O)"@_*NU>< #/)Y%=7!'Y4$<>2=BA<DY)P/7O7$W-S=Z'\0M7U
M)M"U"]M+FPMHHI[2$2'>C2DIC.>=PYZ# SCB@#H+WQ;H6GVUG<37ZNEZN^V%
MNC3-,N,[E5 21@CG&!FFS>,?#T&F6>I2:I#]CO'*6\J@L)' )*@ 9W?*1CKD
M8Z\5Q/AW1]5\&7FE:C?:5<W43Z9):RQV2><]I(UPTP7:.2N'"Y7/*#M4FG>'
M]5-]HU_/ILD*3^([K4GMVP3;1/!(J;\9 );!..A:@#LK3Q?H-[9BZ@OP8C=)
M9D/&Z.LSD!496 9221U ZU;NM=TNRN+J"ZO8X9+2V%W.'R!'$2P#$],95ORK
M@]>T353JOB'4+?3IYT35],OHXXP-T\<*Q^9LSU(P>/:G7=O?>(-8\27S^&;V
M6QN=%AMH;:Z;[.]R5DD9@#R4/S<9P>!TSF@#M-(\3Z1KD\MO87+-/$@=XI89
M(7V'@,%=02ON.*NZG<FSTF\NEDBC:&!Y \P)1<*3E@.2!CG'-<5X.CUA/$DG
MS:S+HPLR#)KD"+/'+N&$1P SKC<3G(R!@FNK\2V\MWX5UBV@C:2:6RFCC1>K
M,4( 'XT 9\WC;1-.M[8:CJ">>]JEQ(;>"5T1&'WSA3L0X."V.E=#%+'-$DL3
MJ\;J&5U.0P/0@UY5?Z7?V:V\D%AX@L;\Z3;1+<Z8%GCN75"/+GA8%05)QD\$
M$\CI7I.B"^70=/&IQQ1WXMHQ<)" $63:-P7'&,YH K:MXHT?0[N*TO[LI<S(
M9(H$A>1Y%!P=JH"3CV^O2F2^+]!BTFUU,ZBCVMTQ2W,2-(\K#.55%!8D8.1C
M(P<USNO:D=+^*FFW']FW5ZO]C3JWV6/S)(QYT?S;>I&<#CGGTS6*+#Q!8I:W
M1LK^RM;_ %.]O9S8VT<]Y:+)CRT (8+NP2Q4'!.* .TE\66-WHJ:AI6H6OEB
M]BM)&N8I!M9I%4H5P&5R&P,CJ03Q6;XK^(FF:)I]^EC=0S:G;.L0C>*0Q>86
M4%"X 7< 2=N[/'2N8M-!UEM(UA'T_4M\_B.RO(OM95I9(5:#+L5XX"$D#IC'
M:EU"RU:U\"ZGX2'AZ_N[UKV25+F.,&&5&N/-$N_/W@#C;UR/3F@#UNJFJ73V
M6DWMW&%+P0/(H;H2JDC/Y4L5ZTFI7%F;.Y1841Q<.H\J3=GA3G)(QSP.HJ/6
MHI)]!U&&)"\DEM(J*.I)4@"@#@X?&'BNU\/:1XAU Z#<65]]F+6EK'+'<8F*
M@!"SL&8;\XQS@UUNJ>,M T:]>SOM0$<T:AY0L3N(5/0R,H(0'U8BO*X/#<3^
M$=.L-(\":C8>*HH($75# ENL,ZA=\IDW9(R&.,'/3'-=>#J'AV[\46LN@WVI
MMJMPUS:S6T0=)0T2IY;DGY-I4_>XP>* .EU/QEH&D7(MKS4 )S"LXBBB>5FC
M;(#@(I)7Y3R.G?J*MVNOZ5>R6,=K>QS-?P-<6VS)$D:[=S ].-R]?6N3\&>'
M-0T/Q!;K>1%A;^'+*R-P.5,B/)O4'VROX8K(T2PU3PY%X1U"XT>^FCM+:^M;
MB*VBWR1&2560E,YP0AZ=,B@#N[GQ9H=I;R3RWWRI=-9E4B=W:9?O(J*"S$8/
M0&KFE:O8:W9?;-.N!/#O*$[2I5AP592 5(]" :\U72;]]*ENM0T+6('?7KJ[
M26PF"W=FDB_*ZJ,AP<[6 SUZ&NO\"KK"Z7>?VL)RINV-K)=0)%<2Q;5PTJIQ
MNSN[ D 9% '4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>guyaragreement007.jpg
<TEXT>
begin 644 guyaragreement007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/GVK)*=PR.5KO*K0WT4]]=6B+*);;9O+1D*=PR-K'ANG..E '/\ Q&LKG4?
M6IVEG%/+<2",(L"EG_UB$D >@R?PJ";P5=:D;N76M;:]N'T^:PMG6U6)8$E
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M2[2"43/<!HX@")&7:S#T)'!J>71]-FCO8Y;"WD2^(-TKQ@B8@!1N!Z\ #\*
M./\ "*:GI_B^[TZ9?LMDUBLWV&756O9(Y-^ X+?,JL,Y&<97ZU+>VXU[X@ZC
MINI7]Y;6MCIT$]I#;7;V^]G:0/*2A!8KM4<Y STYKIM)\/Z1H*2KI6G6]H)2
M#(8D +XZ9/4X[>E)JOAW1M=:%M5TRUO&ASY9FC#%<]1]#W'0T >6:!,MUX5\
M*Z-;G4M1EDBO+C[-:7GV1)T6<KYDDH(; )X5>N>1P*@AC;6-%TN#4;FZ86GB
M\V4834I7,<>TG9YH*ER#P&/(['FO5+GPEX>N[2VM9]'LW@M2Q@3R@!'N.6VX
MZ GJ.]+)X4\/RZ9+IKZ-8FQED$KVX@4(7  #8Z9P ,^U 'FNH7&MZK=^++T^
M?')IMW+#;7(UIK5+%$4%&,0&U@?O$MG<#CM7<^(!)J/PNU!KUAYTNDO+*;>1
ME!?RMQVD8.W/YC@\&M"^\)^']3ODO;[1K*XN5"@220@DA>@/KCMGI6O)''+$
MT4B*\;J59&&00>H(]* /*M.T"UOO$/A&Q:XOEMAX;EE<1WDJO)EX3M,@;?MR
MV< CH!TXID%_/+I=GH,EQJ]_.-9O[6WMX;SRI+B&!FP)9RP8*H(Z')P!S7I&
MG>'](TCR?[/TZVMO(C>*+RHP-B,P9E'H"P!Q[5'=^%]"OK8V]UI5K+%Y[7.T
MQCB5CEG!Z@G)R>^: /);E9;WP_K6G7TERD.G^([".&$:G+,8 [0[D\W(+8+-
MU^Z>G(!KOOB;9Q-\+=;AW2[(;,E2)GR=HXR<Y;WSG/?-;8\*Z NGW-@NC6*V
M=R%$\ @4))M^[D8P<8&#[5>;3[-]-.G/;1-9&+R3 R@H8\8VX],<4 <#-X=L
M[_XDP6$ES?BTA\/H=L=[*KR?OVQND#;VQUY;T]*YZVU/6]3M_#&C.]U?02?V
MAO!U!K62Z,$YC16E'S'"<D#&[J>E>LV&B:7IAB-C806YBA^SH8T *QY+;![9
M).*AN?#.AWFG+I]QI5I):)(TJ1-&,*Y)8L/0DDG(]30!C> )=0^PZG:WTR2+
M:WSQ0+]L^U/"FU3Y3R$98J2>O." >E<LVF6=Q?\ Q"U&75[VTN+*Z\V+R+QX
ME@(MHR)"JD!LD8^8$87'K7ING:;9:39)9Z=:0VMLF=L4*!5&>IP.]9]WX0\.
MW]\;V[T6QFN6D\QI7A!9FP!D^OW1U]* .+T,S>,M3NQXAOKVU>UTVREBM[:[
M>V"-+#ODE.PC)#Y7G(&WI5'PW+>^+]2T"WU;4[]K9]%GFE6"Y> 7)2Y$:2,4
M(/*X;C&<^G%>CZMX9T/798Y=4TJTNY(QM1YHPQ"_W<^GMTJY'IUE%=1W,=K"
MD\4/V>-U0 K'D'8/1<@<>U 'FNB:G?QR>$[>;4;J2*/7=1L6>68DRQQK.L:N
M?XC\JXSW [T:K>W^HW_BNTLM85-NLV<$,,EX\*RCR(R]NDBY,98AON]\^IKO
M[KPWHM[ISZ?<Z7:RVCS&<Q-&-OF$EB_LQ))SUY-,7PKH":=/IZZ-8K9S[?-@
M$"['*@ $C'48'- &%X#NMMSK&E2V^IV=U:21/)97EX+I(0Z_+Y4N2Q4[2<,>
M#V%8VO7&HW&L>++*WU?[*1/IJ0)-=/"C[AEHE=>8S)C&5YR:[[2M%TS0[=H-
M+L8+2-VWN(DQN;U)ZD_6BYT/2KU;Q;K3[:9;T*+D21AO."_=W9ZX[>E '+^!
M;@PZEJ^DSVVIV5W (9FLKN]^V1Q*X8 Q2DEL,5)(;IC@#-5Y[&#6_B+X@L]0
MU:_BMK6QM98;:"^D@5"WF;I?E8<C ]N>>U=?I.AZ7H4,D6EV$%HDC;G\I,%S
MZD]3^-8MQX&TS4O%.IZMJ]I:7T5U#;QPQ2Q;C$8_,W<GLV\<>W- '&6&J7GB
M33_#]I<+JFIWQTU[F2""]^Q121^:8TGDD4AF)"\*,CDG'2F>'==U9[;PR1=S
MW#I>:M$$^TM,)EB23RU9^/, P,,1SP:]*U'PQH>K&W-_I-I<?9UV1;XA\B_W
M1_L\=.E2VV@Z39O"]MIUK"T$CRQ>7&%V.XPY&.A(ZT >7)96\VA> ]>DUB]N
M=1U#4[.6X\V[=TFD8$LHC)VKL.0-H& "*]@22.3=L=6VMM;:<X/H?>L>/PAX
M<AU$ZA'HEBEV9/-\X0@,'SG</0YYR.IK2M;&TL3.;6WCA-Q*9YBBX\R0@ L?
M4G Y]J +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%<(4UB#XLZ:;_4Q+;7%E>&"TA0I'$BO%M)Y)9R&Y)X[
M #OA7D<]]X4\3^,#>W::M87=VUDZW#JD,=NY58]@.TJP0[@1SN/M0!ZQ15"Z
MCGU70I([:Z>RFNK?"3HH9H2PZ@'N,UQ.B+%H_P 28])LQJ5G:-8RAUU":1UO
MY59<21%B02HW%CD$AAQCD 'HM%%4=5TBSUNQ-G?I(\!8,1',\1R.GS(0?UH
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MO:7,"Q6PM5\J6V8 Y8.#SD[>,#&.^:SK'PWJTVO6&JZ_JUO>R:='(EJEK:&
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M]OEL[Z^5IO&<5M(&N&8-&63(()[@X/J /2N^B\#^&8+[[;'H]NLXF$ZMSA)
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MSFM#X4VJVWPZTPK+-)YH=SYLA?:=Q&%ST''0=R?6MFR\(>'].U,:C::7!%=
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M<LD<T@R27>-MR,Q)R2#SDT <)J%_J6FZU>ZMJ%YJDFG1ZGMCU'3+]9;>"/S
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M61F9GDB< ,K,22P.!U/&.*C\4Z+?:KX;;0M+^QPVUS']EN&GW$Q0D8)C '+
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M-OB3-'=70D+V*@/,S("_EMG:>.#P/0<=*Z#4)[_P?X@O8[/4=0U"-O#]W?\
MDWTYFS/"R;2N?NYWD%1@=.*Z^\\*Z'?WUQ>W6G127-S$L,[DD>8BD,H8 X."
MHYZ\5??3[2344U!X$:[2%H%E/41L067Z$J/RH \QT"Y\1077AJ_9]0VZA(BW
M<M_JT,D-TKH6)BBW?*P.&4(!P"#FNP\=W]W8Z! MI<O:&[OK:TDNDQN@CDE5
M6<$\ X. >Q-6]/\ !OA[2M06^L=*AAN$W>6PR1%N^]L4G"9_V0*U+VQM=2LI
MK.]MX[BVF7;)%(NY6'N* /,[^.#PGXRUF<ZY?"*+PVT@FN7-U+;'SL C<<MD
M\@$]<]J--DU2V\9Z-ITIU^SM=4M;I)EU+4Q-)+M0$2*JLWE,"?X2.O3BNVM/
M!?ARR6Y6'28/])A,$YD)D,L9ZJQ8DD<#KZ4[3_!V@:7=P7=IIL:74&1%.SL[
MJ""N S$G&">.E 'ENB3ZE:^%?!&C:>=2F@U*.YN+A+>^$,KF/&(TD8C8O)8A
M2"<''>O0/ L^JD:M9:DSE+6Z"VZSWD=Q/$C(&*2,A/())&[G!'6K_P#PA7AS
M^SFL!I,(M6N#<B-2PV2G^)"#E#_NXK1TK1]/T2S^R:;:QV\)8NRKR68]68GD
MD^IYH X_Q//-J/BJ33;-M<NWMK1))+73;M;.. NS8DDEWJ6)"\*,@ $XYK"T
M&_U7Q+#X(M[K6K^..[LK]KMK:?8\_E2(J9=><_[0P>OJ:]#U/PKHFL7RWM_I
M\<UP$\HON9=Z9SM8 @,O)X;(YJ6S\/:1I[6C6=A%";-95M]@($0D8,X [ D
MT <!;ZGJFEZ6]^^IWEQ:Z%XADM+@S2EFDLVPF7/\90R!LGG"FNM\&W=UJUOJ
M.M3SR/;WUXYLHV8[4MT_=H0.V[:7]]PH\1>'KFZT&_TO0XK&W&JR2"^DN-QP
M)%VNZ@9W/TP#@5NV%E!ING6UC:ILM[:)88U]%48 _(4 6**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG2YM=2M)9XO*(:(!V+LPQD=3DGUH Z#Q5\0=)T&RODM;VTGU2V*H+9F.-Q8
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M%1G PA0J1AL<=,TV1M7L[_389(=4TZ!=&MHUN=,TM;BXGD&=T3R,C>6%XP"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKG?'6LW6@>#-0U"QVB[4
M)'"S#(5Y'6,,1[%L_A0!T5%<:W@.2VAAN=-U_58]9C=':\N;N29)L$;E>(ML
M*D9X &.,=*?>>+M4>[U7^QM"2_L])<Q74LEWY3R2!0S)$NP[BH8?>*@GCWH
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M9,*5Z\@^M=]10!P%QX$U+4M*UFWN[C2;22^L_LD46GV02./G)=F/S,3P,9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX4=?PQZM110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;=YPF+ %?XM^<;>/:NAO=%BF\(?$R9].5[J:[NC&S0Y=@L*%-O&3ALD8[YH
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M] '>VWB#1;V\6SM=7L)[ID\Q88KE&<KC.0H.<8YS57P_XD@UR!RPCMK@7-S
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MZN?SEV/P3PV<'@'\C7CL6GZAI[^']1N'DTO1UEU![4SV!G%F)9MT(>/^#*9
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M<17%O(,I+"X=6'L1P:\6BL;RQ@\.W4DC6&EV5[JD?FO8FXCMG:X;RR4[ J&
M;H,^]=W\.K81VFKW,4]Q-;W5\TL;R68MHW.U0SQ)DG:2.I R<GOF@#M****
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M:1S3W,LZP1L2N<(S??;CGL,CF@#K**X]O'?VJ31XM(T>XOYM5T\W\"F5(@B
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MNPH5DQDA26'&,CBMI_#WB/2;S6%\.W&G)::K()_,N=PDM)?+6-F554JXPBD
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M^^N;.'6;NXM9X$BW201"V;=&C$@%P26W' ^]P.*[VB@#E=.T;6Y_$Y\0:O\
MV?!<0V+6=O;VDCR*=S!F9W95/51@ <<\FNBL/MOV"#^T?L_VS8/.^SY\O=WV
M[N<?6K%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 <W#XUTV[\9KX:LP]Q,L4KS7"_P"KC>,J#'GHS#=R!TXSUHOO&NFV
MGBW3_#<0>XO;J4QRF/[EM^[:0;STW$+PO7'/UK:C'M^*/AXHF%_LZ^S@<9+P
M'_&CQ3'CQ5X-9$_YB<K,0/\ IUE&3^E '0ZMJ<&C:1=ZE<K(T-M$9&6-=S-C
ML!W)Z5BZ?XINWUJTTO5]$FTR:^B>2T8SI*'V %D;;]U@"#CD=>:N:MXJTK1K
M759KB9F;2X5FN(D0E@'SL [$L1@<_7%<CX.UW2_$OB2+5M0U:VFUJ2%TLM.@
MW%+*(C+#)'S2$ ;F]L#CJ >D51U6ZOK2Q,NG:=]ON-P @\]8LCN=QXJ]10!Q
MN@>,-;UV^GA'A8P06MXUG=3'4(V\IUQNPN,MC(Z5J^'/%5AXBTNRN4DA@N;J
M,R+:-,ID !(SCJ>GI69X"5E?Q5D$9\07)&1U&U*XK2=%LK3X=>#;Z"PBCOCK
M5J[SK&!*=UP5;+=<%3CZ<4 >N/J%E'>K9/>6ZW3C*P&50[#V7.:LUX)=6Q-K
MK5AJ>K6%MK4VIRL(/[':;4'8RYB>%_.7<-NS:0 % P>AKWF,,(U#G<P R<8R
M: .*TWQGK^LVK7FF>$#/:>=+$DC:E&A8H[(3@C(Y4UUUK=B:-%F$<-V(E>:W
M$@8Q$CH2/?(SWQ7C'A>[\,6^D21ZIXPU?3;P7EUOM8+V2)$S.Y&% P,C!_&M
M?QPO]O7=B?"XN;NZBT[S-0GMY=C3Z>V#Y)8CF1\$KW&&/>@#TZ;5=.M[:.YF
MO[6.WD.$E>90K'V).#4L]W;6ML;FXN(H8 ,F61PJ@?4\5Y%JMQ8/XHL=12_T
MC3] ET:*/3)-2TXSVZ_,WF1J-Z"-\;,@Y) QVI;""UTZR\'7&M2M/X<A>]82
MW=H88HG8CR"T;,VU OF!"QX!7IQ0!ZY'>6LRPM%<PNLX)B*N") .NWU_"LW6
MO$VF:%% ]W.A\Z\BLP%=?D=R!ELG@ ')]JX$ZCX?T_6O#^M6%N^G^'X]2O5>
M[D!6!GDA $B<X6-F! / )!/?)R[VXT^^L]7U>:)7TY/%]I,TTT)VB#9 &?D?
M<([]""* /6K;4Q-?75O*D4*QRK' _GHQGR@?(4'*XR>#S@9Z&K;7,"-(KSQJ
M8UWR N!L7GD^@X//M7F%Y8R7K^-+_3DWW6GZG::E8[1PYCMHFVC_ 'EW+_P*
ML_6(+O6/",OBC:8X-6UJ"XN!-;M*$T^+*1>9$""R9"R,N>C&@#TW4M?AMO#U
MSJVFB+4Q"/EC@G7$AR!M##(SSTZD\=ZO2ZC8P7<=I->V\=S)]R%Y5#M]%)R:
MX+P(D$WBW5+VQU:ROK=K2*.9M,T[[/:M(&)4[O-8-(%R#@< C)[5SWBY[&PU
MWQ!(DEA=7,TT<DFC:I:$3W+!$"FUF0[\'  X.&!Z4 >SU574]/>Y2V6^MFN'
M!*Q"92S $@X&<G!!_*K$;,\2,R%&*@E3U4^E>'6LNA3^"+K3M/BB/BR76)7M
MU6/_ $@RB[.V13C.Q5'+=  P/>@#VF?4]/MKJ.UGOK:*XD^Y%)*JNWT!.31/
MJ5A:R".XO;:*0G&V255.<9Z$^G->*>,;NUO+/QG"L>DV=WYTP-I+:/<ZA<E5
M 656+#8A !!"D*!FNS\.Z3I^J>//$%]?64%W(MM8>3)/&'VYB))7/3/&<>@H
M Z+2/%=OKUOIEWIL(DM;V25'=ID5H=@.,KG+$X' Z Y/%:Z:A92WCV<=Y;O=
M(,O LJEU'NN<BO(?"ODFV\$VVGK''>6UUJ,5PJIM,<WDR8#C'7&WKVQ6EX1G
M\+)IOAC3WT\R^)[>5?M$<2%;F"?:PFEF.0=F=V=Q(;(P#Q0!Z#::W ^EQ7FH
MM;V#.K,T<ERC!0&VYW X(Z?3.*NM>VB6?VQ[J%;7;N\XR )CUW=,5XOHL^BV
M4O@2;Q L2VL=CJ)5[A<QQOYZ89L\ 8R,GC)'M4[7-K::;$PLK&+1;KQ!/-IM
MSJ:.+.UC\KAS&"H(9_,V X'.?2@#T[5O%6DZ1H1UA[J.>T\U(E:"16#,[A1@
MYQP3D^@!-6[?4O/O;R,QQK;01QR)<"=&$@8$DX!RH&.IZYXZ5XO(D$WA[QL[
M?9KJVCU'3KH26]D882NZ,/(D9+87"ME@3N )Z&M77EAN]5UVXMXC/H9ET::Z
M6!"RR68WEL*.J ;20.P- 'K$&I6-U;/<V][;36\>=\L<JLJXZY(.!2P:A97-
MQ);V]Y;RS1?ZR..569/J <BO*=:DTO4)_%%WX76%],_X1>ZBO);- (9)L9B7
MCAG"[^G(! -;4&CV.E>)? 3V%C#;,]M<1RO%&%+KY ;#D=?F&>>] '<ZK>2Z
M?ILUU#;BXD3&(C*L0;) ^\W Z]Z6?5-/MI!'/?6L3E_+"R3*I+8!VX)ZX(X]
MQ7/?$Q2WP]U4*"21%P/^NJ5S-YH>GWTGQ.N;O3X)Y_NQR2Q!BH%FA&TGISSQ
MW ]* /4JY2;Q[IO]G7MY:J;@6>I1Z=(@D4$L\B1[QC/RY?CUVFMCPX[R>%])
M>0LTC64)8MU)V#.:\IO;737\/^*M(%O"MP?$\'GP+'M8P/<Q;<\?=(W8_&@#
MV&UO[.^5VL[N"X"-M<PR!]I]#CH:2UU"ROC(+2\M[@QG;((95?8?0X/%>7^,
MM(FM=7\0VOARS%M)/X;4F.SBV[]LY!P%QEMA8#OSBE\*)97/C31YM+UG3+D6
M]K*LL6D:.;=5B*@!)W,K;2&VD*1G(/3DT >E:QJ]GH.D76J7\A2UMDWN0,D]
M@ .Y)( 'J:YT^,-6L_LUUJWA6YLM,GD2/SQ<I+)#O("F2-1\HR0#@MC/-6/B
M%IMWJ?@VZCL86N+B"6&Z6!>LOE2K(4'J2%./?%4YOB5H]S#!#H.=5U:XD1$T
M]0R2)DC<9<J?+"C))([4 =7/J-C:W$5O<7EO%/+_ *N.2559_H"<FBZU*QL0
M3=WMO;XQGS953&<XZGO@_E7EU])X?M9/&EKXH@B?5[NYD-JDT6^6X@,:B$0<
M9.#D87HV>E6]%T,7WBR)?$5E'=WD/A6SCF^TH'Q(6D#]>-V1U^OK0!Z.E_9R
M79M$NX&N0N\PB0%POKMSG'O38]3T^6Y6VCOK9YV7<L2RJ6(]0,YQ7E7AS2K6
MS\/?#*\@LXXKR2Z FG6/$C!K:;<&;J0<#KZ"LO29="N? MCIVE11'Q6VJ+)$
MJQ_Z0KBZR92<9V",$;NF./:@#VF;4]/M[M+2:^MH[F3[D+RJ';Z*3DTESJ>G
MV;;;J^MH#N"XEF5>3R!R>IKQ#QC>6UWI?C"../2;*\%S-FS:TDN-0F9, 2AB
MW[M, ,"%*JO>NRAT?3M6\4^-KB^L8+LFRM5C>:,/A3 2=N>F<#IZ#TH ]%6:
M)Y7B61&D0 L@8$J#TR.V:SEUCS->BT^*%9;>2U>X-VDH*JRNJ["!ZY/.?X2.
MQKS!KO4/#GAGPIXAL8I);K4]#ATEUQDFX,8:V9OH^]2?]JN\N]#M=)^&EQHF
M+M[:'37@<VBYF<;"&91W8\G'<F@#>M-1L;_?]CO+>Y\LX?R95?:?0X/%32S1
M0*&FE2-2=H+L "?3FO+_  )=6X\706]G)HVK1_V>ZG4M-MC;R0*&3$<Z E,D
M]!P1M/ %;?Q2-D- TLZC&9++^V+3ST"EMR;^00.2,=1W% '8VM]:7T)FM+J&
MXB!(+PR!UR.HR*;:ZC8WRR-:7EO<+&<.8I5<*?0X/%>1>(D75E\57/@Q5?3'
MTRVBN9+*,F.:03$N%"XWL(=P.T]"!G-7/#Z6EUXH2YTS6--O%ATR=)UT?23;
MQ!#MV+*_FL P(RJXR/FZ4 >H0ZG87%S]FAOK:2?8'\I)5+;3R#@'./>E34;&
M6]>SCO;=[I!EH%E4NOU7.17E>DZ-96'A#X:7EK8Q0WC7EMYLZ1@2$/!)O#-U
M(/?/M5+1I;*P\0:3;6+6.IM_:K?Z'<6AAU2Q+,^]W9"=R@$DEA@C'/2@#UFT
MU9'TMKZ_$-BBR.C%[A&4!7*@EP<<X!QVS@\BK(OK1K>.X6Z@,$GW)!(-K?0]
M#T/Y5Y%IWV6UC\-WFNQK_84.H:MYK3IF&*<W#>4TF> ,>8 3P"?>F365EJ=V
MWV*U5_#5WXILS;1B/$,O[DB9E7H4+?@3F@#V&TO;2_A\ZSN8;B+.W?#('7/I
MD4ZXN8+2!I[F:.&%?O22,%4?4FN2\.64&G_$7Q3!:6T=O;M;6,GEQ(%0N1*"
M<#C. ,_05!\1;VWM9-!2Z@T\1O=NPO=3WM:VK",X+J" S')"[B #SUH ["/4
M;&:U6ZBO+=[=CM6595*$], YQ48UG2V2-QJ5F4D(",)UPY)(&.><D$?@:\6B
MMXKZTUNS8P7-I<>)-,)^SVAMX94<QJS)&2<*<'G)W8SGFNXA\.Z0?BQ(ATFS
M\BTT2!K>/R%\N)S<3$E5Q@-GG(YY/K0!VAU/3UOA8F^MA=GI 95\S_OG.:23
M5-/AF2&6^M4E=_+5&F4,S?W0,\GD<>]>&ZC?VUWH_FP+I-E<IJZ3/I\5J\M_
M"PN@6DFF9LIQDYVXP0H-=#J&B6%SX7^)M[/I\,MX+JZ\J9XP779 C)M/488D
M\=Z /5+B_L[2:*&YNX(99CB-)) I<^P)YIL^I6-M:+=SWMM%;/C;-)*JH<],
M$G%>932Z-;:OXB;Q9:^?->VL'V!I;<RF:$0 %(C@_,)-Y('.2#6%:+)!;>"K
MN_OM.L=,'AV-(+C4[(W-NLY(+#[Z!'*;<$GD @4 >VR7UI#$LLMU D;*75VD
M !4#)(/ICFHEU;36-N%U"T)N?]1B9?WO^[S\WX5Y1HND6UU=^#X)\7^G/J>H
M3PK)8F"'9Y99=D;,W[O<"RY/IQTIE[H6GV_@SQM<PZ; ES#KC?9Y%B&Z(+)$
M0$./E +,<#U/K0!Z[<ZA96<L45U>6\$DIQ&DLJJ7/L">:+K4;&Q!-W>6]N%
M),LJI@'('4]\'\J\A\0I'!XM\5#7=2TFT%T$%LNHZ6UR\]OY0 6!O,7D-O\
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M2%H;(VT&=JAC"I=LH6!.>!G=B@#MJ*** "BBB@ HHHH **** "BBB@ HHHH
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MNC#;T#;3C(],XH ZRBN*/Q&A"37?]AZE_9=M>M8W-]^["1R"7R\[=VYESC)
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MQJ^D_P!H3CP_J=QIVG'%W>+Y:*H !8HKL&< 'D@8ZXS3K[QF8M9FTK3=$O\
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MWB:@-1_LS[ S1AOM&S?C?NV;=O.<_KQ6]HNJRZK;2O/IMYI\\,IBDAN5&<@
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M87%A?6$JQW%M.58KN4,I#*2""#Z^M-U;7[JQU!;"PT.^U*X\GSG,)2.-%S@
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M!&[D4NJ>$-=\0IJ^H7RV5K?7D=I;V]M',TB110SB5BS[1EB2W1<# %>AT$@
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M=:7KVE>*-1U?1+>QO8M3AB6:&ZN&A,4D8*JP(1MRD$9'!XXZU5T+P7>Z/?\
MAN9[B&8:?;WPNW&5+2W$B2?(/[H(;J>F*[(7,#73VJSQFX1 [1!QO522 2.H
M!(//L:&N8%NDMFGC%PZ%TB+C<RC ) ZD#(Y]Q0!Q3^#M2;PK=Z8)+;SY==.H
MJ=YV^5]K$V"<?>VCIZ]^]='XITF77?">K:3 Z)->6DD,;/G:&92!G';-:]%
M'G.K^#]>URUU629+&WN;[0H]/$:SLZK*LKMG=L'RX8<XZYX[UU#Z-<MXZM=:
M#1_98M,DM&&3OWM)&PXQC&%/>MTD*"20 .2340NK<W*VPN(C.T?FK%O&XID#
M<!UQD@9]Z /-7^'%XEAHDTMEINIW&GM>)-97,C+'+'-,9%*OM.UUXZK@Y(]Z
MZSP;H$NA:?=">RTZRDN;@R_9[!3LC7 "J6(!=L#EL#KC'%=)10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<=\5(Y9/AIK?E3F(K!EB%!W#(RO/K78U2UC2K77-'N]+O59K:ZC,<@5
MMIP?0]C0!RD4WB+5]?U/2+37OL2:1% C3_9(W>YFD3?N8$85 ,#"@$G/(K:\
M)ZQ<^)/!]IJ,P2"[F1TD,0RHD1F0LH/;*D@&JLW@>TDE6>/5=7M[HP+;W%S!
M=;9+E%SM\PXP2,G#  \]:WM-TVTT?3;?3K"$0VMN@CBC'. /<]?K0!YAX8GO
M=-\(^%0]RET+KQ%+#B:!#Y:[[C.TXX)*YSU&2!Q3X-?\83:%I&M+K5N#?ZJ=
M.%JUFIC5&E>(.2"&+#:#@$ ],=Z[*T\$:99I!%'->-#;:@=1@B>;*Q2'?D+Q
M]W,C''J:FB\(Z9%I-AIJ^?\ 9[&\%[#E^?,$C2<G'(W,>* ..U+Q;KWAU-=T
MV6[_ +1NX+NRM[2Z-H-Z_:.N8X\!RN#@#DD@5L^%-9UJ?Q#-I]XNIW=@;7SD
MO+[3#:,D@8 Q\*%8$'(XR,'K6Q?>$-)U*35'NHY7.I>3YQ$A4HT7^K9".58'
MG/J*98^$;6SFN[E]0U*[O;FW-K]KN+C,L4?]U"  O/.0,Y )H Z&N/\ 'G_'
MUX1_[&"#_P!%RUU=K +6TAMQ)+*(HU022ON=L#&6/<GN:J:IHUKJ[V#W7F9L
M;M;N'8V/WBA@,^HPQH X'4=<\4G3/%VLVVLQ00Z%=S)!:_9$83+&BN5=CS@A
ML#;@]\FNZU:_EM_"U]J,&$FCLI)X\C.&"%A]>:@D\*Z;)I6M:<WG>1K$DDEU
MA^<R*%;:<<<**L:S8R7'AC4+"U7=+)9R0Q*2!DE" ,F@#DK+5_$6F)X7U'5-
M5BO8-:D2"XMA;K&L#/$TBM&PY(&W!W$YSD8K(C\9ZNM]H]U%K$U_#>:G%:S)
M%I;)8A)'V_NIV4,Q&1SD@X/%=-X;\"VVGV6D2:A->W,]E:JD=M<W'F16SE-K
M[!WX+ $DX!P,"G0_#K2H8;&W-]JLMKIT\<]C;R7.4MV1MR[1CD#&/FW8!.,4
M <MJUQXBUOP3XWOKG6UCLK4:C:16D5JGS)&S %G/.2 5X[<]:GO?$6H^&6O"
M&@O)[;P[:2Q2RP*K-)).\:[BH!V#*\>Q/4UW,?AC34T;4])*R-::E)<27"L_
M),Q)?![?>./2J47@?21#+%=M=7PFL!ITINI=Q>$.SC) '(+GGV'I0!DZY-XI
M\+^']8OY->M[\1:9+/&9;9(Y(YT&0451ADY.0V2..3FKVN:Q>0ZUH=@DBBWO
M[&\DG7:,L4C0K@]N6-30^!=,Q<?;[F_U1IK1[+=?3[S'"_WE7 &,X&6^\<#F
MDL? FGV=];7LM_J=[<6T+V\+W=SOV1N,%0, =!UZGN3@4 <?I.M75KX3\):=
M;:Q-9[M%AE,&GZ>UY=.=H )78RI'UY/4_2I=.\3^)]?M/"UK;ZC'8W.H/?Q7
M5R;16;_1WVJP0G 8XY'09/H*ZE/ 6FVYLFL;W4K&2TLDL-]M.%:6%/NJ^0>1
MD\C!Y/-6-*\%:1HSZ<;,7 &G/</;J\NX+YYRX)/)YZ9.?K0!G?$V&X_X5;K2
M"Z82)9GS) @_>8ZC';/MTK+DT[69_B6]M:ZZ;:5- @\Z[^RQO)(?.EQA2-H'
M7/';C%=UJ^EVNMZ1=Z7>JS6UU$T4@5L'!'8]C533?#MMINH"_%Q=W%V+1+-I
M;B0,S(K,P)X&3ECS0!P*>.]:O['P]9B2XANKNWN)KRYT^P-S(1%+Y0V1X(7<
M>22"!T[UV7@O5=5U/3+H:M;W"2V]RT44\]JUNUQ%@%7*'H>2#CC*\4P^!=+6
MQL+>VGO;2:P:5K:[MYMLR"1BSKG!!4D]"".!6KHFAVF@6<EO:M-(TLK3S33R
M%Y)I&ZLQ[G@#TX% ',>%;2WU/Q9XNO\ 488YM0@U 6<7FJ&,5NL2,@7/0,68
MG'4TS4+BR\+6,VG^%9K>*[O]8BMG0GS([*68 L?+SQ\HW!>!D^];>J^#[+4M
M4;5(+W4--OI$$<T]A/Y9F4?=#@@JV,G!QD>M(G@C1$\/R:,(IC#)-]I><S,9
MVGR&$QDSG?D Y]L=.* .5\1>(_$/A)-9L9-374)8](?4;2ZDMT1XV2149&50
M%8'<"#@=QS5PMXN'B^+0'\21A;K3VOGG6QCW0,CJA2,'C:2X^]N.%Z\YK7;P
M%I=Q9ZE#?7-_?3:A;BUFNKF8-*(@<A%( "C// Y/7-;3:1:MK\>M'?\ :X[5
MK1?F^78S*QX]<J* ."TWQ%XEUU?"MI%J<-I)?17_ -MN$MU9F^SRH@9%;(!/
M/J/F/' J27Q5JD%E=Z;=ZQ#!>6>K&Q:\CLVFFN8_*$H\J% P,F& /&T8)QVJ
MW?> O^)WX;CT^6\MK#3H[YFN8;@++%),Z.,9^\"=XQ@C'6M4^ M*%I:QP7%]
M!=6UR]VE_'/FX:5QM=F9@0VX<$$8P !C% '(_P#"9^((/#WB41W,DEYIMY91
MVL]_9""1EF>,$21@#^\>< X/:M6ZN_%EAJ^IZ)#K"7]V^CM?V<LEHB%)D<+Y
M>%X*MD#G)'K6PG@'2%M]1B>:^F.HRP374DL^]W>%@RMDCCD#('&!@ 5IWNG1
MP:G)X@@MIKK48K)K:.!)%42+N#[1NP 20.20* ,;1/%,OB;7K'^SG"Z:FEI>
M78V@GS93^[CSV*A9"?PI/$EYKLWC'2M#TC5$T^*YL[BXFF-NLS HT8&T-Q_%
MCZ$]\5-X$\.-X?TF[DN+5+6\U&\EO)H%?>(0S?)&&Z':N!QQG.*VY=(M9M=M
MM8??]JMH)+=,-\NURI;(]<H* /-KCQIXDNWU>]TW^TF:QNY;>UL8=(::&X$3
M;3YDH&0S$'[I 7(ZU;\0>*-?T_5KJ:ZNKO1K!5B>SD;3?/M6!12PN'4%T.XL
MO\.  >:Z2]\!:7>W%X3=:C!:7TOFWEC!<;(+ASC<6&,C=@9VD9[TNH>!--O[
MB]<7>H6MO?@"\M+:XV0W&%"_,,9&5 4[2,@<T <[JWBW5[SQ/JUAIUS?VUOI
MRQ)$UCI1O%GD>,29=L'"X90 ,$\G-36FM>*?$&NZ38K<?V&9=(2_O(7M \BR
MB784 ?H#[\X ]<UT%_X*L+R]DN[:[U#39)H5@N/L$_EB9%&%##!Y X!&#CC-
M7-/\,Z9I=_;W=E$T+6]BMA%&&^58@VX#USGOF@#EK?Q3J\L5GH1F3^W_ .V'
MLKB3RQ_J(_WK2A>@W0E!]7K&;QOXDO8KW5M.CU.7R;N2.VTV'2&D@FCCD*$-
M,!G>=I.0< \8.#7H<?AG3(O%4OB18F_M&6W%LS;OEVY!SC^\<*,^BBLRY\ :
M3<SW(-SJ$=C=3_:+C3H[C%O+(3DDKC(!/) (![B@#G=<\3Z[IFNWCWU]<Z18
MQS1_8WDTWSK*6(A<^=*H+(Q)8=5 P.M=/\0%DE^'/B+R9S$?[.G;>H#94(21
MSZC(S[\4R_\  >F:A<7K-=:A#:7[B2\L8;C;!<-@ EAC(R  =I&>];U_I]MJ
M6EW.G7*9M;F%H)$4XRC J0/3@T >;:?IVLS^-;.VM=<-M(/#5NTMU]F1W;]]
M)M4*1M YY.,\>^:5O'6LSZ'X9@WRQWVI-=+=75E9&X<+;N4)2+D98[3D@@#/
M%=MH_A:ST:ZBNH[B\N+B.S6R$ES*'8QJ[.,\#D%B,^@%5F\#Z5_9=E90R7=N
M]C-)/:W4,VV:)I&9GPV,$'<000010!'X+U;5M1CU"#5(+LBUF"V]W=69MGN(
MV4')0@#<IR"1@'@X%9!U#Q!?:EXMF.J1)IFD/)%'9_94;SO]&5\,Q[!F!]^0
M>,8ZO1- M-"BN!!)<3SW,OG7%S<R;Y97P "3[     #'2B/P]8Q+K"KYN-6<
MR7.6[F-8SM]/E44 <AHNJ:YXBELM-L-2CTJ.TT6SNYGBM4<RR3*<*%/"H AX
M !YQD8K%L;S7O$>K>"[B34H;;4I(=62>YB@5@%29$^13QGY5&3GC/4UO:YX;
MN;._L!IND:C<6]MIZ627&FZBMO.54X$<N]E#)C!##Y@=WK6AX.\%QZ)I&@F\
M&-0TV&X55BD+(GGOO9<GEL8 !]J .3U&[UK5X]%M[G5L7.G^*VL#<1VZ#S=L
M;E)"I& P!(P.#GZ5U7Q4CED^'&K>5<-"55"Q"@[AO''/3_ZU7KOP3I=W:S0^
M=>0-)J)U,303;9(YR,94XX&,C!SUK5UG2+77=&NM*O0YMKE-C[&VM]0>QSS0
M!S+7&O:IXFN]!M-;-DFEV<#SW0M8WDN99=^#AAM50$Y &23U%:W@[6;K7?#D
M=U?+&+N*::VG,0PCO%(T99?8[<X[9J*Y\&6L\L%RFIZK;WT=N+:2\@N LL\8
M)($AVD,02<' (R<&M?2=*L]$TN#3;"+RK:!<(N23R<DDGDDDDDGJ30!R.A7W
MB;7M/MO$D6L6L%K/=L!ITT"B(6XE*8,F-_F8&<YQGC%<WI-WKVA^#[C7;;58
MQ9P:W,G]GFV4K)&]Z4;<Y^8-EB01@<#@UVX\!Z4MV'$]]]B%S]K&F^?_ *,)
MMV_=MQG&[YMN=N><5:;PCIC>'9=#/G_8Y;DW+?/\V\S><><=-_Z4 <9XK\6Z
MM8OKUSIVM2L^F;C':66EF>!0B!BMQ,RX5B<Y"L-HQU-:1U'Q)KFOZU:V&LII
MMM96=M<1A;5)69Y$9L$M_#\OUYX([Z=[\/M*OAJ43WFI1V.I2/+<V45SMB>1
MA\S=-PR><9P3VK6L/#UEIUU>7,)E,MW!#!*7;.5B4JN..N&.: .2TWQ)K?BI
MO#UE:7J:7)=Z,NJ7<\<*R,Q)50B!\@#)))()Q@>]9;>-?$,4$&ESW+/?3:O>
M6CWEC8><Z0P 'Y(AGYB2.N0.>N*VM9\+R:=%H<&DZ7?7-OIULUM'/87RP7<0
M^4!27*JZ$#D'D$ BCP[X 1/#20:D)[.]&H3:A ]O=%IK1G)P/-.=YVG#9R#D
M]: -+P7JVKZ@VI6VIPWC1VLB?9KR[LC:O.C+D@H0!N4@@D  @C@5QWC"WNAK
M/Q"E-^YA'AR,F'RUP01. ,XSP03[[O:O1]$\/VNA"Y:&6YN+F[D$EQ=74F^2
M5@,#)X   P   *I:OX-TW6;^\NYYKR-KVR-C<QPR[4EC^;&1@\C>V#[T 85K
MJ6N^']7T2#4M434+34+&>1X5MEC\AXHU<>61R002/F)/O61HGC+Q-?IH^JB/
M4[I+^:,SV(T=EMXH)#]Y)L9)4$'))#8/ KT2;0[.?4-,O7#F73DD2 ;N,.H5
MMP[\ 5CVO@#2K2>UV7.H/8VDWGVVG/<9MX7!R"%QG )R 20.PH M^,;O6++0
M3-HD,LEQYT8E,,2R2I$6^=HT8@,P'0']:Y*'QG?KH=U%:ZLMYJ$FHVUC"U[8
MFWGM#,P7,T6%!Q\Q!  .*[K6]$M=>L5M;IIH_+E6:*:"0I)%(I^5E/8C^M9:
M^!M*:RU""\EO+V:_,;3W=Q-^^S'S&590 NT\C '- ',^-[7Q!9>%KZWNM9MM
M01KBP>UDFA6.5)/M2 AE0!2GW2#P>H]Z?K'BC7/!ESK4-[?+K AT@7]NTENL
M123S/+VD)U3)!]>#S70_\('IDD=Q]LNK^^N)VA+W5S,&D"Q2"1$&  %W#) '
M.>:T=0\,Z9JE_<7=["9C<6+6$L;-\C1%MQ&/7/?- '*:!KOB'_A(;&TN3JM_
M:74<GVF6[T=K1;:15W*5; !4X*X;)R1S65INN^,;G0_"6J2:[;E]>F6VDA-D
MFR$-&["12.2^(^A.W)Z8%=KIG@ZRT[4(+Z2^U*_FMHVBM?MMQY@@5A@[1@<D
M #)R<=ZEMO".F6NFZ)81^=Y.C2K+:Y?G<$9!N..>'- '%WWC#7M&M;_2Y+IK
MV^CUN+38;U+,/((Y(!,6\I.&<#< !@'CCK6_X0UC6;K5[ZPOTU&XLTA26WOK
MW3S:.6)(:,C 5L<$$ =3Z5I7G@W2;X:B9A.)+ZZCO&D24J\4T:*B/&1RI 4?
MKZU/HWANUT:[N;S[3>7M]<JJ275Y+O<HN=JC  4#). !R>: ,?4;C7M0\>S:
M+8:N-.LHM,BNF9+=))#(TDBX&X$;<*,\=AC&<UA6WB3Q-KUQX?TVUU*#3[BY
M&H17MPELL@+VTJH'16X&>>#Q\Q]!6WJ7A*ZU3X@S:L;J]L;8:7';1W-G<!'+
MB61F0@YXP5.2/H<UL6/A/2M-GTN6TB>/^S(98;==Y(Q*5+EL\L25!SGJ3ZT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1NW8&[IG%+CFBB@!" <9 ..1F@J&&& (/8TM% !BDP 20!D]32T4 %(% )(
M&>N.]+10 A4,,, 1[TM%% !2 !1@  >U+10 8S1110 A4$@D#(Z'TI:** $
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M:T* "BBB@ HHJB-:THRR1#4[+S(G"2)YZY1CT!&>#[4 7J*,C.,\U5N]2L;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7L 5U!SM< Y#*<$<9Y&#6IJ7C33M-O;FU^S:A=M9HKWDEI;&1+8$9&\COCG
MR<<XH Z2BH(KN&XL4O+=_/@DC$L;1\[U(R"/7(KC="^(4=UX;34=4L[J.YFO
MIK2WMX;<EYRLCA51<G)"K\Q. "#0!W-%9.B>(;/7?M*01W%O=6CA+BUNH_+E
MB)&5R/0CD$$@U5U3Q?9:7K7]CBSU"\U#[.+KR;2#S#Y99EW9R ,%>Y[C&<T
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M1MV[V'U).,D#D]JWM3\9:?IM_/9K;7][):QK+=&RMS*MNI&07/J1S@9..<4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD:XGG0+P5. @V]6P22.!BI-/TO7O"^IF^M=(.II>:;:6\T45Q'&\$T*LO\9
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M-A;[0!MWX!;^[V]ZZ_XD7UUIW@#5+BSF:"8B.+SD.#&KR*C,#V(5B<]L4P>
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MEW.P#C#<<CYSTQVH YA_%'BF'P]JWB=Y]/-CIE]<1_8A;G=-!%,R,3)N^5\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%4D.69N@(^5=H&-V&QG''1P^(]-:'4F>YV_V6H:\+(5V#RQ)NYZ@J<Y'OZ4
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MZ/PZ6\/6V@^&6T\1,UD\C&*?S$A*%<KEOF89?&>GZ5U%)@;LX&>F: %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KO86<D<\
M;VD#)<',ZM&")3@#YAWX '/I5:V\/Z+9W"7%KI%A!,GW9(K9%9>W! R*T:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M21P"%'S'.#CK6O=^']1?X9^+-/73Y#=WFIWDL4(7YI5:X+*WXK@_2O3** .
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M3VEQ:-*NXP7"@2)[, 2,_C5JBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-6^52QY8C.,GFK7CB_6Q\.$?:+V&2YN(;:+["5$TCNX 168@*6Y&[(P"3UH
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MK4M!T:\U34VEN[:2=$:WO Z7"@L@\S;Q(0H&?]H$UU] !1110 4444 %%%%
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M>B97MV^T",SMN5#NVX8=R.-QZ\8WY_"VMV5UJR:!J=E;66JOYLJW%NSO;R%
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MM)J"I<R;#B1HX=IW '/5@6QQ5R]\:ZHVHZS;:/H4-[#I,<<TL\M[Y0E1XA(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=N%P=W&&QCCK7KU<-X=\%:EI)\.)=WMI+'H8N(HS%&RF6.1 JYR3A@0<]NE
M"O\ $/[/I,KW>F"'58]2_LO[&;I?+,VT/GS2!A-AW;BN>V,UJ>&_%8UN_OM-
MN8+>"_LU21EMKH7$4D;Y 97 7NI!! (_&LC4?A_)>_;YQ<VIN7UD:K:B>#S(
MO]2L1CD7N" W(Z9![5K^&= O-*NKV\O1ID3W 1([;3K411Q*N<G=C<Q)/?@8
M&!0!#\2;JXL?ASKES:3RV\\=L2DL+E74Y'((Y%8&A_\ ".S:Q9+;7GC-KCS
MR"[:_$)(Y^?>-N.._%=?XNT27Q)X3U+1X9DADNX?+61P2%.0<D#Z52M8O'*W
M,(NKKPZUL'7S1%;3ARF>=I+X!QTS0!6C\<O)K@T#^R)!K8NC');>;\BVXY^T
M[]OW"",#&=QV^]4+SXFQVS7]W%86\NDV$[P3S-?JEPVP[7>.';\R@YZL"<'
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MVT.Y1H@N"P.T_-U';- '945Y-9W^OPZ#8ZW-XBO9YH==733"RQB*6 77D'>
MN2Y'.[/7%)XLU_4TA\1ZEI>I:[.^FO((GM(H8K*V,:C*/YAS*0<[B,]< #%
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M2* D8+(C,55B.K 9.3ZFNCK)M?%.@7VIG3;36M/GO02/(CN%9\CJ, \X[^E
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M['^T<X^R^>OF9ZXVYSGVIL_BG0+6^2RN-:T^*Z>3REA>Y0.7X^7&<YY''O0
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M-W&I^+]'GN+2U32M$#26LGFEY99&0* 01\H7DYR22%-=96;_ ,)#HO\ :?\
M9O\ :UE]N^;_ $?SU\SY1EOESG@<FH+3Q=X<OVN%M-=TV<V\;2S".Y0[$7JQ
MY^Z.YZ4 /M/#.D6-Q:SVUILDM6G>%O,8[3,VZ7J><GGGIVQ3SX>THV6IV9M
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M"7MS:_\ $Z@3,!7.2&^;YE/(QQVY.0: .OM[ZUNY[F""=));5Q'.JGF-BH8
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MSUSVXK>^&MG):VWB O?7-SG6KM,3%>"LC M\JCELY/;C@"@#N**** "BBB@
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ML;]NSS&V[NASCT[^M $%OX-T6"RU&U,,\XU*(P7<MS<R2RRQX(V[V8L  3@
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MCIQQ4-WK6E:?=16M[J=G;7$W^KBFG5'?Z G)JOXD\06?A?0+K5[W)A@7.P,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+O(.'*JIQQP,(*T* /+?$UXI\8ZW:NME8.;6*-'FTY[NXU%2I.V(;MH )*X
M/.2:N6=IJ5Y\ (;.Q67^T&T41+&,AR0F"H]\ BO1J* /*==O?#.J>'-0B\/:
M0\EU#H-W'YL$#1"U0Q\12# RQ(&%Y(VD\4S4;U4\036TRV6G-_9EM&LUQISW
MD]\I4DI"NX* I)! !))YKUFB@#QC1K>Y_L+PHKPS;X_#&HQ.&0Y5OW0"GT/&
M,>U:>G^';!7^&2G2H<):2--F ?>^S!LOQUW\\]^>M>J44 <EX#M_LB>(H5A\
MF(:Y<F- NT!3M/ ],DUPUEJ4(\'>%_#OEW!U6RUNV%W;^0^8 MSDLQQ@#D8.
M><_6O9J* /);_1;>;P9\2KA].22[DO;HQR-%ESMC0IM.,\')&.^:L74NF6&M
M^*!XFM&FDU*V@%B7MVE,\0A"F*,@'YA)N)7K\P->I44 >(6D-S8-X4O;^]BT
MZR'AJW@AGN]/-S&DW61",C8Q79R>H7':M'0M"@GU#P;'<6\UW8";4YXEN[(0
MJJMM*XC);:F22H/.,<"O7J* .+^(J6T&FZ'=3P VEGJ]M),1%O$<0)!) !^7
MI6-)H]G>-\2[J73XYI)E"Q2/#DLHLT(VDC^\3T[UZ;10!XMBXLM:2\UC48+"
M"YT2R2VFO=,-VK@(?-C!R-K;CDKU;(]*ZRRL9;3X(75I_ICL-)N1&MS!Y4H4
MJY12@9MN 0 ,YP!T/%=[10!Y/K^BKIWA[P7-:PPV.FVSI)?2?8?/1',&$DDC
M&"V&)^8]"0:HK:F:TU"]M+J6^@N-=TMO-AT_[-;NZS)O>,;B6XVAFP!E>IYK
MV:B@#P_5+9HIO%UAJ]^L-U?7TSQVW]CFYN+J)L>289-XR0, ?W2O..M;GB+3
MM4L=2&E6BW,B^*K2"TN;C;S%+'A99&P2 6@+=SRG6O5** /)?$$L,/B+7=-C
MAL=-"VD,$*OIKW=QJ">7PL7S;0H)*X /()-2^%M.2^U+P$U[:><+?PU)_KH\
MA) 8%YST.-P_.O5:* /'3!;Z99Z=-=6OEV%EXQNR?W!*PPD3 < <+N*^W(KJ
M/'QL8M?\(W.IVS36$%[,\I\HR+'^Y;:[  \!L'/;&>U=U10!XQK%G/J6G>(=
M0T6%T\/SZO93D+:ETEC0 3R+%P73=L)Q][8U5]5@&H:7XMO;'43J0;1/(DDL
MM+^S6[OORHSO)>11NZ#@-R>U>WT4 >=>(M$:T\2:7%X?LTM;A]#U&WC>! @#
M;8O+!(]&Y&?>N:\-6T5Q-X2LH[_-Y8RHTEG;:+Y4UL A$JSR,XPIR03SN)!
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M=)N+VR,[1MY@1.2"K$!E)7*GU'6KB^)[Z*SLX;70]0U6X6QBN+B6,QQH-R]
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M444 %%%% !1110!'Y$7G^?Y2>=MV>9M&[;UQGKBI*** "BBB@ HHHH ****
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M^9$/ QDX[#/&*;!X"T2WNH73[8;6"?[3#8-<L;:*7.0RQYQP22!T!Z 5T]%
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MIL NX(H+PWT,D5RXECF.<L'SGD,PYSUJ^?#&EMINK:>T+-;:K))+=*7/S-(
M&(/;H,8Z5L44 8<_A+2)_#UGHAADCM;+8;5HI622%D'RNKCD-UY[Y.>M1VW@
M[3K:SU"$3W[SZ@%%S>O=-]H8+]T!^J@<X QU/K7044  & !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME=2F(.C%2&1P#A@5Z$8()Z4 66\>V1LH&BT^]DU":]:P&G'RTE2=5+,K%F"
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M.T .Y),#(5LD9&>N:N^$_#$VG:[/J<FA:7I$9MO(CBMI6GE8E@6+.0 %X&%
M[9)[4 :-UXM6'Q4?#]MI-_=W*)%+-+"$$<4<A8;F+,.A7D 9],X-9>D^-4?1
M=%BL;75-:O[VU:Y"$1)*(E;!>0EE1>3@ 'FMFRT>YM_&VKZNYC^S7=I;0Q@'
MYMT9E+9&.GSC]:X:PL;KP/<Z AO-)_M5-(:TGM;VY:"*1%EW!XY=A&Y2QRI&
M2#GM0!I7OC^2[N/#MWIEGJ7DS:G<V5Q8^6@FE9(G^4@G PX!R2,8.:DUKQ]>
MIHQDT_2+R#4;?5K:QO+67RB\>]T. =^T[U8!2#U;G&,UG^"])U'5HM'UIGMW
MCAUS4;R21"0LJ2"1%:/(Y4DY&>W-:>L^$=7N9?$%S:?97ENM4L;^UCDE*AQ
M(MRL=IVDF,XX/:@#4\;>(-2T+P_9WEA92O/->VT+H#&2BO(H93N8#)SM!!(!
M(/3FEO/&GD7EU;6FA:G?O8QH]]]G\K_1RR[MGS.-[A3G"Y[>M2^+=*U+7/#$
M<5I% NH1W%M="&24A"T<J2%-X'^R0#C\*S4TWQ1I&HZO<:59:=<)K#)<LL]V
MR?9)_+5&SA#YB?*",8/7B@#HF\1:8OAD^(OM(.F?9OM7G 'F/&>G7/MUSQ7+
M-XMU*\\9>'[)],U'2K>ZANI7CN1&?/41@J?E9L,#U4X(R*T3X+4_#(>$!=G(
ML1;BXV_Q@9W8]-W./2JJ:;XIU7Q+HVH:K9Z;:0:?%.D@@N6E:5Y$"[AE!M7C
MH>>?:@!FE^.%;2M&M[&QU36;VYTY;X@F&.7RLXW/EE4L3GA<].U:ESXQC7^S
MH;+2=1O+^_MS<I9!%BDBC&,M)YC*$P2!UY/2N5/@;4H_#^@:?>:)I.L)8Z>M
MNRM<M;S03#J\<P4G:1@8X/&>:T+#PUXDT&31]3BE@UC4(-.:PO([BY:,NIDW
MJR2%225/R_,.1SUH U/^$YAF6RAL='U*ZU*Z21_L&Q(Y(5C;8YD+L%4!N <G
M/;-1M\0K#[-8M#INHS7=W=2V0LEC02Q3QJ69'RP4<#KG&#G.*JKH_BNSUBU\
M1D6&H:BUM):W=IYIA1(S)YD8C?:<[/NDL!NZU'IG@[58-8TS5;N2U^T'5;G4
MKV.)R5C\R Q*B$@;L +DD#N: &:WX^O$T"6?3])O(-1M=4M[&[M9O*+1;W0]
M=^TAE<!2">6!. ,U=NO&5MHUUKEQ>+J4@M9;*)[4)&WE-,J@!-IRW+?-R>>F
M:J:SX0U:Z'B.:T^RM+>:G97UJDDA4,(!#E6.#M),;8Z]J34/".KZC=:M=%;6
M)KZ]TRZ$?FEM@@*&09V\_=./7VH T7\?06D&KG4]'U&PN-,L_MSV\OELTL))
M 9"CE<Y4@@D8K8O?$-G8:II]C.'5KV":=9.-B+$%+;CGCAA^1K!\3>$+S7M4
MUF2.:&*"^T(Z<C,3E92[,"1C[O(JK)X>\1>(=7T^?6K6QL;2VL+JSD6WN6E=
MS,BJ7&44 ?+P.M &G8>.H+R;3WETG4;33]2<1V-].J".9B"5RH8LFX#Y=P&?
M;-=77F&@^ +RQN='@GT'0XAITJ/+J2RO(\X0?*4C(&QR0"220.<9KO='OKN^
M6]-W;+!Y-Y+#"5)(DC4X#\@=>0>V0<9H S4\:6#Z%!J8M[G=-?#3UM"%\T3^
M:8RI&<#!!8\_=&:K:CXZ733<W$NA:HVE6D_D3ZAMC5%;<%+!&<.R@G[P7UQF
MH(?!UU'\0GU4S1?V*':^CMLG<+UD$3-CIMV G_>8US&M_#[7]7L=6M9[+3[R
M_GN'EAU6[OI&Q&7W(BQ;2$(7"\<#KS0!UUWXZ2#5M5T^VT+5+TZ4";N:!8]B
M_NA*N-S@L2#C '4<]1G3C\3V,]QHD-N))CK$+7$#(!A8E0,7;G@?,HXSRPJ#
M2-+ETG6/$NI7CPI;7UQ'<(Q?[J+ B-NSP.5/X5S7PTTE5O\ 5M0CN$N=.M97
MT[29$.5%N)&D;!Z$;F"9'_/(4 =1J_B8:?JL>DV6F7>IZBT/VAH+8HOEQ9P&
M9G90,D$ 9R<&LR;XB6/V;3&LM,U&\NM1>:&*SCC594EB_P!8CAF 4CG/..#S
MTS/J>F:S8^+6\0:-;6MZ+FS2TN+6><PD%&9D=6VL/XV!!'H:SM'\&:E8ZOHV
MHW4UL\T=U?WE]Y9.T27 &%CR,D#IDXZ9H Z?4]:_LS2H;QM/O9YIF2..T@0-
M*7;HIYVC'<DX&.M8<OQ!M;&QU>;5-*O[*XTH0O<6S>7(Q25MJ,A1B&&0>^>#
MQ5SQKI.IZQI=K#IK!A'=I+<VWVAH/M,(!S'YB\KR0??&*X[_ (5[JIA\1""Q
MTS3X]4ALQ#;PSL^QHI2S;V*C<2#G/X=LD Z3_A/)CJ,NF#PKK/\ ::PBY2U)
MAR\!)&_=YFT<C&TG=DC@\XG'CJSN[32I-*L+W4;K4[<W,-K$$1TC& S2%V"J
M 2%Z\GIFKJZ/<CQ])K>8_LC:6MH!GYMXE9^F.F"*X>/X<7MK9>'YYM.T_59[
M&Q>RN;.:=HU(+[U>-PIY!R"".0?:@#IY/B#8BVL6BTW49KN[NY+(62(GFQSQ
MJ69'RP4=.N<8.<XYIR^/;-=-NYKG3K^"_MKQ+%M.*HTSSN 452&*D$,#G.,9
MSTK-TCP7?6-SH-R;;3;06NHW-Y<06A;:BR0-&J@D9=AE<L<?2EU+P=JD^J:K
MJ=J]M]H_M6UU*R21R%?RH5C9'('RY^?!&<<&@"WH'B'4=4\>ZK8W5I=V$5MI
M]N_V.XV';(SR98,A(8$!>0>W8YJ_J7BS[+JMQIUAH]_JL]I&LMW]D\L"$,"5
M'SLNYB!D*,G'U%5]"T[77\7ZAKNKVUI:QW%E#;0P03F5DV/(QW-M .=^>/IV
MK%UWP1</XJU/5X-$TW6$U%(SMN[EH6MY$39GA3N0@*>Q!!]: .@?QC'<PV+Z
M)I5]J_VRV^U(;<)&BQYQ\S2,H#9XV\G@\"H4\>65SIFF7%CI]]=7>I/+'!8*
MJ+*&B)$F\LP50I&"<]QC.:P)_!.JPRZ9"UC8:IIT&GK!]A%W):00W&XLT@0!
M@RG('.2,=.:-%\%Z[X<L=#N;:+3Y[[2Y+V-[593%%+#/)O&QMIVE<+P1C&1F
M@"UJGC6\_M3PV]KIVIH9KRYM;K33&@E=TA)"Y)VD X;<&QCG-=1X?\01Z]%=
M@V=Q97=E.;>YMKC;NC?:&'*D@@A@00>]8T6B^(;[6]"U75I+0-9W=S,\$3$B
M")X3&B*VT;R"<DD#J?05J:'H]SIVN>(KR<QF+4;R.>':<D*L,:'/'!RIH YC
M3_'5W8/XCDU#3M2O+#3M5GCEO8ECV6T(VX&"P9@HR3M!P#6[?>,XX+ZZMM.T
MF_U462+)>2VGE[8@R[@!N8%VVX;"YX(]:PI_#OBL6/B31H(---EK=W<.MXUP
MP>VBE&ULQ[?F.,D8(Y//2JE]\/)K/5]1GLM$TS5X;U(_)>]N7B>V=8UC^8!3
MO0[0W&#G(]Z .CG\=VTE];6>D:9?:M/=6":A#]F\M5,+$@$L[* >.AYY'OA5
M\>65UIVE3Z=87M[=ZF)#;V2*B2*(SB0N68*H4\$YZD8S3=!\+7.C^(;>[/V4
M6L.BQ6&(%*#S%D9FVKV7YN.:YMOAU>QV6BSRV5AJ<]@UXDUE-.R))'-,9%9'
M"G#+QU&#DB@"UXI\9WMYH5G'H]IJ=M=2ZM'IUZD9A6>V;()C!=MNY@1M897!
MSD4V]\5:AI.CRC3AJ=_/#KUOITQNO(WJ#Y6Y <@'<&P&_O,3P,&K%IX)OHM,
MLU6STRQE&N0ZC);VK,52),?*7(R[X'7 ';M3[_PCJ[:=K'V86LES+X@BU:VC
M>4JKHAB.UFVG:3Y;=CVH Z37_$D'AW3+:]NK.[E-Q/';I! JO)YC\ 8S@\\<
M&N;\2>,[E?"GB-(K6[T?6]/LQ<+'/Y;'8QPLBE2RL,@CV(JQ\0I+[^Q] >WC
M@6_.LV96.1R8]^[[I8#.,\9Q[XJCK/A/7O$MKX@O+R&SL[V]TU=.M+9)S(J*
M'+EG?:.23T X ]Z .@U7Q5-IUU<P6V@ZGJ(LXEEN98!&B(""<*79=[8&<+G\
MZK2>/+>6ZL[72M)U#4Y[S3X]2A6 1H/)<D LSLH!X''N,=\8^O\ @_5]5UW5
M9)[*RU.VNXT2R>\O)%CL@$VL#"%*O\V6SWS@D5H>$_"VHZ-J&F7%X8-MKX?M
M],<1N2?-C8DD<#Y<8YH Z+1-<M->T*#5[821V\JL2LR[60J2K!AV(((/TKE[
M#7Y[G1-%UF[N[R(:UJR&WBA52%A8,(XVS_"54,Q'.X\<5L^%M!N-*\(C2+YD
M\PR7)8Q-D;9)7<<XZX8?C7.:)I-YJ7@_PMIZ^6EUX>U***]1R1CR R''N048
M>H8&@#1A^(UM-'%=_P!BZHFEO>?8GOV6,1I+YGEC(W[BN[ W 8Y^M6[_ ,;1
MVMY?QVNCZEJ%MIK!+ZZM50I"V Q4 L&<@$$A0<9]>*S1X/U+_A7BZ%NM_M8U
M'[5G>=FS[9Y_7'79[=:E.D^*-&N];@T*.PD@U6Y:ZBN[B8JUI(ZJK93:1( 5
MW#D>A]: $M?%K6>OZZEZ\T]L-6L[&T1%'[OSH8B.N.-S$GOS6OJOC#3=&O-2
MM[Q9U^P6<5W(RJ&#B1V1449R6++C'N.:Y_4?!NLRR:S=6\MK+<R:I9:C:B5B
MHE,"1AE? ^7<4;H#U%0W_A'Q!XBN]:O;];&PEN[.UCM(XYFF$4D$S2KO.U<@
MG&<#H<<XY '7GB[4I/$YMKFRU/2+>/0[R[DAD$3,Q4Q[70JS+N +<$\'J.E:
M<?C81O9:99:5JFK7TFF07_R")28WR,LS,JALKR!U)X[XHWNA^*-?U:6]O[/3
M[*,:-=V$<4=TTK&679\Q.P?+\OU&/?C3\/\ AN^TO7H+VX:$Q)H=KIYV,2?-
MC9RW;I\PP: '#QW9W.G:3/IEA>W]SJJ.]O9QA$D54X<N68*H4X!YZD 9K0\-
M^)(/$L%[)#9W=H]E=-:3172JKK(JJQZ$C'S@9SSCCC!KAH].N?!C>&)'N]-7
M58HKVW-O=SM%#<1/*)#MFV$*Z_(<$<C=Z5M_#.6YN[/Q#?W+V\AN]:FD22V)
M:)U$<:?(QQN4%2N[OMS0!W%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2,P52S$!0,DGH*6N.^*B3/\
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M>:?I_P!J9)E8* 8^2J$!B2 >>.*T;+Q'JWB&YT;2M-UJS1IK"2]NM2MK?<)
ML@C"HC_=.2=VX'&,4 >@T5YM/XJ\1"Q33X[FU&J0^(4TB6[,&4DC:/>)-F>&
MPRY /4>AJ>3Q#K6C_P#"3Z??:U9/+IR6DMOJ%W;[ HG+ ADC^\PV': .20*
M._FFBMX))YY4BBC4L\CL%50.I)/04Y65U#*0RD9!!R"*\@U3Q)J-UIGBO1[B
M]N[VS;PY<7<4UYIILY PRA 4A=RG=U([=:Z;3KS7]"U/PU:ZEJ4-];:LC0-$
MEN(_LTBQ&0;"#EEPI!W9/0Y[4 =M;W$%W D]M-'-"XRDD;!E8>Q'!J2O&/#W
MB>_M/#?A70K&2[MD;2VO)[BSTYKR7'F%%55 (49R2Q![#O7HW@S5=3U;1I7U
M6UGAN(+F2 236KVYN$&"LGEMRN01D=,@T =#17E]_P"(O%,>C>)=?AU6WC@T
M74)XHK/[(K">.-AD.^<@X.!C'3)SFM@W_B+7]2UYM)U2#3K?29_LT,3VRR>?
M((UD8R$G(7YP!MP>"<T =LSHGWF5>"W)QP.IIL,\5S!'/!*DL,BADD1@RL#T
M((ZBO+](U2]U_P 8V6O"X\F*Y\+BY:T,2LHR^"F3SC=SG\*M^'M9UKQ!!HFE
M:?>P:4JZ%;7]Q+#:(Q9I,JJ(A^55&QB<#T Q0!Z0Z+(C(ZAE88*D9!'I3888
MK>%(88TBB085$4*%'H *\WU+Q3X@AUBST&>Y>&YBL!<WEWI&FO>^8YD9%"KM
M.P80DY!Y. >,UUO@_5-1U?0%GU6TEM[M)9(F\RW>#S55B%D"-RH88.#T.: -
MT,&) (.#@X/0TM>2Z)?ZUI-I>6=MJ*27>J>*+BQCGFMQM@P7:23 QN)"<*>
M<5V&B:CJMIXMO/#FJ7B:AMLX[ZWNA"(GVEV1D<+P<%000!P?:@#IY)HH59I9
M$154NQ9@ %'4GV%+'(DT22Q.KQNH974Y# ]"#W%>:>*(+L^/-:D%\1 /"\K&
M'REP5RXVYZ_>^;/X=*?X?O\ 7M$M_!8O-3BNK'5+<0O:K;!/(VVQD0HP.2?D
MP<]<Y&* /2JAN[RUL+9KF\N8;>!,;I9G"*N3@9)XZUY9I/CKQ'J-MI^LPQ:E
M<)=SH6TV/19?)2!GQE9]O+*IW;B=IP1BND^*X8_#^Z"Q+*WVJTQ&QP'/VB/@
MGT- '16WB30KVX2WM=:TZ>=SA(HKI&9OH <FM.N1T6VU :K";GP1I.FQ#)^U
M0722.AP<8 B4\].O>LO2/$^NWOC5_"4US:^?ILKSW=XH7-S!P8T5/X7^<!_3
M:,?>% 'H5%>26_CSQ%?6O]MV<6I3JUR1'I<.B2O$\ DV']^%^_M!;(.W/&*Z
M*._\3:]<ZW=Z5JEI8PZ;>O:6]K/;ADF,84LTK_>4$D@;<8 SS0!W-,EFBA1W
MEE2-$4NS.P 51U)]![UQ_P#PD>H_8O'$I>,/I!;[+A00N+5).?[WS,>M<S+<
MZD_B'6-7DO4DSX0BNFMWMU9&)64[3GMN!;WSCI0!ZO'(DL:R1NKHX#*RG((/
M0@TZO/4\976A6\[ZB(FMVT*'4=/2.,("X4))$,?[;1X'^WCM5*Y\4>(1JW]B
M37EY;W%A8V\EW/8:.UX9;B0$D$*"$08^IYYXH ]/HK&\*ZE?ZOX9LKW5+*2S
MOG5EFADB:,AE8KNVMR V-P![$5LT %%%% !1110 UXXY-OF(K[6#+N&<$="/
M>G444 %%%% !3%BC1W=(U5I""[ 8+'&.?7@ 4^B@ HHHH **** "BBB@"&YM
M+:]A\FZMXIXLYV2H&7/T-21QI#&L<2*B*,*JC  ] *=10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>W]T%66[O) TA1<[5& %51DG  Y/-;-% &%JWA2RU?51J,MQ=PS&TDLI%AD
M66)\_*P(.<$DC&.:E_X1NQV:&N9L:,0;7YASB(Q?-QS\K'TYK8HH Y2'P!ID
M$L*)>:C_ &=!<?:8M,,X^S(X;<,#&[ ;D*6VY[5K^(="M?$FC2Z7>23QPR,C
M[X'"NI1PZD$@]U%:E% '-V7A%[.\BN/^$E\03^6V?*GNU9&]B-O(HM_!&DVL
M>G^2URMS973W:W?F#SI)'SYF]L?,&S@C'0#I@5TE% '*-X TLRN@O-1337N/
MM+:8LX%L9-V\\8W %OFVAMN>U2:AX%TW4;J]D-WJ%O;:@P:^L[><+#<G !+#
M!(R  =I7('-=/10!RNI> =,U&ZOY?MFHVL&H(J7EK:SA(I\)L!(QD?* ." 0
M.0:EN/!&FW%PDHN+V+_B6G2Y$CE 6:#:P&X$<D;B01CFNEHH P+_ ,':1J<.
MBQ74<CKH\D<EL=_78!@-QR,JI(]5%&J^%+;4M4.IP7^H:;>M"()9K&4(98P2
M0&#*P.,G!QD9ZUOT4 9%GX=M-.M=,M;*:[M[?3R2D23'$N00?,S]_DEN>_-:
M]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !117"^,/%#67B2ST1=7?28FM6NYI
MX+83SR?-M2.-"K>CL3M/"]NM '=45A^$;Z?4?#D%S<:E:ZD69PEW;+M$J!B%
M++@;7QPP[$&MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X?7O!.H7FI_;[#7+M'FU"WN)8V2$B-(^FTE"?E&2%)QDGU-;]_IMQ<>
M*-&U",+Y%I'<+*2><N$"X'?[IK9HH XBXT/6]2UZSNKC3]-M;JTED\S4XFS]
MI@*N$B*?>(.Y2RL< J<9XQ'8>&-0NM1L)9]/M=!6RLI+5Y-+E ,S/L^YA?E0
M;21NYR1QU)[NB@#G=8T&YG\*II=M<S74J7-O+YMW)EV5+A)&RV.RJ0..PK%\
M7>$[S7+[4([>Q3R]0MEMVNDO9(@O4$S1 XE*@Y7CGH<"N\HH X1_ E]:Z[I=
MW8ZY=M!%J3WDZ2I"2H,+H,'9D\%4P3PO3D TO_"-ZC=ZC812:5IVGK9W\EVV
MHV)"-*K!P JXW!FWC=DXX/7(QW5% '+:GX9N9M!72(KZZO8;B]A>[>]F#-Y
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>guyaragreement008.jpg
<TEXT>
begin 644 guyaragreement008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNVHH S/#NAVWAKP]8Z-:-(\%I$(U:0Y9NY)^I)K3HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB\S!],=.] '045Q4_C+4&T31;^&WTNSCU"P2[DN=3OA##&S*I\M>-S-\W7
M _"LW3O%$GB;6/!.HH! )Y=0BFCAFWQLT:,N0W&Y<KD''>@#T>BN>\3Z]?:/
M/I%KIUA%>7.I71ME664QJF(W?<2 >!MYXZ5DMXWO;*:;3]1TZ!=2M]1L[240
MS%HGCN&PLBD@'CYLJ1U7K0!V]%>>?$7Q!<)I?B71X(V1[;28;Q)XW(<L\K)M
M'I]SKGO6JGB+6(-4BTK7-.M;5M0M9IK22UN&DVL@!:-\J/F 8'(X.#0!UU%>
M3Z%XKAT/0M&O;RWGN9HO"R7)D\]B9"9$4)M/&2S#YCS7=:1?>(WU$6VM:3:P
MPR0F5+BSN3(J," 8W#*ISSD$<'!Z4 ;U%<+K=WK47Q0L[?1X8)GDT:4LMU.T
M<28F3YR%!)/88'?K3X/'5Y>:7ID=KI<1UN_O)[+[,\Y$,3P%A*Y<+DJ-N1@9
M.0* .WHKS77?$>H7,:Z5?P)9ZG8:SIGFFUF+1S12SC:RD@'!VL"I';OFKD'B
MF2UGO;'2].634KO7I[.%)[EO+)2,.\K$@E5"C[JCKC'6@#OJ*\XTO6==L]:\
M93W6GQ27L#6:I;K>8MP"A!DWL!M3'S'C/!'-/C^(MZ!K<"V^E:C=:99+?!M+
MO3+&\>XAT)VY5P 2!SG(Z4 >B45R.J^-Q9RW!T^R.H06VD'5)6B;DAC^Z0<'
M[P#G/8+T-/\ "7B>\\032>8-(N+7RA(MUIE]YRJQ./+=2 P;OG&/H: .KHKE
M=<U:/3O%MHOV9I)ETF\N%?SF4 (8LJ5Z'.1R>1CCJ:H:5XSUJXE\.W&I:1:6
M^G:\ MN8KEGEB8Q&1=X*@8(4]#QQ0!W-%<-\4Y!'H.E*ZW4D,FL6J316K,))
M4+'<B[2"21Q@&H_#%IH$6K^=I_A_Q%8W$43L)=0^TB+&,$?.Y7//I0!WM%<!
MI/CK6KRS\/:K?:-9P:7K4L=NGEW3/-&[J2K$%0I4E3WS@@^U-N?'FMKH<GB.
MUT6TET0W(@B+73"=E\WRO-*[<;2>V<XP?:@#T&BN"M]7O]/U;QI-;0K=O'J5
MO'&L]P(HH5:WBRS,<[5&23@$GTYJL/B9+#I_B)Y8=,O9]'MXKD/IMYYL,JNQ
M7:3C*L"O3GJ* /1J*XY/%NIZ;K#6?B/3K2UB?3YM0BDM+AI2BQ;=Z."J_, P
M.1QUK%O-:\1:C>^#+N\T^WLK"^U))8_(NF>15,,A5)1M )(.>"0"N/0T >ET
M5Q_Q OM7L;313I#Q(\VK6T4F^5DW N,*2H/RD\'V]:@N/&&MR1:OJ&FZ/:3Z
M9I$LD,_F7+)-.T0_>^6-I& <@;CR1VH [>L[3-"TW1Y;N6PMA%+>2>;.Y=G9
MV]RQ)P,G Z#/ JMJM]'>^";W4+1V\N?3GGB<<'#1E@?;J*YCPWXEUK3])\++
MK>GV\=AJ4,-M#/'<L\J2>5N4R@J!\X4]"<$@'/6@#T&BO,[;XLP3BVU MH_]
MEW%RL"P+J(-\B,^Q9&BQC&<$J#D Y[8KH/B3>ZEIW@6_N=+D6*X4Q@R>84*J
M74':0#SSCZ$T =%8:=::9 \%E"(8WE>9E!)R[L68\^I)-6JXO7O%>L:,^R6'
M0K/RK=9'EU#4?*2>0YRD0VY(&/O,!U'%8%_\0+.VUKPWXAN?-BM[_0YI(K,/
MDR3/)!M0= 3R1DXP,G@9H ]3HKA]9\;W6CSZ9I=TNCV>K7=NUS,;V^\JW@0$
M# <C+L2<  #H3T%5K;XC7.I6VF1Z7I]G<W]WJ$VG2!;S,"21QF3>L@4[D*X;
MIG!QC- 'H-%<_P"&==O-5FU2QU.TAM]0TRX$$WV>0O&X9%=64D \ANA':L[Q
M1XLU'1+R=(H]&MK>"$2+-JFH"$W+'.5C4 GC&,GN>!WH [&BO/M*\2:MKGCG
M0KBV6./2K[03>FW>=LKN>/)P%P6!( ]B>G0Z'C6^UFTUCPK%I;0B.XU(QS+)
M,R>9^YD8*< Y7@GZA>.X .QJ*XMX[JVEMY@3%*A1P&*D@C!Y'(^HK@;;Q7<V
MB0VVE:4DMQ?Z]?606>[?:K(TC&0L02!\A.T#@<"F3>//$5MINKWTVAZ?Y6AW
M!@U K>-F7&UB81L[*ZGYL<\4 =UI6E6.BZ?'8:=;K!;1Y*H"3R3DDDY)))))
M)R:N5P>N?$+[%X@O]*LI-%B?3T1ICJFHBV,KLNX)&,'^$C+'C) ]:K7'Q-^T
M/I@TV/3K=+^P6]CDU:Z,"RDL5\E"%(+@CGGN.#0!Z+156TNWETN&\NH/LKM"
M))8BX?RCC)&Y>#CU'6N9T;Q/KVJPZ?JW]B6XT2_.49+DFXAB()65U*A<' R
M21N'7F@#L**X.+QSJITFU\23:1;)X<NID16%PQN8XW<(DK+MVX)()4'(![]*
MBO/'FMV]EK.K1Z-9MI.CWTMM<%[IA-*J.%+(NS' (/)YY'N0#T&BN3OO&G]F
M1>)A=V@%QHX1X8U?/VE)%_=8XX+/N3OR*R]4^(<UIJ]SI<9T*WNK"&)KM=1U
M(0>9*Z!_+BX.< CYCQDCCK0!Z!17"6WCG4=>O;"V\.:;:R"\TM-1$M[.T:Q
MN4*$*K$G(QQ[^G++3Q?!J=SX9U&[L6MY)HM0,N+ABL!@PL@P,!P2IP2./QH
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M-P+C"DJ#\I/!]O6@#KZ*\O@U_P 1:3<^-KZUL+6[LM.OFGG\^[96*K;Q,R1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC2BK645M<F-(F%JDA) ^\"?X3D=>.:]$OM.M-3@2&]@6:-)4E56[.C!E/X$
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M7\6H1W5A%*FH;/M0;/[W8 %S],#&/2D7PUHPMKFW.G0O#=0QV\Z2 N)(XQA
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MYO<V6K:CK&JW2C7]1BF\,WMK'<WU@(-TS%"(TC"(1TXW#DYP3BNI?2KE+_P
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M:S#,<L;95AG'\P17#^&/#]QIGB7P]YEC=)!:>'G@W7#"4PN98R(RZ@*6"Y'
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MIQO]+-U-;V]A?:6;P2$L6\T.JF-1C+8RW09^7/2NDD\3Z'%HD6LMJEM_9TQ
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MLE_';M*D#L>N#MW$?=R1@9QGM3(_&NDVVB:5>:O>PVMQ?6<=UY*AF(#*"2%
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M\]F9+N,./]4&SC:.@/8=L\UW^G:E::M9B[L9A- 7= X!'S(Q5ASZ,I'X5:H
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MY5LEN.<@^U%QX OC_8TWVC2[^:Q682P7MD!;LTC!MZ(G"E<;1G)QWSS7H%%
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M&QJMU<^(7FQ]K$1W&&0,EPQ(X5=C-@9X(0>]>DP016MO%;PH$BB0(B#HJ@8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M V[2).>F,<5S:_"V_ET#2K2ZU2&2^CO6?49PIQ<6[A5>,<=2D<0Y]#7I?VF
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MLV.@3H\9A$GF7"I&T:EL\*0&Z#.<]1C!EL/!FK6US8QRW-DUI8ZW-J4+)O\
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MF%;KR]CC;EOE)&<\8&.G.T&U7Q!>>)KL>)+C1TTF[:UMD01^3&$C1S),&'S
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MWS[6@P0$=<X<<G[P/7-0Z;X)T'2;V&ZM;:8O;JR6RS74LJ6ZL,$1H[%4R..
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M;#8!(\U5&3C*G/>N_P!8>_32YCIEG;W=V1M2&XE,:-G@Y8*>@YQCGI65X?\
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MS++N:4S%@"IY)?/*G'/2M;4]#BG\#^-6?3@]S/K[,&,6791/%@@XSC&>GJ:
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M 6-TLRF( =3NSBO+M4T34=-T;PE>WDI@ NY[[59C:&Y6&YF4LKO'W"EB@/\
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MS8XZCG)Q5#0/$NK_ /"'^'/)TJZU6\N-+BN9[F6411#Y1G=(V<N2<X'/<XH
M[JBN4TCQU:ZJVB_Z'- NJ&XB5G92(YX20T9QP<[7((/.VM?1-:CUR*\G@A9(
M(+N6VCD)R)O+.UF'MN##_@- &I1110 4444 %17,)N+6: 2R0F1"GF1'#ID8
MRI[$=JEHH SM$T6VT'3A9VSS2 R-+)-.^^261CEG9NY)J+6_#]MKYM4O+BZ%
MO!()'MHI-L<Y!! D&,L 5!QD>^:UJ* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AI&CVVB6DEM:&0QR7$M
MP=[9.Z1R[?AEC5^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH H66CVUAJ>I:A"9/.U%TDFW-D91 @P.W %7Z** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS(0#@\9P37&&>UTRTMK&6UTZ"TC\1:D+>ZU)6-G9!6;:"@*J2=Q"Y( P<<T
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M\F"$!7E5Y0IV@8+#C'?I69K:66JV%XVF0Q7%JW@N?RA#'E=ZR#H,=0P/OD4
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M%6DPA^12.03T&.:\AT>XMY?$G@J33[C1"$DDC\K2K)E%L&MGPDLQ8DL3CY2
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M#(C/.3)CG:!QQGD@4Z'QHL8EDUC1=1TBW6T>\2:Y".IC3!8'8S;7P0=IY]*
M.IHKF-.\8_:M0LK6_P!%O],&H*S64ER8R)L+N*D*Q*-MR<-Z'N,53TOXB0:C
M;:;?OHNHVNE:C*L$%[-Y>WS&.%#*&+ %OE#8QGV(- '9T5RG@C7]3UY-9;4K
M*6W^S:E-!$7,>-JL1L^0GE<<D\'/!-%_XW6VN=1%IHNH:A9Z6VR^NK?R]L3!
M0S*H9@SE002%''N>* .KHKEKOQM&-4AT[2=*O-6N)[!-0B-NT:(868@$L[ #
MIT[Y'OC5T75[?Q+X?@U*S\Z&*Y1L!P%DC8$JP(Y&001W'% &I17FKZ/JR_$"
M+01XQ\0?97TM[PMYD._>)40#/E8QACVKH;GQ2^GW<^EV&EZEK4NFPH;V:)H@
M4RN0#N9=[E?FPH[CU H ZFBN2/CVVN-2L+'2=,O=4:]LX[]'@V*JP.Q7<Q=A
M@@CIUY^N*DGQ+MXXFNSH6JMIT=Z]@]TJQD><'* *F[<P+ #(&/F ]< '<45P
M^H^-%?2-9BO+/4]'O-.-LTJ(T3R;)9 $92"RD'!!].:GU'Q^ME<ZPD&@ZE>0
MZ,^+Z>(QA8UV*^Y=S@MP>@&>/<9 .QHKG;WQ3,DZQ:5H=_JG^CI<M)$4BC"-
MG: TC+N8X)P,X[XK'@\;76J^*?#,>F65P^D:I8373,WEJ00T8R<MD;-QR!UW
M#&<' !W5%<1I?C.,:)H\5G;ZEJ^H7ZS211.8UEV(Y#/(V0BJ"0!ZY'O4\GQ"
MLTL[9QI>H/>S7[::UBJIYL5P$+[6^;;@@## XPP.<9P =A16)H'B(:W)?VTM
MA<6%]82K'<6TY5BNY0RD,I(((/KZU>U2PDU*Q:VBO[NQ9B#Y]H5$@P>@W*1S
M]* +M%>>>#]/U2^U;6'N_%6M3)I>K-;1Q,\6R5%1&P^(\G)8@X(XJ+PQX\O(
M]"M)M6TW4)K9]0ELY-4/E^6':X9(QMW;BHRJEL=?6@#TBBN5O_&Z6MSJ(M=&
MO[^STMMM_=V_E[8F"AF"AF#.5!!.T<>YXK=FU2VBT9]54O/:B#[0I@0NTB;=
MPVJ.22.@H NT5S6G^+9)]:M=+U'0[[3)KR%YK5IWB<2!,%@=C':P# X/YUD6
MWQ.BNK33+U/#NK_8M4;R;*;$699L$A-N_(SM8;C@<9SCF@#O**Y)?'MJFG7<
MMWIM[;W]M>I8'3OD>629P&14(;:058'.0  <]*;/X^@T^TU1M5TJ]L;S3K=;
MJ2T<QNTD3-M#HRL5(SP>1@T =?16+JWB6UTC48[*:&9W>RN+T,F,;(=NX<GJ
M=XQ67IGCM-0N]+231-1M+;5D+6%S,8]LQ"%\$!B5RH)&X#.* .NHKE? >O:E
MX@TF\N-3M)()([ZXA0L8\%5E90HV$\J %)/4\C/6H[WQY%;/J$\.CZA=:7IL
MK17M_#LV1LOW\*6#.$_B('&#C.* .NIDR-+!)&LC1LRE0Z8RI(ZC/&17#6.J
MZEK'Q2N;?.H1Z58V<,L0AFB$$GF>9^\<9+,&VC:!TQR!WV=7\6'3]:.D66DW
M>I7D=L+N6.!XTV1DE1C>PW$E3P/3MD4 7M!T*'0;*6%+B>ZFGF:>XN;@@R32
M-@%C@ =      !4FLZ-;ZY:0V]R\J)#<PW*F,@$M&X=0<@\949JO9>([>^UB
M+3$MKF*:33TU#]]'L*HS%=K*>0P(Y&*S%\=VUQ9:>]AIMY=WFH2SQV]FA16(
MA<I([,S!54$#G/\ $.* .LIKH7C9%8H2" R]1[BN U/QG??VOX::UTS4T:>Y
MN[:YTPHBR/(D? W$[2H/S;@V,?E74^'O$":]!=YLY[*ZLK@VUS;3E2T;@!NJ
MD@@A@00>] #M!T&+0K:=1=7%Y<W,QGN;JY*F25R ,G:   %     %:U<A=^/
M!!=ZO'!H.I74&CR;+VXB\L*@V!\J"P+X!R0!GCW&;MYXID$T46D:+?:MYELM
MUYL!2.(1MG;AY& +'&<#/'7% '145SFD>--/UFYTN*"&XC74[-[NW>50 =C!
M7C//WQD'TQWJD_Q MG&GBRTJ_O)-2FN8;-(M@\WR3@OEF "GD@GL/< @'845
MP\?Q(B>V-U)H&J16D%V+*^G?RL6LV\1[2-^7 )7+*",$>X%Z_P#&RVMUJ*VF
MC7]_::6=M_=6_EA8F"AF50S!G*J02%'&>YXH ZJBN2N/'*-J,UCI&C7^K216
ML5X7MC&J&*0$J0789)QP.IJI:^-+K5?%_A^'3;.>31]2TR2\WGRU.=T8#'+9
M&W<00.I88SC@ [BBL/5M22T\2Z%:M-=(;G[1B.+;Y<FR/<=^>>.V._6L?2_B
M)#J2Z1<MHFI6VFZM(L-M>3>7M,I!(4J&+ '! ;&"1Z$&@#M**YOQGJ%WIUEI
M3VDS1-+J]G!(5_BC>4!E_$'%4+7QA!;6TD<4>HZG?7&K7=I;6I\L.S1NVX Y
M"B-0."QSC'4T =G17+1^.;3RPES87=M>IJ,&G3VDFPO%)*1L;()!0@@Y!/Y\
M5KPZU!-XCNM$6.03VUM%<LYQM*NSJ .^?D/YB@#2HKF=5\7FQUBYTRRT>]U.
MXM(%N+H6S1@HC9QM5V!=OE/"CT[G%9=]XHU*W\>PVECIU_?PSZ,EREDFR(HQ
ME(+.9"NTXP,=<]NM '=45R\7C1+[2--O=+T?4;V:_,BI;JJH8C&2'$C,P5<$
M$=3D],UF7?B^;4ET1[2.YT^8>(%TZ_MI=I8$1NS(2I((/RG(- '=T5S?@C4+
MO4M#N)[R9II5U&\B#-V1)W51^  %<YX:\>7<.A)<ZQI^H2V:W\UM+JI\ORT)
MN&1/EW;B@!52P& ?H: /1Z*Y74/&RVMUJ*6FC7^H6NF';?W5OY86([0Q50S
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M[92B&ZM9]N^-BH8'*D@J0000>: ->BBB@ HHHH **** "BBB@ HHHH ****
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MB@C< ".I!]:].HH YC0/#<^C:_J%T3!]EFL+.UA6(;<&$2!OEZ*/F& ":QM
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M! XKG=4\(:[X@MM>O;U;*VU#4+:WM+:VCF9TBCCD,A+OM&6)8]%P,#K7H=%
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M'2997+-+OR79FZEB23FJNE^$+33=1@OY+[4;^XMHFAMFO9_,\A&QN"X Y.T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP#P#P.3C@&JK^-);GQ9X?M-/M)Y]*U/3I+SST1.1F/:W+ @*&.X8S\RXSS@
M[2BO/M$\9WMWK'A>QBBO;VRU#2WNI+N6&)'=@R .P#84#<<@#^(8SSB7P[XV
ME;PIH)NX+S5M:U"!Y?(M(T#LJM@NV2J*HRHY(R3QF@#O**Y23X@:6EI8RQVF
MH33W=S)9K:1PCSDG0$M&X+  \=<X[YQS50_$S3TMKBXDT;68XK*;R-0=H$Q9
M-D#YSO\ FZ@_)NX(- ';45SFI>,(+'4KFPMM+U+4I;2-9+LV4:,+<,,C=N9<
ML1SM7)QVJ"?Q[IYN[6UTVQU#5IKJQ6_A6RC4AH6)&[+LH'(Z''4=Z .JHKAF
M\>/>ZSX572K&ZFT_5O/,K&- ZE,J5.6&"C ENO XSTKN: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P+W2;J?QSI&
MK($^RVMG<PR$MSND:(K@?\ :L+Q%IGBS6=+U;P[-9V-U:WTC+!J3RA1;PL<C
M='C)=.Q!Y(!)%=Y10!S^J:+)X@L+W0=126/3#'"([J&X_>S$'+!AC@95?7.3
M63HW@N[TKQ[<:PVJZC<VAL8H4-Q<AR[AI,JPVC*@,"/<FNVHH *P?&NDW6N^
M"]7TJR"&YNK9HHP[8&X^IK>H)P,GI0!SMAHUW;^-KS59 GV673+:U4AN=Z/*
M6X],.*B\1Z7J9U_2-?TJ"*[FL4F@EM))?+,D<NW)5B" P*+UX(SR*Z19HFF>
M%9$,J %D##*@]"1VS@_E3Z //#X2UJ^OSK%W%;PW=UK=I>R6R2[A#!"FP#=@
M;G[G''/M726.D75OXXUC5G"?9;NSM88B&YW1F4MD?\#6M^JEYJNG:<Z)>W]K
M;-)]P3S*A;Z9/- &7XWTBZU[P5J^E600W5U;F.,.VT9]S5/QOX9G\1:+81V\
M<4T]A=QW:V\LC1K/M#*R%UY7(8X/J!75@@@$'(/0BB@#RZ;P-?WFDZU]GT.R
MTR6ZB@AMXC=O/*P64.Y=R2H7CA0/7GG%=E?Z1=7'C?1=6C"?9;2TNHI26YW2
M&+;@=_N-6_10!P3>$M4/A*?30L7VA]?.H ;^/*^V";KZ[.WK26OA+5(M?MKQ
MUA\F/Q#=:BWS\^3) T:_CN(XKOJ* .!UGPUX@DN/$UQILHC_ +0O+.5%CN#"
M\T,<:++&'',9.T@&LR'P+J<MYKLL6F6^FP:CH4NGQ(]ZUQ()6)PTC'/7/8G
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M;N%U\R&24DN!E2I0YQM8'BM/1-"CT5+D_;+N]N;J3S9[FZ<%W;  X4!5
M  H \\BMI)_'OC IX,LM> O(!YUQ)"IC_P!'C^4;P3[\5T&M:S=^#?"]AK2Z
M3:Z=IUM(1J.F0[,JCMM#1LN%+!B#CN">]7;GP,DFM:AJ=IXAUO3Y+^19)X[2
M6((65 @(#1D]%'>K*>$8)'TUM0U/4=2&GRM/&MXZ$/(1@,X5!DKSM],YY.*
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M#DDC:B[%/&3G].BT'28]"T"QTN)BRVL*QESU=L?,Q]R<D_6@#1HHHH ****
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MJZ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF79C(/S%F/RL,9%1#0[,?#"XUA?.74KO5!;R70F8.L?]HA0JG/R@;1T[Y]:
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M&)09)" <G'I4.EV\\FF^+ETHVGFZ)?VVH6=OITK/;JZ1AI$0GLP#J1@#)/%
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M21VL>G_:WNFA?:IR<DO]T(%!Y]>,YXJ?3/&VC:K>V]K";N)KM2UH]S:21)=
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MV?R/LT/D[MWE[!MW9W9QTSGGZURFM>/K:QBTF:P@GNXKS5'L)62VD<IL+A\
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MT/I7=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5O-0'B08/ /H>?6K5("#G!!QP: %HHHH **** "BBB@ HHHH **** "BBB@
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M&\?EOY0RAW,VX>C<=^*V$^'VF&TM+2YFFGM[?1FT<HV!OC.SYLCHWR#I38O
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M&-WU#9XK''PWQI$>C#7[U=*@N!<6]LL48*L)/, =L9< _3WSB@#GW_Y"$_\
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MQJN<!8UX!))R>2: .9UW6/$&LP>*8=(&GQV&EH]K(EQ&[27,GDAW"L& 0 .
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M*G!P1DX(ZUF6OP^^P6=E'9ZY=Q7.G2RM87'E1DQ12??B88PZD\Y/.0.>*W-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M90%X/0$D52BN_-\+Z#I5U-'K'VK4;E+1%U"2*T>./=A)9G3=(J=!@'=M'7%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHSSCO10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D7QKM]>.G078
MU..'1H[JW5;2)#YDTA?EG;^Z.P'U/05?^*_B:46D_A72KV*VO9[.6ZO+AG"^
M1;JI.T<_?<C: .<$GWKK?&7A6/QAH::9)=M:JMQ'/YBIN/R'.,9'6HO$?@+P
M[XG%S+?Z9;/?30&%;MX]SQ\$*1],YH K_"^=+CX:: 4E60K:(KD-G#8Y!]ZZ
MZN/T;P+_ ,(]HVBZ;I&JR6<5C.)KLQ0@?;C@ AQGC.!784 %%%! (((R#0!\
MVZMHKZ//J=QXPT777O&NVEA\4Z;<-*(DW?+\@8*H'3!Y&>G KT"?Q'IUE\0-
M.OG'VV.+PJU]_:(=@TD2DL?DSMYQGIGG%/?X1W<-E=Z-IGC"_LO#ET[-)IHM
MT<JK'+(LAY53Z8^N>:W3\.=,_MRTO!*_V*WT8Z,+,KD-$<\ELYS@XZ4 4O"W
MBCQIKCZ7J5SX?T\:%J:EU:WN3Y]JG\+2!L!L\<+S_*N'^%/C:Z<V7A'2XX9K
MQKNYN+R>[<A8H0_1!G+N?3H/SQW&@_#>]T:]TU9O%NHW6DZ6S-96'EK%MST$
MCKS(!Z'C\.*@L?A+:Z98:8MEJCPZEIVH/>Q7RVXW,'^]&PSRI  Z]J *6I_$
M/Q2+KQ:NE:3I;VWAQ]TTMS*X:2/:6(51_%@$Y) Z=<T[6_BM)"/#UMIRZ7:7
M6JZ<FHO-J]P8X($8<+D<LQ((_#\N@'@&(1^,%_M!_P#BI00_[H?N,HR<<_-]
M[/:J5S\-"(M!GTO6Y+#5-(L5L%NS;)*LT0&,-&QQUR1SQGZ4 <_=?&6<^$])
MU.WL[.WEN[R6SNKFX:22UMGC .<Q@LP;(*_CZ9J]>?$[4K'X?)KS6VE7$[7X
MLS<6EPTUK&A_Y;/M!=1_LD;N1ZXK:F\!WYT+3[*V\6:DEY:N[R7,ZK,ESNZB
M2(_*RCL.WZU4T_X7G2]!N[2Q\0WEKJ-U>B]EO+:)(HV8<;#"/E,?^SW^G% &
MEX"\5W?BFTO'NI=(G\B11'/IEP71P1GYD;YT(_VNM=?7(>#O D?A;4=3U2:^
M%YJ&H[!*\=JEM&JJ. L:< ^I[_GGKZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKDHO%E[<>/
MX-"72Y;?3V@N&^U7"[6F>)D!\M<YV#?]XCYL\<#)9XE\92Z5XATC1]/MTN'G
MO((KZ5\[;>.0D*.#]]L$@=@I)'(H ["BF32B""25@S*BEB$4L3@9X Y)]JYC
MPIXHO_$&L:Y;7>F/I\5DT/D13?ZXJZ%LN 2 3QQV[\T =5115'55U1[$C1YK
M2*[W##7<32)COPK*<_C0!>HKA?"VK>,M:O[[[7<:$MKI^HR64ZQ6LH>0(%)*
MDR$#.[N#3_"?Q&TS6]-TQ;^ZCBU.\)C*1PR"'S,G"!R"N[ ^[NS0!V]%8%QX
MT\/VVIOI\VH!9DE$,CB)S%'(<81I0NQ6Y'!(/-;Q(4$DX Y)- "T5PVGZSXO
M\3Z:=;T0Z1::?(6-E;WD,DDEP@) 9W5@(]V,@ -@$9K:;Q7:6&CZ==:W%+IU
MY>+Q8[&FFW@9956,$MCU Z8SB@#?HK D\:^'8M,MM1?5(Q:W,K0Q,$8EI "2
MFW&0WRGY2,YXZFJO_"Q_"GEB0ZH54/LDW6\H,!SC]Z-O[KG^_B@#J:*P-2\:
M^'])OI[&[OF%S;J'FCCMY)#$A&=S;5.%P?O'BI=0\6Z)I@MO.O#(UU%YT*6L
M+W#/'Q\X6,,=O(^;I0!M45@3>-O#L%A8WK:FC07X8VICC=S-MP&"J 26!.-N
M,^W%2V/BW0]12T>VOPPNYWMH@T;J?-12S(P(!5@ 3AL&@#:HJK;ZE:75]=V4
M$P>XLR@G0 _(6&Y03TSCG\1ZU1U?Q3H^A7,5MJ%V8[F5#)%"D+R/(H(!VJ@)
M.,]!]>@H V**YRT\>^&;^ZM+>UU196NV"0NL3^6SD9"%]NT/C^$D'VIUWXX\
M.V-]):7&H%7BE$,L@@D:**0X^5Y0NQ3R."10!T-%9PU[2_LVI7!NT$6F,R7C
M,"/)*J&.<C^Z0<CKVJ[!,EQ;QSQ$F.10ZD@C((R.#R* )**Y:V\;:7;:1I]Q
MJNIVS3WOFF'[)!*1-Y;[2$3!8D97(ZGDCBMK2-9T_7; 7NFW G@+,A.TJ58'
M!5E8 J1Z$9H OT5RGB?Q=_PC?]KS,]O,MCI@NTM%CD\TN6=068 J$)4#U&"3
MQ4K^/- MK6WENKN5'EMQ<,BVDS&)#D;G 4E%R#RV.E '344R&:*Y@CG@D62*
M10Z.IR&4C((/IBL&]\<>'=.O9;6YU JT,@BFD6"1HHG.,*\@4HIY'!(ZT =#
M17&R^/['3?%.N:7JTRPPV/DM"8H))&V-'N=I-H.U02.3@5K:EXPT+2FA6YO2
MQEA%POV>&2?]T>DA\M3A/]HX% &Y16)?^+=#TZ&SEFOMXO8_-MEMXGG>5, [
MU6,$E<$<XQS5.3Q;#/K/AV/39K>YTW5$N7><9) B0$8YXYR"",\8XH Z>BLM
M?$6E/I^G7ZWBFUU)T2TDV-^]9P2H QD9 /7%8VA^/M,U/1]4U.[?[%;6%Y);
MLTL;J"H<HA^91EFQ]T<@D#K0!UM%9>C^(=,UWSUL+AFD@($L4L3Q21YZ$HX#
M 'L<8-/U?7-.T*WCGU&X\I97$<2JC2/(YYVJB@LQX/04 :-%</I_CDZK/?M;
MW5E':0ZQ;V$$DL4F9%=(RRD=1)N9E&0 ".16T/&>@'51IHOSYYG^S!O)D\HS
M9QY8EV["V>-N<YXZT ;U%8-WXT\/V6IOI]QJ 6>.18I&$3M'$[8VJ\@78A.1
MP2.M+%XQT";5I]+CU!3=V^_SU\MPL6S);<^-JX )Y- &[17/V/C;P_J+NEK>
MNS+"TZAK:5#+&O5H\J/,'^YFLSPUXW'B2VT*Y1[>U^WK.9;:2.3>2@!Q&Q 4
M@!ADG@YXZ&@#LZ*P+'QKX>U+4([*TU$/+,S+"QB=8YBO41R%0KD8/W2:B;Q]
MX92\-JVICS%N#:NWDR;(Y0VS8[[=JG<,#)&?H: .DHHKG-/\=^&M4N;:"SU+
MS#<MLAD,,BQR/C.P2%0I;_9SGVH Z.BN>G\<>';:_:SEU ATF%N\@@D,*2DX
MV-*%V!LG&">M7CX@TH6.I7AO$6WTUWCO'92/*9 "P(QGH0>.N1C- &G141N(
MQ:&YRWE!/,SL.=N,],9S[8S7G\/Q/BGTC0M4:-+:VO=2EM+H212$QJJRE=G
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M>^(\,5A(TVHS,;10O,P^SQJ,>OS!A]<UZ110!YO;ZO+I/CWQ6J:'>Z@TD%F
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M,F-P?GW8P,=F.<4MSH&I-\-_$M@EA(;RZU:XGBB"_-(INMRL/^ @'Z5Z710
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M<XQNW#IWK*N[36H_".H^%H] U"2Z.KM<"X5%\AH3=B8.&SR=O&W&0?:O6J*
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M_P OYLYXQY?3WK"?X?21-87%EJD2W=C>7EU&;FS\Z(BX<LP*;P<KP P([^M
M&))XME\2Z?IQ9[4RV?BBUM6FL92T,ZX#!E)YP0V,<].M>IUQ5OX!DCDDEN-9
M>XEEU>#5G=K<+\\:A2@ /"G:,>@XYZUVM 'E7AKQ#KV@^#(]4N;2TET2"_GC
ME)E8W!C:Z=3(.-N%+?=[A<Y'2M+Q7X_O_#LVHR,="ABLCF.RN;W_ $N[0*"6
M15SLSR "">.<59M_A]>QZ<NC7'B SZ&;HW4EK]D"R/F4R^7YF[A-V,C&3SR
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M3Q+/I931XIK>[6V:PN+AHKF9,@&6,L K#DL%YR!USQ6MI'@E-)N-%F%^TO\
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M$MC*P25O,A^7Y\88=,DX^;MS78>(-%@\0Z)<:9<221++M*RQ_>C=6#*PSW#
M'\*YV7P/J&IWMQ=:WX@-TTVF3Z:%MK40!$E*Y<?,WS?+SV/' QR 4=,\?WMQ
MXDTO2KB;0)Y-1\Q3#I]V9I+.18RX$A'##Y2"1CFM"Q\:W%_I^@JEG&NJ7]Z]
MI<VQ8XMS#N\\_AMX_P!Y:;8^![^&]T&>[UJ!X]%<F""VL! C@QM&=PWGYL'J
M,#KQSQ6\):1'>>-M>\31V]Y!93$16D=U"T1WLJ>?(J, 0&,<8SW*MZT )X8\
M>7^OZO! R:2@DD=)[ 7#)>V8 ."Z/C?T .T<9[BN\EE2"%YI#A$4LQ] .37'
M1>![V74M,FU/7!?0:7<>?;,]H%N6(!"K)-N.X#/.%&<#-=E(BRQM&ZAD8%6!
M[@T <)!XTUL:5IWB.\TVRCT&_EB5425C<0QRL%CD;C:<EERHZ ]3BH_AY97<
MNN^)]6U&.T>\.HRVOGQLY<*NSY!NX"# P/K5NW\!W:6ECI%QKK3Z!831RP6?
MV8+*PC;='&\N[YE4A>B@G R:Z'0]$&BG4B)S-]NOI+PY7;L+X^7KSC'6@#5H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***Y_P ;&Z_X1.\6RU&+3[F0QI'/+*8ADR*-F\<J6&5!'(+
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MQ 4C/(Z'(Z\<U0MD.JZOIVK7<]R]W/X+-S(1<.JLY" _(#MQ\Q.,8S@XR,T
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MMV9W03E)D3)4$ CDY&,$@'K@UJ?$/3X;Z_\ "/G27*#^V5C_ '-P\7!BD/\
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MH;!)ZGL: /6Z*\UU*WG\-^([BRL=>O+>*[T&[G>?4+MYDAGC:,+-\Y.W&\Y
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MYC$MM9!G!)X)[&@#U>XGBM;:6XGD6.&)"\CL<!5 R2?;%%O/%=6T5Q X>*5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI3M0\-:)JEI;VM[I=M+!;#%NFP#RAC&$Q]T8XXINI>*-$TF*WDO-1A07*[X
MF9#(O!W*%R2O(YZ<U+:>(-)O_L/V34()A?1O):E&R)53&['TR,CJ* '6^A:5
M9I8I;:?;PK8[OLHCC"B'<,-MQTR"<_6DN-!TFZ@O8+C3[>6*^<27*.@(E8
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M?2+1K[>)/.,8R7'1\=-WOUK/T/Q;YVFZO-K_ -DL)-(NC;74T<V8&(56#*Q
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M".WD=2ZH06;:.K$ $A?<\5'>^+O#^G>1]IU6W4W$0F@"DN94/1E"YW#Z=N:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9]:DEB+J1YB&&(!AZC((S[&NGHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$*3CD\4 >H45Y4FK7WB./3U2XUV\NAH]K<7$&ESQV<<$DJ%O,DE+J6+=E (
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MJ(G6WMGB:VCO+V*XN(@ZDLKE&)QD J6Y(8]<5S>L:AJFFZSJ6JW][JK:;!?
M1ZAI=VDMO:Q@J#%-;9'(Y#'#'G/% 'JU5;;4K2[O;RS@F#W%DZI<)M(V%E#
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MODLN<;E_O#/<9% %@:)IJVVG6XM$\K32K6:Y/[DJA1<<]E)'/K5'_A"_#O\
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M?+MK9F(#[59W/'/"J?Q(J_#XDTI_#5OX@EO(H-.FA282RL  & P#[Y.,>O%
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MAEOHK-MLFWRRS ,6&,C:IW8(Y_&NEFOK2VL&OI[B**T1/,::1@JJN,Y)/04
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M6C,-.U*WN#  T@1N54]&Y_A/8]#3-,\5Z#K-T]MIVJVMS,BE]D;Y+*#@LO\
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MPSIUW#=6NDQ1S02>;"=[$1-S]P$X4<G@8'MQ5B#PGH=M>M=PZ>B3-=&\R&;
MF(8%P,X!(=LX'.:(/%F@7.F7.I1:M:FTMB%GD9]OE$] P/()R, ]<\59TG7=
M+UV*233+V*Y6)ML@0_,AZX8'D?C0 ^+2-/@U>XU6*TC6_N(UBFG ^9U7H#_G
M^59S^"_#KZH=2;2XC<F;[0?F;RS+_?,>=A;ONQG-9&N?$*UTN^\0Z= D4EYI
M6F&]57<XE?:[%,8XP%!)S_%6SHOBW1-=F%K9:G:SW@B$CPQODX[D>H!XR,T
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M:C:)>K\*;VU73;@7KZTT_E"!O,8?V@&#XQG[@!S_ '>>E>I44 >8ZUI=R?B
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MFYP,]58C&2<"N[\$B:VN_$EE<VEU!(-7GN4>6!ECDCD;*E'(PW3G!X[UUU%
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MZ?;&*:^++MS-SC'.['/.,8H [RN,N_&U^HU6\T_03>:3I,LD-U<&Z"2L8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"*545C%$\46X $8/+$\YYIFK:QK/ABZU_2H-8N;E5BL&MKJ]".]J;B9HG;(
M!  # $<'VH ]1HKB+"/4='^(UEI#:]>W]C/I<]P8;LHSK(LD2[MP4'!#' [<
M_A-KYU"^\>Z3H\&KW-A93:?<3SK;E0\I1X@H#$''WCR.V: .QHKR2?Q1KP-M
MX?2?4+MQK-U8O=V:PBZFAAC60 %RJ!OGVEN#A&P,U)=:UXGM/#VL6XGO[-X=
M0L8[*XOS ]RJ32HKK((V8$#G!."0WM0!Z+J.OZ7I5[9V5[=K%<WK[+>+:69S
MD#H <#)')XYK2KRG4["Y\.>-A>C6=5U"6Q\/7EXOVF1"92DB$1G:@^4\9QSP
M.:T([C5]&M?"VLOX@NM0?5KJW@N[>8)Y+B92<Q@*"FT\C!Y .<T >C45Y))?
M>(5\#ZSXC7Q%>_:Q?R6EM"53R8D%Z(P<;<EL C)/0X[9K773-8;QM=^'CXLU
M?[%_9L=]YF8O.$ID=,!MG"?+G:!U]L@@'HE%>56?B/4-<T7PVLNHZO+>W&F?
M:;BTT:"-9I#N"B5Y'(5%R&^48R3Z#%1Z3K6OZU!X9T^35[RU>XU#4+2YF41&
M9XX=VT$@%-WR@%A[D>M 'K-%>7?VQK5O)-X<&L7+%O$2::FHR*AFC@:W$Q&<
M;2^<J&([^U6/$FH:MX7M/[-LM=NM2EO-1MK9% B>\M(Y%<MRQ"DML(0L!C)Y
M.!0!Z317$^$+S6E\0WNG7D6J#3_LR3PG5I+=KA'W%6'[IB2A&"">A!%27S7^
MO>.KS1%U:[TVRL+&&X LRJR3R2,XW%F4_*H3&!W//I0!V5%>4VFK:]X@O/#^
MD/KES:AYM3MKJ[M%17N1;NJHZY4A2>^!W;'MU_C/4+W2O#]K%8W30W%W>6UC
M]K90S1"20*TF",9QG'&,D4 ;-UK.G64\\%S=QQR06S7<JMG*P@D%S[<&K<,T
M=Q!'/"X>*10Z,.A!&0:\NU*VO/#WBGQ!)'K%W=RQ>%9IH)+DJTL1#L1R ,C(
MR,CU[4FK:EX@)2[>ZU@V"Z;;NDVC&&1K:8H6=YX6^9P>",<8!XSS0!ZK59;^
MU;4GTX3J;Q(EG:+N$8D!OH2I'X5P]E=WWC+6-0CM_$=U:65E96LEM+9*L?GM
M-&9/.8,"=O0!>G!S69K_ (EU>UMM9>UUJ*<P>&K>ZBNK=5$33&616E7KP0HX
MR10!ZA//%;6\MQ,X2*)"[L>BJ!DFJMKK&GWMQ'!;74<DLELEVBKU,+'"O]#B
MN$UXZEH%Q'82:S=:G!JNEWWGK<[#LDCBW"1-H&U3DC;TY%8U[X@U72O#16QO
M'A%OX/L[F$  A92^W=^0 H ]BHKA/.U#PSXOMK6Z\075W9W>F75S.UZJ%8I(
M3'\ZA0N%PYRO3BL'3]<U>'5O#%RE[K]Q!J5VL%Q/J$<,5M<J\;L#%$#O3E01
MP..I.: /6:*\MTX^);KP+?>)XM>OKC4(I)WALSL$)2&X;Y,!<EF5&7.?XO85
MT_AS7)/$OB+4+^SN6;1+>WA@@48VRS.HE=_P5HU_[ZH Z*._M9=0GL$G5KJ!
M$DEB'55;(4GZ[6_*K->?Z_J>NG7/$]CI5XL<T-A8M:H[H@#/+('"LPP'95P,
M\9Q6=!J^L#3=<TZRU#5;;6%@AD@L];6)98\R;6:.<91PWW5SG#8]<4 >HT5Y
M+<^(]0TWPWXGC34-<M=1MK%+F*UU:)#+#\Q5I$E7*NA.!CL1[XKH_%_B.]T/
M7K=K9R\4>BZA>O;=I'B$93/?NP_$T =O17EN@ZKXE2\T"[D&MRQW[JM\VHO:
M+;.KH6W0A'W*0<$ #E<YYHT+5]9M-;TO^W[_ %:&6[N&B,NV*XTZ\W!MBQ,G
M,1X!&?3!SF@#U*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT[(C,[EGRY#$<LQZ>W%0>#?#B>%?"UGI2^69(P7F:(85I&)9L>V3@>P%;U%
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M'+'DG SV' [5:HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X>%KO'FF&68OMSSMRN,X]:RX?!^L1:\GB<ZA"=<>X*W$>YOL[61X$ XSE0
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MHQG)K,U;QSJ<RZ.-+TV6*Y_MK^S]0M994#*PC9_+W<@AAA@P[#WJ33?!>M:
MNEWVFSV$VHVD=U;SPSLZQ312SF48<*2K*<?PD'GZT2^"M;^R)?)=6$FMMK2Z
MM*K[UM^(S$(@0"V N.<<D=!0!E^*-<U*5YM/THZF1+XC2RN'6^6)@/)1_+B;
M&45L_@0W/S5M6'BF/3+2XM8(-2U"^?5Y-/M[:XN5=W=4#-ASC;&%!))R>O7-
M2/X,OGU"6Y^T6X5_$4>K 9;/EK"L97I][(SZ8[U$_@O4X+B34K*YM/[1AUJ?
M4K99=WEO'+'Y;1N0,J<9Y ."!UH U!XHU(6<@?POJ U%;D6WV92#&<KN$@F^
M[Y>.K=0>,9K U_QWJ7_"(^(VL[ V>L:4T:2@3I*J"3!#JV,-QD8(!!JQK'A;
MQ/KL$4VHW.G7.V]$[:0SNMHT0C*A#(%W,=QWY*XSQCBJD?PZU#^R/%5HO]DV
M7]L10"W@LHV6&W:,'Y2,#(/'S 9.3P* -2;Q;#I.I:W/J$%^L]M:63-9K,LJ
M>9*TBHD0&/F+#!.<'CIBIW\:SV#W<&M:++8745A+?P()UE6=(AEU##HPR,@C
MOD$U1O\ P5JFL3:K>W=U9VU[=P6+0F#=(D5Q;2/)DY )0EE'KC-/OO"^O^(I
MKB[UF33K>6/3+FRLX;1W=-\R@-([,H./E "@''/)H N:7XUGO=3TFWO-"N+&
MWU>-GL9WF1R^U-^'4<H2N2.O3G!J[X@\22Z-J>EZ;:Z7+?W>I>:(52145=@!
M)8GH,'K[=#FH6\-W)NO"4OG0XT4.)QS\^;=HOEX]3GG'%9OC$ZF/''A$Z3]F
M-R%O?DN2PC==B94LH)7ZX/(Z4 2W'Q 6UTQY9='NO[1BU&/39=/612XF< IM
M;H58%2#QUYQBI?\ A+]4ENVT^T\,RSZE;P+-?0?;(U6WW$[$W]&8A2<#C&,D
M53'@O4K@B^O+FT_M*XUNWU.Z$>[RT2(!5C0D9)"J.2!DD]*OWFC:[I_B6_UC
M0&TZ4:E%$EQ!?.Z;'C!"NI4'(P<%2!T'- $<?CR/4DTZ/0M,GO[R]@>Y,#R+
M#Y"(VQO,8YP=^5P <D'L,T^?QLZ6^FQ1Z+=C5K\RA;"X983$(CAV=SQMR1@C
M.[<,5FZ?X*U;PT^G7NC7-G>7T5K+;7B7A:))O,E,Q=2H8J0[-Q@Y!]LTFJ^!
M]3U0:3J-^VE:QJEF9Q-;W\'^C2)*P;8ORL5V;5"L021G/6@"\/'\3V:QQZ9.
M^LM??V?_ &:)4SYH3S"=^=NS9\V[T[9XK*LO&5_9ZWXEGU6RN8E@N-.MDLFF
M#")ICL+(PX*DL&[=.QJ:W\#:C9VMK?6:Z+9ZO:7[7D-O:VWE6H1HS&8BRJ&;
M*DG>1G/;'%-N?!GB#5(=?N+V[TZ*^U"6RGMDAWM%"UNVX*Q(!8$@9('<\4 ;
MFO\ C*#0+G48);224V.EG4F*L!N4.5VCWXZU5D\:W<,%DDWA^>+4=0E<65G)
M<Q@O$JAC*[=$ # $<G.!@UF:IX.\1^()-:NM1GTR":_T9M-BAMVD9(CO+!BQ
M4$]3V&.!@]:T_%O@]M=FT>^BM]-O+C30Z?9=1CW03(X 8$X)5@54@X/?CF@"
M*;XBV]O8,9=/>/4TOTT][22X1465DWJ3+]W85&0>O;&:Z+1-3NM3M97O-,FT
M^>*0QF-V#JXP"&1QPRG/7CD$8KE(?!FIV^B7$4-IX;CDN+L32Z:EDHM'A"[?
M*9MFXG/S;R.O&,5J^"?#%QX;@U 2BVMX[N<2Q6%F[M!:@* 0A8 \D$G@#T%
M'4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%8OBW43I?AB\NDOQ82 *D=QY!F*LS!0%0?>8DX ]2*
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MD16#$E Y"[L+@9XR:YQ->UO2K?6XKNZU.RLDLXY;6[U:&&:XBE:3855(F/F
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M7=+:.B ,^ /F1I5.1CA3F@#TP *    .@%+7.>%-0N]9.JZI+,6L9;UXK"/
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MI&C.[*J*"69C@ >IH YZ'P-H,=Q)<RV\]W<36SVDLMW=23-)"^-R,78Y'RC
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MQS4UM=6][;I<6L\4\$@RDL3AE8>H(X- $M%%% !1110 4444 %%%% !1110
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M59/"&BJRE66P@!!&"#Y:UY_=RZ1I[^-++Q%9--J>H7,CVRM;-(]W"8U$*Q$
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MD%SM:WT[3'B2R#0./+>5B26S@8.,X)(JY_8T,?PMO+I-/4:@==,PD$7[W(U
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M:3]W=CC-=W\.;=8[/5[B&YEGMKF^:2-S9?98F.U0S1)N)V$CKQDY(]:[6B@
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M(RW/'3FL7POI>O\ B/P%I^CRQ6$>CO=F62[$S&8Q)<E_+$>W 8E<;MV,=LT
M=5=^/H;?[==1:/?W&D:?,T-WJ,6S9&RG#D(6WLJGJ0.QQG%.N/&TCZSJ.EZ7
MH=]J$E@JF:XB>)8EWQ"1""S#.<XXZ8^E9<_A?Q+!HVL>&; :<VEZE+<%+Z69
MA);QSL6D4QA2'8;FVG<.V>E;FA^&YM)U/7Y"Z?9;XP+;X)+!8X%B.[CKE: ,
M?P_XYO;CPMX?>YTNZO-<U.W\U+>)HE\Q%52TQ.X*B?,,9YR0,5HGQW:'3T=-
M.O7U-[TZ>-,^03"<+N*D[MNT+\V[.,8/M7+Q_#W5?[+\/-?Z9H^H7.CVSV#V
MDUPWE7$/R[9%?9\C@KT*D8)YK0M?!&I:?:V.HV-IH]KJEGJ#WB65ON2 QO&8
MC&9-N2VTYW[>HQC% &IX3UW4-7\4^)H+V"YM%M#;*EI/M)B)0EL%200>#G/Y
M=*JR^)]5L_'FOV$&EWVJP06MK*D-NT:B$$/O.7899L#"C.<'I6GX9TK6;?7M
M<U;6$LXFU$P>5!;2M)Y2QJ5P6*KD\YSBJESIOB?3_%NKZMI%OIEU;ZA!!$L=
MS</$T;QAAO.$;*_-TZGU% &CI/C'3=9OK>WMA*$N=/&H02R !7CW;6'7(93C
M([9%7]#UJ#7=#@U:&.2&VG#/'YN 2@) ;Z$#</8BO-_$OAT:7H'A?PYI^JQC
MQ ':T&W'F20W"N+APG4*.7!Z H.]>HI86\6EKIT:;+5(1 J+_"@7: /PH X+
M4_'-Y?IH$^G:;J%IIU_JUM%#?/Y>RXB+X(*ABRAAR"0,CTXK8O?'<=M)J,UO
MHVH7FF:9(T5[?0^7MC9?O[5+!G"_Q$#L<9Q61#X8\5+IOA_0I%TS^S]&O+:3
M[6)W\RXAA8;1Y>S"MM S\Q!(]^)Y_#GB6TLM=T33%TZ33]6GGE2\GF99+43Y
M,@,84AR"6*_,.HS0!JWOC5$O+F#2M(O=76SA2>ZEM#&%C5UW*%W,"[%?FVCL
M1ZUF0>.IHO$FOO?VT\.A6.G6UVDK*@*!Q(22N=Y+8 "XR"O(&>76_AS7_#%W
M?KX<CL;JVOH855KR=HVMI(XEB#8"-O4JJG'!R#ZU!J?@G6=1NM7@GN[>:#5M
M+M[::])V21W$.\A_+"[2K,P.,C&"* -BV\9G[;#:ZIHE_I;W4,DUH;@QL)@B
M[F7Y&.U]O.T^AYXJ#2];O_&FGV-_I]G?Z59B>WN4GG=!]JAY+KM4L<<8YVYR
M""1P89M%\2>(-3TZYUJ#3K./34F9%M;AY?M$SQM&&Y1=B ,QQR>1Z5O^%M,G
MT7PGI&EW+(T]G9Q02&,DJ650#@D#C(H S-,\:_VM=1&VT34'TV:Y>UCOTV.H
M=202Z*Q=%RI&2/3.,UK:]KL&@6$=Q-#-<2S3);V]O  7FE;[JC) ]3DD  $U
MQ2>"=7;Q':WWV+2K*ZBOA//J]C.\4EU"&)V/ %"EF&%)+$=375>*]%N]7M+"
M;3WA6^TZ]CO8%G)$<A4,I1B 2 5=N<'!QQ0!3D\;K:6MQ_:.BZC:W\<\5O'9
MD([7#R9V"-PVQLX.>1MP<XIEQX^M].L=4EU;2[RQN]-A2XEM6*.SQ.VT.C*Q
M##((/.01]*SM>\+^(?%M@SZJNF(UO=PW-EIC.983L#!Q))L#'>'(X&%P.O-4
M9/ %[=:+KL4&D:)H\M[;QV]O!:L7(PX9FDEV \X&%"\8H TI_%^N-XE\-V@\
M/WMG;WTLXFBF>#>ZJ@(;ASMQG<1UXQR>*Q;O7]3U2/PG8Z;+K36FHW-UYUU'
M-!'/)Y9D^3). %VYZ<J .3Q79>(=)U*Z\0>']5TY+:7^SYI1-%/*8\QR)M)4
MA3R.N#U]161HO@[4M/'A7SI+8_V5<7LMQM<G(F\S;MXY^^,YQWZT 2Z?XQBA
MT;3UMH=1U6_O[JZBMX',:RL(I7#EFR%5%P #UP5ZFKP\7RR6<)A\/:J^H27$
MEN;(HJF-D&6+2%MFS&,,"<YXYSC%LO"&MZ-#HU]9_8KC4-.FOM]O),R1S0W$
MQ?A]I*L,)_#CJ/>C5O#OBK5S87.I?8K^))YI)](%T\$(1@HC'F*F9"F&)W+R
M7/H* $U?Q[?MIMK)INDW45Y'K<.FWMM(T19"2I* EMIWJP 8'C/.*V+WQK]G
MNK^.TT34+^'30/M\T!C A;:'*@,P+L%()"YZ^O%<U:^ M:L-'O([6WTB*?\
MMR#5K:U@D9(0J"/,9.S(/R'YL<]<#. NH_#^[.K:O=0Z%H6I'5)//2:^E8-9
MRE K @(?,3(W#[IY(]Z /2+.[@O[*"\M9!);W$:RQ..C*PR#^1J:LK2[2]TW
M[)IZQ6?]FV]DD8>,%'\U>,!,8";1QSQTK5H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *1E5U*L RD8((R"*6B@!  JA5   P .U(B)&@1%55'0*,"G44 %%
M%% !1110 4444 1F"(SB<Q(9@NT2;1N ],^E2444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<Y#XTTRZ\9+X:
MM"UQ<+%*\TR?ZN-HRH,>>A;YAD#IQGK3]?\ %UEH&JZ1IDD;S7>IW*0HD?\
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M@A>4XC620*7/H,]:+B^M+-2US=00!0"3+(%P"< \T 3T5!/?6EK;K<7%U!%
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MM:M&L]Q%$\AQ&KN%+GT&>IJGX=UE/$7AVPUB.%H4O(5F6-CDJ#V)H TZ*Q-
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M-.:XFFMO+41_9V$BYP=W"C(;)/6M:V.DZ;KY;QU+#(C:):1V4^J0A0^%;SP
MV0)"VTE<ENG6O5B 2"0#CI00#U - 'E^C:SHWAWQ5%<70GTG3[K0+5+&/4"?
M,8))+^[Y))<!E^7).".*R?#@T^#_ (5M>:C!#%O2]A62XC (E+@Q)DCAMV[
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MI4]A+X2EUCX?QZ'#;+J$$Q2X6&/;)$/LTFY9N,A]PZ-R<,?6O8  ,X &>:
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MXVCCV]*F@D\/W5YX1B\%1VRZK;R?Z1]GC"O#;^2XD6XP,C+[.&Y+5ZR  ,
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MCG:RLP..1G/:J4,?B_5]5L'U"*TT:PM)/-F2UNVGDNV ("9V*%3)R<Y)P.E
M$8^(-H5%[_9>H#0S<?9QJV$\G=OV;MN[?LW<;MN/PYJ/4/B-:6$FIN='U.6R
MTJY^SW]Y&L?EPGY>0"VYA\P)V@D"LL>$?$7_  BJ^"3'8?V0L@3^TO/;S#;B
M3?M\K;_K,?+G=CO[5=O_  ?J5SX8\8Z=&UOY^L7SW%L2YVA2D8&XXX.4/KVH
M OKXZAB;4DO]'U&QDLM/?4ECG$9:>!<Y*[7.&R,;6P1D5)IOC6*^O;""XTG4
M-/CU)&>QGN0FV?"[B,*Q*-MRP# 9 /?BLSQSH]R1KNM9C^RKX8O+0C/S;S\X
MXQTP#4>G:5XCU]/#LVI1V-E;Z9%Y\<T$QE:XE,)C1MI4;% <L02><#IS0!IP
M^.5:YL#<:%JEK8:A<"VM;V=8PK.<[=R;]ZAL'!*CMG%5[KXC6UL-0G_L75)-
M/TV[>UO;U5CV0LK;20"^YAR"=H. ?PKF[3P#KC2:%+<Z=I_V[3[Z"XO-2EOY
M+B:["M\Q3<OR9ZXSV ]ZWKOPAJ4_@OQ7I"-;_:=5O+F>W)<[0LC KN..#Q[T
M ;4OB_3[>W\02W"30_V&?])1@,NI0.K)SR&!P.G((JM=ZQ/H$=[K>H_:7M;Q
MK6*SL 5\Q)6 4KSA5RS#.6P,$Y[5S_B338=7^)FEV%E=PNL\*MK5LC D1V[K
M+"7 Z99MO/4'VKK_ !3IUUJFA2VMI;6%TS.A>VOUS%.@8%D)P=I(Z-@X.* )
M=&UF75#<Q7.E7NG7%LRJ\=RJD,",@HZ$JP^AR#U JC=^+DM_%)T"#2K^[N$C
MBFFEB"".*)V9=[%F'0KR.N.F<&J/@CPY?:%<ZE+) FGZ?<",6VF1WCW*P%=V
MYPS ;=V1\J\?+6A#H4__  E^M:E,4^QWUC;VR!6^?*&7=GCCAQB@"G:^/K6Y
M:TN#I>H1:1>SBWM=3D">5(['"G:&WJK'@,5 .1TS4-]\1;6RM[N_71]3N-)M
MK@VK7\2QF-I0VP@ N&*AOEW8QG\ZY[1OAS=Z>-,TZ30]$9+*=&?56E=WFC0Y
M&(<#;(<#)W$ Y(STJ'Q3INO^'/ .JZ/%;V4ND+<F:.\,["58I+@.4,>WE@S$
M;MV,<]>* .^;Q39K;^(9O)GVZ&6%P,#+[8EE.SGT8#G'-5;CQDAGMK73=)OM
M3NY;1+UX;<QKY,3_ '2[.RC)P<*"2<'M6+JWAWQ*LWBNSTN#3Y;37P66YGN&
M1K=C L3 H%.[[N1@CKS56_\  5RFJ6VHC2-/UG=IL%I/;W-RT)BDB! =&"D%
M3G!! / (]* -[_A/;.Y33ETG3[S4;J^ADF2V0QQ-&L;!'W^8R@,&.W ).0>W
M-5;GQAJ$OB7PM;6>DWR6>II.\Z3QQQR(5P,$,P(V9W''4$;=W2LVX\#WB:+I
M5E-H.@ZG# LK36L;-;&&5WW!X9<%@.QZ$\'VJSI_A;Q#II\*7#RP7T^FR7*7
M*RW3DI%,1@*[*2^Q0!\V,X[4 =;K6KC1[6*1;*ZO9II5AB@M4!9F.>I)"J,
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MA+Y%RTK3.\>W<H*#:N>QYY]N0#=UW7X=$%I']FN+R\O)3%:VEN%WRL 6/+$
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M\FA98W#%9%(4X;!Z'WH ?135D1RP1U8J<, <X/O2+-$TC1K(A=?O*&&1]10
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M?45BZ'XD_M[4-2BM[":.SLIWMOM;R)B61&VL H.X '/)'.* -VBBB@ HHHH
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M&#<LQ682R1_Q,X4#..< 5ZWY:8<;%P_WN/O=N?6D,,1=',:;T&%;:,J/;TH
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M9&#TH YC_A-](O=:T_2]%G@U>XN"S2/:3+(EK&%)WNPR!DX '!.:\VA_L?\
MX0>QFB,'_"?F^C#$$?;OM?G#S W\6S;NR#\NW\*]K@M;>U#"W@BA#'+"- N3
M[XH%O +@W AC\XC!DVC<1Z9ZT >,ZOH>G3>%?&NK/;(=2AU]Q!=])8 )8O\
M5MU3[QZ8ZU:\8Z58:%<>++32[2*RMI?"QEDB@4(KN)'4,0.K8XSUKUXQ1E64
MQIM8Y88X)]36?K^BP^(-"O\ 2YG,2WENT#2H 652.V: //(YO#MGK^BW/A!8
MI5CT^ZDU(:>09'@$64\W'/F&3&-WS9W>]8&DS:>FL>"+K3T\/VTD]XF4T]VF
MN_+>)\BXFXR22 0PR6Z'@U[?!;0VRD11(A;!8JH!8^I]31':6T6?+MXDW-O.
MU ,MZ_7WH \;GT334^'^N:Z+2+^U8=>F>&\(_>Q$7V $;JHZ\#CD^M:VOP3V
MGB34?!T"N+;Q3<17,;+TC0_\?@S[K&#]9:]1\J/84\M-I.2N.">M9$&@,/$\
MNN7=_+=.L30VD+1JJ6R,07Q@98DJO)[#% &I+:V\]F]I+!');/&8VA9049",
M%2.A&.,5XGX6'A\Z-X'BU/[ -#%M<"[5]OD?V@!'M$_\._9NQNY_2O<JA-I;
M-$\36\1CD.YT*##'U([T <?\/?LXF\1+I)!\/KJ&-.\LYB_U:^:(^VSS-V,<
M9SBLCQ9!;6_Q&GN;>&U369O#MQ_9[NJB22Z5L+L)Y+A>..<9[5Z6B+&@1%"J
MHP%48 %(T4;NCO&K,ARI(R5^GI0!XKX5BM/M_A.2PU#08[YI 91I\$AO)EV'
MS5N#N/?DEQPP&*(?#^F1_!87Z6JK?7MY!'/=+Q*R_;T &[J  !C'3%>T);01
M3/-'#&DK_?=4 +?4]Z=Y4?E^7Y:;!SMQQUSTH \U7P=X=/Q$U;3O[&L_L T:
M"86HB'E"0R3*9-G3?M4#=C/7GFN5:62?PC;22NSN? %SEF.2>8Z]UV+O+[1N
M(P3CG'I3?(AV[?*3&W9C:/N^GTH \[AT;3= \7^#I=,LTMY+FSNENGA7#W $
M2,-YZN=W.3DYKB8KO3YAX8U.SBT.TGGUJW?;'(T^I!6FP_GR\$<$A@01R!Z5
M[YL0LIVKE?NG'3Z5&MI;*SLMO$&D(9R$&6/J?6@#Q#4(+&RT_7K6Q33K8#Q2
M%U-&3"K9D93S@F&\G>1[<GWKL/ ,447BK5Q87ND/:?9HO.M]&A9;5)<MALY*
M[RO! [!2:]!\B+>[^4FYQASM&6'H?6B&"&VC\N"*.)!SM10H_(4 </XXM])'
MC/P7=ZK#9^4+N>,S7*KM!\ERBY;_ &P"!ZXQS7(W.B::G@/Q/KHLXO[5AUZY
MDAO"O[V(K>8&QNJCKP..3ZU[/)%',H66-7 .0&&>?6CRHRA3RTVL<E<<$T >
M)Z['%-K?B\Z[=:!!<I,1 VIQNUS';^6OE-;$,.^<;!G?G/:O8-#%P- TX7<K
M37/V6+S9'0HSOM&25/()/.#TJU);032))+#&[QG*,R E?H>U2T >+>&KG1([
M;4EO?B)=:+/_ &K>9LH[VWC"?OWP=KH6YZ]:T?'$AO;C3)/"5W<7NK_V>YNK
MFSD0M+I^/F)8#!D9A^[Q_%NQQ7J)LK1F+-:PDDY),8YJ1(8HO]7&B< ?*H'
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MMUH&E6G@[Q;?06,*76G:ZR6,H7YK55EB(6(_P+EF.%P.33-=CBFUOQ@==NM
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M<:2SO=6YN&@-TTJGS661<8;>=PSP>0: -V7Q_I5MIL]U=6U_;RV]U%:3V;P
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M\ %SCKS0!KV'C2VCT;3B#J&KWU])<""*&W19G6.1E8D;@BJO R2,\=S4TGQ
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MI.0$*R;CN92RYR,'G&*T_!^I>(-;NK^_OKJS73H;RZM(K:*W(=O+E*JY<MZ
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M<FH:UJ6I&WMI;6U^TF(>0DB[6.50%FVC&6S3F\#PPBR?3-6U#3;FVL8]/:>
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MN+2T#1!865]X&0FYP#QAB>#Z@$=M10!STW@^PFT37-*::Y$&LS2S3L&7<AD
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M(KKJ* .?T_PI'IMJ8X=3O_/EOA?W5SN0/<OQE7PH4(0H&% X%=!110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<SXO%]:6$^KQ^)I](LK.!GF2.TBEW
MXYS\X)R>  * .FHK \&IKH\-6\OB.Z,^HS9E8&-4,2G[L9V@ D#J<=<UOT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>guyaragreement009.jpg
<TEXT>
begin 644 guyaragreement009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKR+XUP:]_
M9T%V-3CAT:.ZMU6TB0^9-(7Y+M_='8#OR>@JS\4]&UW7?$FA0V.BWNHZ;;0S
MRW"6UX+4.[8"@R'H1MSC'.: /5**X_X97NE7W@>U;2(KN&".22-X;N4R212!
MB64L>O)X]B.E=A0 444A. 3Z4 +17BG@;PAIWQ-T.Z\4^*)KRZU"[NI5AV7+
MQBS13A50 X!'OGMQUR[PQX_U?1_!5M%<LNI30>)1H7VB=CEXB,A\]V'3F@#V
MFBO-_%GC368K[Q=HFF0V\<NFZ+]MBN6=@P)'S'CN%R1[@9KGK7XAZ_X:\ >$
MVOX[ 2:DA U*\>:2)(U12IE*@MYC$GVX^N #VFBO)-?\5/JW@70]1U*ST^YD
M?7H( ;"^9XB?FQ(&4@C_ '&_&K/B+QEXAU:7Q=I^A:992:;HUL\-W-<3LDTC
M&-BWE  @;>>O7'49H ]2HKQ'1OB)<:!X1\(:'9R:7'>W6G&YDN]7N3%!&@9@
M!D<EB0?R_+TCP'XN3QIX:74_)2&9)GMYXXWWH'7J5;NI!!'UH Z:BO ?BIK,
MVL>,KY;#6(;(^%+1+F%'G"&>Z+JY4 D;L(.@SR,=Z[_5/B+(=!\,SZ#9PW6H
M^(F5+6.>0K%$< N7(Y^4G&![T =_17D7Q U_QS:?"_69;VQM]+O+>XCB:[L[
MDE9868#=%_$IR0I#8X)(JQ/J>JQ>/-,CDTNSD\0?\([+,ACN)#$6#MMC R 0
M<#DC/- 'JM%><Z7\3)=<_P"$/M]-LX7O-9#O>HQ.+6.+B0_7<"%SZ5P-UX@U
MF+PKIK>'H8K&*?Q:UM,OVJ4F63(*JQ.3Y;8.X#T&!R: /H2BO*[OQ3#X>\>>
M(K_4-/3[58Z#%<3O#.Y$C94>6H/ &XXW8SZTWPQ\6+O4=<LM.U&+2+AM1M9+
MBV72;HS20LB;_*E!Z,0#R.,C'T /5J*\I\%_%/4O$^N6EM*NA)%<,ZR6B7+Q
MW=L1G&5D $AXZ)7<>+]9O="T"2]L(K)YA(J;KZY6"&,$\NS$]!Z#D]J -ZBO
M([+XMZA+X=\674MMI=U=Z$L+I-92.UO<+(<<;L-Q@_7^>OI7CO7_ /A+M&TO
M7-+L+>TUJS>ZM6MIF=XMJ;R),@ G'IZ]30!Z+17@'CGQEXD\5_"R^UF/3;.V
M\/W%TL=O(D[?:5"R@;V&-I!*D8!!&>XKUGXBLR?#CQ$RDJPT^8@@X(^4T =-
M17DNB^+]>M+7P;X9T:PLKFXOM BN1/>2NJQL%Y+;021@= ,Y(K'\3^/?$NL_
M#>.\MHH-/O(=:_LV^\F9@&92,!#UVG.#SVH ]RHKRCQ#\4M4TG6I=%1- M[[
M3[..>_-_>-&DLK*&\J#N3@\$^O..\LOQ.UC5;OPY:^&=)M)IM;L'N5%Y*RK"
MZ$A@2.H&UA[G% 'J5%>/:S\8K_3]2U2*&'0Q%H[+%=0W-X8Y[J0?ZP0+Z Y'
M.<X_"I_$/Q;N[/6XK/3DTJTMY+&*\@FU=Y(Q="1=P5&4;5QG&6.,T >M45Y+
MXIU_Q1+X[\!)IILXX+^*68VXNV:*601Y<,R##*JD%2.I)Z<4DWQ8U/\ X2Z^
MTN.'1;9;2^-K]CU"X>"XF0''F*Y'EX/4#.?TR >MT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'==U"_U35=(U:TMH+[3O*9FM96>.1) 2I&X @C:P(]J .BHKSGQ)J.MKXO\
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MFB9@ 0R.,;E(8'H".1VH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT]7\RYDVL!\I 6)26W%5)R0*Z4> _"XD9_['@.9/-"DL51]V[<BYPASSE0*
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M&&2$8@LOT.T?E0!YEI-UXCT^[T*] U%UO%/VG^T-6AECO 8BX,488[6R 0$
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M-FZE%)VJ3D\@#K0!POA^^U/3]7T>?6KO59/MURT2:C;WZW6GWQ<-M CS^ZZ
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M^\N:BD\9Z+IUE8MJNJV<5Q<6J7!\HLR;2/OCC(3.<,V*QM?TJZ?Q,\EM92M
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MW5IM>%I82:1=-;74R39@)"JVY68 ]' P>0>*YGQAIEC-\2([S6?#NI:KI_\
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MVEI='64M+R6(^'5U)$$Y"E&<84QXP&Y&7SP,\4 =[17.>&?$-]K<DHN+*Q$
MC62*[T^_%U"^3RA.U2&'T(]ZJ>/K]UL].T.WO&L[G6+M8#.DGEM%"OSRN&['
M:NT'U84 ==17 :)XT>T\"H]TIU#5[*\&CM&D@!N;@.$0[CP P*N6]">M27OC
MS4]&DU6WU?P_%%<6&EMJ0,%[YD<RAMNT,8P0>N<CC'?- '=T5Q%WXXU#3[>P
MCO='M+34=2E?[)!/J(6,0JJL9)9-GRD;@-H#<]#4)^)MO'IDIDM;?^U([Y+
M6Z7JF!I'7>KB;&/+VY))&1@C&: .]HK@G^)*VNE:Y+=V-M)>Z3#'<-%97HFB
MGC=MH*2;0000005]/7-3_P#"6^)#KAT3_A&+9=0DM?MD.=2_="+=M(D;R\AP
M=HPH8'/7C- ';54U/3H=6TZ:QN&G6&4 ,8)FB?@@\,I!'3L:X[_A9*7-CHWV
M.RMDO]2@DG:*^O1!%;K&VQMTFTY^;@ +SR>*5/B,]Q8V)LM(6YO[C4GTR2W2
M\79'*L;/N$@4AD( .< X.<9&* .SL;*VTVP@L;.%8;:WC$<4:]%4# %6*\U\
M1^,=>_X1K5X8=/AL=8TV_M+>X\N\+)Y<KH0R/Y>3N#!2" 0"3SC!['7M=;P[
MX5N-9N[3?);Q*\D$4F5#$@8WD#Y03RV.@)QVH V:*\V\1^*-5O?AYXBN?(@M
MS#:K);WVEZA]HBDRW(5P%8,,<\=^M=!8^*-3_P"$@CTK6-$6R>YM)+NU,%UY
MY8(5#(PVKM?YUZ$CWH ZFBN'M_'=ZFM:59:GI5G:)J<IABCCU$2W,#;2P\V+
M8,?=P<,<$XK&\,:E?3:CX166]N9%FGU@2AY6(<),0F[GG:.!GIVH ]%M]+L[
M74KS488MMU>",3ON)WA 0O&<# )Z5<K UOQ!=66K66C:581WNI744D^V:?R8
MHHD*@NS!6/5E  !S[5GOXOU0O8:=%X?*Z[=F8M:W%SLBB2(@-(9 I)4EEVX7
M)SVH Z^BN&F^(%S#!% ="+:Q_:JZ7-9"Z 5':)I%<2;?F0@ YP#@GC(P<[Q)
MXRU]?#>N6\>GPV.L:;<VB2F*\+H8IG7#(_E@DGE2"HQDG/ ! /2J*X/4_%K:
M!>Z_>7&G327-CI]E--!'>EHR9'=2J J "#GYL?-QD#%6)?&NI:;<:A;ZQH45
MM-!I<VJ6XAO?-$J18#(QV#:V67IN'/M0!VE%<]+XI6&X\.QO:@+K".Y<R?Z@
M+"9?3YNF.WK7/V7Q.2Z:PO)+.SCTF_N$@A==05KE-[;4=X=ORJ21T8D9Y'H
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M.,! #S]:ZW0=2N]4TXSWMBEI*)&3$<XFCD Z.C@#*GW /7B@#4HHHH ****
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M5@2WKD'VKT&B@#*\/:3)HVBQ65Q/'<3 LTDD<"PH2Q)PJ+P ,X'4X')-<H/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2.>P)'/K58^$=",]U-_9Z;[NXCNI\.P#RH=ROC. <\\=>^: -JBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXUE#19P>-R$[A_= [UM?$+5M3T7PC+>:4N;@7$$9;<!L5I54]0<YSM]MV>U
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MSRVVF7-K]@F\/#16^T;A(I19 CC P<EQGZ<5LMX;N&NO"<OG18T8,)AS^\S
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MJCD+D#+<D#FB\\&7ESX;\4:8MS )-7OVNHG.<(I\OAN.OR'IZUVM% 'GNJ^
M;EM;U:]L+#P[>+J;B4R:K:^9):R;0I*?*=Z_*#M)7G//-;NC^&)=*\1"_P#/
MA>!=)M]/"I$(R6C=V+;5 50=XX'2NAGGBMK>6XF<)%$A=V/15 R359-7TZ2W
M$Z7D)C-L+OAN?)(R'QUV^] '(67@S5M,LO"_V:YLGN='N+AY1+O"21S%P=I
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M0&V>6ZNI9Y/*/\"L[$JOL,5J6^G6EMI<6F1P+]BBA%NL3?,/+"[0ISU&..:
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MPWKM)<6WVN40/(W5_+#;=W?.,YYZ\T 8%TVL:QKWBQ$\07UC;Z;#!):Q6H0
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M9@A?#("2H(5L')SCMF@#L:*\ST3Q7JUQJ/A*#3[>[N=.OM+GN'-W<H99&5D
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MYW$R&,@CC&/D.:Q[7P9?0>#O#.C-<6YGTF\M[B9P6VNL;EB%XSDYXSBNVHH
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M'0KDKQGL:5= U[6=:LK_ %]].@2P@F2".Q=Y/,DE3878L!M 7.%&>O6NQHH
MPO!VF:CHGA6PTK4S:M-91+;H]LS%71  K'<!@G'(K&TWP[XGT>V31-/OK"'2
M([MIDO/F-RL+2&0Q;"I0GDKOST.<9KK;K4;*RAN)KJ[AACMT$DS.X C4YPS>
M@X//L:L@@@$<@T <!/X0\0QZ-JGAFRN=.71-0EG/VF0OY\$4S%I$" ;6/S,
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MEZY'-)I=_;WB0OY<C0.&"MZ9%:% '">&_!^L:8WA<7\UBRZ'!<VV8&<F5'5
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M!;( 6ED8*H!.!DGW(JQ0!QGAGPG<:;KAU&?2/#FF(D!B2+2K8%I&)&7:0HI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[OM.%C=QK,<*A)9E!'^T3R* ,^^E:T\?^%YXSAM2M+BUN /X@BK*A_ A@/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"J68
M@*!DD]J6N8^(5Q':^!]1>:Q%[$0B/"S.J;2Z@LY3YMBYRP'4 CI0!N6^JZ=>
M1RR6M_:SQP\R-%,K!/J0>/QIT&H65S<26\%Y;RSQC+QQRJS*/< Y%>+2RQS:
MSK<EM=Z7=Q2^$[Y/-TFR,%N6!0A VYA(P!/?@'I71/HL&G7?@1M'LX;6[DM;
MB,RQQA2Q-HS#>>_S@'GO0!VFK>*;'3;BSMXY(KF>>^BLWBCF7="7SAF'7MTK
M;9@JEF("@9)/:O%+-_#ATKP+96UM&OB&TU*U%Z@AQ/#)R)C*<9&7]>IP1FO1
M?B%<1VO@?47FL1>Q$(DD3,ZIM+J"SE/FV+G+ =0".E &Y:ZII]ZDCVE]:W"1
M?ZQHIE<)]<'BEBU/3YIW@BOK:29$WM&DJEE7U(SP/>O(;*:*7Q;?R6UWI=U%
M+X;NT\W2;(P6Y8,A"!MS"1@">_ /2M73]&L=/L?AE<6EA##<.R+-*D8#N'LY
M"^X]3EL$Y[T >G?:K?R8YO/B\J0@(^\;6STP>^>U/=TC1GD9511EF8X 'J:\
MN\/V5P_BJV\'RQO]@\-74M\K$?*\;<VJY[[?,D_&(5T_Q&N8K;PDQN+**Z@D
MNH$D^T,XAB!D'[R7;R44@$CH>AXH Z.SU"RU"-I+*\M[E%.&:&57 /H2#52[
M\1:5:Z5?ZC]N@F@L8VDG\F57*X!..O4XP >]>/7(NKV^\4+I%Q9WKW&@)\^C
MV9MXI=LWSJGS-YC!&(W _P 0':NDU"3P=J^FZG#X:TV*YN1H5S&9;*+$<*[0
M4CD P-Y8 JI!8;3TH ]$TS5;35;*VN;::-A<0K,J!P6"GUP>QX^HJ62_LX;0
MW4MW EL"09FD 0$'!YSCKQ7F&A:[H>D:[HFI274%KI=QX=2VAF"[8VG27+H,
M#[^2>.I.:R[2_@A\)^%1=VMC LM_J4JWFL(_V>U;SY<!X\J"[!B%W$8P<<T
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M>G4BXUNX:]PPY6(X6%?PC5/Q)H ZFBBB@ HHHH **** "BBB@ HHHH ****
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M(V$EFCY#*2I#*6'J.:VCXXT[^R;_ %<07+Z;;2+##<(@(O'+!0(1G+?,0H/
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MT:WL=8U/4XWD:;43$958C:OEKM&WCTZYS7%WOBB&'3KB4ZCK*A-%L;O<@BW
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MM_;6_@:-W@SH46RZPQ^8_9C%\G'/S'OCBLW4?!NMN+TPM!<6]QKCW\MC]J>
M7,!A5 C.HR"&7=CD' S7HE,DFBB!,DB( I<[F PHZGZ"@#RW_A6VH36.OVK6
M.D6EMJD]A*MI;R,41(9,R*QVC<2HZXY)/3K6E?\ P_O9M$U;P];2VG]D-/'>
MZ7'-DB!PX=H&4#_5$CC!R Q&.!7H$,T5Q!'/!(DL4BATD1@RLI&001U!%/H
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M&X*20&(ZX)!Y]C4M 'G>G>";H37L_P#8.AZ/NT^6VC6UD:9Y)'&-Q<HNU/8
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MW* 6W'@=.>/6::D:1($C141> JC % '#S^#]2D^'WB#0EDMOM>H75W-"Q<[
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M7LIK-U!!*LBL2G0A01CISUKT:B@#A'\*Z]!J%E*+BWO\Z$=*N[B>5DD\SJ)
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M5BOH=;DC@GM5MU186DB9U:-AR<%<'<3G.1BN@U[PY%?07-W KM?KI=Q80+O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEQ>O8Z#>7^G6$_V>ZNH67=O! ?RX_O2;<\XQR#C.*348POQ1\/;$ 7^SKXG
MXR7@->>7%K8:5IOB*VN+R^B\7Q:C<2Z3"D\BR,9)"\1B0':ZL6^8X/5@>@P
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M0!2%A*O(??E5R=W/.17H^@64G_"!6%E>&:Z?[ L;_:X=LCC9QO0DX.,9!)H
MLZ5XFTO5?#MKKBW,<%E<1JX:>15V9&=K'. ?;-:D4L<\2RPR+)&XRKH<@CU!
M%>+>&;C0X;'P7=:J+8:+;:;+;RM+&/)@U#]WGS<C ?9N +=\UW'P\6/R]>FL
M(S'HDVI,^G+M*H4V)O9!V0R;R,<=<4 6KOQYIL-CJMQ;H;AM-OHK*6,.H+,[
M1KN'7Y09?S4BNBM;ZSO?,^R74%QY;;7\J0/M/H<=#7CVL6VF_P!E>.M*,$*7
M<FNVKO"L>US TEM@\#[I.[\<UI>+](ELM;UJU\-62VL\_AB3$=G&$WE9@!@+
MC+;2P'?F@#T^VU"RO7D2UN[>=HCB18I Q0^AP>*R/$_B.?0#ID5KIC:A=:A<
M_9HHA,L7.QGR6/'137!^%4LKGQAH+Z7JVES_ &:WE$L.DZ2T&R(IC9<,96V_
M-M(!&=P^IK9^*36L<OA:2^O9[&T75"9;F"0H\8\F3D,.1S@?C0!TFF:SK,T\
MG]L: NE6B1ES</?QR#((X('3C)S[5M?:(1)'&9H]\H)C7<,N!U('>N T?6?!
MD,>H;?%=YJL/V1S<07UT\Z"(?>(4CTX]\XKF_#EIJ=A:ZK;7$%W#K%[H\W_"
M-F>3<T-N Q6W!P,2J2A/<C;_ ': /7X-0LKFXEMX+NWEGB_UD<<@9D^H!R*%
MU"R>]:R6[MVNE&6@$@+@>I7.:\<\,16T^H>%8=/U73/MUJ<O;6&D-'<1*(R)
M%N7,IV@GKN&2V"!6EX3E\,Q:5X?T^]L3/XKBO ;B*)<7<=QN/F2R'(.SDDDG
M!&!SP* /5/M5N81-Y\7E%MH?>-I.<8SZYX^M8<?BZUO$U0:=&+F?3KQ+22)I
MTCW$[,L"3C #]^I4@<UYNNL647@*P\.M*?[7M]=C$]H$.^(?;]^YACA2",'H
M<BI-22QM[+QO8QQ0Q7_]O6DWEK&%<PF2VPW3[N[=^.: /8/M5O\ 9VG\^+R5
MSNDWC:,'!R>G%1RZA90W4=K+>6\=Q+_JXFE4._T&<FO-M1L+@>+;CP6D+G3=
M7OX]79\?*L RT\9/O+&G'I,:YS5H56Y\6VFLZEIMM?7-]*889]*>>]EC./(-
MNXE7=@;0NT?*P.: /8XM5+:UJ%C+;B*"SABF^TM(-K;]^01_#MV=^Q%6[2]M
M+^'SK.ZAN(LXWPR!QGTR*YCQC:QR_#F2WU2XNPHC@\^XBMQ(RLKH2[QY(*Y&
M6'/RYK)^'MXDWB#5XH4TB\3R(6?5=(C:*&8@L CIDKY@'.5/0C/:@#O+N_L[
M (;R[@MPYVH9I FX^@R>:+N_L[!$>\NX+='.%::0(&/H,FN!U6;0K'X@:Q/X
MO6V%K/80)ISWD>Z,H-_FHF1C>6*DJ.2"*S;"7P[I_B!;CQ'9?8=+DT:VCTA-
M77>(D&_S8R6+ 2<QY&=Q&!VQ0!ZA<7UI:)ON+J"%-N_=)(%&WCGGMR.?<4U=
M2L&FAA6]MC+.N^)!*NZ1?51GD>XKRCPQHZ7>M>$8M2L2]I';:I+9P7<>=D)G
MC\D,K>B$8!Z#'I45MHEA:>"XKNWL(8[J+Q6HCE6,!T47^P 'J%"<8'&* /7'
MU*PCG2![VV6:1BB1F50S,.H SDGVI]O?6EX9!;74$YB;;((I VP^AQT->0:S
MHMC/X0\?7TEE&][_ &TP2<I^\4*T6-K=1C)/'J:N^+]&:RUC7+3P[8BW:7PT
M,Q6480R!9\$ +U;86 [\T >H6VHV-X91:WEO.8CB012JVP^^#Q21:E83W'V>
M&]MI)R@?RTE4MM/(. <X]Z\V\[P]?^)M!;P;';;;>VN1?-9Q;5CMS"0J2X P
M?,V84\@@GUJII&CV-AX/^&M[:V,4-XU[;>9.D8$C!X9-X9NI!]#Z"@#TG6M;
M31GTQ7A:7[??)9KAL;"P8[CZ_=_6K;:G8)>BR:^MA=GI 95\P_\  <YKG?'
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MZM=FW0H5Q'YGRX!Y QC H L1>-Y+W5]5M=.TV&YMM.F2W><W\:%W8QYPI_A
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MC62-U=&&593D$>H->%6 GAL?!ESJ%[86FF1Z5+%#/JMHUQ;QS^9C!^=0C&,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&G>-K>^N[&*?2M2L(-1R+&YND0)<':6 ^5BR$J"0& R!^%9\/Q-T^;1SJ_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %8/C32+K7O"=[IMGL^T3&/;O;
M^616//T!K>HH XSQ7X/N?$NL3'S4BM)]$N=/,F<LLDCQLIQW'R'--33/$FN:
MIH3:S965C;Z1,;F1X+DRFYE$;(NP;1M7YR3GGH/>NUHH YKP+IFI:)X9BTG4
MH(8WM)'2.2*7>)D+%@W0;>N,<]*YK5O#/B>/P[XA\-:9:6,]IJ<UQ-!>2W)0
MQK,Q=D9-IRP)8 @XP03TP?04U&RDOWL$O+=KR-=[VXE4R*O')7.0.1S[U9H
MXN[TKQ#I_B?5+W2K.SNH-5M((2\UP8S;21AUW$;3N4A\\<\8]ZB\(>$]2T2^
MT6:[\G;9Z FGR['R?-$@8XXZ8'6NYJ-[B&-XT>:-7E8K&K, 7(!) ]3@$_A0
M!PVE^$=3M-?TZ]E\GRK?5M2O'P^3Y<^[9CCKR,CM5#7=&GTB\NM9FNK.WF;Q
M#%>V N)&6*7-N(3&[ 'RR</AB, [?6O3*CGMX;J!X+B&.:%QAHY%#*P]P>M
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M.:Z6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *PO%^M7&@^'I+NSCCDNY)HK: 2YV"2614!;'8;L_
MA6[5'6-(L]=TJ?3;Y&>WF #;6*L"""&!'0@@$'U% '&:QKOB'PI+<6M[J%OJ
M)N-*O+NUG%L(FBF@0,05!(*'<,=^,<UTOA7^V)='BO-9OX;F:[1)T2&W\M8
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MU%(,VT4@.""V<X!."0" >IH ZBBJ>J:G:Z/IEQJ-X[+;P+N<JI8GL  .222
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '&-X3N;^S\;V-T5ABUN9C;R AL*;>./<1[,IX]JK6.E:]J6I^&AJ&CPZ;#H
M6YWFCN%<3-Y1B"Q!>0AW9.['0#%=Y10!5TZ>\N+%);ZS%G<%F#0B42!0&(4[
M@!G( /MG':N?\,6&K>&_ .G6/V!+G4;<!'@\\(,&0Y.[D<*<^^,5U5% '/\
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M9(;LQ,D5P8PYC)[X[C.#C/.*H>'=#&@Z?+"]RUW=7$[W-U<L@0RRN>3M' &
M !V %:]% !4<]O#=0-!<0QS1.,-'(H96^H-244 01V5I%;QV\=K"D,9#)&L8
M"J0<@@=!S4]%% !58:?9+>F]%G;B[(P9Q$N\CTW8S5FB@"N]A9O.\SVD#2O@
M,YC!9L'(R?8@$5+Y4?G>=Y:^;MV[\?-CKC/I3Z* *UOIUC:2RRVUE;PR2\R/
M'$JE_J0.:FBBCAB6*)%CC4855& !["GT4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!4U2R_M+2+VQ\PQ_:8'AWC^'<I&?UKA(=-\0ZEI?AOP_=:&]D-)N
M;66YOFGC:%EM\$>4%8N2VT=57 )S7HU% 'FT^@7EE\+)+2\:WLKN#4FO$%S,
MJQN?MIEC5F&0 XVCV+#-5M0O?$>K>.I5M-*73-2C\.70M4N)HY6\QI8MI;86
M4+D?+D\X.0*],NK6WOK66UNX(Y[>52LD4JAE<'L0>#5/2?#VCZ"LHTK3;:S\
MW'F&&,*7QTR>IQ0!P&F>']:E\5^'-2?2]:6.S\X7DVJ:DDK!GA904C60J%W<
M9 !Y'&!5ZR\,ZO#X$\&::]GMN].OK6:ZC\Q/W:H26.<X.,]LUZ'10!YE=>&-
M0%G<_:]!EO8VUV[O%^R78ANHHWSLEA8.HSZJ6!P>E(-.\:1Z#;1RMJTMJ-3=
MWA6ZA_M!;/9A%,N0I;?DG#9VG&>M>G44 >2'PEKS:7XM\K2;I#?26$]G%=WZ
MSS2^2X9U9V<X;Y>F=HR #Q6CJ'AO7-1O=7U:+3O*F:^TW4;:UGF0&8PQKOB)
M4D*<Y&3QD#MS7I5% 'G6KZ3KGBBXU?43HTVG@:!=:=:V]Q+%YMQ++@\[&954
M;0!ENISP*UY=%OSJW@J9;?\ =::DJW1WK^[S;[!WY^;CC-==10!QGQ$T+5M6
MT^SN-!16U*!Y(,EPN(9HVCD.21]W*O\ \ JEX?\ !U[I/CR=_)5/#]FKSZ=A
MP3YTR1HXQG(V^6_;_EJ:] HH \[M/#&KQ?#WPSI;6>+RRU.VN+B+S$^1$N-[
M'.<'"\\$FL+Q#X<\5ZSI.L6=QIVK7>I27#O XU)(K'RA)E L:N"6V@##KUY)
MKV&B@#S_ %71=6DUGQ8@T"/4;/5;>W>+SIU2.0QJ%:,X8,KGDJV,9 Y%9)\*
M^(M2TS5["U34[33'MXFMK36KQ)V-S'*LF%96<K&0NTY;OG'%>K44 <#?:;K'
MC+6+.6ZTF?1;:SL[J)GN)8W>26:/R\((V;Y5&3DXR<<5CZ%X3U)'T"PO-$U4
M/ILT3SW-UK3R68\H?*T,8E))) PI0!02#7JU% '!67A34H?B [R1K_PCMO<2
MZI;?."3=2J$9=O4!3YKYQUD]JYS_ (0C4H+"\T&32-5O1-=R%+D:R\=B\+R%
M]TD0E!! ;E0AR1G/->P44 <UX=TR\TO4_%%S<6^U+N_$]N=ZGS$$$:YZ\?,K
M#G%:NAZF=9T.SU(V[6YN8A)Y3,&*Y]QP?J*T*  !@<"@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBN3^)5[?6'@/4)]/D:*7,2/*KE#'&TBJ[;@"5PI/S 9'7M0!UE%>4Z5
M91V7B"6SN9=)L-*N-*FDO;2SU2>YWQC;B?+(H0C)&[.3GOBLS1-5U=M'UV[N
M;J]DU>ST:1]!6=-IEM,-MN-N3NE)"[L\C"_WC0![317FD<.AZ-86E]X>U&YE
MUJYTJXE@CCG:<7S"+=OE!W<AL8/')QWQ6)X:2[BF\)ZC!<Z7#/?2IYUPNK3W
M$]^I0F17C,>-W\7) 0KC(H ]FJI8ZG::C)>1VLOF-9SFVG^4C;(%5B.>O##I
M7CU@+&'P%::Y9:A++XF&J"*%OM3-(SFZVF#9G[OED_+C&/F]Z[+X?V-A::SX
MO\A56X&L.I7S"2$\N,C@GIDMS0!V-G>"\^T8M[B'R9FA_?1[-^/XE]5.>#WJ
MS7D5RLFH21V<US<K#-XVFAD\N9D)C\ER4R#D*<8P*ZGPA:QZ5XM\4Z19F1-/
MMS:RPP-(S+$SQMOVY)P"5!Q0!LWOBK2K&VOIWDDD6QNHK2X$:'*R2% HYQG_
M %B$D>M;=>*:UIE@ECX\BA)AN7UVR0E)3O5&>U.0,\?,20:V=8MY?"6M:]!X
M;$\1;PW+=K#YKR SH^!( Q/S8/XX% 'J5%>1^&H+BSUWPQ/:7&E0"]5O-,&K
M3W4FH1^622RM&!N!PVXD8Y'?%;WB.WT[4/B?I5AJ]R5M)-*G=;9IS&DT@D3
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M?F.W..F>U &[17BFG2&SUGP7?6L$5F=1NE!E;5GN;N\B:)R3,NT)UVDX)PV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\/6=N#;6ESJ$)DQ?_9564AW9L9Y( W8Z]JVH]/LH;V:]BL[=+N8!99UB DD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,?Q!IB^(HM!^U*VI
M20-<>0O)5 0,MZ9SQGKS6??^.-#TV^GMIY;@K;.L=S<QVSO!;LV,"20#:IY'
M?C(SBLF;2['3?BMHSV5K% ]S9:A-.R+S(Y> EF/4FN2A&IV'A+Q9JW]NF"?3
MM4O'.G-#$T,Q\TL%E#*68N" ,$<%<>X!Z_>7EMI]E/>W<R0VT"&261S@*H&2
M361I7B_2]7OTLHEO+>XEB,T"7EI)!Y\8QEDW@;L9''7GI5K4+S2CHET^L?9E
MM(K<2WD,^&6-,9^93]#VYQ7.Z(9_%7B.T\2WBK:6=K%(FEV3,/.82 !II!_#
ME1@)V!)//% ';51U74X](L3=26UY<*&"^79V[32<_P"RH)Q5ZB@#E=*\?Z9K
M-[]EM-/ULL)C;R.^F2JD4@ZJ[$84C(SGIFMW2-6M-<TJWU*Q9FMIU+1EEVD@
M$CI^%<WX _UGBO\ [&"Y_P#04KB?#^FC2O!'A#6[:\OEOIM4MX)";J0QF&2<
MHT?EYV;<'TSGGK0![/17B4MUKM]IFM:\66WO[;4)HTOIM:DB2SV2E4B-N%*[
M< 9!R6W9[C'M<99HU+@!B 2!V- '*M\0=,-U=00:=KEW]EG>WDDM=+FE02(<
M, RJ0<&NELKM;ZRANDBGB650PCGB,;K[,IY!]C7F?A6VUN5_$+6'BBTTZ#^W
M;W]Q+8K*V?-.3N+CK]*L^/M1U71$TB\T;49;K76MY(98(8]\<\(3,D_E;L H
MP##GDG;SF@#TJBO)KTSW>L^']#TV2;5](;2#=Q&75I+8WDA< NTB@LY (.W@
M#=[4W3I]0OY=!T'5=38Z;-J%]$QMK]W9Q$H,4#SC:S$$OGU\L9SS0!ZW574-
M1M-+M#=7LPAA#I'N()^9F"J./5B!^-<#YUMI?B+0-/T[6[NYM(];GMYDFF9A
M$3:NP@WG[X!((!)P3CMQC>*WBU=/%Z374LUO:ZYIB1A+AU6//D*X&TC'+-]#
MSU&: /6(;Z.>^NK14F#VVS>S1D(VX9&UNC=.<=*LUYCJBZBM_P"+O[,NKHR:
M.-/N[2'SW(81H6:/D\[U!!SU)!-4-:\1:AJ6BZSXFTJ\F33[F\M-,M)%G,2I
M ' FE#<A"SNR;\$@*#VH ]=HKS[PI#J.F^-9+!TBL[.33S,]@=6DO7WAP%E&
M]<J""P/."<5M>/%N)?#J06NH16<TUU"BB6=X5N/F&8?,3YDW@8R/ZT ;6K:M
M::+8&]O6981)'%E5W'<[A%X^K"KM>,:HY/A/Q!HDD&I:;=P7NG,]M+?"[C@$
MDZ!6AD.6YVDX;H>@&:U]6D@\&:WK4$.H:I!IS: UU)BX>XD282[ Z>:3AB&^
MF<$]* /4"<#-8FD>*M*UN6TBLI9&:[LOMT6Z,KF+=MR?0Y[5PNC_ &S2/B%H
MEG]FGT^.^L[DS6\VL/>//M52KNIRJG.<$$YR?2H_AG_R$O#7_8J#_P!'B@#T
MS5-6M-'MHKB\9ECEGBMU*KGYY'"*/S(J[7%_%%8W\)P+-<M:Q'4[(/.K;3$/
M/3+ ]B.N:YW7[J[\(7GB&U\.7-S)%'H#7K1RSO<?9YP^U7!<L02I9L=#LSB@
M#U:BO+_#\.I:=XHT#RS';6]]%+YXDUR2]:^41[A(JLN P;!W# P2/2NH^(]S
M/:?#O7+BUGD@GCMB4DC8JRG(Y!% '445Y=XBTZYTK6O#_ARP^UW=E>BYN9X[
MG5I86NIE" *9?F;'+-L& 3]*J@:Q-X>N=+_M2U0QZVL,%H^JRL9$\O<UHUR%
M# YR1U.,*: /6Z*\<N+[R](;27N-7T66'7[.&[CDU'SA;I*!\L4P.=A'.&.5
M)[58\1W=SX9O]<TO1=0NXM.^RV4EQ(UPTIL&EN/+=E9B2N8\MUXQNH ];HKR
M_7HE\,:I-8Z'?7AAN]"OI[F%[N2;RC&B^7,"S$J26(R#@_44[3K-M&U'P/>P
MZAJ#SZI$ZW[3W4DJS_Z*T@)1B5!#*,;0,=* /3JR+3Q'87=Y8VBBXCN+V&6>
M*.:%D.R-E5L@].6'7K7G?AB2XTK5M N-1DN[D:A*T46KV6JM/!?LR,1YL#\I
MP"?E'RD8R!530K>+7[_P/%JU]=$RZ=J!.+ET>X(F3"%@0Q&!G /\/I0!ZSJ&
MK6FF36,5RS*]]<"V@PN<N59L'TX4\U=KR6WN)GETBU^TRW=K8^,'MK.:60R,
MT2V\AV[SRVUBRY)/W?:LK2;K7[K0M/\ $C,D&HSWR"2]GUN3:S&7:UN;;;M
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M+?RU1@ @.T@DG.0>.*L^(K>./Q7XHU*.6>*]7PG]H1DN9%P^)ER%W8X &!C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8L%OF,AG^S"7R)/),V<>6)=NS=GC&[.>.M %JS\+Z!I^I-J-GHUC!>L23/'
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M1ILQN#+86SFXD26;=&#YCIC8S>I&U<'M@43:/IMQ'>1S6%M(EZ0;I7B!$Q
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M?J,KFN?\,:9J_A5/#^I76C7ERBZ+_9\\-LJM+;R"4N"5)&0P."1TVC->IT4
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M34+<WMT'7^T+@232JJ*H=@!A"<8QDG &:Z/4HWFTN[BC4L[P.J@=R5.*M44
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MG=)U[6D\5QZ#K)TVXEFLVNM^GJZ_9RK*I20,S9!W<-QG:>* .MHHI"0JEF(
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M QSC&'.>/2H[#Q[X9U.ZM[>SU,2O<J3 WDR!)<+N*JY7:6 ZJ#D8Z4 =)17
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR%Y0.%=FCVK]3@_E6-9Z%J,7@GX?V?V&1;BPO+62ZCV\PA8G#$_B>?K7HU%
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M9)+5)7C8  'D@$9"_P!XXS7K]59M.M+C4+6_EA#75JKK#)DY0/C</3G:/RH
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MKHM7T>QUW3WL-1A,ULY!9!(R9QZE2#CV[U;BBC@A2&)%2-%"HBC 4#@ #TH
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M(7HH)P*Q]%\*ZUK&D:QIMWJ0MM&O-7O&FMGLSYYC\]B520L $<<Y*D\G!YX
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MY!)$BC<N&YP<Y!P* *VK^*-4LK>P<6FEZ>)[83S3ZKJ"QQ1/Q^Z4KG>W.<C
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M>?/V8W?\!SGWQVJ36/!,&MWFN2W-VZQZI9V]N%1/FA:%W=7!)Y^9@<8_A]Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45RL/C(7?CJ+P];V$XMS#.SW
MDJ%%>2)D5EC!^\ 6Y;IGIGFJDWB_6+BZO)=(TFUNK"SN6MMCW6RYNF0XE,2X
MQA3D<GG:>E ':T4#D5RN@^,D\0>*]5TNVML65G#')#=$_P#'P2[HQ4?W0R$
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M27VLI:M!+:6-Q'%#/"^X2AHD<G\"Q'X4 =!14%[>0Z?8SWERZQP0(9'9C@
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MRV]B8M^UE0+P0".=Q.:] HH \G\&:/?12^!#>:;=1M91:IYOGPX,#-*-N[C
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M0I=%VC!/REB@(VGU]#3]'@EU3Q1;WRW>O7OV2PGC:6\TU+-(]X4>41Y:,YR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME-F9?]&(,P3[/Y6,=#MS][<,YH ]:HKS*)=7O+?QAJJ>);BUN+*]N;2Q2XN
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MDU9TDO$>2)I%ECDWA7*J6,9*[L ;L=P: .AHKQZ%];E\-:1K0\2ZJEY>:X;
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M'(ZEOE#'GYO7% 'JM%<5X;%S8^/]<T<ZO>7UG;V-K+%'=2^8T+.TNX%CR2<
MY.3@CT%+>+=>(/'M]H\NJ7UC9V%C#-'%93&%YGD9P7+#DA=@&.F3SF@#M**\
MGTO4=8\0ZEX=TRXUN]C@/]J0SW%JXC:\6"6-(WR!P?4KCOC&:Z[P)<W<EAJM
MI=WDUW_9^J3VD4T[;I#&I!7<W<C=C- '545Y3=:CJFG:W<:GJ5[JIL%U3;%J
M.G7:3V:1>8%$,L&05(^XS8)#<YJS-+J&J:3XL\0/K]_97.E75U%:PPRA885@
M'R[TQA]V,G=GAAC% 'IM5HM0M9[^YL8Y=US;*C2IM(VA\[><8.=IZ5P.G3W_
M (SU'5&O-7OM)6RL[1X8K.;R@CRPB1I'_O8)V@'CY#Q5>7Q)<1KXC,GB&:2%
M+#3!;7=I '+R2[U+11YP&D.,<X&0>U 'I-Y=P6%E/>7,@CM[>-I97()VJHR3
MQ["G6\\=U;17$+;XI4#HV,94C(->0W-YJ=M=>(M*G75X+.?PQ=W0M]5O$N)-
MZX4.-K-L!#$8SVZ<5Z#%+);_  Z2:)RDD>DAT9>JD0Y!% '0T5Y196NK22^"
MA)XFU@G7K1FO_P!^.<0B4>6,?NSGC*\X)YSS5636]=1[7P[!<ZG>1MK=[:F6
M*X1+J2&% ZQ^:Y S\QR<[B%XH ]AK-O=?TS3I[F&ZNA');6OVR9=C$K#DC=P
M.>0>!S7G3:OXBLK"]TJ:XN;..75;*TBGN+N&XN[6*8C>&9&;!X^4MS\XZXJ'
M7X+CPUK7BJ2SU>]FFA\+F6&2XF\R6 B1\8<\D9&1G/4]L4 >N*P=%93E6&0:
MKMJ%LFI)IS2[;J2)ID0@C<BD!B#T."1D=1D>M><Z_?7>H:AJ<=G<Z_<O8VD>
MX6%Q':06;F/>2[LX,C$$-C! &!BK$^I7-YX4^'NNS/NU&6\L@\@&"_G1E)!@
M=B&)Q[#TH ]'HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDM9(;)$>UEFFA()^1Y<^8>O?<?SK-\0^&1>Z9>1Z;::>\UY<I<7<5Z&,=SM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*_B]K'BW3;6%]
M,D2PTA+B!9+J.8B>=V;[B@?=4=_7Z9K0^*%K<V.F7/B)/%&L:<EO L4=E8N
MLTI8A1R,Y)8#Z"MOX@>%[GQ=X<33;2>*"1;J*?=+G&$.2..]+XO\,W/B6ZT
M)/$EII^I1WMQ&^<RA,[0,>Y[T 6/!6FZMI7A2RM]=U":^U,KYEQ+*VXJS<[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4=:** $ "C   ]!2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME)?IG?:I<(95QURH.16-X;\8+XFUW5;:S6Q:PL)#"LT=X))96&WYO+ P$.2
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M.-Q;)X"@@GTR/6@#?HK,L=9BN;JXMYGM(I%N6@MU2Z61I@J*Y.!RK8)RO)
M/>K4NHV,'VGS;VWC^RJ&N-\JCR@>06Y^4'WH LT54T_4]/U:V^TZ;?6UY!G;
MYMO*LBY],J2,UGZSXITW0]7TG3;R:..74I6C0O*JA-J%LG)Z$@*/<B@#;HJ@
MVNZ0FJ#2VU6R74#TM3<()3_P#.?TJ\2%4LQ  &23VH 6BLV/Q#HDT5Q+%K&G
MO';(LD[K<H1$K#*LQSP".03UJ2WUK2KO3SJ%MJ=G-9 X-Q'.K1@YQC<#CJ1^
M= %ZBJ5AK.EZJTRZ=J5G>-"=LHMYUD*'T;!./QIMEKND:E=2VMCJME=7$/\
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MR._E!E RHXQT]*6XE6YTW5=6DL[D62^+[:[+26S[O("P9DVXW;<#/3I7L=%
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MU+$;?FR[@'!.,8(&>*N>-##:^)?"&H743&U@OI5EE$1<)O@=5S@' +$5V=%
M'C$RVZ^ +_PU)83-XPDO)651;-YCW!G+)<"3&-H!5M^< #'M7K]V&.GS@\MY
M3#CN<58HH \:DT)[3X8>"9K:U%K##);SZDRV7G,H\ML/)'U<*[ D=LY[57U:
M*.;POXUU)+N?4+:>"U266.P%K!.RR<[/FRS $ G&.@R<5[;5#6M(MM>TBXTR
M\\S[/. '\ML-PP88/U H \XUM%\2:@Y\&6\D3V^A7EM-*ENT #.JB&'D#Y@P
M8X_A]LU-;SZ7JMYX-M?#MA)!>:=.KW0%JT1M(!$RR1R$@8)8J,=R,^]>H44
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MBO:H=9T;4;GQ7H>L6#VI2S2>"XCG9E)CE,>60@'YALZ' .>M '+^#/&^I?\
M",^&WU?2[M[>_=+0:E).C,\S$A24SNVDC&[],5KWWC];:34I[?2)KG2]+E:*
M\NUG16#)_K-D9.7"]SQT.,XIEKX,OH/!WAC1FN+<SZ3>6UQ,X+;76-B2%XSD
M]LXK)N_AO<)>ZJMGI?ABZCU"ZDN4O]1LQ)<VID.6 4H1( 22N67&<'- &I>>
M-+72+K7KQ([^^2":QC$2RJ4/G!0IB'&/O G)Y/I76:5<WEYIT<]_IYL+EB=U
MN95E*8) ^9>#D<_C7(WW@:\GN=3:">U2*ZN]-FB4@KM2V*;@0!@9"\ <?2NZ
MH \\\/\ C&YM_"^CPR13:IK&H37?E(\P3Y(YG!9W;HH&T=SR !6H/'T']F._
M]G7!U5;Y=._LX2(6,Y7< 'SMV%/FW>@/?BL1_AO<+INB,]OH^I7FFO=![74(
MR]O-'-*7ZE259?EP=I[BHM2\/CPWX>M]0NGT?2;N'5TNX/L5ELLX#M*!)655
M8J5+ R,!@L.@% '0P>-K@W&K6=WX=OX[[3;>*9K>!EF,WF,P41D=1\O).,<Y
MQBJ6I>,;TV>O:5=:<^EZI#HUQ?6[QW22C:HQG*X*L&*\8_&N<MK+6/&^H>*Y
M;;4[!_.MK*WCN+)W-JVR1W>$2#E@0<,PZ;\8XK3A^'E^+V^N8;+0=*CNM%N=
M-%K8!L!Y"I$C/L4O]W!X&!CK0!W>B3O+X=TZXGD+.]I$[NQY)* DFN;@\?F6
MWM=4DT2YBT"[G6&'46E3/SML1VCZJC,0 >O() KI].L3:Z'::?.5<Q6R0N5Z
M'"A3BN+B\&^(&T&Q\*7-UIQT*TEB_P!*0O\ :)88G#I&4V[5/RJ"VX\#I0!7
MTOQIJ>FV_B"[OM+O+S2[#5[J.:]\Y<PQ"3 V(>65!C/3';.#4NIZ]+;Z_P"(
MEFO+TV<4^DK MM,%*F5\'!((VL<;AW&:67PCXG?3M<T-;K2QI>L7MQ,\^7\Z
M"&9R615V[68J3R2,$GKBK6J>![N[O=5DMY[=(KN;37B5BV56V?<P/'<=/UQ0
M!)JGQ EL;;5]0M= NKW2M*>2*XNHYD4F1/OA4/)53P6]C@'%7=4\57]FTQLO
M#UQ=06\"SS3R3K!&=P)VH6^^P YZ <#->>^)K^33]'\6^'=+U;3L7EQ/ML9T
M<7WF3<M'''_&K,QP_8,>N*Z74O >HWVM7MU+;:-J$5S!%'!+J.^1]/VQA6\N
M/:5;)RW53DT 6(O%]_J?B_2%L;:0Z+?:(]]RZ*PRT>'(ZY4-MQG^+/:GZ1XQ
MDFTG1+/2-.O=5OKC38[UQ<W**T<1X#22$8+,00 !S@G@4W2_!VLZ5)X;DCFL
M)#8:0VE7@9G&5)0[XSMY.4Z''6F:3X/U[PU'I-SI<NG7%Y!I46FWD-S(\<;^
M625='5200688*\@]J +K?$")[73#::1=SWM]=361LRR(\,\08NKDG&!M/(/3
MGGI3)?B&EMIUPUYI4MOJ4&H)ISVCW"!1*ZAU/F_="%3G)Y[8INF>";VROM%O
M9[R"6X@U&[U&^*J55GGC==L8YX&Y1R>@S[4Z_P#">J27.OSVSZ9,FI7T%Q]D
MO8M\4T20I&T<F5.W)7((!Q@>] '0Z)JEUJ<$QO-+FT^>&385=Q(D@(!#(XX9
M>?;D$51U3Q-<6^MG1M)TF34[Z. 7,X$RQ)$A)"Y9OXF*M@8[<XJMX)\+W'AL
M:DTJ6MK%>2J\6GV4CO!; +@[2P'+'DX4#IQ3M0T;6K3Q1/KN@FPE:\M8[>YM
MKUWC&8RQ1U958_QL"N.>.10!S6L>)+WQ-JOA:VTR+4;>QO);@720W8MYA)$"
MKQL1R-A&3@X:NZUO6DT.*SFFA:2*XO(K5G4X$7F':K'VW%1^-<]I/@J[TV]T
M&ZDO(9I;2>]NKUPI7S);@$G8.< $XY/05T'B71_[?\-W^EK((Y+B(B*0_P#+
M.0<HWX,%/X4 8<GQ$T]#XE5;69GT-D3:"!]I9B4 3_MHI3ZBL6S\;:KI2>)[
MNZTJ[O\ 3].U6837 G0>1$ GRHIY;:"21QUXS4T'PYO%OO#5Q->P'[(&?5E4
M'_2I/-\]"O'03%CSC@UI7'@^]F\+>+M*6XMQ-K5Q<2P,2=J"1%4!N.V.<9H
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M)$& [?:9,D#L":[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)DBWM(S.Y=Y'8Y9V8Y+,3U)K$G^'^CSWUY="YU:!KR8S3QVVI30QNY !)56
MY  _"NJHH P)_!FB2Z;I]C!;R6::=DV<EI*T4D&1AMK YY[YSGOFH3X$T3^S
MX[5%NHY([HWBWBW+_://(VF0R9R20<<\8XQ72T4 <RG@+0DCOU:.YD;4# UU
M)+<N[RM"^]&+$DY!_3 Z"KVL>&;#6KJ"[E>ZM[R!6C2YL[AH9-C8RA*GE20#
M@]^1BMBB@#$T_P )Z7I5C965BMQ!;V=R]S$BW#\NQ8D-S\PRQX.>WI6W110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCDGC'0]>.9[KX;W(L]'NI+?3M6OK6:ZFO+6Y9HX9C</O;8V"5*L!C(Y&<XH
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M)%DDQO<* 6QTR>]>41^./$E]:RZU8Q:I-BZ=8=,AT=G@DA60H09@,[R 3D'
M/&*T-;\3:[I7B"\.H7\^DV4=P@M'DT[S;&6'"Y\R9061B2PY*@<=: /2R0!D
MG J%;NV:X%NMQ$9S'YHC#C<4SC=CKC/&:P_'J22?#WQ"(9S"W]G3MO"@Y 0D
MCGU (S[UQNGZ?K$WC#2+:UULVTH\,HTMW]F1G*^=\JA2-HZ@9P>!ZG- 'JE%
M>5?\)SK<^G:#8F69+VZDO5N[RQL#/)MMY?+RD6" 6."200.>.177>"]5U74K
M6^BU6"Z#6UQL@N;FS:V:YC*@ABA P025...,]Z .@CFM9;N9(Y(7N80JRJK
MN@/(#=QGJ,U,2 "2< =2:\XU_P 1:KIVH>*!IK6L5Q!>:7!#(\"G(F*JV\CE
MAACWX[8JIXJN-=MM.\6Z!>ZS]LC/AZ2_CN#;)&Z<NKQX48*D#KU&>M 'J0(9
M0RD$'D$=Z6O+IO$.L6U_8>'X;[456VTN*YFN[+2Q<RR,Y8*I4*550%ZXR?;!
MJ<>(/%>IQ^&; 2G2+[4);N&YFFLOF*Q#*R+&_3< #@]-W?% 'I5%>9W6J>+&
MM/%UW#KT<2^'V81)]B0_:"ENDC!\] 23]W!&X\\ 5/J_B;4+F]6*SUB>U?[#
M#.MIIFF&\E#NI;,S%2J+TP,@GDYH ] -S MTEJT\8N'0NL1<;V4$ D#J0"1S
M[BI:\W\.:O/K_B?P?JUTJ+<7?AVXED"#"[C)!G'MFMKQ7>ZW_P ))H&C:/J*
M6 U!;DSSM LK*(U1@5#<9Y(Y]?:@#KJ*\HN?%_B2YN-9>PEU$R:9<R6MM;P:
M,T\-T\0 8RR <%FSPI&T8ZUM6]]XF\1>(=4MK75/['@M;6UECA:U221998RQ
M5]P^Z".1P?<8H [VBO.=(\4:UXQFTBSL[M-):72AJ%W-%"LK,YD,81 ^0%RK
M')!.,#WJNOB;Q-J%QINB0:A;VU\=6N]-N;U;8,'6*(R"14)P&(QQG&<]N* /
M2+B[MK2&2:YN(88HE#2/(X4(/4D]!4U>/:D=4T:7XAWDNI+?26]K:;EGM(RD
MC&,88KC''(QTYKH-1U'Q->:QXN2QUJ.QMM%6-[=!:)(9&-NLA5RW\.<].>>O
M% 'H-%<!IFMZ[XOOA%8:DFDQV^F6EW+LMUE,LLZ%\?-T10N.,$YZC%;O@75;
M[6O!MAJ&I/&]Y+Y@E:-<*2LC+P/3 % '153?5M.CU2+3'O[9=0E4O':F51*R
MC.2%SDC@_D:\^D\2>(SX.N?'*:E$MI#))(NDFW78T"2%"ID^_P"80"<YQGC%
M:/ANQN/^%H^++J6],JJ+;"- @.&C)4;L9&T9'OGF@#O**X[6+O7;WQW'H.FZ
MJNG6ITPW;RBW25]XEV #=QCGG(/3WS6#H_B+Q/)IGA?7+W5()8M3OUL9[*.U
M54P=Z^8&^]NRF[KCG&.* /3Z:9(UWY=1L&6R?NCW]*\JUGQIJ]G]JU&SUF6[
M6WOQ$;:VTMFLA'YP3:UPRC+X/)5L;N,5G^([._\ [/\ BH_]JR>6K1YC\E,,
M#;Q,!G&>%^7\,]: /9Z*\SU#Q'K:^(;G0X=0U*-=-M83)<V6D?:GGED!;+@*
M510 .  3SR,4^TUSQ;K^I:'IXN/["GN-,FNKP/9AG#QRJGRJ_P!T-G/.>#Z\
MT >DT5YI-XFURQ\3O'J^H3Z9%_:/DP13Z=NLI[<OA<3J"5D*\_,0 W&*ZSQC
MK-WHNA++8"/[9<W,%G \HRD;RR*@9AW SG'M0!OD@ DG %5-.U73]7@>?3;Z
MVO(4<QM);RK(H8=02#UY'YUPFNW.O:9)>:#=ZV;R._TBZN(;HVT:2PO%MW*0
MHVE6#X'&1ZFNB\ VK67@+15>;S=UE#("(U3 **0,*.<=,]30!TE%<)X<OO$V
MN:9IGB7^V+6.UO90[Z;+ JQI 6( 60#>9,8/)P3Q@5F?\)+XC_X0P>.O[2B^
MR&3S?[)^S+L^S^;LV^9]_P S;SG.,\8H ].HKS+4=<\4G3/%VLVVL100Z%=S
M)!:_9$83+&BN5=CS@AL#;@]\FM4ZAK_B/7=8M=+U6/2H=,C@5!]G67SI9(A)
MERW1 &487!Z\T =Q17F-[XLUZ[UZ^TV*YNK4Z=! '?2M+:]CFGDC#L2Q4XC&
M0 !ACR<U8M-;\5^(-9T:P6X_L*2;23>WD;V@=UD64(5 ?H#G//;WYH ]&HKR
MZ\\0>*8]#U_Q$FKQ+#I.J3P1V7V1"LT23;<.WW@<' *XZ#.<UWWB&.:7PYJ2
M07#6\IMWVRJH8KP>QX]J )]/U73M7BDETV_MKR.-S&[V\JR!6'520>#R.*N5
MY5X.DUB33O#OAS3]6%E'_84&I37*6L;2$. B1J"-N!AB6()/'UJ<>)O$U_<:
M;HD&H6]M?'5KO3;F]6V#"18HC()%0G 8C'&<9SVXH ]-) !)( '4FHA=6[7(
MMA<1&<Q^:(@XW%,XW8ZXSQFN:\=070^%VNQ->L;B/2Y?,G$:@R;8SN^7H-V"
M..F>*YJ#3]7F\;:/;6NM&WF'AS,MW]F1G9?.7 52-HZCG!X'J<T >H45Y3_P
MG.MS66B:<TLZWMQ+>I=WEC8&>0K;R^6"D6" 6)!)(('/'(KK_!>JZKJ5I?1Z
MK!=!K:XV07-Q:-;-<Q%00Q0@8()*G''&>] '3T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=9TFVU[1
MKO2KS?\ 9KJ,QR;&PV#Z&KU(2 "2< =2: ,#4_"-GJ.HOJ$5[J&GW4T2PSR6
M,_E^>BYVAN#R,G##!&>M0R>!M+067]FSWNE/9VWV6-[&;:6BSG:VX,&YR<D9
MR3SS6Y%J=A<122PWUM)'&<.Z2J0I]R#Q5AI(T=$9U#OG:I/+8ZX]: .>3P5I
M4 T7[*]U;'2&<V[13'+AR#(KDYW!B,FH(? &DP30JMQJ!T^"X^TQ::;C-LD@
M;<"%QG ;D+G:#VKHX+VTN99(H+F&62(XD2.0,4/N!TJK::LCZ5'?7ZQV 9B"
MLLZ,%PQ ^8':<XSU[XH =I6D6NCI=):[\75U+=R;VS\\C;FQ[9JEJOA>VU/5
MHM52]OK&]2 V[2V<H0R1;MVUL@C&<D$8(SUJ32?$-MJD&HSD"WBL;R6T=Y'&
MT[,?-GL#FM&*]M)X%GBNH9(68*LB2 J3G& >F<T 8>F>"-(TB2Q>U^T_Z#<3
MW,(DF+X>92KY)Y(Y/4YSWK4L-(M=.O=1NX-_FZA.)YMS9&X(J#'H,**LV]Y;
M7BLUM<0SJIVL8G# 'T..]);WMK>;_LUS#/Y9VOY4@;:?0XZ4 8FJ>#K+4=1N
M+^*]U'3Y[J-8KHV-QY8N%48&X$'D XW#!QWJW8>&=,TN_M[NRB:%K>Q6PBC#
M?(L2MN QUSGOFM""]M;IY$M[F&9XCB18Y Q0^AQTJ>@#G;CP3H]UX4F\.2K.
M;&65YB1)B17:4RDAL<?,3CVJ]/H%A/<:3-L9/[*+&U1#A5S&8\$=QM8TWQ!X
MAL_#^DWU[,\<DMK;27(MA(%DD5%). ?IUJV=2M(H;>2XN(;?SP"BRR!2Q(Z#
M/4T 99\':4?"]GX?Q.+6SV&VD64K+$R'*NKCHP]:K'P'I<MGJ$-Y<7U[/?K'
M'/=W$P:4HC;E0$ !5!YP .IS73>9'YOE;U\S;NV9YQZX]*R-2\1VNFZCI5J^
MUTU":6+SA( L1CC9R6_[X(]J );[0++4-3&H3^9YXLY;+Y6P/+D*EN/7Y1S4
M4/AG3X/["V>;_P 22,QVF7[&/R_FXY^7]:=JWB73-'TR#4)IUDMYYXK>-XG4
MAF=P@.<XP"<D]@#6LK!E#*05(R".AH YZY\%:5<P7"$W,<LM^=16XBEVR0SD
M!=R$=.!C!R.3FHX_ VEBWG2>>]NI[BY@NIKJ>;=+(T+!HP3@ *".@ ')]:Z"
M>[MK52UQ<10@+N)D<+@9QGGMDC\Z4W, MOM)GC$&W=YN\;<>N>F* *%QH%C=
M:K<:C,KM-<67V&1=WRF+<6QCURQYI^AZ1%H.D6^F07%S/# NR-KF3>X4=%S@
M< <"H=7\2Z9HVA-K$TZRV@=$5H65M[,P4 '.#R>?8&HK?Q383:SJ6GRR10"R
M\C$\DJA9?-4L-OX"@"G<> -"N;;7H'BF":Y(LEV5DP=RG(*\?+\V6^I-::>'
MK"*^TN[C1T?3+9[6V56^41L$!!'?_5KBK$E^T6JBU: "W^SM.UR95 4A@-NW
M.>A)W=!BIHKVUGG>&&YADECY=$D!9?J!TH R$\(Z8ERDX\_>FIOJ@^?CSF0H
M>WW<,>*JQ> ]*ANXW6>^-E%<_:XM.,_^C)+NW;@N,\,=P7.T'G%= M_9O,\*
MW<#2HP1D$@+*QZ C/!JQ0!@OX1TR30+O13Y_V2ZN7N9/G^;>TOFG!QTW?I6C
MK&E6VN:->:7>;_LUW$T4FPX;:1@X-(-08:G<VTL*Q011QNMPTRX<L6&W;G(Q
M@<G@[N.AJQ;WEM=EQ;7,,WEMM?RW#;3Z''0T 8M]X0M+S5FU**^U&QN)(%MY
MS:3[!.BD[0W!Y&XX*X//6JL?@#2;73M/M+&>^LFTXR_9;FWGQ+&LC%G3)!#*
M2>C ]!WKJJY8^.]-DMHY[56F1M7&E-\ZC:Y<IOZGY<@D>HH GMO!.D6ALVC%
MP9+87'[QY=S2M/CS'<GEF..M-7P-HRV<=J5G>%-).C[6DZVYQG/'WN!S6G=Z
MO&FDSWVGB+4#%P$BN$4,<@$;R=HZ]S5J2^M(KE+:2Z@2XD^Y$T@#-]!U- '.
M_P#"#6BR6D\6K:O%=V]M]D-RER/,FAW%@KDK@X)." "/6B+P!I%M8V-K:S7U
MN+&\DO+>2.X/F([[MZ[B#E2&8'.3SUKJ:S/$.M1>'M#N-2EB:;R]JQPH<-+(
MS!40>Y8@?C0!D2_#_29II5-QJ"Z?-<?:9=-6XQ;/)NW$E<9P6Y*@A2>U.OO
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M+BXDWR3.0!EC]   ,  =*N0WUI<6[7$%U!+ N=TB2!E&.N2.*:=2L )B;VV
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M3GDYZUZ<JJHPH 'H!2T >&/#);6FAJ\MA::'::QJL9;4+8S6D+B9A#O4,H
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MDGDD=/PKD?B(FFQ7_A.^U2*W^RPZMMEFG0%45H9< DC@%MOX@5W5! (P1D4
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M:>;XLCN@;B.$8O([C+>;)*<AO+Y8DG@C'7@5ZP%4$D  GJ<=:-HW%L#)[XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>guyaragreement010.jpg
<TEXT>
begin 644 guyaragreement010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA)=?:5LHX0LH^?S/+$P.?+W=L9QQG%=7:W,5Y9PW4!+131K(A(QE2,C]#4M
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M+WP+K-]=6L<US9Z?<&W=QGRBR<D#H#P.>OYUTO\ 8^FC5QJPL8!J/E>3]I"
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M95,@6-R%!W?*/E'"X[GJ<UM16,>I1^*YM0UK4K67196MK39?R1_98HX49)2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **S-<\1:3X:LTN]7O$M89)%B0E2Q9ST
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MUL0W5M(8I4-M,=K X(R$Q^M '9T57L;ZUU.QAO;*XCN+6=0\<L9RK ]Q5B@
MHHHH ***JZAJ-EI5F]W?W45M;I@-)*P49/ 'U/I0!:HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTZ=/:J0OF1-&#CID8JQ10!PVCZ)XZT31;'2K;5?#SP6<"01M)8S%BJ@ $XE
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MDEG-Y$Z@$;'VAL<]>&4\>M '(2^"=2GT"YA-[IT.HR7T%["L%F([>$PNK*F
M0S [3DDYYXQ5>]\!:G=ZIJUT;C2'?5$4/=7%F99[7]V$98B6QMX)&>A/.:]!
MHH \^O/AW=7>C_8CJ$*O_P (ZNB[O+.-P(/F=>G'2K'BCP7J?B%[RW>XTFXL
M;I L;7UEYDUB=NTF%@1G^\,]#W(XKN:K7^H6NF6PN+N7RXC(D8;:6^9V"J,
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MAD ."58$']#5BB@#B;7PCK<J:-8:MJMG/I>D31S1&&W9)KAHA^[\PEB!C@G
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M&6,*S*R2'.7#@[@QR<MG)S3[;PMHEI9P6D&GQI##<B[09)/G#D2%B<LWN2:
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MGO3&R%,8.0Q.X\Y[UZ#X[U6[T;P;>WEC*(;@-%$LQ4$1"254+X/'RAB>?2M
M>'M)72H]+%DGV**43I#DX#B3S >N?O\ -7KJU@O;66UNH8YK>92DD<BAE=3U
M!!ZB@#SO6[2YT/5(-'AUK4[NTU73KSSTN;DR/&T2!A(C=5SDJ0..1Q6-X=T0
MWE_X(M5U/4($?PP\TCPSE9&!,'R!^JKDCIC@8Z5Z1I?A+0]&EEEL;!5DDC\E
MGD=I6\O^X"Y)"_[(XIVE>%M%T1X'TZQ6!H(WBB(=FV(Y5F49)P,JO';% 'G<
MVOZZFB6&CPW-]=22:_=::US'*B7$D,1D*KYC84.0H&[@X!QR:2]U'Q+8:3K%
MC]JO;$)=Z>+5KF]AN+J#S9U5PQ5F)4CD;^N6'(KT>?PQHMSI\]A-I\3VT]PU
MU(A)_P!<S;BX.<JV><@C%16_A#0;6QDLXM/3RI9DN)"[L[R2(0R,SL2S$%1C
M)[4 <?KNG:QI^IV]C9WVN:MI]O:%Y(K/5$2^CD:1CYK!MOF+C"J,X^4\&NT\
M+:C'JWA;3;V*[ENUE@7,\L0C=R."64< Y!R!QFC5_"^C:Y<1W&H6>^>-#&LL
M<KQ/L)R5+(02N>QXK1M+2WL+.&TM((X+>% D<4:X55'0 4 >0WFN:D+:UU_3
M[O7IXI-4B07T\\<-G-&\X0HEON)*[20"5!XW9KK/ E@+?7_&,HN;J0_VN4VR
MREE_U,39QZ\XSZ #M6I_P@/A?<3_ &2A7S/-5#(Y2-]V[<B[L(<]U K4MM#T
MVSU>[U6WM1'>W8 GD5F_>8  )7.,X YQGB@#D?$MS/J'BF?3K.77KIK6UC9[
M;2YTM4MV<MAY)6=2Q('"@$ *3@YK%T?4M7\26O@."XUF]@6_L[UKQ[:0(\_E
ME OS <'W&#R>F:[[4O">AZM?_;KVQ$EP8Q$[+(Z"1!T5PI <<GA@1S4UGX<T
MC3S8_9+&.+["LJVH4G$0D(+@<]"0/Z4 <%;ZIJNE6$M[)J=W<VFA>(7L[@SO
MN:2S<*N7/\10R!LGG"FNL\'7EUJ\&HZS-/(]M>WC_8HR?E2W3]VI _VBK/\
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M>!D"95_U9([9//!Q6=I?C25-.T*TT[3+[4KK4TNWB^TW:[E\F4 ^8Y'3YN,
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M* 0%3J<Y'TSWYP =+17/ZOXDN+36HM%TK2VU'46MS=2*9Q#'%%NV@LQ!Y)!
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M9)K1Q'.@ZQL5# '\&!_&@#A]*\#:G%XFTW5;Q-&MY[(L9[W3HVCFU#*E<2H
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M_P!X#Y6QN1P<1G/N>*H7OPZGN";K_B6W5U#J]U?Q6][$9()8IN"CC'## (8
MX([UZ)10!P*>!;U]%NX"FC6,]Q?VMR(-/M1%%%'#(K[=P4,[':W+#J> !71^
M'=%FT>366FEC?[=J4EXFS/RJRJ #GO\ *:VZH3ZWIMMJ\6E37D:7\L1G2 _>
M9!G+?3@T 9&K:+JT?B=/$&AR637#V@L[BWO2RHZ!RZ,K*"0P+-Q@@@]L5GZ3
MX)O+#5=)U&>]AFN(KJ\O+TJI4/).H&(QSA5P!R>@JU;_ !.\$W5PD$7B6P,C
MD*H:3:"3[GBMAO$>D+K']D&^C^W^8(O(P<[BAD Z8^X": .<U#POK\3^(+;1
M+O3UL=;9I9&N@_F6TC1A'*A>'!"@C)&#GKTJI>_#^_NM.O[9;NV#7.C66GJ3
MNP'A9F9CQT.[BNZLKVVU&SBN[2598)1E''?MWY!!X(/2K% ',>(?#-YK&LK>
MVM\+3&E7=BLBY\R-Y2FUU^FP]_2N>TCX?7]EJV@7OV/0+$:7*S3?8HW,EUF)
MD+M(5!SEL[3GJ?FKIM3\=^%]&OY;'4=9M[>YB(#QN&R"0".WH15G3O%FA:N8
M!8:E#.;B1XH@N1O=%WL!D=E(- '/SZ3I_ASX4S:-XCO88[;R989)USC<[,R[
M>Y;)&/<5H_#_ $R\T[PE;RZH6.JW[&]O2PP?,?G!';:H5?\ @-=00#U%% ')
MWFA:[9^(=3U'0;BP":JD8N%O ^89$78)$V_>^7&5..5Z\UF:?X.U[08_#]QI
MESITUYI^EG3;A+DNL;J65MZE03D%>A'(/:N\FFCMX))I7"1QJ7=CT  R37+I
M\2_!LA4)K]LV[&,!N?TH RK;P3K=CIVD&*]L9]1L-7N-09I%=(I5F\T$<9*G
M$F>XR.M0W7PXN':&\VZ5>W5OJ-]<K;7\1>"6*XDW;6X)5AA2& /(/7->C44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M56BBGG5&<GLH)&>O:O+]?-A9^'?'>E:O82S:S>W%S/:@6K2-.A4>0R, 1A
M.OR[36JKV.DZ[KC>(=-GN4U&RMELB+-YQ+&L6UH00IVG?N.#C[P- '?76O:/
M96,5]=:M8P6DW^JGEN$5'_W6)P?PI]WK.EV%@E_=ZC:6]F^-MQ+.JQMGIAB<
M'->+:+'<6<'A/4[F^%AIQ\/)!!=2V'VJ-)=Y+J?[A92G/?:16HEA!8^&]#NF
MO=4L!'?W<UG?3:6IA@63/#P9)2-LG9T(S_#D9 /7+6ZM[VVCN;2>*X@D&4EB
M<,K#U!'!KF=6\?:;IMQX@M(_+FO-'T_[:T/GJIE^5V*#J00$&>.-PI/AY-//
MX>G::RM[<"]F\N6V@:&.Z7(/G"-N5W$GCVR.#7,>+T2'6O',+6[^??\ AQ?L
MI6%CYI19]X# 8SRO&<\B@#T'2_$&EZNQAM-0LYKI$#S6\4ZN\6>S '(].:6W
M\0:+>:B^GVVKV$UZF=UO'<HT@QURH.>*XS4--32]7\'RZ=I6?(T^[0Q0)L+#
MR%(0D=,L.,]ZY;3YWNI_!1A>#%OJ$1DL;'2GB6P!1E*22L22<D+SC=R<4 >I
M^'O%.F^)CJ']GS1O]BNFMW"RJQ.. _!/RM@X/?%7=2UO2M&5&U34[.Q60X0W
M,ZQ[OIN(S7-> C#!>>)['RC#=1ZQ/*R&(KF-VRA!Q@@@'&*S/%%^8?'3QN;;
M31_9Z*E]-ISW<ET"[9BB .T8X)&"3N'&* .GU#Q/%::OIME#$ES%?6ES=).D
MHVXB"$ 8!R&W]<]N]7?#^J_V[X<TW5O)\C[;:QW'E;MVS>H;&<#.,]<5Y;X5
MM;I;#P@LEM.C0Z=K$;J\14QGS5PI'8\<#\J]#\!QO%\/O#L<B,CKIMN&5A@@
M^6."* 'Z1XHM]0&JM<B*R2PU)]/#RS#$A4*0>0,$[L8YZ4S4O&NA6'AK4-=A
MU&UO;6R0E_LMPCY;L@.<;CV%<)=::]UIFJVT]H\D4WC>(O&T9(>(O#DD=UQG
MGI4_C326-_XTBLK [9_#41"PQ<22*\W0 <L!CWZ4 >A3>(]$M;"WOKK5[""U
MN!^YFEN45)/]UB<'\*JZCXD2RUG3+".!9TOK6XN5F67@"((1C@YW;^N>W>N
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MM5TQ[FYU$>2 KAR=H7L,#Y<$DBNC\%QS?\)0)I(Y K>&].&]E(RP,N1GUYH
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M#)[?X?:)JL4VKZE';6EO/?:)<WTK17$6Q2Z*F[AEZA>G&,&@#TVVUA;F_DC
M@6T%G'=+,9QOPQ;[T?55PH.X\'D=JA?Q5H\NG75UI^I6-^T$,LHCM[E&+;!E
MAP3ZC/ID5P'BBWN-;OM>GTNUGGM[C1-.D6-(R#-$MQ(\D8']XQY&WKSCO3=3
MOM'U;QE')HME(A'AV_C>3[&\(?\ U>U &4$E<GZ;@* ._P!"\5:5KEI:M%?6
M8O9;6.YELUN5>2$,H8@CKQGK@5!I/CC0=5TJZU+^T;2WM;:YDMWDFN$ &URH
M8G. &VY'J*Y:STB*RL/ADUM8+#)$RB5DBPRAK.3?N..[8SGO6*D=C%I1@FDO
M=-O=.\0W<OVN.Q\V.V+O-Y;2HP^9&5L CH2.10!Z_9WMKJ%JEU97,-S;O]R6
M&0.K?0C@U6O]=TC2IHH=1U2RLY9O]6EQ<)&S_0$\USWP[N)[C2]1:6UM53[<
MYCN[6V:WCO054F41L20<Y!(X)7BN=\;""T\3:G<1W;6ES<6,<;P7^F_:K74%
M&_"(5^96&2" 1U!P>M 'IPN8&N3;+/&9U02&(.-P4D@-CK@D'GVK!U#QEING
M:OIEM+<6@L;V"XF-\URJQQ^44&,]#DOCJ,$5S%CJRZ'XKL]1UFQFTV.]\/6L
M211P/($F1W+0C:"=P#C ZFL'1&M=/'@.]UNPF2"WM]2+M);LXMG:9=K. #M[
MC/O0!ZS+K>E0Z8NIRZG9I8, 5NFG41'/HV<5#-K<#6MC=:=+9WEO=7*0B47:
MJFTYR5/(=AC[HY->9/:0?89=3S?Z582:_+=Z9=)9"6*W4PA"\D+#(C=M^#@8
M+ Y&:GLWN[W2M-8V4&Q/%<#K=V=J\$=VN,M-Y;9*\Y!/0D<4 >EQ:[I$^IOI
MD6JV,E^F=UJEPAE7'7*YS6-8>-['6%E.EM:S>3J8L) ]XBG;G'F+UW9P=J]6
MQ7"Z8XL=:TRRTX->HNK$MI.H::5NK'<[;YA.G! !+9;(((&:EBC59);".VD2
MZA\:)/(@@9<1-*2C9Q@KC/(Z4 >F?\)#HAO8K(:QI_VJ4E8X/M*;W()4@+G)
M(((^H-.N]>T>PO%L[S5;&VN67>L,UPB.5]<$YQP:\R?1D3X7:I,NG@7S:Z\X
M<0_O,B_ # XS]T=?2DUZ2PTS1?'MEKFFSS:C>R7%Q;O]D>031&(>45D ( CQ
MSDC;M)H ]<1TEC62-E=& 964Y!!Z$&LJPUV.^NM6("1V&GR^0UR[X#2*,R>P
M5<@9SU#>G,V@?\BYI?\ UZ1?^@"O-TM9Y?ABL#VTMR++Q!(^K6\:%VEC6\9Y
M!M'+?*5;'<4 >D6NO:/?64UY::M8W%K!DS317",D>.3N8' _&I[+4K'41*;&
M]M[H0N8Y#!*K[''53@\'VKROQ,]MKDOB'4/#MN[V2^&KFWN9HH&1)I208D&0
M-S* _3.-V.^*].T33[73='M;>TM8K>,1)E(T"\[0,G'?B@"9]3L$MY+A[ZV6
M&*3R9)#*H5'SMVDYP&R0,=<UF^(_$MOH%O&Y$4TS7-O"\/G!61)I1&'/7@9)
M]\$9K@/$_AR\U7Q5J7A2*&5=.U0G6/.4'8D@A:(KGL?-$+X^M5?LUWXE\&RZ
MYJFGRB?5M6TZ)[:2,Y$$4D:,"/0MYS?1J /3)O$NGS:+?ZAI%[I^HFT0E@EZ
MBQA@.CR<A/J:LWNNZ3I;0)J6IV5G)/\ ZM)[A4+_ $R1FO.O'6FF+4/%BV5D
M52;PL%Q#%@.XED ' Y('XXJW-<:9H_BCQ))XDLGE2_MK=;(FV:43PB+:T*$
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M#)(&2"1GK0!VU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=W?H9[:*RG\N&U0D[%V 8? QDMG//2@#T*BN5D\0:IIG]F:(]DNK^(9+4S7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M-U^RO=0T2XMM/EMX[EP-OVF(21. 02CJ?X6&0>XSFM*B@#S./X;WLMAKT2)I
MNC+J%M''%9:>[R6ZRH^_S6!"X).!A5''K5Z[\+^)=;U&[O\ 5)=*@:71+K3(
MX;9Y'"O*4(<LRC(^4Y&.,#KFNZN+B&TMI;BXE2*&)"\DCG"JH&22>P I8I4F
MB26)U>-U#*RG((/0B@#C+'PWX@N;G08];GT[[)HA$D;6A<O<RB,QJS!@ @ 8
MG +9/H*H6?@75?\ A(].U&ZCT:WGM+@RSZG8!HKB^7!^22,*$&[(W'+=.*]%
MHH \\_X0?58?#NFZ8]OHFK00&X\^SOU(C8R2EU=)-C,K '!&,'/M4MCX*UC2
M[/PT;:[M)[G2KN>5XIGD\L12AE\N-L%L(& 7/7':NWMKRVO!*;:>.812-#)L
M8'8Z]5/H1Z5)++'!&9)I$C0=6=@ /Q- '+^'HC?>,?$6N#_CV/DZ=;M_?\G<
M9&'MOD9?JAK4\5:3-KWA/5=)MY$CFO+62!'DSM4LI )QSBM8*%&%  ]!4/VR
MV^W"Q\^/[48_.$.X;]F<;L>F>,T 86G^';FTU?7KQY8BFHV]O%& 3E3'&RG/
M'J:O>%]*FT/PII.E7#I)-9VD<#O'G:Q50"1GMQ6M45U=065K+=74R0V\*%Y)
M)&PJ*!DDGL* .;\7:!?:U);>59:/J5FJ,LMCJ:87<<8D20(S*PP1C'(/:L>T
M\%ZYH]GX=FL+NSN;_2FN0T-S)(L1CG.=B/AF 3"@9!R!VK;_ .%B>##_ ,S3
MI'_@6G^-=-UH \]M_!.N6Z'4?ME@^M1ZS)JD(PX@99(A&\3<9'&[#<] <=16
MA+X>\1:K=:?>ZK>V8>VU6.\%K"28X8EB=-JN5#.Q+Y)( ],=^PEECAB>65UC
MC0%F=C@*!U)/:HDO;62\DLTN(VN8T61X@P+*K9"L1Z':<?0T 9>G:+/9^*]<
MU9Y(VAU".V6-%SN7RU<'/&.=PQ6GJ%C!J>G75A=+OM[F)H95]58$']#5BB@#
MA$T7QU!HB^'X=2TD6JQ?9DU7]X+E8L;0?+ V^8!WW8SSBK1\/:[HFLW5]X?F
ML[I+VVAAG34YI ZR1*463>JL7RN,@XR1G/-=C10!QFA^"I]%OO#\HNXYTTZU
MNX[AR"K2RSR)(64= -P;C/<=:8?!E\?"\NE_:+?S7UO^T@V6V^7]K\_;T^]M
MX],UV:RQO*\:R(9$QO4,"5STR.U/H \KTO2O$.NZ7XJT:WFL(M*OM9OH99Y"
M_GPHTA#A5 VMD$X)(QGH:OZMX!O;W7-1G%MH]];W44<=K-J.^1]/"QA"(X]I
M5N1NZJ<GG->BXQ3(I8YDWQ2)(H8KE&!&0<$?4$$?A0!R/A?PE?:)?Z5<7,]N
MXL]"BTMQ&6.YT;.X9 ^7'XUSOB/2W\/> [+2A?0+XC&J276DK'DF25[AFP <
M$C9*0W8 DUZ3-J-E!M\V[@3=,MN,N.96Z)_O'(XJR54L&(!(Z''2@"AH>E0Z
M%H5CI5OS':0K$&/5B!RQ]R<G\:I>*M#GUZRL8+>2.-K?4;:[8R9P5CD#D# Z
MD#BMVF12QSQ++#(LD;#*NAR"/8B@##T'P_)I>J:_=W!AD&HW_P!IBVC)1?+1
M,'(ZY4]*WZJG4K(26T9NX-]RS) -X_>,H)8+ZD '/T-6J ,#Q7I-]J]E!%:1
M:;=1I+NGLM2BW0W"8(P6VL4()!! /2N<TWP#?V>G6D'FVD"Q:Y%J8LX9':&V
MB5<&.,L,G)YZ 9)X%>A50U;7-*T*V6XU74+:RB8[5:>0+N/H,]3]* .6\1^#
M=3U:\UZXL[V&'^T+>SB1&9UW>3([.CE>0KAMN1SUK+C^'=_]JU*>&ST+2H[S
M1+G35M;$-A7D*D2,^P;^ASP,8'6O0-,U;3M:LQ>:9>V]Y;DE?,@D#C(ZCCH?
M:KE '-:'X<N=,\03:A+-"T;Z9:605"<[XC)N/3H=XQ6MK=E<:EH5_8VEVUI<
MW%N\45PO6)F4@,/I5^B@#S?1O %_9:]H&I?V?H&GC37?S_L6]Y;K=$R;VD9
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M[MRNC!6VL"6'0Y![5F3_  _U'[!I,8M]#N8[>>>:ZTH1FULY#)@)@(AW% ,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M87OB.52)=;N3<Q[A@K;@;(1_WPH;ZN: .KHHHH **** "BBB@ HHHH ****
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M(=I]DTYK72M0NKV^GFM4LD"++'-%]]'RVT8P><XP,T =C17*W/C.1+J>VL]
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M6.>&.:)P\<BAD8=&!Y!KEY_&(EUK5='MM*U%QIP*W=['Y82',(D4C<V6/.,
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M5P1D#C //KVKK-:L7U30=1T^-U1[JUD@5FZ LI4$_G5U6#*&4@@C(([TM '
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MHAC0[N.#E3Z\5N*RNNY6##U!S2T %%%% !1110 4444 %%%% !1110 4444
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MBM$GT_4EMI)53(V7&YER/1E^89:MCP?X-C\/Z;HKW+;M1L-/:S8QM^[P[J[
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M-L8+=V$S E?F8.0" 7!]NU 'NJ7]G+YWEW<#^1_K=L@/E_[WI^-2F6-0A,B
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MN"!QGK]*D5E=%=&#*PR"#D$5Y7XELI='U^Y\,Z7 8+/Q9'%%$(5VI;M'A+C
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M >IH N@!0 H  ["EKA(?&L[^-C;WUM>Z3I]OHT][<0WT:#[LD8$@9"V0%+C
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M::TO(K*>S>%6F623!3 5B&!# C!-68?&MD$U%;^QU#3KFP@%S):W$2M(\1R
MR>6S!LD$8!R#P<4 =*0",'D4@    P!V%<S;^-('O9+.^TC5--G%I)>1+=I'
M^^C3&[:4=AD;AP<'FHM+\?6.J76F(-,U2VM]4'^A7=S"JQ3-L+[1ABP. 2,@
M XX)H ZL*%S@ 9.3B@JI !4$ Y'%<_%XRTV;0[35%BN=MU>"Q2W*#S1,9#&4
M(S@$$,3ST!-4/B)K6I:/HMFFF)=B:]OH+8SVJQL\:LZ@A1(<;B"0,@C/7'6@
M#L*0* 20 ">OO7-VGBBSM_#>JWLWV^1="#17C3JGG2-'$KL<*0I)##I@9SVK
MG/%GBO5;*7Q$UA=M#';:):WEL#&I*2/+("W(.<A0,'(XH ]'VC=NP-PXSBEK
MG?'FIW>C>!=8U*QF\FZM[<O')M#;3D<X((-,L_&ME-=_9KZRO]*9K9[J%[Z-
M46:),%V4JQP0""5;# 'I0!TM(5#=0#CGFN9T[QO:7]W8Q2:;J5E!J.18W5U$
MJQW!VE@!ABRDJ"0'"Y JI8_$?3K[[!,FEZK'87MP+6*^EA01><6*A3\V[EAC
M.,9[T ;?B'0O^$AT_P"P27]S:VLAQ<I;[09XR,&,D@D ]R,'WJ]<6%M=00P2
MQ9BAD21$!*@,A#+P.P(!QTX%8&H>.;*QN;Y4T[4KNUTYMM]>6T2M%;G 8@Y8
M,Q4$$[0V*YG6_%.HS>*]66*[U6RTC3='^V++9Q6\B.664^:=Y)884;0,<CG
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M   %4  8 %:U% $%E9P:?:):VR%(DS@%BQ))R22>22222?6IL D$@9'0TM%
M"%02"0"1TSVI:** "DVC<&P,CO2T4 (5!() )'3VH*@XR <<C/:EHH 0J&QD
M X.1D4%0PPP!'N*6B@!"H;&0#@Y&:6BB@#'7P^K>)SKES>W%P\<9CM;=PHCM
M@P7>5P 26VCDDXR0.*V*** $"@$D  GK[TM%% !1110 4444 %%%% !1110
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M$OBVVU:'6#%I-C<Z?)9P6,4PG/F/_P MI&  XP %'J<FNXHH XA--\2:Y?Z
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MBV^K6KD6EPGF(TGRG;[^E7P0P!!!!Y!%>'^%U\/G2/!$.I?8!H?V:X%TK[1
M=0 CVB?^'?LW8#<Y_"N[^'IMQ-XB32B#X?74,:=L.8P/+3S1'VV>9NQCC.<4
M =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN8$L-3BNDM'NX(KBU*&YC7 )3/7DKP<'GI5'P_XOEU:S\+7=[,]E)J%G+--
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MQC86^CR/;7\MO))IPU".YCMQ,(X2R@,5) ).[@>Q]* .G6V@2=IU@C69QAI
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M.HHH A:TMFB>)K>(QR'<Z%!ACZD=ZD1%C1410J*,!5& !3J* "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5'[JS% %(]R*W-*U2SUK3(-1L)3+:S@M&Y4KD9(Z'GJ*YKP!_K/%?_8P7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU=K9M0TJVN&MD\N(NO*I_=]U]CQ5BUT+2[)K5K:QAB-HLB6^Q<>6KD%P/3)
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M:* /'+.PN].T?P[,\7B'2-0CT2*V-U9V)NE<J3F":#8Q!!.03C.X\\5VD/\
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M255V0JK ,V"I/ QD\'FM)M'F%Q\.T6PD\JQ#></*.("+5@-W]WYL#GO7>44
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MUOI&<,F"Q0>4 1\PQDBK?A?Q[H_B&RL!)?6-OJETA;[ +A6D&">,=<X&<8H
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M@\C\Q0!L45EZGXET/1;B*WU/5[*SFE&42>=4)&<9P3TSWK3!#*&4@@C(([T
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M$^/8U[!10!X=K<VI7WAW4K00W5K<_P!HF5]'L](;"@7 ;S7F93NR!OW*1DD
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MV$]E;W.M330QS0F(LC1Q_-M(! )R:[.B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7XE7=Q8?#K6
M[JTN);>>.WRDL3E&0[AR".1755B>+]#E\2>$]1T>&9(9+N+8LC@D+R#SCZ4
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M)MHM1-NUVB!9#;[O+..!C=STQ5+Q#HLNLOI#1RI']AU&.\;<"=RJK# ]_FH
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ML((EWN 1R-Q"K]&-5?$7C'4-#-_,FAH]A8KNDGN;U;=IL+N/DJ5._ XY*Y/
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M[.CT%X-2N'N?M-_8B6XM7?[^S(PXSD@-C!/<5WUM MM:PP*<K$@0':%X QT
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MD^:!DW><6..=FQNPR<=,U2T[PIKK'0+76K^QEL-$*2Q?9HV62XD2,HA?)PH
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MJGG/7'%=-X;TN30_#&E:3+(LLEE:16[.HP&*J%)'Y4 :E%%% !1110 4444
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M,XPHP6*@GWZ8'%3'6-<_X0-O'G]MW(N!*91INU/LWE";9Y.-N[=CC=G.[\J
M/5:*\NU*ZUZXL?&^K1>(KVU_L2XE^Q6\21[/D@23#Y4E@2<8SQS1X@U?7UO;
MF^DNM7M]-6TAD@GTA(9TM7*;G-Q"?G89.>.-OH>: /2A>VQOVL1*OVI8A,8S
MUV$D9'J,C'MQZBIZXS7[M1J7@K6;6993<7HM?,08$L,T+L>/3*(V/:K7BS6I
MO#FIZ-J4MPR:0SS6]ZF!C)C+QO\ @8RO_ Z .IJO8WUKJ=G'=V4Z3V\F=DB'
M@X)!_4&O,O#7B;Q#?2Z9H.HW976)-06YN6"@8LS"L^WITW.L6?K5+PZ-5T;P
M1X>UF#6[LK)JB6S6)5/(\F2Z,9&-N[=\V=V>OM0!ZU:7]K?B8VLZ2B&5H)-I
M^[(IPRGW%%U?VME);)<SI$US+Y,(8_??!;:/?"D_A7G,6N:OJ&HQZ*FI2VHO
M?$%_;M=1(GF1PPJ6$:9! )P!D@G -)XDL;])]!TK_A)6NID\11B.?;&US;(U
MM*=K\;2V,E25Z$9!H ]/JI=:I8V4=U)<W<,:VD/GW&7&8H^?F8=0/E;GV-<]
MX5GOH/$7B'1+K4;B_@L6MWMY;G:90)$)*DJ!D KQQGFN0\4V3KJWQ)G^W714
M>'HCY)*[#N2<8/RYP,<<]SG/& #UE'62-70AE8 @CN*=7FS7>K>$[[1G?5[O
M4XKS3;F6>VG5 @>*)9%\O:H*CJ,9/!'?FJ&@ZWXHE_X1[4V&M3?VA+#]L%W]
ME6S,<HZPA6WC;D%>I(!R,F@#TK5M8T_0K%K[5+N.UM58*99#@ DX K-TSQSX
M8UG4([#3M9MKFZESLB0G+8!)[>@-97Q0\_\ X1S3_LHC-Q_;%EY0E)";O.7&
M['.,]<5KZ9_PECWFW6$T9+0J039R2F0'MC< * -ZBO,O#OB+6+WQ?<:!=:L)
MH-$,TAN(U ?4\<!/NX'E[L/MZMM]ZS-&\1^*;W3])U]4UJ26\N(FFCE^RK8&
M%WP43YMX(4\'J2.1SB@#V"BO/;>;5M;CUO63XGDTD6&HS6T$3+']ECCA;:3*
M",MNP23N&,C&,4Z?Q!J2>%/B!>"](FTVXN4LY,#]T%MXV4#CGYF)Y]: .WN-
M1LK5;DSW42?9H?/G!89CCY^8CJ!\K<^QJ:&:.X@CFB</'(H=&'0@C(->62?;
M+;7O&.K1ZE="XB\-P7"J=A3>8YR.-O0%<CW)SGM=N/%NH^'HYY+R9KD7VBPW
M>F(R@9N0%C:(8'.YI(F_X$: /2:*\JEU'Q'-KUUH<EQK\YTFTMD>;25M@99W
M3<TDGFD9&> H&.#FN[\*7VH:EX3L+O58TCOWB(F"%2"P)&1M)'.,X!XS0!I6
M-]:ZG8PWME.D]M,NZ.1#PP]15BO'O"@U71?!?@K5(M;NY$N[N"TDLF5/($,C
M%< ;=VX<'=NZY[<4_P 4>)=5M[37-8TO4];N6L+EQ%);V\,=A$$8*8WW_-(<
MY!9<\],8H ]>HKS#Q-JNN6&M:I>7%]J]MIENR&VO--BBN;:V4(I<7$7^LSG<
M2?[I&,5V'BW7)=%\$:GK5B$EE@M3+"2,J21PQ]AG/TH WZ*X&Y;5O"^L:&C:
M_=ZI'JAE@N$N5CX=86D$L>U1M *X(Y&"/2KWPY74[KPK8:SJNLW5_<:C:Q2M
M'*$6.+C^ *H/((SDG)&>* .PJO=W]K8^1]JG2+SY5@BW'[\C=%'N<5Y?XB\5
M>(M/34M'LKMGU6RU&:[#%02]@D7GA>G?(BS5Z7Q-J&H7L>I65ZW]ES^(;6PM
ME"J0T2H?-/3^)R1_P"@#NHM=TN>>*&*^B:6:>6VC4'EI8\EU'NNTY^E6)[^U
MM;FUMIYTCFNG*0(3S(P4L0/P!/X5Y;HG_(RZ#_V,^M?^@SUT?CJVGO/$G@VW
MMKR2SD>_G'GQ!2ZC[-)NV[@1DC(R0<9S0!V]%>9RZUJ&E0>(-'GU^\+6FIVU
MK:77V99[N198DD,2   ORP#$' Y/2JMMJ7B5KCQ)I=C<:NDUMI\%_9)J@A:?
M>'?<GR9^5PFW#<C)Z<4 >K45Y?J_CR^N-/UGQ!HDN[3[#3(%B0J"K7-P5;<?
M7RT9#C(&6.:O^'[SQ!:^*;"TG37)+&ZAE^T'6#; K(H!5XO*;.#R"N,#(H [
MF:^M8+VVLY9T2XN=WDQD\OM&6Q] :L5RWB'4;NT\7>'K6"8I#<17AE7 .XI&
M"OY$URNC7^O0:+X*U^Y\07EW+J]Q!;W5M(D8A*21L<J H(8%0<YY.>W% 'J=
M%<WXUU%]/TBW6+4+BSEN;J.!/LMN)IY<Y)2('@,0#\Q!  )K@Y_$GB"PT[Q;
M:Q7>IP/91V,UFVJ"%YXC+*5;.S(*D+P#R,F@#V"BN"\C6K+Q7<>'XO$5[<"^
MT::YBFN5C+07"NB!EVJ %^?.W!'%'AOQ/?\ B?5-#ACD:'[+8O<:O& /]?N,
M*Q'T^=)6_P" B@#LM2U2PT>Q>]U*[AM;9/O2S.%&>PY[^U5-&\3:+X@:5=*U
M&&YDAP9(UR'0'H2IP0/?%8'B)4F^)GA**\ -H(KN2!6^Z;D*FT_4(7(_&K_B
M*[T72M234Y8T?7HM/NGM%&[=)&BAW4XXQD+][N>.: .FHKS>*[UK2M-\+Z]+
MK]S?/JUU:PW=K(L?D,L__/(!05V9!')R <YK+%_XDD\/VNN)XENTN)]=;3DA
M\J,PK"UTT/*[<LPZ@D]@* /7**\LUC5-<T*W\6:=;:[<RO9G39+6[NU1GB\^
M8HX.% *_+Z=S6AJ6I7WA#6)K.?Q%/-:7&D7%V;B^C60VDL10;\(%RIW_ '/4
M<=: /0Z*\RT35]7MO&NAV<D^OO::C#/YW]L1PH)'1 P:-4^9/<$ 8(]*J:1J
M/B!/#7A7Q)<>(;RXGO\ 4(+6XMG2,0-%)(4Z!<[AP=V>N>W% 'K%5K_4+32[
M*2\OIT@MH\;Y'. ,D ?J0*X%_$&KI-/X4^VO_;3:RL$5QM&\6;?O_,Z8XC#Q
MYQU K6^*?_).-5^L/_HY* -+5/&_AG1;][#4M9M;:Z0 M$Y.0",CMZ5JZ=J5
MCJ]C'>Z==PW=K)]R6%PRGUY%<%!>:Y:_$WQ:-&T>VU -'8^89[[[/L_=MC'R
M-G//ITKHO!F@WNB66HR:B;=;O4;^2^DAM23%"6"C:I(!/"Y)P,DF@#I:***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ:Y1I%=5#.%W',K*#R>,G.,U<@\:'4/$2Z7I.DSWT0BM[B6\65$CCAF!*O\
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MAZ30H;UYK+2;*2ZE#BVTNW"1Q(!@ MM4R'J<D#K@ 4 =+1110 4444 %%%%
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M.: /5**\P77O$NGZ3?WEPU^MIH]]!,S7L<0GGLV&)5D"9&4R6##!( ]ZFO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4]5TNTUK39=/OHS);2[=Z!BN<,&'(YZ@5<I&944LQ"J!DDG
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M6\=IM#>>\JB/!Z'<3C%26UU;WMNEQ:SQ3P.,I)$X96'L1P: ):*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N5^(MM<77@JZC@AEGC$L#W,,()>2!95,J@#DY0-QW&17544 >1>()M+UB
M[O;KPK"C6T/AV_BOYK:$I&VY!Y,9X + ACCJ!GUKT/PIIEGI?AG3HK.TAMMU
MM$9!'&%+-L'+8ZGW/-;5% 'C5]#;13Z]:RV9:*#Q1%>ZA;I 27L=D>&( ^=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=UC4*<E025= V<<GGB@#H=1\:Z=IMQJ4#P74KV+P0$0H&,T\W*1(,\M@J3G
M 8<]:J3^/H-/MM3.K:3?6%W86OVQK60QNTL.<;D96*G!X(R,9%44\&:L?"4
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M/)=V>HV,%M<7UCY$C).R B2+C'4\X!P>U73I>O1?$JQAE\1M/=C0[DB<V<:
M_OHP!M''4J?^ ^] 'I5(S*HRQ &0.3W/2N%T3Q;J.N3>&[&,I%>LDTNL+M!\
MOR28F3';=*1CV4U+\28+J>V\/BUO6M2=;M5R(U?DMPW/H><=Z .QBN8)Y)8X
MIHY'A;9*J,"4; .&'8X(//K4M>5$:_:ZC\0-1TS6([1;"X$_EFU63SW6TC8A
MR>BD #Y<'D\UH:EXHU"\NK>.UUB6S>2PAN%M--TQKV;?("<R_*51.F!D$\G(
MH ]$+*&"D@$]!GK2UY7H^HZGXD\3^ ]9FO1 ]UI%S++#'$I4D-#O SR V1],
M<=:[?Q=JDNDZ$9X;^VL9'FCB$\\32D!F .R-02[XSM7N: -VBN&\&^(=1O?$
M^IZ1>7-W=V\-K#=037MA]DF^9G4@I@97Y00<#OUK0US4-4NO%ECX<TN]73_,
MLY;VXNO)61]JNJ*B!OER2V22#P/>@#J:*\XUCQ)XATR[TK09[PM=S"XEN+[3
M+!KF0Q1LJIB( A7.X;L@@8XZBJY\3^*I['3K)&DL[NXUK[ M[=Z<T1FMS"[B
M3RGQA@1CT)7T.* /2IKF"VBDEGFCBCB0R2.[!0BCJ23T'!YJI=Z[I&GRQ17N
MJ65M)*ADC6:X1"Z@9+ $\@ $YKS2_35M)UCQS=7&K+?2VOAZ%W$UI'LF8)/C
M*XQ@$$X[[L&HM32\AU_Q3JQNH93;>%XYT@EM(V3!2?"<C[H89]\X/% 'KZLK
MH'1@RL,@@Y!%+7"6]_KWB#5KO3M,U.+2HM-L[9BRVJR&:65"W(;A4  &!@G)
MY&*AU?7]76]MK%M;2VNQ91R20:-I[WTCRDD%CE"$BX^7.">>>* /0"R@@$@%
MN@)ZTM>36.JZGK^L^ =<N;WR'DL;V2:**!<,4*;\9Y&X #VQQ2Z/XW\2:A!I
MFL1QZE<K>SQF33DT:001P.V,I/MY95(;<3M.#P* /4[BY@M+=[BYFCAA09>2
M1@JJ/<G@5+7-^/[V33O FKW<20O)%#E5FC$B'YAU4\&L34-0\37VN^*H+#68
MK&VT>.)X%^R+(TC-"'*L6_ASZ<\]1B@#OZ*R='O[G6_"-AJ"E8+J]L8Y@0,B
M-WC!Z'J 37"VGQ!U.:_\+^9Y26QC6+6\J/DGD9X4P?X<2Q/^!% 'J%0QW=M-
MYGE7$3^7)Y3[7!VOQ\I]#R./>O.8->\4ZW<>'8+34XM/768;V\\QK59&C@5X
MS" #C)V,,Y_O'T%9VK2:AJ3PQQWL=HT'C(6P>&V0;CY:E7;CEASUZYYZ"@#U
MB*Y@G>5(9HY&A?RY C E&P#@XZ'!!P?45+7FEWX@UB"YU&WTV2TMYY/%$6G"
M4VRD>6]NA+,!C<P)ZDYX SBG7GB?7]!EU[2IKZ&_NX'L$LKN: )M-T[1_.JX
M!"E<\8STH ])HKC=-N=?T_Q]!HFH:NFHV4VF2W2N;9(I!(LD:X.WC&&...YS
MG%2^-M2UK3FTXZ<MY'8.TGVVYL;074T6 -F(SGY2=V2 <8'K0!U$ES!%-##)
M-&DLQ(B1F :0@9(4=\ $\=A4M><V_BF2=O"EP]Y9ZF)+F]2:XBM=CD1P2,!M
M8;HWPH# 8[CH:ACUOQ4-%\->(7U>W:#6;ZS66Q%JH6&&=QA4?[Q8 @$G/4D8
MQ0!Z917EUYXA\4QZ'K_B)-6@6#2=4G@CLOLBD311S;<._4'!P",=.<YJ35?%
MVMW6OZY;Z=-?VT>F2"W@CM='>[2>0(KGS7 .T98#"D''.>10!Z;45O<P7<"3
MVTT<T+_=DC8,K?0CBN&T_6O$?BK4WMK6X_L)K+3[:>XAEM1([3S!FV,&Z(NW
M'&"<]16A\, Z_#C1A)MWB-PVWIGS&SB@#J8;F"X,@@FCE\IS')L8-L8=5..A
MY'%2UY5:GQ!I]GXVUK3=5@@AL-4NKA;1[=76?8BLP=CR,@8&W&.O-:=UXXOM
M/CUL2J'FELK>]T:,J 7\X",1G'4K*1GOAQ0!Z%4)N[99HH6N(A+-N\I"XW/M
M^]@=\=\=*BC@O/[(6"2[Q>^0$:Y6,?ZS;@N%Z=><=*\>\-VFJR:9\-HK;5!%
M/+#>,L[P*QAC\M<JHZ,>#@G/7OC% 'ME%>87?C/7-+T:[LI9_M6HQZ\-(CO(
M[,NVQHQ+YGDI]YPI(P."<>];OA#6M8N]8O=/ODU&XLTA2:"^O--:S;<20T9!
M4!L<$$ <$^E '675W;6-L]S>7$5O @R\LSA%7ZD\"H=.U;3=8@,^F:A:WL2G
M:7MIED4'T)4FN4UNWBU7XI:)IVI1K+80Z=/>00R#*27 =%R0>"55B1Z9S4WB
M Z%X2FU#Q'!'#%JZ:7,XM8W""Y2/#99!UP<#=U 8T =C17#+?^(]"O?#\VJ:
MK#J,&KW"VL\"VRQB"1HV=6C(Y*@J0=V3@YS6#9:_XQN-!\.:P=:M=VKWPL6M
MS9+LB5O, D!!!+C9G&0.<8[T >KT5YG>^(_$NFV^LZ:FHP7-_9:M8VL%Y-;J
MH9+@Q\.JX'&\C(QQ5Z\UW6?#FHZEIE[K%G<_\2IM0MKV]A$2PLKA&5Q&/F7+
MJ1@9ZCGK0!WU%>;:-XIU4>*8=/?4+V_M+JPGG66]THV962/9S'E5+*0W<'''
M-,T?7O$ZZ7X/UN_U6"YAUJ:&WGLUM514$D;,'5A\V[*@GMR< 4 >F4C,J*68
MA5 R23@ 5P%MXJU>6&UT-ID_M_\ MEK&>3RQ_J$_>M*%Z#,.T#W<5?\ BHDK
M_#36_*G,16#+$*#N7(RO/3/K0!UBW,#W$ENDT;3Q!6DC# L@.<$CJ <''T-2
MUYK!IVO3?$'7X++7A:RQZ;9>=<FT1VE?]]M^4_*!US@9Z8(IB>,M1U31O#TQ
MU7[!/?:?]IFAT_3WN[F1\@95-K!(\YY/?CM0!Z865<;B!DX&3U-+7D3ZGK'B
M73?!=W/?M;W2:_/:NPME4LR+.H<H<[3M0@KTRQ]!7I7B&_?2_#U_>Q7%I;20
MPLR379(B0]BV.2,]AR>E &G17E]GXNU>#6C:?VC>7]M/IEU<I+>Z4;/;+$%(
M,>54LIW<@@XXYJUI>L^)HE\(7^H:M#<0Z^%CEMDM500%H&E5D;J2-N#G(.>
M* /1JBN+F"TA,US-'#$" 7D8*H)( &3ZD@?4UPNF>*]6OTT32&DC&MG4)K?4
MV$8PL=OS(P';>#%C_KI6WX\O9-/\)37,20NXN;5=LT8D7#7$:G@\9P>/0X-
M&ZEC:1W3W4=K EP_#2K& [?4]34]>:ZCK7BE[7QCJ=IJ\%O!H,\OD6YM%?S@
MD*2%78\X.<#&#R>3P*;XA\4Z]9W\MQ)=7&DZ;]EBFM+E--^U6SL5RPG=060
M\<8XYS0!Z7N7=MR-V,XSSBEKRN_O=1LO$_C'7+/5$?R/#<5W"JQ*T9.V=DP>
MI 8%O?=S6UI^I>(;/6/#%OJ6J178U?SY9D2V6,1!80X12,D@-GD\F@#NJ*\Z
MU3Q5KD5IKGV.>!;BV\0VVG6S21!E6.009##C/,C=\TU[CQ=_;&O:0OB2/&FV
MD5XER;"/S'+A\1D?=V@QGG&>1SQ0!Z/17E2>.M7UJ>SA@EO;%1I-K>3OI^E-
M>,\TREMIX(5 !]3D\\5?B\0^*-6?PI9;O['NM1BO/MIELSO'DE KHC\KNSD
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M.WC33S9K_:EZEQ/(6D5LC8S*JKL]<DL2:ZC6O#MOK-Q:W7VN\LKRTW"&YLY
MKA6QN4Y!4@X'!!Z"F0^*+"77-0TUY(XELX;>7[0\JA)/-WX ]QY9_.M WD@U
M>.S%L3"]NTQN/,7 (90%VYW'().<8X]Q0!DV7@S2[!]/EB-P\UE<372RRR;F
MEEE5E=I#CDD,>F.U<1:>#=5N;[1;5](O["#3]1CO'WZDLME$$8MB",,7^8\
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MM I+K'(&*X[''2L70O&$&NW6G01VDD1O=*74U+,#M5F"[3[\]: +NN^'+'Q
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M^T0^2)O.C\H]'W#;Z=:J6NI"2TGN;R-;)(II(\R3(055BH;(.!G&<'D9P>:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M);7$2O$$;SL[!C ^Z.16!X>_TK3M$6Y>[*OX)NT=K<;I@OF1#Y!W8#H/:O:
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M^7FW ;N-Q&,#J1G'>N7MXKRV'A9]9GTZSTM;"X%F^O6S2P(QG)C# N@5_(V
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MW;P$QK&^ 1Y:'.026ZGB@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;S6C$-XFQS@XW8ST/:@#3HI%=7&48,.F0<UAW'BJSM_&MIX6:&<WES:-=I(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIYI-3T_4?*G:-)[-&C)7 ($D;<H_)R,^A[XH Z.BBB@ HHHH **** "BBB@
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M) ZD"C(R1D9':@#BO'GA1]3T?7KRQ6:?4;W34L5@4@*0LA<8]_F/?M5Z#P5
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M:?)8Q?VYJDVF:?()+2P=T"1D?=!8*'=5SP&8C@9SBNJR,XR,]<4$@$ D<]*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,)(B/V8'<G]UN!\PYX%>C-IMBUQ)<-96YFD78\AB7<R^A.,D5,((5+E8D!<
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M6P<.VX+D9& W!Q5>#P]KMB=% TQIA_PB_P#95P4FC'V>8*I^;+#(R",KG\J
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M^-M6NKRW5M*O-&BLF8L/F;S)2ZXSG[KCG&.: -M]7M$UBVTK>6NKB![A%49
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MQ.W89,8SN(&>@)P33/!%GK5EI]XFK/>>2UR6LHKZ=9KB*':O$CJ2"=VXCDD
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M6J]7MW $@'^[D'VQGM6MH&CVGQ&M?B+8VM^(K74M0@EANE3?@##@[<CTQC-
M'MA=!U91SCKWIU<(GP\AT^W\62PWCL^K[)H?DVFVDB4[&!SR0^&!XZ"NA\/:
MK<:_X-T[58O+CNKRR24;U)19&3/(!!(#=LCB@#:K(U#PMH&JWR7VH:-8W5TH
M $LT"LV!TR2.<=LUP?A#7O$(\+^&=*@FLIM2U-;B<75S&[+##&1N+C?F1RSC
M'*CGVY[+PUK5]?W>K:5JL=N-1TN9$DDM@1%*CH'1P&)*G!((R<$=: .AX ]
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MVLI!R&4]B" 1[BI-3U&#2-*O-2NBPM[2%YY=HR=J@DX'?@4VUU.*[NC!'#<
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M.N7EA8ZH_F7MK"B'<Q4*Q1R,H6  .,^HP:ZRB@#C-1\ &[DU>*TUR\LM/U=
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M^X-Y=Q$)%R.AP1UH \<$]XEGXBTF.Y:RCAUO3(DBLM0DG%MYCH'5)6 /U&,
MY%=%>>'GA\1:]X<T2ZN[6.YT2*\@4W,C[+I97"N"Q)&=JYYYQS7>0Z!HUO%Y
M<.D6$<>8SM2V0#,9RG '\)Y'IVI]]9R,D]SIZ6D6J-#Y4=S/#OP <A6P0Q7)
M)QGJ: .2\&ZU+XRUR3709([.SLHK00Y(7[2X$DV1ZK^[3_OJNLUO_D :C_UZ
MR_\ H)JOX:T-/#VBQV/FB>9I'GN)]FWS978L[8[<DX'88%:KHDL;1R*KHP*L
MK#((/4$4 >7>'O#GB;Q%\-='TRZUO3K?1KK38$=+>Q;SS"47Y-[2%02."VW\
M*J^+(UAD^)42#")H-HJCT 6:O6;>WAM;>.WMX8X8(E"1QQJ%5% P  .  .U0
M3:7I]P;DSV%K*;I!'<%X5;SD&<*^1\P&3P?4T 9LUU%J'AJ:STZ^MVO9;)DA
M"3*3O,9QW]:R?!&NZ+;?#K3&>[M[6/3[-(+M)7"&"1% =7!Y!W ]>OXUN6/A
M7P[IEVEW8:#I=I<IG9-!9QQNN1@X8#(X)%+=>%_#]]J(U"[T33I[T$$7$MJC
M/D=/F(S0!Y3I>@P:O9^"],U*V=;&^.K210L-K1PN=\6/0@%6'IQ6OH6HZ@_Q
M/T;1-9W/JNDV%Y%).1@7,3&'RYA_O '([,K5Z?):6TMQ#<26\3SP;O*D9 6C
MW#!VGJ,CKBD:RM'ODOFM83=HAC2<Q@R*A.2H;J![4 3UXE<6]E>^ M.UZ^OY
MSK]QK$"W >Z?YI!=J&A,>< (!D+CC8#7MM9<GAG09=0>_DT73GO)""\[6R%V
M((();&<@@'\!Z4 >?:IK!M? GQ&,NH-%<0W]RD.Z;#INC38%YR,D\8IFJ_VA
MK'C;5;.XMK>ZMK*QMWMH[C6);$1JR$O,H1&W'=D;B?EVCUKT2Z\-:%?7SWUW
MHNGW%VZ&-II;9'=E(P021DC''TIVI>'M%UGRO[3TFQO?)_U?VBW639],CB@"
MEX(N+NZ\%Z5-?7D5[<-#\US$Q990"0K9(4G(QDX&3FL3Q?86=QX_\&2W(.?.
MN5!\UD&5B+*."._Y].E=PB)'&J(JJB@!548 'H*KWVF6&IK$M_96]T(9!+&)
MXE?8XZ,,C@^] 'DB.H^'MOXL74+D^*WO$!/VI\M.9PIMO*SMVXRNS'09]Z]E
MK-'AW15U8ZL-(L1J)Y-V+=/-SZ[L9S6E0!XQXML+.&7XGS)E;DV-N1F5CPZY
M8[2<=0.W';%=!?6+^$_%MHFB/=R2W>D7TDL<UP\WGS1>68V(8GYLL1D>M=O=
M:%I%]<O<W>EV5Q/)%Y#R2VZLS1YSL)(Y7VZ5;>UMY+J*Z>")KB)66.4H"Z!L
M;@#U .!GUP* /'?#AU-8O">KI-90SW]Q$)[Q];FGDO@P)D1H3%M#=2!G"%<9
MKV>LRV\.:)9:E)J5KH]A!?29WW,=NBR-GKE@,\]ZTZ /+-$CU%]?\6FT\60:
M1'_;4F8)+:*0L?*C^;+$'V_"KGC6[U'3M,T2\T74FU#Q,&>*V2%1LOEVGS=R
M [<*!NSV( _BKKKKPCX:OKJ2ZN_#NDW%Q(=SRS64;NY]22N35JST32=.:)K'
M2[*U:)&CC,%NB;$8[BHP. 3R1W/- 'EUS*]V/!^F:;.=4TR^MKBYD-[J$EK]
MMN 5R)'56.X%G/E].,?PXI8[F_32(-+O-12/2I?$:V<QM+^28V\)C+?9S.RJ
MV/, 7(Z!MN:]-N/#VBW=E)97&D6$MK)*9GA>W0HTAY+D8QN/KUJ1=&TM-*_L
MI=-M!IQ7;]D$*^5CKC9C% 'GVK?V9H-_;66DZM="*+7;$W5L\SM%:APPVACV
M; )7<0..!GG-\=SPZFWQ @-R9H;.PL&"+,=L<FZ7/ .,X(S^%>G1>'=$@TE]
M*BTBP33I#E[5;=!$Q]2N,'H/RI;?P]HMI:2VMMI%A#;RQB*2*.W15=!G"L .
M1\S<'^\?6@#@]0L;JXU;Q38Z+<S+)9:;I]SIZK,S#S$:9@,DG.[:%/J#S6;J
M_B6^UOPYX@\7Z1<30V@BM;"T(E*!$9T:XDR =I'F;=V,KY9/:O5;+2M.TW_C
MQL+:U_=K%^YB5/D7.U>!T&3@=LFG0:?96MF;.WM+>*U.[,,<85#N)+?*!CDD
MY]<T <!X8M[W3/&UM:QK8V5K/8R2364.KS7IEP5V3 /&-O4@G/S;O:O2*SM+
MT#1]$\W^RM*LK$RG,GV:!8]WUP.:T: /'/"5I_PD=SX9L]3NKR:U;0)IY8A<
MR()7%PJ@N5()P"?T]*[CX>22MX9E@EGEF%IJ%W:Q/,Y=O+CG=4!8\G  '/I7
M06VEZ?9M$UK86L#11F&,Q0JI1"<E1@<+D XZ9J:WM;>T1DMH(H49VD98T"@L
MQRS''<DDD]S0!R_CVZC2QTRP9;R66^ODABM[:Y%N)R%9BDDG54PO..3@#N:\
M_74+_2X/&&GQ3C3K:"YTU)4M+][@6,<SE9F61@"IVC)P/EZU[%J.F6&KVAM-
M2LK>\MR03%<1AUR.AP>]1VNA:190O#:Z7901R1B%TBMT4,@SA2 .1\S<>Y]:
M //O$Z:=X7TW5H= U:]MIY+6W>>!)WE2"%IU1[@,V=C[&;G(R!G'&:/$Z:;X
M5TO5%\.ZM>V]W)81R201SO,L<)F17N<MNVN%9N<C.,X.,CO]/T#1])MIK?3M
M*LK2"?\ UL<$"HLG;Y@!S^-&G:!H^D131:;I5E9QS_ZU+>!4$G^\ .>M 'G^
MLV]IX=U>UMO#MY/Y5[I-[)=Q"[>8%$BS'-\S'#;CC<.N[VJM;Z7!:Z1X*@N+
MN]%IKK1OJD\EY)F>3[.SQH6+?*&;LN,[0*]'L/#FAZ6EPFGZ/86J7 (F6"V1
M!(/1L#D>QJQ<:5I]WIO]G7%C;2V.T)]F>)3&%'0;2,8&!B@#R=VTW1KWQ=8V
MES?S0SZEI]I%';7FUR[(/W)F8DHG!!.<@<"J=_<7FD+XVT^%4TY8M!6X^R6N
MI27(AEW.-VY@-CD8R!VP:];3PUH,>GRV":+IZV<P420+;($<+TR,8..U$'AK
M0;:W:W@T73HX7B,+1K:H%:,G)4C'()YQ0!Q%_92>%?$>FOHLMY)<7NDWSS)-
M</+]HEC2-D8AB1NW,>F.N*ATV/3-/\.:'KMEJ][+KU[9NZ 7#S?VA,8&=ED0
MY& PST&T@#(Z5Z6UI;/<0W#V\33PAEBD* M&&QN"GJ <#..N!5.T\/Z-I^H2
MW]GI-C;WDV?,GBMU5WSURP&3F@#RKPX=35/">K1S64,]_<1">\;6YIY+X,I,
MB&$Q;0W4@9PA7&:]GK,MO#FB66I2:E:Z/807TF=]S';HLC9ZY8#//>M.@#QK
MQ%<ZQ'=ZIX7T^[N%N[&\GUR)@YRULL8D2//]TS/LQZ+BKL6J3:W>:7XAAN9Q
M9ZIXDC@MD#D*;>*"5.GHSAS[\>E>HFQM#>->&U@-TT7DF?RQO,><[-W7;GG'
M2HX]*TZ&WMK>*PM4@M6#V\:PJ%A;D908PIY/(]30!XY:Z-8/HNF6<3S1B3QG
M-%-Y=RX<*K7  SG*DKQD8)SG.>:[OPE;)I7C#Q/H]J\PT^!;2:&&25I!&TBO
MOVEB2 =H.*Z--"TB.ZDNDTNR6XDF$[RBW4,TH! <G&=P#-SUY/K5M+6WBN9;
MF."))Y@HEE5 &<+G;N/4XR<9Z9H YOXDV\=S\-O$2R D+82R##$<JI(Z>XZ5
MS4/AW2]4\=Z?9N9GL(_#JLL<=U( Y,Q^\P;+ 9/!.,_05Z7+%'/"\,T:212*
M5='&58'@@@]156RT?3--\O[#IUI;>7'Y2>3"J;4W;MHP.!DDX]3F@#R"WO-6
MO[7PMH[G[;9N^HIY=WJ,EL+EH9RD:/(JLS%4Y"]\9/2N[^'K7BV.JVUQ<6\L
M-M?M'!'#=O=?9UVJ3$9752VTDXZX!QGBN@N= T>\T_\ L^YTJRELMYD^SO;J
M8]Q));;C&223GU)JS96-IIMI':6-K#:VT8PD4,81%^@'% %BBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JEJVK6.AZ7-J6I3B"T@P9)"I(4$@#ISU(J[7(?% LOPZU5EC61AY)"-T8^<
MG!H O6WC;0[E+QO/N(?LELUY(MQ:RQ,T ZR*K*"R^XSV]:B3Q]X?EL!>QW%R
MT+S"& "SE+7#$9'E+MS(,9.5!%<[K]CK/BV>YNTT2[L%M-%OK5$N6CWW$\R*
M BA6(VC9]XD DC%:&H:7J-@WA#5K?3I+O^R('@N;.$KY@$D2KN0$@$J5QC/0
MG% &U:^,=#NXH'2Z=#-=BQ\N6!T>.<@D(ZD H2!QNP#QZBF:QXEM+6[%C#J$
M4-W#=6D4XD@>08F?:J9' 9@" <\9!/%<W)X;U/Q!;>+-1DLY-.N-1-N^G0S,
MOFI);KF.1MI(4E\<9S@<U&OA[6;GPW:WMW8E=8O_ !!:ZE>PA@3#&DR87.>0
MD2+^M '4'QMH:ZG]A,\^?M/V3[1]ED\CS\X\OS=NS=GC&>O'6HT\66%E:7UQ
MJ&H)*(]2DLHDM[:3>7'2(( 6=QSRHP?PKDI](URVUV9M%TW5M.O9-2\U]ERD
MFF3QF0%I65R2K%,DA0#NZ>M2IH.LZ=JJ:VNF2W(L]?O;DVL;+YDD$R;!(F2
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M<I)IL\9D!:5T<Y5BN<A0#NZ9ZUZ%KNGOJWA[4]-BD$<EW:2P*Y_A+H5!_#-
M&)_PGNCWEO,MA/-Y[6TLUF\]K+'%<[%))C9E <#KP>G/2DL_&]E'H>BRZAY\
MVI7VG17KV]C:23LJLH);:@8JN20,_K6;!-KUYHEGHW_"+R6KVUB\-S/<F,HK
M"$HH@*L2Q9L<D !<YYXK+BTWQ%:1Z-:75GK(LH=%M8%32)(HW-PJXD260D,
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M:-@?M&\H4(QD<J>3Q@9Z5'J7B2UBU2#3X+^**X2_AMKA)('?<9$9UC4C@,0
M<\@#KU%<;KG@?4]5\2:U9K#MT>6&?4+27</EOI(EB QU&"KOG_;JQ8^'];FT
MG0KZ^LBNJW'B$:GJ,88'R5V.@&<\A4$8XH OZ)XOU/4+[0(9EM]M_=:E%-M0
M@[8'94QSQP!GU]JV?&NOR>&?#ZZE&T2JMW;QRM(I(6-Y55SQWVDUS7A_P[JU
MGJ/AJ2XLG1+2\U:2<EA\BRR,8SU_B!%=!X^L;^_\-QQZ;9?;;F*^M9Q!N"[P
MDR,02> , T 6K'Q?HM\EZ1<2VS647G7"7L#V[)'R0^V0 [>#STXI=)\7:1K5
MXMI;27,<[QF:)+FUD@\Z,8^=-ZC<.1T]17&^(?#^L>.)=7NHM.N-+4Z.UA E
MXRJ\\IE60Y",V%&P+DG^,]JLZ!I%U<^*M+OIM+U^$6,<K22ZMJ D6-V39LC5
M6;?G)R>!@#OQ0!W.J:I9:+I\M_J$ZP6T>-SD$\DX  ')))  '))JA8^+='OH
M;V3SY;4V,?FW,=[ ]N\4>"0Y5P#MP#STXK/^(.B7NMZ#:BP662>SOH;SR89?
M*DE5#RJ.>%;!R">X%<K+X1O=?M=>,-EJUM)/IGV2WGUJ\WR2-O#[-@+;4RH&
M2?XC@4 =E9>.M!OKR*T2:YBN)HFGB2XLY8C)&HR77<HRN.]7E\1Z4]CI5ZMR
M3;ZLR)9MY;?O"Z%UXQD94$\XKBKW4+W6_'/AN"XT.ZTMOLE\FZZ*'+F-0578
MQRHXYXSQBH--L]?FTWP3H\OAZ\MCH=U#]LN)7C\LB.%X\IAB6!SG.!B@#K9_
M'>@6]X]N\]SLCN/LTETMI*;=)<[=C2A=@.2!UX/!J;P_K%SJ>I^(;>X$833]
M0^S0[1@[/)C?GU.7-><ZWHWBG5=&U"TN-/UJ;4C>&01Q3Q16 B$VY2BJP+DH
M!PP)W$DUZ#X9TZ[L=7\3S7,)CCN]3$T#$CYT\B)<_FI'X4 -N?%BVWCZV\-M
M;R^7+8O<M,()" P= !N VA<%LL3@' R">7V'CG0=2OH+6WN9O])8I;3R6TB0
MW##.1'(RA7/!Z'G'&:S/$FDW]UXQAFAM)Y+2\T:ZTQ[F$J?L\DC(RLP)!VX4
M\C/-9<-EK>IZ1X8\/2Z!<6,FE7-K)=7<CQ^0%M\?ZHAB6+[0 ,# )SB@#L/%
MFN'PUX4U+6%A:9[2!I$C",P9@.,[02!GJ>@')Q7/M\0(X/$=I;3Q7)M+K2A=
MQQ16$S7#2>85/R ;@H SR/QY%;WC'3[G5O!6MZ?9IYES<V,T429 W,4( R>.
MM8^B6E_<>,;36)]-N+2#^PUM6%QMWI()LE3M)[#/TQ0!J2>--"72K'48[J2X
MAOR1:1V\#R2S$9W!8U!;(P<\<8YQ6AI&L6.N67VNPF,D8=HW#(R/&XZJRL 5
M8>A%>8IX2UBSBT74);34REK-J,<\&G7"QW"+-<&1)%^8!@0!D9S@CTKL_ VE
M3:?::C<3V5W:/>W9F"7MUY\SJ%50[D9"L0O0$X '- '54444 %%%% !1110
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M0/*D0$,9<@LP4$@= ,\GL.: *NBZ.=)TUK:6]N+R:61Y9KB9L,[N<D@#A1V
M'0"L*V\$7'V_3)-2UZXU"VTN4RVB2PJ)=VTJ/,E^\^ Q],G!.:["B@#@X?AO
M+#I-EHX\03_V9874=S:PK;(K920.!(W5_P#QWU.:MW/@)7E%U:ZF\%['JLNI
MPR/"LB*TB;&4H>HQT.00:[&B@#BSX \[^TY+O6;BYGU&XM+F:1HE&&MW# *!
MP%( &.V.I-1?$'23XFN-(T..SO2YN5FEO(XR(HK<AEE5GZ99"5V]3N![5W-4
M=8U:UT/2;G4[UF6VMUWR%5W$#..GXT 6S&AB,6T>65V[<<8]*X/3O"-S<^'-
M-TF6>6RO?#EZ?L=RT(DCE0!A&VT\,/+< X.0P//%=_10!R$7@B=9=9N9/$-^
M;[5$@WW,2K$T3PDE2@'&WD J<Y .2<FKNB^&)=/URYUO4-1^W:C/ MMYBVZP
MJL:DM]T9R23U)/MBMB]U&TTX6YNYA']HG2WBR"=\C?=48J/3M6M=4>^2U9B;
M*Y:UFW+C$@56('J,,.: ,2[\(7#Z_J.IV&M2V0U....[18$=_D7:#&Y^YQ[$
M9YJ*S\#_ -G1^&1::K*CZ%&\"L8583POMW*P/0X1>1[UTL=ZDNHSV0CF#PHC
ML[1D(P;. K="1M.0.F1ZU9H Q-?T!]9GTNZ@OGLKK3KDSQ2+&L@.49&4J?56
M/TJG<>"X+CPYK^C&\D$>L3S3O(%&8S)C( [XQ6IK^OV'AK2)=3U)W6WC95Q&
MA=F+$  *.2<FKUM<17=K%<V[B2&9!)&Z]&4C((_"@#FKSPC=_P!I7]WH^O3Z
M6NI!3=QI DF7"A/,0G[C;0!GD< XS71V=JME8P6JR2RK#&L8DF<N[8&,LQY)
M/<U/10!DV6AQV7B/5=969FDU&.!&C(X3R@P&#WSN_2L>X\&7:SZBFE^(;O3K
M#4IFGN8(HE+J[??,4AYCW8SWP22,5UU% &-9>'HK+4]7O4N)&.HQPHROSL$:
M% <GDDYSS5.T\'06EAX8M%NY&70"#&Q4?O<1-%SZ<-G\*Z6B@#EY/!4$E])=
M&\D!?68]6V[!PR1"/9],+G-'_"%0?\(B/#_VR3ROMGVOS=@SG[1Y^,>F>/I7
M455U#4;32K)KR]F$,"LJER">68*HX]20/QH Y6\\!2SG7+>WUV>UT_6G>6ZA
M2W0R;F0*P60\A2!TQZX(J:X\#&6X$D>JRQH^C_V3<IY*D2H%8*X/52"Y/'7I
M7751NM6M;35+#3I687%]YGD@+D'8 S9/;@T 8)\&W%I<0W6BZU+I]S]BBLKA
MC;K*LZQ@A&*GHXR><XYY!J;2/!5GHM[I=Q;7$S?8+6>#$F"TS3.LCR,?[Q92
M?QKIJK:A>IIUA->2QS2)$NXI!&9'/T4<F@"IHFBQZ(E^L<S2_:[V:\;<,;3(
MV2H]A6$/!FJVNHZI<:7XJN;"'4;IKJ6%+.%]KE54X9P3T45V-% ''R^ +6/2
MM,MM.OIK>ZTZ[:]CNIT$YEF8,':4' 8G<>>,<8QBHI?A\;JWUX7FMW,]SK*V
M_FS&)%\IX22A11QMZ<'TZ\YKM:QV\3Z4%M62X,BW-^VGQLB$CSUW;E/T*,,]
M.* ,N3PCJ4=[/?Z?XCEL[R\ACCOW%JCK.Z+M$JJ?N/CCC(X''%-UC1)KB/P[
MX?B-W<6L%Q'=75W<,9"R0890SGJ[2;./0,>U==10!E>(]#B\1Z#<Z7+,\'G;
M2DT?WHG5@RL/<, :R+3P#IUGK^C:K%+(#I5BMG'#@;7VJRHY_P!H*[C_ ($:
MZRB@#EY?!4$OA?4]#-Y(([^[ENFEV#*%YO-( ] >*;?>"+>\FU.X%]/#<W=]
M#J$$R*,VTT4:HI .0PPIR#U#$5T&HZC::58O>7TPAMT*JSD$\LP4#CU) _&E
MAO8Y[ZZM%CF5[;9N=XR$;<,C:W1L=\=* .;?P5->J\NJ:W<7=V]U:W!D$82-
M%@?>J+&#@9.<G))S["ME=%C7Q5+KOG-YDEDEF8L< *[/NSZ_-C\*U** .>U+
MPPU]XC&KQ:A)!YEBUC<0>4K++&2Q!R>5(+9XZ]*1?"4*Z9X:L?M4A70I(GC;
M:,R[(FB&?3(;/X5T5% ''V?@BZL$AT^U\17L.APS^='91(JNHW;O*\X?-Y>>
MW7'&<5L>*-!7Q-X?GTIKI[7S7C<3(H8J4=7'!X/*BMBJPO8SJ;6'ES>8(1-Y
MGEGR\%B,;NF[CIUQ0!B66A^([>]AENO%\UU C O =/A0./3(&1^%5(? 4$%U
M!J:W\W]MI>M=RZ@4&Z8-PT3+_P \]H50O;:".:Z^J-_JUKIMQ807+,'OKC[/
M!A<Y?8S\^G"&@#G8_!%U;"2QL?$5[::+)<FX-G"BK(FY][(DP^94+$\=<$C-
M2W_@ZXFOM2FTS7;G3;?5<&]ACB5RS;0A>-CRC%0 3STSUKJZ* .-O? <DESJ
M/V#7+JQL]3@2&\@$2R,^R,1@J[<J2@ /7IG@\U(W@8+-:/!JDL21:1_9$Z&)
M6$T04A6SU4@G/'7I6OJ_B*TT>^L+&6&ZN+N^+"&&VA,C;5QN8^BC<N3[UKT
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M[HL7AWP]8Z1#(TJ6L03S&&"YZEL=LDDTL?A_1HKN2ZCTJR2XDG%P\JP*&:4
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M:AY>D3:[+;2?9]0>5HE6 NMLT^%8YD_'&%S72>"+.TT_QGXQM;*XDFABDM%
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M*7MXO/D$L;Q8B_YZ#>!N3_:&1[TW3?&>@:M?)9V=\6GD0R1"2"2(2H.K(SJ
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M:Q!WBGC)8JXR-OWNIXR.:/"FA:K;W/@R6^TV6%[--4-P&&?):24%,GW&<>M
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MG2=#FEGL;9UGE4(\TT\DTA4=%W.Q( ],XK6HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK!IUI:WUW>PPA+F\*&=\G
MY]HVK^0XXJU10 4444 %%%% $<\*7-O+!)N\N1"C;6*G!&#@CD?44EM;0V=K
M#:VT2Q00H(XXT& J@8 'X5+10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% %6^TZTU)(%O(1*L$Z7$8)(VR(<JW'H:M444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME=;10!SO@SP_)X=T-X)TMX[BYN)+J6*V&(HBYX1.!\JJ%7IVKHJ** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .'U[P3J%YJ?V^PUR[1YM0M
M[B6-DA(C2/IM)0GY1DA2<9)]36_?Z;<7'BC1M0C"^1:1W"RDGG+A N!W^Z:V
M:* .(N-#UO4M>L[JXT_3;6ZM)9/,U.)L_:8"KA(BGWB#N4LK' *G&>,1V'AC
M4+K4;"6?3[705LK*2U>32Y0#,S[/N87Y4&TD;N<D<=2>[HH YW6-!N9_"J:7
M;7,UU*ES;R^;=R9=E2X21LMCLJD#CL*Q?%WA.\UR^U".WL4\O4+9;=KI+V2(
M+U!,T0.)2H.5XYZ' KO** .$?P)?6NNZ7=V.N7;01:D]Y.DJ0DJ#"Z#!V9/!
M5,$\+TY -+_PC>HW>HV$4FE:=IZV=_)=MJ-B0C2JP< *N-P9MXW9..#UR,=U
M10!RVI^&;F;05TB*^NKV&XO87NWO9@S>0&4N@( X(7&/]HT[Q#IU[/J+30:!
MI>J12V;6^9R$EC8DG#,0<QG/('(([YXZ>B@#S>X^'.J1:3:1VOB&[>[0Z>DN
MY(BNVW>,DJ60L,;6<+G!8\YR:FU#PCJ4^L7DHLK:>[GO8I[;6WE FM(EV90#
M&1C:X"J=K;SG&37H5% %.PNY[O[5YUHUOY-PT49+9\U1C#C@=<G\NIKFM"\-
M7^C:OJ-TZQ3V]K%)%H\(?;A)',KJQQ\OS;$'7"QBNQHH HWS:H='9]/CMEU'
M8K+%.Q,><@LI8<\C(#8X.#@]*Q?"VC7.GZGJMZUA!I=I=^5Y>GP.&577=OE.
MT!0S;E'']P$\FNHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>guyaragreement011.jpg
<TEXT>
begin 644 guyaragreement011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/B'9!%816,T-U9BXAD$8P)%0L CD=>H/&1Q78T4 9FC:':Z+X=M-$A+RVMM
M( 93DNH&#GZUAZ9X.U+35L+%/$MR=&L)%:"V2$)*R+]V-Y0?F0<#&T9 P377
MT4 <=)X"22]?5CJ4@UXWHNDU#RON(/E$ 7/^KV$J1GDDMUI7\&:A"]];Z7XC
MGT_3+ZX:XE@C@!EC9SE_*ER-@8Y/0XR<8KL** ,2V\-6\.HZY<RRM-%JZQI)
M"P^ZJ1^61G.3D5EV'@W4+9+*SN?$=Q<:9IZ%+6W6$1N1L*+YK@_O JGIA<D
MG.*Z^B@#C8_!>H6.EZ?8Z=X@,<-M81V,L-U:">&4)T<1EAM?KDY((QD'%);^
M CI$6EOH.K/97=C9FR:6> 3I/$6WX9,K@AB2"",9(Z5V=% ')2>#;OR=.N8M
M?N3K5C)+(M_<1B4.)?OH8\@!.%PH(V[1@^M_PSX=ET#^TY+C4GO[C4+O[5+*
M\03#%$3  /3Y./0<<XS6]10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<O\1+FXL_ NHSVL\L$RF+;
M)$Y5AF5 <$<]":ZBH+RRMM0M7M;R".>!\;HY%RIP<C(^H!H \MOM/,.L^/Y+
M#5'L+R2ZLXTEGOI40^8L3%,Y.PL<H& RH; P.*W_  1.UKKFIZ/=6FIV%VL$
M5Q]CN;_[;"J$LN^*0DL,D<JV.@('6NFN?#>B7EY<WESI5G-<7,/V>>22($RQ
MY!VMZC@=?04_2= TG0DD32M/M[02D&0Q)@OCID]3CM0!RES;KKWCG7;34]2O
M;2#3;2W>S2WNW@"APY><[2-Q!&/FR!CIS7*^&KVZ@T'P]!!JQLHCX6OI!.S'
MRHW#QA967I\N2?IFO4]4\.:+K<T,VIZ7:W<D/$;S1!B!Z?3VZ4^#0]*MA"(=
M/MD$$+6\06,82-B"R#_9) R/:@#S"TU#4O#,=P);;48=3ET:YGM675#?VE])
M&@;S,.=Z-T(& "&QSQ6J;2RTK0;+4K?Q)J1O[[3)WQ)=R3"];R"Y< DA"N-P
M*[<=*[/2O"^A:).\^F:3:6DKKL9XH@#MZ[1Z#V'%-L_"7A[3YIYK/1K*"2X1
MHY"D(&5;[R^P/<#K0!YU<Q:AIOA+PFMM>ZC=2Z_+;_;Y9M2>,R$P,XC60Y\H
M,V!\N"0 .^:I:[:WO_"-^)=-OG>&TM9;":&T&K/<RVS-*%8,_#;&&"%8G!!(
M[8]=N=&TV\TH:7<V-O-8!%06[Q@H%7[H ]L#'I5>#POH5KI,^EPZ39I8W&3-
M!Y0VRGU;U/ Y/I0!P.NZG?Z3/XLMK34;J"W@.E6RS-,SFUBD.R20%B?FVG)8
M\YY-.\2J_A6\N['1M1OVANM O[B>*6\DF:%XT7RYE9V+(26(X(!QZBO0;?0=
M)M;>6WATZV2&:%()4\L;7C1=JJ1W !QCTJ"Q\*:!IEM=6]EI%G!%=(8YU2(?
MO$QC:?48)XZ4 <?IUI+H_B#P7-%J6HS2:M#*M_\ :+MY5F(M_,#;6)52&'&T
M#@XK?\675Q;ZYX3CAGEC2;4W254<@2+]GE.& ZC(!P>X%;YTZR,EI(;6(O9@
MBV;:,Q97:=OI\O'TI]Q96MU+;RW$$<LEN_F0LZY,;8*Y'H<$C\: /)M$BNK7
MPIX)\0G5M4FU*]OK:"X>:\D=)(I"RE"A.W &.<9R,YS7:^/;NX@TS3+>&ZEM
M(;[4[>TN;B%]CQQ,3G#?PDD!<]MU;J:-IL=E:V:6,"VUHZR6\00;8F7E2H[$
M5/>V5KJ-G+9WMO%<6THVR12H&5A[@T >;^*;*QTG3-0TVRU6[GVWNF2M8W$S
MS?9MUT@R'<D_-C.TGMD8S63XOOKB>P\4ZSIYU5VTZ:2./4)-5-M%;21@#9%"
MA^?#<?,OS$]>]>GVOA?0K*Q>RMM)M([9Y5F>,1C#.I!5CZD$#!/3 J*Y\'^'
M+R]GO+G1+&:XGSYKO"#OR,$D="<<9ZT <_IVKS?VWXP:ZO76."QM)T#2$+$#
M"Q9E'1<D=1Z5R\"ZOJ^E>'YEEN=7"Z!;2364&L/:7,4C _Z1G($A.,?,>"OO
M7I=YX4T#4+JWN;S1[*>>W01Q/)$"54=![@=@>E-O/"'AW4(+6&[T:RECM(Q%
M K1#]V@_@'^S[=* //9=8O?$FH^'+&R%_?Z;-HWVM8Y=0-C+<R!PA,CQCYBH
M&2JX&6SS79^ )[^70)X]0N4N'M[R:&)A<_:&6-3PCR8&YEY4GKQS6KJ'AS1=
M5LX+2^TNUFM[?'D1M$,1<8^7'W>..*N65C::;9Q6=C;16UM$-L<42!54>P%
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M- $J21R;MCJVUBK;3G!'8^].JO:6-I8^?]EMXX?/E:>78N-\C=6/J3@<U8H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M48P'4 \@#)ZG@5?2^\4?\)^\%G;6,MTV@V\DJS74@@C/G2\C"$ECQV'0^@R
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M=R6;&/\ 9;TK#TGXH+>WFDFX.C?9M5F6&*"UU$2W5NSCY/-CQCG@'!^4D=:
M/1Z**X30/'=[KNL)!%:Z9Y1N)();07V+VU"EAODB8#(^49"DD;AUYH [NBO*
M_#WB?7M'\,_VA/86\^CQZO/;RS/=,;@A[MD#*NW&%+ 8)R<'IQ6MXI\>W_AQ
M]0GDM]'AM;(Y6"\U$1W-VH ):- "!U( /)QT% '?45Y1XUU"<W/BV2"XFC0:
M'8RQA7(VEIY,D8Z'&*]7H **X/4?&FNQ/XCFL-&LI;+0)&$[S73(\RK$LC!
M$(# $]3CI[XOR^*-4U/57T_PY86LS06D5U<37T[1JOF@E(P%5B6(!)/0<=:
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M<6ET9[&72K&: AB5(9IN0.V>/RH [.BL'QK=QV/@C6KN6%IXX;.1VB65HRX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYJW0 =JXB\\!7$VGW<-KJR0W$NNC6HI7M=ZQL"I"%=XW#*]<CZ5V]% ',?\
M".:MJNG7VF^)]6M-0L;J'R]EM8FW9#G(8,9&Y&,CCK@U1N/"?B34]/.C:KXI
MCFTEU\N8PV7EW5Q'W1I-Y49'!*J">>F:[6B@#$M_#L=KXK.LQ2JD7]FQZ>EL
ML> H1V8$'/HV,8[=:SO#'@:W\+>(M:U&SNF-IJ(C\JS*8%MM+L0IS]TL[$#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 57OK^UTRS>[O9T@MTP&D?H,D ?J0*L5S7Q L;O4O ^I6UC ]Q<8CD2)/
MO/LD5R![X4XH V+O6-/L9GANKN.*1+9[ME8\B%,!G^@R/SJEIOB[P_J^H&PT
M_5;:XN=I<1HWW@.I4]&QWQG%<1K<M[XEUC4[NRT758[8^%[ZUC>YLWB,DS,A
M"!6&<\<<<\XSBM*^T6\E?P/#;6TL/V:VGBDD6,@6VZT91N_N_-@?6@"_J7Q!
MTF._TZQTN]M+RYN-1CLY$#'A22&93T8J0 <9QGFM:7Q=X?@U;^RY=5MEO/,$
M1C+<!ST0MT#'^Z3FN!MQ=2:)X*T#_A'-2CO=(O[7[6[6C"*$1@JTBR8VL&/.
M5)X))Q68^@:E%I&I^';UO%$MQ<WTS?9K2VA%M<+),767[0T+;.""=S;@1P.E
M 'JA\4Z&NN+HAU*#^TV<I]F!)?(4/@CM\I!YK0O+N*QLI[N=ML,*&1V] !DU
MSGAC3IK3Q1XMN9K:1!<WL)BF=,>:BV\8R#W ;</KFNGF4O!(B]64@?E0!P=M
M\3K&>U\-7\I@MK+58YC<-(Q)@=$5@@.!N.6 Z<]JZ!O$]E>V>GWFDZA836]S
M?+:L\KL,GG** ,B3CHV*XOPK87DJ_#U9]*O86TF"YM[K[1;,GE2"%5!R1T)R
M W0\XJ671]1_M6X9;"X\L^,H;L$1'!A^SH#)_N[LC/3- ':1>+O#\^K?V7%J
MMNUX9#$(P3AG'5 W0L,'@'/%;5>36=OJ=CK%G:Z59ZQ&HU3?/I5_9">SA0R$
MO-%<E0%X)9<,3DXQ7K- '&^+/&TGAW7+*SBM4FME1;C4Y6)!MH&E6)6'J=S,
M?HC5T6K:YIFA6\<^IWD=NDC[(]V27;KA5')/T%<):^$=6\4/XAU.]U.[TJ+6
M9'M39M:1EC:QYC3.]2RDC<W&/O9JOI<FLV%UX:U+6=,O;F72[>[TNX2*$O)N
M#($N$3JZLJ %ES]Z@#M3XU\-#33J/]M6GV(3>09M_P OF;-^S/KMYQ_6FW'C
M?PU:PVTL^L6Z)<Q">(G.3&?XR,95?<X%>?Z5;3:Q>O<1:3/%&GC?[3+"T>3$
MHM1\[@9"_,03Z$XZU?UBQU#3/&WB"]EN/$45MJ,<#6[:191W*RA(]AB?=$Y0
MY!(SA2&^M '>:GXET71X;>6^U&&);D9@P=YE&,Y4+DD8(Y''-1W/BS0+.QM;
MV?5K5;:[4M;RA\B4#&=N.IY' YKSB+P_J/A[4-%NV?Q%962Z*EF&L(8[V:WD
M$C.8Y (FX(91E5 RF#VK0T'P_<V^I^$IS8:D(5O-1NI#?!&>'S%.UG"*JQ[B
M20N."V* .NC\>>%IGM4CURT9KE@L0#?Q$E0&_NDD$8;'(JSJ?BS0=&O!::CJ
MEO;SE0Y1C]Q2<!FQ]T>YP*XB]T.^/@GQC!'IL_VBZUUIXD6$[I5\V(AP,<C
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M<L(;=0I)9RHSV  XR3U%<ZWCF_M+?4;*ZL+:36[6_@T^)()3Y$TDP#(V2,J
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MK.TB::XGL)DBC7J[%#@#W-8N@12WOCE-8.GW<$#:!# KW-NT3*XFDW(0PX/
M./3!H Z&Z\4:'9Z7;:E-J=N+2ZQ]GD5MWG9&?D R6X]*NZ=J5EJ]C'>Z?=17
M-M)G;)&V1D'!'L0>".U>1VFA:OIUMX9U"9=9LK>TCO[>4Z?:K+/;M)<%D;RV
M1SM91C*KD<=C7<^ ;"2TT_4KETU1?MM\]P#J0199/E5=^Q$7R]VW[I&>YZT
M=;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445SOCK6;K0/!FH:A8[1=J$CA9AD*\CK&&(]BV?PH Z*B
MN-;P');0PW.FZ_JL>LQNCM>7-W),DV"-RO$6V%2,\ #'&.E/O/%VJ/=ZK_8V
MA)?V>DN8KJ62[\IY) H9DB78=Q4,/O%03Q[T =?17#OX]O;Z[DA\/Z)'?QKI
ML.IB:>[\@&.3<0N-C'=\O';KDC'+](\<WFHWFA-/H@M=-UQ6-E.;H/*"(S)\
MZ!< %5."&/;.,\ ':T5P>G?$#4;K2M.UR\\/I:Z+>3I;^<+S?+&7?8KE-@&P
MM@9W9P<XIWB#Q[>^'S=75SI%K'IUM-Y1\_4!'<S+D R1Q;2".<@%@2!VH [J
MBN/U'Q=JZ:UK.FZ3H$5Y_9,<<LTLU[Y(=70L%4;&^;@]>/?FI]+\;6NH7<*R
MVYM;6XTF/5K>>23.^,_ZQ2,<%,KGDYW4 =3165HFL2:KX9M=9FLGMOM$'V@6
MX;>P0\KV')7!QV)Q7/\ ACQM>>)C!+'IMG]AN8FD$MKJ*S26Q R%G3:NQCTX
M+8/'O0!VM96L^'M/UUK>2[6=)[8L8+BVN'AECW## ,A!P0!D=#BN&\%>+M:M
M_"WA5]4TSS+'4#'9K?/>EYVD8':[(5^Z2,9W$]#CM6IK7CV]T262XN](M8M/
MCN1!B;4 EW(I<)YB0[<%><@;@2.>* .LTG1['0[$6>GP^5%O:1MSEV=V.69F
M8DLQ/4DYJ]7EVM:E?1^(-<C2]N52/Q#I$2*LK *CB'>H&> <G([Y->@:WJ%S
MIFFFXM+!KV<NJ+$)!&HR<;G8YVJ.I.#]* -&BO,=<\:W=_X5\86#+;VNI:=I
MWGK/IM_YZ$.& PX52K J<C'<&M:Y\=7<>O7FDV&F6MU)8^4LD,NH"&YGW(K9
MAC*X< -U+#)!% '<45RMYXHU676-1L-!T2._&F!!=237?D9=E#B.,;&W-M(/
M.T<@9K:T76+;7]"M-6L]X@NH1*@<89<]C[@\?A0!H45YCX+\7:S9^#O#=SK&
MF%M.NS%:_;WO#)/O<[5=T*_=9B!G<3R"15N?XHQ1+<Z@MI9MHMO<- \K:@HN
M6"OL:18-O*@@]6!(&<4 >AT5F>(-<M?#F@7FL789H+9-Q5,9<D@*HSQDD@?C
M7,VWQ!=;IK74;*P2>2SFNK<6.I+<JWEKN:-R%&QL<YP0<'GB@#N:*XC3O&^J
MW4NB27?A^*UL];0_8I/MN]P_E&11(NP;0P4X(+8[BLK0?$.IW/AOP_<ZU$[S
M7.O26\<D%\P)^>?[XV#*KMVA.A !XZ4 >F45Y19Z[X@O/L3:BXAQXO:U!ANF
M?<@\T&(C:OR+M7'][J0*U)/BC"B2ZB+2R.B17)@:4Z@HNBH?891!M^YG/&[=
MCG% 'H=%>=>+O%FKW/AOQ4=%TO=9:?%/:R7PO/+F654^9HT"\A">26!X.,XY
MZC4KR]M? UQ>6>U[R/3S(AD?;\P3.<X/(Z].: -VBN#TCQ7K4FD>'M.BTR"\
MUR\TU;R4RWI6)(@% D=_+)W,6'RA3SGG R>C\.:]_;UG<M+:-9WEG<O:W5N7
M#^7(H!X88W*0RD' X/2@#9HKAC\0;F*'7-1N=%$6C:1//;27/VH&266-MJA(
M]O1B5&21@GOC-+9_$-([X6VM6]A;"2UENHWL=06[ $2[G1\*NU@N3QD'!YXH
M [BBN1L?%FK-#;ZAJGA_['I%Q;O<K<QW7FO BIO'G)M 7*C^$M@\&H;7QKJ6
M-)O-1T%+32]6E2*UF%WOE1I!^Z\U-@"[N!PS8)&: .THKDK;QO\ :=)TF==.
M(U"_U Z>]D9N89$9A*2VWD(J,W09XZ9K)E^*,*)-J(M+(Z+#<F!I3J"BZ*A]
MAE$&WE <\;MQ'.* /0Z*YC3O$VI:IXJU#3+?1D%AI]S]GN+U[K!R8U<;4V\_
M> (R,9!R>0,CQ?\ VE>_$#PQI:P[M-=)YY%34)+<R,GEY+!%YV!L@9PQ8YQC
MD [ZBN T_P"(>HW?ARVUN;PX(HM0>*#385O0TEQ,Y(VM\H"*,$[N>!G':K%]
MX[O-$M]6CUG1HX;^PL#J$<5O=^9%<1!MIPY0%2"0""O<=: .WHKB1XO\1'6H
M]'_X1BW6]N;4WEMNU'Y!$" WFD1Y5@67A0P.[KQFM[PWKA\1>'+?55M3;R2[
MU:!GW;'1V1EW <C<IYQT[4 ;%%>1#Q%XDE\*:?>W,9>Z_P"$H\B-(+PYF43R
M+Y3':H"C 7N"!D@=*Z:;Q_+I,&M+KVE);7FF) ZQ6UUYJ3B9BL>UV5<'<"#D
M<=: .WHKDM!\9OJ.O#1K^WL8KJ6W:X@>QOQ=1LJD!E8[5*L-P[8(S@\5B_$.
MYA3Q?X9MKR;6!8RP7C2Q:4\X=V7RMI(A^8@9/TS0!Z/17"Z'/:V&E:K?^'K#
MQ!>W4,:DVNK2W49EQDXC,X/.,]!UP#C-2P_$BPN=*U/6X+25M#T^W5VNR=K2
MS$ F%4(ZC*@DD88X[$@ [6BN'LOB&J7Z6VLV]A;":VEN8GLM06ZVB-=[I( J
M[6"Y/&0<'FK>F^*-;NTM+RZ\-^1IM["TT,L=WYDD0";U\Y=@";AZ%L$@&@#K
M:*Y:/QD9= \,:H+#G79H8A$9O]3YD;/G.WYL;<=!UKFM(\1:K/I5O-K4#,[^
M)VM(6M[]AC]](NUOD&47:!C^(<G'2@#TZBN2@\;^?H^GW T[&HW>I'36L?.Y
MBE5V$A+;>0JHS].1CIFLF3XI0HDNHBULCHD5R8&E.H*+HJ'V&40;?N9SQNW8
MYQ0!Z'15/5;R73]+N+N"SEO)8DREO$0&D/8 G@?7L*Y*W\?7":E?:?J%A8"Y
MM].EU!/L.H_:%(CQE'^12C<CG!!Y]* .YHKBM.\:ZK<W.B_;- CM;76XV:R<
M7N]PXB,@61=@V[E!Y!;'<59LO&R7^F^'YH; _;-6N3;O:F7FW*!O.)..=FPC
MH,DCIF@#K**X/XH7<-I:^'A=WUU9V,NKI'=26TTD3&/RI3C,9W8R!T]*SO#U
MU WC.UC\+:EK%]I!M9CJ/VR6>6&-AM\HHTO(<G=D ]* /3:*\J\,ZG?S6'PO
M:6^N9#=K<_:"TK'SL0.1OY^;! /-=9XYU&]M;'3-/T^X:UN-6U"*Q^TH 6A1
M@S.RYXW;4('N: .IHKSOQ-HX\#:(WB31M0U/S;&2-[J&YO99TNXRX5PP=B V
M"2"N,&J$VOZIH/Q,\0ZE<74LWAR*>UM;N%F)6TWPH5F4=EW$AL?WL\XH ]3H
MKE?"-U/<ZUXM66>26.+50D09RP1?(B.%]!DDX'K4/B7QAJ.A2WSQZ39FSLHP
M[37VHBV:X^7<1"NQMV.F21SQ[T =A17F][XR;3]9U77D2>>QC\-VE_'9M*5!
M+R2_4!L8&<=JT+OQQJ5C)9V-WI%C::K>>9+'#<ZF$BC@7;\\DFSAB6V[5#<@
M\XH [BBN/L_&\VI:#+=V&E+/?07ILIX!=KY,3@9+F8#_ %>T@[@N>0,9JG!\
M1P+/5Q<V%O)?Z?-;VZ0V%X)X[F2<[8U5RJX.<@Y'&,\T =Y17FUQXB\1V/C*
M^FOM) DL_#\ETEE;WQ>&<B53E6*##@9'*^G.#75P>)X+[6=+L+"+[1'?6+7[
MS[\"*+Y0AQCDL6P.1]TT ;U%<UK7B34;/Q):Z%I>D1WMU<VDET))KKR8XPC*
MIW85C_$.@/./J,?3_B#J%Y;Z7J$WAX6^F7MZNGM(;P-+',7,9(0+AD#@KG<#
MWQ0!WM%<+K_CV]T!KJZN=(M8].MI_*/GZ@([F9<@&2.+:01SD L"0.U)XC\5
M:K/9>)(=$TD3VVF0R0W%W]K\J02^5N/E*%.XJ&4G++SP* .[HKSVV\<S6UGI
M6E6D=G<WR:5;W5U-J.H"V4;T^4!BK%G.">F!W/-=;X;UZW\2Z#;:K;(T:3;@
MT;$$HZL59<C@X8$9'7K0!JT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?KFCVOB#0[S2;S=Y%U
M&8V*'#+Z,/<'!'N*T** .)G\.>+M4LX])U77[(Z:&7S[BTMGCNKA%(.TG>50
MG')7\,5)<^%]<M;G6(]"U2SM[+5Y#-*+FW9Y+>1D".T9# '(4'#=#Z]*[*B@
M#E='\&IHMW=&VN ;5]*MM.B1A\RB(2#<3WSO'Y4VR\'S6EGX.@-VC'P^,2$(
M?WW[AHN/3ELUUE% 'EG@[PYKFL>"-#L=2O;9-'CE6Y:$6[+</Y<I=8F). NX
M YQD@ >]2ZA\,M0N['6;".[TE5U">2?^T)+(O=D,VX(S;L8'"Y'\(P .M>G4
M4 8%OX?EAUCQ!?M<(1JL4**@4_NRD90Y/?.<UQ/B+PY&^G>#_!T-W(^JVT:6
M\\D,3 &R,9CG)/10P08YSG;7JM% $;0C[,88F,(V;$* ?)Q@8[<5P]AX&U'_
M (2+3M5U*XTHSV ?-W9V9BN+W<A3]\<XQSN(&<D=J[RB@#C[;P7-!X4\,Z,;
MR,OH]S;SO)L.)!&3D =LYK!N?AEJ,VFZAIT=WI*BYN6N#J#V1:\ES+Y@1WW=
MN%R.PQ@5Z=10!QU_X*FO=3U&[%[&HN]4L;\*4)VBW" K]3LZ]LUH>,?#LOB7
M2;>UAE@5H+N.Y,5S&7AG"9_=R*#RISGZ@5T-% 'G<OP\O[F'7Q+=Z=;G5M,6
MQ6&SM3'%;E2Q! S\P^8Y/'-6/$W@?4_$!O+62YTJ>RN5 BEO++?<6/R@'R6!
M'<;AG!!/<5WE% ''OX9US3-3U"Y\/ZI:1QZBL9G%]"TC1RH@C\U"K#)*JN0>
MXSGG%;N@:+!X>\/66CV[L\5K"(P[]7/=C[DY/XUIT4 >?Z5X&UN#2-&T'4M6
MLY](TR6*?,5NRS3&-MR(26("A@#D#)  XY-,3X>7MJ)M/LI](339;EIUN)=/
M$EW$C/O:-6.5;DD!B. >AQ7H=% &3XET&'Q+X<O-'FD:)+A !(J@E&!#*V#U
MPP!QWKG;7P=JDDDS7TNC6X^QRVR)IU@(_,=UV^8[')&!_"OJ>37<44 <POA6
M46GA*'[4F="9"YVG][M@:+CTY;-9UCX)U"VLM.L9K^V>WT[66U&!DB8.T;&5
MBC<XW9EZCC KN** .'A\$Z@E[\]_;-9QZ\=8A B82?-YF]&.<'EQ@CT.:J0_
M#R]LU;3K.?2$TPW)F6XDT]7NXXV?>8PQRIZD!B. >G%>AT4 <)JG@S6Y+37]
M+TG5;.WTS6FEED\^W9Y87D7$@4A@"K'GD9&3UXKK)M-\_0)-+:3'F6IMS(!T
MRNW.*OT4 <-9>$M?TV/1[VUU#3CJNGV)TZ0/ _D7%N"I7(W;E<%0<C(Y/%;W
MAG0I=$M;QKNZ6ZOK^Z>[NI438F]@!M5<DA0JJ!DD\9K;HH Y%_!"77AC7]$N
M[K*:K>SW2R(G,1=]Z\'KM('UQ5:T\%7MS+(NL/H\=JUI+:M%IEB(FF\Q=I=F
M;)7 SA5]3DGI7;T4 <;:>%]>FM;;2M7UBWDTFVMWMREK"T<EVIC,8\TEB!@'
M.!U.#QC%16OA'6Y8]&T[5=5LYM+TB:*:(PV[+-<&+_5>82Q48X)P.2.U=O10
M!RMEX,6T\=W?B#[5NMI%9X;3;Q%/($620'_:6-?S;UK&B^'E[9J^G6<^D)IC
M7+3+<2:>KW<:,^\QACE3U(#$< ]#BO0Z* ,;1-$?2;_6[EYED&I7OVI5"XV#
MRD3!]?N9_&B_T1[SQ3I&L"952P@N8FC*\OYOEX(/;&S]:V:* .-C\$31>!=&
MT2/4$2_TEXI[:Z\K<GFQDXRN>5()!&>]5=3\$:KX@@U>?5]1LUO[S3CIUNMM
M"PB@C+;F8[B2Q) ], 5WE% &*VANWC"UUSSUV0:?)9F+;R2SHV[/_ ,?C2^%
MM%?P]H$6FR3+,R332;U7 /F2O(!CVW8_"MFB@#A[;P3J$5O%9R7]LUK;:Y_:
MMN5B8/M,CR,C<X)R^ 1CI4^O^!1KU[K4TMXL0O[:UCA_=[C%)!(\BL0>&!+#
MCT!]:[&B@#E= \.:C9:P=0OVTB%4@,26^FV0B5B2"79FRV>,!1QR>M.\2:!K
M%_X@TC6=&O+&"XL(KB(K>0O(KB79_=93QL]>]=110!RYLO&ESIM[;7.K:/#-
M-'L@GM+216A)/S-AG.3C..G./I68/AM;P:7JNA6EX\6AZA;*I@;+O#<+C]ZI
M/7=M4L#U89[FN[HH XBS\%WL\[#5WT>.U^RRVS1Z98")I_,7:79FR5P"<*OK
MR2.*LZ7X=\10KI]CJ&M6[Z981F,"UA:.6Z&PHOFDL0  <D#J0#QTKKJ* . L
M/!.O0P>'M/N]7L7T[0;F.6 16S+).J*R+O)8@$*W8<]:G@\$ZA'BWDO[9K2'
M7O[7@VQ,'P7=W1N<$Y? (]*[BB@#E;;P8MOX]G\1?:LVSHTD=GMXCN'5$>7/
MND:C\6]:QH?AY>V:-IMG/I":8;DS+<2:>KW<<9?>8PQRIZD!B. >G%>AT4 8
MOBW0Y/$GAB\TF*Y%N\X7#LI93M8-M8 C*MC:1GH37,Q> K]M1DO))=(LT?2[
MC3Q::?:&.-/,VX?.?F.5YX'&/?/H%% ',_\ "+RA/":_:D_XD9!?Y3^]Q T7
M'IRV:PO!>FVU]XUUWQ%9R2R:3YA6PWQE%\V0(UPR!@#@LB\^NZO0Z* ,37]"
M?6;O1)DG6(:=J"WC KG> CKM'I]_/X5M,-R$>HQ2T4 <!'X%U?3]&\)P:;J5
MD+W0!(/,N8':.7>A0_*K CACWK4N_#NLZ]H[VNNZA91W<,\=S876G6[H;>5#
MD,0[-N],<9!([UU=% '&7'AKQ'X@^SVGB34].;2X94EE@L+9T:[*$,H<LQVK
MD D#KCK6I:>&D35_$=S=M'<6NLF(- R\!5A$94^N<'\ZWZ* .4\#>#W\&VNI
M6K7[7D=S=F:%G!WI&$5%1CW(" 9K+U/P#?7FK:Y<0SZ4RZM_R]7=F9;FU'EA
M"D9SC;QD=,$G@UW]% 'G]U\/+JYTFZM#J$*O/H-MI.[RS@-$S$OUZ'=TK6\2
M^%)=5U>PUBR-BUY:Q/;M#?P>;#-&Q!P>ZL"H((]QWKJJ* .!N_ 5]=:+:0R7
M6FS7,.HF^DMGL@EG("I41%%Y(4$$%MQR.?9D?PZNW_MB6;4+."XO6M)[;[':
M^7':2V[,R87/S+R,\@GGID8]!HH Y"UTO5+'Q!<>*?$6HV)AATU[9H;6!PD:
MAPY?)))^Z<_A]31^&&B+8V&H:D#*T%U<-%I_G(59+*-F\E<'D#YF(]B*[VB@
M#&DT5Y/&=MKOG*(X;"6T,6WDEY$?=G_@&/QK'A\%31>&]+THWL9>RU8:@9-A
MPRBX:7;C/7#8S78T4 >8ZA\,M0N['6;".[TE5U">2?\ M"2R+W9#/N",V[&!
MPN1_",8'6MG4/">MB37(=&U.SM[+6\O<+/ SO!(T81VC(8 [@HX/0\\]*[6B
M@#@I/ 5W:75K>Z>VDW$XT^"RN8]2M#+&QB&%D0@Y4\D$=",=,5T.DZ1J6D:?
MI=E'?6TJ0LYO7-L(S+G)^14P$PQ'KP/7FMRB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPTB6/1M1:WO(;FRDOY&MS;6S0VZC"[A""S9CW;B"#C).* .O%W;&Y-L+B(W
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M1D[MP&>#SQ75>/[RRC\1:):WD.DQ_NIY8[S6G;[+&1M!4)D*TA!R,D8 ..M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<]>G:BRU:\F^(6K:2\@-G;V%M/&FT9#NT@8YZGA10!T+(K(4905/4$<4X
M 8 ["N%\9>(;K3O$EAILNN)X>TR>W:0ZD\".))0P B#."B<?-DCGM6YX5FU6
M6TN!J-_::E"LO^AZA;;1]HB(!RRK\H8'(XX.!P* -S8N_?M&[&-V.<4;%W[]
MHW8QNQSBE8X4GVKBM.\>V:Z;I4)_M+5[^\L1=H;:R"O*F[:6*@[4Y]3CIW-
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MJ0&!Z,.>W-6-(T*UT70DTFU:5H5#[I)&W.[.2S,Q[DLQ/XUR-WXTU ^ +V[
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M0WOB$R"5(+2_6""*:'RWB'DQEE8=<[BWK[<8H Z@(@<N%4,>K8Y-#(KC#J&
M.<$9KC]5\6W&D^/SI1MKR]MVTI;E+:SMQ(^_S65F)XP, #D_3DU=/CC27TS3
M;VU2[O'U+?\ 9;6WA)F?9P^5.-NT\$D@ T :6JZ)!J\^F332.AT^\%W&$QAV
M".F&SVPY_(4:WH=OKFD_V=,[PP^=#,#%@$&.19 .1TRH%9,_C_1K?28K]X[T
MF2\^P&U6W)G2XVEO+*=<G''8Y'8YI\WC:TB>*"/2]7N+QK=;F:TAM=TMNAR
M9!G )P<+DDX.!0!TBHJ@A5 !Y( K(N/#XO/$=KJUS?3RQ68+6UD5411R%2ID
MX&XG:2!DX&3BL[_A+=/EU""[@U)Y=/?1YM0$*0 AT1TR^X\AADC9CN<X(I^E
M^.M,U74+&UCM=1@74$9[*>XMBD=R NXA3USMR>0,@9&: .GZTTQH0H**0IR
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M$7F)YC*6";N2!WQZ<B@#S[3=-\376H>#EO=%2RM]$W+<RF[20R'[.T89 O\
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MQJ.E>))M-MY+FRGN%&F1S*'%M*J@?O"=AD!3)Y PV,\9/=.ZQHSNP55&2Q.
M!ZU4BU?39Y5BAU"TDD;@*DRDG\ : .$F\+ZYJ=_-K-Q91VT]WK.GW)M/.5C#
M;VYY9F'!8Y8X&>PR:V9=!OVUCQC<B)?+U.Q@AM3O'SLL<BD'TY8=:ZZB@#RL
M^"=0L;NPOI=)N=35M'M;.:"TU-K62":)2,Y#JKH=WJ2".!S7<>$-(DT3PU;6
M<UK!:S;GDDA@E>149V+$;G)9CSR<\G.*W** /.M5T;Q5%?\ B<:3;NL6H7=M
M=QW,-TD;R1JD22Q*3RCD(V&Z>XJ/1M"UK2O%%[KEKH5PD;:2T$,%WJ?VB>2<
M2!AO=G8*#[$@ 'N<5Z310!PG@SPMJWA'59@_DW5KJJFZOI8PJ>1=YRP4<$QD
M' '."ON:O^,['6KV?2O[/2\GTY))/MUM8W@MII<K\A#[E^4'.0&&<CTKK**
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M +^VMF0)<?*%)^92R$J "5(R!Z\U'??#_3KV34PMY>V]MJ5K';3VL+)Y?[L
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M0 C*D@CH2""""#571_"<>FZLVK7FJ7^JZB83 D]X4'E1D@E45%51D@9.,G%
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M5BK;<#<N#@"L37M%FTW5[1],T[74ACL$M5N]'N(C)(%)Q%*LOIU$@.<LW(H
M?X:\7ZQJ<_AF*_6U5]034?M0B4X#02A%VDGIC.?6J5_K%SJVK:6MSY>++Q@U
MI%L7'R+;N1GU/S&KN@> 98/"F@0SWMUIFK:;Y[QS6LB2-&)G+/&V]65Q@@$X
MZKD&M6Q\!Z=8I;A;N^E:'5#JOF32*S/,8RAW';T.2<#'/MQ0!RM_X\U2SNA<
MQZM8W2KJ*6TEA:6$LD21-,(^;K[H< @\X&>,57GN-0T_3?B%=W,UI?11ZI&H
MMY[7*$E;?!.6.0%(&/49]JZ7_A6UH=-32CK6K#2X9Q/;6:M$%A82>8/FV;F
M/0,3^8!%V]\#65Z^MA[^^2WUADDN+=&38LB[/G7*Y!(C4')(Z\4 4I-5\2ZS
M?:\^BW=C9VVD3FVCBN+8RFYE6-7;<VX;%^8*,9/4^U4=-\3^(/%VIPPZ/=6F
MF6TNC6VHEYK8SNKR-("@^91CY>OM[\;NH^"XKR^OKBUU?4M.340/MT%HR!)R
M%V[OF4E&*@ E2,X'?FK^F^&=/TC4S>V0>/\ T*&Q6$$;$BB+%<<9S\YZGL*
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M7)BLQBWC;]XP!S%E2 O0_*!Q5.7R1I7CVRM9--CMP-,81Z/E+=',Q#%.<9X
M)&.1ZB@#WI65L[6!P<'!Z&@.K$A6!*\$ ]*\LU[25\.>(M3@\*6:V4\_A>ZD
M$=JNWS)DD0(^!U<;FP>O-,4>%K72X9/!>UO$$FCW+0'3V#,Y$60UQCDMOQ@M
MSN./6@#U8.K,5# E>H!Z51NM7M+35K#3)6;[3?"1H0!QB, L2>W4?G7DGA6&
MU75?"DVG7V@17<C9E_L]9&NKE/+/F+<=>_)+]& KKO%=KI(^)G@VZU"&S#LM
MS&DLZKDR#88E!/\ $&)*CKDG% '4Z#KEMX@TB#4;=7C2;?MCDQN^5RAX!]5K
M2+J&"E@&/0$\FO%M,T/3;/X?>']=@M(TU;^VX?\ 3 /WNUKPH5W==NTD;>GM
M576(TN+[Q?+K%UH5O?Q7D@@FO_,^VP1 #R&M]IR!C!&SJV<YH ]S+*" 6 )X
M S0'4L5# L.HSR*\NL=&_M#Q5XDO[F!;S6K'3[)[-Y$(V7'DL=ZJ?NL65>O/
M&*Y[PO%#N\)W-M?:%#JDES'Y[VRRO?SG!\Y)^I_O;BW"D#IQ0![ED8SD8I"Z
MJ0&8#)P,GJ:\:N-8T^#X:7>CR7L*ZF->9#:;QYH/]H;^5Z@;><],5H:CX?TK
M5;OXE7E_917%Q;D&W>09,#"SC;<G]ULXY'/ ]* /5F95QN8#)P,GJ:S="UNV
MU[0+36(%>&WN8_,59< J,XYP<5YO9-H=_J\LOC:2V8?V+926#WS@ (8R9GC)
M_P"6F_&2/F^[6'9*\NB> [>[.F_V0VG3%%U@-]F>X## <#@OLW;0W'WL<T >
M[%E R2 .N<TH((R#D'O7BEGIMMJ4&@:=/<6U]I4GB2=8H[42"W6,6TA:)"WW
MH]P;IE<$CIQ7=^.#I^B> S:"S'V'?!:)"DQ@B12ZJ [@';&/XO;([T =<LB.
MI975@.I!S2AU9BH8$CJ >E>%3?9[6[\8VMF-$AB?PK.\L.B B .I(&3T9P&Z
M@#@C-=++HMMH.N>%9M!M8[>_O-/NTED3AKEQ '4R'^,[\')S0!WVK:Y;:0]@
MDJO(UY>1V:B/'R,X)!;GI\IK29@JEF( '4FO$[*+PJ+#P%-9O;_\)#)J-N;T
MJW^DO)M/G>?_ !$A_P"]T.,=:['XAW%FVH:#IUW:65Q]HDFD3^T[@QV:E$'^
ML&"';YOE4^Y[4 =V&5E# @@]"#UI%=6&58$=,@UX7I\5M>Z1-IH>U>P_X3"V
MC6.PW) (VC0LL8SD(26Z'!R2.#727'A6VDUKQAH&BP16*-I]E>6L4"A(X[I6
ME*N%' ),:9QUQ0!ZEGG%-+J&"E@&/0$\FN&\#:@WB[5;SQ;)$T48MXK"VC88
M*$ //Q_UT8)_VRKDO&2Z=;>(/$6HRMHVHO"T;RVE^SVU_!MC4J+649.#U&T#
M+$C- 'K-MJ]I=ZO?:9$S&YL5B:8$8 \P$K@]^%_E5SS8R&(=3M^]@YQ7DM_<
M:+I.O^/=0FL1'>/IEO,L4)6&Z9'1O,*L.1SMW,,XQD]*JZ1:Z<OC[1K&"W\-
MI#=Z?=17-MH^9$D38I43,<"0G!QD9X)[T >L:1J]IK6C6VK6CG[)<QB6-G&T
M[3T)':KP((!!R#T(KP73UM&\(^ K> Z,NE.DWV];S_CU:\")M6?;QOQNP&[@
M>U>A_#9!%;ZS';WEE/8K>X@CL%<6\#;%WK$6X*YYPO )(H Z71=;M];L);R%
M'BCBN)K=O-P#F*1D)X/3*G%:096 *L"#T(/6O&1<69T?3=.N[2SN/M.NZHR?
MVE<&*S!2:0_O1@[SS\JGN">U5M(:.TTS6]5M7LS!H&O0WJ+IRE8%A,2+.(P2
M?EV/(>."1D4 >WY'/(XH)"@DD #J37B&F)>SW]OHMR)63QA/!K,@/1(P[RRH
M?3Y$@3'^U7<>//LCZSX9AUHH/#\ES*+L3'$+2^7^Y$F>-N=W!X) H Z77M<M
MO#^@W.KW"22PP*#LAP6<DA5 R0.215FPN9[K3XKBZLWLIG&7@D=7*<]RI(/K
MP:\=UNRTFYT'QE#IL%M/X?M[NQ:S"*'@BN"ZB;RNP&&4';QEF'<UW7CVPT^'
MP7%8FXM],LDN($0/ 6M@ XVQRJN (C@ \@#B@#I[Z]-I8-=0VTMX05 B@P6;
M+ 9&2!QG)YZ U9+J" 6 ). ,]:\6DGMT\(>*K""PTVW:"YL'DET><O92,TR?
M<7 $; *-P'J#3M=T:PG\.?$+69+=6U*TU5_LMU_RTM]JPL#&?X#DG)&,]Z /
M8;NZ-M97-Q%"]R\*,WDPD%W(&=HR0,GWJG8ZY#?:W?:4L$T<]G!!/(7QC$N_
M &#U&PYKS?Q3I&GZ!J'B.UTJUCM()_"-U),D0P)'5L!V_O-AC\QY.:9JE[!8
MGQ7+<PR30OI6D1,B3F$?.TJ_,X!VIS\Q],T >NK(C@E75@."0<XI0RMG!!P<
M'!Z5X7)]FM-7\26UF-"@CD\)7K2PZ(#Y.]2NW<> S@,>P(!YZUZKX/T33]%\
M.6O]GVJ0O<01RSN/O32%!EF/4D^M &_O7?LW#=C.,\XKD=1\?6^GSZS_ ,2N
M\GM=*9(9KF-H\/.^S;$JE@Q)\Q><8'/->8:5')+IEC=W%[H5MXD.I*)9MDC:
MG]H\[YHV Y*D9&W&W;S6CK7AS0_[)\;3_P!D6'G0Z_:QQO\ 9UW(K&VW ''
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M5!_%Y>S;Q]W9FLV[&BGP9K-W>/"/':7TXC;</MJW/G$0+'_%LV[, ?*5S[T
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M)IMT]C&LEXL+F!&. TF#M!]LXKGH?$-]H]A)/XBM)TEFN8[>R@AV323L8E)
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MAWJ,2R"(*O7OL;GIQ3;+P[J4/_" ;[=1_9%LT=Y\Z_NV-MY?'//S<<9KMZ*
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MJEOO!D4]_/=6&JW^F?:H4@O$MBA$Z*-JG+J2K!>-RD''T!H 3X=?\DW\-_\
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M&(0%\!N"3GCW.5M_ <5J8[6'6M331HKC[0FF*R"-6W;MN\+OV;N=N[';IQ0
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MK+0[2WU*Y:YO$3$LK-N+'/<@#/IG Z=* *?BS5[K0M)BU*W$9AANX1=[U)Q
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M<$;<2.G&<8/K@BJ]OI46AWO@F]TE9!J%_;3)<R-*S&Z/V5I!YF3S\Z@CT[4
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M40J&.>G5UXKS+Q!:Z0^MZEI<6GV+V^D64,;-JVHO%%;(5+ P1JI8G'5R0<@
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MZ^=N/G4M[\^M:/BB;3M9\3ZC$]M87:65E"TD^JZB8K>%7#,'AC126)'5\CH
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M!Q@\XXS0!MR6=K*9C);0N9D\N4L@/F)S\K>HY/!]33DMK>*1Y(X(D=U"NRH
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M/Q9KYTO2?%%R]E_8VI7<<7V)8&$D$4K[(Y/,W?,V2I8;0,$XZ4 =XMC:+!#
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MG?E"%5@6;:!PP.6Z\<UL^-])N;KQ?IMI9D+#XCA%GJ29PWE0N)2WXH9(R?\
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M;TK8NK* )IH_,&9$YXV')4$>HUH_!UYJ7BNYO+F[U'3K33[6+3]-:UG5&DC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M90?,@.2I;;NYYYSF@#.\*>'M)\8V%YK_ (AL(-2O;J\N(E6[7S!;11RM&L:
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M=(B72K"DT<VP85BKCA@.,@] * .3MO%^G>&O#%I::)-+&;G4Y;5(M71Q_9N
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M#*K.$)/3.<#K@U4M'NYM+\0:1'J5K9+#K=O%!:MJ,TL#;HU9K;SP ZAF!SP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:SSB2X4O;-/:R1)<J.28V=0'XYX)XYZ5:UKQ)I?A\VRZC.Z/=,R01QPO(TK
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M- $-CX;MK7^TK::."YTV[NOMD=M+&&$4A(9^#P1O&\>A8^U6+?0K+1]/NH=
ML+'3IIE8J8K=43S,<,P7&<50?QWX=33K*^^VNT5Z[Q6ZI;R-(\B9W)L"[@P(
M(VD9I\?C;09-&FU3[7(D$,_V:2-[>19EFXQ'Y17?O.1@8YS0!$?"$-OH6D6-
MC,8[C29DGM[B09+/R)"W^^&<'_>SVK?N;6WO(?)NH(IXMRMLE0,,J05.#W!
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M9A*R)*C[&+Y)8DL!GKFK&H>'M837=1U>#3WN%M]?@U".W5E#7,0M5B8IDXW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-PV;L9Y#8))&*DN_"5\FI7MWHFNOI_\ :$4<=V)+<3EBB[!(C%@5?;@9.X'
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M5A<7"PDB5T(&U>5; .<X[9KJ?#^BP>'= LM(MI'DAM(A&KR=6]2<>_:N=NO
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MQ#)I]AJ4[7$\2VP>6-W^^8I-PV;NO(;!)(Q2ZKX"@UF[O+R]U"9KKRHXM.F
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MX#"%:%W.7^;/S G&.!CWH W**** "BBB@ HHHH **** "BBB@ HHHH ****
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MV3UH ]+TO5;36;+[992&2'S)(MQ4K\R.488/^TIJY7&_"T*O@2!4N#<J+R\
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M  ))Z"M6O*]<6^\2>*[FQ&BS:O9:7IK6,WEW$<86YG0;VRY&2(\#CIN-=3X
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ML>>>6ZGN30!W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9>,=73<HWK[KD4 3P>%]"MM8;5H=*M(]09F8SK& VYOO,/0GN>II'\+:#+K
MU=])M&U ,'\\QC=N P&_W@._6JNG>.?#>K7MM9V.J)++<KN@_=NJ2X&2%<J%
M) Z@'(P<CBGCQGX>;5?[-&I(;CSOL^?+?R_-_P">?F8V;^VW.<\8H UK2PM+
M$SFUMXX3<2M/+L7&^1NK'U)P/RK.O?#&F7EPD_V:.*7[;%?2.B#=))&/E)/K
MT&>N,CO6PS!5+,0% R2>@KC)OB%IMUK>AZ?HUS%<_;[QH9"\4B@QB.1M\;$
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M>H:QJYNHHM"NX_*5(/[2L][VC#.2C+]\'@[6[CK71Z!H\7A_P]I^D0NTD=G
MD(=A@O@8R?KUI+SQ!I.GS745Y?10M:0+<S[S@1QL2%)/3DJ0!U.*IVWC3P_=
MVM[<1ZAM2QA,]PLL,D3QQX)W[&4,5X/(&* )K#PIH&F:@;^QT>SM[L[L2QQ
M%=W7;_=SWQC-:-K96UDLHM8(X1+*TT@08W.QRS'W)J&75K&&YL[>2X59;Q'>
MW7!^=5 9CT[ @\U4T/Q5HOB4R_V/?"[$2H[LD;A<-TPQ !Z'@=,8.* -BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_ 0#]*],HH \I\26VOWTWBFR-MK*-<;TL;?3;>)+>Y0Q!0\LQ7);.006!P
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MEKFG26&H1M);28WHLC1DX]U(./;/- 'FEGIVJ^)O \OB@V7FZCJ.H6NHFR#
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MJ\I?.V]-^!NQ[9S7/^(K62V\3>']>C1GBMWDLKD*,E8YMH#_ $#HF?0,3VH
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MRJL;1KYC%SR%;&0 .N0<\ &EX2\1:OXD\V\FTRVM=+#S0Q2"X+RN\<I0G;M
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M'Y+:Y:.5E+7V65F.#RRB$$'MYE 'J5WXATNQ@OI;B[5186PNKI0I+11$,0Q
M&>=K<=>*T8Y%EB21#E7 8'V->/Z]8Q_:/B'=F>Z:3_A'('VM<N5):.;.5)P>
MG''&3C&36I=+>^$=0T>6PU#4;R2[TN\>>&ZN7E262*%70JA.$.>,* ,'% 'I
MU%>7P&?2])\(:];:[J%Y?:K=6L5TLUVTD5RLP^?$9.U-O)&T# 7FDNM;O8OA
MAKEV=2N%NXM:FMXY?.(= +W:$!SD#;QCT]J /28+ZUN;JYM89T>>U95G13S&
M6&X ^Y!!_&B^OK73;&:]O9T@MH5+R2.<!0.]<?X2T^*#Q_XVG6:Y9OM<(VR7
M#NOS01N?E)QP>!Z#@8'%3_%2!9_AIK89Y%V0;QY<A3)!'!P>1['B@#I1JEFV
ML-I(E/VU;<7)CVG_ %98J#GIU!XZU<KSF?P]#??$X6+W^IQVT.@1?ZF]D220
M^?)@M(#O..>_/?-<_::QKVK0>&-)=[Z]CD@O7E\J_P#LLMTT,_E*&E&"<+R0
M"">IZ4 >S56O+^"P$!G+CSYE@3;&S?.W3. <#W/ KG/ 4^I/INHVVI3"4VM\
M\,(:[6YEC3:I\N1QU922.><8S4OC2[N;2/03;3RP^;K5K%)Y;E=Z%CE3CJ#W
M% '3T5X]?KJ3>'M=UY-?U:.^M?$+VUKMNF\N*(W2Q[?+^ZPPQ^\#C@#@5+XH
MEO?#+^)["PUO4HX!IEG=I-<7;RO!(UPR,RLQ) (49'2@#URBO-=9N+SP;J[)
MH]_?7_G:)>W<D%W<O<8DA"&.4;B2NXL5(&%/8<4B++H<7A#5;37=0O;C5;F&
M&[6XNVECN4DC9F<(3M3;C<-@  &#0!Z76=:Z[IUV+/R[C#7AD%O'(C([[,[\
M*0#QC^7J*\X\/76H:;JVBW.KW.I3"^N3"FJ6NI_:;*_9PQ4&%C^Z''&U>,8S
MC-0:'%)J^J^ ;V^O;Z6X8ZEES=R#=Y<A*YP>?0^H !R!B@#U:POX-2M?M-L7
M,6]TR\;(<JQ4\, >H//?J*LUY/HM[?:[-H&CW^J7T=I=2ZK+*\=R\<EPT5R5
M2+S 0P 4DX!'"CL*9=7>IBY?0+?6]0^R6_B:WLH[Q;@F8PO;EWB,G5MI)&3D
MCCN!0!ZW17'>%$ET[Q?XDT5;V\N+*VCM)X%N[AIFC,@DW@.Y+8^0'!/'-6_'
MVI7>E>#KJYLYS;2M)#";@ 9@1Y41GY]%8G/:@#I))$BC:21@J("S,>@ ZFL[
M0M>LO$>G_;]/%P;8MA))K=XO,& 0RA@"5((P1Q7#:[8'1M7CT6TU35)[/4M*
MNY+J&>_EE>,Q!2LJN6W)DDJ0" <]*Z?X>VB6GP^T!4DF?S-/@E/FRM(06C4D
M#<3A?0#@=J .EHKC/&ER9]7TK2(/[5N)YDEG-CI]R+;S47:-TDVY2J@MT4\D
M].*Y#1]4U2^BL]!N]1O;>TE\1W-C+*MZ7F6..'S%@\_ACEN,YS@8S0!ZM;ZI
M:7>HWNGPREKFRV>>FTC;O&Y>>AR/2KE>1M9W6CZAXUGTC4;VXETJ>QO KW#.
M\D:1EGA=B<N"FX -D_=]*GUKQ-J=SH/B3Q-I-[,+)[BVTVP99-J)&)%6689^
M4$M(RACTV#TH ]5HKR.\FUW0XM:B1[NQA;0;N?R;K6?M<PE1?EFC))=>I!P<
M9QTJ]?:3J5MHNA1V>K7VH7%ZWVF[LY]7>WFO/W7(BD'W I.XH,"@#TZBO'I=
M=U"XL='T2R;6CYFK7%I>PW5ZL5RC)'Y@@%P"<CY@0P.X@8S77>!I-3BO];T^
M^9EM[:2)K>">_%W/!N4ED=\EL< KNYPQ]* .KO;ZUTVT:ZO)T@@0J&=S@ DA
M0/Q) _&K%<7\5+5+KP).'DF0)=VK#RI63.9T7G:1D88GGN >H%8WB O=:SJ=
MC9OKMVNE6D2.T>JFSAM#L+!V??OE<C#$D,!CW- 'IM%>.:EXGUNQ\'^%->L=
M1FGU:]TPI<VK*TB/&(]SW.P<!HS@DX^;=M]*V=0*3W.CZ+I]YKNM[--^U%;;
M4?LXE5F 6>6?>K')!PHR/; % 'H5S?6MF]NES.D;7,HAA#'EW()VCWP"?PI+
M._@OQ.;<N1!,\#[HV7YU.#C(&1[C@UY#:>=KVA^#)-1O;V26+Q%<6HD2^?<4
M43[<NI&]@$4!^I&?[QSI0ZCJ&I:M!HUQJEY#97GB'48998YV20I$-T<*OG*
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M,D$KGTR :HZIXKT'1;Q;34=5MK:<J'*.W*J3@,W]T>YP*UU8,H92"I&01T-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD4(VQAU5_EX8_,,5Z710!Y-I7A+6V@\+^'P9]+ATJ*75)IUB$J+<22-Y<0+
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M5RC*2<=>=M9^I^%M;?6-;GTK4;*&UUJ%$N?M$#/)"RIY>Z/# '*XZ]",\]*
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MU$QBF6/E77:0002W'<-VQF@"W\.;Z[U'PD;F],_GM?7@99WWO&!<2 (3D_=
M ]..*IOX\O;74M.CU#1K>TMK^\6TB1K\&[0N<*SP[> 3C.&)&:V?"V@76@^'
M6TZ[OA<W#SW$SW$:;,F61GR!S@_-7(V/PTU&UMM)MO.T:,:=?0W374-FPN+W
MRWW?O7)X)&<]<G'0<4 :%U\0M0@MM4U%?#P;2=*OI+.ZG-Z!(0DFTO&FSY@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKF/B'>W>G>!=2NK&[-I<IY6RX'_+/,J G\B: .GHKSK5+RX\
M&ZVL!\07LMG<Z3=W,\MX?M!MGBV;9E''!WD;!@$@8Q6=IMWJT/BSP_9M+XB@
MMM5BN(YGU2ZB8S%82XD2-68Q$$ ]NN,4 >K45YQX?U[5=7O="T"6ZD%_IDDY
MUF13@N(#Y: GTD+*_N :Q;1]<F\->'=9/B;5%N]1U;[#*/,4QK"TDB8"$8W
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M,OS<<<]:XWQ/KNI1Z?K6O:7>Z].+*[81W@DB@L8PD@3RA$6W2@'*EMO)Z$4
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ML-QSC/!SZU)C4-&A\*ZBGB#4+^35[F*VNXYI0T<JRQLQ>-0/W>TC(VXX'.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+QEH<WB3PI>Z1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<K\2;>:Z^'>LP6\,DTSP@+'&I9F^9>@'6NJHH \J^(V@ZEI[SW6BVLE
MQ8:S<VPU"VB4DQ3),C+. /55*M_P$^M699[?1;CQE8ZQI=Y=76JW#RVWE6;S
M"\B:)52,,JD J01@D8SGH<UZ910!D>%;.\T[PCH]EJ#$WEO90Q3$G/SA #SW
MY[UP/AK2;C^T?!C75A+BVGUAV,D)Q$6F.PG(XR#QZ]J]5HH \FN[6;3X[R[D
ML;D6MMXS6[?RK9W(A\M,N%4$E=Q/(!YS6=?V5W!_PEFFW]UJJOJ=[-+%:6VD
MB?[;%(!Y>V4H<$#"\D;-O:O:J* . T;0[E?$WB=VA<7;:=906]W.F3O$3@D-
MTR&P3COBN4\/V%R]EX6T6:YUC[;I]U"\EBNE+$MJT?WW:8J 4//(8EPW<FO:
MJ* /(;'[38ZO86.FQWL\::L7?1=3TLM]C#2,7GCN0   &+*26SG'6NN\%L;?
M5_%-C-#/%.=6DN5WPLJO$ZIM97(VMT/0Y&*["B@#S7QDOV3Q/>74%UJ&G7-Q
M8I$6.FF^M;]07_=%54E6&XCJ,AN]6?#]E=3^,]%OM0T=+.6/PTJ&-(L1V\AD
M7,:]E('&.H'%>@T4 >/6C7VD66BQ&U.G0QWVIE=0;37N6MLSML1$'W=ZGAB"
M,#CK2:'9:@TENTMMJ#G_ (3,W)DN+3R7:)K7B4H% 4$^PP3@\U[%10!RWP_M
MYK;PU+'/#)$YU&];;(I4X-S(0<'L00:Y:XNK/3]3\>VU]HU[-/J<P2V,=C)(
M+L?9HU$:L%(X;/4@#=GL<>I44 >0?V?JWA[7+*XU;4KVS!T*UM%N[?3Q>+YD
M8/FQGY6*DDAAV;\*[KP#8-IO@RRMVCNXQF218[M%21%9V8 JO"\'A>PP.U=+
M10!Y!KFRQ\+^.=#OM)O;G5-0N;JXMA%9O*+A'&8G#A2OR  8)R-GN,["WQ\/
M^*-=-Y97S'4M/M!9^1:R2B9T1U9,J"%8$C[V.#GI7H]% 'B]E8ZEI<7@W4KF
MXOM-M8= 6U,\=A]I-O/E2P="K%-RX&['\..]=Y\/;)K/P_<-B]"7-]-<1_;(
M%A8JQ^\(QC8K$%@" ?FZ5UE% 'G375KH.O>+DUO3+NZ;5)%DM6BLWG%W#Y*H
M(054@$,&&TX^]GIS4/@C0+W3_$FGC5K5FN+;PM:6S2NNX*_FR[H]W3(&T'\*
M]+HH Y7X<6TMGX#TZWFA>%XVF'ENI4J/.?'!Z<8_"N/\37%_-?>+;)4GL9)U
M,<5M9Z29Y-17R0%=IB&7&<KVVA>N:]:HH \[\&Z:[>)HKJZLG&/#.GPB2:(C
M!S)O3)'7[N1],U@(FH>%? /ACQ);64OVZPCFL9;9D*L\<S%8U(/I*(<#T)KV
M.LO4= M-5U*QO+N2Y<6;B2.W$Q$+.#E69.C%3R,]* &^&='&@>&[#3-V^2"(
M>;)_STD/S.WXL6/XUY=XJEU&[L?&6GI%<V<TTDRQZ=9Z0TC7J[ %F>8@K@@=
ML$ 8'.*]GHH \UMM+>>[\9W$MC([7&BVL43O"<O^XDW*,CGG&1ZXIL>C72P>
M 8K.U>WFBTNXB9Q&5\EVM5QN../G]>_O7IE% 'DMKMO/"OA3PW9:3>6^MZ==
MVC7"O:.@M3$P,TAD(VD, V""=V_ZU7O;F:#P3JWAC^SM1?53K+R^6EG(5\IK
MP2B3?C;MVGUSGBO8J* .#32O,U_X@S2V);[5!#'&[19\U1;8*J<<C/IWK!L[
M:2%M(AU#3;^9+SP:EEY<<+!GE"Y:(MC".5SC<1S7K5% 'F'@Z:[_ .$FTR""
M6?5+&*RDC:>_THVUQIR@+MB,NU0^2,$ 9^7-=%X_@BETW3II#J,)MKY)DO+"
M$3-:.%8"1HR&W)R01@_>SVKK:* /(=FJ7VC/=7%A]OL+37K>[FN(-.:WDU&%
M4&^1H#RQ5MO('S!.!Q74:)*NL?$6[UO3;:>/31IBVTL\MN\(N)O,W+@, 6VK
MD9Q_%BNVHH XOQ"XTKQ[I.N7]O/+ID=C/;"6*!IOLTS.A#%5!(#*I7=CV[UP
M_P#9UXUA;ZE;6=_IVFP>)KJ[=%L"\D4;IB.;R64Y )ST)7.<<5[910!X]<Z?
M<7OAWQ9?6SZG?_;)K$"::Q$ G9)5W-'&%#' (!8CG;WQ5K68;O2_&OB6>\O;
M^UM]1CA^S?9]*%XMS&L04Q9V-@AMWRG .[/K7J]% 'FWA30'M/%.C"ZLKEDM
M?#20H]X@9HV\[.PD?+N"X&!VK-F\.WDWPLU2.UL)5O)-8GN)XT@!EFB%X6.%
M(^;**" >&  YS7K=% 'CE]IE]XE_MB32[_5-0NO[$FM1-+IZV<;;BI$/*J6;
M@XXPN3R,UN0WUAK/CGPC-I>DWD*64-S'-))8R0K;@Q86(EE R".@R!^->CT4
M 5=/U"+4H'FACF15E>(B:(H<J2"0#VXX/>N=\>V\]S:Z"((9)2FNV,CA%+;5
M$H)8XZ =S7644 <EK]@;KXA>$IVM3+%;I>L7V;EC8H@4D] >N*XW5]'U'[%J
MDL$%U#;6_B[[9*(;7S6\GR4'F+&0?, <AL 'H3U%>OT4 <'X*A:Y\4:MJRWF
MHWD<MO# UU<62VL<S*6(VKM4L5!P6([XSQ3?$FHV.E?%/0[N_MY9(TTNZVR1
M0-*86,D0W$*"0,97./XJ[ZJ+Z3:R:Y#K#*WVN&W>V0[N-CLK'CUR@H \N7[?
MI\%K=K8-86-[K=W=P7<^GO.]A&R80B$<H9#O.2.-W(R:J1:;>7ZZLEQ;7]W#
M<^)--F+W5EY)GB_=AG,84 +\I[=.O.:]JHH X'7X_LGCMR+280W>@3VL#Q6[
M,AEWE]I*@A3CGG&:Y:RM-1T>ZT+4+R[O],MW\-V=K'/%IOVGRY$7,D3+M8H3
ME3T&<8[5[/10!Y%'IHTO0/#EP9=>TN6&2[>WOC8K+]F$K[MDL"J=JN.0 !MQ
M@D=*[;P#)>2>&<WEE#;-]IF\MHK4VPG3>2)C$>4+Y)(/KGO73T4 >0>)Y]0N
M'\8V"1W%E+<;XXK.STEII-07R0%D:8@K@_=XQM"]<UIZ;<)H&NP:GK5I=M:W
M>@VD%M,MI)-Y;)N,D1"J2I;<IP1SC'45Z910!XQJ?AG4]8U6&;3=)ETVWMM#
MMYETB5<PW!2YD<6\C8[K_#V+#/ KKM,V:S\1+'6QI\\<#Z!A#<0%#"YFY0Y'
M# <8_I7<T4 >1:%;2:#<>']4U+3[H:9:2:I -EL[_99'N28W**"0I0%0P&!D
M=C3IK2\AM-6\7:;I=T(K?7(]0L;3R626:+REAG8(1D;P7;! )P#CFO6Z* /'
M] \,ZI8>(]+T.XMIFL;DV^NWL^T[/M*(P=">F3*(GQ[&H#INIVMGX>U!S>V=
MI9ZIJC3RQV7GM"9)G\N0QE22N-PW <;P>]>ST4 >/KILY@?6UCU34-/77X+V
MZ\VQ$1G1(BAF2%0&(#%"?ER=F>:75[9_$6H>+[O1]+NWMY[;37(>V:+[<(IG
M:55# %B4&WWP.Q%>OU3U72[36M,GTZ^C,EM.,.%8J>#D$$<@@@$$=Q0!YCK=
MRGB?Q?)%H5E=VUY+X9OH(Y[BU>V+N3&%4;P#\I/7&!NX/!IOAZV>]U+PK;BZ
MUB2736W-;MI*VRV0$95E>0J,@YVX4G=P>V:]!TGPO9:3?R:A]HO;R^>+R?M%
M[<&5UCSG8N> ,\G Y[UMT <M\1K:>[\ :M%;P23R^6K".-"S$*ZDX Y/ -4=
M#MX-2\<^(]4^QNUM=:=9)!+/;LF]")=Z@, ?[N1],UV]% 'C>CSZCIFG>%(9
MXY=*V:($.H?V6]U.7W8-N  =G #<@YX':ET2*YTW2/#%W?66H+%:>(KUI]]H
MQDC603A69$7@$NO0;1FO8Z* .?\ '-K/>^ O$%M;0O-/+I\ZQQH,LS%#@ =S
M6%H,<6I^/8M62TE-N?#T,4<TUNT>UO.DW+\P!!X''ICL:[VB@#Q.PT[4M+A\
M+ZA-)>Z=96L-_;^;%8?:#:R-<$J3&5)4,@P& XP!T-=[\/+-K;2=1GS?-'=Z
MA+<(UY;K 7!"@NL8 VJQ!(! /)..:Z^B@ HHHH **** "BBB@ HHHH ****
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ME[>4W8&<Y[XQ4-MX%U.3Q!INHZA+I/G6%P9FU*TMC%=W@P0$DQA0#D;NN<<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM0N-1M(9V24((XB5S\@50>01G).2,\4 =;1110 4444 %%%% !1110 4444
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MIJ L9H8I;Z82&)67)"*H &<#)QGBN2L;^#07^&][J0FAMXM!EBD80.^QRD&
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MKLQ9G8]V)))H T*\7N%M$\!ZGX=FL96\82WDS(HMV,LEPTQ:.=7Q]T*5._.
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M$[*PD! QMQDYSVQUKH)-&MKK6OB//<Z>DSRQ11QO)%N+*+1>%)'KZ=Z]&HH
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M X)'(KJ_AU<37&G:F7M;18_MS%+RTMV@CO<JN90C$D<\$C@E>*[*B@ HHHH
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M0;:PMWDT?4-*>\W%D4D%HL.0>?E#8QWW>U6?$VMZMIWBSPO8V%L9;:]GF6X
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M:$VQ<MA-D2(=_''*GIFM2WMO$^I+-8>(+31/[+N(7AG%I/*TA#*1@!D [^M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>.;[^VY[.#3_ +79Q64:1^4T<<?S>9E2Q+Y."",9&*]&T?\ Y EA_P!>T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1D88<_7BN27X<7MO:Z+<3:?INJSV4-Q;W%G<3,B,DDQD5T?:<,,X((P03Z4
M>@:%KEOKUC)<0Q3020S-;W%O. )(95ZJV"1W!R"000:\QT[Q)874>HOK'Q'O
M=-OX[^ZB6UCE@^1%E94PAC+'@#CO7H'@[0I=!TB:*>TL+26XN'G,%B#Y<8.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'M;OM5@NH-7N+>&>R2V5%@\_[IC8?,=I(SNSD9Z5<^&$%U#H6HFYOFN<ZK>
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MEP7QSC/IS5+1_$NKS>*=.TS^UKR\MM2M9SY]UI!M1'(BJ0T6Y5+KR>"#VYH
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M#7FI&SO+M[RZL?M'[B>1GWG<N,XSC@$ @#.:V[S7K&QUW3]'F<BZODD>(9&
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M<R7 \RT+_>2,X^X<G*L"*L6_@G3((H0\MW/.E^NHO<S2[I)IE7:"QQC '&
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M !U7KU.3DGC'1U M[:/=-:I=0M<+RT0D!<?4=: *&M^'[;738O-/<V\UE/\
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MIW&E+<BZ&GRE&4L'WJIDV[R@;!"D]@.@Q0!S,NBB[U3XCZC96:2ZY"P2PFV
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MCZA= ]5>4[@O_ 5VK_P&F>/K:23PK+?6Z%KK2Y8]1A ZDPL'8?BH9?QKIZ*
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M=OR[Q^\]P*]@  &  /I2*BH,*H ] * /-[31M.TCQ!\/I=/LH;:6>">.>2)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M."<<T7?Q&L[7^T)O['U62PTRZ:UOKU$C\N%E(!."^YAR"=H. >?2L*R\!:M
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M/M-,U;5[Z32X-0S&D2EHGR-S$NJALKR!W(QGG&V^D/'X.?1H!"'6P-J@1=B
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M9R2V<CKW!K$U;2KY/&>I:QIFFZ1XB$D,5O<65Q.J3VA4$[4)#* P8,0<9X-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 52U?2K37-*N--OHR]M.N& 8J1@Y!!'0@@$'U%7:"0.M
M'*_\(%IMQ'=C5;S4-5EN;<6WG7DHWQ1A@P";%4 [@K;L9RHYXIT?@:R8W3W^
MHZEJ4\]G)8K/=RJ6AA<88(%4 $\98@DX'-=,KJ^=K X.#@]#0KHQ8*RDJ<$
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MJ&&0:-B>9YFU=^-N['./3- 'B6GW=G=Z)X2T^_M],G>/3)I4EUVX(M%59-F
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M4O%CLK9I2T+E@'],?+W]1C-<MXD\/^)-6O/$%O/97]ZMR&339(M4^SV<,9C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#OS6CI_AVSTS5YM0MWFWR6D%GY;MN54B+;3D\D_.<DD]!6O10!RMGX&M-/\
M[ -GJ%["^C+)'&PV'SHY&#.CY7H=HY&#70:?9O96[127EQ=%I'??.06 8DA1
M@#@9P/85:HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXTN(QQOC+ ;A[]^V:P]"^)>FVWA;1KS7-4:\GU*2>.":WLG7S#&V-H0 G/(
M]32P>%M7C\=^$]2^R 6>GZ*UI</YB?))MP%QG)^HR*YOPUX!\1Z?:?#^.[TX
M(VD7MY->CSXSY2N<H>&^;/MG% '>67Q&\.7FA:GJYN)[>#3'\N\CN(&26%N@
M!3&<D\#WJA+\5-&;2=8GM[;4%OM-M/M1LKJT>*1U) 5@"/NY(R>P.:P;WPQX
MSM&\?W6AQBWN]4NK>2QD$R!I8U!$FTY^1L'&6Q5'2O!'B&3Q%KE])I%W:0:C
MX>FL8WOM3%U+Y[$8WMN)&?;@#'0DB@#:L/B'<:QX?\):B+I=/FU'4H[2YC>S
M8K,2 2D9/0'(P_(K:U+XI>%M*U2XL9[FY?[+((KJYAMG>&W<G&UW P#7(V?A
M?Q1=^&O =G=:&;2;0M6A:X5KJ)\PH!F48/J2-HR>/>HI?"_C+2-&\3^$[#0;
M>_L]:NYIH=4:[1%B67 /F(?F+*!V[^M '>ZS\0=!T35(M,G>YGO)K07D,5I;
MM,98R2!MV@Y/!/T&:U/#OB+3?%.C1:KI4QEM9"5RRE65@<$$'H17':-X,U+1
M_B-HMYY?G:9I_AJ/3#=%UR9E<\;<[N1SG&.>M:7PPT#4O#GAFYL]4MQ!.^H3
MS*@=6RC$;3E210!R][\1=:TO1_',%P\4FK:5J"6^G@1 ;DF.(LCN< FH[7XB
MZ_>^%_#,"/#'XAO=;;3;W]T"$5&/F$+V(4I^M3>)?AYJVJ?&33M9MX0="D:"
MYOV\Q0/.A#; 5SD\;1P.YI=+^'NJVGQLN=;DA \/QO-?6S>8I'VB9$5_ESD'
M.3G&/E% #=2^*-UHGA*\U 3)JES_ &U)8Q,+1XTA5=N58#J0#P<C)/M5VX^)
MQL?'[6EPEV^D2Z,EY!;163/<&1F'50,C"Y)!P!BL.Z\!>)O^%=:U81Z<KW[^
M(VU*"W\]!YL.Y<$-G )P>"0>*ZS1]&UJ;XJOXGOM+^QVL^A);LK3I(8YO,5B
MGRG)P!UQB@#4E^(OAJ'PO9^(3>L]E>/Y=LJ1,TLLF2-@0#.[((IMI\1O#MYH
M>IZJD\\::6,WL$T#)-#GIE#SS7GNE^ ?%6D>%O"=Y%IL4VJZ#?W,[Z<]P@\Z
M.1OX7!*A@ ",GO[8K1E\%>)/$D?C36+^PBTN]UFR2TM+ SK(0$ PSNO&25 '
MIF@#O;GQEI%K<Z1;R/,9=7@DN+14B)+HD?F-GT.T]*Q_AQX];QQ:ZE)+:/;R
M6URR(HB8+Y?1?F/5N#D=N.*YW2M$\7:AXK\"WVH^'ET^TT.WFMYV-Y'(Q)AV
M;L*?ND@8QD]<XXSM_##2-<\/0:SI6JZ7Y$'V^6YM[L3HZSJYZ!0<C  //K0!
MDZO\3+WP_P#&%M#U#9_PC[1PQF79@P22+E69O0D$<]CGM6QH?C@I<^-+C7[R
M&'3M%O\ R8Y-F-D>. <<L2< =S56_P# 4NO>.?%3ZI:_\2?5--AMXIPZDB1<
M'(&<@J0",C'%<?IGPM\62>!/$NDZB8O[2FOXKFUEDE5DNA'Q\V"2,@?Q8.<9
MH ]%T[XF^'M4%VD/VV.YM[9KL6UQ:/')-$!G=&I'S?AS7+V'Q1NM;^'<6N&9
M-)O/MZ02,;1Y(BK.P55S]X[0 6'0YZ5?LM(\3^*/'VD^(-:T2/0[?2;6:)8_
MM23/<22*5/W.B#.>?Z\<S:>"_%S?":V\*S:%Y5WI^IQRH_VN(K/'YKNS#GC&
M1P>30!Z%KGQ+\.:!JD^GW4MW++:JK7;VUJ\J6H;H9&486G:Q\2/#FBW$4$D]
MQ=.]N+MOL5NTXB@/(D<J.%QS7+RZ3XQ\+^)/%,FAZ!;:Q;Z[*L\%Q+<HBV[X
M((D1B"RC/;L/?C-\0>"O%$/BR_UB+3[C4O[4L(8I4TS4S8I%.D80A@6!:(XS
MC)(S0!Z_8WMMJ5C!?6<RS6UP@DBD3HRD9!JQ6+X1T<Z!X4TW2VA2%K>+#1)(
M9%1B22 QY(!)K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ H)P,GI100""",@]0: /,5\0Z/XVU6WMQJNFV7A
MVRNU:.!KF-9=0F1LKA,Y6(, 1W8@=!UHW5]:6GPX\::+<31_VJ]]?0I:EAYL
MKSR$PE5ZG<'4C']*],30='1U=-)L%93D,+9 0?RJ=].L9;U+V2SMWNXQA)VB
M4NH] V,B@"&VDM)XGTJ6>">XA@1;J#<&(# @;E]&P>O7FN=\,016WCOQ=!!$
MD44?V)4C10JJ!#T '05UJP1),\RQ(LL@ =PH#,!TR>^,FE6&))7E2-%DDQO8
M* 6QP,GO0 ^BBB@#CO '^L\5_P#8P7/_ *"E<+H>B6&G^!O!VNVT)359-6MH
MWNPYWM&\Y1DSG[FTXV]*]HCABAW^5$B;V+OM4#<QZD^I]Z8+.V$,<(MX1%&P
M9$"#:I!R"!V.>: /"[E;BYM-;U*]N]%M-;AU*5%O+BXF^VVS"7$2QHJD[=NW
M"KD,#WR:]XCW>6N_&_ W8Z9JO)IEA+>I>R6-L]VG"SM$ID7Z-C(JU0!P7AS4
MK'P_XJ\5:=J]W!:7=UJ'V^![B0()X&C11M)Z[2C @=*H>(O$5AK^G6TD DA\
M/-KL=K?WJMLBNH@ARVX'_5F38A;H<=<5Z%>Z;8ZDBI?65M=*IRJSQ*X!]LBI
M3;0&V^S&",P;=GE%!MV^F.F* /&O$T=C91^*=/\ #4PBT=;&S>9+.3]U!=&Y
M ^3!PK%,$@>@-;Z^"_#_ /PLB?23IZG39-'2XDM"[>5)-YK*)&7/S/MXW'GO
MUKT&'3+"WM#:0V-M';$Y,*1*$SU^Z!BI_)B\_P _RT\W;L\S:-VW.<9],T >
M+Z*=+U%_ </B2Y62VDTB[4)=2_NYG62,*KY.&PH) /=14JW=H^FP:0L*WVF3
MZ]<QZ4EU>F&S:%(\X=\,7C#EPJC()4=A7I%WX4L+S7+*_EB@:WM;2:U^QM I
MC82,C9QTX*=,=ZU)]-L;FS6TN+*WEMEQMADB5D&.F%(Q0!XI&5/AGQ;IUO-;
M16L>M:<D::9,WDP[Y(0XB8\CG/3'(.*Z>[\)V*^+-7\.:5']@MM0T'S2D3$*
M+A9B$EQ_>!QSWQ7HHT^R5"BV=N%.W*B)<';]WMV[>E-O;62:"9K.2*VOFC,<
M=RT(D*=QD9&1GMD4 <3X)U2X\8:Y_;=TCQC2[); QG@"\;#7'_?.(U_.M;XF
M.T?PUU]T8JPM&(93@CI6MX>T1- TE;,3-<3-(\]Q<.H5II78L[D#IDGIV&!6
ME+#%<1-%-&DD;C#(Z@@CW!H \V;P9H2?$>WTK[%NL)]'DN+BW:1BEQ*DJ*KR
M#/SL [<G/7/:L2UN(+GPOX2TBZMHKYY'OO*CU*],5ILBE9!YGRL9"%("K]3V
MKV3R8C.)O+3S0NP/M&X+G.,^G JO/I6G7-LMM/86LL"MN6*2%64-UR 1C/)_
M.@#R#1&>#PIJNKV4D#CPYX@:YBCLG9H1;^7'YT<>>=FUY".V1Q7H'@?=J%MJ
M/B.0DG5[II8,]K9/DA_-5W_\#J_KV@RZII,VGZ?>)I8N3LN98K=6:2(J5*CI
MM., -SC'2M6TM8;*S@M+=!'!!&L<:#HJJ, ?D* .)^)-GID]SX3GU..W,*:T
MD;R3D!51H9202>@)5/Q KA]462[G\67FIW.BV^H6M_,D-W>7,JW=I&/]0855
M2<8VD!?O$G.:]NN;2VO83#=6\4\1()25 RDCV-1S:987%W'=SV-M+<Q?ZN9X
ME9T^C$9% '!:'HUOJGCS7[_54^TWMC%9-"Q+*L4A@^9E4XP20.HSQ7,Z-X;T
MUO#7P[NS%)]JU*98;R;S6#W$1@D8QN<\I\BC;TP,5[4L,2222+$@>3&]@H!;
M' R>],6TMD2%%MX@D!S$H08C.,?+Z<$CCUH \F^SQZ7?SZ99*8;&V\8V:P0*
M3MC5H49E4=AN)..G-5?['LXO %SXD6-O[8@UQS#=F1M\0_M#9M4YX4J3E>AR
M:]C-G;%RQMX2Q<2$E!DN!@-]0.]'V.V\@P?9X?)+;C'L&TG.[./7//UH \<\
M:2V&I3^+KDVFF^;89A^U:I>MY\<@B!46T2K\HR1@[AN8GK4TVU=>DU2V6)M?
MF\&QW%I(2#++<;7&Y?[S;0/PKUB32]/FO!>2V-L]T%V^<T*E\>F[&<4_[!9B
M2"3[)!OMUVPMY8S$,8PI[#''% 'D'A:".'5O"MU87FAPSW1S*UE<337%ZGED
MN)AMZ@X8L_W6&,C.*]CG@BN;>2"9!)%*I1T;HRD8(/X5#;Z986ES+<V]C;0S
MR_ZR6.)59_J0,FK5 'B'AW2=(U#0OA]8".)HI;^Z^V1Q/C<X@ERKX.>BJ"#U
M'!X-2:Y')H\>NZ-IICMM%B\06<<T4DKQP0P26Z.RLR\I&TA7../F/8U[%%I]
ME#)YD5G;QOYAEW)$H.\C!;..I'&:>UK;L)@T$1$_^MR@_><8^;UXXYH X'P'
M!]B\5:K:VMQI$=H+6)I+#2GDDABE+-A\E0JEEZJ#D[0<=ZUOBE_R3#Q#_P!>
MA_F*Z:SL;/3X?)LK6"VBSG9#&$7/K@5+-#%<0M#-&DL3C#(ZA@1[@T </I%U
M:IJ%H6^)JW^6 %HTEGB4G@+\B!NOH<US5@]N/'L=N9K@^#AJ4GV$G'DG4< E
M,YR8PV\J.F_(["O4$T+1XI%DCTJQ1U(966W0$$="#BK'V&T%LMM]E@^SJ05B
M\L;00<C Z=>: /#9UN+FSUC4KV[T6TUR+4I4%Y<7$QOK9Q+B)$C52=NW;A5R
M&!]S72W47AZ]U3Q?/XRN$CO;.51;,TI22WM_)0H]N"<@E]_(Y+<'TKTM],L)
M;U+V2QMGNTX6=HE,B_1L9%+<:=8W=Q%<7-E;S30G,<DD2LR?0D9'X4 >=)K5
MCI]_XZ%[?^0TEI;2PK=.$E=3:@ A3@DEAC '7BLG2[735U?0;JY2!;N3P8CQ
M22$!GE"J,C/5MI/X5ZW/IUC=7$=Q<6=O+/$,1R21*S)]"1D4/I]E)Y&^SMV\
M@8AS$#Y8QC"\<<<<4 >3PZI<^$?#GAK7;=7F_M;P]!8"/J&O%B#6Y/\ O9=3
M]!3=4T:6P\0Z+X=O3I=S86VC!HDUB=TAGN?,/G., AG^Z<'H&)%>N_9+<Q11
M?9XO+A*F--@PA7I@=L=J;>6%GJ,(AO;2"YB!R$GC#C/K@T <EX&!/@>2234$
MN8XGN4MKJV$DGE0[CA49UW.%Q@$9R%&,UR7@G['I7B+P^B)I=ZU_%(D6IZ7<
MNLLX$>XM=0MDD_+U).UCVS7L$<:11K'&BHBC"JHP /0"J]OIEA:7$MQ;6-M#
M/+_K)(XE5G^I R: #4WN8])O'LEW72P.85QG+[3M'YXKQCPS&1_PBFH07NB0
MZE<W,7GSQ7$TM[=$@^=',NT\_>SN^52!R*]QJK%IEA!>27D5C;1W4GWYTB4.
MWU;&30!XY'H-C+X1TW5F64:C/XD-LUTLS+(L3WKQ-&K Y52I/ [DGK4WB:SL
M="MO'&GVFZPTR/\ LF<I Q41%YR)'7'0D*.GI7L(L[81+$+>'RU?S%38,!LY
MW >N><^M9OB'P]!K^E3V1=;=YY(7>98P6/ER*X!Z9^[CVS0!YMX@ATBQDUVV
M\+-!]@D\,7DE_':R;H@^!Y+G!(WD&3GJ1R<U>@M]#U+Q)>0>+GMS!;Z7:/I\
M5Y+LC6,H?-D3) W;A@L.1@=*])@TRPMH)8(+&VBAFR9(XXE57SUR .<^]%UI
MEA?+$MW8VUPL1S&)8E<)],CB@#R>RUB[\-^'/#GC.]:YG@^SW-A<&3)>6'<[
MVKG/4G8JYZGS:O#PRAU?P1I.M!KAYK:_N;^-F.V:9_*=@P_B4,QP#QP*[C7?
M#\NNW-C'-?>7I<$J33V0A!\]T8,F7SPH8 D8YQVK9:&)Y4E:-#(@(1RHRH/7
M![9P* /&%T2QLO"5]JD$;B^TWQ)]FLIS(Q:WA%ZL8C3)X3:Q&.AS5;5DDO+K
MQ==ZI<Z+;WUK>RI#=7MU*EW9Q@#R3"J@X&,,-OWB3G/2O;39VQB:(V\)C9_,
M9=@P6SG<1ZYYSZU'-IEA<W<=U/8VTMS%_JYI(E9T^A(R* /-H= L_$/B#Q4V
MNQ"]E@L+,KNW*J2&!BSJIQM;('.,C';FJ_A-+*Y\6^$-1U'RGO[CPNDBS3,-
M\LP,8R">K;2WOC->KB"$/(XB0/* )&"C+XX&?6HS869-N3:09MO]1^['[KC'
MR\?+^% %;Q KOX;U5(PQD:SE"A>I.PXQ7GUGK=A>CX8VUKJ$,\_#21QRAF %
MFX.X#I\W'/<'TKU*JD&E:=;2&2"PM8I&?S"T<*J2V"-V0.N"1GW- 'D,.CV4
M'P^B\2I&W]LQ:W^[NS(V]%_M#RR@.>%*D@KT.347B:'0[KPOX[O-=FC7Q!#=
M7,4!DEVS1Q_\L$09SL9=O X.6SWKVC[';>1Y'V>'R=V[R]@VYSNSCIG//UJ*
M?2]/NK@7%Q8VTTP0H))(59MIZC)&<<]* /)=8B.H>,=:BU8:(\%K:6YLUU>Z
MDB\J$Q M)%M&,[]P+#D8 JWHFD1>(O$?A^'7ISJB1^'5G#MYB+,XF 20JVUB
M=I_B'4YKU"[TRPOS&;RQMKCRCF/SHE?9],CBI_)B\[SO+3S=NS?M&[;UQGT]
MJ %=%D1D<!E88(/<5XCIFCZ/<Z+X<TY(XAO\5727<4+[6POVK:KX.0-H QW%
M>X5673[))FF2SMUE9_,9Q$H8O@C<3CK@D9]Z /*-8M8=&LO&NEZ<GV:P@O=*
MDAMXR0D1>2+?M'8''056\0&ST_7=9UF0Z?JPM]10O_I#VVIVC H!'%D$.G3
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MZYKV2\TVPU QF]LK:Y\LY3SHE?:?49'%.N["SU"$0WMI!<Q Y"31AU!]<$4
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MRY.6+'=G(/08Y'-4/$"ZB?BEX4%O>Q16QMKMFB:$MG:8MW.X<D$ ''RX/7.
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M4)YG (5<G)Q@^O%?1/%GB.ZC\*:K?/I_V'7I/(:SA@8-"3$[JXD+'.2G(V\
MXYQD@'H:2)*F^-U=>1E3D<<4ZO,=(\0ZS<6OAO3='CTRP_M*34O-?[,S)$(9
MB RH&&2<G.3U.?8V_P#A+]7BT&Z6\O\ 2;2\L]7?39;V:-MC*%#!TA#99R&
MV!O4]!B@#T.FB1&D:,.I=0"R@\@'ID?A7D&M>)M6UKP-XNL_M\3MIS0;;P6,
MEN9HI,$@QNP*G.1NZ$=N:W-0\27N@:KXB)MK&YU&&UTV))UA,7GS3221C?\
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M)<IM#*ZH_P R]<$<\@\T =-1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5F>(=$@\1Z!>Z/=22Q07<?EN
M\1&X#.>,@CM6G10!S%MX6U2WN897\9:U.D;JQBD2VVN ?NG$0.#TX(-,A\":
M? UM<I=7?]IPWS7S:@2OG2NW#*W&-A7"[0  %&.1FNJHH Y*;P)&\EW%;:UJ
M=IIEY.;BXL(&0(SL<MM?;O0,>2%8=3C&:DU'P3'>7E_+::OJ&GP:D +^WMC'
MMFPH7(+*2C%0 2I&0!WYKJ:* .3O/ =O/=W<EGJNH:?;7MO';WEM;%-LR(NQ
M>64LIV_*2I&1^=._X06U1M-,&HWL/V+3/[+8+L(G@V@8;*G!R <KC\JZJB@#
ME]0\!Z5J>BZ%I=R]P8=',7DL& :144+L?CE6 &0,9Q5K5_#/]H:M%JUCJ=WI
MFHI";=I[=4<219W!65U8'!R0>HR:WJS]&UBVURR>[M5D6-)Y;<B0 '=&Y1NA
M/&5.* %T;2HM%TR.RBGN+C:69IKF3?)(S$EF8^I)/3 ':LRXTV>U\=6^KP0F
M6VO;,V-V%'W"A+Q.?;F13_O+6EIFL6VJSZC#;K(&T^Z-K+O  +A%?CGD8<>G
M>M"@#D+?X?VL*VUFVJZA+HMI.MQ;Z6Y3RD96W*I;;O9%;D*6QP.N*EF\#6LT
MFI ZC>BVO[Z&_>W&S;'-&Z-E3MSAO+4$$GVQ7544 8.J^$M-UK4+NZOO,D6Z
MT\Z?)%N 7R]^_([AL]\]JKV?A&2.Y6;4-?U/4C% ]O LYC58U88+$(J[VQQE
MLUNW5Y]EEM8_LUQ-]HE\K="FX1?*3N?GA>,9]2*LT 4=&TR+1-$L=*@=WAL[
M=($:3&XJJA03CC/%5=5\/IJ>LZ3JJWMQ:W.G,^SRMI$B/MWHP8'@[!R,$=C5
M^TO/M;7(^S7$'D3&+,R;1)@ [DYY4YQGV-6: .;B\&6,7AS3=$%Q<&WT^ZBN
MHW)7<S)+Y@!XQC/'3I6;>?#>WO-/U+2O[<U.+2;^:2=[.+R@%D=MQP^S=C=S
M@GZY'%=M10!C1>'+:.ZUJX\Z8OJZHL^2,+MC\L;>/3GG/-7=)TZ+1]&L=,@=
MWBL[>.W1GQN*HH4$X[\53\0>(H?#\=F'M+N\N+R?R+>VM54O(VTL?O$  !2<
MDU:U'5K72K)+N]9HHWDCA VY.^1@BCC_ &F ]* ,F3P98R7DMR;BX#R:K'JI
M *X$B(J!>GW<*/?WK2M]&@MO$%_K*22&>]AAA="1M41ER".,Y.\Y^@IUCK%M
M?ZIJ>GPK()M-D2.8L %)>-9!MYYX8>G-:% &;J6BP:GJ&EWDLDBOIMPUQ$$(
MPS&-DPW'3#GI6;J/A(W.K76I:=K-_I4][&L=W]E$;"8*,*V'5MK@<;ACC'I7
M25Q0^)5D;>XO!H6O-I]O))'+>I:JT2^6Q5VX<M@%3V[4 7Y?!YB-JVDZWJ6F
MO!:K:,49)A+&#D%A(K#?DGYASSSFL,^![BR\4:-#HUW?:=8Z?I$T"7D11R9&
ME0[7#@AMPW-TZCC&*[Z">*ZMXKB!UDAE0.CKT92,@C\*DH Y0^ [&.PLX[6^
MO;>_M+B2ZCU%65IFEDSYC/E2K!L\C&.!C&!3V\$6\^F3P7FJ:C<WLMTEY]O=
MU$L4R8V,@"[%  QC;@@G.<UU%% '(S^ X;VQODO]8U"YO[MX'-\?+5XO)??&
M$4+L #9.,<Y.:ZJ"-XK>*.25IG1 K2, "Y Y)P ,GKP*IZ'K%MK^CV^J6BR+
M!/NVB4 -PQ4Y )[@U3A\6Z7<MI/V=I94U6>:"W=4P-T0<MNS@@?NVQQZ4 9<
MGP^M9$EL?[5U!=#EN#<2:4#'Y18MO*[MN\(6Y*AL<GMQ6]8:-!IVJZKJ$4DC
M2:E+'+*K$;5*1K&-O'3"CKWK2HH Q->\.+K5SI]Y%?7%C?:?([V]Q"$;&]=K
M JX(((]LUF1?#^S26XFFU/4+F:XO[;4)99F3+2P$%>B@!3@ @#@#C%7=<\6P
M:)JUKI@TS4M0N[F%YTCLHD?"*0"3N9>["K>BZW)K'G[]'U/3O*VX^W1(GF9S
M]W:S9QCGIU% #3X<M3J.LWOFS>9JMM';3+D814#@%>.O[P]<]!69_P (/';"
MQDTK5[[3;JUL8]/:>$1N9X4'R[U=2NX<D$ =3VXKJZ* .3;P%9PVFEIIFHWM
MA=Z:TK17B%))',O,ID#J5;<>3QU QBG67@.PLHX%^W7TSQ:L=6,DSJ6DF,90
M[OE'!R3@8YZ8'%=510!S>J>"['5O[;,MS<QMJZ6ZR-&5!B,)RA7(ZYY.<]*@
MO?!D]V9L>)-4B%W;I;WP41,+@!=I;#(1&Q'79@>U:UIX@M-0@L[BQBN;FWNI
MY8!-'%\L9C+AF?."%RA /J1ZUJT 06-G!IVGVUC:ILM[:)88ESG"J  /R%<A
M>?#BWO+#4]+_ +;U.'2;^:2>2SB\H!9';<2'V;L;N<$^QR.*[:B@#E]0\&+=
MWMY<VFLZAIW]H1K'?QVWEXGVKM#?,I*-MXRN. .XS3+GP- )Y)-)U6_TA)[>
M.VN8[4HPE1%VJ?G5BK!?EW#!QCTKJZ* ,71_#%CH=_<75D95$UK;VOE,V51(
M0P7'?/SG.2>E8MM\.;>W%A;_ -M:F^G:==I=V5DQC"0LK;@"0FYAR0 2< ^N
M#7:44 <E)X$BWW$%OK6IVNE7-P;F;3H60(7+;F"OMWHK-R5##J<8S2ZIX$AU
M"34U@UC4;"TU4'[=:VQCV2L5"E@64E20 #M(SBNLHH @LK5+&QM[2-F9((EB
M4MU(48&?RKEKSP!#=C6+9-:U*VTW5Y'FN[.'RP&=U 8ARA< X&1G]#BNPHH
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MP.  %4   *  *TZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)HE+1QN<'826Z8ZG&*Z>32/#\?C*^TG6O+MM,L--A?2X);AHT12TAED4EOO
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MN^*]?-K;M.TY@B,S)Y;2%!N*==I/7'M4-CI6G:6)!I]A:V@D.7^SPK'N/J<
M9H \T-IX5M=#@ET2^F;5;W1[DC[-.9#=_N"6>?KR#C!.#N./:IXM6L-1G^&U
MG#?17#31N9HXY0Q*_8W!W 'U]>^?2O1+72M.L9YI[.PM;>:8YEDAA5&?_>('
M/XTRVT;2[.4RVNFV<$A?S"\4"J2V"-V0.N"1GW- 'D_A6WL;?3_!T%H(U:37
M;Y+J-'Y.%N0 PS_="\'VK3T-KNZUO3O!<KRM_P (Y=2W%R[$YEA3'V0$]\B1
M2?\ KD:](CTO3X9C-%8VJ2M(92ZPJ&+D$%LXZX)&>O-3K;PI/).L,:S2 !Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,!&QP>_%>8V_CJXTW0_#5O;II6C6MUI,5Q'/J'FFW+G@0JX/RD  Y9CP1P:
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MJ17IB4&*<1JA^7H5(!&WT;&>,U/=>"[K4M&U2UU'79Y[V_>%_M"Q!8X#$P=
MD62 ,C)YR<]>F.NHH R--@UF'5KG[?>"XLQ;0+$?*1,S#=YK #)P?D.">.<>
MIJ:KX;NKC7%UK2=5.G7[6XM9BT FCEC#%ERI(PP);!![G.:Z*B@#EM+\$6VE
MWNDW<=[-+-8FZDE>506N9;@@N[$8QR.@'MVKJ:** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQP.N3^74US6A>&K_ $;5]1NG6*>WM8I(M'A#[<)(YE=6./E^;8@ZX6,5V-%
M%&^;5#H[/I\=LNH[%98IV)CSD%E+#GD9 ;'!P<'I6+X6T:YT_4]5O6L(-+M+
MORO+T^!PRJZ[M\IV@*&;<HX_N GDUU%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>guyaragreement012.jpg
<TEXT>
begin 644 guyaragreement012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBL_6]-DU?1[C3X[V:S,X"F> X=5R-P![9&1GMF@#0H
MKR.\F@T2?Q'J7@U&ATS3='N$N94=F@EO!@IMR2&9 &W,/4 \UKQZ1;>$]=\(
M2Z:TJOJ$CVE^6E9OM68&D$CY)RP9,YZ\D=* /1:*S]9L[^_T\VVGZA_9\CL
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MIN86TPFCSGJKCJ#U'UIGB#4+G2M$N+RTAMY)H]N/M,ZPQ*"0"SN>B@$D]SC
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M\\#% 'H]%><2W7B2?QEX)EUBWL8H9YKB15M'<F,FUD/EONX;_>&.0>.E>CT
M%%>=QS>)%\?>+_[$AL)$C%H[?;'?YV\GA%"],]V/3C@U/8^-M7\0ZKIEOH5E
M9);W.F0ZE-)>.^8U:1D:,!>K?+P>G!]J .]HKRN'XNI*L6I?:-&.GR7(B%BM
MP3>B,OL$F/NY_BV8Z=\U>\5?$"_\.SZE(9=!B2R.4L)[HM=W2  E@$/R9YP"
M#TYQF@#T:BN/N/$6O:EK&I67AVTL&338XC,UZ[ S2.F\1IMX7Y2N6.>6Z<5B
MV][XF?QMXDDTRSLH918V,T\5_*S"-]DA\L;."<YRV<<#@YX /2J*S/#NKKK_
M (;TW5UB,0O;9)_+)SL+ $C/?%5?$^N7&CPV$%A;QW&H:C=+:6R2L5C5BK,7
M8CG:%5C@<G@4 ;M%<#J?C;5_#]IKL&J65G+J6G627T#6Q817$3.4Z'E6# CJ
M>H-=;HS:P]B6UN.RCNBY*I9LS*J8& 2W5ASD]* -&BL+QAKEQX<\-3ZG:VR7
M,\<L$:PNVT-YDJ1]>WWJP+OQKJOARYU2#Q#9V4K6VF_VA ;!G ?Y_+\L[^^X
MK\W3GI0!WE%<:?$?B#2-2L+77[33MFHI*('LV?\ <RI&9-C[OO JK?,,<CIS
M5'2?&7B&>W\,ZGJ-AIT>FZZZ0K'!(YFA9XV=6)/!!VGCJ,CDT >@45R>K?$#
M1+;3+J72K^RU2^B9(DM(+E2QD>18U#8SM&YADUE:]KNMV5CJ6C:]#8^9>Z/>
M3VEQ8EPH:./YT8-SG# A@>>>!0!Z#17 :#KVO:59^&(M9M++[#J<4=M";=V,
ML,GDET#YX;<$/3&#Z]:3PKX\O]?U6"&8Z0@DW_:+ 2M'>66 2-ZOC?TP=H&,
MYY% 'H%%>5VWQ=2<6^H_:-&.GSW*Q"Q6X)O4C9]@D(^Z3R&*8X'?(K4?Q;XH
ME@\0ZA9Z;ISV&C7$\'EL[F:?RB"2H' ^7/XT >@45RTGBR2XU22#2+:.]MX=
M)_M%W,@3<S_ZE Q^5=P5R2>@ K%TGQ_=7'B.TTN>[T*_^UP3/G2YF<V[QKNV
MN<D,",C(QTZ4 >AT5Y]I'C3Q#<6?AK5=0L-.CTW6Y8X!'#(YFB9T9E<D_*02
MO3J,CDU>TWQ'XDUJ--6T[3+&71GNV@2$RE;EHED,;2Y.$'(+;.X'7- '9T5Y
M9=_%M86O;Z.?1OL-I<O#]ADN"+R9$;:SJ.@/!(4CD#J,UZDK!T5U.589!]J
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M,I/;/YT[2O"%Y;:EIUUJFMOJ2:5&T=C&;<1%2R["\A!.]]N5SA1R>,FNKHH
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M>!6#S%"A!CR!LV':%!&,#FGV_@N]A35YSXCNAJ6HS03F[BB$?EO$   @."A
M *GJ.I)YKL** .<T#PO)I6L7^L7M['=:A>QQQ.T%L+>,*A8CY022V6.6)/;I
M70R1I+$\<BAD<%64]"#U%.HH XJV\!W$=OI^EW.NRW&A:?-'+;V1MU60B,[H
MT>7/S*I XV@G R:Z#0-$70K2YMUG,PGO)[LL5VX,LA?;^&<9K5HH *Y1? \
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MDC;Y6?YB!D#<3M''08 ]*Y".>X7X>6GC0:M?MXAEN8RR&[<QN[3A&MO)SLP
M2N ,C&<UZGI>CZ=HML]OIEE!9P/(96CA0*I8]3@?0557PKH":N=671[(7Y?S
M//$(W;_[W^][]: .=\+V+ZAXO\1ZG=:A?R-8ZHUO;6_VIQ#&I@C)^3.#DOWZ
M8&,4OB>R?6/B!HNE2:A?V]C)I]U--%:7+P^85>(+DJ0>"V?TZ$UV-O96UH]P
M]O!'$UQ)YLQ1<&1\ ;CZG"@?@*&LK9[Z.]:",W42-&DI7YE5B"P!]"5'Y"@#
MQN>[U^^L=?UH-)!=V5_/%#>R:TT,5F(WVHC08VD$ 9W9+;L]Q4VN6[6$WQ#U
M2WN+RWO8K2TD#QWLN$9U)? W8P.W'RC@8%>FW/A3P_>ZH-3N='LI;T%6\YX0
M6)'0GU([$]*NMI=@[WCO9P,UX@2Y+(#YR@$ -ZC!(Y]: .1\2ZI)'XSM+:WU
M86B?V%?3L^_,<9S%LE9>AQ\Q!^M<UIU_J/AO!GM]1749])N9;61-4:^M-1DC
MC#^9ASN1N,C  .['/%>C:;X3\/Z0X?3]'L[9]K)NCB .UL;AGT.T<>U+I?A;
M0=$N7N=,TBSM)G7:7BB (7.=H]![#B@#SGP^^LP3>%M3$CQG4)$%S<7.MM<+
M?JZ$MMA(PK#[PVXQC%.T.>[TW5M'OM2FOKJ.^O3#%K%CJIFM[POO"I);OP@_
MW!\I7J*]#L?"GA_3-1;4+'1[*WNSN_>QP@$9ZX],]\=:+;PIX?L]5.IV^CV4
M5Z69_.2(!@QZD>A/<CDT 8/Q,L8;W2]%6=IE4:W9+F*=XN&F4'E2.<=#U!Y&
M#6(\(U.P\7ZI?:SJ%K>:1<SPVGEWLD:VD<2 QL4#8;=]XE@=V<5Z-J6F6.L6
M,ECJ-I#=6LF-\4R!E.#D<'WJA=>$/#M[=Q75UHMC-/$JJKO""<+]T'UQVSTH
M J2ZQJ2_#-M:$6-4_L?[5Y>WI-Y.[&/][M7/6\-MHFDZ9K%EKVH7&IW>GRRI
M!-<R3IJ,@A,F=I)"X(R"H'IWKT;'&.U9.F^%]"T>]DO-.TFSM;B0$-)%$%."
M<D#T!/.!0!P5N#INC>#]?LM9O[K4M4N[6.Y,MX\B7:RC]Z/+)VKM&2-H&W;6
M;':WDOA?3-:_MO5UU"YU\V1E6]DPL#73Q% A.W[O(.,@XYX%>G67A70-.U)M
M1L]'LH+QBQ\Z.$!@6^]CTSWQUJRNC:8MI%:BQMQ;Q3_:(X]@VK+OW[P/7<2<
M^M 'F.NR7&@6'CK3['5;^"VM(K":"22ZDE>W,CD.5=R6P=H.,XZ^M3^*8!H,
MMYIVFW]Y<VU_X=U":[BN+M[C!1%V3 L3M+%F'& ?3BNT\4>%X=>T34[2W6""
MZOUB66=DSO$;A@&]<#('UJU9>%M!TZ"[AL](LX([M#'<*D0 D0@C:?\ 9P3Q
MTYH X.[UV^\)1Q2I++,FL:+"NGQ.Y95OD"QJBCL&$B' _N,:[6;0[K_A!GT2
M/4+DWHL3 M[YS>:9=F!)NSG.[FH;_P .7&I>(=)DF:S71M*87%M;I$?,,P0H
MN3G 50V0 .H'I724 >+#Q_?K>P>+Y9YO[*@M!IMQ:[CL-X;=IV.W^]O"1Y]\
M4GB>TO[?0M9TG4K^\G>W\(Q7$P:Y?#7'FREV.#SSQ] !T%>L'P]HQM'M#IEH
M;=[C[4T7E#:9<[M^/[V><U-<:5I]W+/+<64$KSP?9I6= =\62=ASU7+'CW-
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M98=3GU4PHA64)Y<=NI(9<@KA@"W)-;+Z597WB7X@W=QJU[:2VDD,B?9[QX1
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M+_%PD:S-%%#)*PC;.'PBGY>#D]!QGJ*O6>O:7J%U%;6EY'-+-:K>1A,X>$G
M<'H1G^E<YX6TN\M_$]]>7-G)%%)H^GPH[KC+*)=Z_497/X5R=Q8:QX:^'GA3
M5;2V,>N6$9T\V\GRLPN/D53ZXD\IL?[)H ],M_$>DW<UK%!>"1[J2:*#"-AV
MB)$@!QC@@\]#CC-3:MK.GZ'9BZU*Y6"(N(U^4LSN>BJH!+$^@!-9NFBV\*VO
MA_PW'!/()8V@2=0-H9(R[%R3G+88\ \YJIXNM+Q=6\/:W;64M]#IES(T]M"
M9-LD3)O4$_,5)Z=<$XH N#QKX=.E2ZFVII':PS+!,TL;HT4C$ *ZL RGD=0/
M6M/2]4M-9TZ*_L7=[:7.QGC:,G!(/RL 1R#VKS?4]'U37M0U+6$TBY@MKN_T
MI([>= LLB03;I)73/RC#8YYPO2O5* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%07M[:Z;937M[.D%M"A>260X50.YH GHK%TKQ9HNLS3
M0V=VWG11^<\<\$D#>7_? D525_VAQ2:3XOT+7+S[)I]]YLQ0R(&B>,2H#@M&
M64!UY'*Y'- &W139)$AB>65U2- 69F. H'4DU6TO4[+6=-AU'3YQ/:3@M'*
M0&&<9YY[4 6Z*P]5\8:#HMZUI?WWES(@DD"PO((5/1I&52(P<=6(K;5E=%=&
M#*PR"#D$4 +12.P1&=CA5&34%C>V^I6$%[:N7MYT$D;%"I*D9'! (^A% %BB
MBB@ HHHH ***CN)X[6VEN)FVQ1(7=L9PH&2>* )**@LKR#4;"WO;63S+>XB6
M:)\$;D89!P>1P1UJ>@ HHHH ***R[GQ%I5I+?Q37)$E@(C<JL3L4$IPG0<Y(
M/3..^* -2BBB@ HHJ"YO;:S,(N9TB,\HAB#'&]SG"CU/!_(T 3T444 %%%%
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MU#0K(16,7A_2I(KE(_F,QDC#+&@!& @RISG)QC%=1)&DT3Q2*&1U*L#W!ZT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)"HQX.#T]>U>>6/CUX--\/V-A96YGN]*CO4_M753&74\"-9"A,LG'.0.Q[T
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M<.EP=/#7AB#;A$6.5_V=^,X[9YKT.H)KRVMY[>&:>..6Y<I"C-@R,%+$ =^
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MO@]]:U#69_M:Q)J.B_V6!LR4.Z0[^O(^<<>U=510!1T>"]MM(M8-1DMY+N-
MDCVZE4..!@$D],?C7,W/A77+>36;;1M4LX-/UB5YI?M%NSRV[NH60QD, <XR
M >A]:ZZXO+:T,(N)XXC/((H@[8+N<D*/4X!/X&IJ .<TCPJFC:[%>6TW^B0Z
M1!ID43#Y@(F8AB?HP'X59\6:)+XA\-W.FV]PD$[M%)'(Z%E#1R*XR 1P2N/Q
MK7FFBMH))YY$BBC4N[NP"JHY))/05SUCX\\-:C?06EOJ)\RX;; TD$D<<Q]$
M=E"N?H3F@ T_P[>0WNN7MW<P-/JT$".(D(5'2+8Q&3G!)R/:L,?#ZYLX]$GL
MY-,N;RPTN/3)X]0M3)#,J<AUP<JP.[UR&Q7H%% ''67@RYM[C1+B:^MY);%K
MJ2;RK98D8S+M 15Z*O YR2!UK;\+Z._A_P +:9I$DRS/9VZ0F11@,5&,XK6J
M&WO+:[\[[-/'+Y,ABDV-G:XZJ?<9Z4 34444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %74[F2RTJ\NHH_,D@@>14_O%5) _2N'T2&XCT70?$%QXLO#=:C"KS0
MSR!H;EY(B_EQIP$*GD%>RD'.:]"K"LO!GA[3K[[9:Z9'',-^SYV*1[OO;$)V
MIG)SM ZT >=Q7FNV'PY\/:DFKZM?:AX@FM+>=C<(#$K*S'RMV%1F "[CW.>M
M2WFL>)-!M=8M@]Y9P-%:^2VHWT-U<6C23B)Y!M9FV;6R"W 93]*])?P]I$N@
MIH<EA$^F)&L:6[9*JJ_=QWR,#!Z\5!9>$M"L+2\M8=.C:*]7;<^<S3-,N, ,
MSDD@ G )XH X/6;"7P[XMO'MM8O[B1/"M_+&;J?S)(7#Q?,&/."0..@*G%5I
M[J[T[6=2\1Q7-U-?0>#X+Q4>4E&DQ(.5[KD;L>N3WKO[3P/X<L6F>#35WS6[
MVLCO*[LT+XW)N9B=O X[=L5:/AG1FO[2^-BGVFTM_LL+[FXBP1L(SAA@G@YZ
MT <GMO?#M]X5N8=>O]2.K7 M[J*YF\Q)@T3/YJ+CY-I4'Y<#!K&TJ'7[CX<Z
M;J\7B&^N=3U)XED@GOEA\U S9B@)&$D*CKU.#TKO]+\':!HUZMW8:<D4Z*4C
M8NSB)3U$88D(#Z*!4TGAG1I="BT1[",Z=%CRX<GY"#D%3G((/<'- &+X%U!I
MGU73YI-72YM)8V>TU4K)+;AUX E!/F*2K$$G(Y%4?*N_$FM^*#/KU_IJZ5.M
MO:QVLWEK$/)63S7'\>2QX;(PM=;I&A:;H44J:=;>5YS;Y79VD>0XP"SL2QP/
M4U4U7P?H.M7AN[_3DEG9!'(P=T\U1T5PI <>S9% '$^&[[5O&.O:5+>ZK?V<
M/]@VE_);VDGEK+,9) 2>/ND#D#KQZ5N?$2VDO)/"EO'<RVS2:[&/.AP'4>1-
MG:2#@XR,]JZJ'2K&WOS?0VT<=P8$MMZC&(E)*J!T !8_G3KO3K2_DM7NH5D:
MTF$\!)/R2!2NX?@S#\: /.;G4KG0Y/$NC/KFJM#%<6,=FX N+HM./FB1F(Y;
M:0"Q^7)/:JD>H:]9ZCX@TJ"\O=,+:.ES;#6K^.9H93(4W>8"P3=T ).#@X[5
MZ+?>&-&U+[9]LL(Y3>F,SL206,?W""#E2O8C!JO!X+\.V_V@KI<3M<P&WG:5
MFD::,D$ARQ);H.3DB@# \&WMQ!XCN-)U#^W+2[>T$XLM2G6Z1@K!6DCF!)(^
M905..QQ4OBRZEN?$MMI-K+K=Q*MH9WL=*D2W(!?:LDDS.N!PP"CW)KH=(\,:
M/H4\D^GV?ES2((VEDE>5]@Y"AG)(7V'%&J^%]'UJ\BN[ZSWW,:&(2I*\;%"<
M[24(W+GL<B@#*^'&I7NJ>#89K^=Y[B.XN(#)(P9BJ3.J[F'#'  R.N,UB>'V
MNM3T*P\5WWBB[LKF>]^>%Y ;8+YQC%OY7 R1A=WWMW.>U=UI>D:?HEG]DTRU
MCM;;>T@BC&%#,<G [<]AQ5!?!WA]-7_M1=-C%UYWG@[FV"7_ )Z>7G9O_P!K
M&?>@#@I=0U5OA_>>.?[<ODU.&:61+02_Z,H28H(#%C!R!C/WLG.:WVUB\0?$
M-GO)$%@H:WRW^H'V1'X]/F)/UK<?P7X=DU0ZD^EQ&X,PG/S-Y9E_OF/.PM_M
M8S2ZEX-\/:OJ#WU_ID<UQ(H25B[ 2@=-Z@@-CMD'% '(:3'J/B778K.YUW5+
M>V7P_8W++:S^6S3/Y@+E@,]N1T/&<XK/T$W.OZ[X"U'4+^[:ZDTR\\QHY2@<
MQO&,D#^]_%ZX'I7IUGHVGZ?<?:+6U6*7[/':[@3_ *J/.Q?H-Q_.J@\)Z&$T
MQ5T]%&EN7LRKL#"2<G!!R02!D'(.* ..TC6M5O+S2O"<E[,=3L-0F_M*XW?/
M);089&/_ %T\R 'U^:M_Q=<W<FK^'=%AO)[*WU*YE6XG@;;(5CB9PBM_"6('
M(YP#BI?#N@7EMKVK:_JR62ZC?B.$+:%F5(8QA<LP!+$DD\=E':MC5='T_6[,
M6FHVRSPAQ(H)(*,.C*PP5(]00: .&OWNK+5-/\+V_BBZE@O-3:.>8N#<VL8M
MS*(#*<DEB,AC\V#C)ZU1UC5-3T"?7-'MM6O)[>TFTN:*>:7?+")K@(\3/U(*
MKGGG#&NY'@_0!H[:5_9D1M&E\]E9F+F3_GIO)W;_ /:SGWIT/A+08-)N]+73
M8FM+PYN4D+.TQ]69B6)&!@DY&!B@#E?&NM7]EJ_B&&TOI8A;^%IKN-$?&R4.
MP#CT/'7VJE>^'Y(M<\#O<ZWJ]U/<WDLLDDMT>&-J[$(  %&1T'8D5V-MX(\.
M6L5U'%IB8N[=K:X9Y'=I8FZJS,23T]>*O:EH&EZM;VL%]:+*EI(LL'S,IC8#
M (((/0XH RO&]^;33;*WCN[^&:\NTA2+3T4SW'!8QHS$!,A<ER> #ZUPBZ]K
MFGGQ%I7VG4;)5NM,AC:^N4N9K);ERDC;P6'0 @$G!->I:OHFG:[:I;ZE;":.
M.02QD,R,CCHRLI!4\GD'O5.W\'>'K6"]ABTJ'R[Z-8KH/E_/4$D;]Q.X_,>3
MS[T <1J%E+X?\8:N;;5KZX=/"MQ+$;J;S)(6$@Y#'G!(R,]"#CTHMK+5&U'P
MC"_B;6&76[&22_\ WX^8K&CCR^/W?)(RO..^>:[6R\%^'K W#6^G /<P-;32
M/*[N\38RA9F)QP._':M!='T]9;"5;90^GQM':G)_=*5"D#\ !SZ4 >?:/JVJ
M1ZCHFGR:E<SQQ>(;^P9Y7R\T,<4I0.?XB"!S["J5A/J\7A+1?$\FOZG+>2ZM
M';O"\V8&A:Z,10IC!^7G=USW[5Z3'X>TF*XCN$LD66.ZDO$;)XFD!#OUZD,1
M^-"^'M)72X=,6R06<$RSQQ9.%</Y@;KG[W- 'G]Q?:_J$%W#:7DTY3Q#=Q-9
MQ7RVUQ/ B\)$YZ;20Q (X'452NV76K#P] ^H:VLUIXE%K+'=N([B F)F"LRD
MAR!C:^2<,:]&NO">A7MO)!/IZ%'NFO"5=E83-U=6!#*3[$4Q_!GAZ31QI+:;
M&;,3?:-N]MQE_OE\[BWOG- ''1W5W':>+_$%]XEU*V33[ZYM+9$_>10KA0I\
MK^-MS\9..GO3=)GU2#QMIVER-X@M;/4K"Y\Q-3ODEE9D"8D0(S>41N/<=>G%
M=\WA_27L+ZQ>QB>UOY&DNHFR1*S8W$Y[\#\JJZ?X/T+3+Z&^M;'%W"&5+B25
MY) I&"NYF)(]CP.U 'G/A2\O-$\-^"1:7-U+'<17TTL#R%A(4B8JH'IE<@>I
M-:,%SJ5AX9\,^*5U^^N[W4KFS%S;R2[H)A.P#(D>,(5W$@C!^7G/-=OI_A/0
M]*EADLM/2%H)I)HL.Q$;R+M<J"<#([#BH[3P7X=L-12_MM+BCGC=I(_F8I$S
M=61"=J$Y/*@=: .!GGU=/"NL^)O[?U/[78ZS/';PB;]R(EN]FQDQAA@D9/(X
MQC%=OX[U.[TKPM)-93_9II;B"V^TX!\A9)51GYXX#'&>^*TF\/:2^F7&FM9(
M;.YF:>6+)P[L^\MUSRW-7+RSMM0LYK.\@CGMIE*212+N5@>Q% 'G'B2;4/"-
MQ=V5AK.H7,5UH5]<D74YEDMY844K*K'D EB,=,@8Q4GV?483X6TJ3Q!JK#7&
M>>]NFGQ)E(=_E1$#]VK'G YPIP:ZVS\&^'[&"\A@TY=MY";>=I)'D9XB"-FY
MB2%YZ @5;U#0=+U338M/O;1);:$J8ER5,97A2K @J1Z@YH \LN[K4?#ESXGM
M-.OKN[GNM;L+(W)D3SU1X4R [87?@! S>H)YJ?4]2\1Z)I/B:(/J%G#'I)NK
M<7^HQ7%S#*'V[E*N7V$>O *\=<5Z%!X.\/6VG7FGQZ5!]EO2&N8WRWFL.C$D
MD[N <]<\]:;!X,\/VUC>V::<K17R".Y,LKR/*HZ*78EL#L,\4 6]#TM])L##
M+J-[?R2/YCS7<F]MQ R%X 5<C( Z9KS"S;6IO#/AO6#XFU47FHZM]BF_>@QB
M%I)$P$(QN 4$,<G/Y5[$!@8%9D?A[28K&SLDLD%M9SBXMX\G$<@)8,.?5B?Q
MH X2;4KG0X_%FE/KFI^5;W-G'9S$"YN@TZKF-"Q&2QR 2?ESGM67<>(==\-W
M?B".%-5A6+07OH;?5;M+J1)!)L$GRLVT8))7./EKTV]\-:-J*WRW=A'*+\QF
MYW$Y<I]PYSP1C@C!J&Q\(Z#IUP]Q;Z<GGR0M!++*[2/)&V,JY8DL/E'7- '&
M7^FOH/C#PM=1ZQ?ZHQM[V3R[J;S/,<09W)_=!Z8''(P!6;H.J>*)K/P]KK?V
MD7O[B W,MWJ5N+2:.4_,D<6_*D _* -V5P<\UZ#IO@KP]I%]#>V6FK'<P K#
M(9'<QJ0057<3M7!/RCCVI;7P5X=LM22_M]+C2>.0RQC>QCC<]62,G8IY/( /
M- %?QI?7-A;Z*UM.\/FZS:0R%3C<C2893[&N7\::[J=G?>+8['4983::7920
MA&XBD>9PQ ]2-N?:O0M4TJQUK3Y+#4;9+BUDQNC?U!R"".000"".:S(?!/AR
MWM[J"/3$V7:)'<%G=FE"L67<Q.202>2<]N@H Y/6;O4_!FKWPM-4U#4%;0+N
M^\N]E\T">$IM9>/E!WG*C ]J8=+>R\3^ KM]=OM0>ZEF>1;F8.KL;20^8@Q\
MHYQ@<<BO0Y=,LI]0COY;='NHX7@61N<1L067'3!*C\JRK#P1X<TR_@O;/3$C
MN+<DP/YCMY.05(0$D*N&/RC ]J /.--UKQ5?:):^)D34EN9KH,7GU*WCL?+,
MNPP^4S@CCY0<;]W>NP\(P7NHZ_KNIWFL:A(EIJMQ:6]IYN(%C 7JN.3EC@YX
MP*V1X*\.C5/[1&EQ_:/.^T8WMY?F_P#/3R\[-W?=C.>:U+/3K33_ +1]DA6+
M[3,UQ+@GYY&QEOQP* .&UNP#_%&6X^TW2D>'9Y-BRD(<2*N,>G.<>H!K)\.0
M7NA^'_A[?PZSJ$W]H-;VL]M++F#RGMW8!4QA2NQ<$<GG.<UZ/?\ A_2]3U"V
MO[NT62[MD9(I=S*0K?>4X(R#Z'-*NA:8MIIUJ+1!!IK(]FF3B(JI12.>RDCG
MUH \I36O%5]I%UXC@34DN4O)!&\FHV\5C&B3%/*>)G'&!@DC=DY!Z5VWQ1#M
M\/KXD-Y D@-T%Z^1YR>9^&W.?;-:<O@KP[/J;:C)I<;7#2B=AO81M(.CM'G8
M6]R,UN21I-$\4J*\;@JR,,A@>H([B@#$\17'A^#PZDNL+"^F>9#Y:A2X9MR^
M7L"\DYQC%<L_V[71XLU.77[_ $^32;J6"TBMYMD4*QQJP=UQA]Q))W9&.!BN
MCL? 7A?3;Z&\M=)B2:!MT(9W=(CZHC$JI^@%3:EX-\/ZO?O>WVFQRSR!1*=[
M*LP7H)%! ?'^T#0!@>#/$-]J^KWL]_,8T?1=.N_()PD3R+(7(';H/R%8>A7>
MJ^(8_ ]K<:WJ$,=[H]Q<7C03;'G96BQENH/S=1@]1WKOM3\):%K%Y%=WVG1R
MSQQ^4&#,NZ/.=C!2 RY_A;(JQ9^']*L'LFM;-(FL86M[8@G]W&Q!91SWVK^5
M 'F%Q%=:G!HEI>ZI?RFP\6S6$<_GE9&C"2%2Q'5@!C=UP3ZUK2ZQJL=[<^#?
MMT_]IRZN@AN=W[Q;%\S%P?\ 959(\^H%=E=^$]#OK*6SN=/1X);HWC*'93YQ
MZN"#D'Z&J5AH%Y)XVN_$>J)9*Z6WV&Q6W+,PAWEBSE@/F/RC R!@\G- %/XH
M@GP1*9,_8Q=6QO /^??SD\S/MCK[9K7\17&@P:+#+K*Q/8^?#Y "E\REQY>P
M+R3G!&.V>U;$L4=Q"\,T:212*5='&58'@@@]17/Z?X#\,:7?0WEII,:30$F'
M=([K"?5%8E4_ "@#E9I=0U72O%FOOK]_97.E7=U%:PPRA885@'R[TQA]V-QW
M9X88Q6GX<UZ]U#4]?FO)FC1-,L;E82V%@:2)V?'IR/TK<O\ P9X>U/4'OKS3
M(Y9Y"IE^9@DI7H70':^,#[P-2:GX2T+6+]+Z_P!.CFN%01EMS*'0'(5P" ZY
M[,"* ."\.2ZKXEOO#5M=:[J4,+^'(;Z?[/-L::;S ,LV#QR<^O%;_P .+ 68
M\2,+FZESK5S'B:4N!M;KSW.>3WP*Z:QT'2],EMY;.S2%[>U%G$5)^6$'(3D]
M,TZQT/3=-O[V^L[40W%\X>Y96.)&'?;G /N!SWH T**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBEF9C&P  '4UC>*+:)-*\/74Z:G;2VK#;J&GQ^9)9DQD$M'M;<C?=(VGJ,T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D'!Y% $E%%% !1110 4444 %%%5K6_M;Y[E+:=96MIC!,%_@< $J??##\Z
M+-%%% !1110 4444 %%%% !115:YO[6SGM8;B=8Y+J0Q0*>LC[2V!^"D_A0!
M9HJ*XN8+2$S7,T<,0(!>1@H!)P.3ZD@5+0 445@W/C7PY:2WT<^JPJUBP2YX
M8A&) "Y P6R0-HR?:@#>HJCINL6&KQR/87*S"(J'P""I90X!!&0=K*?QJ]0
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M:7K>KP:]X8E%YK\]OJ<YAN)=1CAB@N 87<-%&/G3E01P!C@DUU7PW_Y%$_\
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MUE)<K'V9E0L!^E<9YNL:1:>&-4?Q%>7SZQ<P6UW#((_+(F0G=$ HV;3R.3D
MYS7H@BC$/D[ 8]NW:>01TQ6#IW@G0=*O8+NUM9=]ON^S1RW,DD=OG@^6C,53
MCCY0/2@#S"#1)#H.EM_;.IC=XNDBP)$P#]HE&\?)][C.>F2>*UKS6_$FH7?B
M*:S.O!M,NI+6S-H;46RF-1\TWF,&;<>3P %(Q7HB^&=(2WA@6TQ%#>G4(U\Q
MN)RQ<OU_O,3CISTJIJ7@C0=5O9[NZM9M]SM%RD5U+%'<XX'F(K!7XXY!XXH
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MD,WV8WDWDI(3N+)'NVJ<\Y '4UK'0-,,6JQ&V^3523>#>W[W*",]^/E '&*
M.+O?&-_H,L]Y>N9H=2T6.\T^'' NE 5HE_WC)$1^-=QH]O=VFBV5O?W+7-Y'
M"JSS-C+R8^8\>^:Y_5/#,VJZ]H,#V5K'HFBR+=12F4M*\BH51 I'"@X8DDYV
MBNNH \ETO4?$"^!=&U67Q#=R7VO75O9&21(S':*TA&]%V_?VC&6)&3TK3U/5
M;[PEJFI:9)XBN'M'TAKV*ZO8EGEM91(L8P%"[PQ<84]QZ<5V'_",:-_PCB^'
MS9*VEJH18&9C@ Y&&SN!!Y!SD&JL7@C0$L[ZVEM)+I;Z,1W,EW<R322(.57>
M[%@ >1@C!YZT <-_PDFL^']8D(_MV6W;1[R[\G6O)S)+"JLK((SN4<D$''7@
M<5:?3[Z+5? 6H7>OW6H-=WGF2QS;-F]K65MT851M49(QR.1^/8V7@S1++4(K
M]8+B>]CC:)9[J[EG?8PP4)=CE?;I^=167@/P]I]]:7EO:3>;9N6M ]U*Z6^0
M01&K,552&/ &.GH, &?\4[9KGP0X6XF@VWMH<Q$#=F=%P<@],Y^H'TJOIHU*
M?QIK_P!I\0WL>G:(UN(X3LVR9MU9S*=N2,\\$<D_AU^K:39:YIDVG:C#YUK-
MC>@8J>"""""""" <CTJ*QT#3=.^U?9X&)NU1+@RR-(90B"-=Q8G/R@ ^O4Y-
M 'FMKKVKQWGAN^BU#7[F#4KZ.":YNX88;2X216(\J+/F+T!4XZ#DG-98T.7^
MS@?[:U3GQH8,>8F,_:"/,^Y]_OGIGM7I5M\/_#MJ]HR6MP_V*19;19;V:1;8
MJ<CRU9R%'L.W'2M#_A&=(\KR_LGR?;_[2QYC?\?&[=OZ^O..GM0!Q%WKNKKJ
M&H:3#J4L7G^(8--2ZVJ7@B-JLC;<C&XD$ D'EOI78Z%:SZ=?7]C-KS:DB^7)
M%#<%3<6X8$'<1C*D@D9'8\GM)=>%=%O(;^*>R#K?SK<SGS&!,JA55U(.4("+
M@KCI4NCZ!I^A+/\ 8HY3+<,&GGGF>:64@8&YW)8X' &>* -.BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH CN)?(MI9L;O+0MC/7 S6)I_BW39O"VEZ[J=U:Z
M7%?V\<RK<W"J%+*#M#-C.,UKWX)T^Y &28FP!]#7C-A!>::WA6_OKS^S;,>&
MX+>*XGT\W*1S YD0C^!BNWD]=I':@#V&ZUC3+&P6_N]1M+>S?&VXEF58VSTP
MQ.#FJTVNV[):/I\]E>1S726[NMVBA-R[LCKN;&"%')!S7FVC6B:-+X=U74(+
MZ?0HVOS&9K K]FDE=61_)7<40@.%R. PZ9J'25@NIFETVQE@M?\ A.$D6,PE
M"J_9QEBI&5!)SR!UH ]5CUW2)M3;3(M5L7OTSNM5N$,HQURN<U0T[Q797-AJ
M-[J$EOIUO9:A/9&2><!6\MRN[)P!G'3^=>=Z>XL=;TZSTX->JNKEFTC4=-*W
M5END8O,LZ<%0&+ MD$'&:62>73Y5\VVM[:-_$>IR#4KVU>>.U.X[2$4@$N"0
M&)P,'UH ] U;QKH>E:-;ZK]OM;FTN+F.VCDAN$*DNX4G=G&%!)/H :O6^LQ2
M2:B\\EI%:6C)BX%TK H45MSC^#KW/(P>]>2I$XT+Q#<3Q3SP1>([&\:1K Q;
MX@8=\HB R%(!/ Y')K0U6W:XU/6+_P"R37&D)K]A=W*)"S"2V%JGS;,9958H
MQ&#]T\<4 >GVNN:3?6$M_::I93V<63)<13JT:8Y.6!P,>]+9ZUI6H7<UI9:G
M9W-S!_K889U=X_\ > .17F6NF'66\8ZEH-O(VFR>''MY98X&1+BX^8KM! WE
M5)!(_O 5T#:5!8>+?!!LK)8$CM+J*1HH]H"^4A"L1[COWH ZW4[Z2PCMFCCA
M<RW,<)$LXB #-@D$_>8=EZGI4;^(=$BO([.36+!;J1S&D+7*!V8'!4+G)((Q
MCUK'\=Q22V6BB.-G*ZW8L=HS@"49/TKC+_1D/P[\<3#3P;V76+J5'\G,C$3#
M8P.,\8XQ0!ZS//%;023SR)%#&I=W=@JJHY))/05R%I\1]*O;;0+R,PQV6JF8
M232W"K]E\N,OA^HSC&1D8SWKL74/&R, P88((X->/^%K.WO[/X=6LMD7^P2W
M4=W%+;D>5,L!/S!AU!VX/KB@#U6+6-,GTPZE#J-I)8 $FZ2=3$ .OS9Q3]/U
M.PU:V^TZ=>VUY!G;YMO*LBY],@D5Y)KVEW:3ZT;:%X--M_$\%U<!+0S*(_LR
M9D\H??42%6('IGM73>!HUG\3ZSJ4%_->Q2P0Q27":>+6WE=2Q!7G+L <$XQC
M SQ0!T^IZ[_9WB#0]*^S^9_:DDR>9OQY7EQE\XQSG&.HI+_7A8^*-)T4V^X:
MA#<2F8OCR_*V<8QSG?ZC&*QO&Q?3]:\,:^\$\MCIUU*+LP1F1HTDA9 ^U025
M!(SCUJ@-2@\6^.].U#2%GFT_2]/NUFNFA=$,DOEA44L!N.$)..E '7VWB#1;
MR]6RM=7L)[ID$BPQ7*,Y4C(8*#G&.<UD2>-[&SN]-M=1:U@FU"\GMH]EXCJH
MCWX9CQC.T#'9FQUKC]*T>.T\"?#EX=/$5S'?VKRLL6'7<C[RQQD9SSFHK2-;
M ^'+Z^MI%MX?$FI>;(8&;8',X0D $X+%<'IR* /3WUS28]472WU2R74&Z6IG
M42G_ (!G/Z57UOQ+I>A02BYOK1+P0/+#:R7"I)-M!.%!Y.<8X!KR V-PND:A
MHFH:A<1ZM-J4CFT@T?S+F60S%DFCF+ $8VG<2 H&.U=#JSZ?I\OCBSUZQDN+
M[4B7LB+5I#<Q>0JHB$ \JX;CC!.?>@#TG2+_ /M71;'4?+\K[5;QS^7NSMW*
M&QGOC-<XGC^U&@S:A-:2?:?M\]A:V4+>9+=21R% %&!UQD]E'4UL>%$:/P?H
MB.I5UL( RD8(/EKQ7F>C^$=0BLK_ ,5:4;EM?LM7O9+>VG<B.6#S7WPA>@W@
MD[NN<<XH ]*M]7NUN+6'4K6SLV>S>YN +T,82I4;0" 67#'+\ $8[@U9M==T
MB^O7LK35;&XND7<T$5PCN!ZE0<XK@]4OAX@U:'5;.WN!!<>%K\;9(B&1R\7R
M,.S9!&/:DBT=;2R^&YL;);>XC4J\B18*;K.3.XX[M@G/4T =V/$.B&^>Q&L6
M'VN-@CP?:4WJQ( !7.022!CU(K-\4>,],\-:=?2&ZM)]0M8?-%@;E4E<<=N2
M..>E>;F;3;?PMX/T6;2[B+7;+6;%;G?:.#'+YZB20R$8(<YP03NW#TX->^PV
MW@;Q1HFI:?-+XAFO[B=5%JSO-NEW1S*P&-H3:,YXVD>U 'KM]KFD:7<16^H:
MI96DTW^KCGN%C9_H">:6_P!:TK2@3J.IV=H H8_:)UCX)P#R>F>*X*:XTK1]
M?\7)XEL9)I=0D5K4FU:7[5;^2JB)" >0P<;?5L]\U'X3T*YC\2>'TURT\VYM
M?"Z1.9DW['\T KD\;@O'YT =_%KND3WT=C%JMC)=R()$@2X0NR$9#!<Y(QSG
MTJ^2%4LQ  &23VKR/1=&2T\$^!VAT_RKA-<5I"L6'4%I@23C.,8'/;%=Q\0+
M.\O_  )JUM81233O$,Q1?>D0,"Z#W*!ACOF@#5LM>T?4A.;#5K&Z$',Q@N$?
MR_\ >P>/QJ2RU;3M2>5+"_M;IH<>:()E<ID9&<'C(KSG4[C3M=UK3I_#-J_E
MV6G7BWLD=JT2I$T.$A;(&6WX(7J-IZ5UW@/3;?3? ^B)#:1V\CZ? 9ML85F?
M8"2W<G)/7U- &MJ.M:7HXC.IZE9V0E.(S<SK'N/MN(S5637T3Q5::,(E9+BP
MEO1<"3@!'1<8QSG?G.>U<)XD2;3_ (B:C?:AJ*6%I<V$,5I/-IINT95+^9$#
M_"V2#C^+(]*HZ9I#Q0:=:3VFK3VI\,:C&8S (KC8\T96-5W$*VTX52>@'3I0
M!ZEI^N:3J[RIINJ65X\7^L6VG60I]=I.*;;^(-&O)[B"VU:PFFM@6G2.X1FB
M ZE@#P![UY39'4+P7.GZ)/#JTC:)<P07HTYK2YL3L'EQ.PPI+-CC (*YJ3P[
M;0WVH^%K6*]FEEL<[[2'1?(-JGE%729RPPIS@CDL<'!ZT >MB_LV:V47<!:Z
M4M;@2#,P R2G/S#'/':L;5/%^GZ7K.G6<LUL+>Y^T":Z:X54MVB"DANV?FQR
M1BO+Q::II_\ ISV=U(/ \D=O:J%.;B)IF#E/7_1_*'US716'AYHM3\ IJ-H)
MI]E]>W9>/<%N)55V)SW#,0,^E 'H2:QIDFF'4TU&T;3P-QNA.IBQTSOSC]:;
M!K>E7-@+^#4[.6S+!!<).ICW$@ ;@<9R0,>IKR?5M,NX6OI(8WM],M?%C7$^
MVS,RQH;=-LGE?Q*)#DXZ'GM4=[IZZGI/B&XAN)]2M[R\TR.61-.^SP3%;A=Q
M09)8A3AFP!P.3C@ ]7?Q+H4>G)J+ZUIRV+L42Y:Z01LPZ@-G!-:$,\5S D\$
MJ2Q2 ,DB,&5@>X(ZBO-?%MDVE>.=-O1/%I>DIITD,$_]G?:(8IC)N<;1PA9<
M?-WVD5T/PZM/LOAF38]RT$UY--#Y]J+?Y&;.4CR=J$Y8 X.#T% $D7C!;SQ[
M+X;LEL7CM8E>ZE>\ D#$-\L<8!W%=HW9(QN_/9L==TC4YYH+#5;*[EA_UJ07
M".R?4 \5PFNZ3?7FJ?$*/3;=A=W&DVR6[*N"[%9MRJWJ1Q^(IHN-*UG6_"J^
M&;&2*33S(UT1:M%]FM_)93$^0.2Y3Y?5<]LT >@66L:9J4LD5AJ-I=21JK.L
M$ZN55AE20#P".GK4KW]G']IWW<"_95W7&9 /)&,Y?^Z,<\]JY?X8:9!IOP\T
M399I;W$EFAF/E[79N2=W<G)/6L;QOIMT?%<%I;6\CVGB6&*QO6120@AE#L6]
M-T+RK^ H [#Q!XCM=#\/W>J*\-P\5G)=PP"8*9U1=QVGGCD<@'&14EEXATO4
MDE2RU"RN+J&/?+;QW*LT?'1L'*\\9(KRFWTW4;CP?XJ2\MI]VAZ-/H=IN0DR
M[2Y9U]<H(!^!KJ-3TF&QUSPF+&Q6%$TZ]A<PQ8PODIA3@>H[]Z .K3Q'I]MH
MMCJ.KWNGZ>+J-6'F7B&/<0#A9. X]QUJI=^,M-T_Q"FGWEQ:V]F]@+U;Z6Y5
M(SE]@49X.>N<_A7"^&WMM#E\.W_B&W=+)O#-M;6TLMNSK%*"3(A !VLP*=>N
MW':M/P[IEC=>-M,N(]!>RLH]"D^S07,>3#NN3CK]TE3G'4!L<=* /1H)X;J"
M.>WECFAD4,DD;!E8'N"."*I:AK^C:3-'#J6K6-G+)RB7%PD9;Z D9K$^',#6
MOA+[.8C$L=_>+'&5V[4^TR;0!Z8QBN3\3W;R>(O$UIL@L))($C1!ICW5QJ0\
MKC8Q.T*"2N #@@DXH ]7#!E# @J1D$=*XG2_'S:SJ]W%80Z7)807RV0E.IJ)
M7)(!<)MP5/.T!LMBMCP/O_X0'P\) PD73;=7##!!$:@@Y[YKAET]XX&V6C*?
M^$W5_ECQ^[$@YZ?=]^E 'HS^(=$BO([.36+!;J1S&D+7*!V8'!4+G)(((QZT
M^^US2=,N(;>_U2RM9YO]5'/.J,_T!.37F-_HR'X=>.)AIX-[+K%U*C^3F1B)
MQL8'&>,<8J+6X9++Q-XL75K[[,M^5,"/I)NS=P>4JA(VSU#!AL]3GOF@#V*L
M\Z[I U0:6=4LAJ!Z6IN%\W_OC.?TJ+PS;2V?A;2K:=KAI(K2)&-RH$O"@?.
M2-WKR>>]>6.D ^']QX9:QF/C%KQF"_9F\QK@SEEN!)C&W&&WYQCCVH ];_MG
M2_[073_[2L_MK,RK;^>OF$J,D;<YR 03[&I;N^M+"-9+RZ@MT8D!II @) +'
MD^P)^@-<IX0TN!/$GBR_FLT%TVK8CG>/YM@@B^Z3VRS=/4T_QS8IJ%]X3BEM
MOM$*ZTCR*4W* (92"?;.* .CL]7TW4;)KVRU"TN;1,[IX9E=%QURP.!BF6>O
M:/J%K/<V6K6-S;VX)FEAN$=8P!D[B#@< ]:\W\0Z5.;WQDEMI\DED;O2[BXM
MH(C_ *1"N#,% ^\2J\@=<8I/$$MIKM[J=]X;MW:UA\-WT%Y/';M&DC,H\J(9
M W,,.<=L^] 'I5IKFDW]Y+9V>J65Q=1#,D,,ZNZ#W4'(JW<7$%I;O<7,T<,,
M8W/)(P55'J2>!7GW]D+9ZGX _L^T2V>.WGC:1(>$S:G&[&,C< <$\FCQ-INO
M0:9I\^O7T.L6%OJMO<74=KIYCVP*'R60.Y<!C&Q'8*>M ';6VN:1>VB7=KJE
ME/;O((5EBN%9"Y. H(.-Q)''7FK$E[:122QR74*211^;(K2 %$Y^8CLO!YZ<
M&O-->N],U"WN=7T72IS:VVJ:=<W=]%"VVX6.4%BJ8RVQ>I []\<0ZQ<V/B76
M?$]REOJ=QI;Z);1>;:6Y#R%9I&)C#@;PN02.<X(YZ4 =S>^,]!M?#NHZW!J=
MI>VMC&SR?9KA'R0.$SG&XG@#N35@^)]$BTNTU&YU:PM[:Z4&*26Y15<]P&)P
M<>U>8L]UJFE^++6$6VMH^@R!-4M].:VD+@-L@9?NNW)8;0",=.16K8:EH]GX
MD36=4B)TNZT>"#3[E[5V2-D9_.CQMRK$E3@@9QWQ0!Z'>:QIFG627E[J-I;6
MKXV3S3*B-GIAB<'-8NG^+O[31Y+>WMS&NKMIV]KM0'4#/F)D?,3QA!U]:X70
M8/["O]$U37+*:#0@FH+9)- S"R\R</%O7!*9B! STZ<4NE6Z/963V-A/;VC>
M-3/%&T#1[8BC8;:1E5Y]L9H ].;Q!HJ:H-,?5[!=0)P+4W*"4GTVYSFHM&UO
M^U[S6+?[/Y7]FWIM-V_=YG[M'W=!C[^,<]*\@U6[FO- N(TCBL[A=569])MM
M+D::$BY!,DL[$]0"VX  Y '%>F>#XI(]7\7%XV4/K)9"PQN'D0C(]1P: .JH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BF32"&"24C(12V/7 KCM*\?27]
MOH]_=:%<V6F:LZ16UR\R,1(X^4,@Y"L00&YSQD#- &[K6@1:S+:S_;;VRNK7
M=Y5Q9RA6 ;&Y2&!4@X'4'I4NB:)::#9/;6K3.996GFFG??)-(W5V/<\#VX%<
MW_PL2+RSJ(TJ;^P1<?9_[0\],_?\OS/*SN\O=QGKCG&*2^^(,UJ-9GA\/75Q
M8:-.T5[<K.BX"@,2BGEB <D<?4T =O17.:KXDO[6X>/3=!GOHXX%GDN))EMX
ML-G"JS?>; R1T&1D\USS^+KG4M6L=2TGSFM;GPW<7T=H[!1Y@DB +=LC+#\Z
M /1**XOP=XMNK^ST"RU>U>*\O])6\2Y9U*SE0N_@ 8.&5L>A]JZ#P_K2>(-(
MCU.&%XK>5W$.XY+HK%0_L& R/8B@#4HKS_2_' 33])LK"TNK^]O4N)D%]>QQ
ML528H1O(^9L]% Z#GI7:Z9>OJ.FV]W):7%F\JY:WN%VR1GN"* +=%<#IOC1H
M=.T2UL=.U#4[K5&O3#]HN$W#R9<-O<@ +\W''  ')J2#XC2RVR7DOAV[@L8[
MX:?>3//&3!/YGE$!0<NH8@%ACKT.#0!W5%<==>.+J*[UI+3P]=7=MHTFR[G6
M9%R-BN?+4\LP#9(X[<\XJ:3QI)=WCV_A[2)M7\FWBN9Y%F2%561=R*I;[S%>
M<<  C)YH ZNBN,?X@V]U_9*:/8M>3ZE;/<QQSSI;[55@K*2W5PQQM&>AYQ5F
MY\92(--MK;1KE]5OH6G^Q7$BP&!%(#&1CD#D@#&<_2@#JJ*X]?'T5Q:6R6FE
MW$VKSW<EE_9YD13'+&NZ0L^2NT+@[AG(9<#FLO3]0US6U\:J&N]/OK.>(VD#
MR[A"ZP(^WY3@HS#)]0W;- 'HE%8NB:])K=KIEY!8.+*^L5NOM/F+B-SMQ&5Z
MD\GG&.*;KOB%M*O+'3K.PDO]2OMYAMT<( B ;W=CPJC<!W))&!0!N45Q5Q\0
MEM[)0VBW9U0:BNF2:>)$W+,Z%T(;.THP PW'!]C76V$UQ<6$,UW:&TN'7,D!
MD#^6?3<.#^% %BBBB@ HHHH Y>T\":?:W-HS7^IW%I93>?:V,]P&AA<9VD#&
MX[<\!F.*ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+4;E(MWEI''"T2QH2,L0"#D@9YZ5W=%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*2MW=R>-H](GMKN2YT:!E?2K,V\4^'D#B,;FWG:2NX$Y/':M3Q)=^#[[PWK
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M)U&Q6^%D;VW%V1D0&5?,(_W<YKR&YMM.L-.5[NVACTVP\:29WQ QP0E3GC&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'WK!^%ZA/AKHBJ,*(6 '_ VKI-.L1IMBEJMQ<W 5F;S+F4R.=S%L%CV&<#T
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M]X&'1@ZMU&/;%:0^'VCO!JD=U/?W<FJ11174UQ<$NWEL61@0!M()XQ@<#CU
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M7^IVMPUHMNJ+ 7C=E",.2 #@[LYZ\5N_$ZTGN]-T2.*\,"-K-FC+Y2N&+2J
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MQ9VSW/[NW9&#+M&,D#I\Q; /%=#K.CV>NZ:]C>JYC9E=6C<H\;J05=6'(8$
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M@VLY+$O$<?+DL<@Y!STIR^!M*-E>07$UY=37LL,MS=SS;II#$X:,9Q@*".@
M')]: -2QLM2M]':UO-7:ZO2' O/LZ1E2<X(0?+Q^N.:\L\)MKUKH7A33-,UA
M+8ZO+>F6=K.-VC$99N!@;B3GDY^][5[+6#8>$=,T[^R/(\[_ (E1F-MN?/\
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M>DFT[?UQ7D^GMX?ETSP;:Z!%"OB6"\MC=)$F+F(#_CZ,_P#$ 1O!W=21C/%
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M&TO3)=4U0P^?)$DBQ)#'G 9W;ID@X !)P:Q_!K6,_B_Q%=Z"(?["DCM@KVX
M@DN0'\PQXX/R^6"1W'M4<VHVGA'XC:M?:U*+73]8M;;[/>RC$2R1;U:-FZ*2
M&##. >: .AT#Q$VKS7MG>:?/IVHV)7S[>5@XVL,JZ..&4X/N"#D"M2WOK2[C
M>2VNH)D0X=HY P4^Y'2O/O$_B1O%7A76UTBTGGT>V>V$E["6_P!*C\U3<+&
M,L%C!RP/.2!5*YET*\\1";P<+1K2/1;M=2DL% AVE5\E6V\;P=V!U S0!Z:-
M1L2TBB]MRT2;Y!YJY1?4\\#WIPO;1K=+@74)A?E)!(-K<$\'H> ?RKRC3?#6
MC8^&0.EVI^TVKM<YB'[\_9A)^\_O?. W.>15"]CTBQ2"#488H]'M_&LP,6S]
MU&GV=VY4<!-QR1TQG/% 'L\5W;3VWVF&XBD@P3YJ."N!UY'%,@U"RN8'GM[N
MWEA3.^2.0,JXZY(/%>1ZG>:6B^)+K3;*UN?#=U=Z?$'W,EB)]Q\R5BG!C \K
M=C@D8/>J,DL+S^-_LUSI4\4OA>1B^DVIAMW93(./F82$!@"P/?':@#VM+^SD
MDE1+N!GA&9560$H/]KT_&I3-$%1C(@60@(=PPQ/3'K7G(T+2]/\ $O@A+/3[
M> 7-G=0W)CC"F9# I(<C[W///>J_A."ZN_$EGX;NUD:W\'F7+N.)6?*VI_"$
ML?KB@#T\R()1$77S""P7/)'KBF"Y@*!Q-&4+; VX8+9QCZYXKB_B/=2>'XM-
M\601-))IKR0R(HR6CF0J!_W]$5<QX6T:[T[Q38>"[@226^F2C6Y)6Z.3"J@9
M_P"N[2M_P&@#T&U\5VTE_IFG7<)M;^_AEF6$RHX0(P7!93@D[AC&>_I4OA_Q
M-9:_IUO<HR033M*%MGE4R$)(R$X[CY2:\R\*)IUMJ'P_N;^*W0RV=]!%+*@^
M:;ST,:@G^+[V/J<46>C:=;?#+2]5BL8$U+^W8Y/M0C'FY^W[/O=<;>,>E 'L
M#WMI%=);27,*7$@RD32 .WT'4U)YT69!YB9C^^-P^7C//IQ7C=^V@QZ#XNL]
M9BA;Q9->71MD=,W4K$G[*T/\14#9C;P,'WK1&LP:%J'C"VURY6'4;VRMGAB;
M[]RWV4(WE@??.\$8% 'H'_"1:>?$<6AK*&NI;4W:D,-I3< !UY)SGZ"G7^OV
M.FZSIFEW#XN-0+B+D #:N3G)[]!ZFO//"ZZ=:^*O!TMW';QS7/A6%+>21 &D
MF'E\*?[P3/OBMWQDNFP>.O!M[J,=NL7G7$7G3(" YC_=KD]]W3WZ4 =!H?B:
MRUNVWADMYC<3P)!)*N]_*D:,D#N"5)K3EO;6&XCMY;F&.:7_ %<;R ,_T'4U
MX^VC:=%\,]3U=+& :DNO/*MUY8\U6%_M!#=1QQQZGUJGK4<8U'Q?!K>H:-;7
MD]V_DI>Z:\]Y)"5 A-NPE7..P4<,#F@#W)F5%+,P55&22< "H8;VUN)GAAN8
M9)4 +HD@+*#TR!TK#U9)X_AO?)<R/+.ND2"221=K,WDG)(R<$GMDUPNA2>'[
MF3P+%X62#^U+<AK[R$Q)'!Y#>:)^X)<I][JW(H ]+O-8BBB!L_*O)?,B5HH[
MA%*J[ ;SD] #G'4XP.:MO>VD5REM)<PI<2#*1-( S?0=37D&EZ1867PA\/WE
MO90QW=S?V)GG$8\R3_2U^\W4@=@>E&H-H$>B>+[36XH6\537ER;9'3-U*23]
ME,'\1 &S&W@8.>] 'K[WEK'.L#W,*RLVU8RX#$XS@#UQS4OF)YOE;U\P+NV9
MYQZX]*\^\)Z/!<^.O$%[JUI!/JELE@!-(@8Q/]G7<4)^Z2>I'H*/B3+=:)=V
M.N:>C-<7-O/HYVC/SS+F$GV$B ?\#H [X7-N8TD$\1C<X1MXPQ]CWZ&J=QJ\
M:26Z6@BNR\Z12B.X0&%6!(<Y//0<#DYXKR_0=+DMM9N?"Q60V/A5+JXB=AD-
MYZ9A_)7G'X5+IFCZ?IW@GX=SVEE##/=7UA)<2I& \K>3(<L>IY8]>F: .T_X
M3[0S:?:1,=AU/^S!\RY\SS-F[K]S()SZ"NAEOK2"6**:Z@CDE_U:/( 7^@/6
MO%I(= MM%O$FMK",Z?XQ#WJM"H\FW:Y;:7XX0KT[8HUG[-_;7BL:QJ&A6YN7
M!M5U#3FGFEMC$OE_9F$JYP<X51D-DGK0![1<7UG: FYNH(0,9,D@7&<XZ^N#
M^53@A@"""#R"*\TT+0K74?&SQZW;)J,T'ARQ1FO8!DL6E#,R'.&..>N,D9K?
M^&K,/AMHV[<VR%E SDX5V 'Y "@#I1?V;7AM!=P&Y R81(-X_P" YS0U_9I,
MD+W<"RNQ14,@#,PZ@#N:\)2_L;BW\/75J-$M)1K=M*]G;PO+?6^Z<!S<3LV5
MZD'<O).,UJW<WA86_C^VOXX'UV>_G2T1DS/(WEKY0A[DASGY>AY- 'L,U_9V
MS!9[N")BP4!Y IR>@Y[TLUY:VS!9[F&(D@ .X7.>!U]:\G@G\-6GBSQ$OC3[
M&UZVGV2,;M0V\^3^\6//5B<<#D\8Z5+X1T,7WB;1$\1V2W-W;>&(&"7:!S&W
MG/M)!_C"X&>HYH ]3-[:"[%H;F$7)&1"9!O(]=O6GB>$QO()4V(2';<,+CKD
M]L5XI<'2!X'U"PFCB/CUKZ0HFS_3#=><3&ZG[VS;M(8?+MK<U^SN8/$UWX1B
MC?['XIGBNBZ [8U4?Z6,]MRHGXRF@#TJ;4;*V>))[RWB:7_5J\JJ7^F3S52#
M6HY_$]YH@A826MK%<F7/#"1G4#'ML/YUY5XNN=/N-0\6VS0:'9W*Q^2([ZW>
MYO;O$(VF!-PV+S@;00""Q%=+X%E:?Q-YS.7+^&M,8N3G<3YO.: .]N;VULE5
MKJYA@5CM4RR!03Z#-8FO^*AH^K:5I5M:+>7VH,Y1#<+$J(N,L2<^H &.>:YO
M59=!M/B'JDWC 6:VLEA"NFO?J#%M!?SE7=QO)VY'4C%8WAG2XVU;P*][8@GR
M]2:W^TQ9D6!9%-N#N&?E0C&>F: /2]9U^QT(V(O7VF]NEMHN0,,03DY(P !R
M?I4.E^)K+4KB]@=X[:6VOI+)4EE4&5D"G*C_ ($.*P/B8FG);^';S4XK<VEO
MK,)FEG0,L<95P=Q/12=N>W2N5U#1=,N/!OQ(U.2Q@DO4OKIHKAHP739&C)M;
MJ,'GCUH ]<N+VUM&C6YN886D.U!)(%+'T&>M3UXQK91/&&O2:_?Z%;13VL'V
M7^V;!I_-@\H;EA(D7G?ORH!;)!]*]+\&PSV_@W2(KF>>>5+5 9+B+RY&&.-R
MDD@XQG))H YNV^)-[+X?3Q%/X4O(]$*^8]TEU$[)&#@MY>0Q []\5W$U_9VR
M1O<74$*R\(9) N[Z9ZU\_:7+X>E^&$-N?%FIMJZP,T>D1SF6-Y@Q*1F#:0RD
MXR#QS7<&YTB'Q9J-SX^ALH'N--M?L@OE#1!=A\^./=D;O,/(')&WK0!Z7<W=
MM9P^;=7$4$6<;Y7"C/U-(][:I L[W,*Q,-RR&0!2,9R#Z8YKQFTN5M;'PQ9Z
MO#IEI*MA<26UYXA#O&D1FPD2QEE!E\O9U(8#CN:9X>L;35(?"^GWD,5Q9#Q'
MJ(\AK<QQE1'*ZCRFSM7H=AS@'% 'L=YJUE96OG/<PDM&TD2>8 90!GY?7\*C
MT76(=9T?3M00"(WUK'=+"S LJLH/XXSC->;ZG%X9T[6/%MIXDMK2-Y((DTJ.
M6(9:V6$*J6XQU$F[A><X/I73^")-)&A>%8I!#_;)T&%HR4_>>1MCW8..F[;Q
M]* .MN+F"TA,US/'#$.KR.%4?B:1KNV2!9GN(EB895RX"D8SD'Z FN)\6-IU
MOX[T6Y\2>0-#6SG6)[H P1W19,%\_*"4W!2??'-<G%I]EJ4FFP1VJOX<N/%K
M/80LG[IXOLKEMJGCRS('P.AY[&@#V:.6.:)98G5XW&593D$>H-.J*VMH+.VC
MMK:&.&")0D<4:A511T  X J6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;5\M2HV\9Z&M.BB@!-HW;L#.,9I:** $VC=NP,],TM%% "%0W4 XYYI:**
MC/6BBB@!"H;&0#@Y&>U+110 4A4-C(!P<C-+10 A4-C(!P<C-+110 A )!(!
M(Z>U0M9P/?QWK(3<1Q-$C%CA58@L,=.2J\^U3T4 (0&!# $'L:6BB@ HHHH
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M12S$*H&22< "DCD26-9(W5XW 964Y# ]"#0 ZBBB@ HICS11O&CR(KR'"*S
M%CC.!Z\ FB2:*$*99$0,P12S 98\ #W- #Z**9'-%-O\J1'V,4;:P.UAU!]#
M0 ^BBH_/B\X0^:GFE=X3<-Q7IG'I[T 24444 %%4[G5M-LI?*NM0M(),9V2S
M*IQZX)J6UO+6^B,MI<PW$8.TM%(' /ID?6@">BBB@ HHHH **C\^(3+%YJ>:
MREE3<,D#&2!Z<C\ZDH ***C@N(;J%9K>:.:)L[7C8,IYQP10!)1110 4444
M%%%,::))4B:1%D<$HA8 L!UP.^,B@!]%%,DFBA"F61(PS!%W,!ECT ]S0 ^B
MBB@ HHHH ***KI?6<MY)9QW4#W42[I(%D!=!ZE>H'- %BBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.
MUW2[76M%N=.O99(K690)FC?82@()!/H0,'V)K1K*\1Z##XFT&YT>YN;JW@N0
M%D>V8*Y7()&2",'&#QR,T >;ZF\30^(?$_A2SCL-+L=#N+6.ZMXQ$MY+P0Z
M8RL>TX?N2<9 K:DTC3_#NM^!7TBUAMWE=[.4PH%,T1MW<[R/O89%;)[_ %K?
MTWP>MBCP7&MZKJ-D\#6[6=VT1AV$8QA(U/3CKWI-(\&6^EW]I=RZGJ.H?88F
MAL8[MT*VRL,';M4%C@8W,2<<4 :NLZ8^KZ>;-;^YLD=AYKVI"R,G=0Q!VY]1
MSZ$5@_"]0GPUT11T$+ ?]]M72:=9'3[%+9KNYNRK,?.N7#.<L3@D <#.!QT
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M$\J8X /+(70$ 9VL,TFI> [/4+S4)8]3U*SM]2C6.^M;61%CG"IL&<J67Y0
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MX28\*<,"#D\8P1CK5B+P1IZ6B12W-Y/.=0BU*:ZE=3+/-&05W87&W"@;5
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MV3>R1XW'D#C/UKR?Q=_9MGKWB#4)&T?4I([B-Y;.^+6^H1,J)M6UE')4X!7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,J&W@%1PWK]?>I:* (C:VYN!<&"+SP,"78-V/3/6B2UMY9!))!$\B@J&9 2
M>HS4M% %5=/MUU)M0"'[081 #G@("3@#ZG]!4TT$-S&8YXHY8SU5U##\C4E%
M #?+C^3Y%^3[O'W>W'I3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?)W>9O\ E;GCC''OQ<U+7/%,U_XL.G7FGVUMH15HDEM6D:?]PLI5CO&T9)Y
M)Y]N=UO!E@WAFXT$SW/V:>Z:Z9]R[PQG\X@'&,;N.G3\ZL_\(S:;M>/FS_\
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MUO7]6\-W.O2N-/NM3L-#MYS=K;>69F,TJX(W'"X' SP23WJUJGBK7O"%[/\
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M^?:+>S\A2DD'/=M_S+SD 5V_@FXU"Z\#Z)/JN\WTEG&TQD'S$[1RWN1@GWH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ;2Q1:JDWVB&.TD9W=8PRB)<%F&3U&0?7B@#TGJ,&LS_ (1W0_\ H#:=_P"
MJ?X51C\;:(^BR:H9YDBCN/LCPO;N)Q/Q^Z\O&XOR. .^>E7-&\0V.N-<1VWG
MQ7%L5$]M<PM%+'N&5)5@#@CH>AP?2@"\EG:Q+*L=M"BR\2!4 #\8Y]>.*AN-
M'TN[CACN=-LYD@XA62!6$?\ N@CC\*R=3\3V>BZQJ']H:BD=G:6,-Q)#Y#%H
MP\CIO+CJ"0!C'&,]ZA_X3S2Y8;\00WXNK6T:[2">REC::(<;T!7++G XZ9H
MZ"\TZRU"$0WMG;W,2G(2:)74'UP127.F6%[!'!=6-M/#&04CEB5E4CI@$8%<
MWIOCNSE\,:+J-]#="]U*%62S@M)&DD;:"Y1,$E!G[W3&.>:LS^/- M])M]1>
MXG,5Q<FT2-;>0R^> Q,1CQN#_*1@CKCU% &W+IMC-;FWELK:2!GWF-XE*ELY
MSC&,Y[U+]EM_+EC\B+RYB3*NP8<GKD=\^]<]<>.]'M]H:/47<0+<3QQ6,KM;
M1L,@R@+E. 3@\\9Q4M]XUT:R:)5:ZO#);+=YL;9YPD#9VR,4!PIP<=S@T ;<
MMI;3VIM9K>*2W*[3"Z H1Z8/&*+6SMK&W6WL[>&WA7[L<*!%'T XKF)?&T'_
M  ENCZ9;1236&H6#W@NT@=EQE-A#8P%PQ+$]/ESC-6]+\:Z/J]];6MN;M#=J
MSVDL]I)''<JHR3&S !N.?<<B@#H719$9'4,K#!4C((JI;Z3IMI:R6UMI]K#;
MRY\R*.%51\]<@#!J#6=>L-"B@:\:5I+B3RH(((FEEF;&<*B@D\ D]AWKEO$W
MQ BA\*27FB?:/MIO(K)EDLI&>U=G4'?'@$':V5!^\<8SF@#NP H    X %07
MEA9ZC!Y-]:0746=WESQAUSZX-4TU&+2_#2:CJUZ?+AMQ+/<2PF(XQG)3JI_V
M>N>*HV?C32KNXFMW2^M)XK9KOR[RSDA+Q+]YEW#G&1QUYZ4 ;*Z?9)C;9VZX
M*L,1*,%1A3T[=O2F7UI++;W#6$L5K?2($6Z:$2;<=,C(W 9/&>]8NF^/-#U6
M\M+>V:\'VU2UI-+:21Q7&%W$([ !B #^1Q5V+Q3I$VD:?JD=PS6VH3)!;$1M
MN>1F*A=N,@@@YSTP<]* )?#VBQ^']&BL$E:=PSRS3N &FE=BSN0.F6)X[=*U
M*P?%NO3Z%IMO]A@CGU&^NH[*SCE)"&5\\L1SM #,<>E4!;^-=,N+2X;4K/68
M7F1+JU6T%NT:,<%XVWG.WKALY />@#??1M+DOA?2:;9M=@Y$[0*9!_P+&:M^
M3%Y_G^6GG;=GF;1NVYSC/IGM6#_PFVB_VQ=:9YMQYMF7%U+]G?R;?:F\[Y,;
M5^7.,GG%&F>-='U6]AM8C=PO<HTEJ;JTDA6Y0#),98 -QSCKCG&* -?^S-/^
MW_;_ +#;?;,8^T>4OF8_WL9ILVDZ=<W)N9]/M9;@H8S*\*LQ4C!7)&<8[52B
M\4:3-I6EZFD[&UU.6.*U;RVR[/G:",9'0]:H2_$'0(KFYB:2Z\NTN#;75R+2
M0PV\@;;AWQ@<]_<$X!H M?\ "*6$OB*_U:[B@NA=0P1K!- K+$8M^&!.>3O]
M.,5O 8&!63XFUV+PWX;OM8EB:5;:/<L:G!D8D!5SVRQ _&L)X?'UI;1:C]MT
MZ_GW*9M)CMO*7:2-RQS%\[@,\MP<=!0!UUQ;07<#07,,<T+C#1R(&5OJ#3+.
MPL].@\BQM(+6'.?+@C"+GZ"L?5?&6DZ1?2V<WVR>:WC$MR+2TDG%NAZ-(4!V
M\ G'7 SC%,O?'&B6<]O DES>37-J+N".RMGG:2$G&\;0>./Y>HH V;?3-/M+
MF6YMK&VAGE_UDL<2JS_4@9-/%G:K%'$+:$1QMO1 @PK9SD#L<D\US]AX_P##
M^IW5C%:37+Q7QV6UR;618)'VEO+$A&-V >/4$=1BF_\ "P= %Q-'YMUY5O=-
M:7%S]DD\B&4/LVO)C:.>_3D>HH T/$'AZ#7M-DM-RV[27%O,\JQ@E_*D5P#T
MS]W'MFK]MIEA9P206MC;00R$EXXHE56)ZY &#6+JGCC1M)NKN&87LHLL?;);
M:SDECMLC=\[*"!P03Z#K1J'CC1M/O7L\WEU<I ERT=G:23D1-G#_ "@C;QU^
ME &Q:Z1IMD$%II]I;A"6410JFTD8)&!P2.*F%G:K#%"+:$10D-&@080CH0.V
M/:L_3O$NDZK=P6UE=>:\]FM]"0A >%C@,"1Z]1U&1FK.EZK::S8+>V,ADMV=
MT5RI&[:Q4D9[9!P>] %#2= FLM;O]8O[_P"VWMRJPQL(1&(8%+,L8 )R<L23
MWXX&*W*** (%L[5&5EMH0R.TBD(,AFSN8>YR<GOFA[.UE6=9+:%UG_UP:,$2
M<8^;UXXYJ>B@"E+HVES_ &?SM-LY/LP @WP*?* Z!<CY?PJ[110!7O+"SU&)
M8KVT@N8U;<$GC#@'UP1UI4LK6-D:.VA4QLS(5C VEOO$>A/?UJ>B@"I;Z5IU
MI<RW-M86L-Q+_K)8X55G^I R:E%I;"U^RBWB%OMV>3L&S;Z8Z8J:B@#!UCPK
M8ZCX9N]#LXX=.@N"I)MX% !#!L[1@?PUJVFGV5AYGV.SM[?S6W2>3$J;SZG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM2U^2SLC-'=:1:6T)WJ-\B7+NR\GLI!YXYK9UO1;Z^\8PW<,.;;^Q;NT,I8
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M^M>%?$WAJST25UO]7OX5U#S(Q#&C7#;F<%M^Y>< *<\<]<>NU!:65M8I(EK
MD*R2O,X08W.QRS'W)))H \Q\1:)XEU(^(K&6SUBZ:X#QZ<;6^2WL_*,853+A
ME=FSG(8$'@=*Z/PIHNH6&O7EW>6AABETC3[=264_O(Q)YB\$]-R^Q[9KLJ*
M/(-0T?6?#_@#PG-;(MOXAM5.F")G!)^T IC(SG:WEO\ \ ->D6%L=!MM'T6Q
ML'ELHHO(:<.H$(1/E+ G+;B,<=SDU9GT;3;G5;?5)[*&2^ME*0SNN6C!ZX/;
MJ?S-7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHH[4 <K%X_TJ:>$BUU!=/GN/LL6I-!BV>0MM #9S@M
MP&(VD]Z?>>.]+LKZXA>"^>UM9UM[J_CAS;P2''RLV<\;AD@$#/)%<VNM:5XU
MU*WLX+_3[+PU8W:NJ&9$DOYHWRH5,_+$' .>K$#'')S[F[M;7X:>-M*N)8_[
M2:^OH1;EAYDDDTA,6%ZG<'0C_P"M0!ZEJ.H6NDZ=<ZA?3"&UMHS++(?X5 R:
MQ]+\7VFHZG#I\MAJ.GW-Q$TMLM] (_/5<;MI!/(R"5.#@]*L7FJ:3IVBW0U:
M[MF2PME>]1V#E%QP67KS@XXY[5S?AR]B\5>)+;Q!?7MG$T,3II>EQW"/+&K@
M;Y9<'[Y4#Y1PHSU.: .]JEJNHMI=B;E;"\O2&"^39H'D.>^"1Q^-7:* .2T?
MQ[#K=\UM;>']=3R[@VTTLML@2&08R&(<XQD=JW=#UBVU_1K;5+-9%M[A2R"0
M -@$CD GTKGO '^L\5_]C!<_^@I7#:%HUIIO@?P=KEL)4U.35K:)[CSFRT<D
MY1H\9QLVG&WIWZT >U45X3<&_N['6]6NKK2+35X-2FC6]N;^=;JT99<1HL21
MGY=NW"C(8'GK7HWQ*\X_#V[ F>&5IK13)"Q5E)N(@2#U'6@#IS>8U-++[-<'
M="TOGA/W0P0-I;^\<Y ] :LUY=KMB_AG6KFT\,Q20O%X9OIK>)'9SYOFQD,,
MDDMGI5:SB\,VOBCP(WA^_$D]T\KW CNC(9U^S2'?*,G+;NYYY/IP >E:'K%M
MK^BVNJV:R+;W*[T$@ ;&2.0"?2I+#5+34VNQ:2%_LEPUM+\I&)% )'/7&1S7
MD.@:-::;X'\%ZY:B5-3EU.VB>X\UMS1R3%6CQG&S:<8Z?C3AINF1:7XCM;:^
ML]/N'\3>44N&?RIU&"D,I4Y5&);GIGCGI0![117#?#N>))M;TM;!;*6TFC:2
M*WO#<VH+I_RR) *_=R5(X)]ZQKJ'1=2U'QE<>)[ORKVPG*VI>Y,;6MN(5:-X
M@",$L6.1U(Q[4 =S>^(X+3Q%::&EG>75W<1^<Q@1=D$6[;O<LPXSZ9/'2KEQ
MJMI:ZE::=+(1=7:2/"@4G<L8!8YZ#&Y?SKSKPG8_;O'.CZGJMM_Q-9/#,%S.
M[Y#>=N"EB.QQQBM7Q39:<_Q/\)W-VD8D:WNU1W;&77RR@'/)RS8'O0!UVB:O
M;:_HEGJUF)%M[N,2QB0 , ?4 FK]>+^'M&M-*\&> M:M!*FI3WUK%+<><Q+Q
MR;@T9&<;<8 '08%5-0^V7O\ PE.HWMSI-MJ%IJ$\<5[=:A/'<V2J?W/EQHA^
M7&T@#[^3G.: /;;JZ@L;2:[NI4AMX4,DDCG 50,DG\*Y9?B'8!(;JYTK6+32
MYV58]2N+8+ =QPI/S;U4DC!90.12>/K.^U+X8:E!'&9[LVT<DD<2D>9M97=0
M#SR PQUYJ74O''AE?#<=^ES;ZE#<[%@LX"DDEPS$ (J$_>SV/3'.,4 =717F
M,\&B:KKOBZ3Q5=>3/8NHM1)<&,VMMY*LLD6",$N7RP[C'M5+P_IS>+-<TQ/$
MZS7#-X7M998'D9 TAED&]E!'S8_(F@#UNBO'/#MDEMH?P\UU9;A]5OKU;>YN
MI)W9IHFAF.QLG! V+@=L54LETN/P(FL65Z9/%*:J8H&^T$S>9]J*B$+G[A0\
MKC&"3[T >W45X;XSN;>[L/%>KV\%NDUE<RPI?WVILMS%-&  MO$B_*N1QEAG
M))SFNF71+'Q+XL\4'51+<I#8V;0IYK*J,T3DN "!NX&#V[=: /3**\DAUZX\
M.^'/"7C.[DFN(I]'%G?98L7?R_,A;_>+JR9_Z:"O0/"FF7.D^%K.VO7:2^9#
M-=.3DF9R7?\ #<Q ]@* -NBO(-,UF!_ /P\M1J"M>MJ5HDD0ES)\I8.&&<\'
M@Y]JKSZ7;IX(UGQ&&G_M>UUR<V]SY[[H5%[MVJ,X"D$Y'0Y- 'KFJ:A#I.DW
MFI7 <P6D#SR!!EBJ*6.!ZX%36UPEW:0W,>0DJ+(N[K@C(S7D/B"#2+_2/']W
MK]ULU>TDGBMM]P4>&'RAY*HN?NOGG ^8L0<TM['<ZGXGCL;V+2YK2WT6UDM(
M-3OI+>/!#>9(@52&8$ $G!48QUH ]BHKQ_1M-7Q'J/A.QUF^.IVITN]<O#/*
M$G59XQ'N)"LV 1R1R5!YZUV'Q"D\K2M)@EF>#3;C5((+^1'* 0'=P6&-JE@B
MDY'!]Z .@U;6+;1DM'N5D(NKN*TCV '#R'"YYZ9ZUH5Y7JUMH%A?6MCH5Q(5
M37=,>>V1RUO Q<XV=@Q RP!]#@9YYSQ3>P3:1K/B"TAMX9H=1=(=0O-38WHD
M24+MCB5<(HP<*6^[R10![O17FUWJ]MI]Y\24N[Y('5(WB227!P;10-H]V!''
M>L6^M1J$>B.TNFZB\7A^V>33-1NI+8H"#F:&0 KN/0DC(VCD9H ]CHKQ9KV7
MQ)JVB1/!;2Z8VA1SVEMKE])$'?<RNY95(D< )R>QR.M=_P##R2>3PA#YU_#?
M(LTR0S0R22+Y8D(50[JI?;]W=CD ')H $\?Z4\R,+;4!I[W/V5-3,'^C-)NV
M8W9SC=\N[&W/>GWWCK2["]N89(+Z2VLY5AN[Z*'=;V[G'RNV<\;AD@$#/.*Y
MM]:TKQGJ$6G07^GV/AJRNE9@9D22_EC?(5$S\L0< D]6(XXYJE<7MI9?#_Q_
MIMU+&+]KZ_06[,/,D:<DPX7J=P=,?_6H ]8SQGM6-H_BG2=>U+4['3+@7#Z<
MR)/(F#'N;/"MW(VG/_ZZL636_P!DATFYFADNTM$\ZW+@OM(VDE>N"01FN>\,
M6MO9>/?%=M:P1P01Q6"I%$H55'EOP .!0!V5%<'XZDM[SQ!I&CO9I>320SW"
MP7EZ;:T*KM!9\*Q=AGA0.,DUQ>EHNK:+I>ERW(>Q_P"$NFM0EI<N8_)\AV,:
M/D,8SDCZ&@#W"BO(M7T[?XVO-&DMM*;3=/TZ#[!;:GJ$MNB1G=OD3:K;F! !
M8G(P/6NQ\*6\NL?#6VM+_4!>FZM9(3=Q%_GC)958%U5B=N/F(&2,]\T =95&
MZU2*SNFBGAN%A2V>Y>Y$>8D52,J3_>P<@8Z UXW#XIO[:2Q\47LDWV?PVD>D
MZC$"</,5D65C[[Q;X^IK5.E3VYM]-U)GEFD\)WMQ=(S'F=I8W;\F8@>U 'HU
MCXDL-1U&ULK;S6>YT]=1B<IA3$Q 'N#R.,5KUX[X8\/Z)K&M>';:2))[)?"R
M2-"DIV-(9%W;L'G!)X/0_04MA(L^E>%M*U:ZE_L-M4U"UF,LS!9/*DD%O$[Y
MR5X. 3SM H ]AJO?WUOIFG7-_=R>7;6T332O@G:B@DG Y/ KR349X=.M?$MM
MI=TPT&PU32VC992T=NQF0SHK9X4#:2,X&X]*M^-KJRUC5O%EM%<1W4,/A-W9
M8Y-RK('=UZ'J/E/Y4 >J03)<6\<\9)21 ZY'8C(J2N1D6TM_A-<C3606ZZ1*
MT;1/D ^4Q.#]<URVCQZ59S^!KGP]=^=J-^0+UEN"[7$'D,9&E&3]UPN,]#P/
M2@#U>JU_=_8-/GN_L]Q<^2A?R;=-\CX[*O<UXS!8G3OA#8:Q:/(MYJ,\$.HW
MDUU(O^CF<@AG&2B8PI*C(!-+JD4^EZ9XKM[6XTJUM_[">62QTR[FG59-V$ER
MR!4)&X$ Y. <<9H ]M!R <$9[&EK@[;5K73?&_BK^T+V.WC_ +-LI8Q-(%!4
M+,&*@]>< X]JY?PLEEJX\-6?B6;=8+X<BGM8[B8HDDV\B1LY&75=GT#$T >E
MZ;XDMM6%NUI:WC1337$!E\H;8VA8JV\YX!*G;Z^U;->+^&9I(;7PO_9,\EPO
MVC7#;LSEO.PSE"3_ !$\'GUK5\.1^'X=%\-:O!?SOXDO(_F:.=GENYS$QD29
M>?D# YR!M*CD4 >IU3U'5+32H[=[N0H+BXCMHL*3ND=MJCCW/6O%_#XO'L?#
MNL?;-(@U6YO8A-=F_GDN[ARW[V&2(1XZ;AM^ZN <C&:[OXG6=C<Z;H;WZ1F%
M-:M%=I&VJJ-( V3V&* .YHKR&ZCT6[TSQEJ.LWIBUBPNITM)#<LDEK&J@V_E
M '@,-I&!\Q)ZUVVI:K+9?#*74]6^UQ3KI8DN?LN$F5S&-VTD85@2>>WX4 =1
M17D.A(-,^(WAR"WM]-L/MEK<>=!8ZB]T\JA RM,2H!.1D'G//-5M%TNWL_!G
M@O7XFG_M:;4[:*6Z:=RSQO*4:,Y.-NWC'3B@#V>BO*W-RFO2_#X/+LFU07ZO
MN/&GG,S*#UQYJF/Z,*Z+Q_(N= M;R=H-'NM2$5^ZR% 5\MRB,PZ*SA0?7@=Z
M .FU75+31=,GU&^D,=M NYV"EB.<#@>Y%1PZQ;3Z]=:,JR?:;:".X<D#;MD+
M!<'/7Y#V]*\D\56FG16'C+3-+*R:):V=I<&)9"T5M=&1@P3GC*;21T'7O711
M>&=#UOXB:C;S0BXT^#1K,01),WEX+S -P>2 .#VR<4 >DT5X=9W.HZQ;>#[&
M^:SN[-]*F=(]4O)(8KB9) OS,JMO94Q@'U)ZBK=C9'5CX;TB^OX[O3I-;O8E
M2SN9F00K [>3YC!6=0P(R,C'&: /9JK27GEZA;V?V:X;SD=_.5,QIMQPS=B=
MW [X/I7+_$*%=.^%VJ6]DSVZ06R1PE&.4 90,'KTK"U[33X8UJQM?#<4L<W]
MCZK/%'YC2&2?;#M8[B<G('^30!Z=6?HFL6VO:5%J-HLBP2,ZJ)  V4=D/ )[
MJ:\OM(_#=OJ'@*;1=0\R_N[H-<[+IG>X'D2%GE&3E@V.3R,D55T[1K2Q^'^E
M>(;<2IJJZT@6X$S9"-?&-D SC85)RO0Y)ZT >O66J6FHSWL-M(7>RG^SS_*1
MM?:KXYZ\.M7*\;FT_3(8O&L,5_;:;=2:["FZ9GV.A6!A')M.Y8W8L"W'7KVK
MI_A[-%;ZGK6DC3XK*>W\F62.SO3<6GS!@#'D H3MR5(]#0!T.J>+-+TF#5I)
MGE<Z5''+=)&F2H?.W&< GCUK<KQ;QA8Z=#=_$EU6..\:QM63Y_G(;)<@9]0*
MZ:33['PCX[LO[/%Q#;W&D7DMXJR-(TS1-$5<AB<O\S<]3F@#T.J>G:I::K%-
M+9R&1(9Y+=SM(PZ,58<^A!%>-6$D4.H^#-1M(+.T;4+Z,>=_:CW%[=1.C;C,
M H7!R,\G!P!BNW^&%GI]EIVMQ6:1I*NKW<<J*V655F<(",\<=* .ZHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@,"" 0>"
M#2T4 92>&= CD62/0]-1U(*LMI&"".X.*LR:3ILVH1ZA+I]H][&,)<M"ID4>
MS8R*N44 59M-L;GS_/LK:7[0%6;?$K>8%^Z&R.<=L]*AM=!T>QN%N+/2;&WF
M7($D-LB,,]>0,UH44 %%%97B343I6@7-Z+N.T,>S]])"TJKEP.57DYSC\: -
M&&WAM_,\F&./S',C[% W,>K''4^]1BPLUMXK<6D AB8/'&(QM1@<@@= 0>:P
MM$\5?VOXLU[13:S1KIKHJ2-;R*'RH+98C;U/ [@9&1S5O6/%6EZ'>P65V]P]
MY<1M)#;V]M)-)(%(!P$!Z9_+)H NRZ/I<VH)J$NFV<EZF-ER\"F1<=,-C(JS
M/!#<Q&*>*.6,D$I(H8$@Y'!]" ?PKF[/XA>'+^>SCMKJ=TNY!#%/]DE$7FGI
M$SE=JO\ [).<\40>+[&TTYI[V^-W))?SVD$=I:2&1V1V&Q8P"S%0O+#CC/ H
M WKNQCNHYB"8;EX7A6ZC $L8;^ZV..<'Z@5S&D^";FVUNRU+4M1L[AK(N\2V
MFGBV,DC*4,DI#-O;:6'&!R34&M?$*Q3PW<:II-QD6>H6UK=_:+=T,0>1 X*L
M <A6/T-3ZE\0M.@\/ZW>V<5VU[IEJ;@VES9S1.P(.QMK*#L)'+=  <XH ZD6
M%FMO% MI (86#QQB,;48'(('0$'FHY-(TR9KEI=.M':Z 6X+0*3,!T#\?-CW
MI-)OQJFDVM\(Y(_.C#%9(FC8'O\ *P!'X]JY'P[\1K&ZM$35GECN6OYK,S):
M2?9T83,D:-)@J&*A>_?MF@#LK+3[+3+<6]A:6]K #D101A%!^@&*CN]'TR_N
M8KF\TZTN)X?]7+- KLGT)&1^%9&H^.M"TNYN8;B6Z9+1@EU<0V<LD-NQ .'D
M52JG!&>>,\XK17Q!IC#5#]I"C2^;O<I'EC8'!Z<C:<Y'% %_R(?M'VCRH_/V
M;/,VC=MSG&>N,\XJ.YL;2\:%KJU@G:%Q)$98PQC8=&7/0^XK%NO&^BVOD M>
M3/-;+=^7;V<LKQPL,AY%524'UP>#QQ6Y9WEOJ%G#>6DR36\Z"2.1#D,I&010
M T6-FL$,"VL A@8-%&(QMC(Z%1V(]JBGT?2[J^COKC3;.6\CQY=Q) K2)CIA
MB,BL>?QYH-M>/!)-=>5'<?9I+M;25K>.7.W8TH7:#D@=< \&C0_%7]L>*M?T
M8VLT:Z9(B)(UO(H<%%+98C&<MP.ZC<,@YH Z6L^'0M(M[]K^#2K&*\;):X2W
M19#GKE@,UG7^NRV7C6RTV1XH["33;F[F=Q@J8WC .>PP[9IMAXYT34;RWM86
MO4:Z1GM7FLI8DN0J[CY;,H#<<\=1TH UKS1],U">*>]TZTN9H?\ 5R30*[)]
M"1Q^%61!"+@W BC\\H$,FT;BH.0,]<9).*QX_%^ARC12E\#_ &T";#Y&'FX7
M<>WR\>N.>.M:%AJ=IJ8N3:2&06UP]M(=I $B_> SUP>,CC.: )%L+-(H(DM(
M%CMVW0H(P!&<$94=C@GIZFL;PYX0T[P_9P+Y%M<7L3RD7IMU67#R,^W/) &_
M'7M5#2_'MG<?\)%-J*R65KI-X8?-DMY%#)M3&21RY9B-HYP5XY&=?1_$^FZU
M=2VEN;F&[B02-;7=M)!)L/ <*X!*YXR* +4FAZ1->27DNEV3W4BE'G:W0NRD
M8(+8R1CC%68[2VA9VBMXD9U57*H 6 & #Z@#I6!KOBK^Q_%.@Z/]EFD74FD$
MDB6\C[ J\8*C'7&?0<G YI\WCC0H-0DM'N)]L4XMY;I;:0V\<I.-C2A=@.2!
MUX)P>: %UCPRVJS:;;"YBM]%M)(Y9+".V'[UHV#1C=G"J" 2NWG'45T-<Y/X
MXT*WU6[TUIKAKBS#&Y\NUD980L?F?,P7 RO3GG! YJLGQ(\-RO&B37K&>/S+
M7%A-_I8&,^3\O[S&1]W/'/3F@#=CT328KJ2ZCTNR2XD<2/*MN@=F!R&)QDG/
M>IS869MWMS:0&!V+O'Y8VLQ.XDCH3GG/K6$GBJRU'^QI]/OUCAO+U[5HYK9Q
M([HCEH\'!C8%<G<.V.XIEK\0O#MY<6T4-Q<F.XF^S1W!M)1"9LX$?F%=H;(Q
MC- &W=:/I=]<K<W>FV=Q.BE%EE@5V"GJ 2,XY/%%[H^F:E%%%?:;9W4<7^K2
M>!7"?0$<5CW_ ([T'3KFXBGENC':R"*YN8[25X('X^5Y I4'D9YXSSBHH/&D
M!\6ZYI-U&]O:Z9;13FZ>&14P0Y<LY&T#"C'K\V,XX .E%K;K+'*L$0DC0QHX
M0913C*@]AP./84LT$5S"\,\22Q.-KHZAE8>A!ZUC:3XNTG6;Q;2W:ZBGDC,T
M*W5K)!Y\8QEDWJ-PY'3U%0>+_%)\+PZ8XM99_ME]%;-Y<$DNU"?F(" _-CH.
MYZ9Q0!KV^D:9:6R6UMIUI#!'()4BC@555QT8 # /O3'T'1Y+J:Z?2;%KB=2L
MLIMT+R ]0QQDCZURL7Q$M+'6/$-KJQG$.GW2JKP64L@AA,2-OE900HW,W)QT
M]C6[J?B[2-+N([>1[BXG>$7'EV=M)<,L7_/1@@.%]">O:@#0N-'TR[NH[JYT
MZTFN(EVQRR0*SH/0$C(%-N]$TF_CACO-+LKF. 8A6:W1Q&/]D$<=!TJ>QO;;
M4K&"]LITGMIT#QR(<AE/0UP-GK?B+5]0UKR_%&C:9#9ZE-:107%EYCE4(PQ/
MFKUSZ=J .ZO=)TW4H$@O]/M;J%#E(YX5=5/L","K,<4<,2Q1QJD:C:J*, #T
M ]*Q[?6[>Q>PTW5-3AEO[F!YDG2$Q13A.6*G)48!!QN)QSTJ%_&NB+IMC?)+
M<3)J!;['%#:R/+.%ZLL87<5QSNQC!!SR* +B^&/#Z.KIH>F*RG(86D8(/KTJ
MS+I.FW%_'?S:?:27D0Q'</"ID3Z,1D5F-XST-=&CU3[4[0R3_9DC6!S,9N?W
M7E8W[^#\N,]^E+9^,=%O3;I'<2I-/=FR$$T#QR),$+['5@"OR@G)X- &R+>
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M=JJQ4,9'^\QP<KCY2><4 =G1110 4444 %%%% !1110 4444 %%%% !1110
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M;D',1#%F+[0 -HQN.>E=/X.TZ[TVSU5+R$Q--J]Y<1@D'=&\I96X]0:Z.B@
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MA3\O"J&C!#' 7@'/?K?#&CG0?#=CIKOYDT4>9Y/^>DK'=(WXL6/XT :U%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$?#NI16T=[HUE.EK&(H0\0.Q!_ /]GVZ5M44 58].LH;F*XBM(4FBA^SQNJ
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M?X<.G/I_]B6(LWF-P81" HD/&\#L>.HK1T_3K+2K)+/3[6&UMH_NQ0H%4>O
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M.;EXGB!4RDY+_P"][U!=^#_#E_?RWUWHEA/=3+MDED@4LXQCGU..,]<5MT4
M4)=%TR?5%U26PMWOUB,(N&C!?RSU7/IR>/>H-+\+Z#HES)<Z9I%G:3.NUGAB
M"G;G.!Z#/8<5K44 9^JZ%I6N1Q1ZI807:Q-NC\U,E#Z@]13].TC3M(21-.L;
M>T20@NL$80,0 HX'L /PJ[10!5.G61U$ZB;6$WIA^SF?8-YCSG9GTSSBJS^'
M=&DT5=&?2[0Z:GW;7RAY:\YX'8YYS6G10!C0^$O#UO!+!%HUBD4T7DRJ(1^\
M3.<-Z\\\UH3:?9W-W:W<]K#)<6A8V\K("T6X8;:>V1Q5FB@#)U3POH.MW,=Q
MJFD6=W,B[5>:(,=N<[2>XSV/%7DL+2.\%VEM$MP(1 )%4!O+!R%SZ D\58HH
M IZGI5AK-B]EJ=G#=VKD%HID#*2.0<&FC1M,6RNK,6-N+:[+&XBV#;*6 4[A
MWR !^%7J* ,G5/"^A:T83J>DVET85V1F6($JO]W/I[=*N1Z;8PW$-Q%:0QRP
MP_9XG1 "D>0=@]%RHX]A5JB@#'N/"GA^[U4:I<:/92WP8-Y[P@L6'0GU([$\
MBEU'PMH.KWJ7FHZ/975R@ $DL(8D Y /J >QK7HH KFPM#=F[-M$;@P^09=H
MW&/.=N?3/.*6SL[;3[.*TLX(X+:%=L<4:[50>@%3T4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9MQGC/3.:S;328]7^*]SK<5O>16EA;B.3SX6C2:[!= Z;A\VV-F&X<'<N.E
M'1^)]<?0=*CF@MA<W=S<16EK"S[%>61MJ[FP< <DGT%<YJGC36?#D6J6^L65
MB]Y!IDFHVLEJ[^5*J$*R,&Y!!9><G(/;%=/XBT*/Q!I8M&N)+::.:.XM[B,
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MIS8V-U]E$B+M&Z27<K!06X53R3R.*X^POM4O='LM-?5+ZW"^+WT]FBOFED6
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M1C@*H&23[ 55AUJPN-333HIBUR]J+Q5VG!B+;0V<8Z]NM9?C^!;CX>>(D=I
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M#>&YN [ZB+/;>"+<&\OCY=V!LW]<=JZR[\(^'K_49+^[T>TFN9,>8[Q@[\#
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MI.N>2=3L(;EH"3$SCYDSUP1R >X[TVW\-Z+9I&EMI=K"D=P+I$CC"JLH78'
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MM%*JL@D"?/M8 $%CR1@#@^E0:]HEW<>%SH6A?8;."2+[(_G1EEB@*E3L4=6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@O;N#3[&XO;EPD%O&TLCG^%5&2?R%3UB^*M#E\
M1Z$^DI<""&XEC%R<$EX0P+H/0L!C/H30!Q/@77+Z+Q#;#5-1,X\2VKWT,+3;
M_LLJL6\E1GY1Y3IQZQM6DOQ!U(V#ZNWAZ-=&AU!K&:;[;F7B?R?,5-F"N<9R
MP/7TR=#6? .ESPVD^AV.G:5J=G=17,%S!:*GW3\RMM )5E+ CWIC^"IF\$7/
MA_[;'YDU^UV)MAP ;KS]N,^G% $UWXUCL+7Q*]S9%;G1755@63)N1(H,)!QQ
MO8[<<X(/6NHA:1H(VE01RE070-N"G'(SW^M>?ZMIMOX@^*VG"T>4I81>9JR^
M61&QC8/;*6(P6WNS<9X%>AT <MXH\7/H.J:?ID$-D;B]21TEU"\^S0C85&T/
MM;+G=P,=C4MOXHN'O] LKK2FM9]5BN'=&G#>08@O (&'#;L@Y'&..P=XET74
MM5D@:TETZ:W",D]AJ5MYL$N<8?CD,,$=P036):> ]0T>PT)M*U&U^WZ5)<L%
MG@;[.RSG+(JALHJ\;>3T]Z +D_CEP]S:VNE^?J U=M*M8#/M65EC$AD9MOR*
M%)SPQX[YK*\2Z_XACCT99=(DMK^/788/*@NR8;M6BD(Q(54[<XR"O&WH>*M0
M>!-3@A>[_M>W;64U=]5AG-N1%EXA&\;)NSM(W#@Y''7'-Q_"^LZA<V5[JNK1
M23P:G%>^3#&PAB1(W38@))R2^XL>OI0!H>'M?O-3U'5-+U/3XK/4-.,1<03^
M=&Z2 E65BJG^$@@CM6[+((H7D*LP12V%&2<>@K)L-$>S\4:SJYF5DU".W18P
MN"GE!P<GOG=^E:\J&2)T5V0LI =<97W&: ..\*>-KOQ/-:R)IUE]AN8R_F6N
MHB:6V(&0L\>U=I/3@M@\'UJ:W\;?:/"N@ZW_ &?M_M6[@MO)\[/E>8^S=G;S
MCKC S5'3_ ^HCQ'IFJZG<Z6TVG%R;NSLS%<WF4*?OFSC'.2!G)':H+7P)KD%
MEI&D/J]D=)TG4(KN#;;,)I523>$<[L# )&0.3@\<@@%RP\=7>IZ[-9VFF6DM
MO!?-9S1C4 +R/:Q4RM 5'R<9^]G'..U,G\<ZLD>MWT'AY)-+T6YEANI3>8ED
M6/EFC39@X4Y(+#T!-1ZEX%U+5M2C:]O--EABO5NHK\V>+Z-%<.(@X(&.-N['
MW>V:SM.T+Q!J\7BW38K^WM-+O]6N8IO-MV,RQL%#&,Y .X' )'!R>>@ -C4O
M'^S5Y]/TB#3K@VT$<TTE]J(M0WF+N5(\JVYBN#DX R.:;!X^N=9N=-M_#VCI
M=O?Z=]O5[JZ\E(E#[&5L*QR#QQGGVYI+[P-/!K-S?Z+_ &25NX(HI8=2M#,(
MFC78KH00?N@ J>NT<UI:/X4DTK6[*_:]6<6^E_8&_<K&7<R!R^%PH'!X H R
M)/B0QT[1WCL+6VO-1DN(674+[R8(9('V.IE"-N)/W0!R,GBKTFNR37OA5[_3
MY[.XN[F=#&EYE(]L,AW':,2J0N1G'4'J,57'@S5+328K.UO=/N8Q<W4T]G?V
MOF6\ZS2M(N>X9<XST.3Q1I'@!M,CT-3=PLNGWMS=R11Q%8_WR.OEQKD[47?P
M,GI[T )#X]OFT^UUZ;0UC\.74R1QW7VK,ZH[A$E:+9@(21T8D YQ45W\0-3@
MM=6U)/#T;:3I%[):74S7N)&".%+QILP< @D%AW SUI8O VKC2+3PU/JMJ_AV
MUFC9<0,+F2*-PZ1,V[: " "P&2!T&:N7/@J:?PGXCT47L8?5[NXN%EV'$8D8
M, 1GG&* .QKE_%/BU]!U/3M-@ALC<7RR.DNH7GV: ;-OR[]K9<[N%QV-=0!@
M 5SOB71=2U62!K.73Y;=49)[#4K;S8)<XPW'(88/J"": .?U?7=<DUWP;+:Z
M9)'=W:W@DT^2\"QY"+AG=005'+ X)Y' )K4M/%^H7.BWTPT/.J6-^;":V6Y'
ME*^%;S#*5&(]K@D[<]L5!H7@1]%D\/L+V-QIC7;O&D95,S\[8QD[47H!D\5#
MJO@&XOK?4%2[MG-QK:ZJ(+F$O#(HB1/*E7/(^7=]<<4 9.N^-;O4?#7B.Q(M
M[74-.^R/Y^FWWGQLLDP'#A5*GY2""._O74^%[F>?Q%XNCEFDD2'4D2)78D(O
MV>(X4=ADD\>M8<GPZO[E-:,M[I\)U.WMHA#:6ICB@\F4O@#/((/7CGVXKJ]&
MT1]+U77+QIED&I7:W"J%QL B2/!]?N9_&@"_J5Y_9^EWE[L\S[/ \NS.-VU2
M<9[=*Y/3?&^HSW&AR:EH<=EI^MH3:S+>>9(A\HR@2)L  *J<8)]\5U>J69U#
M2;VR5PC7$#Q!B,[=RD9_6L)O"3O:>%+=[E&71-OF_(?WP%NT)QZ?>S0!GP>/
M+Y["SUV?0UB\.7DR1QW7VK,Z([!$E>+9@*25Z,2 <XJSX/U/6;_7?%$6HI%]
MGM=1,4!6X+E!Y49"!=@XP=V<]6(QQDTH? ^K_P!DV7ANXU:UD\/6<T;KM@87
M,L<;ATB9MVT $*"P&2!T&:W=%T2]TGQ!K=R;F"2PU*<72Q^61+')L1""<X*X
M3/3/- &Y--';P23RL%CC4N['L ,DUR6F>+]5O(++5+CP_P"1H=ZADCN4N=\L
M,>TLLDL>T!5('9FQD9KK+B".ZMI;>5=T<J%''J",&N/T[PIKL%E8:+>:S ^B
M6*>4!!"R3W,00HL<AW%0 ",X'.!TH ;:^.-0:WTS5;W0EMM#U.:.*WG%WOFC
M\TXB:2/: H8E>C$C(S5<_$'4A93:L?#T:Z/;:@UC/,;W][Q-Y7F(FS!7.,@L
M#U'.,F6V\&:RUEI.BZAJUK-HFES0R1^7;LMQ.L)!B1SNV@ A<D#G;VS5B3P5
M,_@J^T'[;&)+F_>[$NPX4-<^=MQGTXH BO/'5VOB2_TJPTRTN6L)$CD@EU 0
MW4VY5;=%$5PR@-U+#)!K)U7Q!JT%[X_%_ 7TS3[.-XEM[YHY%!C)&TA/E+#)
M)SE2 .>HT?%'@C4O$<M[;RW6ES65T08IKNRWW-CP 1"X([@D$\@D]:?JW@B_
MOI?$D4&HP+9ZW8);MYL;-+'(B;%;<#@@@Y/&<T 9]UXOUG1==\77<]I%<:;I
M>G6T\4/VL@C(D(P/+ZMCDYXVCKGCI]>\0W&GZE:Z7:6B2W%Y975Q&[S;%5H@
MF ?E/7?U[8Z&LO5_!%UJ=[KBB_ACL=9TV.SG4Q$R1O&'".IS@CY^01VZU);>
M&=>N_$%CJVN:G8R&TM)[58;2W9 ?,V9?+,>?EZ=!0!C:/XZO[3PAX7CO8K2;
M6-4M?-22ZO\ RHC&J*3+(Y3*DEA\H#<GKQFNL\+>)H_$EK=DQ1Q75E<&WN(X
MIQ-'NP&#(X W*0P(. >H(XKFH/A_J4.E:$K76EW%_HL3VD/GVC-!/;D*,.I8
MD.-H.X'\.:ZCPSHMSHUG<"\FM9+BXF,K+:6RPQ1#  10.2!CJQ).3]* +VL:
MI;Z'HU[JEV6^SVD+32;1DD*,X'O7%/K/B*Y\:^$8]2TP:;;W)N9-L%Z90P\A
MB$E&U<,.#_$/?BNSUO28-=T.^TFZ+""\@:%RO50PQD>XZUSEKX;\13:]HE_J
M^K6,T6D^:%2WMF1IR\93>Q+'!Y' XZ^V #'TWQZ;?1O#UI96ENLU_9M<HVKZ
MH8UPK[=@E*,9)#G.,#BM^?Q5J+RZ7I]CH@.L7ULUU);75T(X[:-2 2SJK9RS
M # .>O%9L7@?5;+P_I6E176E7]O:VQMY[34K/S()&W9$BX.0PSC!R"/2GV'@
M6_T"VT:;1M2MSJ&GVTMK)]JA8PS12.)"H ;*!6 V\G@8- #Y?$TZZOI<E_I%
MU9WHLK^1X#=GRP83'G@#$@;(*N<8&>.33M,\;:E.FAWFIZ%'9:;K3)';2I=^
M9)&[H602)L  ;!P03VR!GB.\\*ZDD::I?ZK]MNK:QU!90(R S3A"%C&3M5=F
M #DU4\*^'=;U+0/"3:S?VS6&G06]W%#';LDSR"+""0EB!LW=AR0.G2@"IX=U
M^2WTOPU)=?:[JXD359 [7; $12,<.N#OXP!G[N.*V-*\<:E>/X?N+[08[33=
M=PMK*MYYDB.8S(N]-@ #!3@@GMD#. VT\!3VUIH\)OXV-A%?HQ\L_/\ :22,
M<\;<_C6@GA*5-)\(V7VM"V@O"SML/[[9 T7'IDMG\* ,[5/'M[H]P);S2;2"
MP-VML$EU +>,K2!!((=F"O.<;LXYJ6;QGK3WVNQZ=X;2ZMM&>2.65[W8TK"(
M2 (NP\G./;(Z\XQG^&6HG3)]-2\TE4>[^TF_-D3=W'[[S0LC[O4 9'4 <"NP
MTW34\.OXAU&ZN5:"[NVOF(0_ND$2*0>N?]63QZT -MO%4&H:IHUI80^?'J-D
MU^TN_'DPX7:2,<EF8#&1T/I705P/PRT5+2WU/54,K6UU</#IOFH59+)'=HP
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MU+3K6PU[4/$NI7"#3VTQ+.:(QEL 2.Q)QG((?&,5F_"[1)=+\,M=7+3-->R
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M.H;(W<]<=AZ4 >UT5Y7K6K:KX.7Q=:V&HWEVMMIUK=6K7LOG- \LCQL0S=0
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M'17G'A]KG4]"L?%=]XHO+*ZGO3OB>3-L%\XQBW\K@9(PN[[V[G/:LV6_U1O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \N^)EE>64>IZ_J'C"_TVQAM@
MFEV6GS&%GN<<;\?ZS+=NP],9JCXSU+QY#\);6Z$L5C*FG)-J5WN*7&\D#8@'
MW6.<L>,<@5I^*O /BC7/',/B&TUO3DALU"V-M=6QE6$X&7QT+$Y.?IZ"NBU[
MPWJGB+X=W.@7U_;MJ5S (Y;I8RL98,#D+V'% &UH4CR^'M-DD=G=[6)F9CDD
ME!DDUH5A/IFLP6NA6VG:C!!%9F-;T/%N\^-5 *KG[I..M;M !0>!FBB@#PW3
M9/\ A,/#FH^-_$_C#6-&L3=/#9Q6%P8H[9 P52P4$LV3_GMUV@^*[VU^'=O>
M6=R/&%W%/]E-Q#_HZGOND9^@4$9;'I[FJX^'_B;P_<7\/A'7K&#2;Z=K@V=_
M:^;]G=NIC/<=, ^G?K567X0W,'@VQTBUU>&YN;?4_P"TIA>V_P#H]RY&"CHI
M^[P/7OZ\ $Z_&%4\,>(-3N-%47>B3PQ3V\-\LL<GF-M!655P>_&.WY6[CXCZ
MQ =-LF\(2C6=5F<65@U\@W0*H8RNX!"<$_+R?E/-8\WPCU.XT/Q58OJ6G1R:
MX]K(OV>U,44!B;)4("?E[#GMSUKJO%OA#4-5U;1-=T._@M-7TG>L9N8R\4J.
MNUE8 Y^F/4_4 '&Z#\0;C1I?'NL:]'? 6EY!%#ITD_F&*1@P\M#G: 3SD<8Y
MKH+/XH/LUF#5-%6SU+3M-?4TMXKY)TGB4'($BC ;/!&/>L]OA+>:AI7B>VU?
M68IKK6;B&[2XCM\"*5,GE">5YQC/3WJS8?#?41I^N)>R>'[::_TZ2Q@32]+2
M!(RRX,C/C>2>,KG'Z8 )M*^)]W>:GX=COO#,UCI^OK_H=T;M9"7"@X* 9 YX
M.>1SCL)?C)J5]I7@47.GWD]I/]M@3S()"C8+<C([5(? -R8/ T?VZ'/AO;YI
MV']]A%7Y?3IWK1^(?A.Y\9^%CI-K=16LOGQS"252P^4YQ@4 =#J>HV^D:5=Z
ME=L5MK6%YI2!DA5&3CWXKA/#WQ3.K:OI5I?Z)_9]OK"LVGSB]28O@;@)$49C
M)'3KUQ5R+PYXQU2"[T[Q-K>F7.E7=M)!+':6ACD^92 0Q/;.:RO"OPRU#1-3
MT]KN?03:Z=&R1R6>DQI<W!QA6DD8$JPZY4Y/<F@":;XHWECXAL+#4_#1LK2^
MOA90R/?QFX!8X5V@ R%/KG^8S/<?%*"ST'7[RZTMX]0T>^%B; 3;FG9B A5M
MO1N2..BFN=L?@[J]JFFPMJ6D,FG:HE^MRMFPN;O#EL2R9]R !G]*Z36/AI'J
MOQ*LO$_VL)9QF.:ZL]I_?SQ!A$_IQN'Y>] $6N?$^?3-7NM,L]!6]N=.M4N-
M2#7Z0B'<N[8FX?O&QSQBNUT36+77]$LM6LBQMKN)94W#! /8^XZ?A7!>)OAE
M=ZAXJU#7-)DT5FU*%([A-5L!<^2RKM$D6>AP!P1CCG/;OM%TU='T6ST]6C?[
M/$$+QPI"K'N0B *N3DX% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:EJ#7MM;VMA=/!)(\PQM#%5?/8-C(%:<'B?0[G2Y-3AU6T:RC<1R3>:-J,2
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MM+N_GM+EY9QBW6-965B>F6$:G'^UWH [ZBLJV\2Z'>:3-JL&JVCV$)(EN/-
M2,CJ&)Z'D<'U%2Z3KNE:[#)+I=_!=K&VV3RGR4/8$=1^- &A165JWB71-"DC
MCU75+6T>4%D660 D#J<>GOTI=0\1Z+I,,,M_JEI;QSH9(FDE $BC'*^OWEZ>
MHH U**PH?&?AFXN+2WAUVPDEO,?9T6=29,D@ >Y((QUR*?)XO\.1:@+"36K)
M;KS3"8C,,A\[=I]#D$8/4T ;5%8,'B-#XAUVPN_)M[72X+>8W#OM&) Y.[/
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MT@_UHZI[L/0<U<T_4;+5;*.\T^ZAN;:3[LL3AE/8\B@"S1110 4444 %%%%
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M0O<L _V1_*9S/O%SYV-F,8;.[.1C%>OT4 >4:Y;7C?\ "::<NGWSSW.J6%Y
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M947<9I$5O-=0.I<B(<?W3731Z.T?BGP-(NGLL-EI=S&SB([86V0A03CY3]X
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MB8$S)<2,Z GY2VSC!]1G@UZA10!Y/';3ZQJ3W<5SK]^]KI-U$7NM-2T2,N@
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MNY?,D;))Y;OC./H*\OTFZU2U\#>'O%)\0:A>:A<WEO#+!)-NBF2281F,)TW
M$G=][*GGM0!ZY2$A5))  Y)/:O'?%FMZDFG^(=;TJ\UZ8Z?<2".\2>.WLH#&
MP4Q^46S+@@@DKR3P170&SO=>\6^*DN-;U."TL!"+>VM9_+3+VX+;L#)YY ['
M)[T =[:W5O?6D5U:S)-;S*'CD0Y5U/0@]Q4U<G\,K<6_PVT "6:3S+**3]ZY
M;;E!P/0#L*Y*6_U1_ %]XY_MR^CU.&:61+02_P"C*$F*" Q=#D#&3\V3G- '
MHJ>(=,D\02:''.[ZA$@>2-(7*Q@C(W.!M4D<@$YJX]]:QW?V1[B,7'E&;RMW
MS>6" 6QZ9(%<9X0T\0^/O&=Q]IO'(N8!Y<LQ9?FMXVY'J.@]!Q3=0L _Q=%Q
M]IN@1H,DFQ92$.)57&/3G./7!H [33]0M=5TZWO[*436MQ&)(I "-RD9!P>:
MLUY!X8@O=$\)^ =3AUG4)&O9K>UFMI)<P&)XVPHCQ@%<+ANO'.<U7MM:\57V
MBMXEB34DN?MC%7EU*WBL503%/):)G&.!MR1NW<YH ]GHKF?B%?7>F^ =8O+&
M=H+J*$-'*AY4[AS7+:S'J^G>(M-\-6MWKVI02VLU].\=]'%<3.&1-HD8KM1<
MD[5.?F':@#T^BO*CJ'B*30M.L;C4;FTF/B1;#SEN8I;C[.48[)&0LN\9(YYX
M!(IEY::G!'XXAC\2ZT(]"A%Q8?Z3EE<V_FG>V,R+D<*W&": /6*K-J%JNIII
MQE_TMX6G6/:>4!"DYQCJPXSGFO--4U2]UB:\:VN=>N);6PA>1=.GCM+>SD:+
MS"7=G!D)!!Q@@# Q1;^)-7NM/TVYDOI1)/X-GOI-AV@SCR\28'0\G\Z /5*J
MWVI6FFK UY,(A/.EO$2"=TCG"KQZFO/+*35-(N/!NH'6-2OY=6A<7D%Q+NCD
M/V5I1L7&$(90!CMUS68UO<WWAKP9XBN]=O;BZU#5K&:>"24& L[YV(G1-G3C
MG@YS0![!17C4NL>*-0LM9URW74X[BUOIX[>0ZC;PV4"Q2%0DD;N,@@?,6&?F
MR,<5UFBQW^K^/]>GNM6OX[;3IK<06,4P$.7MT9@P ^89.0,XSD]Z .YJCJVK
MV.A:=)?ZC/Y-M&5!;:6)+$    DDD@8 KG_%$UU=^*M T!+ZXL;2]2YFGDMG
M\N24Q!-L:OU7[Y8XYPOUKB]>2YN5O-$N-5O[BWTOQ#IT=O<&;$FV5HV*,P^\
MR$\$\C(H ]774K1M*&IO+Y-GY7G-).IBV)C.6# %<#KG&*2/5;*;4O[/CN U
MU]G6Z\L _P"J8E0V<8Z@U@?$&U!^&&OP>=/B+393O$AW-M0GYCWSCGUR:YNV
MT WOCRVL_P"UM3@AC\.0,SP7!660F:3&9.N!D\#V]* /3Z*\@C\0^(-0TKPG
MI@DU"Z:\-]]IDM)XX)[@6\A11YC%0./F;!!./K79>!KG5FCU6SU3S2MK=!;<
M7%U%/<(A16V2F-CR"3C/)!% '6T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5=0TZTU6QDLKZ%9K:3&^
M-B0#@@CI[@5:IDLL=O"\TTB1Q1J6=W8!5 ZDD]!0!6FTNQN+\7TULDER('MM
M[<_NF(++CH02H_*L_2O!^@:+>+=V&G)%.B%(V+L_E*>JH&)"#V7%36/BC0=3
MMKFXL=8LKB&U4O.\<RD1+C.YO08!YZ<57_X3;PN3<@>(--/V8!IO])7Y!G'K
MZD#ZG% $ECX3T+39(7M-/2(PW#W40#L1'(ZE6903@9!(P..>E-M_!WA^UU4:
ME!IL:7*R-*OS,41VZNJ9VJQR>0 >34S^)]!CTVWU%]8L5LKC/DSF=0DF 2<'
M/)&#Q[51U'Q?91Z7I^H:5-;ZA!=:E;V)>*7(7S) A/'<9SB@":#P5X=MM374
M(=+C6X24S(-[&-)#U=8\[%;D\@9I?&.AS>)/"M[I,#0K)<>7S-G9A9%8@X![
M ]JGN/%&@VFK+I5QK%C%?L0HMWG4/D]!C/4]AWJXNIV+Q7<JWD!CLV9+EA(,
M0E1N(;TP"#SV- &9:>#O#]C!>0P:<@2\A-O/O=W+1$$; 6)*KR?E&!277@SP
M_>W2W$^G*T@B6%L2.JR(OW5=00' ]&!J2\\7^&]/V?;-=T^ N%91)<*"0PRI
MZ]".<U/9^(]%U#4Y=-L]5L[B]A!,D$4RLZ@<'@'MW]* *DW@SP_/86=DVG*L
M%D&%MY<CQM$&ZA74A@#Z9Q3[GPAH%UI]G8OIL2066?LPA9HFASUVLI##/?GG
MO4UEXFT+4=2DTZRU>RN+R/.Z"*=6;CKP#SCOZ5&_B[PY'J"6#ZYIZW;R&)83
M<+N+ABI7&>NX$8]1B@"[IFEV.C6"6.G6R6]LF2$3U)R23U))Y)/)JC=>$]#O
M;Z\O;C3T>XO$1+AM[ 2A"I7(!QD%%YZ\8Z5%I/B[3M8\2ZQH=O+$;G3&56 E
M!+\#<0!T"DA3[UOT 4YM*L;B_%]-;))<^0UMO;G,3$%E(Z$$@5GZ7X.T#1;U
M;NPTY8IT0I&S2.XB4]50,2$'LN*W** ,_6=#TWQ!8BRU2U6XMPZR!"Q7##H<
M@@\5EV?@+PU87(N+73FBE"LH<7,N0&4J>K>A-=)10!F1^'=(A33%BL8HQI8(
MLMF5,(*[2 1V(Z@]>]5+3P5X=L=22_MM+CCGC=I(QO8QQN>K)&3M4\GD =:W
MJ* ,-_!WA]]6_M1M-C-T91.3N;891TD*9VE_]K&?>H;SP)X9O[RXN[K28I);
MEM\P+N$=L8W% =N[_:QGWKHJ* ,:]\*:'J%Y>7=UIZ23WMO]FN6WL/-CXX8
MX/0<]?>K=UH^GWM_8WUS:1RW5@6-K*PYB+##8^HJ]10!AZKX/T#6[QKO4-/6
M6=T$<C+(Z>:HZ*X4@./9LULQ11PQ)%$BQQHH5$48"@<  =A3Z* ,&#P7X=MM
M3748=+B6X64S)\S&-)#U=8\[%;D\@ U;?P]I,FFWFG/9(;2\E>:XBR<2.S;F
M)YSR>:TZ* "N7N/AUX2NKJ2XET2 M(^^2-7=8G;U:,$(3]17444 8VH>$]#U
M.2VDN+!0]M'Y4+0.T)6/^Y\A&5X^Z>/:G67A;0]-:V:RTZ&#[++)- (\@1NZ
M[7(&<#(XQTK7HH PM4\&^'M9O)+O4--CFFE4)*=[*)0.F]00'QVR#CM2ZAX/
MT'5!;_:K %K:'R(GCE>-Q'_<+*02OL216Y10!GP:'I=M+8R064436$30VNP;
M1$C8W* ..=J_E4UGIUIIYN3:PK$;F9KB;!/SR-C+?H*M44 <YJ'@3PUJNI3Z
MC>:8)+N<J99!-(I? "C(5@.@ J2\\%>'K^.V2XT\'[-#]GB=)I$<1?W"RL"R
M^Q)%;]% &'=^#] O%M!)IR1_8XO)@-N[PE(^/DRA&5XZ'BI(_"NA1:)<Z+'I
MD":;<EFEME!",6QG [=!TQ6Q10!G:AH&E:IID6G7EE'):1%3$G*^65X4J1@J
M1V((-+I&AZ;H5O)#IMJL*ROYDC;B[R-ZLS$LQ]R:T** *CZ792:@]^]LC7+P
M?9F=N=T62=I'3&2:SM+\':!HUXMW8:<D4R*4C8NSB)3U"!B0@/HN*W** *VG
M:?::5I\-A8PK#:P+MCC4DA1Z<U2OO#&C:C?RWUW8K)<S6S6DK[V7?"P(*L <
M'ACUY&>*UJ* *3:38M-83&W4R6 (M6R?W65V''_ >.:SK7P5X=L=22_MM+C2
M>-VDC&]C'&YZLD9.U3R>0!UK>HH AO+2WO[*>SNHEEMYXVBEC;HRL,$'\#5&
M/PYH\4^ES1V$2R:5$8;)AG,"%0I _  <UJ44 9S:%IC6>HVC6B&#4F=[Q,G$
MI=0K$\]U ''I5/4O!V@:O,DM[IRO(L0AW+(Z%XQT1MI&]?9LBMVB@"@NBZ:M
MS'<+90B2*V-FF%PJPD@E O3'RCMVJCI?@WP_HUZEY8:<D4\:E(F,CN(E/41A
MB0@/HH%;M% %+5=(T_6[+[)J5JEQ!N#@-D%6'1E(Y4CU!!JE;^$M"M;%K*+3
MT$+3I<ON=F9Y4(979B2S$%1U)Z5M44 %<9X/^'FF>'M,TTW=I!+JEHI)E1W:
M,2'/SJI^4-@XW;0:[.B@#G+KP'X8O9KJ2YTJ.3[6S//&TC^6[MU?9G:&_P!H
M#.><UKVVEV5G<75Q!;JDMUL\]LDF3:NU<Y] ,5<HH H:/HNG:!8_8M+MA;VV
M\N(PS$ GTR3@>PXJA)X+\.RZH=2?2XC<-,)V^9O+:4?QF/.PM_M8S6]10!6M
M]/M+6\N[N"%4GO&5[AP3F0JH4$_10!^%5[S0=,O]3M=2N;57O+562&8,RE5;
MJ#@\CV.:T:* ,U- TN.PT^Q6S06VG.DEI'DXB9 0I'/8$]:IOX*\.R:H=1;2
MXS<&;[01O;RS+_?,>=A;ONQG-;U% %74=.M-6L)K&^A6:UF&V2-B0&'7M5?5
M_#^EZ\D*ZE:B5H&+0R*[1O&2,':ZD,,]\'FM*B@#)M_#.C6ME9V<&GQ1V]G.
M+F!!GY9>?G)SDM\QY.<YJ:31--E_M+?:H?[30)><G]\H39@\_P!WCBM"B@#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D1^*=
M EU<Z3'K-BVH!BGV<3KOW#JN,]1Z=:T)[VUM9[:">XCCEN7,<",V#(P4L0!W
MX!/X5P-S8V.KRV?A+PU:A=-TN_CN;Z^R66!TD\PQHYR6E+?>.3M!.>3BI_$F
MBVMO\1/"FK[IY+NXU"2/=)*66-!:R_*B]%!(R<=3UH [QW2.-I)&544$LS'
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MY;+(><\ 9H ]#HKRJ^U[Q#?:MKT5G-KJ#2I?LMK]AMK=XF=8U8O.7Y.2W08
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+H-C<K/;:5:RW$YE\C3+98HHEP %R%!<\9W$9YZ "@#H:*** "BBB@ HHHH
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MY8/+<6NJV2V]U K _>*@*ZD@X('&#R>* .GN=2LK.*62YNX(DB9%D9W V%B
MH/IDD >N:M5XOXCL[N./XAR)J4TC'4]/5(Y4CV!F-LRL=J@G:,*.>@YR>:W=
M9\0:WX*O=7CEU276(X]$?4(A=11J8YED5,#RU7Y#O!P>1CK0!Z767J_B31-
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M)KB[N7ED\D@_(K$_*.2>._)JZ_A[3I#I9>$M_98(M@6. #&8SGU^4D<UJ44
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M);.$-=:E/9&YWRE0T<,JDX]/EW=*N1^!M$^S7\-TES?&^A%O/+>7+RR&(<A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR!\I.&((!P0*V/!_AJ72+Z_OI=(TK2Q<*D<5M8DR,%7))>0JN[)/  P,=\T
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M#R1DD8 ^M<M:^*?%-UX>U 6XO;B:QU<6LUPE@HNUMC$K[A <*7!8#&.G.W-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV:PB!8AT$8&W;],<5S=O\/=,@&FH]_JL\.F31RV,,USE("GW0  ,C''S9..
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYK?HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP9MXW9..#UR,=U10!RVI^&;F;05TB*^NKV&XO87NWO9@S>0&4N@( X(7&/\
M:-.\0Z=>SZBTT&@:7JD4MFUOF<A)8V))PS$',9SR!R".^>.GHH \WN/ASJD6
MDVD=KXANWNT.GI+N2(KMMWC)*ED+#&UG"YP6/.<FIM0\(ZE/K%Y*+*VGNY[V
M*>VUMY0)K2)=F4 QD8VN JG:V\YQDUZ%10!3L+N>[^U>=:-;^3<-%&2V?-48
MPXX'7)_+J:YK0O#5_HVKZC=.L4]O:Q21:/"'VX21S*ZL<?+\VQ!UPL8KL:*
M*-\VJ'1V?3X[9=1V*RQ3L3'G(+*6'/(R V.#@X/2L7PMHUSI^IZK>M80:7:7
M?E>7I\#AE5UW;Y3M 4,VY1Q_<!/)KJ** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>guyaragreement013.jpg
<TEXT>
begin 644 guyaragreement013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]S>2 E((FE8#T4$G^5<%8S?9O#?@Z]O;=+F]UC5(KJ:1G8;)98I'W#!YVKA
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M8J2K=U.,@^A% &Y17.Z_KFH6VL:;HFCP6SZA?)+,9;HMY4,4>W<Q"\L274
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MYK#7XB7T.M:;;74N@M]LODM)-.M;HRW5KO8JK.RDJ2#C(P.O!- 'I%%>>?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]0TUPTKVH>:16P[Y(PK%QG.,^@KU:?1-+N8;V&?3[:6.^8-=(\8(F(  +>I
M4?D*AL/#.AZ7%/%8Z39P)/'Y<P2(?O5YX;^\/F;KZF@#C-!M]3T[Q;:V3[[*
MRN[*8SV\^MO>22$;=LR;AE2,D$@X.X<<5WVFV\5IIMM;P3RW$4<85)I93([@
M#J6/WC[U1T[PKH6CK/\ V9I5I:-.GER-'$ 2O]W_ '?;I5O2-,AT;1[/3+<D
MPVL*Q(3C) &,\<4 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;-"RQ2;2KVZ;B,,0Y+<9Q@YKT"BB@#D9_!)G\.ZOI/\ : ']H:F;_P WR?\
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M.68E^!CG ]#78T4 <DOA?6K^-[?7O$ N;7['+:+%:6Y@\WS%VF27+L&8#H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBJ%UXKOD\6W>C6FD1RVUC%#/>7LEUY8CB?=DA=I)8!2<9YP>10!U5%>?Z?\
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MD$T6IB,6[3>:L0$$7"'CY2<L.!][H#0!V-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63XFL-3U/P]=V
M6CWZV%[,H1+EE+>6,_,1@]<9 /;.:UJ* .5\)Z)KF@Q16%Q)HBZ9$A"Q6-K+
M&Y;^\6:1LYY))Y)[UHV>BO:^+-5UDS*R7MO;PK&%Y4Q&3))]]_Z5LT4 <9XF
M\-^)/$.B65BVJ:<NV=I+U&@D$5TFX[(R%<-MQC<,\D>G%:5C:>*(=*D@FN]%
M2=6C%O\ 9K21(TC!&Y2I<_P\#!&/>NAHH XGQ1\,M"U^RU P6D=OJ-XXD:Y+
M.1NW DE0V.0,5U]G9P:?9PVEK'Y<$*A(TR3@#MD\U/10 5P_A[P3J&DGPZEU
M?VTT>ABXBB,43*9(I%"KNR3AA@YQQTKN*AM+RVO[2.ZM)XY[>0926-MRL/4'
MN* .,U'X?O>_;YUN[?[4^L#5;7SH/,C!\I8C'(N?F! ;IC&0>U:WAK0;S2[J
M\O+Y].62X"*EOI]J(HHE7/?[S$D\YXX&!71T4 <IK?A_7)O%EOK^B7VGPRQV
M+V;QWL#R AG#Y&UEY^44L^E^+M2T>\L+[5M,@>X*(+BPMI$>.,D^9C<[?,1@
M \8Y//%=510!PS_#J)=$U;P]:W@@T2Z\N:S@*;S9S*P8XR<,A95;:>Y;UHA\
M#W=\+R+67TF&VGLI+/R=+LA%N+C!D9FR00.BCCGG-=S5:RU"UU!)FM9/,$,S
MP2?*1AT.&'(YP>_2@#F(O#7B&^MUL-9UNW:PCM);7;9PLC7.]-F^3<Q P"3M
M'<YSQBJ^F^$M?74?#DVJ:K826^A;DB2WMV5I@86C#,2QPW(X''7VQW%% '#Z
M;X)U"SATBUFO[:2WTK5I;Z I$P=XW$ORMDD;@9>HXP*O:?X,6Q\<WNO_ &K?
M;2JSP6FWB&:0()7!_P!H1K^;>M=510!YY;_#R]L4_LVTGTA-,%R95N'T\/>)
M&7WF,,<J>I4,1D#M7;:M:75]I-S;65ZUE<R)B.X"!]C=CM/!'8CT]*NT4 >=
MCX=W=S_;<\[Z38W&HZ5+IVS3+9HXF+_\M9 3\S#H/0$\G-=!J/AB6^O=$G6\
M\G^SH)X6*#YB9(@@93V(QFMJPU*TU.*62SF$J1326[D C$B,58<^A!%6J /-
MM.^'&H6D>APM-HT,>DW<4[26MD5EO-F06D<GAB"3WR3G-;&F^"IK&\TB=KV-
MQ8:C?7C (1O%QYF%'/!&_P#2NQHH P_$FA3ZNNGW-C<QVVHZ=<_:;:25"Z$[
M61D8 @[65B.#D<&LF[\*:WJEO]KOM9A&K0WL5Y9B.%C;6Y12NS:3N8,&;<<@
M\\8Q7944 <'J/@?5->BU6YU;4;0:C>6T5I"+:)A%!$DHD/4Y8L>_'05MZMX:
M;5/$"Z@;D1Q?V7<6#)MR<RLAW?AL/'O70T4 <19^#-2%OH:WM]:-)I>G7.GY
MAB91(KK&B-@DX($?/KGBKL?A*5-'\(V/VM"V@R0N[;#B;9 T7'IDMG\*ZJH;
MJ\MK*)9;J>.%&=8U9VP"S$*JCW)( ^M '!MX$US^S%T--7LET>'41?0_Z.WG
ML/M'G>6QW8P"3R!S@=.:EOO E\NHZM)I<ND"#5)C.\E]8^=-:R, &,9SA@<9
M ;@'UKL[74K2^N;RWMIA)+9RB&X4 C8Y4,!SU^5@>/6K5 $-I;BTLX+96+"&
M-8PQ &<#&<  #\!BN%TSP-K6CVNE/::G8&^TGSH+=G@?RY[:0@E)!NR'#*"&
M7CCI7H%5K_4+73+4W-Y)Y<(=$W;2WS,P51@ GDD"@#+\-Z%<:5)J5]J%U'<Z
MEJ4XGN'BC*1KM0(J("2<!5').3R:(/#P7Q%KFHSRK)!JEM!;F$ @J(Q(#D^_
MF?I6[10!P&C^ M0TQM-LC<Z1_9^GR*RW$>GJ+N=$^ZCL<J.V6 R<=B:MV?A7
M7M-B_LBPUFW@T07;7"LL+?:D1I#(T0;=MP22-V,[3C'>NTHH \]/P]O;=KNR
ML+C2$T^YNGN!<3:>)+J .^]D4GY6Y)P6' /0XK9F\&QW0\517$ZF#7-FT*N#
M#M@2,'Z@IN'X5T=Q>6UJ\"7$\<33R>5$';!D?!.T>IP"?P-,L]0M=06=K63S
M!!,\$GRD8=3AAR.<'OTH Y$^ &F\%1Z1<WZ2ZHMY_:+WKPAEDN=^_<R$\J<[
M<>E:'AWP]?Z?JD^H7[:7$6A$,=MIMF(D7G)=F/S$G@8X  [GFNGHH P-9T2]
MO/$FAZQ8W-O&VGF6.:.:,L)(I=F[:01AALXSD<UFP^"IHO!VD:&;V,O87T-V
MTNPX<)/YN ,\9'%=1#J%K/?W-E%)NN+4(9DVD;0X)7G&#G!Z59H X"Z\ WT=
MWJBZ9/I"VNI7#W)FN[ 2W%L[\OL).UAG)&X<$]ZM7_@66ZFU1H[U$2\GT^1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/22XE"K-\[A9@O3S$!VOCI\P-6=/\/Z5I<D$EE9I"\%L+2(AB=L(.0G)Z9H
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M6%O!80Q0Z?(9;5$! C<A@6'J2&;.>N36A-#%<0O#-&DD4BE71U!5@>H(/44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP1":94)2,MMWMC@9[9]:\HTCQ9XENK3P+=R6TUU=W\=UOA2X5%N<(I5WX 4
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M0?O9VY[9SVH ZNBO.$\5Z[I_B+Q<5TB?4+>Q:":1#=JBVZ?9D9DCS]YL[C@
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ME9!(K&8C 0J<YQG/&*Z/0]4N]4M97O=,DL)HI-FTR"1)!@$.CC[RG/H.0>*
M-2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K)\36NL7OAZ[M="NX;3495"1W$N<1@GYB, \XSCWK6HH
MY/PAHVN:#$EA<6^BPZ<JLQ-FTK2O(?XF+_>)YR3S6C9:+-:^+]7UEI8S#>VU
MM"B#.Y3&9,D_7>/RK;HH XOQ/H?BS7]#LK%;K2XR9G;4(U:6..XB!.R,$98
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M9YX9[V))()(HY5.<HTIQ&#_O'I5R*X@N'E2*6.1H7V2!6!*-@'!]#@@X]"*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\D&U$F\APN\#:<;P!NQZ<8KM/&-]>QS:'I=G=O9?VI??9Y;N,#?&@C=R%R"
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M<W%K,?MA!NH4NI4AG8#&7C5@K' ')':@#B/$>K:AK&BZM#-=R1PS>#%OV2(
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M/^'$9D^%V@1AV0M8(N]#R..H]ZX_PG->:-9^'%AO[N:*\UG44FAD*D,$^TD
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MKKT*M@$=LCKFM>]\830ZE/INF:3)J4]E#')>-]H2((77<J+N^\Y'..!R.>:
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M%% !1110 4444 %9/B:VUF\\/7=MH%S!:ZE*H2*>?.V/)Y/ /.,XXZXK6HH
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M'!'#9!R,XZ8)KO:* //M6^'L^HKJ$K'3YYFUH:I;0W49DAD7R5B,<HQW 8Y
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M*ZG#*?<$8(J>@#BM$\/^*-'M--T.*^L(](L)1BZ3<;B:!22L3(5VJ2, L&/
MX -9O_"%^)5TB#0$N=+&EVNIK>QSDR>=(@N/.V,N,*1D\@G.!P,YKT1)8Y6=
M8Y$<QMM<*P.UL X/H<$'\:9=W=O86DMW=SQP6\*EY)9&VJBCJ2>PH XB\\&Z
MO/-K4"3V/V*^U:VU2)V9Q(I1H2Z,,8QB(X(/4\XJ]>>#);GQ_!K@N8QIHV7$
M]H0<R74:ND;^F K\^Z+77 A@"#D'D&EH \TO?AQ<+?ZM]CTSPU=1ZC=/<K?:
MC:B2XM6D.7 4H1( <E<E<9P<BO1K:!;:UAMT "1(J+M4*, 8X X'T%2T4 >=
M-X%U:Y\0V=]<1Z/%/;7PN&U>U#17<\8;/ENBJ%.1A22Q&.U7Y?!E\_@74-!%
MQ;_:+G4)+I9,ML"M=>< >,YV\=.M=M10!YGK?P]U/5+S7]\&BW9U(O\ 9]1O
MM\D]FC(%\M$VE1CG#!AC.<&K5]X"U*[T[5X!<VBR7VE6-DO+85X2Q8GCH=W'
M]*[L7EL;YK(3QFZ6,2M#N&X(20&QZ$@C/L:GH *\ZTSP9XD7P_I/AK4[G3&T
MJRGBFEG@+F641OYBQ[2H &X %L\@=!7?7%Y;6CP+<3QQ-<2"*(.P&]R"=H]3
M@$X]J+2\MK^#S[2>.>+<R;XV##<I*L,^H((_"@#SFZ^&UPEYJB6>F>&;F*_N
MI+E+_4+027%MYAW, I0B3!)VY8=<'.*])@B6"".%  L:A0  !@#'0<"F6]Y;
M7;3K;SQRM!(8I0C [' !*GT."#CWJ>@#B=(\.^)]&M+70K.^L(M'MKG>EVNX
MW)@WE_**%=F>=N_/3G&:I?\ "%:]_P (Y_PA_P!IT[^P/-Q]JR_VG[/YF_R]
MF-N[^'?NZ<XS7H=0+>6SWLEFD\;7,2+(\08;E5B0I(]#M/Y&@#FV\+79L_&4
M/GP[M<9S <G$>ZW6+YN/52>,\5F7O@S7&N";#4+:W6?0$TJ:8,XDAD3>5DCP
M.02^#D@@<CFN^IC2QI(D;R(KR9"*6 +8&3@=^* /.]'\ WMIX@T34CIN@:='
MI_FK.ECO>2YWQ%-S2,@)P2/E.>I^:M+1/#_BC1[33=#BOK"/2+"48NDW&XF@
M4DK$4*[5)& 6#'@< &NNM+RVO[<7%I/'/"690\;!AE2589'H01]14] 'FDG@
M37?[+M=/D.EWME9:E<7*V<TTB1WD4K.P$N%.&4OD## XYIJ?#O6(K/5EM9-&
ML9;R^L;RWBM8F6&W\AE)7: ,_='/&XD_=KTVB@#@-6\'Z[XDAUFYU.73K>]N
M=*?3+2*W=WC178,SNQ4$DE5X X [YIFL> 9I/$5_JMKI7A[5#?QQ!UU>(DV\
MB($W(0C;E( RO'(Z\UZ%10!GZ%IIT?0[/3RT+-!$%9H8%A0MW*HO"C.>!7&:
MKX/\2'1_$.@Z3<Z8--U>2>99KDN)8#+RZ;0I# L3AL@@'H<5Z'4$-Y;7%Q<6
M\,\<DULP29%8$QDJ& 8=L@@_0T <O=Z%K]GXGFU;19-.9;RQAM)UNRX,31ER
MKKM!W??/RG;T'-0>%?!=[H%WH<MQ<P2KI^DRV$FS.7=I4<,,CIA37;44 <3I
M_@R^M-=LK][BW,<&KW]^R@MDI.K!0..HW<UG^)M#.E1:MK-S?PVQDUFVU"TG
M:-GCA9(TB_? 8PAPP)!X# UZ-4=Q-%;6TL\[!(8T+R,>@4#)/Y4 >?\ @Z^O
M-<^(.K:K)=Z?>6\>FP6PFTYB\"OYCL4$A^^P!R2.FX#Z[GC3PK_PDL.G2Q16
M4UQI]QYZ07\>^"8%2K(XP<<'(.#@@<5TD)B:!&@*&)E#(4QM(/((Q4E 'F\G
M@#4I=&OXX+?0M-EN;B"3[#81&*&2*,Y:*2545V#Y.>,#L.342_#.YNIM5,D.
MD:3;7VFBT2WTQ"1#(L@D5R2J^9SU.!T ]Z]-HH XK4M$\7>(-)U*RU*[TRUC
MGTV>T2&U9W6:61<"1V905 [*N?O').*U+C0+B;6_#5\)8A'I4<R2J<Y<O&$&
MWCU'?%=#10!GZ]I4>N:!J&E2G"W=N\.[^Z2, _@<'\*X5/AMJ$B: ]UJ%N]S
M#/++K#*#B[#S+/M''0.BCG'&:]*HH XN?P_XCTZ[UM-"FTTV>KS&X+W;.)+6
M5D".5"@B0?*" 2N#WJUX9\(-X;U9I(IUDLUTNTL(@<[R83)ECVYWCOZUU5%
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M;9WORT=I-&THDP)<?(X)! (Y&[TKH/AE]JET/4[ZZD28WNJW%Q'-'&425"0
MR \[3M.,]1BNS=%D7:ZAE]",TZ@#B/$OA*^U;Q2FIBTTG5+/[*L*6FJ,^RWD
M#$F15"LK$@@$'!^4<U%X:\#ZAHI\-">YM)!I)O\ S#$I42"=]R[5QQCN,\=L
MUWE% 'G/B72[;0_"'BLZK?PPMJ>H/>6#)DN)A'&8E QR^^+.!UKJ?!^E3:/X
M8M(+O!OY=US>-_>GD)>3_P >8@>P%;A56QN .#D9'0TM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWCD$=G=-:&1L8D=0-Q7V!)7ZJ:=K>LVN@:3-J5YYABBV@)&NYW9B%55'<EB
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MW /(&<<=<5K44 <AX,TO6M$3[%=:1IMM:L&DEN8M0DN)YY3C+.6C7<3SDY]
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M3?+3S/,V+OQMW8YQZ9H X?2O!FI6>JZ-J-S-;//'?WM_?B,MM#SH5"QY'('
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M0NW(;W&0000?2@#SG6M0U[5M!-K>2WT"VNN:>+>]N=/^SO<(\J8RC#&Y&[@
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M1R61/J%*@^^:PO%,,6I_$#PMI6H(LFFM'=70AD&4FGC"; PZ':&9@/\ "NV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUW* PRP]1ZCD5XMX6DTJU_X1NX\4FW&D+HSPV4E\ 8$F$[AQEOE#>6$ SV!
MJY9K_8_AN'Q9;0RKINDZS<26L80@G3)6".%4\[03YBCT44 >MO=6\<<LDD\2
M)%_K&9P GU/;K2PSPW,*S02I+$PRKHP93]"*\=U73KVTT+PQ?ZB]I;PWVH3:
MCJKWUNTUO%-*A,0E0,ORJ,("3@$+FNI^'$<?VK7Y[2_M+NREN(RIT^S,%H)
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M+1MRVUPV&&W825#J ,[2?O#-97BW3[0:UX^N!:0"8>&5=9!&-P9A<!B#C.2
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M;:\+,P((FWX7ZC9^M>4-- VMZ\;6ZT:>*7PG>@MHUJ8K<LI7"[MS"1@">F,
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M **** "BBB@ HHHH **** $ "@!0 !V%+110 A4,,, 1Z&EHHH " 1@\BD
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M"V.3@=\5)0 4444 %%%% !10#GI1G]* "BBB@ HHHH **"<=:* "BBC/..]
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M^PE 02"?0@8/L36C65XCT&'Q-H-SH]S<W5O!<@+(]LP5RN02,D$8.,'CD9H
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M+V<16XD&&D&T?,P[$]_>J&H^#8KS4KR]L]7U+3&OU5;U+-T"SX&T'YT8JVW
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M<&N3U[P8ESI/A[P=:V%W-IUG-'(^H2R(%CA7<&C)!!+,I*8"XPV2>*]#  &
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MT_=0N '"[%7YC@98Y/ YHTWP1!8ZI8:C<:QJFH3Z?&\-M]JD3:D;*%(PJ#/
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MF,]S=7+!I)GP!DX  P      .E &K1110 4444 %%%% !1110 4444 %%%%
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ML5_[9B@#N68*I9B !R2>U9NN:[::#X?N]9N-TMO;Q[]L6"7[ #G&2:YSQ_\
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M:,Y0N@)4^HSTI^Q=^_:-^,;L<X]*YB#Q_H]Q<0[8KY;&>?[-#J+6Y%M))G:
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MY7S$#8/J,T_8N_?M&_&-V.<>E9@\1:>TND1QR-*VK(9+78N04";RQ]!@C\6
M[TFM>(+71'M89(+JYNKLL(+:UBWR/M&6/8  $9)(ZB@"[:6%O9/=/"I#W4QG
ME).=SD!<_DJC\*EF@BN(C%/$DL9ZHZA@?P-<XOCO2GTQ;M(;YIFO#8BR^SG[
M1YX&XIMZ9"C=G.,=ZU=&UJWUNVEE@AN8'AE,,T-S$8Y(W !P1]"#D$CF@"^(
M8U5%$: 1_< 4?+VX]*##&5=3&A#_ 'AM'S?7UKA=>\:7.C-?FU,U^\>LVMDT
M0M1B!9!&64$-\Y(8D$]VQVKJ]7UNTT/0IM8O_,BM845Y/ERR@D#D?C0!#;>'
M;2#7=3U5\327S0MLD0$1&-=H*^_-:VQ=^_:-^,;L<X]*Y,?$+3S=O9KI6MF^
M$8FCM?L+"26(Y'F*/[N1CYB#D@8R:M-XWTI[#3;FSBO+YM2C:6VM[6 M(47&
MXD' 7!(!R1R<4 ;JVL,2R_9XXX'ER6=$ )/J?4_6L[P_H)T2*[DGO9+Z_O9O
M/NKJ1%0R-M"J J\!0J@ ?XU5L/&FDZ@]A'&+F.2]GFM52:$H8YH@2T;Y^ZV
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M<X55'4\$_0$US&F^.XWU7Q//J)GM-.TN.UQ#<6Y66-W#97 Y8L0N,9SD8ZT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[MM/O1:S.YV[#O++E1\V0&'4=:Z>RL;33;..SL;:&VMHAA(84"(HZ\ <58H
M\JM/!VJV^@:A:WGAR"\AFUHWHM/M[&98C$JAHIBP(E5A@EB,_-SR#76>"-.U
MC3K2^74WNUMGN-UE;7ER+B:"+: 0\@)SELD#)P.]=310!YWJ_AC6G_M^YM;-
M9Y)=<LM1MHO.53-'$L.X9)PIRC#G'2N@\9Z;?:_X&OK"UM_],N8TQ"[J,'<I
M()SCC!KI** .>.E7?_"Q!J_EC[$-)-KOW#/F>:&QCKT[UQUMX;\36&D:!8SV
MM]/I]O!.MU9Z;J"VTGG-+N1F?>NY-I/ ;J>AKU*B@#R:70[OPY\.=8N+^*&R
MO;+57U>P3[2902I5E0.?F8L-T9SR<^]=YX/TJ;1_#%I!=\WTNZYO&_O3R$N_
M_CS$?0"M*]TRPU%K=KZRM[EK>02PF:,/Y;CHRYZ'WJW0!P4W@Z_U#P?XNT>0
MI;S:IJ%Q<6S%LJ58J4+8Y )7![@57T3PW?'Q!97S>'Y].:SBE/GW^L2WA\UD
MVCRE\UAMY.2P!QC@'FO1:* /(XO"OB:\.A2W^FW\NI66I6]S?7EWJWF12*KY
M8P1!MH'?E5( QR:O#PSKL7B!9].TJ72KMM1\ZXOK2_Q97$/F98M;EB=[)P1M
M'S'.ZO3J* /-)M \20>$]4\&6^E1RV]W+<)%JAN$$:0S2,Y+IG?O4.1@ @D#
MFMB#PY?P?\)J@B!74D1+,EQF3%HD7/I\RD<UV=% 'F;:!XC1["VN[&_OM/AT
MNV@BM[+5/LL<4ZKB3SMK*S@_+@C=P#Q4>C^'?$N@6/@Z1-(CNY=)BO8KR".Y
M13B1UVF,L<$D#/)''!P:]0HH \Z@\+ZU/JEIK-S:I!/<>(!J,]L)5;[/"MLT
M*@GHS?=)QG[WMFH]%TEI?BCJ$$4L<NC:;*VI1JASLNKA I4]N LK^WFBO2:J
M6&F6&E1/%I]E;VD<CF1U@C"!G/5CCJ3ZT 8WBS3+^ZFT;5-,@6YN=*O#/]E:
M0)YR-&T; $\!@'R,\<5R>I^%/$'B7_A)+NXTY+"2[>PFL[=[H;I/L[,Q1WC/
MR$^H/&1SQ7J%% 'G>D^%KF;4KNZ;0I]-']G2VL<E_JLEW,SR8R%_>.JIP,]R
M<=*RHO".LA- O[W0[N9[+25TJXL[35/(E!C(*RJZ.JLIYRI8$<'M7K-% 'GF
MB^$=0LM1\/7ATV*T6&^O+NZB6[>=HQ)"43<[L2[GY<D<9_.KM[X<U*8>/_+@
M4G6+=8[/YQ\Y%KY?/I\W'-=M10!Q\N@:@VK^&;A85\NPTRYMYSO'RNZ1!1[\
MHW3TJEX(\,:IHNH:?-?0+&D/AVUL'(D5L3))(S+P>F&'/2N]HH \H'@758-,
M\.7$UA-=2Z=]LBN;*VOS;R%)I2ZLDBLH)&!E2P!!]172^&-,U#0K*YN(]!$4
MU]?H7@;46FE2'"KYDDCLP9P!G:IQC S7944 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$8G)W!00,<=J])HH I7&CZ;>1PQW>GVMPL  B$T2OL^F0<5<  &   .,4M%
M%5=,L$CAC2QME2%_,B41*!&W]Y1C@^XJ5+:WCN)+A((EGE $DBH SXZ9/4XJ
M6B@""[LK6_@,%Y;0W,).3'-&'4_@>*6VM;>SMUM[6"*"%?NQQ(%4?0#BIJ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44FY=VW<-V,XSS064,%+#<>@SR: %HHI,@DC(R.HH 6BBD)"@D
MD #J30 M%%% !12$@$ D GI[T$A1DD#MS0 M%%% !12$A1DD >]+0 4444 %
M%%% !12;E#!2PW'D#/-!95(!8 GH">M "T444 %%("&&001ZBEH ***9'+'*
M"8Y%< X)4YP?2@!]%(2 0"0">GO0"&&001ZB@!:*** "BD!##(((]J6@ HHH
MH **** "BBB@ HHHH **0$, 000>A%+0 44F]?[PZXZ]Z"0,9(&3CF@!:***
M "BBB@ HHI 0<X(.#@XH 6BBB@ HIBRQN[HLBLZ?>4')7ZTXD#&2!DXYH 6B
MD!!Z$'!QQ2T %%%("#G!!QP: %HHHH **** "BBB@ HHI,@$ D9/04 +1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(02I .#C@^E
M 'EVH^'=+M=8TW2-#1KKQ0E['>WFJG!F@BW[G:9Q_>7*!.ASTP*=XQ\/:3&;
MJRLXFU#QCJTYGL[AL&>S&X8?>.8XHP./7&.236SHG@/4M!9A:>+[[RY9S<3A
M[2W+3L3EB[E-QSTSG@=.E+#X$U*SU74M0L?%U];S:A,9IC]DMY#_ +*[F0G:
MHX S@4 =BZ3&U9$E"S%"%D*Y ;'7'?GM7$^"+&?3O&'BZWN=0N+^</:-)<3X
M#,QB). .%'/ '05U]O:7$-]<3R7\LT4J1JD#*H6,KG+ @9RV1G/IQ4%CHL5C
MKFJZHDKM)J)B+H0,)Y:;1CZT :=<G\3O^29>(O\ KR?^5=969XAT:+Q%X>O]
M'GE>**\A,3.@&Y0>XS0!S4FL^)KS7]2TC1CI4$6G6=O.);N&20NTBM\F%=<#
MY/O=O0YXW_#VL3>(O"&GZM&D=O<7MHLH5@75'*_4$@'W'%.L] ALM9U'4EFD
M:2^@@A="!A1$& (^N\_E4OA_1XO#_A^PTB&5Y8K.%85=\98#N<4 >4:-)K\V
MG> I%NK.>_EU"^\F2:-]JKY<H8O\Y+D?,1@KG@>]=%>^(K]].O++6;33KN\T
MW7K&T+I&ZQ2+(\3+(%+$JX#^I&1WZ5M:3X%CTJ;2S_:=Q/#I=U//:1NB#8LJ
M,I0D#D#>3GK4]WX+M;RXU"5KJ93>ZC:Z@P 'RM!Y>U1['RQGZF@# /CC5%\6
M2Z;<7.E6!6_^SQZ??0RQ2SP[@!+'.6V,Q'(4*?3.:ZGQ7K<^A:1'+:0QS7MS
M<PV=LDI(3S)'"@L1SM&23CTK,OO SZB\UM<Z[>R:1-="[>QD5'(8.'VK(1N5
M-PZ#D#@$"MS7M$M_$&EM8W$DL)#I+%-"0'AD1@R.N<C(('6@#C/%Y\11^'IK
M?6OL$\(OM.>"[M(VBR3=1[D:-F8C'!!S@YJ#Q3\0=1T*;59H[_1/^)>_RZ8(
MY)YY8QC):1&Q$3R0"IQQDUOS>!WU!)WU;6[N]NI7MR)=B1K&D,HE"JBC'+#D
MG)^F*JWOPY%WI^KZ6NO7L&E:G-+<2VT<4>X22'<W[PC)7=SCKVSB@#8L]>N;
MGQ)X@TYHXA#IT%O+"P!W,9%<G=SC^$8QBN/F^(>K_P!F:%=SS:=I,-_IB7;W
MUU9S36[3-_RQ!5AY8 YRQ/7VKJ+[P?+<:M<7]GK=W8F]MX[:^2&-&\Y4R%(+
M E&PS#(_GS4,'@FXTZQT^VTGQ#>V8M;)+%PT:2QRHO1BC# ?D\CKT.<4 9&J
M>/[J*]TS38[S2K&>?3EOKB[=)+N'YB558A&5W E6.XGH!US73>#_ !!)XDT$
M7L\*Q3QS202; P1RC8WINYVL,$9]<=JSH? ,.EQZ<VA:I=:==65J;/SMB2B:
M(MNPZL,9W$D$8QD]N*Z#1M+_ +'TU+0WEU>2;F>2XN7W/(S$DGT R>   !0!
MY]XN\/:5&\]A81M?^,M4N#<6UTV#/9KO&)"XYCB0< =\8Y)-6_&NBZ# +^>^
MMFUCQ!JR^3IMNX#2QL$  A_YYH#\[/QC))/05?M_ >IV.I:C?6/B^^@FU"<S
M3-]CMW8^B[F0G:HX S@5)-X'OSXDOM<M/%-[:W5VJH<6L$FQ%Z(I=20O? ZG
MDT =-H]O=6FB6%M?3^?>16\<<\V?]8X4!F_$Y-<OXH?51\0/"$=G=P16[O<E
MXY(F;=B/YLX<#[I(''!YYZ5O0V>JQ:S8L^H//916+1W&]47SIMR;7P!P<!\X
MP.1QZ,UKP^=6U+2=0BOI;2YTV9G1D16#JR[70AAW'<<B@#S[PMK'B'0O!NEZ
MA_Q+GT=M3:U:W,;^>5DNV3>'W;00S?=V]!UJYJOQ)O(]1UG[#<:;%%I<[P+9
MW%M,\MXR#Y\.IVQY.57AN1DX%=2O@NU7PK;:!]JF\F"[6Z$N!N++/YV/3&>/
MI4-WX+F:ZU$Z;K]]IMIJ<AEN[>!$)+D ,T;D9C+ #.,\\C!H NZU>W%]X"O+
M_3G%M--IYGC,R$E 4W8(!!SC(Z\'UZ5QO@^75K/3-%\-Z''HUG.^E1:G=71L
MVV;7 5!L#@M(=IW.6'3ISBO1KG3X[G1YM-WNL4ENT&XMN8 KMSD]3]:P9/!A
MA_LR?2]6N+"^L+%;#[0L:2":%<8#HPQD$9!&,9/K0!SPUNYUO7O"GVZ&**^L
M=<N[*Y$))C9TMI?F3/.T@@X/(SBJO@K6-6ET/0O#VB&S@G-E->W%U=Q-*J)Y
M[HJJBLN23GDD  =ZZVR\$6=BVE2+=W$D]C>37TDTF"US-*C([/@ #[_8#& *
MJV_@%=-M].;2=7N;*^L89+<7(C1_-B=RY5T(P<-R",$?C0!5L/&VH&]L8-2M
M[2%%U*XTK4)8]VU9DC\R-T)/"LN>#D@D#/'-30OB%J6LV5HAL[:'4KO5H[>.
M$JV!:/&)Q*1G.?)SWQN[=JU[OX?6%WX1NM"DO;LR75Q]KFO\CSFG+!B_ P.F
M, 8 XJY;>"].M/%T7B&%I%DBL5LTM^/+&. _^]M^7Z4 <OI7B35OL6@:?HMG
MI=J^IWNI1N7C<QQ>5*YWA0V23@DC/)/859C\9:Z5;1S%I[:Z=8;2TG".+?:(
M1,92F[=PAQMW=>^*W-.\%VNFS:3*EU,YTV>[F0,!\YN&8L#]-W%97B/PRME;
MW%]:PZC<W$^KIJ'FV6SSK-O*$>]%((D&% *GJ'/I0!I>'-7UNX\2ZUHNLBQ<
MZ?#;213VD;)YPE\S)*LS;?N 8R>_//&#K.MZAH'C_7]3GN(I=-L-!CN?LHC;
M<PW2X ;=@,7'+;>F!CC)N^!-,U&/7?$&M7QU!DOQ;1Q2:A&L4LGEA\MY:@!%
MR^ , \$GK6MJW@^VU?7)K^>ZE$%W8'3[RT"J4GB^<KSC<I!<G(/I0!SVA>/+
M^YUS3+*[N=.O4U ,&6RM9HS9N$+ ,SDAU."N?EYQQS5>T\9^+I/!5CXBF@T8
MMJ,]K#;6J)(-IDD"$LVX]<Y&!QGO74:9X6O;2]M)KWQ'J%_#9(R6\#A(QR-N
M9"@'F$#IGCOC/-)%X,M8O"NDZ +J8PZ;-!,DF!N<Q.' /;DC% &&^N^-5U'6
M]+670S/I=LEX;DVTH6575BL>SS,J<HV6W'C'%5]3^(.HQQ:1<++8:/9WVF17
MJW=_:RS0R2OSY.]&41X&"6;^\,"NQ/AV ZMK&H>?)OU.UCMI%P,($#@$>_[P
M_E68/!ES:6ME!I?B&\LUM[".PD1HTFCE1!@-L885^3R.O<'% &Y:7T\_A^*_
M$4,UP]L)?+MI0Z.^W.$?N">AKB/#GC34-<G-K>7^DM+):2/<:>();6ZM'"YV
M[9&/FCJ"0%Z9KM-+T&STCPW!H5J9A:0P>0K;R'QC!.X8P>2<C'M6):^")!?6
M%SJ6NW>HC3HY$LQ+%&K)O0H2[@9<[21SCU.30!S7@W6/$.C^%?!+77]G2:5J
M @L5ACC<31@QDHY<MM.=O(VC&>IZU+J/Q"U'3[_>;_1)E2_2VDTRWCDEF2-I
M1'N:96V*^"#M*@=NM=7%X/MHM#\/:6+F8QZ)+#+$^!F0QH5 ;Z[NU9'_  K?
M_B3KHPU^]728;@7$%LL48*L)/, =\9<!OI[YQ0!S^H?\AC5?^QST[_T7!73?
M$DW*Z9HALUC:Y_MNS\H2DA-V_C=CG'KBKT_@NUGNKF<W4P,^K0:H0 .'B5%"
M_0[!^=:>M:+%K26*RRO']DO8KQ=@'S-&<@'V- '-+XEU[3YO$&GZB=)GO-/M
M(;N"X!:U@99"Z_O-S-MVE"<YY'H:HZ1XUU?4=;N=(M;_ $C59I--EN[2XMK2
M6*-94*@(VYR'4[QRK \>];VN^"+/7I]4FGNIXFO[>W@/EA?W9AD:1&&0<_,W
M(/! I]AX4G@\20:]?:U<WUY%;26NUHDCCV,5;A5'!RO7)SGV% &6GC\W%MH]
MU;P1^5+ILVIZDI4EH(XUP47D8;S,KSG[C5EZ)\1KZ\OM':XFT^XAU258WL[6
MVF66SWC*DR,=L@!P&X7KD9%=3I7@G2]*O-<G7S)EU=B)8I#\L:$LS(OHI:1V
M^K5#IG@ZYT^73XI/$>HW&G:<0;6T(1.@VJ)'4!I H/ /7 SF@"K\0GU1&\-+
MIEW!;F36(4?S8V<,<,5SM=<KP<COQR,<\S;:MXBT'3O&6LV/]FG3[#6+F66"
M>-VDG VE]K!@$XZ9#9->@^)- _X2"SMHDO9;*XM;I+J">)58HZYQE6!!&">*
MI2^#+:;P]KVCM=S>7K,TTTL@ W(9  =OTQ0!B:]X\N(/$UWI%E?:=IXLH8Y'
MEOK:6<S.XW!%$9&T 8RQR>>!Q73^'=9F\1^$[75(X1:7-S"3Y<JEECD!*G(X
M)7</;(]*J7WA2=]6FU/2-:N=+N;F%(;KRXDE64)D*V&'#@$C([=0:VM+T]-*
MTRWL8YIYU@0)YMQ(9)']V8]2: /*O!-SJFG:;I]K81Z3_:^OW=[))?/:L"J0
MROO:3#YE.6 497 /?&3HZSK5_>3VND:LEN;_ $SQ%IP::V4K'-'(VY&"L25/
M!!&3TZ\UT2^!8;?3--@LM2N;:]TV>>:VO%568><[,Z,I&&4[L8]@<TL?@6W(
M$UUJ-S<W[ZC!J,]TZJ#*T6-B!0,*@ Q@>_- '.:)K5_9>=I.DI;_ -H:GXCU
M-4EN5+1PI'(S.Q52"QZ #(Y/6M%O&.M:;JCZ;J<5C(]G?VL-W<P1NB/;W.Y8
MY%4L=C"0 $$L,=*TI/ MN(@]KJ%S;7T>I7&HV]VBJ6B>8L73:1AD(8C!]J</
M \$VE:U;W^H7-W>ZPJBXO6559=@Q'L4#"A#R/?))- &##\1=0N4UJ**TMA=+
M?0V^DA@V+B.29H5=AGGF.1CC' %(WB74K*]O+;1[#38[B[\4-I[-(K[6'V57
M\UL-RPP.F 0N.#S6Y;?#_3+;4_#U\DTQ?1+;[/&AQB;Y2 [^K#<Y^K&IU\%V
MJZ@+S[5-N&L'5]N!C>8?*V?[N.?7- &+)XRUK2X=9L+Z&QNM6M+NTM+62%7B
MAF:YP$+*68KM).<$Y XQ6GI>K>(H/&RZ!K#:;/"^G/>)<VD+Q,661$VE6=L
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MR3@_-TQVJU56WM9X;Z\GDO99HIRAB@95"P87!"D#)R>><U:H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)7YDGE5B,-G@# SQ_"?45W7B+QAHOA9K6/5+EUGNF(@@AA:623'4A5!.!ZT
M;M%<FGQ+\)OHUUJZ:IFPM;A;:6;R7PLC8P,8SWZ]JB;XH^%%TV"^%[.R7$KP
MP1K:2F64J 6*IMR5 (.<8H [&BN:G\?>&8/#EOKQU-7L+E_+@:-&9Y'SC8$
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MO,,Z"1-Z%&P>F5(!'T-6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAF0,-R@YP2/0X/Y&GUP7@_2O[(^(?BF!KRZO)7L[&26XN7W/(Y,^3P  .
M  !79Z;%>P6*1ZA=1W5T"VZ6.+RU(+$K\N3C P.O.,T 6J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCOX9%,[-*=TF_<I5MQY(*XX&,8K7T/1(-"M)88I[FXDFE:>>XN9-\DKG&22
M . !@  8Z5IT4 <M?^!K.]N;]XM3U.RMM1;=?6EK*JQ7!("DG*EE+  ':5S6
MW;Z7':7J303SI!';+;1V8?\ <(JG(8+C[V.,YZ 5>HH S[?1[:VUV^U=&D-S
M>Q0PR@D;0L>_;@8Z_.<\^E-T&RO-.TB.VOKI[JX625C+(Y=MK2,RJ6(&<*0N
M<#I6E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-WIN*[ER#@C/2@!U
M%(S*B[F8*/4G%+0 4444 %%%% !1110 4444 %%%% !1110 44@()(!&1UI:
M "B@D $DX [FB@ HHHH **** "BBD) (R0,]* %HHHH **** "BBB@ HHHH
M**** "BD!!Z$&EH **** "BBB@ HI"0!DD #N:6@ HHI&8*,L0!ZDT +13!+
M&QPLBD^@-/H **** "BB@D 9)P* "BCJ,BB@ HHHH **** "BD)"C)( ]32T
M %% ((!!R#2 AAD$$>U "T444 %%%% !1110 4444 %%("",@@@]Q2T %%%(
M""2 1QUH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-*L$,DK_=12QQZ
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M;65NN#R",$9/K0!S=AXZU76X-*L-/ALX=5O+BYBDN)HY&@5(,;I$3*LP;>F
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MWX ., $UF:<MG=^$U@DU+2X;>#Q)<"UCN;=FTV7]WD1LI;Y4.XLF3C., YH
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MH0G.>6&,XQGC-2:I\0-,TIM1=K'4[FTTTE+N\MK</%$X&2F<@DC(S@$#/)%
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MBWEMXGA'_+-D!7\NE<M;?$73+K3(K^/3M6$5R\<=DK6N'O&<$XB&><!223@
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M'(7Z**U[S3[+4%B6]L[>Y6*02QB:,.$<=&&1P1D\U9H **** "BBB@ HHHH
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MP<4 5?!>J:Q>R:G:ZG%?/#;2(;6[O;06\DR,I)#* !E2#R ,@CBJ_P 5M_\
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ME5E@VLH5QW(W,0?4T <_-XPOM!COC?,LRRZ/#?:8BQJNZ7 C>(8 SF1HB/\
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M\+<]?EZG&:GUFXG_ +4UNPNQ9VEZ;*&%B^G/=W.IGR?^69SM"[B5P ><DXH
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MX>DBN3JTFKW$J6RP.6:-[@2"3.,;-ISG..W6@#UF[UG2["[BM;S4K.WN9O\
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M_;6E?VG_ &;_ &E9_;^OV7SU\WU^YG/Z4VYU[1[.80W6K6,$ID\H)+<(K%\
M[<$]<$''N/6O)=MK_P ( /#HLY/^$T^V;MOV=O.^T^?N\_?C[N/FWYQMXSVK
M;NM%MKFT^)\\^GI+/*TBQN\668"T0KM)'9L].] 'I<\\5M;R3S.L<42EW=CP
MJ@9)/X5QT/B_Q%J&G#5],\)^=I3+YD)EOA'<SQ]0ZQ;".1R 6!/'2M*33I]:
M^'#:9YA2XO-)\C>^>&>+;D_B:Y0^*[ ^&M/TO4-2UKP]K%E&D4UI:69:61U7
M;M3,;JZD\@K[<T =TOB'2AHMKJUU>16-I<QJZ->.(<;AD [B,'VJ9]:TJ.RC
MO7U.S6UE!,<YG4(X ))#9P< $_@:\P?4-5B@\*?\)"MM9:B;"9Y-4U2S:?8Y
M=?W2QJ559"N#D\X& .M4?#^F"^?0K:\LWFME\47LA2:T\I=ODNZL8R/D!)!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVDI81SQM&^TX.&&#C\Z9IUC%I>EVFGVY8PVL*01ESD[54*,^^!5FB@ HHHH
M**** "BBB@ HHHH *S[O1[:]U?3M3E,@GT_S/)"G"GS%VMD8YXK0HH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3K!M1:"0Q.981G)1D<KG(Q@D=J=:>.%N+V&VET/4[8W=M)<V#2B/_2E0!BH
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M) WF0XXP?FR#GL:9K'@[4[S6]6U6TDMEF-W8WEBLK':[P*P97P. 0Q&1GUH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*?N. "5/O@C\Z\HU.34M3O--TR\UB[>32_%*V27<0C5I5:W,BLWRD>8N2N0
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M88JR,IR&5E(*L#T(.:S(O!.AII^HV<D,]PNI(([R6YN9)99E P%,C,6  )P
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MR#S4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;I([(VV?/AA<Y#/G(; (&/0$YS7H=G:QV-C;VD18QP1K&I8\X48&?RK@])\
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M7S7+NIRI5E)/0J>@H?P)I[Z4EI]NU$7*7GV\:AYP-QY^,;\E=OW3MV[=N.U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Q]&^;=C&2?:N5.O:U<?#Z^^(#^+[^WUJ&]*II8F MD D"B$P]SM.<]<?B:
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M"6)&XG.!@'-=7X*EU:'6=8TZ^\]+6%898(+O4$NKB$MNW!F#%MIP"N[_ &J
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MWVESRV"QP3DUR>N2W&A>(/B!K%A=7*7<%C9%"\K,D?F%U+E"<':.1D8'/J:
M/6:*X58)O#7C'P[9VFL:C?0:HLZ7,5[=-/G9'O$J[ON<@ A<+\PXJSXZ75)I
MM)@TV5Y SR/-I]OJ'V.XNE"CF.3@_*3DC(SD<T =C17D4WB#4;G3M$T>PEUJ
M0S:G<VMXD]PD-VIC0N(/.SCN/F!W$+US3FU/Q!917.C37=S96\^K65JLDM^E
MS=VD4H)=2X)(R5 4MS\_7@4 >MT5YQXCW^&=+U*"P\27TKK/I\GV>XN&EEME
M>Y5&/F,2VUQD8)['L:3QSK-]9ZMX@AM+^:'[/X6EN42.0CRY?,(#@#HV!UH
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MQ!W$5U?@-M5:'5&U%97@-R#:W=S9"UN+E=BY:2, <@_*"0"0.E==10 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5?<@9<G>6)!SP1CIDCGK0!TU%%% !1110 4444 %%%% !1110 4444 %%%%
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M8+?6,ADMV>1%8J5R4<HW!]U-7: .;U#PG]MUN_U"/498(]0T_P"PW5N(U8.
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M_K DA&4#\Y'/4XQFKLW@S3Y/%>GZZK.C65K]F6V 'EL &52?=5DD ]FKI**
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MZ?I,<C2I96\=NLC#!8*H7)_*K]% !1110 4444 %%%% !1110 4444 %%%%
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M#DN,8Y/?BND6")9GF6)!+( '<*,L!T!/?&3^=+##%;PI##&D42#"HBA54>@
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MY#IUE9V<Y#;)(K=1M9ARV!C/09]<55\.:$VB6UTUQ=_;+^]N#<W5SY8C\QR
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MQ?ZN:2%6=/HQ&15A88DF>98D660 .X4!F SC)[XR?SH ?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC"-H( JQLPQOVKC)'7\!5O2].MM'TJUTVS39;6L2Q1KWVJ,#/O5NB@ HHHH
MKWUA9ZG:/:7]K!=6TGWX9XPZ-]0>*K6WA_1K*(Q6ND6$$;1&$K';HH,9.2AP
M.5R2<=*EU75;'1-.DO\ 4)Q!;1X!8@DDDX  ')))  ')KFM5^(6GVOAK6=0L
MXKEK[3;<S-97-I+%(,@[&9"H;82/O=!SDC% '0Z7H6D:(LBZ5IEG8K(<N+:!
M8]Q]\ 9J;4--L=6M&M-1L[>[MF()BN(PZDCH<'BN//Q!C@\31VEQ#=&UFTF*
M\BABL)FG+F217R@7<% 0=0.O7D5MS>,]#CTRPOX[F2YCU$$V<=M \LLV!D[4
M4%N.^1QWQ0!I6.D:9I?_ "#].M+3Y!'^XA5/E!)"\#H"2<>YJQ):V\T\,\L$
M3S0$F*1D!:,D8)4]L@D<=C6#/X[\/6^E6^HR7DGDW$[6T:BWD,GG*"3&4V[@
M_P I&" <X'<5K#5;/^QAJTLA@LO)\]GG0QE$QG+!@"..QH BO_#VBZK=176H
MZ18W=Q%_JY9[='9?H2,T:CX>T76)HIM3TBQO)8>(WN+=)"@] 2.*YV#QU#J?
MB_1=+T\3+;W4%Q-,+JTDA<JH4QNF\#*G+<C/3M6C9^.M OKZ"V@N9MMQ(8;>
MY>VD6"=QGY4E*[&/!Q@\XXS0!IZAH6D:MY']HZ797GD',7VB!9/+_P!W(XZ"
MIH=,L+=X7AL;:-H0XB*1*#'O.7VX'&X\G'4]:QW\<:#'J1LC<3?+<"U:X%M(
M;=9B<>69=NP-GC&>O'6K4GBC2(M(OM4>Z(L[&=[>XD\MOD='V,,8R<-QD4 7
MK'3;#2XI(M/LK>TCDD,KI!$J!G/5B .2<#GVJ#4M!T?66B;5-*LKUHCF,W,"
MR%/ID'%96H^/O#^E7MY:7-S<>;9,JW9CM)9%MPRA@SLJD*I##DGU]#BSIGB_
M1M6U![&UGF$RPFX0S6[Q++$" 9(V8 .N2.1D<CM0!K_8[7SXI_LT/G0H8XY-
M@W(IQE0>H!P./84Z>"&ZMY(+B*.:&12KQR*&5@>H(/!%86G>-M#U2]@M;:>?
M_22PM9I;:2.*Y(&3Y<C*%?@$\'D#(S4%O\0O#ES<P117-P4FG^S)<&TE$/G9
MVB,R%=H8GMF@#4L_#6@Z<JK9:+IUN%W;?*MD7&X8;H.XX/K5L:?9"*UB%G;B
M.T(-LGE+B$A2HV#'RX4D<=CBL/PUXJ&OZOKMB;::+^SKOR$9K>1 ZA$.2S #
M=N8\>F#T.39NO%VCVFOIH;RSOJ+%,Q16TC[ _"LQ52%7/&2<"@!FAZ!<V.KZ
MEK&IW4%UJ%Z$B#0PF-(X4SM0 DDG+$DYY)]JOZ]IAUKP]J6E"7R3>VLMN)"N
M[9O4KG'&<9K-L_'&A7]]#:P7$Q$\ABM[A[:18)W&<JDI78QX/0\XXS4-[\0?
M#EA/<)<75P(K>7R)+E;25H%ESCR_,"E=V>,9Z\=: -+1O#FE:&@:RTZSANFC
M5)KB&W5'E( Y8@9.2,U)%X>T6#57U2+2;&/4'R6NEMT$ISU^;&:0Z_IHCU:0
MW!VZ22+P[&_=XC$A[<_*0>,UDGQ9&GB>6*6>&/1DT1-3,[J5(R[#))[;0.,4
M = =/LFGGG:SMS-<1B*:0Q+ND09PK''(Y/!]:9-I.FW&F#3)M/M9+ *$%JT*
MF(*.@VXQ@5B1^/-'F\Y(UOTG6V>ZBBGL)HVGC7&3&&7+]1P.>>E4]!\9_P!L
MV7AR\FE6T.H6LLTUL]K*#(416)C8_P *[NO(8'@T =';:%I%G91V5MI=E#:Q
MR"5(8X%5%<'(8 #&X$ YZ\4FIZ!HVM-$VJ:597S1?ZLW-NLA3Z9!Q65IOC[P
M]JUU906ES<$7P_T6>2TE2*9MNXJKLH4L #QGL1U%-N/B#X<M9Y(Y;JX$:3_9
MC<BTE: S9V^6) NTMGL#V/I0!TR(L:*B*%11A548 'H*H7F@:-J%]#?7NE6-
MS=PX\J>:W5W3'3#$9%4?&GB%O"WA.^U>. SRP+^[38S L3@;MHR![\?6L>;Q
M]#9^+);&XBNVM&TR&\@BBL)GN,L\@<L@7<H 5>H&,^] '3:AX?T;5KF*XU'2
M;&\GA_U<EQ;I(R?0D<5;%K;K=&Z6"(7!C$1F"#>4!)"YZX!)./>L6;QIHD5G
M87,5Q-=C4(S+:QV=O)-)*@QEMB@D 9&<@8/'6LS4_B'800Z%<:?'/=0:E?M:
MR%;28M%M5MX*A<APR@;3SU." : .HBTS3X# 8;&VC-OO\G9"H\K=][;@<9[X
MZU OAW1%U8ZJND6 U$G)NQ;IYN?7=C.:EU75K'1-/DO]1G$-O'@%B"223@
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MHFF7DEY8:186MU+G?-!;HCMGKD@9HL_#NB:??R7]EI%A;7DF=\\-NB.V>N6
MSS6+IOCW3YO#6BZC>I<K>:E KI:06<KR.VT%RB!2Q09^]TQCDY%=!I6K66MV
M"7NGS>; Q*Y*E65@<%64@%2",$$9% $4/A[1;?5'U2'2;&/4'R6NDMT$ISUR
MV,\TLF@:--JJ:K)I5B^HIC;=-;J91CIAL9K1HH SKO0-'O[62UN]*L9X)93/
M)');JRM(>KD$<M[]:$\/Z+':36B:18+;3(L<L*VR!)%7[JL,8(&3@'I6C10!
M2CT?3(K>6WCTZT2&:-8Y8U@4*Z*NU588Y 7@ ]!Q45IX=T2QL)K"TTBP@LY\
MB:".W14DS_>4#!_&M*B@"%K2V>XAG>WB:: ,L4A0%HPV,A3U&<#./05))&DL
M;1R(KQN"K*PR"#U!%.HH S;'P[HFF07$%AI%A:PW (FCAMT190>,, .1R>M:
M$44<,211(L<:*%1%& H'0 =A3J* ,[4- T;5KF&XU'2K&\GA_P!5)<6ZR,G?
M@D<5-#I>GVSQ/!86L30[_**0JI3><OMP.-QY..IZU;HH P?$&@3ZEH]SINE3
MVNG)?NPO9/LVYI$==KE<$#>1CYCGZ5L6EK#8V<%I;H(X((UCC0=%51@#\A4U
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCS%R<@_>P#B@#JZ*1B%4L>@&352'5;"X%F8;N&07J&2V*MGS5 !)7U&"#^-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>guyaragreement014.jpg
<TEXT>
begin 644 guyaragreement014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI')5&8*6(&0H[^U><V?Q#
MO3KNDV=W-H,WV^Y%O+96-T99[-BK$;V!*M@K@XQR>,T >CT5YU%XW\1'2$U^
M73]-724U'[%)&)'\]E^T>1YB_P (P2/E.<X/(Z55\8:_KVL>$/%\NFVMDNE6
M27-DQD=Q/(44K)(I'R@*<X!R3M/(R* /3Z*@LN;&W_ZY+_*O/I?B)?6FL64-
MU)H1^T7Z6<FFP77FW<"O)L#LRDKD9!*X'7&: /2**S]<TV35]&N+"&Z-J\P
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M[3Y'F;/-S]W/\6S'3OF@#T&BN+M?$OB*]U/76MM.T]].TB>6W(:8I-.ZQAU
M)^11EE!)/0GTYHZ/X[OKWQ):Z,UYH%])>03,C:;,SBVE10VV0Y(8')Y&#QTH
M ]"HKR/1O'6HZ+X.T*+4;S3OMVJ3W/EW=],XCCCC<[FD).6;)  !'4<C%=IX
M,\6KXGCU")GM);BPF$3SV4A>"964,KH3R.X(.<$'DT =11110 4444 %%%%
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M#WVY]CWIN_.\OD'[3Y^W&?7Y<Y]ZZAT62-D=0R,"&!Z$&AW6-&=V"HH)9F.
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M'*L5/![9'!Z$<U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ<\UKI5
MY<6\?F3Q0.\:8SN8*2!^=>>Z4D%CX:T'Q(FOZA-J]];>88Y+EY4OYFA9S%Y>
M2J@$'&T#;MQ7IE9-EX7T'3M2?4;/2+."\?=F:.(!OF^]CTSWQUH \Q\/SZY]
ME\+ZWYKI-J%Q#]IN[C6VD2\63[\8@(VJ1SM5<%2N/6H-8U.Z.ER>)M..J;3J
M:K#J=SJIC5Q]H"&-+925*8W+A@#@%C7J=KX4\/V.J'4[71[*&])9O.2$!@6^
M\1Z$]R.M1-X+\,O<S7#Z%8-+.Q:1C #EB<D^Q)ZD=: .!U^>\L=5UG6[J:^O
M-.M;Q3]NTO52DFGJNS,36S$(W?/4D-TJ+4;C6=8U3Q9<D3J=-N&BMIEUEK1;
M)%C5E<Q 8;.2Q+9!''05Z1=>%/#][J@U.ZT>RFO<JQF>(%B5^Z3ZD=B>E&H^
M%= U>]6]U'1[.ZN5 'F2Q!B0.@/J!Z&@#@-6&LZI<074CMJFS2+>2>UTS5VM
M);25@Q:= "%D#=MQ_AKT+0+R#6/"VG7<,UQ+!=6B,LLWR2L"HY;;C#>N._2D
MU7POH6MS1S:GI-I=21KL5Y8P2%_NY[CVZ5J1QI#$D42*D:*%5%& H'0 =A0!
MXWX<MECTSPWHZWM[;6&IZIJ(NV2\D#2&*23RX@^[*;L9.T@MM/<FNU\(O):>
M)O$NB17<]SIU@UNUN9YFE:)I$8O'O8DD#"G!)QNK8?PGX?D@NX'T:R,5Y+Y]
MPAA&))/[Y_VO?K5W3-)T_1K06FFV<-I!N+;(4"@L>I/J?<T <G>VXU[X@ZCI
MNI7U[;6MCI\$]I#;7;V^YG:0/*2A!8KM4<Y STYKE/!B_P!JVWA?0;K4+E=+
M>PO+I?(N&@-Y*MSM +(02 K%MH/?)Z5ZAJOAW1M=:%M5TRUO&ASY9FC#%<]1
M]#W'0U'<^%]!N]-ATZ?2;1[.!B\,)B&V-B225]#R>GK0!D^!+F=X]<L7NYKR
MUT[4Y+6UGF<NYC"(VTL>6VLS+D\\>U<MXL^W1ZWKVIM+>WVGV2HQDTS5C!/I
M86,,V820DF>7YSD'&*].L;"STRSCL["VAMK:(82*% JK] *S]0\*:!JU^M]J
M&CV=S=  >;+$"6 Z ^N/>@#D;9(/%FN>(Y=2U;4+:&P6#[&L-V]MY$30+)YY
M"D DEFY;(&W'K73>"-2O=7\#:/J%_P#-=SVJO(V-N\XX;'N,'\:M:IX7T+6K
MB.XU/2;.[FC7:KRQ!CMSG:?49['BM555$5$4*JC  & !0!Y!'/<+\/+3QH-6
MOV\0RW,99#=N8W=IPC6WDYV8 )7 &1C.:Z?P;8O>Z]K^K7>H7\TMMJUS;6\+
M73^3'&-O'EYVGDGJ..,=*Z)?"N@)JYU9='LA?E_,\\0C=O\ [W^][]:T+:RM
MK/SOLT$<7G2M-+L7&]SU8^I.* .8\1F2?QOX<TXW%Q':W5M?":.&=X]^%CP<
MJ0<C)P>HSQ4/PHLXK3X:Z,T;2DS0"5_,F9\$\?+N)VCCH,#VYKK9;*VFNX+N
M2"-[BW#"*4KED#8W8/;.!GZ46=E;:=9Q6EG!'!;1+MCBC7"J/0"@#Q[Q?J%S
M)IGB;7=..JLUA<R1Q:C+JIMX[>2,A?+C@4D. PQ\RC<2>:W;BPDUWQ!XQ:ZU
M/4TCLH+=[2*VO9(5A<V^XN I&3D#@Y'7CFNPN/!WAN[O)[NXT.PEGN,^:[P@
M[R1@DCIDCC/6M"+3+&%KAH[2)6N559R%YD"KM ;UP.* /.?#TLWC*_L;?7-0
MO%CC\/6-Y'#;W3V_GR2JWF2DH06P0HZX&>G-4-(#:UKO@JYOKRZNFANM2MX;
MK[2Z_:(H6(C<[2 20.3_ ! <Y%>D7OA30-1M+2UO-(LYH+1!';HT0_=(!C:O
MH, #'3BIKCP_H]W!903Z9:O%8NKVJ&(8@9>A3^[CVH \J6P:Q\%ZWXCMK_4(
MM0M==N&@V73K$B_;-I7RP=C!@3G()Y]A5G4IM:U?5_%D[+.ITRX:&WF766LU
MLD6-660Q@8;.2Q9L@CCH*]0;1M,:PEL38VYM)I#+)#L&UW+;RQ'J6Y^M5=2\
M*Z!K%ZMYJ.CV=U<J /,EB#$@<@'U ]#0!Q^C07GB'QJCZIJ=WBUT?3[LPV=V
MZ0/.QD+/A2,J=O3H0>1P,;/Q&GDAT"Q$>H3Z>LNJ6D,EQ#)Y;(C2@-SVX/TK
MIX[&UBO)+R.WC6YDC6-Y0N&95R5!/H-Q_,UE^*O#X\2Z?:6;M%Y45];W,J2I
MN61(W#,A'N 1^- ' >*K^^\'S>(+'0;V[:W&EP7#">Y>8VDCSB,L'<L5RA9N
M> 4SBE<:QHEQ<QQ&2P@GT>[D>&;6WO))&1,I-'NY4@\$@X.X>E>CZ?X=T;2K
M2>TL-,M8+>X_UT:1#$G&/F]>..>U0Z?X3\/Z4EPECH]G;K<QF*;9$!O0_P )
M_P!GVZ4 <))H]Y'X3\/&TU6ZN[W4C%<75K>:K+"U^?))9(Y 3Y>"=VT8!"\U
M!;:G)<KIGAU[G6-.MY-;DM-06YO-\L.(#*D"3J<E&.W!W;NHS7I=[H6E:CID
M>FWFGV\]G%M\N%T!5-HPNWT('3%1+X8T)=&;2!I-G_9S'<UOY(V%LYW$>N>_
M6@#S;7IKS2IM>T+2]6OULX9]+:*7[2TDEJ\UP%>,.Q+$%0K;23]X]C74Z+:'
M0_B-=:1:W=[)8S:4EV8KJZDGVRB5E+ N21D=1G'%=!;>&M$L]/\ L%OI=I':
M&59C$L8P9%(8.?5@0#D\\"KWV*V^WF^\B/[68O)\[;\VS.=N?3/- ')>-9_M
M&L:1H\4>I74\R33FRL[O[*DJ+M&Z24$, "PPJ]2>1Q7'Z/J6H7=K:Z'=7]S;
MV,GB:>PEDCOWE=(E@\Q8!/PQR_RYX..,UZGJN@:3K@A&J:?;W?DDF(RIDH3U
MP>HSW]:B_P"$8T+^SI].&CV0LIV#RVXA4(S   [<8R J\^PH XG55@TZ]M?#
MMEK]^;"YUB*"\5KER]HK0LZPK,3N =E7^+(W8&,UFZQ--HA\;6ECK%\;>R&E
M-$LEX[FUWS-O4,22 1R<GH<= *])C\,Z'#H\FD)I-F-/E):2W\H;'/J1W/ Y
MZ\"LO2?!&G:5JFMM':6G]F:E!!";,1#;\GF;MP/#;M_Z4 8GC#5;B'Q+JUM;
M7TL?E>$[RX\N.4C9('7:^ >&ZX/6J^CV]QK/BV22YU#472PTC3[J&VCNW1'F
M82$LP!^;.W!!X.><\5V5EX1\.Z=%+%9Z-90I+$\$FR(?/&V-RD]P<#@^@K0M
M]-LK2=I[>UBBE>-(6=% )1,[5^@R<?6@#Q[0[OQ!<:/H?B,R-'>7=Y%YUY/K
M3&*??)AX/LY&T<94*!D$#GK6A)<7>G:P^LWTU]=V/]L;%U73M4++&IFV+;R6
MK?+M!(0[03WZ\UZ'%X4\/P:N=5BT>R2_+E_/6$!@QZM[,?7K0?"GA\ZO_:QT
M>R-_O\SS_*&[?_>_WO?K0!1^(EO=W7P[U^&R#M<-9285.K#'S >Y&11>:WX:
MB\!#4;DVT^@M:J%B"JZR+@!8PO0D\#;ZUTU847@KPQ!J@U.+0=/2\#^8)5@4
M$-_>'8'WZT <S';0^)/$7B5=4U&_L8M,$*6D,%V]L+:-H5?S2%(!.XMRV0-F
M/6LGPVU[XSU72$UJ_P!0$,GAR*YEAM[F2W6:0S.HD.P@Y*\\<<CT%>AZIX7T
M+6[F.XU/2;2[FC7:KS1!CMSG:?49['BKR6%I'>"[2VB6X$(@$BJ PC!R%SZ9
M.<4 >3Z+"VJZGX!N-0N[R>XCDU&'S6NI%+B%V";L, 3A1D_Q#@Y%-M/MEOX#
MAUQM:U-;K4=2^P7-T]VY6VMC>&,E 3M4A1C=C(W'FO3I/#>B306L$FEVC16D
MQN+=3$/W4A8L67T)))JPFDZ<FF/IJV-O]A<,&MS&#&P8DME>AR22?K0!YQXB
M@&@W>M:-IUY=S6-SX:O;F>WN+IY_)=0%1P7)*[MS C.#MSVKN+&::V\#VT]O
M'YD\6FJ\:8SN81@@?G4ECX7T+3+2ZM;+2;2""Z4I<(D8_>KC&UO48)&/>M2*
M*."%(HD"1HH5548  X % 'E=ONLO#'A/Q):ZS?W.JZG=6B7/F7CNEUYQ E3R
MR=J[06(V@%=GUK>^&FF6]A;:^T+7+$ZS=Q?OKF24;4E8#AF///)ZGN3716OA
M70+'5&U.UT>RAO26;SDA 8%OO$>A/<CK6A:V5M9+*MK!'")96FD"+C<['+,?
M<F@#ROQ\9+Q/'=M/<7!M[:TTZ2*-9W548M)N. 0.>,^N!Z"O4[6."UBBLHI6
M;RHQM624R/MZ DL2Q^I-0SZ/IMU]L^T6-O+]MC6*YWQ@^<BYPK>H&3^=5['P
MYI^FZHM]9PI#Y=FME''&H"I&K%L>O4\>G/K0!S7C6RM]1\<>#K2YNIK>*0W@
M/DS&)I/W:G8&4@C/L02.*PUU"[L-6CTN#4KJ33;/Q5!:PS27#.Q1[8LT+.3E
MPKG&&)[#L*]'U30M*UM8UU33[>[$>=GG1AMF<9QZ=!^51'PUH;:)_8QTJT.F
M]?LWE#9G.<X]<\YZYH \X\<SG4;/XDVKW<TD-G9V;)$L[!8WVN2, XYXR.AX
MS7ISQG3-#D6Q629K>!C"LDC2LY ) +,2S9/<G-5[7PQH5E9W%G;:39Q6US&(
MIXEA 651GAAW^\W7U-7K&QM=-LHK*R@2"VA7;'$@PJCT% 'DR65O)HO@+7'U
MB]N=0U#4K26X\Z[=TF=E9F C)VKL.0-H& ,4^>:>3P!JGC*35[^/Q!;74Y11
M=N(XG28HEOY.=A! 4$$9.[.>E>B1>$/#D&HG4(M$L4N_,\WSEA 8/G.X>ASS
MQUI\GA70)=7&K2:/9-?A@_GF$;MPZ-_O#UZT >;7]QK>LZKXJN)([A&TV8Q0
M2+K36BV*")6#F,##9)+%FR"..@J75&UG4G6^FE?5!'I-O)/#I6KM:2V,A1F:
M9%R$D#=06/\ #C&*]#U+PKH&L7JWFHZ/9W5PH \R6(,2!R ?4#T-+JGA;0=:
MGCGU+2+2ZEC78KRQ G;UVGU'L>* )]"OHM3\/Z=?02S2Q7%M'*DDR@.P9006
M XR>^.*\NTB*ZM_"/A+Q&=6U274[G5+>"9Y;V1D>&28QE#&3MQM[XSD9S7KZ
M(D<:QQJJHH 55&  .P%4UT;3$LK>R6Q@%K;2++#$$&V-U;<K =B#S0!YG<O)
M<^#/$GBRXUF_M];L+J[$(2[=8[=HI&6*'R@=A# +G();?]*W/!]G'_PL#Q5>
MN+A+ETM&>-KB1E4O%N8;2V.",#C@<# XKI[CPKH%UJPU2?1[*2^#!O/:$%BP
MZ,?4CL3R*M#1].76#JXLH!J+1>2UR$ <IUVD]QP* .9\0AM5\>:5H-Y=W-OI
MDEC/=>7!.T)N9E=%"%E(8A58M@'Z]*Y>"^O+C5(/#,FJWK:+_;\UD+P7+"5X
MTMQ*L!E!W?ZPE<YW$+C->F:KHFF:Y;K!JEC!=QHV]!*@.UO4'J#]*C?PYHKZ
M,NCMI5F=-7[MKY(\L'.<@=CGG/7- '#ZJ8M/EM?#UCK]^UC<:W';79-PYDM$
M:%G$"S$[L,RK_%D;L9YIVIF#0=2L=/TW7;V2-==LUGM9;AW^S+(C_)O8DE6(
M!VDG'XUVB>&M$CT9](32K,:<Y)>V\H%&.<Y([G/.>M,3PIH$>CRZ2NCV8T^5
MM\D'E J[?WCZG@<]>!0!P7B[5KT77CF*RU2XA:VATM8C%,?W#O*V[:,\$@C/
MKQFO1M(TF#1; 6=O-=3(&+;[JX>9R3U^9B3^%5K?PIH%I:2VMOH]E'!,$$L:
MQ !]C%EW>N&)//<UL4 >26<E[K%]H-A<:IJ"07.M:O'/Y5TZ-)'&TA5-P.0!
MM XZ#IBNM\#^;;7?B32C<W$]M8:EY5M]HE:5T1H8WV[F)) +'&2:Z"+1M,@E
MAEBL;=)(9))HV5 "CR9WL/0MDY]<U/!96UK-<2P01QR7+^9,RK@R-@+D^IP
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[]KV31+9IGD\UA@^6S]=Q3.TGW(K:73[1=2;45@47;PK TO<Q@E@OTRQ/XT
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M;RS29#.6RI*C;]T'&6Y[5VW@ZZU:\\'G[=-'+?1O/#'*)HY2P5F";V0E=X&
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M+03>=*7:2R94#!S_ !E/-W GGY*[ZS\.Z/I[6AM-/AA^QF4VX08$7FG+[1T
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MR2_\" A'_ 36IK1FT?X@6NO3V%Y=Z>^FM9[[2W:=[>3S ^2B@MAAQD _=&:
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M\1CC+!Y?-D.P8ZM@@X]ZWKW3IAXX\*3P6CBVMK.[BD=$^6/*Q;5)[9VG ]J
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MCCD82R%RX&>,!#M&",]#[4/\1-)M?$,UI>WEO#8?8(;J"8AB\A=I WRXS@!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 A 8$'H>*JZ7IEIHVF6VFV$7E6EL@CB3<6VJ.@R<D_C5NB@
M HHHH S)=!T^?7H-:F222\MT*0[IF*1YR"RIG:&()&[&<<5?\B'[1]H\I/.V
M;/,VC=MSG&?3/:I** "BBB@ HHHH *ANK=+RTFMI&D5)D*,8W*, 1CAA@@^X
MY%344 4M)TFST338K"PB,=O'D@%BS$DDLS,2222223ZU=HHH **** "BBB@
MHHHH **** *U_91:C8S6<SS)'*NUFAE:-Q]&4@C\#2:=IUII.G06%C"(;6!
MD: DX'U/)/N>35JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBH+R\MM/LYKR\GC@MH5+R2R-A54=230!/16+I?BS0]8>=+
M._4O!'YTB31O"PC_ +^' )7_ &AQ3=+\8Z!K5ZMI8:@LL[H7C5HW02J.K(6
M#CW7- &Y15#5M:T[0[1;G4KE8(F<1IP69W/154 ECUX /2DTC6].UVU>XTVZ
M6>-',;C:59''565@"IY'! H T**IZCJUAI,<,E_=) L\R6\6[J\CG"J .223
M_7H*N4 %%%9T>O:7-+81PWL4K:@':U,>664(,L01Q@"@#1HHHH **S=9U_2]
M MXYM3NU@$K;(EVEWD;T5%!9C] :9HOB32?$ G_LVZ\QX"%FB>-HI(R>FY'
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MG+YMNY8+( 0&P2"1GJ,@X/0]1Q3[B\MK0PBXGCB,\@BB#M@NYR0H]3@$_@:
M)J*JV.I6FI?:/LDPE^S3M;RX!&V1?O+SZ9JU0 445#=WEM86S7%W/'!"I +R
M-@ D@ ?4D@#W- $U%58-2M+C4;NPBF#75HJ-/'@_('!*\]#G:>GI5J@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM[;7&GQ20WLXN+A6S\\H"@/G.00%7!&,8I^C^']+T%)AIMJ(FG8-+(SM(\A
MP-SL2QP.F3Q0!SLVQ?C-;&[QM;1&%COZ>9YW[W;_ +6W9TYQ3/&6N:=H:ZW>
M:?'&?$UMH[2AQ&6*0AL*6/3 8DX/)P>V:Z76= TOQ!;);ZI91W*1MOC+9#1M
MZJPP5/N#46E>%]%T6VN;>PT^*..Z_P"/C?F1IN,8=F)+#&1R3UH YAXKOPSX
M@\-I;Z[J&HQZJ\D%S'=S>:),0M()4'\&"HX7C#=*YO2AK4WA_P #ZC)XGU<W
M.MS+;WA,P*F-HI'^52,*PV ;ASR3FO1M*\(:#HMU]IL-/6.8(8T9I'?RT/54
MW$[![+@59A\/Z5!::;:Q6:+!IKA[- 3B%@I4$<^C,.?6@#SN\OM5L=/U?28=
M=O8Q:^([.SAO)I-\L<4HA9@6/W@-[?>S[U<U;49_"FIZQI@U[4/L3:2MTD\W
M^E36TQF$0";N3OW# )P"/3-=%XG\&VVM6306\%NIN=2MKR]$N2LZQLFX$<\E
M$VXZ5<@\&^'[?3[VQ73(W@O0!<B5VD:4#[H+,2W';GCMB@#@5U+6-*UZYM =
M<M()]#O+D1:I>I/)YD>W;(NUFV?>/&<'TXK0TK^T]/N? ]])KFI7;ZTOEWT5
MQ-NB;-LTH*KC"$,HP1SCKFNLM_!7AZUE,T>G S&)X&FDE>21HW #*69B2,#H
M3QVQ6A_8VG;=.7[*N--P;3D_NOD*<<_W21S0!P>FZSJMQ>:?X/>^G.J6>J2B
M]N-WSO9Q8D1B?]L20H3WRU=1XW;4O^$?6/2KI(+J2YB0*;A8'G7=\T4;GA78
M @&F:#H%Y!XDU7Q#JR62W]VD=M$MH694A3)&68 EF)R>.-JCG%;6IZ58ZS8/
M9:C;)<6[D$HW8@Y!!'((/((YH \NN?$VI:7X>U:RM9-;@U);RSA:WU%XY);1
M)VV;HYBQ5PV&P6/RGKQ2ZA?^(]$L/$,8;4K.W&B3W,:ZAJ4-Q<1S)@!X]KE]
MI!.<\ @8QFO0K;PEH-KIUY8)IT;V][C[2)V:5IL<#<SDL<=LGCM4=MX+\/6E
MK>V\>G*R7L7D7!EE>1Y(_P"YN9BP7GH#B@#GYTO/"0T+5KC6]0O+*6Y\K4C=
MS;E7SE 5P, *JR!>.P<U@SZWXAO;?0 C:C)'XBN[J]\JUG2&9;=%!AB1W("
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MLA\V;!:3J<<\=\\YQ6+9>(?$.NQ>&]-8ZE="339KFX-A<QVTUPZ3>4"78KP
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M[N*!$MVF:P:2X,B*RH"5S&0N<<;=IQ0!Z//XFT*VTZ'49]8L4LIP3%.TZ[)
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M5\V\667UY!R1W!H ZJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT$$<RR)=/)C9Y<G *G/).,8/I5?_ (6%!8QZBFLV!M+JSM1=B*WN%N!/&6V
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M5S"1D*3COG!SBJTGC+^RI;Y+:PO]1N9M>;38X7N5XD\A9!M)&$CXZ=LL>>E
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MT.I7$,9$BMA5D9=G 'W< 9[]: .MHHHH **** "BBB@ HHHH **** "BBB@
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MGZ9J36SSV<*6X>V+;61%"J?F&02!S3I_%>@VVKKI,VK6J7Q=4\DOR&;[JD]
MQ[ \FK]_?VNF6<EY>SK!;QXW2-T&2 /U(% '/>+/#]_K=Q"8[;1]1L1$R26.
MJ1?*KDY$B.%9@<<$=.G2LJQ\%ZYH2:#<:9?65U>Z?:SVDR7AD6-HY75P$8;F
M&PJ% .<@=J[^B@#SNW\$^(;%=.N;?4-/DU"UU2[U"0R(ZQRB8,"N!DK]X^N/
M?O<;PGKDMOJE[+<Z8^JZE<Q27%M)"9+1X8UVB [ANY!)+X!SVQ7<44 >:)\,
M99='U&%QIEF\]Y!>VUA!&TME"\78JV-P?)#8 [<<597X>SWUIJD5W;:'I/VJ
MV6&!-(LU^1U<2"1I"JLWS*GR<# [GFO0JPM7\9^'=!OA9:IJL%M<E!)Y;@D[
M22 >!['\J .:"Z^_Q+T :X; #^SKU46RWD9S#N8E@,9XPO;'4YIECX+\20V/
MA_2+B]TS^S=$O8IXY(U?S;A$) # C"G![9R>XKM-'U[2_$%J]SI5XEU"C^6S
MH#@-@''(]"*T: /,X_AI<6HDT^VLO#;V;W32IJ%S8++=QQL^\IM92KD9*AB>
MF..*Z%O"MR;#QC;B>'.N-(8#SB/=;K$-W'JI/':NKJLU_:IJ,>GM.HNY(FF2
M+N44@%OH"R_G0!R,OA#55U#S+>XLS!/H*Z3<"3<&5D$FUTP,$$OSG' K!\1:
M%#>7OA+PO!>JVIPVR6FIQQ G=8A5:0L>REHE49_O&O5:,#.<<T    P!@"N5
MUKP?_;FLZM-<3JMGJ&C#32%SO1M\C;O3^,?B*ZJB@#C8/#_B+4;_ $4Z_=:<
M;72)?/3[&'WW,H1D5F# !  Q. 6R>]9=KX)\1PZ=HVBO>Z9_9>D:C%=1RJ'\
MZ=$EWA6&-JG!/0G) Z5Z-10!QESX.NYO"OBS25N8!+K5S<30N<[8Q(J@!N.V
M.U-NO#.OV=WK T.ZT];;6%5IOM0??;R^6(RZ!>'!"J<'&".O:NPM[F"[@6>V
MFCFA;.V2-@RG!QP1[US4GQ*\'12F*37K99 2"I#9R.O:@#8\/Z=)H_AO2],E
M=7DL[2*W=TZ,40*2/;BL37O"EUJ_B.:Z$MO_ &=?:3)I=XC[A*JL6(:/'!.6
MZ&NEL;ZVU*QAO;.99K:9=T<B]&'K5:TU[2KY[5+:]BE:[21X N?WBQL%<CZ$
M@4 <W;^&O$5[+HEMK=WIQL=(F2=7M0_FW3HI5"P;A!SD@%LD=J[6BB@#SO2?
M!?B*/0M$\.ZI>Z:^EZ;+#,\L ?SIO*8.D>", !@,MG) Z#-5S\-;FW:ZL[2S
M\-O:SW3SIJ%W8K+=PH[[V3:RE7(R0"3P,<'%>F4C,%4LQP ,DT "J%4*!@ 8
M %<+JOA3Q#)<>)8-+N]-2PU]<R/<!_-@8PB)@H'# A1R2,9Z&NLL];TW4&MA
M:7<<INK?[3!C/[R+(&Y?4<CZ9'K5^@#FM'\-W&F^((]1DFB:-='M]/*KG.^-
MF);Z'<*SM%\%WFF/X;,EU W]E?;?-V9^?SV)7;D=N^:[:B@#RJW^&6JQVME"
MZ:%]IM+Z*ZDU/RW>ZO=DH?#L1E"0.<%N0!P*Z!/!=XNKK>?:8-@\0MJVWG/E
MFV\K;T^]GGTQ7:T4 %<A=Z#X@L=;U>]\/W.GB/5MCRB\#AK>54$>]-H(<%0O
MRG'(Z\UU]% '%1^'/$NBW]]/HM_877]HQQ&XDU ,KI.D8C,H"##;@H)7CD=>
M:F\->"V\-ZK9RQ72S6UMI"V&6&'>02EV?'0 [CQFNOHH X.T\&:MIT'AY[6Y
MLGN-+OKN>19=X1XYVD)P0,[@'';&14DO@K4#\/9O#T=["MRUW)<;LL(Y4:X:
M7RWQAMK*=IQ[]:[BB@#S5/AW?FXU.:.#0],CO-%N-,6UT^)E2-W((<MM&_H<
M\#&!UJYX]$>G^"+"P6Y5=<B> Z4J#<TES&5P%'<')!_V6-=]1@>G2@#-\/Z1
M'H/A^PTJ-MPMH51G/5V_B8^Y.3^-4/$NBZAJ-_H>H:;);+<:9=M,4N=P5T:-
MXV&5Y!P^1]*Z&B@#SZ7P5KO]@W7A2&]L%T"XED_T@A_M,<+N7:,+C:3R5#9Z
M'I7H"J%4*HP , 4M% 'GGB/P+JNO:A<&3^QV$EPLEOJIB,=]9H"#L4H &Q@@
M$L.O(-7=>\+Z[JM[?QQRZ0]M=J8XKVXM_P#2[*-EVND>%PW\1!)!!;G.*[:B
M@#C!X9UG0=6O+KPT^G-;WEO!"\-^7!A,*;%92H.X;<94XY'7FMWPSHB^&_#=
MAI"S&?[+'M,I7;N8DDG'89)P.PK6HH Y/7]#UV;Q7I^NZ))IV^WLY;5X[TO@
MAV1LC:/]C]:AU/1O%/B'0+S3=5DT>)I)+>2%K4RD?),KMNW#T7 QWKLJ* ,1
M=$F7QM<:YYL?D2Z;'9B/G<&61W)],8<?E7"V&C:[X=\2^&-*TZ6QFO++0)HY
MO/+K%*!+%P& )4Y(.<'IC'.1ZK10!PUGX%N8[O3+N[NX)IEOKN^U#8I57:>)
MH]L8YX *CD]!FH8/!NOMHVG>&;R]T]M#L986$Z!_M$\43!HXV7&U3\J@L"<X
MZ#-=_10!YQIUA:ZQ\6[Z_L+D3Z98JLUPBCY%U':T/7H6$8Y'8X]:TKSP7>7/
MAGQ+I:W, EU;4&NXG.<(I,9PW'7Y#T]:[4 #I10!Q_B7P2?$NIW\DURL5K=Z
M0;#@9='\W>'QT(&!Q5/2/!=];ZE#<W.G^&;!8()$W:99*))W9=NXL4!C !/"
MDYSR<<5WE% ''0>$+N+PUX0TPW$!ET2>WEF<9Q((XV0A>.Y;O6AX7T74-#DU
M>"YDMI+2XOYKNV:/=O E=G97!XX) &.M=#10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "-]T_2O$=)U7Q3IGP;TQC9Z3_ &'+:^1+=9DEDMXG)4R/%@!@
M,\@$_EFO;SR,50L=%T[3=$CT:VM573HXC"L#$N-AZJ=V21R>M 'G6L:O>^"[
M:.PTJ]\^VL/"ZM [@,I<2QQK*?4!3G&<8K7,.J:%XUT"P/B.]O[6^M[IIXKK
MRR2Z(I# JHP/FZ=!QBMB;P=86FD20:1:P+<QZ>]A;?;&DFB$1.[RW!;)7.!Z
M@<#CBL'PYX)N+;Q19:M<:7;:9%8VTL*1IJ$MX\K/M& S@;(U .%'=NU &%X4
M75-$\&>!]3BUN\D6\N;>TELW">0(9-PP!MR&& =V<YSVXI^G6VLV.AZW_9&H
M7D\TGB2:*6+SXDFDB5F+^274+YC<$Y[*<8KT>/PUI$6EZ=IJ6F+33I(Y;6/S
M&_=LGW3G.3C/?-5)_ ^@7#7K/:2@WEPMU(4N95VS+G$B8;]V_)R5P3WH I^!
MM3:]BU*TEO=3EGM9UW6VJ6ZQW-LK*"%9EX<'!(8=CCG%<OXTD3Q)XNO-*?3-
M2OK+3=/>#=8PA_*NYU&&.6'*H 1[N:]#T?0=/T*.9;*.3?.X>:::9YI96 P"
MSN2QP!@<\5+I^DV6EF[-G#Y9N[AKF<EBQ>1L9.23V &.@QQ0!P%CXIU/Q%I7
MA/3A=S:;>7TTUMJDL8431R6Z'>@W A69AG.,@5%XFTRY\S1+"7Q1<W;0>(84
M0HT8G@5XBP$A .6&"5) X;G/6NSN?!NA72W0>S96NKH7CO',Z,LX7;YB%6!1
ML#&5QGO3'\$:!)I!TQK24PFX%TTGVF7SFF'_ "T,N[>6[9STXH V;ZT2_L9K
M222:-)D*,\,A1P#Z,.0?<5YKIF@6[>!O'VA6$D.GP'4+F&)Y'VQQCR8OO,>W
MJ?<UZB!@ #MZU0BT3388-0@6U4Q:C*\MVCDL)6=0K9![$ # XH \\O[C5M1\
M4>$+>?1O[#Q'=P%OM$;G:;9@2FPG]VI"')QSMXJBS:O:>'/!.DG1H;=+'5+*
M)+^*YCDBN0#@M#M)8[UW,=P'&[K7HVD>$M'T.Y-S9PS-.(O)22XN9)S''UV)
MO8[5X' QT'I46G>"M"TJ_BO+2UD#P%C;QR7$CQ6^[[WE1LQ5,Y/W0.N* /-M
M/EUBU^'5[K=V-,N-/CU&>6\TZ:V+27!%T0S-)NXD! VC;_"M=U\4 S?#G50C
MB-CY(#L.%/G)R:OS>"= GU-K^2TD+O.+F2$7$@@DE'(D:(-L+9 .2.O-:>K:
M38ZYIDVFZE )[2; DB)(#8((Z<]0* ./GAUC3/$L.@P^(+VZ75M-N7$MP$+V
ML\>P+(NU1A3O^Z1C(&*3PWXFU#Q-J>AVZRM"UG9//K" #F<,85C/I\Z2M_P
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M1M3LM7\1:UIUI%96SV\6GO+M+,9-Y(16]%ZXK>LO$&G:!X:BU*WN]4U72GO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEY]ELKI9Y/LL5X"@.TQ2%@C ]#G:: -.BN._X3ZUN?$7A^QL(9[BRU:&:47
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M>;O4[2>1N7VYKC+'PAK&EV_AR^NK'5W$&CBPNH-+O!%/"XD+@_?4.IS@@'C
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M^4)?8TGFA0W 8*W&[C)%8X\/:S=:Y<7L6G:T;>70[RS$FJWB22M,^PJ-@<A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYGV\9X')XYH Y_2/&7B>XTKPWKE_!I0T_6+F*V:VA202QF3(5PY8@C(SMV\
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M1\0M1T&?4Y5O="Q8RX&F8>:YEC&,LSHV(B1D@%3CC)JAXQ;-_P"-B.\.C?\
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MMK#)Y2.)$D<,=ZGKC:!QCG!J]9>"+6SETR<WL\US:7LU_--(%W7,TL;(Q;&
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MC']TUA^(]$CTWPMXCMH;.^U277;F218;>,$QRO&JJ2?X5!C4[CT-=#X9T?\
ML#PW8:87\R2&(>=)_P ])3\SM^+%C^- &M1110 4444 %%%% !1110 4444
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M-5>>ZN+Z_LXGN)KBX>3=@'  8D# .. .G.: .WJK!J5I<ZC=V$4P:YM%1IT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0Y
M*G!P<<$B@#S#4]#MM-U;2K#2[NYO?%\EZEU<7OFMN2#S,R-*,[1&5R@3H3C
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MW"9X^[G'&:AU7P#>7MIK.FV.OM9:5JSR2SV_V42.DC_?V/N&%8\E2#U.",T
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MZHRSF7[??27ARN-A8*-O7G[O7WH Y#Q5\0+_ ,.S:C(SZ%%'9'*6-Q>9N[I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXNVC,H:(2;4 0_-UY/'3UXI-XJU"7QEIE^ACCT*7P\^I21O,P94S&Q;:%P7
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MQO*H6QGMG%<SJO@35;K3M;T?3M=@M-)U:26:1)+0R2Q/)RZHV\#:S9.",C)
M/<=1KVD'6O"^HZ,)_)-Y:26WF[=VS<I7.,C/7IF@#E;WQWJ6F6VFIJ5EI5C>
MZJ[O:"XU#9#% JJQ:5RO##<!M7.2>M1M\3470+RZ\FQ>[L[Z*RFDBO-]FOF
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MU,02SR!0S+"I4Y S@%L9/';-:#^,=1U/5K*P\.Z=:W O-*CU-+B\N&B1$9L
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M=WW"O7YLYYS5JX\%:CJ.@ZM:7VK6ZW=\T+1FVL]D%OY3!U 3<2V2.26Y[8H
MW]8UH>'_  Q<:OJ,0+6T >6*!MP9^!M4D#.6. 2!65:>(]9MM<TW3O$&EVEL
M-3#BVDM+EI=DBKO,<F57G:"01D<$5J:IHG]O>%IM'U28%[FW$<TUNNP!\#YT
M!)QAAD D_C699^&]7GUO3M2U_5[:\_LQ7^RQVUH80SLNPR29=LG:2,# &30!
M#;>-I)_">@:V;%0VJWD%LT7F<1B239D''..M'@._UF_?Q"=6:%EAU6:*(I,S
ME=N 4 *C"CC'KD\#O0MO &JPVFE:6VO0'2=*OX[RVC6S(E<))O"2/OP0 2,A
M1V)Z8/0Z!H5UHFH:PS7L4]E?7;7D4?DE7B=_O@MN(8<#' _&@#>HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3+*UO+O4[>.WNP#;N&W><,9R@&2PQSD4 7I+&UEOX;YX$:Z@1XXI2/F16QN
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MIP6.,?W&H [&BL*]\9>'-.O9+.[UBUAN(G"2HS<QD@$;O[H^8<G YI^I>+M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^5  .<$\"E/Q)M6T6&XCM(SJ4M^VG?96NU$2S*-S$S8QY87#;@,G(XSQ5?\
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M+RZCCO+?S()([ARS1L.H(^7##N.G-=%X8T2YT>"[:\>R,]S+YGE65LL,4*@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)([!510,DDGH *XBS^)^E7EMH-Z9+6WL=26<SRRW*_Z*T:JP5CTW'<./<=:
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M0P11)AU ^\6";@O]W)SQ71_VKIYM+:[%];_9KID6"7S1ME+_ '0IZ$GMCK0
MUM(L&FL)C;J9-/!%JV3^Z!78<<\_+QS65#X%\-6]]%>1:6BS0S>?#^\?9$^<
MY1-VU,GKM S5X^)=#76!I#:O8C42=OV4SKYF>N-N<Y]NM:;,J*69@JJ,DDX
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MST7O]1TH ZBBLW7M:M?#_A^]UB[9?(M86E(+!=Y X4$\9)P![D5S\?Q&T?\
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M?M,KW=LMOYORJID6, %58CN 3R<<UV-% !1110 4444 %%%% !1110 4444
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MM&Y!:-U8JRG'!PP(R.M<?X;TJ7QSH@\1:GJ^K0RWLDC6L-E>O EK&'94 5"
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M;Z/-8YAT6Q@E^UQOL<J9@&4KSD8/'?=U% &XOC.XO])TZ^T?1VG%W&[R-=W
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MF>!(PLD"^(;S-Y<R72$IY\AW,&"D'@?+P?X10!UU%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]6L;FVLT+3/!<HX7T!(. 3T&: -BBO.+#XGRZ@VAV\5II O-6+2)%_:X(AB
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M.MK.[,"3S3@)(@52'W' '+%<<X*GFM&SO;34+5+FRNH;FW?[LL,@=6^A'!H
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M[$\S;'C*AXV<@>N.]>R44 >3RV$RZ)HGB'5K.62VO=9.JZI#Y1<QQO&RP;E
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MQ& XDMV:V!.<8*Y#9Y]:O^--&O'UCQ';Z':-')<>&T7;;Q[?,(G;*C&,MLR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5G:[K5KX>T:XU.\$C10@#9&,L[,0JJH]2Q 'UK1K#\8>'
M5\4^&;K23)'&\A22-I$WH'1PZ[E[J2N"/0F@#,/CEK/[9'J^CS6-S#82W\,8
MG243QQC+J&4\,,C(/KD$TEEXWN;J]T^";P_=VR:I \NG/)-&?.*IOVL ?D)7
MD9_'%9,'@*\DAU/_ (D_AC2&GTV>SB738,EY)%V[VD,:LJC^Z >O).*Z!_#E
MTU]X3G$L.W1E<3C)R^Z QC;QZG/..* .>\->*=1U+2/"ESJJ7:WM]=W"((9H
MU2XVQRL-X ^[\I ''*@]*K:%XHUW4V\*RWYD@^TZQ?0RXD7$T:+<;5(7LI11
MSUVYK3T/P;K%A'X;@NYK$Q:)?7$JO$[EI8GCD5<@KPV9.1G&!UINE^"]7M;C
M28KJ6Q:STS5+NZ1HW??+%.LW!!7 8&4=\8'6@"W;_$*.=+;4#I-PFA7-PMO#
MJ)E3DLVQ7,>=P0M@ ]>02 *BO?B.;--1NO[ O9=,TR^-E=W22)\K!PN43.YQ
MEESTZ]^<9&E?#*?319:>ND^%VMK6=6_M5[0/=R1*V0I0IM#XP"^X^N,ULW7@
MR_G\+^(-+6>V$VI:JU[$Q+;50RH^&XZX4],T 61XZCLWU2/7=+N-+>PLQ?%6
MD27S(22HQM/WMRXV^I')I]GXRE-_!9ZKHT^G274,DUING242;%W,C;3\K[><
M<C@\\5!XF\$R>)-3U1Y;B.*UO='6P4@%G202M(&(Z%>1QGGFJ.C^"+JWU.*Z
MFT3PMI@@MY$WZ9; R3R,NW=N,:F-0"> 23G&<4 6]*\?OJ T2YGT&[M--UEE
MCM;J25&_>%"P#(#D [6P>^!P,U9\#:WJVM+K9U2V,7V;4YH(270X56QL^7^[
M@<]\U##X1O8O#7@[33/;F71)[>6X8%MKB.)D.WCU88SBM#PQH^HZ+>:W'<M:
MO9W=_)>6SQLWF?O#EE=2,#'&""<^U &)!XTO-/UGQC)K%K*--TJ:%+?RV1FR
MR1[44#DL[/D9Z;@#C%;6F^*+B;6H=)U?1YM+NKF%IK7=,DJ2A<;ERO1AN!(]
M.A-9&J>"]3U&_P#$R+<VL5GJK6]U;S?,98;B$1A0RXP4S'DG.><8J_9Z-KNH
M>)K#6->_L^ :=#*EO!8R/)O>0 ,[,RK@87 4 ]>M &GK.L7MA<V]KI^C7&H3
MS*SE@PBAC5<?>D;@$YX R3SV%8?_  L.)M'L+R+2+N6ZN]1?3/L:.A9)U#Y&
M[.TKE/O9Q@YIWBSPM?:UKUE?);:=J=C#;O$VG:C*Z1"0L")0%5@QP,8(Z=#5
M#1_ >I:=:Z7#)-IX^QZ]+J;+;JR)Y;QN-B+CY2"_3I@=: -!?'H@CNAJ6D3V
M=Q97MO:WD9E5UA6;&R7<."O(ST(YK>M=:CN_$-_I,,+DV,43S39&T/)DA/J%
M )_WA7-ZYH]A9)XPO_$%];6^DZO!#"'9L&/;&4YS_%D@KC/-6_AUIU[9^$H;
MO52QU74F^VW;,,'<P 4$=L($&/:@"6_\67,>K7VGZ3H=SJC:>JF\>.5(PA9=
MP1=Q^=]N#C@<CGFN>O\ 7[OQ)XN\*1Z6U\NBWEK)>[[:Z$)EPT8^<=<)N.5[
MD^U;,^B^(M+UW5[W0&TV6'52DLBWLCH;>94";EVJV\$*IVG;R.O-)HO@N31+
M_P .-#<I+;Z5IT]I(SY#R/(T;;@.@&4;OQD=: )/%&MZMIOBGPO96%L9;>]N
M95N '1=X6%VV\\C&-W'7;CO6!H?CC4;'2KNZU'2[RZTZ#5[BUEU S)^[!N61
M-J$[F5<J">W;.*ZGQ)H^HW^IZ%J6F-:F;3+IY6CN695='C:-L%0>1NR.*RI/
M!E^_@34-"$]M]IN=0DND?+; K77G 'C.=O'3K0!;U'QH]OJ&HV^GZ-<:C%IF
M!>S1S(FUMH<H@8Y=@I!(XZ@9S6W_ &JMWX>75M+C^UI-;B>W4,$\P%<CD].#
MWKB=6^'T[ZYJ][9Z1X;U%=3<3"75H=TMI)M"G;\C;U^4,%)7DFNYL-/%AHEO
MIR&/]S;K#F.(1J2%QD*O"CV'2@#SWP5XFU&#PWI"RVNHZMKNL1&[$<UXI7RP
M%W29/$298 *!G/:M2Z\63:E=>'UMUN=/N%UTV.H6CL-RD02/M)!(93\C CKQ
M2:?X/UK0;3PY=:;+83ZEIFFG3KF&>1TBGC.TY5PI*D,@_A.03TIUMX*U,WMG
MJ5Y=6K7S:W_:EX(]P15$#0K''D9. 5Y.,\_2@"+0/%]U#X?T^!H+C5M8O[V^
M2"+S O[N*=P69VX557:.YY  K4L_',,VH6VGW>G7%G>/>FQN(Y&4^1+Y1E3D
M<,KJ."*S+/P9K.D0Z3>V$UC+J6GSWI,4SNL4T-Q,9-NX*2K#Y.=I&01[TMSX
M*U>^TK6;N:[LX?$-_=P7D#Q;C#;/!M$:@D9;A3DX&=QXH NVGQ$T^^L;VXM[
M6=I+?5$TR.(D SL[JJNO^R02WT4U4M/&GV86UG:6&HZG=7VH7\$*2S)E6AD.
MX%C@*@&<=P !R:9IOP[DTWQ+HEY'=1'3K&RB2:#G=+<Q(Z))T_NROGGJ!5C2
M?!E_8:QI=Y)<6S1VE[J5RX4MDK<.60#CJ,\_IF@"PGCR,Z1)/)I5TFIIJ/\
M98TX.A9KC 8 /G;MVG=N[ &I;'Q=>7=]JNFR>'[J+4]/M4N#;^=&PGWEMH1\
MXYV]3CGCM6!X@T5M#M[S5KG4+:UE;Q"FHV<\BLT,9,2Q;9B!\JD!@6Z#*FD\
M+WFL:SXJ\3ZK:W.E7<HL+:VMI;=W>T$JF5MGF=7QN!8@<;L8XH ](B9GB1G0
MHS*"4)R5/I3J;%YGE)YNWS-HW[>F>^/:G4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<\
M\-M!)/<2I%#&I9Y)&"JH'4DGH*DK.UVTTR^T6YAUD)_9P423^9(44*I#98@C
MC(&>Q[\4 ,TKQ+HFN>=_9>JVEV80#((I02H/0D>GOTIFF>*=!UF[>TTW5[*[
MN$!8QPS!C@'!(]1GN*YFRLD\9ZY/K]S:/;:#_9LNGVXDS%)>12$%Y#C!2/"X
M7H>2W'%+IR1^*/$NC7VD6P@\/Z")%M[K;C[6[(8]L7_3)03ENC$#&0,T =Y5
M:QU"SU.W^T6-S%<0[V3S(FW+N4E6&?8@BN7\>Z\+"*RTDR75M'J+,MQ>06\D
MA@A7&_;L4D.V0H/;)/:J7PDO-.E\*W-GIP=8K74+H*AA= J-.Y0#<!GY>W4=
M#@T =M>7UKI\227=Q' CR)$A=L;G8A54>I)(%6*X'XCZ+:3'2=8E,TES#JEA
M'"K2GRXLW";F5.FX@X)ZX&*[Z@ HJ*YF6WM9IWD2-(T+L[_=4 9R?:O++#Q%
MK$>I^&KM-2UN\@U*\2">6[M(H+.971V!A7 D'W05/.0.3S0!ZQ17E$>J>(D\
M*+XJ?Q!<O)%JQMQ9^5$(7A^V>25;Y=Q;!^]D=!]:T=0\1ZQ9S:QX;%XW]L3:
ME#%ILY1<K;SY8-C&#Y:I,,D'[@S0!Z-16+XJU!M)\+WMVM^ME(B!4N7A,Q5F
M8*,(/O,2< >I%<!_PEFLZ!J6I OK5Q;1Z%<ZA''K,4*N98BH!7RP&"G=R& ]
MJ /6:*X.676/#6D?VW<>)FU$G3IKB6RNDC FE6(R#R-BJ0!@Y'S?+[C-.LH]
M9L=.L=5N/%;7#7=F\DUM<)$$>0Q%U\@*H(VD="6RH.?6@#N6177:ZAAUP1FE
MKS+2+_7[?1_!FI7FO7-W)KEW;_:(WBC5$1K>5RJX4$9(3//5>,9Q2^)?%VL:
M9J7B.ULYG=EN].M+4)&CM!YX.]E!P&;T#'&2.U 'IE5YKZUM[NVM99T2>YW"
M&,GF3:,MCZ#FO-)/$_B'P]:ZY,T&K3VEOI3W<#ZPD E2=2!C]T?F0AL\CC:>
M>:NR:5J&G>/?!KWFOW.IB47183I&,/Y'+)L484^ASCCGK0!WTU]:V]W;6LLZ
M)/<EA#&3S)M&6Q]!S5BN'\:6EQ?>,O!]O;7\EB[27>9XE4N%\GD+N!&2.,D'
M'6LR7Q!K.FW%QI#:E)<M9>(+"T%W(B;Y8)]C%'P -P#$9 '&.] 'I$TT5M \
MT\J111J6=W8*J@=22>@IX((R.17EOQ'O;RZA\9:7]MECL[?08;E8XPOWR\H8
M$D$X(50?TQ7=77GZ7X0N62[FFN+>RD9;B8*7+!"03@ 9_"@#8HKATUW439_#
M]S=G?JC)]L.U?WP-J[GMQ\P!XQ6!8ZIXB7POI/BB?Q#<RR3:JEK)9F*(0-"U
MR8<'"[MV.=V?PH ]7HKS">]\0/HWBW7T\1S1-HUY=?9+411>24B^;9)E=S;A
MQP1C@]:LZUK=[J.JR0V6HZVK1V<,OV/2+6(F!W4MF:64;>1C"Y' )/6@#OC?
M6HU 6!G3[6T1F$.?F* @%L>F2!^-$U]:V]W;6LLZ)/<EA#&3S)M&6Q]!S7E2
M>/-9CT6UUF1HY9O^$3DOV3RP%:<2(H<X&<<DD XK7DTK4-/\>^#7O-?N=3$H
MNBPN$C&'\CEDV*,*?0YQQSUH ]%(# A@"#P0:1$2- B*JJ.@48 KE?'%QK4,
M>G#2OMAMVF8WB:>T7VMHPIQY8DX(#8SCG'2N>7Q-+/X?LK:/Q%JCW3ZA+;ND
M>F :BP12WDE"-JLH*EGV@8]": /1;N^M;%8FNITA665(8RYQN=CA5'N3Q5BO
M'6U;4;V-]/U"2^D6P\3Z6L']H+&+A4=HWP_E_*>22.^",\U-XJ\3ZK;6^O:K
MIFK:S<-IT[B+[+:1+81!" 8Y&D&Z0YR&*D\G@<4 >N45PEN-;UWQKXBMT\07
M5E9:>8%MX((HR"TD )+%E)(!.0..<^U0Z!XGU37;OP]I9F\J]MDFDUO:HSNA
M)AV=.-\GS<=EH ]!HJKIMK/9V$5O<WLE[,F=UQ*JJSY)(R% ' ./PJU0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6=KNAV'B/2)M+U.-Y+.;;YB)(R%L$$<J0>H%:-9^MZJFB:/<:@]O
M-<>4!MA@7<\C$A54#W)'TH R(O 6BQPW,)EU26*Y@:WE2;5+B12C=1AG./J.
M:?I/@;1]$NK>>RDU-3;C$<<FI3R1@8QC8SE2,=L57C\97%G>S6>O:,]A,ME)
M?1>1.+D2QQXWJ, '>-R\8P<\&EL/%U\VJ:9::OH+Z<FJAOL<GVE93N5"^R10
M!L;:">"PXQF@#H=.T^#2[%+.V\SRD9F'F2-(V68L?F8D]2?ITJFOAK3$TJ33
M(XY8[62X:Y8),ZMYC2>83N!S@MVSCMTJ_>WMMIMC/>WDRPVT"&221NBJ!DFL
MKPGXC7Q5H2ZHMG+:!II8O)E/SKL<ISZ'CIVZ4 :&I:7::O;Q07L9DCBGCN%
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M]:9'D@N%;R#&F[# 9Y/3M4VL>([?1M8TJRN0B17WG%KB24(L(C3=DY]>G44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9/B;7X/#'AZ[U>XBDF6!1MBB&6D
M8G"J/J2.>W6M:B@#S/PYXDT8W&H>)-5U47VM+9LS06T$@2UMU^8Q1;E&XDXR
M3RQQT H\*>(--\3^)K75M5U!3JA5TT[3$BDV6:L/F)8J TI48)Z#H/4^F44
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MCD[@:=!-HND^([FX\3:>UI97&D6D6G1WT1F\N-5;S(,_-\^2N1DD\=:]1HH
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MQ DEVY5TW*"(OE)'3KT]Z[.B@#Q^\L4M+O4C+9,=!M?%:3WD$<)*"(VJ?.4
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M#J2/3<HS[5C+I/B'6]?TW4=9MK&QCTR.;RX[:Y:8SRR)L+9*+M0 G Y.3[4
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M1,BMG<K;#P/<<Y]N70>$-=T>31]6M5LK[4X+F]N+VW:9H8W:Z8,WEMM.-I
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M&7.1WQY,XS]*AU3QC=:MIUYJ%C]G?3(?[*1$EA60--/+&[GD=5C>/'H3GJ*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTSP9I.D)I$=IYX327G:U5I-V/-SN!XR1\QQ_6M>]U"VL(BTTT:OM9DC9P&?
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MM)+E[=+J!ITY>)9 67ZCJ*R++Q3;:K#'-IL+7$?]H/8RDR(ICV%E+X)Y&4X
MY(.<4 ,TKP=I^F:FNIRW6H:C?(ACBGU"Y,QB4_>"#HN<<D#-9Z_#?2ELX;$W
M^JFPMIUGM;0W(\NW97WC;A<D ]F+8!XKJ_M=M]J^R_:(OM&-WE;QOQZXZTDM
M]:0N$ENH8V9M@5I "6ZX^O(XH Q)_!6E7,VLM.US)!J^TW5J9?W6\!0)% Y5
M_D7D'M267A&"QN9;U]1U*_OC;-;0S7ESEH4/)"%5 !) RV">!S6UJ%XNGZ;=
M7K(76WA>4J.I"@G'Z5Q\?Q!OH]'@UO4/"=_;:-+$D[7D=Q%-Y<; $.R*V[:
M03@9 [4 =9H]I<6&B6-G=W+W5S! D<L[L6,CA0"Q)Y.3SS5VJ\NH6<%O'/-=
MP1PR %)'D"JV>F">M4[SQ!86.L:9I<LG^D:B',."-N%&22<]\@#UH U**A%W
M;&Z-J+B+[0!N,6\;\>N.M34 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M['.*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDW^AZ%$;Z!X;:\TZ(K*CQIN99"1E@5!.X8Y'(YH ]$J"[O;33X#/>W4-M""
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M1XTO7LK#2W2*"0R:O91$31AP TR@D9Z,,\'J#S0!TE%>;-XJUNT\4-;ZK?\
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M8B::.'[.C;_+'^L;<5!)R0.QQ0!Z517.>"]9?6M(FEDU2WU%H;AHA+' T#@
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M=^T#GK\A_,5I.Z1KN=E5?5C@4 4-=T6V\0Z-<:7>-*L$X7+0MM=2K!E(/J"
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M[I)9'8*J*.,DDT 8^J> ]/U.]U"<W^I6L.I($O;6VF"13X78"1M)!V@ X(!
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MCI(,HRL,XR#F@#@/#/@EY(M0N=7CO;<W.JP:A#%/<++.#"$VF5AE<LRDE5.
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M2S#+'&6(Z#%3>$]6T_Q/XDCUR^UO2Y-2\AX[#2;6\CE:TB;!<MM/S2$ 9(X
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M<@LX098CH2>^*>((@01$@(8L#M'!/4_6@#QS7;9](L?&6F:0B6FE1:K8&:%
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M9JF;7Q!XBU30/[0T4:7#I4QNIY6N(Y!+((FC58@A)VDN22VW@=*KV7A?5H?
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MTWQ!%)IW]FWLNXV!A97BMR2 _F[CEP,$C: <D<=: .T>1(E#2.J D#+'')X
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M!GKM_6@#M;I;:2UEBNQ$UO*OER)+@JP;C:0>#G.,>]21QI%&D<:*B( JJHP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9*AL'GIFM32?#Z:/J>J7<%[<O#J$_P!H>VDVE(Y" &92!NYP."2.*UR0HR2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$1QUV[BQ],DUVXMH!$L0@C\M3N5-@P#G.<>N>:%MH$N'N%AC$S@*T@4;F Z
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MTFO-1A(:"[:XU"2-P=WGO@=<@,#GD@5J65A;ZMJ>@6-\GG6LOB'6?-B8G;(
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M6_V:Q8/-Y4FU@$&<8R.IZ GBL3PUH&N:=KFF?8M+O]%M(BW]I0/J"SV,@V'
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M3((SFM;6K'41XYT#5;6Q:ZM8H+BUN&21%,/F-$0Y#$9 V'.,GVK$L_"^KP^
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M@EOU::25\XV)"CJV.Y;GKC%8]MXXU_6-*\+G2[;3H[W67NHI'N%D,41@+ L
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M=0\9#.VXE6X*MUZBM*;XCQP>)KR!HHCHL.FO<I=#.YYEC28IUQCRI%(XSG-
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M"(6"L& 3CH2&R?2@#UBBO.=9^(5Q'XAU#3;"\TNQ6PCC+&_@EE-Q(Z!]J["
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M.NS2Q/I=MX>@O1:!6W88R$*#NP&+#EMO(P,<9JUH'CV]N]?TRPO+G3;U-0#
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M,[=O /4UW6L&X71;YK21([@0.8W=20IP>< @_K0!;1$BC6.-51% 5548  Z
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M1:!=Z3--)"EPH'FQX+(00P(SQU K4HH P]+\/&PU'4-0GOI+JZO[>"&9VC5
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M,02CJW49 (Z$&MZB@#FK?P@L4FDSW&JWMY<V%Y+>--.P)E>2-D(QT10'X5<
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M]I"M#9WGDQDB @+Y3IC#C"KSP<@'-;6@: FAI=R/=37E[>S>?=74P :1L!0
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M=F[FFG50=Y15( 4  ?)P.W2MRB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCD6.2 /B5-K$E9%7)')!R*U]8\=KILVL7,$,=SIFE:;'=2R*2&DFE/[J,'H
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M74Y..F<CD<UTGA+6KW6;&]748H$O;"]ELIC;Y\MRF/F4'D AAP2: -^BBB@
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MBYP<'N#V(Z@^HJ[10!QC^![^_B@L=:\3W>I:3"ZN;1[>-&GVD%1+(!EQD#/
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M;'6;C[#*8;B:VTZ66-& !(+*#T!!_&NBL+^UU33[>_L9UGM;A!)%(O1E/0T
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MW8]Q0L?8%P?PK(UY=:;Q9J<?DZQ%:201"S_LB"(?:FVG<)IF4E<$X&2H YH
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M-L\"D9.,(Y+#CUZ]:\_\2:=JGB:/Q1JEGI%[;Q3:*NGV\-Q'LFN9-[.3LZ@
M' SC.37J2#"*#Z4 >>'XH02:?'?(D<$":Y_9T[3QR +#EP'&0OS'9G'.,X(S
M756GB_0;VPO;V+442"Q_X^C.C0M#QD;E< C(Z<<]JXB'2=3=X[&32;L&V\7F
M_,C1_NW@=Y75U.>0,C/H2*D\7>&=6U74_$\EG;3E9(],EBV,%-QY,DC.BD\;
M@,8SQG% '<:1XFTC7998=/NF>:)0[Q2PO$X4]&VN 2I]0,5/JVM:?H=JEQJ%
MQY2.XCC"HSM(YR0JJH+,< G '8UQ_AC3Y;CQ@-4:#Q$R0630_:=8=(SEV4F-
M8P@+#Y<[LX';.:U/'5E]KL;!S8:C<""Z$GVC3)MES:?(P\Q%Q\_7:5]&S@XH
M AUGQ[86FDZ=JEA=6\EG+J<=E=/,CJ800=X*G#*XP."._2M6U\8Z!>6%]?1Z
MBB06./M1GC>)H<\C<K@,,]N.>U<5;Z;X@O[*P%Y;W=S!#XCM[B"6[MTBN6@5
M>9)54 <-P"0#@#(JWXDL-<BUGQ1>Z9IS3?:+;3EC;R5E+!))#(45OE9U4@@'
MOB@#J+3QIH%XEZT=\R&R@-S<)/;R1.D0SE]KJ"5X/(!J-/'?AJ33Y+Z/4PUL
MDP@#K#(?,D(R%C&W,A(_N@UP4VD:Q?:IK5S';Z]=PW'AF[M(I]31%>29BI"*
MBA=H/;(&3FMGQ'H.H?9/!U[!'J*Q:5$T=S'INW[1$'B50RJP(.TC! YPQQ0!
MU2^+]!;1WU0:@OV5)?(;,;B02_\ /,QXW[^1\N,^U6](UW3M=@EETZX\T1/Y
M<JM&T;QM@'#(P#*<$'D5YU_8,LNEZG?R:-XAN!<:A;R":6[6.^ C3;]HC14&
MUESC:3EE&>.AZ;P*NL+)JIU WLMB9(_L4^HVZ174@"_-Y@4#(!P 2 >OM0!V
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !116/XJUJ7P]X:O-5AM3<O %Q'S@98*6; )VJ#N. > : -B
MBN 3QY?)X8U75L:/J$=H(3#<:==;XY-[A2K*?F1ESGGKGZU=\::[- NIZ*D8
M"R^'[V\\X,0RL@50!_WWG/M0!V5%<)H/B#7-/A\-6^MV-HEGJD26\$D$S-)%
M((BZB3(P=P4\CH>.>M95KX_M]+\/:#:VJZ;ITM_]ID#ZE>,L$"1RD$EF.YF8
MGA<^O0"@#U"BO/;'XCRZK9P6NG6]C=:S-J+Z>IBN=]J=L?FF8.!DIL[8SGCW
MJ/Q)JGC"--'ADMK.TG_MN& RQW#^5=(5++@#Y@N<AE/=1C(H ]&HKD?B3=ZG
M9>"Y9]+F6&?[3;*[EV4A6F12 1ZD@'V)K&CO/$\?CKQ*NFP:?++'964DWVF9
MQ&K[)/E0 9Y.>3C&!P<T >CT5YQ<?%&*9=(CMIM)TZ:^TU-1DDU:[\N.-7.!
M&N.7;(;GC &>^*?!\0]0UFVT2/0["PEO=1FNK=S+<DP1/!]Y@ZC+H1R"!SD=
M* .SAT+38-<N-:2V_P")A.@C>9G9OE&.%!.%'RC. ,XYK1KS/4_B?)9WFI0I
M/X?A.E'RY[>\O_*FNI54,XB&.!D[06ZD=JEMO%=X?%^I:P\J'P_%X>@U)8MS
M;UC/FMN"_=WG;@^P6@#T>BN+MO%.O6TNC7.M:;8PV&KRI#$+:9FEMG=2T8?(
M ;.,$C&#ZUVE !17E^H?%J*VEU*ZBGT066GW#P-:37P6]G"-M=T3H.<[5/+8
M[9%9VM_VM=^(O&NKP_8G?3M)1[*9I90UO&\4IS&!P&*Y)]\4 >PT5Y1I_B:/
MPAINC>'X6T'3;N>Q%_//?7;)#ACM7&?F>1L$GH!@]>*V+#XA7.O6VF6VC6MG
M)JEY-<12,UP7MHA 0'<,HRZG<FW&,[N<8H [F[M8+ZSFM+J)9;>=#')&PR&4
MC!!_"GPQ+!!'"F[9&H5=S%C@#')/)^IKS[4]4\6-X@\*03VUK92/J%Q%,BW#
M&*Y587(<8YVD9(#<A@.W-6- \3>1<6-N+!(+&_U74+0R^<SE9TD<K][/#A7X
M[' '% '>45YW??$OR+>V91IUJ-0OKB"QN;ZX\J#R(>&E<^[<*HZY'-;G@WQ=
M'XG34(3)92W.GS+%)+8S^;!*&4,K(WY@@]"#0!TLD4<RA98U=0P;##(R#D'Z
M@@'\*?7#^*_&6H:#>7:(^AVL-O$)(AJ-[MEO#C)$:+RN/NY/4]L<U2U#XCW
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MPOM4TF"ZN-"DCU5_+2"POO.GM7*EE$B]QQM)&,$CK0!Z/161KOAS2O$$4?\
M:=L9_(#&/$KIMSC/W2,]!UK@O!<>C>%?A9:>-)[:62\33C)-)Y[L923TP3M&
M3@9Q0!ZI17G6E_$DSZK;V%S<Z#=R7D$LD(TJ^\XPO&A<I(/0@'##N.E+!XV\
M3/X>T;5I-'TW_B=7%O#90+<OE1(CL6D.W 'RJ>,\$]QR >@RQ1SQ/%*BR1NI
M5D<9# ]01W%/Z5YW<>,?%=M#XA#:7I+2^'U\Z[<7$@6>,QB4",;<AMN<[N,X
MZYX74_%ZZ5=>(=5M--$LT&G:?.-TS RB5W 7&=JXYY'7//04 >AT5R%MXCUZ
MUUV?2=6TRR>=M.DO[464Y^;8RJ8F+@#.77#<#KTK-TKQ[>W7B73]'GET&YEO
MXY2J:=>&5K61$+[9.Q!P1D8Y'2@#T&BO+/#.L7[Z7X7EUM(KJ6XUJ\CBG%Q)
MNCV_:,D]FQM*@'(VX[BM6+QQK']C6OBB;3+-?#MQ,BA1,WVE(7<(LI&-IY()
M4= >IH [ZBO/;[QQK\%GKVJV^EZ>VF:)>2P3"2=Q+.J8+% !@$ ]^I]._0>.
MI67X=^(I8V96&EW#*P."/W;8- '145Y?JWA73]"^'[^(]%>YL-6LK%;Q)TNI
M2'95#%74L596Y!!'>M?7?&>H:>4:-M#T^$VL<Z-JM[L:X9@24C1>1C &3W/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^:M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12.2J,P4L0,A1U/
MM7'>%M:\0:CXJ\0VFLP06RVT%K);6<;A_*#^;G>X'+':,XR!CCU(!V5%>=PZ
MQKFF^+-%TN]\00:AJ=[(WV_2XH4$5K%L9MZ,%#@*0H^<G=GH*]$H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>guyaragreement015.jpg
<TEXT>
begin 644 guyaragreement015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR7W$[B>2>2:V=)\2:5KE[J-GI]SYL^G2^3<+M(VMDCC/495AD=P:UJ .;O\
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M9F <D\_,><5-%X!;2]0M;K0=36R$.GQZ>5GM1<'RT)(9"2-K?,<]0?2NTHH
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MJ%S]AV7LBI (PK ! =K DD$,#QQQ7H*^"_#*3R3+H5@))'WLWDC[VX-D>AR
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MI'Y4"O$#Y:=-H/\ =]NE37_AO1-4LK>SO=*M)K>V_P!1&T0Q%QC"^@QQQVH
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MAEFVJ!YCD %CZD@#\J /,=%_MK3-7T"X@5PM[')YJW&NM=?VB/*+!D1AA6!
M.5P "1TKT'1-0U:_28ZIHC:6R$>6K723>8.<_=Z8XZ^M-TSPKH&C7CW>FZ19
MVMPP*F2*(*0"<D#T'L*UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?AF]T"^N-$U"YC/AJVT^1+6,.\4\9W%7!(P/FQGID<T =?/XQT&WT^VO7O\
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M>R>PABW,6>&5AN!P<J%/4X('->C:9JL>J-?*D$\)L[I[5Q, -Q4 [EP3\I#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'B?1#
MXC\/7.E"X^S^>4/F[-V-KJW3(_NXZ]ZUZ* .:UWPS<WVN6VN:7=VUO?Q0-:N
MMW;>?%+$6W %0RD$'D$'N158^%M9BTRVC@UZ.6[2662Y6ZLP]M<!_P" Q!@5
M"X&WYCCG.<UUU% '"1_#V>TT"VM;+4[>"^@U;^U5D%G_ *.LA!!18@PVIANF
M[KSWJ_-X+:;PMXBT4WX!UFXN)O.\G_5>;VV[OFQ]1FNK)"@DD #DDU%9W=O?
MV<-W:3)-;S*'CD0Y5U/0@^E ',7?A75H=2U&ZT+6H;%=31!=+-:F5D=4">9$
M0Z[6V@<'(R :KW?@ W=SJ,<FJ22:?J6FPV-TDJ%YRT0;9*)=WWLMDY4Y(KJM
M,U.SUC3X[ZPF\ZVD+!'VE<[6*G@@'J#5N@#D;3PGJ<\X&N:K:W-HMO);F"SL
MOL_G[UVEI3N;)QG 7 R<U6MO!>LB70HKSQ#%/8:).LEO&MEMDE"HR+YC[R"0
M&Z@#/)(].WHH IZK9S:AI=S:6][+93R)B.YB +1MV(!Z_3O7(KX!NKFXU:\U
M"^L%O+[3)=-#6%AY"8DZR2 N2[9 QR .?6NZJIINIV>KV?VNQF\V#S'CW;2O
MS(Q1A@@'AE(_"@#&NO"GVI_#Y-ZR#28Y(R43#2;X#%D'/RD9SWK L/AS?VMI
MHMDVK6"6FD74-Q&+;3O+>Y\L_P#+5MYR2">0!R<G/2O0Z* .4'@B&7P?J/AZ
MYO'=+RZFN1,B;3&SS&5< DYVMCZXJ;1] U>WU6.^U75;2988C%'!967V=7)Q
MEWRS$M@< 8 R:Z6B@#!\6^'6\3:1%:)<1PR0W,5RGG1>;$Y0Y"R)D;E/<9':
ML*7P#?7C:S+>:O;"34]);3/+MK+RXK<98@JN\D@;CD$\D]1TKNZS;GQ!I5HD
MKS7L86*ZCLY-H+;)G*A4. <$[U^F>: *&H^%8M3O-'EGG!AL+>>"2+9_KEEC
M$9YS\O ]^M9%OX*UE6T*VNO$,4VG:)<)+;1K9[9951611(^_!(4XR ,]2*[B
MB@"KJ5I)?:;<VL5U+:22QLB7$/WXB1PP]Q7&-\/[R_N;Z\U/4;#[9/IL^GK+
M8Z?Y&_S0 9)?G)<C P,@#GUKO:* .<N/"WVB7P\YO60:0DB':F#+N@,60<_*
M1G/>N>L?AQ?VMCH]@=7L$M-*NX;F/[/IVR2Y\ML_O6WG)(SR .3DYZ5WMW>V
MUA$LMU.D*-(D2LYQEV8*JCW)(%-@O[:YO+NTB=FFM"JS*48!2R[A@D8/![9H
M Y\>"K>7PQK6AW=TTD6IW=Q<F1$VM$9)"ZXY.2IQSWQTIVD>']8M]5@O-4U>
MTG2WB:..&SL?LXE8X&^0EFR<#@# &36UJVK66AZ9-J.HS>3:PXWOM+')(
M!)))   [U-97<5_90W<*RK'*NY1+$T; >ZL 0?8B@#*\6^'CXFT3[ MPL#K/
M%.IDB\R-RC!@LB9&Y3CD9%<;XF\':G#HGB+5IKR"ZN)M"EL4LK&Q,2+SN78-
MS$G.<YSG(Z8Q7IU0/>VT=[%9/.BW,R-)'$3\S*N-Q ]!N'YB@#F-.\-ZK+J&
MG:EKFK17ATZ%UM(XK4Q'<Z;2\A+-N;;D<!1R3CTP/!7A76;[P=X9M]8U%1IU
MF(;H61M#'/O0[D1W+8VJV#C:"< $^OHFGW]MJFGPWUF[/;SKOC9D9"1]& (_
M$59H Y0>"(9?!VH>'KF\=TN[F:Y$Z)M,;/,9EP"3G:Q'UQ4</A'4+TW$>OZI
M;7%K+9R6AM[&S^SJX<89W)9B6QT P!DUU]% '(6WA;76BAM=1\1K-9VMM)!"
MEO;&(S;D*!IOG(?:#G  &>:I0> +W3[S3[JPU.Q:6WTN#3F:]L/.VB('$D7S
MC83GD'(Z5U%]XATW3M6L]*GEE-[><Q110/(=N0NYMH(5<D#<V!6I0!P^G> [
MO2;?PZMKK*/-H\]PQDFML^?%,Y+*0&&&P<;NF><=J6T\"WFD0:9-I6K11ZG8
M"XC,L]L7BGBFE,A1D#@C!Q@ANWOBNWHH XZ'P-($MYKG4_.O_P"V$U:ZG\C:
MLK*A01JN[Y5"[0.3T[YK:LM$-GXHU;6?M&\:A#;Q>5LQY?E>9SG/.?,]!C'>
MGZKXATW1KNRM;R67[3>L5@BA@>5FQC<<(#@#(R3P,UJ4 9&I:(=0U_1=4^T>
M7_9CS-Y>S/F>9&4ZYXQG/0UROB7PZNFQWVK?:+PS3ZQ#?PSVEIYQLF6)8MSH
M#F1, [L<X?VS7H-% 'E.G:!J/C"Z\4RW.HR/;W]M:6T5ZU@T"%HW=V$<3'=M
M&0,D\DGGBN]O- %WXHM=8-QM6&QGLS"$^]YC(=V[/&-G3'>MFB@#A;/P7KNG
MZ'I^FQ:[8W$=E ;7R+O3R\$T7&PLGF9\P8/S X(.,5?T7P_J'A>ST+2M.N%E
MLXYYWOSY*JI5P[C8,_(!(5 49X^E=710!F^(=)_MWPYJ6D";R/MMM);^;MW;
M-RD9QD9QGIFL:P\+:G_:VFWFM:Q%?1Z4C+9I%:^469EV&20[FW-M)' 4<DXK
MJZ* .!M/ &J6]KI&F/K\+:3I%['=6L2V6)7",6"2/OP< D9 '8GTKH?#^@W.
MAWNL%KV.>SOKQ[R*+R=KQ,YRX+;B&&<8X&/>MVL^+7--F*!;I5+W3V:*ZE"\
MR9W*H(&<;6.1Q@9H RO$7A,Z]?R7(O1!OTFZTW;Y6['G;?GSD=-O3OGJ*F?P
MT6O?#5Q]KQ_8JN-OE_Z[="8_7Y>N>_I6_3)94AA>60X1%+,0,X Z\"@"AK^B
MV_B'0;W2+IG6&ZC*%D/S*>H8>X(!_"L&'PEK%PSKJNN0-$+66V0:?9?9V<NN
MWS')9LL!G & "<UU5G=PW]E!>6S%H)XUEC8J5)5AD'!P1P>AYJ:@#@=/\ :A
M;'04FU33TM]&G66.*ST[RO/PC)F0[S\V&/(P,D\'/%S3O!^K:9':Z7;Z_P"7
MH5I<>=%#% 4N"@;<(6E#X*9X/RY(XKLJ* .1/@DGP5+X=_M 9>]-WY_D],W7
MVC;MW?\  <Y]_:NKEB2>%X9%#1NI5E/<'@BGT4 <=I?A'6;"'3]-?Q$QT;3C
M^XC@@,5Q(@!"))('PRJ".BC.!FLNR^&U_:Z?I>G?VO8I::9>0W4;0:=LEN#&
M^X><V\Y)&>0!SS[5Z+10!P^I>!K_ %:[2.^U:UGL([U;N*22RS>1 2!Q&DV[
M 7(QG;G;Q[T/X'U&"2^MM,UFWM=-O;E[EPUD'N("[;G6*3=@ G.,J=N:[BB@
M#,M%U)->O4E8'2U@A%L-@!$GS[^<Y/&SJ!U[U4\3>'6UU;"XMKE+74-/G\^V
MEDB\U,E2K*Z9&5*DC@@]"#6]10!QS^$=6N]+O[6\UY$?4)(UN/L=KY21VZ\-
M'$-Q*E@3ER3UX%,;X?11Z?J&F65^;33I+B*\L(4BS]@N$8-N0DX*%E!V8'5N
M>>.THH XR^\(:SK=K=+K&OH\DIMQ'';6S1P1B*992=A<Y=MN-V>!V]6:KX)U
M2[E\006&N0VFG:Z";J-[3S)48Q"-MC;P &"C.0>^,5VU% '(?\(EJ=A?-=:'
MK,-H]S:0VUX)[3S0QB7:LJ?.-K8.,'(Z<<57L/AZ;*RL+?\ M3S/LNC7&E;C
M!C?YK*?,^]QC;T[YZBNWHH YO_A$\V_A:$W8(T,C.8O]?B!HO7Y?O9[],>]>
M=QVU_<V^B^'-/NM1^S6FJ02#3;C2WCDMHHY@Y$L^2C(H'R[>6^7DU[110!6U
M"T&H:;=632/$+B%XC)&<,NX$9!]1FN*T_P"'^H6W]@QRZIIZ6^C3I+''9Z=Y
M7G[49,R'>?FPQY&!DG@]N^HH X6X^&T<TWB:1-2:-M6V-:_NL_8G#^:6'/S9
ME^?MTQ4EUX!9;3PVFGW=KYNB0M$JWUJ9XIMRJ&<J&!#Y7(.>Y]:[:B@#AX/
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M(4\_=.<$=#QZ5#;W%_9>$_#7BQ-?O[K4=1N;07$$EP6@F$[*'C6+[J[0QP5
M(V<YYKTN2PM9=0@OW@5KJ"-XXI3U56P6 ^NU?RK,M?!WAZRU,:C;Z5!'<J[2
M(1G:C-U95SM4G)Y !YH \\G?5D\#>)O$2Z_JGVZ.]NK:V7[0?*A1;O:N$[D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHX RISW .0:XGQ-K6O1ZQXUM$*QV-KX>\Z%X[HAXF*S8=0$^\2N/O<!003G
M /2Z*XC1O%VI02Z-::WI*6EOJ%HTEO<B[\U\QQAV\U=HVDKD\%NF*K6'Q-6[
MDTZYFL[.+3-2G2"W9-05[E-YQ&TD.WY0QQT8D9&?8 ] HJEJNEP:Q8M9W$ES
M'&Q!+6UP\+\?[2$']:X/P5H%L^HZ[=7.I:Q)_9>LR0P"75)V18T2-@&4OAAE
MCUS0!Z317GUG\3X[DV5[)9V<>D7UPL$+KJ"M<KO;:CO#M^522.C$@')%2W7C
M_488/$-]'X>1]-T1YXI9VO=K2O&,@*NP\'(R<\9[XH [RBN('C#Q$VL0Z3_P
MC$"WEW;&[M=VH_((U(#>:1'E6&Y>%##+=>,T:=XJCUS4/"MPUG<6\U[]M1HE
MNCLB>+Y7#*!B094X)QCKWH [>BN!TOX@ZE?66BZK<>'DMM)U6X2U247N^5'<
ME5)38!L+#&=V><XJ36_'M[H<DMQ=Z1:Q:=%<B#$VH!+J12X7S$AVD%><@;@2
M.>* .ZHKS#4O$6K0W7CD:C SZ=836R0K;7[1R(&$9 4A.-P8L3G@_+R.:Z.\
M\4ZK+J>IVNA:''J$6ED)=22W?DEY"H?RXAL;<P5EZE1DXH ZRBN)C\=WFKZA
M;6GAS1H[W[3I<6IK-<W?D*J.SKL;",=V5[9')Z8YZ'PUK:>(_#UGJR0/;_:%
M.Z%V!*,K%6&1UP0>: -6BO-]!\/Q^)-2\3W-[JFM)+!K,UO";;4YHEC0*A "
MJVW@L>U6]!\2:Q;^'+V!X&U>_P!.U673//DD$*NB\B65\': I ) .3VYH [V
MBO+]<\>ZK=>%O$$=C!9PZGIDULDLMI?^;%LE88*/LSNX*D$#&<YK9U#QW=6V
MJSZ7;V&FM>64$<EZMSJ@@59'7<(XB4RYQSDA1R/7@ [>BL_0M9MO$.A66KV>
MX07<0D4..5SU!]P<C\*Y:3Q]>+ILVOIHBMX:AF:-KO[5B<HK[&E$6W&P$'^+
M.!G% '<T5R$WB[59[K4FT;0!J%AID_V>XD^U;)97 !<0Q[2&VY[LN3D"EN/%
MNJS7FIC1- &H6NER"*Y=KKRI))-H=DB3:=Q4,.I7)X% '745S:>+-]OXFE^P
MLO\ 8@SM:3!F_<+-SQ\OWMO?IGVJB/&>I7>M:?IFF:$EP]SIL&I2R27GEK#'
M(Q4K]PEB,#'KSTQR =E17G$GC2_U?0%U.XT*2UTMKZ&"&6+4BLKR"Z6(\!/N
M9R>O(!'0YJW?>/M3MX=<OK?PZDNFZ)<O!=S->[7<( 6:--AR0&R02/0$T =Y
M17)WGBW47U/4+?1-%34(-,1&NY)+KRF+,F\)&NT[FVD'DJ.0,UL^'M7.O>&M
M.U=8/)-[;).(2^[9N7.-V!GKUQ0!IT5PR?$B'R_#9DTYTEU>=X)T\[/V-DD$
M3;CM^;]ZRKVZYI6\4G4=>TQ8+&7+7]]:6C"]*1S&&)LLZA3E2ZLHZXQNYZ4
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M>5$RF:&2(H V2<,,G..*2#P3K!TS3O#UYJUK+H%A-$Z;8&%Q-'$P:.-SNV@
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MVM^5<2O;FWNBA.V88VD]B-PYQVSC/>JVJ^$-!UJ*RBU#3UF2Q4I;#S'7RP0
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MEQO/)(LL@WL(Y''1GC!VL>!R0>E:U]96VI6%Q8WD0EMKB-HI8R3AE(P1Q[4
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M/&D%W')N^Y;!B4&.1P" .]=_H7@S1=#2&6"PB%VMN(6?<SA00-P0,2$4D=%
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MCN8]YD8J^PX7>%(&[&>.M;EQX7T6[LKBTGT^-X;BY-W(,D'SCSY@(.5;W!%
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M_P#Q+2J65C,)#Y/$+&!!\W'RG.>O>@#KSXGT%=,@U)M8L18SDB*X,ZA'(!)
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M"B'E@25[CKWP:36/&,R:/XBM=5TR\TRZL+%+O%I>*7>)RR@I(!\K H0>#^-
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M!XZ4 =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP5..X/!% &;X7L=0TOPU8:?J1MFN+6%8-UL6*,J@*I^8 Y('-:Y ((/0T44
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M=!97?]HEU\QH00LH903D[FRIZ\<UVU5H;^UN+VYLXIU>XM=OGQCJFX97/U%
M')0>&_$NCZC_ &GI^HV6H7MU9QV]_P#;U:,2/&6*R*4!Q]\C;CH!SFG:+X)N
M-)U+1+M[V.=[1;Y[M]I4RS7+HY*CG !4CD],5VE% '"MX*U*WNY-4L;JT_M&
M+6)]0MEE#>6\<L8C:-R!D' SD9P0.M13^"M<U.Q\2-?WUC'?:K+:SP>0K-'"
MT!4JIS@D909/N3@=*[^B@#@;SP5K/B.^U&YU^ZL84O-)?3EBL=[>42X</E@-
MW(Z8'0#WJ^^C>*M7MKBUUC4-/@MVL9K799*S>?)(NT2/N VA>2%7/)ZUU]%
M',Z*OB#31H>E7D5D\,=I(EU-;K(0"FU8]K' &03D$9ZXX%=-15)M8TY?LO\
MIL)%U,UO 5;<))%W94$=QL;\C0!1U319K[Q-H.J)+&L6G&<R(V=S>9'M&/H:
MY6Q^&LPTZWL+^\B: :)<Z7*T6=VZ657#KD= !W[UZ+6?K&MZ;H%FMWJEVEM"
MSB-68$EF/10!DD\'@>E ''Z/X%N[>^LC>Z=X9M[>UC99)=/L5$]V2I4$EE'E
M=<G:22>,@5R=K?7-[;^%?#EAK%E>066J6Q6V2!UO5AA?/[]"<1[%7D]R!C&:
M]JCD66))$.4<!E.,9!I<#).!D]Z /*]4^&6J7]GJ]KMT.2XO9Y)DU>XC>2[V
ME]RQG(PH'"Y4XP/NUOZMX,O=0O=:G2YMT&H7FGW" Y^46[(6!XZG:<5VU% '
M :GI,&BZ3XO7Q!>V<>@ZM*\R2C=YJ22(J[<="05!7!R34GAVTU[1/AJ]ZL27
M'B2\!OIDGC8[YG(PA"\C"[5Z\8YXS796U]:7SW,=O,DK6LODS ?P. &VGWPP
M/XU)%<P3M*L,T<C0OY<@1@2C8!VGT."#CW% $M97B31$\1^'+[2))FA%S'M6
M51DHP.5;'?! .*U:K+?VK:D^G+.INXXEF:+N$8D!OH2I'X4 <H_AWQ#K6HV5
MUKUQIJ+I\4WD)9;SYTLD9CWON V@*S?*,\GKQ70>&M,DT3POI.E3.DDME9Q6
M[NF=K%$"DC/;BM2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUESP>>&8<^M 'G\UYK6HZ)XF\21Z_<V4VE7-VEK:($\A5MR1B12I+%]I).>
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M.&:.4I%C"FU/#<=V Z]Z .ATCQMH>J^'%UUM0M;2S,C1LUQ<(NQ@Q #'. 2
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MDGG.B[S$Q7[CXYQR.#SQ0!UE%<W:^,K2^MO#LMI!)*VM@M''D PJJ%G+?[I
M4^Y%8EK\2[BZLM)OU\+WPL]6?R+-Q/&6>;!(4KGY5.UOF/IG&* ._HKCAX^C
MATZ]:^TJ>#4[6^2P^P+*CF6:15:,*_"X*L#DXP ?2F7'Q 33K+5FU32Y+:]T
MVU6\:W2=91-"6V[D<>A&""!CCUH [2BN0_X3'4/M<MA<^'Y[*\EL9;RQ$EQ&
MPF"8!5L?<8;E..1SUJ[X$U/4-9\$:1J&IIBZGMHW=]RGS<J#OP.!G.<=J .B
MHKA(/&2V,,<5M9:CJ-Q>:S>6,4<DZ%@\;.3@G $8VG'H/7%=!X=\0/K;:A;W
M-A)87^GSB&XMWD$@!*AU96'!!5AZ4 ;=%<S>>*[B+Q8V@6>C37;110W%Q<><
MD<<,3LRECNY)&W.!U&?2J%I\0DN!9WKZ3-%HM].L%O?-,A)+-M1FC^\J,< '
MKR,@4 =K2,-RD9(R,9%<EI_C>75-2>.ST6>:P2]:R>XCG1I(W5BA9XA\RID=
M3SCG&*AN/'L\7]L7$7AZ[FT[1[AX;RY69 0$ +,B'EL Y(X]LGB@#?T+0+;0
M8+A(9[FYGN9?.N+FZDWRRM@*-QP!PJ@    "M6N4N?&4TM]>0:'HL^K1V*(]
MU-',D8!90X1-WWVVD'' Y'.:@_X3TW][:VN@://J;W6G1ZC&WG)"@C9F7#%N
MC97&.>OL30!V5%<2OQ$BNK?1_P"SM,>6\U2*61(+BX2 )Y3!'4L<@MN. !G.
M">!5Z[\8M;VFE*NCW7]JZEO\K3YW6)H_+^^SL3@*..1G.X8'- '445C>'O$"
M:['=HUL]I>V4WD75L[A]C;0P(8<,I4@@_P JYZ3QA>:7XO\ % U2%ET72[*W
MG5E925W>9R%ZDN0 !GC:/6@#NJH7FCVU]JNFZC*9//T]I&AVM@9=-AR._!K(
ML/%=T^L66G:QH<^ER:@CM9L\R2ARHW,C;?NOMYQR.#SQ6IK6J7&F6\)M-,N=
M0N)Y1$D4. %X)W.YX10!U/? YS0!I45@^'/$IURXU*RN+%K*^TZ1$GB\Y95^
M9=RE77KQ[ C%<OXCU?4X?B+Y;QWHTK3-*;4-EM>B)92K9+.HY8<;-I^M '80
M>'[:'Q%/K;W%U<73QF*)9I-R6Z'!81KCC<54G.3QZ5K5@_\ "3P[_#B_9G_X
MGF?+^8?NOW+2\^O"XK$MOB))/;6NHMX?NH](FO!9&\:9,K(9?*#;.I3=@9Z^
MQH [FBO.?&7C74/^$9\32:+IEVUO8)+;-J44RJ8YE&"43.XJI(!;V. <5NZE
MXGU'3_,6TT"XO(K6W2:>YDF6"-LC.U"WWVP.>@&0,YH ZFBN/;QV;F72(='T
M>XOYM4T_^T(%,J1!$^7[Y/3[PZ9Y_.J]A\1'O8],NVT"[@TV^NUL?M,DJ92<
ML4QL!R5#@KN]>V* .XHKBKCXAQPK=WR:5-+HEG.T$]^)D!!5MKNL>=S(K9!/
M7@D T_4?'5S;7VMP6/A^YOHM%VM=S+.B+L,2R90'EFP3Q[=>10!V5%<1!XKU
M"Y\>K!#:RRZ(^BI?(4*ESN)(<*!N). FW\>]6K/QG=-K.EV.IZ#/IRZIN%JT
MEPCN&"%]LB#E#M!]<'@T =;17,^ +VYU#PA!<WD\D\QN;I2\AR2%N)%4?@ !
M^%<WI'C74M-L=9O-0TR\NM+LM7NHIK\S+F*,3$#:AY9$&,],<X!Q0!Z55'5M
M*M]9L?L5V7-NTB/(BD 2!6#;6X^Z2!D=QQ6')XR<>)=0TN'299+730CWU^9D
M6.%&C\P, >6XSP/3WJ#3_'ANIM,DNM'FL]/U201V5R\Z,Q9@2@D0'*;@..O.
M <4 =C17'7GCBYT^2.XN_#UU;Z5)>+:"YFE1)<M)Y8?R3\VPL1[XYQ4EQXTN
M/M5^=/\ #][J&GZ?<?9KFY@==V\8WB./[S[<\].0<9Q0!UM4;[2K>_NK&ZD+
MI/93>;#)&0",@JRGCE2"01]#U -<+#XQU;2[_P 7S-I5YJ5AIM\7DE$Z*((1
M!&Q5%8Y8CYF(XZ]<FO0/MMO_ &=]O,@6V\KSBY[)C.?RH G(R" 2/<=JIZ3I
M=OHVFQ6-KO,<>27<Y:1F)9G8]V+$D^YKFK7QW-*NG7=UH-U::7JDBQ65V\R$
MLS_ZO>@Y0/Q@\]1G%5_AY<:IJ=SKNI:I]L5SJ$]O'')=^9%&J2,NQ$'"E< ;
MOXLT =U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMD4*JL (/7&W+#N6:K?AWP?=6&O6^H7&C^&=-6VB=?\ B56H,DSL,;B[(IC
M&?E&<YY-=Q3)98X(GEFD6.- 69W. H'<D]* ,'Q;HVH:M!I<NEO:B[T_4$O%
M2Z+*D@"NI4E02.'ST[5RM[\.+@7^K&STSPU=)J-R]RM[J-KYEQ:M)RX"E")
M#DKDKC.#D5Z(+RV:^:R$\9NEC$S0AAN"$D!L>A((S[5/0!S>E>&YM-U?7+D2
M0F"^AMHH51=I3RHRAR   .> *H6'@^]M-*\%VCW%N7T%@UP03B3$#Q_)QZL#
MSCBNSHH XF;P9?2:G-="XMPDGB&'50"6SY:0K&5Z?>RN?3'>B?P9?2^"=:T0
M7%N)[_4)KN-R6VJKW'F@'C.<<?6MN]\8^&M.U+^SKS7=/@O,@&&2X4,I/0'G
M@_6ML'(R.E 'FFM_#W4]4O=>+P:+>'4B_P!GU&^WR3V:,@7RTCVE1CG#!AUS
M@UJ)X3U>'4A-'+8M!<:%'IER&9PR2(),,GRX*DOSG!P/PKMZ* .2\-^%;O1M
M4LKJ>>!T@T*VTQ@A.3)&S$L,C[ISQW]JY=[!_ D^A2R:MIEKJ"P7<#/?EDM)
MHGG\T+YN/D<$@@$<_-Z5ZK3719%VNH9?0C- '&?#+[5+HFJ7UU(DWVW5;BXC
MFC0HDJ$@!D!YVG:<>HP:T(_#ERE_XKN#-#MUA4$(R<IM@$9W<>HSQGBNEHH
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M<4 <Q--XAU+5?%SP>(Y;*'29E6SAC@B*Y^SQR'S"RDLN6Z @\GGIBG+XHO\
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M/:VFGVT-NZQV%T;V(F1BS3$,"[L3EB=[9SZT <->WGBBTL?&+)XIN6_X1O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<^U 'J:ZC8M?&R6]MS=J,F 2KY@'^[G-9VE^*=*U9M0$%S&@LKIK60R2*-S
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MC,RDHR9SM1GR4' [@"J]G(^@>#M'\7)!)(=+U"_BNHT7YGMI;F52,=\.(V_
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MTY[;@1[<CO7%WGCJ[NSX4N='TZZ:WU.^E@N(G\I74QK(&C.YN"&0G(XPAYY
M-JS\8PV]FD4$6HZI?W6HW=O;VQ\L.?*D8/SD*L:X !)S@CJ30!TVCZ5;:'I%
MMIMF'\B!=H+G+,<Y+,>Y)))/J:O5Q\OQ!L[:PDEN-,U".]AOH[":P"HTR2R#
M*8PVUE8$8(.#GZUIZ%XD.KZA?:;=:9=:;J%DL;R03LC91]VUE9&((^5A[$4
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M\V.X*%U!^;:5( PP.,,#ZX .QHJO8W$MU8PSSVLEI+(@9X)2I:,^A*DC\C7
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M"LUE)<F,B;:NXJ0K$HVT$X;T/<8J7PGXK/BVR%_!I%[:6,D:R03W)0";.<@
M,2,$=2.>HH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,B\+3:.Q#MCSWVX/W?N\'GK[5K6VB7^C^(K/5)S8G3(]$2QOI)9RAA\O<V\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<P6D)FN9XX8AU>1PJC\30!+144UU;VYB$T\49E8)&'<#>QZ 9ZFI: "BBB@
MHHJG=:KIUC*(KO4+6WD(W!)9E0X]<$T 7**K6FHV-_O^QWEO<;,;O)E5]N>F
M<'CH:LT %%%% !1437,"7*6S3QK.X+)$7 9@.I ZFI: "BBC(SC/- !145O<
MP7<?F6T\<T>2NZ-PPR.HR*EH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2^%=)FN(+S4]5U&:Z\BV@C19&CCF<9;<550J[ 22.2.IK4E\?Z;!I*7LEGJ
ME-^-.>S$0,\=P1D(0&P<\8()!W ]* .KHK$T+Q)'K5W?64EA>:??6.PSVUT$
MW!7!*,"C,I!VGH>QJK8ZG>2_$;6-,><FSM]/M9HHMH^5W:4,<XSSM'Y4 =+1
M6+K/B.+2;VVT^&QN]1U&Y5I([6T";@BX#.Q=E55!(&2>2<#-4U\:VDVFPW%I
MIVHW-U+<O:?8(XE$T<R EE?+!5P!G);'(P3D4 =-17+6_CNQD*QW-A?6=P-0
M33IX9U3,$KKN0L58C:V5 ()Y858O_&6F:=+JL<R7#?V:88Y#&@;S)9?N1(,Y
M9SE>./O#GK@ Z&BL/2/$J:EJ4NF7.G7NF:A'$)Q;W80EXB<;U9&92 >",Y&1
MQ6#KFL:F_P 2=,T=&U&UTV*T>\GDMS %EVN@RY<EO+ )!  ;)X]0 =U17)V7
MCVSNY;&1],U*VT[4)1#9:A/&@BF9ON<!BZAOX2RC.1ZUB:+XFU6XO/#:W-\3
M'=:CJD5QE5 :.$R^6#QQM"C\N: /1Z*Y*T\?V5T]G,VF:E!IE],(+34I8T$,
MK,<+P&WJ&/"EE .1ZT\?$#1Q:Z'.Z7*?VQ=&TA1D&Z.0,4;S.> &PO&>2* .
MJHKE;CQ1;7.L6-M!->PA=7?3V*1H4G=86=E))R%'J.=RXZ56M/B/8W:V=PND
M:K'IMU="S6_DC01"8N4"D;]V-PQN QGO0!V=%<=JGQ$LM,CU.Z&DZI=:=IKM
M%=7MO&AC61>J@%PQP>"0, ]3P2-;Q3K%QH_@S5-7LH&FGM[-YHD !P0N02"1
MP.IYS@'&3@4 ;=%>=6WC35QXFLX&TK4KK[1H<5U]@A2'>LGFNK2%BX4 @# W
M=QQG-;H\=:?-I6EWEE:7MY/JA=;6RB11,2F1)NW,%4*1@DG'US0!U%%96AZ]
M;Z[#<&.">VN+64P7-K<*!)"^ <'!(((((()!!K,O/&T%MJ-[;0:1J=[#82K%
M>7-K&C+"[ -C;N#M@,"=JF@#J**YO4O&$5EJ5W96FDZEJ;V**]XUFB%8 PW
M'<REFV\[5R<$>M0R>/+!]3LK#3;#4-4DN[2*^C>TC4H('8J')9AC!'(Z\CWP
M =517.P^,M.GT73-3CBN2-1NELXH-J^:LI8JRL,X&W:Q// 4]:S[/QE;P:;"
M%74=5O;N_NK>VMUBC65S%(P;^(*$4#&XD<8SR: .RHKECXYM/LL&W3-2;4I[
MB2U33/+43^8@R^26V;0"#NW8P1S6IH>O0:Y%<A(+BUNK27R;FUN5 DA? 8 X
M)!!!!!!((- &K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)>T/S?-YAE5^GI@'FNAHH \VUGP3=#Q-K&I6^B66KIJ>R2-I[UX#;2*@0A@
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M  <"N=\4^$-7U36+^XL]*LDOIBOV+6K:]>UFMQM _>JHS)M(..H(P.*])HH
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MW,B;0KKM(*HBCT.<9) R>U,TSP)INF)IT:W5[/#ITTTMK%.ZLJ"2,H8_N@E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUE((KR]AM]T%NYQD,V<G&1G:#C/.*+[QYI=C<7B_9=0N+6P?9>WMO;[X;=L
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M<L9""=TCEV P!QECBJ^O>'8M<DL;@7ES97EA*9;:YMMNY"RE6&'5E(()'(H
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M%"J%;YA@=>3FEMO UJM_/?:AJFIZE=3V+Z?(]S(B_N6(. $50I&WJ.>3G/&
M#F])\7:A>0W]O?ZG:SSC3)IIM.O=-DM)XI%7.%5LB2/J#SGIR<U8TS5O$&JW
MFD:1I=U8:9;OX>M;]W%IYFQV)78B[@ O ^@&.^1M0^!8/-234-8U/4C#;2VM
MM]I:/]PDB[6(*H-S$ #+9K0TOPO9:3?6]W!+.TEOIL6FJ'8$&*,DJ3@#YN>3
MT]J .''Q#U2[L=!M3(MG>7D-Q+>75OI\MWM$,OE?)$F2-S<Y;@#CDD5.WC+Q
M))H"2BUN8Q#J+VUSJ*:3*6\@)N69;=L-R2%/4#!//%="/ =C!9V$=AJ%_975
M@\[07D3(9 )7+NC!E*LI)Z%>,#OS3_\ A"+=+*%(=7U2*^BN7NO[0$RM,TCC
M:VX%2A4C V[<# QB@#$/BO69O!2ZAIMW;:I(M_\ 9Y[RPLWD>&#J7:W)#"0<
M KSC.>G%;O@K7)-;L+MI-5L]2\F?8DL,+P2!=H.)8FY1\Y]B,'BF+X&M$TZ2
M%=2U%;V2\^WMJ*R*)C/MV[L!=F-HV[=N,=N]:.A^'H=%EO;DW=S>WU\ZO<W5
MR5WOM7:HPBJH '0 4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 CMM1FV
MEL#.!U-06-T;RP@NFMYK8RQAS#. LD>1]U@"0"/K2WO_ !X7'_7)OY&O)/">
MCV&OWWA:VU6 7=LOA.*0P2DE&;S% ++T.,G&?6@#TCQ!XB30FL84L+J_O+Z8
MQ6]M;; S%5+L2795 "J>];(.0.Q]*\9T?2;"^N?!$=Y:QW(AU34[5#,-Y$47
MG^6F3SA=HQ]!4#C2_P#A!9M6::/_ (3P7K*'\S_2Q=>?@1 9SLVX&W&W;SCO
M0![=1FO*%T6QN+/XB:W/#YFH6T][#;RLQ/DK]E7(49P,[CGUX]*CM_">C+K7
M@F(VFY-1TZ=M0#.Q^V%8XF7S>?GPQ)YH ];JEJFK6FC62W=X[+$TL<(*KDEI
M'"*/S85Y,LEG!I-OX?DM8KBW_P"$AO[>TM[R[,-FB1ER$E.&+* ?E3') ]*R
M7@TZ7P_XDMYDTQM.LM>T]T2U)-K &:)9=A;HO+ G@?>Z4 >YP7;37MU;&UN(
MQ!LQ,Z@)+N&?D.<G'0Y YJS7C^NRQQ:EXC2*8Q:,U]I$=W) Y54LR@#88=$(
MP"1V)JMXICTO3E\36GA5H$TP^'99;R*R<&&.;>!$WR\*Y7?TY( )H ]IJAJ^
MK0Z/9+<2H\C22I##%'C=+(YPJC/N?P )[5QT.B6'AWXA^&UTN#[.;ZQNQ>,K
M$FX*>459\_>;+-\QYYK3\3$GQOX,23_CW-S<M@]/-%NVS\<%\4 =;17D5_'X
M?N5\:7?B:>)-:M+F46KS2[9K>$(# 8.<C/4;>K$YS4^AZ#!XGU_4O^$HM/M5
MTFBZ<TD4V<),\<F]MO0-D=>HYQ0!ZM17*>!@VK_"_1DOW>?[3IRQRLYR7!7:
M<GZ5YM%K%[9/I^LWDDWE>"C'IMZ.?WA=Y(9&QW^00/GWH ]CNM9M[37=/TB1
M)3/?1S2QLH&Q1'MW9.<_QC'![UHUY+;>&X;S5? ]IKD'GR7-KJ%]>0N3M>60
MQ2,K#^( OC!X^4539[.TL)?#[6J36G_"2W%O:6UU=F"T1%B#A)6PV4R20F.3
MCTH ]9U;5K31=-DU"]=EMT9%)5=QRS!5&!ZE@*NUX'/!8R^&?&MHZ:8UC9:C
MI\L<5D2UK S,BR%-W3C<"1@?>K8UB"UO/&6JV]T/#SZ9:V-L=,34[AXXX[<Q
M\O!MX^]D%AR,+S0![)17D7]J7GA+1= \52W#ZE]JTQ]/FD".//D :2U8A@&R
M2"F2.=XJMJ.BSZ=K6@:#J9TJXM(]):;;K$K+;SWC2$S-P,,XR" >@8XH ]FH
MKQC3]-AUD^$M,O[J+4=,DU/4%18'E\HPK$Q6,,P!=%88!Y!  R17:_$6!++X
M6ZM;VH,$<-LD<00XV*&4#'T% '99%%>:'P7X?7XDKI7]G(=/ET<W$UJ6)CFE
M68*)'7/SN S<G)YSUKEK=KF\TWP98WS6$NEFVNU1-6E<6\LR2[45B,[F$8.T
M-QU[B@#W2L63Q)"NHZE80V5Y<W&GBW,B0HIW"8D KEAD* 2V<<#C->96^P:)
M86=_J%K-X9;Q$\-Q]F>3[/%%Y1VP[W W1>=CGE>0N>,5#?1:/:/XUBT!XOL:
M7.C + ^8XV\_YE3' 'L. 2: /;:*\0\:S:?J"^,+W[+I:W%D[P+=:E=L;M)5
MC&T6\8'R+G&T[N3DFO2M2U1;3X;SZG<M<R*NE^;(ULVV4YCR2K=C[]NM '2T
M5XUX?2VT_P"(?A9+*'0[,W4%P)8M+NFG>1/*W*9GP QR,@D9)!.:CTC1K&S\
M#^$]?AB*ZN^KVZ->;B9"CW!0IG/W-IQMZ4 >L:]K-OX>T2ZU6[25X+90SK$
M6() XR0._K6C7A>OPZ#/X'\1WNL2PCQ4NHS1LSR8N%(GQ'&HSGRS'MX'&,GW
MKU7QKITVJ>#]1AM<B\CC%Q;$=?-C(D3\V4#\: -^LZTUJWO-;U+2HTE$^GB(
MRLP&UO,!*[><]CG(%>.3Z]?7=S=>([%YO*\7+)I-@O.(G4QQQ-^9N&S[5T<'
M@_1+_P 5^*[6]LEN8;&PLH;=)"2(P(7&X#LW ^;J.U 'J-%>&6\MUK,WAJ/6
M&TJYM6\.6\T":W,ZPR2DD2N."&D V=>0#D=36A8Z;#K<7@G3M1NDU+3I;O4
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M=(H3+(^(F9%4#G)<+5JW\9Z/<6Z2[YXG:]2P>":!DEBG?[JLI&1D$'/3!ZT
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M?-CS_P!-!7J%4H]'TZ+5YM6CLH%U"9!')<A!YC*.@SUQP/R% %O8 FQ1M7&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KF0PVL
MLJXW(A89]A7 Z7XJ\3+H_AO7M6_LQK+6);>&2UMX75X?.&$<.7(;DC*X& >I
MQD][=JSV4Z*,LT; #U.*X3P;X(NXO#OAM=:U*^D33XHITTV54"PSA?XF W,%
M). 3QQUP* (+;QEXE'AR[U^XBTQX'NGL+&TCC=6:;[3Y*.[EB O7( [9!YQ5
MO4_$OB+PQ)<6VJR:=>R2Z7=7MG/;V[Q!98$#-&Z%VRIW#!!!X(]ZVE\&:?\
M\(E-X=EEG>VDEDF$H8+(CM*90RD#@JQ!'T'6LK5_!UT^D:Q>76I7>LZJ=)N;
M.S$D<:! Z'(54 &YB%!)] .* &1^)M?TEM$O-?.GR6.K*5:.UA=7M9/*:51N
M+'S 0C \+SCM6/I/Q*U"]DTF]>2SFM]1GCC;3H+*<2VT<APK^<3M<C(+?*!U
MP>.>AT'P9)'#H\^L:G>7_P!@M@MM:7"H%@9H]C;BJ@N0I*@GH">IYJ73_!#Z
M>;*V37]2;2+"426UAE%"X^ZC2 !V1>RD]@#G% ')^(-:\5ZQX&\77WVG3;2P
MM#>6B)'!(9G$<A7=NW@*2H(Z'D9[X'2-XLO/#]WJ-KK[6LD=MI2ZC;36\31^
M<%RLJ8+-R&V8P?XQ6F?!]DWAG5M">><V^IR7,DK@@,AF8L=O&."W&?2L#7?#
MEQK>L^&M)N8KZ[&F2_:;O5)8TCCFB SY7RX!+.L>0!T7- &[?:_?:%\/VUS5
MK:-]0AM%EFMX<HOFD#Y!DD@;B!GGUK/;5?%.E:MINGZI<:5,VKK+%!+;VLBB
MUN%C+@,#(?,3"GNIX]^.HU;2[36])NM,OHR]K=1F*10<'!]#V/O6-I_A*2'5
MK/4-3UN]U66P1DLUG2-!%N&TL=BC>^WC)]3QS0!D?"2P:T\!6MW(MF9KO=*T
MD%OY;O\ ,?\ 6,6.]LYYXX.,5FVWQ U(:OI*R:EHUXE[?+:36=C;RO\ 9PQ(
M!%QN*,00,\#/.*[C1O#]MHWAJ#0DDDFMHHFBW.<,RDG/3ZU@6WP],-MI%I-K
M]_-9Z//%-90&.)0OEGY0Y507XXSQUSUYH RI_%_BF/2=5U\?V4-.TS5);0VO
MD.9)XDG\O=OWX5L=MI!()XS@:NI^,KO1I/$]M=00M=6,<4VFHJD?:5E^2-2,
M\GS05)&.HK0E\%V<OAK4]$-S.(=0NY;MY!C<K/+YI XQC/'TK-U?13X@^).D
M7#:?=16^CH\D]U( L5R3L:)%YRVUQNS@8*^] $_CR^U&P\ L1<""]N'MK6:Y
M@RHB\R1$=USDCACCGC(K$\5Z#X/\-:4BCP_>VK6Z?:%U72[+=+;%#DNTO7/'
M.[.1UKT#5-,L]9TNYTV_A$UI<(4DC/<?7L>X/:N6F\!7=Y9MIE_XNUFZT=EV
M-:,(E>1/[CRA [#'!YR?6@!DOB76[GQ5>VUD]A%I&G6EM>W$DT+O-(CARRKA
M@ <(<'L>QS5:#Q3XD@TC1_$FH#33I6IS0*UG%$XEMHYV"QMYA8AR-R[AM'?'
M2NIM/#MI9ZOJ%^A9A>VT-L\+8**D0<#'?D.<Y]*QK3P%';BPM)M9OKG1].F6
M:TT^0)M1D.4#.%W.JGH">PSG% %:?QEJ,7@;6=;6*U^TV6HS6L:E&V%$N?*!
M(W9SM]^OY43ZUXKO-6\2QZ8VE16NC2*L2SP.[W),*2%"0X"?>^]@]1QP<OO?
MAU'>17]D-=U"'2KVZ:\>R18]HE+AS\Q7=MW#.W/7\JJQ^$M4O_$OBV1M5U#3
M+'4+B)2D*QD3Q"WC4E2RDH<[ER/Z T :6N>)YG^%%WXFTU&CFETO[7"#R8RR
M9!]]N<_A58?#OPN?#,:-!'#<K$LQUA2!=+(!N,WG'G.>>3C\*ZR/2[*/1UTE
M;=/L"P"V$!Y7R]NW;],<5RI^'LDE@NCS>)M5ET  +_9[>7EHQTC,H7>4[8SG
M'&: 'MJ_B'5];U2PT"YTZ&'2EB1IKR%I3=2O&),?(RA%VLO.#R>!Q6=8>,=>
M\3WNE6NC+86 O-*:^FDNHFF,3K+Y;(H5EW#/?C@9]JW+WP>S:E<WND:Q=Z0U
MY&D5TELD;+($&U64,IV,%XR.P''%6-)\(:=HFH6=U8F1$M-._L^.(G(V;P^X
MGJ6R/UH Y;2O&'B:XL/#VLWJZ6MEJ=\+"2TAB?S%8EU\P2%L?>3.W;P#U)I\
MWBKQ4FE:]KZC2_[/T>]N8OLODOYEQ#"Y#-YF_"-M''RD$CMGCH(/!EG;Z)I&
MEK<SF+3+T7L;G&78.S8/'3+G\JY[2? ]]?PZ[;ZEJ5_;:;?:Q=32Z>%3;/&9
M25PV-RJPQD \CTR: %\3^-K_ $^[OOL>K:/;K;6ZS06DEM)=3W&4W?.(V'E
M]!D'UZ59B\2>(M=UNVL-';3K**;1+;4VEN87F9&D9QL #KD?*.>V#USQ>NO
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M"6+:0K-&L90H1M9<+T/.>0:O^'_#\>@QWC&ZEN[N^N#<W5Q*JJ7?:%X50
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M9'% '/V_Q%N=/ENOM\]MJMO'I\]YYUG8S6WE/$-QC;S"00PSALCH<BMF*_\
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M6MO=/%'I?V*=YYXT<HS"8':K'!(7:1T!-=POA*P3QJ_B@-+]K:W\GRLCRPW
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M_$&(ZG!&30!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%9^MSZE;Z/<2:/:QW6H8 @BD<*F20,L<C@ DD=3C
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MMV+$Q30/&\<Y4L$=2,J2!P3P<C'6I+_Q;H^FS7T5S<.)+(PK*J1,Y+RY\M%
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M227Q$^IQS6=MI5[]G21K:0;P53 Z?,Y9CA1R05..<D [*BL?1_$VGZU<SVL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M['D@*#RPK$LN>_';CKC'T3PEJ44.@Z1>:/K!DTZ>$SSSZL39*(B")(D#DDG
MPI48SSP*];HH \GG\'ZQ&NG:@]G?/]CU34I);>QNQ#.T,\I*R(P8 G &5)&0
MQ[U/+X8U.3PMK5Q;:/>I=W-_:7,=O>7WG7,\<$D;9=F8JK85@!NZ 9->HT4
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MDW.H:J]Q;)O7]XA\K#9S@?=;KCI38]3U*Q\<^-(;'0)]2,QM0C0R1J%?[.H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY:6*E8+=8EA\SY=H,S*?WF![ 9Y(-5].\"FP3386U62:WTW4I+ZU0PJ"H=9
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MFB>*0;D=2K#U!KBM$\-S3^&])T6^::"3P]J"&.0Q\7"1$^40?0HRY(Z$$=J
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M?R6;+;L61MBJ=P)YYW9^F*YC4?#[>%AHQL7U82V_VI?[1L;/[3M663S#%)"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQMC6&;:HD8 N . QZC%=/X-=H_A;<.C%65M0(8'!!\^;F@#NJ*\ATW1S)'X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFXECN+:6%Q%_?"NH++[@&I]#\2Z5XDCFETFX>XBB(!D\ET5L]"I8 ,.#R,T
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M0W_^CF?[,%\E_-,W_//RL;]_^SC/>FCQMX=_LJ74I-1$-M#,MO-YT3QO#(Q
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MSJ\FMK<+$HL=3EM(O+!&454()R3S\QH W:*** "BBB@ HHHH **** "BBB@
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MG!/4#/TQ7.'POK%OI_A^^>VU-%T^^U+SX=/=5N%2>9BDB@\$8 R!SAZ]<HH
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MTENY+74;2Z:&'!=DCF5FV@D G /&:S(M)OIK7Q](;"5&U09M5< -(#:(N/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_<M%Z_+][/?IB@#F+3QT=-T#08K6#3]-BOA<L+C4[J3R$*2E=F_!)9LD\D
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M))DGB>!D0YPY60*=O!^;&/>L1?B!8:AXFT'3-(G2>*_DF$K202(2BQ,ZO&6
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M7*^QV.>!A1M7'/.3@\<;>A^,]%UR>&TMKT->O!YP0Q.BR 8W&-F #@$]5)H
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M<]00!@')Z5V'@>QFTSP)H5E<P&"X@L8DEB88*N%&X'WSFM^B@ HHHH ****
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M,!QL8]QDYX]*DMO -_IMAIGV'6XSJ.FWMS<Q7%S:[DD6<L75T5AS\W4$=.E
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M$-GY<</V>3?M1=Y^4C Y.0<G)SB@":;QM?Z'<:I!XDT^VB:STTZE&UC.T@=
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M_P"$<7499);=KC4+@3RI:6_D01D*% 1,G'3)).23F@#HJ*** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\\<ESR0)60@JQ&<9! .?:MFBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUQ)?)%(3CYA&A&7('7IR*M7?Q)O9_$\.B>'O#K:L\UA%J"3&[6%?)?')RO&
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M$53\!7IU9D.@V,.OSZWB:2^EC\H-+,SK$G&5C4G" E03@#)% &D %    '
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M I()PX)'(XX)%7- \/ZE9:M)J&HSZ:O[CR8[;3K/R4ZY+LQ)8DX QD #UZT
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MWBR0V'A>>.Q4OKNT!&FP(2T#2CG;S]W'0=<^U5K/PSK\D-M8:KKD,FFVMN\
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M<7*@ DQ1[2".2!D@DBIM)U?6+SXEZK:,L)TE-/M98QY[;DWF3#!-F-S$8//
M4<G.!F:E\.+^\'B&WAO=,6+6))9&O)K(R7<8<8\L/NQM'0>@XQGFNAL?#M]8
M>*QJT=Y;M;36$-I=0M$=Y:+>59&S@ [SD$'I0!F^/8+^2\TJ1[35;W04\W[=
M;:5*R3,Y"^62%969!\V0IZXZUG:'XBT?0M'U[4-/U2_O;&V,6S2+L2"YM)6.
MT)F4[MKL5QG@'.":Z?7M$U6YU2TU?1-42SOK>-H7BN8S+!/&Q!PRA@001D,#
MGJ*R)? EYK,6K7&O:G"VI:A!#!')90&..V6)_,C(#,2QW\DD]L<4 4?&6M^)
M(?!>NIJ&E#3Y$LA/!=V%X95!WJ#&6*H5?GMD$9YK5_X3.]TO4)8/$FE0V$7]
MGS:C%);W7GG9%MWHX*KAP&!XR#ZU#JGA3Q%XATO4+75]<M5\^T^S116D#)$"
M65C*X9B2WRX Z $]<UIZ_P"$XO$&K17%S-BU&G75A+$!\S"?9R#VP$/YT 8^
MD?$4WFI:7!?6^FQ0ZJVRW^RZDMQ+"^TLJS(%&W(!Y!(!X/K67KWBS6M7\.V>
MI66FBVT:YU2UC@NTO")RGVE%WL@4 (^",!B?F&1R<;>B^$-5LKW3OME[I9M;
M <-::>(YKHA=JF1B2!CJ=O4^G2JC>!-:32K;0(-9M$T2TO(KF!3;,9RB2B01
M,V[&!C (&>![Y -:;QD8?#WBC5?L(/\ 8<\\0C\W_7>6BMG./ESNQWZ5C3>+
M!H.M^+M2NS++!#%IX@MC+@>9(K *">%RQ&3Z#/:IM6\#ZU=V_B+3;#6+2WTS
M6Y'GD\RU9YHG9%5E4A@"IVCJ,@$_6K.I> 1J?]M^;?!#?K9F%A%N\F2WR58@
MG# G''ID4 2^'_&AU/7O[%O4TT73VYN89-.OQ=1LJD!E8[5*L-P[8(Z'BE^(
M_P#;0\':E+I-_'8I#9SS3S!29B%0D+&<X7.""W4=N>1/H/A[4K/5VU#49],4
M+!Y,=OIUEY*$D@EV8DL3Q@ $ <]:UO$&F-K7AS4]*641->VLMN)",A2ZE<X[
MXS0!+I+,^C6+,Q9FMXR23DD[17*:3XZN]8UIK:UTZR>W2\>TEB&H 7D 5BOF
MO"5&%XS@,3@@\]*["RMS:6%O;%MQBB6/=C&<#&:XJ[\"ZCJ6JVLE_?Z?/#:W
MRW<5[]BVWVU7WB+S <8_AR!RHZ=Z ,K3_%NMZ+8^(]1DTU;S2;'6[I9II;TB
M41^;C$:;2"%!Z%AW KH/$WC#4="FO6CT[3UM+.,2&6_U$6[7/R[B(5VMG'3)
M(YX]Z6Y\%2W'A+Q#H@O4#ZM=W%RLOEG$8D?=@C/..E4M2\!7UUK&MW,%WINS
M5@-UQ<V1EN;8>6$*QMN QQD>A)X- &-XIUZXO%U>^LKFY@AF\&F]A19"I1F9
MB&X/#8(&178>++Z_L/AQJE]IS*+R'3GD21G*E,)DL#@_,!D@=R ,CK63/\/K
MB?2WM#J,89O#BZ)N$1QN'_+3KT]OUKJ-6T<:KX6O=%:;R_M5F]J90N=NY"N[
M'?KG% &#+XBURRTK3 VGZ<LTMJ)9[J]U$Q6Z'@!0^PLSD<GY0!ZFN>O?B'9O
M_P (EXDO)S86#-?K<Q)-YB.T:E  1@298?+QSD5K2>"=8EU'3]3FN=%NKN"P
M%DZ75DTD4>')$D2[\AB" >><#D4:;\.!;PZ/;ZA=07\%A/?22+);X\\7&[@C
M. 1N/_UJ +>I^-KK2M/TK[9IUK::GJLCB"WNKX)'$BC<6EDVX! *Y"@\D $]
M:T/"GBI/$?V^!TMTO+"58YQ:W GA8,NY61P!D$9Z@$$$5BOX"O1IVE1KJ5O<
M76C32BP>]M_-1K9QCRI1GD@!0&&/NCCK70>&]%N])CNY+ZXM9)[J4/Y=I;"&
M&%0,!5')/<DD]3VH Y_5OB*;34]4M[&WTV6'2FV7'VO4EMY9G"AF6%"IW8!
MRQ )X'K65=:AJ?B#Q]:7EA!!<:?'HL>HV*2:E+ OSL2)&1$(+9&W:<C SU.*
MV+_P1?KJ>JSZ1=:7'#JDGG2F]L?.DMY"H5GC.X Y !VMP#]<5KVOAAK77UU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'CGQ-UW5M2\1+X:.C>(3X;C"M?SZ98M
M(]V2 ?+5N $Y )SUR.U6M=;P^TF@7NI?#K4;K2O[/,,#^0TDEI@X$3VXX'&,
M,3WKUFB@#S3X=R:GX3\%Z)I^J:3J;O?7KI#$D>\V,3-E?-.?E4=?;->ET44
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M?='<W^EBPV-J.HZ.+.XA8-\L(?K)[]1^7/L-% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 8,?C3P[-JBZ<FIQFX:8P+\C>6THZH),
M;"W; .:9J'CGPUI6I3:=>:HD=W"5$D8B=BI(##)"D="#^-<]);6_B62U\.>'
M[58/#VF7B2W=X!\C212;_)A_O'>/F;H.1R35*]CU30=+\4^*-)\46TJ17L]W
M+:?9D:-B@53"[GY@P"!>".>U 'I]4[75;&]OKRRMKE);BR*K<(O/EEAD GIG
M':I$(OM.4NLD0GB^90Q5DW#ID<@C/6N.\%Z79:-XQ\6V.GVZP6T;6>U%)/)B
M)))/)))))/)H [FJ.JZO9:)8F\OY7C@#!2R1/(<GIPH)_2KU% ',:=\0O#&K
M7J6=CJ$DL[R>4%^R3 !_0DH /QK=TW4K35]/AO["836LPS'( 1N&<=#SU%<Q
MX _UGBO_ +&"Y_\ 04KC/#4%]H_@GPEK$&LZ@9)]2@MGMC(/LYADF*%?+QC.
M#G=USW[4 >R57OKVWTW3[B^O)1%;6T32RR$$[449)P.>@KR)]9\4W]AJNO6Z
M:HEQ;WLR0.=0MH;*%8Y"@CDC=P<$#YBPSDY':O0?'3%OAMXC9EVL=*N"1G./
MW34 1VWQ$\,7<T,,%].[S,JI_H,X!).!R4Q^-=17'>'8O&8L=*,]YH)L?*BW
MK':S"3R]HX!,F-V.^,5@3ZOJ*?$4^%1K<HTJ6[6X:[RWF1N5+_80^,#.-PYS
MM)7N* /4**\BOM4\2ZI=>)KVV75T;3;R:WM)+>^MX+6W$0&#*DCC<#]YBP(P
M>,5L6;ZCXLU?6$OM9N]*&G6MKY4=A<!41Y(1(TK$9$@W' R2N%/K0!Z+4,EY
M;0W4%K)/&MQ.&,49;YG"C+$#OC(S]17(^&]7N+KQ-K$4VK+?6L6E6$\4RX6-
MRPEWRJN2 &V@]?2N7T$7&LZG\-=2O=0O9+F73;F21A,1O*^6>?7.<'U 'I0!
MZGI^H6NJ6,5[9R^;;R@E'VE<\XZ$ ]JLUY7HOBB]TC1O#?B'6-0GFTV[L[B"
M[,C9"RH7DC?ZE4=/^^:BEO\ Q,\GAS2;G^U)IM0M+C4[N.RND@E+%U*PAW9=
MJH'P0IR<#MF@#UFJUMJ%K>7%W!!+OEM)!%,NTC:Q4,!R.>&!X]:Y[P)=:K-I
MU_;ZJ7+VMZ\,)FN(IIA'M4A93&Q&\$D<\XP3UKF=5OM>O-5UNRL;V601:U'&
M+..]6VFFA^R([1PNW0[CO(&,@'D4 >H45RG@74?M=A?VLD^IM<6=T8Y(-35?
M/M\JK!"RDAQ@Y#9)(/M7+>(K_5K#6-7U.YO-5.F6TZ^5>Z3=1R162JJEDGMB
M02<[BQ^8X8=* /5*JC4K0ZLVEB8?;5@%P8L'(C+%0V>G4$5RUOJ]P^M^-E:\
M?[/:6]O);@MQ$&@+$CTR1FN8T&TG\2>(]$DN]8OH)9?"-I-,UM-Y<LSEVRQ<
M<X!.3CJ2,^E 'J,NH6L.H6]A)+MN;E'>)-I.X)C<<XP,;AU]:LUY1I_BK64;
M2GDNI+O[/;:RI/07GV9U6)R!P20.W<FH] U#Q-CPUJS?VH?[0FA%W+?:C;&U
MG249/E1!\J1G*A1G"X(- 'K=0V]Y;7?F_9YXY?)D,4FQL[7'53[C/2O/M(:[
MU71W\47OBB[TZ==1D3RV<?9H8TN#$(6BX!+  9/S9;.>U7_AO8"S3Q&PN;J7
M.M7,>)I2X&UNO/<YY/? H [**\MIKF>VBGC>>WV^=&K9,>X9&1VR.:FKR?4)
M[GP[J7Q'UBQN[C[5$;81^;(7CC,D:9<J>#LSQZ 8Z5OK%=^&O&'AZRAUG4-0
MM]5$\=Q%>S>;RD>\2IQ\O(P0/E^8<4 =G/>6UK)!'//'&]Q)Y<*LV#(V"<#U
M. 3] :CL-2M-3BEELYA*D4TD#D C$B,58<^A!%<CX[L!>>(/!N;FZA_XFC)^
MYE*?\L)3GCO\N,^A([UR<<%]IGA+Q!XCM-9U"&XM->NFAMTD @V_:RK*R8^;
M.6Y//(QC% 'LE%>2ZAJ7B+5M4\3SVRZP@TRY>WM'M+ZW@@M]B*P:1)'!?).X
M[@1MZ5WKW&I7W@-KE%1=4GTPR 0.'43-%GY6!((W'@@F@"M<?$'PO:W<EO+J
MJ@Q2>7+*L,C0QMG&&E"E%.?5N*Z56#*&4@J1D$'@BN0\(OHJ_"?3&?R/[*&E
MK]IW8VXV?O=WOG=GWS6?'-'K_B+3-%T[4+W3]!CT2.^MTM':"28,^Q021N"J
MH'''WAF@#T"BO)[34=9U75-(T.37+U84U;4+&6[A8++<Q0Q[ERP&-P/RE@,\
M$\'FH)GUBS\-:_J@\1ZK)-H>K&VLU>8%6B$D?$HQ^\)#D9;L!CW /7Z*\VFC
MOM2O_&UR_B34+3^RI_\ 1(X9MJ08MXWW,,?,I)/#<<-ZU6?6+[Q(UJ4?79;D
M:5;7$]II<T=I':22J6+22NX+$]EP0 .AS0!ZE17E&@:AJ_BIO"$%UK5]!'=Z
M-<7%VUK((VG9)(U!W <'G.1@]?6I[#6-5TVSLM0N=3N+BRTS7KG2KMIFYDMV
MD,<<DA[E&V<^A- 'HEWJEE8W=E:W,XCGO9#%;H5)\Q@I8C@<< GFKE<;X;A_
MM_34\2ZC(69KR:^TWS6(6VA*-%'QTP4RY]WSVKG_  O?ZI8:UHRZ[=:NLU]N
MC%S]JCN[#4&*%@8RIS%T+* HX&.: /4JS)?$.E03W,$EV!);3Q6\RA&.R27'
MEC@=]PYZ#/.*QO%UQ=2ZUX=T2&]GLK;4IY?M$]NVR0B.,N(U;^'<>XYPIQ7&
MEKO0=2\21VVJ7,T@U[2H3/(^9#&_E HS#K\IV\\D=>: /7J*\JN]1U73M;N=
M3U*]U7[ NI[8M1T^ZCGLTB\P*(98,@J1]UFP2&YS5ZS:[U>QU7Q#>>*+O2I+
M34YH47>/LUO'%+L"/'P&W 9))S\PP10!WUIJ%K?/=);2[VM9C!,-I&UP Q'(
MYX8<CCFDU'4K32;%[V^F$-NC*K.03@LP5>G/)8#\:\WU#5=5N#?6R:Q<VF[Q
M?'8+,C#=' T$9*+G@9)./<U5\6O<Z;%K^@"_NKZQ2'3KR-KJ4RO [W84IO/)
M!"!@#TY[4 >IVVH6MW<7=O!+OEM)!%,NTC:Q4,!R.>&!X]:LUY=K.K:O)J.K
M6=OJMS;9\365E&\9&8HI(8RRKD$=6)Y'6I+V_N?#5YXGTQM?U+[+'9V<UM-*
M/M4\4DTCQE8]V,EBJ@ G )STH ]-HKR%]5UG2M2UJT5]:LXF\-W=[''J=ZD\
MJRQE0LBE6;9]X\9[=.*V-NI>'=$T#Q#+K>HWL;SPMJBW,VY/+F4(650 %579
M6 [#- 'HU%<WX,O+K5K&]UJXFD>"_NW>RC8\1VZ_(F!VW;2__ ZXSQ9J=].W
MB:\TV[U^<Z8KA9K2>.VM+-TB#%6#-F8YY/RGK@8H ]7HKS>Q74?%7B2[@N-<
MU*TMDT>QN1'93>5^]D$F6R!G^'IT/&<XJIX;U/5/&$N@V.H:M>6R?V&M]*]G
M)Y+W,QD,>2PYPH4$@<9<9]* /2;#4K35())K*82QQS20,P!&'1BK#GT((JU7
M&_#*-HO"]S&]R;EEU2]!G.,RG[0_S<<<]>*YG5[K4[WPEXO\2?\ "0ZA8WNG
M7%W!;PPS!8H5B)55*8P688.X\Y88Q@4 >K.ZQHSL<*H))]JBL;VWU&Q@O;23
MS+>XC$D;[2-RD9!P>1^-<'9+J&J>+M?EFUK48[?3(;62"UAEVQLSP;FWC'S#
M(''UK L-;U_6SX>T[&KW<?\ PC]O?3?8+R.WEFE<E2[.[*2!MZ ]6Y[4 >Q4
M5YGI^NZSIEIH>K:U>'[''>7&F7VZ>.0;&8^3+(8R4#JRJC8[L:B&J:C>:3HS
M7-YK3W>MSW%_'IVG%4F-OQY:>:S*(D52A/.26^M 'J-%>06^L:Z_A^YL?[2O
M[6>+Q3!IR22S)-/%$_EY1G&0Y&]NN?0YQ5O6M3U7PG/XDT^SU>\GC2SLIH)K
MV3SFMFFG:%V!/4  -@Y (]* /5**\X\3S7G@?1M5N=/\1W=U<FQ#1V=]()I%
M;S$0SJS'@ /RN-N<=*?X??7M/\6Z=:S1ZI'8W<$OGIJVI6\[.Z@%9(@KEO4,
M -N&!P,4 >B45QWBPW5SXN\,:5%JMU8VUX+HW MI-C3!$1@H/4=^1SC.,5S%
M[?ZPLK^'X-;OA%!XD@L$O@X,Q@DMS(T9;'+*21DY/3/2@#UBBO/K+3KK5O$>
MM:/-XAUB"WT:.WBMC%=;9'+Q[S-(V,N<G: >/E/%9OAW5]4\:7.CV.H:I=6L
M7]D->2/8OY#7<@G:(-N'(7"AL# RX[8H ]3HKRJ]U+5Y]:TOP[:ZCJ.M6T5I
M/--<:;<16TUPZ3>6%9V8?<'#;2"3@FEL=2U^_DT?P]J-_<VB3ZE=PR7$=U$U
MRT4,8=(GDC)"OEB&QAL)VS0!Z5;:E:7=Y>6D$P>>R=4N$P1L9E#@>^58'CUJ
MU7D*/=Z%JNO1V^JW,S?\)+I<+W$C@NT;+""C$=?E.TGJ<<\UK^,=;U"SU+Q=
M':7TL:V?AI+B)4?'E3%YOF'HV OY"@#T>BO+=6_MK3=0T'0X+[7-2&I1S7MT
M\=Y'%-(R+&/+C=BH1,L6*J<^G&:B^U>*IM*?3A-,9(=5*+:MJL"7T]OY6XQ>
M:C$!U8[N2&*#J.M 'J]%<KX%U#[787]K)/J;7%G=&.2#4U7S[?*JP0LI(<8.
M0V22#[59\<ZK=Z)X+U/4+%Q'<Q1@)(RY$99@N_!_N@Y_"@#H:*\X\3-=^"=)
MO;FQ\474]Q)9_);Z@XG;=YB*;A2?NA Y)7&WD<#%2Z@+WPKKNF6EKK6HWL.I
M6MV)DO)_-*M'%O65#CY>>"!\OS#B@#T*JUAJ%KJ=H+JSE\R$LZ!MI7E6*L,$
M \%2*\WTJ?4M.T+P5KG]O7]_=:K-;07<4\N^*594).U.BE,9R.3M.<YK/A\0
M:]J-MX>TQ6U*Y%W+J4LYL[F.&>80W#(B"1V7  (S@YP!VS0![#17E NO%4^E
M-IXFF,D&JF-;4ZK E]<6_E;C%YJ,0'5CGJ&*@9(ZUUO@74?M>GWUM)/J;7%G
M=&.2#4U7S[?*JP0LI(<8.0V22#0!U5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLUO+^Y$$9NV81QK@EG;;R0, <=V% !X3\!Z5X=T_2F>SA;5+.T2)YE=V02;
MKLBL<*6.<D $YYZUHS^$="N=-AL)-/3[/!*\\.QV5HG=BS,K@AE)+'H>]$'B
MO1&OAIDNKV)U)$8S0I)]TH/G//0#!Z^E/TSQ7H&LR31Z=JUK<O$GF.J/R$_O
M#U7W'% $1\&^'CI":7_9D8M4F\]0KL'$O_/3S =^_P#VLYJ]I.C:?H=JUMIU
ML(8W<R/\Q9G<]69F)+'@<DGI68GCSPI(S*OB#3R5C\TGSA@KQT/<\C@<\UJZ
M7J^GZW9"\TR[BNK<L5\R-L@,.H/H1Z&@"[1110 4444 %%%% !1110 4444
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MA:7%I?\ BHS6\L*3:R\L1="HD4PPC<N>HR#R.X-=110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O
M\1-3U'1_ >JWVED+=119$F_:8QG!8<')]OUKJ*Q_%6BOXB\+:EI$<RPO=PF-
M9&7(4]B1Z9H Y.+7?$T7C?6H+;2!>R)I]G*UJVH;(;=OWNX*Q4Y9N/X1G;R1
M@5=;XBQ74&D#2K**6ZU&R^W>7>7:VR0Q9Q\SX;+;L@  ]">!6KHNAZA:Z[J6
MKZC/;-/?6MM"Z6X8*K1^9DC=S@[Q^5<U#\-[FPM=$E@_LF^O+"P^P3Q:A;EX
M94W;@RGDJP)/8Y!- %N3XEP-I^GO;V4 O;NZFLWCN[U88898A\P,P# YXVX!
MW9[5<O?&\UCI^G"?2!#JM_-)#%:37:I%A,EI#-@CR\8(.,G<.*@/A#5H=#MK
M2.?1KAO.EEN[&?3T2TF#]%"J,KLP,$Y)YSVQG1?#*6WTRQ:*339+VSO9[J.T
MFMR]FJ3 !H54DE5& 0>QR<<XH ZGPSXF3Q ;ZWD@CM[ZPE6.XBBG$T?S+N5D
M< ;E(]@00015;4O$VIQ>*)=!TK0UO9XK..\::6[\F,*S.NW.QCNRG'&#DYQC
MFQX6T*YT9+R2[_L]);J0,(-/M5ABA4# 4'&YSU)+>O %8-[%KW_"U+^319+-
M?^)-;JZWD;E&/FS8(*G.1Z=\]J )?^%A7%ZVDPZ-H$EY=ZA!/*89;E8?(:%U
M217.#T)(R.X'KD/N/'EXEI?ZM;Z"T^A6$TD5Q=BZ D(C.V1XXMOS*I#<E@3@
MX%3:%X)?1-3TBZ%ZL_V.TNHIV9-K32SRI*S@= ,AN/<53N/!FN#2]3\/66I6
M4>A:A-,[.\3&X@CE8M)&O.TY+-ACTST.* -"\\77TNI7UIH&B#5%T^-'N9#=
M"')==ZI&-K;VVD'G:.1S5:\\?2#4)[/3=*CFEM8(I;I;Z]6T9&D7>(U4@[GV
MD9!P!D#-23>&=:TS4]1N/#=[8PPZE'&)5NXW8P.B",.FT_-\H7Y3CE>O-9]U
MX!O8-4N;ZR;2-1EO8(DN)-9M/-=98T">:I'7< "5X&1UYH OP^.GUB2RC\-:
M5_:+SV*7\OGW MUAC8E54G:V7)5ACI\O6J/@;Q3<2Z3X>L[V*XEN=4EU%C)/
M+EXA%.^%/7/!"]>-M7(O">KZ+>6U]HE]8O<_8$LKM;JW\N.78699%6/ 4@NW
MRXP0>HQFJMIX)UK2].T&2SU*SGU32IKQV:XB813K<.S-]TY4C(]>AH M7_CV
M2UCN!;:.]U<)K?\ 8T<2SA?,<Q!P^2, 9(!].OM277CB^AOQI<>D6?\ :<-L
MD][%/J:Q1PE\[45RAWL0I/0 <9(S45GX'U) DEYJ-M+<'Q -9D:.(JN/*"%%
M!)QSTR>E2ZWX,N+CQ+<ZWI\&C73WD"13P:K;&159,[71AR.#@KWP.10!"WQ)
MBNUTE=*LH))M1MWN%6_O5M578^QHPVUMSALC XXSFNPTR[EOM-M[J>SELYI4
M#/;RD%HSW!(X-<C<^#=4&E:?8I)HNIV\,#1W%IJ%@B0M(6W>:@C'R'DC'/&.
M<Y)Z#PIH;>&_#-EI#W/VAK=6!DP0.6+;5!)(49P!GH!0!S-IXQEM8[6UL-+N
MKZYO]5O[6-+B]^ZT3N22Q7A/E.  =HX&:Z/PUK\VMIJ$5W8?8;[3[DVUQ")O
M-7.U7!5\#(*L.P/M61IO@NYL=2TNZ:[B9;/4K^]90IRRW&_:H]QOY^E;6C:+
M)I>K:[>/,CKJ5VMPBJ#E (D3!_%"?QH Y+Q'K$MAJ_C)IY[U[2UTRQD2&WN6
MB9"TDH8HW.TG R0.<5KZCXROH;C5SI>@G4++1\K>3_:A$Q<('98TVG>54C.2
MO7 S4?B#P7<ZS-XD>.[BC&K65M;)N4GRS$[L2?4'>/RKF/$U^^B7OBK3].U6
M*T;4<RM9W-D[S22O$%)MBIPX; '(.U@?I0!I6OB?7+WQBTNE:8UY'=:#9W@M
M9KWRHH"[2$\[3\QX'"\[>2,5-%XPU/6/$7@Z73;79INIVUQ+/%).%8,I56!
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M1WFR7>D@1G5 /N!@1G=GJ<8KL_">A-X:\,V>DO<?:&@#9< A1N8MM4$DA1G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-6/RG<E,XS\H/>L'PG/K=OXHN=.O(=1CTY[,3HFJ7EO-.D@?:=OENS;&![\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%(Y*HS!2Q R%'4^U<?X4UK7]1\6>(+36X8;5+>"TDM[.)PYA$GFYW.!\S':
M,XX&..Y(!V-%<)!XLU'4OB+IMI9LJ^'YHKN-7V@FZEBV;G!QP@+;1CJ0QY&*
M[N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW59U'3DD#CM5O?&9M-:N+0:>'M+:\M[&:8W 67S)@FTI%CYE'F+DY!^]@'%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>guyaragreement016.jpg
<TEXT>
begin 644 guyaragreement016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M #Q,7#LH)P-@RP]1G/:@#T*BN*U_Q[_8LFNS+;Q366E0VZ%S)M\RYF;Y4W=
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MJ**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYL$RS2&0AXMPR5)P&!!Z^N*72/ <&DS:1,EZSR6%S<W3XB"+*\ZD-A1PBC/
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M*[F Z$$XQWKH?!-E!I_C/QC:6UU-<11RVH!FF,K)^Z/R%F))Q[DG'':NIN-
MTBZL;BRGTVUDMKF4S31-&"KR$Y+G_:SSGK2Z7H>E:(DB:7I]O:+)C>(8PN['
M0G'4\G\Z .(;1K#5_B1XK%[J5Y;"&TM'"VUX]OM^5_WI*D9V]LY R<CFN>T[
M5O$'BBYT.SO(;B]C.B)=^5'J+6)N',C)YI9.6^54..@WY[BO3]2\)^']7N6N
M=1T>RNIVQNDEB#,P' !/<>W2IM4\.:-K4,,.I:9:W*0?ZH21C]WQC"GL,>E
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MUJ^FB:7'8W5BEA;K:W6?M$(0;9<J%.X=\@ ?A5SRH_)\G8IBV[=A'&.F,>E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=@B($*K@OAL9/4&JG@WQ/KNG>$O#<]]86\NEW=TMCYQNF:YW22,JR%2N-N[
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M+MFO5B6Y,8,@B<LN?8D G\JRM>UZ]L]6T_1=)M(;G4KU))LW$I2*&*/:&9B
M2>64  =^HQ0!T%%<'=>/=1M;&2%M'B;6X-4BTR6U%P?*+2J&217VYVD$'D9'
M/ISV6G-?/I\+:G';QWN/WJ6SEXP<_P )(!(QCJ* +5%<=KE]K,/Q)\-65HT(
ML)[>Y>9&F9=^TQY) !!*AOEYY).<5SG@[Q/KNF^$O#]Q>V%O+I=U=BR\YKIF
MN,R2LBR%2N-NX@8W9QS[4 >J45YU<>,UT.WU.2"TAA+Z_)9/<WMT_P!GC/EJ
MWF.V#L!P%"CC)ZCFNN\-ZI=ZOI9N;R"UC<2,B26=R)X9E&,.C#L?0@$8/UH
MUZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5B*YR<\+G/'6NAHH Y#2/"FL65UIZWFM6TUEIXQ&MO8B*6XPNU?-?<0<=?E
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M$-6O[/5(M4UBU)O-/EL8X[*R\F*/>"#*P+L6;IQD #/KFM0>&R-8T&_^U?\
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MN8P%6-%W?*H4  DD]^:[*BB@#"UC0;F_\1:+K%I>QV\FG&5)(Y(?,$L4FS<
M0PVM\@P>>O0UG0^"3#X1TC0O[0!.G7L-UYWD_P"L\N;S-NW=QGIG)]:ZZB@#
MD6\(ZA;I?/IVLI#-<ZG)?E)K;S(75T"&*1-P+#C.01SCBKOA/PQ_PC4%_OE@
M>>^N3<RK:P>1"AVJN$3)P,*,G))))KH:* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV[0 ,Y!XP0:NZ=XQ%UJ-E9WVC:CI?]H*QLI+KRRLV%W;3L8E&VY.UL=#W&*
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MQCI6CXPT'4]5NM)DMH4O;"W$@NM/>\>V$S, $8LH.[;AOE/'S5U]% 'FFE^
MM5LK&2W\G3;96\16^JI%;.WEQQ((]R#*@EAL/.!GKQG%:$W@_4I/ 6KZ*&M_
MM5WJ,UU&2YV[&NO-&3CKM]NM=W10!PFJ>#]2O-0UJ>)K?9>ZKI]Y%N<Y\N#R
MM^>.OR''X=*B\<^'3=3ZSJUW>1VFGG2(H1/M9S%+'.90S*HR4!VYQVS7H%!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N/^*?_),/$'_7M_[,*["L_7-&M?$.B7>DWID%M=)LD,;8;&<\
M'\* .=TF#5/[1MOM'@71[*$,"US%>H[Q^A"B(9.?<5G67B;79_'+>#I+JV\^
MUF:ZFO@%S+:X!2,)VDRX#''"C/\ $*W+;P:;:ZAG_P"$F\12^4ZOY<MZ&1L'
M.&&WD'N*?%X(TF&&V"-<BZM[UK\7GF#SGF;[Q9L<A@=I&,8 '84 <5+XX\17
M8U+4M-349/LUW+#:Z=#HTDT,Z1N4(:8*<.VT\@X7@$'FM]-0\2>([W7)=(U.
M#3(=+G%M!;SVP<32"-)&,Q/*K\X7Y<$8)YZ5H77@'3+J>['VS48;&\F,]UI\
M-QM@F<G+$C&X;B,D*P!J34O ^GZE>7DXO-0LTOE5+VWM)PD=R -OS#!(^7"D
MJ5) H KVNOZC)>^+HIGA_P")9#"T 0956:W#MS_$-WKVKE+:[U2_\1:=K,U^
MI>;P?]KEA,"%')V%E^A8[OPQTKL;[P'I=Y=SS17-_9174"6]U;6D_EQ3HB[5
M##&1A>/E(XXI[>!],W:<8KB]A-C8'3E\N4 2P;0-K\<] <C'- '/:;XRGT73
MK&XU8Q#3[CPY%J%LL48C"RQH/-C4#U#H5';D"JUSXH\11W^G:)=7%Y;7B:9'
M>WT]AI373F61F C"A2%5=IR2,GCIS76WO@G1M0TG1=-N8Y7M]'>)K;Y_F/EK
MM 8XY! Y'>IM7\+VVJZC#J4=Y>Z?J$41A^TV4@5FC)SL8,"I&>1D<'I0 WPA
MJFHZMX?CGU:TEMKQ)9(F\RW:#S0K$+($;E0PP<'IDUO5C:?X9L]+MM/M[.XO
M8HK.1Y2!.3]H=\[C+G[^2Q;GO6S0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%<'=^(/%>E066KZG%IT5K=7\=K_90
MB8W"+))L4B4.59\$,5"XQGGC-5)O&VI7?BO4M+L]>\,:>EO>"TM[>_C=IYB$
M0L>)5'WF91QVH ]'HJAKFI+HV@:CJ; $6=M)/@]#M4G'Z5R_@OQ)JFOW"FYU
M_P -7@6 //::=&_G1,0.I,K# /!XH [>BBJ.JQ:G-8E-)NK:VNMPQ)<P&5,=
MQM#*?UH O45PGA34/&&L7]^;S4M(^RZ?J4EE-'%8.KRA I)5C*0N=WH>E.\)
M?$;3]8TO2QJ,QBU"\8Q;DM95@,N3B,2$%-V!TW9H [FBN>N/&V@6NHR64MY(
M&BE$$LXMY&@BD.,(\H78K<C@FK7B?78_#7AV[U5X6G,(41PJ<&21F"HN>V68
M#- &O17'EO'E@+>^F?2M15I$%QIUK;M$\:$@$QRM(0Q7.?F R >E7]2\;:#I
M5]-:75W*'M]OVEXK:22.WW<CS752J9'/S$<<T =#17.ZGXY\/Z1=RVMS=RM/
M#$L\B06TLQ2)@2)#L4_+@<GH*?IWC/0=5U.+3[.\:2:9&>!S!(L<X7[WER%0
MKX[[2: -^BN:LO'WAS4+BWBMKV5EN)?)BG:UE6%I?^>?F%0N_P#V<YIU[XZ\
M/V%W-;W%U,!!*(9[A+25X(9#CY7E"E%/(ZGC/.* .CHKG-3\<^'](O;JSNKJ
M<W%H URD-I++Y*E0P9RBD!<'J>/RK3L]<TW4+R6TM;I9)HH([A@ 0#%)G8X)
M&&!VGD9Z4 :%%9D>LVE_X=?5["Y4VK0/+%.\;;< 'YMN 2.,^XZ5DCQUH]G:
MV$5Y>O<7UQ817FRSLII#)&X/[Q452P7*GKR.,]1D ZFBN1F\>V#:]X<LK$/=
M6FLQR2K<QP2L !@+@A<#DG=G[H'.,YJ[%XVT";4ELDO)"SSFV2?[/(('E!QY
M8FV["V>,!NO'6@#H:*YF]\?^&]/NKFWN+V4-:2^5=,EK*Z6YX_UC!2JCD<DX
M_(U+K7C+1]%EFMIKAVN8X/.<16\DJPJ<[6D9%(13CJQ% '0T5R&F>.K,>&M#
MO-5:5M0U"PCNW@LK26<@%06;:@8JH)QDUT,>L65QH@UBUE-Q9-"9T>%&<NN,
M\* 23[ 9]J +U%<;HOQ#TV]\*Z5JU^LT-S?C"6D-K-)([@981H%+.H!'S $>
M]=)I.L6&N6(O-.G$T.XHV5*LC X*LK %6'H0#0!>HKGI_&V@6VI/8R7DF^.8
M6\DRV\C01RG "-*%V*V2!@GO27GCCP_87\UI<7D@,$@BGF6WD:"!SC"R2A2B
M'D=2,=Z .BHKG=5\<:!HU[<6=Y=3?:+=%EGCAM993%&1G>VQ3A<=3T%/L/&F
M@ZGJ*V-I>.\LD;20N8)%CG5?O&-RH5\9YVDT ;]%<WIGCWP[J\]I'9WLKK>'
M;;3/:RI%,V,[%D90I;&?ESG@CJ#47A?Q:FJP00:A)''J%S<7J01I&P5T@F9.
M#R,@;21GN3B@#J:*I6>JV5^+PVLIE%G,T$V$;Y9% +*..<9[9YXZBJ4?BS0Y
M5T=DOT(UG/V#Y&'G87<>W''KCGCK0!M45SMQXHLSJEI#;7\?EBYN+>>+[-([
MR/%$798R!C*]3US@@<US%G\4!<V_AR]FA:WMM0N+J&Y3[+*SY128Q&,9<D[0
M< \Y'!!P >DT5G:+KNGZ_:27.G3.Z1RF&5)(FC>.08RK(P!4\C@CO7,ZIXZ&
MCP>8[+>[];&G'[/:3'R4RNX$ '<X!XQPQ/&<8H [>BN>G\;Z#;7[6DMS,"DJ
MP23?993#%(V,(\NW8K?,."1C/-:NJ:K9:+8/>W\WE0*57(4LS,QPJJJ@EB20
M  ": +E%<9K?Q$TZQ\,WVIV*7$UQ:2Q0R6LUI-')&SD8+H5#*,9() !Q@')K
M1OO&^AZ>P2:2\9_(6XD2&PGD:"-AD-*%0F/H>&P>#Q0!T5%<JOC>TE\8V&C6
MZO-:WFG&]2ZC@D96RR;<,%V[2I)+9P#@<$\ZD?B72)=,TW44N\VFI2)%:2>6
MW[QGSM&,9&<'KB@#6HKC=&^(6FWVF:I?W_F6<-G?O:)OMI5,GSE4"@KEG..4
M4$CH16BGC?P^=,O;^6]>WAL61;I;FWDBD@+D!=R,H8 DC!QC\C0!T-%8ND>+
M-'URZ%M93S&<PF<1S6TD),8;;N&]1D9_F/6K^G:I9ZM:&[LIO-@$CQ^9M(!9
M&*MC(Y ((ST.* +=%<[9>./#^H7\-I;WDA-PYCMYGMY$AG89RL<I4(YX/0G/
M:LG0?B+I]RLT.K3&&X349[/S$MI?(0K,R1J\F"BL0%X+#K[B@#N**XZ3Q3=+
MK.KVDMQ:6T5GJMG9PL\+N765(V*_*?O$N0#T'&:MZC\0/#>E3W4=Y>RHEHWE
MW$ZVLKPQO_<,BJ5W_P"SG/;K0!TU%8.J^,=%T:[DM;J6Y>:&,2SK;6DL_D(<
MX:0HI"#@]<5GR^.+9O%5OI%L&>WN-,:^CNU@E="<KM.0N-FTDDYZX'!." ==
M17+Q>--,MM(TF6\O#=W5]:+<*MA9S2&1< F01JK.J<_Q?3K5BX\;^'K>SL+H
MZAYL6H!S:>1"\K3%<;E554G<,_=QGKZ&@#H**Y]?&V@OI"ZFEW*T+7!M1&MM
M(9C,.L?E;=^_C.,=.>E:&CZW8:[:R7%A*[K%(8I4DB:-XG&"59& 93R.".]
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MZ+J^DCP9+-I=RXM)+^&Y6+:6@$TGR.02/EP,DC.!VK*TOPEJ=MI%AX;N]/\
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MDLT+EB?7]XY%4/#.BZM%/X1@NM)N8/['NKY;B23;MPZOL=2"<J=P'US7I]%
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MP<''IUI/$.C:OXH?6]5BT>YMHIK:RLX+:XVB6?R[D2N[*"<  D#)R<&O4Z*
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M]2P;)#'J#UXK,\3>%]3UO4O%T=O'L2_T>V@MI7.$>1'E8H?0<J#_ +U>@T4
M<'.-4\3Z]H,W]@WFF1:69I[A[K8/F:%HQ%'M8[@2V2>!A1ZUM^!-/N-*\!Z'
M87<!@N8+.-)8CC*MCD''O70T4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XI\0P>%O#MUJ]PGF+#
MM58]X3>[,%4%CP!DC)[#)K8K)\2:%#XDT&XTN:5X?,*NDR $QNC!D8 \'#*.
M.] ',Z5X\N=0U.31U;0[O49;22YM#IVH^?$S)C,<AQE#R,'!!&?3%6M"\<7'
MB)[AK#1I_*L;9OMJR-M=+L?\NR@X!88.6) &5]>);;PYXA62XN9M<L8[K[*U
MO;"TT_RXD8X_>NI<EVXX&0!SUJDGPVAL[2[LM-U.>UM=0T][2_!7>\\I!Q<;
MLC$F6;=UW XXP* $TKQY=3^*-,T:_31B^HK(5CT_4//EM61"^V4;1V!&1W%4
MX?B!X@FTW3-57P_9FQU"\-A"GVUA+YI9E5S\F FY<'DG'..U7]-\$:A;ZKH5
M[<ZEIZ1Z0S^7;6.G^0DH:)HR6^<_-R#QQUXYR+5MX)-OX=T32O[0#'3-16^\
MWR<>9B1WVXW<??QG)Z=* *%SXZU;3K358KO1[:75-/O;2V\FVN#Y<PN"H4JS
M*"#\Q&".HJEXO\1ZM%X<\2:/JMM!:7ZZ/)>VT]C.S(R [6&2JE64E?J#VJ;Q
MMX9O%@U2^LKF4SZGJ6F,@BAW-;^5(B[^IW8^]T&,5=O_  /?ZY;ZM)K.KP27
M][I[:="]M:&.*WC8[F.PN2S$@$_,.@ H KZK\0C9:Q=Z79R:+&^G11F<ZIJ0
MMFF=D#!(Q@]B,L>,G'K75Z-KEOKGANTUNT5A#<VXG5'ZCC.T^X/%85[X/U"/
M6+[4-%U*RMSJ"(+E+RQ\_:Z+L$D>'7!V@<'(X%=)9:?]BT:'3S<23&.$1&:7
M&YSC!8XXR>M '"Q?$?4HO"EEKVI:9IUG%JKPQ:<DE\5&YPQ9IF*X1 %+9&21
M@=:H:YXX;5_#.MZ=]HL#?6ALYEN-*O/.BDC>X1>&&"K @@J>Q![UTS^!L^#-
M$T5-0"WFC&*2VNS &4R(I7+1D\J06!&>_6HKCP7J6IZ7J4&I:O;^=>&#8MI9
M^7! L<@?A2Q)9L<DMZ<<4 )XJ\9ZCH%Q>E8-'@MK2,2(=1U$0R7GRY(B4 X_
MNY/4]L<UER^(M4OO$\\ZI&=%E\,B^%N;AU<!@QS@# ?("YSPO(.>*T;[P)>S
MZIKD]IJ=G%#K'^NEEL?-N81Y80K')O "X'&5.,FGKX&O(GLS#JT01-#&CW(:
MU)\Q0IVNOS_*=QR0<\<>] $%CXHU>XETK1M"TJT9GT2WU#S+R[<+&K9782%9
MF/ Y[\D^\EGXYO\ 6K;1H-(TN :I?PS3S1W,Y$5LD3^6Y+*I+9?@8 ]3BM71
M/"AT?5;6]-X)?(T>#2]GE;=WEL3OSD]<].WK7+7VBGP:NAO#J%S!=6XNXSJ*
MZ:US;E)9?,\J6-&W#DC:P.,J<]<4 =;X4U^\UZWU+[?8)97-C?/9O&DOF*2J
MJ=P; X.[CCIBN77Q7K&CZ]XNEO(8[N&&^MK2QMH[AMQEE2,1H,KA0=^YCV.>
M#6K\-[2]@TC5+J^:=VO]4FNHY+B'R7D0A5#%#R@.TD \@8HU+P+-J&IZU.-5
M$,&HR6]U$%M\R6UU"$".&W89?D&5(YSUH NZ;K^JQ^(H]#UZQM(+BXMGN;6:
MSF:2.0(5#H=R@AAN4^A![5B^+;>^U+XC^&-.>*"73?*N+@QM<R1[F0Q98A1@
ME0WR@G!R<XK;TSP]J7_"0IKFNZE;W=U!;M;6T=K;&&.-6(+L078ECM7O@ =*
MNWVAF\\3:9K'VG8+*WN(/*"\OYNSG=GC&ST/6@#EI_B#>V.JV,-];:1#'=WR
M68LEU$/>Q;WV*[(!M]"0#P#UIMYX_P!;MK75-3BT*UDTO3-3:PES=D338E$8
M9%V[>K+U/KZ9++3X:W]MIFGZ8-8L4M+"\ANHWBT[;-<&.0.!,^_YOJ ,G!]C
ML3^"3-X=U?2?[0 .H:F=0\WR?]7F99=F-W/W<9R.N<4 96N>*=0M]+\3:=KV
ME6PEM-*%\BV5X^V2)BRE2^U65@5ZCU[4Q_$4^@^(?%-^T;3V<%SIRS*TA_<0
MO& [J/;()'H#6UXC\%G7[G6)A?B#^T=)&FX\G=Y>'=M_49^_C''3K4>J:1I^
MCV_B;4=5EFN++5XHH9((+9I' $?E8 7)).?08_6@#8LM;:_\3:GID4"_9M/C
MB$D^[DS."VP#V382?]H5R>H^*%\,>)?&.H7):6."#3DAA:78IDD,B@9/"@DC
M)[ 9[5M_#W1+K0_!UI'J)=M2N<W-XS_>,CXX/NJA5_X#46K^!H]8N]<GDOFC
M;45M#"4B!-O);EF5^3AN2.,#@$=Z *>C^/WO-3N-+E&E7]X+)[RW_L>_6=9-
MF 8B2!M;)&">"">F*CT_QY?S^(;/1[B/1);F_AE:**QU'SGMY$3=LE&T<'D;
MAW!XJU)X-U34[/4H-6UJ!1=V+V<::=9^0B;NLC LQ9NV,@8R.^:;IW@K4(-9
MT2_NM1TY(])\P):V&G^1'('C*$GYR=W0^G!&.<T 36OCE;RP\.2Q6@6XU0R&
MXB=_^/58E/GDG'.U@%[9)%8MA\5HKJ33[N0Z.-/O[A((X(M15[V$.VU'DBQC
MKC*@Y4'O@UT.D^";;3/%&L:NUP9HKY2L-JR86W#G=-@YYWN QZ8Q5'2_!&IZ
M8MAIZ:U;_P!D6,JO$$L@MU(BGY8GEW$%1P"0H) [4 =O7%ZSXCUFZN==LM#T
MVVG@TN+9<RS7#1N\C1[]D0"D9"E3DD<G'O71:9_:?VW5/M[*;<7(%GA I\O8
MN<X)S\V[DX/'2L34/"NIG4]5N-&UB&QAU=5%Y'+:^:RN$V>9$0RA6*@#D,,C
M- &1X:\1ZQ<Z'H.CZ-:6UU>1:':7=Y<WUPR(N],*ORJQ9FVL<] !WS5H>/+^
M]318-.TB(ZAJ$]U:S0W%P52VE@^_E@IW+P>@YXZ9XEL_!6I:(NGS:'J]O%=P
MZ9!IUS]JM#)%.L0PD@4.I5AENY&#CWJQIG@==-N=$N%U!YI=/ENKBX=XQNN9
M9P=[<'"\DG'/&![T 9'_  GNOQZ;=ZC<:'8I:Z7??8;_ &WC%G;S%0M"-G*@
M.I^8@GD=LDU?XF"SU+5HK1M%$.E.8Y8[W4A!<7+JH9A$F#TS@$]3D>]:USX)
M-QX>US2O[0"_VIJ#7OF>3GR\NC;<;N?N8SD=>E0W?@O48[[5'T;5K2TMM4E,
MTPGL?.E@D*A6:)MP S@'# @'GVH I7WQ'E;4UMM+ATP*UE#>0)J5X;9[U9%W
M!8<J5R!QDGJ<>]-UG5]9C\:WT,D4?]EIX=>Y>V-RRL.3D_*,;\C;D'@<@YXK
M0USP;J6I136<.JVDNG3VZ0-!J5C]I,)5=IDB(90&(Y.01D9]J6Y\#S"YMC8Z
MH(X$T8Z/,L\)D=X\':X8,,,#R>#GVH KZ=XGU6_AMM/\.:7:R-::;;7%P;V[
M=0ID3*1*0K%FP.6/MUS73M>23>&GO;FSDMI6M#)):N_S(=N2A9>XZ9%<_!X.
MU72)(YM!UFWMYI+&"SN_M-F95<Q+M65 '7:V">"2#QZ5T,&E-#X=726O)[AQ
M;&!KFX;?(Y*X+,>Y[T <AI/BG5KF+1-(T+2;4M-H-MJ(DO;Q]L2M\NPG:S.>
M!SWY)][-IXYOM8L]%ATO2X?[5U))WDCN)R(K98'\N0EE4EOGP  !G/:M'P_X
M1.AWUA<F]$WV318-*V^5MW>62?,ZG&<].WK5"V\"W>EVVERZ7JL4>IZ>UT%E
MFMB\4T4\ID9&0.#P=N"&ZK[XH )-=N5UKP^-;THV=V7O59DNF:-1''DNH&-Z
ML.FX CTK&U'Q#X@UBV\*ZD^G0VFE:AJUJ\+173&98V)*^8NT###G )QP.>W1
M0^#KF2]TR\U/5WOIK:6ZDG#QD))YR;-B#<?+11T'/ZU2A\#:O'#HVG2>((GT
MG1[J*>VB^QXFD2,_*DC[\' X!"CL30!FW/Q9@A^U:@K:/_9=M<M T#ZB%O9%
M5]C2+%CIG)"DY(&>,BM+4/&6NI<>(SINCV4UIH3 S23W;(TZ^2LI" (<-@GJ
M<=/4X5/ NHVBS:?I^L6]OI$MRT^/L0:ZB#/O:-)=V-I)."5) .*U3X5/D^*8
M_M@_XGI8@^7_ *C,"Q>OS?=SVZX]Z ,NSUG5M0^)=HD)B&D3Z(MT(FF8, SC
MYMN,;\X'7IGGM5GQ+??8/&_AJ629X[9+>_DF )P0L:')'?'-3VGA6ZL->TG4
MK;48]EIIJZ=<Q/ 3YR+@AE.[Y#D=P>*N:QX<CUG6M-OII@(;2&YAD@V9\U9D
M"GG/&,>AZT <II?Q12\NM*DG.C"TU2=(8H+?4EENX"_W#+'C')P" ?E)[\U-
MJ?Q!O=(OD-Y;:1# UZMK]B;40;XHT@02>6 1W#;<].]7=(\&ZKIK:;:2:U;O
MIFG,IB$5B$N)E481))-Q! XR0H)QVK,'PTOUTAM'CUBRCLQ="Z$RZ?\ Z3,1
M,)0)9-_S<CJ "<#Z$ U[KQM)::;KADL5.I:??+90VHD_X^&D*^00<<!@XSUQ
MAO2L[6/B0;/5M3L[5M$4:7A9UO\ 4A;R7$FT,5B7!Z @;CP3QVS6UJ'@V&_\
M;6/B(W3(ENH,MH$^6>1 XB<G/51(_;T]*J7W@[44U35+G1=4L[6+5&$EPMS8
M^>T4FT*7B;<N"0HX8$9&?:@#IM)U.#6='LM3M=WD7<"3Q[A@A6 (S[\USVN:
MPFF>+%(M6DFBT2[NU?SV5<(\?RE.ASD?-U&/>M2SMM2LM7MK59C+I,.GA&:1
M5WM.& #;@<G*[LC  X]>,&_MTUKXEM:".<V\.B7%K=2B)E5&E>(JH8C!)4,>
M,]* -(>*9"GA1OLJ_P#$](#?/_J<P-+QQS]W':L*R\>ZW+H<'B*[T6S@T1[E
M(7<73-*B&7RFD*[<;0<'KG )JWIW@O6(;OP\VH:]!<6V@L1;Q0V1C,J^4T0+
ML7/S $= !P>.>)9])T_PQ\-9M&U5Y[VT,4L#FWMF=Y/,9B $7<<_-@'U]* -
MK3]:;4?$6K:?% /LVG"*-Y]WWIF4LR ?[*E#]6]JR?$WBC4-&O9(H8]'MK>*
M$2"XU74! )V.?DC4 GC')..HP#5GP%HMUHGA"SAU!F?4[C-S>NWWC,_+ _3A
M?^ U3O\ P=?2>*+_ %BQU"SB-_%''(US9>=+;[ 5S"^X!<YS@@C///2@"K:^
M.=4UN;1[?1-)MC+J6E?VB6N[DJD W!2IVJ2W) & /7BG6WCF_P!2M-*MK'2X
M!K5]-<PR133GR8/L[;)6+!<L,[0!CG=VQ5SPSX*;P]=:7,=0%Q]@THZ;CR=N
M_P#>*X?[QQPN,?K5>/P-=6*6ESIVJQQZG:7EW<12RVY:-H[B0N\3H&!(^[R"
M.5S[4 .\!76H75]XJ.IQB&Y35MAB64R(F((ON$@?*?O#@=:BUCQEK=KJ/B*'
M3=(LYK?0HDGGEN+ID,JF+S"J *?FP#R3CIZ\;/ACP_=Z&VJS7VHK?7.HW?VJ
M1U@\H(?+1-H&X\#9QSTQUZF&X\*&>3Q4WVP+_;T"PC]U_J,0F//7YNN>WI0!
MF1>+M3DNK:#4M*MX+/5=/GN[,PW+-(H158K)\H )5QRI.#D<]:Y276D33+V^
M:WG:R'@VRN!9_:Y!C+R\>9][.,#=U.*[VX\)&>71'^VA?[,L9[/'E9\SS(T3
M=UXQLSCGK6/)\-6DT:?3_P"U0/-T"WT;?]GZ>46/F8W=]WW>V.M $EEJ^O1>
M-?%RM EW:65K;O;VL=P0V2KE0H8!06YW$GC Z]H[#Q_<MK\>E7JZ+-+/:S7"
MC3;_ ,]H&C )20;1C()P1Z'BK>M>![C5KW7S'JPM[36K*.WGC$&71T!"LK;@
M-N&.5(Y]144'@?4'U33[Z[U+3XULH)X$M;#3_(BQ*FTM]\G=PI],#&.] $6F
M>-]:FTO1M:U/1[2UTK5)K>)&CN6>2(2J0K."H !?8.O1_:NET?6FU?4]8AC@
M"VEA<"U2;=DRR!09..P4L%^H/I7/>(-.MM#^%">'[HW-XZV26-N;6W9GDG5/
MW9"KG:=R@Y)P#CFN@\*:/)H7AFRL9VWW80R74G]^=R7D;\69J .=N_'=ZOBB
M]TFTM=,+V<Z1?9+J^\BZN58*2\2L-I'S<?-SM/2H]:^(WV+6M3L;-]%4:7M$
MPU'4A;R7#E0Q2)<'H"!N/&3CMFK'B/P/J'B$WMG/JMI)IEVX?;<V/FW%KP,B
M&3< O3()4D$]ZDO/!NH1:GJ5UHFJ6EK'J6UKA;NR^T-%($">9&V]<$A1PP(R
M,^U $5MXVU+7-:L[/P_IEM+;3Z=;ZD]Q=SM'LCD9U*[54Y8;?IP?:K%GXVDO
M--T,I8J-2U&^:SFM3)_Q[M$6\\DXY"A#CIG*^M:.E^&O[,U]M3^VO.#IL%AM
MD7YCY;.V\L."3OZ8'2J^G^#8;#QM?^(A=,Z7"DQ6A3Y8)'""5P<]7\M.WKZT
M 8FB^*KF6RT_2]"TV)KZ[FOI2+NZ<QPQQ7#(SLV"QW,1A1TSV J?4_'MYI?]
MGZ??V>G:;J]TTVXW]\([9(XR!Y@?&6#9&U< ]<XQ4EMX%O-*2PN=*U6&/4[-
M[O\ >3VQ>*:*>8RE&4.#P=N"&[=.<4Z7P3J)ELM376TGUNW:8R37EL9()4E(
M)C$>X%%4JNW#<8/7)H T_"'BF+Q1874@%N+BSN6MI_LLXFA9@ P9'&-RD,#T
MR.1VKHJY[3]$U>PTB6(:S&VH3W(G>?[(!$BY&8TCW<+M! )).3GGI70T >=_
M%'P_I_\ 8%WK:BZCU S6L?FQWDR#:9HT(VA@OW21T_6F:[IA\+:[X5M_#5M(
M\ES?3[H;B^E*.?L[C+,Q8A1][ ';UKKO%.A'Q)H$NEBX^S^9+#)YFS?C9(KX
MQD==N/QIVIZ(=1US1-2^T>7_ &9-++Y>S/F;XFCQG/&-V>_2@#G)OB!-I6C:
MQ)K%C;Q:EIM['9&.*YQ#*\JHT;>8P&Q</DDC@ ]:ICXG?9[?6(YO[(O;NRTU
M]1B;2[_SXI%0@,C'&48$KV.0<]JU]2\"IJ3:Z[7YCEU&\M[VW=8@3;2PHBJ<
M$X<93)''!(]ZAN?!FJZKINKV^IZQ:A[ZQ:RC2RLO*ABW=9"I<EFZ?Q  4 5K
M_P =ZGI2Z?:ZE;:-8:AJ)>6#[5J!2"&!0IS(Y49?+;=JYSR<X%;GA#Q3%XHL
MKMA]F^T65P;><VLXFA<X#!D<8RI##MD'([4S7?"\VH7FF:E87<$&HZ?&\2FY
MM_.BEC<+N5UW ]54@@\8[U>\/Z3=:5:3"^OEO+F>8RNT<(BC3( "(F3A0!W)
M/4YH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "JVH7\&F64EY<EQ#'C=LC9SR0!PH)/)JS7,?$.[N;
M'P-J-Q:7$L$Z&+;)$Y5ES*@.".>A(H Z>BO)_$5Q?V6K:UK%S<:C=:;:7*D7
MNDZIM.GJJINCDM6(1^<D_>)#=*['X@WMQ9_#O6KRRN)()TM2\4T;%64\8((Y
M% '3T5YCK;7_ (,U</IFH:C>/<:'?W,D5Y<O.KSPK&R.%8D*<L00N!CC%21Q
MR:(/!^I6.MZA>W&K7,4-TMQ>/-'=))&S,X0DJFW (*  #B@#TJJT5_!-J%S9
M(7\^V5&DS&P7#YVX8C!^Z>G3OUKF/'_VJ5?#MG;7]W9+>:O'!.]K*8W:,Q2E
MER/7'X'!Z@5S&LWU_HE[XATVUU6^CM(1I%M]HEN&D:UBED=)9 S$X;'\7T/:
M@#T^_O;?3=.N;^Z?9;6T332L 3M1023@<G@&I+>>.ZMHKB)MT<J!T.,9!&17
ME/B*V&CZIX@TFUU;4)[-O"-[<-9W-X\XC?*J'^<D\C/4\<XQDU>L-,DTG4_!
M\$6JZI(FKVLT-ZLE[(5?%OO#(,XC((X*;<"@#T2QOK74[..\LITGMY,[)$.0
MV"0<?B#1:WUK>O<I;3I*UM*8)@I^X^ Q4^^&'YUR?PHM4M?ASIA229_-#NWF
MS-)@[B,+N)VCCH,#.3W-<C'')IC:Y'::A?6JW_BU+"XN/M3DQ0M&C$J6)"L3
MA=_7!'/ P >Q45Q>C(^C?$*XT&UO;NYTY],%XT5U<O.UO+YFP8=R6 89.">J
MY%,UNW.J_$JQTFXU2^M[)M*EG-K;7;P><XE4 DH0> 2>"/RS0!V]5KV_@L$A
M:<N!-,D";(V?YG.!G .!GN>!WKRZ'5KJ]M;31'NM8U*1-3OH+:.TNA"]Y!"0
M TL^Y2 N[&0<L1WYJ+3-7U6+29;5KRZC-KXOM;-5:]:=TA8Q%HFEZN,LP(.?
M3G% 'J>JZI::+ID^HW\IBM8 &D<*6P,XZ#GO4UW=V]A9S7=U*L-O ADED<X"
M*!DD_A7CWB"!M9^'7B+7[_5[Z._2^F@,'VIA#$J3[%A,6=G*A3DC=ELYKO\
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M)@_/G<%8 $!CV;L:WI-'V>,+#PO+J^KG338S7Q+:A*);F;>BX,@(;:H.[:I
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M#5(KFRNMLMKJ,XG>WW(K!5E!.],'())/./2@#J;JYBL[2:ZG;;##&TCMC.%
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MI9ESWVUR-S=7VG:S<:Q?W.HW-@NK;$U33=4WQ0H90@MY;5B% !.QBH)SSUH
M]-T_5+35/M7V24O]EN'MILJ1MD7&X<]>HYZ5<KQNZL);?PWX[\06^IZC;WMA
MJMU+:K!=/'&A3:>4!VOGH=P/''%=&D!\3>(?$W]I:QJ%DNF-%';1VMX]NL"&
M%9/.(4@,2S-][(PN/6@#T&J]I?VM^LK6DZ3+#*T,A4\*ZG#+]0>*\P\-3ZEX
MPUO1GU35-1AC_P"$?M[UX;6X:!99O.<"0A2.H&2.AR/05O\ PST^*RL-<,<M
MRY.LWD9\ZX>7 69@#\Q.">YZGJ<T =Q1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57O;&UU*T>TO($GM
MY,;HW&0<$$?J!5BL/Q?XB3PIX7O=8>+SC F4CY 9CT!(!P/>@!UYX1\/ZAJ9
MU&[TBUFNR5+2.GWROW2PZ,1QC.>E:5[8VNI64MG>P)/;3+MDB<95AZ&LB\\:
M>']/2W:ZU#89XO/1!#(SB/\ OLH4E5]V %.U'QEX>TD6QO-4A3[5$)K?8&D\
MU#CYEV@Y'/;MSTH U9+"TFO8+R2WC:Y@1XXI".45L;@/8[1^59VG>$_#^DWQ
MO=/TBTM[G! DCCP4!ZA?[H/?&*JS>/?"UO>-:S:Q!'*DS02%E8)'("5*N^-J
MG(/4C/:KVC^)=(U][A-,O!/);[?-0HR,H;[IPP!P<'!Z'% %VYL;6\>W:Y@2
M5K>430EAG8X! 8>^"1^-9NMZ$+VQU'^SQ:P7]ZD:2RSP"5)50G"2*>JD%E]1
MN.*=J_BG1M"G2WU"\\N=T,@BCB>5PF<;BJ D+GN>*R-6\=V&G:GX?*W5N^DZ
MK#/(+A0SLQ0)L"!>23O/&">* *OAWP#'8ZG>7M_8Z1;Q3V36/V+3XF$;1L07
M+LV"Q.%&,< =ZZ\Z99-+9RFVC+V0(MFQS%E=IV^GR\5G'Q?H T>/5?[2C:SD
ME\E&569FDY^0(!NW<'Y<9XZ4J^+=!;17U<:E$+&.3RG=@05DSC85(W;N1\N,
M\]* +FF:-INBQ31:99PVL<TIFD2)<!G/4X_"J\OAC0YY[^:;2K6234%"79:,
M'S@.FX=#C Y]JAC\8^'Y-*N-2_M.)+2VD6*=Y5:,PLQ 4.K ,N2PZ@=<T_2O
M%>B:T]REA?I(]LH>575HRJ'HV& RO!^8<>] %C2= TK0DE32["&U\T@R,@^9
MR.FXGDX[9Z5D:OX-L]=\60:IJ4,%S:16#VPA<'<',BL'![< C\:N:9XQ\/ZO
M<FWL=2CDD$9E7<K('0=60L '4>JDBC3/&&@:S>"TL-1CEF92\8*,HE4=2A8
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M*@U#4-0U*QL[R[GU&6\BE,>2JL05!SU*G)&>F>*UKSPEX?U#47U"[TBUGNG
MWNZ9WXZ%AT8CL2.*V:* *-GH^G:?(DEI9Q0O';I:JR#D1)G:GT&3@>]8?B'P
MH^IZ+;^'K!+&UT263-[&R$OL#A\1@< L0V2>F<BNJHH 15"J%4 *!@ =JH'0
M]+-FUH;&'[.UQ]I:/;P9=_F;_KN^;ZUH44 9]WH>EW[71N[""<W<*P7'F(#Y
MB*254^P+$CZU4MO"VD:3FYTC3+2"_2-UAF923E@.&;[Q7Y5_+BMNB@# \*Z!
M+HMO?3WKV\FI:C=-=W;VZ%8]Q  5<\X"@=>IR>]:.JZ-INN6JVVIV<-U$K!U
M$BYVL.A!Z@^XJ]10!E6WAG1+.&TBMM,MHX[24S0*J<)(007]VP3R>:=<>'=&
MNX[Z.XTVVE2^97NE= 1*R@ ,1ZC YZ\"M.B@#'MO"N@VFFW&G0:7;):7+!IX
M]N?-(Q@L3R>@ZU/JVA:7KL4<>J6,-TL3;HRXY0]"5(Y'X5HT4 9UOH.DVHMQ
M;Z=;1"VA:WA"1@!(V(+*!Z$@9]<5!I?A30=$NC<Z;I5M;3%2@=$Y53R57^Z/
M88%;%% &+9^$?#VG:E_:-GH]I#=@L5D2/&PM]XJ.BD]\8S6E=6-K?>3]J@27
MR)5FBWC.QUZ,/<58HH Q)O"'AZX%Z)='M&^W2K-<?)_K)%SA_9N3R.>35[2]
M'T[1+4VVFV<5K"6+LL8QN8]6)ZD^YJ[10!CZEX4T'6+Q;S4=)M;FX"A/,D3)
M91T!]0.V>E3'P]H[1R1MIMLT<ELMFZM&"&A7.U"#_",GCWK2HH R=-\,:'H\
M=Q'8:9;PK<+LF^7<9%Z;23DD<GCIS4%KX,\-V5O=06^C6D<5W'Y,RA/OQ_W/
M9?8<5NT4 4=3T73=9LUM-1LH;F!6#*DBYVL.A!Z@^XJK_P (IH']B-HW]DVO
M]G.^]K?R_E9LYW'N6R!SUK8HH RW\.:-)875B^FVSVMTXDGB9 5D8  ,<]\*
MO/L*CM_"NA6NF7.FP:7;):71S/'MSYI_VB>6_&MBB@"N]C:R7T-\\"-=0HT<
M<I'S*K8+ >QVC\J;<:;97=RMS/;1R3)$\*NPY"/C<OT.T9^E6J* *0TC3Q!8
M0BSB\O3RIM%V\0E5*#;Z84D?0U+=6-K?>3]J@27R)5FBW#.QUZ,/<9JQ10!D
MZOX8T37I8Y=4TRWNI(U**[K\P4]5R.2/;I4YT/2B4/\ 9]MA+9K-5\L;1 V,
MQXZ;3M''M5^B@##L/!WAW3)X9[/2+6*>!MT4H7+IP5P&/(&&(QTYJ:U\,:)8
MW(N+73+:&47#7(9$QB5E*LP]"02/QK6HH QH_"7A^+5_[5CTBT6]\PR^:(QP
MYZN!T#?[6,U:?1-,DL;RR>QA:VO7:2YB*_+*S?>)]<U?HH 9+#'/ \$T:R12
M*4=&&0RD8(([BL9_!OAV32[;37TBV-G:LS6\>W'E$G)VGJ,Y[&MRB@"O8V%I
MI=E%9V%M%;6T0PD42A57Z 5FOX1\/R:M_:C:1:F],@E,I3K(.CD=-W^UC-;5
M% %!]$TR2RO;-[*$VUZ[/<Q%?EE9OO%O7.*K:IX4T'6KE+C4M)M;F9%"!Y$Y
M*]=I_O+['(K8HH K1Z=9Q7OVR.VB2X\D6_F*N#Y8)(7Z D\5%9:-INFWEY=V
M5G%!/>N)+EXUP96&>3[\GGWJ]10 4444 %%%% !1110 4444 %%%% !1110
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M6+]X#G;A3C!R3Q7JM% 'E?AFTU:RUG1;73K/6X+.%V%W8:K"LD%BFQA^XN"
MQYPH"DY!YQ7I6GWIO[=I3:7-KMD>/9<H%8[21N !/RG&0?0U:HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9VNOZ59P?;XI6MGM+EI-DB(9#')E1R5!PPR.#3&\"S:M#JTGB/53>7FHVHM
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M*C8&"G+G=G!QP#UJ/2?!U[#XFM=<U6]L)KFT@>%7LK'[.]QOP"TS;VW=. ,
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MS\HRHZ8ZD]3FMV*S;55\53WNNZI:2:+,UM:>7?/&+>..%&65P#B0L26)?.:
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MPLJX*0Y!V#VRJ_E5ZB@#/70]+2S@M%L81;V\_P!HBC"\))N+[A[[B3^-4)?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$C\8>'I=6_LN/5K9KPR&$
M1AN#(.J!NA;_ &<YIU[XMT#3]4&FW>JVT-V2JF-F^Z6^Z&/12>P)&:Y6:TM=
M?DM/"_ARU6+1-+O4FO;T9*+)')YGDQ$\LY;[S=%&1R3BN=A.LQ>$/%NK2/ID
MEE;:I>R7>G7-MO-V$D.0[[OE.T*% !^ZO7/ ![%++'!"\TTBQQ1J6=W. H')
M)/85E:3XKT+7;E[?3-3@N)E3S/+4D$IG&X XW+[C(J?48=/U/P_/'JB*-.F@
MS.LK% (\9.XY&!CKS7-:4)?%GBFP\10VS6NBZ;#+'8,Z;9+PR  OMZK$ ORY
MY.<],4 =M5'5=7L-#L3>ZE<"WMPP4N5)Y/3H":O44 <S8?$'PKJE[%9V6L13
M7$K^6B+&_+>G3BMW3]0M-5L8KVQF6>VE&8Y%Z,,X_I7+^ /]9XK_ .Q@N?\
MT%*XWPPFI:-X)\):O#K=ZWVC48;5[-MGD>3),4*A=N<C.=V<Y]N* /8Z0D $
MGH*\>?Q#XIU"RU/7+2/61<6][,ELJS6J6")'(4V2*[A^0IW,0"">. *]=9B]
MH6*[24R1G..* .77XF^#74,FN1,IZ$12$'_QVNL5@Z*ZG*L,@^U>8?#H>-/^
M$ T+[$V@?8OLR^7YPF\S;[X.,U-XWU_5="\3Q:?9:LL=OK,2)(\J[O[+^=4\
M\8& K;MHW<;P#G&: /2J*\TUC4=9N_&-[HEL-?DM-,LX"ITN6W21Y) W[R1I
M6!/W< #C.[/:DT?4]?\ $U[HVCZGJ$^G.--EN[E[*2,27#K-Y2_.NY0,?,0I
MZMCMB@#TRHIKF"W>%)IHXVF?RX@[ %VP3@>IP"<>QKB](U"_A\9Z7I$NO+JD
M*V%[YLJ!1ODCGC50^WC>JL5/3G/ KFYWN]=U/1)+C4[L>5XMOK:,Q.!MC59M
MN..P7 ]B: /5+2_M;\W M9EE-M,8)L9^20 $J?P(_.K->;'7=5M7OM6>]D:R
MTWQ*]K<Q'&W[*Z(G_CC.&^@-4;_Q-KMV+:6SEOFM=<U>6&V6S,8E6UAC8?NS
M(0H:1D9LDYVGCG% 'J]%<=X*N]9;4-7L-1COEM;<Q/:_VA- ]RH8-N5_*8\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M76UE;2]5L[P0_P"L\B97V>A.#P/>H['Q5X?U.Y%M8ZU87,Y8J(XKA68D DX
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M'E7#3+LDSTVG//X4 1Z;X:TG29+62SMW62UMVM87DGDD98F<.5RS'/('7IC
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M;.\".-]Q]/OXQ[4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKV"B@#RBXBN+>37K62SN_,O_  G#%;;;=V5WCCGW)N P&&Y>#SS6I/I$\;^
M([*U:!K>":)G2(@0;K1@-V!\OS8Z]_>O0Z* /(K9?M'@KPYX5MM)O8-?L;NU
M,P:T=5MGCD5I9C*1M(8!L$$[M]1:O<36WA#Q9X<_LW49-4N-4N)X8H[.1E>)
MYA() X&W&WWSD8QFO8J* .0T1FMOB/XH@FAN$-VMM/!(86\N1%B"-A\;<AN,
M9S77T44 >6V.GWJZWISM9W 5?%U_,S&)L",Q2@.>/NDD8/3FH+'06_X0'PC;
MR:6_F)X@6>>-H#N4>=*2[#'3&.3VQ7K-% 'ENOZ;>/K?B1H;*=DEU;1I%*1$
MAPKIO88'.,<GMCFH[R>ZLM+\760TF2>=M=6Y(GLI)8U@<Q8G"@#S=NTMM!S\
MO->K44 >.O!J.JZUXBE274=36Y\+W%O#=2Z=]F223=Q&@V@G[W?.<G'2EU*Q
MU#Q%92?V5:W>Z;PE]F7S(7A+2+, T7S 8)"L/?.>G->PT4 >?+=VWB'Q7X6D
MT73KNW33/-:Z>6S>W%O$8B@A.Y0"2Q7Y1G&W-96EZ--;_#7P/"NG2QW$&K6D
MTJ>20\>93O9AC(X)R3VKU:B@"EI^J6^I27J0"0-9W#6THD0K\X56XSU&&!![
MYJ[44-M#;&4PQ*AE<R2%1]YCU)]3P/R%2T >2>&[.2Y'@>SGT^YWZ7J-ZMTL
MULZB)_+E9#EA@C)4AAQG'>H_$>C:D]_KL]M;W4=I#XCM+V7R+;S2T8MD#2)&
M01)M<AB #]T]Q7K]% '!^"X6N?%6JZLMYJ5ZDEM% UU<V2VL<S*6(VKM4L5!
MP6([XSQ7>444 >?:-JT?@>XU?2M8M+]8I-0GO+.Y@LY)XYXY6W[<HIPX)((.
M.Q[U!?7NJ7EYX;\2ZUHT\&G6M[<L;9(6DE@C9-L,LD8R0PYSC.W>/>O2** /
M(M8L)=;T[Q=?VFFW/]F:E>::L,3V[(9RDJ>;)Y9 .T@@9(Y"$UU:Z4A^*&I7
M36(\IM"AA64Q?*3YLNY0<8SC;D>F*[*B@#QKPQ>6_A_5O",FL65TKQ>&"FX6
MKR/;MYJCYE4%ER/ESCOCO4L(U'2X],G-D^F6=UJ.H74%W)ISW$MA&[ QQB,?
MZLN"QY''3&:]2.DVIUU=8*M]L6V-J&W<>66#$8]<@<U>H \9T[3+R[@9+JSO
MKA7\9071:[L_*:2+R5_>L@4 *2/08[\YKIM0\-OK7B+QK9&)X8[[3[+R9]A"
M^<OFE6![E2$/X"O0*J:G8+J>G36;7%S;K* #+:RF.1<$'AAR.F/I0!R/P[GN
M]?6]\6:C 8;F\6.TBC;_ )9QPC#X^LIE/T KFM>%S8:IK,6E1WSW%Q?K,=$O
MM+-S;7SY3$L<H'R X!R6^4KR!7JFG:?:Z3IUOI]E$(K:WC$<: YPH]^_UJU0
M 5R'BQFM?%?A'4'AG>U@NITEDAA:3RS)"RKN"@D DXST%=?10!X=;Z7?IH+>
M&[Z\UG^T3J!=K.WTM"'<S;Q.MP4QMZ-N+9&,>U:6M:3JC-J5W'%>1VUOXL%W
M*T5KYK^5]F11*L9!\P*Q!X!Z$]17K]% 'B>NP"?PYXLU9Y=3U*"=;&*26XLE
MMDNBLZG")M4L0#M+$<Y SQ6UK[?\))>7][HEA>+;VOAR^M9W>SDA,CNJ^7"J
MLH+%=K' &!G'>O1-7TFUUS3)-/O59K>1D9@K;3E6##GZJ*O4 >=7FCW"MX#B
ML+5H'@MKB(ND9 @W6C ;B!\OS8Z]_>LFU N_"?A7PS9Z1>V^MZ?=VC3A[1T6
MU,3 S2F0C:0P#8()W;_K7K=% 'EE]HTK> OB*HTZ1KFZO[MXU\DEY<*NPKQE
MN1QC\*JZE!>:9XF\2O?WNIV\6I)$T MM*%VMW&(0GE9V-A@P8;20/FSW)KUV
MB@#F_"\\6EZ;HOAR9;Q;Q=-651<+DA$VJ59A\NX;E! KI*B-M";L71B4SA#&
M)".0I() /H2!^0]*EH \XEN;?0]7\80:SI%W?2:K*LEJL=H\JWD/DJ@A#*I
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M4<PD6)N=HQC&X=<#@<T >A5A:_X@ETJ\T_3K&P^W:G?E_)A:7RD5$ +N[X.
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MEH$9)M/U2WWQ.21B16 )##!'<$'L>:M>$=!?PSX:MM*>X$[1%V)4$(NYRVQ
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M\)7M[<L-#N='DCD4@8BGC4RJV?\ :19!CU45WWA9]2;PK:7.KRYO[B,W$H?
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MWL;2:[NIDAMX4,DDCG"HH&22:\WU'6]:>74;:UU-[9SXJ@T^.58U8QPO#&2
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M?3I)K.*.\A=[Q7:VV-N$H7&XJ1P0,BO.M.U#5U\5Z=I;W?B..TU.SN1(^J+
MKET52)(E7+(1N.0PQR..*S_#.J7WA_PIX+:&YFN(9-)O;MX)-I#&.)&1!@9
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M)YL\,4,LDLSR,ZQ@A,EB>0&//4YYJ)?%GAQ[K[,NO:89]AD\L7:9V@$D]>@
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MQZ;<W$.G?8+JV8FUB8;]X>/:K;<,6XQR#ZT 7_ &K76M:%=WEV9]YU*[1$G
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M;\C2O+)S&$(;:0PR<Y&,'.,4YO&AM8I!J>B7UC<1W5M;F-RKJWGN$5E=3M8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "*BHNU%"CT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY,WBOQ1?VVHZS8+K)E@O)8[6TBM8#9-''(4VR,WS[CM.6!&">!@<]UXZ8O\
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MO$6M^#6\1VO]I3:J;?3K:[M)+N./?')+,T)!V*H900&QCVS0!Z?61J_BG0=
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M/'S@''2GWOAO2=1NKVXO+43M>VJV<ZNQVO$I9@,=N7/(Y_*M)9X7E:))4:1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVG&TC9(H!*\CGAAR..:MU!;V<%HT[0IM:>4RRDDDLY &23[ #V  H GHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *IZKJ*Z5ID]\]O<7 B7/DVT>^1SG "CUR?IZ\5<K#\7Z7J&L^&;J
MQTNY%O=2%"&,C1AU#@LA9?F4,H*Y'(S0!0C\<1VUY>6NN:7<Z3);6+ZAF62.
M56A0@,048_,"1Q[\9K,/BS5+SQ?X7MGTK4-+M;TW$A6=HV$Z"$LH;:QVL#@[
M3CKWYQF)\-;B\U&]DDT[2M'LKW2)].>*SE::4.[(RR,Y1=_W>G;'4YXVH=(\
M5ZAX@T"\U:+2H+?2O.$IMYW=KAGB9 X!0;1D_=R>IYXY (K7XFK=6FEWJ^&]
M5^QZJWE64N8LRS8)";=^5!VM\QP.,].:GN/&$=YIK&>WU'3+NUUBVL;B!&C9
MP[O&5&X$J8V#C..<$]Z9I_@[4;7P]X,T^26V,VB7*37)5VVL!%(AV<<G+CKC
MO27_ (.U&ZO-5F26V"W>MV.H1[G;(CA$6X'C[W[ML#ITY% #[OXBQVJZG<C0
MM1ET[2[I[:^O%,86,J0"P4MN<#()P. ?J*DO?%UIHNIZ\TIOKEX)[2W2W+1A
M/,E4;0A) 4'.6+&H;OP=J,_@[Q9I"RVPN-7N[F>W8NVU5DQMW'&0>.< TNH>
M%-4EN_$5Q FF7*:C):,MK>J7CF2) KH_RG;GLP!QQ0!%XE\8ZQ9^$KZ[M]#O
M;+4+:YMX6$OELFV1U&]'SM<$';QR"1D#K6G%XQEG\12:-%H-^\ULL+WL@:/9
M;"1-PR=WS$<C"YZ'VSS<?@#5AX=UZTMHK/35O7MI+/3$NY)H(6BD#L=Q4;=^
M ,*N!@=:Z73=#U6/4_$&HW$EO:SZK;VZQ^0YD\B1(BK')49 8\>H':@"*#QO
M(UWIJWGA_4;&SU.;R+2YG,8)<J64/&&W)D*<9'IG%8ND^+=1O[=7U:*]LV_X
M21K&'R6BPP#R*(GP3\J[<,>I/0FJ6G_#[5TN= GFT[1X;K3;N*:[O_M<D]Q>
M;00Q#,@*YSNVY.3@<8K4A\(:VL_D.;$6L/B0ZQ%*)FWO&[2,RE=N PW #D@\
M].X!M)XTLY-#MM1%K<>;<7XTX6AQYBS^88V4\XXVLQ]AFJUQX^A@%W>)I-[+
MHMG.UO<ZFA38C*VUV"%M[(IX+ =CC.*9!X-N8OB%)K!GB.C@M>16HSN6\=%B
M9\8QC8I/7.7-<Y)\,[B%[VR@T7P]=17-V\T>IW@+30QNY8JT6PAV&2 =P&,9
MH ]5!! (.0>]<YJ7BQK/Q3'X?M='O+ZZ:WCNG>%D5(XF=D+$LPZ%>@Y.>.AK
M0L;J\;6=1LI+9$L;9(?LTRAOG+ [U.1C(PO3/##OP*J:+<+X[N=;9HOLLNF1
M687)W[UED<G&,8PX[^M &9%X_@E2*^_LF]70IK@6T>J$IY98OL5MF[>$+<!L
M=P<8YIFJ_$*/3H-5OH=#U"\TO2W>*YO(3&%\Q/O!5+!F /!;& <]@37.:;\,
M9].CM=,71/#TD%O<!O[6E!>=X0^X Q%,>9CC=NQWQFLKQ+?S:=X;\6^']+U+
M298;FZN%6":1UO5DF;+0K#M_>;F8[7!Q@YYQ0!ZI9Z_!>ZMJ6G)#(LEA!#,[
M'&&$H8@#W&PYKF]-\7MJ?B*TOX_M*Z7/X=.H_90F]]WF#G:N<MMXP*GGT3Q%
M8>(K^^TA-/FAU.S@MY3<S,C6SQ!QN "G>,/TRO(ZUF6/@/7;/3+>"'4+>VNH
M?#9TI;B)V)2?<"&' ^7CKU]J -RV\97#ZE9V-[X=O[*6_BDDL?-DB)E*+O*,
M QV-CUX]ZR?#GCR^G\+:7-?Z9<W6L:C/-';6\)B!F",Q+YW!411P2>>.^:KZ
M-X&U"U\3Z#JW]D:/IRV'FBY,-S)//<;XF3<9&0' )'RDGJ3GC!=IGA#Q'I-K
MH\T*Z=+>:)/<I#&T[A+JWF.3D[,QN#MQPPX]Z -6X^(=M:6,KW&DWZ:A#>Q6
M,NG@(THDD&8\$-M96XP0?RP:T-.\6)<75Y::G83Z5=6EHEY+'<.C?NB6!8%"
M0<%#GZBL)O!VLWU^VKWKV45]<:O9WDL$4C-'%! " H8J"SG).< 9/M5?XAV,
M.L>(M#TRQOHTU*[+V=[ C?O#8.-\I8#D#]V ">[8H [G1M2&L:+9ZDMO+;K=
M1+,L4N-RJPR,X[XQ5/7/$(TBZL;&"QGO]1OB_D6T+*ORH 7=F8@*HR/Q( J<
MW5Y%XBM]/BM8_P"SC9O(TP#9C=64*O3;@@GOGY36=X@TC4I-;TO7M'6VFN[%
M)8'MKF0QK-%)M)PX5MK HI'!!YH K67CVUNP@DTV]MI3JXTAXI@NY)O*\PDX
M)!7MD$YZCBKUUXKM[6[UFV%E>7$NEQP.R6\>]IC-G:$&>N1R3@#KG&:XC2])
MUS6(M:N%%C_:^G^*Q>^29&$+[;>)?+W[<_=;&[;U'3FM"[\)^*M17Q'>23V-
MK=:I]C*6]O<R!=D);?$TH4,-RG&Y1W(QCJ ;/_"=1V<NHPZUI-WILUE8-J)1
MGCF\R%3@E2C'Y@>,''44R3Q9/<Z)JDMWH^IZ:D>FRWD5U$\4H9 I^ZZEE$@Z
MA3]>0#6-IO@;5+36[S4K.PT32%N-)ELD@A+7&)2ZL'D+(OF X(([#'7/$-MX
M!U3&JFWL-,T..ZTNXLVM+&[DDAN)I%PLA4HJQA>>@)^8T >B:9,+C2;.<-(P
MD@1PTF-QRH.3CC-<YX4\4VU_:Z%9*U[/)?Z?)>)<717>51U4[]O&X[QT&.*E
MC\+>']+2UUO4X+:._LH(A)>O,552B!,Y) QQCD5ROA'2-:3PWX,U[2(+2XEM
M]+DMI;:[F:$,DK(P96"MR"@XQR#0!U$GCFV\O9:Z?=75])J,^G06B%0TKPD[
MVR2 J  G)/IQ7/Q^*KR5_$\VH?VG8QVVJ6%O';J8_,A+B$%0>5*LS$D@\JW%
M3V7@WQ!IR6NJ+)I\^L6NJ7=Z8=[I#-'<9WINVDJ1P0<'I[TLOA#Q!J-MKDM\
MVG176I:E97:1Q2NR1QPM%E2Q4$G$9YQR?2@#8NO&WEW5]]DT34;ZQT^?[/=W
M=N$(1QC<%0MO?;D9P/7&<4RV\2BW35VM[;5-3G35S9);A4.'\M&PIX"1@'.6
M/!)]0*K+HGBG2)-6LM$?3Q:ZC>27<=]-(WFVAD(+CRMA63!R5^8#GGI5+4/!
M6M/%?>5);W$-QKC:A+9M<O"MU 8538[JN00R[L8(.!F@!^N^,KN;P]JT45M<
MZ3JVG7=DDT;NCX269 "K*2""NX>O6NM\1:Y!X;T"ZU>YBEEAM@I9(AECE@O
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M*GW<1E $<D EMQP<XJI=?#G7+RR>">TTB?45O%N#K-S=2233*)@X55*?NCM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P/&FL76A^%[B[L=@NFEA
MMXGD7*QM+(L88CN!NS^% &_17 :[=^(/".GW3CQ"FI-<+#%;B]BC66&629(S
M)B-5!C&_."." ,\U#K>IZ]X1N9+1];FU);O2;VXADN((EDMYX$#!AL4 H=W0
M@X('- 'HM%>?:;?^(+'5O"<M]K<E_%KD4GVFW:WC1(F$!E!C*J&'W<?,3G-/
M\.7?B#6-(TKQ1+XA2**]E#R:=+%&(%A9B!&K;=_F=,$L<GC% '?45Y#I?C#Q
M1J6GV>OP)K$S7%PK&Q^PQ"S\@R;2HD^_N"\[B>2,8Q6C+JWB1M'\::[_ &ZZ
M1Z3)?06=HEM%M'EKE&8E<D@GZ<<YR: /3&8(I9B H&23VJ.UNK>]M8KJUFCG
MMYE#QRQL&5U/0@CJ*X2.]U_2M;T1+S6WOXM7L[AYH9+>-$AD2,.#'M4'')&&
M+5G>']2\0>()/#NGQZV^GP7'AV.^N'MK:'>TN\+\N4*J.>@&.. .M 'J-%>9
MZ5XAU[74T+16U5K6YG>_^UZA#"GF2+;3>4 @8%5+9!/!QCCK70^"[W5;B?Q#
M9ZKJ OWT_4OLT,WE+&?+\F-AD* ,Y8Y]\XP,  '5T5Y)J?B[5[='U>RUC4KR
M./44B*Q:<BZ=Y1G$93S'4.QP<;E8_-TXJ[J.I^)I;#QIJUOX@DMH]!N9A:VR
M6T3+((X4D*R$J20=V!@@C)Y/& #TZCI7!:EXQO- U"_FOV\RTN=(6^TZ+8!B
M9<*\((&6+,\1&<_>-+XV;4[+X2R)?WC/>-%;Q:A<H AVO(BS$!0 !M+=.U '
M00>,_#%UJ0TZWU_39;PML6%+E"S-Z#GD^PK7:UMVN%N&@B,ZC D*#<!]>M<9
MXUBL]-\)26:>%/M^AP6K32&VGCA%NJ#<"N2#D 9!7GBHH]3UG5_&4T=MJTUG
MI5IIUG?FV2"-WE+F0E"S G!"X/?.,$<Y .]HKS&'6_$4'A#3/&LVM&9;N6W>
M;2_(C$ AFD5 B$+OWJ'!R6.2#Q5N]\3ZO#X"\7ZFEX%O-/U"Z@M9/+3]VB2
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MPF4; $+ @'E\XQQTSGI5'6/$]EI4MK"KQW$\][#9O%'*NZ(R-@,PZX% %O\
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MU(-3L+J&2:WOK::*+_6/'*K*GU(/%+'J%E+)-''>6[O ,RJLJDQC_:&>/QH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX=EL;#7]$M;%M/U4B_=1;R6Q@U2Q+;][RE20RC)W%@,Y'7BO:L#.:,#.<<T
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M?/MN-.WBVNB54F2,-T&>"!D9!P:Z#0M"M]!L9+:&6:=YIGN)YYV!>:1OO,V
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M"@&N-\0^'=8U#Q1<7$EBFJZ;);QI:02ZB]O%;.,[S)&H^<-E3GD\8Q0!I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&WU&[O[RVDO9+0KMBM\Y;R6/RNV5&">.>.U 'I"312221I*C/$0)%5@2A(R
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M;J+3GN7@BC;E1&F2S%F^\> ">.E 'K=YI6G:BT;7UA:W1C.4,\*OM/MD<5;
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MVV\2R+)]OMX# @#?(1SAB,<L S@'/1C6N)HC(T8E3>N,KN&1GIQ3R0!DG %
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MZA=12)+.JX><M9N_[QNK?.H/.>E>JE$8Y95)QC)';TH,:$*-H^7[O'3MQZ4
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MDE;:DGRL04ZY()(P>*W!K%LWB!]%19&N4M1=2, -B*6*J"<]20V!CHIK OM
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MFMDB*7]OI\<.Y\9,,[.^?3@C'K6=JG@B]AUK7)K?1(=534YC<03/J,EN('9
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MX=$T2RTNW_U5I"L2D]6P,9/N>I^M9-[X0CN-:O-2MM7U&P:_C2.\BMFCVS!
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M>^6)K(UGPYJ.I_$*UU&VO+S3X(=*DB%W:F,GS#*IV%7# @KD\CL.<UV>:,T
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M#:.!_6LWQJDUMXIN-'B:1(_%L$%N&4GY'CD"S$>A,#Y_X!7ID4,<$8CAC2-
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MX?"AN=N<Y^;H>*]OJG!I.FVN?L^GVD.7$A\N%5^<?Q<#KR>?>@#R*TT>RM_
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M@3S$_>1&>-MV<X'RJ3@\\5)XS\(:GXBU761;(J17.B16T,K2  S)<-)L.#N
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MEMZDK,ADWKP3TW#GH>QH U8/'6B7%[%!&]UY,T_V:&]:V<6TDN<;%EQM)R"
M>A(P":U-:UJQ\/:3-JFI2F*TA*B1PI;;N8*.![L*\OTGP5J5KIVFZ!=:/JLS
M6MQ&)+J36'^PF-'W"18Q)G=P"$V !N^*[#XH-(GP_OFBC6219[4HCG 8_:8L
M ^U %R/QQH[0W\DPO+5K*U:]DBNK5XG: =9%5AEAQCCD'@XIB^/-&?3TO%2_
MV33>1:Q_8I!)=';N!B7&77'.X<8[USOB#2==\6MJ5Y_8LVGF+0[NQMX+B:(R
M7$TP7CY6*A!L&"2,ENE:^L:7J5K=^%]8L[!KUM)CDAGLXW17*R1JI9"Q"DJ5
M'!(R">: -*U\::-="#$L\4DMX+%HIH&C>*<J6".I&5R!P>AR,'FH]6\36L-^
M+""_\BX@O;2"<FW,BGSF^6//&"P[_P .03UK E\,:KKMIXIU*>T.G7NHFWDT
MZ"1U:2*2W&8G<J2H)?L"< =:;'X9UF7P]I\]S: :O=:_!JNH1K(I$2B4';NS
M@A(U5>,YQQ0!9\8_$2UTC1=8.F?:'N[+,7VD6CO;I/D?NV?&W/..O4@=>*W=
M4\8:9I-\]E(EY<W$,0FN%L[5YO(0YPS[0<9P3CK@9Q7%ZKHWB.W\(>(/"EGH
M$EZUY<W$UM>B>)8FCED,GS;F#!QDC&,$@'.*L:QX;U&T\7:UJ4>GZU?P:DL3
MPG2]4-KY<B1A"D@\Q./E!##.,GB@#J[SQGH]J;18GN+Y[N#[5$EC;O.WD_\
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M#1V+PO*7W/&) P8 \J$.2,YYKOO'>EW>L^"=2TZQA\^YF5 D>X#=AU)Y) Z
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M0P(93@9!'851M?!$#SWMUKFH7&LW=W:M9-).JQK' WWD1$ "Y[GJ<#FNIHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC ,"P.#N !&>3^-5]=\)ZW/8Z(FFQ;)+O3H]'U?YP#% =I+CGDJ!*HQ_STH
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M8V1PC@@!QNR.0#C&>:@.B:Z+36=2TC3-5M[J6.W@B;4;Y9[N6)9-TFT.S(A
M)VY/4D\<4 =E:^-=&N&O$F:ZL9+.W-W,E]:R0,(1UD 8#*]N*?IOC#2-2N)8
M UU:RQP&ZVWMM);[H1P9!O RHR,^F>:XFV\.ZM/XAO[T:-J,]G/H<]FJZY?"
M1II2Z'8P5V\M2 1QCH2<<4EKX:UV_M]0TJSCUK3=(NM*GMI(-8NDG6.9@!&(
M6#,^T?-G)P1C S0!V>F>-M%U:^M[6![J-KI2UH]Q:21)<@#),;,H#<<_3GI4
M%C\0_#VHSV:6\UT8KR00P7+6<JP/*?\ EGYA7;NX/&>O'7BLD0:WK]QX9L[C
M0)],32;E+J[N)I(RA*1L@2+:Q+!BW4@8 ]>*@L_#6K1?#SPOIC616\LM3MI[
MB+>OR(L^]FSG!P.>* .VUC6K'0K(7=_*R(SK%&J(SO([?=1%4$LQ] *YO7/B
M!:6OA#6]3TZ.X-_IT1#6MQ:2*\3E24,B$ A#UW=/>KOB_3K^>;1-4T^U-[)I
M5[]H>T5U5I4:-XVVEB!N&_(!(SCK7-:UHFM^)+7Q;J::3-9O?:2FGV5G,Z>;
M,5+L7;#%5Y? R>@YQ0!V&DZDUIX334]:OV81Q--/<3VAM2JC)YC/*X'Y_C3-
M,\8:7JFH+8HM[;W+PF>)+RSD@\Z,8RR;U&<9''7GI4GB:+5G\(WT6B*AU0V^
M(%?:1NXS][Y<XSC/&<9KCM+T359/&ND:I]@UP6D%M<Q33ZO>I(^]U7&(U<A1
M\N,@#)/3 !H Z33?B#X?U6>Q2UFNC%?G;:W,EG*D,KX)V"0J%W8!XSU!'48J
M\GBK2)-$AU=;AC:33BVC_=MO,ID\O9MQG._C&.U<K9>&]5A\"^!]/:R*W6G7
MEI+=Q[U_=*@;<<YP<9[9J*ST>=OBI<Z8I5M&LY?[=V@YVW$JF-4([?,)9/J1
M0!VNN^(=-\-V<5UJ<KQQ33""/9&TC-(02% 4$DG:<>_'>LZ;QUH\ B!347E>
M 7$D$5A,\D$9)&Z10N4Z'@\G'%.\6Z9=:E+X>-K!YJVNL0W,W(&R-5<%N?0D
M=.:YG6O#^H6GC/5]46RUR\MM2CA,1TC4/(*2(FPI("Z\' (;G&30!U=YXQT:
MTCLFCEFO7O8O/MXK&![AY(N/GP@.%Y')^E,E\;:&EE874$\UW]O5FM8;2W>6
M60+]X[%&1M/!R!@\=:YC2-$U/P??:;J$6AS7<!TE;*:ULIUEDMI!*TG!D9=R
MG>03G@J.U64M_$&GZ]IWB:ZT(3M)8RVES8Z>Z;[;,OF(1N8!^.&P>O(R* -N
M3QWX?CT^SO?M<KQWDSV\*);R-(95!)C*!=P?@C:1G-+'XXT.32Y;[S+E?*N1
M:/;/:R"X$Y (C\K&XL001QTYKF=,\-:S_;^EZO=6'D";7+K49X/,5C;1O:F)
M V#@L2%)VYY;VS3]8\.7TU_XEGET.2_M;G4K2XB6&Y$,VQ+=$:2%@PPZL#@$
MC//KR :.M_$.TLO#<^I:?;W,MQ!>0VDUM-:2K)"SLN=Z8R/E;(/0D@ DFM!O
M'6B+JDFF[KPW4*AYT%G*?(!C$@,AVX3*GOW!'4&N2DT7Q/=>$=:MS#J=S +N
MTGTZVU*:)KLK'(CRAG!QSM.T,V>.>M=#I>D7]Q?^+[F>S>T75Q 8/.*EO^/5
M4(;:3C:V0?H<9H W1XBTUK;2+@3MY>KE19G8W[PM&9!GCCY5)YJ@GCG0I-06
MT6:X*O<&U2Z^RR?9WFSCRQ+C:6R".O7CK7*Z;9^(;F+P1I\_AZYM$T.5!>3R
MS1%3LMWB!CVL2RDG.<#J.#SB[X=B\0Z'H^G>&%T R/:7.U]0F=#;-!YA;S!A
MM_F$'A=O#<GB@";2?'3:S DC%]//]N-IZB:RE_?(&<*@)QAR$R3_  G@BM9_
M'>@QWS6[3W'E)/\ 97O!:R&V6;.-AEQM!SQUQGC.:Y>WT+6O,BLWTJ9%MO%;
MZEYYDCV26\CRMN7YL\;ER" >>_-02:)KX\#7/@1=$F:2662)-3\R/[/Y+RE_
M-/S;PX!^[MSN'7'- '5WWQ T#3[F\@FENV-C)Y=Y)%9RR);< Y=E4A1@]?KZ
M5T-S>VUI8RWUQ/'':Q1F5Y6;Y50#).?3%<5)X?U(^'?B!:BT)GU2:X:S7<N9
M@ULB+SGC+ CG%:OB#0;O6?AU<:+$5CO)+)$42'Y=Z@':2.Q(P?K0!-I_C71M
M1N/(1KN"1H6N(1=6DD/GQKR6CWJ-P P>.>>E3^'O%.F>*(I)M+-S) BHPFDM
MGC20-G[C, &Q@@XZ$5S=[#K7BG6-)GDT&YTN/3$N))6N9(B9)'A:,1Q[&.5R
MQ)8X' KH_!MA<:7X)T.PNXO)N;:QABFCR#M<( PR..N: -NBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJAP=VTC@<$YK0U'Q/XE;5/$L&E6NEBWT,(Y:Z,A:<&$2%1M/RGD_-SU''4T
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M2]V."H 7')Z\9J2Y\:ZKID&IVE_:6;:GI]U91LT);R9HKB0(' )RI'SC!)Y
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M:9H.KV^I17FJ>([B_$$31Q0QPB!&)QEY I.]N..@'.!5_0(]2BT.T36)O.U
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M&<R.T\[RLSD#))8D\XSCI3;7PYH=EI\NGVNCV$-E-S+;QVR".3_>7&#^-:=
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M4(BC#$!0J)D[5"JH R>E &[1110 4444 %%%% !1110 4444 %%%% !1110
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M(V;L&VL,XXYK$\-66M0ZM;0VD&NQZ4EG*ES;ZSL<6[[0$2"3[[<C!Y*X'TH
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M.>VSI[UAQ> Y+&#3Y--U<V^I6,MTT=P]N'1XYY#(T;IN&1G;@A@?ESWKLZ*
M.67PC<2Q:>U_K4]Y=6VIC47E>/"DA&01HF?D3#>I[]<TFL>"8]6/B(M?O$=9
MAMX\K&#Y)AR5;K\V21QQTI)_B)X?@>5M][+:0.4FOX;*62VC8'!S*%V\'J02
M!74QR)-$DL3J\;J&5E.0P/0@^E &180:W%K&+V]6XLELHU)$*QA[C<VY@ 2P
MXQP>!QC/.&:KH$U_XBT?6;:_^S2Z>)(W0PB0312%-R]1M/R#!Y^E;E% '*0>
M"8X/"^B:(+YBNEW<%T)?+YD,<F_&,\9Z9J*7P9J$,NH0Z5XBET_3=0N&N)H4
MMPTL;N<R>5+N&S<<GE6P2<8KL** *>H6"W^CW6G>8R+/;O!O/S$!E*YYZ]:Y
MC3_"OBK3-/M;&W\91BWMHDAC!TE"=J@ <[_05V=% '(:EX#CU6^OM3N-1D&K
M/+&]A=K& ;!8^55!GD$EMW][<>G%+<>$=3CO=1FTCQ =.CU,B2[C%H)")=H5
MI(B6&PD*.N[D9KKJ* .5N/"5[;ZBU]H>N264\UK':W37, N?.$8(23E@1( Q
MYY![BHF\%WEK>V-YI&OSVUS!8BPFENX1<M/&&W!B21A\ECGD<]*Z^B@#C+'P
M$^F6OAZ.SUB03:-//()98 _GI,Q+JPR,'!QN'UQ2W7P_BN? R>'!J4L4D5P]
MQ#>I& \;M*SD@9]'9>O0UV5% '-:CX2#OI-QHUX--O-*A-M;N81+&T)"@QNF
M1D?(I&"""*T=#TRZTRUE6^U.;4;J:4RR2R#:JYP J)DA% '3)[G/-:E% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>9&WS@?* ^2<9&>2*]@K(D\*Z#+I,.EOI%F;&"02Q0>4-J/S\P]^3SUY-:]
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MEC0DA[F=IG.3GEF)-06_AO1;73/[-@TNUCLS()3"L8VLX8,&/J<@')YX%:E
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MS <#/- '7-XYT>_B7^Q=7T^:19[=)#+OV;9'"X! ^^<X ]<9Q5\>+_#YU?\
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MT:#48I-14N&@7)*E?O \8'0]:DUCQ'I&@F%=2O4@>;/EQ[2[N!U(503@=SC
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MM*%BVEMIY'(Z'GIG%97BCPS>:EXWCLEM))=#UKR9=2D RJ-;!R ?]_,0_P"
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M=+G\):UJVC7)\FSO+:YCT^SRT1=T:-FB3.W<J<XX#&JEA8ZK;7-IX@NM%O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *YV]\#Z!J%]/=7%K,3<.)+B%+J5(9V& #)$&",>!U'..:Z*B@   &!P**
M** "BBB@ JEJNDV6MZ>]CJ$'G6[E6QN*D,#D,&!!4@@$$'-7:* ,K1_#FFZ&
M\\MG',UQ<;?.N+BXDGE<+]T%W).!DX&<<UJT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !12.2J,P4L0,A1U/M7'>%=;U[4/%?B&U
MUR&&TCMH+26WM(W#^2K^;G<X'S,=HSC@8X[D@'945Y7X0\6W.N7>G7%[XNN8
M3?3.T-B^EJD$B[FVQ+.4 9MH'1LYS7JE !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5SUCH]Y!XQ\0:FQ1(+ZUM8H'!R0T?F[LC_@:_6NAHH X*;2_%6NQ:/I>L6-G
M EA>PW5QJ$,X(G\IMR^7&!E2Q SG&!G&:[VBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>guyaragreement017.jpg
<TEXT>
begin 644 guyaragreement017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKR_4M"M-.U;2M/TJYN+SQ?)>)=7%_YC;T@\S,C2\X$97**G0\8'%.
M\5^$-$U'Q18:+96DD5]J$CWM]<I<RYBMU8%B!NP"[,%''&6/:@#TZBJ=_8&[
MT>?3X+J:S,L)B2> _/%D8RI/<>M<)HMM;Z'\3(=.LK&ZTFRDL94"SR%UU*16
M4[UPS#*J&)+$,0W3% 'H]%%4=5TBPURQ-EJ5LMQ;E@Q1B0,CIT(H O45YIX
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MY_"@#HZ*\]\.6-U=?%;Q1?W\=E*]F888) ',D2M$"%7)P 03N]2:OW5SJ_\
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M02*A?8^?O @$!ACD=.:L^#_&]]XCU""*631V66)GGM()62ZLF !"NC\OW!(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWFN&)<[2>FT9.<5/I7A/5=/;3K>7Q-<3:7IQ'D6Z0"*215&U%ED!^=0.V!G
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M8L?"F@:9;75O9:19P172&.=4B'[Q,8VGU7!/'2M6*)(8DBB0)&BA551@ #@
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M7%Q&\DAPB3O'B(L>@_C /J:C\2ZQJ&G^*=#CN;;0[FRN=2CBM S,;J,LI!D
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M7-O;V=I:7$=F=4DN3 [%]V7)SR I*9(Z&NBU6+4;SQO=:%#;WEU8:=I\#VT
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MR[:Z:XL8)3=*BSET!\T(24#>N"3BIS96S7R7Q@C-TD;1+-M^8(2"5SZ$J#^
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MD,G+R;<!0"<+^-5HFUW5]-T..2\BUAXHKKS+"WUAK>6X190J2B5,"1D VD'
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MQM6DFT.3X@:EI<]S'=M>V4)E:Z<"..9(=[X8D*1N.&Q\HX& ,5Z=>>%]!O\
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MY"2J[2HQM XXK&34+M/^$:UVT.JK'J&K6\8O[W53NNXI),%?LRDH%*G@<%0
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M"GA^#5CJL6CV27Y8OYZP@,&/5AZ,?7K0?"GA\ZO_ &L='LOM^_S//\H;M_\
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M<%E)R,]UJGJ?AZ^U?2_$5Q;6&OW$DUA%:12:JZB2;]Z'*K$%!PO]XGN0!WH
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M^Z96)<, 3D# '7FO2]*U6/55NRD$\)MKJ2V83  L4/WA@GY3G(_D* +]%%%
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M;6_EA#75JKK#)DY0/C</3G:/RKBO%/CZ_P##CZA/);:/%:V3?+;W>HA+J[4
M$M&@! ZD $Y..U:=SXVCL&\1"]MA'_9=M'>0 -S<Q.IVX&.#O5DQSSCUH ZR
MBL35->?0_"$FM:E:XFAMUDEMHFS^\.!L!/\ M$#-<E?:UKFG^--&N?$-M;VE
MK!IU_<O]BN&D5@JQDJP*K\R@=>ASQB@#TBBN+M?%VM1'1[S5](M;?3=7E2&$
MPW+/- T@S&) 5 .>AVG@GO5[QCXI?PS!8%$M4^V7'DFZO93';P?*6R[ '&<8
M XY/44 =-17&MXPU%-&T]AIMI-JNHWAL[1(+T26\N S&;S "0FU2<8W<8QWK
M1T/7KZYUF^T/6+2"WU&UBCN%:VE+Q31.6 9<@$$%2"#[<F@#H:*Y[Q[))#\/
MO$4L3LDB:=.RNIP5(0\@UC^.+B:'X/7L\4TB3"PB(D5B&!^7G- '<TC*KJ58
M J1@@C@BN2N?$7B"?Q)JFD:-I5E,-.AAE::ZN6C$A=20@ 4\\'D\#\:KV_C>
M[UXZ7;^';"![J\L?M\QO92B6Z;MFT[02S%PPXP/E)H V--\%^'](OHKRRT\)
M-"&$.Z:1UA!X/EJS%4XX^4#BMN.*.%2L4:HI8L0HP"2<D_4DDUPP\>ZE</IU
MC::-"=6N+ZXT^XAEN2(X98DWEMX4ED*X;IGG'6MWPQKMYJ_]IVNHVD-M?Z;=
M?9IA!(7C?**ZLI(!P0XX(H WZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&=-T<S_:/L<"P^;LV[\#KC)Q^=<_<^"M2BN]4&D:O:VEGJ<S7$PFL?-F@D8
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M^V?\@-U8GR_]=B!HO7Y?O9[],>];=G>6^H6<5W:3)-;S*'CE0Y5U/0@]Q4]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/[DA"@Q_P$D?C0!Y/-K.H^3I>OV-SKTL%SJT,8O[J\2.VN(WFVE$M0Q^7:2
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M\)171"3,J;SO!^4'&.^.F>>M);^*K[PUI.CZQJ%U/=V^J>'8WC25RV;Z.,,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(N_#_P!MC\R>^>[$VPX -UY^,?3BNQJEJVKV.AZ=)J&HSB&VC*@MM+$DD
M DDD@8 H XZ\\!7R7^JG2YM(6WU.=KAI;VP$T]J[@!S&<X89&0&Z$]ZZC5M&
M.H>$;[0XI@AN+&2T65E&%W1E Q P.^<#%:%I=17MG#=0[_*F0.GF1LC8/JK
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M&,KM+^Z/5!O)PO\ LC IVD^$="T2Z%UI]@(YE0QHS2O)Y:'JJ;B=@X'"XZ4
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M,*_7K@=>_4Y- 'G5Q+K3>'KS74\1ZG'=Q^(7LH$$@,20F[\K:4(PV Q()SC
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M[;PEH5I9_9(=/01&X2Z8L[,SRH05=F)+,00.I/2KDVCZ=<W<]U/:12S7%O\
M992XW!XLD["#P1EC^= '":1'KT'B.RT^<ZO;V-_;3)<'4=5@EE9@H*R0[7+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-LK$,!M."K9&<\'T-:?C31-1U#Q!J46E6[K)<>%[BVCD1=JL_FIMCW= 2-P
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M@@6U=TOHW"^6/,"E5"XVG<1MVYH ZVQ\30SZSJ]C=F&V6RO8K.%VDP9G>))
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M3(V)!CYE^7IQS@]J -ZBN%A^(EQ):Q:FWAZ=-':]^PR79N$W*_G>4&"=2F[
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ME".6YM+>X67="V?WD; ?/@*WRX!^4CTR[_A8>FOI6IZQ!!+/I%F4CBNXR/\
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M(8DBB0)&BA54#@ =!6%;^"=!M=22^BM) T<QN(X3<2&".4YRZQ%MBMR>0.]
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MO;W$3"!;9_LUY+#YL2C"I)L8;P!Q\V: .'OM0>U\4ZAXIL]3N+WRO"B:A$H
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M/'G.QBC#<N<G!]:KKX(\/1V5G:0V+00V5RUU;"&>1#%(Q);:0P(!R?EZ<]*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %07EM]LL9[7SI8?.C:/S(2 Z9&,
MJ2#@U/10!!96=OI]C!96D2Q6]O&L44:]%4# 'Y5/110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ,,?_K5K:SHMEKMBMI?(S1I*DR,C%61T8,K CH013]4TJTUFT2VO$9XEFCG
M5B/GC<.IX]U% 'G^L^(-=\'76MVAU635=FF17=M)>Q1J8I7F,)SY:J"G(;&.
MW6KVH?VWHFK:?I4_B*ZOX=8M[F)Y)885DMY4B+AX]J ;3@C:P;&1S757OAS2
M]2O;FZO+83O<V?V&57)VM#N+8Q]2>>M5=,\'Z7IEZMX'O+NXCB,$+WMT\YAC
M/54W'C.!D]3CK0!P?A_5+S0?"O@,BX>ZAETZXG>.2./.U+7>J*0H( (Z]3W)
MK?TF?78='TGQ)>^(Q<)>6_VBYL)8HTB(:(NJ0$*&##@<EL@&MO3?!>CZ4FG)
M MPZ:<TAM5FG:01!UV%1N/W=O ':FZ?X'T73+RWN(5NG2T+&TMIKEY(;8L""
M8T)P."0/0' Q0!Q.A^)_%-W%HFKXUBX^WS1&YMY+.%+-(9#UB<?/E00023NP
M<CGCM?&>IWUA9:=;:?.+:XU+4(K(7)0/Y(;<2P!X)PI SQDBFVG@+0[.[MY8
MUNS!:S>?;63W3M;P2<G<D9.!C)QV&>,58\7Z;<:MH#6UO8V]ZWFQNT$TK1%E
M5@24D4Y1QU5O44 <1XBU37_#_P#PE-@VMO?Q6FBQWEJUS;PET=I'4[\(%;[O
MIC&..YU=:\4ZKHESXATPS"6_F6"31-R*,F8B(+@#G9("QSSAAFH]#\!FZNM<
MN-9LYK>VU*TBLS!+?M<SNJEF9WD)."<@  \!:["_\.Z9J6L:;JMU;[[S32YM
MGW$;=PP<COT!&>AYH X2_P!=U^Y\2:KI4%WK:+I,<,*2Z;8PR^=,T0<O+O'3
MYA\J[>_/I8LM3\2^(];TO3YM1FT43:(+R[CMHHV<3"78=I=6 !Z]^,?6NHU7
MP=IFK7\M\\E[:W$\8AN'L[IX?/0= ^T\XR1GK@XS5NR\.Z7IU]!=V=L(7M[,
M6,2H3M6$-N"X^O>@"AX&U.]U;PK!<:C,LUW'/<6\DH0+YGE3/&&P. 2%!..]
M<-IMQJND_P!J6MGJ\_GZIXJ>P$\T43>0-F]I% 4 N0NW!RO3CKGT_2M*M-&L
M?L=DC)#YLDN&8L=SN7;D_P"TQK)G\$:+</J)DCN=M_.MS(@N7"QS+C$L>#\C
M\#E<=* *NBW>I:=XTNO#E[J4NIP&P2^@GN$198\N49&**JL. 0< ]1S5;Q7J
MMROB"#3+75=3A(M?.:UTBS6:X)+8#.[JR(G! '!)SS@5OZ-X;L-$FN+F!KB>
M[N0HFNKJ=I97"YVKN;H!D\# YJ+4_"FGZIJHU)Y;VVNS"())+2Z>$RQ@DA6V
MGG!)P>HSUH J^ -7O=<\&6=]J+E[LO-%(Y15+;)70$A> <*,XXSG%<M/JGB0
M:#XH\1KX@=?['OKL6UD((O)>*%S\DAV[B2!@$$8X/)S7?:)H=AX=TQ--TV(Q
M6B.[I&6+;=S%B 3SC)-<II/P\MFFU:76/M#)=ZK/=FU2[?R)T+[HS)&#@GIQ
MWP,YQ0!2\1>(-0N-0U!=/U;5XVM;6.1+72[&.00.R;_](DE4KSD?*&7CZT:3
MJ_B'Q1K.B1)K+:?;S>'[74[A;>"-B\K.00"P.%/?Z#&.:Z>]\%:3?ZC=WDAO
M(_MH47D$-T\<5QA=HWJIY^4 'U YS5K2O#&F:-/;S6<<BO;V*:?&6D+8A0DJ
M.>X)ZT >>:)<:GX;TF_U9=6N+BR@\3W$=_'-'%@PF9HVDRJ @[F5S@X^4X '
M%=UX8U*\UFYUB_DFSIWVQK:QCVC&R+Y'?.,G=('_  48K/UOPP]IHNMV^@V!
MNY=<=UN(;F\*P0F16W2A3G')R0O)_"NBT/28="T*QTJWYBM(5B#'JV!RQ]R<
MD_6@#F'U_4EL?'\OVG#:2TGV,[%_= 6J2#MS\Q)YS5."[U[7O$EKID>O3V%J
M= MKZ1K>"(R-,[N"074@ X&1CL,8YSNZIX%T75KZ\NKC[8OVY0MW##=21Q7&
M%V@N@."0,#WQSFM*ST&PL=06^@C83K9QV()<D>4A)48]<L>: .'TSQ%KGB"R
M\*::VI-9W&H1W<EY>V\2;W%NX3"!@54L2">#C!Q6.FK:QX=&LV,-W/<WU]XG
M%HUY!;HTH3[+&Y*IPADVJ!TQG)QVKT)_!>CMI5G81I<0+92O+:SPSLDT+.26
MVN#G!W'(Z$5%'X"T&+2[G3Q#<-'<70O7E:Y<RBX  $JR9W!OE!R#Z^M ''WO
MB3Q3INAZVD4FHKY)LVL;S5+6)909)U1T=4 5A@\' /)] :]&TVPO+/2S:W6K
M7%[<'=_I<D<:N,],!5"\=N*RT\#Z,+.\@F%U<O>O$]Q<7%PTDLGE,&0;B> "
M.@P.OK724 >)Z-I]^VA^"(H-8N$FFUN^V3/%&QA %R&VC: 20"?FS@MZ<5O7
MVM:SIMAX@TZ;4FO7TW5M/AANKB&/>T4SPDJP"A21N8 @ ]^M=;8^"]'T^X@E
M@6YQ;7<EY!&]PS)%(ZL&V@G@'>QQTR<U/=>%-)O9+]YH7+7T\%Q/B0C+P[?+
M(],;%^M '%ZEKVN:;XANIM5U'4M/LTOU2WFCLXI].:WW !9&4&1'/()+  D=
MJ[W7]7AT#0+_ %:XYCM(&E*_WB!PH]R<#\:R[CP)HMS>3S.+L07$_P!IGLEN
MG%O++D'<T8.#D@$CH2.0:UM7T>SURS2TOT:2!9HYB@8@,R,&4''49 ./:@#R
MGPE>MX=\1Z#-<V.J6\FL1-:ZK-=V4D,;7CNTT;!F&"=SR(/8CTK0U#6?$D_@
MC4_&%KX@DM'CN94AL/L\30I$DYBP<J6,AQG.<9.,8KT76M%LM?TYK&_1FA+I
M("C%65T8,K CD$$"O.M;\"ZGK,]]8G2(X([R]\YKN'4I%M=N\-YAML\S;1@\
M8W<YH TKC6-<BUKQAJ3:K)_9WA_]Y#IZ0QXF_P!%60J[$;L;CD8(/)YZ8IZ!
MKOB=K[0[B4ZS=QW[JM\EW90Q6\:LA(>%E^8 ''!+9&3UKOX-%L;>YU*=(=S:
MDX>Z#G<KD($Z'C&U0,5EZ=X&T;3+RUN(OMDJV6?L<%Q=O+%;9&/D5C@<$@=<
M#IB@#A++Q?XHU#3D\06J:S*\ER2EBMG#]B, EVE-Y^??M!.[/WN,8JUJ^L^)
MDTOQ9KEOKSQ+HNI-#:V8MXC'(@\LD2$KN(^<@8((]377-X"T-KLR%+K[,UQ]
MJ:Q%T_V8R[MV[RLX^]SCIGG%79_"NE7&FZKI\D+FWU2<W%THD.6<A02#V^XO
M2@#CM9\0:YX,O-92;4Y-76/1&U"(7$,:>7,) F!L5?D^8'!R1CK3]&U?Q);Z
MY80S-K=W:W44HNWU*SAA6%PA97B*8."1MVG=U!S7:W?A_3;_ %"6]N[<322V
M;6,BN<JT+-N*D=.M4--\%:3IMY%=*][<R6\30VWVN[>86Z,,$1ACQD8&>N.,
MT <AHVK>)(]%\&Z_>Z]+=G5[B"WN;1K>)8MLB,0R[5#!@0"3G!YX XK9^'-I
M/;OXF:74+BY!UJX0+*L8 (QEOE4<G(SVX& .<[\?A?2XM+TG34B<6VE21RVJ
M^8<JR A<GOP3UJ73= LM)U#4+RT,ZM?R^=-$TS-'YG=E4G"D]\=<"@#BO%FL
M:_IVNZC+)?:K8:7 B-:7-A9Q75NGRY<W*X,@YSTP-O.<U'%;:AJOC3Q7=:9K
M\MA&MG92K):Q1OYS&)RI.]6^3V&"<]:ZK4_!.DZK?75U*U[";Q0EY%;7;Q1W
M( VC>JGGY>,\$CBM&UT'3[*ZO;BWA\M[R*.*4 _+MC4JH [8!/2@#@QXIU#6
M;#03_:FHPW%UI,5Y/:Z+9++,7?\ C9G5D2/(.!P2<\X%1:%J][KEY\/[[46+
MW9N-2BD<HJEMBR("0O .%&<<9SBNL'@+1HOLGV5[ZT-M:)9!K6[>(R0K]U'(
M/.,GGKR>:LZ=X.T;21IJV=N\::;)-):KYA(C,N=XYZCYCC/2@"A\,/\ DFNA
M?]>__LQKC-!EUGP_\.[+Q##K4DD$5Z4.F^3'Y+Q/=&,KG;OWY8G.[&>,5ZGI
M&E6FAZ3;Z98HR6MNNR-68L0,YZGZUAV7P^T&QE@,2WC003?:8[22[=H!-G/F
M;"<9R<^F><9YH XVX\5>)K\ZSJ6G_P!L"2RO)H+2U@LH6M'6)BN)7;Y\MM.2
M"-N>.G/H'B.]G@\#ZM?Q+Y5PFFS3*KJ&V,(R0"#P<'UXJI>^ ]$O[NYEE6[2
M&[D$MW:173I!</Q\SQ@X.<#/KCG-;M]86^HZ9<Z?<)FVN(6@D53CY&!4@8Z<
M&@#A+&?7_$&NW&GPZ_/IUM;Z197(^S6\18RR!\G+*1M^7D8],$<YZ3P=JEWX
M@\#Z7J-VX6[NK4-(\:@?/T+ =.HSBKUAH-AIM[+=VT;+-+;PVS$N2#'%NV#'
M_ CS4ND:5::'I-MIEBC):VR;(U9BQ ^IH \TA\=:XL_AZ.:X3_0G,/B F-1E
MC/\ 9D/3Y?G#/QC@>E6(M8\2:[=^'XK?6Y+"WUM]0N%>.WC9TMT9/("[E(R5
MYR<_?/MCKY_!.@W"ZXLEH<:YM^W8<C?M&!C^[W/'<YJ]'X?TZ*YTN>.$J^EP
M/;VH#'"(P52,=^$6@#S76'U#5(/)DU2:)K7QC#:I)##$I(Q'ACE""P))S[\Y
M&!5^]UW7(VU&WLM06"8^*8-.28V\9*Q/#&3D8PQRQ.3ST'3BNON_!VD7EE>6
MSI.BW5Z-0>2*=D=)QMPZL#E2-HZ4\>$M)#,QCE9FOX]19FE))G1556_)1Q0!
MQVHZ_KOAN;Q#I?\ :KW\D*V!L[N[BCW0FYE:)BVQ55@I&X<>QK8L6UK2?B#9
M:/<Z]/J5A<:;/<E;B&)9%D5XESE%7Y<,<#'<]>,:7B'PW%>VFKW%I96UU?W]
MM';R17CL(I41B0IV\J?F;##H<'M6'X5\*7MMXO.NW5E/9I%8M:(EUJ+7DTA9
MU;)8DA54)@ '^(F@#5\1ZE=6?BW0+>!U6*>WOG<&-224C0K@D9')[=>]<UH^
MJ^(X=+\%ZY>Z]+>?VS-#!=6C6\2Q!9(F8,NU0P8%03R0<G@#BN_O=&LM0U"T
MOKA&:>T25(B&( $@ ;COP!5=/#&EQZ;I&GK$_P!GTF2.2T7><JR*57)[\$]:
M ,'XF6TMSH^D"*]GM3_;5D-T2H3DS* ?F4\@\CW'.1Q7/M;:S#J'Q U"PU^X
MLS82K,B)#$WG2):1MF3<IRIP!A=O4^V/1=;T6SU_36L;X2^47216BD,;HZ,&
M5E8<@@@&H8O#6G16VJ0!9675!B[9Y2S2?NQ%G/8[5'X\T <+<>*]9UK6?LEN
M^KVL%OIUK<-_9%I%,SRS*6RYD!P@ P !SSSQ7;^$K_4=3\+V5UJ]OY%^RLLR
M;=N2K%=V,G&0 <9XS5>[\%:5<O;21/>V<\%LMH)K.Z>%WA7HC%3\P';/(SQ6
MOIFFV>CZ;!I^GP+!:P+LCC7/ ^IY)[Y/6@#SCPE_PDN-?_LO2]$N;;^W;[$E
MY=21R9\YLC C88_&MO4)==OO&6G:%%JATJ%](>ZNA9QHY$BR(N$:1#@9;J1T
M'0$\6S\/=)%S=3P7VM6QN9WN)$MM4FB0R.Q9B%5@!DFM:R\.V-C?6UZC7,MU
M;VK6B2SSM(QC9PYW%CDG*CDT <1IOB#7M7_L;07U5[>XFN]0AN=1BAC$LB6L
MFP!0045FR"3@]#@53O+S5)+TZ?J>I&__ +/\66$,$IB1#L*(^#M !;YN3ZYQ
M@<5TFO\ A3RK.TCTG2Q=1QWLUY($O'M[F.20EB\,H(QRQRIX(/M47A;P,EK:
M74NJVQBDGU5-2B@6Z:9HF155-\AY=B5+-VRU &5+K'B*:RNC9-=M!'KUY!<G
M3(H?M0@0D)Y:N-K<XW'!;%5+B^N]>3PI';Z[/)>1Z[- US-9"&X@Q;RG9)&1
MM\P*>NW'(.*[BX\%:/.AVK<P3"\EO4N(+AHY8Y9/OE6!X!Z$=/:I+/P?I%E]
MD:..9I;:[>]$TLS.\DS(49W8G+':<<^WI0!3\)W>HKK/B'1;_4)-0739XA!<
MS(BR%)(E?:VP!3@D\X%86IZBVE>*?&MW'?1V,BV.G*EQ)"9=K,TRC"#EF.<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9=[^5(T98#J0=I->9:%+96&OZ/:V+6.J$:DX^R3VA@U2Q+%][R,A(91DY+
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M_+(9+ES,=HSC[PR6 Q76^-S:0>(_#-[K*H="@DN/M#3+NACF* 1._8#[X!/
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MWFD?%"\N=/AFNA+.(I9(@S*%M(V7:3TPQ)X[T >G7>HV=B46YNH(I),B-))
MID/HH/4_2JWA[6%\0>'=/U=(3"MY LPC9LE=PSC/>O.4FT2WUC5W\811R->Z
M;:"P:YBWF:/R</'%P?G\PL2HY.0:Z7PA'>-\'=,BLLI>G2 L&>")/+^7]<4
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M1?:+[^QG$BE=Y:80\D>IW#(]ZY_0;'0]<\;:?<QVEG=V2>&XQ#F(-&K>>X;
M(P#D$>O7UH ]'EO;6WM/M4US#';8#><\@"8/0Y/%/@GAN84F@E26)QE7C8,K
M#V(ZUXBL$\'A_P '237%K9Z1:7>I(\M]:&XMX7$SK#O3<N %#!6)P./:NZ^&
M\*)!K,]M?1W=E/>[XFM[$VUMNV*',(+ME21R>!NW8H [BBBB@ HHHH ****
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M==6V[RY;5E((;&0R.K*PX'49&.*?H6AV^@64L$,T\\D\S7%Q<3L#)-(V,LV
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MD#,SEMN<!1P3G\ZN)XSTZ]GT/44FOX;6ZLKRY,)1=H$6S>)!R=RG(&WCK[4
M=E17-Z#XLDUN:VW:'J%I;7D!GM;IS')&Z\<,49MC$$$!NO/<8J?QCK$NA^%[
MRZM1NOG M[-/[T\A"1CW^9@?H#0!NT5Q7AWQ')I.B:Y;>);XRW7A^1OM-RR_
M-+"1YD<F!W*G;@=U-6[+QF\VMZ=I5]H&I:=-J*R/;-.8V4JB[CNVL=K8Q\IY
MY'O@ ZJBN)L?B1;WNC)JPT/4X[2X9(K(L(]UW,S%?+1=V000>6P, G.*N?\
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M9;Z+J,^DB[^QG4HU0IY@?82$W;R@;@MC'7MS5B?QE90:!KNKM;W!AT:>:&9
M%W.8\9*\XP<\9Q0!T=%><ZMXPU"'4/&,%U#?6VG:;9P217%J8?,CW!B6&2<E
MNV1@;3G&>>EF\86%K:^()KF.:(Z(?](1@-SJ4#JR<\ALX'3D$4 =#17+7/C)
MUNYK6QT'4;^>TACFODA,:_9]Z[@GS,-SXYVKGMSR*VK/58-3T.+5M-5KN&>
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M(SMQG'>H-+T748];UW4[Q;>,ZG;6J+''(7V.B,'!)49&6X/?T%=-2$A5+,0
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M.UN/+2Z4#:-XQUQQD8...E6]+\,Z?I%W!<VOF^9!I\6G)O?(\J,DKGCKR>:
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M"._UJIXI\3ZEH&JZG;*Z,+C3%ETL,@XN?,$17_:RTL)Q]:ZE=(M5U^36AO\
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MC] !Q@ #I0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_(,,6Y^!DKO)SCO[UTWC.[2U\$:Q<M9RWL:VCEH(G9&D4C!&Y>0,'DCG&:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8R@$-\N,YR#Q0!U(4*,* ._%+7&2^,[F;Q5X:L[/3KPV&J6LTTC20JCJ5*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5E>-OERC ,<'D9QVK>T33-5N/%=YXCU:UBLF>SCLK>T2;S6"*[.S.P &26P
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MXX($3'.><U>\5^#KKQ)J]^1(D5K=:')8"4G)64RJZDCTXYKM000"""#T(I:
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MCCHPST(]:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,EM;R33/-,]Q//.P+RRN<LS8 &?8 #B@#G?$>L3:;XJN/(@MO-@\.7=VDSQ
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M^RV'V"*+=E!'O#Y.1DMD=<]S0 SP9J]YK?AM+G4/*^V1SSVTK1*51VBE:/<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$C'1S0![,DL<B[DD5AZ@YH\V/#'S%PGWCGI]:\?G_X1;_A+-6_X18V7D?\
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MX([@XY'0CB@#M$=)$#HRLIZ,#D&JU[J=K8:5=:E-*#:VL3S2,GS8502<8ZG
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MD,:QH<JBJ %^@[5)10 W8H<OM&\C!;'.*&BC8DLBDLNTDCJ/3Z4ZB@!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ#ZT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0@E2 2"1U':@#S"_\/Z0N
MIZ=X>\/6XN-;MKZ.^OM68 RVR[][&64 9=QE0G<'D "I_%/A3P]K7B[3] AT
M+34EN=VHZG=):H)?)5N%W8SF1S@G.<!JU='^'KZ$ MEXKUU8C.9Y8V-N?-<G
M+%SY6XY[G.:Z*WT2WM_$-[K0DE:YNX(K=E8C:B1EB-O&>2Y)Y]* (_$=M=R^
M%-3M=*B4W;V<D5LFX( Q0A>3P .*XSPSI\?A+Q#H^F7WAC0[.>^MWBMK[3AN
MD#QH&9)"44DE03N'4CI79:AX>M]6CU.WO[BYN+/4(5A>U9P$B !Y3 R"<@DY
M/('2J>F>$A9ZK;ZE?ZOJ&JW-I$T5H;LQ@0JV Q 15RQ  +')Q0!T=5K[3K'5
M+8VVH6=O=VY(8Q7$2R+D=#@@BK-% 'GGP_\ #FAK>>(KA=&TX3VNO7"6\@M4
MW0J F AQE0,G&*QO!^I>(=$\%^%KUKJRDTRYO8[$V8MR'5))2@?S-WW@2#C;
MC''O7I.CZ);Z*=0-O)*_VZ\DO9/,(.UW ! P!Q\HK/A\&6$/A[2]%6>Y-OIM
MS%=1.67>S1R>8 W&,9ZX XH Y1_$VJ66FW$EE:Q6=J==OH+N\M=/:X\A$=MK
MM$AR2Q'+\_3FNP\(:O)K>@K=RZA87["5T%Q9!E5P#QN1N4?&,KS@U5;P3!&F
M^QU74+*Z%]<7J3Q,A(:8DNI5E*LO/ ()&!S6GH&@P:!:3Q13S7$US<-<W-Q.
M1OEE; +$* !P ,  8% &1\1];.B>#;GRYO)NKUELK=\$[&DX+8'/RKN;_@-<
MKX0\3:1X:@\4:5I\K7&FZ7;-JEBI5D)BV9D0;@.D@)Z?\M!7H=]H=OJ&MZ9J
MD\DI?3O,:&($>67==I8C&20,@<_Q&JFO>&K;5[NVU)D9[NS@GB2'>%CN$E3:
MT4G!^4X'3H>: .?CU?Q98WGAB74+S39[;6;D1SQ16S(UN3"\@5&WG</EQDC/
M'OQF1^-?$EMX/_X22\FL'6\N/L5G:QVCGRW\\QB1RK%F& QV*,G  .:CT;P[
MJEUK_ALO:Z_;VND2-+(FJ3PM% /*9!%$4^:7EA\[9PJ]><5V0\%Z;_PB2^'6
MDN6MDD,L<P<"6.3S#('5@."K'CCMSF@#DS\0]0TBVU:2Y$FJP6U@;J&Z_LR:
MR'F[U3RF#CG)92".<!JNZ#XNU67Q!9V%S.=1AO(I#)(FCW%H+215W ;I.&0X
M(&<'./6MM/!5O<1WPUK4[_6&O+;[(YN61%2+.<*L:J <X.[&>!S4FF^%'L]0
MAO+S7=4U)K:)HK9+ED"QAA@D[%7>V!C<V: .0T_Q1XSNM(\+ZF]WI6->D%MY
M'V1L6Y,;L)-V_+'"$[>!R!GO4U[XYUC1K*^L+R6VGU*'6(]-BO$M'*;'A$WF
M&%"68JI8;0>3CWKJK7P=86FF>'[!)[DQ:'*LMNS,NYR$9/GXY&'/3':F7O@G
M3KUM0D:XNXY[R]COUFC<![>:-%16CX]%Z'.<GM0!RDWCS6K+1=>9,7TEE!#/
M:WLNG36B2%I C1NC_P 0X.0<8;V-:%_J/B:SU"^T2^U&QF:ZT>XO(9X+1H_(
M>,JK+C>=RD/P<@\5K2^!H;S3]2M]3U?4;Z?4%C26XD9%*(C;E5%50BC/7C)S
M6I>>'[2^UJ/5)GE\U+*6R\L$!2DA4L3QG/R#'/<T 4?A^MROP_T#[5.LSM80
M,K+'LPIC7 /)R0.,]_057\7Z[<Z5=V%M#JUEIJ3K(S/);O<SN5QA8X5Y(Y.6
MYQP,<UL>'M&'A_1+;2DO;F[BME$<3W&W<J 85?E4 @ 8Z9JKJ_A@:CK5OK%K
MJ=YIU_# UL9;<1MOB9@Q4B16'4 @B@#D++QKX@U+3=(BMFLUO;G6;C3))YK2
M1%*1H["3RBP96PH.TGKQQVL2^+=?T\ZEHTTEE=:K%J=KI]K=^28XR)T#AW0,
M>5&[@'G Z5N:=X#T[36M&CN[Z4VNHRZDK32*Q:61&1MQV\CYB?7/?'%37_@O
M3M0EU6:6:Z674)H+CS(W"M;RPJ CQG'!&T'G/?MQ0!C:'!JMO\5-035KNWNY
M!HL/ESPP^5N7SI/O+N."#GH>F*Z[6;R33]%O;R%K99(86=&NI/+B! X+MV7U
MK-T?PJ-+UNXUFXU6^U&_N+=;>22Y\L*$5B1M5%4#J>G\ZT-<T:U\0Z)=Z3>[
M_L]U'L<QMAAW!!]00#0!Q6@^,=0G\5Z?ILFJ0:I;7UM-(98],EM5B>,*?D=B
M1(I!/3D<<\U#H_BGQ3)H_A?7[^YTY[75[F*UELHK9E*"3(#B3><G(!(QC!QV
MR>DMO!VS6['6+_6]2U"\LDDCB,WE*@1UP1M1 ,\ YZY [<5+#X-L(-!T71UG
MN3!I$\4\#%EW,T9) ;C&.>< 4 8J^+]4-I_996W_ .$@&M?V9C8=OEY\SS=N
M<X\CYNO6N\KBM+T1[_XDW_B>?3;BRC@MA9PB<KF>0,VZ8*I.!LVJ">2">!7:
MT >2>*]2\0>(OA_K>KQ7-E%I/VAX([(P$R-%'/L+F3=PQ*DXVXQQUYKJ9-2\
M1ZWK>M6VB7=C90:3(L"BXMC*;F8QK(0Q#+L0!E'&3U/M1J/PZM+^&]LEUC4[
M;2[R8W$MA T8C\TMN)!*%@"WS%<XSV[5=U'P<MWJ5Y>V6L:CI;7ZJMZEH8]L
MVT;0WSJQ5MO&Y<' 'I0!A:1XMUGQK+:Q:++;:6HTR&]N9)X#.?,D+J(U&Y1M
M'EL2W4\=*V=(UK69?%2:-JL5I'(ND1W<RV^6'G&5T.TG^'"@X[9ZFED\#VD#
MVDFBW]YHTMM:+9![38V^%>55A(K D$DANO)YJ(> ;2U>QDTG5-1TR:VM3:-+
M Z.TT18N=^]6^;<2=PP<L: ,6U\6>(=5M?#,-I+8P7.K3WT4TTD!=8UA9@I5
M=PR<+Z]3^%5V\4>+;;1=2U6>\TUX]&U+[#-$MHP-XHD52^=_[LX<8 !Y!['
MZK2O!&G:0FBI;SW3+I#7#6_F.&+><26W'&3C<<?KFG3^#+"?1M5TQI[D0ZG>
M&]F8,NY7+*V%XQC*#KGO0!R>J>/=4?5-;73[A8%TN=K>&U.DW%S]K=%!;=*G
MRH"3M&.1U/I6G%KOB7Q#KL]EI<]KI<*:9:WW^E6C2RJ\N_\ =D;EQ]WGN,>_
M&G?>"8[F\OY;/6=3TV#4CNO;>U9 DK;0I8%E+(Q  )4C./7FM.P\/V>G:O<Z
MC;M*'GM8+4QLV55(MVW'?/SG.2>@H X73=6U7Q'XI\"ZL;F"V6ZTNZEFMUA+
M+N5H@^#N[Y&./EP>N>/4#TKEK3P-9V"^'_L>H7T+:(CQ1,"A,T;E2Z/E<8.T
M<C!KJ: /*K?QOXEM_ ^F^(-0N+!I-9EAM[6&*RD86Q;=ND8*Q:3Y5)V@#G S
MWI-1\1ZOJ?A?Q9IINFF2'2)+F+46TJ:U##:P>(H^/FQC# _Q=..>R'@G3AX1
ML?#HGNEAL"C6MRK@31.ARK@XQD?3'M34\')+9ZM%J.KZCJ$^IVILY9YF13'$
M0PPBJH1?O$YP<GK0!QEIXAN]$^P^&[2[MK!;;3HKJ:YM]%EG$CR9V((XR0N%
M7EB<L>F.:T8O%GB?6SX<L[%;;3+O48KPW,ES:2,$,#( Z(Q4X;.0#T##TYZ.
M[\'QO=V][IVJWVF7L5JMF\UOY;>=$OW0ZNK*2"3@@ C)J:Q\(V.GW6DW$4]V
M\FF0SQ1M-+O,OFE2[.2,DY7/&!R>.F #F'\6>(+2#Q/K5U-9-IFA3S6XM4MR
M)+EEC4J=^[Y!N9>QXS[5%IWCK4[:_M_MTK:E;302R7/DZ/<6HM&2,N,/(,,I
MVE><'.#[5V$7A;3EL=:LIA)<6VL3R3W,<A&,NBJ0N ,#"CW]ZJ6'@X6UW;S7
MVM:GJD=K$T5O!=LFQ%8;3NV*ID.WC+9_/F@#DKR;Q'J,7@G5M3NK%[6^U2WN
M/LL,!1K?=&Y0!RQW\'!R!STXKU.N/MOA];P3:8K:UJLUEI4ZS6-G(\?EPX!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>7=Z5>-?0V4OF(Z",>5(P!/S;S@-U.3UI;36[&[L_AA;6^H137&8VDCCD#,
MMG(&W <_>XY[_2@#U2BO%_#!M-*US0;D&PU3[;=O#%JEE<O'>2E@^?M,+C+
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M.,:V6O/^0)C[< C'R\C( X^;/3COQ5;4/'FB:;-<I-]M>.S(6[N(;.22*V)
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M>"1S6GH5WK?AW2;RXU*'4KBSDOX8;"&_GB>[2-RJ$NRD@_,20,EL5W9(49)
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M%/;M4%]#XB\4:%)H+:#_ &4CZ=-;W%S=.C 2&/:HAV,25SR20/E&,9/'?T4
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MFDCD9V8(B1J^1\JY+%CUX%;J^!H&M7%UJ%Q<WLVH0:A<7;JH:1X64HH4#"H
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M#ZE,^H7%]<:A<"XFEG"@[MBKP%  'R\#MTH CM==N9_$OB'36CA$.FP6\D+
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M#C(XZ<<4 <[;ZYJWB#Q9X+U&!X[.VN]/NI9K26)V(96C$@SN )YPI(XY.#G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M12Q)Z$C)P:Z+6-.75]"O]+:0Q+>6TEN9 ,E0ZE<X[XS0!YGX8TGP[+;:,S>
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M9P3M^[GH2:WW\%W5K?VMYH^O7%G-'8)I\SSQ"Y::-"65LL1A\LW/(YZ5'9>
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MTR=X&LIIV6ZNC&<.8^R\@A00<X[9JSJOQ."ZM?6VGWFBVT=E'&V-3F9'NF9
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M0!CM(SP,8Z'C/04 =S17B,%[XBO-#G\29,&H+?NOVR?6FCBA*S;! UOC;MP
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M4T@R,G<HR<>F:R_'5ZMIH,,1EODDO+N&VB2QD$<LS,W^K#DC8" 06R"!G'-
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M$A2&"\K@?-CTK3^&.GM'X-TW5;B^O[R]U"SADGDNKEY!G'&%)PO!QD=<<Y-
M':4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-[.(S'%'&\A99"0C94$;21UZ#C/456M_'_A>ZM[FXAU56@ME5I9?*D"#)V@
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M#2DN$L-'L[=;E/+F\N(#>G]T_P"S[=*NKIEBKV;K:0AK)2EL0@_<J1M(7T&
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M&3CZUG6_A3P_::J=4M]&LHKXL6\](0&#'J1Z$]R.33O#&MIXB\-:?JRH4-S
MDCH49=K%06 W $@'.#T/6F:OXIT?0[E+:_NF6X=#*(H8))G" X+E44E5]S@4
M *GA3P^FKG5ET>R%^7,GGB$;MYZM_O>_6B;PIX?N=6&JS:-927X8/Y[0@L6'
M1CZD=CU%21^(]'FN;6"._A9[NW-U;D$[98AC+*WW3C()&<XYJC)XZ\.1PV<I
MOV<7T;26JQV\KO.JD E%"DMUSP.1STYH V1IUF)+N06L0>\ %PVT9EPNT;O7
MCCZ54?PYHLDME*^E6C26,1AMF,0S%&5V[5]%QQCI52?QKX=MM'MM5EU.,65S
M(8H9 C$M( Q*;0,AOE8;2,Y&.O%1W/COPY:+"9;Y_P![ MQA;:5C'$W1Y %)
MC!]6Q0!8LO!_AS3I8Y;/1+&"2-Q)&Z0@,C $#![<$\#U-3P^&]$M[B2XATJT
MCEDN!=LZQ $S $>9_O?,W/N:K:EXQT'27B2YOBQDA%P/L\,D^(CTD;RU.U3@
M_,<#@T7_ (QT'31;F>^+_:(!<Q_9X9)R8CTD/EJ<)_M' H F/A70#K']K'1[
M(ZAO\S[1Y(W;_P"]_O>_6KG]F6.V]'V2'%[_ ,?0V#]]\H7YO7Y0!]!7/7'C
M6UM=>"R7%O\ V'_8_P#:1NU5F./,"@Y&?EP<]*Z&74[.'4+6Q><"YND=X8P"
M=ZIC<>. !N'7U% %>'0[.WUI-3B18Y([,64:(H 6,-NQZ^F!VY]:L:CIECJ]
MD]GJ-I#=6SD%HI4##(Y!^H]:-3U.RT>PDOM0G6"W0@%R">2<  #DDD@ #DYJ
MC9^+-$OK*]O([X1PV(S=?:(W@: 8R"ZN P!'3(YH =;>%= M(I8K?1K&-)HC
M#*H@7]XA.2K<?,,^M+I_A?0M*M[B"QTFS@BN5V3JL0_>+C&UO48)X/'-9Y\=
MZ)+INH75K/)+)9VQN6@DMY8I'3LP5E#%2>-P!'-:/AK6D\0^&]/U5$*&Y@21
MT*,NUB!N W $@'.#WZT )IGA?0M&$PT[2;.V\]=DOEQ#YU_NG_9]NE1Z?X1\
M.Z5*);#1;&VD&</'" 1D8(SZ8)&/>EU?Q7HVA7*6U_=LMPT9E\J&"29U3.-[
M!%)5?<X%68M=TN>73XX;V.5M0B:6T*982HH!8@CC@,/SH ;<^']'N](BTJXT
MVVDL(0HBMVC&R/;]W:.V.V*BA\*Z!;VTUO#H]E'#/&(YD6%0)%!+ -Z\DGGU
M-9/B#Q[IVC?91$6N"^IC3Y]D4C>20 S_ '5.2 5P.^>,X-=:#D9H @>RM9+V
M.\>WC:YB1HTE*_,JM@L ?0[1^0JAIOAC0M'O)+O3=)L[6XD!#20Q!3@G) QT
M&><"LRV\:Z7;:+IUSJNIVS37PD,)M()2)MC8(1,%B1D<=3SCBMK2-:T_7K'[
M;IMP)X-[1D[2K*RG!5E8 J1Z$4 5K/PIX?T_4VU*ST:R@O"6/G1P@,"WWB/3
M/?'6M=E5U*L RD8((R"*YW6/%D&D^+=%T)XG9M1$A,@C=MF,!1PI')/)S\H&
M3US67H/Q&TR\C,&J74<%Z;^:S CAD\I2LS)&K/@JK, IP2,YZ<B@#H--\+:#
MH\\L^FZ196LLJE&>*$*=IYV^P]AQ6C:6EO86D5I:0I!;PJ$CBC7"HHZ #L*P
M_P#A*K*R74I=2O[<QV]_]CB6WAD:3<45A&5P2[\D_*,8QZ&M/2-:T_7;1[G3
MKCS8TD,4@9&1HW'565@&4\C@CO0!?HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/%VDR:WX3U&Q@XN6
MBWVY])D(>,_]]*M;=% 'CA\*:_>RV%W+ISQ/XCDD77$)_P"/>+SUE0'U_=*T
M?_ JO>)+/Q!>S^)[(VNLJ;@.EA!IL44=M<(8@ \LI&XMG((+#@  &O5:* .'
M\':3>VGB&2[NK.2%&T/3[=7=<?.@DWI]1E<_A69;:=KNE?"?1[.UL)4O(;E6
MN42!))X8_.9F>-'RID&01P>N>M>ET4 >,:IH.M:@OBF2&RUNY2\T-;>VEU+;
MYLTBRL2 JXV#YN%('0GO7=:[I-W<^,M&GMK8FWBTV^@>0#"HS^5L4_7:?RKK
M:* /)[G^T-'^&/AO6DTZXM]7\-B*!K:X4*TH*B&1%YY#%@1ZE17H/A;1SH/A
MJQTYWWSQQ[IY/[\K'=(WXL6/XU-J&A:;JMY97=];">6Q<R6^YVVHW'.T'!((
M!&0<'IBM&@#DG4VWQ9CEEXCO=%,4+'H7BF+,OUQ(#^!]*XR[\(:VMYK'E6+M
M#H3FZT+!_P!:\DZW+*OTV>7_ ,"KU>ZL+6]EMI;B(/):R^="V2"CX*Y!'L2"
M.A!JS0!YWI/AW4+:]\%7-S:,9TDO;S47QGRIIT+$$_[S%?PK.UOPQK%Q/JMY
M#;7H2'Q)%J"I:LJRRPBV2,M%NX+!B2 >NT]\5ZK10!Y3-X>OM4T;Q=/;66MO
M/=Z5]CMY-5E02W# .VT1A1M +8!8\[CQCFNC\/075SXTNM8ETZZM8)M'M84^
MTQ[6#K)+N4C)P>5/XBNSHH \:T_PSK&EP^'=0N8-:ABATZ:SF32]OGP.9RZD
MJ0<JP].1@5KZ/X<O8KWP[='3;^.,ZU=7T_VV99955H'59'V@!"QVG:,X)ZYK
MTZB@ KS/4?#VHS>"_&UHFGR-<7^KO-!'MYF0F+##U'RG\J],HH X/Q3IVM-X
MCU.^TG3TN7/AY[> 3(&C>7S<["#P3CG!XK"CT?5]5\2Z/,!XAD@6UNX)KO5(
MXXA"\D.%VQH!@9'7&.@!->LT4 >701:K/IG@S0V\-7T,^CWEM]KG9%\F,1H4
M+(P/S!LYXZ#K@UDCPMJ<.D7?ARZM/$EU-+>286">..RFC>8N)#(5)3 .2#EM
MPX%>ST4  & !7FFFZ!J<>K:+)-82B.'Q'J5U(67A8W6;RW/L2RX^HKTNB@#S
M35= U*X\0:I*EA(\$OB+3+E6V\-%&D8=_H"#GZ5)XP\-:KJ^L^(&LK0R+-IE
MCY6XA4G>*X>1HLGN5P.>/F%>CT4 ><:U9:EXYU*%K32[[2XK;3;V!Y[Z,1%I
M)XPBHH!)(!^8GIP,$U- VIZQHECH">&Y[&>*QDMY[N\C54M&\DQCR6!.\EB.
M5_ASGTKT&B@#R70M"OW;PUI]U8^)3-ILT3SK=3QI:6YB4C<C!3Y@/0*.H;DB
MK\>@:DOPLM-.^P2"]75UG:';\P7[?YF[_OCGZ5Z710!Y?XDTK59[WQE:0Z5=
MR_VC)87-M,B QN(S"KKG/##:QQZ FI=;TBYD^)$>BPJ#I6LO#JEZH/W3;<,"
M/1V^SC_@+5Z76=9Z%IMAJ=YJ5M;!;V\QY\Q=F+ = ,D[1SG P* -&O)WTS6!
M\/[CP(-#O&OWF>);W:OV8HTQ?SS)GJ <XQNW#IWKUBB@#F?#FG7%IXG\674]
MNT<=W>PO#(P_UB+;QKD>P8,/SI?B#87.J> M8L;.!I[B:':D2#)8[AQ72T4
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M)S)+MW2#Z+N0?7/I5'4]<U>7Q*^A:#;V33V]JMU<SWKL$4.S*B +R2=C'/0
M=ZL^#=%FT'PK96=VYDOF4S7DA.2\[DO(2>_S$CZ 5%JOAR]EUTZUHVJII][)
M;BUN!+;>?'*BL64[=RD,I9L'/?D4 <\NKZK'XPN+Z?2S'?IX;65M/:Z0*)!.
M_'F$[0./O>G;/%2:3XZFOO$#:+<W&B7XELIK@2Z5<M((F3;E'SZAN"".G2IK
MWX;1WUG<03:S=RM-IBV+33 .[,LQF\QB3R"QQLZ8XZ5;MO!U^=;L]5U#6897
MMK6:U2WMK(0PA9 O(&]B&RHSR0>, 4 8^A^)M7NK7P_I&@:980_:-#COPUU-
M(R0C(79W9NHZGU)/8S:5XYUR\M= U2ZTNQATS5;L61C2=FF20[AOZ!=NY#QU
MP0<]AL^'_!R:#=Z;.MZTWV'2$TL Q[=X5@V_J<=.GZTRV\$I;:!H>E_;V8:5
M?K>B3RL>80SMMQGC[_7GI0 SXGSWUO\ #G6I;"18Y!;L'<L00AX.TCO5#2[K
M6+.67PUX<TS2(/[)A1[II9)!$9)=SA(P!NZ<EC_>Z&NH\2Z*/$?AN_T=IS +
MN(Q&4+NVY[XR,UG7WAG4%URYU;0]973IKV)(KM);43HY3(5U&Y=K $CN#QD<
M4 8L/CK6=;GT>VT+3+-;B_LY[B47TS!;=H91&ZY4'=\Q('X'VK>\=W4=CX$U
MJZGMEN8XK5V:$NR!QZ;E((_ U#HO@JVT+4-,N+:ZE=+&QFM-LBY:5I9%D:0M
MZEE/&/XJT_$NBCQ%X:U#1VG, O(6B,H7=LSWQD9H Y^]\2^(I=;UO3M&L-.,
M>E0Q3-+=RN/,WH6V *.O!Y/3C@]H;?QEK6N7^FVFAV%BGVW1XM4,E[(V(M[$
M;,*,L>GIW/M706_AU;?5=;OOM)8ZI'%&4V?ZO8A3.<\YSGM5/P_X/30;RPN%
MO6F^R:1%I84Q[=P1L[^IQGT_6@#+L?'&IZU:Z-:Z9I]JFK7Z7$DXN)&,-NL$
MGEN>!ELO@ <=>3Q1_P )SJ6[^QO[.MO^$C_M'^S_ "_-;[/_ *KSO.W8W;?+
MYV]<\>]3P> YM.M].DTO5_L^I6#W.RXDMMZ21SRF1HW3<"0#MP0P/R^^*7_A
M F\G[7_:\G]O_;_[0_M$P#;YFSR]OEY_U?E_+MSGOG- #-7\8:KX9T26;7;&
MQBNFO([2TG%SLM9MXSO8GYD"@-N!'\/!.:R3\46@T_6QNTG4KO3[1+N.33;@
MO#*C.$*GNK D=SD$&MVX\%W6H6,QU'79Y=4:[BO(+F.+;%;21C"!(B2-N"=P
M));<<GIAMYX-U+5]*U2UU?Q 9I;Z%(5$%MY4,"JV[(CWG+$]26].E %6]\1>
M);6YO-*OK73H;J?2Y[VTEMI781F,J&1\@9(W@AACITK:\"S7UQX%T.?49$DN
M)+*%RZLS%@4!!8GDL1U]ZFU+PY'J6NP:E)<,@CL;BR,07[PE*$MG/&-GIWJ7
MPSI%SH/AZSTJYOEO3:1K#',(?*_=J %!&3R .O>@#FKCQEKC:=JNOV&FV4FA
MZ;-,CI)*PN)TA)$KI@;1@JV >NWMFKEKXEUC5O%]SINF6EB=,M$MII[F>1P[
M)*I8!% QNX/7 Z>O$-UX$O)+?4M+M==:VT+4II);BT%L&E42',B1R;OE5B6Z
MJ2,G!K=TOP_%I>N:GJ,4N4O8[>,0[<"(1*5&#GG.?TH K^+==O="M=.:PM(K
MJXO;^.S5)9"B@N&Y) . "!V/&:P+SQ_?:!;:]'KMI9&]TW[,8FMYBD,WV@E4
MW%QE,%3N// S74ZYH@UHZ83.8?L-]'>#"[MY0'Y>O&=W6LO5O!$&KWNLW,M[
M+&^H1VHC,:#=;R6[.Z.">OS,.,=O>@#&TWXF0"[OK?4+O2+T6^GRZ@)](N#*
MNV/&]&!Y#<@@]#STQ5N'Q/XF@OO#PU/3-.2TUJ?RQY$SE[;,3R!6R,,<+U&!
MP>.AJ[_PCFI/!J,FMZF=626QDM5L;: 6T3JPY)!9LN>F20!D\5R&D6^J:KX@
M\*PK=ZQ<VVE2M+*E[I;6HMU$+(!(Y $LF6"@IQC<?>@!WA[7;?2= \)75] 9
M@EIJ=PTYD;=&L9+-@9PV1QSTQQ6]#XI\30S^'I=1TS3DL]:N%C7R9G,EL&C:
M0*V1ACA>HP!@\'@U)'X!@M=+TNWDG>]CTRUO(3!Y80W(G'*YS\OI^/:N9TJV
MU35-9\*6J7>L3VVE3^=+%?:6UL+9%B=0))" )9,E5!3C&XGUH LQ_%V&14U+
M[1HG]G/<B$60O/\ 3A&7V"3;TS_%LZ[>^:TK_P :>(8K;Q'J-IIFG-IV@W,D
M4PEF<2SJBJ[;<#"D*W4YR>PJ]9^"=0T^*+3;/Q#)!H<5QYR6\=L!.J[]_E";
M=]S/'W<XXS5R7P<DNA>)M,^VL!KLTTID\O\ U/F1JF,9^;&W/;K0!1T:_P!6
MNOB=K43S1-IBV%I)'$6;*!C+@@= 20=WL%K1\2Z[J>FZMHNF:5:6T]QJ;S(&
MN'94BV)OW' )/&>._'3K4EIX;FLO%3:Q!J $,UG%:W%LT&=YCW;&#Y^7[YR,
M'-6M0T07^O:/JAG*'36F81[<^9YB;.N>,=>] '''QSXEATN_U*XTO3!;:1?_
M &*^"3N6F(=5+1#'R@!U.&SGD<8YFU3Q4=!O_%-Q;:?'YD%[9PRW$DDAC4/$
MG[V0#.U5!Q\H&>,^M:USX)2XT'7-+^WLHU6^:\,GE?ZHED;;C//W.O'6I+KP
MG<M?:O?6.LS65U?W,%RC)'E4,4838PS\ZL!R..OM0!C/XZU1/#PO8(-(U*:3
M4(+*VELKO=!/YI R>K(03@@Y]:;JOCN_TC4K?1+VZ\/6.IK:_:;J>[N62WP7
M942,'#,2%R<]/?-6H/AX?/FO+K48C>SW]I>RM;68AB/V=LJH3<<$Y.6))Z>E
M:FK>&KR?7AK>CZG'87KVXMIQ-;>?%*@8LI*[E(8%FP<]^10!A6?C_4==708M
M%L;)I]2%VLSRS%HH&@95+*5'SJ=W&,9RO3FEN/'.L16\5E'IEFVMC6!I,T;3
M,(06A,JR@XSM(VDC&>HIFH^'-;@\1^%(['5;J2XMH+YI]1N+?SD+/Y9VNH(
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M.<]N-^<#/]WWI^@^)=3U#3]%TKP[I]C"ZZ-;WL[7<LC1PJXPD:XRS'Y6Y)X
M[DUJ6_@J>TN]+G@U8 6NDC2KA&M@?/0#AA\WR'//?TJ*U\#WFD)ILNBZTMM>
M6NG1:;-)-:>;'<1Q_=8IN4JP);!W=\'- %1/'6K7\FD6-AI=JFI7D]Y:W*7$
MS>7;RVY 8@J,LIY(X&<CIS6_X5UN\UFWU&+4;>&&]TZ]>SF\ABT;D*K!ESR
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M@4 =!17C]TMZOA+7O$O]LZK_ &A8:S.MK_ID@BCC6ZV^68\[64@D?,#Q@#
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MPN/6NA\'W5Q=?#71KNXGDEN)-,CD>5W+.S&,$DD\DY[T ;UC>0ZC807MOO\
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M_P!IA<27#NN#!$V=K$C.2>>N,#H *K&V_P"$C\0^*O[3UC4+(:5(D5JEM>/
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MG*AE( SU"@G.!Q4GASP=H_AZ&VDM].M$OTMUADN(X\%C@;B/0$C)QU[UT%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6.)R0BY"L2YPW&,#')H^'U]?WOP_BNY%>6^::\*QW4QSN%Q*%1GPV ,!<@'
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M #8BDKK@H^S.3]T@@$9)SQ@Z\OBM='OO$4UU8SM>6PL8S;QW9D26:9<*D88
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M_+?&ZDFTBS0Z;<V"VNGV9CC3S0OSYSDG*],#C'U(!)X.O;JX\3)'-<S21_\
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M#JUI,UV'L1<1RLFPR_)D$KV)]*X>QFN8_!?@+2[:^FM(]:*M>7D+8D):%YV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+=B5=I ).]LJ<#/>H=,\$ZCI"^%3;7UJ[:1:2V5R)8VQ+'(4)9,'AAL[\<T
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M17DWVP(Y= #((DVG?MSCDKD@@4RZ\>7DUY>1:'HBZC%:V$.H-/)=B%6BD5F
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M*H".. ...E.TOP7H>CWD-U:6\_F6ZE+99KN65+=2,$1J[$)D<?*!QQTK?HH
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MJ,]43S&.Q>!P,5O44 <[8>!_#^FWT%W;6DH:W9GMHGN97AMV.<F.-F*(>3T
M]JN+X9TA-.M[!;3%K;W8O(D\QOEF\PR[LYR?G)..G;&*UJ* ,RX\/:3=2:B]
MQ9)*=2B2&[#DL)43(4$$X&-QZ8JC:>"-!M%N@+:>=KFV:TD>ZNY9G$)ZQJSL
M2J^RD?I70T4 9YT33S+IDAM_GTS(M#O;]WE"A[\_*2.<U3LO"&BZ?'%':VTL
M<<5V;R./[3(524@@D M@+R?E^[SG%;E% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M()9%VL;2(>7!D>ZC?_P.MGQ=HNI:O'I,FE3VT5SI^H)>?Z2&*.%CD4KQSSO
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M73M5NI;M;B8R><A=@S1[0,8R,;L]#TH T]7\>S:=>Z[#;Z!<W<&AA'O9UG1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?3</SKS"Y\2^)/#]GK;"/5#;1V"S6\NM>0989C(L>?W1^9,/NY'!0C/-:O\
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M#_._!*[ER2W/ KL?!W_(<\9?]AC_ -MX: .MHHKSGQ3JM]+K6K6]AJ>N.UC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 56U#3[35=/GL+Z!)[6="DD3CAA5FD9E1"
M[L%51DDG  H YR#P+H<*709+R=[FW-J\MQ?322+">L:NS$JOT(S5X^&='^U6
MUP+&-7M[1K)%4D*8#C]VRCAEXX!!QVJS9:QI>I12RV&I6=U'$<2/!.KA/J0>
M*;::WI-_!//9ZI97,,&3-)#<(ZQXY.X@\=#UH S=+\%:)I%]!=VT-R\ELK):
MK/=RS);*1@B-78A....W'2B#P1H5OJ27L=M,/+G-S';FYD-O'*<DNL1;8&R2
M<@<$Y'-:EKK.EWMW):6FI6<]S&,O#%.K.@]2H.138M<TF>]ELX=4LI+J$$RP
M)<(70#KN4'(Q[T 8W_"OO#GVGSC:SE5N1=QP&[E\F*8/OWI'NVJ2P[#N1T)J
MU/X,T*YDU-IK1W74RK749G?8SC&'"YPK_*OS+@\#FJVF>-;+6K2UN].^SR0R
MWLMK+YEVB-$$\SYP.=V=F0HYVMGM5K0/%ND^(K/[1:74(S<RVRQM*A9F1F'
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M/'!?ZI8VDTGW(Y[A(V;Z G)H OUS^I^"]%U:^GN[F.Y22Z4)=+;W<L*7*@8
MD5& ;CCGMQTK3O=8TO3 3?ZE9VH #'SYUCX)P#R>Y!_*B/6=+FOEL8M2LWNV
M02+ LZF0J1D,%SG&.<T -M-&L+&_N+VVMQ%/<110R%2<%(]VP!>@QN;I63_P
M@6@(EDMO#=6OV.W^R1-:WLL3&'.?+9E8%AGGDUL'6-+74AIIU*S%^1D6IG7S
M3W^YG/Z5;DD2*-I)'5$4%F9C@ #N30!BV'A#0],6R6SLO*6QN);BV42-B-Y
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M%/\ =!QSTKIJ* .2U;PA!#X7?3-'TVUN0]RMQ/%>SR;K@Y!9O.R767@$/SC
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MF,^Y9DE+J",8;?D +QVKU+X@S^1X+O6.GI?(6B5XI%=D53(N7<)\S*OWB!U
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MH"<]J;>6":CH7B:>"Z?4K6\N]-21X=.^SV\S"=-Q0;B6.T@,< <#DXX]KHH
M\V\2:/&GB;6X;'3U5)_"DR;(8<*[ASL& ,%AGCO71>$=:TN30-!L[9R))[+*
M(L#J,Q@"3)Q@$,>^,]LUT]% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYP!T&,<YYYO%VKI<:;J-MK&H7T-SJD5M+MTY8]/,4DNS$<C*'8@'A@S9(]*
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M) (QG&0,@CV/2LVXUS6+*UU+3KF_%[+I_B"PM4NIK>/>\4K0L0P"[=P#D;@
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M8]6^V7,$5C=6=[/!'O19KD0LD@4!6Z'! !P?4 T >F2RQP0O-,ZQQ1J6=V.
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MJ-Q_;=AJ5X;V73-1:UCN6C5&D3RT<;@H R-Y&0!G% '3T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1E2,D9'44M% '(:;\
M.=*TD1K8ZEKL,4<GF"%=3E"%B=QRN<')Z^N:Z&#2+2WUF[U9%;[7=Q1Q2,6R
M-L>[: .WWS5ZB@"K#81PZC<WRRSM)<*BLC2DHNW.-J]%)SSCKQZ5';:1:6FI
MZAJ$2-]HO_+\\EL@[%VK@=N*O44 <WIO@?1]+O[>Y@-VZ6A8V=M+<,\-J6!!
M,:'@<$@=< D#%=)139)$B0O(ZHHZLQP* *6F:1::0;TVBLOVRZ>[FW-G,C
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M7\/Q_9;WPI)#,UW:G4=3EMA%:FW3RS QVQ(68[-V[;ST->OD!A@@$>AI: /
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MN3N!X) ZUG6LOAJ[\2>%!X,CM1-;^9]L^R(%,5KY+ I/CH=^S ;G(SZUZB
M  , =A0 !G  SUH \5T?PYI#>#OAO(VF6YEN+Y!<.8QNE!AE8JYZLI*KP>,
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MJ*_MH+KP[XLDM-1LKRRG:PCE_LJR-O:&3SURR-YC!GVD!MOHN>:]RI  !@
M>@H K6.F6&F68L["RM[6V&?W,$01.>O &*\<L;'1KO3]&TAK6U9XO&$ZWML(
MP"!_I1C#C'(V@8!XQQTKVVB@#R36ELM%D\>01Z7$^GLVGEK92T4"EQAI'V<A
M!@%L=0,'J:R&F@?6?$1M;K1[B*7PG> OH]H8;<LI7"[MS"1@&ZCH#C%>Y4@
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MABP,:X 8$ JJUWVE:)I>K?$+Q==WFGVUY(HM%A>>)9-H, SMR.,\9QUP*[[
MSG SZTM 'B7AEDETCP3%HOE+?PZ=J,,@C 4I="&/A_\ :SMSGVJ'PQ#;R/X3
MMX-4TI-4M[F-IK:STIUOT(!\Y;AS+D _,&9EP200.E>YTF "3@9/4T >*Z5+
M8:?XATV&S;3=4<ZNW^B36Y@U6T=W;>[LI.]5#$DL "N.>E=U\4H(9OA]J#30
MI(L+P2G<F[8!*FYOP7=GVS788&<X&?6EH \G6Z\'1ZWXBE\2"P>VNXH#I;31
M@I+9>2H5;?CGY]_"<Y(]J[;P3;WH\ Z/;ZPCM=?8T69)QEL8X#Y[XP#FNA(!
MQD#CI2T >)>'K'1]0M?!6F/:VLI@U>^6]MO+'$BI,RB1<=<!.O;%7]2M8;%_
M$UE:0)!:Q^)=*=(8UVHI8VY8@#@9/)KUZB@#Q2:6PT[Q%)]F;3=3G;7/-.F7
M=N8=3BE:;EXY%.709W L,;!C.*])\<:M/I/A2Z:RYU"Z*V=D!U,TIV*?PSN_
MX#70X&<X&>F:6@#RA]*UKP->>&=6NY-,.F:>JZ3<&SBD1O(E(4.Y9B#MD"M_
MP(U@:NV@P> [ZRU2VC_X2Y=2,DY:$^>7-SQ)NQGRS&1@YVX('M7NU<I-X(6Y
ME,-SKFISZ4;D77]G2,C(6#[PI?;O*!L';N[8Z<4 <];Z,MSJ'Q#U&RLXGUV.
M=X[&X* R1O\ 8TV[&/W22QZ=:Y[PQ%;37_A6+3M5T@7]NV7M]/TITND7RR)%
MN6,IV@GJ6&2V"*]MI  "2 ,GJ: /!-%@WZ=I%G<:KI</B%-11Y8(M+=M36<2
MY<N_FC*D9W.1MV'Z5JZWHUA/X3^(FHR6<3WR:NXBN"@\R,*(2NUNJX))X]:]
MFP,YP,],TM 'D_BS1WTW6M9M/"]DMI/+X7DVQV<80N5F & .K;2P!Z\U3T)+
M"?7])?2=6T>4V]E.)(='TIH2(C&1LN&,K;?FVD!AG</K7LE( !G  SUH \AT
MC1]/T_PC\-+^TLH8;V2\MO,N$C D8/!)O#-U(/H?0>E=+\.UTZVO/%-C;QV\
M-Y%K$[2Q(@5UB9LQY']W&<=NM=U10!Y+XLN[&?Q=KUK/%HEI.MK%$'U.W>ZG
MO%*$@6\6Y1@$E?ESENHJ/P7IUEK.K^&#J5K%>K%X3B*K<()%#^8%)P>,@9'X
MFO7< D' R.AI: /%]%&GV2>&I->6%?#UM-JD$9N0#!#.+DB+?G@?('"D].U=
M=\+_ .S_ +%XC.DQB/3VUN9H J[5VF.+E1_=].V,5W) (P1D4M !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 53U748](TR>_FBGF2%<^7;QEY'.< *HZDDBKE8?B_3M3U;PS=6>D7/D
M7DA0JWFM'N4."R;UY7<H*Y'3- &>/'"V\M_!JFBZAIUQ::?)J(BE:)_-A3[V
MTHY&X$@8)'44EEXZ2[N[.%]#U.V34('FT^281XN=B;RH <E25Y 8#/M7-)X!
MU)M0U&[M]*TW3(KO0[K3A$ET\TAEDVE7D<KR.".^/?.!U,GA^\^W>$+@M"(]
M'607.6/>W,?R\<\GVXH L6_C#3[NQT&ZMXYY/[;<+;Q@#<GR%W+C/ 4*0<9Y
MXI?&6MW.A>'S-8I&]_<SQ6=H)/N>;*X12WL,Y_"N7\#Z9%/XSUN_M;J*ZT73
MYI(M,:([D5Y]LLX4C@X; &/4BNO\4Z"/$>A26"W!MKA72>VN N[RI48,C8[\
M@9'IF@#F]0L=3T$0W"^/&DU0,KO;:K+!';W"9^8!0@9!C."I.,=ZU[CQG!%X
MDN-&BTR^G-HL<EW=($$-O&ZDAV)8''!X )X-<[X@\/\ BGQ=ITFE:GH?AV"6
M2/R9-6\YIF1.YBC,88'K@%L"M^'PO*VK^)WN746>K6L%LA0_. L;HQ([?>XH
M CLO'D%U+I\DVD:C::=J4@BL;^=4\N9F&4RH8NF[^'<!GCIFK1\9V \,2:]]
MGN?LR79M"F%W[A/Y&>N,;N>O3\JPX/#WB6]LM!T34X=/AL=(N()I+R&=F:Y$
M&#&%C*C820I;+''.,U2N/"GBDZ#=>&H(-.^PG4S>)>M<MO:,W/G[/+V<-GC.
M<<>] '07OCI+;4M6M+?0]4O1I!7[;- L>U%,:OE=S@N<-T SP?49Z2VO;>\T
M^&_MY1);31+-'(.C(1D'\J\]MV\12>*/'-IH]I8317%U%'YMQ<-&8'-K$"Q4
M*=ZXQP"#D>_'=:)I4>B^']/TE',D=G;1VX=A]X*H7)^N* ./T*VUWQGH4?B)
M_$E_IC7FZ6RM;1(O*@CR0F\,I,A( )R0.<#%;,OB*^T>RTFQU*R.H>(;R-LV
MNG$;6* ;WW2%0J\CKW; S67IFF^+_"NG-H6D66EW]C$S"PNKB[>)H$))"R($
M.[;G&5(R .E2MX;U[2Y]"U6UNH]7U*PM9;6\%W*8C<K(58LK8.TAE& 1TXS0
M!/+\0K"&QBE;3=1^V/J TU[ (AFCN"A<*?FVX( PP./F!SC.*TOQ(6"#47E\
M-ZPKZ4?^)FG[D_94VA@V=^'RISA<G .<<9@B\'ZQ/J5OK%X;1+V;7(]1N88I
M"R11);M"J*Q W-C:2< <GTYMW_A74+FU\=QQM!NUV/;:9<\'[,L7S\<?,#TS
MQ0!=O/&:Q:U-I.GZ-J&IW,5M'=L;?RU3RWW8.YV7GY>G4YXZ'!_PF<5W::?-
MHVE:AJC7T+3HD*I&(U4@'>TC*JL"<;<DY!^M<];OKVG_ !!U6'2K*SO&72+&
M.9)[@P[6!F"L"%;(^]D<'D8J'_A ]7LHM)MGB@UJQ@M9%GM'O9+6,74DID:7
M"@[U^8K@] .G- &]_P +"LGM--D@TO4IKK4)Y[6.S1$$B319WHV6VC&T\YQ@
M9S4MMX[LY8XOM.GWMI-_:2Z7<12A";>9EW*6*L05;*@$$\L*Q?#7@?5='GT(
MSBQ1-/U"^N)%MF(0),K! @(XP6QCL!3_ !!HT%AH/C6?6+ZVL[?4K@7-I,TF
M"CI#'L//\0>+( R3B@#L;+68+_6-2TV&.0MIYC6:4@;"[KNVCG.0NTGC^(5G
M:OXK&G:Q_9-II-[J=ZMM]KECMFC79$6*@_.Z[B2IX&>G;BF^!=/NK+PO#/J*
MXU/4':_O!C&)93NVX_V1M7_@-9OC'PU=ZSJD4QT/3-6ME@V1&6X:UN+:3)^9
M954DJ01P,$$=\T 17GBV_C\::;%9:?J-Y;WNC-<I8*B1.K^8GS/YA79A20<G
MJ<8K3A\;0WFDV-WI^D:E=W%Y++"MFB(KQ/&2)!(S,$7!4C[W/&,U5\/>&-7T
MS6M)O-1ODO&M=%:QGG+DN\IE5\\C)&%(R>36--X+UV."TC,<-]9)J%_<7&GB
M]>W6832EXF+*.=H)RIXY[XH T+WQA-?P:4UG'<Z?<)X@BTZ^MIPA9?E+,N5)
M!!!4Y!K7\&:C=ZEIVI27DS2O%JMY A( PB3,JKQZ  5S&D^ ]5L8PA@TZV0>
M(HM5$-M(VR.(1!2HRH)8$=<#/7C.*Z[PIH]SHMC?PW1C+3ZE=72;#D;))6=<
M\=<$9H Y^7Q=J.G^,_$MHNF:AJMM9Q6TJQVPC @0QDN<NRY)(X49)P:V)/%X
MGBL6T?1]0U4WEHMZGD!(U6)NFYI&4;C_ '1D\=J=;:%=P^(/$U\QB\K4XH$@
MPQR"D;*=W'')%<G'X(UR"#1K:[L[35[2TTF"S^R2W\D,4,Z?><J%(D!&!DC(
MV]* .KTSQII^JOHPB@NHUU9)S TJ@;9(CAXVYX;ANF0=IYJ&3QU9G]W9V%[>
M7,E[-96T$00&X:+_ %CJ68*$4Y!8D<CZ5BVO@G6;+X<6.E6TEE%KNEWCW=E(
MF1"&\YV Z9"E'92.V:-5^'A&E^&4MK6UU%]%CDCEM;J1HUN1(!O8. </O7=R
M,')H Z[0]>AUM+I/LT]I=V<ODW5I<!=\38##[I(((((()!!J'5O$$]AJ"V%E
MHE_J=R8?.<6_EHB)G R\C*"Q(/RC)^E5/!GA^71(;^6;3M/T][N8.MM9$OL0
M+@!W.-[=3G  SBLWQ+X;U34_$YNVLK;5M,:U6*&UN;Z2".WE#,6=D52'# K[
MC;B@"R/B%9SP:,UAI>HWL^KQ326UO&J*RF)E5U<LP"D$GG./E//3-BP\<V-Z
M^GQO9WEM)=WDU@ZS*O\ H]Q&I8QN0Q'(!P1D&L?PGX+U31)/#/VHVFW2X+^&
M;R6."9I5=-HQTP.1V]ZI^(],&@^#O$,U]=VT%Y)JTFJ:7\_S-*I5HT ZEB5V
MX&>&H [O3-9@U:ZU*&WCDVV%S]F>5@-KN%5F"\YXW 'IR#Z5FR^+5'BN3P_;
M:3?W4\/E-<3Q!!%"DF<,Q+ ]CP 3P>.*L^$M(DT3PS9VEP=UX5,UT_\ ?G<E
MY#_WTQJ/3='N;3QAKVJR&/[/?Q6J1 'Y@8PX;(QQ]X8H Q=(\:H^D:1#8VFJ
MZU?75LUSL(A258@Y7?(2RH,G@ 'G%4KOQ]+>7GAJ\TNSU%H+F^O+2:Q\M%EE
M:.-@ 03A<,,Y)& .:S-/LKOP->Z,GVS2#JG]DM;7%M>W36\;HLS.KQR[""07
M.5QG!!JQX(TC4=3@T'6W>W>.'5M3NY9$RHE64R*K1@CE23D9[4 :&M>/KP:(
MLVG:3>0W\&KV^GWEK+Y6^+<Z$C)?:=ZN K D?-DXZC5E\<!;Z[@@T+5+J*QE
M2&]FMQ&YA=E4XV!][X##)4$=<9Q69JWA'5Y_[>GM/LKS7.L6>I6L<DI4.L(A
MRK':=I)C;L>U4?$7@[6]9U"ZN4TK3(=0GV&VUBWO)()[3Y5R'"+F7:0<'.",
M @4 >DS2B""25@2J*6('7@9K"C\764ND>']2$%P(M;EBBMU(7<AD1G&_GT4Y
MQFMN2$RVC0.Y):,H7QR<C&:\\T[PSXI%EX5TF[M]-BL] NHG:XCN6=KE41D4
MA=@V\-D@D\T :B_$:V:/[7_8NJ#3$O38S7[+&(XI/-\H<;]Q7=CY@"!GUR!!
MXM\<2VNC>)%TC3M0F.G6\L4FHP+'Y=O/Y>1PS;FVDJ6(4@=^]#^#]2;X>W>A
M!K?[7+J+72G>=FPWGG=<==OMUJ'4_#GB6WL/$^CZ1!I\]GK;SS1W-Q<,C6[2
MIAU*!3NYR5((Z\]* -?_ (2UX?LMA::7?:OJ(LHKJY6V,:B)6'!9G91N8AL*
M.>#TJ&;XAV3?V8NF:9J.I3:E;R3PQ6Z(K*(V"NK[V 4@DCGN,=<5C:EX$N%U
MH:FNCZ=K(GL8+>6"YN6A,,D0(#*P4@J0<$8SP"*U/#_A"\T?5]$N76PCBL].
MN8)TM%*()994D^13_#\K<DY/7'- &YXKOUTSPCJE^\US;K!;/(9+8*94P.JA
MOES]>*S-&\0ZE?>/-;TB:RF%C:6]L\4I,>%+!R2<-N.[ QQQM.<9YT?&.DW.
MO>#M7TJT,8N+NU>*,R'"[B.,GTJII^DZG8>.=1U#RK>33M0M+=&D\TB2)X@X
MQMVX(._KD8QTH T-:UI]*:UA@TR\U"ZNF810VP48"C)+.Y"J/J><\ UCM\0;
M*+1VOI]-U".:/45TR6S"(TJ3G&%X;:P.Y<$'N*/&6AZGJ]_I<MO"E]IT'FBY
MT][Q[82LP&QRR@[MN&^4\?-6%I?@/5;*Q:W,.G6ZGQ'!JJQ6SMY:0J$W*,J"
M6&T]AGKQG% '10>.+1(=7.K6-WI4VDPK<7$-QL<F-L[64HS!LE2,9SGBLZ/Q
M3J=[XZT#3Y-,U#2H+BVNII(;H1D3 !-ARC-@C)RIP1D5+K_@RZUS4O$3^?'#
M#J.F6]M _)*2Q22/EA_=RR]_6GVVG^)]2\7:/JNK6>G6=OI\$\;I!<M*TCR!
M1N&4&%^7@=?6@#7\2:BNG#2=T]U%]HU*& "W"G>6W?*V[HIQSCFJ'@77]2\0
M:?J$VI64MNT-_<0QES'C:LC*%^1CRH !)ZGH2*N^)M'N=7_L;[,8Q]CU2&[E
MWG'R)NSCCKS4'A'2M2T8:M:7L4'D2:A/=6TT4I8R++(SX92HVD9 ZG- #=4\
M;Z=I%MKTUS!<YT9HEEC55+2^:%V%.><EMO..0:I^(?&=C'I5R();Z/&FQZC]
MIM%0M'&[A4QN.-S?-[8!]J->\(7.J>.-+U6*2$:< O\ :,39W2F$LT&!C!P[
MG.>P%8=G\.]6MO ^OZ3)<6\M]>&.WM'+G:MK#@1*QQD'&XGW:@"?5_$.K6^M
MZS!%>NL4&NZ5;1J /EBE$7F+T[[C^==OKFKP:!H5[JURDCP6<+3.L8!8@#)Q
MD@9KE-3\'ZE=ZOJEU&UOY=UK&G7L>YSGRX!'OSQU^0X'\JZ#QAI-QKO@[5]*
MM#&+B[M7BC,APNXC R?2@"E9^-H)=22TO]+OM+6:VDN[:>[";)HDP7/RL2I
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MIFGE=B068N0H5< #&"3U.,8K2\7:5JU_-H=WHZVKSZ=?_:GCN9"BNGE2(5!
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M (&?;/ H ]1HKS6/Q+XM.FZS#:6>HWLEN()+:\N-*:WE9&?$H$;!5=T4;AC
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M "BBB@ HHHH **** "N;\>Z1=:]X*U'3+.'SIYQ&%3>%R!(I/)(QP#WKI**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYY(YQSS0!T">.]+;19]0DM[Z*6"[%B]B\(^T?:#C$84$@DA@00<8.<U7\/\
MB:\UGQQJUA+;W=G;VMC;O]DNHE5TD9Y-QRI(8%0G1B/QS6=>>$M7-QJ=_;)
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M9&3=@X.US@XZ@5CZIIOBK78XM0EM+2UET^_@O+'3WF#%PBLL@DD4$ L'.,9
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M;7@N=0NL2/;_ #PJ(YV)4Y/S$J>?1B/>M.+Q3XDC\,V'C*XFL6TNZEA9]-6
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MMKAXQ!;F/[--%'YFW.X[T(!&3@Y ]: .XHKC(O%&H/H7@:\(A\W6Y;=+KY.
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MDJ']T <#IGOSTILJZSJ'Q.NCI&HV5H9-!M9))S";A3^]FVA!N4$')Y]!TYX
M/1:8\L:.B/(JLYP@)P6.,X'KQ7G0\;ZA>>']!NI=2T[2I;V*4SD6\ES*[HVS
M$4*\[2022<XX'?-5+#7[OQ#?>$+B^VFXM]=O+5G6%H?,"03 ,8VY0D8RIZ&@
M#U".6.:,212*Z'.&4Y![=:%EC=W19%9TP'4')7(R,^E<K\,_^1!L/^NMS_Z/
MDK%BA\0OXW\:S:-?65JL4ELVVXMS+YT@MD(4D,-JX[C)Y]N0#T>BO+F^)%UK
M$]A%93G2XY-,AOII1ILU\V^7.(P(^%4;3ECUXQWKMO"6LW6O>'+>^OK1K6Z)
M=)4,;Q@E6*[E5P&"L & /.#0!MT5Q=UJ_B+4]8UV/1KJQM;?1BL7EW%N9#=2
MF,2$$AAL7#* 0"<Y/M5+3/$VO>(UT&PLKBTLKJZT:/5+RZ>W,H&\A0B)N Y.
MXDDG  H ]!HK@=.\8ZM]NL8=22V\J/59M&OI8D(4S;0T,BY)VALA2#GEAS5"
M[^(&I&WL6B>.WBU>_N5L[E;.2X,5I#@;_+3EF=N1T ##/2@#TVBO,6\;^(#I
M,L5ND<EXNJVME;WMS82V\<\<QQN,;X8%3D'!QP,=:TS=^+I?%!\.1ZQIZ/#I
MD=W-?&P)+.TLB@"/S, 85<\GH?7@ [NBO+1\1=1O+/0;;S(["[O+::XN[F*P
MENPOER>5A(TR?F8$Y;@ 8Y)%6[+QEKNJQZ=I,*1VVI75]/;_ &Z>RDC1H8D#
M^:D+D-E@RC!. =W7% '>0VFG+J5Q=P6]J+Y@J3S(B^:1@8#,.>F, U8,L:RK
M&TBB1P2JD\L!UP/Q%<7X(COXO%/C%-3FAFNA=VX:6%"BN/LZ;3M).#C&1GKF
MF>+8=2G^(7A6/2[F"VG-M?;IIHO,")^YR0N1D]!R>^><8H [JBO/HO%^LV;J
MFH_99%T_65TS4IHHRJO'*BF*8 D[/FDC##GJ:Z3PYJ]UK<^KW+",:?%>M;6>
MU>7$8"NY/<&0.![+0!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6EXB\0KH$-F%LI[ZZO;@6UO;P,BL[[6;DN0  %)R33O$/B&/PYH#:K<VEQ,
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M_:5N4= ;.X)8LT9V]&W'(;<,<5M:OK=MHPL_.5Y#=7D5FHCP2K2' )R>E:=
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M"K5)[6XT>_O-&GM[1;(-9[&#P+]U6616!V\X/49/-;&CZ5!HNEP:?;R321Q
M_O)Y"\CDDDLS'J2235ZB@#S?Q3I6H'7-7>RTO75^WP(F_2[F$0WA";<3;\-$
M1TW*>5QSD8K7L/ [0:+H 34KG3]7TS3TLFN[/8=ZA5W(5=65EW#(R,BNQHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%8.N^*+?1=2TO3_(>XN;^X2+
M:AP(49MOF,?3)  [\^APLOB:)/%UMX?2SN&>6.1WN60K&I55;:"1\YPPSC@?
M7B@#=HKFXO$]R-;M;*]TEK2"]DFCMI&G!D/EAF+/'CY%(4D')ZC(&:C\*>*Y
M_$X$ZV-K#:/")59+]990&P5#QA05R#GDT =116%XD\31>'8[7=9W%S)<3QQ
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M&YV)P!STZ\GL,FJ&AZW+JEQJ%G=6B6UY82*DJQ3>=&=RAAA]JG.#R" 1^(-
M&S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<W!H$[>*O$EW<JOV+4[.VMT*M\QV"4/D=OOBNDHH \X
ML?#/B!M+\/>&[JQM(;+1KN"8ZC'.#YR0G*;8\95FXW9X'S<G->CT44 %%%%
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MN[?*=H"AFW*./[@)Y-=110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
.444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>guyaragreement018.jpg
<TEXT>
begin 644 guyaragreement018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@LBAAN!!P1GD'I0 ^BBB@ HJM8WT.H0O+")0J2O$?,C*'<K%3P>V1P>_6K-
M!159+Z*349K%5E\Z&-)6)C(3#$@8;H3\IR!TX]:LT %%4+O6+.QU&UL)W87-
MU%++$BH3N6/;OZ?[Z_6K%E=QW]C!=PB013QK(@D0HP!&1E3R#[&@">BJLFI6
MD6H+8-,/M;0-<"$ EC&I +?FP'XTZQO(M0L(+R$2"*>,2()$*, 1GE3R#[&@
M"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^0IE]H>E:G=P7=]I]O<7%N&6*62,%D### 'T(H \XT*P;0M/^'E]:W^H/-J
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M@/\ .Q()&?UQU-7]2?\ M749K2"+4KS^S].MS,%U0V%M:%D+!]R'<[$<Y((
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MGN%9'#1/&(B%4G&1^\/."#@8JCI&BWNAZ_H<7]EW8MCH!T_<L@G6WE#A]KN
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M_)&@7@X)('0&K3?$_P"SZ=K9D33+Z\TVWCNE.F7GG0S1L^S&[&58'J#Z@]Z
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M(XE/L"6;ZJM86F^++R.TTBQT;28GGU.\U&-1<WC[8C#*V6+$$D'DX'3@#CH
M>BT5PL7CK49(1I_]E6YU\ZH^F"$7!\@LL8E,N_;NV!"#C&<\>]1:YJ.MNFBQ
M:I9K93Q^(+6+S+:<M%<QD$Y7(#8[$$=1WH [^BN/E\:RQ^#=2UW[$A>SOY+0
M0^8<,%N/)W9QQQSBL[Q-XDUJ_P!)\5)HNG6[V.FPS6LT\ERR3/((MSF,!2/D
MW#J1D@@8ZT >@T5YDGBO^P;'4;Y;%[FYL]$TV9BUPW[[S&=<;3PI')SU.>>E
M;$GC/4=%O[R#Q)IUK D6F2ZG&]E<-+\D94-&VY5^;YEP1P: -C5/!V@ZS>O=
MWUB7FD0)*4FDC$RCH) K ./9@:VXXXX8DBB14C10JHHP% Z #L*XVW\4>(H=
M8T&TU;1;*&#67=4>"Z9VM\1-)M<% "WRCD''7VSI^*-?O=%FTBWT^QBN[G4K
MLVJ++,8U0^6[[B0#P-O/'3.* .AHKASXZOK&TU6WU'2X6UBRO(+**"UG)BN'
MG"F+#,H*CYN<CC!ZTM]XSU;05U*WUO3;,7D&ES:E:M:3LT4ZQ ;T.Y058$KV
M((/MB@#MZ*XZQ\6:K'K&F6^MZ=96EIJEO+/;R171=H=BARLN5 'RG.02 01[
MU:U;QI916ML-#FLM6O;N[2S@CANE**[!FR[+NVJ%1CT)XH Z>BN.N_%.N:5:
M^1J&B0'4Y[R*SL?)N3]GN6=2V[<5W*%"MNRIZ<9S574O'6I:!;:Q#J^EVQU&
MPLTO8A:SLT5Q$S[#@LH*L#P01W% '=T5PUWXF\1V]S=Z7?:=86UW/ID][920
M73.%,94,CDH/F&\'(!%9^C>*O$PTCPKID%A97NI:CI/VLSW%VX4*@C^9SL)+
M,'YP#\QZD<T >DT5Y[XE^(-_X<:]N+FVT>&VM)-HM9]1"W=RG&7C0 CG)(!.
M2!SBM2Z\2ZY=:GJMOX?TFUNX=)*I.;BY,;3RE YCC 4@$*R\L0,G'O0!UU%>
M9ZEXLUW1_$7BC4)+:)[&PT>WNDM)+A@R$^:>@! 8D$-ST5<$]NSO=<>U\3Z1
MI @#+?V]Q,9-W*>5Y> !WSYGZ4 ;-%>?+\0;V#6=,M;^WTB(7]VMK]BBU$27
MEN6)"LZ ;>H&0#QGJ:U_ $TLVA7K2R/(PU:^4%F)( N' 'T H ZJBO+?%?B?
M7-7\&:CJ.GV$$>C?:A;QSBY9;@A)PAE"A<;2RD8SG'/M6CJ/B]= N/$<\5D@
M>/5;>U>>XN7\E-\$9\U^#Y: $#"CDX]2: /0:*X>7QKJ=OX:.H_V;87LS7\%
MI;FQOA)!="1E4,K8RI!;&&'4=Q3-4\<:IX?@U:'5]-M/MUG8"_@^S3LT4T>\
M(P)905921V.010!W=%<UXCU^\L-3BTFR@B::YT^ZN4EDD*A&BV #@'KO_2N7
MT_QU>:3X.\)PW\NG?VIJEF)5N;^],<(C5%)DD=ADN=P^4=23S@4 >FT5YR_Q
M17^Q6G6/3OM,6HC3Y[D7A>RCRF]9?-52=A&!T&&.#C&:Z[PWJMWJ^F-<7<-H
MC"5D26SNA/#.HQAT8<@'.,$9!'T- &Q17%W7BW6I6UB[TC2+6XTW2)7AF,UR
MR33M&,R",!2!CH-QY([4ZS\7ZEK?B1+'1=.M9-/6VM;V6ZN)V1O)F#$!5"G+
M8&>2!P>: .RHK!\0Z[=:;=Z9INFVD5SJ6I2.L*S2%(T5%W.[$ G &!@#DD5@
M:AJ.L3:SX6CU2S%C<+K,D+B"8O%<(+:5@RG@[3Z,,@C\: .]HKSZZ^(-[I^J
M6D=];:1#%<WR6?V$:B&O8P[[%D* ;>X)4'@'K2#Q7/IS7$6F:4LUS=>))=."
MS7;;2WE%_,R0=J_*,J!P,XYH ]"HKSNX\<^);6SUV:30].)\/MF_*WCXE78)
M/W7R9SL.3NQSCKVGU7Q]=P>(;G2[&WTS?;Q121PW][]GEO=Z[L0Y7;QTR3U!
M''6@#O:HZMH]AKEG]DU&W$\(<2*-Q5D8=&5@05(]00:Q+^YDTOQWHLB[E@UF
M*2UGB)X$L:F2-O3.!(I]?E]!74T 9VD:%INA12QZ=;>5YS[Y79VD>1L8RSL2
MS<>IK1HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&LV
M-SJ.ERVUG?R6%R2K1W"*&VD$'E3]Y3C!'<$U?HH X%OAP]]%K4FH7UI#=ZG:
MI;YTVR\B--CEUD92S%WW8Y)' Q4\O@O5]3OKJ^UC7;>6>?2+C2U2WLC'&@E*
MG?@N23\IR,X.1C&.>WHH XF'PY>Z<--N_$&MI>:=H*&2W2&R9'=@A0/)AFW$
M*6P% R3FLGPUX2O;KPKX=U.WD2PU6TCN $O;4R))#+*7VNF58'A6!!!%>F44
M <<W@R_:SM;@ZTIUNUO6O8;G[*!"A9"AB$0;/E[21][.><TV]\(:SJ%F)KGQ
M K:JFH17T3FV8VT)C7:(UBWY"D$DG=DDYKLZ* ,?Q%HC:_I4-F;D0M'=6]P7
MV;L^5(LF,9'7;CVSWJ/_ (1X_P#"1:KJOVG_ (_[**T\KR_N;#(=V<\Y\SI@
M=/>MRB@#@K?X?7FG3Z1/8ZE8R36.EQ::QOK S* ASYD8#C8QSR,D'CTJ2S\!
M7FFV.BI:ZTC76E7]Q=K//:[A*LV_>K*&'.)#\P.,CI7<T4 </+X!N);>_@_M
M:, ZL=6T]_LN3;S,S,P<%L2*=Y&/EX)YI]UX*U+5=(U:VU/6+?SK^*.)%M+/
MRX8%5MV0A8EF)ZDMZ>E=K10 CHKHR, 588(/<5P\'@34%TZST&?6XY?#MG-'
M)';BUQ.Z1N'2)Y-^"H(7D*"0*[FB@#(\/Z(=#AOXS<>=]KOY[S.S;M\QRVWJ
M<XSC/?TJOJ'A>'4]?FU"YFW6\^E2:;+;A>65V#%MV?08QCO6_10!QMIX.U5G
MTBVU;7(KS3=(E2:VCCM/+EE9 1&97WD';G/R@9(R:D7P25\%P>'O[0&8KT7?
MG^3UQ=>?MV[O^ YS[^U==10!BC0"/$VHZQ]I_P"/RQBL_*V?<V-(=V<\Y\SI
MCM7-P_#V[L&T.:RU&QEGTW3%TX_;K$S(0"#YB*'!1^/4Y&/2N^HH X6V\ WU
MC9:>+;6T:]L=5GU%9YK3(D\T.'5E##G]X>01]*F?P+<0W+:A8:JD.IQZG<7]
MO+);[XPLRA7B==P+ @#D$'(!KM** .+/@6XNFEO+_54EU.XU&TO9Y8[?9'MM
MV#)$B;B0.O)).6)]JW8]$*>,+C7OM&1-816?D;.FR1WW;L]]^,8[5KT4 <QJ
MEK+8^.])UM(V>WN+>33;DJ,^668/$Q]MRLOU<5!I7@DZ9=Z//_: D_LZ>^FV
M^3CS/M+EL?>XVYQWS[5UU% '&W'@:7[5<ZA::FL.HG5FU.UE:#<L9:%8FC==
MPW*5!R05/(].9&\):E>FWN-4ULW%U'J<-^52$K"BQ@@1QH7.W.<ELDDUUU%
M' WO@#5+FQU'2(=?AAT>\O6OO+^Q[IE9I1*4W[P"F[G[N>V:MZGX,U.4ZW;Z
M3K<5EI^M%GNHY+3S7CD9 CM&V\ ;@!D$'!R179T4 <1>?#TW5GJ$']IA?M>G
MV5EN\C.S[.Q;=][G=GIV]35_Q+X9AU2\N-2N!+<0C2+JQ>RA4>9,)"C?*Q.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(Y*HS!2Q R%'4^
MU<9X8UCQ#JGBCQ%9:PD-D(+>U>UMHF$A@$GFY+-CYF^49[#&!W) .THKSS;X
MIA\;Z=HL'BV>]5%%YJ(DL8%6. '"KE5SN<@@<\ ,?2O0Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BL'7?%%OHNI:7I_D/<7-_<)%M0X$*
M,VWS&/ID@ =^?0X67Q-$GBZV\/I9W#/+'([W+(5C4JJMM!(^<X89QP/KQ0!N
MT5S<7B>Y&MVME>Z2UI!>R31VTC3@R'RPS%GCQ\BD*2#D]1D#-1^%/%<_B<"=
M;&UAM'A$JLE^LLH#8*AXPH*Y!SR: .HHK"\2>)HO#L=KNL[BYDN)XX@(D.U
MTBIN=\84 N..I/3N14U;Q=+IUWJGDZ8;BRTB)9=0G,X1D!7>1&F#O(3YCDKU
MP,F@#J**P+WQ5;6OB;2=$BA:XEOV;?*A^6 >6[KN]2WEM@>@)],UM)\6S:QK
ML]C;V5I]GAGEA:0WZ^=B-BA;R=N<;E(ZT =1163KNI7^EVOVFTL+>YAC1WN'
MGN_($2J,YSM;(QGTQBN>;Q[="WTG=H]O;W>H6SW1AO-06$1(&54&XKRS;L[<
M C!H [>BN>USQ5'H*:7'/:M+>7T\,)@C?(A#R)&SEL?=5G4=.20..U6]\9FT
MUJXM!IX>TMKRWL9IC<!9?,F";2D6/F4>8N3D'[V <4 =712,0JECT R:J0ZK
M87 LS#=PR"]0R6Q5L^:H )*^HP0?QH N455U*[EL=.FN8+26[E0?)!%C<[$X
M YZ=>3V&35#0];EU2XU"SNK1+:\L)%258IO.C.Y0PP^U3G!Y! (_$&@#9HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "L#3=)NK;QKKNJR!/LM[;VD<)#<DQ^;NR.WWQ6_10!SWAW1[J
MQU;Q#J5\J?:-0OMT15L_Z.B*D8]NC''^U70T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 </KW@G4+S4_M]AKEVCS:A;W$L;)"1&D?3:2A/
MRC)"DXR3ZFM^_P!-N+CQ1HVH1A?(M([A923SEP@7 [_=-;-% '$7&AZWJ6O6
M=U<:?IMK=6DLGF:G$V?M,!5PD13[Q!W*65C@%3C/&([#PQJ%UJ-A+/I]KH*V
M5E):O)I<H!F9]GW,+\J#:2-W.2..I/=T4 <[K&@W,_A5-+MKF:ZE2YMY?-NY
M,NRI<)(V6QV52!QV%8OB[PG>:Y?:A';V*>7J%LMNUTE[)$%Z@F:('$I4'*\<
M]#@5WE% '"/X$OK77=+N['7+MH(M2>\G25(25!A=!@[,G@JF">%Z<@&E_P"$
M;U&[U&PBDTK3M/6SOY+MM1L2$:56#@!5QN#-O&[)QP>N1CNJ* .6U/PS<S:"
MND17UU>PW%["]V][,&;R RET! '!"XQ_M&G>(=.O9]1::#0-+U2*6S:WS.0D
ML;$DX9B#F,YY Y!'?/'3T4 >;W'PYU2+2;2.U\0W;W:'3TEW)$5VV[QDE2R%
MAC:SA<X+'G.34VH>$=2GUB\E%E;3W<][%/;:V\H$UI$NS* 8R,;7 53M;><X
MR:]"HH IV%W/=_:O.M&M_)N&BC);/FJ,8<<#KD_EU-<UH7AJ_P!&U?4;IUBG
MM[6*2+1X0^W"2.975CCY?FV(.N%C%=C10!1OFU0Z.SZ?';+J.Q66*=B8\Y!9
M2PYY&0&QP<'!Z5B^%M&N=/U/5;UK"#2[2[\KR]/@<,JNN[?*=H"AFW*./[@)
MY-=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>guyaragreement019.jpg
<TEXT>
begin 644 guyaragreement019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRC< Y&<\]O2MCP3X0C\%Z/<Z=%?2WBS7<EUYDJ@-\V.#ZGCKWKI:* "BBB@
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MO7_"/:/]FL+;^S+7R-/D$MI'Y8Q XZ,H[$5!<>$/#EWK*ZO<:)82Z@K!A</
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M2W6U61(P&$*XVIG^Z,#CVJM)X2\/2Z*NC/HUBVFJQ=;8PC8K$DY ['D\CUH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMG&:;>>,O#NGQP/=:M;QBX@6XA&26DC;.&4 9(X/3TKCM2GET(>.+>ZT>[U
M:DSW$,\$0DC9#;JGER-G$>W:?O8X.1FK/@W3Y_[<T"_:U?R%\)6T G*':'W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQMCV\@Y&>>,]\5T] !116)X@UB_TO[,EAI\-PTVXO/=7/V>"  #[[[6.3G@
M<X/2@#;HK@XOB-)-H,%[!I"7%X^K_P!D-!!>*T9EP2&63;AEZ<X'4^G,S>/+
MFPAUF'5M'6+4M.:W5+>UN?-2Y-PQ6(*Y5<$L"#D<8SS0!T=]H-AJ6J66H7:2
M2363;X4,S",-V8IG:6'."1D5IUPNF:GKL_Q0BM-6LULE&BRR"*WNS-#(?.C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+,X\Y,@ >V:R;>+2O$OC6!M'M#_9<>D3V>HN+=H4<.4$<)! RP <X_A![9H
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MYF-C%<YP.N/2NBKSOX)13Q?#6U%S!)#*US.Q212I&7)Z&O1* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBLH>(M.,"S;Y]C7OV$?Z/
M)GS=VW&-OW<_Q?=[YH 8VO0QZY?64QBAM;&TCGN+J60*J,[, ISP.$))SW%3
MPZ]I5UI<^I6FHVMU9P*S236\JR*H49/(/I7#:A:PZCX.UG5;Y+Y4O]66X66T
MA$KPQQ2+'%(4/WD B#E<'ACQ65:W-UJ4.KZ6HM;Z/59K2S.KVEDUM]H5BWFJ
MZDD$I$K\KQ\P% 'I=EJX;PO!K6I1K9*;074Z%MPA&W<03CG _E7/)XL\37.F
M?VU:^$E?2RGG)')?;;N2+&0PCV%02.0I?-;GBO2)-<\(:MI%NPCENK22&,G@
M!BI S[9Q7%WOBVRN]"M+.YOO$&AZU;1A)+"RLV,KR!<;1F-E9<C@@XP>M 'H
M5IJ=I>16K1RA7NH!<10R?+(4XYV'GC< ?0FECU*QEG$$=[;/,S.HC652Q*'#
MC&<Y4D9],\UYU:WU]HFJ^$-7\4_:(Y&T:>VNIVB+[;AFB8*^P'!(5OQ&*HPB
M6W\+7/BQ+6XBETKQ#=ZAY<D921K5Y")1M/(S&Q;![J* /6([F":26.*:-Y(6
M"RJK E"0" P['!!Y]:YF?Q1JM_JU[8>&]'AO5L)/)N;N[NS!$)< F-,(Q8@$
M9X &:G\#6,]MX:CN[Q-M_J<CZA= ]5>4[@O_  %=J_\  :YJUU"#PB_B'1M<
MFOM.CO;^>\L]3MX&=728[L!@K!74Y&&'IC- '7Z)K[:C87<NI6+Z5<64K174
M<[@HI #;EDX#(00=W'OBKNGZQIFK0//INHVEY$AP[V\RR*I]R"<5Y5(NKZEH
M6HSSOK.J^'X=6LID^WV^)KBU0@S8C"J67=SC;R%IWB:$^)KW6+KPG;2RVW]B
M&WNI((6C6Y?SD81+D#<PC$HXZ;P.^* /4=/UO2=6>5--U.RO&B.)%MYUD*?7
M:3BLK4?&NE6NH:?96EW9WLUQ?BSG2*Z4M;921]S 9_YYXP<=?:N1U%[7Q%K>
ME'P; T4UK87D<T\=LT"PJ\)6*)B0.?,V$+VVD\53M9M'N$\ 6%CIDL6HZ==Q
MI=*;-D:UQ"X=9&(QDO@]><9H ]574K%UM66]MV6[_P"/<B52)N,_)S\W'/':
MJLNKH-4M+.W:UF6222*=OM2AXF5-V G5CR,CC .:\DGTS4K6XND6TN#%X)E-
MQ984_OTDN!+A?[V(%*<?WJW]*TZZAOO!-W<02"ZO)K^_N_E/R/-$S[6], JO
M_ : .]M_$.BW=ZEE;:Q8373IO2".Y1G9<9R%!R1CG-:5>2:3HR6OP\^'[1:>
M(KJ/4[621EBPZ[BV\MQD9SSFO1I/$6G16=Y=.\_E6=S]EF(MY"1)E1P-N6&7
M7D9'7G@T :M%9L^NV%LVI+(\P.FQ+-<X@<X5@2-N!\YPIX7)I_\ ;-D+N*VW
M2^;+;&Z4>2^/+& 3G& >1\O7VH OT5F0:_I]PNF&-YB-25FMLP.,@+N.[(^3
MC^]CTIH\1:<8$F#S['O/L(_T>3/F[BN,;?NY'WON^] &K165<^(M.M$U)YGG
M TXH+G;;R-C< 1MP/GX(^[G'>IIM9LH+JZMG:7S;6V^U2@0N0(^>A P3\IX&
M3[<T 7Z*SXM:LII=/B1I=VH0F>WS"XR@ )W''RG##AL'\JBC\1:=+9VETKS^
M5=W/V6$FWD!,F6&"-N5&5/S' ]^10!JT5E3>(M.@M[Z>1YQ'8S+!/BWD)#MM
MQ@ 98?.O(R.OH:EEUNQAEU&-VEW:=")[C$+G"$%AMX^8X4\+D_G0!H45';SQ
MW5M%<1$F.5 Z%E*G!&1D'D?0U)0 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;3/.M[(!HR;_ &2L?+?:,"/CYANSUQQ6E3)IHK>%YII$CB0%G=V 50.Y)Z4
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M'[1_I/FA-@;=C&-GR[<;<=JU-$T"UT-;IH9;BXN+N02W%S<R;Y)6 "C)P!@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ;!<7EO+=(LMG;BZN%(/[N(Y^8\=/E/Y4 :%%9\.N:;<7%G!%=HTMY;FZMU
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M;TVWN;RWEND6:SMQ=7"D']W$<_,>.GRG\J -"BL^#6]-NKFTMH;I'FN[;[7
MH!^>+CYAQT^8?G6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (%"YP ,G)Q2T4
M4 %(%"C"@ >U+10 A4,,, 1Z&EHHH **** #&>M%%% "%0V,@'!R,]J"H;&X
M X.>12T4 (5### 'OR*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **:[I'&TDC*B*"69C@ #N31%+'-
M$DL3K)&X#*ZG(8'H0>] #J*89HEF6$R()64LJ%AN(&,D#TY'YT2311%!)(B&
M1MJ!F W-C.!ZG@_E0 ^BBB@ HHHH ***@N[RUL+=KB\N8;>%>#),X11^)XH
MGHI%970.C!E89!!R"*6@ HJ-)XI2XCE1]C;'VL#M;T/H>1Q[U)0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/SU.>@XH OT5GP:8T%S:S'4;Z46]M]G,<D@*RGC]XXQR_'7@<GBM"@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?:)T+<QQ\_,?0?*?RH NT52AU?3KBXMH(;R%Y;FW^TP(K<R1<?./;YA^=7:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F>3%C'E)C=O
MQM'WO7ZT^B@!AAB8.#$A#\N"H^;Z^M!BC)8F-26&UB1U'H:?10 P11@J1&H*
MC:I Z#T% AB4(!$@"'*@*/E^GI3Z* &>3%@CRDP6W$;1RWK]:##$V_=&AWC#
MY4?,/?UI]% #?*CW;MB[MNW..<>GTI!#$NS;&@V#"84?*/;TI]% #/)BP!Y2
M8#;P-HX;U^M!AB974Q(0YRP*CYC[^M/HH 88HR6)C4EAM8D=1Z&@11AE8(H*
MC:I Z#T%/HH 8(8E"@1( ARH"CY3[4>3%@CRDP6WD;1][U^M/HH 888F#@QH
M=_W\J/F^OK2^7&6W;%W;=N<<X]/I3J* &"&)=F(T&P83"CY1[>E'DQ8 \I,!
MMX&T<-Z_6GT4 ,,,3*ZF)"'.6!4?,??UH,499F**2PVL2.H]#3Z* &"*-65A
M&H*KM4@=!Z#VI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(Y*HS!2Q R
M%'4^U<=X4UK7]1\6>(+36H8;5+>"TDM[.)P_DA_-SN<#YF.T9QP,<=R0#LJ*
M\H\/>,]5OM8T:-M<%UJ=Y=R0ZCHGV=%6RC4/EE8*&&PA1EF.[/%>KT %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>guyaragreement020.jpg
<TEXT>
begin 644 guyaragreement020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWQ%K<PU*=1=6$[K&%!&$P''(Y[=Q0!],T51TNW2TT*SM[2!X$BMD2*&9B6C
M4 *QY)(Z&O,O"%OKEK\;M3BU_4TOKU]$65O)0I%%F5<(@/\ "/4\G))H ];H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ=*FI1M);*MK(S,JG!RH&1U[U-HOQ%\,Z_'?&POW:2QA,]Q#) \<BQ@9+;6
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M<6P!N?L]L\JP \_.5&!Q74:=J%IJVG07]A.EQ:7"!XI4Z,#0!9HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N/^*G_)+O$/_7J?YBNPJO>V-KJ5E+9WMO'<6TR[9(I%W*P]"* /)='\'>+?
M%>E^$'UV_P!&AT731;7D$=E'(9W"H-@<MP#CKCC]*G^'.IZ;HOBOQS::U=V]
MGJ[ZM).6N9!&9(#RA!;JHR3[!A7J]O!%:VT5O!&L<,2!(T48"J!@ #T K*UG
MPEX>\0S)-J^C65Y*@PLDT0+ >F>N/:@#Q*'^P+[0OB%=WSW4/A>]UB);2ZLX
M]P24$DR =-N2F?8@5NZ9JNIZ3\0_#6GZGK.B^+H[SS$M;R.!/M=HNW.[<N<
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M8U"I'&H55 Z  =!0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!DC!^5@>,]:=]OMO[3_L[>WVKR?/V;&QLW;<[L8Z]LYH LT45DZUXETKP_Y
MU"X=9;@D0PPPO-+)CKM1 6(&1DXP,T :U%9NBZ_IGB"VDGTVY\U8G\N5&1HW
MC;^ZR, RGZBI]3U.ST?3Y;^_F\FVBV[WVEL9(4< $]2* +=%%% !1534-3L]
M+BAEO9O*2:>.WC.TG,CL%4<#N2!GI5N@ HJI!J=G<ZE=Z=%-NNK18VGCVD;
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M%_;R;[6>)9HWP1N1AD'!YZ&FZ;J-IJ^FVVHV,OFVES&)8I-I7<IY!P0"/QH
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MTVP2&9T$9D+,[!!SM!8DA?8<4_6O#FC^(HHH]6L(KH0MNB9LAHSWVL,$?@:
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M%P)-@?+<(#GD#CIQ5GP?=75EXG_LO4TURSNI[-I5MKZ]%[#,490TD<N20?F
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MD\.RS2-#<LLA!^S_ "!^JKDCA2.F.E>F:5X4T+1)9)=/TZ**5X_*+DEVV?W
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M ,2)J=Y"4):W0AU4-Z!4$8.>],70[Y?A/]C&FSB^.L^>8A$?,Q_:.[?C&?\
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M.%-0+7&E:E9"6VM$W-NDAN2HQ@$E<,2=V,4 =_;^+O#]WJO]F0:K;O>%VC5
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<O/
MV@W][/<SV]P5N9!+<6ZW4JP3N,?,\0;8QX&<CG'.:Z/I110 4444 %%%% !1
M110!E:SX>T_76MY+M9TGMBQ@N+:X>&6/<,, R$'! &1T.*GTG1['0[$6>GP^
M5%O:1MSEV=V.69F8DLQ/4DYJ]10 4444 %%%% !1110 4444 %%%% !1110
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M<7FU*WCL0GG;#"8F<8X^7)&[=SFNZ\)> M*\.:=I326<+:I9VJ1M,KNR"3:
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M9I%>$MUVN&W*#Z XITGA+2Q8Z996D$=K;6%XEY&B*22ZY.<YZDGDG.<GN<@
MWJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVT.9;;1-4N['3$TZX@U*(M"X4EE=&VDJ02W;D'MBO3** ,7POHTNA:*MI/\
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MQD\FNIHH YSQ'H%]>ZCI^M:-<P6^K6 =%%PA:*>)\;HWQR.54@CH1T.:H_\
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M(NYB)'#>< H#JP.48!5P5(Z5%;>#M#M40+:R22+=)>&::XDDE>9!A69V8LV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/&W_  BQFA%Y]E^T<RC).?N!>N=H+?2K6G>)]"U>]DL].UBQN[F,$M%#.K,
M#@G /(S7&^,;2^N/%>I6UI%<+-J?AN6SM)DB8H9PSMM+@80X/4D=:9'<0:Y=
M^#K/1]*O;6XTJX66Y,MF\(LXEA9'C+, "6)484G.,]!F@#L/$OB :!:VWE6K
M7E_>SK;6=JKA/-D()Y8_=4 $D]@*I6>L>);;6+2RUS1K8V]YN"7>FRO*L+@9
MVRAD! (!PW3/'&:A\:VEW'<Z%K]G:37ATB\:6:VA7=(\+QM&Y1?XF&X''?!H
MA\7RZWJUG9:!874D#%FO;R[M)8$MT"G &\+N<MC@9P,YH UT\3Z#+JYTF/6+
M%M1#%3;"=2^X=1C/4>G6F7OBWP[IUU]EO=<T^WG\SRC'+<*K!L X()X^\.OJ
M*\WAB=_A]IG@^/2KU/$EO=0[R;1PL4B3!GN/-QMP0&.X')W8K8GTB231?B<6
MT]VFNWF$.826F M$V[>/F^;.,=\T 7]:\?&U\67.A:=+HQ>SLFNIVO;WRB6P
MYV  '& FYB>@.:Z.]\3:/I0MDU+5+&UN+E T<<DZC?[C/49XS7 ZKI]_+;>)
M,6=R[2^#H84Q$Q+RXGR@XY;D<=>15VWDBT'7]8DUG3+RXBU2PM4M3%:/,)%2
M(J\!V@[3N).&P#NSV- '1Z7XSTZ;P=I?B#6+FUTQ+Z)7"RS #<1G:"<9K2E\
M1Z)!I\%_+J]BEG< F&=IU"2  D[6S@X )_"O*+#3]3TNS\%:C<RZAIMK;Z,U
MJTT5A]H:UF+*?G0JQ7<HQN [8/6M'1]$D>]\.3M;:A/;2:_=7A:\M1%@&W?$
MGEJ!Y:EQN (!R<]Z .PU?Q_H&F^'8];AU"TN[62YCME:.X7!=F //^R"6(ZX
M!K1@U^V:?4I)[S3TL+6.*43BY!(1UW;I.R#T.>1S7!>(;"ZB/C2:.QN6A_MC
M3+I1% S;T06YD90!\V-K9QGH:-:>[^V>*+^VTMKFVNY]+=))[)Y5CCV@M+Y7
M#.4X.WJ".>E '77_ (XTD>%]8UC1KVSU-M-MWF>**8'D*2 V.0#CK6MJ>IMI
M_AN\U58@[6]F]R(R<!BJ%L9_"O)=3AU'4KCQ7.CZGJ:W'AF2&*YDTXVXE<.3
MLC4*"<;AC.2<G' KT[Q!#++X"U2".-WE;3)46-5)8L8B  /7- #4\7Z/;Z-8
M7VK:C9Z>]U:QW/ES3A2 P!XSR1DXK*\3^/[32QHT.EWFDSSZK)B&6YN]D*QA
M6.\E0202NT8[FJ7A_3)1XM\.W%Q92 6_A=8O,>(XCDWQY7)'#8SQUQFL[0M,
MN[>Y\+)]BGCCM]>U1B/*($<;"XV$\<*<C!Z'(H [Q_$^A0ZJFDS:Q8)J3$+]
MF,ZA]QZ#&>I[#K1<>*-!M+YK&XUFQBNUW;H7G4,NU0[9&>,*0WTKS:XC>+P%
MK/A&72KV7Q%<W5P8]MHY6>228M'<>;C:  5.XD$;<5KKH\RV7Q'E>R=[NX#I
M%+Y)W3 6: ;..?F+#CN2* .K'C7PN3<@>(=,)MEW3?Z2GR#.,GGU('U.*M-X
MBT5=&76&U6R&FO\ =NC,OEGG& V<9SQCUKD+?11'KGP\*Z<5CLM.N%8^3Q"W
ME1  \?*<[NO?-8\@OM+L@!8FW@_X2:^E^VR6#W'V-"7*2)&/[Q.T-R!NH ['
M5_B!H&F^&SKD&H6EY;?:([8>5<+@NS $9[$ EB.N%)K1MM?MI9=1EEO-/73[
M5(I%G6Y!PCINW2=D'<<\CFO+I;;49M+\:7+0ZI=B2]TRYCFFL#%)<)')&7=8
MU4< (>,9P!GK6AK-G=:AJFN:G#I]W<Z?_:.E7LD/V=MUQ;I&"X"$ L1P2O7Y
M<8SQ0!Z'9^*-!U"PN;^TUBRFM+89GF2=2L0QG+'/''K3M/\ $>B:M>SV>G:M
M975S!S)%#,KLHS@G /3/%><>*@_B63Q'J>BV-XUH/#DUI)*UK)$;F9F#(JJP
M#,5 ;G'&[%=3=:<8/&O@][:S*06]E=PNT<>%C79%M4D=.0<#VH [*BJ6DZI;
MZUID.H6HD$,N[ E0HP(8J05/(.0:NT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%;P3I>E-<+;/%?RNDL[.7<Q=6)//(H ]9K.T[7=.U6_U"RLKCS9M/D$5R I
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MR(FRW3>WS,%SCT&<D]@#7&?$Z:[$&A6L;0K8W6H".[^T3M!$XV,421U!(5F
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MHNE06[6\.F64<#((S&D"A2H)(7 &,9)./4FK,EM;RRK+)!$\BJR*[("0K8R
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MMAPC /#NVY!(Z@D CJ,\BK>FZI::O:M=64IE@662'?M(!9&*MC/49!&1P<4
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M6$K.BR-%(KQLCQNO5&5@"K#T(H OT444 %%%% !1110 4444 %%%% !1110
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M!^H/!'-8>G:!K>DWGA[4YM+DE;^T[ZYN[:VD1C:BYSM&20&"Y&['OC->FT4
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MO'Y/E1,'!3#;B[8 QM&,G/OZZ0""#T-5[*RMM-LH;*S@2"VA4)'$@P%4= *
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !116;I.LP:O:3WD2E+1)GBCF=AB4(=I<
M>B[@P'J!GO0!I45G:KJ\6F:+-JJH;FW@7S)/)()$8/SL/7:,G'?%7XY$EC62
M-@Z. RLIR"#T(H =1110 4444 %%%9=_KEOI^MZ;IDJ-OOTF=9,@*@B )W?]
M]4 :E%,$L9B\T2*8\9W@\8]<T1S131B2*1)$/1E8$?G0 ^BLI-?M9?$B:+$#
M)(]FUX)E8%-H<(1]<FM*26.)2TDBH ,DL<8'K0 ^BHQ/$71!*FYQN5=PRP]1
MZT-/"DRQ-+&LC?=0L 3]!0!)16?::U9WNLZAI<+,;FQ$9FR./G!(QZ\#GZU<
MCGBE#&.5'"G#%6!P?0T 2452N=0\F2W2"%KDRSK%)Y3K^Y!4G>V3TX'3GD59
M,\(G$)EC\TC(3<-V/I0!)169I.M0ZO/JD443H=/O#:.6Q\S!$?(]L./RJ^T\
M*.JM*BLQV@%@"3Z?6@"2BF2310[?-D1-QPNY@,GT%#RQQ#,DB)_O,![4 /HI
MGG1&8PB5/- R4W#=CUQ09HEE6)I$$C#*H6&2/84 /HJ.2>&+_62HG('S,!R>
M@HEGB@3?-*D:YQN=@!^M $E%9EWK<-GKNEZ4T;M)J*S-'(N-JB,*3GZ[JT7D
M2)"\CJB+R68X H =13#-&(?.,B>5C=OW#&/7-*LL;HKJZE&^ZP/!^E #J*SM
M5URQT?0[S5[B7?:6D;22&+#'Y>H'O5MKJ!(%FDFC2-L89F 'YT 344QY8XXS
M(\BK&!DLQP!^-4;S7+*RU+3;"5R9M19U@VX(^5"Y)/I@?F: -&BD#*V=I!P<
M'![TUIHDD2-Y$5W^ZI8 M]!0 ^BF--&CA6D0,3@ L,D^E/H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FJ>?\
MV3>_9<_:/(?RL==VTX_6O,+BZTZ/X;^ K26ULIH+F. *^H3&.SC=8"29L<-S
MG"G@M]*]:K+TO0[;2[*>Q3$MF\[S10R*"(@YW%!ZC<6(],X[4 <'\/9+,7GC
M6$2Z<VGJ\3D:=$8[7#0D.44D\':02."0375?#OS_ /A7/AW[3N\S[!%][KMV
MC;^F*U=8TB/5])N-.,A@BN5$4S1C#-'GYD![97*Y[9J_'&D421QJ$1 %55&
M .@% #J*** "BBB@ KA_%^F66K^/O!]KJ%M'<V^V]<PRKN1B$3&X'@C/.#Z5
MW%(54L&(!(Z''2@#QJY?3],T[4M(:QM#8?\ "5M#;Q7<IBLK?]RDF) !@IN)
MPG0L16;&ZB#QC!;26#:8+C3)+U='B:.#[.783E "<C:N&9>N#Z5[H\$4B,CQ
M(R/RRLH(;ZTY8XT^ZBKQMX&./2@#SCPZ/#(^++GPQ]A\@Z(WG?8-OD[O.3'W
M?EW8QG'.,9K0\1:58ZO\3_#]OJ-K%=0+IMY)Y,RAD8AX<;E/!ZYY[@'M7:Q0
M0P@"*)(P.@50*?M4L&P-P& <<T >+V6B:;9^#]/U*"SB2^A\4+#%<[?WD<0O
MC&(U;J$V<;>G)XK*\87FGW6E>)[V*'0[2]COI0/M):?4S)&X 9.08EPN1C(5
M:]\\M-NW8N,YQCOUS33;P&1I##'YCC:S;1DCT)]* /&_%$5O;:IX_P#[-CMH
M=6FMK.5#$@$SVY(^T,NW#$$9W8_GBI](BLUUQVTF_P##YC_L>X^T0:#;,L;Q
M[1L,IW%0P/W<_,<M7K_E1^8'V+O VAL<@>E-CMX80PBAC0,<L%4#)]Z /)],
MT73M+\)_#JYL[2**XO+ZQDN9E7YYF^SRG+'J<;CCTKG-2OM/N-,34[:+0[.[
M.L)($8M-JBL+D!C(^08^,Y!! 4A>XKWW8F%&Q<+]T8Z?2F?9H [OY,>Z3[[;
M1EOKZT <OX*_Y"7B_P#[#C_^B(:XJ^/@_P#M?X@C739G4?/'V=9\>;C[-'M\
MG/._?_=YSM]J]A"JN< #)R<#J:RM.T"UT_4M3O0?-DO[H7)WJ#Y;"-(\+^"#
M\Z /)9DNGUPKXNGT&.8:-9^5_P )!$SJ?W?[_P OY@ _F9W?Q?=K2\/:'::S
MK_AFVUH#58HO#\TL9NH64/\ OT$;%'R<A&P,_6O6I8(9PHFB20*<C>H.#Z\T
M_:N[=M&[&,XYQ0!XI&^FZ;XBBGB_LC5I6UT_NG5K?5X96E(.2"3(BYS@X!0>
ME.O_ .P/^$:\4G5O(_X3+[;<_9]V/MGF[S]E\G^/;CR\;>,9]Z]F\B'S_/\
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M=4<-:;&<@B"(84L"OS$$'! KUG8I))49(P3CJ*C-K;D1@P1$1G*#8/E/MZ4
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MM[Z7R;61#D2O\V0O_?+?D:JVOC/PY>ZDFGVVK6\ES(S)&JD[9&'4*V-K$8/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !56RTZVT[[0+6,QK<3-.ZY)&]OO$#MD\G'<D]ZM44 5=1TZVU6
MR>SO$,ENY4NF2 ^"#@XZ@XY'<<'BK5%% !1110 4444 %%%% !1110 53U#2
M[/5$@2\B\Q;>XCN8QN*[9$.Y3P><$=.E7** "BBB@!DL:S0O$VX*ZE3M8@X/
MH1R*I:-HMCH-A]CL(W2,NTCM)(TCR.W)9F8DL3ZDUH44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1Q00P&0Q1)&
M9'+OM4#<Q[GU/ YJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***SM1OY+2_P!,@22U5;J=HF$SE78!&;$8 Y;Y>AQQF@#1HK"M
M_&GAJZU"&P@UNRDNICMCC60'<W]W/3=[=:UKV]M=.LY;R]N(K>VB7=)+*P55
M'N30!/167IOB/1M7MKBXL=2MYHK;F=@^/*&,Y8'!48YR:BTKQ9H&MW;6FFZK
M;7-P$\SRT;DITW#/4>XR* -FBL6T\6Z!J%^]A8ZM:7%VH8B)),[MOWMIZ-CO
MC.*R_"?Q T?Q'I^F+)?V<6JWD D:T23)#8R5&>I YQUH ZZBJU_J%GI5E)>W
M]S%;6T0R\LK!57MU-9\/BSP_/I<^IQZO:?8[=MDTK2;1&W96!Y!.1@=\B@#9
MHK&M?%F@7MA=WT&K6K6UG_Q\NS[?)STW X(SVSUJ73?$FC:O;W$]AJ5O-';<
MSD-CRAC.6!P5& 3D^E &I163I/B?0]=FDATO4[:ZEC7>R1MSMZ;@.Z^XXJ;5
MM<TO0H8YM4OH;5)&V1^8>7/7 '4_A0!H45S/A[QC9ZS;W-Q)/;)#_:CV%I(D
MF5N, %2#W)&3QZ5K76NZ58FZ%UJ%O#]D\O[1O<#RO,.$W>F3P* -"BN;M_&.
MEWEQ]HMM4TZ325LI;EYA*=X\MPK-C&-@R<G/7%7=-\5:#K%_)8Z=JMK<W4:E
MFCC?)V@X)'J >,C- &O16%'XT\-2ZA]@36K-KKS1"(Q(,LY8+M'8G) P.E)X
ML\4VGA/3(+R[VD3745NH+[?ON 6S@_=!+?A0!O45QT?Q$T:#6]6L=4O[.SCM
M98EMW>3!E1XD?>?09?&>E;NJ^)-&T1(6U+4K>W$X)B#-DN!U( Y('KTH U**
MBMKJ"]M8KFUFCG@E4/'+&P974]"".HK(\)ZY+XBT/[?-"D+_ &FXAVH21B.5
MD!Y]0N: -RBL;4/%OA_2M0%A?ZO:6]U\N8Y) "N[[N[LN>V<9IVK>*-#T*6.
M+5-4MK621=ZH[<[?[Q Z+[GB@#7HK!G\1*GBC2]-B\F2SO;&>[^TA\@",QXP
M>A!$A.?:M6PO[34[*.\L9TGMI1E)4.589QD'N/>@"S17G$'C3Q9+X7N?% TW
M17TNV,[O";F1)BD3LK8RI7<=A(YKK+WQ=H>F6UK-J.H16ANH1-'%+_K-A .2
MHR0!GD]* -NBLJZ\2Z+9:7!J=QJEJEE<8\B;S 1+GD;<?>_"J!\66UQK.@6^
MFRV]W9:HMR3<(^=OE*#@?B2#GIB@#I**K6&HV>J6HNK"XCN+<L566,Y5B#@X
M/?GTKC;#Q#XRUIM3GTRPT,VMI?W%HB7%Q*DDGE.5SPI SB@#NZ*YC3O'6CW/
MA33->O[B/3X[]?DBE?+;QD,JXY;!!Y Z<U>N?%OA^TTN#4Y]8LTL;@$PSF4;
M9,#) /<\'CK0!LT5@VOB>Q>/4[VXU'3ETRU,3).LWW4>-7!DR  3NX SD$=S
M5K3O$>C:M:W%S8ZE;S0VW^O8/CRN,_,#RO'/- &I17)VWCO3=3\4:7I6D75M
M>Q74,\DTB.=T>P(5P/1MQYZ''%=90 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML"*2"L>'() Q_%D9^@KOGCU3P[\2_!^CRZY?:G'<QWTL[W)4M(1'D#@< $<
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M 03QP0?Q% #H_#NDQ:;I^GI9J+33Y$EM8]S8C9/NG.<G&>^:S-+T"\;QG?\
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MKO3;N.PC6?3(#;V;@G,,9 4J.?0 <_UI7\/:5)I^HV#V:FUU%WDNX]S?O6<
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M:6VF+IJ1;K18_*\N5C)E,8P2Q)/'KFJ^J^(=&T+R_P"UM5L[$R?<%Q,J%O7
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MVB^7\6SSVK TOX<7>F+9Z=%#X?\ L-I.KB_-@KWCQ*VX(=RE=W\)?.<<X!H
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MEBJ+,P51GH . *AO/&EXLNJRZ9H,E_I^DR-%=W N5C<LH#.(D(._:#SDKDY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,DKO1@PR"01D>A!'X57FU;3[=-\MY"J^>ML3O!Q*Q 5#Z,21Q[URWPJMGM_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH "0 23@#J:YK3O%UK)X>_M[4YX+33[F<K99!W21YPAQR69
ML%@ .A'H36WJ=O)=Z5>6T+;998'C0^A*D"O.([F_;X?^"7T^VF2&&..&\N;:
MQ%U<6;)$8SY<9#8.\%2<$@9XH Z^;Q3;WWAR_P!3\/2PWTEEEI(&5E8[<,R%
M3@JQ7.,CJ1U%;=E>0:C86][:N)+>XB66)Q_$K#(/Y&N \)BXTJ[\9:KJD>IB
MS=(9TN=3C5))HTA(9B%  ^[TP"!C(%='X!LKC3_A_H-K=*5GCL8MZGJI*YVG
MZ9Q^% '1T444 %%%% !7->(_%L/AS7=&M;QX8K*^6X,DKY+*4"E0H'4DMC&"
M:Z6N7UNPGN?'OA6[2V>2"U2\\R4+E8BR(%R>V>0* +Z^+=!?1?[875(/L'F>
M5YN2/GSC9MZ[L_PXS[46GBS0;W3KN_AU.'[-9_\ 'R\F8S#QGY@P!'XCFN&O
M;76M/.J20:?<)#-XF:=KF*Q%S-!";=!YT,9!R=P*[@#C+<&LW^P]:O)O$ETM
MIJ]Y&T^F7<7]HQ)'+?1P2,TB!0JJ#@<*0#TR.: .YTKQK9ZWXP&DZ;+%/:C3
MVN7?:RR*XD50I5L8!#9Z<UK:MXET?0I8HM3OX[>65&>.,@EI I .T $D_,.!
MS7.:5<2ZO\3/[6BT?4+6S71VMS<W=LT)=_.5MN&YX&>O7G'2M"_L)YOB7HE\
M+9WMH-.NT:;;E4=GBP,]B0&_(T 3VWCGPQ>75I;V^LVTLEV0L.TDAF/12<8#
M'^Z2#[4^[\:>'+#4&L;G588YTD$4F0Q6-SC"LX&U3R."1UKCXM#OX_!%O;+I
MTRW \3BZ:,1$,(_MQ;?CTV8.?2L3Q/;>(-2T/Q+I_P!DUF.ZEN9C#IUAIR):
MRIOR)6FV9D9E&XX8,6XQ0!Z'9^-=.N?$NN:1+(D"Z5&DCS2,0I&"7)) "A>!
MUYJ[IGBS0M8\_P"PZC'*8(_-D4JRL(_[X# $K[CBN#\4Z-JNI7?C*PM;"]+Z
ME;V-Q;2K'B.40D%X]Y&T.<$ -USZ5-9:?<:IK7VU1XIN6MM-N8_-U6&.W5&D
M4#RE01*TA.,Y!VC:.3F@#J$\:Z3J<MHNBZK83AKN."8R;^0Z.P5"!@N=O?CA
ML\U9;QIX<35!IS:K#]I,WV?&&V>;G&S?C;NSQC.<\5S4.CWL7A#X=VJ6,RR6
M5U:/=1B,YAQ;N&+#MACSGN:YC4+?Q!J.A&UEL]:2\344EDTNTTY(;*%%N0Y8
M.$S+D#=\KDDG)'6@#T_P_K4VKW6N12QQH-/U%K2,IGYE$<;Y/OES^5,O?&OA
MO3KV:SN]6@BG@<),I#'RB0""Y PHPPY.![U7\)6=S:7_ (H>X@DB6XUAY82Z
MX\Q/)B&X>HR",^U<FNI_9]6\?Z>FAWU]/>70CB:WMS(DC&UC41NW1 ,YRV!A
MC[T =UJWBK0]#ECBU'48H9)$\Q4 +ML_OD*#A?\ :/%1ZCXQ\/:2+8WNK6\8
MN8Q+!@EO-0]&7;G(^G;FO/(- U;PSJK->W7B$)+I=E D^BV\=P'>&/8Z.&C<
MKS\P/"G<<FMCPAX=N=+\0Z"TFGW4,%OH4T>;EUE:&1[A'"%U55W;<\ #@8[4
M =8OC#P^^K#2UU2$W9E, 7!VF0=4#XVEO]G.:2Z\8^'K+5#IUQJL$=TKK&ZG
M.U&;HK-C:I.1P2#S7!I:ZK9:RD&D66LP.=5\V;3+RV%Q8!#*6::.<J-G!+@!
MLACC%27%O?V?A+Q+X3?0;^ZU+4+B[-O.EN6@G$[L4E:7[J[0PR&((V<=J .W
MU3QGX>T:ZEM=0U2&&XB :2+#,RJ1G<0 <#'?H*DU#Q7H>EQVSW6HQ 7,?FP"
M,&1I$X^<! 25Y'/3FL+1M&N[7Q%XH>YMW<36-G!'.R'$Y2)PV#WY//UKF=-B
MUS3K3P]:W%OJVG0QZ%!$UQINFK-<O*,[H7=D;RP." 0!DGF@#N&\4Q7&N>';
M?39+>ZL-6BN)/M"'/$:J1M_$D'/I6KJVM:=H=LMQJ5VEO&[B--V278]%51RQ
M]@*\Z\&Z-JMI)X.^UZ==PM:2:K]H\Y<F/?)E-Q''S#H1P>U=-XJBN+7Q/X=U
MT65S>65C]ICG2VB,LD9E50L@0<MC:0<9.&^M &HWB[0%T=-6.J0?8GD\E9,G
M)DZ; N-V[@_+C/M0OB_P^VD_VK_:ULMB)1 TSMM"2=-K \J?8XKD;DW<FM:3
MXH7PQ<P6%M>W1D@B@S<R"2)46Y:(#=NRI7'+;2#[51O=)U#6=0OM7CTF[BL[
M[6]+>.":$K(T<+ 23.G50<]\'"Y- '4:I\1-$M?#&K:Q87*7K:='EX/F1MQ'
MR @C(!['&*T;GQCH-E:VD]SJ"H+J,R0H(W9V4=6V %L#UQ7)^,]$U*_U#Q>;
M.QFE%WX<C@A95XEE$DQ* ]VP1Q[BEU34-3NM?M+F.UUK3;";3E"3V.E+)=R2
M;VS#(71C$!P1D '<3F@#KY_%F@V^DVNJ2:G ;.[.+>1"7,Q]%49+'@Y '&#6
M7<_$#1X]4T&UM9X[F'5I)%$Z%B(]JGL!U+#:0<8YS7'^&-/U3P_;^&M4U'2-
M1DBLO[2M[B%83+- TMQO23:O+ J""5!^]Z5L3/=R:WX<UL>&KFSM5U*[,D<$
M&Z4K)$46:5 ,J6/7.2!C/I0!W=CJ-GJ2SM9SK,()GMY2O\,BG#*?<&LW4/&/
MA[2]0:PO=5@AN%V^8IR1%N^[O8#"9[;B*NZ7JD.J"\\F&:$VMT]LXF0*2RX^
M8<\J<@@]Q7!3+>:1I_B[1)M!U"^NM5NKF:UD@MS)#<+,N%#R?=3;]T[L8"\9
MH [2Y\5:'9ZS%I$^HQ)J$K*B6_)8EON]!T/KTYK8KB/!>AWND>(M5-["Q8:=
MIUN+DJ<2M'&X?:>_.,_45V] !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 55LM.M=/-Q]EC\L7$S3R*"2-[8W$#M
MDC)QW)/4FK5% %74-.MM5LVL[R/S+=V4NF2 V"" <=1D#(Z$<'BK5%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5+33+.PN;VXMH=DM[*)K
MAMQ.]PH7/)X^50./2K=% !1110 4444 %%%% !1110 4444 %%%% !1110!'
M%!% K+#$D:LS.0B@ L3DGZDDDU)110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV33;:"2_T&Y$=Y;SR^7S##) ZYP<$D\<=P>E>E5''!#"\CQQ(C2MOD*J 7;
M&3ZG  S["@#CH%OM&_X2;Q?K5O':RW%O&L5G')YI5(E;:"P !=F<\#V'-;/@
MW29M#\%Z-IEQ_K[:TC24>CX^8?@<UL300W"!)HDD4,K@.H(# Y!Y[@@$?2I*
M "BBB@ HHHH *X_X@^&=1\0Z?:?V1)'%>Q2/"SNV/W$T;1R@>^"&'NHKL**
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M15)13@RG>RJBG*D9/\0 S5J?XA:;%964L5AJ4]S=W,EFME'"OG)/&"6C<%@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!4ATK3K:\DO(+"UBNI/OS)"JNWU8#)JW110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGY)8E4I&-P4ELL#CGMFC6?B/I.B>-].\*36]W+?7WE[9(E4QQEV*@,2P/;/
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M4J 6)8GDX^E>(>&[O28-0\3+?^/[_P .RG6[DBUMW"JXR/G.5//4?\!KZ.
M  & *J-I6G.Y9K"U9F.23"I)/Y4 >+?$FYBGC\-77@[4+N^\4-9NL=U;8+SV
M@C8.\GOD$CWW8YQ6;K+^%1X3^&YLYI(]$-XXO'#E9,E5$OF%>0<YSCMTXQ7T
M!%9VL#AXK:&-PNP,B $+Z?2L'6O!MEK&J:)>AQ;#2[IKD111+ME8@ AORH \
M8NII++2OB-'X#FE/A^**V,36SLR(Y*^=Y9_W=V<=OPJQX9AMH+W5QHE_HZV;
M>'9FNK/3)[B97.P[9'+IM60'@@D'GIUKWZWM;>TA\FV@BABY.R- J\^PID%A
M9VJ2);VD$*2??6.,*&^N!S0!\Z:KX-T6#]GNW\0BT:35I4@>2Z>5V('F[0,9
MP %;;T]*]]\/6^C)H5C_ &&L#:<L8%L\;;QM&1PQR3U/YFM$VMN;8VQ@B-N1
MM,10;<>F.F*=##%;Q+%#&D<:#"HB@ #V H X[XBVD5_#X;M)P3#-KD"2*&(W
M*4DRIQV(X/L:Y#4/"NAHGQ&C33H5ATZW6:QB PEK(;4.7B7HC%@"2,=!7L+Q
MI)MWHK;3N7<,X/J/>FF"$^9F)#YHQ)\H^?C'/KQ0!XS?9U+Q-=?V\^A21+I=
MI):#7'8*(S'F1XL<;M^<L/F&%J03V]Y;>&].U/\ LS4YDTE[A;O79GBM6C,F
MU6$;KEY-H'+8P.<\UZ]<6%G=+&MQ:03+&<H)(PP7Z9Z4MQ96MWL^TVT,WEG*
M>9&&VGU&>E 'C&A6]OK&A^$+"Y*3V7_"0WT0CC+",Q*DY5 "<[,8&TG[O!JW
MJ>FZ?8GQ1HT5U;Z7ID6KV+P031,UGN>%6,<B@@+$S=>0,X^E>O"V@#!A#&"&
M+@A1PQZGZ^]#VT$BRJ\,;"7B0,@._MSZT <1\-Y[=9]<T^"PL+4VTT32-I=P
M9+)V=/\ ED" $( &Y1W(/>N7\9RZ9J.K^*C-9Z-YUG$L)FU>=GF!\H,OV:(#
M*@[N"&RS9KU^WMH+2$0VT$<,0Z)&@51^ IKV5I)<K<R6L+W"C"RM&"P'H#UH
M \OT'2K#Q/XDT<ZU FH(?"-E*4N/G1G9WRY!X+<GD],FJ^FSG0_!7A?Q8[R-
M%I-Q<6=V22Q^QO,\?/<["L1'LIKUN.WAB(,<,:$*$!50,*.@^GM6-K_APZ[:
MV]@+PVNF;]UW:Q0J?M*[@VS=_""0<XZ@F@#S^.PA2;PN_BL1KI^KO=ZA>QW)
MQ UW)L:*.3/!VQ[E /&4JE-:V5Y<?V;8'?X9/BFUBM%B<^5@P-YR1D'[F_(P
M..6 KV:>WAN86AN(8Y8FZI(H93^!I%MH$BCC6"-8XB#&H0 (1TP.U 'C_B*T
M;05\;:?H,2V-@JZ;++%!N2.*-W99F 7E047YMO8$UK^#+>"U\<!--NM!C@;3
MV:XM-$#F)_F79(Y^X'^\!W()ZXKTL11AW<1KN< ,V.6 Z9]>M1VUE:V2LMK;
M0P*QRPBC"@GU.* /.?'JR7/CO2;6^_LDZ6;&5X8]8+?9GN-XSD#@N$Q@-V+8
MK&M;"'4-)\,6%Q=0WVFOXEF2);?S!"(1#+^Z4MR\8(8=P5XZ5[#<VMO>0F&Z
M@BGB)SLE0,/R-*((0L:B*,+%_JQM&$XQQZ<4 >,ZIX:T>#0OB+)%8QH=*E+:
M>%R!9G[/')F(?P$N23MQFM&5/"-UXV\5MXJDLRZVMJ\8NW V*8?F>,'H^<<K
MR./6O53;PLLBF&,B7_6 J/GXQSZ\5DV_AFSBU[4M5E5+A[UH6$<D0(A,:;05
M/J: /*7GUY=(>=FN1J__  AL1=AGS@//.X^N_9D^N?>MZ.Q\*MXI\/6?A,6;
MV][;W$>I1V3AEEM3$<--CJ=Y4!FYR3[UZAY:>;YNQ?,V[=^.<>F?2H([&WME
MF^R00VTDN2SQQ $MZGU_&@#S'P\^I:GJ%IH,@:2?PA#,)&<<37'S1VI]_P!U
MN?ZL*Y_PW&&@\,WBWVAP:U+>Q>?+'YKZC-)G]]',!S@C<&W?*O!X&*]>\/:"
MVBQW<MQ>M?:A>S>?=73QA-[!0J@*. H50 /KZUI)96B73726L*W#C#3",!R/
M<]: /$=3B\/R>![RZU1[<>+SJQ6<N_\ I/F"Z&$QU\ORP,#[N,&O2_B-)/%X
M(O&A>:.+S(1=/"2'6W,JB4C'/W-V?;-=$]A9R3F=[2!IBNTR-&"Q'IGKBK!&
M1@]* /'M=BT*SN[Z'P>;1;23P[?MJ26# PX$8\EFV\;R=^#U(S7?^"]#T[1O
M#=F;&V6*2ZMXI;B3DM,Y099B>I-;4-A9VT4D4%I!%')G>D<84-GKD#K4ZJ%4
M*H  & !VH \&O4:>+Q#=:C>:':ZU'J4JI<W'FG4+<B3$(A"\[=NW:%&"#WYK
ML?\ A'=-\0>.?%0UJSBO3#8V819 2J,R2;F4'HW P>HKT)[*TDNDNGM86N$&
M%E:,%U^AZBI1%&'=PBAW #,!RV.F: /&M"FTK4/^$>;QM+;26#>'('LFU%QY
M+39(E;+<&0+Y?/7'([U3TJXTR?P]X>TTVUK=PS7FIS6YUBY,=J46=@#("#YC
MX88!Z<FO4]8\.WE[=0SZ;JQL%CB\HV[VRSP<'(8(<;7&2,CMVXJ?2?#.GZ7H
M5OI+QB\BB9I"]TBN7D9BS.>,9+,3QZT >2:3-;-HHMKV:U/AF/Q5)'>"V++:
MK$8 T:\GB$RD'GY3D=C1J3V%N/'(\)2Q+IP&F+.UJY\F.(R2>=LV=$P3NV],
MM7KNLZ*^HV:QV-Z^G3K*)?,BC#+)@%=LB'AU(/0^@]*@\/\ AO\ L::^N[B\
M-Y>WQ032>4L2!$!"(B#A5&3W)R30!YQ;0W%E<ZT/#-UHD=Q_84[_ &305=D9
M^/*D)^Z),Y _B;/?%3Z?!X0B\5> 9/#SVANI3,TWV=P7D7[+)EI<<E]W=N?O
M>]>KVUE:V2LMK;0P*QRPBC"@GU.*2.PLX96EBM($D9M[.L8!+8QDGUY//O0!
MQ7Q*33)+KPFFLNBZ>VK8F,C;4(\B7 8_W2< YXP3GBL!M+BND\6KX66(V.F3
M6E_IJ6QS"MY&&>5(\<8("*0.,N?>O6)8(9U"S1)(!G =0>HP>OL2*HZCID\N
MCM8Z1>+I+GA)88%;8.^%/&??M0!SW@>Y7Q'=ZIXO4-Y%\RVUCN'(MXLC/_ I
M&D/X"N+\:6FDV^J_$5VAM([^71()(20HD<$2^85[GHN2/09KUK2-+MM$TBTT
MRS4K;6L2Q1@\G &,GU)ZFIY;.VGD\R:WAD?:4W.@)VGJ,GM0!YY>:+;>&O&&
MBCP[:);75WI5^LFSK<.BQ&,R?WFW$\GGFN4\,Q)M\*W<-]H<.K2W<7GR0>:^
MH3L?]='..3_>W;OE4@'CBO<C'&TBN44N@(5B.1GKBHDLK2.Z>ZCM85N'&'E6
M,!V^IZF@#EOB-%)_8=AJ"Q/+!IFJ6U]<QHI9C"C_ #D =< [O^ U/=>.M!>7
M3;?3;JWU>ZOIT2&"SE61E4_>D;'W549))KJ:K6^GV5I*\MM:6\,DGWWCC"EO
MJ0.: /'KT:(WA3Q'?:E)$/&L5[<B%R_^EQS"0_9EB_BVE?+P%X()]ZFUC1;3
M4+;XD:EJ5JDNHV<$<D$C<_9Y5LHVW1_W6W <CG@5ZZUE:O=+=-;0M<(,+,8P
M7 ]CUIY@A82 Q(1+_K,J/GXQSZ\<4 >5W^DV6BZI9MI\ @>_\-7[7CJ3NN&5
M8B'D/\399OF//-5M"7P_#!X$G\,O ^LS.GVUH&W320>2WG>?CDX;;C=T. *]
M5U#3H=0L+BU8*AE@> 2!02@88./\]JBT;1;31=.MK:".,R0V\<#3B,*\@10H
M+$?2@#Q/[7831:!K5G!H]I<7&M0.LAN&FU-@TX#^:V!M&"05.0 0/2M75=#T
MZ;PCX_UN6V5]3M-2NWM;HD[[<IM9?+/\/.3QUSS7KZZ=8K)+(MG;AY2#(PB7
M+D'()..>:E-O"8Y(S#&4D)+KM&&)ZY'>@#S'Q1)>:-KNH:78[U;Q=!$ENZCB
M*Y!6*9O;]TRO_P!LS75^+H+K2OAOJ=OH2R1S6U@8[<0_?157'R^X4''O5Q_#
M[W'BJ'6;N_::&T1A96?E*JP,RA7<MU8D @9Z!C6W0!Y4(O#5IK_AO_A"WM=\
M\4_VW[&X/F6WDL=TV.IW[,%N<DCUK>^%>B:=IW@72+ZVME6\O;&%[F<Y+R87
M(R3V&< =A@5V$%E:6S2-;VL,32G,ACC"ES[XZU*D:11K'&BHBC"JHP /84 .
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L?6/$5OI%U;V8M+V^O+A6D2VLX@[[%P&8DD*!D@<GG/%;%<9XMTS6KW7K
M*2*WO;W15MW62TL=0^R/YVX8=V#*63;D8!X]#0!:?Q]HZ:39ZAY=\1=W;6*6
MZVY,RW"ALQLG4'*$>F<=N:=!X[TN2-C/;WUI+%>Q64\-S#M>!Y<>66P2-K9&
M&!/6N:T/P=K-E::-%/9PQ&T\13W\B)<>8J0O'*%PQY;!<#GGO6EJWAS[1)XV
M?4Y8K6QU.& 6]R\@&QHXC\_MM8 _A0!U<.KVMQK=WI,6]KBTBCEF(7Y5WEMJ
MY_O?*3CTQZU@ZSJ>K:CXLC\-:+>)8>5:"\O+TQ"5T5F*HB*WR[B58DD' '2F
M_#B"\D\,_P!MZFH&I:T_VV?C[JE0L:_0(J_F:=K6E:O8^*H_$VAVT-Z[V@L[
MRQDE\HR(&+(Z.1@,"S#!X(/44 /T^76]&O[M=3U:/5]*2U:<7+1QQW$3J>4*
MI@,",D$ 8(P>M,M_B'I5SIB:@EEJHAG>..S5K0AKQG!($0S\V I))P !G..:
MYZU\'7MYKT^L1^&-/\/J+"Z@\J.5'FNI90,,Y0;0!@]R>36I)X=U>TT'P;<V
MEM'/J.@1HLMFTH42@P&)PK=-PSD9X..O- &I'XYTHVT\D\-Y:SV]S!;3VD\.
MV6-IF"QDC."I)Z@D<'TJUJWBO3=&GOH;OSM]E8'49=B9_=!BO'/)RIXKD=4\
M,>(-<.L:T]C%:WLSV/V2P>=266VF\T[W7*AF)(&,@8&35/Q;::Y=V/BO7M1T
MM=/M7\.26D<1N%E?<&9CNV\#[W8GIUYP #M=+\86&IZC!9?9;^TDNHFFM&NX
M/+6Y08)*'/8$'#8.#G%,\6ZU?:?_ &7INE>4-3U:Z^S0R3+N2%0I=Y"N1NPJ
MG SR2*S;*TUW7==T"^U+3(].M])220L+A9/M$KQ^6-@7D( S'YL'H,5I^+=%
MOM133=1TGRCJ>E77VF!)F*I*"I1XRPSMW*QP<<$"@".ST_Q5IFL6AEUD:SIT
MVY;H7$$<,D!QE70H &&>"IR><YIB^/\ 2&F5A!?C3WN/LRZF;?\ T4R;MN-V
M<XW?+NQMSWI+>X\6ZOK%B9M.&A:=;L9+G?<1SR71VD"-0N0JY.220>!C%<XG
MAKQ'_P (9#X&;38A:1R+$=6^T+L-NL@?<(_O^9@8QC&><T ;]Y\1]&L9;WS;
M;43;6%S]FO+M+8F&W?('S-GIR.@.,C.,U8A\<Z<ZZG]HM-1LY-/LS?/'=6^Q
MI(!GYT&>?ND8.#GJ!6+?>%-5G\(^+=/C@0W&I:H]S;KY@PT9:,@D]N%/!I_C
M?2KOS?$>K[!]C_X1>XM=^X9\S+-C'7IWH VM,\;:=J5Y:6_V:_M!>QM+9S74
M'EI<JHW'8<Y^[SA@"1R*BM/'FFW=U8I]BU.&UOY?)M+Z:VVPS.02H!SN&<'&
M0,UBV=EXC\0IX;DGTZ'38]+B-PMP9UD$\I@:--BCD)\Y8[L'C&.]9%MX3\17
M$_AZ>]TR[:_L;^&>_O;S5C,)0N0QACW%57G.,*0!@ T =6WQ&TA7D;[)J?V2
M&[:RGO?LW[F&42>7AFSTW8Y (Y&<5I2>+=+ATW6;Z5I4CTB5X;I&3Y]R@$;1
MWW!EV^N17-S^%=6?X>ZUI"P)]LNM3FN8D\P8*-=>8#GH/EYJOKFDF_\ BE:6
M-I-&]E?)'>ZK"IR0;5OW9(_VF>,>XCH [C5M9MM%T675;U)5MH55I JY9 2!
MDC/;.3[ U6;Q7I*>(;O1'G*W=I9_;9LCY5CSSSZC()'H16AJ=A#JNE7>G7 S
M!=0O#(/]E@0?YUY2WP_\3W6A6<ERT(UJZN7MM2<2C_CS>)(6(/<[84;'J30!
MT$'Q D;Q+=(ECJ=Y92:9:7MK;6UH&D0/YA=FY&. G!.?0=:W)?&^E?8],GLD
MN]0DU.(S6MO:0[I'C &6() 4#(!W$<G%.TW1KBS\;ZMJ/E(EC/8VD$!4CK&9
M=PQV #+7+Z%X:U_PQ!X=U"+3EO;BUTR33[RS2=%=0T@D5T9CM/(P02.H]* .
MXT37+/7[%KJS,B^7(T,T4R%)(9%^\CJ>A']17*?\)Z^F>(?%%M?VNH7=KIL\
M9#6EJ'6VA,".6<\9^8N>YP.F*VO".DW]@FJWVIQQPW>J7S7;6\;[Q"NQ452W
M0G" DCC)JE_PC^H8\<_NE_XFQ_T3YQ\_^BI'SZ?,".: +M[XST^VNDMK2UO]
M4F-NMTZ6$'F>7$WW68D@<X.!R3CI5*/Q=%=^)M,>UOHSH=SH]S?.Y4#E)(AN
M)(R,!F!'Y]*S])TGQ!X4O&NK72%U-;W3[2*6-+E(V@FACV$$MP4(QR,D$'@Y
MJE9_#W4UMK>QNI(@DNBZC:7,\3?+'-<S+)A0>2HRW/M[T :,GCQK_7_#-M86
MNH6MKJ-R^9+JUV+<PB%V!0G)'(0\[3@],5KZ7XWT_5KJTC@L]12VO2PM+R2W
MQ#/@$_*P)(R 2-P&<<5B16/BF_U#PK'>:+!:0Z/,6N;@72.)#Y#QAHU'.W+<
M@X/(XX)JEHGA?7+'7M.EM-*;1/+N"^HO;:@6L;E,-D1P%B5+$@C(7;SR: .]
MUG6+70[#[7="5PTBQ1QPQEWD=CA551U)-5=%\2VVM7EW8_9+VRO;14>6VO(@
MC['SM88)!!VL.#VJMXTL]9O='@CT9IMRW4;745O<""66 9W(DG&UCQSD< C(
MS6/X.\.W^E^+=4U*737LK*[LX8XEFOC<R[D9R?,9F8Y.X="1C'.: +>N>*;G
M1O'5AIP@NKNUN-.FE%K:0!Y'E62, YXP I;J0/QQ4UOXLL]4N]!EM+R>WBO)
MKF)[:6V 9GB1MR2$G,94J3QG.,=#5J;2KM_B%9ZN$7['%I<ULS[AD2-+&P&.
MO16YKF+?P=J8U&T>YB5+9-6U6YE99 2L-PL@0@>IW#CM0!LQ?$3299;+%IJ:
MVM_<I:V=XUMB&X=FP-K9R!U.2!D D9K,TGXB+ NJ?VO!?R0VNL7%F][%:_N+
M=!,4C#L,9XVY(!ZC-<ZM]J3:#X'T<0V$UG!J=E'#?6]T'^U1Q'ADCQN4[5RV
M>F".<UT5UX5U:7P#XETE($^V7^I7-Q OF##(\^]23T'RT =W>7=O864]Y=2K
M%;P1M++(W1549)/X"N+'CB2_\5^&[&VM;^RM;XSR/]MM@@GC6$LK*><8.#@X
M/(R*Z3Q/HY\0>%M4TA91$UY;/"LAZ*2."?;-<M+I_B7Q!K6@G4=&CT^UL4N$
MNI5NDD+-) T8,8'.W)[X/(XXH U[/QYI5[<VJI;W\=G>2^1:W\MOMMYWYP%;
M.><'!( /8FH+[XC:18+=3O:ZE)86TQMY+Z*VW0>:&VE0V<GYOESC;GC-<OHO
M@:_M$T;3+GP^";">(S:A+JTSV[K$<AXX1)D.<# *A5/J.*S=9GO]/^'FI:!9
MQV-W8C4'@BO5NAN;?<[O*,6-WFAF*XZ<9SVH ]&/C731K]YI M[YI+%L7=P(
M/W%N/+$@9WS@ J?S!]J;IOC;3M2O+.#[)J%K'?9^Q7%U;^7'<X&[Y3G()4$@
M, 2!Q5/_ (1:ZNQXXMK@B"+7&VV\H()VFV2(D@>C \5AZ#X1OH]1T5;KP[]F
M.GN))[N?5YKB-F52H,$?F<$D_P 8  R,&@#I1X]TIK@8@O\ [ ;C[*-3\C_1
MO-W;,;LYQN^7=C;GO6[J>I6FCZ;<:C?S"&UMT+R2$9P![#DGV'6O+;+X?7MG
M8Q:%)H)NECN?^0C-JTPMFA\S=N,"R [\<;0,;N<UZ#XPT6?Q#X5O=-M9$CN9
M-CQ&3[N]'5U#8[$J ?K0!23QQ:N987TO5;6\^S-<V]M=6^QKE%QG9S@D9&5)
M! /2H_ASJ.IZSX1MM5U6ZN9[B["RXF@CB5 5!Q&$'*<\%LFJSV.O>(O$.FZA
M?Z2NEPZ9!<81[E)6GEE39@;> @&3DX)..!6WX/TVYT?P9HNFWB!+FULXH95#
M @,J@$9'6@##T;Q^LVFZQ?:O:7-LEIJ3V<""#YI3NVI&J@DM)GJ/4^G33B\;
MZ4+;4)+^.[TR33XA/<07L6V01G(5E"DA@2"/E)YXZURE_P"#=:O=/U2S:Q4B
M'7SJ]J1=^6+M&9BT>Y3NC8 GGUQVIK^!KW5+/5WAT==)FDMX8[7[;J$EU-(\
M<JRX<[V58R448&3R3[4 :?B3Q\8?#&L/9VU_I>JVUG]K@6^M@I=-P4NHR0<$
M@$'D9'%;NF^,;'4=2:P:SU"SG-NUU"+RW\L3Q @%DY[9'!P>1Q6#XCMO%OBO
MP]JU@='AT^&6R,:02W"2233%E.0RG:J  ]>22.!BMO5='O+KQGI>I11J;:WL
M+N"1BP!#R&+:,?\  &H K:9\0])U6333%::E%:ZDP2TO)[;9#)(5)V9SG/![
M8.#@FDL_&-I;Z3;22S7FJ7=W>7,%O#!:A99#'(P8!0<!4 QN)&< GDU0M?"^
MJ1>#O!.G-"@N=*NK66[7S!A%1&#8/?DCI533_#.NZ(VD:I#8I=W%E<ZBLMF)
MU5GAN)RZLC'Y=PVKP2.">>* .A'CK37LX)(;74)KJ:>2V%@EO^_61!EU8$@#
M P<DXY&#S5&\\9F]CT=],\^V=]=CTZ^@N80LB?(S,A!SC^$Y!Z'K5/5K/QCJ
MAL+B\M)38F>=KC3--O\ [/,$(41!I0R[L$.6"L!\PZXK/TCP9K5J4#V$=N@\
M31ZF$%WYVV#R-ARS'+,#P?4],B@#T/6-7L]#TR74+Z1D@CP,*I9F9B JJHY+
M$D  >M9$?C6S:*^\[3M3MKJRM_M3V<UN!,\.<;T )##KG!R.F,XI/'?A^X\1
M^'5MK4*UQ;W,-U'$TK1B4QL"4+KRN1D CH<&L#2]$U73KV^UC3_#'V:Z2Q-O
M:QWNJO<2R2,P)RQD9%C&T$_Q'';H0#H6\<Z(8KV:WEDNH++3_P"T9YH$W(D1
M4LHSG[Y4$A?3TI=+\9Z?J=_:VGV6_M3>1M+9R74'EI<J!DE#G.<<X8 XYQ7%
M3>%=0\%^!O%NG QW>F7>D7%T]PH5&CNO*(D7:,91L K_ '<$>E;-II^N>);C
MP[)J6F)IUIIL32O*MPKFX=H3&!&!RJX<D[L'H,=Z ->U\>Z5=W%N$@OULKJ?
M[/;ZB\&+>:0G "MG/)& 2 ">AK/U/Q_936&KK9?VG:BP=XIM1%B)(HI$D",@
MW$!F.>GH<^U<[H_@._L[?2M(N- \S[%/'YNHRZM,UN\<;9#I ) 0YP,*5"@^
MHK9N?"FJR> /$>DI GVR^U*XN(5\P89'N-ZDGH/EH W=2\:Z?IM]=VPM-0O!
M8J&O9;2W\Q+8$;OG.<D[><*"0.U-O?'&FVVH+8VMKJ&I7+VD=ZB6$'F;H7+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\X#]N14E_P""%N;G43::UJ&GVFJ-NOK6W\O;*Q4*S*64LA8  E3S['FNKHH
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M.:065UMB+10OC="1MVNG /(SGO6[H.@0:#!<A;B>ZNKN8W%U=7!&^:0@#)P
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MV_B8^Y.3^-4-9\*1ZCJB:M8ZE>:5JBQ^2US:%3YJ Y"NC@JP!)QQD9ZUT-%
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M?>O;I8HYXGBFC22-QAD<9##T(-5XM+T^"(10V%K'&%9 B0J %;[PP!T/<=Z
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MQ%%$+>(1Q$&- @PA'0@=JY*[\"W.H7+Q7NN-/IKW F:)[53<,H<2"(SYR4#
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M*Q;3PUJD?PY\(Z6]B1=V6H6<US#N7Y%28,Y/.#@<\5K2:-?MKWC2Y%L?+O\
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M<7BB6^TK4K9;1+VXL5LF@?RMH=@DGF,-P&<97!Q727UA=2_#VYTY(2UV^E-
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MQ"GA[PSX<;P_=(^D:I;R7-VTD?DM$DI.Z/#;FR"#C Q@]\9M2:)K+1:EI_\
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M!U# ,,$9'<4^@ HK$MO%%K<ZZ^D+:WJ3K-+"9'B CS&D;DYST(E7''.#6W0
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M7?LAN9;9MZX.^-RC?AD&K] !161K_B*V\/I:"6VN[N>\F\FWMK2,/)(VTL<
MD# "DDDUK*=R@X(R,X/44 +1618^)M*U+Q!?:+9W(GN[&-7N-G*IN) 4G^]Q
MR.U9L7C[2);F("*^%E+<?98M1-L1;/+NV@!_0M\H;&TGO0!U-%%% !1110 4
M4V21(8GED;:B*68^@'6LFU\3:;>W6E06[R2?VI:->VK[,*T2[.3GD']XO&/6
M@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ-&F!@;5(P./2@#RVWNGNM+T;1KF1=8DEO;S[+!'J;I:M%%@;)9F3?+L+87
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MW\"/'=1:+!(DBR,"K.L^XCGV'T[5JVVEP:GXS\37EY)<2/IUM:/:)Y[JD3F
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M<+FK#>._#JZ9:Z@U\X@NIGMXE^SR>895SNC*;=P;Y2,$9)X'45EVVB7T>H>
MG-H0FFV4L=R>/W+&!% _,$<5G6?AW5$UVPGDL7$,?B:]O68D8$+Q2!'Z]"2/
M>@#<_P"%D>&/+\PWEPJH_ES[K*8?9FSMQ-\G[KG^]BK^J^,-%T:]>TNYYVFC
MC$LRV]K+-Y"'HTA12$'!ZXKE=5\/:I/X7^(5M%8NT^IW3O:*",S*8(E!'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUE2XB4Y7<A(PP))!![GK5K3/!%MIEYI-TEY-+-8O=2RR2@%KF6?!=VQ@#D<
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M8W!LYP1&!CWS6_=:YI]F+_S)RSV$2S7,<2,[HK9V_*H)).T\#GBM '(!'0T
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MG3V2,8.V;9E@>Q&S]:SK/P3>1WNAW-YKQG71G)MH8K1(8V4QM&=P!)+8/4$
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M/:AI#RM"E[;O 9%&2H88SC\:T:* .3\3>#KGQ!)I)BUEK2/33O6)K99DDDP
MKLK'!*\X]"<UMZ-9:E96SQZGJQU*5GRLIMUAVK@<87@]SGWK1HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?$-
MM+JOQ#TC2I-0OH+"33;F::&UN7A\TK)$%R5((QNZ@@]NA(KMJKM8VKW\=\T"
M&ZCC:))2/F5&()4'T)4?E0!Y/IZWUOX=T;7&UK59KU=?73\RW;E&M_M1@V,F
M=K949+$%L]ZGN9;BY\&>(O%LVMW]OK%A<W?DHEVZQ6YAD98X3#G8VX*N=P).
M_P"E>E#1-,6TCM!8PBWCN/M*1[>%EW[]X]]QW?6JMQX2\/W6J_VI/I%I)>[@
MYE:,$EAT8CH2.Q/(H X6>VO-;N?&UW=ZIJUL^GQQ26D%O>R1+;R?9$<D!2,_
M-V.1UXY--@B_M/Q7IVJ7,UR;J;PB;E]MPZHSDH#\@.W'S$XQC.#C(!KTK^R[
M'=>M]EBS??\ 'T=O^N^79\WK\H ^E5IO#>C3R6,DNFV[/8QF*U8IS$F,;1[8
M[4 ><>'K*70_#_P[U*VU+46EOWM[:XCENG:%HGMG8*(R=J[=JX( /'.:71;F
M^T[5])O=4N-1N([V^,,>KV6J&XM+PN6"(\#'$8[?(O!7K7IHT?3EMK&V%G"(
M;!E:U3;Q"54JI7TPI(_&J5MX2\/VFJ?VG;Z1:1WF]I!*L?W6/5@.@)R<D<\T
M 4O&MU<6L>@FWGEA\W6K6*3RW*[T+'*G'4'TKA+J/4'\.:EKJZ[JT=_%XC>T
MMV6[?9%";P1%/+)VL,,?O XX'0 5ZU=6-K?"$74"2B&59H]XSM=?NL/<5 =$
MTPV;VAL83;R3_:7CV\&7?OW_ %W?-]: /,_$CWWAQ?%^GZ;JNI+''IMG=P/-
M=R3/#*\SHQ5F)(!"C(SBM3_A'<>/VT(ZUKC:=+I7VR6,ZE+N>82[-V_=N48/
M*J0I(''%=Q=Z)IE\]P]U8PS-<Q)#,77.]%8LJGV!)/XU/]AM?[0^W^0GVORO
M)\['S;,YVY],\T >06&KZ[K</A;2Y3>WT4FG3SR+'J!M)+IXYO+&Z489MJX)
M (R6R<XJ]8W>K7CZ/X?U/4IHK*?5KJWDD@O]\Q2.+>D#SI@[MQ8'D,0@YY->
M@W/A70;S3K?3Y]*MGM;=BT$>S'E$Y)*D<C.3TI[^&=#DT5-';2K7^SD(9+<1
M@*K9SN'H<\YZT >9S"31%\91Z?J5VYCUG2XQ,UPS2*K- &0OG)P"5Y)..#GF
MF^+]0NIK'Q1K&G2:S(VFS21QWYU/[+!;21@ QI"K?O,-P=R_,3C->EV_A70;
M2SEM+?2;6.WED262-8\!W0@JQ]2" <^HJ*Y\&>&[R\GN[G1;.6:XR92\8(<D
M8)(Z9QQG&: //=:N+G2=9\9:_82W']HQ:%9SQ_OW**SF4,VPG:0H&X C Y/<
MYTM#35]-\3Z/'^_@M+V&87"WNM_;#=8CW"2-3T(.,[<##=.E=VWA[2'OXK]]
M.MVNHH#;)*4RPBP1L]QR>#ZFH=+\*:#HER]QINE6MM,Z["\:<A>NT>@]A@4
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M/2+'5+^.P#:9B>>Y:9[-)Y6CF=7<DCA0>3P3FO2CHFF%V<V,)9KH7A.WK.
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M#.B7&BQZ/+I5J=.B(,=N(P$0CD%0.AY/(YY--MO"N@V<'D6VDVL41DCF*I&
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M>*TMHK:WC6.&)!'&BC 50, #\* )**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HKE%FEU?X@WUNLA2'1K*/RQC(^T3[OG([[44
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M[T =S17G5U\2I9%T8VL>FV"ZEIR7R2ZM<M%&S,<>2K!<;AW)[$<&NVM]1/\
M8,>IWT/V4BW\^:(2"01_+E@&7AL>HZT 7Z*X:V\9:TMII.LZCI5I#HNJS111
MB.=FG@$Q B9P5VD$E<@'C=WQ4'@"UO;CQ'XHU;4HK9KH:A):":.:1F556,[
M&X"#@COG- 'H%%>1^+-2UW9\1HY9T^QVMK;^0(YGW1Y&5VC&!D9+>^.M=0?%
MVJ:/J;6_B2PM+>!].GU"-[.9I"BP[2Z/N49.''(XX- ':45YSHWQ-%[J6DQ7
M4NAM%JL@BC@L=0$UQ;,REE$JXYSC!(Z$CK7HU !1110 4444 %%%% !1110
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M]V/E('4\U*W@V]U6VU&#Q!JZ7,5W:&U6&RMOLT<8)SYF"SDOD#G.!CI77T4
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M!73*G@Y((((R>N:73O&VB:GJ,5A')=6]S."8$O+.6W\X 9.PR* W'.!S714
M<;_P@9U&VU=O$&J/?W^IVZVS3PQ>2EO&I+*L29;&&.[))R:D7PEJE]?V]WKV
MN17K64,L=JL%GY(#R)L,C_.VYMI(P-HY/%==10!S">$ FC>%=.^W9_L"6&3S
M/*_U_EPM%C&?ESNSWZ8J)?!(6PAM?[0_U>N'5]WD]<S-)Y>-W^UC=^E=939)
M(X8GEE=4C12S.QP% ZDGL* .%NOA_J,FF2Z':^(%M]#:Z^TQVYL]TJ?O?-\O
MS-X!3=G^'/;.*N7O@_44U/4[G1=9@L8M4827$<UD)VCDVA#)$V]=I(4<$,,C
M/M5BW^(7ARYN8(DNYUBN'$<%U+:2I;RN>@65E"'/;GGM744 86F>&QINO2ZF
M+R2;S+"WLMLBY8^47.\MGDG?SP.GO63I_@:XTO\ X1IK35E$FC+/$Y>VR+B*
M5E9@!N^0_*,'GZ5V=% '!K\/)[0:3+9:G:M<Z<UUM^VV/G1,)Y3(2$#@JR\
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M,CKUK)N/!NH:A;23:AK\CZL+N*\MIXH2L%J\8*J$A+'Y2&8-\V6SU&!7844
M<1>^ [O68-4EUC6(YM1OK>.U26"U\N*"))!)A4+DDENI+>GI6IKWA4:WJ3WG
MVSR=VEW.G;?+W8\[;\^<CIMZ=\]171T4 <^WA<--X9D-W_R! PQY?^NS 8O7
MY?O9[^E9-AX'U'38K?3+;7ECT2WG$D<268%SL#;A$9MV-G;.W..,UVU% ''2
M^#M3BEU"VTWQ UCI6H7374T26Y^T1LYS((I0XV!CD\J2,G%-U#P+/>SZXJZL
ML=EJMQ;71A-MN>.6)HCG?N&01$!C'!.<G&#T^H:I9Z5%#)>R^4D\\=M&=I;,
MCL%4<#N2.>E26U]:WCW"VTZ2FWE,,VPYV. "5/OAA^= '*W?@S4MVKVNEZZM
MGIFKRO+=0M:>9+&SC$AB?< N[KRK8))%:6D>%8-&U#49[:;]Q=6MM:QP[/\
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MNW]>G[G-=\NB:8EG8VBV<0M[!D>UCQQ$R@A2/H"165IF@7@\7W_B+539FX:
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M0N;XJ-*BU0FX9_N+(8G$+-Z .1R>^*ZC^R;#_0/]%C_XE_\ QZ\?ZGY"G'_
M21^-3W=I;7]K):WEO%<6\J[9(I4#*P]"#P: .-\8ZKJ&FZKI+W.G:-=:7)J=
MK%;-+._VA9'8+O5=NW*[F/7I7.W%SJEIX?\ %WB1=:U%KNTU*YL[9'G)@MXO
M.5=WE]"5#,P)Z8 Z"NZTSP-X8T:]6\L-%M8KE.$EVEC'_N[L[?PQ6I%I5A!;
MW5O':1"&ZD>2>,KE9&?[Y8'KGO0!P>KQW'A76+"UTW6-3N8]1L;SSX[N\><@
MQP[UF0L24.[ ^7 ^8<<5-%K%TVF?#4_;Y3+?M$;C]Z<SC[([-N_O?-M)SWQ7
M5:3X5T+0YI)M-TR""5T\LN 2=G]T$YPOL.*AL?!7AK3+N.ZLM&M89XI/,B=5
MYC."/E_NC#'@8'- 'GRS7T'@2^\5)K^I3:K:ZE,D,37;&+"W100&/.UMPQU&
MX;A@@ 5V/Q/CFD^&^M+"KG$2M*$ZF(.ID'_? :F^'/A_I6E(MQ?65I<:DMW/
M<K.%)&7E=T.#P64,!G&1C@UUY 92K $'@@]Z ,#7=0\.0^$3=:D+>XT5TCV(
MJ"1902-@11][G& *YSR9?$6J>*YK[6]1T\Z5.(+6.VNFA6W00HXE900'W%F/
MSY&!BNBM/ OA:PU%+^UT.TBN(W+QD)\L;>JK]U3[@"I]4\):!K5X+O4=*M[B
M?:$9V'WU'16Q]X>QR* ."T6;4_&>I6YU+5=2M$?PU:7CPV5RT ,[O*/,^4@C
M@9QT/&<X%'AZ?4DM? 6MS:SJ-S=:Q)Y5ZDUP3#(I@D<8C^ZI!1>0 3SG.:]-
M33;*.]>\2VC6X>%;=I ,$QJ257Z L?SJ&+0],@M]/MX[*)8M.8-:(!Q"0I7*
M_@Q'XT >86LU];^ 8O%::_J5QJR:CY:1/=LT3K]J\OR#%G:<J>N-V><X%1^+
MM4OGL/$VM:9/KLATZ>1([X:@+:VMWCP#&L(;][AN"67YB<9KL_"_P_TK1+6V
MEN[*TGU.&:6;[2JG&YI&96P>-P5@-V,\=:T;GP3X:O;JYN;G1K662Y):8,I*
MNQ&"Q7INQ_%C/O0!R\EI=>(?$_B>.XUG5;>"SM+62WBL[MX521XF);Y3SRHX
M/'7(-4K?Q??Z'I>A>(]4N9KBUU701OC+';]MCC\Q<#H#(I<<=2HKTB#2K&VE
MN)8;9$DN$2.9AU=4!"@_0$BL#5?"CZA<:)IT45C#X=TR2*X$.UC*9(\[$7^$
M)]TD]>".] &GH&GWEMX5L[/5+J>>^:#_ $F8R'?YC<MANHP20,= !BO,_"L$
MO]D^$M#74M0MK+4YK^:X>.[=7=HG(6)7SE <EB%()VGU->R5A-X,\.-9SVAT
MBV\B:?[2Z $8E_OK_=/N,4 9WA">XAUSQ'HC7MQ>V>G3PBWEN)#)(GF1AFC+
MGEMI]<G#8)KE/$^IZ_%>ZUX5TW4;E-3GN_M]E+YAW+;>2TA4'KM\V(ICT?%>
MF:7I.GZ+9_9--M(K:#<7*QC&YCU8GJ2?4\TYM+L7U9-5:UB-^D)@6<CYA&3D
MKGTS0!Y/JVJS^,=*?6+>]GAL+C5]*M++8_$9#HTDB@\;M\FW./\ EG6KJSWG
MAR?QAIMEJNHR01^&SJ$+7-T\LD,W[Y24=B6'W%.,\$<5W</AW1[;38-.ATZ"
M.SMYA/%"JX5) ^\,/?=S4MUHVG7LMS+<V<<KW5M]DF9A]^'D[#[?,WYT <%8
M)/XEN==?4M>U*P&EPP);_9[MHA"#;K(9W ($F69OO9&%QZTVQTA/$?C?79#K
M6H"+^RM/=9K&=K;SF992LAVD'L2%SCYN0<"NRU#PAX>U6:*:^TFWFDCC$0+
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MZ_JL#73RP6WB71TB0OE8L^46 ';G)/O6]\/=/CM;_P 62)-=.3K4L>);AW&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44CDJC,%+$#(4=3[5
MQ/A[Q!X@N/$/B:/6;6*%;*UMI[:QA<.8PPE)#.!\SG8,XX';N2 =O17F=AXD
MUJTT?PSXCOM=CNX=<NH()+ 0QK'$)N@B8#?N0XSN+9P>E>F4 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW)$5VV[QDE2R%AC:SA<X+'G.34VH>$=2GUB\E%E;3W<][%/;:V\H$UI$NS*
M8R,;7 53M;><XR:]"HH IV%W/=_:O.M&M_)N&BC);/FJ,8<<#KD_EU-<UH7A
MJ_T;5]1NG6*>WM8I(M'A#[<)(YE=6./E^;8@ZX6,5V-% %&^;5#H[/I\=LNH
M[%98IV)CSD%E+#GD9 ;'!P<'I6+X6T:YT_4]5O6L(-+M+ORO+T^!PRJZ[M\I
MV@*&;<HX_N GDUU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>guyaragreement021.jpg
<TEXT>
begin 644 guyaragreement021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%(^3+'[@P,"F>*_'VH>'I]2?S=!A2R^:.QN+HM=7:!0Q90A^3/(&0>F3C-
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M'YOF8\X%;E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2?V1I=K9F7'F-#& SXZ9/4TRV\*Z!9ZJVJ6VCV45\26\](0&!/4CT)[D=:
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M8HT?E9V8P?3.><U'XCU.Z.D:GXETYM4(AU K#J=QJIA1=LP0QQVZDJR<%<,
M3R37KJZ-IB65M9+8VXM;:198(@@VQNIW*P'8@\U0E\%^&9[JXN9M"L))K@DR
MLT"G<3U./4]SU- &)X6T^W@^(_C2X1[@R>=;C#W$C+AX58_*6QUZ<<#@8'%9
M^M:?;_\ "R=<NB]QYH\->8!]HDVYW2H?DW;<8 XQC//4YKNTT?38]7?5DLH%
MU%XO)>Y" .R<?*3W' _*F7>AZ5?ZA#?W>GV\UW#&T4<SQ@NJ,"&7/H03Q[F@
M#SC0[!]"TWX>7]I?:@\VH"*"Z26[=XY$:U=POED[5VE5Q@#IWK)TB]\0W6A:
M;XE9FAO[B\3S+R?6F$3YEVM ;;&T#&5"CD$ YKV$:58"*RB%G#Y=B0;5=@Q"
M0I4;?3"DCZ&J:^%/#Z:O_:RZ/9"_WF3SQ"-V\_Q?[WOUH Q?BL&/PUU<*P5O
MW."1G!\Y*O:;9>)8=0ADO_$^GWEJ"=\$6F^4S\'&&\TXYP>AZ5MW^GV>JV,M
ME?VT5S:R@"2&5=RL <\CZ@5C6O@+PE8W<5W:^'=-AN(7#QRQVZAD8<@@]C0!
MQ=AJ%RWQ#&@/K-XWA^&^EDMK@N^9KH*&-F9<Y*IEFP>N-O.W%9$=]XBO=$O/
M$>7@U"._D47DVM-'#!MF*"!K?&W;@!<'DYSGD5ZXN@Z2MA#8KIUL+6"4311"
M,;4D#;@X]&R2<]<FH)/"GA^;5QJLFCV37X<2>>81NWCHWNP]>M ''&*+6IO%
MNI:QKE_ITNE7C0P/!=O&ME$D:,LGE@X?=DD[@<]*F76)4A^(DDFHR[;6)'@9
MI"OE V:,"H_@RV3QCG/>NMO_  OH.J:@E_?:19W%VF,2R1 MQR,^N.V>E)?^
M%= U34%O[_1[*YNU4+YLL(9B!TSZX[9Z4 >>:=;A_$G]IM<W9O#X.@N-YNY.
M7(=2<;L'H#C&-WS=3FDB\2:CX9T?3=0EN;B[_MKP];_9$FD+YU!45549/'F>
M8I/J4)KTB3P[HTUQ:W$FF6K36D)@MW,8S'&5*E ?3!(Q[U*^C::]O96[V-NT
M-BR/:H8P1"R#"E?0@<"@#S6ZM=9/B>V\,R?;-3AT_1X9=O\ :\EHT\K,P>9G
M7YGP5 QG"Y]Z[/P'<WUUX1MGU"ZBNYDDEC$\<PFWHKL%RX #,  ">Y!K2U?P
M[H^O"(:KIMM=F+/EF5 2N>N#U /<=ZO6UK;V5K';6L$<$$2A8XHU"JH'0 #H
M* /*="GN]-U71KW4IKZZCOKTPQ:Q8ZJ9[>]+[]J26[GY!_N#Y2O6J<E@UEX1
M\4>([>_U"+4+37KM[?R[IUC0"ZP5\L':P;)SN!SGV%>GVWA3P_9ZH=3MM'LH
MKTLS^<D0#!CU(]">Y'6K3:-ICV-Q9-8VYM;B1I9HB@VR.S;F8CN2W/UH \Q\
M774M[_PE6H60U6;^S \8O&U4V<-G(D0;;'&ARYR0267YB<9Q5+7;B2\TSQ9<
MS-NEFT'29';U8O(2:]0NO"7AZ^U"2_NM&LIKJ0#?))""7P, GU..,GFISX>T
M=H)83IML8I88X)%,8PT<>=BGU"Y.!VH R/B/<W-IX U6>SN9;:X5$V31-M9"
M9%&0:PKN*Y\)^*IH=*NK^Y$V@W=V8+JZDN!)<1-'L8;R<$[B"!@>U=_>65MJ
M%I):WD$<]O)C?'(N5;!R,CZ@4-96SWT=ZT$9NHXVB28K\RHQ!*@^A*C\A0!Y
MG"G]FZ1X/UNRUF_NK_5KJVBNC)>O(ETDH_>_NR=J[1EAM V[:O\ @#1K)?#L
MN;R]A*:Y<L/].D^=H[B0*AW,<@CJ/XNIR:ZVR\*Z!INI-J%EH]E;WC;OWT<(
M##/7'IGOCK3D\,Z''<2SII5HLLMRMW(PB +3+DK(?]H$GGWH U:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **:[K'&SNP5%!+$] *Y/3?%RIX;M=;U,S-
M_:TY.GVD$)>0QL"8U  R247>2>F3S@"@#KJ*Y>3Q*^L:%JLNB+/!JFG<O:7D
M!1]P <(P/9UX##UR.E;NE:E!K&D6>IVI)@NX4GCSUVL 1GWYH MT444 %%%%
M !117%>-_$&I6&L:%HVF/<VSZA,_F74-GYY551CM4'C.0,^@YH [6BN7_P"$
M]T47.P_;#:"X^RG4/LS?9O-W;=OF8Q][Y<_=SQFK5KXNTZ]\13Z);0WLMS;R
M-%/(MLQAA8+N 9^@R.G_ .J@#>HKG?&_B*;POX9EU*WMFGF$T42J(RX&]PI)
MQ[$X]\#O3+CQWHEGH=_J]W)/;V]A,L%RDL)61'8(0-O7HZG\_2@#I:*Q=0\5
MZ1IDUY'=7)7[';QW$S*A8!9&*H!CJS%3A1R:Q=9\<QCPSKTMC'=66K6&GO=Q
MP7UL8VV@':X!X9<C!]#P<4 =I16+;>)=/>#4FFF,;Z5&KWF]<;%,8DW#U&,\
M^Q]*IS^.=+A,:QV^HW4C6R74L=M:/(UO$XRID ^Z2,_+UX/% '345!97MMJ-
MC!>V<RS6TZ"2*1#PRD9!K)@U6XOO&=UIMNX6STVW1KGY03)-+DHN>P55R?7>
MOI0!NT5Q^C>(]:U#Q[=Z9?:>+"P73Q<6\4C*TK_O2F]\9"YP<+D^_/ H:IJW
MBS1;2#6;^ZLT\[4([=-&6 ,6C>78H64-DR;3O].",4 =_16%::K<1^,;[1+M
MPZO;K>V;!0#Y>=CH<==K8.?1QZ5;US7;#P[IO]H:E(\=N)$B+(A<Y=@HX'/4
MT :5%<@WQ&TA#<Q-8ZP+JU7S)[7^SY/-CCQGS",<+^.?:KEUXVTF%K9+9+S4
M9+BV6\6.QMFE80M]UVQT![ \GL* .CHKF[CQSH<-II=S%+/=+J@<V:VL#2/*
M5QN7:!D$9Y!QC!SC!K*U7XB01:987>FV=W*TNJII]S#):OYD!R-ZE>SX(QZY
M[T =S17 6?Q%AL[K7TU>*]:&PU%HC-!9LT=M#L0J9& ]2V>I Z\5N:GXVTK2
M[RYMY([Z<6B+)=S6MLTL=NK#(+D>W/&>.: .CHIJ.LD:NC!E8 @CN*YF^\?:
M/I\]T)([Y[:SE\BZO8K5F@@?C(9QZ9&<9QWH ZBBO,]:\;ZM:>)/$AMTNULM
M#L1*ML+#<MQ(5?YGDZJF0I&,9 )KI(_&MHFFZ6\UI?RZA?6_G+96]JS2A1@,
MY7^%<G@D\Y&,T =117,7/C[0[>PL+M&N[@7[R1V\-O;.\K2)]Y"F,A@<@@CC
M!KH8;@36<=R(Y5#QB0(Z$.,C."O4'VH FHKS)?B3=RZ5I>H2VL]NDNO26$R"
MT8F2(><%5!R2^40''?(KJH?&^C/INH7MPUS9_P!G.J74%U R2QLV-@V=3NR,
M8SG- '1T5C:1XFLM8O);)8;RTO8HQ*;:\@,3F,G < ]1GCCH>N*GUFSU2\MX
MTTO55TZ57RTC6RS;EQTP2,?6@#2HK@_ ][XAU/2X]=UCQ%"]FDERDMO]B2,8
MC=TW%\\?=W=/:MG3/&VE:I>6MO''>PK> FSFN;5XX[K S\C$<\#(!P2.10!T
M=%<A%\2M ETR?4PM^NG0E%:[>S<1,S2"/"MCYB&(!QTY]*4_$721)<0&QUG[
M9;J))+3^SY/-$1'^LQC[OOUSQC- '745RLOB_3H[IK\:D7TT:*=3\I+8DF+=
MGS ^<].-F*L:;XUTK4]1BLD2\@>>%I[:2ZMFB2XC7&YD9AR "#VX.>E '145
MS%EX\TB^N[**.*_C@OW\NSO);1T@G;!("L?4 D9QG'%9.G^.)M3:X$WG:=Y.
MO)I\9>R8B9"<",Y/#'G)_AR.* .]HKF+GQ[HMI=3QR?;&MK:;[/<7R6S-;0R
M9P5:3&!@D GH#U(I-1\?:/IM[J%J\6H3OIQ4WK6UH\BP*4#AF(&,8/UX/'%
M'445'!/%<V\<\+AXI5#HZ]&4C((KB(9_%&N>*/$=K8^((=/M=-N8X8HVL%FS
MNA1R22P/5C0!W=%<9I7C8V^EWR^(55=2T^__ +/D2SC9_M,C -&8TY/S*P..
MV#VJ+7/B'#:>%M;OK"RNUU+3$4O:7=LRLF_.QF'=#@\@]J .XHKG+OQGI]I+
M%!]CU.>[: 7$EM;V;O)#&20&D ^[D@X'4X.!6UI^H6FJZ?!?V,RS6MP@>.1>
MC _R^E %FBJVHZA:Z3IMSJ%[*(;6VC:660@G:H&2<#K618^,--NY+F.>*\T]
M[>W-TZW]NT/[D=7!/&!W[CN* .@HKG--\:Z7JE[;VB17UL]VC/9O=VKQ)<J!
MDE"1SQS@X..<5D>%/%LM_I^B76JZE'&]QHLE_<1?9PJG:Z R;\_* #C;CG.>
MU '=45RUOXXTO4 88A?6;S6TEQ:375FR+.BKDLF<;L @X."1[52\/>,YM2\2
MV>CF.:Y@DT>WO1??96C$KN"2Y&2%4@# _O$C/% ';452U75;+1-,FU#4)O)M
MH0"S8).2<  #DDD@ #DDUC1^.=)\C4'NHKZREL;5KR6WN[9HY#".KJ#]X<8X
MZ'@XH Z:BLO0]=MO$%H]U:07D< ?:CW-NT7FC (=-W52#P:AU?Q/9:1?16+0
MWEW>R1F86UE;M*ZQ@XWL!T&>.>IZ9H VJ*YF?QYHD4.F20O<W9U-)'M([:W=
MWD,9 ==N,AANY!QC!SC%/7QQHS:&-5W7(4W)LQ;&W;S_ +1G'E>7C._V].>E
M '1T5P^F^/()=7\32W[RVFFZ7#:GR[BW9)8WDW[E*XRQ)"8 SG(QG-;%IXRT
MJX^UK<K=:=+:6YNI8K^!H6$(ZR 'JH[XZ=\4 =!17-V/C;3KZ]BM/LFI6\MQ
M"\UK]IM&C%PJC)V9ZG!!P<&K4?BK2IM-TB_BF=X=6D2*TVH=S,P+<CM@*Q/I
M@T ;5%<Q!X]T6XNH43[8+6>?[-!?M;,+:67. JR8QR00#T)Z$U<E\6:5#HNH
MZL\DGV33YY+>X/EG(='V-@=^: -NBL&3Q=IR^)6T".&]GOHV03>3;,Z0AQE6
M=APH/J??TIOC?Q!/X8\(:AJ]M!YT\$>8U*%E!/ +8[4 =!17-W?C;3K698!9
MZG/<B!;B:WM[-WDMXSG!D ^Z3@\=3CI6WI]_:ZKI]O?V,ZSVMP@DBD7HRF@"
MS17/ZKXPTW2K^6R:&^NY[>,2W(L[5IA;H<X+D=,@$XY.!G%1W?CC1[:XM;>
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MT27S=Y1=Q+D8[FNWHH \VL?#NNZ7'X:N1IC7$EAJU_+/!'/&&$4[3!7!+ '
M=21G/M2:?X=UW1)-)U9=,:[ELKO4A-9QS1B1HKB8NKH68+D!5X)'#'N,5Z55
M6[U*QT]H5O;VVMFG?RX1-*J&1O[JY/)]A0!P&N:'XAUV;2M;O=+D5K*ZN/\
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MT .1&=RMP.Q&",GF@#EV\6>([CPOHNHJ;A+>XFNEOKRRL?M,D(25ECQ&/X2
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M;1E#IN&UAAE92",=1VI-!\,VGA^>_GM[B[GFOY%EN'N9=Y9PNW=T&,C''3T
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MTI9/+!19P8%?<,8W ELY[UV'P[A6VTG5K6)!';V^M7L<,2C"QH)CA5'8<]*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %)@9S@9]:6B@!,#.<#/K2T44 %( !T %+
M10 A (P0"/2E(!&",BBB@ I" PP0"/>EHH *.HP:**    8 P**** "BBB@
MI,#.<#/K2T4 )@9S@9]:6BB@"MJ%E'J.FW5C*S+'<PO"[)U 8$''OS1IUC%I
MNFVMC"6:.WA2%6;&XA5 !.._%6:* $P,YP,^M+110 4F!D' R.]+10 4444
M%%%% !1110 F!G.!GUI:** ,>_\ #Z:EKMCJ-S>W+061\R*Q&T1&4;@)#QN)
M 8X&<< XS6Q110 4A 88(!'O2T4 (0",$ CT-+110 4F 2"0,CI2T4 %( !G
M  SUI:* # R3CDT444 %)@ D@<GK2T4 )@9S@9Z9I:** "D  &  ![4M% "
M = !]*1HU9&3D!@02IP>?<=Z=10!#:6L-C9PVEM&(X((UCC0?PJ!@#\A4N!G
M.!GUI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBN>3Q?8R2682&=HKW4'T^WF &UV169GZ_<S&ZY[D>AS0!T-%4=7U2+
M1])FU*6-Y+> !Y?+Y*ID;G]PHRQ]@<5=1UD171@RL,A@<@B@!:*** "BBB@
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MAK:VDC$!6=@"?ES*#@A2>0*Z33;Z2_T^.ZGL;FP=B<P76S>N#CG:S#GKU[T
M7**"0!DG I"0,9(YZ4 +14<\WDV\LJQO*T:EO+CP6; S@>YIMM/Y]G#</%)
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MJ=I,8989;<;Q&'(5IXU;Y2#G*DCIWXYI+7QM8R3WL%[8ZCILUI:F]9+R$ O
M#@NH0MGGC'!Y'%3^--)NM<\+S6%DJM.\]NX#-@82=';GZ*:R_$V@:[>Z[>:A
MHL\=M,VARV<$[-@I,TJL/IP#SV- %J'QS;M<K;W.BZQ9RRVTES;+<0H#<K&
MS*FUSAL$?*VTU>3Q3ILT>AO 9)1K0W6H11]WRS(6;G@ =?<@5R.C^$]2B\8Z
M)J_]CM906B3I<O=:HUW/(SI@'+$C;D=CDYZ#%7O#7@N\TW7]0:]=#IEO%+;:
M0B-DQQ3.9),^A!V(/9* -&U\?:;=36S+9ZBFG74XM[;4GA MY7)PH!W;@&/
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MU2[65K>W :3RE!(7(!.,C@9R?8&J;^+=)C\1W>AO*RW5I9?;I6(^01YYYSU
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MUF)XS=+&)6AW#>$)(#8ZX)!&?:I'=8T9W8*BC+,QP /6O--;UW6?"U_J5O\
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M#W,;WNHZEYL^GV<<DRQ03%0J(1MR=RY8@]">2<T >LTV21(8VDE=4C099F.
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M-4=XVB20;@H"Y&\C( SB@#J**** "BBB@ HHHH **** "BBB@ HHHH ****
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M;^>)H_)V[O,W#;CUSTQ7D6A:1:7^H^![6_VZC9"'4Y(%FMF2,Q[XB@".6)0
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M>REVV\X Z$=SBH)/'UM/=6=MHVEWNK37E@NH0_9RB+Y18K\Q=A@@]NN3CUP
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M .I/TS47A_Q"FN?;H7LKBQO;"807-M.5)1BH8$,I((*L#G- &S1110 4444
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MW$Q#G:5CEWMM..3CV%8;_#6Y@:\L(=#T&[BN+IYHM4NV8R11NY8J\6W#L,D
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M?#.CW.CG63<M&?MNIS7<>PDX1PN,\=>#6M!>VUS<7$$,\<DMLX29%;)C8J&
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M5:> ]"LKRWFBCN3#:R^?;6CW4C6\$G/S)&3M!&3CC SQB@#EK37=;M/$-O\
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MWUQ;1E9+Z?SYR6)W/M5,^W"CI0!=HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<&L.US:66 K6NV-0DA X60L@<@=#COF@#T.BL#2-:GU'P!9ZV<+<SZ8MR>.
MYCW'CTS7'V.L^,;B/PE*^LV>?$<!+)]B&+7]SYH9?FRS8!'/&3G&!B@#T^BO
M-X/%'B!U30A=V[:I)KDVF+J#6X $4<7G%S&#C?M^4#IGFF:UXH\1^'H]8TMK
MRVO+^V%C/:7;P! T<]P(F615.,C!Y&.#ZB@#TNHOM,!G2 3Q^:Z&18]XW,HP
M"P'<<CGW%<+<W>OVVIZQX?O=7CNA)HSWL-R+58VB8,49=H.".A&>1ZFN<\.V
M>L2W_@B&TU9()G\,NS7#6RL4B)@(55S@D?*,G/&>,T >Q45YD_BCQ.VAP,3,
MPMM2NK'4+^PL?/D"Q,51Q#DX#8^8@'&.G-==X/U9M9T!;E]2MM0=97C-Q!$T
M6<'@/&W*/C&1ZT ;]59M3L+:]ALI[ZVBNYP3% \JJ\@'7:I.3T/2O-O%7C/5
MM-.MW=CK*R/IKMLLK33)+B$*H!(GGVX1CSD!AMXZUG>*K&^N]9\=7HU%4\KP
M]%(H-JC$1LLYV!CRO0\CDY]J /8P00"#D'H12UYA<^)-6L;K2?#T5]=H8]*C
MO)[RTTEKJ1]S%40(H(0 *<DCGC&.:?%XE\5ZJWA_3HW&E7=[+>0SW%QI[*62
M$ I*D4F"-P/0],GTH ],) !). *C%Q UP;<31F8()#&&&[:3@-CKC(//M7+?
M$2*Y'POUU!=8F33I#)*(Q\^$^;CMGGZ9KGX+#7)OB"EO::TEM,OAVW,UV;17
M9OWTNT!2=HZ\]>GOF@#TVBO*E\?:O>V'A^U#RV]U>07$UY<V6G/=L!#+Y7R1
MJ#C<>22"!T[BNQ\%ZOJ>K:;=?VI;W"2VURT,<\UF]L;F/ *R>6XR#R0>V5.*
M -"7Q-H,$SPS:WIL<L;%71[N,,I'4$$\&KUK>6U];K<6=Q#<0-G;)"X=3@X.
M"..M</XUT;2CXB\).=-L]UQK!\X^0N9,P2D[N.>>>:;XCUZ?2/$EKX:TA9M.
MMELS>2R:?I373<N5551%(49#$L1Z#O0!Z!17F<7B;Q7J8T'3HW_LR\O;J[MI
M;JYT]D+QQ)O258GP1N'8\ D^E-U/7?%EO!XMNH=7MEB\.["B&S!-R1;I(X8Y
M^4$DXQR-W7B@#TQW2.-I)&5$4$LS'  '<FB.2.:))8G5XW4,KJ<A@>A![BO/
MY]8U_3]0DM-2O;6^AO=#N;Y8Q:A%@DCV?*.3N0B3'S9/'O46E:GXAUF_T[2M
M/U&VTRV_X1ZSOF:.S5R)'+KM520H7Y1QCC&!C- 'H](2%QD@9..:\UC\9:E?
M>'] FFU:#3[B[BF,XM+%[JXE>-]G[N)5;"$@DDYQD#WK+?5M9\1V_AB2:_,%
MQ;>)9K,R&S"-)LCEVNT9/RMM!!7U/M0!ZW%<0SF00S1R&)_+D",#L; .#CH<
M$<>]25YNOB+4O[2O=)TX6EK=WOB.6R2Y^SC$<:6R2LY QO? (!/MGI3=;\4^
M(O#L&N:8]W;WE_:1V5Q:7;P! R33B)ED4<9&#R,<'VH ]*JG?:MINF%!J&H6
MEH9,[/M$RQ[L=<9(SU%<[I-[K=EXV?0M4U*+489M.-['*+80M&PD"%< G*G<
M",\\=35;Q%9VM]\4/#$-W;0W$7V&^.R9 ZYS#S@T =A:7MK?P">SN8;F(G'F
M0R!US]14]>>74-KX8^)"G1XK2RCN]&N)[R+_ %4 :)D\N5P!Q]Y@6QTJEI/B
MW5Y?$.A6O]L27\&J^9%*YTA[>"-Q$SAH9& WC*]\Y'/% 'IX(89!!&<<4M>.
MZ+KVJ^'_  /HUK#=R2W&J:K>1+-'8F=X$269I&6-,EV)4D=AN/85VO@W6M5U
M&[U*SU"*]E@MO+:VOKK3I+-I@P.Y2C  LI'4<$,.* .JFFBMX7FFD2.*-2SN
M[ *H')))Z"G*RNH92&4C((.017/^/?\ DG?B7_L%W/\ Z*:N>@U;7?"S:"=5
MOX;^SU"!T>&*W$9MW2 RC80<LN$*G=ST/M0!Z%4<UQ#;('GFCB5F" NP4%B<
M <]R> *\OT3QKXBO3HVHE+^Z34)HA<6*Z),D-O#)T=)]N&V @DDD,,XQQ78>
M-KU['1[*1(H)"^IV<1$T8< -.BD@'H1G(/8\T =)17F6H^(/%7]F>+-:MM4M
M8;?0KR9(;4V@;STC57(=LY'!P,8/?FM+5/&5[HLWB"*X59)%LX;O2$"\R>9^
M[$9]2)=OX.* .[J/[1#]I%MYT?GE/,$6X;MN<9QUQGC-<7!=>)M8UJ_TFWUB
M"Q;2(+=)IA:+(;FX>/>203A4'' YY//%<]8ZWJ_B'5H=6L$B@UA_#-QL0+NC
M,T=R%( /\+,AQ[&@#UFBO/[CX@23Q'5-.17TZRT)M5O$QDM(X_=19_A/R2$_
M052TCQ?KZ7NFRW8U&_M[I6-[&=#FMDM?D+!DD9<%01M^8DG(- 'I,UQ#;A#-
M-'&'<(F]@-S'H!GJ3Z5)7D]Y/X@U?1O"&O7VHV[VM_JUC<&Q2W"B!7<% KYR
MQ (!SUR<8Q7=>+-4N]%L+/4+=E%O'?0)>AES^X=MC$>F"RMGT!H WJBCN8)3
M((YXW,3^7)M<'8W'RGT/(X]Q7F8\?:Q-)KEM'Y*S3W,46A'9G>CSO;ECZX,9
M?Z$55UR:^U&26."YALS!XR@MPT5LN7.R(J[?WF!)Z]>!VH ]7BN(9VD6*:.0
MQ/LD",#L; .#Z'!!Q[U)7DZR^(-.C\?:OIFJP6\6G7\MQY#VHD^T.EO$S!B3
MPI  &W!R3S7:>*)IK[X<:K<02?9Y)=,DEW ;L QEB/Q&1GWS0!O_ &F#SDA\
M^/S9%+HF\;F48R0.XY'/N*EKRJVL]7DUSP3;VNJI#<MH-P7NFME8K'F @*N<
M9^Z,G/&3C-.F\<ZU#:6>E22DZA)JEW8RWUK8-.WEV_.]85S\S94=P.30!ZG1
M7*^#-9U34VU*VU*&[9+61/L][<V#VAN$9<\HP'S*002.#QP*IRW/B;5O%?B"
MPT_5K>PM=.6 P VJR,[O'NPQ)^[GTYYZC'(!VU%>;Z3XG\0>+=5T>*PO8-,M
M[C1X]1N,VXF8OYI1D7)&%..OM[TV7Q+XD?PG>>-H;ZV6QMY9732S;C#P1R%"
M&DSN$A"DY' .!B@#TJHX[B&666..:-Y(B%D56!*$C(!';@@_C7"7_B[5+*+7
M=-#1MK O((M*W)@/'<X\IB.^PB3/_7.H+_6=<MKGQ.NE6HDEMM1M8I9K6S62
M<0M!&SR;!CS'&< '.!V.,4 >A37$-L@>>:.)2P0,[!06)P!SW).!4E>8GQ1-
M=>''8ZC::J\.L64 ^T6)AFB5Y8QB6)P-K@EMK =@1R*M3Z[XEO-'U[Q+8ZA;
M6]KI<]RD.GO;!A,EN2&WOG<&;:V,8 XZT >B45YR=<\2:Y>^()-,U2'3[33[
M:WN+=&M!*[F2 2;6)/"Y].>>HQSU^DZT;WP=8ZY/&%::PCO)(T[9C#D"@#7J
MK'J5A-J$MA%>VSWL*[I+=95,B#U*YR!R/SK@H?$'B6V\/Z-XKO-0MIK349;;
MSM.2W $,4[*J['SN++O4G/!YZ5:^&UA<03^);BYNTN)&UBXC9OLZHQ92,L2.
M>>..@Q0!WM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 -DC2:)XI%#(ZE64]P>HKC],\)&;PQ9Z+J37,$^C3E+"
M^MY L@101&ZGD?ZMMK!@02#P1BNRHH Y)O#,N@Z3K<NC37E[J^J!5::[F5CY
MF-@D/  "@Y('9< =!70:/ID&BZ+8Z7;9\FS@2!">I"@#)]^*NT4 %%%% !11
M10 5GWNCVU_JFFZA,9!-ISR/"%. 2Z%#GCG@FM"JUWJ%EIZ;[V\M[9<%MTTJ
MH,#&3R>V1^= '.'X?Z67,7VO4?[+-Q]I.E></LWF;M_3;NV[OFV[MN>U;FFZ
M/;:5/J,MN9"U_=&ZFWD'#E57CC@805*-4T\V<=X+ZV^RR?<G\Y=C?1LX/0_E
M4,NOZ-#;07,NKV$<%Q_J96N4"R_[IS@_A0!%J?A^WU35M,U-KBZM[K3F<Q-
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M\D<I@E0Y5%E4 $LN[Y3TQFN@3QS<20V2KX<OA>ZBS&PM6EB#31*H8RL=V(U
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M/RR3A'Q@'('/%0ZYH^I77B?P_J^G_966P::.XCG=D)CE" LI"G+#;T. ?44
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MVDEY;K*Z/Y\:8W %2<.,KE3Z]35SQCHUWX@\)WVEV,L4-U.$\N27.U2'5LG
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M_>$8.,N.O->C 84 G) ZGO0!P]IXT2TL[**"TU/4[F_U&\MH$=X]^^)WR">
M$&TX]%'.36_X=\0#78[U);*:QO+&X-M<VTK*Q1MJL"&4D$%6!!K!TKP;J%C?
M:)/+-:E;#4M0NY0K-DI/YFP#Y>HWC/3OC-;FAZ-<:9K/B&\F>)H]1O$GA"$D
MJHAC0ALCKE#TSQB@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y+Q)/>7GBS
M1/#\-_<6%K=PW%S/+;D+))Y>P+&K$';]_)QS@4 =;17G<LNH-K6D^%5\433P
M337C3W<)1;@+$$*V[.,_./,R6P"0!TY-9M_JNN6MS=>'H-;NC]FUVRM([]@K
M3"&=-S(QQABN>"1W&<T >K45Y9<VVL1S^,;-/%&L"'1;9+FS/F(7WM"7(=MN
M74%>%Z<GKQB[ITFI^*?$C03Z[>V5N-$LKOR;-UC)ED\S+@X)P,=.AXSTH ]&
MJ*>ZM[4Q">:.(RR"*,.P&]ST4>IX/'M7D=IXI\0:^^B:<PU.X7[#/<7#Z3)#
M!+<LEPT*OND90%PNXA>[CM4EXNK:OI_AJ/5[J]@GM_$IM4=;B$RM'Y<A5I/+
M+*)% VG\>.: /3XM:TV;?LO(ODNC9G<=O[X?P#/4_2I;/4+6_-P+682?9YF@
MEP#\LBXROZBO+-5-WK=Q9BYU&\3R/&;VL1B<+L3RV(QQU&#C_>-71K>KW^K'
M1/[3GMH[SQ'=VK7,>/,CABA$@C0D8!)&,]<9Q0!Z?17E6MZKK6BC7M$L]:NI
M3:S:8]M>3;7EA$\^QXV./F&%R,\X;'-='HPO=)\?W.B/JM[?V<NF+>#[:X=X
MY/-*':0!P1CCU'% '95%=7,-E:375Q((X((VDD<]%51DG\A7#>,]>U+P[K%T
ML-P^S4]+,6GH>0EZL@1<?[WG*?\ @!K#@\2:W=Z5<VG]H2B\T#2+]M1E7&9+
MA"\4)/U$;R?E0!Z8VLZ:D#S->1!$MOMC?-RL."=Y'7'!_(U9AEAO+:*XB*R0
MR*LD;8X((R#7DEW;RW&J:W?S7UV\C^#(YG0N-C%DF!!&.F1N^I)K6T./4=#O
M/ X_MJ^NHM5@:&Y@G*F(8MC(I10!MP5 ]QUR>: /2J*Y3QKJ#VYTNQBO=1BE
MNYV_T;3(E:XN55"2%=B%C )!+?AD9KBDUSQ NG:EIRZAJ%I-!X@L;.&2[>*6
MXACF\LLK,N5;[Q]>N#0![!17F]W%KUCJ?B+0=+UJ_N94TJ#4;)[IP\B3>9("
MF[ RK>6 0>F3BM;PUXBD\6^(7O[*=UTBVT^$&,='N)@)"#[HFP?5S0!L:OXM
MT/0;R.SU*_$%Q)'YJQ^6[DIG&?E!XS4VC>(M(\0),VE7\5SY#!957(:,GIN4
MX(S[BN1UHZT/BY#_ &&M@UQ_8+;A>LX3;YXZ;03G.*QK36M1M;3QMXKOA!'X
MET^T%K)IT41"0! S(Y)),@;=N#<<#% 'K=%>8:5>>);#5M++G55@NXI!=RZS
M=VC1,PC++)&L<A888<JHQM)],TWPU?:K#JVF6>NWVN6]UJ$+QM(\D5Q9WCF,
ML&@D3_5' + 8'''- 'IEM=6][ )[6:.:$D@21L&4D$@\CT((_"HX-0M;F\NK
M2&8//:%5G0 Y0LNY<_4'->2:!#J$/A#P=I]EK5_:KJ>IW,<\B.I98PLQ*KD<
M?<SGL3FM2_UG5]-NM:TF#5;D[=1TS3HKN;:[P)+&@>3I@L<DY(QDT >EW-U;
MV5NUQ=31PPIC=)(P51DX')]R!4M>6>.])DLO#6J6+>*+RZ3=9SI:3R*T\>;A
M4+;NI0Y& 1PR\'M2W]]KM[XIUG2[;_A(9;?2(X(('T^XMD.]H@YEE\UE+DD]
M,;?E/<T >I56L-0M-4M%N[*99H&9D#KG!*L58<^A!'X5Y]HU]K?BW5+6PU+4
MY],:WT>"ZD73IH_W\TCNI?>-P*#RQP#C+<YK:^%ZLG@"S5YA,XN+L-*  '/V
MF3YN/7K0!/)\1O",-S);RZW!&\4AB<NCJJL#@@L1@8/O74*RNH92&4C((.01
M7D&D6GBV]\%^(+?2Y=$6PEO=10K=))YN#+(&^;.T=\$@CUK?\)ZW]LU?PQ;V
M+SQ:5-X;:9+:9LD,CPHI)[D D9[YH ]!JM<:A:VMU:6T\P2:[=D@0@_.P4L0
M/P!/X5YHVJ>(-2TQ&M;JZNHQK6H1S6]G=1PW4L$<C!!$7ZJO&0"#C'-6](\0
MW,]WX8MHM3U"8-JMW:W:7T(BG7;!(ZQ2@<,5^7YAUX- 'I-%>2Z3>:W'X7\,
M>)9O$&H3W5YJ4%M/ [+Y#123&,KMV]<8.[.<^W%5WU[Q5J%GJNN6D>L+/;WL
MT=MBYM8[&-(I"@217<,<A?F8C.3QQB@#V*BO+/$.IZW::KJFHW5WJT6FP.AA
MN]*DBGALE5%+K<09W$YW$GG@C&*/$6J:O;ZKJFIO?:L-)A*-;7NDO%-#:*$5
MG$\!(8]2Q//RL,8H ]3HJE;P&2^.I)?3R030(J6^1Y0Y)W@8SD@XZ] *YK43
M>ZYX\FT/^U+S3[*STZ.ZVV;B.2=Y'=<EL$[5"=!W;F@#LJ*\GM-2US7M0T/1
M9->NX$^U:G:7%Y:;4DN4MV0(^<$!NQ('][UKU6)/+B2,NSE5 W,<EL=S[T /
MHHHH **** $95="CJ&5A@@C((H5510J@*H&  , "EHH **** "BBB@ HHHH
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MC!*)XTCE=&63)._>"&W<G)SDY.:W:* ,2[\(:%>V4UI/8YAFNS>OMF=6\_\
MOA@P93]"*6X\)Z'=6=Q:36(:*XNC>/B1PPGX_>*P.Y6XZJ16U10!AP>#]"M]
M/ELDL=T4TZ7$K23.\DLB,&5F=F+,05'4]O2M'^S;3^UO[4\D?;?(^S^;N/\
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M_9R21VH0D"-7QOXSSG R3DUJ444 %%%% !1110 4444 %%%% !1110 4444
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M>TVTN5 +0SW*(P!Y'!.: -FBJ&E:YI.N122Z3J5I?1QMM=K:99 I]"0>*OT
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MVS2 22#GD+UQP?RJ_0 4444 %%%0W-W;68B-S/'")9%BC\Q@N]VX51GJ3V%
M$U%%% !12,RHI9B%51DD] *CMKF"]M8KJUFCFMY4#QRQL&5U/(((ZB@"6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#;1;ML,S!-H*[0V!C.#G))R:L#Q'JMOHM_97>NNMU:ZX=-CNX[(2W-Q'Y:R
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M':J,=@4[AO'RG(/'TYXK*.E:K=?$O4;:V\0W-HT>C6GFW201-+,WF3;205V
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M=U86%KI>GV]A8PK!:VZ".*->BJ.@K#U#P+H^HW=W-(U[%'>D->6T%T\<-R<
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MWKRO.!GWK-M]#?PM\0(FN'O=2M]1@>'3]0O9Y+A[";',1+$@*X&0V <@@DT
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M3)M/$RY$L@RA5^A4@J0>.O.,5TT.H2PZ&=1U>V6P>*)I;B)9?-$07)/S #/
MSTH T**XG3?B";NZTLWFF):V6JR".TE6]260,P+()8P/DW =BV#@'%16_P 0
M[N:SM]4?P[)'HTE[]B>Z-VI=6,OE!A'CE-V!G(/7@]2 =W17#ZIX_N[.RUC4
M[+P_)>Z3I3R137 NE1W>/A]B$'*JW!;(Z' .*T-7\3ZE8R/]BT-9X(H%FDN+
MN\6VC)8$[$)4[F '/0#(YH ZBBN-@\=2:LNF)H&D-?7-Y8+J#QS7 @6")CA0
MS8;+$A@ !_">15>/XCK<:;8/%I+)J-]=7%O%9W-RL03R&*NTDF"% P. "<D
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M'^C77R2B25 "DNT;EYPRX'<=\T =I17F]MK=S'=SK/->W#MXLEM+=%NBB@"
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MQR@8'G=G SBM&U\47M_XNOM%M-%9[;3Y4CNKYKE55=\2R*53&6/.".W!SSP
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MV5R]PK,RHH<^8@'R?*<CD^^*JV'Q'6[DTZXFTU(-+U*=(;6X^V(\P+G$9DB
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MN\%_'&MK)-Y@A'D1DA#TVDY8<#.[. : .QHHHH **** "BBB@ HHHH ****
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M\=R)8VC =#G*$AR"%P/:LK0M-GO(/ NC1ZSJUK97&@/=3K;WCJSL!!@!LY4
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MK:;,-6ANK.9#)9ZG.)VMPZ @+*"V]3@D9.16H/!OAQ;&XLET>T6VN&1Y8U3
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M_P 4C=6/N: +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&24$QQA6=V ZG:H)P.YQBHKSQ=X?L;:TN+C5;<17D9EMF4E_.48R4VYW?>'
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M-3@^RV9(N9)"8_).,_,& (X/?K3;3Q?H%]9WEU!J49BLH_-N=RLC1)@G<58
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M-)EU>S34"P06YF ;<>B_4]AU- &O14-V;D6<QLEA:Z"'REF8JA;'&X@$@9]
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M2VTS5[.[GC&YHX90QVYQD>HSW'% &M17+>'/%4^NVFAW#QV< U&VFF>(S'S
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MFQGO1KEB;:";R))1,"HD_N>Y]A6CIVI6.K627FG7<-U;/D++"X921U&1W]J
M+5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZU10!Y)=6UY;ZYH^N1V>H^'=+-E<0QK:6*W+VSM-OR\>QBGF+@G X/!-=?\
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M>[8(XZ\BO3** /)KF6ZC\67.NF\UJPL-0TZ".VFM](\]ODWAXG1HV:,Y.X#
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M\L@$;CM&&Y((&1QUJAXCU[4-*N(8;2VL%C>-I)+S4KW[/ A! " A6)8]>@
MZ]JZ!%V(JYS@ 5RFN^$[O4/%,&N6<^G,Z6GV7R=1M#.D?SEO,CPRX;G!]0!0
M!G6OQ#N]3T_07TS2()[O5IKFW"->8BC:'.YO,"G<AVD@@9(QQS5B/QU=P6$T
MNHZ7%#+8ZM'INH>5<%HXE<+MF4E02O[Q,@@$9/I2Z'X$GTB;17EU-;@Z;=WM
MP6\G:9?/W<<' (+?C[4W6])L-'T+Q9)JTTLUKK<Q81P6[.ZLT*1JH"Y);*9!
MX&2* .@T[6SJ6O:M816X^SZ<8HFN-^=\S+O9 ,?PJ4YSU;':LGQM>7C3Z%H5
ME=RV;:O>F&:YA.'2)(VD<(?X6(7 /;)JUX&T>ZT7PG:1:@Q?4I\W5\[=6GD.
MYL_3.WZ**M>)/#R>(;&",74EG>6LZW-I=Q %H95R <'A@02"#U!- '(W,'AC
MPSXGT^WL-?N],U!;B-)[>:6XN([M'X",')7<<C#9R#^57O\ A/+V-==U&XT>
M./1=&FGMY9Q<YFFDC/RA$VXP<J.2.3[5+/X8\2:W-9Q>(-=L6L;6YCN?*L+(
MQO.\;!EW,[MM&0"0HY]:MCP7#-X?\0:/=W+/%J]W/<[XUVM%YA!&.N2I .:
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MCF)I5D#[>4*A3]T$ GC(P2Y\?7NEZ=K/]J:7;QZAI=Q;POY=R3;E9L;9&D*
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MU&V5/O1NI#*P^C '\*P9?">L:O=I=:]JMI-);6L]O:K:6K1J'E38TKY=LG'
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MU;4?[.5;RTO60R1V]]:26[R(.K(' W =\=*WZQ-4U'1X-?TBSNH4GU64RM9
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M:2QO)97UV+H0!U^7RY<DLIVDX8Y!["@#LZ*** "BBB@ HHHH **** "BBB@
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MI+94C $3$$%A[D,<GODUCR>/='-CJ4L!NC<V5JUT;6>RFAD=!P&"L@)7.!D
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M-]GD\@39QY?G;=F[/&-V<\=:#XVT#^U+K35O)'NK42?:%2VE81;%W,&8+@'
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M:=(DEIH]I%*@8+(L?S %=I&[KC!(Q5Y='TY;:RMELH1!8LK6J;>(2JE5*^F
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MRAM8W;>XC7!=O4GJ3]:OT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXIFGMGB^U:NTD3LN/,C\F( CU&0P_.@"QXM\4V_A2QM+F=-_VB\AM@.?E#N
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MF^(M'^ K/U/2;_2_$WB223_A)/L^I,DEL-(@BDCF41*GE/NC;805(Y(7!^M
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M\5W>D06BHCI):AT"YZ[MY.3RH&.]3V_C#0+G3[N^CU*,06>/M)D5D:+/0LK
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MFR\-67A?61JO]EQV!>ZMQ#!&_E!&=G8_=')X!)Q0!V5UXQT&RM;*XN+\*M[
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MALCO79>!-/DMEU>^DBU5/MUV) ^J,@EF"HJ^88T1?+SC&#R=H)QF@#KZ***
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M; /4$=...3_A"KO2[ZRN?#FJ16(@TV/3'2YM?/#1(25889<.-S=<@YZ5V-%
M'%VO@O4M*\/Z9ING:W$_V-94E2^M/-@NE=RWSH&4AAV(/KQS2:3\/DTIM*=+
M]2;*2\E=$MPD;-<#D(H/[M5[+S7:T4 <I!X,\GP[X9TG[?G^Q)X)O-\K_7>6
MK+C&?ESN]3BJ4/@74+-'TZQUJ"WT9[EIPHL@;J-6?>T:R[L;22>2I(!Q79W-
MS%9VDUU.^R&%&DD;'10,D_D*HZ#K4?B#2TU"&TN[:&3F,7481G4@$,!D\$'B
M@#G?$G@G4/$)OK.75K5]+O6R8[JQ\Z:UX (@DW@+G&1E3@G--\0>![_7([RP
M?5[:32KL >7>67GSVWRA3Y,F\!<XSRIP237;U4U/4K31]-N-0OI?*M;=-\CX
M)P/H.30!3UW0(=<\.R:0\\L((0Q3K\SQNC!D;GJ0R@^]8MUX/U37+6]B\0:]
MYWG0+#"EC 8(XF5PXE*L[;I-RKST !&.3716^KVMUK-[I49?[39QQ22Y7Y<2
M;MN#W^X:OT <=+X/U35K@W.O:S;W,T5G/:6@M;,PI&95VM*P+L6;'& 0!SZU
M=/A0-#X7C:[!70\9S%_K_P!PT/K\OWL]^F/>NDHH X[2O"&K:8FGZ:GB#&AZ
M?*)((8H"EPZ*25BDEWX9!QG"@D#!J"T\"ZAI\::99ZU!#HJ7'G(BV0^U*F_?
MY0EW8VYXSMSCC-=Q10!RLW@WS?#WB?2OMV/[<GGE\SRO]3YB*N,9^;&W/49S
M6A<:!Y^N:'J7VG;_ &7%-'Y>S/F>8JKG.>,;??K6U10!S?C'PC%XNM+*%[IK
M4VUP)&=4W&2(J5DB/(X921GZ5%8>"XK#Q5K>MK=LW]I1[(H-F!;E@HD(.>=Y
M1#VZ5U-% '*P^#?*\/>&-*^W9_L.:"7S/*_UWEHRXQGY<[L]3C%51X&GMO*N
MK#5$BU.VU&[O8)I+??'MN&)>)TW D8(Y!!RH/M7:44 <I;>$KXZKIFJ:EK3W
M=W:7DUW(!$5C^>$Q".-2Q\M0#GJ23G/6M32]$_LW6M;U'[1YG]ISQS>7LQY>
MR)8\9SSG;GMUK7K'TWQ':ZKK-_IUK;7;"Q<Q2W318A\P8R@;.2PW#MCKS0!L
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<;XKN)8?&/AU5NY+:-K;4"[KDA<1(0
MQ7OCJ*[*HI+6WEN(KB2")YX0PBD9 63=PVT]1G SCK0!Y7X.+:3K^@1W<?FO
MJ,$BPZE8:F\T5_B/>7FBD^93A2<CH3CI76>)B7\;>#;>3_CW-S<RD'H9%@;9
M^A<_A6W8^'=$TN[EN]/TBPM+F7/F306Z([>N2!FF:]H_]L6MOY4HAN[.X2ZM
MI2,A77L1Z,I93[,: .'FM]/UB_\ &5UK^H3P76F3E+;;=O#]C@$*LDB $#+,
M6.[G)&.V*@\+6T_B?Q19W6O2733P:%IUYY G>-//+2'>RJ0">.AXY(Q7H=]X
M?T;5+N*[U#2;&[N8?]7+/;H[)]"1D5<6UMTNGNE@B6X= CRA '91D@$]2!DX
M'N: .:\3S2Q^*_!R)(ZI)?S*ZJQ 8?9I3@^O(!KA-*L1;>#/"WB-;J];5I=7
MMXI)WNI&W1/<&,QE2=NW:<8Q[]:]@EM;>>6&66"*22!BT3N@)C)!!*GL<$CC
ML:B&F:>MK%:K8VPMX7$D4(B78C [@RC& 0><CO0!XW<K_9&D:^FEMY1N/%0M
M+PM>O$%MS@X:0;C&&8A2X&<-5J_&HZ1I7C&UBDL[&!-$:;[#9ZE+=-#+\P60
M,R+LW#/ /.T''>O5FT72FFNY6TRS,EXH2Z<P+F=1T#G'S#ZU':>'M%L+":PM
M-(L(+.?(F@CMT5),\'<H&#^- '!:E92^%M:TR70Y+M[R]TF^>999WE^TS1QH
M\;,&)&[<3T]<=*H06&C1-\/-0M-1FN+Z]O$EF9[MY#<$V\A=V4DC(8XS@8W$
M5ZPUI;//#.UO$TT 98I"@+1@XR%/;.!G'I5&#PWH5K>M>6^C:?%=-)YIF2V0
M.7Y^;<!G/)Y]S0!YEH+G3-7T6_NG.H1WU^T,.LV.HN7N&<N D]O(.@[A?N[1
MC%=5\3K.TN]'T@W8/EKK-F"?,* *TJALD$=N_:NE@\.Z);:H^IP:1817[DEK
MI+=%D)/7+ 9YJU>V-IJ5H]I?6L-U;2??AGC#HW?D'@T >82P:=?V7C'4=6U*
MX@O]+N)8[1UO'C-G$D8,)10P'S?>S@[B<<UUE]<7=W\);FYOU*WDVAM).I&,
M2& EACMSFM>X\-Z%=74%U<:-I\MQ;J%AEDMD9HP.@4D< =O2M&6*.XA>&:-)
M(I%*.CJ"K*>""#U% 'E6FP6FCIX(NO#UY-<WVH+LN4-TT@N8?L[,S,I) VN$
MP1C&<>U8VA2:M-I.A:\TUC!J5U?1"6^EUB9Y9W:3#P-;B+:.,KL!PN <\9KV
M"QT'1],NY;JPTJQM;B48DE@MT1G'H2!DTD?A[18M5;58](L$U%B2;I;=!*2>
MIW8S0!B1DQ_%R=(N$FT-'G Z%EG8(3[X9Q^%<Q\1KR[M]2\2""ZFBV>&XY$V
M.1M?[0PW#WQWKO\ 3M'^R:QJ>J3RB6ZO7100,".%!A$'XEF)]6/M5NYTS3[Q
MI&NK&VG:6(0R&6)6+QYSM.1RN><=,T <=;:5!X<^)&E6NGRW0AOM.NFNEFN7
ME$KQM%M<[B?F^=N?>IO%"1ZCXXT+1]2FDCTF>VN9O*65HUN)U,85&(()PK,P
M7O\ A78-:V[W4=T\$37$2LD<I0%T5L9 /4 X&?H*AU'2]/UBU^RZE8VUY;YW
M>5<1+(N?7!'6@#SC;I=WKNB>'TU>]N?#QFOE(EN' DGC*;8/,X+HH9R!DYVX
MR=O%"Z>1H[S1K+4;LZ1#XGLK2VFCN6+HCJIEB63.<*S$=>,X[5ZC/H6D7.EI
MID^EV4FGIC9:O IB7'3"XP*DBTC38+2"TBT^T2VMW$D,*PJ$C8'(91C (/.1
M0!YC<>&[$7_C>R66^6TTVSBN+* 7LH6"5H79G7YNN44\YQSZFIK".R\0^++*
M+7KZ5U?PQ9W0MVNFC21RTF^0@$9(XY[9SV&/3#8VA>X<VL!>Y4).QC&95 (
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MR&9X]8GO7OX_*+;RC1 ;E.&W9'<=\5%X64:=JN@"^!NUU19(8M5T_4Y)%O\
M=&S$SPO\RG )RI^5N.!Q7IUAX>T72KJ6YT[2+&TN)>));>W1&;OR0,FBS\.Z
M)I]_)?V6D6%M>2YWSPVZ([9ZY8#/- 'DF@:39W.E>#]+2:XCM[S5=16\CANG
M4N$$Y"DAL@81<@8S^-:&JRR66LZMI2WES;Z2=:TVRG87#@Q6YME^7?G*AF"*
M3G)W'GFO3H-#TFVNC<V^EV45P96F,J6ZJWF,""^0,[B"03UP34LNF6$RW2RV
M-M(MWC[2&B4^=@8&_CYN !SV% 'F'C+2O#]KX:U[3[&]N9%M[BPFELVG=HK4
MM,JY5CT++DE=QQ@' ZU6U"*ZU#Q)XCMWBM9+72XX4LVN-;FM#:0>2K"5 J-N
MR<G>3GY<=N?4;?P_HUKIDFF6^DV,5A+GS+9+=!&^>N5Q@_C45SX7T"]6V6ZT
M/39Q:H$MQ):HWE*.BKD< >@H X+2!_PD.LVMKXJU'SDAT&VN;<PW,D,<[L7\
MV<8VDD;4Y(&,YP,UT/PK\O\ X5SIOE3&:/S+C;*QR7'GR88_7K71ZCHFE:ND
M2:EIEG>+"=T0N(%D"'VR.*M6UK;V4"P6L$4$*DD1Q(%4$G)X''))/XT >1:7
M;7UQ8^*TB\;P:+ VL7ZM#)!"VT;SEBS$, ?;\*T?!&L++J_AUI$73K63PQ^[
MMC(1'\DRC*[CS\H!R><&NYE\)>&YKI[J7P]I,EP[F1Y7LHR[,3DDG&2<]ZLZ
MCH>DZND*:EIEG>)"<Q+<0+($/MD<4 >3VK3Z]HNBFWO;:^\R^U.1=.N[R6%;
MU!.P5ED7/*#& <C#9[5J:1JGVA_!L5LU_"D6JWMK-%<W7GD%(9LIY@_UB*<!
M2>P'I7H-UX>T6]L1976D6$UH',@@DMT9 Y))8 C&2223[FIXM+T^".UCBL+6
M-+3)ME2%0(<@@[!CY>"1QV)H \FT.Q%GX1\#>(([J];5+J_MH9YY+J1O,BD+
M*4*D[=N,8&.V>N:IW<NK7UMXDU>:2RM[ZSU">*._N-9FB>QV/B)1 L94KC:<
M9._<?6O9ETRP2VM[9;&V6WMF5X(A$H6)EZ%1C"D=B*KW'A[1;O4TU*YTBPFO
MX\%+F2W1I%QTPQ&>* /+_$GGQ:CKFM73KJ,%GY33/::E):W>F%8T)6-&&Q@>
M6'0MN(YJ?Q8'N-9UK5 PU*UMK6*1X4U&2SN],'E[MT8(V-G[W/?CG&*])N_#
MNB:A?QW]YI%A<7D>-EQ-;H[KCIAB,\47_A[1=5NXKK4-(L+NXBXCEGMT=E[\
M$C- &9XA^SZQ\-]0E82M!/IC3*)"4?\ U>]=V,8.<9%<;HFF6%WJ>A:'J,DJ
M:6OAZ&\M[8W+HDT[']XQ.X%BHVX&<#=D"O5)8HYH7AEC62)U*NC#*L#P01W%
M4K[0='U.SAM+_2K*ZMH<>5#- KI'@8&T$8'''% 'EEBCZ]>>'])N;^\N-(_M
M74K>*1;EPUS;1J2@,@(+ $8SGD+76_$VPMA\+-5M]K>5;6R^6#(V1M( R<Y/
M'K76IIUE']FV6=NOV4$6^(E'D@C!"<?+QQQVJ6>"&ZMY+>XB2:&12KQR*&5@
M>H(/!% 'F]KX7TC5_'?B"WE,[V=OIMBL*17<BKSYV&R&RQ&."2<9-8-K?ZOK
MT'@NQNUCOH+C1FG,5WJ$EJMU.K*N6=%8NRKSM/\ >)[5Z_9:5IVF@BQL+6U!
M18SY$*IE5SM7@=!DX';)J&Y\/Z->:=%IUSI-C-8Q8\NVDMT:-,=-JD8'X4 8
M7P[DNSH5Y%<W<%PD%_-%!Y-R]P(HQC]V9752^TEAGGC SQ7$7*67_"->,];.
MJ7(UO3]5O!9L+M]T#K(?*C5,XPQP,8YW8[<>OVMI;6-K';6EO%;V\8PD42!%
M4>@ X%<_H_@G2].O+J^NK2RO+Z6_GO(KE[9?,A$CE@H8Y/&>O'X4 9-GJWV7
MQ3XO.HW:V_EZ?9S!))<!/W<FXJ">F>"1[5SOA:P7Q%J/A>#4[F\E@3PO!=&-
M;F1 \HD #MM()(R>M>GWNAZ3J5Y!=WVEV5S<P?ZF::!7>/O\I(R.:EM]-L;1
MXWMK*VA:*$01F.)5*1@Y"# X7/;I0!Y 1:Q^"-9UZ#4[A_$5KJ]Q':G[6Y:.
M07+". )G!5@1\N.0Q_#3NHK'4;/QIJNLZC<6^J:9=3I;.MV\1LXT0&$HH('S
M<-G'S$XYKL- \$Z7HQ-Q-:65UJ NIYTO&ME$J"25G"ACD\;L=:U;OP_HU_?Q
M7]YI-C<7D6/+GFMT=UQTPQ&10!Y?JJZAJDBZA>"'4)X]&MI;NP.H26,]@Y1F
M:6+C823GD]"H&:)+RZ\4>(HX_LRWFGKHUK=6<&I:K)9,5<,7E/EHV]Q@ GC;
MCCK7I^I>']&UB:*;4])L;V6+_5O<VZ2%?H2#BG:EH.CZPD2:GI5E>K#_ *L7
M$"R!/ID<4 >611:EK&G^'UFU"PUV:.RG8V$FH30"X02[5F24*-[JH"DL.Y(Z
MYKO?!VHB_P# =I=V2W;E8I(T6\E$LA9&9<%QPXRN W<8-:M_H&C:K;0VVH:3
M8W<$'^JCGMU=8^WR@CC\*NPP16T"001)%#&H5(XU"JH'0 #H* /(;4V\'@KP
M]XFM-2N9?$UW=VJRLUT[-<2/(JS0LF<;5!?Y<#;M'2NI^'.E6=A/XFDMXW5A
MK,\.3*S?*H4@<D^IYZUU$7A_1H-4?5(=)L8]0?.ZZ2W02G/7+8SS5R"UM[;S
M?L\$47FN9)/+0+O<]6..I.!S0!+1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C:W
MXGT[0+FRMKO[0]S>[Q;0V\#2O*5P2 %'N#^?I6S7#>,+NZL?'?A&>TT][]PE
M[N@B95<KLCR5W$+D>A(SS0!J2>.]"AT;^U)9ITA%U]C>)K=_-CG_ .>;1XW!
MO;'.1CJ*;+XZTN,1(+759+EX?/DM8["1IH(\D;I% RN2#@'DXX!KGF\-:U?3
M?VK-I_D37GB.UU![0RH6@@B14W,0<%OER0I/4=:UIH=7\/\ C#6-4M-%GU:U
MU6*#;]FEC1X9(U*[6$C+\I!!R,X.>* -O3O$VDZM>0VUC="9Y[07L3!3M>(M
MMR#Z@\$=1D9K/M_%EA?:I926^I*EC+;74NR2 @2"%U5I Y/RJO/;Y@<]JY:X
M\'>(]-\':,VD+"?$-JURD@60!%CNBY< G&1&S(P]?+XZUH:QX'FGET_2]/3R
MM.A\/WFE^>6'[MI!$J9'4YVL20.WO0!._CZ*_P#$/ANRTQ+J.#4;B3+W-F\:
MSPB%V#1LP&1N"^^"/6K-GXYTZVTO3/M=W<:A=Z@)VM_LMB^Z?RWVL @S@C(Z
M]@36=##XBU+5O"*7/AR2RBTB9FO)WGB9<_9WC'EA6)*DD=0#R..N&>%O#&KZ
M=>^%9+NS\M;"UU%+@^8I\MI9D9!P><@'IT[T = /'.B-H\.HH]RXFN&M$M5M
MW-P9USNC\O&[<,'/H!GI5S0_$VG>(9+R*R,ZS63*EQ%/ T3QL1D*0P'-<.^D
M:EHVNV^J?9XI+H:]>S6]BUQ&CW<,T0&8R3C> N=I(X#=*U_!%S=7WBWQC=7=
MF+1VN;9/*$BR%2L(X9EXW8(R 3C.,F@#8U;QEI>CWL]K,E[,UK&LMTUM:O*M
MLAR07*CC@$XZX&:=J'C#2["Y2V5;N]G: 7)CL;9YRD1Z.VT< X..YQP*YGQ=
MHFHSZ_>7EAHVIB[DMT6TU'2+]826 /RW"NX4J#T.UN#BJ=SX9UNSUV;4[ZTU
M;5)+ZQMEF?1M2-H5N(TVL&7S$!1CR#SCGCF@#K+_ ,=Z'8Q:=(LMQ>?VE"T]
MFEE;O,TR+MW8"C/ 8'!]#Z59_P"$MTG^PI]8,L@MH)S;2*8B)%E$GE[-O7.X
M@8]Q7/:!X6OM+U;PM(;".""QT^\2=4G,HAEEDC<*&<[FZ-S[?2BX\*:B_P 0
M59(U_P"$<EN$U:;YQ_Q]HAC";>N"?+DSTRE &K'XLLK&UOY[V^>Y*:G)90Q0
M6C>87&,1*HR7(Y.X<?3%2CQQHO\ 9LMX[W,3Q7"VKVCV[BX\YAE8Q'C<20<C
M'!'.< US(\.:W8:C_;,6GFYDM/$%W>K:+*@:>WFB\O<A)V[AG(#$=#TIWB'2
M?$/B6*UU.729;9;'45GAL(;L07<L/E%&)E1]HDRV0 P&!@GF@#I%\;Z-_9]W
M=2M=0/:2)#-:S6SK.KR$"-1'C)+$C&,@_@:O:-XAL]<>YB@CN8+BU*B>WNH&
MBD3<,J2#U!&<$>E<(OA:ZN+'6;IO#%U,MR;:-;;5-5>6ZGCC8LQ#^8RQLI)*
M8;KG)&:WO!-CK-G>:B;H:I%I#+&+.WU:Y2>X1QNWG<K-A/N@ L3P>E $.K>-
MKJVU?Q1ID%K(ATS2?M<$[6[%3)MD;YFZ;?D7'J=WI5WP[XXT_6/[-M)%NXKN
M\MA+%)-:/%%<$*"_EL1@XZ_3D9%9NO:/J\NO^)C;:;)<6^KZ$+6&=)4"I,BS
M?*P9@>?,7! QZXJS=>'K^XD\&*(2J6$<B7;*ZYAW6K1COS\Q XS0!?M?'6B7
M=Y##$UT(+B8V]O>M;.MO-)DC:DA&"200.Q(X)K5UC6;/0[);F\,F'D6&..*,
MR/+(WW551R2:\RT;P9J5O::/HEWHVJR/8SQ>==2ZRYL=D; B2.(2YW< A"@
M/L*[OQKITFIZ&D*:2-45;B.22!9_)E"@_>B?*XD'!&2.XS0 +XVT;^S+F]E:
MZ@-M,MO+;36SK.)6QL01XRQ;<,8SG-,3QUHPM-2GN1>6;:;$LUU#=6S1R+&V
M=K@$<@X/(STKE$TSQG%HMZEJ=8%DU];M#;7=U"^H+;@'SMLF2H).W;EL@ \@
MD50O/"&NWD7BEK?2=01-1TB.WMAJ&H+/,\BR,2&)=@G#< ';@=B2* .S'Q$T
M5K@VRV^JM=%!+#;C3Y?,N(SGYT7'*\=>.WJ*MOXUT4:1I^HPR3W*:B2+2""!
MGFE(SN 0#(VX.<X QS37TN[/Q%M=5$/^A1Z1+;-+N'$AEC8+C.>BDYQCBN)'
M@S6+;3?#EW-97TKZ>]]'<VEA?>1.$FF+JZ.KJ#P!E2PR&]10!Z1HVMV6NVCW
M%DTG[N0PRQ2QF.2*0=5=3R#R/S!K+U/QSI&E7-Y%*E],MCC[9-;6CRQVW ;Y
MV P,*03C.!UJ+P1H\VFP:E<W&GSV4E[<^8([J]:YG954*K2.68;L#H"0 !S7
M+>)=$\3:L_B2TFLM6NFNO,33FMM02WLEB,8"^8JNKLP.<A@P/ Z4 =CJ7C;2
M--G>)A>7/DP+<3O:6KS)!$P)5G*C@$ GUP,XK::^M4TXZ@T\:V8B\XS$X4)C
M.[/ICFO-=4\/:J&@FBT+5([\:;!#!?:1J"0NLBI@QW"LX5E#=" W&:Z[5-$U
M+6_AU/HM]<Q_VI<Z=Y$TZC"&8I@GC^$M[=* ':7XTTG5;ZWM(UO8'NT,EHUU
M:O"MRH&28RP&>.<=<<XQ4GAWQ=IGBD.^EI>/ J!A<26SQQ/G@A6(PQ!X('2L
M/R-=\1:IX<6\T&72HM)N/M5S-+-$P=Q$R!(MC$E27R2P7@=,UL> ]+N]%\#:
M3IU]#Y-U!#MECW!MIR3U!(/6@!-1\;Z/IE[<V\XO&2T94N[F*U=X;=F (#N!
M@<,I/H",XJ*[\6V&CZAK#:EJ.;:UEMHO*2V;,+2CCD9W[CSP..E<UXFT+6GU
MS5+K1])U*UU2<J;34M-OTC@EPH ^TQN^#M(YPAR,8YJ75/"^MW6LZE<?95E6
M?4M)G#JZ@.L)7S6 )R ,'@\GMF@#9;XCZ*GVE&MM6%S:C?/;?V?+YL4>,^8R
MXX3'?_"JWB;Q<]GI^J7FE:C%(8M"_M&VA-N2#DG;)OSR#P-N/>K;:-?GQ-XJ
MO/L_[B^TVW@MWW+\[J)MPQG(QO7KZUREUX.UZ3P]):K89F/@Z+3 OFI_Q\@G
M*9S^O3WH [._\;Z9IDLT$L=]<RVL2RWAM+1Y5MPR[@7*C XYQUQS3KCQOHT.
MIV>GQFZNKF[@BNHEM;9Y<PR$A9"0.%R.2>F1ZURNN:-XDO[_ %BVGL]6N89H
MECT[['J"6UJB^4 ?.VNKD[\YX8$8 K3\'Z!J>FZS8W-[:&%(O#5E8.2ZMMFC
M9RZ<$],CGI[T :OC#Q1)X9&D>7:37'VV_2W?RX&D*H02<;?XN.!WY]*2\\>:
M)8W=Q%*UVT-K((KJ[CM7:"W?CY7D P",C/IGG%-\;V.H75II-QIUD][+8:G#
M=O;QNJ,Z*&!VEB!GYNY%<[+IGB&R\/\ B#PQ;Z$]U_:D]TUO?^?$(42X+$F7
M+;PR;R,!6S@8H [3Q+K#:%X6U+5XHC.]K;/,B*I;<0,C..=N>I[#)KE8?B!*
MNN:;%<6EX\-YHXNQ:P6+M,9?,VDA<9"X!//'3GD5TFJZ/-+X$O=$MF\R=],D
MM(V8XW,8B@)],FL3PWINJGQ)IVJ7NF264<6A"RD662-F6591Q\K'@@9SZ$=^
M* -1O'&B?V7I]]!)<7(U LMK;P6[O-(5R'&S&1MP<YP!1_PF^BG2TO4>Y=GN
M39BU6V<W'G@$F,QXW!@ 3SQCG.*Y72O#^N^'[G3-8&E27C6\NHPSV<4L?FB.
M>X\Q)$W,%)PHR"P.&]L4EUX;U.]@U'5-0\/-.=0U1+HV$-V([JVC2$1+)'(K
M!1+D9(W8P2,T =:OC31O['FU*22XB2&X%J\$ENXG$YQB,1XW%CD8 SG.:MZ-
MXBLM;DN(8%N(+JVV^=;74+12H&^Z2IZ@X.",C@^E>?W'A7Q-J.@H9_[3ECL=
M7CO+*SN[]5O3 (RC*9D; ?+,RY;M@GFNB\'Z+-;ZY?ZK+I>H62201V\3:GJ#
M7-S( 2QR/,=54$\ '/)/&: )M>\6/H?C33M.DCGFM;JPGE$-M;M+*\JO&%P%
MYQM+D]N*N?\ ";Z*=&M]326>1+F9K>&W2W<SM,I(:/R\;MPVG/IC/2BYTN[D
M^(FG:JL.;.'3+B!Y=P^61I(BHQG/(5N<=JXR\\&:QOBU V=W)]EUS4+DVUG>
M_9YI()R=KHX88(X.TL,@D4 =A<>,+)_"^K:I9B43Z?&ZO:SQ-'*DVW*HRMR"
MQ*X['/%0R>-;#2%^R:D]W//9)''J-Y!:.T,,A52=[*,+U!XZ C.*P--\,W\D
MY9M)O+2WOM3MY;@WU^;F<P6ZEU,A+L!F0(H52>.M-\3:%K+ZYJEUH^DZE;:I
M.5-IJ6FWZ1P280 ?:8W?!VD<X1LKC'- &M<>.1IGB_7--O8;NXM[2"WFA2SM
M'E9%97,C,5' X7K^&:UKKQGI$$=BT#7-^]]!]IMXK*W:9VAX_>$ ?*O(ZXYX
MZU6TK2-1@\4^([ZZB4I>VMI''*I&)'1) ^!G(&6'7UKBK+P9J^E)H5[=:=JU
MP(]$AL+FWTK4OL\T$L;%ADB1%=3N(^\<$9H ]2TO5+/6M-BO[";S;:4':VTJ
M00<$$'D$$$$'D$5@K\0M!::10UYY$-T;2:[-J_D0S!]FUGQ@<XYZ<C)&:L^"
M])ET?P\(;BS^R3S3RW$D)N6N&4NQ/S2,3N8\$D<9)Q7!6,6L:[X.USPU::+(
M8K[5;V(:CYL8AC0W+[V8%M^X<X 4YXYZX .\_P"$VT?^VKK2]UR9;,L+N86[
M^3;[4WY>3&U05SC)[&F6'CG2-0N(H$2^B:XC:6T-Q9R1BZ51N/EEA\QQSCKC
MG%93>$[Z]TCQUIT@%N=8N'^RRLP(93;QH&..0-RD8/-((-=\0ZCX<CO-!ETJ
M+2;@75S-+-$RNZQ,@2+8Q)4E\Y8+P/6@#HX_%&E2Z?I%[%.SPZM(D=IM0DN6
M4MR.HP%).>F#638^-+&'0]*EGN;C4[N^5VB6SLG\R54;#-Y8SM4<#)/\ZH>'
MO"FHV'C.=KJ-1HFFM/)I.'!RUP0S\=1L^=1GL_%9WA[0M=\++H6IMH\UZ\6G
M2V%U:02Q>;$3-YBNNY@K ]"-WIUH U]#\>VT^AW6IW\CR*^JSV=C%#;L99E5
MCL41@;BVT9.0,8.<5KIXST4Z1>:C+--;I9.(KF&>!TFC<XVJ8\;B6W#&,YSQ
M7"OX1UZ:TM-3N=,N4N+?6;V\EL+*_$,QAGR,QRJRC<.."1D9'>K2^$=2FL+[
M4;72KFWNQJ%G>06^HZBT\]RMNV[;(Y=U0G+!0"<<9]@#H=(\7/K/CJ;2HH;B
MWMHM-%P\%U;-%*LADQGYNH*XZ<5/<^+3:^/DT"6WD6U_L]KI[DPMM5@PY+?=
M" 9R?7 JMI$>KZAX^EUN[T2;3;'^RQ:Q_:)8FD9Q+N.0C-@<\<]NV:K^*= U
M+4_$\IM[5WL]1T.XTM[E'4?9G=LAF4D$K_NY- &KIOCC1]3O+6WB^V1"\S]C
MGN+5XHKK S^[9A@\<CID<C--\7^*)/#1T<1VDUQ]NODMW\N!I-J8).-O\1P,
M#OSZ5B)9Z_K2^&M,N]"DTY-(N8;FZNGFB:-S$A 6$*Q8[B>K!<#-;/C:RU"Z
MMM'N=.L7O9+#5(;M[>-U1W15<':6(&?F'4B@#*LOB+;6EUKD>L+=&*PU.2 S
MP6;M%;PX7:9' P.2??UK?U7Q=INE7QLFCO+JY2(32QV5J\YAC.<,^T' .#@=
M3C@5SMQX;U63P7XYL5L_]*U2ZNI;2/S%_>*\:A3G.!D@CG'2J6I^&=1L_%.H
M:F-/UJ_@U"W@V#2M4-J8I8TV%9!YB J< AAG'/% 'H=KJ-I>Z;%J-M<)+9RQ
M"9)5/!0C.?RKC=+NO%_BK1E\0:?JMGIL%R#)8V,EGYH:/)V&5]P.6'/RXP#W
MKH/#&C?V5X1LM*GMHX"D)62".5I%0L264,W)ZGDUS>C2^*?">A1^'H_#4NJ-
M9J8;*]BN8DADC!^0R!F#(0, X!Z<4 ;TOBI=,L--75[*XCUB\BW?V=:(;B0,
MH&_&S(VC/WCQR.],D\>:#'I]I>>=<.MW.]K'$ELYE\Y028S'C<&X(P1Z5D_V
M=XCT?6=(UZZ@;7;E=,:QOUM/+C<.760.BL54KD%2,@XP?6J>G>&-:.N:;J]U
M9+"9M=N-1N(!*K?9HVM3$@8@X9B0I.W/+>V: -?_ (65X?$+RNNHHD$GE79:
MQD LVSC]\<83_#GI5O4/'6CZ=J5]8.E]-/8!6N_L]I)*($90P9BHZ8/UX/'!
MK U3PSJ]QX7\?6<5GNN-5NWDLU\Q1YJF&)0<YP.58<XZ5'#J.JV?C7QK!I^@
MRZD9GME1XY8T"2?9D $F]@=G?(SWXH ZF^\8Z7:2V\4*W>H33VXNDCL+=ISY
M)Z2':, 'MZ]JAF\=Z%'9:7=1RW%PFJ*YLT@MG=Y2F-RA0,@C/0],'/0URD?A
MOQ!I TS2IHM6O],M=+AMXAI-ZEL#.N?,\UBZ/M^[C!.!GC-3^%?"VLZ<G@M;
MRR$;:8=0%UB97$?F,=A!SEL@_7UQ0!U%IXTT:\MK:99)XQ/??V?LF@9'BN,$
M^6X(^4_7CD>M:EOJMI=:K>Z;"[-<62QF<;3A=X)49]<#./<>M<5?^';G_A'?
M&WVO;:&?4&U&QN&=<*8XHF23@\8>,]<' -;/@"VN/^$<_M:_C\O4-9E;4)U_
MN;\;$_X#&$7\* .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@EL[::[@NI8(WN
M+<,(9&7+)N #8/;.!FIZYG7]6U,^(=-\/Z/+;VUQ=PRW,UU/$9!%%&5&%3(R
MQ9QU.  >M '345YQ>>,/$5M;S:6OV!M9M]:M],:X,3"&1)D#+)LW9! 897)Z
M'!YXZ36+_4]!\(&XN=1TS[?&522\N4,4 RX&[8"23@\*#R>,C- '1T5Y6_Q
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M(D4ACTY''K0!Z+17FFC>*O%,ND>%M>U"XTY[36+B&VELX;9E:,2 X<2%SDY
M)&,8..V:OP^,-4DLX-,*V_\ PD!UDZ;( AV!%/F-*%SG'D8(YZL* .\HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J"UL[:QB:*U@CA1I&D98UP"[$LS?4DDFIZ* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *@AL[:"YN+F&"-)[DJTTBKAI"H
MV@D]\  5/10 4444 4M3TC3M:M5MM3LH+R!7$@CF0,NX=#@U=  & , 444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6+KGAV/6+FSO8KVYL-1LM_D75MM+!7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-% !10#GI10
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MHB8 SS]S/XUC)X<UR[\8>+9+;5;G2[2\>WCW?9E<2J+=5+1LWW6!R,\CVXH
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M2%<XX^8^M=/X$@%GXKU2UM+C2([06L3R6&E/))#%*6;#Y*A59EZJ#DX!QWH
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MDX&3@5UM><>.O$.C:QX%N-"TS4K+4-4U%([:UM;:=97+EE^;"DX"XW$G@8K
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M1]5MM<TJ#4K(N;:X!:)G7:67) ./0XR/8B@"]58:?9"=IQ9VXF9Q(T@B7<6
M(!)QU )Y]S4.L:Q9:%ISWU_(RQ*RHH1"[N['"JJCEF)(  KF=9^(,-IX<UNZ
MM;*\BU73K0W LKRV*MM.0KD \ID<D'C!SB@#L1!")))!$@>0 .VT98#ID]^I
MJ*STZQT]76RL[>V#G+B&)4W'U.!S7%#QW/#XJ2TEL=1F@FTB*[2S@LRTP<R.
MKL1V&%7J>XQR:W'\;:/_ &5IM_;FYN_[2S]DM[>$M-+M^]\O;;CDG % '021
MI+&T<B*Z."K*PR"#U!%(8HS#Y)C7RMNW9CY<=,8]*YJ?Q]HMOI45_(+SY[S[
M ;86S&=+C:6$93KN(''KD=CFMVWOQ<:4M^+6ZC#1>9Y$D168<9VE?[WM0 6^
MEZ?:6TEM;6-M#;R9WQ1PJJMGKD 8-3F"$O&YB0M%D1MM&4R,''IQ7FMK\1KZ
MXTGPOJ<]K/"M]J$UO<PQVI8R@1R%!&.2?F"#/J#GBNJB\<:0^EW=[*MY ]I<
M+:S6DMNPG$K8V($&22VY<8R#GZT ;QM+9HY(S;Q&.1M[J4&&;KDCN>!S0;2V
M9BQMXBS.)"2@R7'1OJ,#FN>'CO2DM=4FNX+^QDTR!;BX@NK<I((FR ZC)##(
M(X/:I]*\8:=JNJKIR07UM/)";BW^UVS1+<1@@%D)ZXW+P<'D<4 ;;VMO*9#)
M!$YE39(60'>O/!]1R>/>HK;3+"S""UL;: 1YV"*)5VYZXP.,X&?I5?6M;M-"
MM8IKH3.TTHAAA@C,DDLAR0JJ.^ 3Z8!K*3QWI/V*]GFBOK:>SFC@ELYK<B?S
M),"-549W;L\8- &]!I]E;%3;V=O$5+%?+B5<%OO8P.^!GUQ1#IUC;W<EW#96
M\=S+_K)DB4._U8#)JGHVOVVM-<Q1V]W:W%JRB:WNX3&Z[AE3Z$$9Y!/2F:QX
MCM-&N;>T:"[N[RX5GCMK.$R.47&YCT  R!DD=: -+[);>1Y'V>+R=V[R]@VY
MSNSCUSS]:?+#'/$T4T:21N,,CJ""/<&J.B:W9Z_IPO;+S0@D>)XYHRCQR*=K
M*RGH017)7GBVZC^(=[9W%U<V&BZ59+<7!-HI20GS,L[G)5<(-NWDG(H [2UT
MRPLG+VEC;6[$8+11*A(_ 42:9837BWDME;/=*-JS-$I<#T#8S61IGC'3]2OX
MK%K:_LKB>)IK=;VV:+ST'4IGJ0""0<'!Z5FP?$W0KC38]26#4Q8S21Q0SM9/
MMF=\X5.[$%2#CO0!U?V"SW6[?9(-UN,0'RQF(8Q\O'''I38=-L+:ZDNH+*VB
MN)?]9*D2J[_4@9-<P_Q)TB-+O?8:PLUC\U[!]A;?;)C<'?L%(Y&"20#QP:TM
M0\7Z=97$%M##>:A<S0"Y6&Q@,K+">CGH #V[GL#0!J:?IUOID4T=NI FGDG<
MGN[L2>GUQ^%6$ABC9VCC1&D;<Y50"QQC)]3@"N9NOB!HEO#ILD O;YM2BDEM
M8[.V:1Y A <;>H(W<@XQ@^E=#=7MO8V$U]=RB"VAC,LKR<!% R2: &VVFV%G
M/+/:V5M!-+_K)(HE5G^I YK,\.^%K'P_8PPK'#/<Q-*1=M"JR8>1GQGK@;L=
M:BTWQGIVHW<=J;>_LY)XFFMOMELT0N$49)3/4@$'!P<'.*SH/B=H5Q'9S);Z
MIY%\O^AR_87VW#XSY:=RW7VX//% '81PQ1;_ "XT3>Q=MJ@;F/4GU-06FFV%
M@TC6=E;6[2G,AAB5"Y]\#FL$^/M%CT:74YUO($AO!8S026[>=',<84H,DY#*
M>,YR*S]?\<A/#&LRZ>ES8ZM81Q2&WO8-KA'<*' .0RGYAD9P1S@T ==:Z986
M4LDMI8VT$DO^L>*)5+_4@<T1Z;817KWL=E;)=OPTZQ*';ZMC)K%U/QMIFF7M
MU:F"_NOL2AKV6TM6E2V!&?G([XYP,D#FKUGXDTN^N[NWAN 3;6\5TSGA&AD!
M*NI[K\IY]J - VEL8&@-O%Y3-N:/8-I.<Y(]<\_6@6MNMVUT+>(7++L,P0;R
MOIGKCVKG3X\TMXK-K2UU*\ENK5;Q8+:U+R)"WW7<?P@]AU/858G\9:1'IVG7
MEN\][_:6?L<-K$7EFP,MA>,;>^<8Z'F@#7N-.L;R:*:YLK>>6(YC>6)69/H2
M.*>EG;1F,I;PJ8RQ0J@&TM]XCTSW]:J:+K=GKMI)/:>:K0RF&:&:,I)#(,95
ME/0X(/N""*N7-Q#9VLMS<2+%!"ADDD8X"J!DD^P% &7K^BSZKI4]C87PTTW3
M$7,T<"NTB%2K 9QAB,8;G&.E:=G:0V%E!9VR".""-8HT'1548 _(5@Z9XVTS
M4[ZUM1!?VIO5+6<EW:M$ER ,G83WQS@X)'.*E\-^+K#Q4C3:;;WWV8(&6YFM
MFCBDYP0K'[Q!!!Q0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;=-;?%M+N!R/LR1Y('( 8'BNVJ/[1!]I^S>=']HV>9Y6X;MN<;L=<9XS0!Q
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M!C\K[3Y8\S9G.W=UQ[4 <)K?A*XMO%MSJ=MI-_J-E=6D,*PZ=JC63P/%N !
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M2E,GGZ>9##M;"_.NULCOQ61J7@BQU"]O;F._U*Q%^ +V&SG")<8&W+ @D$J
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ML!6B?C8X'().,BJ7@_P]?V_BK4->O+?4+=);..UC74KI)[B0AF8L=A*JO*@
M'L2>M %S6;S7+KQS!H.FZE'86SZ:UW)+]G65PPD"@+NX'7OGITYR,-/%VJ3>
M'M,%UJ\%G>/>7=K/);6+W%Q<>3(R PPJ&ZX!8D$#\:[PZ/;'Q NM9D^UK:FT
M W?+L+A^GKD"L5O >G*;:2TO=0LKFVFN)8[FWE7?^_??(IW*5*DXZCC YH Y
M:W\8^(9_#TBQ7"B_C\11:4EQ=V?ELT;A"&>+(PPW]!CIVJQ-?>+TNO$]@OB*
M'_B2VZ74=P;!-\Q>-F",/NA04/(&3NZ\<]':^ ])M(FC26]</J4>J,TLV]FG
M0+R21G!V@D?EBM%_#MB]UK%P3+OU:%(+CYA@*JLHV\<'#'UH X6?QOJVJZC#
M:VLM[8QQZ;;7<KV&E/>L\LRE@IP"%0 ?4Y.#Q4ESXI\4RZ1HMW=6FHZ5;RQ3
M?;I[73#/+'*C[5S$P+)&R@MG!/(''6NEF\#V.ZUDLK_4M.N+>T2R,]G,JM+"
M@^57RI!(YP< C)P:&\#:=%#8+IUWJ&FRV4+01SVDPWNC'<P?>&#9;YLD9S0!
MH>%]2;5_#=E>O>VMZ\B'=<6JLJ.02"0K<J>.0>AR*X#4_&VK6CR:A;:P;Q(M
M06%[:UTMVLQ$9A'M-R5&7P>2#C=QBO1]&T>TT'2XM/L@XAC+,6D8LSLS%F9B
M>I)))^M<X_PVTJ2Q.GG4-5_LT3>?#9"X BA??ORORY(#<@,6 ]* ,?6/%&N:
M7XCNUU"_DTFUCND2T,VG&2RGA.WEYUR4<Y;J5 XZT:UXHUS2_$5X+^_DTFTC
MN46T,VG&2RGA.W)>=<E'.6Z[0..M=#?> ].OY[S?>ZBEE?2^==Z?'.!!,_&2
M1C<,X&0K &B^\!Z=?SWF^]U&.ROI?-N["*<""=N,DC&X9P,A6 - &<^H^(]<
MN_$%QI6JP:?;Z1<-:P0/;+()Y$C5V,C$Y"DM@;<' S5;2/$>M^.+@#2[]-&A
MATVUNI/]'69I)9U9@OS<!%"]N3GJ*W=1\$6%_>WEQ'?:E9+?@"]@LYPD=Q@;
M<L,$@[0 2I4D"G7?@K3YIXIK&ZOM)D2V6T)T^41[X5^ZC @CY<G!&",]: ,.
MYUW4K#6KDWDFC0WD'AP7,ERP/DK+YK+]_&_R\C.W^M4=.\2ZQ<>(;;2EU>\N
MK?4;*X9;FZT@VOE2(%(:+<J[U^8\$'MS733?#_0)K5[7R)4MFTY=-$22$!8E
M?>"#UW;N<YJ2T\&6L&LVFK7.I:G?WMHCQ1R7<RD;'&"NU5"^AR!DX&2: /._
M#OB+5=/\,^$]#M[R\43Z5]MDN+333=2QQ@JJ1JB@C&2278'L.]=#;>*?$=[9
MZ9I3))8ZC>ZG+9K?7-BT1>".,R^:L3]&8 +@Y&0WTK9M_AYIMG964%IJ.JV\
MMAO6TN8YU\V&)L9B!*D,GRCA@<'O5D^!]*_L>.P66]66.Z-ZM\)_](%P<YDW
MD8R02,8QCC&* ,SP;;W]MXV\71:C=I=S#['B=8Q&77RVQN4< ]N.#C.!5/Q)
MXKUW39=>TBR:)]6:XMO[)W1C!CE4DY'\6TQ3?I74Z%X8M- NK^[BNKRZNK\H
MUS-=2AV<H" >  .#C XX& *?=^&M.O?$VG^()D?[=81O'"0WRD,".1W(!;'I
MN- '#:KXSNM7T+4M1LEMGTZWL]/;RYH5D5IYY$=@<_W49./5L]JR?$L%^D/Q
M*D-]YJ_:K()$\0 W$0%<D<\#Y??KUKT"V\!:)9^&KO08%G2RNKG[3)AQNW[U
M88..@V* /04[4/ ^FZC>ZK<2W%ZJZHL0N8$E C9HRFUP"#AL(!UQC/% %73+
MS7-/\<)HFIZG'J,%UITEXKBV6$Q.DB*5&#RI#]\D8ZTOB_6KFPU"PLK?5_L(
MFCD=DM;)[R[D(P!LC"L G)RQ'7 %;[Z/;2>((=:)D^U0VKVJC=\NQV5CQZY0
M52U;PQ;ZIJL&J1WU]87T4+6_G6<BJ7B)#%&#*PQD9Z9]Z .*L?%OB/4]/T:U
MANXX+RXUJYTV:XFM-K&.-)&#&,GY7PHXZ9'IQ5N;Q%XBTJP\1I+=I?2^'[RW
MEDF%NJ-/:LB22*5' 8*6Y&.@KH=.\#:3IAM#;O=G[)?2W\?F3;SYLB%&R2,D
M88GDYR>M2W^FKI<>M:E8Z9/JEWJ1C\ZT$J*)-J", %L #:.<GU^E #=&UFXU
MKQ+J_P!GE1M(LEBMXV4 ^;.5WN=WH%:,8]<UD6MI;:S\5M:_M2&.<Z79VPL(
MIE#*BR;S)(H/&25"Y]!BMCP/X<_X17PAI^DN0T\:;YV!)W2,<MR>2 3@>P%2
MZWX5L=;NX+XSWECJ,"&..]L9O*E"$Y*$\AESSA@10!QRZS;:;J?B*XL_#VH:
M%J[:)+>[)_)\F7RLA7VQLPWY;&3U JQ!J7BICX?TZ76H/MFNQO=M<+9J!:1)
M&K-&BYPQ)=1N;L"<5O6O@33(8]0-Q<ZA?7=_:O9S7EY<&240L.47@*H[\ <U
M;U#PK8W]CIUOYUU;3:;C[)=V\@6:+"[3@X((*\$$$'TH Y5_%.N:=J;:)<W4
M-S<6VLV5LUV(0AFMYP3AE' <8(R,=C@5-XI\5:OIEUXIBL9(0=/L+.:V#H"!
M)+*ZMN]1A1]*V&\!Z4^EW%I)/?27%Q<I=R7[3_Z29DQL<-C *X   P!VK'\1
M>  WAK7UT^6]U#5=4@AAE>[N%)D$;Y'/RA>&(XP.!QGJ :-K>ZWH_B[3=)U3
M4H]2AU.VFD5A;K$T$L6TD#'5"'[Y((')S5?Q%!%JGQ*\.Z9J*++IR6ES=QP2
M#*2W"E%&0>"55F(],YK:TKPK:Z9J?]HR7M_?W:PF"&2]F$AAC)!*K@#K@9)R
MQP,FI]=\.V/B"&!;IIX9[:3S;>ZMI#'+"V,$JP]1P0<@]Q0!F:G;Z!X=U277
MD6*WU-=/G(MXG$9NHXP'.5_B*\8/;=6-#K'B73K+P[K>H:G;W=OJ]S;PSV*6
MP18!/]TQN#N.TD9W9R,]*Z'2_!]AI][/?7%S>ZI>S0FW:XU"42,L1Y**  JJ
M>^!SWJO8> ]-L;BR8WFHW-KI[^9965Q<;X;=@"%*C&3M!(&XG':@#DX_$7B^
M30[#6TU:T N]7.FI:O9@H$:=X0[,"&+ @' (! Q[U:U+Q'XET:W\26 U&"\O
M;";3_LMU-;J@(N) I5U7@@8/(P>:ZR/PAID>D6>F*T_V>TOA?QDN-WF"4R\G
M'3<3QZ5E>-/!W]JZ5J[6$<LM[J<EDLZ>:$&R&922IXP=I8]>PQ0!#<:UK7AS
M5[C3M0U:TO$ETJ:^@NKJ(0+!)$5!#[/^69W@],\$9-9VB^*]5/BG2K)]3NM1
MM-0@G9I+C26M$5T0,#$652R]1SGMS71_\('I<\-^FHW-_J<E[;?9'FO)@SI#
MG.Q-H '.#G&20,DXIUMX*M8M5L=3N=4U6_O+)72"2ZG4A5=2K+M50/?.,D@9
M)H Y?1O$/B@Z-X2UZ_U6WN(M8N(;:>R6U5%59%;#JX.[=D GMR>!5YO%>K)%
M<:&98_\ A(!K0L(G\L<P-^]$NWIQ!N_X$M=%%X1TV'1M&TI6G^SZ1+%-;$N-
MQ:/.W<<<CGVK,L-"GO?B/>>);S3&LEMK7[%;;Y58W!WL3-A2<#:0HSSACD"@
M#L:*JV=B+.6[D%S<S?:)O-VS2;A'P!M0?PKQG'J35J@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7 &QN23Q@4L/C+Q!J=QHVF6D>GVNH7%S>V=[)(CR1QO;D N@# D'L">XYXY
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M(QU/45+IG@O3])NM*GMI;@MIT5P@,C!C,TS*SNYQRQ9<\8ZFNC!!Q@@YZ49
MSR..M '+3^!K.2.9H;ZZM[PZD^IP74>W?!*Z[2 """I&000<@UIZ)HDFE/=W
M%UJ=WJ-W=,K22SD*H"C 5$4!5'T&23R36L&5EW!@5ZY!XJCJ^LV>BZ//JEVY
M^RP*&8QC<3D@#'XD4 9&H>$7GU2]OM-UN^TMM055O4MUC82E5VAAO4['V\9'
MH.XJQIWA/3])U'3[JR\R-+#3VT^&'.5\LLK9)ZELH.?<UN%U4 E@,\<FE#*6
M*AAN'49Z4 8^M^'QJ][I=['>SV=UITS2Q21*K;@RE64A@1@@X]15.3P992>&
M;[0C<SB"\NY+IY.-RL\WFD#C&,\?2ND#*6*AAN'49Y%&]=P7<,GH,]: .6O?
M!;2WFH2:?KNH:9;:FV^\M[81D.Y 5F1F4F-B  2#[\&MG4='@U#P[=:*SR);
MW%JUJ6#9=592N<G.3@]33[;5[2ZUB^TN)F-S9)$\P*X $FXK@]_NG]*O4 8&
MI^%HK^WTSR+VXL[W2_\ CTNX0I9<KM8$,"K*PZ@CL.E5O^$.D-DX;Q!JAU)K
MI;O[=O4$.J[0HCQLV8XVXP>O7FNHHH Y"3P#!<:9J<-SJEW+?ZC/#<S7X6-7
M5X2ICVJ%V@#:."#G)R:T['PU%9C5V>[FGEU7:;B1PH.X0K%D   9"Y^IK<HH
M Y-? ZV::>^DZQ>:?=V=A'IS3QI&_GPI]W>K*1N!R01CJ>U+%X%M;2YTZ:SU
M&]A-I:26<FXK(;F-VW-O+#.[=\V1C\JZNB@#D8_ J6,6FMI&L7FGW=E8)IYN
M$2-_/A3[H=64C(.2",8R>U6M.\%:?IEQI,T$]RTFG&X??(P9IY)_]8[G'))Y
MXQ7244 <S-X-CS>2V>JWUG=7&HG45FA*_)(8UC*E2"&0JO0@]?I5W0/#R:(U
M]</=S7E]?RB:YN9552Y"A5 50   !_4FMFB@#FF\&63W$DQN9\OK":N1Q_K%
M0(%Z?=POUK3MM%AM?$.H:RLDAFO88870XVJ(R^".^3O.?H*TJ* .=U#PG'?:
MW>:DNH7, OK#[#=0(J%)% ?:V2,@CS&Z'!XJ;_A&+79X>7SYO^)(08>G[S$+
M1?-QZ,3QCFMRB@#DK?P0VFV.G0:3KVH6,EE"\&\!)%E1FW?,C*5R#T(P?K6U
MH.A6OA_1(=*MB\D,>]F:7!9V=BS$X ')8G  %:=% '$CX>O#92:3:>)M6MM"
MD#*=/3RCM0]8UD*%U7G&,Y [U?NO!J+>_:M%U2ZT:1K:.TE%LB.LD29"<.IP
MR@D!AV/>NGHH P=%\*6.@W[75G).<V4-D$D;=\L1<AL]2Q+G)K/B\!06=AI,
M>FZG=V=[I:2107B!&9HW.61U(*LI.#TX(!%==10!RK^"(WL(%.L:@=4@NVO8
M]29E:196&UL*1L"%3MV 8Q[\U&O@"UET_7+:^U2^O)=9,;W%PY175T VE-J@
M#&!@8["NNHH XYO 0NYKVYU37;^^NKS3)M,>1UC0+%)@Y554 $8Z\YSSVQ8G
M\&LEY]LTG6KW2[B2VCMKAH4C<3*@PC$.I < D;A74T4 4;#2X-/T:'3$DGEA
MCB\K?-*6D8=R6ZY/K6%8^"C;W^FSWNN7^HPZ62UC#<+'F,E2F6=5#.0I(Y/N
M<FNKHH YJ'P99P^'-)T1;F<P:;=17,;G&YFCDW@'C&">*S+GX;QW&E7FCC7M
M1BTBYF>X%I&L0V.S^8?GV[BH8YP3]217<44 <U>^"[.^U6XU"2YG62>[L[ME
M7& UN?E XZ'O47C_ $F[UK0K2TLQ/O\ [2M'=X" \:+*I9P3T*C)_"NJHH Y
M"X\!1:C::HNJZM>7UYJ%NMJUTZQH8HE;<%154*,GDG!R:U-<\.KJ]W97]O?7
M&GZE9;Q!<P!6.U\;D96!#*< X]0"*VZ* .<'A""7PWJ.D7VH7MXVH%GGNIG'
MF!SC#( -J;<*5 &!BFR^"K$^'=+TJWN;FVDTMEDM+R,KYJ2 $%SD$-NW-N!&
M#N-=+10!RLO@H7FE:E:ZEK-_>SZ@T1EG<JNP1L&540#:HXYXR<\GI6CJ'ANT
MU+5SJ$\DNYM/FT]HU( ,<C*6/3.?E_6MFB@#-T#2GT/1+73'OIKP6R"-)9E5
M6V#A0=H X&!FL;2_ T&F0Z5#_:5W/#I5Y)<VB2*@V!D9/+)"C(&]CD\^^*ZN
MB@#F=0\$V&HSZI<27-S'/?7$%TDL3 -;RPJ%1DXZ\<YSG)JYH^@SZ??7%_?:
MQ>:E=S(L6Z8*B1H"3A40!023R>2:VJ* .9UCPE-J/B)=;LM=OM+NQ:"T;[/'
M$X9 Y?GS$;G)[>E,E\'W%_IKZ=J_B/4=1M99HY)4ECACWHIR8SL1?E8XSW.,
M9P374T4 <O-X%TV6VU2T6>YAM+^=+M8H6"BUG4@^9$<?*2P#$<C/;DT+X,6[
MCOEUW5[W5OMEJ;1EEVQ(D9Y.U$ &[.#N// QBNHHH Y2/P2+CS1K.LW^JH;.
M6RC6;8@2.0;7)V*-SD #<?ZTFF^"&L]4TJ_O->U#4)-+1XK1)EC551DV$':H
MW'&/F// ]\]910!RFB^!K?1I=+8:E=W$>EO/]D254&Q)0 4)"@D#!()YYJYI
M7A#3M(US6-5A\QY=4(,D<A!2,<E@@[!F9F/J36_10!R5AX'.GFRMDU[4VTBQ
ME$MMI^455P<JC.%#L@[*3V .0*V]=T6'7],%C/))&@GAGW1XSF.19 .>Q*@5
MI44 8T7AJR6773-OGBUIPUS$_P!W'E+$5&.<%5_6LVP\$_9[K3GOM;O]1MM+
M;=8VUP(PL;!2JLQ50795) )]<]>:ZNB@#FH/!EE!HFDZ6MS.8M,O1>QN<;G8
M.SX/'3+FM.RT6&QUK5-4221I=1,1D1L;5\M=HQ^%:5% &,OANV6YUZ<32[M9
M"B8<83$0B^7CT&>>]9I\$K;?V?-I6KWFG7EG8QZ>9XTC?SX4'RAU92,@Y((Q
MC)[5U=% ',6?@72[-M,*R3RBR%SN\Y@QN6N,>8TAQR2>>,=:JVW@ 02Z4DFO
M:E/8Z1.LUC:2>7MCV@J%9@NYP <#)X%=C10!S5EX,LK+4[6^2YG9[:]O+U5;
M&"UP3N!XZ#/%9GB3PPEM9W=Y:6VH7<]SJL>H%[.1%GM&$8C\R(,,/@*,J>H9
MOI7<44 <+X&TG48_$.NZW??VD4O8[>&)]2")-)Y>_<VQ  B_. !@=">_.M?>
M%'GU^XU>PUF\TZ:[@2"Z6%(V\Q4SM*EU.TC<1D?E7244 97AS0H/#6@6VD6L
MLLL%ON"/*06P6+<GOC.*7P]H<'AS0X-*MI9)8H6=@\F-QWNSGI[L:U** .>U
M/PN]UK+:OIFKW6E7TL*V\[P)&ZS(I)7<KJ1N7<<$>N.:=:>$[2SNM%N%NKN5
M]*AGBC:>3>TOF[=S.QY)RN>,#GZ5OT4 <U<^"[*YT77-,:YG$6KW374S#&Y&
M.SA>.GR#KZU)K?A&TUVZOIY[B>-KO2Y-,<)C"QNV2PR/O?I70T4 <S)X,MY-
M1O[@7]TL&H6"V-W; )MD5595<$C(8!VZ''M5>/P1+;)83VGB"^AU.SMC9_;!
M%$3-!G*HZ%=IV]B #UZY-==10!RK^"8UMM/:VU?4(M3L7E>/47999',IS('#
M#:5/'&!C QC%:'AOPY'X<@OD6]N;R6]NVNYIKDKN,C*JG[H  ^0'&.,^E;5%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>0139+6WED\R2")WVE-S("=IZC/I[5( %4*H  & !VH 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\7E76^X=A< VCN P)Q@,JXP.,<4 >K5FZ_KEIX<T6?5;U96MX2@984W.2S!
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MJ_7C>NZAJ%A'K%[I\KK>+X4T\^:&.Y%,T@=\X)!"ECGMC-:_AJVNM-\::9%
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M'/!^8X/7\JO^*/M/A"Y\3VOAV6XMXCHD%UL,[N(G,[1O*I;<5/EY)(_NY[4
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MM);74,<\$B[7BE4,K#T(/!%2T4 5;33+"P4K9V-M;AD6,B&)4RBC"KP.@!(
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJDTMMI-Y/
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MX>#[3,)%7!9"&(53G:#WR>E<JT][?066C#6-0-E'XKDTY+F.Y82RVPMW8H9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'97&!N6TFS*7''.Q4F7/JHK3^*EJ;GP-*!<SP[+JU)\I@-V9T7!R#TSGZ@4
M=)I6NZ9K8D.G70F\H*9!L92NX97(8 C(K1KRW7-6UJQE\06%GJ]PCVU]I5K;
MSR!691+L#D\8).236E+I^J'QC9>&E\3:L+)=*ENI9M\?GROYP RVS P&[ <
M>] 'H%%>4:1J.O+HOA?7KG7[RXGN]56PGMV5!"\6]X\[0N=_R!MV>I/;BO5Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(FP1E70AAP2.O-0OXMT"/1XM6;5;?[%,_EQRAL[WZ;0!R6X/&,\&@>+?#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSR9FD=ECD'4*P"[Q@D8P17I]_I=GJ9M3=Q>8;2X6YA^8C;(H(!XZ]3P>*N4
M>1W6F7>KQZ]>0?\ "37TJZ!=6J2ZE:I;[WD&1$L8B1G.1G/0=!G-;WB+3A%H
MGAD_9-7MVLD"K>:4FZ:R/E;>8MK%U/W2,''%=]10!Y391:Y%)HNNZEIMS=6M
MAJ=T6,5AY5S+%)&%2X>!1G?NW X&[!SBDU'2[[6[W5-6ATB[CL;[5M*\N&:W
M*22)#(/,E:,C*K@@?, <)DUZO10!R;PW%I\1]2U7['<26HT.)=\49/F.LLK%
M%]6P1Q[BNFM9_M5G!<>5+#YL:OY<R[73(SAAV([BIJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[OR!$JC.<[6R,9],8KGF\>W0M])W:/;V]WJ%L]T8;S4%A$2!E5!N*\LV[.W
M(P: .WHKGM<\51Z"FEQSVK2WE]/#"8(WR(0\B1LY;'W59U'3DD#CM5O?&9M-
M:N+0:>'M+:\M[&:8W 67S)@FTI%CYE'F+DY!^]@'% '5T4C$*I8] ,FJD.JV
M%P+,PW<,@O4,EL5;/FJ "2OJ,$'\: +E%5=2NY;'3IKF"TENY4'R018W.Q.
M.>G7D]ADU0T/6Y=4N-0L[JT2VO+"14E6*;SHSN4,,/M4YP>00"/Q!H V:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"GJKW\>DW;Z7#'-?B)OL\<K;4+XXW'TS7%>%-(UZT>:+6?#\;3
MZBI&HZL^I++*_P IP @080= H( ![\Y]!HH \\L?#OB*6P\/>'M0M+:.PT6X
MAE>_2?=]I2#_ %06/&5)(4MG@8.,YKT.BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>guyaragreement022.jpg
<TEXT>
begin 644 guyaragreement022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUW;/ &.>_IG!H Z6BN5M_'MA/<V2G3M4BL[Z<6]K?RVX6&5SG:!\V\ XX)4
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M;RJD MWQ6VCK(BNC!D8 JRG((]14)OK,300FZ@\VXW>2GF#,FW[VT=\=\=*
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M-ZJ20&(Z@$@X/L:FH X;PY9>*]%TW2?#J6%JEK8.L<NI&8,LUNI. L?W@[#
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MK3I&)4F5X)#&ZNAW*0PZ$$5G0^"-/%M=VMY?:MJ5M=0F&2"_OI)DQD'(!/#
M@8(Y% &%HVNZ]:ZNT-W)J=SIS6<LLMWJVGK:BVE0 @Y0 %"-V002,#GFLW3?
M%&L_VUX>_P")OJ5];:I,8)VGTM;>VR8G<- S(KD KQG<".M=A:^"-*AEFENY
M;[4I);9[3=?W+2E(6^\B^F>,GJ<=:BM? 6EVUQIT[W>I7+Z:X>S^T7;.(0%*
M[0.A&#CG)X'- &/IGBC5[[^Q-$:X4:TNH30:I((UQY5OR[8Q@>8&AQ@<>9QT
MK#L_&GB?4;%-=M(]6F,ER=FFIIBFU: 2;=OFXW[]H)W9QNXQBO1[;PYIEIXD
MO=?A@*ZA>QI%-)NX(7 X'8G"Y]=H]*S&\ :*UPQ+WHLFN/M3:<+EOLIEW;L[
M/3=\VW.W/:@"7QW?3:=X8-Q;^7YGVRT3]Y&KC#7$:GA@1T)Y[=:Y#5]>\41:
M;XLUNVUI8HM$U PV]G]EC9)5 C)$C$;L?.0-I!'J>WHNKZ3:ZW8?8KP,8?-C
MEPK8.Y'#KS]5%49_">EW.F:OI\B2_9]6G:XN@).2Y"@X/;[BT <=K^M^)/"\
MFN6SZT;UTT*348))+:-/(E1PN% '*G/1LGCJ:M9\5_\ "5V>BOXG81W^GO>2
M2K91;H&1D4K%E<;3Y@^^&.%ZY.:ZC6/"NF:Y-<RWJ2EKFQ>PDV/C]TS!B![Y
M'6KAT>T.LV^JE7^U6]L]JAW<;&96/'KE%H \W7QKKMSIOAZP,]U]KNWO1=WE
MA9++,RV\IC&R,@J"V02<$#L.:MP^)O$TL%KI$C7-I<W>K"S@U.[LUCD,'E&4
MMY9^7S/E*=,=\=JZB3P1I#6%K;1&ZMWM)Y;BVN8)RDT3RL6?#>A+'(.1C'I0
M/ VC#29+$BZ9Y+D7C7C3M]H\\=)?,ZA@.!VQQC% '"ZA)J>@WWC>2:_2^N(X
M]*$<\UO'DHTK##J!M)Y/( ['&:U/%?B+4X=0UI=.UJ^5]/B#1VVFZ:L\<;"/
M<?M$KH5!/HK#"X[UT,?@'1U@U*.62]N'U(PF[FGN"[R&)MR'/;'3CC  I][X
M&TJ^N[^9YK^*'43NO+6&Z9(9VVA<L!SD@ '! ..<T <7)K5];>(Y_%CW+L4\
M(1Z@UFJ)Y;'YSLSC<%W?-G.??'%:.@:]XF;5M',YU>]@O3MO5N=,6"*#*%@\
M3J =H8 88MD'.:Z=?!6DK<6,P^T'[)8?V=Y9E.R>WP0$D7HPY)^M,TWP1I>F
MWMI<B>_N18@BRANKII8[;(V_(#WV\ G) Z4 <AX1URXT&QT1[NX5-$O)=2AD
MW* (ITN)9%;=C.&19!CU KN/"%YJ.I>&K74=3/[^]W7*1[0OE1.Q,:<=PA7.
M><YK \2>#?MN@V?A.PT[?I4UW]HN;N2X -N/-\QP!]XEMS*,< -S7=*JHH50
M%51@ #@"@#R'PS<:YX>^'FAZXNK^=9_:8X7TWR$V&*2?R^&QO\P;MV<X[8J6
M;QAXFOO[5U+31JI:UO)H;2QATQ9+:58G*D228W;FVGD$!<]#BNOT_P"'FBZ:
MUHL4E_):VDOGP6<UTSP)+G(?;ZY)/IGG&:?>> ='O;FZ9Y+Z.UO)?.N[&*Y9
M;>=^,ED]\#(! /?- ''3ZA?>']?\>>(4N9)9;>UM72VGBC"AG1M@8A0V$)['
MD9SD\UO75YX@\,:MI4%YK;:K%J:SQ.)+:.,PRI$T@:/8!\OR$$-GJ.:Z5_#>
MERS:K)-;^:NJQ)#=1N<HZ*I4 #MP35&P\$Z99727+W%_>RPPM!;F\N6E^SHP
MPP3/0D8&3DXXS0!Q4?B3Q1:^$O#M[<:M/=7GB)H0/L]A&QM$\II',: ?.[ #
M[V0#DXQQ75>#=4UFZO\ 4K+48]0EM(5CDM;R_M%MY7W9#(P4!3@@$$ <-[5I
M3>$=*G\.V.B,DRVU@(_LDB2E986C&%97'(8#O[FIM%\.6>ARW5Q%)<W-W=E3
M/=74IDDD"C"C/8#)P  .30!YYKEK<I<_%25]0EDB_LI?W)1 O,#E>0,_* 0.
M><\Y-:B:IKGA:[T8WVJG4K6]TZXEDMC;I&(FAB$@\LJ-V",C#%O6NGO_  ?I
MFH7VIW4KW2G5+0V=W'',1'*F"H)7^\ 2 :N3:#8W%YIMS*C-)IZ.D +<8=0K
M COP* //]!\4>*+I]"OW&K7:ZA+%]KMGTQ8[6&*0?>BD W?+D'+%MPSTKTZ:
MV@N0!/!'*%Z;T#8_.N<LO 6CV-S:2))?2VUE)YMG937+/!;OS@JI],G&2<=L
M5U% 'E_A?4H_#/P'M=>@LX9+JVTYG7*?>;<0,D<XSC/M4^E:YXE@U:TBF;6+
MVVN(9?M4E]IB6Z6\BH65HRH'RDC;M;)Y'-=G8^&],L/#*>'D@\S3%A,!BE.[
M<ASD$_B:H6'@C3+&[BN7N-0O'MXFAM1>732BW1AA@@/<CC)R<<9H Y&VU?Q:
M/!/A_5Y/$"27FMW-E$ ;.,1VZR9#$ #+$@@G)ZCC .*FGN?%<=QXJLE\4R;=
M$MTNH)S90F28O$7V2?+MV@H?N@'YNO%=FOA?3%T?2=+"2_9M*DADMAOY!B^Y
MD]ZE?P]823ZO,RR;]6B6&Z^?JJJ5&/3AC0!P&J^+]7AL]9U&T:"&X30-/O(C
MY*G;))(^X$D9*^Q/':MB34M;\.^)&LM1UZ*\MI])N+WS;J!(DMI(B@SE #Y>
M'Y!R1CK6S/X'T6XM;BWDCF\N>R@L7Q(<^5"24'UR3S5S5/#6F:U=?:+^%I2;
M.:R9=Q"F*7;O!QW^4<]J .&T?Q+K+>)M M6U75+RUU42QRR7>EK;1!A"TBM!
ME%<C*_Q;@0>M4_"L]]I>G>'4:]:YCNO$%_&ZRP1DJ%-R3M(7()9<D^Y P.*[
M:T\#:;:W^G7TEWJ5W<Z<3]E>YNF?RE*%"H'3!!Y.,\#GBGVG@K2;*[CN(FNR
M(;U[^&)YRT<4KAPVT'H#YC''J: .4B\0>(T\&V7CB35U>&>2*232A;Q^4())
M0@57QOW@,#DL02,8J+4=<\41Z%XH\0Q:X(X]%U">."R%K&4ECC8?+(Q&[D$@
M%2,8SS75Q> =&AN(V5KTV<5Q]IBT]KEC;)+G<&">S<@= >U7)O">ESZ-JVE.
MDOV75)9)KD!^2TG+8/;I0!G_ !._Y)CXB_Z\GK,^(^G6%O\ #NYU&&V@AO[)
M8I[.>.,+(DP9=FTCG)/&.^:['6-)M==T>ZTJ]#&UNHS%($;:=I]#6);> =)B
MN[>XNKK5=1-LXD@CO[^2:.-QT8(3C([9'% &)XFU[4UU?4+6RUF_BDM+=&6U
MTO31<>6Y4MF=W0JH/&%#*<<UFZ9J=]?^*]%\27%Y(ID\*&^FMHHTVM\T99 2
M"0"3GKG@#.*[.]\%Z9?:E>7K3W\(OPHO((+EHX[C:NT;@.?N@ X(R!S2VW@O
M2K.;2);=KJ-M+MC:0[9CB2'CY)!T8<#KZ4 <9H7BKQ1>#1-3*ZK=+J$L1NK5
MM,5+6*&3^**0#=\@(.6)# 'I7JM<O9^ ='LKFU=)+Y[6SE\ZTL9;EFMX'YP5
M0^F3@$D#MBMZRL$L3<[)KB3[1.T[>=*7VEL?*N?NKQP!P* +5%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNKDWD$C^6T4JQD*N5)!)XSC@YH ]&HKC/B5_: T+3OL%W';L=6LE8O$7SF=
M.C+QG!([@8XZTS^UO%&KW^L1Z/<:9!%I$@MC]HMG<W<XC5VZ./+3Y@!]X]30
M!VK,%4LQ  &23VH5@RAE(((R".]<O+K*>(?A;<ZQ'$8EO-)DF\LG.PF(Y&>^
M#FL+0M7U_0-*\)MJTMA-INHQQ6@B@A99+9C"6C.XL0^0A#<#D\4 >C4UG1 "
M[!02 ,G&2>@KRK3OB9J-['8ZJKP2VUW<(ATN+3I_-CA=]H?S_N,P!#$8 QD
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M( R3@4BLKH'1@RL,@@Y!%<3)K'B"_P#%.O6,#:='I6E+$9%E@9Y)Q)#O*Y#
M+@YYP>H&.*S-"UW7]23P_I&C_P!E:;#-X>@OW=K9I%B).W8B!Q\O3&3P!WH
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MN"\@$,$DDJ1>< 4#L 22.@]30!R=AX&U/2]/M["R\;:S%:VT:Q11B&V.U5&
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MI* ,B#P_;P:AK-XLLI?51&)0<839'L&WCT]:K:+X1L]#NK&X@N)Y&L]+CTQ
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MM&N-#.EJE[;Z):LENSEOW9!WLIFQD +S]WT%>Q=1@U&D$4:;$B14SG:J@#-
M'B]HEU;>#?&5OXE$W_"3MHC,KW#AF:S$1"!2 .5;<'Q_'SSD5IVA\.R:OX9_
MX1'[,9DM)_[1-KC<(/)/$^.=WF[,;N<Y]Z]*UO28=<T2_P!,F=HTO+>2W:1
M-RJZD$C/UJQ:VL5I D4:CA0I; !; QDT >2^#M&T[6=4\)QZE9PW<4/A.&1(
MYE#*'\P -@\9 )P>V:N6-I-_PE$/@$QM]@L-1?5\X^4VF1)%'[XG?&/2.O5
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M7PZ%?3+R.1="B(0#8K*LDF<.>"0, C!/>F>&AX=/A_P&GAX6O_"1"XMVN?(
M^T"/;_I'FX^;9MSC=Q]W':O:4@BB4+'$B*.0%4 "E6*-'+K&BL0 6"@$@=J
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MFQDD\#IS4D>D^)=9U#0AK=OI]I;:1-]I>2VN&E:ZE$;(NT%1L7YB3DD]![T
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M!QAMVW&[/&#6E<:-XEUF?3+S4C9P_9M8CO%M(WW""!8G0C?M&]RS9Z #H.E
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MVK73S_98&@>-8E=AEL,V>< 9..E &U!XUADL=1>;2-2BO[">.WFT\(LDI>0
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MI<8<*=KKA3TQU%=3X-T"71+:]>?3]/L)+N?S!;V1+"- H"AG(&]NO. .<=J
M.FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTXQ-.(]JLRAV(!QN5CEAZ4 >N45YCKFO:YI>O7\^H:CJ>G6$-R@M;B"SBN+
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M4@XYZ8([]_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)S?#G0)FF0?;
MXK*=S)-I\-[*EM(2<G,8.,$]0, ^E=910!A:EX2TS4;BWN5^TV5S!#]G2:PG
M:!O*_P">9VD97T';MBI++PMI&G2Z:]G:^3_9L4L5L%<X59""^<GYB2H.3SG/
MK6S10!BMX5TEM,GTXPO]FFO?MSKYAR9O-$N<^F\ X_"N>L/A[;W%]KL^L?:3
M%?ZD\_V>*[=8;B+"[1(@.#R&X[C@Y%=W10!SM[X*TB]U&ZO'-Y%]L55NX8+I
MXXK@*NT;U4C/RX'N.#FK.F>%]+TF:QEM(I%>QLC8P%I"VV$E3CGKRJ\^U;-%
M '%^)_"LMQX:N/#NCV"/;ZK<O+=7$T^/LQ>02-( 1ECG) &,$#M77VMM#96D
M-K;H$@@C6.-!T50, ?D*EHH YYO!>CO>W-R5N<W%Y%?/%]H?R_/C(97"YP"2
MHSCKBKEYX;TK4;R[N;RU$[7EF+*=7)*O$&9@,?5CSUK5HH P=*\(:9I.H)?)
M)>W5S%$88)+VZ><PH<95-Q.,X&3U..M7[K1[*]U.UU"XBWSVL<L4>3\NV3;O
M!'0YVBK]% '+V?@#0[*\L;F/[:W]GR>9912WDCQVW!&U%)P!@]/8>E++X"T.
M:[DE9+H6\L_VF6Q%TXMI)<[MQBSM/(!(Z$\D5T]% &2WAO36LM9M#$_DZPSM
M>#>?G+QB-L'M\JCI5>X\'Z3<WOVIEN$D-B=/D6.=E66'# *R@X8C<V#U&:WJ
M* ,"3PU965U:ZK8P3M?:?9?9;>)+ED6:-0=L;]B,G@D<$YJMX*\/2:):ZC=W
M=M#;7^JWLEY/#$^]8MQ^5 W? Y/;+-BNHHH R-9\-V&MS6]S.US!=VVX0W5K
M.T4J!L;EW*>0<#@Y'%10^$='@TVUL([=Q#;7:WJDRLSO.&W;W8G+$GDY/-;E
M% %'6-)L]=TFXTR_1GMIP X5RIX((((Y!! /X57L?#MAIYO&C,\DEY%'%<23
M3,[R!$V*23WQU/>M:B@#FW\#Z1MT_P"SM>VCV%HME%+:W3Q.8!C",0>1QGUS
MWIH\!:%'I<.GP1W-O#!>&]@:&Y=7BE.02&SG!#-Q[FNFHH YKQMX?E\2:58V
M,:!HUU&VFG'F%#Y2."^".0<9QCFI;?P7HT5IJ$%Q%-??V@@BNI;V=II)$&=J
M[B<@#)(QCGGKS7044 <]8^#-*LIY+AGO;N=[=K59;RZ>9HXFZJA8_+GC)ZG'
M6I;GPEI5SI&FZ;MGA33%1;.:"=DEAVKL&'!S]W@YZ]ZW** .<_X0?1#IC631
MW+,UR+LW37+_ &CSP,"3S,[@P QZ8XQBEC\$Z,EA<VLB7$YNYXI[B>>=GEE>
M)@R;G)S@%1@=/;FNBHH I?V5:?VW_;&QOMGV;[+NW''E[MV,=.O>J.J>%=/U
M75$U)Y;VVO!#]G:6TNGA,D6<[&VGD DD=QD\UMT4 <RO@+0H=.M;.UCN;1;2
M:2>UEM[ETDA:0DN%;.=ISR#D5K:/HMEH5FUM9+)B21II9)9#(\LC=79F.23Q
M^5:%% '-?\()HOVPS8N_(-S]K-E]J?[,9MV[?Y><?>^;'3/.*+WP)HE_=W,T
MJW2PW<@ENK2.Z=+>X?CYGC!P2<#/KCG-=+10!SVI^"](U2]FNG-Y;O<QK%=+
M:73PK<(!@!PI&<#C/7'&<5?M=!TZQU%+ZUMQ%+'9I8HJ'"K"I)50O08)K2HH
M I:3I5IHNG)862,ENCNX#,6.7<NW)]V-<_\ \*YT P+;'[<;2.83P6IO)/*@
M<-N!1<X'/UQDXKK:* .:O? NBW]W=32B\6&[D$MU:1W3I!<.,<O&#@YP,^N.
M<U)XXT6X\0>#=0TJT1'EN @"NVT$!U)Y^@-=#10!@V'@_2;":>9EN;R2: VI
M:^N'G*PGK&-Y.%/?U[YJ+3O ^C:;=P7""[N/LJ-':QW=T\R6RL,$(K$@<<9Z
MXXZ5T=% '-Z?X&T;3;JUFB^V21V9+6EM/=/)#;$@C*(3@<$@=< \8I+'P+HN
MGW=M+#]L:&TD,MK:2W3O!;N<\HA.!C)QZ9XQ72T4 <Q)X!T-X=.2,7<#Z<)A
M:2P73H\7FL&<A@><D=^Q(JW:^$='LX+"**"3_0KIKR-VE9G>9E96=V)RQ(<]
M?Z5N44 <Q+X"T.:[DE9+H6\L_P!IEL1=.+:27.[<8L[3R 2.A/)%;&LZ-9:]
MIKV%^C-"S*X*.49&4AE96'(((!!%7Z* .<M_!.D07DUZS7EQ=SVCV<T]Q=/(
M[Q,02O)XZ<8QCGU-6&\*:9YVC3(+B*32(_)M6BG93Y>%!1\'YE.Q<@^E;=%
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M%_,SNW#Y<8(QCC%:Z>"=&&F:E93I<W0U)0MW/<7#O-(!]T;R<@+V QBNBHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU.T=FI$91T \M,A1][&.G)XKNO#OAZW\-:3_ &9:7-U-:J[-$MPX8Q*?X%(
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M31-&)7[&GABSN@-OS>8<J>?3"CBL6U\27%UJ7AG7]0 DDAL-:D<1KMW+%*@
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M:AC20$J#@$;\<<<4ZP\%:;87EE>K-=S7EM<3733S2 M/+(GELS\ ?=P !@#
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M_JY?-7:_!/!S@\ G\#7#>.;Z&W\5Z3%.NF68%K,T>IZI"\T2$LH,:(&5?,(
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M()RUQ$HMQF8EP/+XS\WIQSS7#^!9-+N/&GBZZT6)5L9OL;+)''LCE;;(&9.
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M,G$";@H )*X4-SDFJ_ARXTVP?P[?>*5C%@WAJW@M)KN/=&DP)\U.00'(V>Y
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M70I[@6\6J%DV,Q?8K%-VX(6X#8[@XQS72:KJ*Z5ID]\UM<W/E#(AMH]\CDG
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M;>$!ZMCISC'- '5T5YZ/'M[IE[XLGU73;EK#3+V"WA$1C9@'$0  !R23)O\
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M>)1<.%A*RDY"JOS,><$9QC/%=.GCRU?1ENO[.O!?M?-IJZ:-AE-RN<INSMP
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M4H6,[B<A@ /F!SGG.>: .'\3ZKK'A1?$&FVFL7=TJ:-_:%O-<E7EMY!*$(W
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MN /E/'YFI]2\)Z-JK6SSVKQ2VT?DPRVD\ENZ1_W-T;*=O'W>E $7@J]U._\
M#$$FL#_34DDB=MT9+A7(5F\LE0Q &0#P<UYYIJ:EI'@=O$-KK=ZC0ZU*J68V
M>08VOC&ZLNW))W,<YR.,=*]9T[3;/2-/AL-/MTM[6%=L<:= .OXG/.>]4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ=/IME;(DE[J%R(8E?.%0 M(YQV5 ?J2H[U'J'B_P[I5^;&^UFSM[D%0T;R
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M8T3;",%2&90!R.M 'J]Y?6NG6C75Y/'!;H0&D<X49( Y^I IO]I6/]HR:?\
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M/[.N)H+C6=(<?N699(U\O>1QRHP<GH,'- '>:=XHT+5X+J>PU6TGBM1FX99
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M$'B55P=^WNN#P3Q7$NFMW>D7]T]K<ZE;VFJZ?=QWG]EFUNKQ(W4R9BP"Y0
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MFZEB6$NQSM123M [<DD^O'H*MUR#WC:CXSUK>6-KH=DB)$&*AII5+LQQW"!
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M(Q@CN#F@#TRBH+,W+6<1O$B2Y*_O%A<N@/L2 2/P%>=SZF;;6=?^T+-<1_\
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M>W>;8GF2H0!N/"#)R6] 36QX:\;#5]?DT2ZDTJ6Z^S?:HIM+O?M$3*&"LK<
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MG.]&619'0MNP0=H .!CWIESX(U,V>IZ-9:W#!H6I32RS1-:EIXA*294C?>%
M8EL$J2-QZUW%% '-VWA1;63Q%Y5R%CU:...--G^H"P"(=_FZ9[5K:+IQTC0=
M.TPR^:;.VCM_,VXW[%"YQVSBKDCK'&SM]U02?H*S=,\06.L+:-9F9X[NT%Y%
M(86"F,D 9)& W(XZT 8PT^2S\<:NI#"VUZR0I+MR$FB4HRGZHR$>NQJD\/\
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MY-,T.ZCGM8TLRLDBH"%$C;R"0&QP!ZFN^HH P?#>A76@RZK')>17%I=7LEW
M@A*/$9&+.K-N(89(QP.E3ZAHAOO$>C:J+@(--\_,>S/F>8@7KGC&,]ZUZ* .
M.NO SS?VA-#J7DWDNKKJUI-Y.X02+$L>UES\X(5@>1PWM4-[X%O=<MM:DUK5
M87U#4;#[!&]K;%(K:/);A2Q+$L<DD]@!BNWHH KV"7<=C"E_-#-=A<2R0QE$
M8^H4DD?F:YB[\$M=7E_/]O"_:M8M-3V^5G:(1&-G7G/E]>V>AKHM,U6TU>":
M:S<ND-Q+;.2I&'C8JPY]P>:6YU*VM;^SLI&8W%V7\I%&3A1EF/HHX&?5@.]
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MJ7AF[-^S?V1#LN$\O'VR0997//RXD9WQSRU=E>W<=A8SWDRR-'!&TC"-"[$
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ME)&*C++['K^--U3POH.M727.IZ19W<Z#:))H0QVYS@^HSV/%:RJJ*%4!5 P
M!@ 4 >+WNN:Q9%--CU"Z+^%;N:[U!FE8M<6PFC\M7.<D&"1SSW2M47UYJD.C
MR7&HW<&F^(];G9I(YV0BW6-Q!$K Y02>6I^7!.X^M>COH^FR2WLKV-NTE]&(
MKIC&,SH 0%?U&"1SZTEQHNEW6DKI5QI]M+IZHL:VSQ@QJJ_= '08P,>E 'EV
MORW>ERZ_H.E:M?I90SZ6T<GVEWDM))KC:\:NQ+8*A6VDG&?0UN#1;=_&J^&I
M[_4TTRTTP75M'_:,RO+(\KAW,@;<VP!0 3@;NE=?;>&]$L]/^P6^E6D5IYJS
M&)8@%,BD,&/JP(!R>>!3]6T#2-=6)=5TVVO!$28_.C#;<]<?7OZT >7^$[F:
MWMO"L%MJ$TMO)+K19Q(<3[9&*NV.">^?>IM%@N+'0/ .NC5-3FU#4;BWANWG
MO))$ECDB<E2A.WC P0,\9R2<UZ7!H6DVJVZP:=:Q+;^9Y(2( 1^8<OM]-W?U
MIZZ1IRVMG:K90""R96MHP@VPE00I4=L D4 >37DAF^'S^)Y]<U"#7I-1$4BI
M?2*JM]IV&W$0;: %[8SQG->N:E--;:7=SVT?F3QPN\:8SN8*2!^=<->_#R[U
M/4G:^;17BDNEFDOTL E[)&L@=8RP^4= I8<D#I7H= 'D]N#9>&?"?B.TUF_N
M=6U.ZM$N2]X[I=><0)4\LG:NT%B-H&W9]:W_ (::9;V%KKS0M<$G6;N+][<R
M2#:DK <,QYYY/4]R:Z*U\+:!8ZHVIVNCV4-ZQ),Z0J&!/4@]B>Y'6M"UL[:R
M61;6".$2R-,X1<;G8Y9C[D]Z .,\72?VAXIM-'A@U&_F2R:Y>R@OS9PA2X42
M/(I#,<@@*,@<G'2N5T.YOM<L_"6GW.JWH@EU34;>5H+YRTL48D*(91AG'R@;
MN"1Z5ZCJOAS1M;EBEU33+6[DA!"--&&*@]1GT/ITI]OH6DVCPM;:=:PF"1Y8
MO+B"['<89ACH2"0: /.I#J&DV'B0V-[?2P^&]8BNHHI+AY&:W\F-Y8BQ)++M
M=R <\@5UGA"\EUN[UG7OM$DEC<W/V>P3>2GDPY4NHZ?,^\Y[@+5[6M)NI=.O
MH]#^PVEY?M_I$\\)<,"NPM@$98 #&>.,5=T?2K?0]%LM+M!BWM(5A3/4A1C)
M]SUH YG78_[7^(&G:'?75S#IITZ6Z2*"X>#[1,'5<%D()VJ<X![Y[5P=K<7L
M-M9:-I\\]Y97OB+44FD^W&W>YV9*(9P,_,<DXY;;CO7L.JZ'I>N0)#JEA;WD
M<;;D$R!MI]1Z5"WAC0GTIM+.D67V!G\PVWDKLW?W@,8!]Z /*]5L[N;0]3T_
M4)72WL]8TX6]LFJR3R6WF2QAT9Q@D<AE#9*[N,8%:/B2YOK63Q596FI7T"6\
M^C0V[K<.6B#2*K$$DG)'7/7OFO1;?PYHMIIPTZWTNTCLQ*)O)6(!3("&#GU;
M(!SUX%2S:-IMR\[S6-O(UPT;S%HP3(8SE"?7:1QZ4 ><>(8IO#-SXHL=,O\
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M\</D)(J %8\@[!Z#(''M0!SWP^GN)?##Q7-S-<M:WUW:I+,Y=RD<[JNYCR2
M ,GTKF/%ESJL7B#4_"UIJ%S#/X@>VEL)5E;= H!%QL.?E 6$'CO)7I5K9VUC
M$T5K!'"C2-*RQK@%V)9F^I))--ET^SGOK>^EM8GN[8,()F0%XPPPVT]L@<T
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M&+RXEGB*MLMWB#1[6)923GD C(X/.+WAN'Q%HFCZ7X870=[6<X2349GC:V:
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MZJEQ=)O7]V@,N6SG!^\O3/6@#?N/'NAVUU)$[7A@BN/LTMXEI(UO'+NV[6D
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M+\)[KP_I]LKW0TU;:*!),C<% VAF(R..IH M:-XI;5/&.NZ(UI-&FG>6(Y3
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MFEB8,XB9!'%L8E@2^22!P/7BMGP'IEUHW@;2-.OH/(NH(-LL>0=K9)ZCCO0
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M** "BBB@ HHHH **** "BBB@ HHHH **** #I0"",@Y!K/U[_D7M3_Z])?\
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M*(ZL%8DJ</@C)Z4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M21>4B(5< @*JC@[E'.3G/L*7PSX/NHK+P_/K&JWET--MT>VLIHT402F/:2Q
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M=3M-7UR^O)[_ ,K,N%1(?+8,FR,#:/F&3G.[O769&,Y&*0R(KJA=0S= 3R:
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M^UR[LKC29+2+0Y)+JR\-HZ(V#\C[P2JR8W '[V#GM7KT4$,$(AAB2.(<!$4
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MJR-+=LPA!7[/&,%%)(VD'ELFO:51$W;5"[CDX&,GUJ-K2V>X%PUO$TP&T2%
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M;FD61 &+.5"@*6'+ <CJ<5:T33-5G\4WOB/5[>&S>2TCLK>TBF\TJBLSEG;
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M,N6^;=(8MN!W^X:J>--)U75/[,-BKW%E#,S7MC'>-:M<*5(7]XO.%;G;D T
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MK<W7E;6W(P=6VD$94@]^>] &Q<?$'3X8+5H=/U*ZFN[NXLX(((E+O)"Q#=6
M ^4D$GIUQ3K[QREE'=3#P_K,UO91K)>RQQ1@6^4#E3N<%RH/.S<!ZUE:#X1U
MFRNO#\]]]E,EGJ.HW5R8G)&)]^W;D9/WA]*H^(O!NNZQ<^((I[*'4#>EQ87=
MQJ,B16L90 +Y &-RG)SCDD9(H V6\7W4WB_4=.CMKE=+BT=+V*ZC2,X+>8?,
MY;)!"@ 8^\#D8P:FM?&D0L=*M[.RU36KZ?3HKV00QQ*ZQ,O#R9945F.?E!/(
M.!BJ4/AO6K?5%D6VMW@N?#T6FS/Y^&AFC$AZ8^927 SD8ZU'I'A_Q#X5DL[N
MQL;;4&ETBTL;NW:Y\HQRP*0&5BI!4[B".O //2@#4?X@Z:Z:5]AL=0OY]329
MK>"")0X:(JLB/O90A!/.3CY3STSL:!KUOXAT][J"&>W>*9[>>"X4+)%(APRM
M@D?D2.:YC0/!VI:7K.BWUS);R/$NH37IC8[1+<R(X5 1DJ,$9]O>KEA!J?AE
M;UOLD5P=2\0%PJR'*P2E07X'50"2/0'F@#2\::Q=:!X,U;5;*$RW-M;/)&
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M N]V/S-P>@ ' YH Z>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[9WD\"!TWW B9) H"L.X( /)],T >G$X&35=;ZT>XBMUNH6FEB,T<8<%GC&
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M_LGQ=KD&N^1'H=[.EO:"UC9)4C56*R,1NYR0-I!'7)H ]/9E1&=V"JHR23@
M4RWN(;NVBN;:9)H)5#QR1L&5U(R"".H-<)=7FN>(]0\1Q6.K_P!FVVEQI%'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4*%Y9$100"S, ,DX _,BGT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <8QN-7\>:ZD4@272M-C@LR>B2SAV9_KA(Q] ?6N)M6@TF
MQ\&P6OAR^T_7+;4K:WU"ZEM#'N+_ "39E/$P<DMP6]>,5Z,VES6GCB348H3)
M9:I9BWN\?\LY(BQC8^Q5W4^X7UJ'3O!%O8W5B\VJZC?6NG,6L+2Y=#';G!4'
M(4,Y ) +$X!]>: &Z=(;#XDZOID?_'O>V4.HA>RR[FB<C_>"QGZ@^M=77/:3
MIMQ)XKUC7;N(Q^8L=C:(W7R8RQ+?\"=VQ[*I[UT- !1110 4444 ,F_U$G^Z
M?Y5XMX=T^XOXOA?&9[8VO]GSN(9K42@%0FX\MU(( ./EY/.:]K90Z%3T(Q7/
M:9X-T_25T%8)[IAHD$L%OO93O60 $OA1D_*,8Q0!E_$&._>^\)"RODMMVLJI
MW0[\MY4I!/S#@8/'?(/;GF;;4?$&A:)XJUVRO+-;&QUR[<V<EN6:=?.^?,FX
M;3SQ@=N<YX]%\0^'XO$-M:1O=W5G+:7*W4$]L5#I(H9?XE((PS#!'>JDW@W3
MY_#^KZ,T]T+?5+B6XF<,N]6D;<P4[< 9Z9!H Y;6/'&I/K^LVEA=_9$TMQ#%
M'_8]Q=_:I=@<[WC&$7Y@N!SU/H*Z\>(C'X&/B2ZLI8&CT\WLMJX*NA";F0Y'
M7@BJNH^#([O4+V\LM8U+3#J"JM['9M'MFPNT-\R,4;: -RD' %;::9:)I TK
MR=UD(/LYC<ELQ[=N"3R>* //]"\:ZS<ZCHYGD>^CU%PES;Q:-<P+9[E)#+*X
MVNH.%.>N<BH5\4^+Y-&L];CNM,\JYU<Z9':/:M@@SM"LC.'SD, < 8('O74Z
M;X*CT^YL6DUK5;RUT_\ X\[2XD3RXN"HR54,^ 2!N)Q4T?@S3X]%L]+$]UY%
MKJ(U%&++N,@G,V#\N-NXXZ9QWSS0!S.H^*/$NC6WB2S>XLKV_P!.DL#;3FW,
M2N+B4(590QZ8/(/>G^(-2UG3[?6-"UB[MKY+S0;RZ@GAM_),;1J%="-QROS@
M@]>"#FKOC;P@VHZ3K<VGBXEO=4:Q22-9 H5(9@<J>"#M9B>>PQ6C'X*MW^WR
M:AJFH:C<W=D]A]HN&C#0P-U5 B!03P22"20* ,+0=1\0ZU$VGZ->V>GP:396
MD9:>V,QN)7@63!^8;4 91QR3FK&D>.I[J30[[4$AMM,U33YF/?R;F$DN-W=2
M@<C_ '*TI/ T*2^;INLZGICR6T=M<FU:/]^L:[5)W(=K@<;EP?TK+\5^$XK_
M $31O!VG:3<#3XY8F-VK@);1)D."2=Q=D++T.=Y)- %>R\0^*]8O=#LXI[.P
M;5+"XU!WDMC(T,8D3RE"[AEMCJ#GN3Z5!I_BGQ4VEZ3K5Y=:>UO-JJZ7-:Q6
MS N/.,)E#EN#N&=N,8KNVT.U/B"UUD-(L]M:26B1J0$V.R,>,9S\@QSZUGIX
M-T^/1K72Q/=>1;:@-11BR[C)YQFP?EQMW''3.._>@#BKCXB:O-_:.HV+.R6E
MU)#!I::/<2_:4C<J29U&U7;!(QP. <\UK7NN^)[W4O% TR]LK.UT9(Y84FM#
M(\Q:W64HWS#:,D\@9Y]N=6?P';2RW<<.KZI:Z;>3FXN=/@D18G<G+8;;O4,>
M2%8 Y/3-::^&[-)M<E$D^=9"B<9&$Q$(ALXX^4=\\T <GHUYJ.K_ !)TW4OM
M4<5M=>'(KHVWE9P'8$J&W==V#G'08]ZWM?U75&\1Z;X>TB:"UFNH);J:ZFB\
MWRXXRBX5<@%BSCJ> #P:EM?"%K8ZEI-]:WM[$^G6*Z?L#(5GA4<"3*]01G*X
MJSK?AV+6;BSO([RZL-0L]WD7=J5W*K ;E(965E.!P1V% 'G?B6\UC6X[?1+^
MYLOM&G^(K6UF<6F^*Y#JLD3E"W& ?F3)!/<5TWQ)@NHO T45E<QVQCO+)&VP
MY4CSXU  !&!D@X]!COFM&#P/IT5M#&]S>33KJ*:G+=2.IDGG7IO^7&W  PH&
M !C%:?B#1+?Q%HTVF7,LT*2,CB6 @.C(X=6&01PRCJ* .*CMO$,GQ \3)IFJ
M6EM+'86+332VAD\UPLN %W *I^8GJ>F*J_\ "QK[4UT6"*;^S7NM)CU&YGBT
MV:].YR5"*B9VC*L26]@/6N[T_P /PZ?J-[?_ &JYN+F]MX()WE*_-Y08!L*H
MP3O)/;T K)B\ VEE;:8NEZIJ.GW6GV@LDNXC&SRPYSMD#(5;GD' P30!?\'Z
MU>:[H"W5_;-!<I-)"Y,#PB7:V!(J.-P5A@X/3..U>>>'+$SMKCCP!8ZU_P 3
MJ]'VR9[<,?WS<?.,\5ZCHVD0:)IJ64$L\P#,[S7$F^21V)+,Q]23VP/2N?B\
M FTFNVL/%6OV45U<RW30PO!L5Y&+-C=$3C)]: *?BGQ1>>!;+2[T:=;)I4T/
MV7[ C)&UO<E<Q@-D*4X*G X^]TJ'6_%.L:3>:/H5S>QPW\UF]W>WMOILMT%P
MP4)'&F3U)^9N,+ZFN@;P;8W5S!/JMU=ZJ8+1[1%O"A7#\.Y"J/G8?*3Z< #)
MS ?!$*6NF"UUC4[>^TV)H+>_#QM*8FQ^[?<A5UX7J,_*#G.20#!LO&6NZI%I
MVE0I';:E=W\]M]NN+*2-&ABC$GG+"Y#98,HP3@'=U K5N=5\1Z*^D6NHRV5P
MUWK*V@N(HROFP&)WR4S\K[EQP2,#WJT? ]G_ &?;Q)J.HK?V]TUY'J7FJTXF
M8$,>5VX(."NW;CM3)/ 5G+I[QR:EJ#:@UZE^=2+IY_GJNU6QMV8"_+MVXQ^=
M '->/M6U.\L/%FF17$4$.GOIQ0B+<S"5_F!.1W"GZ CO5J^UW4]&U'Q+<QQ6
M<LFE)I\MY,EMM>XA(;SB<$\A067KC!'-;!^'UA+9:S#=:EJ5S-K A^TW,DB;
MPT1RC+A0JXXXQC@<=<Z=AX9M;.XU"XFN+B]EU""&"Z-QMQ((U*YPJ@9(8Y[>
MF* .9U_QW>:>VMW-@D,UG9O:V-NQC:0/=2D%F.SEE1'3Y5&2<BK/A;Q-J5YX
MB;2[F:;4+5[8SK>MI,]EY<@8 QL)!@Y!R".>"#6A9^ M'L_!Q\,JUU):%S)Y
M[R_O_,W[P^\ ?,I P<?PBK>D>&SIVI/J-WJ^H:G=F'R$>Z9 L<><X"QJJY)
MRQ!/'6@#(U_5;^R\77<>EZ;;7=]%X?EN+<&/]X[B4 )NZ[3UV]S4?@SQ-=:M
MJ\UE<ZQ;73+;B1[::PDLKN%]P!'EMD,G/4'@X'.:W-4\*V&KZC/>W,EP'GL&
MT]ECDV@1LP;<"!D,"!@Y_"HM+\*BQU=-4O=6O]4O(8&MX'N_+'E1L06P$1<D
M[1DG)XH QM4&H+\6["2&]1($T6XD\IH=V0)8LC.[J3M.<<8QSGBAI_B3Q*?
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M "[03N4E6V_+E2#@"@"@NI^)]=UG5;/3;JPTT:4(HG$D!N/.G:,2$9W+A!N
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MCC4*B *J@8  Z"N3C^'UB@CM/[2U%M&BN!<1Z273R%<-O SMWE W(4MC\.*
M.&U1-57PSXW=[V&X8>)+98D:$J/,$MK@D[C\N-HQ[$]ZZ/4_%NM^$+G5X=6G
MM=4$&D_VC T-N8"'\SR_+(W-E<E3GKUZUMW/@6RN9-5#7]^MOJ5U#>2VZLFQ
M)HVC;<N5R,^4H()/&<8J[J?A33=8U&XN[Y9)1<:>VGR0E@$,3-N)Z9#9'7-
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M4MDLEQ),1\L;1NA8$$8XXYZU)HVEC5?'KW>M64,^IP:!8/FXB4^5.6E+,!C
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MPQ:M=/!9%G'SH Q$K9QA6"Y'7[R^O%O2?$]CJ<UW"[QVTT%]+9)'+*NZ5HR
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MDW["P!' .:Z/P&D$OBW5+NPU73KVV:TB2;^R; P6AD#$J=WF,&D"Y!QV*YH
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M0!Z=9ZS#)I4%[?M!8/)&)'BDN$81Y./O X//<<5=DN[:*U^U27$26^T-YK.
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M$]ZC-#*UJ(U!5P\2J!N/RX-:UK\18+O2[:^30M55;]HTTV)ECWWA92QVC?\
M*%"DDM@8P><T =I17G_B+Q]=VWAS4GLM+N[76;&XMHI[6;RB8DE< 2 [MK*P
MRH()PQY  .-BZ\9-%>36EIH.I7UQ:0I+?1P&+-KN7<$)+@.^.<)GMSR* .H
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M0YR".0?:I=,\&ZK;ZQI>JW<EJ;C^U;K4;U(F)6/S8#$J(2/FP N2<=S7>T4
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M0#@G))PWX32ZUKMCH_B_Q.^K7$_]EW=W;6EAL00A5("L_P NXD$^HX'UI/\
MA =1O-1LX[G2;&T6#44O9;NWOYFB;;)O_=6Q^6-WP 3VRW)S7H,&A:;;VE]:
M):JUO?RR37,;DNLC2??R#V/ITH X"UUOQ'HU]!-+%KMU:O:SR78U46J@ND1=
M6B\ILC)7:5Y&&![5!H.N>*)3X?U)AK4_]H2Q?;!=K:I9F.0=8=K;QMR".I8
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M?,;]V50QKSGYOE8CG-<#+X!U&_OX8;C2;&U1-16\EO(+^8Q,%DWYCMCE4D;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$"Y/0$\XKA=0L+RSD\6Z9?W.KHVI7DTD5I::4LZWL3@! LI0@$#"\L-NW/%
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M-,TKQ+_9^HW=G:V1T]+R.[EG #EG90H]>%SQ6!9W-QX?\1WE_P"*K*XGFO\
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M.6491)YE0D9QG!/3/?I7E>H6%Y;'Q9I>H7.L!]3O9Y(K2UTI9Q>QR8V;92A
M(&%Y8;-N>*WX9(_#.NZ__;FGWUXNH6ELELZ6CW!N%2'8T)**0&WAC@X!WYH
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M'EV#*G.W"D[LYKL_']I/<:1I\T=K+=V]GJ5O=7=O$A=I(4;+84?>P<-COMH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M):M]I$FH7FE(D5M)"JV&GB(S,Z[=\A))&!GY5QR3SVK8TW2+_2/#.BZ39WD
MDL8[>&:5XB1+&@ <*,_*2!P><>];E% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '-I?3ZCX^EL(YG2TTFT26958@2S3%@H;U"HC''JX/85FZ3?>(6^)M
MQ::O/ EJ^EF>"SMR62,><%!9CC<Y'7@ =!ZFW;1'2OB7?-)Q#K5G$T3GIYL&
MX,GU*.K#_=;TK0_L6?\ X3G^W?,C^S_V;]CV9._=YN_/3&,>] '#W.IZO)X3
MU7QS'J]XDMI>3-!9*P^SFWAF,91DQR656);J"1C&*Z]=0FL?'JZ?)-(]IJMF
MUS;J[9\J6(JKJOH&5T./56/>L2Y\&:V^GW_AN&>P'AZ]O'G>9F?[1%%))YDD
M2IC:<DL V[@'H:U)(CJGQ+MI(Q_H^B6,BR,.GG3E,)]0B9/^^OK0!U=%%% !
M1110 R4D0N0<$*:\ATW5]?UBS^'ME)-J#PWUK)<75Q!>^3).R@?>;[V%!R1_
M%G':O7Y%+QLHZD$5Q6@>#+[28_!ZS7%NYT2TG@GV%OG:0* 5R.GRGKB@"]\0
M=8U+0_"C7FE1[KC[3;Q%MRC:KRJI^]ZYV^V[/:L1/%6NV?BGQ.B:-=7\5I%:
MS-"+E%6V!AW,JD_>8G/ X..HR*Z?QAHMSK_AFYT^RDACN6DBEB:;.S='*L@!
MQS@[<<>M5=/T#4([[Q#>W;VJRZM! H2%F98W6'8W) XW=/;TH BF\<1S-IL.
MC:?)J%S?V*Z@J-,L"Q0-C:SLW<DX &>AZ8K8\/ZY!XATL7L$<D++(\,T$N-T
M4J,593@D'!'4<$8-<3)\.)XH]"N?L&AZM<V.D0Z9<6VI(3$WECB2-MC%3DMU
M7D'MBNP\*Z+)H.AI:3)8I,TCRR)86RP0J6.=JJ ,@# R>3C)H X/5]6LS\0M
M?L]8\2ZYI\%NEJ;6&P:3;\T9+Y"(W?'I726OB'3O#^@6%ZEWJ.HZ1<71BEU&
M]<[K;)VAG#*I";AC..,YZ4V;1?%.G^+]9U;1AHTMOJ2VX*WDLJNAC0K_  J1
MSD]ZEU'1/$/B72X-,UM]-M[.6X)OULI9"9H  5C4LH(W-D,>/E&!UX %/CR%
M](M;^#3;B5M1NFM],A+JC72@$^;S]Q,*S9/.,''(%-_X3^""TOEO=.GAU2TF
MA@^P1R)(9GF.(O+<$ ACGDXQM.>E9EYX!U"ZT73K*XDT[46T:[9[!+]#)'/;
M%2HCF&TX8 X# '[JG'6B+P!>&PNI8[?0M)OQ=V]W9P:?:@0QM"<@2.%5I-V6
M!X&,\#U -:;QG=:?#+_:WA^[LYDGMHE D$D4@FD$8*R#C*D\KP>GK4GB7Q1-
MIQU?3[&V9[ZUTAM0CDW*%^\R]_3;N]^E4=5\/^*?$.G7@O[W3[68-;R65I 6
MEA22*42;G<JK'<0%P!@ =S0OAC7M3U?5=1U>;3X#?:0VFI#:,[B++,=Q9@-W
MWCV'I[T 4[3Q;=6]M8WU]:W\MZGAU[^2UCG0QRJKQY? '^L(.1SP"1C-=%>>
M,=.M+JV3)DMY=/EU.6X4_+#;H 0Q]=V[@#T-9WA_PQJMIJ>EWNJM8G[)HS:9
M(EN[,'/F(58;E'!5.?<]ZJ:)\.FL]'U_3=1O!-'?P-I]HZ9+6]D PC3G^(;V
MSVX% &AIOC9[F]TV*_T>;3[?5"193/.CEFVEPLBJ<HQ4$@<],9!IWQ!U2[TC
M0[*ZLC<&3^U+1&CMSAY5,JAD&<#YAQSZUD:!X%N]/U/3);C2/"UHEAR]U8V8
M,]TP7"GYD'E<_,<%CGC(%=%XPT6_US2;>#39X(+N"]M[I'G!*#RY _(')Z=.
M/K0!FW7CTZ7:ZM_;&CSV=YI]H+W[.)ED$T).W<K#C(/!!'''7-22^,[R&.RA
MF\/3Q:I?R2?9;)[F,$Q(JDRNX.$'S 8Y.>.:S=7\&Z[XDM]:N=2ET^WO[O3?
M[.M8;>1WBC0OO9G<J"22!P%X [UH^,/"!U[4-+U.&TTR^GL%DC:SU./=#,C[
M<\[6VL"H(.#W% $L'C-[K3IFM]%O)M3@O!936,;*WER%=P9I =HCVD'?[@8S
MQ5=/B!%#:ZJ-0TR:"_TZ6&%K2&5)C,\QQ$$8$ DGCG&,<UDS> -2;1HHH[;0
MHS_:'VJ?2K:,V]I+$$*B)G1-SD$[LLI!/&,"F6_PXOT_M>6/^R-.DN)K*[L8
M;*)A#;RV[,P5A@;E.1EN#R>!@4 6O%GBG6(/!^N&;2KW2+ZTABFCECD$J.K2
M $+(O&[@@J>>1U!K4C\;_9;VYMM=TF?21%82:@CO*DH:%" ^=IX8;E^7GKP:
MJZOH'BGQ)HVJ6VHW6G6WVB&**WM+=V>)660.TC.4#9(&  ,#WZU<\2^#V\1Z
MN999TCLY-(NM/DQG>&E:,A@.F!L/?TH 98>-VEO+"+4M'GT^'40QLY6F20L0
MI?8ZJ<HQ4$@<]",YIWASQI-XB>SFBT6=--O59H;M)TE"8&0)54YC)';GG@X-
M9.A^!KVRU*PEFTKPO8"R5MUUI]FIGN'V[5;YD'E==QP6)Z9Q2:5X'U2'Q+IN
MJ7,&C6<UH[-<WNF[XY=0!4KB2,*$7)(8\MR.,4 =KJ^H/I>FR74=E<WLBE52
MWMDW.[,0![ <Y)/ &37-/X]>R&LQ:IH[VMWIFGG43%'<I*)8AD<,.C9&,$=Z
MU/&6B7NO^'VL;&>..3SHY&CE=ECG16!:)V7Y@K 8)%<A_P *YU%SK;0VNAZ7
M'J.BR:=':V(8)'(3D.S;!OSDY. 1@#!ZT ;\'C6[:]AMKGP[=6S7MI+<Z?NF
M1C<>6H8HP!^1B".N:NVOC"SOH_#K6D+RMK:F2-00#$BIN=F^AVKCU84E[HDQ
MUOP]JC3PI;Z3!.L^XD$[XU4$<=!M.<XKG?AYID$NO:WK-I<K<Z1',]KI+*/D
M$;OYLQ0]U\QMH(_YYT =?X@UZ/0+*&4V\MU<7,ZVUK;18#32MG R< # ))/0
M UQ_BSQOJEMX5\0VZ:9-INN6=GYX7ST<")\J)D<?>P001@$'%=1XIT2ZUBVL
M)M/FBBO].O$O+<S F-V 92K8Y *NPR.G!KG=6\&:YXBM=?N=2FT^#4;_ $T:
M=:PP.[Q0IN+$LY4%B6/91@#O0!U>@VT]AH$$,JW;3JK%EN[KSY"<DX,G?^E>
M=0>,/$<VC^'[V>UN'GF\0SVIAAE0&X0?: (ST "E5!)_NYKUKM7!:=X-UBV;
M3()IK$VNG:W-J$3HS[Y(I!,<,"N P,HZ'& >: +P\>16VGZM)JNF7%G>Z9+%
M#):*ZRF5I<>4$88!W;@.<8YS5S1_%$E[K)TC4=-;3[YH#<Q+YZ3)+&"%;#+T
M8$C(/J,9K)UWP'-KDOB-I)[8#49+.:U$B&15> =)%/!5B,$<\$U/X8\*3Z9K
MCZC/I'AW2T%OY*0Z5;@L[$@EVD**P'&-HXYY)XH U?$?B-M!DTR&+3I[ZXU&
MX-M#%$RKAMC/DD\ ?+R>PYK(N?B"MA9W7VS1KE-2M+R"TEL8Y%=F,Q_=LC<!
M@WOCD$'%-\=F_&N>#SIA@%X-2D*>?G8?]&ER"1R,C(S@XSG!Z5!+X,U;4+F7
M5+^>R34;C4[&ZDBA9C%%!;/N"*Q +,<L<D 9/;% &@?%VIO=1Z;;^&II=76#
M[1=VOVN,);(694!DZ%FVD@#MUQ4VC^-K/6+[3[:.VGA^W03.AFP"LL+A)86'
M9ESGT(!IM_HVM67BBYUS0383&]MHX+FWO9'C ,98HZLJMV<@KCGCFLF\\ Z@
M?!D%E8ZG%'K\5W+>B^*%4$LQ?S< 9(7;(P ]AF@"S'XQM+[4=(O M]%;3"_,
M(CD'ES1PX!=EQDYP2N#W]ZL:)XQGUV&*?^Q9X;"ZMVF@NX;B.8*  =LFW_5L
M0>!SR"*DF\)/%?\ ATZ9/';6VD6=Q:KD98;XT1& Q@XVY.:Q-*\":G#K]KJ4
M]MHVGR012I<S:674Z@60J#)'M55&3N_B.0,&@"[I7C!Y-)T.STG3[W5;ZZTU
M+UA<W"*T<)P TLA&"Q.1P.<'H*E/Q!25--BL]&NY]0O9Y[4V9=$:":$9=78G
M&!UR">.F<XJII?A#7?#B:-=:7)IUQ>6VDQZ9=P7$CI'($.Y71PI(();@KR#V
MQ4VD^"KZQU;2=2N+NWEN([R\O;[8"JF2=-H6,?W5P!R>V?:@"5_B#%!HT]S=
M:9+!?P:BNF/:/,@43, P)ESM"%6!W?AC-;VB:K=:G#/]LTN;3YH7"E7<2)("
M 0T;CAAS[8((K N?"FJ"+7OL[Z;-_:.J+>?9KR+S(IHA%&ABDRIVDE"<@'&!
M[U8\%>%[CPXVIR2QVEI#>2(\6G64CO!;;5P2I8#EB<G"@<"@"/7?%%OX?UO5
MIY1>S"QT=+QX%D'E%?,<<+C(?CDYQC%6M-\5W%SKUOI6H:)<:<UY;O<6;R2H
M_F*A7<&"GY& =3CGZU0\5>#;[7KO6YK>XMXUO]%73HQ(6RKB1VR< _+AA[^U
M;%YHD]SXLT35EDC$-A;W,4B$G<QD\O&.,8&PY^HH H^.]:U71;/27TJ RO<:
MI;P28=5RK. 4^;^]TSVK M?&FK:7-XLN)](O-0L=-U%WEE%P@%O"(8V*("<L
M5^9B.!SUYKJ_%^C7NM:7:KISVZW=I?07D8N"PC<QN&VDJ"1GUP:S?^$3U!_#
MGC"PDFMA<:[)/)$59BD?F0)& QQGAE/0=,4 -U7Q=8Z-JVJ7DK7TL5MI5O=>
M4LB^40\CJI53C:Q/5B<8QTP:V-"UR\U666*\TB2SVHLD<R3+/#*K9'RR+QN&
M.1[CK6/<>$]5-[>W5I=V<<DVCV]A'YL?FJ7C=V;>I&"C!MOKR:;X2\(W6B:_
M>:F]IINEP3VXA_L_3)':%WW9,IW*H#8X "]">30 [Q]<:C;_ -E&-]4BT8RO
M_:4VE(6N$7;\F-H+!-V=Q49X%4/#WB+3-.L=:U2#Q3+J^A6D"RF*Y9GN[:09
MW*=P#$-\N W.<UT?B'3M=FO+'4=!OXHY[8.DEG=L_P!GN4;'WMO(8$<-@]2.
M]<]<^!M3\1R:Q>:_-8VEW?:>+")-/#.L8#[P[LP!=MP'&   1WH =XB\5:RG
MA36_/T.^TBX&E3W5K=+*L@4JO1F7[CC((!Z\X/%:&D^,+A[_ $^PU;1[C3Q>
MVKSVMQ+,C^8$52P<*?D;# XY[]ZJZIH?C#Q#H^H6&HW>EVL<VG36JQ6K.ZSR
MNN!(Y9 44<X5<]3DG%:FH^&I=0U?0;EY(_L]A;W$,ZY.Y_,C5/EX]CUQ0!GV
M?Q!2Y-A=RZ3/!H^H3K!:WK3(2Q<XC9HP=RJQQ@\]1D#-9/BWQOJ,WA?4[K1]
M-O$L8K@6R:I',H.]90C,$SNV9#+N_3'--T;X<7.F/IEHVE^%Q!83(QU-;-6N
MYT0Y4%63"N<#+[B>XYJ:^\&>)1X>O?#&GW.EC29KEIXKB9I!,B-+YIC*A2#R
M2-V>G:@#J#XHA"^(S]FD_P")'_K/F'[W]RLO'IPV*YZ+QDEIK.LZK>RSC2XM
M%L;Q+8?,5:5I>%'3<QV+^52ZKX7\1->^)8]*GTT66O(/,DN2XDMV\D1':H!#
M@A01DC!]:KW/PZN-0L-1L[JZ@5+K2+&R1E4OMEMV9MQ4@ J25X[C/2@#<TOQ
M7+<ZS!I6J:4^G7-U"TUM_I"3+(%QN4E?NL P..F,X)Q4/CK6M5T:'1CI5N96
MN=3A@E =5W*3]SYNF[IGM53PYX1N=/UZ'4;C1O#.F)!"R!=*M@7F=L#<79%*
M #/RC.<\DUK^+M&O]9T^R_LU[9;NROH;R-;DL(WV'.TE02,YZX- '+6WC/5M
M*G\67$VDWFHV&FZB[2S"=%$$(BC)5%)RQ7YF(X'/7FNAO_&#+JC:=H^F/J<\
M5NES.?/2%8U?.P9;JQ )QZ=2*K-X3OG\/>,+!IK83ZY)/)"06*Q^9 D8W<9X
M*GH#Q69J7P_F.LMJ<&E^']6:XLX8)HM6C)\IXUVAXVV,<$'E<#.T<T =IH>L
M6OB#1;75+/?Y%PNX*XPRD$AE(]000?I7)Z;;WGC:_P!8O+K6-2LK&SOY;&TM
MK"?R/]4=K2.PY8ELX!X  XKJ/#FE-HGA^STYS;%X4.\VUNL$>XDL=J+P!DG^
MO-80T/Q'H.JZE-X<;2[BQU&<W3VU^\D9@F8 .59%;<K$9P0.<\T /&J:GX6T
MVST[4'?7-5NKIX+ 1;4>:, L&E)PH*J/F8>W!)J.X^($>GZ5JL^H:3=07^ER
MP)<62NKL1,X5'1APP.3Z'*D<5 ?".NQ0Z=J8U:*\U^TO)KMOM)<6["5=CPIU
M,: 8VD9Y&2.345YX+UC5K;6+N_N+*/4]2FLB(H68PPPV\H<+N(!9C\_.!R10
M!9_X3?5O[2NM*'A*Z_M."!;KR?M<6PPL2 V_.-V5(VX/UQS3X_'IU";2H-&T
M:XOI=2T\:A&&E6)8X\@$.3G!R0.,\_G6JNB3KXUO-:\R/R)]-BLU3)W!EDD8
MD\8QAQ^1KAM+TG7_  YXGT#2M/.GW%W9>'#%.L\CI%(!,HRKA20<X/*\C/3K
M0!UD7C*6^TVVFTW0[VYO)9Y;>:V8JBVLD1(<2R<JO(XQG=D8JI_PL.)=%DO7
MTFY-U#JBZ7+9Q2([><V,;6SM8'<O/'7G%9=S\/M3:*PDE.G:J_VJZN]0L;MW
MBMII9B"&7"MG9C # Y!)X-2:;\/]1L[-X#)ID0;Q!!JRQVJ-'''&@3=&JXX(
MV$#UZG'2@#2E\?/80ZK_ &KHD]I<:8L$T\2S+(#!*Q7S58==NUB1QT[UOQZW
M%-XFDT6&)G:&T6ZEF!&U-S%47ZG:Q^@]ZR-4TJTM-9US7-:NK6+1KO3(;*;S
M7V[0&DW;B>,'S0!S5+X6Z7<VGA4:A?RO->:@5?S9%VL8$41PY';**&^KF@#8
M\0>)9-&U/3--MM,FO[S4A+Y*1R*@!C"D[F;H,'K[=#FL2/XC3-:->R^'+R&S
MMKT6%_,T\9^SS>8(SM .9%!9<D8Z]\&N@U+19[WQ7H>K))&(=/2Y616)W-YB
MJ!CC'&TYK$N/!E]-X7UK2UN+<37^KF_C8EMJH;A)<'CKA2/3- %C7?&=WHJZ
MA=?\(]=2Z;IQ_P!(NGF2$N H9C$C<N #UXR00,U<_P"$QL8Y-;%PCPII5LEX
MSL1^]@="P=?Q5EQZBN2UOX=:IJLOB!'@T6ZDU)Y6M]3O=\D]JC+@1JFTA=O0
M,&&,YP32>(M)AU;Q;X<T6"[B:]6W6'68(CN'V5"DHW>@+J%&>HD;WH ]&L+M
MKO2[:\F@:V:6%97BD.3'D9*D^HKE;7XA1W L[Y])GBT2]G6"WOVF0DEFVHS1
MYW*C' !Z\C(%=C+&LT3Q.,HZE6'L:\TTCX:W&F'3['^R_#!M[*=6.J?8U>[F
MC4Y"E2F YX!?<?4#- %_3/%\UA97J3K/J-_<Z]>6=E;^8%)5'8X+-PJ*JGFK
M_P#PG\$-G>+=Z;/'JMK<0VW]GQR)(TLDW^JV.#M*MSR<8VMD<5E7WPZN+FV$
MKKIEY<P:S=:A%;WL9>WFBF)RCY4X;!!R <$=Z=%X!O/[/N)HK?0]*U!;VWO+
M2#3[8+ AASA9'"JTF[<V3@8SP/4 ?XH\7Z_9>&-1>/0[G3]1MY+<;S(DD1CD
MD"Y1\8)ZJ5QD;@>G-=PLUP=/$QM<7/E;S;^8.'QG9NZ=>,]*Y'5O#_BGQ%H>
MJP:A=Z?;RSK +2TA9GAC:.02%GD*AB6( X& !W-=A:FX-I";Q8EN2@\U86+(
M&QSM) )&?4"@#@?#7CG5)_#&C_:],EO=;U*2?R(DE1!(B,2TC-T15R%Z$DXP
M.:ZO0/$"ZV+R"6TELK^QF$-U:RL&*,5#*0PX92I!!KD]+\&>(M'M])FMYM,D
MO=(>XAA5WD$=S;3,&(<[24<$#H&''O72>&M$O=/NM5U3598'U'5)DDE2VSY4
M2H@1$4G!;@9)(&2>@H Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 0J"02 2#D9'2EHHH *0* 20 ,G)QWI:* "BBB@ HHHH **S]>OI=+
M\.ZGJ$$8DFM;26>-#_$RH6 _,5YQH-YXE2?PY?R'5"NH2(MY)?ZC;&WN%D0L
M3%&'RK X90HS@$'- 'J]0VMW;7L)FM9XYHP[1EXV##<I*L,^H((_"O--"U;4
MK[QP_ABXUR9].T^:=X+I2PDOV 7,)?&"8MYW8/.%ST-8NFW&I:5X8T?3M-FU
M*7^U=;OHIC%<HLNV.28[(WD(5"VW).<G!QR: /:Z*\DN]2\2V.C:S9_:KVQ\
MJ]T];1[F\AN+J 2S*KJY1FRO<;^H)'(%7-9U'5/!E[XB@LM2O;Z.+03J$(OI
M/.,4P=D+ D?=Q@E>G% 'HL^HVEK?6EE-,$N;PN($P?GVC<WL,#GFI+N[MK"U
MDNKN>."WC&7DD8*JCW->>MH[:9X\\&2'7+[4/.6Z+"[F$FYO(Y=./E!ST''3
M '?6^*L G^'.J@RRQ[ C?NVVY^=1@^HYH ZB'4K2XU&ZL(I@UU:*C3QX/R!\
ME>>G.T]/2K5>9P^'Y;SQSXI@36]5M4MK&R"O;W&V21]DF&=L9;&.G0Y.0>*S
M8?$>O^(!X7LMFI3BXT-=0N1IMQ';2SRE@F2[,N%'4A3U8=J /7J*YCP+=:I<
MZ)<1ZLQ:>VO)8(V>>*64Q@C:)#&2N\9VGOQD]:S;FVNM;^(FKZ;)KFH6EG;:
M?;2QV]I/Y1+NTH+Y'/&T<=#D9S@4 =S17CMIXE\0^(&T'3V&HW*M83W$[:;<
M1VTETR3F%7+LRX7 #$*>2X[5:@N_$6HR:#HMYJMY9>;JMY:R2P743W#01PEU
M61HRRB08VGOQG@F@#T^#4+6YO;JSBEW3VA43)M(V;AN7G&#D>E6:\NU36-6T
MZ_UO2H-4N5C%_I>GQW4K!WMTE10[@D8W'U(ZMFF^)M5U7P1=:C9Z=JMW>1R:
M.]VIO9//>UD65(_,#'G:1(3@Y&4],T >DS:C:6^HVNGRS!;JZ5VACP?G"8W'
M/3C<.OK5JO._['.D?$KPPO\ ;-]?K)9WAVWDWF,&Q'EU.,@'CCIQP!S6]XZU
M"[L=$MH[.Y:U>]O[:S>Z0#= DD@5F&> << GH2* -S^T;0ZJ=+\X?;1 +@Q8
M.?+W;=V>G48JU7D'B."Y\,ZUXEDLM8OIIHO"[2PR7$WF2P$2MT?KC(R,Y[]J
M[+4M3N8_&?ABTBNF$-S97DDT:MPY58MI/TR<?6@#I+S4+6P\C[5+Y?VB98(O
ME)W.W0<#CIU/%6:\ET2?5X/"'A'69]>U*ZN]7O[)+@2S9C"'=E54#C(QGUQF
MFW=QK">&/$7B4:_J0NM-UBXCM8!*!"(DN=NQDQ\PP2.>@QC&* /7**\SU"74
M-5M?&>JMK]_ITVCRS06D,$H2.)8XE<,ZX^?>6)R>V,8KNO#T\MSX9TJ>=VDE
MELX7=V/+,4!)/XT :55;O4K2QFM(;F81R7DWD0*03O?:6QQTX5CSZ5Y/>>*=
M<LEM[!;^9I_#U[-/JSL?FGM4FC5 W^]%-N_X!5F_:]\1#P_?-J-Q#'J/B:4V
MDD3#=%;+#,B[,@@;@A;/^WF@#U"_O[73;<3WDOEQ-(D0.TGYG8*HX'<D"K"J
MJ*%4 *.@ Z5Y;>ZCJFB_V_I<.K7LT5EJNF+!+<2[Y529X]Z%^I'7KV-78#>:
MS#K^MW7BB[TEM/U*:WAPX%O;QPL /,CX#[AR=QZ,,8H [RRU*TU!KI;682&U
MG-O, "-D@ )7GV8=/6K5>/S6MY#H_C_7K/6M0M9[#4;F>WBMY L6Y(HVRZX^
M?/ (.1@<8KUNVD,]I#*W!DC#'';(H J2:[I<9A!O8CY]V;*/8=P,X#$IQT(V
MMG/3%:%>)0:0XTW3X(=2OHWE\:W$7FF7>Z!3< E<@@,1G)]>:U=8UG6?#4?B
M;2K'4+VZ$5SI\=M-<2+)+ +@E7P[\=OEW' )]* /6**X+PM+K=GXM:PN8]0B
MT^6R:4Q:IJ$%Q,LBNHW)M<ML()!SP"!C&:O^/I;X0:#:V.H7%B;W5XK:6:W(
M#^6R2;@"<\\<'L0#0!UV >U53J5H-572S,/MK0&X$6#DQA@I;/3J0*\VNWUN
M?Q5J.A6[>(;NTTFV@6)[34(896:12QEE9V4N>P'*_*<BJ2^(-7MI%UVZ$$VK
M6_A&ZE)B=)$=TG7#90E3G ) ..HH ]@HKR[0Y_$5OJN@O*=5\B_REX^HZE;.
MDX:,L'A17)5@0" @QMSZ9JQI&MZK?7FD>%I+V8ZEI]]-_:DX/S/;P8*$_P#7
M3S(?K\U 'I-%>.3:[J8CTS7;&\UZXAN-5AC^W7$L<5I/%),$*);[BVW:< [0
M>,YJSJ<VL'P[XR\0+X@U*.XTC4+@64,<H$*K&5(5EQ\X.2.>W3% 'JB7=M+=
MS6D<\;7$*JTL0;+(&SM)';.TX^E1W>I6EC-:0W,PCDO)O(@4@G>^TMCCIPK'
MGTKD/#]D!\4_%-U]IN2?LUDWEM*2GS"3M[8X],GUIWQ"MFO+[PE;K>269DUD
M+Y\1 =1Y$V0I/0GH#VS0!V]%>3ZS?ZQI<NLZ#9:W>E(+[2Q;W<CB2:$7$NUX
MRQ'S# R-V>&P:LZL=7MO%5KX6M)=?O[.VT[[8S07\<5Q,[RLN7D<J2J@8 7U
M&: /3Z*\L36=6N-)TK3-0N]4DOWNKI!;:7+ US=11' ,DRN$C*[E#8()/XU5
MT_7-;DL&T:6_OK7S/$PTPSS3)+<00&$2E/,&06+ J&Y(W=<B@#U._P!2M-,A
MCEO)A$DLT<"$@G+NP51QZD@5:KR_Q;826>ER:5#XDN+I_P"U]-:))V$L]EOF
M4 ESDL"1D!AQ@]147B+5M6\%S>([6PU.]O%32K>[@-[()6@DDG:%F#-V PV#
MP"/2@#U6JMUJ-I975G;7$P2:\D,5NI!.]@I8CCI\JD\^E>92:IXE\,RSSI!J
M8@_LRZF:+5]0M[AGEBCW(\:HY;KPP VX8<"ISIDMKKW@&^EUZ^U![NX>25;F
M4.KL;60[T&/D')&!Q@B@#U"BN;^(%[=:;X"UF\LKAK>YAMRT<RG!0Y'-<]J;
MW_AC5[.WMM;O[Y-1TZ\>87,N_:\48=9DX^3DXP/EY''% 'HM%>5V/]JKI'A"
M"7Q%JAD\2&-[RZ>49C MVE\N+CY-QP,]>/6I-0O-9T:Z\06-CJ=[>PZ(MIJB
M>=)OD,9+^= [=6!1"PSSR/:@#T?4-0M=+LGO+R7RK>,J&?:6QDA1P 3U(JS7
MF.L>(;^^T7Q/X@T[49DL(9K:RL#$V%.V1/-D'U+E,^B5!K&I:KINLZCJE_?:
MK_9L%\!%?Z9<QS6UM&"H,4UOD'(Y#'!/.>* /3+74+6]ENH[>7>]K+Y$PVD;
M7VAL<CGAAT]:LUYA=ZWJLM_?Z8NI3V\=UXH73OM"D;H(?LR2%$)^Z68$ ]MQ
M[U7\3:CJWAI?$6D:?K-Y,D6G6U[;SW$GF2VLC3^65WGD@@9P??M0!ZO17G-^
M-4\/>(;K3[3Q%<,MUH5S<K-JLX:."XC9%63)&$7YSD?=XZ4[PA>WMGXDATW5
MFURUNKFT=EM[^X2Z@N&0KNDBE4Y! /*X PPXXH ]$HKG/&VH?8-!4+>W=K+<
MW,5O']BB#SREF_U<>X@*S $;CTY->>WVMZYI%OXMM$N-5LA!I,-Y;KJ-VEQ-
M YD92P=6; ( ^4D]/>@#V6BN!N/MWASQ)IEI#K-]?Q:E9733K=2^9M>-%994
MX^0$G&!\O(XXK*TFXU.P\.>"]?.OW]]=ZI/:P74,TNZ*5)5^8!,85DZ[AR=I
MSG- 'I.GZE::K:"ZL9A- 7>/> 1\R,48<^C*1^%6J\I\/ZE/H.C:#JSW3II3
M:KJ%G?(3\B^9<R^7(?3#J%SZ/7:>"KB^O_#JZK?R2%]1E>[BC<_ZF%S^Z0>G
MR!3]2: -B#4K2ZO[NQAF#W-GL\^/!^3>-R^QR/2K6!G..:\X71VU3Q]XR<:Y
M?:<(4M"HM)A'M;R>'?CY@,=#QUR#VIV7C?4-+T_1_$>L2.]GJNB,YAZ*+N)2
MXVCMYJ%N!W44 >IT5E>&[:_M/#EA%JMP\^H>4&N9'.3YC?,P'L"2![ 5YWXM
MU6_E7Q/?Z9>:_,VF>8$GM9H[:TLWCC!*$,V9CGD_*<YP,4 >L,JNI5E#*>H(
MS5;3]1M-4MFN+*82Q+*\)8 C#HQ5ASZ$$?A1IEP]WI-G<R8\R:!)&QTR5!->
M1VNIZI':Z1HNGQWK17VJZM).+&>.&:01SL0BNY 4?-DX.<+QWH ]FHKR>;4O
M$D.C3:?)>W=DXUVSM;>62ZAGNHHI67<DA0L,C)(W<D$9S4VLZIJO@^;Q39V>
MJ7EU'#I5O>0/?/YS6[R2O&S GJH"AL'CCTH ]2) &2< 5G1:UI4MS8I#=PR2
M:A&\ELT?S"9$P20PXP-P[]^*XJ]L+K2O%FCZ5%XDU6XM=0LKPS1SW.]BRHN)
M%;&1]X\#@8X YKG/#ND/=6GPUMDU*^@6;3;J622*7$@&R'Y%;'RKG'3GK0![
M317*^!KB[>VUFRNKR>[&G:K-:PS7#;I#&%1@&;^(C>1FJVH"ZU[Q]<Z))J=[
M865GIT5RD=G+Y3SO([J6+#G:H0# XRW.: .@UGQ#IGA^.!]2N&C^T2>7"D<3
MRO(V,D!4!8X )Z<5?FGBMK>2>>1(H8U+O(YPJJ!DDD] !7DED;K7/$?A-K[4
M[R66UU'4;);F*79YZ0APLF!QE@,,1UQ7?>/(?/\ A_XA3S)(\:=.V8VVGA"<
M9]#C!]030!JPZK93WJV<4X>=[<72J <&(G ;.,=?QJY7DUWJ&HZ-I5]:VFI7
M>RV\&F\B+REF6;<^'!]1P![ 5>73=3'BC1--?Q-K+0:IITUS>?OP"7C,>/+(
M'[L$R'A<< 4 >ET5X^NOZ_<6/A_14FU*\,]]J,,TMM/'%<SI;2%47S'( .,$
MD88A?K79>![G5V.K66I^=Y=K<*+875U%/<(C("4D,;'D')!;D@CK0!UU%%%
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M8PQ(V/@KN!!'(#'![=>M:"LKJ&4AE(R"#D$5D0>*] NM7.E0:O:27P9D\E9
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MQPV,\DYE9]HRS.J[4 4[4&<;CS72Z9X3T/1WMFL+!83;&0P8=B(_,VAPH).
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ML+E<RB4C:V_)Z$GYCD<&I];>]MO"OC7P\NCZI/J-[?W$]LL-G(\<D4A5@XD
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MM^Z1QG=D8Q6AK.GW\</B>Y&GWDB+XCL;Q5C@9FDBC%N79 !E@-K=,]#7J5%
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M%4*%C$Y5@0PPQ P<^M;_ (:T&?3_ !=I)FL[D1VOAJ.U$MP Y1_-&4+@;2P
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M=B02ZA"D#3;453((E1=@. .1D[<]Z[&B@ HHHH **** "BBB@ HHHH ****
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M0S7<SKYA=20@"@X/!Y[<<'-;&A:(-%.ID7'G?;K^2\^YMV;P/EZG.,=:Y?\
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M7AF35]+.D64EI8Z;=RLVHJMOEY59@S;"" K,<Y8@]<]:Z)45(U15"HHP% X
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M@NYTDN3BV:>TEACG.,X1W4*W'H>>U '2T454L=3L]2:[6TF\PVD[6TWRD;)
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M@FN'V^8QR!+M^[O4'#X_V@:74O!_A_5[TWE_I<,T[*$=B2!(HZ!P" X'HV:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$%8S3LI*D-D8)7 Z9J[X.T;4+74_"DUW831"T\,FUE:1,>7-OB^4^APK?@*
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M[855 R22>@KRVXLM7M-9G71;#6;2ZDU3S7L9D6XTV5#*&:8.P_=DC+X!!#<
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M-PLO&XA6(VE@.J@Y'.17$V]CJU[XKT:]V>(KN"*UNXY9]2MT@6-WB&%6-57
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MK**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNV2(Q1P#W&Y3@UQ?BKX@ZAH$^J2K>:$HL'RNFL7EN9XQC+%D;$1/. 5..,T
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M$#.>V":LP^#[MVM[^SUBYTN:YTZ"TOHDA1RX13@J6'R.-S#//TKLZ* .-MO
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M&.I&,<5T&C::=)TN*S>]NKUU)9[BZ?<\C$DDGL!D\ < 8 K)L_&/VR\AM_\
MA'/$,/FN$\V:RVHF>['=P*Z6@#C[WP-+,VIV]GKMU9:7JLCRWEI'$C$LXQ)L
M<C*;N_7DDC&:V+/P[;6.OG5+=R@_L^*P2 #Y42-F8$'K_%C\*V** ,77= ;6
M+O2KR"^DL[K3;@S1.L:N&#(492#ZJQY[51F\%6\WAC5=#-Y*(]0NY;II=HRA
MDE\P@#T!XKJ*I2ZK:1:JFF-(3>/;O<K$%))C4JI.>G5@,4 85YX0NCJ&HW&D
M:_<Z7%J9#W<4<2/E]H4O&QY1BH )YZ XS72VMNMI:0VR/(ZQ(J!I7+NP QEF
M/)/J33+&[%]8078@G@$R!_*N(]DB9'1E/0^U6* ./_X0J_LGNH="\37>EZ?<
MR-*UJMO'+Y3.<OY3,,H"23CD DXQ4G_""VUC#I1T&]FTRZTV%X(IM@E\V-R&
M<2*WWLL V<@YKK** .4M? UO;FRFDOYY[R'4SJEQ<2*N;B4QM'@@8"J%8  =
M-HJ>[\'P7=GXGMVNY%&O_P"M(4?NOW*Q?+Z\+GFNDHH \_A\,ZU)XR\0RV>J
MW>EVTL%I"LJP*ZS!8R"5W=&7U'KR#Q6A'X#73;ZTNM!U233C!8)IY#0)-NB5
MBP(+?=;+')Y![BNPHH Y/2/ MOI T54O[B8:5<W5Q&90"TGG[\AB/3>>>]5_
M$>C0:?HGB=_L=]JC:\^#;6T6YE<PB->>P^0'<>A-=I10!R>GZ!JFC>!K#2]/
MNRFIH\4ES<?*V]VD#SL=PYSE_?TKI;VS@U&PN+*Z026]Q$T4J'^)6&"/R-1Z
M=J=IJL$D]E+YD<<TD#-M(^=&*L.?0@BK= '+Z7X4U"QN+!;GQ+?7=CIXQ;VV
MQ8RWR[5\UUYDP#TX!/)S1_PA5O\ \(BOA[[9+Y0O!=^;M&[/VG[1C'IGCZ5L
MG5[4>(!HOS_:S:F['R_+L#A.OKDU?H Y&[\"17EQK!;4[B.#4;B.]1$10UM<
MH$"RH^,_\LUX/'6I3X3O;RUU2/5O$-U>O?6+V("QK%%$C @L(QP7Y^\?H,"N
MIJA#J]K/KEWI";_M5K#%/)E?EVR%@N#Z_(: +%E;"RL;>U5BRPQ+&&/4X&,_
MI7/3>"K>:^GNC>2AI=7AU4KM'#1HJ!/H=N<^]=110!S&L^"[;69=<>:[FC_M
M:RBM'V ?N_++D,,]3E^GM43^$=12]?4++Q'-:ZA<P)#?3"UC9;@ID+($/".
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MMK/?SO?M$KE#+\P$@Q@@DD=L]L&NQT#05T2.[DDNY+R^O9O/NKJ10ID;:%
M'"J%4 #VK8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI5C/>1XV7$MNC2+CIAB,BG7.C:7>7#W%UIMG/.\?DM)+ K,R9SM)(R5SVZ4
M>?>(K!O">IZ?!X>^T";^RM5N$5YGE,LXCAVL=Q.3D#\2?6K.A:9X65- DAU.
MZDO-4M'614NGD^WAHLN9NN,<G=\N#@9YQ7H+VT$EQ'</#&T\098Y"H+(&QD
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M29FPZEOO  @XZUU7B[0[S5[:PNM,DBCU/3+M;NU\[/ER$ JR,1R RL1D=.*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"*"UM[42"W@BA$CM(XC0+N=CDL<=23U-2T44
M%%%% !1110!%;VMO:1F.V@BA0LSE8T"@LQRQP.Y)))[DU+110 55FTVQN+ZW
MOI[*WDN[<$0SO$"\8/7:QY&?:K5% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45B/JT]QXQ31K4J(;6U^U7KD9/SDK
M$@],[78_[H]:S-)\4:GJ7CRXTF?2WL=/2P-Q 9\>=*1($W$ _*O7 //<XZ4
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MZLT; _: Y0H1C(Y4\GC STJGKWBM;/4K*PT^1'N/[4MK.\5XSA%E5F !X&[
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M-;2+;S2#.424KL8\'H><<9IOA+Q4/$SZNOV::'[#>O;KOMY(PR#@$E@/FZY
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M;[XHZ.L0XTW3KB:X/IYS(J*?KY;G_@-=;4$-E;6]S<W$42K-<L&F?NY "C\
M!T^OK0!/1110 4444 %<SIFFWD'Q#\0:C+ 5M+FTLXX9<C#LGF[AZ\;A^==-
M48N(3.8!-&9@,F/<-P'TH X*X\/ZF_@_Q_9K9L;G4[J[>T3*YF#0HJD<]R".
M?2LR[\/:IIOB'5KQK+7[J+48X'@_LJ]6(!TB6,QR@L,<KD-R,$^E>J4@8$D
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M4T&70M;31;J00/>FZL5N5GN(_M#*PDW,0&;*?, ?XCC.*]-I&8*I9B !U)H
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M>1--N<1,0@VLN!URW/; KH+[P3YUU?OIVLWFF6VI "]M[=$(<A0FY"P)C8J
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M)*NXMN*,,!\D\C'7&, 5;T[P[-H0T'3])N94TNQ25;E)"I,VX?*3QG=O.[C
MZ^U "^)=9O[.]TC2=)%NM_JDSHLURI>.%$0N[%006/0 9')ZUR-EJ6L:)J'C
M:[O)])COENK-&N9F,5L%,2CS""V?N\[-V2> >]=QKV@)K8LY4NYK*^LI?.M;
MJ$*6C8J5((8$,I!((-83_#N.6.[EGUN]EU"XO8+\7;I'E)HAA<)MV[<<;<=/
MSH QX?B#J,=IXF N=/U)],TO^T+:ZBM)8(W/SC:R,Q)&5'*MCGUJ\NM>,SKV
MGZ2TNBH^IV3W<<HMY#]D"%-RD;_WOWU .4[G':KTO@%;Q]7FO]:O+JXU73CI
M\\C(BA$R<%%  &-QXYZYK;.@0G7=.U7SI/,L;22U1.,,KE"2??\ =C\Z .2'
MC;4W\,Z==7%YHVF7$MU<6MU<W 9T#0NR?NHMP9RQ7.-WRCUJ'3?'VK:G91V-
ML+&35I]7?38KIH)(X2B1><93$QW9V\;=W)[XK8'@%+:2RN=.U:YM;VSFNY(Y
MO+20%;B3>ZE6&.#C!'/'>LW5?!_]BZ8\UL^KZC<RZLNH-=P-']IMI#'L:15V
M[7!Q@ICHQQT% #;SQQK?AZ+Q,FL16%S+I4=I]EDMD>-9VG9E!<%F*@$#(&>A
MZY&&V/CO53=75HOV77)C8375N;&SFM\31@$0L'+9W9X(.>",4WP_X2FUIO%$
MNM'5#;:M]F2*6\"17),()\P*HQ& Q&T8_AR1SST47A*YF:X;5O$6I7S26K6J
M;"MN(E;JX$8&9.!\QZ=@* ,WP9XMN]=U-[6XU72;O%OYDD$5O+:W-O)D JT4
MC$LO)^;CD>]7_$/BN7PYK$B74<7]GG2I[N%\'>TT)!9,YQ@JP(&,\&I=-\)R
MVVM6VK:GK-SJ=S:0/;VQEBCCV*^-Q.P LQVCD\=>.:G\3^%++Q5%81WDDL?V
M.Z6Y4QXRX (9#_LL#@T <_HOC35-6BTBRN+2UCU*3[9_:L05BL(@)0A1NXW.
MT>,D\$UR*7*WNA7URMM!;++X +B&!2(X\F3A022 /J:]+T_PA8Z=XCUK6HI)
M3/JJJKHQ&V+ PVW_ 'B 3[BJ$'P]L8-->R6]N"C:'_8NXA<^7\WS]/O?-]*
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M%25R =IQD9[$5Q>I?$'4M/O6D_M'19ECOTMI-,MX9)9$C:4)EIU;8KX(."H
MZ=:]!TC3$T?2H+%+BYN1$#F:YDWR2$DDEC]2?8=!Q7)GX;@Z0-&&OWZZ3%<"
MX@MECC&QA)Y@#-MRX#=C^.<4 0ZCXE\4M<>*Y--.DQ6F@-E5GAD=[@"!92I(
M<!>I^;!ZCC@D]E;:@;K0H=2CC ,MLLZQL^ ,KNP6[?6J!\+VYB\1)]HEQKA)
MFX'[O,*Q?+^"YY[U;;1+:7PR=!E:1K5K/[&[ X8ILV$Y['% '#:7X_OY->T:
MVN-3T?4(=1D>*:/3[>4"U81LXQ,6*2#Y2#P">HJEJNJ^(?$'AWP_KD_]GII5
M[K%C)':I&XFAC-PNQC)N(8GC(VC&>O'/46O@65+C19;S7[RZ71G#6D1BCC3:
M$*88*OS':>N>W3DU$/AXJQV=DFNWZZ18WD=Y:V 6/;&R2!PA?;N9 <@ GC/?
M H QM5^(U\FI:RMA<6$,>ES- EI/:32R7CH 6Q(AVQ@DE1PW(R>*UX/$VN^(
M;^\704LK:"QMH)G2^A=GGDEC$@CR&7RP%*@MAN3TXJY>>"Y'N]1?3M>O]-M=
M3?S+RWMU0[G("LR,P)C9@!DCZC!IU_X.8W=Q=Z5J][ISW-ND%TL6V3SU12%.
M7!*N <;A[=QF@"GX3\7ZAKM]H\-U#;(M[H:ZC)Y:L")#(%P,D_+@_7WJJWC3
M4'\-6]^]UI&G/+J-S:/<W>XHB1R2(NV/<&D<[!P".YZ<4WPYX,O1X;\-7:ZA
M=Z-J]GIBV4X2-'RAP2K*X(!##(/\ZO0_#V&RL]+33]7NX+O3+BYF@N9%24GS
MV)<,",'KUX/% '*:GXIUK7O"]W%%>V8GL==LK8W4=K+&MPCO$RGRV<,O+#(R
M0P!QC(-:&I_$+48M2U6WMKS38#I3>1Y4UE/(U[*$#/AD;$2Y.T9W'N:W&^'T
M+Z?JT#ZS?27&HW4%ZUTXC+QS1%2K ;=N,HORXQCBI9O!5QYUY)8^(K^Q&HA3
M?K#''^]D"A&D0E?W;L ,E>. <9H UX]8:Y\)+K<,+1-)8_:EBF!RI*;MK#CI
MT-<0_CGQ!8^&M&U#4GTF*?7C$;39;RLEHAC,CM( Q,AP%P!MY/7'->@OIT3:
M.VF!Y!$;<VX9F+-MV[<DGDGW-8]QX/MYO#^CZ;%>W%O/HZQ?8KV/;YB,B;,D
M$$$%<@@C!S0!RS?$/58M$UAH4LK^\L9K18+D6\L$-PLTJQD%6)*LO.<$CD'V
MJ_\ VMXU/B"_T$7.A^?;V<=\MW]DEVE6+J(_+\S/5#\V[IVR>-23P6;S3[R#
M4M:OKRXNY[>:29]JJGDNKJJ1@;5&5Y[G/)Z5JC0X1XBN]9\V3S;FSCLVCXVA
M49V!'O\ .?RH X5_B7<WB:+#!-9:7+>:5'J-Q/<6LMRJER0(T1"#U5CDGH!U
M-7K/QOJVM6NC65C!:VVJW\]S%)/-$[0HD'WI$0E68-N0J"1C=STK1@\!KIT&
MEG2-8NK&]L+(6'V@1I()X0<@.C#&0<D$8QD^M3R>"T-AIZPZO?IJ=A+)-%J,
MC+)(6DSY@8,-I5L_=  &!C&* .4T[6-8\.ZCXEOK]+-]FNVL6HO&C!1 \$2"
M1 6RN,HQ!W8&X=LUW&BZS<:MK.MQJD0TZQG6UAD .Z24+F7)SC +*HXZJU8.
MH>'5T+PSXA21-3\07&ML1,BHF]G:()VP%7Y1S_#QZ5T'A+1&\/>%K#397\RX
MCCW7$I.3),Q+2-GOEB: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "DR"2,C(ZU3UFZ6QT/4+MQ,R06TDK"#
M_6$*I/R_[7''O7CFC&SMO$W@JYL8=$LY+N8AA8W33W4L;0.?](DP QSC.0?F
MZ'@T >X9&<9YK.U[6;?P]H=YJMTDCPVL9D=(@"Q'L"0/UKR;3M%L+7P%H'B"
M* #6/[:A7[9D^9L:\,93/]S:<;>E5?$D6@3^#/%UWK<D \4)?7$8:23%PH\S
M]RB#.?+,>W@<$$GUH ]JU+4;?2M*NM2NV*6UK"T\K 9(502>!UX%5(_$%I+K
MEOI2I+YT]B;Y7(&P1AE7!YSG+#M^-9OQ#MHKOX;>(HYHEE"Z=-(JL,X94+*?
MJ" 1]*Y2ST/P_K7C#0+;[+:76E)X>DDCA3#0LWG1@Y X;DMP>_N* /4B0!DG
MBBO#'$WV/0=*E:R.B1:KJEOY>IR.+8M'*1!&Y'4!=^T'C('H*[OX;IY4&LPP
M7EE-8QWN(8;#S#!;ML7>D;,,%<\X7(!)% &MJGBQ+/5GTG3M+O=6U&.-99H;
M38! K?=WN[*H)P<#.3CI5O0/$-KXAMYWABGM[BVE,-S:W*!98' !PP!(Y!!!
M!((/6N9TC4K'PYXZ\46FLW<-G+J$\5[:37+B-9XO*5"%8\$JRD$=><U0\3>)
M;+7]&:2U61- 36;>VO\ 4$;;%<P?\M"&'/EAMB%NF,\XH ]+!!&0<BC<,$Y'
M'6O%?%*:991^*K7PL\,>E#0UDNDL6'DQW/F@(1MX5RF[..H )KH#X,\/)\2H
MM,_LV(V$NC//-;-DQSRK,JK)(O1V =N3D\YZT >EYP,T9XSVKQ.P&E3V7P^M
M]?F0V&=1AVW,G[M]C[8T?)P5^4  \$@"I9KK3XK6[TNV@ANM N/$"PZ:DUV8
M;+(@#2*S ',0D#X0#!;@=* /9@01D$$4H(/0UX,PB_L7QMI]M)8Q6J7NE;8]
M)=E@B9IU#F,]C\HR1CD>U==<^$M+7QEJ7AW3K=+&RU+P^YEC@^5?-$H59<?W
MAGKUH ]+I"0.IQ7G?@G4+OQ9KD>IWR,CZ'9_8)5;I]N8_OS^ 1 /]\U%X_L[
M6[\56GFW&BSRI8,1IVN!D@9=_,D4G19.,'@D#'2@#N)M:MX?$5MHK))]HN+6
M2Z5\#8%1D4@G.<Y<=O6M+(QGM7D>DVFE^+-:\'?:]/D:Q_L.Z9;6ZE,P.V6)
M1N8_ZQ>X)Z_*:JVR6D9TS2=4<)X7A\0:C;/%,Y$(V$^1$Y/\&=V >,@"@#V;
M.1D5GZ[K$&@:%>ZO=)(\%G"TTBQ %B .V2!G\:\IU"2SL['Q,ND2(OANSU32
MY(S"V8(7$R&<(1P% V$@< DU+XZU6RU34/%IL+R&ZCB\*E'>%PZAO-8XR.,X
M(/XB@#UR2=([9IVSM"%\=R,9JII.KP:SH%GK%NDB6]U;K<(D@ 8*RY ."1G\
M:\\U&+0+KQ+XG_X2R2!7M[6 Z<;B3:T<!BR7AR?O>9NR5YR /2NI\"_\DNT#
M_L%0_P#HL4 ;6AZQ;Z_H=EJMJDB0WD*S(DH 8*PR,@$C/XUH9&<9Y]*\/\,P
MZ!!X5\#7.@R0'Q')=6R3-%)F=T_Y;K(,Y\L)NX/  7':JETDEQ;:W>W]YHEK
MKD>I2HMU.\IO[=A)B)8E4$E=NW:J\,#WYH ][I 0>AS7)_$:;4(/AUJ4MD[)
M<".,2/'N!6,NHE(QR,)NZ<@5PMO;P6=Y>KI=UH$,4FAW33VNBM(Z2KL&R1SC
M:&!Z,3D@GK0![/D9QGFLBT\0V^HV-G>V%O<W-O=7+VX>- /+VLZEV!(PN4(]
M>1Q7G^GZ!IFFR?#V[M;54N=10PWTN26ND:T=F$A/WAN //3'%9WA^WTR+PMX
M2M[2.V60^)I$NXXL9S_I( <#OM"\'MB@#TG_ (2_37M].GA$\L5_J+Z=$RIC
M$BF0$G)'RYB;GZ<5OY&<9Y]*\7T&WTRUTCPY#8QVT=PGBZ9+E(L!EP;H(& Y
M'R@8SVK*MTFFTQM0NKS0[7Q'_:95KJ1I6U%)_.P(PB@DKC " ;=ISB@#V_6M
M5@T/1;[5+E7>&S@>=TC +,JC)QD@9J:2]ABTYK^4E($B,S$C)"@9/ ]J\:\2
MQ:!<>'?'MSK\D \0Q7%RENTLF)TCV_Z.L8SG8RXR!P<MGO7IVM6T5YX"O8)H
MEE1M.;Y&&02(\CCZ@4 :UA?0:CIMK?P$^1<PI-&6&#M8 C/X&K->-Z'#X;N9
M?"MGJOV!M!.@K);Q2LOV:2]R/.W#[ID QP>1EN]=G\.) ^B:BMO(\FEQZG/'
MIKEBP-N",;2>JAMX!] * .HL[MKO[1NM9[?R9FB'G #S ,?.N"?E.>.G3I27
MMXUI DJ6L]UNE2/9  2 S ;CDCY1G)]@:\HGM(M2OH;.Z#/;R^-KA)$#$;E^
MSN2IQV/0CN,BC4K.WT>]U_2].B6VL(=;T:2*VBX2,N\>_:.@R0.!0![#02!U
M.*\@UC6+&P\'_$FQNKZ*&]>]N?+MWD D8/#'L*KU(//(]#Z5>3P[I6O>)?%S
M:K:)=B"RM/)64DB(F!LLH[-P/FZ\4 >HD@=3BJ$VKVL&L1:42[7DMM)=(BKU
M1&53SZY<<5Y;HC:9J]SH2^,Y;>:S;PU:S6@U!QY4DISYS_,<&0#R^>H!S4EM
M;^'3XK\.W< +02:%=K8SW^/-D9)8Q'@MR2%+;>^TT >JV-RUY807+6\ULTL8
M<PS@!X\C[K $C(^M3D@#).!7C=GJ4_A#PKX7\26\;RB_T)-/>,#.ZY$>^V)^
MIWIG_:%+JNBR:7K?A_0+]M)GL(=)9U&L.PMY[LR9F?CAGYR >@8D4 >R49&<
M=ZY#X;[QX691>PW=LMW,ML\'F&-(PW"(SC+*IR >1@#!XKBY]*\KPMXZU_3X
M7;7(M1O8HKE2QDAAWC>$QT^4N>.<T >NW5TEI9SW3@LD$;2,%ZX R?QJAI6N
M)J\=E-!9726]W8QWL<\BJ$ ?!"$@GY\'..GO7EMA;6UKJ<7]E77A^&.72KII
MX-':63[3%Y?RO*<8!#8PS<G)&34,T^HV^A0R:4THO%\!VYC,6=R_,-Q7'<+G
M&* /; 0<X/2L7PSXB7Q/IIU&#3[JVLW.;:6<I^_3GYP%8D#C^+!KSKP]ING/
MXGTBWLYO#GV6[M9A=6NF&67[9!LZS9&,ABIW/R22.^*Z3X7G2](^'/AU ;:U
MEU",$#(4SS$'/^\VU?R% '>4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !56'3+"VSY%C;19?S#LB5?F_O<#KR>:M44 1?9K<1+$((O+5MRIL& <YR!Z
MYYJ.73[*>?SYK.WDFV[/,>)2VWTR1T]JLT4 (0&4J0"",$'O4,-G:VP006T,
M6Q2J^6@7:"<D#';/-3T4 0265K+;O;R6T+PN27C:,%6).22.AYYI\,$5M"L,
M$211(,*B*%4#V J2B@""[L;2_C$=Y:P7$8.0LT8< _0T\01+!Y B00[=OEA1
MMQZ8]*DHH K1:?906K6L-G;QV[=8DB4(?P Q4WE1^:)=B^8%V[\<XZXSZ4^B
M@#$U#PS9ZAJ^EWLBQB*P6=?LWE I()0 <C\,_C6F]A9RV8M)+2![8  0M&"@
M Z?+TJQ10!7%C9JFQ;6 +A5VB,8PIRH_ ]/2DN[9YH)C;2);WC1%([DQ!S'G
MIP>HSSC-6:* ,KP]HB:#IAM?/>YGEE>XN;EU"M-*[%F8@<#K@#L !5VZL;2^
M14O+6"X53E1-&' /J,U8HH 8(8A(L@C3>J[5;:,@>@/IP/RICV=M)!) ]O"T
M4I)DC9 5<GJ2.]344 0QVEM%:_98[>)+?:5\I4 3'ICIBHX]-L88?)BLK9(B
MI38L2A=I.<8QTSVJU10!!-96MS)%)/;0RO$<QM)&&*'U!/2I4CCBB6*-%2-1
MM55& !Z8IU% %:'3[*WG,\%G;Q2E0AD2,*VT=!D#I[4KV%G)=I=O:0-<H,+,
MT8+J/9NHJQ10 =:K6^G6-HDB6UG;PI+_ *Q8XE4/]<#FK-% $?D0_NOW2?NO
M]7\H^3C''IQQ3%LK1'+K:PJS2>86$8!+]-WU]ZGHH @6RM%D:1;6$2,_F,PC
M&2W3<3Z\GFD-A9F\%X;2 W0&!.8QO ]-W6K%% %>;3[*XF$T]I;RRA2@=XPS
M!3U&2.GM4X  P  /2EHH J-I>GO:_97L+5K?=N\HPJ4SZXQC-6D18T5$4*JC
M 4#  I:* (OLUN&#""+(?S =@^]C&[ZX[UC:_P"'/[=FL1]K6VMH;J*ZN8TA
M!:X,;*T8+Y^4 KZ'(/:MZB@"M+I]E//Y\MG;R3;"GF/$I;:>HSC./:IA#$K.
MRQ(&< .0HRP' SZT^B@"M-IUE<VZ6\]G;RPQXV1O$K*N.F 1@4^6UMYC&9;>
M*0Q',9= =A]O2IJ* (OLT'E)%Y,?EQD%$V#"XZ8';%)=6=M>P^3=VT-Q%G.R
M5 XS]#4U% #41(XU2-51%&%51@ >@I$BCBW>6BIN8LVT8R3U)]Z?10!6@TZR
MM?-^SV=O#YO^L\N)5W_7 YJ5+>&-E:.&-65!&I50,*.BCV]JDHH KV]A9V;R
M/:VD$#R'+M%&%+GWQUIXM;=5B58(@L1S& @PA]O2I:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **K:BUXFF
MW3:?'%)>B)C DK80R8^4,1VSC-<?;W6NZ-XOT/2KS76U9]1BE>\MWMXT^S!$
MR)$**"$W83#9SGKD4 =S17&:;K?B"X^)$FFZA;Q6>G'39)[>W5Q)(Q65%$CL
M!P2"<*#P#SST[.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHK!UWQ1;Z+J6EZ?Y#W%S?W"1;4.!"C-M\QCZ9( '?GT.%E\31)XNMO#Z6=PS
MRQR.]RR%8U*JK;02/G.&&<<#Z\4 ;M%<W%XGN1K=K97NDM:07LDT=M(TX,A\
ML,Q9X\?(I"D@Y/49 S4?A3Q7/XG G6QM8;1X1*K)?K+* V"H>,*"N0<\F@#J
M**PO$GB:+P[':[K.XN9+B>.(")#M0-(J;G?&% +CCJ3T[D5-6\72Z==ZIY.F
M&XLM(B674)S.$9 5WD1I@[R$^8Y*]<#)H ZBBL"]\56UKXFTG1(H6N);]FWR
MH?E@'ENZ[O4MY;8'H"?3-;2?%LVL:[/8V]E:?9X9Y86D-^OG8C8H6\G;G&Y2
M.M '445DZ[J5_I=K]IM+"WN88T=[AY[OR!$JC.<[6R,9],8KGF\>W0M])W:/
M;V]WJ%L]T8;S4%A$2!E5!N*\LV[.W (P: .WHKGM<\51Z"FEQSVK2WE]/#"8
M(WR(0\B1LY;'W59U'3DD#CM5O?&9M-:N+0:>'M+:\M[&:8W 67S)@FTI%CYE
M'F+DY!^]@'% '5T4C$*I8] ,FJD.JV%P+,PW<,@O4,EL5;/FJ "2OJ,$'\:
M+E%5=2NY;'3IKF"TENY4'R018W.Q. .>G7D]ADU0T/6Y=4N-0L[JT2VO+"14
ME6*;SHSN4,,/M4YP>00"/Q!H V:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GJKW\>DW;Z7#'-?B)OL
M\<K;4+XXW'TS7'^#-/\ $.EWA;5= B-W>'=?ZL^I++(Y . $"#" \!00 #WY
MSWE% & VDW1^(,6L@)]C72GM2=WS>8958<>F >:WZ** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .'U[P3J%YJ?V^PUR[1YM0M[B6-DA(C2/
MIM)0GY1DA2<9)]36_?Z;<7'BC1M0C"^1:1W"RDGG+A N!W^Z:V:* .(N-#UO
M4M>L[JXT_3;6ZM)9/,U.)L_:8"KA(BGWB#N4LK' *G&>,1V'AC4+K4;"6?3[
M705LK*2U>32Y0#,S[/N87Y4&TD;N<D<=2>[HH YW6-!N9_"J:7;7,UU*ES;R
M^;=R9=E2X21LMCLJD#CL*Q?%WA.\UR^U".WL4\O4+9;=KI+V2(+U!,T0.)2H
M.5XYZ' KO** .$?P)?6NNZ7=V.N7;01:D]Y.DJ0DJ#"Z#!V9/!5,$\+TY -+
M_P (WJ-WJ-A%)I6G:>MG?R7;:C8D(TJL' "KC<&;>-V3C@]<C'=44 <MJ?AF
MYFT%=(BOKJ]AN+V%[M[V8,WD!E+H" ."%QC_ &C3O$.G7L^HM-!H&EZI%+9M
M;YG(26-B2<,Q!S&<\@<@COGCIZ* /-[CX<ZI%I-I':^(;M[M#IZ2[DB*[;=X
MR2I9"PQM9PN<%CSG)J;4/".I3ZQ>2BRMI[N>]BGMM;>4":TB79E ,9&-K@*I
MVMO.<9->A44 4["[GN_M7G6C6_DW#11DMGS5&,..!UR?RZFN:T+PU?Z-J^HW
M3K%/;VL4D6CPA]N$D<RNK''R_-L0=<+&*[&B@"C?-JAT=GT^.V74=BLL4[$Q
MYR"REASR,@-C@X.#TK%\+:-<Z?J>JWK6$&EVEWY7EZ? X95==V^4[0%#-N4<
M?W 3R:ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  ##L    $" 8    Z$]4,    "7!(67,  $SE
M  !,Y0%USO"5    6TE$051XVNW;,0T   S#L/ GO2'8O\.13*!_JP8
M         . 1(P               ,X.                Y]E!DB1)DB1)
BDB1)DB1)DB1)DB3I30NQFHYL!"X=/     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $X @D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I RL,J0><<4M% !1110 4444 1F[MQ=BP,O[UHS($P?N@@9_,BI*
M3:H8OCDC!-+0 $9& <>XHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HH!YQBD5PQ( /!P<@B@!:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HI H7.,\GN: BB0R9.2 /O''Y=.] "T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)&6*
MNI!QR#_]:EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HZ444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6=I?A;2-'UW4_$6GB=;C5WB>^5KJ1HV>-!&K
MK&Q*HQ0*I*@;MBYR16C10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44#/<44 %%%% !1110 4444 %%%% !1110 44?A10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]F&J2VKR1Q1(!\UQ/<'!:0*Q4-A0,HJ(&9Q)^NW_  3J_P""5G[,_P#P3G\
MP:-\,?#2W?B*42/JGB2]=I;B9Y#E@&;G Z!C\Q&>@8B@#AO^"0W_  2*^'O_
M  3V^%EKXK\?P6_B/XL:S$EQXA\27T,4S:=+MF7R+-]I:%?+F9)-KD2$9^Z%
M%?:E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1102!U- !7Q?_P %<?\ @M+\"/\ @E1X8T_3O$^BOXD\9Z_83W&BZ!;7T<:0
MJC(BR7)!:2-7+/Y>V,AS#(I9, U\N_\ !<'_ (.(/"?[-^F:A^SC^QCXVT_5
M_%%Q80OJGC30KU+J.Q63YC;VS(&C\UD*YG!81[V50)06B_$[PI^R=^U-^UM9
MZE^W3^TUI/B:V\%:[?W-RGC+789OLVKW.^9Y3'<RD"=P\<VY@6.]&SR"0 <[
M_P %,O\ @J+^UE_P50^+EKXA^,.M+<V]JTL'AS0=+M%BMM,MWE,GD1JB@M@L
M!YDA>5D6,.[;17Z^_P#!LS_P1$TKX=V-O^V7\>-"MK^2XA==$@N$.V:3Y<,$
M8?-"N7![.ZKQA"#^?7_!)C]A6S_;K_;1TOPU\,_#$L7AS3IE,^K7:,%6.-@[
MON(7("Y&T\NI&W+$5_5MX!\#>&_AGX+TSP#X0T];73=)LTMK2%5 PJC&3@ %
MB>2<<DDT :_3I1110 4444 %%%% !1110 9&<9Y]**0(H;?CGUI:  @$8(J.
MT@>VM8[>6ZDG9$"M-*%#2$#ECM &3UX 'H!4E?'_ /P5=_X+&?LV?\$O_A5>
MWOBCQ)8ZQ\0+FW"^'?!4$N^9Y7'R2W 4@Q1#(."5:3HI W.@!Z7^WO\ \%$?
MV</^"<OPIC^*W[0_B&:""[>2/2].LD5[F]= I<(K,!A0ZDDGC<.I(!_#31M#
M_P""AW_!SA^V!;:GXH6]\+?!?PI*)2VQK6Q@MFDY6/*GSI)"A&X;I#QDXB_=
MV?V(?^"9/[;7_!=S]I:7]M;]N_4)]/\ AQ<ZFUY);W,,ML;X*R)%;PQMG.(2
M0,91%0*=N0I_H6^%_P */AQ\%?!-A\.?A3X,L-!T33+<0V6GZ? $1%!)Y[L2
M2268DDL2222: .;_ &8/V4_@1^QW\*=.^#GP!\ V6AZ386T<4CPP()[UU!_?
M3R*H,DA)8YX W$*%7 'HM%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4#..3SWQ110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%?,G[>'_!7']B?_ ()[:/J47QL^)\,OB6SL
MDFMO"&EJ9+NX=\;(V? B@.TB0B1U;R_F56+(K 'T?XA\0Z!X2T&]\5>*]<L]
M,TO3;22ZU'4M0N5A@M8(U+R2R2.0J(J@L68@  DFOP<_X.!_^#BFU\3Z1KO[
M%_["WB$W>CS+)8^+/'>D709-75E*R6ELPY^S!B4DD7/GG*J?)R;CX>_X*1_\
M%P/VS/\ @J?\29?AEX/>:Q\(3:]YGA7P5I=K&XLY' MXR9@HDN'*,5+R8 :6
M5D2,.$'Z3_\ !%[_ (-A-)^$D^C_ +1O_!1CP[9:KK]L\-]HOP_>>.>""4!P
M?[24*R388JZQ*[*>!)QOB(!\G_\ !&G_ ((;:A^T+H-U^W)_P4AN+SPK\)-'
M U%(;P-!<>(FV!@(\+O^SY<!G0;I&_<Q!G9VB\__ ."G'[8?B']NSXR:+^Q3
M^R'X732OACX-OI+3PEH.E6:Q1VMOO!(8;R6GDP))92[O)([?-BOT)_X.FO\
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M?N@  'X$_L"?\&HG[8'[0=O;^/OVM]07P-I,EZC&S\022G498M\BRLMJ!N#
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M3A\0_M>_M:P_M%?%72!>>&/").HWG]J6<DD-U(!MA0_(8V=G(94<@,D4I(<
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MGB1 ""K9&_'13G9DY^<_)^GX  P!0 RWMX+2!+6U@2.*- L<<:A550,  #H
M.U/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YCXO?&;X6? 3P%J
M'Q.^,7CG3_#^A:9 \MW?ZC.%4!5+;47[TDA (6- SN<*H)(%?DI^W)_P=7>
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MHG[*7[,_A#4='\&QWL<-MX<T:\DN(IIW^1[NYE$<9E(#,B[E554E54%Y&?\
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MH7]G/_@@%_P2P_9K?3M5\._LX0^(=:TZ5I/[=\7:G->R7+;RR^;;ADM&"@A
M!  0@+;FW,0#^>#P?\&/^"K_ /P5#U2,2KX\\2S%WD,=]'/<>1;R3,[%C@E8
MS+/(Y;(7?.SG[Y)_3K_@GS_P:;>'O#T(\<_MU^/I9[F6W62P\.>'9HC<6DS
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MKTOQ##++K5RJ$J2+20 0JS!E#2LC+A9%21-A;C?^"^G[-7[.7P__ &BO!?[
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M0 4444 %%%% !7Y&_P#!T+_P6-\*?LI? FX_8L^!OQ+C_P"%D>+XV@\8VEC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2X?$T]U+<R>(=4N+C4K[SY#F243WDDL@D8YRX.X[FY^8Y]GH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  SCDT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPASS Pathways plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">33 Broadwick Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">W1F 0DQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">676-6461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, par value of &#163;0.008 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMPS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,561,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001816590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 260,110<span></span>
</td>
<td class="nump">$ 165,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">44,979<span></span>
</td>
<td class="nump">35,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">305,468<span></span>
</td>
<td class="nump">201,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">2,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Long-term prepaid expenses and other assets</a></td>
<td class="nump">8,176<span></span>
</td>
<td class="nump">6,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">319,135<span></span>
</td>
<td class="nump">213,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,584<span></span>
</td>
<td class="nump">12,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">11,194<span></span>
</td>
<td class="nump">14,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Debt, current portion</a></td>
<td class="nump">8,988<span></span>
</td>
<td class="nump">5,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">29,999<span></span>
</td>
<td class="nump">34,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, non-current portion</a></td>
<td class="nump">21,553<span></span>
</td>
<td class="nump">24,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_WarrantLiabilityNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">71,857<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">123,668<span></span>
</td>
<td class="nump">58,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, &#163;0.008 par value; 92,848,326 and 68,552,215 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">763,436<span></span>
</td>
<td class="nump">704,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(16,311)<span></span>
</td>
<td class="num">(16,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(552,596)<span></span>
</td>
<td class="num">(534,732)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">195,467<span></span>
</td>
<td class="nump">154,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 319,135<span></span>
</td>
<td class="nump">$ 213,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">92,848,326<span></span>
</td>
<td class="nump">68,552,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">92,848,326<span></span>
</td>
<td class="nump">68,552,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Fair value of underlying ordinary shares (in dollars per share)</a></td>
<td class="nump">92,848,326<span></span>
</td>
<td class="nump">68,552,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share)</a></td>
<td class="nump">$ 0.008<span></span>
</td>
<td class="nump">$ 0.008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 30,880<span></span>
</td>
<td class="nump">$ 24,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,736<span></span>
</td>
<td class="nump">13,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">49,616<span></span>
</td>
<td class="nump">38,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations:</a></td>
<td class="num">(49,616)<span></span>
</td>
<td class="num">(38,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>OTHER INCOME (EXPENSE), NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="nump">19,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit', window );">Benefit from R&amp;D tax credit</a></td>
<td class="nump">8,448<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="nump">2,133<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,124)<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">32,106<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(17,510)<span></span>
</td>
<td class="num">(34,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(354)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,864)<span></span>
</td>
<td class="num">$ (35,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders - basic (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding - basic (in shares)</a></td>
<td class="nump">89,192,252<span></span>
</td>
<td class="nump">64,222,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding - diluted (in shares)</a></td>
<td class="nump">98,641,623<span></span>
</td>
<td class="nump">64,222,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign exchange translation adjustment</a></td>
<td class="num">$ (117)<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (17,981)<span></span>
</td>
<td class="num">$ (35,223)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Offering</div></th>
<th class="th"><div>ADDITIONAL PAID-IN CAPITAL</div></th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>At-The-Market Offering</div>
</th>
<th class="th"><div>ACCUMULATED OTHER COMPREHENSIVE LOSS</div></th>
<th class="th"><div>ACCUMULATED DEFICIT</div></th>
<th class="th">
<div>Ordinary shares </div>
<div>COMMON STOCK</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>COMMON STOCK </div>
<div>At-The-Market Offering</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,943,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 225,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 621,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,926)<span></span>
</td>
<td class="num">$ (379,610)<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,509,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares to settle vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares to settle vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of ordinary shares to settle warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of ordinary shares to settle warrants exercised</a></td>
<td class="nump">37,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares tendered for withholding taxes</a></td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">5,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on foreign currency translation</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,342,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 259,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,962)<span></span>
</td>
<td class="num">(414,797)<span></span>
</td>
<td class="nump">$ 699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">68,552,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,552,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 154,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,194)<span></span>
</td>
<td class="num">(534,732)<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares to settle vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of ordinary shares to settle vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">3,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on foreign currency translation</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">92,848,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,848,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 195,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 763,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,311)<span></span>
</td>
<td class="num">$ (552,596)<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders&#8217; Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in GBP per share)</a></td>
<td class="nump">$ 0.008<span></span>
</td>
<td class="nump">$ 0.008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,864)<span></span>
</td>
<td class="num">$ (35,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Non-cash (gain)/loss on foreign currency remeasurement</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash share-based compensation</a></td>
<td class="nump">3,935<span></span>
</td>
<td class="nump">5,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expenses</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_TransactionCostsIncurredInConnectionWithWarrants', window );">Transaction costs allocated to warrants</a></td>
<td class="nump">5,778<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="num">(19,460)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(7,887)<span></span>
</td>
<td class="nump">8,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred and prepaid tax assets</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(1,402)<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(575)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,956)<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(3,556)<span></span>
</td>
<td class="num">(3,572)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(45,657)<span></span>
</td>
<td class="num">(20,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares and Pre-funded Warrants, net of issuance costs</a></td>
<td class="nump">140,357<span></span>
</td>
<td class="nump">26,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholding tax on stock award</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">140,359<span></span>
</td>
<td class="nump">63,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">317<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">95,019<span></span>
</td>
<td class="nump">42,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">165,470<span></span>
</td>
<td class="nump">220,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">260,489<span></span>
</td>
<td class="nump">263,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Reconciliation of the cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">260,110<span></span>
</td>
<td class="nump">262,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 260,489<span></span>
</td>
<td class="nump">$ 263,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_TransactionCostsIncurredInConnectionWithWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Incurred In Connection With Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_TransactionCostsIncurredInConnectionWithWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text">Nature of Business <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Compass Pathways plc, or the Company, is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin treatment through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. The therapeutic candidate currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company has funded its operations with proceeds from the sale of its ordinary shares, American Depository Shares, or ADSs, including in its offerings pursuant to its at-the-market, or ATM, offering program, proceeds from a loan agreement with Hercules Capital, Inc., and proceeds from a private placement transaction, or the PIPE. The Company was party to a Sales Agreement for its ATM offering program, dated October 8, 2021, with TD Securities (USA) LLC, or TD Cowen, under which the Company was able to issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through TD Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">hrough February 27, 2025, the Company sold 5,491,836 ADSs under the Company&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> ATM offering program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, resulting in $54.8&#160;million in net proceeds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 27, 2025, the Company entered into a new Sales Agreement to govern the Company&#8217;s ATM offering program with TD Cowen, or the Sales Agreement, under which the Company may issue and sell from time to time up to $150.0&#160;million of our ADSs, subject to the terms of the Sales Agreement. Sales of its ADSs, if any, will generally be made at market prices. To date, the Company has not sold any ADSs under this Sales Agreement.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 30, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">the Company entered into a Loan Agreement with Hercules, which provided for aggregate maximum borrowings of up to $50.0&#160;million, including a term loan of $30.0&#160;million, which was funded on June 30, 2023. On August 16, 2023, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell and issue in a private placement transaction (i) 16,076,750 ADSs and (ii) PIPE Warrants to purchase up to 16,076,750 ADSs, at a purchase price of approximately $7.78 per ADS and accompanying PIPE Warrant to purchase one ADS. Each PIPE Warrant has an exercise price of $9.93 per ADS and is exercisable for a three year period beginning in February 2024. The PIPE Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the PIPE Warrants. Through March&#160;31, 2025, PIPE Warrants were exercised for 3,752,050 ADS, resulting in $37.3&#160;million in exercise proceeds. The Company will receive up to an additional approximately $122.4&#160;million in gross proceeds if the PIPE Warrants are fully exercised. During the three months ended March 31, 2025, no PIPE warrants were exercised.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company issued and sold (i) 24,014,728 American Depositary Shares, each representing one ordinary share, nominal value &#163;0.008 each, of the Company and accompanying warrants to purchase up to 24,014,728 ADSs, and (ii) in lieu of ADSs, to certain investors, Pre-funded Warrants to purchase up to 11,044,720 ADSs and accompanying 2025 ADS Warrants to purchase up to 11,044,720 ADSs. The offering price was $4.2750 per ADS and accompanying 2025 ADS Warrant, and $4.2649 per Pre-funded Warrant and accompanying 2025 ADS Warrant. The Pre-funded Warrants have an exercise price of $0.0001 per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $5.7960 per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after three years. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#8217;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the Company&#8217;s ADSs on Nasdaq </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exceeded the warrant exercise price of $5.7960 for the three consecutive trading days prior to the date on which the notice of forced exercise is delivered.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company has incurred recurring losses since its inception, including net losses of $17.9 million and $35.2 million for the three months ended March 31, 2025 and 2024, respectively. In addition, as of March&#160;31, 2025, the Company had an accumulated deficit of $552.6 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March&#160;31, 2025 of $260.1 million will be sufficient to fund its operating expenses and capital expenditure requirements at least </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">through the planned 26-week data read-out from our COMP006 study, which is expected in the second half of 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial conditions.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Market volatility, geopolitical tensions or instability, including from the effects of announced or future tariff increases, resulting from the ongoing war between Ukraine and Russia and conflict in the Middle East, fluctuating inflation and interest rates and the related impact on U.S., UK and global economies, instability in the banking system, the risk of economic slowdown or recession in the U.S., significant changes in U.S. policies or regulatory environment or other factors could adversely impact the Company&#8217;s operations, financial results and ability to raise additional funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:130%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December&#160;31, 2024, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position for the reported periods. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2024, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 27, 2025. The condensed consolidated balance sheet at December&#160;31, 2024, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company&#8217;s significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to warrant liabilities. Estimates are periodically reviewed in light of changes in </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our year-end consolidated financial statement disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03 - Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was uncertain whether it would meet the R&amp;D intensity condition and be eligible for the enhanced effective rate for their tax submission relating to the year ended December 31, 2023. The Company sought clarity from HMRC in the form of a non-statutory clearance and received a positive response in April 2025. Therefore,&#160; the Company intends to file a resubmission to claim relating to the year ended December 31, 2023 at the enhanced rate, which results in an increase in its R&amp;D tax relief claim of $3.9&#160;million. For the period March 31, 2025, the Company recorded an additional $3.9&#160;million prepaid for the 2023 R&amp;D tax credit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 30, 2023, or the Effective Date, the Company entered into the Loan Agreement with Hercules, which provided for aggregate maximum borrowings of up to $50.0&#160;million, consisting of (i) a term loan of $30.0&#160;million, which was funded on the Effective Date, (ii) subject to the Company achieving certain performance milestones and available until June 30, 2025, an additional term loan of $10.0&#160;million, and (iii) subject to the approval of Hercules&#8217; investment committee in its sole discretion, and available during the interest-only period, an additional term loan of $10.0&#160;million. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan will mature on July 1, 2027. The outstanding principal balance of the term loan bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in The Wall Street Journal plus 1.50% or (ii) 9.75%. Accrued interest is payable monthly following the funding of each term loan. In addition to accrued interest, payment-in-kind (PIK) interest of 1.40% will be added to the balance of the loan. Payments under the Loan Agreement are interest only until the first principal payment is due on July 1, 2025 (or if the Borrowers achieve certain performance milestones, the interest only period may be extended to January 2, 2026 and, upon the achievement of certain additional performance milestones, the interest only period may be extended to July 1, 2026), followed by equal monthly payments of principal and interest through the scheduled </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maturity date, July 1, 2027. The carrying value of the Company&#8217;s outstanding debt approximates fair value, reflecting interest rates currently available to the Company.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred fees and transaction costs totaling $3.3&#160;million associated with the initial term loan, which are recorded as a reduction to the carrying value of the long-term debt in the condensed consolidated balance sheets. These fees included $0.4&#160;million of facility fees, $0.8&#160;million of company fees, $0.7&#160;million in warrants, and $1.4&#160;million of end of term charges. The fees, transaction costs, and the end of term charge are amortized to interest expense through the maturity date using the effective interest method. The effective interest rate of the Loan Agreement was 15.6% as of March&#160;31, 2025.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company issued warrants to Hercules to purchase the Company&#8217;s Ordinary Shares equal to the quotient derived by dividing (i) the amount equal to (a) 2.5% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price of the warrants. Upon receipt of the first term loan, 94,222 shares became exercisable to Hercules with a fair market value of $0.7&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Loan Agreement includes a financial covenant requiring us to maintain a minimum level of $22.5&#160;million of cash during the period commencing on July 1, 2024 (subject to adjustment if certain performance milestones are met). If the Company meets the performance milestones, the minimum cash covenant will not apply if its market capitalization is at least $750.0&#160;million. The Company was in compliance with all covenants of the Loan Agreement as of March&#160;31, 2025</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:107%">.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future principal payments and end of term charge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PIK interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, including End of Term Charge, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.150%"><tr><td style="width:1.0%"></td><td style="width:84.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Interest expense associated with the Loan Agreement for the three months ended March 31, 2025 and 2024 was $0.9 million and $1.1 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, as of March 31, 2025, information about the Company&#8217;s warrant liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:58.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 13, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 ADS Warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,726</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Warrant Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-funded Warrants and 2025 ADS Warrants are accounted for as liabilities in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging, Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815-40&#8221;), as both warrants contain contingent exercise provisions that do not meet the requirements of the indexation guidance under ASC 815-40 and could require the Company to pay cash to settle the warrants. The warrants are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pre-funded Warrants are considered to be Level 2 in the fair value hierarchy as the inputs used to determine fair market value are observable against the Company&#8217;s stock price. The 2025 ADS Warrant are considered to be Level 3 in the fair value hierarchy as they have been recorded at fair value using the Black-Scholes model, using unobservable assumptions that have been probability-weighted for specified data milestones. As of March 31, 2025, the assumptions are as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:58.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 13, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.7960</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.7960</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;141.9% to 148.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;146.1% to 158.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 to 4.2 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 to 4.4 years</span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the fair value of the Company&#8217;s warrant liabilities for the three months ended March 31, 2025:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:58.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-Funded Warrants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS Warrants</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial fair value as of January 13, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,220</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,726</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,633)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,455)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March 31, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The fair value change of warrant liabilities at March 31, 2025 was $19.5&#160;million, which included a $1.6&#160;million loss upon issuance of the Pre-funded warrants and a $21.1&#160;million gain in fair value between the initial fair value and the fair value as of the balance sheet date. During the three months ended March 31, 2025, there were no transfers between Level 1, Level 2 and Level 3.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ordinary Shares</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each ordinary share entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through March&#160;31, 2025, no cash dividends had been declared or paid by the Company.<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>At-the-Market Facility</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may have issued and sold from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">hrough February 27, 2025, we sold 5,491,836 ADSs under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">our ATM offering program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, resulting in $54.8&#160;million in net proceeds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 27, 2025, the Company entered into a new Sales Agreement under which the Company may issue and sell from time to time up to $150.0&#160;million of our ADSs, subject to the terms of the Sales Agreement. Sales of our ADSs, if any, will generally be made at market prices. To date, we have not sold any ADSs under this Sales Agreement. <br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-classified</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 30, 2023, the Company entered into a Warrant Agreement with Hercules, which provides Hercules with the right to purchase a number of the Company&#8217;s Ordinary Shares, equal to the quotient derived by dividing (i) the amount equal to (a) 2.5% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price. Upon receipt of each term loan, the Warrant will automatically become exercisable and will expire in 10 years (on June 30, 2033). On June 30, 2023, with the receipt of the first term loan, 94,222 shares became exercisable to Hercules with a fair market value of $0.7&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 18, 2023, in connection with the PIPE, the Company issued and sold warrants to purchase up to 16,076,750 ADSs, each representing one ordinary share, at a purchase price of $9.93 per ADS. The PIPE Warrants became exercisable for a three year period beginning in February 2024. Through March&#160;31, 2025, PIPE Warrants were exercised for 3,752,050 ADSs, resulting in $37.3&#160;million in exercise proceeds. During the three months ended March 31, 2025, no PIPE warrants were exercised.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company evaluated the terms of the outstanding Hercules and PIPE warrants in accordance with ASC 815-40, D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">erivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, and concluded that the warrants meet the criteria for equity classification. As such, the warrants are classified as equity instruments in the condensed consolidated balance sheets and are not subject to recurring fair value measurement or remeasurement.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Liability-classified</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, in connection with the 2025 Financing, the Company issued and sold (i) 24,014,728 ADSs, each representing one ordinary share, (ii) in lieu of ADSs, Pre-funded Warrants to purchase up to 11,044,720 ADSs, and (iii) accompanying 2025 ADS Warrants to purchase up to 11,044,720 ADSs, each representing one ordinary share. The Pre-funded Warrants have an exercise price of $0.0001 per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $5.7960 per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after three years. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#8217;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s ADSs on Nasdaq exceeded the warrant exercise price of $5.796 for the three consecutive trading days prior to the date on which the notice of forced exercise is delivered.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Financing comprising of ADSs, Pre-funded Warrants and 2025 ADS Warrants, resulted in aggregate proceeds of $149.8&#160;million, with issuance costs of $9.4&#160;million. Since the Pre-funded Warrants and 2025 ADS Warrants have been classified as a liability and recorded at fair value with changes in fair value recorded in the condensed consolidated income statement, the aggregate proceeds have been allocated first to these warrants at their respective fair values at the issuance date. The residual has been allocated to the ADSs issued as part of the 2025 Financing and recognized within equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#8217;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2017 Plan typically vest over a <span style="-sec-ix-hidden:f-410">three</span> or four-year service period with 33.3% and 25% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire 10 years from the date of grant. Restricted share units granted under the 2017 Plan typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted on June 30, 2020 were subject to 25% vesting upon the earlier occurrence of (i) the one year anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for three years for the remaining 75% of the allocation until vested in full.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted share units granted on June 30, 2020 are subject to 25% vesting upon the earlier of (i) the one year anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is 20% higher than the listing price for at least five consecutive trading days.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company was authorized to issue a total of 1,148,947 ordinary shares underlying outstanding options granted under the 2017 Plan prior to our initial public offering, or IPO.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Share Purchase Plan</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 340,053 ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in our capitalization.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 1, 2021, the Company launched the SIP, and the ESPP, through which employees can purchase shares at a discounted price. At the end of six months, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a 15% discount.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Share Option Plan</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#8217;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and other key persons (including consultants).</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2020 Plan generally expire 10 years from the date of grant and typically vest over a 4 year service period with 25% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by our compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is 7,938,129 shares as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,026,449 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares remained available for future grant.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted under the 2020 Plan to employees generally expire 10 years from the date of grant. There are three potential vesting terms for the grants including: (i) 25% per year over four year service period, (ii) four year service period with 25% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years, (iii) monthly vesting over four year service period, (iv) monthly vesting over three year service period, and (v) 100% vesting on the earlier of the next Annual General Meeting or the first anniversary of the grant date.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>2022 Inducement Option Award</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company granted a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant to our chief executive officer. The non-qualified share option has a 10 year term and one-fourth vested on August 1, 2023 and the remaining three-fourths will vest in equal monthly installments over the following 36 months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#8217;s 2020 Plan and the Company&#8217;s standard form of non-qualified share option agreement.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.206%"><tr><td style="width:1.0%"></td><td style="width:60.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:70.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,864)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of pre-funded warrant liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - diluted</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,497)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,187)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,192,252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,222,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Weighted-average pre-funded warrants</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - diluted</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,641,623&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,222,178&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share by dividing net loss by the weighted-average number of shares outstanding. The Company computes diluted net loss per share by dividing net loss by the weighted-average number of shares and dilutive potential share equivalents then outstanding during the period. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within the weighted-average number of ordinary shares used in net loss per share for the three-months ended March 31, 2025, are ADSs issuable upon the exercise of the Pre-funded Warrants, as the Pre-funded Warrants are exercisable at any time for nominal consideration, and as such are considered outstanding for the purpose of calculating diluted net loss per share. There were no Pre-funded Warrants outstanding during the three-months ended March 31, 2024. The Company&#8217;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, options granted and warrants (other than the Pre-funded Warrants), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.690%"><tr><td style="width:1.0%"></td><td style="width:61.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,187,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,073,719</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,418,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,170,255</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,254,085</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of March&#160;31, 2025 or December&#160;31, 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#8217;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:4pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The table below is a summary of the segment loss, including significant segment expenses (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Research and Development:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development expenses </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General and Administrative:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,864)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,187)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span>Other expenses include subscriptions and memberships, consulting fees and company insurance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of a consulting agreement between the Company and Alithos, Inc., a company founded by our co-founder, former chief executive officer, former chairman of the board of directors and former greater than 5% shareholder, George Goldsmith, the Company provided consulting services to Alithos. Through March 31, 2025, the Company recorded $0.6&#160;million in other income as a result of this transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,864)<span></span>
</td>
<td class="num">$ (35,187)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December&#160;31, 2024, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position for the reported periods. </span></div>The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2024, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC, on February 27, 2025. The condensed consolidated balance sheet at December&#160;31, 2024, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to warrant liabilities. Estimates are periodically reviewed in light of changes in </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our year-end consolidated financial statement disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03 - Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK R&amp;D tax credit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT recoverable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance premium</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of term charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future principal payments and end of term charge</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PIK interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, including End of Term Charge, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.150%"><tr><td style="width:1.0%"></td><td style="width:84.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, as of March 31, 2025, information about the Company&#8217;s warrant liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:58.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 13, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 ADS Warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,726</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Warrant Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text">The 2025 ADS Warrant are considered to be Level 3 in the fair value hierarchy as they have been recorded at fair value using the Black-Scholes model, using unobservable assumptions that have been probability-weighted for specified data milestones. As of March 31, 2025, the assumptions are as follows:<div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:58.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 13, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.7960</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.7960</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;141.9% to 148.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;146.1% to 158.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 to 4.2 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 to 4.4 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock', window );">Schedule of Fair Value of Warrant Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the fair value of the Company&#8217;s warrant liabilities for the three months ended March 31, 2025:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:58.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-Funded Warrants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS Warrants</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial fair value as of January 13, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,220</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,726</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,633)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,455)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March 31, 2025</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about asset and liability measured at fair value under fair value option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.206%"><tr><td style="width:1.0%"></td><td style="width:60.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:70.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,864)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of pre-funded warrant liabilities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ordinary shareholders - diluted</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,497)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,187)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - basic</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,192,252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,222,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Weighted-average pre-funded warrants</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of ordinary shares used in net loss per share - diluted</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,641,623&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,222,178&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></div></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.690%"><tr><td style="width:1.0%"></td><td style="width:61.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,187,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,073,719</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,418,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,170,255</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,254,085</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text">The table below is a summary of the segment loss, including significant segment expenses (in thousands):<div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"><tr><td style="width:1.0%"></td><td style="width:71.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Research and Development:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development expenses </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General and Administrative:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,864)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,187)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span>Other expenses include subscriptions and memberships, consulting fees and company insurance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">19 Months Ended</th>
<th class="th" colspan="1">41 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,864)<span></span>
</td>
<td class="num">(35,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 534,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,110<span></span>
</td>
<td class="nump">$ 262,888<span></span>
</td>
<td class="nump">$ 260,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PIPEWarrantsMember', window );">PIPE Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ProceedsFromWarrantExercisesFullyExercised', window );">Proceeds from warrant exercises, fully exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">2025 ADS Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanOneMember', window );">Loan Agreement, Term Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockMaximumAmountAllowableForSale', window );">Maximum amount of stock that may be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockAmountAuthorized', window );">Amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,491,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockAmountAuthorized', window );">Amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="nump">16,076,750<span></span>
</td>
<td class="nump">16,076,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | PIPE Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember', window );">Underwritten Offering | 2025 ADS Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember', window );">Underwritten Offering | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,044,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,044,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfOrdinarySharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfOrdinarySharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ProceedsFromWarrantExercisesFullyExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises, Fully Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ProceedsFromWarrantExercisesFullyExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_SaleOfStockAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_SaleOfStockAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_SaleOfStockMaximumAmountAllowableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Allowable For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_SaleOfStockMaximumAmountAllowableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cmps_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditCurrent', window );">UK R&amp;D tax credit</a></td>
<td class="nump">$ 30,112<span></span>
</td>
<td class="nump">$ 20,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_PrepaidExpenseResearchAndDevelopmentCurrent', window );">Prepaid research and development</a></td>
<td class="nump">10,234<span></span>
</td>
<td class="nump">11,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT recoverable</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance premium</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">44,979<span></span>
</td>
<td class="nump">$ 35,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditPayable', window );">Research and development tax relief claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_PrepaidResearchAndDevelopmentTaxCredit', window );">Prepaid research and development tax</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_PrepaidExpenseResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_PrepaidExpenseResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_PrepaidResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_PrepaidResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances', window );">Number of shares available for purchase, percent of principal amount of term loan (as a percent)</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsExercisableFairValue', window );">Fair value of exercisable options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_FacilityFeesMember', window );">Facility Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_CompanyFeesMember', window );">Company Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_EndOfTermChargeMember', window );">End of Term Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees and transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes, face amount</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate, prime margin (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_PaidInKindInterestRate', window );">Paid-in-kind interest rate</a></td>
<td class="nump">0.0140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_DebtInstrumentMarketCapitalization', window );">Market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanOneMember', window );">Loan Agreement, Term Loan One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes, face amount</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanTwoMember', window );">Loan Agreement, Term Loan Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes, face amount</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanThreeMember', window );">Loan Agreement, Term Loan Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes, face amount</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount', window );">Debt instrument covenant, cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_DebtInstrumentCovenantMinimumCashOnHandAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Cash On Hand, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_DebtInstrumentCovenantMinimumCashOnHandAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_DebtInstrumentMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Market Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_DebtInstrumentMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OptionsExercisableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Exercisable, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OptionsExercisableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Exercisable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Number Of Shares Available For Purchase, Percent Of Principal Amount Of Term Loan Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_PaidInKindInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paid-In-Kind Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_PaidInKindInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_FacilityFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_FacilityFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_CompanyFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_CompanyFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_EndOfTermChargeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_EndOfTermChargeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cmps_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cmps_LoanAgreementTermLoanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan payable</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LongTermDebtEndOfTermCharge', window );">End of term charge</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LongTermDebtIncludingEndOfTermCharge', window );">Future principal payments and end of term charge</a></td>
<td class="nump">31,425<span></span>
</td>
<td class="nump">31,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_DebtInstrumentPaidInKindInterestPayable', window );">PIK interest payable</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(1,641)<span></span>
</td>
<td class="num">(1,909)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of long-term debt</a></td>
<td class="nump">30,541<span></span>
</td>
<td class="nump">30,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less: current portion</a></td>
<td class="num">(8,988)<span></span>
</td>
<td class="num">(5,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion</a></td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 24,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_DebtInstrumentPaidInKindInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid-In-Kind Interest Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_DebtInstrumentPaidInKindInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_LongTermDebtEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, End Of Term Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_LongTermDebtEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_LongTermDebtIncludingEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including End of Term Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_LongTermDebtIncludingEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Principal Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">December 31, 2025</a></td>
<td class="nump">$ 6,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">December 31, 2026</a></td>
<td class="nump">14,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">December 31, 2027</a></td>
<td class="nump">10,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_LongTermDebtIncludingEndOfTermCharge', window );">Future principal payments and end of term charge</a></td>
<td class="nump">$ 31,425<span></span>
</td>
<td class="nump">$ 31,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_LongTermDebtIncludingEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including End of Term Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_LongTermDebtIncludingEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jan. 13, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_WarrantLiabilityNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">$ 71,857<span></span>
</td>
<td class="nump">$ 92,946<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember', window );">Pre-funded Warrants | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_WarrantLiabilityNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">31,587<span></span>
</td>
<td class="nump">37,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">2025 ADS Warrants | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_WarrantLiabilityNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">$ 40,270<span></span>
</td>
<td class="nump">$ 55,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) - 2025 ADS Warrants<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">2.86<span></span>
</td>
<td class="nump">3.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0.040<span></span>
</td>
<td class="nump">0.046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Minimum | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">1.419<span></span>
</td>
<td class="nump">1.461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">Maximum | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding</a></td>
<td class="nump">1.488<span></span>
</td>
<td class="nump">1.587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCommodityMarketPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCommodityMarketPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Warrant Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="nump">$ 19,460<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Beginning balance of fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Initial fair value as of January 13, 2025</a></td>
<td class="nump">31,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="num">(5,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Ending balance of fair value</a></td>
<td class="nump">31,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">2025 ADS Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Beginning balance of fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Initial fair value as of January 13, 2025</a></td>
<td class="nump">40,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="num">(15,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Ending balance of fair value</a></td>
<td class="nump">$ 40,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="nump">$ 19,460<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_GainLossOnFairValueOfWarrants', window );">Gain in fair value between initial fair value and balance sheet fair value</a></td>
<td class="nump">21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="num">(5,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_GainLossOnIssuanceOfWarrant', window );">Loss on issuance of warrants</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_GainLossOnFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss ) on Fair Value Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_GainLossOnFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_GainLossOnIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Issuance Of Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_GainLossOnIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">19 Months Ended</th>
<th class="th" colspan="1">41 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances', window );">Number of shares available for purchase, percent of principal amount of term loan (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsExercisableNumber', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsExercisableFairValue', window );">Fair value of exercisable options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 37,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PIPEWarrantsMember', window );">PIPE Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember', window );">2025 ADS Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance costs of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cmps_HerculesCapitalInc.Member', window );">Hercules Capital, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsExercisableNumber', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_OptionsExercisableFairValue', window );">Fair value of exercisable options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,491,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="nump">16,076,750<span></span>
</td>
<td class="nump">16,076,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | PIPE Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember', window );">Underwritten Offering | 2025 ADS Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfOrdinarySharesConversionRatio', window );">Ordinary share conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember', window );">Underwritten Offering | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,044,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember', window );">American Depositary Shares | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockAmountAuthorized', window );">Amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember', window );">American Depositary Shares | At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_SaleOfStockAmountAuthorized', window );">Amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfOrdinarySharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfOrdinarySharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OptionsExercisableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Exercisable, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OptionsExercisableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Exercisable, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Number Of Shares Available For Purchase, Percent Of Principal Amount Of Term Loan Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_SaleOfStockAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_SaleOfStockAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_A2025ADSWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cmps_HerculesCapitalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cmps_HerculesCapitalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmps_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmps_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2017 Equity Incentive Plan (Details) - 2017 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>day </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares) | shares</a></td>
<td class="nump">1,148,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Options Granted Before June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Share-based Payment Arrangement, Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Share-based Payment Arrangement, Tranche one | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Share-based Payment Arrangement, Tranche two | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche one | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche two | Grant Date June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice', window );">Percentage amount closing price is higher than listing price</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days | day</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_OptionsGrantedBeforeJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_OptionsGrantedBeforeJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cmps_GrantDateJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cmps_GrantDateJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2020 Employee Share Purchase Plan (Details) - Employee stock - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum', window );">Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance', window );">Maximum increase in shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod', window );">Stock plan, offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Saving period (in percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2020 Share Option Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>vestingCondition </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,026,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,938,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_NumberOfVestingConditions', window );">Number of vesting conditions | vestingCondition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Vesting condition five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember', window );">2020 Share Option Plan | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,074,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease', window );">Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_NumberOfVestingConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Vesting Conditions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_NumberOfVestingConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2020ShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=cmps_ShareBasedPaymentArrangementVestingConditionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - 2022 Inducement Grant Option Award (Details) - 2022 Inducement Grant Option Award - shares<br></strong></div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember', window );">Share-based Payment Arrangement, Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember', window );">Share-based Payment Arrangement, Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmps_A2022InducementGrantOptionAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmps_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">$ 3,935<span></span>
</td>
<td class="nump">$ 5,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expense</a></td>
<td class="nump">$ 2,411<span></span>
</td>
<td class="nump">$ 2,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders - basic</a></td>
<td class="num">$ (17,864)<span></span>
</td>
<td class="num">$ (35,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_FairValueChangeOfPreFundedWarrantLiabilities', window );">Fair value change of warrant liabilities</a></td>
<td class="nump">5,633<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to ordinary shareholders - diluted</a></td>
<td class="num">$ (23,497)<span></span>
</td>
<td class="num">$ (35,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding - basic (in shares)</a></td>
<td class="nump">89,192,252<span></span>
</td>
<td class="nump">64,222,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Add: Weighted-average pre-funded warrants (in shares)</a></td>
<td class="nump">9,449,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding - diluted (in shares)</a></td>
<td class="nump">98,641,623<span></span>
</td>
<td class="nump">64,222,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_FairValueChangeOfPreFundedWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Change Of Pre-funded Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_FairValueChangeOfPreFundedWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">59,170,255<span></span>
</td>
<td class="nump">21,254,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember', window );">Unvested restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,003,044<span></span>
</td>
<td class="nump">647,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,093,492<span></span>
</td>
<td class="nump">8,187,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">49,073,719<span></span>
</td>
<td class="nump">12,418,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_UnvestedRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmps_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 30,880<span></span>
</td>
<td class="nump">$ 24,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,736<span></span>
</td>
<td class="nump">13,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">49,616<span></span>
</td>
<td class="nump">38,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(49,616)<span></span>
</td>
<td class="num">(38,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value change of warrant liabilities</a></td>
<td class="nump">19,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit', window );">Benefit from R&amp;D tax credit</a></td>
<td class="nump">8,448<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="nump">2,133<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,864)<span></span>
</td>
<td class="num">(35,187)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cmps_SingleOperatingSegmentMember', window );">Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">49,616<span></span>
</td>
<td class="nump">38,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(49,616)<span></span>
</td>
<td class="num">(38,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit', window );">Benefit from R&amp;D tax credit</a></td>
<td class="nump">8,448<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="nump">2,133<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,124)<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(354)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,864)<span></span>
</td>
<td class="num">(35,187)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_DevelopmentExpensesMember', window );">Development expenses | Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,696<span></span>
</td>
<td class="nump">13,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_PersonnelExpensesMember', window );">Personnel expenses | Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,069<span></span>
</td>
<td class="nump">6,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">5,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_LegalAndProfessionalFeesMember', window );">Legal and professional fees | Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,364<span></span>
</td>
<td class="nump">2,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_NonCashShareBasedCompensationExpenseMember', window );">Non-cash share-based compensation expense | Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,411<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmps_FacilitiesAndOtherExpensesMember', window );">Facilities and other expenses | Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 3,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cmps_SingleOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cmps_SingleOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_DevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_DevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_PersonnelExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_PersonnelExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_LegalAndProfessionalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_LegalAndProfessionalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_NonCashShareBasedCompensationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_NonCashShareBasedCompensationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmps_FacilitiesAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmps_FacilitiesAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amounts of transaction</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -(TJ%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( -(TJ%KFV($*\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( -(TJ%I;8USBR@4   8>   8
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ME)^2]^0M\8FN<%5GOD$=ELTO^C-GW9GA$V=^HVI$HO$9"8,P.0"?'X=?0C'
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MULR09O1"10,H+832(L4!889QQ&]MF,+T8<K?,+%77X/!9H0F-U":!Z7Y4%H
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MPB6#\04#VTYGZWC3Q 9_,)[&)9H5/6AH0P"=+XWQKTZ8F?Z)S/\ 4$L#!!0
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M1365A?N/]Q^&[MS G;5T,2VE>""'B]M.#V)0L@M6'#"BX.KQ*0]VCN2[YH8
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MYMZ_$.\.Y"U)&MMA%-)Y9&59XY)A.M$W?FR\!8YAS; 8 B7QQ*3A':@J*-P
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M>E1M"(!EYTK.T4Z5VQA=KS=>/\]:&5(_"ZFEW*/(?"4[SJ]4&O/(7$/1J+O
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M"S4?H/VI4G8]80&;3[G1?U!+ P04    " #2-*A:KK,B?EP(  !!%@  &0
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M=CU^5N$[:0=B,NJ+\7 \>T;?I'%UPOHF7^'JG=P 65Y<62N+I>+K?U[-G;>
MR;^ZG ^ZI]VZJ73>N%(FZJ*'VG#*/JC>Y???C4Z&/SQC^;2Q?/J<]F]*TK.:
MNNT\I!Z!'YV*FR^5]AMQ6R0($BI(W&6R$)^09"O\2K&$+#;??W<V'IW^X,1*
M [16)S(3CA2O3$9+99&B\N<NL;H,];BTB@/O^FT]8BV=D)5?0<>O,,@;H9VK
M%!@ V=&)QS/6"[']1Z(J-*F#AC7JG/X;WBP\T[4+CK5Z)U1>9F:C2%=ABJ/F
MEJW-53Y7%BH6O'9NI$WI)M46E&*L&XB/ADU7CYX Y*IDU=YDK6"2+G@)T2<)
M!SL;J^BG>!.6+X%'\J>LK*MP29;2(J]LSJ;0S>&\](6QVR7T9( 5XN<JV]"C
MU_W.E#UU3<@49E'X=W5];-^*TIH'C6(G[W@E6T^*;N"$+:UV2KR3A8P5UMC*
M9MZ\N^VW(A$R\NEO[:0\T5O'JEX]N!^(W:SMYC$&+#J\;S]#+06K K((?BKF
M&U[>E>KW<><Z0553 %M]?E,2[A%KI!_V/A#NL09 YYW-G@Y#F2F4F R9Y(8!
M JB27[ K^3B>O6!5NEB*JC0!2DK:3$.S29+*6H68DJDO]:N )NC;8 F"42#2
MUJ'5UF%(I>>UO#_GX*6.8O5/=)WIL.-N\/Z,:-I4%Z0O%"#93Q6+>D\^HPB2
M%7$I92U#KP_A)$:EQBB(B1I?0EXI+&2J:_)L%<T1M.(4GL?]$5"3!$*J@)Z,
MM4 [*FM195E(:C<5'(ZT_)9 _^[H+K0%'E*YB;&A;>BYTX]'.77-+GV_+PWT
M=+W28"023C+C2!=*,FGR',6U0TA>@+>7*T:T+':V#R*4(8DL*@E'%D0W"9"L
MDHJI!TE.:2T\1*E<<=VA?6/SNG]_'<>C6(Q'XX#XJ#^:GO5?3T^?N,N5EVTX
M-)5W'E7/UU]1H/"%D&8@:($?[34V*ZMYIA/LN5 6BCASMW?O!P$H-Y%+!'=)
M<5?!*W3*H.]C!YG^IE3#T3?W=W?]2$*!;2/_7#/_ -_W"H^I"T70@M]D2:P;
MBVO;7]V!Y7.5R!Q0AG,\_[;073\JE-LGRL:9#VJIJ82Y^NX]$,Y$CAN:B<5/
M1R/:%U HXI2]UCX@CB/X,7I9QQK,&*>.-#C3P@"6$@ADY+.JI#RU #&9#OO#
MV>0)'+"JE-;K1)>2 =NP?VO_V*D<P=OS7D7%@:I;LMLS[$'J3,ZS /S&KK6F
MJ:+"4(ZM M.CW^,PY(@M />?95&1;4#]'*$KF,N(?+;/D9HQ[[$K0$9!T<(S
M:*VIEBMN^O"5 ]NT?B0VH"B")4/ZMB0U:FBS71M;9SNX@R.?YRK52"\\PF"8
M*!9[BPL6I"IF,IN-D(2SX5,U3'98P#-0-.GPKH!\JH)W6]275%%U.P;DC T)
M/)RI;8D'D+DVI4<:C/.7>E!A@I"Q/[@RTV#I<)-J0@=R C\,):(E3521R%(#
MAOI7S@6&@4*\QUQ 9H6,CG;Y+9-5@>-S0/7]+:J<$KZM^3K!@:"WXTI"'%5S
M11TK#YM3[1)3A<F0^!@D&V#,1B^HD0AN)*Y?RW5@=:X:[:F(=4"=VC:8P>Q/
MB2=KGVL9=;]V\H&7@#A-2L?3"O:*$9II;7!DT4"#888*U'F[3U??.IIN8[HO
MLT.+-5_VM^6S8PPI.3A#-[46$O7_)]/&))Z*UBXT]_:9C?Q!ER;?5[I$F3VH
MS)2\$=;EVGMT)91'+C_#;#Y#',T#("CITJWB;7.0$7*-'+CZ)++O%?HF &(!
MO-;@WLH6 91+ZK/:$%(<->F7T)Y53#(T1U09F,J[5\^/V;7K2T39,J#58XF-
MQ&A8SY'6Y$]GL0"4SME\&J8YXA-">00RQWV\G4#KT:*>$&/2PU37,;E1H&DN
MYZBS*354YS+C1E)KXIJ%36S.[@3,'@W:(T97%QWWAZ?3_F0\JX^I^U1;EVJ[
MM\:$=L1V'V5_4-_<[L0D_T>U4>Z!85"8_M?ZGK$'FMJA7L8-XUM+D@*/_A6U
M[W8RF?Y2.<_K.[I9-3^B]D5O2?M<3";3*6_\GW8W@D 8NP['C_&02^XI/+MW
MERH<.>V_GISU1^/7K8 ].1Z(/CT++ M(CT_ZT^GK+<*H)M0^NA:5K^HW)H/.
M\W6718CGMM]^*Y/P-EA&40WGU]+0JQ\Z1M0E'=[4[+RYX%=/@>[>\)1&W *N
M">3#M;^@1'1P49R[#OW\A*K^]Q35CY-?O:ZQX+?<>C@@LWTQ\$2(;'P)N=%P
M^&+?U=9IG7E*/7IQ58 O,O&7D&;Q3JD@89\/3N@:%)6!>%O1H3#237O&JT$F
M^973%^RC%[IY_1"@R(>3>IX+1'4RQ 0]?#I!TRD0]5*D54Q*,"*>59.55@N
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MG?6$#5_NPHTW)7\MFQN/^80O5]R[:0%^7Q@P?KRA#9K/IY?_!E!+ P04
M" #2-*A:D@%)AAH%  #)#0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6RM5UEOVS@0_BL#=5$T !/K\I7#0-(#6V ;!$V[>5CL RV-+:(2J9)4G/S[
M'5*R;+>VV^XN8,@4CV^^.3FZ7"G]Q12(%IZJ4IJKH+"V/A\,3%9@Q<V9JE'2
MRD+IBEMZU<N!J37RW!^JRD$<AJ-!Q84,9I=^[D[/+E5C2R'Q3H-IJHKKYQLL
MU>HJB(+UQ$>Q+*R;&,PN:[[$>[2?ZSM-;X,>)1<52B.4!(V+J^ Z.K])W7Z_
MX4^!*[,U!J?)7*DO[N5]?A6$CA"6F%F'P.GO$5]C63H@HO&UPPQZD>[@]GB-
M_L[K3KK,N<'7JGP0N2VN@DD .2YX4]J/:O4[=OH,'5ZF2N.?L&KW)F$ 66.L
MJKK#Q* 2LOWG3YT=M@Y,#AV(NP.QY]T*\BS?<,MGEUJM0+O=A.8&7E5_FL@)
MZ9QR;S6M"CIG9[?D]S^4,7"'&NX+KO%R8 G7K0ZR#N.FQ8@/8"3P04E;&'@K
M<\QWSP^(3T\J7I.ZB8\"?N#Z#)*(01S&PR-X2:]DXO&2 WAON99"+K>4A+^N
MY\9JBHF_]^G;PJ7[X5R>G)N:9W@54"(8U(\8S%Z^B$;AQ1&R:4\V/8;^DQ[Y
M50SX5" L5$E)2)8 R^<E@D%K:%+; BPM9ZJJ&\M]MJB%GWI-4UP^OWPQB:/Q
MA7$)(#+@,H=<E(W%'"2)*IVHFD09)^J<9&G$G:  <FE6]#YUCQ1NFPHUMTJ?
MP^T:A5NKQ;QI^5D%2N="4K5HH0M5YJ@-G'9$?H-7T9A-1NF)&R9#%DW&)_".
M"PV/O&Q(I8++)3IMR%.GB\9S67&MN22!@L]%*:Q  T,V2A+P>L87OTYG;0UB
M$2<LG8YW"+U!J2AW6U4??*' _)0_DO9$3C;5G&Q'''?1#32&((7<8^/> I,I
MBZ8QBX<QC%(6QS&+QA.XSO,]@KXW@8$I2],I2\9QK_O_Q6]MDNF$C=*(C>)D
MF^'M897(<.%9')ZT@^'P9/_F+9/3]G1K^Z=-X'8QC>O(W<-T_DQ0CR)W:=$O
MTZ0+_]5A6W0FH'O.6,H'.GVV7_#A1/F/HOLLI&L-:F516L'+#AJ_-H)2 )V/
M"4YN$X6\T;X(D!@B(U1^!N]E5C8^,H0MR*4_H/ +D4#UQ:-95Q1.J[8HX)ZB
MP,!MOWYS;T 8T_B4:VK5<L$GU)DPN"Y,=YM8?NABF<Z;0VL>NL/PP-R"\Y*E
M!L,S;!.T)+=1OY&[LD15D'D;$ZIIB*>#6"\3]+9!USK6C:Y52S+C9=:4!./L
M?3 $?,QH9VIZ2+67^@'/_<B>Z4X\]A6\#Y3R>1,]!C,"=H60P:H0!"+:>(!&
M/J)QW+_Q.-NLT!L5R<P-6X\W4CAOJ-K9T,#2J4&+SI9]W7FE2 =G-"X/^>R$
M04&1!W.D\,6G+CX76E7[;JLC:=:%!2X6U I2E]B4.8&Z<DY^;#+TJP=\T^=S
M3\#N7*2;O/O.0+XW\)J[MI$L2#UHI9IO74J1B)PLWF:B\R3[5TK^U$VUDXQP
M)!F]M_PM/<>,4WIW$=%%7]69T3NHX,ZY]+/BM ^IUMH_W0M\/AY-$+$P3%B8
MIG2)C-EH..[:FG6035DX=1=O#!-WY[)A.-ID$-UPX3AAXV@*4<S2:,*F<0Q#
MNCK'(5V=1"&BOY2%D[W=YF"KO::.9>D_(@SYAGS9=MK];/^=<MVVYYOM[4<.
MJ;X41+?$!1T-S\;# '3[X="^6%7[9GVN++7^?EC0MQ9JMX'6%XH"KGMQ OJO
MM]D_4$L#!!0    ( -(TJ%JR.VT:100   (*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;*56VV[;.!#]%4(%^E18CI.T06H;R&6+!M@"0;N7A\4^
MT-38XI8B59*RXK_O&5)6[38UL+LOMGB9F7-FSI"<]\Y_#C51%$^-L6%1U#&V
MUV495$V-#!/7DL7*VOE&1@S]I@RM)UDEH\:4L^GT==E(;8OE/,T]^N7<==%H
M2X]>A*YII-_=DG']HC@K]A,?]::./%$NYZW<T">*O[>/'J-R]%+IAFS0S@I/
MZT5Q<W9]>\'[TX8_-/7AX%LPDY5SGWGP4"V**0,B0RJR!XF_+=V1,>P(,+X,
M/HLQ)!L>?N^]OTO<P64E ]TY\Z>N8KTHK@I1T5IV)GYT_7L:^%RR/^5,2+^B
MSWLO9X5078BN&8R!H-$V_\NG(0\'!E?3GQC,!H-9PIT#)93W,LKEW+M>>-X-
M;_R1J"9K@-.6B_(I>JQJV,7EG6L:'9'E&(2TE;AS-FJ[(:LTA7D9$8(WEFIP
M=YO=S7[B[EQ\@(,ZB%]L1=6Q?0EH([[9'M_M[*3##])/Q/G9*S&;SBY/^#L?
M^9XG?^?_A:^XUT$9%SI/XJ^;58@>HOG[N2SD(!?/!^%&N@ZM5+0HT"F!_):*
MY<L79Z^G;T]0N!@I7)SR_N]+]C_<B5]I(XUX]$X159@.XIUWC8AH3!%=^G\E
M8DTP:UII=]#F3JQ(2-%*'W>\Q^BH-S+UH./C8/4/.I(7E)&Z"4(C4H7PR1\\
M.8] .""$<IT/&*_%J@M '<)$_'80JI=!6!</8V4$D;P&ZH/ 3*S25=I>RRU]
MVZ1&NCLQU"H("E&NC$9;50('7W)KM%QI=HEU! 8J:%/5HSB9W#TI:E;D]Y,7
M$_& 1FBL7FN5D3S81-+RD6*>H7B<3:2%/*>(TP6D+,A<)KGQ1+EJL98QK>(,
M1C*VTFM".N#44](?5CAV-NRE]])F&ABVWFV1_D0362 /5/H8\U'67[ZXFIV]
M>8L</;6Y4SKL]HP:1 Y0Z8"5S];U%GI0LL.JCG"]=893/!0_81\TT\B*/8!%
MB$=9T#EGZRXB'M X4:%\QYFJ!S&T$F7FB2$ :*V(^ +YTFF/>B*3.+7)YETR
M7PZ>##RF1<W8ORN:@QBRDB#!]ZZG+?D?9>])0;M"U=)O*!RC9LE(%AAN"ZY,
M3M?). ]\9[%':17A6HAUPG;CHU:&D@)O0G!*)X,?LW'"^9ZG6V.5!9;[ P2B
MPXBU@.FD)U#E:F+&*=5YCT8AB/2PC8>=1N,<P5)?:T.,!MD%<6XI-)B01S4=
M9<1U0;MQMD*'=E(2!Z>.NR0ZF*=N316TXXD1]P)@V-_3WM-(BP-!>(=44QY'
MP9%%BR=-PAV7#C7EH\3YG*UUUD?C.N:?9,5Y&<K9NHB\I ,D89H\=["7!_=R
M0Q %OSX"-[V-^8H>9\<'SDV^U[]MSZ\CG#4;D!"&UC"=3MY<%L+G%T<>1->F
M6W[E(MX,Z;/&(XT\;\#ZV@'Q,.  X[-O^1502P,$%     @ TC2H6@:+9L[2
M P  60@  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULE59M;]LV$/XK
M![4(;$"-14F6)<<VD)=U*["V0=)M'X9]H*631%0B-9*.TW^_HV0K+I8&Z1>*
MY-T]]]R1=]1JK_174R-:>&P;:=9>;6VWG,U,7F/+S;GJ4)*D5+KEEI:ZFIE.
M(R]ZH[:9A4&0S%HNI+=9]7NW>K-2.]L(B;<:S*YMN?YVA8W:KSWF'3?N1%5;
MMS';K#I>X3W:/[I;3:O9B%*(%J412H+&<NU=LN55[/1[A3\%[LW)'%PD6Z6^
MNL6'8NT%CA VF%N'P.GS@-?8- Z(:/Q[P/1&E\[P='Y$?]_'3K%LN<%KU?PE
M"ENOO=2# DN^:^R=VO^&AWCF#B]7C>E'V ^Z8>9!OC-6M0=C8M *.7SYXR$/
M)P9I\ .#\& 0]KP'1SW+&V[Y9J75'K33)C0WZ4/MK8F<D.Y0[JTFJ2 [N[G'
MBE)LX0X[I:V0U6IF"=8)9_D!XFJ "'\ $<%')6UMX!=98/&]_8SHC)S"(Z>K
M\$7 CUR?0\1\"(-P_@)>-,88]7C1:V.$OR^WQFJZ$?\\%^Z %C^/YJID:3J>
MX]JC,C"H']#;G+UA27#Q M=XY!J_A/ZZ\_A)"/A2(URKMN/R&]3<@)((5-::
M]U(SZ)_W:I9O&X2M*U80!OBQ6D&58$E^4(9&&>.#D'FS*WH044E1BIR3[*B#
MC]0Z#!J8"$G&:F>X+,QT28XTXG>W!NC,\WH\=#?$\'FD>$1:4E &>U6"@AM\
M(**=<[8\73QY?@LA\Y,LH0F+_"R.X1:U45)B\Z24^$&2T9@$,7Q2\EW.30VF
MYAK?N8(O(*?<D2KO^\C!#)@_)XZAG[ 8WO-<-,(* G.\%&5*/^$SIYNY<1%E
M\"M*"JOI%2\+*FGAKJ+K3<OGR,V)'*-Q'C#X':N#8:=5B<9U1MHHD?0R/TH<
MG3A>O().%@00^6&0_43 A,T8C7,VAR_*DF/UOP.".*.$)!"E_GP1G9R@NR\P
M&:13F SR*3$5&AYXLT/(:RXK=/=LS[5V]Z@1?'N,@V5^G 1P]B8-67@!5Y3$
M4E@HM6KA[HRWW<4-W=U'R#46M)]2'E**D%'6/DB+5*C6W5;5NCBB-*$Q)#SJ
M[-2W78P']Q6]8T34T44S)2T613!9I,1UQ#DF9,)\%L93]PVR= J?^SP?O*1!
M!"Q,R:I?.FZC731W5F$83N$3#K5$%W3"%GZ:D.2MT_!9NI@">ZZES$[:?8NZ
MZA\U0X>VDW;H_./N^&Y>#L_%D_KPZ%+952[@!DLR#<X7<P_T\) -"ZNZ_O'8
M*DM/43^MZ>U'[11(7BIECPOG8/R;V/P'4$L#!!0    ( -(TJ%J$8U?9SP(
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MW\_PI8<4'K0]*\[]<#-,NE&VG0"]MY^?RW9L/(>WPY<%Y))?08D9IT;#C],
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MZ8VFV+:RG03M1HO:-M-&:&Q-NRQP>((T 7B_%4(?-R9!/X[3WU!+ P04
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MF54#X4/"\0@/>^*)YC <,Q9B^@P,)FNJN"^E2N/47U8H)=@C:YTX/)5X0BZ
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M!C\J:T#W*RG-?F,)NE_)Y#=02P,$%     @ TC2H6F)9H--) P  N <  !D
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M@SB,LP-X2>]MXO&2-_"NN99"+G>]_>M\;JRFY/A[G[\=7+H?S@GFU*QX@=.
M%&%0/V(P^_@A&H9G!\BF/=GT$/KLC@18MC6"6L!KX@PNN!$%<%G"E:A;^VO
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M0O'E[KGGCG='+?=*?S$UHH6GMI%FY=76=HL@,$6-+3?GJD-))Y72+;>TU-O
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M\N</:5K\^*8:X"7-OFUG^_K_ %!+ P04    " #2-*A:G;(""GX#  !P#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RM5UUOVS84_2N$5A0MD$6?
MMN74%I!:&S84PX*DZ1Z&/=#2=424$C62MK/^^EU2BN;(BN!Z>;%%Z9[#>P[)
MJZO%7LBOJ@#0Y+'DE5HZA=;UE>NJK("2JDM10X5/-D*65.-0/KBJED!S"RJY
M&WC>U"TIJYQD8>_=R&0AMIJS"FXD4=NRI/*?C\#%?NGXSM.-6_90:'/#318U
M?8 [T/?UC<21V['DK(1*,5$1"9NE<^U?I;YG #;B"X.].K@F1LI:B*]F\&N^
M=#R3$7#(M*&@^+>#%7!NF#"/OUM2IYO3  ^OG]A_MN)1S)HJ6 G^!\MUL71B
MA^2PH5NN;\7^%V@%30Q?)KBROV3?Q,YF#LFV2HNR!6,&):N:?_K8&G$ \*,7
M $$+"$X%A"T@/!40M8#(.M-(L3ZD5--D(<6>2!.-;.;"FFG1*)]59MWOM,2G
M#'$ZN9%04Y:3GQYQ)RE0A%8Y^5T7(,EJ*R54FEPK!5J1=REHRKAZ3WXD]W<I
M>??F/7E#6$4^%V*K$*86KL:,#*^;M;-_;&8/7IC]-RHO2>A?D, +)@/PU3@\
MA:R#1P/P]'1X^!SNHHV=ET'G96#YPA?Y-H"6Y60EE%879$5KIBEGWR"_(*W1
M%P<&M\:F3&5<J*T$\N?U6FF)9^&O(2^;V:/AV4V!N%(US6#I8 50('?@)&]_
M\*?>AR%G7Y,L?26R9ZZ'G>OA&'MR_XG<OJ5E_2$EFCZ2#!> Z2'[&IJII3'E
M<)>$GN\'"W=WZ,MQ5.#-^E'I:$IG"HXZP=&HX*<C:YBIS J[HW+880VOL2(/
M:F\8)P>J?-SS44_[0)0?AGWMH]F=J7W2:9^,:O]R_1EU9V('DJXY#$F='(O
MEV!/Z4"0[\U[0D=3.5/HM!,Z/6F1686%@589$)RD9-MR2/)T8'7]N"?Y."B(
M>[:DHSF=J7C6*9Z-*FYJ8M:^=*BMC4-B9\<Z(G_2$SL0%,8]1]+1?,Y4&W=J
MXY/6%YKWKCW#XD0'XB-Q432?]7;O*CXN=Y,X\'L>C&9YI@?SSH/YJ >W+Q0P
M6\<E< 8;DG'*!O?\*/7WO@Q?DRR='QL_/RA SZSRO?_Z-.]_57UCVF #YHVG
MT_99HY-_KP.OQ=98Y1YTM^9;!)O&!RR+A,,&Z;W+&9X$V;3WS4"+VC:\:Z&Q
M?;:7!7X2@30!^'PCA'X:F!ZZ^\A*_@502P,$%     @ TC2H6@FA6T5H!@
MI"\  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULM9I=;]LV%(;_"N$5
M0PJDMDGY(\D2 XG58AF:+FC:]6+8!2/3L1!)]$C:3O?K1TJ**,H*:Q4G-XDE
MZ[P4'_'0[Z%XON/B4:X84^@I33)YT5LIM3X;#&2T8BF5?;YFF?YFR45*E3X4
M#P.Y%HPN\J T&9#A<#)(:9SU9N?YN5LQ.^<;E<09NQ5(;M*4BN]7+.&[BQ[N
M/9_X'#^LE#DQF)VOZ0.[8^KK^E;HHT&ELHA3ELF89TBPY47O$I^%P8D)R*_X
M*V8[6?N,3%?N.7\T!]>+B][0W!%+6*2,!-7_MFS.DL0HZ?OXMQ3M56V:P/KG
M9_4/>>=U9^ZI9'.>?(L7:G71.^FA!5O23:(^\]WOK.S0V.A%/)'Y7[0KKQWV
M4+21BJ=EL+Z#-,Z*__2I!%$+P*,7 D@90)H!XQ<"@C(@.+2%41DPRLD47<DY
MA%31V;G@.R3,U5K-?,AAYM&Z^W%FGON=$OK;6,>I6<CN%7J'/E$AJ'D"Z"AD
MBL:)?*O/?KT+T=&;M^@-BC-T$R>)?E+R?*!TNR9Z$)5MS(LVR MM!.B&9VHE
MT?MLP19N_$#?;W73Y/FFKXA7\(]-UD?!\!B1(0G:[L<??D.%#L=Y^+@E/#P\
M?.3I35 ]@B#7"WR/X#J32FQT0BGT]T=] ;I6+)7_M-S=5:$V:E<S\\297-.(
M7?3T1""9V++>[-=?\&3X6QLI2+$02,RA.*HHCGSJLP^,242S!5*"9I(6LTK$
MI6H;L%=>K:X,"S%<I)B9:+>SH*_'Y;;.!JA%A\VX8C/VLOFT2>^90'R)Y(H*
MPVFK4YS>)PSI7PZTWHAHI>?.8[1F(C)#4%^Y%G$6Q6N:()KR37%.,9&BA-,,
M'5$M\GSYVS;"Q1UA4H,R[.?Y5L<R/^RRT-N_GZ0WJ>A-#J3'UV942<2>=,=C
MF0,\TE-C0;45@U>ZZT KQ,8U5J<C0DB#%5"3#JMIQ6KJST(:"[2ER8897G5.
M);LV1E[)KHRF^\DX[$\;B(!:=!"=5(A.O(CRZ3[.="XQJ30B[> D:\/BE>F*
MI1##@8/EM('E9)\=[N/J(J>[IU5W3W\P(J(XB=5W9";HMFYZP[MV$U(L!!)S
ML.&A-69#4%M0R@&!!%4+H=1<E#6/BP&]@5^L,TC<EGFC1N9!M>D"(A80\0*:
M\W1-LY=SU!_>&0FD6@BEYJ*SYAW#NG<,:M]!U4(H-1>E=? 8TL+[Q3J#'+6E
MZ4DS35_#Q6-KX['?QW\S57KV @X@BUSB@%0+H=1<;-:_XPELBH*:=E"U$$K-
M16GM/?Z!O^^6HJ#.OE1KI&C3VD.UZ0*RYA[[W?U[S497/E],I3S79>%#J[7W
MBW0& ZD60JFY &VY@$]ADQ6T?@!5"Z'4W$526T$0KZWNF*Q^L:X@2[5&+=FT
MO5!MNH!L74#\=<%'LY1U^2 8,T.M%0IH+0"J%D*IN?!LS4 (:*(2T!H"5"V$
M4G-1VAJ">(VU+K^R+1,J-NMD&5=,'J.E;JU<>6V%60A.:MDU'C:65OV-=D;T
M&K4!L;4!\=<&U\\+9H(JLU MXI2A5/^^QH<L1I?B>.0N,^/F:K3_)CHC>XUJ
M@=AJ@?BKA3NE42WL4J,AUPIGW KG=+I'![0H@%)SZ=BB@/A7]6]IO'@79^\>
MX^P01H48'C<&T*B)"-3L0ZFYB*S9)WZS_WZY9/EK^0/X@#K]4JTQ(O%XTK0/
MK^'UB?7ZQ._U;ZAX9 I%=!TKFL3_46.P6NF VOU2K3[W3YN3?PC5I(O&NGCB
M7_5WG=5Q40_E)__,V@<0J(T'50NAU-S= =;&![ O @)0(P^J%D*IN2BMX0_\
MAK^[T2H%Z\D6-(V6O]'.B%[#U@?6U@?^5P$O9^Z7'6\E!.KK0=5"*#6796UC
M#_#.'MBM/;![>U[#_P?6_P=^__\3F3O:VRV!]S(7U.]#J;F(K-\/_'[?D[DK
M?;*5$>A+ U"U$$K-I6GK@P#VI4$ ^M( 5"V$4G-1VCHB\-<1/Y&[T[U?W?W<
MA2PY0B@U%Y$M)8*#-@55HRWB6Y91D\41E2O$,[2BV:(5%6AM$;1L 2*DW]R.
M!]5H06M0V[Z<,O&0;P.7FH$>'<6FX.ILL=5\CL_"?$=VX_PE/KO,-UX/K$RQ
M?_TF7RF2*&%++3GL3_7D(HHMX<6!XNM\D_0]5XJG^<<5HPLFS 7Z^R77 [<\
M, U4&_-G_P-02P,$%     @ TC2H6N-R"[PK P  I0D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULK99;;]HP&(;_BI554R>-YAR@@T@MK%JU@U /
MV\6T"Y-\$*N.G=D.M/OULQ.:<0AI+\8%B>WO>_V\/F:TYN)!9@ */>:4R;&5
M*56<V[9,,LBQ/.,%,-VRX"+'2A?%TI:% )Q623FU/<>)[!P39L6CJFXFXA$O
M%24,9@+),L^Q>+H$RM=CR[6>*V[(,E.FPHY'!5["+:C[8B9TR6Y44I(#DX0S
M)& QMB[<\XGKF(0JXCN!M=QZ1\;*G/,'4[A.QY9CB(!"HHP$UH\53(!2HZ0Y
M?F]$K:9/D[C]_JQ^59G79N98PH33'R15V=@:6"B%!2ZINN'K3[ Q%!J]A%-9
M_:-U'1OI'I-2*IYODG4Y)ZQ^XL?-0&PEN,&1!&^3X+TVP=\D^)71FJRR-<4*
MQR/!UTB8:*UF7JJQJ;*U&\+,--XJH5N)SE/Q%.8*]="$YP5GP)1$?(&JRM,I
M*$RH?*>;[V^GZ/3D'3I!A*&[C)<2LU2.;*4)C(Z=;'J[K'OSCO3V%8LSY+OO
MD>=X84OZI#M]"DF3'NRFV]IW8]YKS'N5GM]E?DID0KDL!:"?%W.IA%Y9O]JL
MU5I!NY;9;N>RP F,+;V?)(@56/';-V[D?&@S^I_$=FS[C6V_2SV^ Y$CRC%#
M!7["<PIM;FN)J)(P9\$J]AW]&]FK;1LO1>WP!0U?T,GWD:5F%2J#F618+%L!
M:XUPJVLW,(MJA^^%H!V\L,$+._&N2F462R$(2TB!J1G%O-HZ>E,@>!5\>,#E
MM]"_%+6#'S7X42?^[/JSWL6:#Z3J6@#10>?]L+\'>!@3!<-VO'Z#U^_$NV<X
MYT*1/Y#JXUCO3R)EB5D"*.%2M9XY_0.*GAL%[AYK6]30.4([:&@'G;03+,03
M84NTPK0$,_&4LV6OFGU#WX8[.)Q5)SS ;8MRHR-S/VQPAYVX7T#*<WVM"*'7
M*RK,.'/6QC@\'*S!<##88VR)"D/7;V=TG7]7DM-)^8VSWBL8-RK;AX_GAJ&_
M!]D6%D2AMT=I;]VAY@-&7U5+PB2BL-!YSEE?VQ3U-T%=4+RHKM4Y5_J2KEXS
M_1T%P@3H]@7GZKE@;NKFRRS^"U!+ P04    " #2-*A:&A5$:HP"  !_!P
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MM-)*OEDLW=&4)JND,2*CY]$5L816S[.277[G)+O:JIZSA5;GL%)TOE'P3/Y
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MB&H1I<G);;I.IKKK!+_JA):?4,U"-;O6-E]UZIQU.IWM=U_1J2ZJ>:CFHUJ
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MF?UI[I/'E"D)3NX?'F7UHM8& )$%(#HV %$; $06@.A] +@CS&Z/8 M W!(
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M-QA%F)8/B/LK0OCAI&R@V3TS^Q]02P,$%     @ TC2H6L3%3H)O P  1Q(
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M)O5<6S/S":9PN.@&EG$F2 (+A+2.3_!=XX5I+":2Y=IWS9E$%Z>'$1IMX"H
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M4V4%<'TMI3D,[ 9-WSW[%U!+ P04    " #2-*A:$%H]:7(#  "'#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6S-5UUOVS@0_"N$#CBTP#7ZMJS4
M-I"X/;1 6P0U>GTX](&1UC91B=21E)W[][>49-FR%>$""(5?8I+BCF:&NPIW
MMA?RI]H":/*49US-K:W6Q:UMJV0+.54WH@".3]9"YE3C5&YL54B@:1649[;G
M.!,[IXQ;BUFU]B 7,U'JC'%XD$25>4[EO_>0B?W<<JW#PE>VV6JS8"]F!=W
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M3(R'4MVO:#6<5KXO=KY1BV\,;E@NEP+\FL_H[+#]4.FLQ:(GL1?(Z?"&\/<
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MUQ*H+V^'AV^Z!/*/4P+YO99 ?7D[#((N@?S^2B#?4ML$QL.9Q0J%L 4BOBZ
M?'<!U&WV^9:=<Q\:AZ06JP &+5)U=>+_9'^=3*N#E%(M*Y\J7UBVN6_5.=F.
M<MR]=][M'V?&]72:707A&&?COJZ&?'<UU&G&6<X$@MA(8XO5",<M::QK(=]=
M"W6<<>81-8R]YO&@Q0HCKREUN/>"CLJ/1?G>DE  6^=R]_I+?77W;M0%/+TL
M7R%J7#^'I^?EFT)#[6;WPM4-X8MBNRRE<^72>S]2T>.[=YAV7R1;E:\!/3"I
MDK3\N*1D1GEAH'Z?,R:?OA0WJ-\DF_P/4$L#!!0    ( -(TJ%H!9;R9+ (
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MF_OU'V%3,LP6$W)=-(UPO6_#(^KCL?.9':A*P&#I8;:8$.MB >O0@]U"JTW
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M82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3
M%+(F*&1-4,B:_"=9W[5>_?7_IG:-:U4V1W_6_=2;?P)02P$"% ,4    " #2
M-*A:1L=-2)4   #-    $               @ $     9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( -(TJ%KFV($*\@   "L"   1              "
M <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -(TJ%J97)PC$ 8
M )PG   3              "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ TC2H6EMC7.+*!0  !AX  !@              ("!)0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -(TJ%J)%/^)"P8
M #09   8              " @24.  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " #2-*A:4\V*R)8"  !6!P  &               @(%F
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ TC2H6@3"
M16=X!0  $A4  !@              ("!,A<  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( -(TJ%KY1R82.@D  ,U5   8
M  " @> <  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #2
M-*A: 4IV CP"   N!0  &               @(%0)@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ TC2H6O2N)8>U!@  NQP  !@
M         ("!PB@  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( -(TJ%J/N*6ZRPP  ",A   8              " @:TO  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #2-*A:!)E @ST'  #U%
M&               @(&N/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ TC2H6A@@?N3] P  X@@  !D              ("!(40  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #2-*A:]O7@N,\'
M  !)$P  &0              @(%52   >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( -(TJ%KV_9'<H 4  -8-   9              "
M@5M0  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ TC2H
M6JZS(GY<"   018  !D              ("!,E8  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " #2-*A:M/Q-1< )  !*'0  &0
M        @('%7@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( -(TJ%J2 4F&&@4  ,D-   9              " @;QH  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ TC2H6K([;1I%!    @H
M !D              ("!#6X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " #2-*A:!HMFSM(#  !9"   &0              @(&)<@
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -(TJ%J$8U?9
MSP(  &$&   9              " @9)V  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ TC2H6E"6B91# @  F@4  !D
M ("!F'D  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #2
M-*A:$ZV'ZT0"  "*!@  &0              @($2?   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -(TJ%H\)F0L-@8  /41   9
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M970R-2YX;6Q02P$"% ,4    " #2-*A:3P)N(S\$  !<"@  &0
M    @(%9DP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M -(TJ%H  @BEV@,  $T(   9              " @<^7  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ TC2H6JWC 0NY#P  9O,  !D
M             ("!X)L  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " #2-*A:G;(""GX#  !P#0  &0              @('0JP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -(TJ%H)H5M%: 8
M *0O   9              " @86O  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ TC2H6N-R"[PK P  I0D  !D              ("!
M)+8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #2-*A:
M&A5$:HP"  !_!P  &0              @(&&N0  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( -(TJ%J4)XH=-@,  !X.   9
M      " @4F\  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ TC2H6J?UH1U^!   )QH  !D              ("!MK\  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #2-*A:-%W.W#($  #V%0
M&0              @(%KQ   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( -(TJ%J5#(P3-P,  .D*   9              " @=3(  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ TC2H6N%U@AN,
M#0  ^\(  !D              ("!0LP  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " #2-*A:G)#QL_\$  !K'@  &0
M@($%V@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -(T
MJ%IN8%,:. ,  .,)   9              " @3O?  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ TC2H6H'UTC([!0  22,  !D
M         ("!JN(  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " #2-*A:Q,5.@F\#  !'$@  &0              @($<Z   >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -(TJ%J1Y32^(P,  ,8+
M   9              " @<+K  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ TC2H6@[D&"BK P  @PL  !D              ("!'.\
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #2-*A:$%H]
M:7(#  "'#P  &0              @('^\@  >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( -(TJ%HQ\\!4M 8  %4F   9
M  " @:?V  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MTC2H6@%EO)DL @  T00  !D              ("!DOT  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " #2-*A:7DE-GG4#  "9&   #0
M            @ 'U_P  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -(TJ%J7
MBKL<P    !,"   +              "  94# 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( -(TJ%H;;SVY% 0  -P>   /              "  7X$ 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #2-*A:_2S5I:X!  #!&P  &@
M        @ &_" $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #2-*A:)OJ'I[4!  #<&P  $P              @ &E"@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     -@ V +$.  "+# $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>206</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Shareholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/Debt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/ShareBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SegmentReporting</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/NatureofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Debt - Components of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/DebtComponentsofDebtDetails</Role>
      <ShortName>Debt - Components of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Debt - Schedule of Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails</Role>
      <ShortName>Debt - Schedule of Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Fair Value Measurements - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Shareholder's Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholder's Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2017 Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails</Role>
      <ShortName>Share-Based Compensation - 2020 Share Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails</Role>
      <ShortName>Share-Based Compensation - 2022 Inducement Grant Option Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/SegmentReportingTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cmps-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://compasspathways.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cmps-20250331.htm">cmps-20250331.htm</File>
    <File>cmps-20250331.xsd</File>
    <File>cmps-20250331_cal.xml</File>
    <File>cmps-20250331_def.xml</File>
    <File>cmps-20250331_lab.xml</File>
    <File>cmps-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="436">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cmps-20250331.htm": {
   "nsprefix": "cmps",
   "nsuri": "http://compasspathways.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "cmps-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "cmps-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cmps-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmps-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cmps-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmps-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 173,
   "keyCustom": 33,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 33,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 147,
   "entityCount": 1,
   "segmentCount": 57,
   "elementCount": 448,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 436,
    "http://xbrl.sec.gov/dei/2024": 28,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://compasspathways.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://compasspathways.com/role/NatureofBusiness",
     "longName": "9952157 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "9952159 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://compasspathways.com/role/Debt",
     "longName": "9952160 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://compasspathways.com/role/FairValueMeasurements",
     "longName": "9952161 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://compasspathways.com/role/ShareholdersEquity",
     "longName": "9952162 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://compasspathways.com/role/ShareBasedCompensation",
     "longName": "9952163 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://compasspathways.com/role/NetLossPerShare",
     "longName": "9952164 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://compasspathways.com/role/CommitmentsandContingencies",
     "longName": "9952165 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://compasspathways.com/role/SegmentReporting",
     "longName": "9952166 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://compasspathways.com/role/RelatedPartyTransactions",
     "longName": "9952167 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "9955512 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://compasspathways.com/role/DebtTables",
     "longName": "9955513 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://compasspathways.com/role/FairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://compasspathways.com/role/ShareBasedCompensationTables",
     "longName": "9955515 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://compasspathways.com/role/NetLossPerShareTables",
     "longName": "9955516 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://compasspathways.com/role/SegmentReportingTables",
     "longName": "9955517 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://compasspathways.com/role/NatureofBusinessDetails",
     "longName": "9955518 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "cmps:NumberOfOrdinarySharesConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "cmps:ProceedsFromWarrantExercisesFullyExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955519 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "cmps:ResearchAndDevelopmentTaxCreditCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "cmps:ResearchAndDevelopmentTaxCreditCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://compasspathways.com/role/DebtNarrativeDetails",
     "longName": "9955520 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://compasspathways.com/role/DebtComponentsofDebtDetails",
     "longName": "9955521 - Disclosure - Debt - Components of Debt (Details)",
     "shortName": "Debt - Components of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails",
     "longName": "9955522 - Disclosure - Debt - Schedule of Principal Payments (Details)",
     "shortName": "Debt - Schedule of Principal Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9955523 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "cmps:WarrantLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "cmps:WarrantLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "longName": "9955524 - Disclosure - Fair Value Measurements - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "shortName": "Fair Value Measurements - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-69",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
     "longName": "9955525 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrant Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955526 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cmps:GainLossOnFairValueOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://compasspathways.com/role/ShareholdersEquityDetails",
     "longName": "9955527 - Disclosure - Shareholder's Equity (Details)",
     "shortName": "Shareholder's Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "cmps:NumberOfOrdinarySharesConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
     "longName": "9955528 - Disclosure - Share-Based Compensation - 2017 Equity Incentive Plan (Details)",
     "shortName": "Share-Based Compensation - 2017 Equity Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
     "longName": "9955529 - Disclosure - Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)",
     "shortName": "Share-Based Compensation - 2020 Employee Share Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
     "longName": "9955530 - Disclosure - Share-Based Compensation - 2020 Share Option Plan (Details)",
     "shortName": "Share-Based Compensation - 2020 Share Option Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
     "longName": "9955531 - Disclosure - Share-Based Compensation - 2022 Inducement Grant Option Award (Details)",
     "shortName": "Share-Based Compensation - 2022 Inducement Grant Option Award (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "longName": "9955532 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "longName": "9955533 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9955534 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://compasspathways.com/role/SegmentReportingDetails",
     "longName": "9955535 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://compasspathways.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955536 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "cmps_A2017EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "A2017EquityIncentivePlanMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Equity Incentive Plan",
        "label": "2017 Equity Incentive Plan [Member]",
        "documentation": "2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_A2020ShareOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "A2020ShareOptionPlanMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Share Option Plan",
        "label": "2020 Share Option Plan [Member]",
        "documentation": "2020 Share Option Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_A2022InducementGrantOptionAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "A2022InducementGrantOptionAwardMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Grant Option Award",
        "label": "2022 Inducement Grant Option Award [Member]",
        "documentation": "2022 Inducement Grant Option Award"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_A2025ADSWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "A2025ADSWarrantsMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 ADS Warrants",
        "label": "2025 ADS Warrants [Member]",
        "documentation": "2025 ADS Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r611"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r60",
      "r114",
      "r439",
      "r468",
      "r469"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r13",
      "r366",
      "r369",
      "r415",
      "r464",
      "r465",
      "r716",
      "r717",
      "r718",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r611",
      "r836"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r728",
      "r729",
      "r730",
      "r731",
      "r778",
      "r838"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares tendered for withholding taxes",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r311"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r643",
      "r653",
      "r685"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r646",
      "r656",
      "r688"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r681",
      "r689",
      "r693",
      "r701"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r344"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares",
        "label": "American Depositary Shares [Member]",
        "documentation": "American Depositary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r65",
      "r274",
      "r793"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r92",
      "r107",
      "r133",
      "r173",
      "r181",
      "r199",
      "r203",
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r361",
      "r363",
      "r397",
      "r436",
      "r516",
      "r582",
      "r583",
      "r611",
      "r624",
      "r748",
      "r749",
      "r795"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r116",
      "r133",
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r361",
      "r363",
      "r397",
      "r611",
      "r748",
      "r749",
      "r795"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "documentation": "At-The-Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Axis]",
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Domain]",
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r105",
      "r569"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r67",
      "r129"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r67"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r111",
      "r112",
      "r113",
      "r133",
      "r155",
      "r159",
      "r166",
      "r168",
      "r175",
      "r176",
      "r210",
      "r243",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r284",
      "r285",
      "r288",
      "r291",
      "r298",
      "r397",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r504",
      "r526",
      "r547",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r711",
      "r724",
      "r732"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r175",
      "r284",
      "r285",
      "r286",
      "r288",
      "r291",
      "r296",
      "r298",
      "r474",
      "r475",
      "r476",
      "r477",
      "r595",
      "r711",
      "r724"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "verboseLabel": "Exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "cmps_ClassOfWarrantOrRightThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ClassOfWarrantOrRightThresholdConsecutiveTradingDays",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Class of Warrant or Right, Threshold Consecutive Trading Days",
        "documentation": "Class of Warrant or Right, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r85",
      "r437",
      "r503"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r235",
      "r236",
      "r565",
      "r742",
      "r747"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMON STOCK",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r728",
      "r729",
      "r731",
      "r778",
      "r835",
      "r838"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in GBP per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r504"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of underlying ordinary shares (in dollars per share)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r504",
      "r522",
      "r838",
      "r839"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, \u00a30.008 par value; 92,848,326 and 68,552,215 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r438",
      "r611"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "cmps_CompanyFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "CompanyFeesMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Fees",
        "label": "Company Fees [Member]",
        "documentation": "Company Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r120",
      "r124",
      "r432",
      "r445",
      "r446"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r574"
     ]
    },
    "us-gaap_ConversionOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockLineItems",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock [Line Items]",
        "label": "Conversion of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockTable",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock [Table]",
        "label": "Conversion of Stock [Table]",
        "documentation": "Disclosure of information about stock converted into another financial instrument in noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r256",
      "r286",
      "r421",
      "r428",
      "r435",
      "r571",
      "r573"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: current portion",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r131",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r241",
      "r242",
      "r252",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r268",
      "r275",
      "r276",
      "r278",
      "r409"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r46",
      "r83",
      "r84",
      "r136",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r610",
      "r725",
      "r743",
      "r744",
      "r745",
      "r792",
      "r794"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, prime margin (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails": {
       "parentTag": "cmps_LongTermDebtIncludingEndOfTermCharge",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan payable",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r279"
     ]
    },
    "cmps_DebtInstrumentCovenantMinimumCashOnHandAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "DebtInstrumentCovenantMinimumCashOnHandAmount",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument covenant, cash on hand",
        "label": "Debt Instrument, Covenant, Minimum Cash On Hand, Amount",
        "documentation": "Debt Instrument, Covenant, Minimum Cash On Hand, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r409",
      "r410",
      "r591",
      "r592",
      "r610"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r281",
      "r409",
      "r410",
      "r610"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r254"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r610",
      "r725",
      "r792",
      "r794"
     ]
    },
    "cmps_DebtInstrumentMarketCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "DebtInstrumentMarketCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market capitalization",
        "label": "Debt Instrument, Market Capitalization",
        "documentation": "Debt Instrument, Market Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r136",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r610",
      "r725",
      "r743",
      "r744",
      "r745",
      "r792",
      "r794"
     ]
    },
    "cmps_DebtInstrumentPaidInKindInterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "DebtInstrumentPaidInKindInterestPayable",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIK interest payable",
        "label": "Debt Instrument, Paid-In-Kind Interest Payable",
        "documentation": "Debt Instrument, Paid-In-Kind Interest Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r30",
      "r33",
      "r42",
      "r77",
      "r78",
      "r136",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r610",
      "r725",
      "r792",
      "r794"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees and transaction costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r794"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r791",
      "r792",
      "r794"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27"
     ]
    },
    "cmps_DevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "DevelopmentExpensesMember",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development expenses",
        "label": "Development Expenses [Member]",
        "documentation": "Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r313",
      "r341",
      "r342",
      "r343",
      "r600"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share attributable to ordinary shareholders - basic (in dollars per share)",
        "terseLabel": "Net loss per share - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r155",
      "r166",
      "r167",
      "r168",
      "r172",
      "r357",
      "r360",
      "r373",
      "r374",
      "r433",
      "r447",
      "r575"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)",
        "terseLabel": "Net loss per share - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r155",
      "r166",
      "r167",
      "r168",
      "r172",
      "r357",
      "r360",
      "r373",
      "r374",
      "r433",
      "r447",
      "r575"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r169",
      "r170",
      "r171"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_EndOfTermChargeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "EndOfTermChargeMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of Term Charge",
        "label": "End of Term Charge [Member]",
        "documentation": "End of Term Charge"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Major Customer [Line Items]",
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r100",
      "r121",
      "r122",
      "r123",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r174",
      "r211",
      "r212",
      "r223",
      "r300",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r412",
      "r415",
      "r444",
      "r464",
      "r465",
      "r466",
      "r482",
      "r547"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r643",
      "r653",
      "r685"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r640",
      "r650",
      "r682"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "cmps_FacilitiesAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "FacilitiesAndOtherExpensesMember",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities and other expenses",
        "label": "Facilities and Other Expenses [Member]",
        "documentation": "Facilities and Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_FacilityFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "FacilityFeesMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Fees",
        "label": "Facility Fees [Member]",
        "documentation": "Facility Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value change of warrant liabilities",
        "verboseLabel": "Fair value change of warrant liabilities",
        "negatedNetLabel": "Fair value change of warrant liabilities",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r389",
      "r390",
      "r392",
      "r423",
      "r424",
      "r425",
      "r591",
      "r592",
      "r596",
      "r597",
      "r598",
      "r604",
      "r606"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r380",
      "r604",
      "r782",
      "r784"
     ]
    },
    "cmps_FairValueChangeOfPreFundedWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "FairValueChangeOfPreFundedWarrantLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value change of warrant liabilities",
        "label": "Fair Value Change Of Pre-funded Warrant Liabilities",
        "documentation": "Fair Value Change Of Pre-funded Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r431",
      "r604",
      "r607"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r302",
      "r307",
      "r377",
      "r378",
      "r390",
      "r424",
      "r591",
      "r592",
      "r596",
      "r597",
      "r598",
      "r604"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r377",
      "r378",
      "r379",
      "r380",
      "r390",
      "r425",
      "r591",
      "r592",
      "r596",
      "r597",
      "r598",
      "r604",
      "r606"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r380",
      "r604",
      "r782",
      "r784"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r389",
      "r390",
      "r392",
      "r423",
      "r424",
      "r425",
      "r591",
      "r592",
      "r596",
      "r597",
      "r598",
      "r604",
      "r606"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionQuantitativeDisclosuresTextBlock",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Warrant Liabilities",
        "label": "Fair Value Option, Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of information about asset and liability measured at fair value under fair value option."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r785",
      "r787",
      "r788"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gains (losses)",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r401",
      "r544"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash (gain)/loss on foreign currency remeasurement",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r524",
      "r622",
      "r789",
      "r790",
      "r837"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r689"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r689"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r689"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r689"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r689"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "cmps_GainLossOnFairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "GainLossOnFairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain in fair value between initial fair value and balance sheet fair value",
        "label": "Gain (Loss ) on Fair Value Of Warrants",
        "documentation": "Gain (Loss ) on Fair Value Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_GainLossOnIssuanceOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "GainLossOnIssuanceOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on issuance of warrants",
        "label": "Gain (Loss) on Issuance Of Warrant",
        "documentation": "Gain (Loss) on Issuance Of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r528"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "cmps_GrantDateJune302020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "GrantDateJune302020Member",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Date June 30, 2020",
        "label": "Grant Date June 30, 2020 [Member]",
        "documentation": "Grant Date June 30, 2020"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_HerculesCapitalInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "HerculesCapitalInc.Member",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hercules Capital, Inc.",
        "label": "Hercules Capital, Inc. [Member]",
        "documentation": "Hercules Capital, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r87",
      "r91",
      "r434",
      "r442",
      "r577",
      "r582",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r231",
      "r232",
      "r382",
      "r386",
      "r391",
      "r461",
      "r463",
      "r531",
      "r568",
      "r605",
      "r806"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r382",
      "r386",
      "r391",
      "r461",
      "r463",
      "r531",
      "r568",
      "r605",
      "r806"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "verboseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r98",
      "r149",
      "r150",
      "r173",
      "r189",
      "r203",
      "r349",
      "r350",
      "r353",
      "r448",
      "r603"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred and prepaid tax assets",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities",
        "label": "Increase (Decrease) in Operating Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r722"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "calculation": {
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: Weighted-average pre-funded warrants (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r168"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r681",
      "r689",
      "r693",
      "r701"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r705"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r705"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r705"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r272",
      "r282",
      "r593",
      "r594"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r720"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r184",
      "r203",
      "r582",
      "r719"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs of warrant",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cmps_LegalAndProfessionalFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LegalAndProfessionalFeesMember",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and professional fees",
        "label": "Legal and Professional Fees [Member]",
        "documentation": "Legal and Professional Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r46",
      "r47",
      "r49",
      "r50",
      "r51",
      "r52",
      "r133",
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r362",
      "r363",
      "r364",
      "r397",
      "r502",
      "r576",
      "r624",
      "r748",
      "r795",
      "r796"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r86",
      "r441",
      "r611",
      "r726",
      "r740",
      "r786"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r104",
      "r133",
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r362",
      "r363",
      "r364",
      "r397",
      "r611",
      "r748",
      "r795",
      "r796"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance of fair value",
        "terseLabel": "Initial fair value as of January 13, 2025",
        "periodEndLabel": "Ending balance of fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r779"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement",
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_LoanAgreementTermLoanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LoanAgreementTermLoanOneMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement, Term Loan One",
        "label": "Loan Agreement, Term Loan One [Member]",
        "documentation": "Loan Agreement, Term Loan One"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_LoanAgreementTermLoanThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LoanAgreementTermLoanThreeMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement, Term Loan Three",
        "label": "Loan Agreement, Term Loan Three [Member]",
        "documentation": "Loan Agreement, Term Loan Three"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_LoanAgreementTermLoanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LoanAgreementTermLoanTwoMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement, Term Loan Two",
        "label": "Loan Agreement, Term Loan Two [Member]",
        "documentation": "Loan Agreement, Term Loan Two"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://compasspathways.com/role/DebtComponentsofDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Carrying value of long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r265",
      "r280",
      "r591",
      "r592",
      "r610",
      "r804"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "cmps_LongTermDebtEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LongTermDebtEndOfTermCharge",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails": {
       "parentTag": "cmps_LongTermDebtIncludingEndOfTermCharge",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of term charge",
        "label": "Long-Term Debt, End Of Term Charge",
        "documentation": "Long-Term Debt, End Of Term Charge"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_LongTermDebtIncludingEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "LongTermDebtIncludingEndOfTermCharge",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtComponentsofDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://compasspathways.com/role/DebtComponentsofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtComponentsofDebtDetails",
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Future principal payments and end of term charge",
        "label": "Long-Term Debt, Including End of Term Charge",
        "documentation": "Long-Term Debt, Including End of Term Charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails": {
       "parentTag": "cmps_LongTermDebtIncludingEndOfTermCharge",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 31, 2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r136",
      "r270"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails": {
       "parentTag": "cmps_LongTermDebtIncludingEndOfTermCharge",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 31, 2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r136",
      "r270"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails": {
       "parentTag": "cmps_LongTermDebtIncludingEndOfTermCharge",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/DebtScheduleofPrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 31, 2025",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://compasspathways.com/role/DebtComponentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/DebtComponentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, non-current portion",
        "verboseLabel": "Non-current portion",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r308",
      "r345",
      "r380",
      "r429",
      "r460",
      "r462",
      "r470",
      "r494",
      "r495",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r566",
      "r567",
      "r587",
      "r595",
      "r599",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r750",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_MeasurementInputCommodityMarketPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputCommodityMarketPriceMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market price",
        "label": "Measurement Input, Commodity Market Price [Member]",
        "documentation": "Measurement input using market price of commodity."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r606"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r606"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r308",
      "r345",
      "r380",
      "r429",
      "r460",
      "r462",
      "r470",
      "r494",
      "r495",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r566",
      "r567",
      "r587",
      "r595",
      "r599",
      "r606",
      "r607",
      "r608",
      "r612",
      "r750",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Expense [Axis]",
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/SegmentReportingDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r69",
      "r88",
      "r102",
      "r117",
      "r119",
      "r123",
      "r133",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r164",
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r357",
      "r360",
      "r374",
      "r397",
      "r443",
      "r525",
      "r545",
      "r546",
      "r622",
      "r748"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to ordinary shareholders - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r144",
      "r145",
      "r152",
      "r153",
      "r165",
      "r168",
      "r360"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to ordinary shareholders - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r154",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r168"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_NonCashShareBasedCompensationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "NonCashShareBasedCompensationExpenseMember",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash share-based compensation expense",
        "label": "Non-Cash Share-Based Compensation Expense [Member]",
        "documentation": "Non-Cash Share-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647",
      "r657",
      "r681",
      "r689"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r735"
     ]
    },
    "cmps_NumberOfOrdinarySharesConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "NumberOfOrdinarySharesConversionRatio",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share conversion ratio (in shares)",
        "label": "Number Of Ordinary Shares Conversion Ratio",
        "documentation": "Number Of Ordinary Shares Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_NumberOfVestingConditions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "NumberOfVestingConditions",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of vesting conditions",
        "label": "Number Of Vesting Conditions",
        "documentation": "Number Of Vesting Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING EXPENSES:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations:",
        "terseLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r577",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities - current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities - non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expenses",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "cmps_OptionsExercisableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "OptionsExercisableFairValue",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of exercisable options",
        "label": "Options, Exercisable, Fair Value",
        "documentation": "Options, Exercisable, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_OptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "OptionsExercisableNumber",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options exercisable (in shares)",
        "label": "Options, Exercisable, Number",
        "documentation": "Options, Exercisable, Number"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_OptionsGrantedBeforeJune302020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "OptionsGrantedBeforeJune302020Member",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Granted Before June 30, 2020",
        "label": "Options Granted Before June 30, 2020 [Member]",
        "documentation": "Options Granted Before June 30, 2020"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances": {
     "xbrltype": "pureItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for purchase, percent of principal amount of term loan (as a percent)",
        "label": "Options, Number Of Shares Available For Purchase, Percent Of Principal Amount Of Term Loan Advances",
        "documentation": "Options, Number Of Shares Available For Purchase, Percent Of Principal Amount Of Term Loan Advances"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Ordinary Shares [Member]",
        "documentation": "Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r80",
      "r471",
      "r472"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r611"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term prepaid expenses and other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange translation adjustment",
        "terseLabel": "Unrealized loss on foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r8",
      "r81"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSE), NET:",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r741"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r645",
      "r655",
      "r687"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r648",
      "r658",
      "r690"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r648",
      "r658",
      "r690"
     ]
    },
    "cmps_PIPEWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "PIPEWarrantsMember",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Warrants",
        "label": "PIPE Warrants [Member]",
        "documentation": "PIPE Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_PaidInKindInterestRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "PaidInKindInterestRate",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid-in-kind interest rate",
        "label": "Paid-In-Kind Interest Rate",
        "documentation": "Paid-In-Kind Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of withholding tax on stock award",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "cmps_PersonnelExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "PersonnelExpensesMember",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel expenses",
        "label": "Personnel Expenses [Member]",
        "documentation": "Personnel Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "cmps_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsNarrativeDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueofWarrantLiabilitiesDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants",
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid expense and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "cmps_PrepaidExpenseResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "PrepaidExpenseResearchAndDevelopmentCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development",
        "label": "Prepaid Expense, Research And Development, Current",
        "documentation": "Prepaid Expense, Research And Development, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance premium",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r588",
      "r741"
     ]
    },
    "cmps_PrepaidResearchAndDevelopmentTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "PrepaidResearchAndDevelopmentTaxCredit",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development tax",
        "label": "Prepaid Research And Development Tax Credit",
        "documentation": "Prepaid Research And Development Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of ordinary shares and Pre-funded Warrants, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of pre-funded warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "cmps_ProceedsFromWarrantExercisesFullyExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ProceedsFromWarrantExercisesFullyExercised",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercises, fully exercised",
        "label": "Proceeds from Warrant Exercises, Fully Exercised",
        "documentation": "Proceeds from Warrant Exercises, Fully Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r301",
      "r308",
      "r336",
      "r337",
      "r338",
      "r345",
      "r380",
      "r426",
      "r427",
      "r429",
      "r460",
      "r462",
      "r470",
      "r494",
      "r495",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r566",
      "r567",
      "r587",
      "r595",
      "r599",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r616",
      "r746",
      "r750",
      "r782",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r301",
      "r308",
      "r336",
      "r337",
      "r338",
      "r345",
      "r380",
      "r426",
      "r427",
      "r429",
      "r460",
      "r462",
      "r470",
      "r494",
      "r495",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r566",
      "r567",
      "r587",
      "r595",
      "r599",
      "r606",
      "r607",
      "r608",
      "r609",
      "r612",
      "r616",
      "r746",
      "r750",
      "r782",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r640",
      "r650",
      "r682"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, amounts of transaction",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r419"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r420",
      "r422",
      "r479",
      "r480",
      "r481",
      "r529",
      "r530",
      "r531",
      "r551",
      "r553"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r256",
      "r286",
      "r421",
      "r428",
      "r435",
      "r572",
      "r573"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r568",
      "r582",
      "r803"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ResearchAndDevelopmentTaxCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ResearchAndDevelopmentTaxCreditCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UK R&amp;D tax credit",
        "label": "Research And Development Tax Credit, Current",
        "documentation": "Research And Development Tax Credit, Current"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefit from R&amp;D tax credit",
        "label": "Research And Development Tax Credit, Income Tax Expense (Benefit)",
        "documentation": "Research And Development Tax Credit, Income Tax Expense (Benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ResearchAndDevelopmentTaxCreditPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ResearchAndDevelopmentTaxCreditPayable",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax relief claim",
        "label": "Research And Development Tax Credit Payable",
        "documentation": "Research And Development Tax Credit Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r683"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r642",
      "r652",
      "r684"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r649",
      "r659",
      "r691"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r105",
      "r129"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r79",
      "r440",
      "r467",
      "r469",
      "r478",
      "r505",
      "r611"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCUMULATED DEFICIT",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r211",
      "r212",
      "r223",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r365",
      "r367",
      "r368",
      "r370",
      "r372",
      "r411",
      "r412",
      "r464",
      "r466",
      "r482",
      "r838"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "cmps_SaleOfStockAmountAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "SaleOfStockAmountAuthorized",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount authorized",
        "label": "Sale Of Stock, Amount Authorized",
        "documentation": "Sale Of Stock, Amount Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_SaleOfStockMaximumAmountAllowableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "SaleOfStockMaximumAmountAllowableForSale",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of stock that may be sold",
        "label": "Sale Of Stock, Maximum Amount Allowable For Sale",
        "documentation": "Sale Of Stock, Maximum Amount Allowable For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://compasspathways.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r30",
      "r33",
      "r42",
      "r77",
      "r78",
      "r591",
      "r593",
      "r727",
      "r792"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://compasspathways.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r75",
      "r77",
      "r78",
      "r79",
      "r111",
      "r112",
      "r113",
      "r175",
      "r284",
      "r285",
      "r286",
      "r288",
      "r291",
      "r296",
      "r298",
      "r474",
      "r475",
      "r476",
      "r477",
      "r595",
      "r711",
      "r724"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r173",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r208",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r233",
      "r234",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r579",
      "r582",
      "r583",
      "r589",
      "r613",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r173",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r193",
      "r195",
      "r196",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r578",
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowable increase in shares authorized for issuance, percentage of outstanding stock (in percent)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Allowable Increase In Shares Authorized For Issuance, Percentage Of Outstanding Stock Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Saving period (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ]
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase in shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Increase In Shares Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of shares outstanding number of shares reserved for issuance may increase (in percent)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Percentage Of Shares Outstanding Number Of Shares Reserved for Issuance May Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage amount closing price is higher than listing price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Amount Closing Price Is Higher Than Listing Price"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock plan, offering period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020EmployeeSharePurchasePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Tranche one",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Tranche two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedPaymentArrangementVestingConditionFiveMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting condition five",
        "label": "Share-Based Payment Arrangement, Vesting Condition Five [Member]",
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Five"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedPaymentArrangementVestingConditionFourMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting condition four",
        "label": "Share-Based Payment Arrangement, Vesting Condition Four [Member]",
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Four"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedPaymentArrangementVestingConditionOneMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting condition one",
        "label": "Share-Based Payment Arrangement, Vesting Condition One [Member]",
        "documentation": "Share-Based Payment Arrangement, Vesting Condition One"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedPaymentArrangementVestingConditionThreeMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting condition three",
        "label": "Share-Based Payment Arrangement, Vesting Condition Three [Member]",
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Three"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareBasedPaymentArrangementVestingConditionTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareBasedPaymentArrangementVestingConditionTwoMember",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting condition two",
        "label": "Share-Based Payment Arrangement, Vesting Condition Two [Member]",
        "documentation": "Share-Based Payment Arrangement, Vesting Condition Two"
       }
      }
     },
     "auth_ref": []
    },
    "cmps_ShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "ShareOptionsMember",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options",
        "label": "Share Options [Member]",
        "documentation": "Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting percentage (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r130"
     ]
    },
    "cmps_SingleOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "SingleOperatingSegmentMember",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Single Operating Segment",
        "label": "Single Operating Segment [Member]",
        "documentation": "Single Operating Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://compasspathways.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r101",
      "r173",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r208",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r225",
      "r233",
      "r234",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r579",
      "r582",
      "r583",
      "r589",
      "r613",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r111",
      "r112",
      "r113",
      "r133",
      "r155",
      "r159",
      "r166",
      "r168",
      "r175",
      "r176",
      "r210",
      "r243",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r284",
      "r285",
      "r288",
      "r291",
      "r298",
      "r397",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r504",
      "r526",
      "r547",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r711",
      "r724",
      "r732"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r57",
      "r58",
      "r100",
      "r121",
      "r122",
      "r123",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r174",
      "r211",
      "r212",
      "r223",
      "r300",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r412",
      "r415",
      "r444",
      "r464",
      "r465",
      "r466",
      "r482",
      "r547"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r174",
      "r412",
      "r430",
      "r473",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r527",
      "r528",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r547",
      "r617"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r174",
      "r209",
      "r412",
      "r430",
      "r473",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r527",
      "r528",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r547",
      "r617"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r644",
      "r654",
      "r686"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r54",
      "r79",
      "r474",
      "r547",
      "r560"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares to settle vested restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r54",
      "r79"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r54",
      "r79",
      "r322"
     ]
    },
    "cmps_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares to settle warrants exercised (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r54",
      "r79",
      "r482",
      "r547",
      "r560",
      "r623"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares to settle vested restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r57",
      "r58",
      "r79"
     ]
    },
    "cmps_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares to settle warrants exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "documentation": "Stock Issued During Period, Value, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r72",
      "r506",
      "r522",
      "r548",
      "r549",
      "r611",
      "r624",
      "r726",
      "r740",
      "r786",
      "r838"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS' EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://compasspathways.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r132",
      "r283",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r300",
      "r371",
      "r550",
      "r552",
      "r564"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the cash, cash equivalents and restricted cash",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cmps_TransactionCostsIncurredInConnectionWithWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "TransactionCostsIncurredInConnectionWithWarrants",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs allocated to warrants",
        "label": "Transaction Costs Incurred In Connection With Warrants",
        "documentation": "Transaction Costs Incurred In Connection With Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "cmps_UnderwrittenOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "UnderwrittenOfferingMember",
     "presentation": [
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Offering",
        "label": "Underwritten Offering [Member]",
        "documentation": "Underwritten Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "cmps_UnvestedRestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "UnvestedRestrictedShareUnitsMember",
     "presentation": [
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted share units",
        "label": "Unvested Restricted Share Units [Member]",
        "documentation": "Unvested Restricted Share Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://compasspathways.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r94",
      "r95",
      "r96",
      "r97"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT recoverable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://compasspathways.com/role/ShareBasedCompensation2017EquityIncentivePlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2020ShareOptionPlanDetails",
      "http://compasspathways.com/role/ShareBasedCompensation2022InducementGrantOptionAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "cmps_WarrantLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://compasspathways.com/20250331",
     "localname": "WarrantLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedConsolidatedBalanceSheets",
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liabilities",
        "label": "Warrant Liability Noncurrent",
        "documentation": "Warrant Liability Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://compasspathways.com/role/DebtNarrativeDetails",
      "http://compasspathways.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants and rights outstanding",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://compasspathways.com/role/FairValueMeasurementsScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://compasspathways.com/role/NatureofBusinessDetails",
      "http://compasspathways.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (in years)",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average ordinary shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average ordinary shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r168"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://compasspathways.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://compasspathways.com/role/NetLossPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average ordinary shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r168"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-31"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001628280-25-023426-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-023426-xbrl.zip
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MB'U%QXX'<F>/T;?HD=N'^YWB62DKU7*UE0N>"W>@?VYQJ\RKN4>W,:]JQ8U
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MH_9YGC0E2=J/#DE?^3^^=Q][UX]?_Y >KQ_N'WO2P_?'I^_=NY[4NY= _?5
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MA=% (B'(GJ5GUWGUA]'="LA:RJ9FT(%ILV1-C[L>+56%52Z9(+NM?(X>6_O
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MR;*DJW\'KNGA*0B68260NR/DSF T%,K_YD:!%[IV/.\MC*&.J8_;O,D-/B,
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MYKSFSW%8):RARJU67N%QD2BS#<$\KLY^V3JKH' +SASR.E'N7Z-N%\)4Z\3
M(J=CGF:S*!D->P@;"UXHTMKRU(0Y,(,&S)#;WHM([UF/_Y[C$VN+O,\-S0ZQ
M2;0CT)R.="G2/G"MEML^<([(+K8[+%A<L/@Q[0/7ZKGM Q^8QV?V@1>V8A<B
M_R&A='[IN_CRDAW<9:\=8LN6Z+HS@F^CZ2C9CH\;K"Y<MB439O;L@@4S)JX?
M;K5Z6/06MYJQG0/\8I#&,C[1P7=XW//A BOQ4UD*@7 :-=Q3'3N>B91QX6)%
M(/.%AENI(0\DW@JQ7YV^0OHP@\!?_LK\9GE(#V64?Q?MY!5&"/S2XH9.0?;8
M%66NP%GBO[AH9#]3:S7;BC;0M:K1JK64?M]HZH-6O]HR^JV6H9%_87YH^-+0
MG6XB/M-RWZ7D9YD,8,D7Q'HE$P]Y( E.@&4XHWJ+=8U:!O@90"N\P]0LJ/G%
MO4-2:VO_A^,3Y)?CLG2$"ZST[.)3P!0L7P#(_1+EJ[U0X/GPS+RPT<=HX_+^
MVT/WZ4EZZ/9^_]'] WY\O2R0!$J?]!T3.+Z#P ZERF52JMS$4N4IEBK+,V.*
M(E<_!#8)#!,6\'%QKIOQ*&X+K4W]V3_2-":%*E)HF=P%(QA"7SRD-VM[W+O/
MQ#;_8JPV12_\ 3;' SC!@"OVY_T@QO<4W5>FIUN.%[BT!Y_X8K$*SI&=T>!F
MD&D'U.CZX36<  6;9(PDX0; TW?$A_>1J;\$'JS'0R*:6<*<LH9[X;@\72G^
M'HZ=\D5UM=8YO/I@B,-R>@36_D#\(0IW:6SILN2X+(GJDIL!LF1BNE;?!,[4
MAS;,['DBA28"&)@&6$G(F,"R8#E0*^KF-(9_8'7LHL<XFF+FEZV#4B&\]Y/M
MO(3 M"7$+##UD!++'U:DWO3[^'F#OE#+&>.X)O"[:;^ 86H^L[?A+91T6J,J
MC3T3J&'2A_%\4%P^#@I+ ?/Q>2AA<<$RF"+/8+$ )-"X@Z> LG \Z3IPG3%E
M09@[Q_6'4I=1 4$[-UJ+QVJ-3H<N Z6:,")\Q*!C^,.#Z2PW<0I* W.@]H+^
MO[&D!2#,-;V?/"X5 -I<GX !:,*'=58Z'9^( 1G"E0V#CR &8-Q9HH&U!N!/
M($5%YQ1EJ1_X:&5*ECDR.1W)$;H9^OJ<V*AO^H[+$OUL6'<\*OOZE)0\?'F,
MJ5.LE8,M_:03S ;T'-NFEHSYA_!JE' (?XU=D_K8Z@&-6\N">P$:N$@,KC]A
MBY^N0&93L4S6ZX'1PK,#CH+-)NK2Y\#BD^"OH2W-.S0CJ#RJH\1!@R>D6I!'
M)M(\W,3&$E$G-'B?TS^VMP.1%?@H3V%$I@$E&,6%SUD3B9DH,[!Z-2T+Y@%N
M&GP)*PZ8 X /,N'TJRA=64X9SC'Y,CA50/A> CD !AICF"7/Q'R#[(<EK5C,
MDJW; 1B2,>9W$@9G$Z6(PV@%BZB!$N;BGJT-O(;P<^G3'?%&RH"B$$@R+ $>
M1 #$V&1?-^V!2X"H IT)=+P$; 6& [@-"6P!JX[A<SAG&#'N%%B1KE\HR)]!
M4N"Q6K3-S]X, E(@Q=PB+V#R;1# %$T?&2CF%>EU2&T9!X=W73GYB0A3"!4*
M_\(D LJK0'K@.:_PDXY B R))X6=4E!83\F:L\QXH9 _+IFU4<&G9UNOR)$<
MMJ4KRIP\I+.G\!Z06/?J:89D >QLF,$ 7K.?0:,%+K9\8 (-[Q"_#-\L QQ_
M4I\/T?LFQR_@],#''<ES\R22Y< DR+-+:<AKL);?@;0#P)=T&9'IK:U79$:&
M\^\#2[PP^K6(SH?P78 X#X+$2O?A]N%Z5OV]$H\YW$R*$.D)Z4/JQO- _83K
M@E6D+((;S?>Z[_1!5K1D2:VJBLPGW[N2GE H,4Z0/GQ_ZGZ4OGZ]9%.!>Y?.
M*Y(OES*O0Q-$AC\W+>88(5P]+^"\YX$,#1$+Y(7WV+_!&'_^5Z;#NM69\%4]
M,B'UT=B[0"#<#UBIQF_DS1P%HRX3&5W,-L=98=%@LFE3Y\;4?,3ZP?5J95GF
M%7".%>H.!G-&?"SQW&4& +69B%FZ3I@!X&%AJ3-%+&[O;F;6>L?>N1_<AYS!
MB1^L9A J:' \(G/-+!286,?%O@(SP93B=5:GZVR5.HY-%U8YQWYR;#Q%]("Y
M]A'+ OZ?8<$5Z2'!8GASGD27$*$?";FDP%JZO[@O218N^(;VW0 !H3;9?.NS
M\AL\%F,YFKGL6D"SN@3-D5>4H.H(Z1S9V+4&Z\?UI@)C,\I.8+Q=ZM3E6EN1
M6]IB9V5&R2&KIVC"-$3M"Q^I@JV0E".C;158?JB&LDD[-5W:I9 &^LO@2'&=
M^DAU"I:.<9^=-J92KUX%VJA5EB6_14(/UH3]SB*]5I$.21;W]CH69?$>YF<R
MO8E>P[Q@@AO<@$\U_]((+]:<H78,M?;<P,NUYHA,=J,MM<VT9:@F W_HN !M
M(S.I*!LK2">(K+.$2XFP +2,O.BDUASD*N&%&04+%C2+0S"C&50.T+X%_D^?
M C@-@*0O<6L.32P=C?J>PW3.+#V@68J.)A/=>&%&YH'A/C^5O&SP@PLFX)7_
M"6PJ:57&)YI\4,Y=P:-?T<3NIIO8<LA-<6UE-'S),SS\C%;UB)N!4M]Q77;@
MD-'0>SBIMEH27]&^?VNCQXESO %;GO-49DY20>BN9:2D:T,8YW _!-:6;57U
M/:T*<\HV6!7'Y>O44W3F:+0B =5V@^? \R6E$='M"MI)N#)@C^I#++*7$,A)
M-W!1+#.WSN!A&BL,+# I#3IOC><F?3#_?_;>O+EM)$L<_"H(;=>L'0&Q2/"V
M9Q6ALN0J==N6QE)-[^^O#9!,2BB#  N'9/6GWW=DX@9)4#PE1,QTR221R'SY
M[O-]94VPMT=-L-O!SD-ZL]_3^]W\13%;1 B\L^!D:(]& T\10',%7*:MHSIY
M=_G)=10G9GQ*$BE(;N3; AX#B "R9R'QW0B>6),[?*HAG+'@Z#?XUGB9_$EZ
M)V?]1C^OL:%W#,]!%YB*Y"<O,G6/58W5LAO<FK':[9<8JW#.AG:)UG?J<"CH
M@45&XU2B*USOT@8++^V3;?K^]52^^]K[CI).S8V@:XR^].6W?JOHD&"1#QO#
M]N(;!2U%'HM<+R0"%X?>P.[+[%CM!M-[:#O788!!#)0Q=R!@\K<S";WH=M1V
MARC(L5KY69A>-G0FZ^\3+>JLI+K>-#KLXDHS%]2-1_%83Y())N7!VAA!&ID^
M')]=M9Y 4#@NNF+1G?^(3M1["^07!Y2BC!/Y,>OPY+C@B<X<WG]6GZ8V@GMC
M)P 57[/D:K>4C9'>]!/N)=XRWDA%EMAM[I$E]L#T:P,W-/1F"4=\B57;;2W6
M.EX^+3+6/'HM+.UHY DH9\0F&(.R9._RKGFRJZ600\=O'$&I( E6!0CQSD70
M^!R"Q9,81U,1-C@ VS :G>7  4,%:"WR7<O(2!KG,>XQQ0W%B-_0+L*(QI@Q
MS K;&$@B M*E-9^*Z>B8XA^4X'$%ZJOI*/:6\420*CEABQ^-SS4TQNX^?8<]
MG'?=T9NMCMXW"G2.;(C&3(1H7NP<+SWYUO2-7F=%Y[CCSBQD"(]88*,A*;4_
MEI[N?C0O4S&Z*>=-+E&W@E[8 PT7K*]FP27A1>C*ZQ+9/5DM\6ECFG[Z4 48
M6Z@Y1;@;67.?3-O&"2I9):HR$O>6(#$K_\KN 59H6R)$@/$W&,N6<5U./W$]
M^/3&$Z?2@MV<D=3M'!CH,"K6TIL=!-TBBS&%2L@'27%]Q8 9+ <,*Q<)/S(:
M(^CX6,L:25-5YR6L C3X3L,H-(1+C<CLG3+!K'>2SJ9.TF_227J=?/D0G21/
MH\L/)NV3 NI^,!_%!LW+]5!Z#0.SWV+1T&PMN>]8#R,;TYK-Q,0B7;<<*.+G
M''-X,.$E80P!JT0UD1_+LX--0W(Q:6P,CNBW;?2'O65TDX%CW G/U/PY['-J
M 8@F9F!JH(^B/'%$&:3())$PIES\Q39_-Z=";,3F[[>3-K^?-?K18SNFK+7T
MYD<"Z"P%"ST7$H.WRT>30W"#0F"\&V'RR3,GA_D/&(*+? 3J:?+B%<7T>*[N
M>W2K [:ZF'?DX=^88*-CKN%$V&#W>7Q/CAM(C*0-3N+=R5 6CJ@6J =$48G@
M0;X94Y1CAC]U"P/K+#H!P;^9_L3\.Y/(_FLFZ;@NF-E P8Q17C!3U[ZL5_M2
MGAN_. M^3R@@?J)O0W"&KC1XMB.$\C67FQ)"G7(AI%A-Z?8GYG,U([MPU]BK
MTD?^A_DHH%DCV[GS3$3I"R25:C9WORME2_X\XWA]C+M1*'1"M0HJQQA/2[G1
MKI.([94S;RHH(#9_7)ZFPDQ;RZ&,<,S#QC\0.B!Y?'@AB!\X/]=+C,4\R(23
M,9='_K)J-#GGQ2R9;O=-!%<.2O\O\)X"OV0?AZ#T&P5ZN_)(+C4O%L]<>L'6
MP.9M=QOY*:O1UA2=+?5VTB$PZ$&N]#G'*U";OHK=RKIL8EP8<4AGL4S('3T>
MAS-,NT<=4DRML154OL5<RE )J+X+]'J(R:7I82S'/X_??<&O+H(?F,;=KM$H
MR#64 $Q[W4&[!<#X7#+ U524GD79/DC:<U58)'%6@1_^*WPA6,<.L0@@O? (
M*%T\"C_J+EW8!A19QP.I[677\'+PKM7)+@]8ZJC>;!28<0HSR5P886W"%*]'
M9KI1C4DB(1] B4!W$)@,$BY'H0\!*[&<0A9G<)4E*+:V,/V@,'MH[TE.*E.9
MVG_;I@,(JQD]>$;\8"L+M+G)J1L&G'"'V6E8-M9L]N (X>19Y:10B!5QD0U8
MBAEBI_()X(<]12P ;.@U]IH22YW5"=>U1TO5&&5<NR3DN!(J0.RFVH>X',DS
M41*65"-1S:7(5&^DR"HR8."GV4752B;C%3D%'-:XQFYH3Z3A#Y_=D[&B6;#D
M.-IDW#< H4[;8X,Z?@\E\_#^1JI\DV*_XIZ*>NXH0HP1B1'J ; 3/_1,MDZ5
M><9E5 EB0*2)2,<</R#7F'""IYFJH$)"(E^Y^NVC:=FL)SLRN1&+'N>!*H](
M%5-BR!Z64VZ1I!5<?B<2MTVL:!H!?%0!&Y(G7;VL=L'JMU&@0$@?4$/[D53M
MI8?;Q1!Z!+%Q,ITI54S#:954IC?!X+HU"OG-GF:#;N60@4M:X;WL[\"H"?"0
MU;5)C 1(N"-RH"<8$P*3N&\29 3#4KS!P"O6;0*D,,HC9!( 0;\ 0Q6&J$ V
M,?@8K1DB!4AW?$587SD+]M%%)P#2B@[RTYV[6.O&57N.3W58Y//P TE1R1N/
M:K(8I@0KX*4N%K41,4BV$YBPPVDTSM9/9@E$:[C.O2N#2D G ;!B1_OSAX?*
M! ']>^C[ELG"QW6F@%*!8KE?K<D$,.$2Q(VN36VL[C-E"L*4BRQE]1_F ()(
M0DR.RR[)#8+\.V(L?S9N&[KVY[_H)_>V.T)!!R]U9Y8@E(^@$96NFLX/?*'_
M[ =BQDH8%L02V?&38\VWW:<)3I@ R&#* %4 JQ7XG<FZ1C45WN(-:7@U8\Q8
MI,>C,DKA/%J>RU6E\ U3ZQ1.@@6P3 H2]>UG=<9B9U>,Y#&"*RK(\-0<\Y%L
M;BN";D@>D.48W5C%(;9B_X3>@OX)TBW6@4TE:=O81T<%\E$853LJW,9H!OHY
MIN["W=U(_,KW21@T\UT+!LU\GX3;<#;#B#<@?>(-6OP*3;UCK?8)_,J"C1A1
MKZL5S_\;9H==3S-G?^;_+3A_T6M;^?.7XXJ1QI7.-E&%5OR JH U7@%Y"!9X
M9<E6&D<DS(I;444M5*HTG&*=88229^Z)N<D)XR1N7&^&K(^*#,P8G^>@2(VM
M.9:"Q*4FK)S$%L&?#FV$>I(0I&4*#*EWQ-I_/S^_86UH8_N6^HT/>"^3(64Q
MIEH?!'7(&LR2Q4TIUR>1%8T1'>F\N  YA@'SE/G;(35)5^?'5AQ2!86+-N]E
MDKTGIMA! ;5;D"1_A3ZUR2 EU,%.&7)8L8.>03OAL$K]UB$YBDPG,O%-RTND
M=+K%U?KQ255L(UJ B__A;'(N5*,@T))D70=-'6W5"+"0H2(/(]I)*KM@ZR:J
M\"EKV.&.%YXU4\FZ&+#$^B@%?\NFCAW8W@6-- GUY<NRNI)9'#5'2E;&@#!<
M%;HU".E4.PCU^T)\]1](Z1D),N(E ?\%.FG [H[@(44'VR, Y5AF=Y(GL%D)
MNPT0>JQ&QUPB%^QC^OQ.V(CD_!D(06LU3__%-B:5PU@V+! =Z?82Z_$+:AV9
MMY1P%#D9#> FP!Z E<N.A&^< -S1TN4V!559";9OF;B"2^L0(]&^0_J7^#)U
MW0 !A@:D[-J4Z/P@7U/2*C"K[6DYG6)U_2#59:I4*S *M +CE6@%-[%@XWA>
M#(\CYH;&0FYH*&Z8TB2JR&%)TXRMK"7X6<>&*1VKF%!@/Y^"/0BK^>'(MR86
M\%'T2)W;-K,XU3@K'EZ(7"7A?TE(?H$]D1S:F^LD]FI1EZDEU'&,*+K4Q#@:
M%38;JHMD0*K-44+K5)X E",3X#:>-6)!@@T1-4.A7+(]XI*FB"^01BL+Q:PB
M58DE_^F+Z^DE:(7HT/-C)MPN8,+M5\*$_^3,INC4QXC2;)"DI[96XJ@Y\RNR
MF%3 R4^8%8CM,_.'T(0"&KNN?#^<S9EELH>>O< I?3_12 Q^+Z37R[:B!F#L
MUXMU$\HJ(^2[I^:%A0^IY#+..:@.@=A-F=^F14%IV<=,1N<F<6E-W,8L,F62
M3+,<1-(TB]A!M;[-BIEPNSYE*<0M^Z(TF@24&C&6TQ.\871$@V'AB4=+//%N
M;,0O GSL'EVLD=2)<5M(C&O7B7$[2HR+_9N%WZ*L.ZRT.6+]8\L;AS/,&AXC
MW\1XA!_Q*=!RX>.&]BDF89&B?ISV[26T$>D7L!(96\\J5?B' RHTZ,S<BU-Y
M'#CP,;$PUAG% (&52&/2]1,28FG<H)*B @!,^)4]E\-AQ!B7>)D[KT)IP293
MU'&4:PE3JGD*&D<WHO[*B13;1(>1S^>WOZFBS?/;/^F;T^90.]4X94R[,W]B
MQ\0[=P[(T^\TWW_0KF:8 B[!  (Q_J46]ZNF^#Q: "PT+7Y&R?P ?IO01)*Y
M-]10=<8^.94,H&*O2!.^:H2#?"3I:4'U2E)<7"J/+Z*D*B1*$/4@M#FBBF6X
M-B5N".?!I)!O<C$*;:JM"NQ*:4W8#W4?@O) *2-^XCWD\4N[^_Q$3P"N9(C@
MW^KJB=8 V*Z+*A1,;Z(R.<R).P]47P  G<JED]YP]N0[,L<? 9QXQA-!_(#-
M-COL!_^:R =@">!*H-($6,_\;T%\*VZW*[#,DX/0U"XJ.C.\:"(P9P'CVI1N
M&86=T46*QSX5SG(M*PGK8\H]4)3T#?%?4E*GE)(ZI\UV3$F1O4IFJ?'Q>Z3?
MHKGJB0?9R9=_+G]TR8HQ$E82[Q-TIKV[#4<!D:=A-$^)0C._!M&=W8,F%RXA
MTTF2CA?1HU3<,W2Y<4KIZ7$.A#7+FP:*^*63-?_]LA?T#X04DWE2%GN:D[]7
MG3WD%C=(NB^@V-5,EM52%[ WS/&D+K0K#X/ 4,HGOJQS,K@+-*EN@5.HFW<*
MW:!OPII$E$S(12_0Y!LT?L5ZZ0I=4LTKG>Y"@+[JB<DGUP]\V28:.R_*G9X[
M$]H>[VK1:(M!;P5E\M#$@KJ/5*8Q1PA5!J;TL<@0,?(4%3E2!9/O2(-Q0]C(
MQ'__X26BD1,,(YN?AH11AN3<%Q_4'Q^!K.>V^?S!<NA$]-#'-+VAH9J9$4:O
MXZ^EO3OL-YI=,GGE8%/Y8FD--^"K7_.?]UL-HU/\5;/1JOAYI]FO]$39IEI&
MHV54??E.-M5=N-22L;)%(QA?_K."\8K2V;.388*#97RZ*;-%N4@E.WGOC9P_
MTG:R('CI).(E0-K:\RO//#SL>\'LAA50L@;C4C!V7H;6Q8.]5YX92])Y'T-2
M__R7]OV_S-G\XP5Y.L JFUA!1CNO@E<9.*PTK5<^\S;G\58[_.N9N%LR5)MJ
MJ+_+L4N@[U_$HX3NS)^?"#VE<5)UK.X JU2;>JN5KU.M.%6WTIUM;C9V350U
M42WI7+Y[HAJ@]-3[1T!4+U55CX%$E NA;'#=UG1%HQH<"QG.<=/>(H$FKT4Z
MVHHI<5T"')Z<M9JZT2[K5UMU5OSN9%>-/"LQ[BTBS[!)/1G;[1=S[PTASZ[M
MKGW@Q?^>WU$P&?:$OM*U6/(",VLEJBH VRNDJA*6K*(-U#7D?#(1$]"">#@8
M7LBZM(33GG2C63;.I:HB=&!\^&U@3 D?WA+&8*=YO=7,MW3:#\:\)079<E27
MD[DG9E8XJS7C?;%A>257ZD8JDU$;R:C9*AO)6"O 1X C2QAO'D?R:- Y.3,&
M+Y:^NU%D5= <-BK*<6;_OWH;QW@59L5U0:)(;5OL2Z@E\I36U0Z[P,_T3JM[
M(-IAC3X[E'<;0!\<X:*W!R_6B@[$N-ADHLB*60TR>ZT]QZX-(>;"41SB;8;4
M-@F:UT/&JYDVTG6;3E]=EZ[[)V>=CC[LO]AKL,$;W:8\J>FXIN-]B^-MT/$
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MZEX4KQ&)%C4?W202=0X+B=Z"<?,YI'SU7":L'$:[E-762EFME%67-E<4.P,
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M!%;( EN7!#HG9UV]V\JWOWCU5N7>Q-HWUSE]F5!+JQAU7_\M@>:P.<B6[%'
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M,X%UI49,&ER/^XGW3!'B*_\/(!_AW<'9OC!<Z/-"(NJ@L[: B!YH"<Q6<5(
MCK-53)":P@3DJA)(SD C&TE>&QZ;C38;:+S "JL'F[<I9'8E2\[CD0O9TJM5
MW-,F_!F8-JY1,4NTU1PN2YA>%R\R%>X56W4D, );=>BMSD ?=O)UMCDNP_DS
ME%6;K&S)VCA%]GZ4M8 M.U3?VGDXLH%+J_XZQ.*O;JY7Q;J#CA2!1G(IW=7<
M,$%3S0<V&C#:I4:6#2\L/604M;B\O;G1I5N>XP_2(_\;>>1!I;T5\#%UGV!E
M#C-)YQB'D!9-LKU@\<]5S2@@$P>]8T5)?>1@KF1)=XOOXMY"NXDH^U9%Y%&$
M?L80S^?35EG9!6(L!2#PE JW[6=48(7W*(LNDJPE&7V'W7 *^@OX3*MY\'RF
M?W+6[C3U9K>@#CC+93 ]W\3&]M;<).$<A7T28(XZFT2)IW'S$KE.&OZJ"P@)
M^0C\!0TP+&?L"<1@RI>/BF_T1(6OZR0_!PSD/M?I!Q(^K:A9'4;[X*R!;'\D
MTR::DE@D36!&;ZS65]7+TLBP(;WL''5LA-Z5!,Z5DT4)H!*5!Q1K<=?31,(U
M)0=]-7]:LW!6J+1ABX]R>S@I<>*[+E"$B;[B['U %3$6]%AJ+C79$I5);6%#
MQ+7A*Z&2@VZB=8T";F72&YZ<=5M >H."Q/T<]#Q904,A;XF(Y< V,:.0<3IF
MZ7.;6MIP]!7XJ>LQV9;39ZPO, ?UDW:\-&5DN%T\"@X8F](IX,]M"VQ#_H?J
M_(KG<)'\$D^CWC$VYR3!_\.5FZ] N=42O55;1;U5;3-TQ@]2ZMQ>W>A1K(ME
MLN),;"?& ?8QZFQ*EJOKQNX3$\L?HVF&N0S<<.B<^2_!?;K$ F]MB"$1+T&N
M>2UUQPI6>+M)5K@LR<^:X;HZ;6%OI @F$Y5'AT[7J&66"V=0R6^+[&WEQ?3-
M1_H)QXN 9$(_CH*MSO)7B-FN ^0+>=68LLHMB,G@5BK>!;#7(C[>QFJT(@^6
M0IW7HM^SQLL1X)64^F-VR5YEE>ZJ*4<QYUG44CS2^O58.TK!&1<IS8V*5"EF
M9_LW":(MD3O_R5?!T(@,Z3RV,/'L#]8<Z/A1V.Z<7E0736V]:&I0%TWMIFAJ
M:=IO$5,\-!Z(60PX)H'J(&?F#R'SV4]'K!&@U#?]!_G/*&.4<R5\E?*9J\V<
M3D&J8C5E(D,RP3Y1KR)E]H=X1E7!1U_;.Q[MQ74P#E:R8/+_^[>1SZAX:L7$
MJM8^$ZO:1N7$*A:8:R1*E1QTFW'\]%G;)V>=PJ-N)$6JU3Z,4&V[LSA%2OG%
M]Y"7^&K80,+O7.1:K>R_6=IV N[ =;C5/7L+V!7S7;X1-+_/81!Z8EU_3+L+
M2*,W^QV]78 [JB@AZVE1!F/2;RRE2@%CS.J>&W*6QF\B'\^F?*?D^%S2AZ6,
M$Q0G2V[$&9?T8C(.)'R9:<=X CD46GPUGY4WKY!U]!(<<ON^3KC%8H]>F2./
MO&4KFBF15H1H9_EJ];0;SXQFGQ:Y\L+1*?KN?"I9C4LDZ9]KN?:( #B@4@X_
MH@8Y?4K6-!9I&8N2(\K83%D+V92,DGVQ*G.0_LE97Q^V!WK+&)8V@^:IGWMJ
MLT>LNR#D?FB34PQN!X@S@LEAL$]PO2SJM[F2F_+N^;^O/MDW@:T#DG=&3^]T
M"K#U(#$BDHFH5(FL/)R2_)>U#Z]*T5J4R*&X(?#R.$I0U0 KSB_>D0$V7*.R
MY8[F'9O>@KXB4B?'$G_RH:TN#%(]!:7=\4DM4S6YJ],L;24R=]%9@PDWRG[@
MJM-4%::O11Z%#^L%G@\D@;93ED"+7<K(!B6K:0FF%J?*[C(3OF-PJ5%QNFS:
MCDY'L\O.5)S]NM,SM5<_TYJ^@>*TU-UCX1+?P.Y] KH,[:O?13M8@1IRC?5W
MCSG=:M3PN-9!C6(U:F<)XIW>PE$#V6-2Q]/'ZJS::!T(D6 7HV91GG:&/!*E
M#N2]@+-HYXZ#O6I^9Q5$^RH$/^$M)BCVK%+3F^,/0U-C;LH_NW(FH>02,E!*
MEW%L::9R;@*[A9)Y+$HE-:D1!,X/XW9-R;X;+V_LVS*6]K@^$+.J V95K]G4
MFP7D4Y2GA7Z,&$68"&0V]OC!$E-L$R<+ &0\2F9ME4/[P?271B*,?89<.N4:
M/X_[HM :H" *%M U9(&=&X]>XLE+D<B-)2HQ:?F<3!6B\ RWN )VI(0/=OL'
M XG;_4>B.2Y:6@M\VQ2\M/$(A%VP*N()O1$(.75J)0QA9QT;'.QPLSR/F+3+
MW6[+GR\R1 MST#G!HBR[!!VIF)2B6O4LV'#4NZB1:W"U>L^N6\RW"^U,QRYL
MU87M\'*7$U^=?QZ5?$H^D;MH:OCUVS,>F(+Q^4Y?W5Q/KR-@^W18&39/N9W%
M3_P[T5#/Y% %#=#!&T\ZHO'?TB/!88PX"17YFER+JMU,7](@1=(1&4/8_\1_
M_^%%[0<"<A)%V36P8P_=.;8Y]\4']<?'B>7/;?/Y@^40).BACVF= U-"@%E0
M7$5FSM#K^&N96=)O-HQF#]6 P(/_GZ@7R[R3!D#VU_SGO6:CU^L4?M5LM H_
M+UNJU6^T^OU*2Y5_WNL4OV3/FS(6/O$K09ZA#_>+F$/-@-*9/A^:6@OPX]?T
MSX:YGQGSG_C#@GRI#"XP&FR:6 ?+>A@VV5&(]LE7D@#:97J>540[P61ED+P$
MA/'/)+$1<<YID+,UT1 6'X\*N,D@214@OG:@=+: 67F7^W@LQ'2Z"#B8LK<;
MT"R7G 2;[R7"L!1>QO+SEZ)-%G.:6@&(*(/QH&!4I==QRTBE%)SF%/!SU1*W
M6$&[9"5C-7.N'6MMF!VF=XVR/L?9Z]S8%>*W=)6K7F$YLUE&3H7,JD;')>C8
MW0LZ8O<]O==Z$^A864S(R.PQB8G?2\VBM01% 01>)?'U]D)\&#K2.ZU\+6Q%
MXBO&TZW15^9UE=G]6T&J_EZ0BM).NP5U><>)5&]!M[^C_$5V4);[QM:4Q=+1
MU(:[F[@ANJW4@5ZF;QT<%/^Q1P"](K:U%Z:%(]CU8?O%3&OC-[LGLZFF[9JV
M-T_;^U%(^B=GW<(,]K=(VZ3._$J1H&2]=VKB3EW_O?GZ[V%Y_??J,Z@&W6@&
M55TTOE[1^!',[AI4G=UU:7J8*^*KF9GY6'VOF1^/U6OFIW)]$X'VQ?5]#9;B
M;AAKS>.BI==.9L@>!P2!-3YW)A<6,HQ)23I"[QC3$>Y2*3HRJ"\"RIB7'3[0
M$@N#5">W7"L4!!#'91A$F@/W:.,]8BHZV74?CB?;8-AK  95S3;H-QN=[G S
M@7VC,6A52UPH_[S3JO;$PDWUZAR!-7,$ZN!_]>#_\M.^&7!UUD&FJH8M<>9=
MYWL76W4DM+&E8D9N;!-;-H9453-^UKBG0F6YMP\]@J]+R7LS"#QK%++ QK3K
M5(*V:GUVRBI#\=46 .>X?31'Y$QY]R)/J0_[A[^RFC4@QQ7-?T;-/JH'N',3
M'4@D8I"F7=6_TL.,DKX^Z.5C^.]7N)'-.4$6^#%K9#YT9,ZY!O>$S.V3LW97
M;PWR0PJVA<P[%E([<6P4(\3G>&Z]FALSQ48RI].0-'<Y65ZS+7-DV59@B:P+
MISQUY+4'\XL]YU38CV#]7X3J)P+J]?3&$Y\)HO]F@'Z)X5F9'CKH/.^U\]WT
M%SK/=\?@WQXJE 117H@*4^NGF)S^1WAN$19T3\[(VV1\W"T>U I\F0(O/7T+
M5?C5S._CUH=6/.-AD_^>U7[I6*\L&W!P;UOO#%?7E59V"&W?)*B)XS42Q^;-
MB'6)HU_9D-@><4@QFHGAMSB(NREG7"838GM>OZ4O>OWNV0OAN#3?J8J#=K,7
M\G:=K?^F?X"V;,*>S7NQH/%GR.W9"^*QBWVPK]RJ*>F)LK#-I(+Z.0,]W>4D
MT3"W@MLG;G+2&YR<#89Z:VCH1M>H;=T#PHK^'K%B>'+6Z^B&8>BM_N!56[Y[
M] J>3R8?M!Q/S;L%WZ8O<!U62?W L3;;M*4^RZV@$JX%T'1-VY:C+\X=Y1Y:
MT3\8DTB_>7(VQ(:[>KM?\\U#0I'%?'-C*%+@-TQ@1ZOV&QZ'+KK0G5A45+F^
M]^3H*6LM/56Z$7**266&:P##'>B]3DOO&16C,H?@?:MQZ>7:[<9PJ;V^?EL[
MJ]ZNLVJU2-:*KHXZ0^= 7>NJ_&*A^#-*/>R%51Q%3*AS<H;M!>ODL1HU7XJ:
MV<$0+T7-+J)F-U\4?GRI8 <D"RID+A37V'Y<0;P>/ZUN!@2OD,C7E#]1'#=/
MYCV20*NG+V_D:G:9Y%#344U'FQ*6"^BH7U%<[HV.5FB"<!RUPVIH!1<)"U4*
M7.#B&SWS9$NL,XZ^A@^QGOBIW(FH!H#&3@;NQ9][<7GE\0M?'94U8V?U>, 8
M+XU3T1\!#7'F 2SGI.:93GC$!XV1I3D$C1>U7-_''5_1I#3!(ZKD.-,%(*O@
M\E4CV7B^!(]9T$2Z@)8F:>HTE.[\XM;G^;Q(A.%<C<OY*;RQQ>,5\-\W<=1.
MA0MT;(%?\ATM+=>@A4WLK0^8 3"D'7*6BTV36JV)\.2D5FHNZ?.D65Q"?8TS
M-1((H,XX#[VYG $!W& <8K,2Q(]2E%7C^)[P?QRW<.LEF+8,GIT4_40E_!%B
MV\\QMOMB# MCKK8NQX;RY#P<D*Q&B*1O7(^_@7\%P,F":/($R@3X07;B!<)2
M15BU=W*(QH/IE-W9>UU[ ,S31D)@9SB)G]%8PTR[@@5L0:*%F$YQ<N^3&]H3
MG(\;N+!UG!\C!S#E[V8C$S/. =H*T+<1G"_E>3[#<3[%)\GWI,CWG^@/CK3_
MA&+ET5VFY\;$+#>':W,<D$%(Q$T#<:[)S VSU %$35.ZY;0]( I]+7Q9*3,^
MQ=>T!7R-$!\)$I!N; *GC,=2X@(SB9&$ZP\FT@G\7V"=1M3)B'M,?34ZC=ZP
M<E^-7JLQ'&QHBD>O,6@M'G.Q^N>#X8:F>/26-ONH^VK4?37JOAK[[ZNQJ5Z[
M +<]&>I_+M;.MC)+XPU$T5OMQ2/J7ZCLG9-24SFZCD,!]6:SK3<[6Q]OL/>^
MDC6V5L#6Q1E$>\'601-S0?IZKYLO6#HT7-W1'(W]B8G;Y&S*>F[&8F(R#I"8
M6I@5W1QB<6S%K.B#G8-08UX.\]H'B'G&R=D JT[U;K-W()CWZK7Z?V<+5!:8
M?FL<]A502N< *:5]<M8!)MUOZ_U6OC?\)NYR7>7X+?#.[@%B1 <,-IR'-="'
MQHO%=C%=[US77>9)*GM^+1?3\>/E 6)E]^2L.]1;_:9N%.16;'"&;XT*JU=F
M[ <5L.%."]"@HS<'2U#A+591O&"LR8KQV;/_'GF_GKTTBV3)*O6(E;5BV5A"
MD$HI7FO$RK!5CUAY_2-6AE5'K&"1M!5@P3260G\B-G(OG#$P_0O+']NN'Q8E
MA0SZ^;DK@WY^[DIB><I+2+U@K1$L])8%=V&D[Z*SS:N@%8N:&Q5?SA=Q;]K:
MC>>"!HTDX1];UMYG2F[!'+; I?_JR;$MVLQ\QD0G4YN;7O",O\&&G/<R!P:8
M3CCZ"U.BX(NQ;5HS'S-3+#P4K0<K1:DO8S?T.+%M%/JP#]]/IV<^F;[FN$'R
M7;P#8&*8TI-X,>=93NCGE/02_6@<(>,SQBV%]PB@$CX*6\M_P.0OV#0NF^C;
MB]E=L"O*&6##*<J[@1]?B+' G,74-YW&LGL^?-2] MR;.=84=%X$ZK$A[A5G
M_3FHE=H%R)7&8Y+^B)R(J+ VZJ',OLQ[3XB9S,HU _K6M #'M$?3LP0@(BSJ
M"9D_9G)"8B(1T9)YOW//?03$)P2[EX/%K32(B],IQ<\Y<62-9!?N&@Z2V)7E
MPS<_'/?)B;._ ECZT;41N279T=XEM<[,":X I_"#%!1D5NXT#$)*''6U"1!.
M&E(/D@SGIC4A2I$O@&-1&J6'><R8O0J0G(BI</A7TE AU8^_M'#O:0!H+I A
MTS 0_Q_NDP"C*\]P/)3G$^R[[=T+/[UK)%8323NT YG)2^EPY>\Y0L0VQP@
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M]>W\VZ>K\R_:I^MO%U=W\C?,";Y?WO[YY>Z6_W']6?[WYO+[.?[N-J]"KXJ
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M1N41L<,Q1SL]$3G^U"TDG561+\/U[@&K_T,P1:0.3* *Z4.1055=&Z'UA'>
MR2T(?W1(<HA@;,[1E<MQ3@R-H<]3+0 T!0@D.'D%8W8"DYS1XIFZMN62+31Q
M.<2)Q\602])H FMJ0LE$/@>;'E4(#A'?)-OHD2.D]S32DED^^N$>A1.RK44_
MF7(NL&3U*I^)&0;2@D1;0#0Q\>/H [U'0MK%)!!B+YC8"Y [O[A-R2),4<7?
MH;\/_NUC:#!*<<9OS. 4%CV%5_X0 46>SN^^ZM$#"H/US$;0QP1H&:="TV;_
M$-XXM 7=(.U5?:!]P5^?JU_+P%9F13@YAK'9I3+CT$V4/!LM>7-U<TDP).8\
MIPQUE#W:K8DOBMY!=X(GA/,4'(>SP:['@8OQAX&N(B'DQKW0;L488ZB(H>_^
MO#U_KWWY\HGC?A>@W3P)V \I/C($^"2W0\P<;7+?#QD9@-?:\NZL&2<BX7_#
M.?[YCU87+)=T4K&\6;Y(<NIY9"!B#! QV!&96]>CX'>\-]./4 6P])Z\?MGD
M]BR\2B 2'*2Z(4_\68R\$"%A]/78\0;VZT3KZIUA2Q^T>P1*>5M[&L='6R[#
MQ8.$KRXU+<E#_M'M- :YY'<'=!Q%Q(V]PO;:*4$%,CXICX9X!&8(9/$^0\<S
M4-HKD:]62+D@'/^2[K14)4D!Y37D!ZGGK:E&4NX)%I>"!*7L"#<X(7\0LVSD
MFF/,R+SCR%DLIE$"$26@\$G0 "DUV2T<D8)"F2('%UTU)!J2A[W=U*,(T9[(
M@J&40O^% IGQ/RKZ(5/G'KXFM_+,_&G-0C =7,^CA&1"5DD$.1&6U#],PGQ6
M%N"1?[3S/Y:4AV$GJ1!EH$BI N?A/9@V6JL70S9+W F9#;)N3"9SXH1)S2>B
M=E)@R(U.E$YV#1$_L+<E&HGVSGJ/^VGV>WJ_VV02PP7>6? %JBF:FFZ$Z\_5
MEAALF0=UI&@S_A%1-06N4<7\25G;0/[_Z#?Z [0\\2&V(<=2(2;/0^*EJ7>B
MU@!/-+1+5"A2/WM JQE]&X 95O+-_Q@VANW4NX!OR)^1GL/F,$<OGH7I*8LX
M#I1:2;;<-#HRN)D"#?+;D8C>3]=O@I+M/]BHW(.UBID'Q#C1_/*!KZ&1+!,#
M $%C.S%*$9<?LY@E18C48V: ]K/Z-+613"$;(VE<S9;>-"E[\981$FVX2T-O
M\GUFQ6>[WVAK"<F9@+82GZC1(J^7^4@23<RX;@#MF30RM RCT4DN"\P/[2&E
M5UO3_#')B)V&*$NB_3>TBS "%=_G#'C+@X]."#A>MK(/;H#6?"H&Q]$)DRM@
M.*:CL)05!^("[*LC(8K$;G3T9JNC]XU!3.PI^GLJI_?,LWK,*3 V:XD028Z_
M0:.9:RUD;,_UX-,;3YQ*!KF(K;3T9@=?TRS9(@5_D:!77T0FX\1J*S((Y-?_
MZ#0,9&"E_"C[,CXU/M;K#.FQ_*F6KR*Y2 $\I+U>Q,PH0M1*;S5&6N)GUFPF
M)A;15ODKQ,^YY5&@U4DP $SS!9KBQ_(@7K"O;J,_[#47[BLN S(U'ZM IA;F
M"Z"7"H@!\<,196\FEB+WG$S107Z-93SHYD&J3STT$E3.FMA#NIH763:P//EH
M="BIW>8W\6Z$N5KD_$6^3K4YBK^KITD 9@HP6OV/ODS:?$_95D\/KDVE/=)-
MK&-4>B)LZS'*,'<#"5G:X"3>G52 N/C9UV-5AY(S*(1K<PH&7XY*S\KNA\@*
MV.TWTY^8?^/(#."U,I].32(MO^<H'9)N 7V4JM [P+1X3+*BXA(0I)[:,JKU
M^$966BC!O_24E!M \#A"/JP<8Z ^8NXNYDW@'Y8<?@XO\B._)/XQ#S+:IB.;
MT[$Q]8]6OS&,Q"-QGG:W842?I.]B@<2C9SF0@QD3K'H@DTA4]9'/!=,_BY0'
M,LDF),S'XY"J 9""Q=0:6P&C1]=H]-3.N+PN42,HS\0Z!:;H DPP3A%5T8U=
MGXL3&6Y<$^F(1$FD)^>T<?U$HD("E=E'UIKQ*VEJ,B-*N.$IT0=?8OJ^.[;H
M +1PVGU),*':Q3 (/;9&T>%*<:"H]T3"+URZ,3WE+@X$59CH>5\QJ'H(3]?C
MS"S;PC8WNK*.96&-[(4S0RHQ;>L_K"\FCHY, "7O/>?/<$C!X6@0'G4!6%2?
M'EWI;Q2A(N&ML'<:>IRSG\C2E'=*2C3\2Y@R"=,!6N1("[Q.L>D8Q@E:P)+"
MV%M,>/#"TA?:#<4]\9Q/<4[0@WCFTR5O,$HIHIA,=*%%>9"<VQBY9"OM*?*W
M9^G-#AY(7\<5'=<YC59)X U8"JZG)# %<8&HYG,,&Q40"8<%T65_3]E1,@Z1
MJ-T)7/<'FX,J$C1U\7*UO[DP5.9$ :? 70&O<)0;'G][>+D[J5R#=J_.YGGK
MV3S)#K/%#1Q:E)"20"207-VBIB#[ROGIU#D_1Y/SLR=-D[43]O4K*69-28H]
MN"Y;"R#[.,T!W3"Q#R:1],.6"%:LR>*3I/A%6:?J+(*2 ')#^\R:P8P2)5B[
MY>85E"R4B"I<W5S'KGVEZ.F)]@U9_8I^HZ=4CA(%+E(L*,.&*H3&<9@]UJY3
MVHNXQZ0(M--#AS4SY:O@+AI1CT(WU<RP<9!^>^T\SBTB*).N0V74B22')!:@
M6R AV+'@ FUK]'6C+SF<<W.(T%-W0K';.,HOJW31TXP_@M,_8?TUZQY@6?P)
M#]FP#AI\UBQ2L0!F*JD@=1TRMX"50%]%DXJ1CF)+J%_J20W/W5?\CNF1FJ"(
M;"Z$"FQ3 S70"J-T(/%WR-ED,JU!!](;!:J7"GUP[\(1'=:$/8F%P8/E34XY
M9T#>H+(45*[)!!5[;!I"!@*:\_>))C&\#*D\(\D,,=87J8Q8IVU2/PK\-= 1
M(#VMG%CH]:3+GQ.6[3/N6V!M'QJ#D>%TZ0(@_Q=9H_@'HO$C4*L3[!V2_S!Z
MH) >)/!BMTA1?X"H^40Y:(F;C["!+B976DHZA^3[1CZ0Y#NP4M1YEU?C7#+Z
M$/@_Z@T>KNXIOA!;[W$/"LI)PZS29&45ML(Z=<,@3O%5-5*4,YKH)\!<.6J'
M5%AULU=T4:XZ[E)"*06JN10%\'P_G,T3#:50TZ)<.00Y7,63YR+OE6X&;N,@
M?CZ8&..EM+0H-5;!/TXJ]%W743TM(PG6T&Z%4(U\R%EK?/QBP35-5%.,3W*A
M[VHA^:O/4I1_3URJ:O]#K: .V(]:W$;GJSGV7,08=P8RZ5/<3(7 0(5*5-#W
M/7:=?8&OJ 7LX9ZU%!&36J],UHZ:/\Q2H& 'ISMW;2M@]Q!U*$LHN8"2L(1,
M\(<OIG:(B:(RD#N5;5RD7<!C5SVI5#EQ#Q9)M2/3X=9ES^2KRW:9P_SG,740
M^[-QV^#-V>X(M\4;%LD-R%YWT^RH;OGZE)X?7S&MC.<=4\JSEW27"N?1 C)4
M*A)H/EXX#Y1G')Y,ZE"81#BF'=$1L'T9ZF$*LC[0R<1]<O@58UG/)N& FRC=
M87P??@Q71WD& U2@,O45428LIP&H_-&HH@*V(.V[P 2<FD8FGMP\W*\KH[51
M!]\_?WB8-D\[^(Z=]DSI,X8[M\9!5,E'M4[:I8GM#\AUBYUR58,6=:,JHL1M
MZ*0!Q+WPN"V=HD?DBL1&74[352G-!\QQ\OI["Z@PP50(V9X9#Q3'!DR)40D-
MJ0B9$H0'.C?EK-G6S.)6$'J$)S)"]_GB7-<N+N%_;B\_T041?M^8E.:/_[[#
M_DFHT6O7U#A9UZ1P4<26@')Y4TF.IMYY(,-2WGYJOTBK48Z02SV?9J%-25*)
MGLT>AQ@EK3'^)HGP'L22R;8^IOU, #0^9G28A-"HF"">4.]FK)[  E" A W:
MS#W9D1Z9\G::A#F.C_LJ:8*E>"+LF1WU$9W(3^#<Y[:D/@QPZ9Q1D[@[1EDS
M '8VIS>"24R]B^BZ3>F%2%_:5$PHEF'CCMCEH'[! 4X+:.3)27*FJ6?.Q)/K
M_? Y#VN&RI0GNV?Y"F JA3T3?8HC!/CV1.$1_A.0AYTC%,;+]B'QK4!J?7S!
M<5,3Y0> .V.KCG=/8"U:@[:-ECLW;<+=*_:?V!$V$J)Z:VQZ)TLA,)$*&0N7
M%G#+-'D]E*NE"E!0XZ09$&8D;^1MCH1$)-D'*<%K8WX^"B?W@E=0O@RZ(+\0
M;(D'J7NI)R3Q4);*#_&,"0P^1E-L5NK\!VO*-1_,#BB@;7'OT"MRM,DD P<S
M# G;)(GRIN514EQC=;+*->(N)F9=)I4Q38^(UF1[T@C'6,8@@PZE"R#!0;:C
M@1LKL=R\C%AWNLR.!4;+D,V^%(XA!9B8O)#QKT6Y@3&#3*)(6K4;I[7<0BV/
M* &1,A4S+FH EQ7I)!\23Y$ >XX+DX#Q2Y\>H[NB.3?-UH28H#7-K(#;Y!(&
MNE-=.9^D"N9S\M]$>W01U9-:)<@%V#%3;M0[F)U8?E+C8N/*]>S)DS41#>TS
M6%2D%"EP*\L*:Y<PT4)(547Q Y./1*E.#B>Y,*5P.E-$N@E%=E'[YL1U)SR?
MD3!63C3!TM=C;^<(DUW(G*3Q-7!)#^X3.R\C#X"2:[$!C]9W9/5'79A<3\G;
MG!LW^FUD=F+ EW+V,8-@'JC"GI!KF[B=2X&:MFI_[^$*_;WW9#U^4HV"".F1
M4+_'.M)U)&OWWTJVM&=;\;F^LX_\B%1K;C575-=16%G(+(0K%V.W?A0O2/XR
M5TQ84N HV8F#2@F+9!+?2'5)!5-E6:R5WX'ICGY(>3JJBCG.H4GR7-*(N,F>
M7%!7!3O1(=4!4QK1RN;4P>!JW+A93LU=F=Q2:(L)'0<S%.![,M'K(H$]QT:1
MWU=)I4/Y!9^AX2/MA$C2S=R)L,%JC<VP<NJS:7P/5903_XV,C>1[X_(P8A /
ML%>1)E"._)+'E+O=8PV"G&"P>'$]D6(V":,T6N52 4T?(!<U95;Q.=JV+(3/
M9.Q) F<7F#)%X4Y";.7/90A1L#@7EZT3J.H$JCJ!:ML)5-TZ@:I.H%HL Z/$
M8&F#E::71['49>G#/H9)*8>)^R3)DHP"<;>6EBDSFV7C"3&G,KAT/&0*]BF6
MMBKA).5V[ M(!!:*T[F.39.A=D6QZIW290HSYM?)*;=\TDA ?XAF",7]I!,J
MA8,C);%!3\G0H5SBVM+MIEKZ)^<IK=[8=K%X/]UCL8SL5;F_K*TT;%H=YJX)
M=.+66JJ_DQI''*<U%BF&!2V"DK>8K"W(/LXU!JN/.ZJOMO+5RO29\7-^5%N<
M'9?I_I3@Y@X%AFD\RJJ=H*I<O1[YYW.>Y<C5Z6A3\]'EZ3&R)X?RYM68LS7,
MX9KVC.==^7,XV(EQ+XK=3&6(7/8,4]/K,)DJ>^VQ/,Y\4U_E#JXR&AX1]\O+
MAT-E^I=*B.8*2.5/1T%_.A*.F%I!U+=O68=([I[YO%@34_X_+CU$1X,<M#5W
MYRIV6"/)=I%DKN+3= F<WIT.HM&W4?)UQ XXG6<^MP&->,I7_$@8/,@X<GU]
M6[N^5,M$BN8#/>/?X3QN-I?,I8_==Q2@3WOS0/:R/+8R7D9D"O9S9,X5J8.Q
M2I]>5/7'*FW,B D*LCECC2C;0Q0G\)ZY0BI=$\&)U9XLNGCQ2+Y(L5O(].N+
MWMI%NR.TPA4[()8N_SV/<^\"FEWHB[''?0$#65J=R3K]"1J]CW&2Y]00M97D
M>GW%.S#<L0VS&3IC8O\)#NPGNQ16)M^E=\L\O6;:V[YHJ8!+?2R90,/)@ NN
M2#;!T:3.+IUT?N;NJ"N/&HS&Z80SFH!+@]YFH:,J,I(JQ-Q\=CV?QC'75[^M
MJT\R;C-RQD^2-EFFB_K6A'6RJY74_(_.?7ZNIOY(:],- \II=5DWY;0:7VB/
M)FBT(^J+3=4E6.,DZTM4;YYYHE?L2Y4E3,)/^-=2?K5T4@ F\]$( +.@.B/*
M-^2J\3AE,>N'W\">&SC''E0#$[V%NFI<2.G^^,=EB&W:89]JN":VKD4_)"7C
M77Z5/XN_Q=W^01-QQV8BOSU9\918X.L?W\\YK<]1+LR<Q?G,30XI6YOJQ&3Y
MH.IZ4^";DC7'W+D(>"9-%>'T"W**8.$;<UYJQH@H0+O@1@3Q8(MDPF+RFB;"
MQEYAF,J1\;1'_MD2SYD>%]V-HFI&V:%I-K."]#C)1+IDY.Z-G;P2,82:GE#B
MX\\@B"J1R7.&];C 064Z_9YH%G6>;A9U;"P.I[A';;"BS@BY/A-IA$DTA3!#
M0!Y=M8O(.'_B?EW,9'1-3O?0J,Y!MI/@5@G4E"+N+!&7Z&:8T4BP<$NWL8C:
MDOE S &-QDQV/Z )I^@E5$4,R?5SI01%?:%@+8KI4W^HA9VA&MH?*H,YT3PB
MWE("W%* 1N5K\0BZ:)_Y#AO9'?-D>@QXFU%M7T*ICXMG=(W$D)SF 2\+9"1<
MU>FH<0(IMYU\P\M(^7#R+@F45PZ*<1U>$QP_,_I-^M?)JUJ:@WEG_M0^46%!
MG6)7I]C5*7;;3K'KU2EV1Y-B=RBZ6)J3_Q?82A\OM  8MZP(DQ//HC$C!3^1
MS>6COB)__BO1=,1#X$VD(H6#HP(><LC"T!&!S,>6.A4K/F!?>138"3'7C\KU
MJ2W_TA1Y/9GT-TH>C4:DS$PYC@&-NG!&:>83[1)I=NY1OVC08VZ_7F)C=.XQ
M2MXK?%[U<H_:[W+NR1.8NMX]=16^AVMI:/\3 B>8/D<9Y]S<Q==LN'XL-L1S
MXJNV[,6IJ*+LM>V+ (7=?4Z4%' *I;QL*H?4"0_#F7)XT(@U4+JE00@*@WBD
M5O"@>(*I*0?)G5*I-581QNZ&N D^U:2#K@IRX$'0U'1_@WVT=D:_:LC@V+.H
MRCB>3<<5K7\ $7XU_X)/XW;CWQ.U79]",(AF7('XQ]?OGPBZ,6A32,QV$)(T
M&&;_88I7YE.4V6K-A1H]6M*#.5/<#C PN8U9SH&;#OJ6E,7PH B0OY8:($+$
M_O52$N4:/;F3L\NI7QX@&+<JX$Y#J;<IEHB-%AW46^.A2 4L0G%)&F["F[@
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MFL"YJ6GVV<RN2G)5952M-D%!<JI%U(KR]^9U@8U02TSYPE]99Y7>]Y=4%9+
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MEU)JRT8=F$@_2,J&;5[L959Z"'A0XUG#:,K$:J+-<VMBK6*CW$+7Q=/%1_E
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ML8]T6M46U$X6YI"9PE Q?/P;*^]J@E1B:",C8Y3N5UDQ=1GN9;^56]W*UCA
M4W]0%$*%(.@&LB0=SLLHX6.D5&Q\@E(\A6TM1:Q"=$[[;=WJMJKMHXO>;HBE
M4XF,\8$^8%47S.E$(&$7@QCGR$5V4,_[[=KJ=KD6PD0<&X/*C%Q"TH9(F;$<
M"[&+?#YGVTML6CY4_29M<Y,FT10S.TFI2Q944RW+F\>4;-.I;D72L)!U)"9.
MR,+A_L6:"H52Q91]"2+D@\H":3$=W& G#+;7;98032)L?D0!(#7#9B.GX50<
M%!6.M[J >H</<RZ-I)\D2]YK@*W?P[ 7V,RIS9CN5W^[J]\@=S4G&<O?BH@8
M%;H 4 SD4X?6(T=MHP6W?&C"L5 L$8IW95?:DC**0+Q;P\P+9G*T35-M=MB?
M0\FO): NM 4:'[ &0? CXIUN^-<_]1?/-J73VMJCA2FTP!I):7H8IS>(6\!X
MS6UJ^90)&8@D@BB(!E?HB<'J[:5B6)@(^N_JU[IQ*?'J873O+C$0B%X.GLBH
MM^$9HTP4/R%[8M8]<ZS61@PX^&S896Q:T:<VIM+2;"FPERH8!3PS2XK^:MKJ
MINOK1$ARD' CG3$9ZAA-.([K/0 (OQYTID4,7*LDGL8?M6DP1K7*XX0L2XHJ
M"KO4#2+T>EG9[D7!N''JCC6%K12#!I3%*"E@;S1I$Z-M-7FKPGIQTL1V( F9
M1M9V"66:J4A%$1AAUC84I4-<JL7+FZ Q-4Q04I 8I10^V4Q%IP7#B4F87GBV
M[MZ2;^NC&7P.+D<>@>4NV.Z!D(N^J9GS5MH,G&TF\;J&OR7PMK]E4O7L-T07
M#@ ?=VN8;S7(TJ]D<=0'3'E@^'[$SB&A1T+W4:)*D CK!^80NKL,2),ZZ_9)
MXE*,P=Q.[O+B"]?98Q$9OGPOEEL52Z9D(;(7M&,XD(Q84PI[X XQO'/L@>(:
M]]6*/>JA+;L#;3GNH2T]M*77EU^E+ZGT0_D,-G]O7$:RR<"3%"^>$D(+4SO<
MWES84.W#/9DZ3GSL!Y /I^)I"']KBX,8.J1]?U<^45[>:VC09%B7'A-3M*@V
MO"W[77I4]$0+<BIFOBB?0&T$#E!"\'7ZXUB.L:&UC< ZEM(M07%)!:ZI>VS&
MMW5^7E+Z'=,A=(]+?,&GN.<%D22[()-M++5FB*D/%&XW9I2XPG$T2]36KQ<
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M['3 !?05>=B/6!VY$)W !%,CKA73N$4Q4 AUQPTU(NIY7.OU7KF8=($8J$!
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MW,>F0@Z--E=0;U[+'KD3)"4/U" .3UK\N=WSB]FVN*EW9K2>&61GU.,("B#
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MSRD17P\Z=001\.[-B\QT.H&CBC8(%Z<L^"F4%;FH1/T_WB0N9:]7JZ+9<%N
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M!0GVMMN@H;/?#WR=4^NE?[26BZ(IK1IOT-+EJ]+MZ(^+]Q2=0Z>8^WK]![F
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M A]9T3"JA:@*%XLPOVFA'/?.QA=)0OYWF_3">(OW0A]"$!&!O4S.'[>,UPR
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M4+BB;"P"VH0&5(\7V>7\+TLD:3U0$S@35X=S[T-KG(SW^!P-5+0:\)M)4:[
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M(CL@VV[NW[T(= 8]35 +2 JY&^U=@SB%'DD7Z,7\RX46OB EB\[Q?$X+NQZ
M>XY,UWTF/@8SH\N"C[[ELN&(-I9I<&U-5R*7%2D/?!3OT+LZ MX[#K"P#TZ&
MRS^9=^ZC_J;DI@QL8Q1MQ!]#[67P! !24=]E;V R6=U"'LRM^K0R.RJUD?1Z
M6;?H]A4(@WXY)&Y"Q<;4W!!FH)_>I.3&$G]23!MY*7&]$AF8.&"&S-0?1SO)
M:> [_4)=+[E)@VRIV6UQ;KP>9YPE)DQ'@N\(1\(K\QKOW.*ZHCYE;FQ]Z>>A
MWA0+*97HH_$7)7OX[N7SOX&$?==3XKJ%$#1SGD;?7D5M.70>B3"]T5JK-,+,
MT01[M[18D/Y,U08C)A.BA*MF6*1Q>C@TN$&K<?;HJ/#;Z'AK1,>^)OGL4G>5
M1<82!T@7/[HCPXN&6H6 "IQ6EJ7JTJ?Y[H-O<<H]>0L;G8KH5!LQW'!IWLO<
MN3LV,1'.A<-+"8R@%+3H);2?A>P*%5LW9"FEYHOTI9+G:&8$%B<DH*03&/XY
M38$/!JM=NK2U $GQ(.&'Z: A15"W%0YD <61*(] DXIFT6U$*MF@!^^=V=+C
M;SRUE331B3WR^T-6BSNI'A#"+%Z5.2_61TKW+LD0R@?0R%9.*)T+D>>(Y::Z
M,1+#6-\7FNM/EY-_\[]W/H9[^OC)GT74:"?\>,^)/ZYNJB(/:XS^;G[]7(^6
MGV1[:2'D^?.?GNG67^0;QU25$1J><F(^9B?&X9/B9V$ZQ;B:.S[SP]E4;C_[
MJVA"T\6Z,ER)@W*ZO>ZU-J&'L. +>/"B*RLO0CR.LGE %>B7@>CL4 J"%M'G
M?-AI4J!?&^6+!7F2\#"AL4477JP7X/AA4(N:D6@7M?5?GL[[1-U.JA-XE]ZY
MS?;M.F]8VU3R\=(.$.^CO'AV9%576#.1/F[B8N'N$=W3&CG-QN$863FF+3AX
M\O>(E7@\UFA &+T]YT"H9X#GASE.%?JX],?8SLD0C-TSHT>>]1YY[(,Z3FK;
MF1%DZ2CQB_:,^$D>]NOZ]LA]41-K16^\MP*Q*A @1!N7Y,':A*$E#P%#H_4O
MR:/1EXROJ%T05%+B>(#[2GIZ#=:[C"'(_\_>NW4W;ES;PG^%+^<,>PRH8[>=
MV\Y3I^TD?;(=]W"WM\?XWB 2E) F 08@)#.__JLUUZ56%0"*:ENVF,T7NR61
MN-1EU;K,-2<1;]8;)_,;D=&)I-.Z-=?1\K?)BZO!=*8?QI&/BM0'2[S@TM_S
MOB/3VK@UXN@:=1ZS%%RBMEK]6%'2BXE7Z2)WPX9L1&Q52KZJ>J=:87*@(9^_
M<\ >FW6,IW.*)X?E//'RR=E0^@UZ33RY>]<_5.2V60^![WC?VEGP]CLZ"\)D
M[XB<& OT'\$*HO#)-OMK(\/URGOI(:%R-N%JXM0D[#9MB*"M]-,X\^J$77+F
M1YI")+%3NK!MNR+>5%V'/OBX/HAYXHROF&5)'ZO!RCVZZ!PVHOHR;2O?Z^NQ
MM!G9 2(^XBBN#'Y;&%NJ$5<K2=4K.2>2WT3[9AEG.43C7M(T-%V?[\2'L;'8
MC#Z%$,DB\C LWIW35BDYUB0!+P-'VRP[G 2YN12(1ZP48Q>UE/Q0T7++X^<%
M!4V0<RZ?K1Q3\;A4$*CRU/2A4=]R"N&K'&J@8.@VN\OK,'N.LY&7[/499*^_
MN&2O+]GK9WF>FBNH%6F(IA+T(3QP(\F#D@#G,'U@KLM"=3;_ENASQU?M4Y!*
M_DZWF3& 4<W3Y9[3]'*L;;Y6CPMI/9?+E(2"9AOTP=SYRPXUI:RL 5CR$6UG
M<'7&_I%OYU])KRK.F0\CS9F.T1!.07 #IA&=/P3Z(^D?[S*L8P[D-GQJ@P/^
M6/2@$LKV.,[Q)W\\/.\6?=X>Y,6-8-3N -W>\.BC?.T5TR-,3+A &ZV9+*%O
MK]<:I!?"\Y:X1S@>JQ_!Y$W01UM!/GHMQJ(4;O6@EDZHT,*._6GZ<Q!:]V$Y
M+?F<=L7HB"@2QQ[)G^K&3O\)@@$" %,W8UBI(;Y:#\[_-L5482^, #YW3W,>
MZ&A7JDR0TX]P:]X;^>C4SA>_'BW!JWW2<8F55(@@6%?="AY;_YPD0\)X;]C#
M?A46,WEY$_X\L_N^_!(+',S(MAA!L$A 0_CX!?O5:^$T$#!HOA.3DHJ?LDWX
M:[\L=Y40]\\N>;L;TSU3!MO$L<1Y5CLZ?V-O!SC;SE=3Z%X:]XE3J]JBTEPD
M:1D8XS.,^UYG&#+4UX0_8=2#_HCR:AH?$.B4@C,&BS1<,O.CK^UC+6N4.8.4
ML^?++!1Y*:&2*@^ZL!<]X0L)31H-3DX2M:M4@TZM?0*L>;&8*3?/=_F,K-+Q
M(O+BD^SH!KKV,4C03V<+S+\!;.]GKC$OO@G3UT+V).\>X 00Y6+"0+6'JO)T
M!C%KKWE,13LJI]I,^5>J>=/)/I<V8_.BV$IJ(J0,'YD=*#K&HQL3./1\4**1
MX?3E13=)HO;73 BA93J49#BOAU2'O;,F"5)?I8#^(N>7_/*:VF-8U9+X6R4;
M94@3( F.3ALV&#FZ09U$T7/7(DC9*[4,Z9Q<L4<CQ3-%WDV<MN.5Y:CW :=-
M7,KG:18?"3Y)6R-=@B,L,=[GG&HR1^INQOGT!H._J&E+E+M<L@1#3P+8880Z
MJ'9+VGTVZ_X\1_I!%$A:DI]M0DU2R"Q7>6\ !HP6;=KTT/;E8+ZPS^IQB<7:
MEJJF:S?1FBU&2(+(G/1W);FPI]4R_^)5V*B+3[[^^M6GXL2(:6<[]?7W5L'Z
MBA[0*3-\9^^'#4^?_.KM=T;I1#>E4_6NW(BSC4[2<BL)V?!G^OSBDT1]H0O;
MN!-B-3&5]*E/)YCA&RULC6Q0&GMRAC&.A/235R0RM0COO?B&4[SO..!S_<7R
MA?S%R<&D,F2\YJ<:_!U#JD@[80I9T3U21 2^VU)^X^ MW<-))E]?GKX2R;K(
MX(8-@])2NB0^#=?XU+4&^],N':,P-'8X?U*'+Y%^5BUZK./[("2*W6Q2Q@CF
M)1CRNK]EP:GD!@00R,?_+*L1[V65DG&EIKTKPK(+FB5VJW%"HH\@K+F^U:0L
MP$T1/+_I8O"6 =<&3(N[TG( M5>>$O?#K3$'290TBE4 ^$9\-=X2.#F;OLI;
M'N$YPU/"#<9FK4)C"#M)O%+5D\U@&O%NOB*>EIK]?>-B]IL!WW=EM^P=^G)=
MD>S5BINKK"RAS;S8[=K\SD>AD-VL&<EATC;9I,!/8Z=4,?JJVKENNXDII$S
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MXN9%X6#*_FOJ)B:0V$P<B*%6=ZU)(4"H9!G"H_@+\/\'XZ3>7E9&8Z#-(AS
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M'DK&G^G)<6!9VK20HMU&1*+V<:MHWJ..#/!")IK0ZL?WDI=Y5$[LM"3#.56
MOITE&'5>K%M-RE':<GJ)NH:7TM6J@FPJD4':&JMV.;!NRG =7&]N"%A744\E
MICD3X;RP+%O1>4L$<K2^?Q-\,L/R3#^I11N37;ZL8!-"F?PM]B,UQK/,FKX%
M8";8"M]1S(B]9B";M@::I8&)J7T9<,%FM1)2QUU9FP+)4:9$''\3U(<Z5]CV
M,1"%\K:BLS?UND)=+#&3?!2>=E-=?'KS8ZM&:4^Y=SA? .6B&=#A! 'F\5(N
M2=]G>@F[!K8[\3OE?'*VWV. I)<9F08]*\<\ TK0RB6"N3[F'9QW6KR86B?,
M8TV:K+J'?-/<),&(*K])Y+PKI<<X52[EEGJ_;W,*TB/PB1]N&1Q%TAYT&+&/
M$@[,2GJ"14 )75/7("QE@Z#CCNY8,,O1;%!GX4'F85N5W'=5HA26;&ZO&MT-
M&]$"[1C+&0*P(1* L2<2C(1;(O1H\1@KK\-XL9HJBJMX^O2HGX1MZE$JGB"R
M#,P^Q^2(E#5+#W0MAFJX)SD/'TJ^6/PCM6="?"F"B^D!//?DY='GMN2"2S31
M;+?, 8MFSMJ5,$4A3T25KBLF?.1^]C#P9'_=;&+=,HVKIP?>$54T>VA4[F#T
MYC5UQ%_J%6=0K_CB4J^XU"N>0Q,$LL,;.\<-Q/\(1(/RTTPQ\LPV%\0:QH/%
MB]/@=8LMP'\>QHG4*=J%&5['Q[.X(U2E0&YGF=P0@;&C;=).^?N/$M#Z7P^E
M6SMB:.D$<=$(BZK1#/VMW"]OKWXH?R2-ZU>:E!6909DQ]<Y,Y5#HW5B,(#9;
M=EN/QK*%IIFEAQ9<$AU++<EI%5 $31PRSW-^'@*-J.<+X#R1W?A(B%V-3L(;
M\FSK;:44@'MR^ E75KMN%%<PC/ST+S];'*I2@=,$5 X_;6K*J\*WT3B ^A@B
MTOG%XG\D6L%\]M:"1#M:97P)IKJWX,@_0I3(<.LK>$,EH;169#AZ%0 >\[$\
MPAA1PY"C'481@9!&-&Q*,$2I_67E_5T\+3$ 8?RD^T)IB7:5Q1!"$&',<I%)
MSA''_94$P=EKAWJQ-8"8]+AJJ3LZYO#L0CA!X]15-\.FE**GDDZ0@N:QE]?1
MT@&F:B$:AF)?F[!.AR>O*9'E[2J;9WY_ [MW!)+O]I"N(&/]B.MI7=@@/ZM,
M313@/H \Z2H9\>6"%%K6[:9N/;8-S?5#KW$<''<79\RT!N0,@.XAIP\;1(#/
MUL0?E^FLE%J*D(EL<&MFJ:>, !:O3)JT;-'*^LM7K^0,KITB/-REQY$:34#6
M$,=GE$U5<)]K">A-]ELF'N>#F1AW!'U%FCMOH3_\VFU%>C(E3Z&O?E>1WCN_
MZ:LE-M_G?_S#ET:,DIYD2S%,NA#\V64"UIS2R;\H:,8^6MGLT<.=AQTW5 4+
M(2:7&\,RG A!"U216L3I":P) P.)=3U)K??'WQ%!=RPIX-NI90E/3U,\MBI*
M2Z>V.27Q(N]H8^5(A:5N+#4D]XI3]%H^0>(C*F]$0Y5HJ62C)'4742SB/,%6
MLKGJ*]B(75<'BMK+,*I[7J"??^D/,QA5M.6LXT#*<BZ8?8&6J%Q-5R-N+7:(
M&1I8T]W1,>@[VS21 A05A%GP";/#ZDXU<Y/:7[@H(.<1?R"_\8O%W]K["OV_
MKN&)BINU]'S9:*FB#)7'DPH6.?G"=D=^_$&S&"YQM*K*%5F,?N+37,UBL6[G
M0$1>O0P[#V"SNPHMTGY]2/)4238ZMCC#.ZB:F[W5$=UBT/0W:B6*)9=JY-'^
MY9DMV"4^IW7GQD^0VS%Q+WY,:>"4O64U/DJG68M#3.,[K3*EL\4"-.*-:WWQ
M2D^]TWN3:%5HJ[;:9\1T\XU)?=LVV)C\9BS(/G$( ^BN6C=N MVE;%Z<HZT5
M"BUF_ Q1U>1]?D:'_C^H!/;F6"N!!'2:":\AX;;J8.G#6C3FS+ V:(Y[37I[
MCS:$SF'CES?56?I![V^/ZQMQV"$-1G/I?M?,,Z'I=>P;R$/ L?'K7"V[DY#T
MW5A.U[L3YX*<79^Y.3))[V\]\$+.!7;#@_T9%+_W7Y?\\SGDG[^\Y)\O^>?4
MLB;O_L7O,EM[]2L:6T(NOOS=GWX]<%LZ-I]_R4M <@!9ZSAT,,B&4M-OSRVJ
M+!*J<K $J-H[T4DTE)9;<!<[PE<K%#]&N?AAZB&&%"5/PCDU>1KF4TY8)B*]
MA,_L&U5(TE3XIT>=YI<U]\@UYR=@1.%A_;</JJ]?9NE)9VFF?@;DQHA19ZY/
M&/E24]( =7S"%4-YT4J4%#A68F@ >$K&4CSIED[!3>TQ/9[+1O^/74)@8CI:
MG=6HQ-7->$%=IO^7\BUHD&AW5M"E5F?"51;*3?!\FW*L.$2^Q\"S6GDVG>1#
M/Y6*\%B<>EDD3[I(6$HV5<CUK&U>2^6(W%K4+Z]*(-:2P^$RB4\\B2G;4';8
MPG ;/];&"?C-E2UQ0DRE< IN^#P8K\-<BV^AY.R 15)C)?I 7'LGG CG>5Z6
MR-,>!I-()\I]4_I_5H#9:4]/<+M$7 [66*;7IVP90Z^>9&PC#F:B:Y1\CYLD
MXYW04LA'U#1^@149RTVE KO;\I^ME\Z6FL-E43UU))DPUE<=33 =$6DU$7 X
M!HYP#5+*D!FS3H::DT++T'QHD"_>'-Q*FO(7R#-AET?]D3;VX,C'U/9=%L93
M1QYZMNA.5JHAJNCX6;:D492'_Q-LQV6"GGZ"EK<MH0AHGHQ4U_!XCBS/BCO6
M=TJ:/HN^6G85[US:I%>W[3U7D5+^$;H3]252V1H!2'HC"Q2/L6TFT4,>P.C-
MSU&,\=TM$U(9(V=O_27M,GCA!7,&/(:<\X(=UL']88JU5JE#,@=4FY2!HI$H
MJ-KN-NU!Z*F5$#B);+D9O9ZEER6WA.Z'\\XST]Z+D\Y]M\C;,]APKJWK>4[(
M<:U?ES ("Y"67<E,:JN[NE<R/AOD'%S25TV->$/[E0ON,:<&<T+Y!DLBWUU1
MFSBWJ%W7K=-?H*PD@3/*)8H8V C;,!(/] %@+Q@"P?WEQ>)=:]V4J+"'B:A7
M8:8(ETN-\@R/"VNCHH9&XR0DU/*J[I>;%F*A= -MDC64($$!I$NW4;X>T$-;
M2Z"^N;RW\ 1MR-NY >P'0.R5"^,?'G5UX0=FXK0G]^ZZ,_#R[C6P],'=U@N1
MVX7&P_NV^Q!=O1GF:-F#CBI^/)[8;&"\;J'S2V-7K5(2^^PA9S9AG.C1N65L
M#5/O722 K/AL1H.2#<&+Q7_'SGQYZ=CJB;"&F69-/J$R#-^%)/ L0 ^_O8 >
M+J"'9WG8,O!4F7$]![)17#..6]5?8'; EJNQF72[(X)O&S:'JW)+E (I4?Y=
MN1F8=_PH/34@8CT=9&C![L.VH.!!+BD4*T<O$9GM[LMN%44]++A@O_6^\JP4
MTL'BA(.,C#_FFS*"Q&/,KY$+1J[B]1ZTK4B(.^0BP)Z6X=49TE%U6RZ]01T\
M-@_=>UD#AMIAUA):<CDLDDG[" 880M<)BL\QP%A_U:H\7.W;JU5Y<*FXL_0Z
M4]T*^"1<Y0 .N@V3>.#V>J:I2/U\:3S!6$&%YK;5DYQYD;V$=[.L=NIZ^*SI
M+/,ZP.L\P<[;"X%'.#6.1\!**Q^]J:%)%3'XPG:5TCF4[$&B>5&HFFY;;'S*
MT16& O!(HW[N,>;"%D9W\JN<1#_O-E%?;=97]OS6!N,NYD9+J3D[>A]J@Q,#
M(+\744WB6.'JLU"%3BM6Q6WF/5)$W+@>M[[(=VG\$TY_L"0]'-3-!'3OXH:^
MA/<_/\!\!&T2YF\>4[0+KA76[(0&E-L[J2?HF7"LM5%.%5X DZ>1&&U&9?#)
M)">*M0;YY_4).,UX(1Q&.\7QQY'5E3+3V<WLZ>A\V!R8?';_B+/LN:Z?!^5]
M78E(K*<1;Z$9T2\&;3C3GR61,<++M)TO615I:R_/EC3P0;0:7)ES\V8+B*R/
MI<Z)@E"4"'RD^K-A,.9K*F(ULG3&A/#(>S 8<O.U%-\BTT]XG]VFA'O))DE(
M@6(^8-UQ<EB$1_8L/.+7;Q25>IRP,"B@&/+8LUI7!#+%!^ )2I4J[4P!8:1Z
MBG(Z07=$-2R+J&N2$7)CUTV\PW&5C8SKZ7'\L&\2]KXD@^&$U=('"\Z1GC7B
M9T@'X'$;:;V>F\,YIMY?64F*!%WFQ(:D?!%>M?/]_H*Y4!4TL]J64_+DM _$
M.'<B4)<60ZM-I3:AZBJ0#0\)<8#P!O2Q!5+PWMX7I8TG_.UA!]]4O'L?LZ1B
M\27$+_NNOAX( S[#@G%4V/;$!=QH#W_OXDYQ%1'-V=2D)V-Z7LMY/ E@%Y7T
M4?@U=&%2_<8(-VC"G^KU@=.+0J[*KM^),\S^=<>D#IU0RH3/MRZBS%SU>8/,
M5[QM-RNTXL*\_N1P5"RDB@G1K[4X1X03W/L,T@E56E1.0=^'+\'+[-'&7OUX
M.G(^6GC4QB9[K=WG<K!5ADM!RCQZYK).6#PJC&UW,S@\VX//-;&QM%N!TT4'
M.2GM!7IM'[<4NCZB:48R@7_*6Q=6L#+\(G>ON$NR074B])#JA7DB?,<MZ;@+
M3/?-<>BJ'AK9&)P'I1,K(/JX8;O33FJ[ R^!_9X"+*:L"-\^^%N!QK\7/D!\
MW'NKP@ \\1AT1]1\"0"DP?9=W4##J2(0&N@TC?W?<P7[4;0,O";/WUL##,$2
M*R?%G)#")ZF7ZRI\\NZ4?:Q!9%>9GQ5V5KU7BD/F7@[QZM"53-N"/<3"0SP"
M(59;*5QI7=Z!DM@6@I!.QP5>V&04BYP?F=)JU I?[P_36]>GMBY%A3,H*OSN
M4E2X%!6> Y-?X@TQ'J)'=MC8;/6\=>F./)UNMCD2>[%Z*?,>3ZLI<_C%!A =
M1LY#73/O>7+X"G%%7SA?;I3M)]*/*%O_,[E+19+?$0E&A;)2ZKAN!F$<21W2
M$]_HQ>(=PYK((?!N^[KM'N]R<TJ1:)FM=4>C7G"G".[7&'X=/()'"Q=@,8U)
M#?#.8W^9^%J(,N3 MJBC$]P A2PXL+M*];V3PS.&JUY)4&<,B[):^:6H9";D
M;>A'U>'HJ^I#EF4;ZX>;KF0FXDVUF$XB";M&"_;C:K>/BZ/PJT-IJ/HL 7>?
M)=W@]8;->P6,!@&$SC*K]F:B@423+%2,U Q]FEM1$4\DU!G-L3Y,4ODDJPU7
MUV;I\4K(Q'$4K,@TW?XZO)Z9+^X?P34&+?G+/Y+JR&>?"17UMF043@2;#.%_
M&Q$$@<T1%[Q44T<$=]Q*L5*GV)HG(X!%1B)Y( P7<K!4S'#K/=NPY%-V0@PM
M/&C68\DOY86M\.+!0Q1>Q6)R!WN5+%CE35_=&W'W;KC>U/TMO26%>C_66R8%
M^?P/5"+>W_8RBG!"E:)1*!G)8+$147^5E@I\:= 7&JPI_R*BPNL*Y1O(ML$@
MKZM.$NEE+^1><E7F?H1%(4[ Z?=,"!I'O$$Q*<C#J ;1@<D'!D&%OQ*7B8AQ
M;'&_^\H2FSB ;L,&V:0]-.NZVLA6N*E9@2SRRCD=#BY5#HT_@%H::\*?,37.
M_"26]*TD[TISB'HNJ=XE^:ZC[5S1]&-,XBH(>Z-(@%RRQQ(B&2*1@BPSI+%X
MR5-9JQ&NIR@@.)WY0M#=&SV?+VN<H85\?V*:B),Z#U-LE9)RE=1(&C:F*7^N
M^TBBGUR<M!@:SDY3.*Q^K'NM$8B1/I:UG!",(593"HIG3U/O7/;5?L^2OK$@
M0;M@<U=I(LFE>S3*GR)7F[JLUFB$=*(1'\Z?VWDYW1?JJN8FA#+:J%X3\1@?
MVE,RZ>D9[D]\Y5,:NXDXI8BY#>D.C]A8A0C\T+-(@Y)=_@?L 3]Q#K8084EU
MDR&31L D/@]B>9]D.3PX*6EUKZ*@][[:[D*,!H8Q(:TJ&^Y#"&OZMKZNG?>>
MLK Z^/+#);M.6B(YRHEE.*Q:]8]XQ6&[)UB%L*8J CL\34Y]T;?FF$7Q0<M6
M/I!M'I?["H'#3VP=^-M)!&;3ZF#9^C"T("PVU.?1R.,IT%:/H*3/H\G"L6)"
MJE4[:B4)2(I*]=V$U8;9Z2VEB2QE4KJU?EP8I<<\(QSKJ$'"@";E8_M LBLW
M3;T.QSKXH^EZQM[<'LK-WC1?N.SB8%,NQ.4)VM0J;Y-<=8P3]&#K"IR>_!<.
MC()EZIKJT$N2 'SAFO=.5@.<#_*$V;#'W( 74GFP_/MB\3I%FL]U<!R%E6>H
M\6E@B8!WM"?IEP#QO!HW#8F\K2LDD!J...T^-3^U9B 3MT_.H_AT?)J-I>-B
M[(TKQN/<'?VKZJ[=5UJ>U'>_0-[/(CO]^TMV^I*=?IY>I3^R:DXWT@ROB+>9
M)KXS#F?'JVHI&N%5S<];/9IFCUW]P$/Z-'7O@$)%/*A7H#!?53'9JNZGW8VH
MG"D]PG;9/)!9L,.8S^D8-C#)742Z;DTVF?&/VA"4O6I1!#9G;Z)';?H@CA&1
M*Y>6X7SN/RQ,HMZU"4X?PPZSN V7#D<XSZ!KJC-)0!KXPZ[*!=V?9]STLV!>
M1_T /*>\?'I*]203Z_)-26- ;-=0JOJ:H*&0=^*L8XABJ R-(( :*]7?[:K=
ML(]A;R* $SV8YSH'1ZV,A@^2GDBK^,5B2OV9V6X\$)!]%RX+'<48H"W?35YP
MIX?4Y:;, 2H1#)\0BQ(G$;$%>ETSE^TQLYO% [QO8]6+\H%+DCQMB75:$G=L
M0)SK*IK<E+=JK5P4??:NWN9@28=<D^AFS5489H8)[[(Y])PD9 -'\5%X+V8Q
MW(O$+#\ !^)-=0.GT=E?]=2]I1LYZ9)@7IIE>O75NVE8M7\%OH&[,D*7)46G
MC-^5O4")HK;7213J1=Y'ZE;'6'>=M9>(XJB9?]EVKFO')>#PLDZ')CKT-A?.
ME6\]\;>R ^65K/2=8TOTB&,H9;75]B^.MGI>(L>OS2HM#F:Z4*4 +ASZDZON
MLG&_P=';I<K4_*+_:X_ [Y4C'MLI:J6:,DG=A$\G&CR4_S2QC1,5[Q_3SC*!
M*Y9%PAG0W:9</EN"_X_CH]"VIZ1_*Y(5H<DCZH7'#O*H(?48_"XYH> '*)=A
MW?8BJ<0UV2LM:S_7 3Y%C([?OM#^B)NNE'-4LQNNGC31S("L;<X&$K7@;KKV
M?F^J?^;4H$B[J3]4(-2$AR6"PQ,+&R-/CQA'O'"*"9TR6V44#*Z#P:7FLNX
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M0_@<IQF.Z4%ET=!/1)5[\&JLX+51K:><N3ZE]@8ID3)\FMJWRIJ_J0,9A@;
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MF> W/IW'QH8X6CR1F*T,72=4IE%A -HJ-66@[?G$-CI.TD._K[:L;:H9O8S
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MP8MZD] Z1:_RH\:)LH>@&X[5J6OAQ2^5+9SI5^FC&X5'Z\20'B%Y/R6W.:0
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MTSH"*6PP#2A<D, 4(]MK4([XOK@TN)PM845<R'IJFC6&Z(A4ZM]Z0\^VJ[7
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ML@Y&J;#4^ 1_#PKBB@.YT;K7YII[SWQAG);>E[XNM Y1U!W[:U)ER'<TI5'
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MW9D7Y)WQ)!=@#7+4(BJ[ 2/#I ?7W)^<=SW%Q%YO"SP*4=DTO<R<9#Q#4]G
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MP#VIXXE-L;L@'\)>AE=8:7.KK,2_N&]VQ%/)2SO291YJ IW8C:@[3[&J\9/
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M.YBB926[JB>D&R]5=GKYQ56/896&A5#M@T68ZW!U-&,0.46^;)M\/=IZHZW
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M5F*?G5VMF&X)W@\N,.//^\3^B9[^Z,I3]UDCLRC"C@SMKBDK=?(H;PS?%[1
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MX98\UM[F3Q+6+AP#\GN+5KH=48E')/?-=_(_X5V"O**@HA=TP:1.NN/ =LP
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MZO?#6CV:U6WI)^!9;P=BO2V E1]N)0,48$:U+CATZ(TR;^OVP-+_/H6S_)W
MR915KNFD4$KW(1T6C 0LP3JM\AI'7C8#O(QH2\$YF+*,4X02M&4*GWJ$(CN/
M!SH&!>(VWDI@!C/(FXBN9](8EGON3OF/".6&>,=?SG8Q2++XS@B<V(U";3E:
MN -.V>%YW2W)$23&2G1<VP\$ TV^@B3\9O .:3^N+IS!B.$!;IFP;#.T%=J5
M5JT">A5')H>JV<?/HIC>#I.'5K3[@>)=+'X57P.;%^)94_(NZ''L_..'' T&
M<2>9O17^E8=;S!]8L\AX6VNVEA*N-O-=+!YE4/0&!-=M0RU4(WX#(5/E7F4A
MV=YHTR%W#$:&B6C2#81V:AXAVWHIPXNC6^J76W73M>1 9[G+YJ_I]>JGP-:$
M:_8XVLS=[#,!S8@J$367.>I:]>BC9S*E-X+)X!&%OG-1@$M1ORD/ Z:+KIE^
MC;,YE7U($R>DZ,"L6ZG5.Z?V'T5J_R_GU/XYM?](8MZ_"2'?-"GL (-$DB V
M!EY*OJ%X9"X7Y@95(_,>?(I&*O0QN:I-RHIGM?%IS XN&63.$R5/X2>S(DVR
M"VZWH)&BA^"F69WR&$>\+8\[G?IV1.V8<OEI()1YIRKXP9(M8^:#>J#H<@ /
MBC?D([&HAUW1-D.GK-GFCV:*S2)>P :^[:=(D%*IS&9:V48?9V.0J:K$%#40
M(U=\JX(<\7K-#)'!,')K(,6%91=$E-&^ZK=C#'C!PWV%*^:2<+T(;^A"_\K;
M-:V!3>*+,<!J6^S@O0=#*LUZ/$=V5505T"+MJJR;X!;+3&-BKR0.JH&:GI,_
MBBN@_W(CH,)&? S?C!Y-6^QM=$O&W(WL)<%Y6F.L%H@6Z3S*L/-EU33K(,QM
M37%^\ ;#[1]G)_&OA0+<AG0\.K<"30?2=[&G*-)9IZJ&2;UN)[$S,]!U_+J_
M,43DJ-:T(,8=M@UIJNAJ&TG^H]RE%Y+Z'[<&%_5E?BF)RJC%.RYI2E3(2[0!
MB8QQ.*4;YHMW,NI9>,8\B1=3K8[":Z\OXV5\8"H:@XMR;7*,9K0!W2GSC<>9
MDT^+2YQ!3#O#(2>JH]S=+A:O/D6C,I2/[#&]#.J9- 4CA)A4)$K/SBVM,NH]
M-QR@V]CJ48DK\PF R#D1\P"*W95B#LH9E+GBQ#=:RX0$Y<Y >[WF210X&LB!
M3[R2K&@.)CWFV"[KJZ#SK?XT:R9 JO[/@2KB3'R'YCIIR"&L'K5TZ!QN>J=\
M!RX,X>I!%_O#//N?V(1!Y"/<5@_9)?@H_Q,U]WT[\%QPUH[K$ATV7&JXRJL!
M]IE_P)0.0J#H!I8/DM^([8;Z?3'W;<'D[30^?13B!U'LU6],\.;HD-.T_6/5
MQL*?S<7E.<TL^C,\[$#>#Q]/J8[2KX/^N2J)E+$@^DV<B/HX9&5$HRV[<+%X
M:QL##X4 DBN_34J0,1X2P \EIZ[@^GU8O$M6[C5FD:@> LX5KB6 V*1I;KBK
MY!FU#0KORP7C##FJ9SR562_@"@/64A39S(B7L11OM1C+^Z@-1-)A_DL^P6O.
M0 JLGL%0IZU-6O"F<D?;-IJI1;-#TZ$?C6\N-T[Z.M4QYF42!DA2N!LR$=;#
ML(Z;FF3CZ:<O0M@0KA<4*$_!>T'='I++??'F13;&P>-ET0?YY7/</_S'5]F$
M4BSQ]B*I5^RRY+?A;JY'>5#?$8.,(?1ID3P!)Y8N[T02824T+>OZ.#>F5LWE
MP%A? 3%LRK;KM: O>>-5E8>W6,N?8/ES\M7ZLJ]BKQ!?5$=1-4-/K4>V^J.K
M X>2SPC8B4M?+%Y0[FGQ(PIY/,:$Y&#0\CJO@.TW('<P]8(Y ^#L>=@@>HIG
M??.,G@)_^_([;?+;,-$M\\^P.R*LM%MURB_#=<$2J(\/.MW^NC&,V.RY:0N\
M-4I=-(J8_5+H08(*T!KK,>SR7>%6F['FE;"M68/O J2Y\GC74G.ZU?X%1<MD
MB%A/2,H:$)3TFEP^+3%K?FZK]'B^?_?SV[ PI$S)Q,;9QM?AL?U"K2AF9S7I
M7H_1 1T<*0F9=KF(3OR67!]UQOB,/$TE[#NW,XNDTU-PO7'57%+_&E$]- +B
MH(?2(X.*)5R">".63JE,S[TW=]8D<TQCYW'B9U"?[QX%8K[@G%R8F93[GW(A
MSJG]!Y3:_^:<VC^G]A^DF_ "*=&.DNZBY\2;-Q>4ASM' EU2H$(?6EN("2BA
MHA)%=Q6<(DC-=UEOD$/@@NE0]EJK)3"F!P6DW OL5JLJ+]E;BQ!^$$$(E?^,
M\2%OV3N:B362EM?T?MKT2GT!UVQJ/>F\EI#A^,+1(AID=2!AX]:<$I<;>F=Y
MQ$_G4JWD>/1]OOJ@@2IFYB2V)6P"7U]9(S#.!JU\\#7X<L6:D]LQ/^6^P37R
M[$^;)#POB AGL+M%=\]/=GJTA8,0A/->7K$(Q645+A'(E^Q99:0?+GB@813D
MI3"\3.1//)/4+;U8:#D-.\US*8LK87DAS$+P'-;DBM#\*>R^V^5D,A0GF8[\
MDIY- 3:@].T<SH#=P)PI$)P;1O[@V-D3#T8Y6*N#'6"^]ZI@^.CX6</)(=;#
M$I ^!>3@.YK%ROF&FD*(L3R>S!949SS!^;5[7AN>IW8W2E_,?%SR'MD!%@X8
MQ;RN2Q[V*ZS'/-0OQ!.K8 CH):1;QBT':H9]B CVN-L@@;1[>SO>[DGB^_$#
M:4<4XUMU+B^3H]NOUO&Q'7VS:&;_3,@-(]!>YW5_\LW4*T8^HN\B/43"1_,9
M4@3NC>^8)H#7.TH5/,*8?,K_@S/Y?MA3Q!V<"=H6I"J&BGO0%5&H@J*<7YY!
M-=,D49V'Y;^VP%#G]T43U$LR/J+Q*4DO$,4T2"$B@8*:\O1R\,<Z=ST:LM=V
M_@HA8ABTMN484]W(50873H964\BJ.#Z71A4LU"BAQU4#Z9$*NF\I#!<H[7"2
MB):0R8W6-\[('J>#:?KI2@FD*'7_?:&>!;'1&9/U\7$"(Q6KT@UUD FZ]&B1
MVN<2K5%1., 2P#!/G8'*X._Q=AU90] ?RV4Y+22'3;K9I.7<I[CUO].N(;G>
M:'KLPSR+=RPMO/4HCQ3?K5,$LHCRSA($8R0VP\C-O.N:%3>!0N;2'L2'/YOE
M1M#(D76:?WL'$8V_\RM"$SP2^\IS/A/V#,L443[_=CT.D-!&//C_NM-2)Y'I
M5]^,%O_9G[CZR$%^\]V?YR*G:_.E<+39G U20\PI$S<BG5^F(TI]9YE-3+4F
MBN##:=8YN50CX]*;<)V@"AV99S"A[66AX!M,#H $"<I6T<Y$ET1*\/_9^7EN
M:4+0KE.Z/;_53(U>MU=FNW]W/DSW>)@XY<]M%V9C)I49ZI4QULGNN[-^^V.V
M)"V@ID$P DET5EK11EC:>$K>"DFAC)&"4D>FRJP5E3=MB)2)QZU1GBM4*RE!
ME=SWO-OWNMM^5W5LJ(N?-LTQ>@V.DLZ[<^]GD? @RI[H(&/P-^WP98KB8*NF
M7)OS/)M^R!7BW'FZ4$/7^COFX7_61>*.BI_"]U+&D7'0=Q:4>Q44-RMGLMM#
M%]85)&D\?%2(=]8T-K5M::3L>7/^J,UA?W-%W'>2[9#AQER1(F)7F1^Y#N%<
MWF:+=Y1F7+SO49"[=$XK-9 SFO^\?W_8_N6>L)7X)P]&O L,[Z6GXHTA'F&]
M+*Z((. 3^W8&-3P@4,-?SZ"&,ZCAK$1_EQ)EC\.%%KLBIYX-2I_M")"@C1QM
M+[-8."O@4@&NHY[+>^#?$F=UZ0DRSA;QCTO;E+OET'9<RR0#J(0@1.EH#8=)
M]2RM$0@GP'G'[G7'E$8*TP\P_'AEO!9NSJ;,9O DY>>-N5_G<A1@ARW(%D=&
MGW/3!O6N\BZ!M-'X<:KR2K)L0==>%1PN+-LF7Y^W\%ZW\+II/W")V9?@9RCJ
M>>N&&G4@XCW%-*)FMV.NH8@=1VO +S]@OVW8QR]U$('S5OYQ";=Q=;?KB?(X
M\@'DEUSFFZ]X^UI>M)<L DI >;9Z]YS=CIVR<6IZ'"< \T=%0D'3<!<KW)K\
M.O8A=P/&%6!V@2>!6.7[2#NJFO;D=.'SGO[^/4V!%4;+-]K5RZ)YYB:"KR9'
M\IJ2:W2!IBV[';5>AA7?E2MF[@KG>2!D$]&Z$_*X<[\L\K;?_C;D'\!??=AO
M&UQZ0VP12IK2TCC&DWF11XL7 @(H=H4SBI-0J& @3YN_R;D9".VL?61Y67',
MMSHLB_898\ [P4 "QKIR?;7XDA03>QS \5]D*"?E2H71(UP[W'W=M'Z %2%%
MZT<Z .Z_RZM"><^5+J >-?-2KT&0TW80)I?K(C*D$:B+H']<886MJN(*:A2>
M3++D07'VY=$N)M/580:E5Y^KB( K.8"NPE8:!KAZK@F!7*3M#HV;@-0R)^^!
MV4+03A"^GW)Q,P& 4O3)DUZ5[="1G VU\/@1TR\3TF73TYUH F@&4P?\]$5%
M]!"[H4Z@O/37GKDR1+(O%B^".4FE/8L$"(V377K6\,PE4UA06@X,P81R)(3\
M6+_)D0#%H1PTUZ=1M%<4;8ODZUB R>3%69+]M9&;ZGER;=T)NT1XWA")[%+0
M:R:=>L2#+*S:*IL>+FC2E,IJE*FH8.,H0E*DUSEH@>@5L5,5#\C R%OE E3N
M#4&ZOL&]J'D7A"@,ZF5*%+Y=>"_9'(\KE848<PHN7D+IA.?#)G8)7-W O@1>
M:/;$GJ*].)#PEF-MX5.'B\_]-JG07VJKO5 F-A;70>LE0X>I*S5?#+AKUS=5
M(1(A<R3"$\G0W"Z+!V)'N5Z213L909?M=L!HT%-O<7=6Q]F">H2;'?]@19#E
M[D.)+X<+KC'F#M0?O<CT==O4E\0&;Y,J#XRVM=@T?$EDTTT6(SZ2<LG8#[4$
M../<88!EH(69.\07BU_147T=QV/R++&PM?LB['VKLA@IO(2LVRF_IBZ)[(86
M03J%><C!;P1DP=STI;*<Y!+'->,F"+U;(30SP83D,FLE?$"Q86+!Z._7Q;(K
M>QMZ+$*B5/MT?1Z(0.!WM.H"W=T'%5CE(<3$2!%:&!KL0&7=2Q)UXY5S4_8B
MN;Z0.L77BVA"XX#R9![ZZ'@G00H(#0ZZ(QZC)4V;$DJ$X.!JWC==5V+)2!G,
M2-MM#J0LOL+IP[4P'!!G14CS!];UW'_@&KV=39!LZ?(@=7NH/ 0@5*B/*7 Y
M3>DQB :?J(EX,+D2^H1-7;%U!8%;A$,:GQ(AFMU ;6;ZIH4Q%EIG-(3Q%5;7
MADEP1U^*F'^$<F)+JK-),FW9^% WUU6QO@PJ, ZLYV&C6(08,B8>0&+W)Y9^
M/;+T<B]GO&5\HX[KP6*SCXV!'/0#8CT6&T-2-N\[^-Q$G[H$YT+T8RA$_^>Y
M$'TN1"<Z\T]2D3=%$'-1@]'.S9#<S_ A50TSN\S96@OVJD*H[2243+\\#7O
M@&<*T?<U";H\Z0X8,;/[L47F-)&+=L4C8Y1CE",.>M"+Q3_*#P5-D<DLG&WJ
MD>^O_<&.BQ4B\?;'=U]]\P5/]SO$6#F&9N&YUNB5E2"U,5=XM PRD$0((R79
MZ=D;F<]^'.?KT"-RD>[*&?_S:& R#0"K#XFDW!0+JVWS0:L(!7)T$OCW#4>@
M$ P>GF$-MSP&H(XC&0IZ@E7%W)0\O&PC/>3"B4??*_H<O&D6TCK^4>:!-&K*
M3*1AMR_Z$@56F\TV[N-2?WO#9*CI_ :&VMI8HF1"T)A83R5CWY55LSHLR>%2
MKKW;B4M\-$QA2M@A1VRMUY[^\O^V=_7-:>-,_*MH<C?/))U@_ ($DKO.T$!:
MGJ:$ _+<]:\;88O@*=B<;1KX]H]V)1M#3 )Y _O<FVM) %F[6NVN5KO[BS5S
MB&T 3MQ"BCRNB/1J1-VHSV*+[F]8=7^Y[&PM%""?8C'POE>Z2:Q \L022Y:A
M,0S0>G""C$ZBI[*;W1V*3BR$@OY<$$440.0H5E_7Q[(,_YY%U0PR#AGOJ,HE
M"F)S0E*H(P]P$0PR]AU#28$RYSLF.C-!.Z@(4<M=Q3&CF' _EJR7:R002<*'
MB4'BCC\,& <@FZ'''^8>RBQ_RODF/L 76>P1V)[C\9/.>N!.'_74GW#!7F>4
MW",]((^TEF:/%&9K6[\?V4;UK*890]-0K6JIJ@T&UIDYK [4JC6H5BV#_LT)
M/<K]V#3[L0]NM@S@?JO?_$9TA=RVN\W/K5Z_V6TV2*]^W20W5Z3YQVVK_QU
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M4%ISB/7]>O@5A33_^M+ZU.H_Z=(?FO\.Z:R6:\Y$2]0QX*):8<EU<SZR!W9
M6GR6<]%3W/;)'S. &O7&"P@J8*-5!ZKM)ER5%_[ ABK\.!^VW,"R'8\AJH")
M!F<)T2X#!0E#@ADC6+0%N'T$S9 %15C"-'J,OWWL8&:5!)]$#*QEU\,65$M7
M5 WM4-3 GO0*7T^VK2 _'!'CQXU&\Z\'TW[OU%ZNIA15W3FWMZJ@^MTA\W7S
M[XWJ;B-MFE.9VU/M[%6&JBC52NG 1BHK>DE_E9&JREFUO(]<XV3_8<6I>C?W
M0>Q"J0RW<7/V.4V1;[KS_="6B8A[CN!OQX(&\TW/Q@+1C9<3FIY.VEJ1:05[
M%K>MNUR(2EN!=FT:$'[\L2T2SOUU4UA?XU$;Q[C84;U,;,L:L_VL7 _Z+/$3
M;Q%\I2TNS3)!]!5TOEE321DG>=U.9)Q<7.$&]\S?,"&#<VA/IR-#T7>XWWZ^
M$=U,]6,Y*,/AFY'^V'G^-YIX4F="\"_V/D$R\B"0.PJ"J7]>+-[?WRM\GLJ=
M^[-8]\R1_9/Y16;=4:\(/3Z*6E6KE&MJD<]7J^A5O:KJ_)51UO6B),G0AP6-
M:G,(^+I#JHP";OWKL%AC4==:EYV]99,-:*A1[_5(AP8C!!N?CDU^[*0?7R-M
MY[ V"![\KPI:L?ZR/)##HLHPC()>JO+_,D753LKLX,FI%;5245?7,JNR8GE*
MRBZI[KGE2:7E*9WIJF&@Y=%J1E4MZ_BR5"NRBE:K&:6_V;Q6*TB+TV!X947J
M=Q[#&[*X2=F'C"J9M6>5M[-G^T@JUO2E42MKI>PM6ZVF'-=?6$)^@$O&3=S9
MJHE;KEAV#-TA'['>='E1V<#Q 3- ^/.EAH?DW"XSF3T-R+%L\([77-+0$>X<
MK-]CO1[O4E&ZOK^5DT)KO&.(_; 8P$7W=7RT_4SP!=$!\5(OX]RK11$.F'JL
M,(3AK7M,7@J$LW:%SEG."^"%5'.=Z%WRIWC[[6,B>],0J-NKA:\9)8]+0,&H
ME74]H_3%C]_9HDS5BII:W%!$F#$CO?M))S?2F31,N6E.,LCU1B^WQ&DG+_N6
M.*N4_7LLL:8JVB\?]FR,HRR)_&+CN1<;;*YQ;?.##FQ/7H+O9DH/:_(34=@$
M" U=Y@<TS;1 9GP302G23 4BCJ29@.AJ+M546%AHD68*H'?L69H)$$7#J5Z#
M 0ON =06FXGX/F9##1$?B%RGF2X[S9.?V($T>5_AEZ3-%^599[_\,NDUO6,]
M]XZSX1WK!0"T2Z=S')\[^,9I]&/B-*32C8D3D$8O)C[_=#HQ<0H"5YZJ<"^D
MUKM_N"L:S&0(3%'!13+23%&2HPEI]RDFZ92T'%-!/ZW/?TFNW3F=Y'[:WOTT
M(_?3TN^GW<T6U*.A+I>^VGHP<!E06U/]J?,JDLA-FV>11(/T+C(29DBB,$V1
MAJ3Y+X,-*2?D\VQ!/KNN=6\[N1'>NQ$NO4G-RWJY<_+CL2==Z6*?53>Y!Y)Z
M#P3<_5+!']-).B-%\;E'D:*VJQ!-ND?UJ6>/B:%*&\V/T2FF\!OU^<D,W$*&
M+5TOH;/6(.S!LO0,!PNT=73B.G<K->"A.V*C03PE7_ENPR[S9Q<^CL;N&#_B
M.9;KX @]=Q:,XK_X1F>6/V8+TO[2(U<NG[%X=M^;^<&IY+GH-ZOKR',]MU/[
MJ[/6%.W#WFJ:<O7\8@5@3J9^X1]MKI?G;&YHFLE<0]5-SF>A$"Z!XT/H1PB;
M<#KS_!GE^Y]KN9[$0. ?%_T2&>E1;T =YA=NYK"#ZR8"ONJJRC>JZ(!K'-.3
M@E;B?Q>ULB5>G8(VZ7BV8]I3.B;-J$7TC6@1_;QV$OG^?J7]K>?[.SO[6S>'
M^][?5[:#S4OE[DY?87^N65Y%L^C<<\A52V94BPZNPYRK%RC=>$*U:%5RJ_24
M2R52,II1Y@<HZA,)GI"HB6IJ91M-]+@W@8>,=6UD\U>Y/OI7ZR--U916NW<
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M7# ,B9DT?ZI5^JU[84W)#']^]W]02P,$%     @ TS2H6N)L<"+P%@  _=$
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MMLDQWIKAW5/$GC1R[3Z+ISWE(+*M<]NR<Z *)\VH1#\J:U,AAIYYZ]??WDO
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M/Q3C ],H(O/29B:+0J^<MP*;,V8=F'V%PYII^S:+FDA]N,#% L_*<>N":-B
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M'<[5K] \BI@E$RI43Q \"\%YII4&@8XD[?RA;"H'>/7K#28.)K 8O&+:JLS
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M=ZGDFF0W$:576]ZOD_'DPKPZ\9[8[71A(8C:_Z=X!C7M K,PFAN>-+9NJ?4
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MW.U%-,9)F KL!+$O,C]* R_2N2^N31&T^L*O>'_85.J#?BZ6.5L^2_/ZW'A
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MX^W?/J,/][>_H-N[Z_O+AYM/?T&75P\WO]T\W%Q__O-4+L\69MNNCPEXD[M
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MNFU?XH8R;.][&B2]+:T5T6%V8C1;N6%C@KS"46$M;3Q/TYEU/SDJ[NMMXOB
M,ZO82HO!5FN5B%@"0R]#4TQYAKTMZM&C.TGT1$= VZ5:CY%ZFUJM T*?+-8Z
M-,;L.WTOG@O!ELW&+B,T$8FG3HP3B@ES'4R3E.*,N2D- AIE/($L,OW))UY7
M^J1@R\D> GJ::2H73!.U1 (KW3'>+2G9WM2S*M4QH5XKT=%G#.^LL:^";U;B
M-COS!EU=_6@1$D$#GCA8^#S!Q.$"QS&-L.]2GA 21@G7ZG\X#7L3*^ZQ"ZPO
M%[O[J]=WGU7]%:::D=8N4LT4M,:QW1>F9R7>[C7 [(SM-P"_3#<)4+;NV]EE
M;MXK>9, >W!K;QHJAG=Q#D]\NM.>1>+X:4PS#PN721\G)@0G42:-K><S/_58
MDE !NB5PFA;(:,+O %P=G!\#L_P'4-(S;I9DAUDJS:/>"W195<4RE1^:*BY8
MK>6>N[":[:(AO:VT^P%*\R;5CXM\D#*O,<3@;/6VX,N<%DUU]6V:M)\0$28Q
MCBF16Q?/#7#JN QG7I*X(O0BE^AWFSM&8>J\D)9D6Q %<)AW% Z-\\YSA82I
M[E:^AIQ)<OSQ]ZY_,GFNP&:GCZ\$MW2L."3+X-'AT8'S'0\.\;UW!#CXH/DM
M&NF.7.:\S@UI:TEU'U(6\#A-_12S+ TQ2529]R1)L.MF81#&E(6 _MACU*8^
MY=N2K^^JK>L\J;9<GL&-F].@:9@9FU! (YE[*#398AWQ,V[GG(8#?E?'"BQG
MW=PY#H_=FSRC4NK<ZSD]R>RW?$;E.7;G9WR0@5F[E' YM8ULSB[NY"ONZI;X
M(LR2S,><48$)2RF.>1#AE/$L<N14D:]U8CA"9V)3INBV_0;:,S)%&J"T PAI
M6"\[<L/LUG&130S6@.P 4V4' S,C!7S],.LT+MB@71H8/I]%&I=ASQ9I/&X6
M=VE3L=JO*XUH*'>R'+N1JL?@912G<>A@UXO]+(IB+E*M"\I'9Y_8XL#R*8_+
MKQ=#,98*9D^Z(N?VDPN."F I\+$_]ZRACJ-BO0YN''\(ICQ<+!==P/WZ._NJ
M\D$^T2>Q8&' '#>+<!2S!!.2$)SX<NU.HM0C(I.+>:"U=I\B,+$*=2111Q,I
MHGH*=1*389VR(2E,K8!":BO7F"0#&7MR:*-:\B\[C3HYX2Q*-29.IU>CSYGF
M-Z3535Y61>U\O*/ELOS\7 C*;_/?:+%4 6)5!\Q=1-1U@I@1'$=)AHE/8YQR
MU6F:!2SEC/@"5LA9E_#$JGB3RT&BK% AB5V@YV+Y)- 3+1Z7.?J)RJV?JM;$
M)(? $LS:N.HMA5.@!5-GQ0':L7"!:B90PX6ZCMSQ45< M)F/ 9/<6JZ&)MF9
M\SA@8!SF> #'G]%Y]4&.K1N.AFGDA-QE6(3,PR0*?!P3G^"4DHC*G[D46 *^
M/_O4V1=UMRY%S+SSZA8(/54W%@^FS_J2F75>?2V!S<ZKV[GG[[SZ6JRCG5</
M'C*(7!FW3ZXS==6^]3;+1+','YM;G L:!)%P H'=S)$^<Q@)J88ID?\4U(V]
M3"[PD7:\RS9W4SO<=3+]L_S9!5JWA$%E&*=Y)1H!MK<$&NCO]TJTGVP1_ZYK
M$?^JE+OB^**]\U!'\SJNT=V;OR5 */ MWY99 /%MWAHL#CD5JH/12^M$YXMY
M3H777J1T,B)F+N='Z;RVIT@+7XB !H1@YM1'U0G#21P1'(1.&/G$$5Y ('EL
MO;E!ZY1I[=K5CA[,W>R#H.=L&HH&6QD^:L@#=C*/<&[)Q>S//*N#>42DU^[E
ML4<,G,N[0CS3I:K'*N1 59KUO?@F5NMGI:4/]/M5(?BR6O@Q"S/50,83D8^E
MXL281JH2.XD<RAB)J:-?1U6/YL2.8,N$J@%=<U$?[?,='ZJV&L#7T,11P\^S
MCPY,1SM@.@:0Y #U6*BO9S=,V,<'X&'9Q\G,;[*!%\P+@DD^Z-MH3C6?QP*3
M;<\/ 0XUSII_6N>-YT*+V^)SI8KSU%<.N^3\A<,]DOC4Q7[FJUM*E.(X\",<
M,]>36^PD#&'-MS1H3FPL&PZ:.I,7Z)D6Z%M][U7U)?S+N[M=IT)H=VT--/7<
M%\L8P4QF"\_G!AY)7S6];CAH+PAOVP=:S:S7E=A>AOTHQ;DS[74A.))QKSWT
M[%HYU]]5P*F]RW/S]*QN(R]9X[^]/(COU3LIU3\,B^7H33ZQ@7A=WJ7N!]6Q
MI2Z;O&;,N#R.)I;#5F,6&&$V!(P@^J*X0C5;%D+V9T-BHSZ.)L6W*I # V2@
M0@YP(C-7Y;@CU&;4+F*6NI$?1SBMZ\ERZN#$C04.21")Q(\8S[2N 6E1F]CZ
MW)_8P\&<D6&\]-P0:RC C,<> /V]A[6F[" !+?D;P[1F]32TQ'[M8^@-.K>P
MPFCXM3P5?VVNZ-/8$T'@$NQ35<^$1PPG3&Y9,B%2P;/$==W4K*;"F9Q-?1+8
M\JG65IVSCQ*E X<?YU9;./<MZIFG-WDWP,/#@]?R3O>UO#-X+6>48+ $H?7J
M"^?R]4:%%RS!>;KF@BT"\.W@0\$E&6GXET5-\[W<:^KN]HZ-G=@R[HBA]T,9
M?'IRCN_$SA419F >"EKW3ND?:^M*#-I-#8EEM%DZ.N%L>Z$A<?I;G<'G3(H8
MU-=ORK^H.P2"OQ/9NA#_:Y,+WU$W=-IK) Z/A2!IBH.0I9AD*<&4<Z;:FCH!
MSP+*'*UZ;-H4)U;!E@74\H :)I#B OG.!5*,0 H"Z&"H<39E&QF8YNJ 8E0N
M00<=2/D$RR@9EE,XYQ,"UE@ "#Q<<T%GHAEK, #DVJ_) !EHV%+H62C[FC]^
M5)TXNFR E[9+V\*-.*%4>'(O%WB8."3"B=S68>X%<>SS),PXZ%[A,+G)K6%+
M'*T4]7Y:#,*(-3P VP(-PZ>WG;('"M00=GC4A"_0EO2V.:+%SCU:0MKJRC-,
M;-Z..UJ"'W33T1MEL(E0&6'U_D0U*Q/%?94#.BP<'SVQWC9);#VJZ%Y4FR('
MMT@X(;O&UN)LL8&;"T.)81N+0:',MA;'IYQO<S$HTM[V8OC)L[,ZFC)*-V6Y
M$7P1AXPD2>3@P'=B=6$IPVGLICAQ"'%XQ+)(@,H\GZ S:_;&LB99IVXT%=3,
M<S;VL-);,BT@ -/(_=R,AN8%:JA.DHQQ3"S["1A[5-XJZ>*8J .)%D<?AR^$
MU_^L7BY_+WAYR?_^(0>G3YP8/G5,[9\;=69?AQ-+)$EORJJ..5Z@#^MUE:\A
M<;93"(ROAQ:$AZF?AMP3)#*,B&FT1)Z:<[8U<D2H_B(Y]BA<Z6[R<BF??"CX
MW7JU9'+G=5>LV25?/\L-[H<5?=15O]&))E;$EC[JPL =%_71N6)%\+J-1\N1
MOE*.(S2NGE;!@2DJ$!?T1;%C25VUQ392W/'99U-A;4'[RJP_R,SY;?.F)9E-
M0:4(BY0+CX@XQBSPI-?K)"%.DRS"H1-Z01)3GT:@V-%K A-K>)>0O^SHH>="
M/"TW3S _]P 6/0?W'&%A&MO)N25EL4?]"2%L]9Y_/?V\/>5/"'?0*_[4<X89
M.\H%;IS?]YO=;<?&*>XUU2JOOXN"+4NYI0J]+$TH5]7@$HX)"3R<ILS#F4]X
M&CC"(7J5=LU9F/RDN:&CDCWJS2A:MZ<6QMM3 YCU%'M:\&"JKY,8,Y@7T_71
M*U6:<<-N*0VFM=O:YX-F*RT&SL"\^2_& !TDNIC/9*-@V,=E+FXJ\50N1"S"
M@&8ICDBDSN))AFE"'9QZ;AH%01JE#BBA\ 2=B4W3JRI7Z(LBC&K*P"2_4SCI
MF1T+TL-LBY'@9Q;S.A!KDMI=.RIO6*KK0-3ARER'C\/W[JHX()=:S^IV0[=9
MMF12'PQ"9Z,33:R3-7VT90!U')C$T,9!&=^N6\4#IJ7C4$P05M.6UVB?/C[[
M;/MT;4'[^W3]01/<YVFSE!+JA4G@N]CS57,?EL68.IQCUPU3WXNR+"#<VJV>
M63+A9KC; RI%;1D1F-:/W?.9H'(U0-XYKOV\195K  2@*T!6\L .SM<N-]77
M=;'\3[FQ39,P]?S0Q1GSV^-KFD8N#ITD2DGJ1DD*L@8#M&8]PJ9;LA:/L7NX
MZ5D"2VC +,"QXVRT(SSAB?:A=%.=:O<HO>W)]J'(HZ?;1X88Y+SO[P'NZBCD
M_U[FO*M1?4=?FKM[KNLY/"0XIBG!1#@Q3I5?E;+0RZ@GXDRO'S*$Z-31^YO_
MC99=*>[GAB0@EUL7N6$5GPJ/LW;BJK+(DN.;'"LNT+9>^=UD( %RWB< RRSM
MW1)HL 1XH/2#.?"Z<\V7!@^4;B\3'CK6S FJZY??9I>,J2Q+%?M4)Z4OS9^[
M'7W$B9>XA.# #P0FB;*4,9%_<U(G3"F)?5AD4H_LQ :SJ;Z_SM"=*F77J@O,
M%]*$3\\ML@\*S&IN\=AQ<-%D,[R@+^W_K49&S 2WY#QI$IW5CX(!\=JE HXV
M;,(EEH]?*\$OOXF"/HI/&[43N\W>JY;LHCTSN=U4924WVI*%11R&?A)%'#L.
M"3$)$H%3UW$P"=U(574+/0Y*! ;2G]B$=-P@VK"CH.SW6$;K'2L((]YP:;[W
M@J+O>U%*(^[@Q'-<:;?= "=)ZN#,$;'(!$\RUX.4\9T2?7BIWQ\=?3VS/R&F
M,/N_A;/E!#6L;.M)E*C'Q@5J&;38ZLT,"%O-X(#4YVT79P;-04,YPVG@)V>_
MY,_+]\N2/2R?!/^P+E2NQ6]T!<EW'9AB8JO^RZ>[&Z1(K];EIA"HY@!EZV(_
M9:2N>:A_;C8$R?B)F24T8!8! H35O%8-:8U.RH;FG>V,3$.X_NF8SN-G)-8U
ME\'*YKK!@C$2<E=0[$4J!24-.:9<!<>((QT'(@11QV#Z#L,AB8E]@N8>8;F[
MYE;^#R1JP@;9</O8A)PSKM)S IHEF&2.CZG*+'2%1_W4)S'E?-%TQ/E<T:*:
M Z'7Y/0W>^)QF>?*,4KI:C '5A<>XC(_X&F .2<9)G$081I0#S-"?#<F3BA"
MOX7G.N?S@=,1TX;FNG$8;>&BYP6>)RG,K#?S7Z#+JBJ6Z::J6PY6:U5_V>H%
M^-,RV<Q1W"<P?P[B40&/YA@>?]+@E..R>O@J?J'%/T35=8#ITA@RGR<T"S#S
M'&F_/>;)K5_L81[$7I)XB<\<K0):PV0F]K\N*RP)XX;RMB$2I"G]27PT3B^L
M2 U3R.,"FU3D.2TYX$C""@)FAQ# 5P\[;!B5:_!XX?3H^0X41B78.T(8?]K,
M;^R.(-ILC$_K?-W5[EBD0>SZ+N'8)R*6#F0<X\0G#J8T\B+!24B\;)&+1U4T
M_D$_[#= 4NNC3)J/\H"P]H>Y/?\2(X6!P8AEC'AAS%S,/>)B$B8<QW&0XLS)
M(M?WTL0)M(ZB;4%EH1&T=8ST?"A+DL-L]U;HENH%ZM.UYTQI"&?)JQJB-*M[
MI2'R:S]+9PC,Z*FF\==Y)3VV2\[EU.65.ETI7A9.3(F(W  'L>KFSE.Y'0R\
M!"=2@ZGOQ#[WM>K GR(PL;(V)%%+\P*U5/5T]B0HPXIJ0U3@5@<HI;9:CHDR
M$)Z20QLUE'_9:=_)"6=1N3%Q.CT;?<[\1E1708YQZ3Y$OHL3TIT84N)%.'(R
MFI @("EA!AY$C\0\'L-'B<Z?NQI[Z'E=P-,+^K#H+8%0*8W3JR:HEW>$=XNW
MF=ZD$MX1D8[=6CJOQETWTP>Z+.I0_"^"JG!]72WF7J@O<+<-S%B:,.%'.'.I
MU"[IDV,:.0*'/DE=GOF. ^M>HD-TXI5,L="<05R@+668HFE!IZ>!M@&!J>91
M+":XW "1TI(2:Y&<5;LA(+Q6>]!8,WMP*=?I.N=A^4U\5C/7=5^OO[/5A@O^
M08JCCI(V5=M-Z9H6ZCR@[+JX?=S>MXV\T V"B&/&I)-+:B<W<:6[&\?$(5D2
M)XX/L1FV&)LZ#-EC$^WX1!VC2'T1J,>JRI3HF-TU+CSC K2U-ZAGNM[BO0 #
MI7.^$K!1M(V?)<-IC:U9C:MM,%\;8.OS&Y[!C_56.=5:I4O>.;B#Y<0T<+PL
MP9E/50%SG^,X\@.<T3#-,BE;$$>@VC>V.9S8;.^RUMHL0!N7WNR_)CV3_*;@
MPVRSA=(Z!PF'4]S/FPQ26X?:UOF;]TQ\*G@/CM0G(V1HR6G=*TL=]*N"!K?9
M@^2D5/U)U_G[]1-=Y@MIAK,D9'+?'7(B'6DWPC0,"4X$]X27QKZ7@/J;CY.<
MV-8J!FIU52R@+PU-:"N_<=PT;:55-(#&#P8$W&AIRV;+"HT3G->L: -P8"?T
M1YHI_L=U_O@@BB<5R5L($3O$]QWL",_%A 413OW8E2Y82I.(,QX'+B2!LC\Y
M2)GAJ9-7M"A>5+CH6YW/*[_FE22.I5EX0ER2AZGU'BIZ"FPJ*TQ5%16LR*#W
M0T*!5?08]Y:4<6_J6=7NF%"O%>SH,_ K W=YF5_ROY=W1?'Y&[LJJS;LJGE=
MX,3PB1? .^EWU#[NKCX[NBN6ZP)]%L6W)1/2%2X!_5I.@3"L0);DA^F1GN@6
M8\\:4AI="C@UYVP7 D:$ZE\&&'L4GMOPOLW3^[ L&5TUI2\_R)^5"YZEA 8L
MQGY"?4Q\DF(:TQ@'P@L]SXEI%#'=!(>35";6SXXN:@BW95I135H_U>$T1L-Z
M:4URX/FLB="@S(=1H8S2'T[/.EL.Q*A@_42(\8<-<KM[[FK3^JH7,PJRU!$1
M\7 81QR3E',<!R3!?A@&KI\2%GE:9:G&"$U]L%*3Z\7E  G.0_ ,*Z--H0TV
MA[=95WNJ%5\CM@43'Y#A;0D&LQQO8SA@V=X:,@[F>P^-GR_C6T.*O9QOG>?A
MOOGE:K6MSWE%*_$H9Q0ES$$?FF-J@[-:]2J^[HCK^^6# (P[Y[9DA]F=4V);
M]LEUA#-RS <GGLT[UQ&O[Z)K/0]7P:NO*J[-[X0H_E*L-\\&5:@'IIA8 5O*
M2)%&-6V3RM-#$(SKH"7I82HX)/@$=:8U9#32Q*%Y9U-$#>'Z>JCSN&%B55F*
MJKQ,RZJ@K%JPR*<T$@'.$E4L5FZ-U9UY7_X1BB".&7&)UIW+X]-/O31^_GS]
M\!F8EK0OOUYPUUPJX*)7TT%?.DHV\WN.BF K2V=_\GES;8X*=I Q<_PIT]YI
M:R8$+U6BS=^H.K2MMOUT%AEW:>3X"8XC-Y/[W(1CZG@1#KW036+7"Y( =$XZ
M1&SJ '%+NLE,J[X*)'JMFWYOF-%T1+6PT]-&6X@ 0\9[8+1T=WV4;+9A&Q?/
M6DNV 5(SMV<;%_JP59O&&/.@\H,<NN!9Z @_3%7)T B3)"*8>O)OGB#442MD
M$FM?E.M//%?H6-&"QXIKT?7#PU"!#"/"@[(8A8#[C)\5]:TGFCW0VV?_6&QW
M[_<VVGUU-U3OY=;P.LL$4_O$.ZER*H[V*!9N$*<.2U+L90''A'E4ZDVHKM([
M7N)D"6,4E&P/HCZQ2FTI[@J5%U1W!V@&I]YR.!E(0#5]78)[>[E<L7*!=OCM
MN)FJLY@F")/T&QNC_89=R#1A&>Y-ICN)61+%NSRK7C>X!R11'!D^4Q+%.Y&+
M;%F=Z'8/2Z(X!L)XC,B"_$"/6$OT"2)%(Y(:)U(<FW/61(H!H5XG4@P]:I@#
MS+X*OJE/8,2C>HGWHK[XG3_>Y-FZ>*H/RMZ]M+_<?9F,)B'G/,6,4())Y#*<
MA)1AEI$@8(PS'H2@Q& S/B;6\XZK.E&V(8VVC*$>9Q?U/8'F"6 RL>$+T',3
M9H 59CZ,$)76I*[X-TDM_S,ALI6];,C%O"G-YT%UD.=\YG1P9Z.NM?IY5VKU
MOLI_*[?Q=K#SH3G=Q$:J*2#;8T,J5+4I<O1;V3O%T7=&=$$:=TXFP =F;?2@
MF<!9 4INY+SHTIC-F0$*W7=NH$--TM0.KE;M+E[])K<VTNQ<K7.^5$;G@]S=
M=/5)"4F\+'%QY@8>)IF7X=0E 8Z$?!=>YG*: #+8C'B8V'ZTA!'K**-,DH:D
M>)DA.VP_9L(+Z+T<NPFZ8^D"=5ANN4**+9.ZJ(:@0E+J)@?7,-O.#&1;27AG
MH3*<GV<V]8RI>V?)OI_5=]Y4!O;]]EG-5;ZZ*_N-+E=J[_!A7=S)[^VKY*@-
M6]UF=\4R9\MGNFKR#F\S=2?HXYKFE_R;*J1>+JA'A5!W"?R !IC(5ZJ*)68X
MY,1G*1,)TZLC,Q6#$Z\,AX4).F[KEAK/+;\7Z+GA6#WYW/&,:),F*W]67\A;
M2;[13U1.TCVN6=%@LK>KL0"]\3N#K4XML]NJ!+>[J@3;]R991G?;]]9RK9[<
M\MVE-\N?U7<.%>^H8_Z-WQA@=7OC-V>V]+WE&X0MDQ/".[B&3D%WO@5V0M3V
M5M\IZ9C%F6^KKZ*XR=GZ25SFO"UVO,O(HTY"DM"/<")HBDE(71RGG&$2,!&S
M*'0S6/OZ87(3+YNW#W^]OD<WGZYN?[E&/UW_Q]WUI\_7?Y1*??WP9UAP> 0U
MO1BP/2R RY&BBQK"B.:\JS<^3:JCGI26HK4CQ&8-RNH)_CKVJCD*INQE42U^
MH=^73YNG=COJAGX6AX&+O23TI%ZG!,?,5??_>!9G448<H947>3#SQ"K<TM+3
MUD.QAQ7S+&%@.MB2L7A_YB3S0ZHE!_742OYKIU*'\\VB/2?%Z!3E] /P8X>F
M?Y(JGMI4?"K+S5.]0K]?JBXG0G)JD/H FW7J1*F:&;3E!NW803M^3'(C@."-
MGTI,AQM,-Z&037!,80:%T6D%D-1LAQ9F$/3/+@QG>),2R>]>CD]P^7U9+D@@
ME^0P2C$+688)58NU*QB6BSA/'=\AE('Z^DS(Z\36[%35WB^*]KPED0??F-X&
MX =Y#S#K:/@*YBZ!K /.CU$5>9#3_TJ%DG4@MUP[68NDH4%G3 5<RCOZHF(S
M7?.4A#I!%&0.=M(DP23-?&F+>8!]YM(@RWR2QC!;?)3,U&:T)8J>&ZI PWD<
M&4V;=[:\0'/5B=H2G*#;S+!(MHS,<2+SVH=!00]4>_CIL[12VH"[]6K)EN"@
MV^D))O\&U=%X1W2:6\6CLMG]&(\1>HL/<D#@$Q_ET B#(^XZ'O]8"-'D0S8!
M^MN\R_T(PH1F)"0X#82+2>PZF"99BEV6130+/,%"K6N+&K0F7CB:$ZN.^D7O
M&$MR #B#' %L6)4MPP#3Y4$$3/*)1J  G*S:@\3LD-3LXX =;^K).'A2.3+%
M?(>.>K+LG1]J#CFSZ]O')4V7J]J1;GM*\=M\VU'J'2V7Y:_Y.BU%\4VM[#>Y
M=-#EKZ7(<E3]S=37 A:A[X0131U,,I&IP\-$VKT@P$'DNH%TG0-'+T5S*@8G
M-I;]#FH]CE'',EKGO<YJ-=<7J,\WJAE'^YRW=RZ P0[K[U;/VWK+-P:SZV_T
MLLS;Y5E&U'9K/5OLO4T;/LO@GFS99YL.O+Y&NRUK"L_^'T&+ZYR_IY58",<7
M@L84QX(+3$24X,2+7.PDH>,&#J<.TZI%-41D8@/<DNV*%RO"2%)&[[4K!0PB
M-&P";<D-,V-&(H.J=8S)9%2YX^2DLU7Q&!.K7]%C]%DS_^M>K%2#Z#M:5"^]
MSB)-XE>YUVUD$8J4)6$B,',S7VHGRW 22!4-XLB/_2B,G!A4VP- >V*E;3E!
MSXH55.WH7K2)RV6=N;S[.<P1@H"LY^-,!!U,[SO4:B[00Q^URQUJ#QJH@3T2
M _DM.1L0RK/Z$0:0O'813*:8N6_D>VG_%#?JE.876OQ#5'?%DHDNA;5>(S,F
MB!]Y',>>D'8JCD,<1Y3BU!&N[]',D99KEA:2&LQ.;-@^TV]JZ_#<M%!0_2-A
MURUF>5]Z)N]'>0LP&VFAK63'?U-VL)$ U2)<;'/_+?E:<V+]UOTF=5C]K]%Z
M$@"ZM2Z4$)I6SL(O<UZG*<L?%QO!>YO8[BPX3A/?2:C<-_*884*(M/B)B+#G
M$A8SYGE.F)QQ2C[*P/3GYXHN$EWBO,JB7]=I]:L=+V>=JH]C;'3>;A6Y\T[B
M:]":NP@=GCUVIC^GUX9BFA/\<?)O>;:O#<[(J;_^/.<44/\D96RFVV8#!%X@
M-\(^P5%"(TR<2+J@89Q@CT>!FV9NDC@P"W2"T,26YM/M)WSUZ_W]]:<'U!18
M!]Y4.@F0IOFP(#;03-04+]".YH05V$\+9K46^Q$R;U"5_;2PQ^NS#SP/OWYT
MK[R8.C?6H7$4,"?$KN.FF @:8YHR#SN^1SSAN$X8:9T*[LTZ]=Y-'867U5+%
M5-M ?5/_#)!WO(_"L/H9RP;<$9F)!;J3="#&&?>1=G/-=A?I@/W^/:3#7QK4
M615KU4Q:NZYJ\_C$W_O=]2U29 "54ELQAK]K0PE@7_4H\[#RIOOLFI4S;>>8
MKWSI/M-[Y4I?_0K^Q<IUX7ZS$JZ3!J[<GCX43WG%/ZSHH^XW?'*"J9VI=8X5
M8:0H8W<O[J.2:9:Y"KGJ?_.G@1C7 BL8P/1"3WST17%AZ1[;J)1&ZG1ZUMD4
M;%2POLJ-/VRV^6FNB7]<EV5S44+EM6Z6^>/MLRCJX%'Y3F3K0C3//=#OZF:%
M=.0D#?FNBY>;2CS57IX<*05?U04^FWKB"^:G'LWD_DD(IZLC+"*!O2SUPH!S
M%O!H4:GJ@'K[IPEY!5F-+<> M,:R1&G-'%HV11,JQ1YL'S;EN]+;ROT@;P!F
ML]HJ%3\IMO_81-UWG*,=Z]T+:I^ON6_VD#MNMST0[.TB9\#4TD9T2DYGW<O.
M /GK[? <)(W<,.7+B?7EM\>Z3*LZ-KA\J@!>V-'Q,SAAM8<N_[O\)@%\E.I:
MEP/>/Y.K#[I!OMAQ-+1<L;.!@'MBYV, ]<0&A31UQ(Y/.J<?-BC6*S=L^%DS
M+ZRMFEE'=5C(A$\RAL,HB3!A@8MCRCS,8B<+W9BZ601JX-F;>V*U[&JWFMRD
M[R.@YXL8R@73,DV1P(O^$>8M+=+]F6==5(^(]'H1//;(1 E'Y:F3[OH/U4?M
M,N=W\EVK0,;[]1-=YHO45S?LXECN4H2#B:]:?GJAP$GB)<(-*/>=P&JBD0&3
M4Y]**\)U7S[TI2$(U.-)7HR>07AKN(%G5 "D[2?\G '%7(D^)BS^6 D^9X ,
M3NPYAQ9\WW"[J<J*YG)K\JBNDDCW\^4FYY SB-,S3+UW !U)# @ZOBFP(R/,
MK/1HHHZHZMS(E]^6?"-W!_9.-<;%,]H0#$P[VY9@7+3^ID#CZ7,;N)U9XV97
M0H\ZU!,\"['+1(J)0Q-5C#>0/D[(XI1DB<.866\W6RQ.?0S?:U)VJ@Y5QW07
M+-RRK09UC*ORW$V>KVE3.&LO5=,_>M-7!3-C$[REF1K-V<;6>@\Z:PR^47LZ
MVP"?[EQGG1+<T:K#2ZR2"_?JY8XN^6_EU?JS6 E6"=YFVX!KRT+FG-@8[X<J
M6YZ08@I]*_]4ZS3-5:O(AKLNP4C??P/A-^[1304=S#@:HC9!C5D3/(R<0A"A
MV=Q$$_'[CJ/1>#-7\KW(1%$(OCU?:O,S1;40091%-!+833.!24P\3.-4>H@B
MY,+Q!'4X*,WY-*F)K4E'6)VM(UH3A;EF R#IN5AV1(=9@ZW4NW-KM$V %A8/
MJL>%L^2K#!":U><8%_BU[Z QXHQ#VK:<%_1L=I:J;KWC2(,#5ZV:;6<*97Z\
M:J_!PH (YQV>SEEX;$"(HT>EY[?_^TM!\TK=0?Q?FUSXCH3 :;\8"88;^8&#
M/;5B$1ZZ. [J&SM)Y D2IA[5"F<,DYE8=VJZ]95?I"@CW[E BCB@ N!IA(9U
MRI[<,/4Z);))]</3L@,*'UK!P*SF(?CUP\H=CDHV6.GP].CYBAR.2K!7WW#\
M:<-K@KSI:$I7RE6_R:_H\[*BJ^Y34^U",Y;B@$4))I2G.%9E"T,:!CQSHS@F
M6O59M:A-?0C\_OW-P\WMI\N/Z.[RYCV^^82N+N]N'BX_ N\-#B*FYU%;PP%F
MGW9DZWTU7N:HI6S1&P#):.LRX2"M>6\4ZHA]<*U0:Q#<R6Z.29\>[Z3W7A5/
M.>@RRM'!\V1J+)_JDN"2L*CJ^Q>0RR?'A1[WPL^6%ZB,)T6U>M%D4"HC]_SX
MC+,YZ8,"]5WUX0?-ELNK%2W+V^QSM6;_^"C?59W O'"HR[CC".FE,XI)1"(<
M\RC%J4@"PE.'91$HUG24RM1!:T53G3'55-$711?5A(&Y4L<ATEL7SQ8<&'(V
MD!F\#@[*9&G].TYCUG5O4,S7Z]WPPV:J^4G\WNMA4*QS^5?69!'5'0U>FC]W
M!R.I:N";B !S$@B5-)!BZD8<)]13[BTGF0 E#4 9F%BA[X4JH;9Z03=EJ4K(
M]'MM[#$'4V\PS'J:/R5XP!B9^/TT5A=-GY(7]*7]_R3G[J9@6+(F8/*S&AI3
M<%[;(.-YS,S3ZW/T]^H(7O %]T+F>YF#H]@-, E]#R=9&&,G<.,XS=(H"?W%
M-U&D:UT[=((21&/Z] "*4Z&5NA+Z+ I4ULDIM*J*9;JIZA25:HVZ>U_-K[^N
M5Q*_$F'$&Q;KVH]\O5K1HC<+L KD*:"IGWA^E*:8\$@Z:9DJVQV'! <B(L1+
M7<\A('-O 6:3$XE#D.>!3\^,6P %9JT/,Z)4+<J:J#U[/"*5);-[BLJLUG5$
MU-=&=.QQPPS1BE:U)>[[B?4E*A$X3*BZ98EP?$R\V,=)FL4X<DCBD)B2)$I!
MB9ZG*,V\VS*X6W8:)#U5M2+Z>?LMR]?/1B6RE75XDLZ\R8-CXA[D (X.,*VV
M(35@^717UV^^6I>J0%IUN5(O3*[[[6TG-W2HXX8>#IGT;DA$!*:1$V(O#>*$
M4N+$+J@]J [1B96X90$U/%R@F@LDV4!;/@SOFVDAJJ?FMG&":;P5B R*3^C+
M;*V*A ;)F<M!Z(-P6-<!,-:@Y*%X;DLP;UNV7:F-F"CJWA:].Y)9X+'$)])+
M3QUI-<*,XYA['G:I<+PP"5D::EU>!5&=>NWO$:TO+@&-! S!82LQ&2Y QP .
M":S4(E3$<THQ:M.:KU0C5/R]4H[@P69>1%LS)G_\*"2M^^7CU^HV^U525<F&
MET_KHEK^9YV"<MW4%E\D+LT("3CF'I-[ >8'F&9NB)TDC@C/$M=)0<D)4 :F
MWNFO<\QH^16M%#O;BNHP1P(,JIY3,254,,NQY035K%R@FAF\SK!DI\D8OFB]
MCR5#]X)O+#?Y,87"DM\!)C^K#V(*SFM_Q'@>>,I$>T,!<NN[-V1JFP"ZYMT7
M95BOSY "IJ[=I1U[][6/L&V4U="?9[9<AB/,]S,8COT:WLCR.J^6U4OMTJNV
M6-]4WQ.Z[4<B]]X\<AP<)+YJ9NEFF#I>A&,1D83&3N9D6E'Q,4(3*T9#&O5H
MJ]13.MHJ P;6L!+9A  8!#>4'M3>4D<THQ:7@Q//UN921[Q^JTNMYPWKIJD&
MN)><"_Y OZMC_&7=X[;["DGL<L(#@=V NIBD-,.IFV0X\BA/ Y^P*(I I=0&
MR4VLN+]=/J"B*2^AB ++JPT#I>?+VA,?IK0U7503KF^W[4A/T.%'3TA;Q=J&
MB<U;OTU+\(.2;GJCX-[EO2B[(/S[M5!1M7OQS\VR$%V)%?"]=_T9)\\WVC*"
MN.0$Y>M*JG;-R[9HC[[S"D!JW+>=!B28OO?Q44S44?#[5_A,<)L=+KN1_PP@
M,YM[#1>][WT;C#ZC[&,ZWM\P/5H%K2T_66^*U3F\ROJCCV(1,4H=AQ.<9O)=
M$>;&6+H*'N;2K0]2W^-1"*N)- 67$]ND)L?^6UON]'E+]MPFL]9?EIZK\N:O
M &;Q++25;5Y@5Z^V8;V.Y[7,6RXN.16V-JM+6N=Q_O*24\%\M+[D9,0,T]0W
MZD[7;;8-:7X6CW72Z2*-LR3VB(\3UV%R7Q=0' LF_QG&&8TI]1FAH'ST4Y2F
M#E+6=%6:SWH;G"];TL!<\Y-8Z=E+*PC ;-Y.^-W)Q.<QX>$)XF."V<H$/TEG
MWI3O,7$/<KM'!QC4:SBL1+LS)*VMN%KGS47.VURT%X*I0QE16NTY+,8D3AE.
MXRC D2^]LS 1CAMH-74T9V'J"$Z[.+..,%KGFG&<,V =-@#S@&7N#6V]G!U'
M%ULO9\L4DER9E(XP0Q105F)R9,U*3I@A;*D@Q5F8#!:K,)MYOD(69TF^5^3B
MO)G,_+$/=%FTX;Z_;\I*D;K-_D858>EG$">@;NADV'%$B(GP7)RZKL""I)0F
MC/I>P!:Y>%3] 1_T7;-!HEJ*DC2*<D!:6UD4"^A;'8-F7Q7(RF?YO6$!K7;=
MR&$>VS":/ E\FJJ:?%[$,7%8AFD@P?6XQT@29@[W'=A=I_.!/.?&TYM@&'&7
MA(' H9,03 (_PK'+/1RD;IBXA) P#;HO\I.HWN9[[ C_T$CJ[2&L?6$P;Z$&
MI#LBZ@@K4#K2]C836A):VE ,TYIU4Z$E]NN-A=X@PY5H78CE8]X<,K&7!SEG
M2>MLM;_09:Z:[#7-]![H]P5S2)"0,)*F,_$QB:(8)TP:5N'$'H]#SN6J!8D5
M &A/O)UH.4'B>VL('B4#)?I)77H4)3!8"X%4TQQ, Q3,."A2;>?/"]0!UK&$
M>CQ==-T_)3L6#08< UOF T!Y7F,"A^3 M!A,81#%:.MH?Q"B;#=^09:*E"8)
M=C(F,$E<AE/B<NPQ5X@P\^4?6GG4QZ>?V%QT9<$50< 6^1 %C8#"6;+!-+PO
MEDD(X% ^P/;^+#G-MNY:KQ&V(3\IQ>!F^W#4?!OIDQSO;9)//S65V_%K7@BZ
M6OZGX N/.)Z;J0O7J:J9$\0)3GE L!M$(:'$S6(OZG8?MCR/'7F#G0CPZ**[
M<_&3\CK^^'-=:6&=HZQ=8UFWQA;BJ<G-?=+.+C7"VY93 L30R&;M:* ?WD$Y
MQ&,V#Z5'^@=S40Y!@?LH1^8XLP;$;?9AF=.<+>GJ;EW6L;_+M*Q4UBVTTL'
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M6ID-ITE,;" D354L3U%%#5F "AW'1,-0G"TIS%8<"FEB,(Y+"[ 99TMM9C8
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M6@FDSH:EBA=;?E&I&$:;?#G0T'>:%Z096)P1=J#-K)%K6$,-;ZAA[J))V;U
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M31>(4>IA$808122,)8@>121.!"+"E1#B* E=TPX_(^$SB=+GDC!9M;!R2*G
M^S\D?U$1>R^X<)0%LPHABX1/W(@CZC(7X2A*4,93#P6)F[@QPQ3[:?,]O,[9
M^WP+MX0!IV\VSQ=0+PAI#P^8:WO0-*DU+F9/>Y*F23TRVN^:U$7LO=HF]0C>
MTS>I[RW#NT[^J';%>_Z\+E0"*3"U\]SK$Y[!:HK.CN0DZ9U#<MFZ1SM'9MZ;
MLP%A3^[*AIXW#7!?R54+5=3-^,__Y&^+P",D"0(7"<95:)L3E @>(4;"+'4I
M%6FF=0]VEL(\0>V&J%-1=219:#C[&!?=0/8(:8U"V/J"&@2OSP@S(FQ]O.+,
M >LS IV&JL\]:&;Q?^4YEZM=YNR2/2WSI=+=S?*5-[DT349Q&"0X9@E!/ PS
MA#&59PX_%8@K=YDPXJ8!J(!0B^K$ZMCP4-7"D ,N8(Z>'H)Z&ZAU7&"*VX;D
MD(%=/IS][&V0S)9V6CV:LVZ[(!B.]V#8RR;7662EHB)5:GD=+:D3(2]7J_4/
MU17JT[I0SRQ"[+O4#Q@*<.0A[(4)2D@4(C\6 1&<1U&D56H(HCK395#3AD3=
M]53I7=5$3'6SDW&G7*\@3;:U\=2Y:ID ): 7+E>O(L;U@/8M7DV+AAT?JGF=
MHYZ= BC(S<$$@!D&]FT!!XRT P'H#X3K+C9CG!HHWV$8&?HRO CAZSK_59KM
MIJ+A(R]IL7Q67QSP-+GAE2:VC9(!].OEY=VVU:73XD&_L$ #D'Y#:!\+F 7L
M@V&"R7#ZHAH5#&@L/UN=@+ZH[?( P%M&ZGO'UU_Y^O+UL6K*3#<O9+5ZNR-+
M!J@;&EAF!L553;J_RO]=ODKO\9$?W2TW[#B*'W"IT!!&6NIL"QZX+MM#!JK7
M.C*;*G7OVG-JM(Z01^JL]8I9#*2Q$LI]JYK;5G6T;+EY^T**?_)-U9VI.<9S
MD@9!F,3(8[$\WA">(9($ C&?>(FJ\B%"0 (A^J0G/^,H>I#NB0;HZ05!IL$$
M9@-:/-2MN2^<'1M.@U7=<LY^0 0NOZ6H"(#PK*$1."#'\1&#%484"WY?K^0;
MY?5_OT@*7]<;WMF3R4U2&M (B2!F"+M^BDB &4J\,$N2R',Y!DU)T*8\L2&I
M$F0:/O[5J3DQ* 34PE#/GDR"#/!&I"([46<EL'PVR_ZTZ,Y?^0>!H[/X#[2
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MN&I[U=S;)*X?Q"Q($,,)15BP!*6A<)' (0^"+*893[23^L[3F5B?VX2=+65
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M>K,52ZI\7?5W8 ,3'93U--LV=L  8(OZ/C/,V3(P38880&);F6(Z).?-& .
M<)(Y!GG7X$!05RZ4US]Y09>E2F_9%34L(AK)S3MP42 \C'"LYNNX<8(X"T4J
MDHR$2:1]*N@A-+&YJ$IP7K<%2WS/@+.N>0+XSGUP:9P7+($ T_N&J$J\V)&]
M:)5Q61(?<'ZP!(/9(<(8#MB90D/&WH-%W_OSG2XTI#@X8N@\;YKG*GA1</9I
MF1/)MQJC6?Y:K,MR0;%+8I8)Y/.0J.!%C++ =Q%+$]]+1)!Z/C#;]0REJ>T4
M;TIYI%'/2VG7E7-#%75H?NLYI/2\%"ORPTQ4G=5:EB^*8#4B5>IG1=-F7NN
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M95ZX69J$5 TD\FB ,&4)2GR2H3AC+.()CUG(#483G2&G]6T>/8_HMYP\J5/
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M413'L9?%U!=NXD'[?IJQHO4U'MT2M"'FJ(_/N?\7\O3\'Q^K*0VTX@V@TH:
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M_M>O;WY+G_%+@.ELN0JS5!=83O]AN?[FFWD*J[74'Z7KIZV_4?\&%[\&]5O
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M4TM@C0C9H04LL7:'*0Z"14< X$8Q:Y5\L"OPH1;J.@UC%S.VT>T]ANA@07<
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MIM#4>YNH( M,VN48T3P5S@=AL(/\I2=$[XZ;9WPH=>&JW".9R]:K&0V=:CI
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M]72 O@?;T6MT1:3:2R"H2'+S&3POAKBBV%*@SCRT#O6/G@,P9'KP<$#89TC
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ME75@%^\R]GZ!7\,T7[@>F4=DVB4044KRG@WQ@R9#[9IL>&9.-2^.>8RFWGH
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MZBB)=F"9;C[+_!(2;CB::(9:>.'K2#D$57@&)Z0$GS5AOC *=UN_.FRC92<
MF6<"H*:"[P! U_;"^\4TX44WA8EWVEL9)"1$2\RX6//=R5U,7$N=ZF57\XY9
M6VC9"4#VF0&HB> [ -"]%VZOON,B39>XYNSRA\OSGR[Y)!5CA'(,>*FYSK43
M8Q F0/;1,FED0-?\OND00G>"GGMFT!M>91W@\H*!DUG></#N;+5<A5F>;GJQ
M3[CS*1BC(,14$Q<B\9/(6ENFF'32.NM:=UY\C*:=T.:?&=J:*J(#8+U?S,DR
MYV5M2'3.V\7>69+QQN0#11)1I>H^2G(?)7,@7/&1D7.IFO<F>(B>W>Y%V3-#
M5#,-C!W:/<3(+V>GIS\N_I8GQ(U7UBO@]>U9,9;(HZ0PQ8E@G0]!!2%N FOK
MJ]VN:^X&GF=UJSZ0P#NP2O>>Z9<7<9?=U%Z$TU/,/_^X?;Q/L!B1ZKP3C[8.
M\(T*G!<.I!*!:68-R\V'WAY'\F[P?"XW]V/H<6SS=R^O'PE=R\_STURO\8C?
MV@WPXR)4;^%E^$'"I0@Z*EX@2+.^H.'@$A/ 59*BQD?E]L7&%D-XR.J[8>ZY
M7-T_C1(Z,(YO<?5ZEN9?L+8/GK!(_@'6?LVJ7OYJ3D:=H0;MC(XQ*2V;-["]
M0<!N('IN%_"'R[@#@'RH/>!FF"]ZBIZD=/;E;-VT_"66:9JN)I@"RY%Q0(>^
M]CBM$^Z+ BNB%,FB;?^F^#A5NT'IN5S.#Z2-_?'E-_B:X:>ZYL=V3EI8?J8P
MN/[GU;^?3;^%TW4OMM4+,KX_B-/UD)&),4'Z)!&L4@9H_V@(&%Q]D7#.IA)*
M-JU=L5T(VPULS^TBO[U..F[3N<M4["-:=^[S\4\YZ'O(%I_'3E'.V1A;A 74
M2,C2#($"S,U]A=7TOQ1;GRLC3?I>NYL?2-6T->J6>XG?\'3^=5W^%;Z_((*F
MJW.U353QT1<L@*:6H <G*/JFKT2F&$::;'D..WGYNZTW=L7ETT'HAN\_@#+&
MCBEOFH/[&;S@2S*T,3L+Q=0!P+7G8*BM=X)%1>9>NNCU3B#;8]&QJSA'0MI0
M:ND@=MB,*,RYSMSXODDWJOFYE]S$E*.V%G@6')35&:(RY#D8E[CA)H7<NAG2
MPQ2-FWTX!@('T%0'N#N7V.L9R2?,$DZB%SEH;2K!))IJH9U8SZT.UC!MC&D^
MJ?0V#>.F%HZ)K:.TT0&:KDGF8C\D&8PI)8-3WH)*S()SA8,V62?GO1:VM>6Z
M2\6XV8=C(NI(C72 J9N'_DUA7; DO%71&@_(<GVO0 ;!AP2<,Y.48+2+Q#!&
MZR&RQDU9[,".-=/9X3"<$]?'QP./A#COPX]U=9]@R6HB#T(P&E1,FD*<5 <B
MD"-:0F(%F\2;Y^N-F]'8:[QYB#(ZB3<?X6RBHXB\< ^:6V)$)0<!,8--DD1)
M'H*Y/7WNX5#SD?7&35L<.\ILJ8R.+W-K"OK;^FR['D1^^*WMO9_3ZGKV<2*;
MW</&U3U84CZ)@LQ!9"F!\J* 2\X".5+,,X$\FM9.[/V4M*WTV-2D*R$%3YJV
MAW,>E#0&7,W]T,KGX&5!A<.VN>Q@#%(#O3]<V[&_J#MPO>]IXRB23M)J$D&N
M-9<E4?"0= '%(BG96AU9ZP&H!_9$?:+6A@<H]O&&J/M(N3N<7&OK%[U*@?D(
MW'%1KR\*Q.(DG98\9T0>VB<R/YN&J'OI>->&J/L(?&RG][Z&GLD:YTO64$RI
M[=>0G*J2 W@5A4=1&-GAG3S<Y],0=2^5/=80=1_Y=:7_NZT[HS1TOD8#S-=Y
M.>3.@S<DG*2\-8IY);'L#X7GTA"U#2J.DVJ7 /GX^_RBP;S!6C\60;-0Z@52
M 4\1&6 0Q&0J)>3=6I ]O,[8+UU/ I##I-HG0$C7%VB7**137(+V49%;QNF,
M-4*0I*R)EB'CVAP!D:N5QGZR>AJ0'"C9#CS4S;CF=^7B1KHZ8#EEFUW)P,D-
M Q6$)J0S 2E:;QCJDE/KN/<>,GHZ?XZ/98Z5<P=0>3VCSYI^>4]_S#>7CV_G
MZX9IJ4KGH@EDMO7-S$+Q)!EE#2<9%0TB**,L"4K$UF6_N] UKHM[M/)OC]1L
MK8FQSZM?0IJ>3E<_?L'+*3D%A<E*)F ND(6.M=]TM@4<$U8D5IQFNTV N/O9
MXX*AO?+F[20Y-A!>U(ONV77JF63*UO$HV@A&U*L$Y*73H6JY\,EG)_5NXU;O
M?/2X!\RP,#A.CAT<-N<%<^?$6U^$"Z@AUE:<Y*-QB+Y(X)'%S#(+/+8>SGR#
M@'%#G<&@<KRPQ[87KV;Y7:EN^(O/8?'I,I87/KJB-$C&(YVM@4&0A'HGT6:+
MAD6V6W1S[\>/&](,:S>.EV<'MN.F[_[FLH[)*)&L=A94\6L32&P8<KZ2(?\]
M*,\I4!OTTOW-7BVXG^CJI/4[S6'R[@XVUWK."9F-,SY"04T&D6$=?8(>A!="
M<Y&S]*U/GZ.:_3W15?V!BMZUT]\^4N\./3^'Y73Y&]$2\KO9OX;%M&ZR#V&%
M?*(98\;4LFW'J\2*@^A2'4:M!*NIIJA:]Z_=E;:>KER&0%<CK72'MK5/@,M5
M964]X3B3>Y"J[C[A)-F@8ZZ%N[[^8:0'SXDS;706UE1/KW7KF=VIZ^D@' )Q
MS31S,.:^X2+.FZ1BKNLO_L=TEJ\S-3&(G&>F0$I-NZ<8#Y%9!MS89 27HOC=
MAA_=__D]O1\<!Y!60NS"^FR6_64ZJ\4XZRCDKXMU8Q(F8BFQ7BM0S*$PUV&V
MIC8;S#*3T (S[?LB;R%F[-J6(6Q+"[EW :!M1O)5*9AJ,NLU.^D2A28J\=H.
MB<)/HQUX(Q!(CE9R%;)IWE%H+P+'+F=YRD/L6/V,?6'T[FO5R_+F#(V3;V%Z
M>C[UY_W9(GT.RPO^WI7WB^DL3;^&TTU<LKD>63\#YV]U%RXGCF+D;'B]40](
M#F2I3[Z1SG&!)C->)UOM=MTT '%CE\(T/C_'5E\G\#WOHUEYWHAB(C6YDC%R
M0$[.@PJUH[G1%DJQW&CD=#;LYH9M6V'LFI=A@'2<(/M#PR]ANMBT5+*:W$@N
M-;D Q0")21$?)M2YC#%P@3G8W4KN'EADW(;:3X")P\0Y-BQN"N;%_!O.ZNO.
M=%;GW-5.7.]F_Q)F^?R>+22?E;*2F/*QFC\%GCD/P@2EM<.BRF[SX/9:=N36
MV<VQ,YS,^T+3KV'Q=UQ=5AV&S;RG+*,SP8*7F:(/HRCZ,)$<P&2%DB$P%G9+
M3G]\K9&[9@^,FZ.EVT%L=Q$MG"<[508G/!A&@,]D+FN2I4L!0J$_O(B>\:!]
MD:U?WNXA8^26UD,$:L<*N_/ZVYK&,I_1!R[G95V)>%P9[K:/:UF-NQ/)PQ;E
M>B6*L60KG% 555%#X$Q!9J0_9[P*:HAW[J&+<B]:AIZ?H8EVC3?20,J)SE!A
M,WC-$_@DHT!?O,!AW]%NTC/^R^R12'CX#N@(X8_MP+R9;R;A5(9NY;=,7(K1
M>O*\8E25C^SHE,4 MN041"P6^6[9A0\L,OZK:B-D-)5F3ZAX/4NG9[7[_FV&
M".)*A!B 0K\$BGQS\#$SD"E)"@<1"W-[PV/;:N._A0Z%DR;R';O5T4U[>/<A
M[Z*]3K!%)841*(BKB?V,0;0!0>L8D,G"M-^M^F['!<=_(6T)FR&DW$%0=-_+
MW5M<3:01&G7.8'DD7YT53N>H38#,9<\,>C% ,M"]I(S_6MK<?SE>Y/W,-KAN
M3B>9FX3("HA,.T"I@A3<>206O LI6<Y9ZR*KZ^N/_][9&"H'"W?$,^FZ."XZ
M!QKG,:8LP+HZ(3D%5AM85J-H>38YD/_5ND7MM>7'?VH<( (Z1+1]6HVW\UDZ
M9X;0+;B,%G*HR8[!6HA9&."\N&28C]*V/G7NIV3\1\4!+<F! F^8Z3?,I=QO
MZ3/FLU.<7[VMDU=6W;5CAIOL^,DMK^KV96386[NDN3?).#(N"2EX#AJB((S(
MG$H,.KK0O,9MF%N[ZWO@UUKYO!ZI^ &_GLOV6D[&!ZSE2KFF<OQ"=(33_XUA
M,0E<!E&\H*B0*U#H)9!/+X#"0Y]M\B'XUC-;CJ6YR]N_?1#UD"$;7(D=!&A[
M\/MZ]I8LP<??\?0;_CJ?K3XO)TJ[;)@2D(NM22.,?$:9"G!,Y"683*)HW<[M
M*(*[O))\(K@>J;[GAM6Z&3_^/I]XIXQFWH*,C,(:[^O\-D&;DB=M"W*-H?6C
MT"%T=GD)^F3(/$19S^(B/=IB1(@,LO4&%.<)G(VBECHP+%X:W#$;K=E%^E/?
MB!Z"H6'DV^S2HGUX<9EO]RN&*KWU#KERTR]__&8:8FUS,JWM+=:_F>>S#W5\
M-^VE3^LROR-"D0&H:!6V#"V@1B'.)1U7&V%Y+;ZV3DDK0:;HZ@6; &>8!N:5
MYE%D7G+K@L2'Z#GV-'Y(YN]NR?QOLWE<XF(]%^OU[.O9BGX\G]6./6LX;$KQ
MO;.>K(&M"5Z,_&6%X% *$$9RS8+S&%JW7VO-P[CA4#/TW3[+1U5U!X[GO</L
MU]W,T)1@C8Q@52"I\IK0*@P'8XM,TB-/V+KN;RLQG8!O%(S<GK[<1&&](N^\
MV8WBPAGGR?=QV9)GQ1&B<QP$5[D(Y,7KUJ\>#Y S+OH:*7P7&!T@_;%#E?>T
MZ%EU;\XYN>B-%IEC040/.=?K>5\[7M6$E*08&BNXYH;O%)UL6:!#3!RBO7EC
M48X-AY.JP).7O]UBP6%VE@DB/-L,M3$24(#&*%R311LF75"[Q:KW?_ZX=V^#
M@*&!(#LX8RY/[I]_7(NN?EG@OY_A+/U86U$O2_05STS5W'I&(78TV0-/VB4;
M'1>F]=/$#F2-"ZFN/)[62NP)E_<Q=+YUL91"08T ]'522N1U>D&QH$T,:(6@
MH]X,A<OM9'7BB;>"PC:H-=)+IU!;7N[@<[..C-F$)0-#))G)I,$YIR!;E:UE
M*177.OML%[HZ 5LK,.P MJ,TTQ/:?OYQ^>6_3'%!1'W^\::.EMQ$+D0=\XH#
MRYPBETA[- B30%D591W>8[0<[LQ]@+)QWZIZ/79;J;(G@%[?='?Y.]_>U@5?
MHHU0GV(V+01=J)*TNECC<U;F2>SB-@([,9 -$;*+C6RBKIZPN-Z_R[7$Q,5P
MLWJ!4[>J8Q%!91;!)U:[?TF1*>X.=R+6=LB[2TXG.&L/@FUP.U(CG8)+GK,B
M#!HL)"(F:N9S'5GB0D:0VDLE,^-1MKY>?8"<3D+=4<!UB$9Z M?QCLJ;RZ8)
MDGQ:RU0!5.3E*NXC!.Y$;=/DE&?"*CG814Q#/L9-5>G3A1P+)F-?1Y_?GEZP
M_^-:_8"G4R3Z8B"G7-D($IQ6$G31UB4R!=KMUMUM^QJ=G-JC*7_>7A,=-U=Y
M)(]HW5>1A(WYO"#BY/>PR+^MYNGOYTW2ZC_>H&.Y//NR^=YP*5?'T?-$R5<-
MA?84:5A!2!<P> BE5E KPG1@S$',)D74M2-1ZYSU9Y6&%2@"];7Z,R+G=)8Y
M"ZYP!*$=)\Y<S%[WZV'TGH:U#_H&3\/:1]4=.-3;DSPRUAD6=##QZ 6H) L$
MDC1P.@6]*5J%YE>E_UG2L/;"R,YI6/LHK%?D7;YN:!Z=<J!C3:QDA?:VTY*V
M-7)E9?)./0GV>KCL;*3P/=*P]I'^V('.EG01VF&F"!8@VSJ36R0*'A4%CSHZ
MJ5*0):#<*<@Y(N]FE"2LO72W0][-/H(<$0O+Q6KR(<P^;>8A>RYU4*$&:Z4.
MH*OC!2,B8.U_*17+1>]TATV?>LUTT-^NS,:-!3NY2!SS>#I< 3V@YASL/MC$
M52R0#!+9NM3NJ2)!5$K:P)6V>:?A(+O@9DQ#<H2R;JO[ ,F-K/#S/MKGA)N0
M;?!90?&*[!NO;X11&"C*H0O"(W,[E;(^HO(;BXZL]$-4-F\AO[$5'[Y?(UQA
M1%N, \:2!%6R ^=,I(/-*($LN*1WJC)Y3/'7%QWGG&BF^(/EUT&T<>V:;7WN
M?:1_M[9^5MK"1>9 GHP%Y;P%KX($*83S(B6;FP]DW4;+'RP'Z)@HMXFZ.H7=
MN:=>.TXJ1:ZYYZQNH))J=8. *"-J08ZUT:WO3+=3,VY TT;;.T#H -%W"*(7
M\R]?YGFZ^K$9\?!^,4T7MIW+)$)QK$9^AGRYH,&SD,@TAY T$R;+UA?-NU/7
M'\@.P<,C,&NDG YAMV;E7^>GI+'ZD'F1)YQ1)4Y6GMO:XK)V%O%!6$"9?-%:
M1"U:5YCO1-BX,?D3@>UXE72(LP_3Y=]_62!>'Q5YSIED*CJC*+R@X(+.@^I2
MQ!@@^90C.:3<2!P8;-NI&]=]>R+$-5).A["K8V_2"O/+Z;=IQEF^QIG3(6-*
MGLRU)4\V*P_.% \\)W)F)9-)M4X0VYVZ<=.^G@AVC933 >P&R4[R1EA30@"G
M"FV]: R%6C&2VQQYD<Z0P6]M%_\K@W'0 'ATF'2P5>Y]YSJ?J(EKU^?RA\OS
MGR[YQ*%SRA@%C,1+QQ JB,Q82%*6G+VU*K2>\'T0H7^8G(8#\;7+@W1393=L
MAGTXIB]8.*$S;,W#N[/5<A5F>5UY>?/0F_ L#4<ZU5 Y<N29%Q"X-9 LQQ"%
M#U:VAO(^]/UAGCW;('@PU78/W-H\<B(5N?S..W!<E9J%QR"JS"&PP!3QIG)I
M??7T&$U_F OUX0&ZMPJ?;T+ZY8_GY59R/BGH"5I]/K3L4_?VW%D$3Y%%'@WC
M-FL%-O!Z/UJ'_R5O(!?.DT^$P=W2+_ZP6>0N,12L-GE@"10* S':!(498:04
MH9C_RB(_.(M\'_0-GT6^AZI[C=36+WA1*958R>3B</JC9JOZX.E<<3EXZ5.*
MS6\F_M-DD>^#D9VSR/=16*_(.[^ E,S)S(6%H*V@'<TED/N4 75F)F,PV'SV
MRS/,(M]+X7MDD>\C_;&SR+=UH$S6ZI#0@C.UT7Z]5O;1>K!6%2E-=#R:Q]S"
MY]G,<R_M[=+,<Q]1C@V'+;GP&:VP%B5(QTR-V2DRTCY#$<;1_R\VI;(3&IY;
M,\^#P=! D!V<,8,$\C:)S(25=89'C;6%@R!-@(Q:,89&)CE8)[*G?K)Y#G>
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M._"-.O#O UN37X<5V(>O4?D+^_F\#>8R+H5A:2QC0'ELEATP-58.$(GCN29
M1U1N=W.G,#_+^_,QNU >I"J@W'/YUP7<--4F]:LR6FL0#]1Q+B1:9HK2&[UW
MJ<E]9JZ]EJ*PJY,'WNV-W/OJNO1>=3EUHXF>+M?4;-W-B7EAO I :HL U5!$
MS9#X"]>2"DS<J_3F7<6DMHQ>E@3'PM7DU%T%IN)EI*0S2EM&'8@3"'%KY2S:
M4>$ -!X+@SD)5&:V$MU#HL^@/\0QNU!_1"J@TR AD1(1SY"*QXAHB^,Q J.D
MU^CZ,4F(YM)3,T@%DI\X)+H3K4X1$MT%XPIXOBW2EE AN>064)\:/6"<NML9
M"S!G!.(4VR%SIY']SPB)[L2-%B'178"J@&O/:\BG\ @HHYMB#!;Q/*T,T*D^
M'#98:T(5\IOW![\:,^3=GONB40^1UB4R'4D9 !0H&0T_I5%XP[E(/8Y88,Y#
M9OTP5*IA.^P-X][&#%UT6OKD]WJ!/*V?U:S>-A,W2H@\=0- )*Z=$,\SEMFX
M=(2.QR;&$/""(>>U@1AO)/P>C%'J\/DJ.-,'Z^TQ14,I_IRH]53[WPOEH>0.
M.&NB3RI=-,C!"X!<JEFAD.&L:]VH#I^OJ=O"2:C53_%G1:W(DO7RL0XJSZ4
MS*=J)^D5RG!# )(Z8&4CAW3(3ZXG <K>;)2@5T_EGQ/!/C1WT]44A2 ^&!4M
M,XS>)$T9EHK'(XN.IQ6%I8*6Y#=>3]\OZYD7H%=/U9\5NT;WZP6D##:$16UR
MSU.=)(V!UO$8K"U&GH@4G]DU%ZG+]\M&MI9@5S_55W#&RQ &C"@TR#@,$%$I
M7U!+H)2(=IM0C;R(G!*Y'P%.E#]]!KV/CGJ_/BWVM;#=')ZQV9SQJW*^V%!#
M+=/ 0YL2CR@'A@@!N!"4,R\%&^:-(8?PE5_Y9F;=8!6=NU"@%N[W2FG=UND@
MN, ]A !C'\V.YA88&H^ F#J)$7&2^I,_L>5N>5%S8O/1*Z $$6I9!'U6_]Z^
M!MH1J)Q-"4:" BIY]#8-9, PYXR*)]8@LR<S##&1LT]6+K(Q9*-&!>LC3OVV
MF2P>/]_J'Z.Y'B^#E;Y$*DSO%[4+/MS-[Z;^,0/;2Z<@B@ZHM9[%TW2(!VD(
M U",0&-,H"I[NY?.0IY]/O(QO!X6TGHN2/I5&7A>@6.IEV=U.%Z6R'FFL+6J
M?M</ZS(%UR&8H#PCJ:6-B<A( R2D#G#MD$K-K[7:J*0T4%F*;%,Z^P3E/LNF
M+@@ZL:J"_6,YIS01[ZZ#T4Y;XP''.*J?P61') 20(:XP\2K^> BW:/7]LZ^]
M?[0WTP>(6DB4H:39LX(QBS:MUQS%U62M %ZHE%\6?Z<],0 :(2WG@7*>O?KX
M0'-I16[Q,Y.[-$%*>S[KN6R^14352AWW"&$!1]Z"%+P(3(B_8U8HS['C6+>K
M"[3S$ZW8)W\R]F74^CD6'<$?)^[.+O2[6"S+/,ME398!ZH^T^-S@I4BZ3KF.
MJB3">HX@5 !3@@!%B /-T[T<CD<W)H*D.G<]XY^E*DFP1 0K)7!,IB:-#(/H
M?&N .">41%.!?U4EV6Z33\C9X:J2=(&_ C_Y1>T$2YBU5&G@>:KKPBQ-6>X,
M:,.58T0SS'+[MC]C59).%-A7E:0+'A5Q:1TU0ZV/4S9 VY3R0KU,)34YX"PN
M1&XDC>MT(#;5$.W?'\G]54FZJ+7T^>)BOP.T"G>B4'"#D0?(D*0<$8"./P,2
M&F(5<CP0V^JLT>IS=;"B#YB;M4KR:K8" [*[6@)E" L<520IC0<C2S10+.DI
ML*"@1I+SW(E#/WW9DF.VJ3Q(54"Y+;49J,(..2>B7ECT(T4*AR,F .L\"E8[
MH57NL\_YE"WI!._ALB5==%UZ,]M:>L,[#RV."K#!JM3H@@/ED 9..Q,(ILK)
M=C'X9U&VI!-<!\N6=-%=!:;B>?HF1%H':0P@BUH&-HE. P'8"@,M8E99D=E&
M=,V)/H.2)<?L0'W1J(=(JS6E))=(: >\%$EX9X"1$ -&G0I,IWJJN2N25YH3
MW0G&O3G1771: 2%VK*/%0HEK*:ZWI\1);#0)QF @A:1QS;@ #,,"**."Y!C9
MJ,+3O#]N$Z\*,O4A0;O7P:,1.0NR/26 4XD=YRR :(Q3XE-T^0Q'",1%ZH3T
MA"%[HLYNV\2K*7UZ6++U0Z1>LG5Y9F4V4 %9W :$2I5X3-P5N%@4M_.8,,L8
MJ:9CQZ=.J6%G4+7FJ#N"TV)_SFP_%%/B& I$404@L2DN0%N@&=4 VB",D(H@
MD[M<?-&@HYH3QSIQ\E1!1UT(4LM"R9) YQ2#,MDF%I0 U$,*)/4<2*^<1]8B
MA+/7LSYI#F7-&61'+X634^"<N;\W1\@[J30G.'J=C .*)8LH( ,LBM@@*3RM
M9QW\U.EC1=9$-FK4LCYRI99:8YBTA )O*8MS%U$+R! @"'=2I*YNH9K6Y'US
MC&M..BOB+!U+A+.+K%V?]YJPW8+$+3/^UF</L>WXW6%C;8]10AU!MP8)C9R/
M3CPB\; ="0ND, &X8 B36G!*<[=Q^EF";HFPGD9C @1"$E!'#5#>8. =8\QK
MRYSZ%72[U<B?D+/#!=UV@;\"%^?C)-HR_QAD\2G]'])\TR,82V56,>* 29^Z
M5Z4.,5QH@!P.4@2LK<GMR.\1YV<)R>U$D&88M.HEWNH-@VEH! J+98Q2,2(?
M#])Q,L9B 35F&J'<_9KV"E26?-E@;T>G'AA40*B4>1X%^'XQ<>_\O1\W/]*<
M5J[6X_MHW#NP8X!KE;K%<@$T#G''<!1Q2X-S(K=;TT*L*LG5AP3-L(A40++?
M_,1/]3C.Z,+=CB:CY'K,1_?^Y:2TI9HKZ("PR1.Q6@%E.0:$&R8<)<&PW"'"
MK00K>\L['-'RHU(!U3)<>2AEH C: RL75QXH  6M (P0*HQ1GN%JWNJZO5>?
M04S[,7[>B;&O@.T7X\6_\6[[U%<K^3I$MV:Q?%U8Q.6AE)5N.0@&>:VI0(SD
MKL'23K*S?TONQ)?-GGWYP>M-R7L_-<W 5Y^??=R]9NEA8S'AI^N^]WHZ&4UN
M'O\FJF)D=71_1N.[J)XC;CV/_62N"\^L4\]TU[GYZ<<;(<FED)(XD,I@+#M[
M:,5\>GVB%GI"N,L=K[5+EF/M8]3[TG]*VG\,NOC6/"N'][T91RLS6RC^F@JE
MI# <:"LYH $B(--S-$>6I)83A+G<6W]'$<M:S"R<V;2#0X)4.N7H@QY-_]3C
M.__V>]I4+L/5U'^X2ZOWGSKM,_-/(VU&X]%\Y&?7QAD9W1P+M$M][U'TLA7"
MT?/&V#"%2>"!'K)XG;]:UG',2JAA-5Z!N]=^I:SVCVO"M542:1"<3(6-=)R@
M8Q 83Q!FJ7^YSGUUTUG(LA$CA4U:'Z#Z,[&9ZW$6)O[3IR 5[RZBXZAO_,OH
MQF=E+I<6VWMNC;02&"H5H%YIH .-JH0H,)CN7$/N\L"=!"P;I3$( X<#J ([
MN"B,FDYC>KQ:4<NHVOE\.C)W\]5:T^/QLJ#"[&*R-OZS:TKC'(F/WH/G'E"'
M%5#>84 U])(%JKW+S<4CQ"U;?7<09IX*O IXNF,1KFS^J[5X[0DSE*;JOB(>
M\*G  D@C<4JBM'%;H(K;W$_''44L6T[WE)8R"T@5[-1;;QBN@S:,.4D!]LG@
MJ^CX&LPM\$@2Q./$"+*9F;95D+(5; ?AT_$*K\!R;4YB[:8Z@KT25@"AL(F*
M811(',]/$@LG(:)29"\)MD.4LM5G3\*</DJO./1UYR7HQ60^<FFNHWO_U=N[
MZ>)P_OYO.[Z+Q_:D_'0O?K<4XO6=Z1#WPYE$&OS^> C5#7V_3)UTG#(&G+6I
MFP$WP+"4TR ,(TAR8T+NTBM#W2\_O7ON!^+#2R N7P&Q?/STPB$F%O4%TW44
M\QAH&C<)'HC0R")+LL=OY9U!I;?371BW.\;UY!!7X <<.><W#]L'6,3@(1JX
M0$$#PYV.CC03T8<V!B"N@PC2*)N]3-N TZDET/;T+-U\UJZ$,M6NGF?50ZFA
M&@?H04 : HI]=.JL9L 2Q[#54#B2>RL\)%-9'E=#GE:D[HEDZ4?)/R;W?A8/
M%E_BK].17=]R_#$9S=>5_1SF7#,'@8>8 XHH UH0!8(0-GK/! ;9[BGR\+=J
M)%Q?8)OAM%R:- OA5U>R*_$9L1AKS@!*Y2HH4@;(N+8 ,\()K* ,O$.SNQ=C
MEWV5'HX41VJQ@CUM=1>_$AX%9O"B?*SB/)5N<$!Y[ '$CL4?&1?-;.X;Z^<"
ME'T['H0GQRNZ I8<N8]_>@RP-(X+;Q "7J6C&PPAGMHT I89)@QDU-K<1^)<
MLM<2DGWN)X)^9#C_17!QV]Q-YM>!<>DA"0!C0>+*CTK7.$[:42H9=E!)F#LM
M)HO@-?IU0W,N+_%[$*#BZ_^O_B:]^G_Q/YKIHN[F$<4L=@R5K3Y%&U$S79-O
M?NOQTI*E5\&@HDL84FJ7U"H]^%@0HA<1L-8,B>P5$7;(<G3<XNI-_?*'3REF
MDYO5AU*_1"^CCXL3F>-,C8ZG<T$%0(3X0+4V3&4/N-XE3.$;O!P\>!6'F$7Q
M%6RE3][,^VA3YP__'+EH?>[]Y,Z_>?A=_[N9OKV;S9O;%"3^\*C#]6R7+HQ&
MV"H8HL^2LLJH,@@8J'DTJ]PZ :TG-GL=VN/%+NQ%#L'*4X-9 7\_Z_FB0,LJ
MJ6MQ'VDT90RZZ$BGG"X*?3S2.4*!"488YKV%,'>TUQ8Q:GFW.!$5-@WDD;A4
M0*V/DSC6Z'99)VU1[>=S,U_F%D;MK"XB#(?!N.@^,L%@/+YI!R2U'A!JI1%8
M,@5SO[6UD:LL^8X&_U5D:V8D2M_YOJX_L;ZT#-'&>RAYJ@40S;].5:,X\R#:
M?8F#PQ:9=EV3=GZB='F/W% VV?5:FAU1.;-F,O'CC3FP("DQR /%L8MS<!)H
M$Z*6HK:$%P(RX5IQ8\<'2M?C&)(9.71:FA>?_,VBJLC5M E^-HNXZ/$'_S@5
M(;GF6J;]6>-X\G#1<S0BVEIC'')"!]\RRW'_=\J^# S+DHP:+DV6S\WDK9Y]
MWUL"86T;!9<86@E4H'SU4!;B'[&4'B&*@MML(;J#..V_638Q;%@2#:3YTH3Z
MH.TJNS<ND,OY=S_=,*5<"0+CA$ PT$=3RE/3PC@9@4/@TN/TRM:*1H>^5#9W
M:UCR9-5R!8>HQ_I:;^YFHTFTJ>LCYK+Y-U2!!T@!)20%X'L*M*(0<,6D$%YA
MZG.?GO8*5,O+8IDS>SZL:B#>4O;U>H380QV5(1B/;AX)T?/'S@%'D;><QXG@
M[%>4SP6HI&GQ\<!N4J:WEDMO9U_CTHE+;>/^?F5DE=',>Q& 5"*JQ&D$I+,T
MKB(E%69*B\U,BET!6'N^4L6S2!_DFB'46(')>&5U7]C<IY=KI*31TA 0G"5Q
MP<092>\A"%IY"9F!G.:N^M92M%K:'Y?9OX; KP):[JU;>^TU1)1  S1/;2^%
M44!#"P&#3@ADC9$H=^+H7H$*9RH-08$N=80[X5$!N0[4JKW6T)AHMR&(QX[4
M'89$8^ZBKV!QJF B?/POM^-T0*3"=;5.0+"<F%1 L4?G8'V2O>:,:>L8!RQY
M ]1(!@SW$L0?*R@%=1CECL!Y)43AXE@GH-%Q>J^).$\EOZZ1]H8II0&D(I4Q
MEM&E1)A')\$:+(R(YYC<-P9;Q"A<U^J4Y.FI^PKH\UBP\,+].^HF;=*7X;'B
M$4IQIA@1X)5)P3;6@NAL4N X8CIXBM'F:\G11-HK4.&"5">@5#X\NI-++<DU
M\3>I+O2W/%<(VQW!;_KOMU&>T:I08?SCROZ^B=MZ&,VO*95(Q&,UP))&*\R]
M!P9[ XBD!@?.C=T,E]MQN=#O^X4K30U(M%.!4IY^3V\1*14R37 YK\7;1/S)
M-0DN>$D9\-Q']2GL@$ZOW-YY"$V0T7;GSG_>)4OA2E0G,&Q94*AAPVRF?G0S
M>7L7OSVQ#]^B89YIFY#Z38\FR05XXT.3$I?^OJ9$!6P- \ZD>YJX3$"<J $P
M^!!8P,SJW'Y8!_$*U[ ZQ68Z$%85T'"]?%86^G,S:=;.Z+64<24)&H!2*+7E
M"1+H%,OE'6(4,FBISUUV>8\XK6BFSIEFN;"H@%:+Q_3G$U@:Z_6E"C/*(RTP
M@#8%WV.;ZD33^ NG+)IQK@E'F9FU7Z)V%ZGPG-F5$9(*"+;+M61$::[BB1D3
MH0"U/JX3QPW BAL8B+',Y;ZA/\;U1V=].9\#A(S-?C*U)+AFT9Y*0CQ !'N0
M(NF!@H$"%(\EG%,8;/;6,2\$:,><L[YU[Z_PJIM#K;I57^GI_+F7.#LB2_C0
MD+FRA3N)GBEK>-<WG]IZ&\]3:%\DEC:I,:0&4E ;>0*UI! &;7(GUAZ2Z?@'
MYJWC+[/D9Y?AV<^N+91"<QSBI$/<DUUT^@SA$M#X,TZ5PU+ECGWH(%[9Q^>L
MW'G]ZCP,2.4+&RS&GGG[OV^:^__CK5L.OVQ=.;I-50)&,SMN9G=3?]A:O6#;
M\T&71+/NB5_;O]#1>/46_DA[%3]UO?S*[>(3CWM@;W7L'K&G>7D^X.^3'Z,T
MZ+<X[3?Q+_^31<S7HQ99_P>Q6*_E5AHI>))Y(9^??V]<9KPVQBP2R=$/K>W:
MJ 2KJ_C9^?1VXCZ,]4T6I%Z.6"14HA=.6S51"4IIQ;^=S-PT'TP;0Q:)2NAM
M_5[KHA*@_M'\]21?7@NX8^@B;_^]@-NOF\( /NZIHUOO/C33E'CWIQX?O=SV
MC5OD-;T3="VT4L/"F[V-;K+_UCR*NVA8EF_U'1B_R"MU]R783DO5XCD0C&7>
M>S.A5PEH'R=N=#]R=WJ\R(0\!JB-H<H>RO;KO#FD@-)+:3Q^DFN=_WS4(MHV
M8#&$=NB\::> "A[]ENL__N,#BZ97M=@78Y<]++=:17N54@%8VTLR7*0(U)M%
M?NSLS</3O[G2#^EGB\D\S6CBKL9Z\JRM1U[,!Q&Q;,'@K638S",>$)D*B/?^
M]L>X>?!^T:!\V:7@H"GOE2:Z\SME<XV'1'<S"?20JBN@PT*VBQ_Q\W:T4,67
MU"EW]O7BR]=!:''X>V7K7IR0'JU57]KOV[;I1D<HS3#_(6H]<)%XQN./41MZ
MJ0&Z/R9N.GZX>=8IZW9^/&Y;1RT3)]@=M7TJJ0&R]W]/[=5T9#.LKZ>ARD3<
M=0?GU>1K0.2WE!KV3L_]8^K8\=!L&;-,;%MWC':KHS!8+U?VP^__F2^H]/;[
MY.;*'F?V#@S="KJR3Y/ME%-K&,[[Z>*]8* 0G->C9PF_.2!TAM";+]XV]W[Z
M<!E>?>L5&7KQOM4'CEBRJU'7GSG^<G[K@,7N%;O@\WRQ[E-+82.;VEVNRKBE
M/>#H2_IMXQ7#:Z_>FU9*^!_]?#*(=](6E%\/)[\>3CIA\[F9?/9-#E!>CE3N
MH7&?KIL#$Z]H7_%QR-O19*&S9%^S;3"O!BYFU/IZ!FW45-KDW=S,5Y,Z^K;I
MY5#% D#[HK5=%87Q60LTT>.'V6B6)[9IYZ#%@D&/]+UWJJ<P>E_G_[F:VLOI
MM]GT_6P^NM7+IZ5\4?*M/E L4K0OJEW45ACAR[MYM/%Q'Y_<9#2ENT<M%CK:
M%\N#"JIG _S<S/_E'W=JGRN,N\T'BD629M@L#ZJM,,(?XJ#-Q*]GFN-!=,>0
MQ2)*^Z*X7S5UX?;NSG]K5A4:4K7PT$SMPK4^UMAV^4ZQQ^Y,"+=18H6P_SEJ
MQJN^[/]H;OW;E+\\??BD_QH"^[T?*_=PGI,!;?19(0WBC/][I\>C,+(KZ;_I
MOU?56HX.ENCUP7)/]3GIT%:O=5$BFK&QGJP$_GC[(Y5+B!,PJ1?60Q[?K=\7
MR\4&9")%-\W6<P++Z>+M&;9< $&&0UB=OMX6 3.?HS>';05B57==AW54T:M
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MU\.KZ_[%B(PNR?#ZP^"*!'5:#AH']/#-?M"J]OH79R1H,O^*7%^<#89D]-.
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MU\&[JFH(OR<PE@TNO+2/ A^V2ILE27 O0&62"&LY_X>^,59 0W"<";#/*3D
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M=&WM?6F3VT:VY??Y%1@Y7IN,H-C%I3;+=H0LR=TU;<MZDOP<\ZDC"23)=($
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M'I!C*)+&\^Q68!$=(\Z9P*J\>8QX'2\2L5YN&L[I!A\E1VGK]M#O>GHV_,N
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MQ(W.'!8'Z8PK-#1:-0C-ZXI[G*F_$UE(U<9:B?9PS1V6FJ[ FEE$M$\1WR(
M(,;,GN$1Q<5W/D+FKB3&XC*U<Q?$S>YOYHY/X3"^FU@C<<CAFPFPR_+J9.Y
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M>^-^3\&CE76&2@F 11.]$%K",Z"U/@*SR++/(V0X&,DT1JFD3ZSJV?J>4W-
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MZ9G5.E<UQVG7MU)>IWI"=M8P!FU?B.87=Q&U!]%TD$($'J*,K2]2Q*3%+F7
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MHCHM2]##SE3_<D!4DR([JL[2V[='@" $=]JR[<!P[>,??4[;&S8J,"#XM,;
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M*%N7QT#6./D,(R$/$.%MB$6 PJ)1<QUCF%T3X4N)";W.XJCZBHLCVU'K@">
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M(8P1FYF/1X+&0N=[(+F0R*_H'J(?F<2X5KB25BWM'!4Z6Z-"O%4V46+ [^I
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MM]SYUXO+TVX[5.C_[@(>+BM0WZ\1";\ 7?$YGFT\G81ZJ7J51L%K_^O*9XD
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MRB PPGX8#M)93!1R$$PRO7(^K,A)+AI5U+^FS*X)&@?_->& FI2Y38'J-D
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M/"=I,0_S_ 1I<_!^4;$(C\QI=68,I).6BFPPK(XYT< D3R;Q_=Z\4]LC+2@
M;1P18DN;;UP%+QW) WLM"*D$R.SJFL6U3>Y%QDK5YR8$D(F&@9^.YM'U78WJ
MPHH#BB#'"#^=S%?4RI/L*N.\YE3^P41%U>@!*D[P$I<"2F-%+QN,G(2#P-Y
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M["WV@,6',3[!O!9HY8&ZND5<+QU8X%Q<>J$DWJK^37)!6RGQ&FXQ6[UO#B%
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M#VM4C.' -#'$LP1"PO(70M_;NA>W$T]#; ?PW312'8*^BN,UE@*<C:I?AE!
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M<RTR,#(U,#,S,2YH=&U02P$"% ,4    " #3-*A:BJ,E?FH.   ZF0  $0
M            @ %\W@( 8VUP<RTR,#(U,#,S,2YX<V102P$"% ,4    " #3
M-*A:XFQP(O 6  #]T0  %0              @ $5[0( 8VUP<RTR,#(U,#,S
M,5]C86PN>&UL4$L! A0#%     @ TS2H6F%U?%*"0@  &_X" !4
M     ( !. 0# &-M<',M,C R-3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( -,T
MJ%K810Z89[L  -M@!P 5              "  >U& P!C;7!S+3(P,C4P,S,Q
M7VQA8BYX;6Q02P$"% ,4    " #3-*A:W(3*23EY  #3L 4 %0
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MC 0 8VUP<RUQ,7@R-7AE>#,R,6-E;WAC9F]S96,N:'1M4$L! A0#%     @
MTS2H6G1*GS[F80  :N "  \              ( !B9($ &5X,3 Q+6MA8FER
M+FAT;5!+ 0(4 Q0    ( -,TJ%I0*5A91 L  )1%   .              "
M 9ST! !E>#$P,BUT97)I+FAT;5!+ 0(4 Q0    ( -,TJ%I4)%4@R1$  '>5
M   .              "  0P !0!E>#$P-"US;&%M+FAT;5!+ 0(4 Q0    (
M -,TJ%H<3C1Y D@  %C^   2              "  0$2!0!G=7EA<F%G<F5E
>;65N="YH=&U02P4&      T #0!C P  ,UH%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>cmps-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmps="http://compasspathways.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmps-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-09</startDate>
            <endDate>2025-02-27</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-27</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-16</startDate>
            <endDate>2023-08-16</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-16</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:FacilityFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:CompanyFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:EndOfTermChargeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cmps:LoanAgreementTermLoanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmps:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-27</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cmps:HerculesCapitalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-19</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmps:A2025ADSWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:OptionsGrantedBeforeJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cmps:GrantDateJune302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2020ShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">cmps:ShareBasedPaymentArrangementVestingConditionFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmps:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmps:A2022InducementGrantOptionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:UnvestedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmps:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:DevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:DevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:PersonnelExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:PersonnelExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:NonCashShareBasedCompensationExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:NonCashShareBasedCompensationExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:FacilitiesAndOtherExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:FacilitiesAndOtherExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmps:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cmps:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="day">
        <measure>cmps:day</measure>
    </unit>
    <unit id="vestingcondition">
        <measure>cmps:vestingCondition</measure>
    </unit>
    <unit id="segment">
        <measure>cmps:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0001816590</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-25">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-26">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-99" id="f-410">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-128"
      decimals="INF"
      id="f-458"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-129"
      decimals="INF"
      id="f-459"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39522</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">COMPASS Pathways plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">33 Broadwick Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">W1F 0DQ</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-11">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-1" id="f-12">716</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">676-6461</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-14">American Depositary Shares, each representing one ordinary share, par value of &#xa3;0.008 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-15">CMPS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-17">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-18">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-19">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-20">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-22">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-23" unitRef="shares">93561753</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-29" unitRef="usd">260110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-30" unitRef="usd">165081000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">379000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">389000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">44979000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">35821000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">305468000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">201291000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">1463000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">2006000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">4028000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">3774000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">8176000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">6595000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">319135000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">213666000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">8584000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">12283000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">11194000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">14495000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">8988000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">5513000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">1233000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1725000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">29999000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">34016000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">21553000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">24652000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">259000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">303000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">71857000</cmps:WarrantLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">0</cmps:WarrantLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">123668000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">58971000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-63" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-64" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="3"
      id="f-65"
      unitRef="usdPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="3"
      id="f-66"
      unitRef="usdPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-67" unitRef="shares">92848326</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-68" unitRef="shares">92848326</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-69" unitRef="shares">92848326</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">68552215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">68552215</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">68552215</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">938000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">702000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">763436000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">704919000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">-16311000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">-16194000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">-552596000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">-534732000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">195467000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">154695000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">319135000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">213666000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-85" unitRef="usd">30880000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">24901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">18736000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-88" unitRef="usd">13672000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">49616000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-90" unitRef="usd">38573000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">-49616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-92" unitRef="usd">-38573000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">-19460000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">-8448000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-96" unitRef="usd">-3101000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">2386000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-7" decimals="-3" id="f-98" unitRef="usd">2260000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">2133000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">-783000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">1124000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-7" decimals="-3" id="f-102" unitRef="usd">1098000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">803000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">128000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">32106000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">3608000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">-17510000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">-34965000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">354000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-110" unitRef="usd">222000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">-17864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-112" unitRef="usd">-35187000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-115" unitRef="shares">89192252</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-116" unitRef="shares">64222178</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-117"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-118"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-119" unitRef="shares">98641623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-120" unitRef="shares">64222178</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">-17864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-122" unitRef="usd">-35187000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">-17981000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">-35223000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="3"
      id="f-127"
      unitRef="usdPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="3"
      id="f-128"
      unitRef="usdPerShare">0.008</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="0" id="f-129" unitRef="shares">61943471</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-130" unitRef="usd">635000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-131" unitRef="usd">621645000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-132" unitRef="usd">-16926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-133" unitRef="usd">-379610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-134" unitRef="usd">225744000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-13" decimals="0" id="f-135" unitRef="shares">86510</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-136" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-137" unitRef="usd">219000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">220000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-15" decimals="0" id="f-139" unitRef="shares">2509798</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-140" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-141" unitRef="usd">26194000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-17" decimals="-3" id="f-142" unitRef="usd">26219000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="0" id="f-143" unitRef="shares">50705</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <cmps:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="c-13" decimals="0" id="f-145" unitRef="shares">3752050</cmps:StockIssuedDuringPeriodSharesWarrantsExercised>
    <cmps:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">38000</cmps:StockIssuedDuringPeriodValueWarrantsExercised>
    <cmps:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">37220000</cmps:StockIssuedDuringPeriodValueWarrantsExercised>
    <cmps:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">37258000</cmps:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-14" decimals="-3" id="f-149" unitRef="usd">185000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-150" unitRef="usd">185000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-151" unitRef="usd">5129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">5129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-18" decimals="-3" id="f-153" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-3" id="f-155" unitRef="usd">-35187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-156" unitRef="usd">-35187000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-20" decimals="0" id="f-157" unitRef="shares">68342534</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-158" unitRef="usd">699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-159" unitRef="usd">690222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-160" unitRef="usd">-16962000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-161" unitRef="usd">-414797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-162" unitRef="usd">259162000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="0" id="f-163" unitRef="shares">68552215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-164" unitRef="usd">702000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-165" unitRef="usd">704919000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-166" unitRef="usd">-16194000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-167" unitRef="usd">-534732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-168" unitRef="usd">154695000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-29" decimals="0" id="f-169" unitRef="shares">24014728</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-170" unitRef="usd">233000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-171" unitRef="usd">54583000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-172" unitRef="usd">54816000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-32" decimals="0" id="f-173" unitRef="shares">164422</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-32" decimals="-3" id="f-174" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-32" decimals="0" id="f-176" unitRef="shares">116961</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-32" decimals="-3" id="f-177" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-33" decimals="-3" id="f-178" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-180" unitRef="usd">3935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">3935000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-34" decimals="-3" id="f-182" unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">-117000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-184" unitRef="usd">-17864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-17864000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-36" decimals="0" id="f-186" unitRef="shares">92848326</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-187" unitRef="usd">938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-188" unitRef="usd">763436000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-189" unitRef="usd">-16311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-190" unitRef="usd">-552596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-191" unitRef="usd">195467000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">-17864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-193" unitRef="usd">-35187000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">37000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-195" unitRef="usd">61000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">376000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-7" decimals="-3" id="f-197" unitRef="usd">333000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">1411000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-7" decimals="-3" id="f-199" unitRef="usd">-230000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">3935000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-201" unitRef="usd">5129000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">582000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-203" unitRef="usd">555000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <cmps:TransactionCostsIncurredInConnectionWithWarrants contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">5778000</cmps:TransactionCostsIncurredInConnectionWithWarrants>
    <cmps:TransactionCostsIncurredInConnectionWithWarrants contextRef="c-7" decimals="-3" id="f-205" unitRef="usd">0</cmps:TransactionCostsIncurredInConnectionWithWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-19460000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-207" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">7887000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-7" decimals="-3" id="f-209" unitRef="usd">-8136000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">254000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-7" decimals="-3" id="f-211" unitRef="usd">322000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">1402000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-7" decimals="-3" id="f-213" unitRef="usd">-837000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">-575000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-215" unitRef="usd">-545000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">-3956000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-217" unitRef="usd">3517000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">-3556000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-219" unitRef="usd">-3572000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">-45657000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-221" unitRef="usd">-20828000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">140357000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-223" unitRef="usd">26219000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-7" decimals="-3" id="f-225" unitRef="usd">37258000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-227" unitRef="usd">185000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-229" unitRef="usd">220000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">140359000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-231" unitRef="usd">63512000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">317000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-233" unitRef="usd">-45000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">95019000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-235" unitRef="usd">42639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-236" unitRef="usd">165470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-237" unitRef="usd">220638000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-238" unitRef="usd">260489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-239" unitRef="usd">263277000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-240" unitRef="usd">260110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-24" decimals="-3" id="f-241" unitRef="usd">262888000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-242" unitRef="usd">379000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-24" decimals="-3" id="f-243" unitRef="usd">389000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-244" unitRef="usd">260489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-245" unitRef="usd">263277000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-246">Nature of Business &lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Compass Pathways plc, or the Company, is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is developing its investigational COMP360 psilocybin treatment through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. The therapeutic candidate currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company has funded its operations with proceeds from the sale of its ordinary shares, American Depository Shares, or ADSs, including in its offerings pursuant to its at-the-market, or ATM, offering program, proceeds from a loan agreement with Hercules Capital, Inc., and proceeds from a private placement transaction, or the PIPE. The Company was party to a Sales Agreement for its ATM offering program, dated October 8, 2021, with TD Securities (USA) LLC, or TD Cowen, under which the Company was able to issue and sell from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through TD Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;hrough February 27, 2025, the Company sold 5,491,836 ADSs under the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; ATM offering program&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, resulting in $54.8&#160;million in net proceeds. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On February 27, 2025, the Company entered into a new Sales Agreement to govern the Company&#x2019;s ATM offering program with TD Cowen, or the Sales Agreement, under which the Company may issue and sell from time to time up to $150.0&#160;million of our ADSs, subject to the terms of the Sales Agreement. Sales of its ADSs, if any, will generally be made at market prices. To date, the Company has not sold any ADSs under this Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On June 30, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;the Company entered into a Loan Agreement with Hercules, which provided for aggregate maximum borrowings of up to $50.0&#160;million, including a term loan of $30.0&#160;million, which was funded on June 30, 2023. On August 16, 2023, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell and issue in a private placement transaction (i) 16,076,750 ADSs and (ii) PIPE Warrants to purchase up to 16,076,750 ADSs, at a purchase price of approximately $7.78 per ADS and accompanying PIPE Warrant to purchase one ADS. Each PIPE Warrant has an exercise price of $9.93 per ADS and is exercisable for a three year period beginning in February 2024. The PIPE Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the PIPE Warrants. Through March&#160;31, 2025, PIPE Warrants were exercised for 3,752,050 ADS, resulting in $37.3&#160;million in exercise proceeds. The Company will receive up to an additional approximately $122.4&#160;million in gross proceeds if the PIPE Warrants are fully exercised. During the three months ended March 31, 2025, no PIPE warrants were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Company issued and sold (i) 24,014,728 American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.008 each, of the Company and accompanying warrants to purchase up to 24,014,728 ADSs, and (ii) in lieu of ADSs, to certain investors, Pre-funded Warrants to purchase up to 11,044,720 ADSs and accompanying 2025 ADS Warrants to purchase up to 11,044,720 ADSs. The offering price was $4.2750 per ADS and accompanying 2025 ADS Warrant, and $4.2649 per Pre-funded Warrant and accompanying 2025 ADS Warrant. The Pre-funded Warrants have an exercise price of $0.0001 per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $5.7960 per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after three years. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#x2019;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the Company&#x2019;s ADSs on Nasdaq &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exceeded the warrant exercise price of $5.7960 for the three consecutive trading days prior to the date on which the notice of forced exercise is delivered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company has incurred recurring losses since its inception, including net losses of $17.9 million and $35.2 million for the three months ended March 31, 2025 and 2024, respectively. In addition, as of March&#160;31, 2025, the Company had an accumulated deficit of $552.6 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March&#160;31, 2025 of $260.1 million will be sufficient to fund its operating expenses and capital expenditure requirements at least &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;through the planned 26-week data read-out from our COMP006 study, which is expected in the second half of 2026.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Market volatility, geopolitical tensions or instability, including from the effects of announced or future tariff increases, resulting from the ongoing war between Ukraine and Russia and conflict in the Middle East, fluctuating inflation and interest rates and the related impact on U.S., UK and global economies, instability in the banking system, the risk of economic slowdown or recession in the U.S., significant changes in U.S. policies or regulatory environment or other factors could adversely impact the Company&#x2019;s operations, financial results and ability to raise additional funding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:130%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <cmps:SaleOfStockMaximumAmountAllowableForSale contextRef="c-40" decimals="-5" id="f-247" unitRef="usd">150000000</cmps:SaleOfStockMaximumAmountAllowableForSale>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="c-41"
      decimals="INF"
      id="f-248"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-42"
      decimals="INF"
      id="f-249"
      unitRef="shares">5491836</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-42" decimals="-5" id="f-250" unitRef="usd">54800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cmps:SaleOfStockAmountAuthorized contextRef="c-43" decimals="-5" id="f-251" unitRef="usd">150000000</cmps:SaleOfStockAmountAuthorized>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-44" decimals="-5" id="f-252" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-45" decimals="-5" id="f-253" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-46"
      decimals="INF"
      id="f-254"
      unitRef="shares">16076750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-46"
      decimals="INF"
      id="f-255"
      unitRef="shares">16076750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-47"
      decimals="2"
      id="f-256"
      unitRef="usdPerShare">7.78</us-gaap:SaleOfStockPricePerShare>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="c-46"
      decimals="INF"
      id="f-257"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-48"
      decimals="2"
      id="f-258"
      unitRef="usdPerShare">9.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-49" id="f-259">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-50"
      decimals="INF"
      id="f-260"
      unitRef="shares">3752050</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-51" decimals="-5" id="f-261" unitRef="usd">37300000</us-gaap:ProceedsFromWarrantExercises>
    <cmps:ProceedsFromWarrantExercisesFullyExercised contextRef="c-51" decimals="-5" id="f-262" unitRef="usd">122400000</cmps:ProceedsFromWarrantExercisesFullyExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-263"
      unitRef="shares">24014728</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="c-52"
      decimals="INF"
      id="f-264"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-53"
      decimals="3"
      id="f-265"
      unitRef="gbpPerShare">0.008</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-53"
      decimals="INF"
      id="f-266"
      unitRef="shares">24014728</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-54"
      decimals="INF"
      id="f-267"
      unitRef="shares">11044720</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-54"
      decimals="INF"
      id="f-268"
      unitRef="shares">11044720</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-53"
      decimals="4"
      id="f-269"
      unitRef="usdPerShare">4.2750</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-54"
      decimals="4"
      id="f-270"
      unitRef="usdPerShare">4.2649</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-54"
      decimals="INF"
      id="f-271"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-53"
      decimals="4"
      id="f-272"
      unitRef="usdPerShare">5.7960</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-53" id="f-273">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-53"
      decimals="3"
      id="f-274"
      unitRef="usdPerShare">5.7960</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cmps:ClassOfWarrantOrRightThresholdConsecutiveTradingDays contextRef="c-52" decimals="INF" id="f-275" unitRef="day">3</cmps:ClassOfWarrantOrRightThresholdConsecutiveTradingDays>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-276" unitRef="usd">-17900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-277" unitRef="usd">-35200000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-278" unitRef="usd">-552600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-279" unitRef="usd">260100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-280">Summary of Significant Accounting Policies&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December&#160;31, 2024, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position for the reported periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2024, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC, on February 27, 2025. The condensed consolidated balance sheet at December&#160;31, 2024, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to warrant liabilities. Estimates are periodically reviewed in light of changes in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our year-end consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03 - Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December&#160;31, 2024, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position for the reported periods. &lt;/span&gt;&lt;/div&gt;The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2024, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC, on February 27, 2025. The condensed consolidated balance sheet at December&#160;31, 2024, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-282">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-283">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to warrant liabilities. Estimates are periodically reviewed in light of changes in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-284">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our year-end consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03 - Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-285">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UK R&amp;amp;D tax credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was uncertain whether it would meet the R&amp;amp;D intensity condition and be eligible for the enhanced effective rate for their tax submission relating to the year ended December 31, 2023. The Company sought clarity from HMRC in the form of a non-statutory clearance and received a positive response in April 2025. Therefore,&#160; the Company intends to file a resubmission to claim relating to the year ended December 31, 2023 at the enhanced rate, which results in an increase in its R&amp;amp;D tax relief claim of $3.9&#160;million. For the period March 31, 2025, the Company recorded an additional $3.9&#160;million prepaid for the 2023 R&amp;amp;D tax credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-286">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.050%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UK R&amp;amp;D tax credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <cmps:ResearchAndDevelopmentTaxCreditCurrent contextRef="c-3" decimals="-3" id="f-287" unitRef="usd">30112000</cmps:ResearchAndDevelopmentTaxCreditCurrent>
    <cmps:ResearchAndDevelopmentTaxCreditCurrent contextRef="c-4" decimals="-3" id="f-288" unitRef="usd">20712000</cmps:ResearchAndDevelopmentTaxCreditCurrent>
    <cmps:PrepaidExpenseResearchAndDevelopmentCurrent contextRef="c-3" decimals="-3" id="f-289" unitRef="usd">10234000</cmps:PrepaidExpenseResearchAndDevelopmentCurrent>
    <cmps:PrepaidExpenseResearchAndDevelopmentCurrent contextRef="c-4" decimals="-3" id="f-290" unitRef="usd">11332000</cmps:PrepaidExpenseResearchAndDevelopmentCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-3" decimals="-3" id="f-291" unitRef="usd">1200000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">1109000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:PrepaidInsurance contextRef="c-3" decimals="-3" id="f-293" unitRef="usd">1018000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="-3" id="f-294" unitRef="usd">280000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-295" unitRef="usd">2415000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-296" unitRef="usd">2388000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-297" unitRef="usd">44979000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">35821000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <cmps:ResearchAndDevelopmentTaxCreditPayable contextRef="c-12" decimals="-5" id="f-299" unitRef="usd">3900000</cmps:ResearchAndDevelopmentTaxCreditPayable>
    <cmps:PrepaidResearchAndDevelopmentTaxCredit contextRef="c-3" decimals="-5" id="f-300" unitRef="usd">3900000</cmps:PrepaidResearchAndDevelopmentTaxCredit>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-301">Debt&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On June 30, 2023, or the Effective Date, the Company entered into the Loan Agreement with Hercules, which provided for aggregate maximum borrowings of up to $50.0&#160;million, consisting of (i) a term loan of $30.0&#160;million, which was funded on the Effective Date, (ii) subject to the Company achieving certain performance milestones and available until June 30, 2025, an additional term loan of $10.0&#160;million, and (iii) subject to the approval of Hercules&#x2019; investment committee in its sole discretion, and available during the interest-only period, an additional term loan of $10.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term loan will mature on July 1, 2027. The outstanding principal balance of the term loan bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in The Wall Street Journal plus 1.50% or (ii) 9.75%. Accrued interest is payable monthly following the funding of each term loan. In addition to accrued interest, payment-in-kind (PIK) interest of 1.40% will be added to the balance of the loan. Payments under the Loan Agreement are interest only until the first principal payment is due on July 1, 2025 (or if the Borrowers achieve certain performance milestones, the interest only period may be extended to January 2, 2026 and, upon the achievement of certain additional performance milestones, the interest only period may be extended to July 1, 2026), followed by equal monthly payments of principal and interest through the scheduled &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;maturity date, July 1, 2027. The carrying value of the Company&#x2019;s outstanding debt approximates fair value, reflecting interest rates currently available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred fees and transaction costs totaling $3.3&#160;million associated with the initial term loan, which are recorded as a reduction to the carrying value of the long-term debt in the condensed consolidated balance sheets. These fees included $0.4&#160;million of facility fees, $0.8&#160;million of company fees, $0.7&#160;million in warrants, and $1.4&#160;million of end of term charges. The fees, transaction costs, and the end of term charge are amortized to interest expense through the maturity date using the effective interest method. The effective interest rate of the Loan Agreement was 15.6% as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company issued warrants to Hercules to purchase the Company&#x2019;s Ordinary Shares equal to the quotient derived by dividing (i) the amount equal to (a) 2.5% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price of the warrants. Upon receipt of the first term loan, 94,222 shares became exercisable to Hercules with a fair market value of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Loan Agreement includes a financial covenant requiring us to maintain a minimum level of $22.5&#160;million of cash during the period commencing on July 1, 2024 (subject to adjustment if certain performance milestones are met). If the Company meets the performance milestones, the minimum cash covenant will not apply if its market capitalization is at least $750.0&#160;million. The Company was in compliance with all covenants of the Loan Agreement as of March&#160;31, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:107%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future principal payments and end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PIK interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal payments, including End of Term Charge, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.150%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; Interest expense associated with the Loan Agreement for the three months ended March 31, 2025 and 2024 was $0.9 million and $1.1 million, respectively.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-44" decimals="-5" id="f-302" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-45" decimals="-5" id="f-303" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-55" decimals="-5" id="f-304" unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-56" decimals="-5" id="f-305" unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-57" decimals="4" id="f-306" unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-44" decimals="4" id="f-307" unitRef="number">0.0975</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <cmps:PaidInKindInterestRate contextRef="c-57" decimals="4" id="f-308" unitRef="number">0.0140</cmps:PaidInKindInterestRate>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-3" decimals="-5" id="f-309" unitRef="usd">3300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-58" decimals="-5" id="f-310" unitRef="usd">400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-59" decimals="-5" id="f-311" unitRef="usd">800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-60" decimals="-5" id="f-312" unitRef="usd">700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-61" decimals="-5" id="f-313" unitRef="usd">1400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-62" decimals="3" id="f-314" unitRef="number">0.156</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <cmps:OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances contextRef="c-3" decimals="3" id="f-315" unitRef="number">0.025</cmps:OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances>
    <cmps:OptionsExercisableNumber contextRef="c-3" decimals="0" id="f-316" unitRef="shares">94222</cmps:OptionsExercisableNumber>
    <cmps:OptionsExercisableFairValue contextRef="c-3" decimals="-5" id="f-317" unitRef="usd">700000</cmps:OptionsExercisableFairValue>
    <cmps:DebtInstrumentCovenantMinimumCashOnHandAmount contextRef="c-63" decimals="-5" id="f-318" unitRef="usd">22500000</cmps:DebtInstrumentCovenantMinimumCashOnHandAmount>
    <cmps:DebtInstrumentMarketCapitalization contextRef="c-62" decimals="-5" id="f-319" unitRef="usd">750000000</cmps:DebtInstrumentMarketCapitalization>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-320">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of term charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future principal payments and end of term charge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PIK interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-321" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-322" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <cmps:LongTermDebtEndOfTermCharge contextRef="c-3" decimals="-3" id="f-323" unitRef="usd">1425000</cmps:LongTermDebtEndOfTermCharge>
    <cmps:LongTermDebtEndOfTermCharge contextRef="c-4" decimals="-3" id="f-324" unitRef="usd">1425000</cmps:LongTermDebtEndOfTermCharge>
    <cmps:LongTermDebtIncludingEndOfTermCharge contextRef="c-3" decimals="-3" id="f-325" unitRef="usd">31425000</cmps:LongTermDebtIncludingEndOfTermCharge>
    <cmps:LongTermDebtIncludingEndOfTermCharge contextRef="c-4" decimals="-3" id="f-326" unitRef="usd">31425000</cmps:LongTermDebtIncludingEndOfTermCharge>
    <cmps:DebtInstrumentPaidInKindInterestPayable contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">757000</cmps:DebtInstrumentPaidInKindInterestPayable>
    <cmps:DebtInstrumentPaidInKindInterestPayable contextRef="c-4" decimals="-3" id="f-328" unitRef="usd">649000</cmps:DebtInstrumentPaidInKindInterestPayable>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">1641000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">1909000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">30541000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">30165000</us-gaap:LongTermDebt>
    <us-gaap:DebtCurrent contextRef="c-3" decimals="-3" id="f-333" unitRef="usd">8988000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-4" decimals="-3" id="f-334" unitRef="usd">5513000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-335" unitRef="usd">21553000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-336" unitRef="usd">24652000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal payments, including End of Term Charge, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.150%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-338" unitRef="usd">6587000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-3" decimals="-3" id="f-339" unitRef="usd">14172000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-3" decimals="-3" id="f-340" unitRef="usd">10666000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <cmps:LongTermDebtIncludingEndOfTermCharge contextRef="c-3" decimals="-3" id="f-341" unitRef="usd">31425000</cmps:LongTermDebtIncludingEndOfTermCharge>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-5" id="f-342" unitRef="usd">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-7" decimals="-5" id="f-343" unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-344">Fair Value Measurements&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, as of March 31, 2025, information about the Company&#x2019;s warrant liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.838%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;January 13, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 ADS Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,726&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pre-funded Warrants and 2025 ADS Warrants are accounted for as liabilities in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging, Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 815-40&#x201d;), as both warrants contain contingent exercise provisions that do not meet the requirements of the indexation guidance under ASC 815-40 and could require the Company to pay cash to settle the warrants. The warrants are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pre-funded Warrants are considered to be Level 2 in the fair value hierarchy as the inputs used to determine fair market value are observable against the Company&#x2019;s stock price. The 2025 ADS Warrant are considered to be Level 3 in the fair value hierarchy as they have been recorded at fair value using the Black-Scholes model, using unobservable assumptions that have been probability-weighted for specified data milestones. As of March 31, 2025, the assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;January 13, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.7960&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.7960&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;141.9% to 148.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;146.1% to 158.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8 to 4.2 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 to 4.4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the fair value of the Company&#x2019;s warrant liabilities for the three months ended March 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ADS Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial fair value as of January 13, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,726&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value change of warrant liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,633)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,455)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value change of warrant liabilities at March 31, 2025 was $19.5&#160;million, which included a $1.6&#160;million loss upon issuance of the Pre-funded warrants and a $21.1&#160;million gain in fair value between the initial fair value and the fair value as of the balance sheet date. During the three months ended March 31, 2025, there were no transfers between Level 1, Level 2 and Level 3.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-345">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, as of March 31, 2025, information about the Company&#x2019;s warrant liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.838%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;January 13, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 ADS Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,726&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-64" decimals="-3" id="f-346" unitRef="usd">31587000</cmps:WarrantLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-65" decimals="-3" id="f-347" unitRef="usd">37220000</cmps:WarrantLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-66" decimals="-3" id="f-348" unitRef="usd">40270000</cmps:WarrantLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-67" decimals="-3" id="f-349" unitRef="usd">55726000</cmps:WarrantLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-350" unitRef="usd">71857000</cmps:WarrantLiabilityNoncurrent>
    <cmps:WarrantLiabilityNoncurrent contextRef="c-68" decimals="-3" id="f-351" unitRef="usd">92946000</cmps:WarrantLiabilityNoncurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-352">The 2025 ADS Warrant are considered to be Level 3 in the fair value hierarchy as they have been recorded at fair value using the Black-Scholes model, using unobservable assumptions that have been probability-weighted for specified data milestones. As of March 31, 2025, the assumptions are as follows:&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;January 13, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.7960&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.7960&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;141.9% to 148.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;146.1% to 158.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8 to 4.2 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 to 4.4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-69"
      decimals="4"
      id="f-353"
      unitRef="usdPerShare">5.7960</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-70"
      decimals="4"
      id="f-354"
      unitRef="usdPerShare">5.7960</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-71"
      decimals="INF"
      id="f-355"
      unitRef="number">2.86</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-72"
      decimals="INF"
      id="f-356"
      unitRef="number">3.37</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-73"
      decimals="INF"
      id="f-357"
      unitRef="number">1.419</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-74"
      decimals="INF"
      id="f-358"
      unitRef="number">1.488</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-75"
      decimals="INF"
      id="f-359"
      unitRef="number">1.461</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-76"
      decimals="INF"
      id="f-360"
      unitRef="number">1.587</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-77"
      decimals="INF"
      id="f-361"
      unitRef="number">0.040</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-78"
      decimals="INF"
      id="f-362"
      unitRef="number">0.046</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-79" decimals="3" id="f-363" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-80" decimals="3" id="f-364" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-81" id="f-365">P3Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-82" id="f-366">P4Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-83" id="f-367">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-84" id="f-368">P4Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock contextRef="c-1" id="f-369">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the fair value of the Company&#x2019;s warrant liabilities for the three months ended March 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ADS Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial fair value as of January 13, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,726&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value change of warrant liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,633)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,455)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-85" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-86" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-87" decimals="-3" id="f-372" unitRef="usd">37220000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-70" decimals="-3" id="f-373" unitRef="usd">55726000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-88" decimals="-3" id="f-374" unitRef="usd">5633000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-89" decimals="-3" id="f-375" unitRef="usd">15455000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-90" decimals="-3" id="f-376" unitRef="usd">31587000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-69" decimals="-3" id="f-377" unitRef="usd">40271000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-5" id="f-378" unitRef="usd">-19500000</us-gaap:FairValueAdjustmentOfWarrants>
    <cmps:GainLossOnIssuanceOfWarrant contextRef="c-88" decimals="-5" id="f-379" unitRef="usd">-1600000</cmps:GainLossOnIssuanceOfWarrant>
    <cmps:GainLossOnFairValueOfWarrants contextRef="c-1" decimals="-5" id="f-380" unitRef="usd">21100000</cmps:GainLossOnFairValueOfWarrants>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-381">Shareholders&#x2019; Equity&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each ordinary share entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through March&#160;31, 2025, no cash dividends had been declared or paid by the Company.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;At-the-Market Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On October 8, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, under which the Company may have issued and sold from time to time up to $150.0&#160;million of its ADSs, each representing one ordinary share, through Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;hrough February 27, 2025, we sold 5,491,836 ADSs under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;our ATM offering program&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, resulting in $54.8&#160;million in net proceeds. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On February 27, 2025, the Company entered into a new Sales Agreement under which the Company may issue and sell from time to time up to $150.0&#160;million of our ADSs, subject to the terms of the Sales Agreement. Sales of our ADSs, if any, will generally be made at market prices. To date, we have not sold any ADSs under this Sales Agreement. &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-classified&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On June 30, 2023, the Company entered into a Warrant Agreement with Hercules, which provides Hercules with the right to purchase a number of the Company&#x2019;s Ordinary Shares, equal to the quotient derived by dividing (i) the amount equal to (a) 2.5% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price. Upon receipt of each term loan, the Warrant will automatically become exercisable and will expire in 10 years (on June 30, 2033). On June 30, 2023, with the receipt of the first term loan, 94,222 shares became exercisable to Hercules with a fair market value of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On August 18, 2023, in connection with the PIPE, the Company issued and sold warrants to purchase up to 16,076,750 ADSs, each representing one ordinary share, at a purchase price of $9.93 per ADS. The PIPE Warrants became exercisable for a three year period beginning in February 2024. Through March&#160;31, 2025, PIPE Warrants were exercised for 3,752,050 ADSs, resulting in $37.3&#160;million in exercise proceeds. During the three months ended March 31, 2025, no PIPE warrants were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company evaluated the terms of the outstanding Hercules and PIPE warrants in accordance with ASC 815-40, D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;erivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, and concluded that the warrants meet the criteria for equity classification. As such, the warrants are classified as equity instruments in the condensed consolidated balance sheets and are not subject to recurring fair value measurement or remeasurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Liability-classified&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 13, 2025, in connection with the 2025 Financing, the Company issued and sold (i) 24,014,728 ADSs, each representing one ordinary share, (ii) in lieu of ADSs, Pre-funded Warrants to purchase up to 11,044,720 ADSs, and (iii) accompanying 2025 ADS Warrants to purchase up to 11,044,720 ADSs, each representing one ordinary share. The Pre-funded Warrants have an exercise price of $0.0001 per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants have an exercise price of $5.7960 per ADS and are exercisable following a specified data milestone. The 2025 ADS Warrants will expire after three years. Once the ADS Warrants become exercisable, the Company may force the exercise of the 2025 ADS Warrants (by way of cash or cashless exercise, at the Company&#x2019;s option), in whole or in part, by delivering a notice of forced exercise to the holders, provided that the closing price for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s ADSs on Nasdaq exceeded the warrant exercise price of $5.796 for the three consecutive trading days prior to the date on which the notice of forced exercise is delivered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Financing comprising of ADSs, Pre-funded Warrants and 2025 ADS Warrants, resulted in aggregate proceeds of $149.8&#160;million, with issuance costs of $9.4&#160;million. Since the Pre-funded Warrants and 2025 ADS Warrants have been classified as a liability and recorded at fair value with changes in fair value recorded in the condensed consolidated income statement, the aggregate proceeds have been allocated first to these warrants at their respective fair values at the issuance date. The residual has been allocated to the ADSs issued as part of the 2025 Financing and recognized within equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cmps:SaleOfStockAmountAuthorized contextRef="c-40" decimals="-5" id="f-382" unitRef="usd">150000000</cmps:SaleOfStockAmountAuthorized>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="c-41"
      decimals="INF"
      id="f-383"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-42"
      decimals="INF"
      id="f-384"
      unitRef="shares">5491836</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-42" decimals="-5" id="f-385" unitRef="usd">54800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cmps:SaleOfStockAmountAuthorized contextRef="c-91" decimals="-5" id="f-386" unitRef="usd">150000000</cmps:SaleOfStockAmountAuthorized>
    <cmps:OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances contextRef="c-92" decimals="3" id="f-387" unitRef="number">0.025</cmps:OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-93" id="f-388">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <cmps:OptionsExercisableNumber
      contextRef="c-93"
      decimals="INF"
      id="f-389"
      unitRef="shares">94222</cmps:OptionsExercisableNumber>
    <cmps:OptionsExercisableFairValue contextRef="c-93" decimals="-5" id="f-390" unitRef="usd">700000</cmps:OptionsExercisableFairValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-94"
      decimals="INF"
      id="f-391"
      unitRef="shares">16076750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="c-95"
      decimals="INF"
      id="f-392"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-96"
      decimals="2"
      id="f-393"
      unitRef="usdPerShare">9.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-49" id="f-394">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-395"
      unitRef="shares">3752050</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-97" decimals="-5" id="f-396" unitRef="usd">37300000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-51"
      decimals="INF"
      id="f-397"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-398"
      unitRef="shares">24014728</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cmps:NumberOfOrdinarySharesConversionRatio
      contextRef="c-52"
      decimals="INF"
      id="f-399"
      unitRef="number">1</cmps:NumberOfOrdinarySharesConversionRatio>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-54"
      decimals="INF"
      id="f-400"
      unitRef="shares">11044720</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-54"
      decimals="INF"
      id="f-401"
      unitRef="shares">11044720</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-54"
      decimals="INF"
      id="f-402"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-53"
      decimals="4"
      id="f-403"
      unitRef="usdPerShare">5.7960</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-53" id="f-404">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-53"
      decimals="3"
      id="f-405"
      unitRef="usdPerShare">5.796</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cmps:ClassOfWarrantOrRightThresholdConsecutiveTradingDays contextRef="c-52" decimals="INF" id="f-406" unitRef="day">3</cmps:ClassOfWarrantOrRightThresholdConsecutiveTradingDays>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-98" decimals="-5" id="f-407" unitRef="usd">149800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-98" decimals="-5" id="f-408" unitRef="usd">9400000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-409">Share-Based Compensation&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors. To the extent such incentives were in the form of share options, the options were granted pursuant to the terms of the 2017 Equity Incentive Plan, or the 2017 Plan. In July 2019, the Company&#x2019;s board of directors adopted the 2017 Plan. The 2017 Plan provided for the grant of Enterprise Management Incentive, or EMI, options, to its UK employees, for the grant of options to its U.S. employees and non-employees of the Company. The 2017 Plan was administered by the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2017 Plan typically vest over a &lt;span style="-sec-ix-hidden:f-410"&gt;three&lt;/span&gt; or four-year service period with 33.3% and 25% respectively, of the award vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years. Options granted under the 2017 Plan generally expire 10 years from the date of grant. Restricted share units granted under the 2017 Plan typically vest over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and quarterly thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted on June 30, 2020 were subject to 25% vesting upon the earlier occurrence of (i) the one year anniversary of the date of grant, or (ii) the date of the listing of the Company's ordinary shares on any stock exchange, followed by straight line vesting for three years for the remaining 75% of the allocation until vested in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The restricted share units granted on June 30, 2020 are subject to 25% vesting upon the earlier of (i) the one year anniversary of the date of grant, or (ii) the first day following the six-month anniversary of the listing of the Company's ordinary shares on any stock exchange on which the closing price of the shares is 20% higher than the listing price for at least five consecutive trading days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company was authorized to issue a total of 1,148,947 ordinary shares underlying outstanding options granted under the 2017 Plan prior to our initial public offering, or IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Share Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2020 Employee Share Purchase Plan, or the ESPP, was adopted by the Board in September 2020 and approved by shareholders in September 2020 and became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form F-1 in connection with the IPO. The ESPP initially reserved and authorized the issuance of up to a total of 340,053 ordinary shares to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator. The number of shares reserved under the ESPP is subject to change in the event of a share split, share dividend or other change in our capitalization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On October 1, 2021, the Company launched the SIP, and the ESPP, through which employees can purchase shares at a discounted price. At the end of six months, shares will automatically be purchased at the lower of the opening and closing price of the shares for the saving period minus a 15% discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Share Option Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved, the 2020 Share Option and Incentive Plan, or the 2020 Plan, which became effective upon the effectiveness of the Company&#x2019;s Registration Statement on Form F-1 in connection with the IPO. The 2020 Plan allows the compensation and leadership development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;committee to make equity-based and cash-based incentive awards to the Company&#x2019;s officers, employees, directors and other key persons (including consultants).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2020 Plan generally expire 10 years from the date of grant and typically vest over a 4 year service period with 25% of the options vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by our compensation and leadership development committee. This number is subject to adjustment in the event of a sub-division, consolidation, share dividend or other change in our capitalization. The total number of ordinary shares that may be issued under the 2020 Plan is 7,938,129 shares as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, of which &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,026,449 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares remained available for future grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted under the 2020 Plan to employees generally expire 10 years from the date of grant. There are three potential vesting terms for the grants including: (i) 25% per year over four year service period, (ii) four year service period with 25% of the vesting on the first anniversary of the commencement date and the balance vesting monthly over the remaining years, (iii) monthly vesting over four year service period, (iv) monthly vesting over three year service period, and (v) 100% vesting on the earlier of the next Annual General Meeting or the first anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;2022 Inducement Option Award&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Company granted a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant to our chief executive officer. The non-qualified share option has a 10 year term and one-fourth vested on August 1, 2023 and the remaining three-fourths will vest in equal monthly installments over the following 36 months. The non-qualified share option has other terms that mirror those of non-qualified share options granted under the Company&#x2019;s 2020 Plan and the Company&#x2019;s standard form of non-qualified share option agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.206%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-100" id="f-411">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-101" decimals="3" id="f-412" unitRef="number">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-102" decimals="2" id="f-413" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-103" id="f-414">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-104" id="f-415">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-104" decimals="2" id="f-416" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-105" decimals="2" id="f-417" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-105" id="f-418">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-106" id="f-419">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-106" decimals="2" id="f-420" unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-107" decimals="2" id="f-421" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-107" id="f-422">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-108" id="f-423">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice contextRef="c-108" decimals="2" id="f-424" unitRef="number">0.20</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAmountClosingPriceIsHigherThanListingPrice>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays contextRef="c-108" decimals="INF" id="f-425" unitRef="day">5</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-109"
      decimals="INF"
      id="f-426"
      unitRef="shares">1148947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-110"
      decimals="INF"
      id="f-427"
      unitRef="shares">340053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum contextRef="c-110" decimals="2" id="f-428" unitRef="number">0.01</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardAllowableIncreaseInSharesAuthorizedForIssuancePercentageOfOutstandingStockMaximum>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance
      contextRef="c-111"
      decimals="INF"
      id="f-429"
      unitRef="shares">510080</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumIncreaseInSharesAvailableForIssuance>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod contextRef="c-112" id="f-430">P6M</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="c-112" decimals="2" id="f-431" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-113" id="f-432">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-113" id="f-433">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-113" decimals="2" id="f-434" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="INF"
      id="f-435"
      unitRef="shares">2074325</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease contextRef="c-114" decimals="2" id="f-436" unitRef="number">0.04</cmps:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfSharesOutstandingNumberOfSharesReservedForIssuanceMayIncrease>
    <us-gaap:SharesIssued
      contextRef="c-115"
      decimals="INF"
      id="f-437"
      unitRef="shares">7938129</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-110" decimals="0" id="f-438" unitRef="shares">2026449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-116" id="f-439">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cmps:NumberOfVestingConditions
      contextRef="c-115"
      decimals="INF"
      id="f-440"
      unitRef="vestingcondition">3</cmps:NumberOfVestingConditions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-117" decimals="2" id="f-441" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-117" id="f-442">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-118" id="f-443">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-118" decimals="2" id="f-444" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-119" id="f-445">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-120" id="f-446">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-121" decimals="2" id="f-447" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-122"
      decimals="INF"
      id="f-448"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-123" id="f-449">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-123" id="f-450">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-451">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.206%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-3" id="f-452" unitRef="usd">1524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-3" id="f-453" unitRef="usd">2614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="-3" id="f-454" unitRef="usd">2411000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-455" unitRef="usd">2515000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">3935000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-457" unitRef="usd">5129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-460">Net Loss Per Share&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.459%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value change of pre-funded warrant liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,192,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,222,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Weighted-average pre-funded warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,641,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,222,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic net loss per share by dividing net loss by the weighted-average number of shares outstanding. The Company computes diluted net loss per share by dividing net loss by the weighted-average number of shares and dilutive potential share equivalents then outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included within the weighted-average number of ordinary shares used in net loss per share for the three-months ended March 31, 2025, are ADSs issuable upon the exercise of the Pre-funded Warrants, as the Pre-funded Warrants are exercisable at any time for nominal consideration, and as such are considered outstanding for the purpose of calculating diluted net loss per share. There were no Pre-funded Warrants outstanding during the three-months ended March 31, 2024. The Company&#x2019;s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, options granted and warrants (other than the Pre-funded Warrants), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2025 and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,093,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,187,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,073,719&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,418,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,170,255&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,254,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.459%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value change of pre-funded warrant liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to ordinary shareholders - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,192,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,222,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Weighted-average pre-funded warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of ordinary shares used in net loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,641,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,222,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">-17864000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-3" id="f-463" unitRef="usd">-35187000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cmps:FairValueChangeOfPreFundedWarrantLiabilities contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">5633000</cmps:FairValueChangeOfPreFundedWarrantLiabilities>
    <cmps:FairValueChangeOfPreFundedWarrantLiabilities contextRef="c-7" decimals="-3" id="f-465" unitRef="usd">0</cmps:FairValueChangeOfPreFundedWarrantLiabilities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-466" unitRef="usd">-23497000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-7" decimals="-3" id="f-467" unitRef="usd">-35187000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-468" unitRef="shares">89192252</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-469" unitRef="shares">64222178</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="c-1" decimals="0" id="f-470" unitRef="shares">9449372</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="c-7" decimals="0" id="f-471" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-472" unitRef="shares">98641623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-473" unitRef="shares">64222178</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-474"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-475"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-476"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-477"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-478">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2025 and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,093,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,187,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,073,719&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,418,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,170,255&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,254,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-130" decimals="0" id="f-479" unitRef="shares">1003044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-131" decimals="0" id="f-480" unitRef="shares">647657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-132" decimals="0" id="f-481" unitRef="shares">9093492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-133" decimals="0" id="f-482" unitRef="shares">8187506</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-134" decimals="0" id="f-483" unitRef="shares">49073719</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-135" decimals="0" id="f-484" unitRef="shares">12418922</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-485" unitRef="shares">59170255</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-486" unitRef="shares">21254085</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-487">Commitments and Contingencies&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of March&#160;31, 2025 or December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with its Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company&#x2019;s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-488">Segment Reporting&lt;div style="margin-bottom:4pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The table below is a summary of the segment loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and Development:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facilities and other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;General and Administrative:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facilities and other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(49,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(38,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value change of warrant liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;Other expenses include subscriptions and memberships, consulting fees and company insurance.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-489"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-490">The table below is a summary of the segment loss, including significant segment expenses (in thousands):&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.460%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and Development:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facilities and other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;General and Administrative:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facilities and other expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(49,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(38,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value change of warrant liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;Other expenses include subscriptions and memberships, consulting fees and company insurance.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-136" decimals="-3" id="f-491" unitRef="usd">21696000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-137" decimals="-3" id="f-492" unitRef="usd">13944000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-138" decimals="-3" id="f-493" unitRef="usd">6069000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-139" decimals="-3" id="f-494" unitRef="usd">6604000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-140" decimals="-3" id="f-495" unitRef="usd">1524000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-141" decimals="-3" id="f-496" unitRef="usd">2614000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-142" decimals="-3" id="f-497" unitRef="usd">1591000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-143" decimals="-3" id="f-498" unitRef="usd">1739000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-138" decimals="-3" id="f-499" unitRef="usd">5061000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-139" decimals="-3" id="f-500" unitRef="usd">5501000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-144" decimals="-3" id="f-501" unitRef="usd">9364000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-145" decimals="-3" id="f-502" unitRef="usd">2447000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-142" decimals="-3" id="f-503" unitRef="usd">1900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-143" decimals="-3" id="f-504" unitRef="usd">3209000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-140" decimals="-3" id="f-505" unitRef="usd">2411000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-141" decimals="-3" id="f-506" unitRef="usd">2515000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-146" decimals="-3" id="f-507" unitRef="usd">49616000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-147" decimals="-3" id="f-508" unitRef="usd">38573000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-146" decimals="-3" id="f-509" unitRef="usd">-49616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-147" decimals="-3" id="f-510" unitRef="usd">-38573000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-511" unitRef="usd">-19460000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-512" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit contextRef="c-146" decimals="-3" id="f-513" unitRef="usd">-8448000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit contextRef="c-147" decimals="-3" id="f-514" unitRef="usd">-3101000</cmps:ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit>
    <us-gaap:InvestmentIncomeInterest contextRef="c-146" decimals="-3" id="f-515" unitRef="usd">2386000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-147" decimals="-3" id="f-516" unitRef="usd">2260000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-146" decimals="-3" id="f-517" unitRef="usd">2133000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-147" decimals="-3" id="f-518" unitRef="usd">-783000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpenseNonoperating contextRef="c-146" decimals="-3" id="f-519" unitRef="usd">-1124000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-147" decimals="-3" id="f-520" unitRef="usd">-1098000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-146" decimals="-3" id="f-521" unitRef="usd">803000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-147" decimals="-3" id="f-522" unitRef="usd">128000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-146" decimals="-3" id="f-523" unitRef="usd">-354000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-147" decimals="-3" id="f-524" unitRef="usd">-222000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-146" decimals="-3" id="f-525" unitRef="usd">-17864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-147" decimals="-3" id="f-526" unitRef="usd">-35187000</us-gaap:NetIncomeLoss>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-527">Related Party Transactions&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of a consulting agreement between the Company and Alithos, Inc., a company founded by our co-founder, former chief executive officer, former chairman of the board of directors and former greater than 5% shareholder, George Goldsmith, the Company provided consulting services to Alithos. Through March 31, 2025, the Company recorded $0.6&#160;million in other income as a result of this transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-1" decimals="-5" id="f-528" unitRef="usd">600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-529">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-530">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-531">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-532">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
